

2013-2017: CANCER IN NORTH AMERICA

Volume Two: Registry-specific Cancer
Incidence in the United States and Canada



EXECUTIVE SUMMARY: Cancer in North America: 2013-2017

Members of the North American Association of Central Cancer Registries, Inc. (NAACCR) participate voluntarily in an annual call for data to develop a multi-registry, aggregated data resource for cancer surveillance and research. NAACCR issues an annual call for data, and the member registries data submissions are combined and used to create the CiNA Monograph and other useful CiNA products for data analyses and cancer incidence information (e.g., NAACCR FastStats on-line query system, NAACCR Maps on-line query system, CiNA Public Use Dataset, and CiNA Deluxe Research Files). These preeminent cancer data resources are unparalleled in geographic scope, timeliness of statistics, and assurance of standardization of information and data quality, with standard data quality metrics reported for all contributors.

In May of 2020, NAACCR released a five volume monograph, Cancer in North America (CiNA): 2013-2017. This release is the 30th publication of the series and the 28th release that includes statistics for both Canada and the United States (U.S.). This year's publication includes cancer incidence data for all 50 U.S. states, the District of Columbia, Puerto Rico, and for 11 Canadian provinces and territories. We also report data by 5 regions: California (excluding the Greater Bay area and Los Angeles), and 4 SEER urban registries (Detroit, Los Angeles, San Francisco/Oakland, and Seattle). CiNA includes registry-specific data on stage at diagnosis, survival and delay adjusted estimates of counts and age-adjusted rates for selected cancers. These delay adjustment figures provide a projection of the likely volume of tardy reports of cancer for the time period and is recommended for use in assessing current cancer incidence trends.

The CiNA Monograph encompasses five separate volumes:

Volume One: Combined Incidence for the United States, Canada, and North America

Includes aggregated cancer incidence data by site, sex, race, ethnicity, and stage, including pediatric cancer and cancer by stage at diagnosis from the high quality registries in the U. S. and Canada.

Volume Two: Registry-Specific Cancer Incidence in the United States and Canada

Includes registry-specific cancer incidence rates by cancer site, sex, race, ethnicity and stage for all NAACCR member registries submitting data for inclusion in the monograph. To help interpret the statistics, data tables for each registry include demographic and data quality information and registry descriptions are presented.

Volume Three: Registry-Specific Cancer Mortality in the United States and Canada

Includes registry-specific cancer death rates by cancer site, sex, race, and ethnicity.

Volume Four: Cancer Survival in the United States and Canada

Includes cancer survival data for the U.S. and Canada from 61 registries on more than 13 million cases diagnosed among North Americans between 2010 and 2016.

Volume Five: Cancer Prevalence in the United States and Canada

Includes cancer prevalence estimates for the U.S. and Canada from 61 registries on more than 18 million cases diagnosed among North Americans between 2007 and 2016.

All CiNA volumes are available free of charge from the NAACCR website, along with accompanying technical data including population data and supporting appendices.

This publication is made possible by the continuing efforts of the NAACCR member registries. High quality, standardized cancer incidence data aggregated across the states, provinces, territories, and regions in North America is made possible by the dedication of our members to cancer surveillance. The Editors would like to acknowledge the fine work and support of the National Cancer Institute, the National Center for Health Statistics, and Statistics Canada for their assistance in developing this publication.

We hope that Cancer in North America: 2013-2017, with the companion CiNA products and resources, facilitate studies of cancer burden, so that we are better able to identify, and understand, appropriate and important measures to control the myriad diseases known collectively as cancer.

The Editors June 2020

CANCER IN NORTH AMERICA: 2013-2017

VOLUME TWO: REGISTRY-SPECIFIC CANCER INCIDENCE IN THE UNITED STATES AND CANADA

**A Publication of the North American Association of Central Cancer Registries, Inc.
(NAACCR)**

Editors:

Recinda Sherman, NAACCR Inc.
Rick Firth, Information Management Services, Inc.
Mary Charlton, State Health Registry of Iowa
Prithwish De, Ontario Cancer Registry at Cancer Care Ontario
Don Green, Information Management Services, Inc.
Brenda Hofer, California Cancer Registry
Jim Hofferkamp, NAACCR, Inc.
Mei-Chin Hsieh, Louisiana Tumor Registry
Chris Johnson, Cancer Data Registry of Idaho
Betsy Kohler, NAACCR, Inc.
Bozena Morawski, Cancer Data Registry of Idaho
Sarah Nash, SEER Alaska Native Tumor Registry
Baozhen Qiao, New York State Cancer Registry
Hannah Weir, U.S. Centers for Disease Control and Prevention



June 2020

The Editorial Subcommittee of the NAACCR Standing Committee, Data Use and Research Committee publishes this monograph. We are grateful to the National Cancer Institute, National Institutes of Health (NCI/NIH) for providing support for the production under Contract No. HHSN261200444001C/ADB Contract No. PC-44401. We acknowledge partial support of NAACCR staff by cooperative agreement U75/CCU52346-05 from the Centers for Disease Control and Prevention (CDC) and by the NCI/NIH Contract No. HHSN261200444001C/ADB Contract No. PC-44401. Its contents are solely the responsibility of the editors and do not necessarily represent the official view of CDC.

CINA PARTICIPANTS 2013-2017



SUGGESTED CITATION:

Sherman R, Firth R, Charlton M, De P, Green D, Hofer B, Hofferkamp J, Hsieh M, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Wier H (eds). *Cancer in North America: 2013-2017. Volume Two: Registry-specific Cancer Incidence in the United States and Canada*. Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2020.

TABLE OF CONTENTS

SECTION I: Introduction and Technical Notes	I-1

SECTION II: Average-annual Registry-specific Cancer Incidence by Race, Ethnicity and Sex, Age-adjusted to the 2000 U.S. and 2011 Canadian Population Standards

UNITED STATES REGISTRIES

Alabama	II-1
Alaska.....	II-11
Arizona	II-21
Arkansas.....	II-31
California.....	II-41
CA: Greater California	II-51
CA: Greater Bay Area	II-61
CA: Los Angeles	II-71
Colorado	II-81
Connecticut	II-91
Delaware.....	II-101
District of Columbia	II-111
Florida	II-121
Georgia.....	II-131
Hawaii	II-141
Idaho.....	II-151
Illinois	II-161
Indiana.....	II-171
Iowa.....	II-181
Kansas	II-191
Kentucky	II-201
Louisiana	II-211
Maine	II-221
Maryland	II-231
Massachusetts.....	II-241
Michigan	II-251
MI: Metropolitan Detroit.....	II-261
Minnesota	II-271
Mississippi.....	II-281
Missouri	II-291
Montana	II-301
Nebraska.....	II-311
Nevada	II-321
New Hampshire.....	II-331
New Jersey	II-341
New Mexico	II-351
New York.....	II-361
North Carolina.....	II-371
North Dakota	II-381

Ohio	II-391
Oklahoma.....	II-401
Oregon	II-411
Pennsylvania.....	II-421
Rhode Island.....	II-431
South Carolina	II-441
South Dakota	II-451
Tennessee	II-461
Texas.....	II-471
Utah	II-481
Vermont.....	II-491
Virginia.....	II-501
Washington.....	II-511
WA: Seattle/Puget Sound	II-521
West Virginia.....	II-531
Wisconsin	II-541
Wyoming	II-551
UNITED STATES TERRITORY	
Puerto Rico	II-561
CANADIAN REGISTRIES	
Alberta	II-563
British Columbia.....	II-565
Manitoba.....	II-567
New Brunswick	II-569
Newfoundland and Labrador	II-571
Northwest Territories.....	II-573
Nova Scotia.....	II-575
Nunavut	II-577
Ontario.....	II-579
Prince Edward Island.....	II-581
Saskatchewan.....	II-583

SECTION III: Stage at Diagnosis by Age for Select Cancer Sites

Alabama.....	III-1
Alaska	III-3
Arizona.....	III-5
Arkansas	III-7
California.....	III-9
CA: Greater California.....	III-11
CA: Greater Bay Area	III-13
CA: Los Angeles	III-15
Colorado	III-17

Contents

Connecticut.....	III-19
Delaware.....	III-21
District of Columbia	III-23
Florida	III-25
Georgia.....	III-27
Hawaii	III-29
Idaho.....	III-31
Illinois	III-33
Indiana.....	III-35
Iowa.....	III-37
Kansas	III-39
Kentucky	III-41
Louisiana	III-43
Maine	III-45
Maryland	III-47
Massachusetts.....	III-49
Michigan	III-51
MI: Metropolitan Detroit.....	III-53
Minnesota	III-55
Mississippi.....	III-57
Missouri	III-59
Montana	III-61
Nebraska.....	III-63
Nevada	III-65
New Hampshire.....	III-67
New Jersey	III-69
New Mexico	III-71
New York.....	III-73
North Carolina.....	III-75
North Dakota	III-77
Ohio.....	III-79
Oklahoma	III-81
Oregon.....	III-83
Pennsylvania	III-85
Rhode Island.....	III-87
South Carolina.....	III-89
South Dakota	III-91
Tennessee	III-93
Texas	III-95
Utah.....	III-97
Vermont.....	III-99
Virginia	III-101
Washington	III-103
WA: Seattle/Puget Sound.....	III-105
West Virginia	III-107
Wisconsin.....	III-109
Wyoming.....	III-111

UNITED STATES TERRITORY

Puerto Rico	III-113

CANADIAN REGISTRIES

Alberta	III-114
British Columbia.....	III-115
Manitoba.....	III-116
New Brunswick	III-117
Newfoundland and Labrador	III-118
Northwest Territories	III-119
Nova Scotia.....	III-120
Ontario.....	III-121
Prince Edward Island.....	III-122
Saskatchewan.....	III-123

All Appendices are available on the NAACCR website:

<https://www.naaccr.org/cancer-in-north-america-cina-volumes/#Appendices>



Section I

Introduction and Technical Notes



Cancer in North America: 2013-2017, Volume Two: Registry-specific Cancer Incidence for the United States and Canada

Introduction and Technical Notes

INTRODUCTION

The North American Association of Central Cancer Registries, Inc. (NAACCR) is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America. NAACCR annually produces this statistical monograph on cancer in North America to provide cancer incidence, mortality, and other cancer burden statistics for the U. S. (U.S.), Canada, and North America.

Annual cancer statistics for the U. S., for Canada, and for North America are presented in each of the five CiNA Volumes. This year marks the 30th annual release of the series of Cancer in North America (CiNA) monographs; and the 28th year CiNA has included data from both the U.S. and Canada. The *2020 CiNA Combined Monograph* includes data from 67 central population-based cancer registries: 57 from the U. S. (50 states, the District of Columbia, and Puerto Rico, plus 5 regions (California--excluding the Greater Bay area and Los Angeles plus 4 metropolitan areas) and 10 from Canada (9 provinces and 2 territories).

NAACCR issues an annual call for data to member registries to create the CiNA monograph and other useful CiNA products for data analyses and cancer incidence information (e.g., NAACCR FastStats on-line query system, NAACCR Maps on-line query system, CiNA Public Use Dataset, and CiNA Deluxe Research Files). For more information on these products and the process for gaining access to them, please visit www.naacccr.org and select *Cancer in North America CiNA Data Products* under the *Research & Analytic Tools* tab.

This monograph is a testament to the continuing commitment by population-based cancer registries throughout the U. S. and Canada to collect timely, complete, and accurate data make this publication possible. An Editorial Board of member volunteers, with support from NAACCR staff and staff from Information Management Services, takes on the responsibility to oversee the call for data, evaluate all submissions, and make all editorial decisions in production of the monograph. The objective of this work is to provide timely and useful information on cancer burden for all geographic areas and race/ethnic groups in the U. S. and Canada.

CONTENTS OF THE CiNA MONOGRAPH:

The CiNA Monograph encompasses five separate volumes:

Volume One: Combined Incidence for the United States, Canada, and North America

Includes aggregated cancer incidence data by site, sex, race, ethnicity, and stage, including pediatric cancer and cancer by stage at diagnosis from the high quality registries in the U. S. and Canada.

Volume Two: Registry-Specific Cancer Incidence in the United States and Canada

Includes registry-specific cancer incidence rates by cancer site, sex, race, ethnicity and stage for all NAACCR member registries submitting data for inclusion in the monograph. To help interpret the statistics, data tables for each registry include demographic and data quality information and registry descriptions are presented.

Volume Three: Registry-Specific Cancer Mortality in the United States and Canada

Includes registry-specific cancer death rates by cancer site, sex, race, and ethnicity.

Volume Four: Cancer Survival in the United States and Canada

Includes cancer survival data for the U.S. and Canada from 61 registries on more than 13 million cases diagnosed among North Americans between 2010 and 2016.

Volume Five: Cancer Prevalence in the United States and Canada

Includes cancer prevalence estimates for the U.S. and Canada from 61 registries on more than 18 million cases diagnosed among North Americans between 2007 and 2016.

In the U. S., cancer statistics are calculated for the following race/ethnic populations: all races combined, white, black, Asian or Pacific Islander, American Indian/Alaskan Native for PRCA counties, Hispanic/Latino (all

racess), non-Hispanic white, and non-Hispanic black. Race and ethnicity information is not collected in Canada, and thus is not presented.

Rates are presented as average annual, age-adjusted rates using three different standard million populations: the 2000 U.S. (Census P25-1130), the 2011 Canadian, and the World (WHO 2000-2025) standard populations. We believe that presenting cancer rates adjusted to all three standards enhances the meaning and utility of the rates for users in the U. S., Canada, and international settings. Recent volumes of the CiNA publication, including sections containing rates standardized to the World Standard and the population counts used in the calculation of cancer rates are available for download on the NAACCR website, <https://www.naaccr.org/cancer-in-north-america-cina-volumes/>.

CiNA Volume Two: Registry-specific Cancer Incidence for the United States and Canada

The incidence data presented in *CiNA Registry-specific* represents 100% population coverage of the U.S. and 77% of Canada. The *CiNA Registry-specific* is comprised of five sections:

Section 1: Introduction and Technical Notes

Section 2: Average-annual Registry-specific Cancer Incidence by Race, Ethnicity and Sex, Age-adjusted to the 2000 U.S. and 2011 Canadian Population Standards

Includes cancer incidence average annual counts and rates for the each population-based cancer registry. The rates for the U. S. registries are presented for all races combined, white, black, Asian or Pacific Islander, American Indian/Alaskan Native, Hispanic, non-Hispanic white, and non-Hispanic black populations for all ages combined. The rates for Canadian registries are presented for all races combined and for all ages combined. Data tables for each registry includes demographic and data quality information and registry descriptions to help interpret the statistics reported.

Section 3: Stage at Diagnosis by Age for Select Cancer Sites

Includes the frequency counts, percent distribution, and age-adjusted rates of cancer by summary stage at diagnosis for female breast, prostate, lung, uterine cervix, and colorectal cancers. Data for U.S. registries are provided for white, black, Asian or Pacific Islander, and American Indian/Alaskan Native populations with American Indian/Alaskan Native data limited to PRCDA counties as well as for all Hispanics combined.

TECHNICAL SECTION

SOURCES OF DATA

Cancer Incidence. A cancer registry must be population-based and a NAACCR member in good standing to be included in NAACCR data publications. All cancer registries in the U. S. and Canada are NAACCR members, including the three territories in Canada and three U.S. territories. An annual request is sent to all members to submit voluntarily a data file for use in CiNA, CiNA research and data information products, the U.S. *Annual Report to the Nation*, and other annual publications. All NAACCR member registries receive support from the state, province, or territory. In the U.S., they also participate in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program or the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) or both. In Canada, all registries submit data to the Canadian Cancer Registry maintained by Statistics Canada.

Population Estimates. To assist the reader, population estimates by age, sex, and race/ethnicity (where relevant) used in the calculation of rates in the monograph are available for each central registry, the U. S., and Canada. These data are available online on the NAACCR website at <https://www.naaccr.org/cancer-in-north-america-cina-volumes/>.

Population estimates for 2013 through 2017 for the U. S., individual states, and SEER metropolitan areas were obtained from the SEER program. These estimates were based on U. S. Census Bureau population estimates for these years and represent a modification of the annual time series population estimates produced by the

Population Estimates Program of the Census Bureau with support from the NCI. The population estimates incorporate bridged, single race estimates that are derived from the original multiple race categories in the 2010 Census. These bridged estimates are consistent with the four race groups enumerated in the 1990 Census and were produced under a collaborative arrangement between the NCHS and the Census Bureau. The methodology implemented by the Census Bureau to develop these county estimates is comparable to that used to produce national and state 1990-2000 intercensal estimates and is described on the Census Bureau's website.¹

In 2007, the U.S. Census revised their methodology for population estimation. This revision impacts all population denominators for 2013 to 2017. The main effect of this approach was on specific age groups, particularly, two of the oldest age groups, ages 65-74 and 75 and older. In many states, the new method results in a larger increase in the younger age category and fewer in the older age category than estimated in previous years.

The NCI modifies the Census data for the population estimates for the state of Hawaii. The Epidemiology Program of the Hawaii Cancer Research Center has developed its own set of population estimates, based on sample survey data collected by the Hawaii Department of Health. This effort grew out of a concern that the native Hawaiian population had been vastly undercounted in previous censuses. The "Hawaii adjustment" to the Census Bureau estimates has the net result of reducing the estimated white population and increasing the Asian and Pacific Islander population for the state. The Census Bureau estimates for the total population, black population, and American Indian and Alaskan Native populations in Hawaii are unaffected. The details of the methodology are described elsewhere.²

For **Canada**, Statistics Canada provided the estimates of the Canadian population for all Canadian provinces and territories, adjusted for census net under coverage.

CODING, 2013-2017

Incidence Data. All cancer registries use the International Classification of Diseases for Oncology, third edition (ICD-O-3) to code the anatomic site and morphology. Cancer incidence statistics include invasive cancers only, with the exception of *in situ* cancer of the bladder. Although tables include incidence statistics for breast cancer *in situ* and benign tumors of the brain and central nervous system, these cases are not included in any counts or rates of total cancer incidence.

The SEER program site recode groups were used for classifying types of cancer, using anatomic site and morphology. Using this standard ontology, only squamous and basal cell carcinomas of the lip and genital organs are included in the data reported. All categories used to present pediatric cancer rates in Volume One are based on the International Classification of Childhood Cancer, third edition (ICCC-3).³

Summary tables of all codes and site groups for incidence can be found in the electronic copy of the CiNA Monograph Appendices on the NAACCR website, <https://www.naaccr.org/cancer-in-north-america-cina-volumes/>.

Behavior Recode Selection used in the CiNA Publication. The CiNA publication uses the SEER Behavior Recode variable for selecting tumors for inclusion. In the CiNA publication, all *in situ* cancers of the bladder are considered malignant. Invasive cancers are selected based on the selection from the Behavior Recode variable values "Malignant", "Only malignant in ICD-O-3", and "Only malignant 2010+". But one exception to this selection is the delay-adjusted incidence statistics in Section 5. For these statistics, invasive cancers are based solely on the "Malignant only". For some statistics, non-invasive breast (behavior recode variable equals "*in situ*") and non-malignant Brain and Other Central Nervous System (behavior recode variable "Benign or borderline malignancy") statistics are available. For more details on the categories, how they are defined, and how the Behavior Recode variable is derived, see <https://seer.cancer.gov/behavrecode/>.

Summary Stage used in the CiNA Publication. In this year's call for data, Derived Summary Stage 2000 (data item 3020) was reported for diagnosis years 2004-2014. The SEER Summary Stage 2000 field (data item 759) was reported for diagnosis years 2015-2017. Some registries continue to record and report this information for years outside of these ranges.

The CiNA publication presents data from 2013-2017, a timeframe that spans both reporting diagnosis years for Derived Summary Stage 2000 and SEER Summary Stage 2000. For diagnosis years 2013-2014, the Derived Summary Stage 2000 field was used. If the field was blank or unknown, then the SEER Summary Stage 2000 value was used as long as it was not blank or unknown. For diagnosis years 2015-2017, SEER Summary Stage 2000 was used. If that field was blank or unknown, then the Derived Summary Stage 2000 value was used, as long as it wasn't blank or unknown.

Hispanic/Latino Ethnicity Identification. The ethnicity available in medical records and reported to cancer registries is enhanced using the NAACCR Hispanic Identification Algorithm, version 2 (NHIAv2). The NHIAv2 method is described in detail elsewhere.⁴ NHIAv2 uses a combination of NAACCR variables including direct identification of ethnicity from the Spanish/Hispanic Origin variable (NAACCR data element 190 values 1-6, 8), and information indirectly derived based on an evaluation of the strength of birthplace, race, and surname (including maiden name when available) associations with Hispanic ethnicity status. After applying NHIAv2, cases not ultimately classified as Hispanic are classified as non-Hispanic, leaving no cases with "unknown" Hispanic status. The NHIAv2 algorithm allows the user to run the program using one of three possible options:

- 1) All Records: Surname portion is run on 0 (non-Hispanic), 7 (surname only), and 9 (unknown) for all counties. After the algorithm, item 190 codes (0, 7, 9) are either NHIA - Hispanic or non-Hispanic.
- 2) Option 1: (The default) For counties with 5% or more Hispanics, the surname portion is run the same as for the all records option. For counties with < than 5% Hispanic, surname portion is run on 7 (surname only) and 9 (unknown). After the algorithm, item 190 codes (7, 9) are either NHIA - Hispanic or non-Hispanic.
- 3) Option 2: For counties with 5% or more Hispanics, the surname portion is run the same as for the all records option. For counties with < than 5% Hispanic, surname portion is run on 7 (surname only). These become either NHIA - Hispanic or non-Hispanic. All cases coded to 9 on item 190 are converted to NHIA - non-Hispanic.

A comparison of the direct and indirect categorization of Hispanic ethnicity is provided in Appendix F available from the NAACCR Website, <https://www.naaccr.org/cancer-in-north-america-cina-volumes/>.

Asian/Pacific Islander Identification. The information on Asian and Pacific Islander populations is also enhanced by submitting registries using a NAACCR developed algorithm.⁵ The NAACCR Asian Pacific Islander Identification Algorithm version 1 (NAPIIA v1.2.1) uses a combination of NAACCR variables to classify cases directly or indirectly as Asian/Pacific Islander for analytic purposes. It is focused on coding cases with a race code of Asian NOS (race code 96) or Pacific Islander NOS (race code 97) to a more specific Asian or Pacific Islander race category, using birthplace and name fields (first, last, and maiden names). Birthplace can be used to indirectly assign a specific race to one of eight Asian groups (Chinese, Japanese, Vietnamese, Korean, Asian Indian, Filipino, Thai, and Cambodian) and three Pacific Islander groups (Samoan, Micronesian, and Polynesian). Names can be used to indirectly assign a specific race to one of seven Asian groups (Chinese, Japanese, Vietnamese, Korean, Asian Indian, Filipino, and Hmong) and three Pacific Islander groups (Hawaiian, Guamanian, and Samoan). The algorithm uses the following NAACCR standard variables: Race 1 through Race 5 (NAACCR Items 160 through 164), Name – Last (NAACCR Item 2230), Name – First (NAACCR Item 2240), Name – Maiden (NAACCR Item 2390), Birthplace (NAACCR Item 250), Sex (NAACCR Item 220).

Misclassification of American Indian and Alaskan Native Populations. The collection of accurate information on the cancer incidence in American Indian and Alaskan Native (AI/AN) populations is hampered by misclassification of this population within cancer case reports.⁶ In order to address this problem, cancer registries in the U. S. coordinate with the Centers for Disease Control and the Bureau of Indian Affairs to link their case files to the enrollment files of the Indian Health Service.⁶ This process identifies significant numbers of American

Indians and Alaskan Natives that were otherwise classified within the cancer case report. The improved information on this population enables calculation of much more accurate cancer incidence rates. As presented in the incidence volumes, the data on American Indians and Alaskan Natives are restricted to those counties where Indian Health Service Clinics are located, namely PRCDA counties (Purchased/Referred Care Delivery Area counties previously known as the Contract Health Service Delivery Area (CHSDA) counties)—with the exception of data from Kansas and Minnesota due to limitations in county-level reporting from those states). This restriction assures that the incidence data presented is the best available data for this population.

DATA QUALITY INDICATORS AND REGISTRY INCLUSION

NAACCR assesses the quality of cancer incidence data from individual registries using several data quality indicators, which are described in detail below. Results for these indicators can be found in the *Cancer in North America, 2013-2017* Appendices on the NAACCR website (<https://www.naaccr.org/cancer-in-north-america-cina-volumes/>). A dash in the tables indicates that data were not submitted for the year or were not able to be calculated.

In order to be included in the registry-specific statistics in *CiNA Registry-specific*, the registry must be a NAACCR member registry, submit stage data, submit data to NAACCR by December 3, 2019, and a manual review of the data must not show significant deviations from prior submissions.

Missing Case Information. NAACCR has developed standards for completeness of data on key data items that are needed to produce meaningful cancer incidence statistics. These key data items include race, sex, county of residence at diagnosis, and age at diagnosis. Cases with unknown sex or age are omitted from all calculations. Cases with unknown race and county of residence were included in the cancer counts and rates for all races and/or all counties combined.

Death Certificate Only Cases. The proportion of cases identified by death certificate only (DCO) is an indicator of data quality and completeness. Central cancer registries use death certificates to identify potentially missed cases and to conduct follow back on cases that have cancer on the death certificate but who are not incident cases in the registry. Cases without follow back information are considered DCO cases and may have incomplete or missing information, including date of diagnosis and stage at diagnosis. For DCO cases, the date of death is used as the date of diagnosis. Registries that did not use death certificates as a source of case ascertainment have “na” listed in the death certificate only row on the registry description page.

Data Reliability and Accuracy. All data submitted to NAACCR are evaluated for reliability and accuracy using the EDITS program and a specific set of edits incorporated into a Call for Data Edits Metafile. An edit reviews the internal consistency between and among data elements, such as anatomic site and morphology. Cases that are identified as having errors are reviewed by registry staff and resolved prior to their NAACCR submission.

The NAACCR Call for Data EDITS metafile is available on the NAACCR website here: <https://www.naaccr.org/call-for-data/#datatools>. An inter-record edits program, developed by the Centers for Disease Control and Prevention, is used to identify errors among the records reported for persons who have had multiple tumors diagnosed. For example, an inter-record edit will identify whether birthplace is the same on all reports of multiple tumors that are reported for one individual.

Timeliness of Data. The NAACCR standard defines timely data as data that are available for use in incidence statistics within 23 months of the close of a diagnostic year (i.e., December 3, 2019 for all cases diagnosed in 2017).

Site-Specific Microscopic Confirmation. This criterion is not used by NAACCR to determine high quality for the purposes of this publication. However, it is a useful indicator of quality of data collection. A proportion of microscopically confirmed cases that is too high or low may suggest problems in case ascertainment or abstracting. However, this proportion varies by cancer site. For sites that are more likely to rely on a clinical or radiological diagnosis, e.g., cancers of the pancreas and brain, confirmation rates that are too high may suggest

that some clinically diagnosed cases are missing. Also, registries that do not use death certificates for case finding have an artificially high proportion of microscopically confirmed cases, because DCO cases by definition do not have information on whether the tumor was microscopically confirmed. While no NAACCR standard has been determined for microscopic confirmation, the guideline we use is that the proportion should fall between 92 and 96 percent of all cancer cases, based on the experience of the SEER program.

CALCULATION OF STATISTICS

Counts. Counts are the average annual count rounded to nearest whole number. Cell suppression rules were applied based on the five-year aggregate count.

Rates. Rates are per 100,000 population and are age-adjusted by five-year age groups to the 2000 U.S. standard population based on single years of age,^{7,8} the 2011 Canadian population standard,⁹ and to the World (WHO 2000-2025) population standard.¹⁰ Rates for children and adolescents in are expressed per million population. The incidence and death rates in this monograph are annual averages for the period 2013 through 2017.

The age distributions of the three population standards are as follows:

AGE GROUP	2000 U.S. (Census P25-1130)	2011 CDN.	WORLD (WHO 2000-2025)
00 years	3,794,901	376,321	17,917
01-04 years	15,191,619	1,522,743	70,625
05-09 years	19,919,840	1,810,433	86,870
10-14 years	20,056,779	1,918,164	85,970
15-19 years	19,819,518	2,238,952	84,670
20-24 years	18,257,225	2,354,354	82,171
25-29 years	17,722,067	2,369,841	79,272
30-34 years	19,511,370	2,327,955	76,073
35-39 years	22,179,956	2,273,087	71,475
40-44 years	22,479,229	2,385,918	65,877
45-49 years	19,805,793	2,719,909	60,379
50-54 years	17,224,359	2,691,260	53,681
55-59 years	13,307,234	2,353,090	45,484
60-64 years	10,654,272	2,050,443	37,187
65-69 years	9,409,940	1,532,940	29,590
70-74 years	8,725,574	1,153,822	22,092
75-79 years	7,414,559	919,338	15,195
80-84 years	4,900,234	701,140	9,097
85+ years	4,259,173	643,070	6,348
Total	274,633,642	34,342,780	1,000,000

Standard Errors. Standard errors (S.E.) of the rates were calculated using the formula:

$$S.E. = \sqrt{\sum \frac{w_j^2 n_j}{p_j^2}}$$

where w_j = the fraction of the standard population in age group j , n_j = number of cases or deaths in that age group, and p_j = person years denominator.¹¹ For many registries, the standard errors of the rates are small, as the population covered is large. However, for registries that cover a small population, the standard error may be substantial.

Confidence Intervals. Although not reproduced in the printed monograph, bar charts of the registry-specific, age-adjusted rates with 95 percent confidence intervals¹² are available on the NAACCR website (<https://www.naaccr.org/cancer-in-north-america-cina-volumes>). The confidence intervals allow the user to assess the precision of the estimate and is an approximate and conservative indicator of whether a registry's rate is statistically higher or lower than the rate for the combined U. S., based on whether or not the upper or lower limit of the confidence interval overlaps the 95% confidence interval for the U. S..

Comparison of Rates. In addition to true regional variation in cancer risk, differences in cancer incidence or mortality rates between areas may be due to either differences in the demographic makeup of the population or differences in data quality. In making valid comparisons of cancer incidence rates among registries, it is important to review the data quality indicators for each registry and consider differences in the racial composition of the populations being compared before conclusions are drawn about variations in regional rates. Interpretation without consideration of these factors may contribute to misleading or inaccurate conclusions.

The standard error of adjusted rates can be used to evaluate the statistical significance of rate differences among comparable populations. For example, if the adjusted rates in two populations are R_1 and R_2 and their standard errors are $S.E._1$ and $S.E._2$, an approximate confidence interval for the rate ratio can be calculated using the following formula:

$$(R_1/R_2)^{1 \pm z/x}$$

where $x = (R_1 \pm R_2) \sqrt{(S.E._1^2 + S.E._2^2)}$ and $z = 1.96$ for 95% limits.¹³ If this interval does not include one, the two rates are statistically significantly different at a p value of 0.05. This test can be inaccurate for rates based on fewer than 16 cases or deaths, and it should not be used for rates based on fewer than six cases or deaths. It should be emphasized that this kind of comparison of adjusted rates must be undertaken with caution as misleading conclusions may be drawn if the ratios of the age-specific rates in the two populations are not constant in all age groups. In these circumstances, the ratios of the adjusted rates will vary according to the standard populations used.¹⁴

Cell Suppression. Counts and rates were suppressed (indicated by “-”) in the tables if the race, gender, and site-specific number of cases for incidence was less than six or when the number of deaths was less than ten. Complementary cell suppression was employed, when necessary, to prevent the contents of a single suppressed cell from being calculated. These counts are included in the calculation of all sites combined. A dash is also used to indicate not applicable, as in the gender-specific cancers. If the rate was less than 0.05 per 100,000 then the rate is listed as 0.0.

SEER*Stat Variables. The following SEER*Stat variables were used to create the statistics for the registry incidence pages: Year of Diagnosis, NAACCR Registry, Sex, Race Recode (W, B, AI, API) IHS Modified, PRCDA 2016, NHIAv2 Recode, Site recode ICD-O-3/WHO 2008 and Behavior recode for analysis.

REFERENCES

1. National Center for Health Statistics. U.S. Census Populations with Bridged Race Categories. September 2003. Available here: https://www.cdc.gov/nchs/nvss/bridged_race.htm.
2. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Available here: https://seer.cancer.gov/archive/csr/1975_2006/.

3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer* 2005;103:1457-67.
4. NAACCR Latino Research Work Group. *NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2]*. Springfield (IL): North American Association of Central Cancer Registries. September 2005. Available here: https://www.naaccr.org/wp-content/uploads/2016/11/NHIA_v2_2_1_09122011.pdf
5. NAACCR Race and Ethnicity Work Group. *NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]*. Springfield, IL: North American Association of Central Cancer Registries, September 2010.
6. Espey DK, Wiggins CL, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. *Cancer*. 2008 Sep 1 Suppl):112030.
7. SEER. 2000 U.S. Standard Population vs. Standard Million. 13 December 2004. Available here: http://seer.cancer.gov/stdpopulations/single_age.html.
8. Day, Jennifer Cheeseman, *Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050*, U.S. Bureau of the Census, Current Population Reports, P25-1130, U.S. Government Printing Office, Washington, DC, 1996. Available here: <https://www.census.gov/prod/1/pop/p25-1130/p251130.pdf>.
9. 2011 Canadian Standard Population. Statistics Canada, Table 051-0001 – Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). CANSIM (database). Available here: <http://www5.statcan.gc.ca/cansim/a26?id=510001>.
10. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series: No. 31. World Health Organization 2001. Available here: <http://www.who.int/healthinfo/paper31.pdf>.
11. Breslow NE and Day NE. Statistical Methods in Cancer Research. Vol. II. 1987. International Agency for Research on Cancer: Lyon, France. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: Preliminary estimates. *National Vital Statistics Reports* 2001;49:1-32.
12. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. *Stat Methods Med Res* 2006;15:547-569.
13. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D., Thomas D.B. Cancer Incidence in Five Continents. Vol. VIII. 2002. International Agency for Research on Cancer: Lyon, France.
14. Esteve J, Benhamou E, and Raymond L. Statistical Methods in Cancer Research. Vol. V. 1994. International Agency for Research on Cancer: Lyon, France.



Section II

Average-annual Registry-specific Cancer Incidence by Race, Ethnicity and Sex


Age-adjusted to the 2000 U.S. and
2011 Canadian Population Standards



Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	4,830,460	4,842,481	4,853,160	4,864,745	4,875,120
White	3,413,210	3,415,557	3,415,679	3,418,594	3,420,990
Black	1,308,223	1,315,502	1,323,269	1,328,921	1,334,075
American Indian/Alaskan Native (AI/AN)	35,962	36,229	36,569	36,811	37,281
Asian/Pacific Islander (API)	73,065	75,193	77,643	80,419	82,774


All Races Population 2013-2017: 24,265,966
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	193,377	196,014	200,148	205,822	210,912
Non-Hispanic White	3,247,043	3,246,887	3,243,514	3,241,370	3,239,420
Non-Hispanic Black	1,292,600	1,299,646	1,306,969	1,312,210	1,316,946

Hispanic/Latino Population, Census 2010: 185,602
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ALABAMA CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.3	97.9	100.0	101.9	99.6
Missing Race	0.5	1.0	1.0	1.5	2.3
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.3	0.8	0.7	0.7	0.8
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.7	2.3	2.4	2.1	1.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.1	Prostate	94.5
Oral Cavity & Pharynx	95.4	Testis	96.9
Esophagus	92.9	Bladder (incl. <i>in situ</i>)	97.2
Stomach	94.5	Kidney & Renal Pelvis	91.2
Colon & Rectum	94.9	Brain & Other CNS ¹	79.7
Liver	54.0	Thyroid	98.2
Pancreas	81.3	Hodgkin Lymphoma	97.5
Lung & Bronchus	87.3	Non-Hodgkin Lymphoma	95.1
Melanomas of the Skin	96.7	Multiple Myeloma	85.8
Female Breast (excl. <i>in situ</i>)	95.4	Leukemias	84.4
Cervix uteri	89.3	Brain & Other CNS ¹ <i>non-malig</i>	51.6
Uterus Corpus & Uterus NOS ¹	97.6	Breast <i>in situ</i>	100.0
Ovary	90.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,953	517.6	2.02	618.5	2.38	12,566	403.3	1.66	471.0	1.90
Oral Cavity & Pharynx	563	20.3	0.39	24.8	0.47	224	7.1	0.22	8.4	0.25
Lip	36	1.4	0.11	1.6	0.12	22	0.7	0.07	0.8	0.08
Tongue	163	5.8	0.21	7.1	0.25	57	1.9	0.11	2.2	0.13
Major salivary gland	54	2.1	0.13	2.5	0.15	34	1.1	0.09	1.3	0.10
Floor of mouth	25	0.9	0.08	1.1	0.10	12	0.4	0.05	0.4	0.06
Gum & other mouth	58	2.2	0.13	2.6	0.15	42	1.3	0.09	1.6	0.11
Nasopharynx	23	0.9	0.09	1.0	0.10	7	0.2	0.04	0.3	0.04
Oropharynx	33	1.1	0.09	1.4	0.11	9	0.3	0.04	0.3	0.05
Hypopharynx	32	1.1	0.09	1.4	0.11	6	0.2	0.04	0.2	0.04
Digestive System	2,728	101.7	0.90	122.1	1.06	2,175	68.0	0.67	80.2	0.78
Esophagus	224	8.1	0.25	9.8	0.30	53	1.6	0.10	2.0	0.12
Stomach	232	8.8	0.27	10.5	0.31	163	5.1	0.18	6.0	0.21
Small intestine	75	2.8	0.15	3.3	0.17	73	2.3	0.13	2.8	0.15
Colon excl. rectum	952	36.3	0.54	43.0	0.63	929	29.2	0.44	34.3	0.51
Rectum & rectosigmoid	380	14.1	0.33	17.0	0.39	271	8.8	0.25	10.3	0.28
Anus, anal canal & anorectum	38	1.5	0.11	1.7	0.13	72	2.3	0.12	2.7	0.14
Liver	314	10.8	0.28	13.7	0.35	115	3.5	0.15	4.2	0.18
Gallbladder	18	0.7	0.08	0.8	0.09	33	1.0	0.08	1.2	0.09
Pancreas	398	14.8	0.34	17.8	0.41	363	11.0	0.26	13.1	0.31
Respiratory System	2,513	92.5	0.85	111.1	1.01	1,750	52.3	0.57	62.9	0.68
Larynx	205	7.2	0.23	8.9	0.28	52	1.6	0.10	2.0	0.12
Lung & bronchus	2,279	84.1	0.81	100.9	0.96	1,676	50.0	0.55	60.1	0.66
Bones & Joints	29	1.2	0.10	1.3	0.11	24	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	105	4.3	0.19	4.8	0.21	88	3.1	0.15	3.4	0.16
Skin (excl. basal & sq.)	769	30.1	0.50	35.0	0.57	526	18.1	0.37	20.4	0.40
Melanomas of the skin	725	28.2	0.48	32.9	0.56	491	17.0	0.36	19.2	0.39
Breast (excl. <i>in situ</i>)	45	1.7	0.12	2.1	0.14	3,753	121.6	0.92	142.9	1.05
Female Genital System	-	-	-	-	-	1,359	44.9	0.56	52.0	0.64
Cervix uteri	-	-	-	-	-	239	9.4	0.28	9.9	0.29
Uterus Corpus	-	-	-	-	-	606	18.8	0.35	22.7	0.42
Uterus, NOS ¹	-	-	-	-	-	34	1.1	0.09	1.3	0.10
Ovary	-	-	-	-	-	353	11.5	0.28	13.3	0.32
Male Genital System	3,611	126.5	0.97	155.5	1.17	-	-	-	-	-
Prostate	3,486	121.0	0.94	149.9	1.15	-	-	-	-	-
Testis	95	4.3	0.20	4.3	0.20	-	-	-	-	-
Penis	25	1.0	0.09	1.1	0.10	-	-	-	-	-
Urinary System	1,502	57.6	0.69	67.9	0.80	663	20.8	0.37	24.5	0.43
Bladder (incl. <i>in situ</i>)	835	32.7	0.52	38.4	0.61	247	7.5	0.22	8.8	0.25
Kidney & renal pelvis	640	23.9	0.44	28.3	0.51	399	12.8	0.30	15.0	0.34
Ureter	19	0.8	0.08	0.9	0.09	13	0.4	0.05	0.5	0.06
Eye & Orbit	28	1.1	0.10	1.3	0.11	20	0.7	0.07	0.7	0.07
Brain & Other CNS ¹	184	7.2	0.24	8.0	0.27	157	5.5	0.20	5.9	0.21
Brain	177	6.9	0.24	7.7	0.26	145	5.0	0.19	5.5	0.20
Endocrine System	152	5.9	0.22	6.7	0.24	399	14.9	0.34	16.2	0.37
Thyroid gland	129	5.0	0.21	5.7	0.23	377	14.1	0.34	15.4	0.36
Lymphomas	574	22.5	0.43	25.9	0.49	480	15.5	0.33	17.7	0.37
Hodgkin Lymphoma	65	2.7	0.15	2.8	0.16	54	2.1	0.13	2.2	0.13
Non-Hodgkin Lymphoma	510	19.8	0.40	23.0	0.46	425	13.4	0.30	15.5	0.34
Multiple Myeloma	225	8.5	0.26	10.1	0.30	200	6.1	0.20	7.3	0.23
Leukemias	394	15.6	0.36	17.7	0.40	295	9.7	0.26	10.9	0.28
Acute lymphocytic	36	1.6	0.12	1.4	0.11	27	1.1	0.10	1.0	0.09
Chronic lymphocytic	138	5.3	0.21	6.2	0.24	91	2.7	0.13	3.2	0.15
Acute myeloid	112	4.5	0.20	5.1	0.22	95	3.2	0.15	3.5	0.16
Chronic myeloid	52	2.0	0.13	2.3	0.15	41	1.4	0.10	1.6	0.11
Other leukemias	56	2.3	0.14	2.6	0.16	42	1.3	0.10	1.5	0.11
Mesothelioma	29	1.2	0.10	1.4	0.12	8	0.3	0.04	0.3	0.05
Kaposi Sarcoma	10	0.4	0.06	0.5	0.07	-	-	-	-	-
Ill-defined & Unknown	492	19.3	0.40	22.5	0.46	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	155	6.1	0.22	6.9	0.25	302	10.1	0.27	11.6	0.30
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.04	746	24.3	0.41	28.7	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	10,533	501.9	2.25	597.5	2.64	9,485	407.8	1.95	475.3	2.22
Oral Cavity & Pharynx	466	21.8	0.46	26.5	0.56	180	7.6	0.26	9.0	0.31
Lip	34	1.7	0.13	1.9	0.15	21	0.8	0.08	1.0	0.10
Tongue	138	6.4	0.25	7.9	0.30	48	2.1	0.14	2.5	0.16
Major salivary gland	46	2.3	0.15	2.6	0.18	25	1.1	0.10	1.2	0.11
Floor of mouth	20	0.9	0.09	1.1	0.11	10	0.4	0.06	0.5	0.07
Gum & other mouth	46	2.2	0.15	2.6	0.17	33	1.3	0.11	1.6	0.13
Nasopharynx	17	0.9	0.10	1.0	0.11	4	0.1	0.04	0.2	0.04
Oropharynx	26	1.2	0.10	1.5	0.13	7	0.3	0.05	0.4	0.06
Hypopharynx	23	1.0	0.10	1.3	0.12	5	0.2	0.04	0.2	0.05
Digestive System	2,026	96.8	0.99	116.1	1.17	1,535	63.5	0.75	74.8	0.87
Esophagus	175	8.1	0.28	9.8	0.34	37	1.4	0.11	1.7	0.13
Stomach	154	7.5	0.28	8.8	0.32	99	4.1	0.19	4.8	0.22
Small intestine	52	2.6	0.16	3.0	0.19	48	2.0	0.14	2.4	0.16
Colon excl. rectum	709	34.5	0.60	40.9	0.70	659	27.4	0.49	32.1	0.57
Rectum & rectosigmoid	287	13.7	0.37	16.6	0.44	193	8.4	0.28	9.9	0.32
Anus, anal canal & anorectum	28	1.4	0.12	1.6	0.14	62	2.6	0.16	3.1	0.18
Liver	226	10.2	0.31	12.9	0.39	83	3.4	0.17	4.0	0.20
Gallbladder	13	0.7	0.08	0.8	0.10	21	0.8	0.09	1.0	0.10
Pancreas	306	14.4	0.38	17.4	0.45	254	10.1	0.29	12.0	0.34
Respiratory System	1,967	92.0	0.95	110.2	1.13	1,442	56.5	0.68	68.1	0.81
Larynx	145	6.6	0.25	8.2	0.31	42	1.8	0.12	2.1	0.15
Lung & bronchus	1,798	84.2	0.91	100.7	1.08	1,382	54.1	0.66	65.1	0.79
Bones & Joints	21	1.2	0.12	1.2	0.12	16	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	83	4.4	0.22	5.0	0.25	62	3.0	0.18	3.2	0.19
Skin (excl. basal & sq.)	755	37.5	0.63	43.8	0.72	506	24.1	0.50	27.1	0.55
Melanomas of the skin	716	35.5	0.61	41.4	0.70	480	23.0	0.49	25.9	0.54
Breast (excl. <i>in situ</i>)	34	1.7	0.13	2.0	0.15	2,747	119.0	1.06	139.9	1.22
Female Genital System	-	-	-	-	-	988	44.5	0.66	51.4	0.75
Cervix uteri	-	-	-	-	-	160	9.1	0.33	9.5	0.34
Uterus Corpus	-	-	-	-	-	440	18.6	0.41	22.4	0.48
Uterus, NOS ¹	-	-	-	-	-	17	0.8	0.09	0.9	0.10
Ovary	-	-	-	-	-	272	11.9	0.33	13.7	0.38
Male Genital System	2,311	104.1	0.99	127.1	1.20	-	-	-	-	-
Prostate	2,204	97.5	0.95	120.4	1.16	-	-	-	-	-
Testis	83	5.4	0.27	5.3	0.26	-	-	-	-	-
Penis	21	1.0	0.11	1.2	0.12	-	-	-	-	-
Urinary System	1,241	60.4	0.79	71.2	0.92	508	21.3	0.44	25.0	0.50
Bladder (incl. <i>in situ</i>)	729	35.6	0.60	42.0	0.71	198	7.8	0.25	9.2	0.30
Kidney & renal pelvis	488	23.6	0.49	27.9	0.57	297	12.9	0.35	15.2	0.40
Ureter	18	0.9	0.09	1.0	0.11	11	0.4	0.06	0.5	0.07
Eye & Orbit	26	1.3	0.12	1.5	0.13	18	0.8	0.09	0.9	0.10
Brain & Other CNS ¹	150	7.7	0.29	8.5	0.32	127	6.0	0.25	6.6	0.27
Brain	145	7.4	0.29	8.3	0.31	119	5.6	0.24	6.1	0.26
Endocrine System	123	6.4	0.27	7.2	0.29	310	16.5	0.44	17.9	0.46
Thyroid gland	108	5.6	0.25	6.3	0.27	297	15.8	0.43	17.2	0.45
Lymphomas	456	22.8	0.49	26.4	0.56	374	16.0	0.38	18.3	0.43
Hodgkin Lymphoma	45	2.6	0.18	2.7	0.18	36	2.0	0.16	2.1	0.16
Non-Hodgkin Lymphoma	411	20.2	0.46	23.7	0.53	339	13.9	0.35	16.2	0.40
Multiple Myeloma	142	6.8	0.26	8.0	0.31	108	4.2	0.19	5.0	0.22
Leukemias	309	15.9	0.42	17.9	0.46	224	9.9	0.31	11.0	0.34
Acute lymphocytic	30	1.9	0.16	1.7	0.14	22	1.4	0.14	1.2	0.12
Chronic lymphocytic	102	4.9	0.22	5.9	0.26	68	2.6	0.15	3.1	0.17
Acute myeloid	96	4.9	0.23	5.6	0.26	75	3.4	0.18	3.8	0.20
Chronic myeloid	36	1.9	0.14	2.1	0.16	28	1.3	0.11	1.4	0.12
Other leukemias	45	2.3	0.16	2.6	0.18	30	1.3	0.11	1.4	0.12
Mesothelioma	26	1.3	0.12	1.5	0.14	7	0.3	0.05	0.3	0.06
Kaposi Sarcoma	5	0.3	0.06	0.3	0.07	-	-	-	-	-
Ill-defined & Unknown	393	19.6	0.45	22.9	0.52	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	123	6.3	0.26	7.2	0.29	224	10.2	0.32	11.6	0.35
Breast (<i>in situ</i>)	4	0.2	0.04	0.2	0.05	527	23.2	0.47	27.5	0.55

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

ALABAMA

II-4 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,025	541.5	4.72	654.7	5.54	2,817	384.3	3.32	451.4	3.82
Oral Cavity & Pharynx	82	13.8	0.72	17.0	0.86	38	5.1	0.38	6.0	0.44
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	20	3.2	0.34	4.0	0.41	8	1.2	0.19	1.4	0.21
Major salivary gland	7	1.1	0.21	1.3	0.23	9	1.1	0.17	1.3	0.20
Floor of mouth	5	0.9	0.19	1.0	0.21	2	0.2	0.08	0.3	0.10
Gum & other mouth	10	1.7	0.26	2.1	0.30	8	1.2	0.19	1.3	0.21
Nasopharynx	6	1.1	0.21	1.2	0.24	2	0.3	0.09	0.4	0.11
Oropharynx	6	1.0	0.19	1.3	0.25	2	0.2	0.08	0.3	0.09
Hypopharynx	8	1.4	0.22	1.7	0.27	1	0.2	0.06	0.2	0.08
Digestive System	643	117.6	2.22	141.5	2.60	590	81.0	1.53	95.9	1.78
Esophagus	46	7.8	0.55	9.7	0.66	16	2.1	0.24	2.5	0.29
Stomach	70	13.5	0.78	16.3	0.92	58	8.2	0.49	9.6	0.57
Small intestine	20	3.6	0.38	4.2	0.43	25	3.4	0.31	4.0	0.36
Colon excl. rectum	223	42.4	1.36	50.1	1.57	249	34.3	1.00	40.6	1.16
Rectum & rectosigmoid	83	15.0	0.78	17.8	0.90	69	9.3	0.52	11.0	0.60
Anus, anal canal & anorectum	10	1.9	0.28	2.1	0.30	10	1.3	0.19	1.6	0.23
Liver	80	12.3	0.65	16.0	0.82	27	3.5	0.31	4.3	0.37
Gallbladder	4	1.0	0.22	1.1	0.24	11	1.5	0.21	1.8	0.24
Pancreas	87	16.4	0.85	19.7	0.99	104	14.5	0.65	17.1	0.75
Respiratory System	522	95.5	2.01	116.0	2.36	290	39.2	1.06	47.1	1.25
Larynx	56	9.5	0.61	11.8	0.73	8	1.0	0.17	1.3	0.20
Lung & bronchus	461	85.0	1.90	103.0	2.23	277	37.4	1.04	45.1	1.22
Bones & Joints	8	1.4	0.24	1.4	0.24	8	1.0	0.17	1.1	0.19
Soft Tissue (incl. heart)	20	3.6	0.38	4.0	0.41	24	3.3	0.31	3.7	0.34
Skin (excl. basal & sq.)	-	-	-	-	-	13	1.9	0.24	2.1	0.26
Melanomas of the skin	6	1.2	0.23	1.3	0.25	8	1.2	0.19	1.3	0.21
Breast (excl. <i>in situ</i>)	10	2.1	0.31	2.5	0.36	934	126.1	1.90	148.6	2.19
Female Genital System	-	-	-	-	-	340	46.5	1.16	54.1	1.32
Cervix uteri	-	-	-	-	-	72	10.4	0.56	11.3	0.60
Uterus Corpus	-	-	-	-	-	154	20.2	0.75	24.4	0.88
Uterus, NOS ¹	-	-	-	-	-	16	2.2	0.25	2.5	0.29
Ovary	-	-	-	-	-	73	10.0	0.54	11.6	0.61
Male Genital System	1,104	188.8	2.72	234.5	3.27	-	-	-	-	-
Prostate	1,091	186.6	2.70	232.1	3.25	-	-	-	-	-
Testis	8	1.4	0.23	1.4	0.24	-	-	-	-	-
Penis	4	0.6	0.16	0.8	0.18	-	-	-	-	-
Urinary System	239	44.8	1.38	53.0	1.60	146	19.8	0.75	23.5	0.87
Bladder (incl. <i>in situ</i>)	91	18.7	0.94	21.9	1.08	45	6.3	0.43	7.5	0.50
Kidney & renal pelvis	147	25.7	1.01	30.7	1.17	97	13.0	0.61	15.4	0.70
Ureter	-	-	-	-	-	2	0.2	0.08	0.3	0.09
Eye & Orbit	2	0.4	0.11	0.4	0.12	-	-	-	-	-
Brain & Other CNS ¹	30	5.0	0.43	5.6	0.48	27	3.7	0.33	4.0	0.35
Brain	28	4.7	0.42	5.3	0.46	23	3.2	0.30	3.4	0.32
Endocrine System	23	4.0	0.39	4.6	0.44	76	10.5	0.55	11.6	0.60
Thyroid gland	16	2.9	0.34	3.3	0.38	67	9.3	0.52	10.3	0.57
Lymphomas	100	18.4	0.87	20.6	0.96	88	12.3	0.60	13.9	0.67
Hodgkin Lymphoma	17	3.0	0.33	3.1	0.35	16	2.4	0.27	2.4	0.27
Non-Hodgkin Lymphoma	83	15.4	0.80	17.5	0.90	72	9.9	0.53	11.5	0.61
Multiple Myeloma	79	15.1	0.82	18.0	0.95	88	12.2	0.60	14.4	0.69
Leukemias	60	11.3	0.69	12.9	0.78	52	7.2	0.46	8.1	0.51
Acute lymphocytic	5	0.9	0.19	0.8	0.19	4	0.6	0.13	0.5	0.12
Chronic lymphocytic	23	4.5	0.45	5.3	0.51	14	1.8	0.22	2.2	0.27
Acute myeloid	15	2.8	0.34	3.2	0.39	17	2.4	0.27	2.7	0.29
Chronic myeloid	9	1.6	0.24	1.8	0.27	9	1.3	0.20	1.4	0.21
Other leukemias	8	1.5	0.26	1.7	0.30	-	-	-	-	-
Mesothelioma	3	0.6	0.16	0.6	0.18	1	0.2	0.08	0.2	0.09
Kaposi Sarcoma	4	0.8	0.17	0.8	0.17	-	-	-	-	-
Ill-defined & Unknown	85	16.5	0.86	19.5	1.00	102	14.2	0.64	16.6	0.74
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	30	5.4	0.47	6.1	0.52	74	10.4	0.55	11.9	0.62
Breast (<i>in situ</i>)	-	-	-	-	-	199	26.9	0.88	31.7	1.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	67	300.2	18.69	355.3	21.84	89	266.8	13.50	307.8	15.49
Oral Cavity & Pharynx	3	9.4	2.94	11.9	3.60	1	3.6	1.58	4.3	1.93
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	22	89.0	9.67	107.1	11.39	21	67.1	6.95	78.9	8.06
Esophagus	1	6.4	2.99	7.4	3.49	-	-	-	-	-
Stomach	4	13.5	3.43	15.5	3.85	4	11.9	2.82	14.3	3.33
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	18.6	4.17	23.4	5.03	7	21.8	3.91	26.1	4.56
Rectum & rectosigmoid	3	9.8	3.08	11.7	3.62	2	6.5	1.95	7.5	2.23
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	6	21.9	4.58	27.1	5.52	3	11.0	3.02	12.4	3.36
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	10.0	3.62	11.9	4.27	3	11.3	3.06	13.5	3.65
Respiratory System	10	53.2	8.27	63.4	9.68	9	30.7	5.00	35.7	5.70
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	10	51.8	8.21	61.5	9.58	8	29.7	4.90	34.8	5.61
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	26	70.6	6.62	82.4	7.75
Female Genital System	-	-	-	-	-	10	27.2	4.12	31.0	4.69
Cervix uteri	-	-	-	-	-	2	5.7	1.66	5.4	1.61
Uterus Corpus	-	-	-	-	-	2	6.3	1.90	7.7	2.28
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	12.2	2.91	14.0	3.27
Male Genital System	15	68.5	8.75	81.7	10.21	-	-	-	-	-
Prostate	14	66.8	8.70	80.1	10.17	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	4	21.9	5.53	26.3	6.54	3	10.5	2.68	12.5	3.13
Bladder (incl. <i>in situ</i>)	3	17.6	5.28	20.7	6.17	1	4.0	1.73	4.9	2.07
Kidney & renal pelvis	1	4.3	1.64	5.6	2.18	2	5.9	1.93	6.9	2.23
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	5.7	2.04	5.5	2.02	2	4.9	1.77	5.6	2.07
Brain	2	5.1	1.96	4.7	1.86	2	4.4	1.70	5.1	1.99
Endocrine System	1	4.1	1.64	4.6	1.85	6	15.0	2.68	16.6	3.02
Thyroid gland	1	4.1	1.64	4.6	1.85	6	15.0	2.68	16.6	3.02
Lymphomas	2	11.8	3.95	13.3	4.50	3	9.1	2.39	9.8	2.57
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	11.8	3.95	13.3	4.50	3	8.3	2.32	9.0	2.51
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	7.7	3.18	8.0	3.52	3	9.8	2.90	10.6	3.21
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	1	4.5	1.80	4.9	1.98
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	13.4	4.22	16.0	4.98	3	8.8	2.61	9.9	2.86
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	3.3	1.34	3.7	1.57	2	6.3	2.02	7.5	2.35
Breast (<i>in situ</i>)	-	-	-	-	-	9	22.5	3.55	25.5	4.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10	216.5	33.32	259.2	38.94	7	166.1	30.15	193.2	34.21
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	67.7	18.49	80.1	21.45	-	-	-	-	-
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	39.5	14.13	48.8	16.63	1	28.2	10.91	35.6	13.62
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	39.5	14.13	48.8	16.63	1	28.2	10.91	35.6	13.62
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	60.1	18.98	69.7	21.56
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	41.1	14.71	50.1	17.62	-	-	-	-	-
Prostate	2	37.6	14.29	45.2	16.91	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	112	239.3	11.93	281.2	13.78	113	223.1	10.36	258.7	12.13
Oral Cavity & Pharynx	4	8.6	2.12	10.2	2.50	2	2.7	1.06	3.3	1.29
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	4.8	1.68	5.6	1.94	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	26	55.7	5.60	67.2	6.57	17	37.6	4.43	43.5	5.12
Esophagus	2	3.7	1.32	4.4	1.55	-	-	-	-	-
Stomach	4	6.4	1.61	8.0	1.99	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	7	18.7	3.50	21.6	3.96	8	19.2	3.35	21.8	3.79
Rectum & rectosigmoid	4	8.2	2.07	10.4	2.52	4	7.1	1.64	8.6	2.03
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	8.1	2.01	10.3	2.46	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	6.5	2.03	8.0	2.44	2	3.4	1.11	4.3	1.48
Respiratory System	9	22.4	3.86	26.6	4.46	8	21.9	3.56	26.1	4.17
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	8	21.3	3.82	25.1	4.39	8	21.6	3.55	25.8	4.16
Bones & Joints	1	1.0	0.41	0.9	0.36	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.5	1.13	2.6	1.18	1	1.5	0.65	1.6	0.75
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	3	9.1	2.58	10.3	2.90	3	5.2	1.60	5.9	1.81
Breast (excl. <i>in situ</i>)	-	-	-	-	-	31	57.4	4.88	68.2	5.96
Female Genital System	-	-	-	-	-	20	36.0	4.02	41.0	4.66
Cervix uteri	-	-	-	-	-	6	8.1	1.51	8.4	1.70
Uterus Corpus	-	-	-	-	-	8	16.3	2.89	19.0	3.34
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	7.0	1.79	8.5	2.18
Male Genital System	29	63.3	5.91	77.3	6.99	-	-	-	-	-
Prostate	25	59.6	5.85	73.5	6.93	-	-	-	-	-
Testis	3	2.5	0.70	2.6	0.76	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	10	25.6	4.09	29.6	4.65	5	11.1	2.43	12.8	2.79
Bladder (incl. <i>in situ</i>)	4	13.6	3.28	15.5	3.70	-	-	-	-	-
Kidney & renal pelvis	6	12.0	2.44	14.1	2.82	4	9.3	2.23	10.6	2.53
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	1.7	0.61	1.9	0.78	3	3.9	1.29	4.4	1.49
Brain	2	1.4	0.56	1.7	0.75	2	3.8	1.27	4.2	1.48
Endocrine System	3	3.0	0.91	3.4	1.17	6	9.3	1.80	11.0	2.22
Thyroid gland	2	2.9	0.90	3.3	1.16	6	9.3	1.80	11.0	2.22
Lymphomas	8	12.6	2.53	14.2	2.91	7	16.2	2.98	18.7	3.43
Hodgkin Lymphoma	2	1.4	0.48	1.3	0.46	2	2.9	1.17	3.5	1.45
Non-Hodgkin Lymphoma	6	11.2	2.49	12.9	2.87	6	13.3	2.75	15.2	3.11
Multiple Myeloma	2	7.0	2.23	8.0	2.52	2	4.7	1.64	5.6	1.93
Leukemias	7	12.8	2.89	13.5	3.16	4	7.4	1.96	8.3	2.27
Acute lymphocytic	3	2.3	0.63	2.1	0.59	2	1.3	0.46	1.2	0.42
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	3.1	1.33	3.3	1.51	1	2.9	1.36	3.4	1.59
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	12.4	3.12	13.6	3.45	3	7.3	2.12	7.5	2.18
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	3.6	1.28	4.1	1.50	3	6.3	1.70	7.3	2.03
Breast (<i>in situ</i>)	-	-	-	-	-	7	13.4	2.45	16.7	3.06

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

ALABAMA

II-8 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,450	508.2	2.29	604.7	2.68	9,398	412.5	1.99	480.5	2.26
Oral Cavity & Pharynx	462	22.1	0.47	26.9	0.57	178	7.7	0.27	9.1	0.31
Lip	34	1.7	0.13	2.0	0.15	20	0.8	0.08	1.0	0.10
Tongue	137	6.5	0.26	7.9	0.31	47	2.1	0.15	2.5	0.17
Major salivary gland	46	2.3	0.16	2.7	0.18	25	1.1	0.11	1.2	0.12
Floor of mouth	20	0.9	0.09	1.1	0.12	10	0.4	0.06	0.5	0.07
Gum & other mouth	46	2.2	0.15	2.7	0.18	33	1.4	0.11	1.6	0.13
Nasopharynx	16	0.9	0.10	1.0	0.11	4	0.1	0.03	0.2	0.04
Oropharynx	26	1.2	0.11	1.5	0.13	7	0.3	0.05	0.4	0.06
Hypopharynx	23	1.1	0.10	1.3	0.12	5	0.2	0.04	0.2	0.05
Digestive System	2,006	97.8	1.01	117.3	1.19	1,521	64.0	0.76	75.4	0.88
Esophagus	173	8.2	0.29	9.9	0.34	36	1.4	0.11	1.8	0.13
Stomach	152	7.4	0.28	8.8	0.32	98	4.1	0.19	4.8	0.22
Small intestine	52	2.6	0.17	3.1	0.19	48	2.1	0.14	2.4	0.16
Colon excl. rectum	704	35.0	0.61	41.5	0.71	652	27.7	0.50	32.4	0.58
Rectum & rectosigmoid	284	14.0	0.38	16.8	0.45	190	8.4	0.28	9.9	0.33
Anus, anal canal & anorectum	28	1.4	0.12	1.7	0.14	62	2.7	0.16	3.2	0.19
Liver	223	10.2	0.31	12.9	0.39	83	3.4	0.17	4.1	0.20
Gallbladder	13	0.7	0.09	0.8	0.10	21	0.9	0.09	1.0	0.10
Pancreas	304	14.6	0.38	17.6	0.46	252	10.2	0.29	12.1	0.35
Respiratory System	1,959	93.2	0.96	111.6	1.14	1,434	57.1	0.69	68.7	0.82
Larynx	145	6.7	0.26	8.3	0.31	42	1.8	0.13	2.2	0.15
Lung & bronchus	1,791	85.2	0.92	101.9	1.09	1,375	54.6	0.67	65.7	0.80
Bones & Joints	20	1.1	0.12	1.2	0.12	16	0.8	0.10	0.9	0.10
Soft Tissue (incl. heart)	82	4.5	0.23	5.1	0.25	61	3.0	0.18	3.3	0.19
Skin (excl. basal & sq.)	752	38.3	0.65	44.6	0.74	504	24.8	0.52	27.8	0.57
Melanomas of the skin	713	36.2	0.63	42.2	0.72	478	23.6	0.51	26.5	0.55
Breast (excl. <i>in situ</i>)	34	1.7	0.13	2.0	0.16	2,725	120.5	1.08	141.6	1.24
Female Genital System	-	-	-	-	-	974	44.8	0.68	51.8	0.76
Cervix uteri	-	-	-	-	-	156	9.1	0.34	9.6	0.35
Uterus Corpus	-	-	-	-	-	435	18.7	0.42	22.5	0.49
Uterus, NOS ¹	-	-	-	-	-	17	0.8	0.09	0.9	0.10
Ovary	-	-	-	-	-	269	12.0	0.34	13.8	0.39
Male Genital System	2,292	105.2	1.01	128.4	1.21	-	-	-	-	-
Prostate	2,188	98.4	0.96	121.6	1.18	-	-	-	-	-
Testis	81	5.6	0.28	5.5	0.27	-	-	-	-	-
Penis	20	1.0	0.10	1.1	0.12	-	-	-	-	-
Urinary System	1,233	61.1	0.80	72.1	0.93	505	21.6	0.45	25.3	0.51
Bladder (incl. <i>in situ</i>)	726	36.0	0.61	42.4	0.72	197	7.9	0.26	9.3	0.30
Kidney & renal pelvis	483	24.0	0.51	28.3	0.58	295	13.1	0.36	15.3	0.41
Ureter	18	0.9	0.10	1.0	0.11	11	0.4	0.06	0.5	0.07
Eye & Orbit	25	1.3	0.12	1.5	0.13	18	0.8	0.09	0.9	0.10
Brain & Other CNS ¹	148	8.0	0.30	8.8	0.33	125	6.1	0.26	6.7	0.27
Brain	144	7.7	0.30	8.5	0.32	117	5.7	0.25	6.2	0.26
Endocrine System	122	6.6	0.28	7.3	0.30	305	16.9	0.45	18.2	0.48
Thyroid gland	107	5.8	0.26	6.5	0.28	292	16.2	0.45	17.5	0.47
Lymphomas	451	23.1	0.50	26.7	0.57	369	16.0	0.39	18.3	0.44
Hodgkin Lymphoma	44	2.6	0.18	2.8	0.19	35	2.1	0.16	2.1	0.16
Non-Hodgkin Lymphoma	407	20.5	0.47	24.0	0.54	334	14.0	0.35	16.2	0.40
Multiple Myeloma	140	6.8	0.27	8.1	0.31	107	4.2	0.19	5.1	0.22
Leukemias	303	16.0	0.42	18.0	0.47	220	10.0	0.32	11.1	0.34
Acute lymphocytic	28	1.9	0.16	1.7	0.14	20	1.4	0.14	1.2	0.12
Chronic lymphocytic	101	5.0	0.23	5.9	0.27	68	2.7	0.15	3.2	0.17
Acute myeloid	94	4.9	0.23	5.6	0.26	74	3.4	0.19	3.8	0.20
Chronic myeloid	36	1.9	0.15	2.1	0.16	28	1.3	0.12	1.4	0.13
Other leukemias	44	2.3	0.16	2.7	0.18	30	1.3	0.11	1.5	0.12
Mesothelioma	26	1.3	0.12	1.6	0.14	7	0.3	0.05	0.4	0.06
Kaposi Sarcoma	5	0.3	0.06	0.3	0.07	-	-	-	-	-
Ill-defined & Unknown	389	19.8	0.46	23.1	0.53	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	121	6.4	0.27	7.3	0.30	221	10.3	0.33	11.8	0.36
Breast (<i>in situ</i>)	4	0.2	0.05	0.2	0.05	523	23.5	0.48	27.9	0.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alabama, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,021	544.6	4.74	658.4	5.57	2,813	386.3	3.35	453.6	3.85
Oral Cavity & Pharynx	82	13.9	0.73	17.1	0.87	38	5.1	0.38	6.1	0.44
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	20	3.2	0.34	4.0	0.41	8	1.2	0.19	1.4	0.22
Major salivary gland	7	1.1	0.21	1.3	0.24	9	1.1	0.18	1.3	0.20
Floor of mouth	5	0.9	0.19	1.0	0.21	2	0.2	0.08	0.3	0.10
Gum & other mouth	10	1.8	0.26	2.1	0.30	8	1.2	0.19	1.4	0.21
Nasopharynx	6	1.1	0.21	1.3	0.24	2	0.3	0.09	0.4	0.11
Oropharynx	6	1.0	0.19	1.3	0.25	2	0.2	0.08	0.3	0.09
Hypopharynx	8	1.4	0.22	1.7	0.27	1	0.2	0.07	0.2	0.08
Digestive System	642	118.2	2.24	142.1	2.61	589	81.4	1.54	96.3	1.79
Esophagus	46	7.9	0.56	9.8	0.67	16	2.1	0.24	2.5	0.29
Stomach	70	13.6	0.79	16.4	0.92	58	8.3	0.50	9.7	0.57
Small intestine	20	3.6	0.38	4.3	0.44	24	3.4	0.32	4.0	0.36
Colon excl. rectum	222	42.6	1.37	50.3	1.57	248	34.4	1.00	40.7	1.16
Rectum & rectosigmoid	83	15.0	0.78	17.9	0.91	69	9.4	0.52	11.1	0.60
Anus, anal canal & anorectum	10	2.0	0.28	2.1	0.30	10	1.3	0.19	1.6	0.23
Liver	80	12.4	0.66	16.1	0.82	27	3.5	0.31	4.3	0.37
Gallbladder	4	1.0	0.22	1.1	0.24	11	1.5	0.21	1.8	0.24
Pancreas	87	16.4	0.85	19.8	0.99	104	14.5	0.65	17.2	0.76
Respiratory System	522	96.1	2.02	116.7	2.37	289	39.4	1.06	47.3	1.25
Larynx	56	9.6	0.61	11.9	0.74	8	1.1	0.17	1.3	0.21
Lung & bronchus	461	85.5	1.91	103.6	2.24	276	37.6	1.04	45.2	1.22
Bones & Joints	8	1.4	0.24	1.4	0.25	8	1.1	0.17	1.2	0.19
Soft Tissue (incl. heart)	20	3.7	0.39	4.0	0.42	24	3.4	0.31	3.8	0.35
Skin (excl. basal & sq.)	9	1.8	0.28	2.0	0.31	13	1.9	0.24	2.1	0.27
Melanomas of the skin	6	1.2	0.23	1.4	0.26	8	1.2	0.19	1.3	0.21
Breast (excl. <i>in situ</i>)	10	2.1	0.31	2.5	0.36	932	126.7	1.91	149.3	2.20
Female Genital System	-	-	-	-	-	340	46.8	1.17	54.4	1.33
Cervix uteri	-	-	-	-	-	72	10.5	0.57	11.4	0.61
Uterus Corpus	-	-	-	-	-	154	20.3	0.75	24.6	0.89
Uterus, NOS ¹	-	-	-	-	-	16	2.2	0.25	2.6	0.29
Ovary	-	-	-	-	-	73	10.1	0.54	11.7	0.62
Male Genital System	1,103	189.8	2.73	235.7	3.28	-	-	-	-	-
Prostate	1,090	187.5	2.71	233.3	3.27	-	-	-	-	-
Testis	8	1.4	0.24	1.4	0.24	-	-	-	-	-
Penis	4	0.6	0.16	0.8	0.18	-	-	-	-	-
Urinary System	239	45.0	1.39	53.3	1.60	146	19.9	0.76	23.6	0.88
Bladder (incl. <i>in situ</i>)	91	18.8	0.95	22.0	1.08	45	6.3	0.43	7.5	0.50
Kidney & renal pelvis	146	25.9	1.01	30.9	1.18	97	13.1	0.61	15.5	0.71
Ureter	-	-	-	-	-	2	0.2	0.08	0.3	0.09
Eye & Orbit	2	0.4	0.12	0.4	0.12	-	-	-	-	-
Brain & Other CNS ¹	30	5.1	0.43	5.6	0.48	27	3.7	0.33	4.0	0.35
Brain	28	4.8	0.42	5.3	0.47	23	3.2	0.30	3.5	0.32
Endocrine System	23	4.1	0.40	4.6	0.44	76	10.6	0.56	11.7	0.61
Thyroid gland	16	2.9	0.34	3.4	0.39	67	9.4	0.53	10.4	0.57
Lymphomas	100	18.5	0.88	20.8	0.97	88	12.3	0.60	13.9	0.67
Hodgkin Lymphoma	17	3.0	0.34	3.2	0.35	16	2.4	0.27	2.4	0.27
Non-Hodgkin Lymphoma	83	15.5	0.81	17.6	0.91	72	9.9	0.54	11.5	0.61
Multiple Myeloma	79	15.2	0.82	18.2	0.96	88	12.3	0.60	14.5	0.69
Leukemias	60	11.4	0.70	13.0	0.79	52	7.2	0.46	8.2	0.51
Acute lymphocytic	5	0.9	0.19	0.9	0.19	4	0.6	0.13	0.5	0.12
Chronic lymphocytic	23	4.6	0.45	5.3	0.52	14	1.8	0.22	2.2	0.27
Acute myeloid	15	2.8	0.34	3.2	0.39	17	2.4	0.27	2.7	0.29
Chronic myeloid	9	1.6	0.24	1.8	0.27	9	1.3	0.20	1.4	0.21
Other leukemias	8	1.5	0.26	1.8	0.30	8	1.1	0.18	1.3	0.20
Mesothelioma	3	0.6	0.16	0.7	0.18	1	0.2	0.08	0.2	0.09
Kaposi Sarcoma	4	0.8	0.17	0.8	0.18	-	-	-	-	-
Ill-defined & Unknown	85	16.6	0.87	19.6	1.00	102	14.3	0.65	16.7	0.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	30	5.4	0.47	6.1	0.52	74	10.5	0.56	12.0	0.63
Breast (<i>in situ</i>)	-	-	-	-	-	198	27.0	0.88	31.8	1.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


ALABAMA

II-10 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	737,045	736,307	737,547	741,504	739,786
White	519,447	517,008	515,824	516,129	512,003
Black	34,990	34,963	35,152	35,974	36,398
American Indian/Alaskan Native (AI/AN)	124,835	125,767	126,650	127,563	127,766
Asian/Pacific Islander (API)	57,773	58,569	59,921	61,838	63,619


All Races Population 2013-2017: 3,692,189
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	47,670	49,258	50,549	52,137	53,075
Non-Hispanic White	483,946	480,449	478,623	477,934	472,930
Non-Hispanic Black	31,422	31,322	31,328	32,030	32,382

Hispanic/Latino Population, Census 2010: 39,249
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ALASKA CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.1	104.1	100.6	99.2	105.0
Missing Race	0.3	0.2	0.5	0.2	0.5
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.5	1.8	1.7	0.9	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.8	Prostate	90.1
Oral Cavity & Pharynx	96.8	Testis	99.2
Esophagus	93.9	Bladder (incl. <i>in situ</i>)	95.4
Stomach	96.3	Kidney & Renal Pelvis	87.9
Colon & Rectum	94.9	Brain & Other CNS ¹	81.8
Liver	51.9	Thyroid	98.0
Pancreas	77.4	Hodgkin Lymphoma	97.0
Lung & Bronchus	85.9	Non-Hodgkin Lymphoma	95.3
Melanomas of the Skin	98.1	Multiple Myeloma	82.9
Female Breast (excl. <i>in situ</i>)	98.2	Leukemias	84.4
Cervix uteri	99.2	Brain & Other CNS ¹ <i>non-malig</i>	35.4
Uterus Corpus & Uterus NOS ¹	98.3	Breast <i>in situ</i>	100.0
Ovary	92.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,484	437.2	5.64	513.5	6.46	1,380	403.2	5.11	469.8	5.81
Oral Cavity & Pharynx	61	15.0	0.93	18.5	1.11	21	5.9	0.62	7.1	0.72
Lip	2	0.6	0.22	0.8	0.25	-	-	-	-	-
Tongue	18	4.3	0.48	5.4	0.58	6	1.7	0.33	2.1	0.38
Major salivary gland	2	0.7	0.24	0.8	0.27	3	0.9	0.24	1.0	0.28
Floor of mouth	-	-	-	-	-	2	0.5	0.18	0.7	0.21
Gum & other mouth	6	1.6	0.35	2.0	0.41	3	1.0	0.25	1.2	0.29
Nasopharynx	6	1.3	0.27	1.6	0.32	2	0.6	0.21	0.7	0.23
Oropharynx	4	0.9	0.20	1.2	0.26	-	-	-	-	-
Hypopharynx	5	1.3	0.29	1.5	0.32	-	-	-	-	-
Digestive System	343	99.9	2.68	118.4	3.08	248	74.3	2.23	87.8	2.56
Esophagus	30	8.8	0.82	10.7	0.95	10	2.9	0.44	3.5	0.52
Stomach	35	10.8	0.89	12.5	1.01	18	5.3	0.59	6.3	0.68
Small intestine	8	2.4	0.42	2.7	0.46	7	1.9	0.34	2.3	0.40
Colon excl. rectum	99	29.3	1.47	34.5	1.68	94	29.2	1.42	34.0	1.62
Rectum & rectosigmoid	57	15.8	1.02	18.8	1.18	39	11.5	0.86	13.5	0.99
Anus, anal canal & anorectum	6	1.8	0.38	2.2	0.44	8	2.1	0.35	2.6	0.41
Liver	45	11.4	0.84	14.2	1.00	17	4.8	0.55	5.7	0.64
Gallbladder	3	1.1	0.34	1.3	0.39	4	0.9	0.23	1.2	0.28
Pancreas	45	13.9	1.03	16.4	1.18	39	11.5	0.88	13.8	1.02
Respiratory System	222	70.5	2.36	82.8	2.70	160	49.3	1.84	58.4	2.12
Larynx	16	4.3	0.53	5.2	0.63	3	0.9	0.24	1.0	0.27
Lung & bronchus	202	64.8	2.28	76.0	2.59	155	47.6	1.81	56.4	2.09
Bones & Joints	4	1.0	0.27	1.1	0.30	3	0.8	0.23	0.9	0.24
Soft Tissue (incl. heart)	16	4.4	0.54	5.0	0.61	9	2.3	0.36	2.6	0.41
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	54	16.7	1.12	18.9	1.25	43	12.3	0.88	13.8	0.97
Breast (excl. <i>in situ</i>)	4	1.0	0.26	1.2	0.29	421	120.1	2.75	140.8	3.13
Female Genital System	-	-	-	-	-	170	46.6	1.68	55.0	1.93
Cervix uteri	-	-	-	-	-	24	7.2	0.68	7.6	0.70
Uterus Corpus	-	-	-	-	-	89	23.3	1.16	28.5	1.38
Uterus, NOS ¹	-	-	-	-	-	3	0.9	0.24	1.1	0.28
Ovary	-	-	-	-	-	35	9.9	0.79	11.4	0.89
Male Genital System	331	90.5	2.47	109.1	2.88	-	-	-	-	-
Prostate	303	83.4	2.39	101.8	2.81	-	-	-	-	-
Testis	25	6.0	0.56	6.0	0.55	-	-	-	-	-
Penis	2	0.7	0.25	0.9	0.29	-	-	-	-	-
Urinary System	186	58.3	2.13	67.9	2.43	77	22.8	1.23	26.7	1.40
Bladder (incl. <i>in situ</i>)	101	34.4	1.71	40.0	1.95	29	8.8	0.78	10.4	0.89
Kidney & renal pelvis	82	22.6	1.22	26.5	1.39	47	13.7	0.94	15.9	1.06
Ureter	2	1.0	0.34	1.2	0.38	-	-	-	-	-
Eye & Orbit	2	0.4	0.14	0.4	0.16	4	1.3	0.28	1.5	0.32
Brain & Other CNS ¹	27	7.0	0.64	7.6	0.68	19	5.6	0.59	6.2	0.65
Brain	26	6.8	0.63	7.4	0.68	18	5.2	0.57	5.8	0.62
Endocrine System	27	7.0	0.63	7.9	0.70	71	20.1	1.11	21.4	1.16
Thyroid gland	24	6.3	0.60	7.1	0.67	67	19.2	1.08	20.5	1.13
Lymphomas	77	23.0	1.29	26.3	1.46	52	15.0	0.99	17.5	1.12
Hodgkin Lymphoma	8	2.0	0.33	2.0	0.33	6	1.6	0.31	1.7	0.33
Non-Hodgkin Lymphoma	69	21.0	1.25	24.3	1.42	46	13.5	0.94	15.8	1.07
Multiple Myeloma	20	5.8	0.65	6.8	0.74	13	4.0	0.52	4.7	0.60
Leukemias	48	14.2	1.00	15.7	1.10	28	9.1	0.79	9.8	0.86
Acute lymphocytic	5	1.2	0.26	1.1	0.22	5	1.3	0.27	1.1	0.23
Chronic lymphocytic	14	4.2	0.56	5.0	0.65	6	1.9	0.37	2.3	0.43
Acute myeloid	15	4.4	0.55	4.8	0.59	10	3.3	0.48	3.7	0.54
Chronic myeloid	7	2.1	0.40	2.3	0.44	4	1.4	0.32	1.5	0.33
Other leukemias	-	-	-	-	-	3	1.1	0.29	1.3	0.33
Mesothelioma	5	2.0	0.43	2.3	0.48	2	0.5	0.19	0.6	0.20
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	54	18.6	1.26	21.8	1.45	36	11.8	0.92	13.5	1.04
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	31	9.3	0.83	10.6	0.94	54	16.3	1.04	18.7	1.16
Breast (<i>in situ</i>)	-	-	-	-	-	101	27.6	1.28	32.8	1.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,158	432.0	6.30	508.2	7.21	1,004	395.4	5.89	460.3	6.67
Oral Cavity & Pharynx	48	15.3	1.08	18.7	1.27	14	5.3	0.68	6.3	0.78
Lip	2	0.8	0.27	0.9	0.31	-	-	-	-	-
Tongue	16	4.8	0.57	6.0	0.69	5	1.9	0.41	2.2	0.46
Major salivary gland	2	0.9	0.30	1.0	0.34	2	0.8	0.27	0.9	0.30
Floor of mouth	-	-	-	-	-	1	0.4	0.15	0.5	0.20
Gum & other mouth	4	1.6	0.39	1.9	0.47	3	1.1	0.31	1.3	0.36
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	4	1.1	0.25	1.3	0.31	-	-	-	-	-
Hypopharynx	4	1.3	0.32	1.5	0.35	-	-	-	-	-
Digestive System	240	87.6	2.81	104.4	3.24	156	62.9	2.38	74.1	2.73
Esophagus	23	8.4	0.89	10.2	1.04	6	2.5	0.48	2.9	0.54
Stomach	19	7.6	0.86	8.8	0.97	9	3.5	0.55	4.2	0.64
Small intestine	7	2.9	0.52	3.2	0.57	6	2.3	0.44	2.7	0.51
Colon excl. rectum	67	25.4	1.55	30.0	1.78	59	24.7	1.52	28.6	1.72
Rectum & rectosigmoid	39	13.5	1.04	16.0	1.19	22	8.2	0.84	9.9	0.98
Anus, anal canal & anorectum	5	1.8	0.41	2.2	0.48	7	2.4	0.44	2.9	0.51
Liver	33	10.3	0.88	13.1	1.06	9	3.6	0.57	4.2	0.64
Gallbladder	2	1.1	0.38	1.2	0.43	2	0.8	0.27	1.0	0.31
Pancreas	34	13.0	1.12	15.3	1.28	28	11.1	0.99	13.4	1.16
Respiratory System	164	65.3	2.55	76.8	2.91	113	45.8	2.05	54.6	2.38
Larynx	12	3.6	0.51	4.5	0.62	2	0.9	0.27	1.1	0.32
Lung & bronchus	149	60.3	2.46	70.8	2.81	109	44.2	2.02	52.6	2.33
Bones & Joints	2	1.0	0.32	1.1	0.36	1	0.5	0.21	0.6	0.23
Soft Tissue (incl. heart)	12	4.7	0.65	5.2	0.72	7	2.5	0.44	2.9	0.51
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	51	20.4	1.39	23.0	1.55	38	15.4	1.16	17.1	1.26
Breast (excl. <i>in situ</i>)	4	1.3	0.33	1.5	0.37	317	122.5	3.25	143.3	3.68
Female Genital System	-	-	-	-	-	130	47.7	1.98	56.6	2.27
Cervix uteri	-	-	-	-	-	17	6.8	0.77	7.1	0.79
Uterus Corpus	-	-	-	-	-	68	23.8	1.36	29.4	1.63
Uterus, NOS ¹	-	-	-	-	-	3	0.9	0.28	1.2	0.34
Ovary	-	-	-	-	-	28	10.8	0.97	12.4	1.08
Male Genital System	276	94.0	2.80	113.5	3.27	-	-	-	-	-
Prostate	255	86.8	2.70	106.2	3.18	-	-	-	-	-
Testis	19	6.4	0.68	6.4	0.67	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	154	61.9	2.48	72.2	2.83	56	22.5	1.42	26.2	1.61
Bladder (incl. <i>in situ</i>)	89	38.5	2.03	44.7	2.32	24	9.4	0.91	11.1	1.05
Kidney & renal pelvis	63	22.2	1.37	26.1	1.56	32	12.9	1.08	14.8	1.20
Ureter	2	1.1	0.40	1.3	0.46	-	-	-	-	-
Eye & Orbit	2	0.5	0.18	0.6	0.21	4	1.4	0.35	1.7	0.40
Brain & Other CNS ¹	22	7.8	0.78	8.5	0.83	16	6.3	0.75	7.1	0.82
Brain	22	7.6	0.77	8.3	0.83	15	5.9	0.73	6.6	0.79
Endocrine System	21	6.9	0.72	7.9	0.79	49	19.5	1.28	20.7	1.34
Thyroid gland	19	6.2	0.67	7.1	0.75	47	18.3	1.24	19.6	1.30
Lymphomas	62	23.8	1.48	27.2	1.66	41	16.1	1.20	18.7	1.35
Hodgkin Lymphoma	6	2.2	0.41	2.3	0.42	4	1.7	0.40	1.8	0.41
Non-Hodgkin Lymphoma	56	21.6	1.43	24.9	1.61	-	-	-	-	-
Multiple Myeloma	14	5.3	0.69	6.2	0.79	10	4.2	0.63	4.9	0.71
Leukemias	36	13.7	1.11	15.2	1.22	23	10.2	0.99	11.2	1.08
Acute lymphocytic	3	1.1	0.30	0.9	0.26	2	1.0	0.30	0.8	0.25
Chronic lymphocytic	13	4.9	0.67	5.8	0.77	6	2.4	0.48	2.8	0.55
Acute myeloid	11	4.0	0.59	4.4	0.63	10	4.3	0.64	4.8	0.71
Chronic myeloid	5	2.0	0.44	2.2	0.48	4	1.7	0.41	1.8	0.43
Other leukemias	5	1.8	0.40	1.9	0.43	2	0.8	0.29	0.9	0.33
Mesothelioma	5	2.2	0.50	2.4	0.55	2	0.7	0.25	0.8	0.27
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	43	18.8	1.44	22.1	1.67	25	10.7	1.02	12.3	1.14
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	21	7.9	0.84	9.1	0.95	39	15.9	1.19	18.1	1.33
Breast (<i>in situ</i>)	-	-	-	-	-	80	28.6	1.51	34.3	1.75

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	40	405.3	35.68	479.4	40.54	33	324.9	27.85	390.7	32.59
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	7	81.5	16.77	93.4	18.59	5	49.8	11.11	63.3	13.63
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	17.3	6.84	20.3	7.51	2	16.0	6.17	20.5	7.66
Rectum & rectosigmoid	1	19.5	9.01	22.0	9.71	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	17.7	6.94	19.4	7.43	-	-	-	-	-
Respiratory System	5	62.8	15.07	73.4	16.82	4	53.1	12.29	59.9	13.62
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	61.0	14.95	71.0	16.65	4	46.2	11.28	52.9	12.68
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	11	102.7	14.73	125.5	17.60
Female Genital System	-	-	-	-	-	2	21.3	6.60	25.6	7.66
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	17.4	6.21	20.5	7.04
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	15	138.5	20.26	171.5	23.86	-	-	-	-	-
Prostate	14	134.8	20.15	167.7	23.76	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	16.6	5.78	19.7	6.61	2	27.3	8.71	32.7	9.94
Bladder (incl. <i>in situ</i>)	1	12.6	5.40	15.1	6.14	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	2	21.3	7.90	25.5	8.97
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	6.7	2.79	7.9	3.35	-	-	-	-	-
Brain	1	6.7	2.79	7.9	3.35	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	17.3	5.78	19.8	6.51
Thyroid gland	-	-	-	-	-	2	16.4	5.71	19.1	6.48
Lymphomas	3	23.0	7.99	25.5	8.44	2	19.0	7.37	22.4	8.42
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	22.5	7.97	24.9	8.42	1	17.4	7.20	20.4	8.18
Multiple Myeloma	2	25.6	8.85	29.5	10.02	-	-	-	-	-
Leukemias	2	26.7	9.99	29.3	10.77	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	1	12.0	5.22	14.4	6.05
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	20.7	7.95	23.1	8.86
Breast (<i>in situ</i>)	-	-	-	-	-	2	23.5	7.85	27.2	8.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	57	309.2	20.74	354.3	23.29	82	290.2	14.95	331.5	16.86
Oral Cavity & Pharynx	2	9.2	3.14	10.5	3.47	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	4.8	2.04	5.6	2.32	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	17	99.1	12.14	114.8	13.77	15	52.7	6.38	62.5	7.42
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	3	18.0	5.63	20.6	6.39	2	8.8	2.64	10.4	3.07
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	22.5	5.20	26.3	5.89	4	12.2	2.92	15.0	3.53
Rectum & rectosigmoid	3	17.4	4.92	20.9	5.82	3	8.8	2.44	10.8	2.91
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	23.0	5.99	26.5	6.77	1	6.2	2.39	6.8	2.61
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	3	10.8	3.02	12.6	3.45
Respiratory System	10	56.3	9.15	64.8	10.24	8	32.1	5.35	36.8	6.01
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	54.9	9.10	63.0	10.16	8	32.1	5.35	36.8	6.01
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	24	81.2	7.71	93.8	8.77
Female Genital System	-	-	-	-	-	14	45.8	5.64	51.8	6.35
Cervix uteri	-	-	-	-	-	2	5.5	2.01	5.7	2.09
Uterus Corpus	-	-	-	-	-	9	29.2	4.41	33.0	4.96
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	9.6	2.64	11.1	3.04
Male Genital System	10	54.6	8.46	62.0	9.35	-	-	-	-	-
Prostate	9	48.9	8.24	56.2	9.15	-	-	-	-	-
Testis	1	4.6	1.78	4.3	1.63	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	4	24.5	5.74	27.1	6.27	4	18.1	4.08	20.2	4.51
Bladder (incl. <i>in situ</i>)	1	9.0	3.76	10.4	4.32	2	7.6	2.73	8.5	3.05
Kidney & renal pelvis	3	13.7	3.95	14.8	4.18	2	8.7	2.74	9.8	3.03
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	1	3.8	1.56	3.9	1.62
Brain	-	-	-	-	-	1	3.8	1.56	3.9	1.62
Endocrine System	1	4.3	1.75	5.5	2.26	7	22.9	4.00	23.3	4.07
Thyroid gland	1	4.3	1.75	5.5	2.26	7	22.9	4.00	23.3	4.07
Lymphomas	5	25.8	6.08	30.4	7.06	2	5.3	1.92	5.9	2.14
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	5	24.7	6.03	29.4	7.03	1	4.2	1.76	4.8	1.99
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	10.9	3.65	11.3	3.91	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	15.9	4.79	17.9	5.35	4	17.0	3.89	19.9	4.45
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	11.1	3.44	11.5	3.53	3	12.0	3.27	13.7	3.61
Breast (<i>in situ</i>)	-	-	-	-	-	5	18.0	3.81	20.0	4.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	221	514.9	17.15	604.2	19.79	257	513.4	14.96	602.8	17.25
Oral Cavity & Pharynx	10	18.1	2.66	23.1	3.31	6	11.7	2.24	14.1	2.64
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	3.6	1.27	4.6	1.55	1	2.5	0.97	3.2	1.20
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	3	6.0	1.49	7.6	1.86	2	3.7	1.31	4.2	1.45
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	78	178.8	9.90	211.4	11.46	71	148.9	8.22	176.5	9.57
Esophagus	6	14.7	2.86	17.6	3.34	3	6.4	1.63	8.4	2.09
Stomach	12	27.0	3.62	31.2	4.10	6	12.8	2.35	15.0	2.71
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	25	58.7	5.72	68.9	6.56	29	63.8	5.50	74.2	6.31
Rectum & rectosigmoid	13	28.8	3.97	34.7	4.70	15	30.7	3.73	35.1	4.20
Anus, anal canal & anorectum	-	-	-	-	-	1	1.9	0.79	2.6	1.04
Liver	7	14.3	2.47	17.1	2.90	6	10.4	2.01	13.2	2.52
Gallbladder	-	-	-	-	-	1	2.1	0.78	3.0	1.12
Pancreas	9	21.7	3.65	25.7	4.24	6	13.7	2.54	16.6	3.01
Respiratory System	42	111.5	8.40	130.8	9.64	35	74.3	5.84	88.1	6.74
Larynx	3	9.7	2.64	11.1	2.99	-	-	-	-	-
Lung & bronchus	38	99.4	7.89	117.1	9.07	35	73.0	5.78	86.7	6.69
Bones & Joints	-	-	-	-	-	1	2.4	1.01	2.4	0.98
Soft Tissue (incl. heart)	2	3.8	1.17	4.6	1.41	-	-	-	-	-
Skin (excl. basal & sq.)	3	6.2	1.83	6.4	1.90	3	5.4	1.40	6.8	1.73
Melanomas of the skin	2	4.8	1.67	4.7	1.70	3	5.4	1.40	6.8	1.73
Breast (excl. <i>in situ</i>)	-	-	-	-	-	68	132.4	7.46	156.5	8.63
Female Genital System	-	-	-	-	-	23	44.0	4.27	51.6	4.94
Cervix uteri	-	-	-	-	-	6	12.1	2.32	12.8	2.46
Uterus Corpus	-	-	-	-	-	9	16.7	2.55	20.4	3.06
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	7.0	1.60	8.7	1.97
Male Genital System	27	65.3	6.35	77.7	7.43	-	-	-	-	-
Prostate	22	56.2	6.00	67.7	7.06	-	-	-	-	-
Testis	4	5.6	1.32	6.0	1.42	-	-	-	-	-
Penis	1	3.5	1.60	4.1	1.86	-	-	-	-	-
Urinary System	25	56.8	5.65	66.7	6.53	14	26.7	3.35	31.7	3.92
Bladder (incl. <i>in situ</i>)	8	21.9	3.80	25.8	4.40	3	6.6	1.84	7.7	2.11
Kidney & renal pelvis	16	33.0	4.03	39.0	4.69	11	19.6	2.75	23.5	3.26
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	3	4.9	1.29	4.8	1.34	2	3.4	1.10	3.6	1.17
Brain	3	4.7	1.27	4.6	1.33	2	3.0	1.00	3.1	1.06
Endocrine System	4	8.6	1.99	9.0	2.09	12	21.9	2.96	23.6	3.19
Thyroid gland	4	7.7	1.93	8.0	2.02	11	21.4	2.94	23.0	3.15
Lymphomas	7	15.4	2.97	17.7	3.38	7	13.5	2.38	15.8	2.76
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	6.6	2.20	7.5	2.52	2	3.8	1.31	4.5	1.52
Leukemias	8	15.6	2.81	17.6	3.23	4	7.4	1.68	7.9	1.84
Acute lymphocytic	2	1.9	0.65	1.6	0.54	2	2.1	0.72	1.9	0.69
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	3	4.7	1.50	5.5	1.73	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	2	4.8	1.66	5.6	1.97	2	3.5	1.28	4.1	1.45
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	8	19.2	3.32	22.3	3.75	6	14.0	2.66	16.0	3.01
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	6	15.3	3.32	17.9	3.90	11	21.0	2.99	24.3	3.39
Breast (<i>in situ</i>)	-	-	-	-	-	14	28.8	3.51	33.5	3.98

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	36	345.1	32.14	405.0	36.57	43	335.6	26.42	381.0	29.53
Oral Cavity & Pharynx	-	-	-	-	-	1	7.5	3.09	10.0	4.13
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	11	91.2	14.42	108.0	16.21	6	51.6	11.17	60.5	12.82
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	16.8	6.22	18.6	6.71	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	17.7	5.95	21.9	7.00	2	15.8	4.96	20.5	6.30
Rectum & rectosigmoid	2	15.6	5.39	18.9	6.34	1	6.1	2.56	7.1	2.98
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	17.6	6.70	21.4	7.59	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	10.7	5.19	13.4	5.94	-	-	-	-	-
Respiratory System	4	46.4	12.13	55.9	14.16	3	23.4	7.31	28.7	8.52
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	42.6	11.75	52.1	13.80	2	19.8	6.37	25.2	7.74
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	16	123.0	16.24	138.5	17.90
Female Genital System	-	-	-	-	-	7	47.8	9.28	54.8	10.68
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	3	20.7	6.06	23.8	7.03
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	14.3	5.81	15.7	6.47
Male Genital System	7	60.6	13.41	75.0	15.86	-	-	-	-	-
Prostate	6	57.0	13.32	71.2	15.77	-	-	-	-	-
Testis	1	3.6	1.60	3.8	1.69	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	65.3	15.96	75.8	18.31	1	12.8	5.70	14.1	6.00
Bladder (incl. <i>in situ</i>)	2	31.4	11.85	38.8	14.33	-	-	-	-	-
Kidney & renal pelvis	3	33.9	10.69	37.0	11.40	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	3	17.4	4.70	16.7	4.61
Thyroid gland	-	-	-	-	-	3	14.9	3.92	13.9	3.71
Lymphomas	2	18.0	6.70	20.7	7.38	2	18.8	6.11	21.3	6.84
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	19.5	8.43	21.0	9.27	2	11.1	4.36	12.2	4.82
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	20.8	8.31	23.1	9.01	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	14.6	6.03	16.3	6.46	2	13.4	5.82	16.2	7.09
Breast (<i>in situ</i>)	-	-	-	-	-	2	19.4	6.42	23.9	7.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

ALASKA

II-18 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,127	434.9	6.42	511.5	7.34	966	396.8	6.03	462.3	6.82
Oral Cavity & Pharynx	47	15.6	1.11	19.1	1.30	13	5.2	0.69	6.2	0.79
Lip	2	0.8	0.28	0.9	0.32	-	-	-	-	-
Tongue	16	4.9	0.59	6.2	0.71	4	1.8	0.42	2.1	0.47
Major salivary gland	2	0.9	0.31	1.0	0.34	2	0.8	0.29	0.9	0.32
Floor of mouth	-	-	-	-	-	1	0.4	0.16	0.5	0.21
Gum & other mouth	4	1.6	0.40	2.0	0.48	3	1.1	0.31	1.3	0.36
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	4	1.1	0.26	1.4	0.32	-	-	-	-	-
Hypopharynx	4	1.3	0.33	1.5	0.37	-	-	-	-	-
Digestive System	230	87.0	2.85	103.7	3.29	152	63.5	2.44	74.8	2.79
Esophagus	22	8.5	0.91	10.3	1.07	6	2.6	0.50	3.0	0.56
Stomach	17	7.0	0.84	8.2	0.96	9	3.5	0.56	4.2	0.65
Small intestine	7	2.9	0.53	3.2	0.58	6	2.4	0.46	2.9	0.53
Colon excl. rectum	65	25.6	1.58	30.3	1.82	57	25.2	1.57	29.1	1.77
Rectum & rectosigmoid	37	13.4	1.06	15.8	1.21	21	8.3	0.86	9.9	1.00
Anus, anal canal & anorectum	4	1.6	0.40	2.0	0.47	7	2.4	0.45	3.0	0.52
Liver	32	10.1	0.88	12.8	1.07	8	3.3	0.54	3.8	0.61
Gallbladder	2	1.1	0.39	1.2	0.44	2	0.8	0.27	0.9	0.30
Pancreas	33	13.0	1.13	15.3	1.30	28	11.4	1.02	13.7	1.19
Respiratory System	160	65.7	2.59	77.3	2.96	110	46.5	2.10	55.4	2.44
Larynx	12	3.7	0.53	4.6	0.64	2	0.8	0.25	1.0	0.31
Lung & bronchus	146	60.8	2.51	71.3	2.86	106	45.0	2.07	53.5	2.39
Bones & Joints	2	1.1	0.33	1.2	0.38	1	0.6	0.22	0.6	0.24
Soft Tissue (incl. heart)	12	4.8	0.68	5.4	0.75	6	2.3	0.44	2.8	0.51
Skin (excl. basal & sq.)	54	22.7	1.50	25.4	1.66	41	17.3	1.27	19.2	1.37
Melanomas of the skin	51	21.1	1.44	23.7	1.60	38	16.1	1.22	17.8	1.32
Breast (excl. <i>in situ</i>)	4	1.4	0.34	1.6	0.38	303	121.8	3.30	142.7	3.75
Female Genital System	-	-	-	-	-	124	47.2	2.01	56.3	2.31
Cervix uteri	-	-	-	-	-	16	6.9	0.81	7.2	0.82
Uterus Corpus	-	-	-	-	-	66	23.7	1.38	29.5	1.66
Uterus, NOS ¹	-	-	-	-	-	2	0.9	0.28	1.1	0.34
Ovary	-	-	-	-	-	26	10.5	0.98	12.1	1.09
Male Genital System	270	95.2	2.86	114.8	3.34	-	-	-	-	-
Prostate	251	87.8	2.75	107.4	3.24	-	-	-	-	-
Testis	18	6.6	0.72	6.6	0.71	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	149	61.8	2.51	72.0	2.86	55	22.7	1.45	26.5	1.64
Bladder (incl. <i>in situ</i>)	87	38.7	2.06	44.9	2.35	23	9.5	0.94	11.3	1.08
Kidney & renal pelvis	60	21.9	1.38	25.8	1.57	31	13.0	1.10	14.9	1.23
Ureter	2	1.2	0.41	1.3	0.47	-	-	-	-	-
Eye & Orbit	2	0.5	0.19	0.6	0.22	4	1.5	0.36	1.8	0.42
Brain & Other CNS ¹	22	8.0	0.81	8.7	0.87	15	6.5	0.78	7.3	0.86
Brain	21	7.8	0.80	8.6	0.86	14	6.1	0.76	6.8	0.82
Endocrine System	20	7.2	0.75	8.1	0.83	47	19.8	1.33	21.1	1.39
Thyroid gland	18	6.4	0.70	7.3	0.78	45	18.7	1.29	20.0	1.35
Lymphomas	60	24.1	1.52	27.4	1.70	39	16.0	1.22	18.6	1.38
Hodgkin Lymphoma	6	2.4	0.44	2.5	0.45	4	1.7	0.41	1.8	0.43
Non-Hodgkin Lymphoma	54	21.7	1.46	24.9	1.64	35	14.3	1.15	16.8	1.31
Multiple Myeloma	14	5.3	0.70	6.2	0.80	10	4.3	0.65	5.0	0.73
Leukemias	35	13.7	1.13	15.3	1.24	21	10.0	1.01	11.0	1.10
Acute lymphocytic	2	1.1	0.31	0.9	0.28	2	0.8	0.28	0.6	0.22
Chronic lymphocytic	12	4.7	0.66	5.6	0.77	5	2.3	0.49	2.7	0.56
Acute myeloid	10	4.1	0.61	4.5	0.65	10	4.5	0.67	5.0	0.74
Chronic myeloid	5	2.1	0.46	2.3	0.50	3	1.7	0.42	1.8	0.44
Other leukemias	4	1.8	0.41	1.9	0.44	1	0.7	0.28	0.8	0.33
Mesothelioma	5	2.2	0.51	2.5	0.56	1	0.5	0.21	0.6	0.23
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	20	7.7	0.85	8.8	0.95	38	16.0	1.23	18.2	1.36
Breast (<i>in situ</i>)	-	-	-	-	-	78	29.3	1.57	35.1	1.81

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alaska, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	38	408.7	36.65	482.2	41.54	32	341.1	29.66	410.8	34.73
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	7	85.3	17.75	97.2	19.60	5	53.4	11.91	67.9	14.62
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	17.2	7.14	19.6	7.73	2	17.1	6.59	21.9	8.19
Rectum & rectosigmoid	1	20.8	9.68	23.5	10.45	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	18.8	7.36	20.6	7.86	-	-	-	-	-
Respiratory System	5	66.1	15.87	77.1	17.68	4	57.0	13.16	64.2	14.59
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	64.2	15.75	74.6	17.50	4	49.9	12.13	56.9	13.63
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	11	105.4	15.59	129.3	18.63
Female Genital System	-	-	-	-	-	2	21.1	6.86	25.5	7.96
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	16.9	6.41	19.9	7.26
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	14	137.0	20.28	169.2	23.81	-	-	-	-	-
Prostate	14	133.0	20.15	165.2	23.69	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	17.7	6.14	20.9	7.00	2	28.9	9.21	34.7	10.54
Bladder (incl. <i>in situ</i>)	1	13.3	5.71	15.9	6.49	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	2	22.6	8.36	27.0	9.53
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	7.2	3.00	8.4	3.57	-	-	-	-	-
Brain	1	7.2	3.00	8.4	3.57	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	17.5	6.07	20.2	6.87
Thyroid gland	-	-	-	-	-	2	16.5	5.99	19.4	6.83
Lymphomas	3	24.5	8.47	27.0	8.93	2	20.7	8.01	24.4	9.16
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	25.9	9.42	29.7	10.62	-	-	-	-	-
Leukemias	2	21.9	9.30	24.6	10.25	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	1	12.6	5.47	15.2	6.36
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	22.4	8.56	24.9	9.53
Breast (<i>in situ</i>)	-	-	-	-	-	2	23.8	8.27	27.0	9.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,634,999	6,733,840	6,833,596	6,945,452	7,048,876
White	5,653,318	5,722,119	5,793,292	5,871,895	5,947,741
Black	347,372	359,039	372,196	386,552	399,158
American Indian/Alaskan Native (AI/AN)	377,970	384,354	389,979	396,282	401,632
Asian/Pacific Islander (API)	256,339	268,328	278,129	290,723	300,345


All Races Population 2013-2017: 34,196,763
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	2,015,937	2,062,188	2,112,291	2,162,819	2,212,922
Non-Hispanic White	3,813,233	3,841,014	3,867,732	3,901,787	3,933,182
Non-Hispanic Black	295,924	305,911	317,478	330,098	340,651

Hispanic/Latino Population, Census 2010: 1,895,149
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ARIZONA CANCER REGISTRY

Initial Operation: 1981
 Population-based Data Available: 1995
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	94.6	95.6	97.0	98.3	97.9
Missing Race	0.2	0.4	0.5	0.5	1.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.2	3.0	3.0	3.4	2.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.4	Prostate	93.3
Oral Cavity & Pharynx	95.2	Testis	98.3
Esophagus	89.9	Bladder (incl. <i>in situ</i>)	97.0
Stomach	93.2	Kidney & Renal Pelvis	89.8
Colon & Rectum	93.9	Brain & Other CNS ¹	83.3
Liver	54.2	Thyroid	99.2
Pancreas	80.5	Hodgkin Lymphoma	96.9
Lung & Bronchus	87.6	Non-Hodgkin Lymphoma	94.2
Melanomas of the Skin	98.5	Multiple Myeloma	83.6
Female Breast (excl. <i>in situ</i>)	97.4	Leukemias	84.8
Cervix uteri	94.0	Brain & Other CNS ¹ <i>non-malig</i>	50.2
Uterus Corpus & Uterus NOS ¹	97.5	Breast <i>in situ</i>	100.0
Ovary	90.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,935	409.8	1.47	486.2	1.74	15,505	370.1	1.37	431.0	1.57
Oral Cavity & Pharynx	557	14.1	0.27	17.3	0.33	208	4.8	0.15	5.8	0.18
Lip	16	0.4	0.05	0.5	0.06	5	0.1	0.03	0.1	0.03
Tongue	202	5.0	0.16	6.2	0.20	71	1.6	0.09	2.0	0.11
Major salivary gland	57	1.5	0.09	1.8	0.11	35	0.9	0.07	1.0	0.08
Floor of mouth	22	0.5	0.05	0.7	0.07	9	0.2	0.03	0.3	0.04
Gum & other mouth	51	1.3	0.09	1.6	0.10	39	0.9	0.07	1.0	0.08
Nasopharynx	17	0.4	0.05	0.5	0.06	7	0.2	0.03	0.2	0.04
Oropharynx	26	0.6	0.06	0.8	0.07	8	0.2	0.03	0.2	0.03
Hypopharynx	23	0.6	0.05	0.7	0.07	7	0.2	0.03	0.2	0.03
Digestive System	3,249	83.6	0.67	100.5	0.80	2,424	55.8	0.52	65.8	0.61
Esophagus	287	7.2	0.19	8.7	0.23	74	1.7	0.09	2.0	0.11
Stomach	271	7.1	0.20	8.4	0.23	161	3.8	0.14	4.4	0.16
Small intestine	78	2.1	0.11	2.4	0.12	76	1.8	0.09	2.1	0.11
Colon excl. rectum	946	24.8	0.37	29.3	0.43	908	21.0	0.32	24.6	0.37
Rectum & rectosigmoid	475	12.5	0.26	15.0	0.31	300	7.2	0.19	8.6	0.23
Anus, anal canal & anorectum	37	1.0	0.07	1.2	0.09	77	1.7	0.09	2.2	0.11
Liver	447	11.0	0.24	14.0	0.30	159	3.6	0.13	4.3	0.15
Gallbladder	23	0.6	0.06	0.7	0.07	53	1.2	0.08	1.4	0.09
Pancreas	526	13.4	0.26	16.0	0.32	452	10.1	0.22	11.9	0.25
Respiratory System	2,211	56.0	0.54	66.5	0.64	2,005	44.3	0.45	52.3	0.53
Larynx	148	3.7	0.14	4.5	0.17	34	0.8	0.06	0.9	0.07
Lung & bronchus	2,021	51.2	0.52	60.6	0.61	1,948	43.0	0.44	50.7	0.52
Bones & Joints	44	1.2	0.08	1.3	0.09	28	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	141	3.8	0.15	4.3	0.16	94	2.4	0.11	2.6	0.12
Skin (excl. basal & sq.)	1,321	34.7	0.43	40.6	0.51	735	18.2	0.31	20.9	0.35
Melanomas of the skin	1,256	33.0	0.42	38.6	0.49	702	17.4	0.30	20.0	0.34
Breast (excl. <i>in situ</i>)	46	1.2	0.08	1.4	0.09	4,734	114.3	0.77	134.3	0.89
Female Genital System	-	-	-	-	-	1,772	43.3	0.48	50.9	0.55
Cervix uteri	-	-	-	-	-	224	6.5	0.20	7.0	0.21
Uterus Corpus	-	-	-	-	-	922	21.8	0.33	26.3	0.39
Uterus, NOS ¹	-	-	-	-	-	48	1.2	0.08	1.3	0.09
Ovary	-	-	-	-	-	435	10.5	0.23	12.3	0.27
Male Genital System	3,454	85.2	0.66	103.8	0.80	-	-	-	-	-
Prostate	3,249	79.1	0.63	97.6	0.77	-	-	-	-	-
Testis	174	5.3	0.18	5.2	0.18	-	-	-	-	-
Penis	24	0.6	0.06	0.8	0.07	-	-	-	-	-
Urinary System	2,085	54.2	0.54	63.8	0.63	821	19.1	0.31	22.3	0.35
Bladder (incl. <i>in situ</i>)	1,220	31.6	0.41	37.1	0.48	342	7.6	0.19	9.0	0.22
Kidney & renal pelvis	825	21.5	0.34	25.5	0.40	457	10.9	0.24	12.8	0.27
Ureter	27	0.7	0.06	0.8	0.07	16	0.4	0.04	0.4	0.05
Eye & Orbit	27	0.7	0.06	0.8	0.07	28	0.7	0.06	0.8	0.07
Brain & Other CNS ¹	259	7.0	0.20	7.8	0.22	199	4.9	0.16	5.5	0.18
Brain	244	6.6	0.19	7.4	0.21	183	4.5	0.15	5.0	0.17
Endocrine System	265	7.4	0.21	8.3	0.23	756	21.4	0.36	23.1	0.38
Thyroid gland	236	6.6	0.20	7.4	0.22	738	20.9	0.36	22.6	0.38
Lymphomas	784	20.9	0.34	24.0	0.39	620	14.8	0.27	17.0	0.31
Hodgkin Lymphoma	85	2.5	0.12	2.6	0.13	68	1.9	0.11	2.0	0.11
Non-Hodgkin Lymphoma	699	18.5	0.32	21.4	0.37	552	12.9	0.25	15.0	0.29
Multiple Myeloma	247	6.3	0.18	7.5	0.22	175	4.0	0.14	4.7	0.16
Leukemias	507	13.8	0.28	15.3	0.31	347	8.7	0.21	9.5	0.23
Acute lymphocytic	69	2.1	0.11	1.9	0.10	52	1.6	0.10	1.4	0.09
Chronic lymphocytic	134	3.5	0.14	4.2	0.16	80	1.8	0.09	2.1	0.11
Acute myeloid	169	4.6	0.16	5.2	0.18	120	2.9	0.12	3.3	0.14
Chronic myeloid	66	1.8	0.10	2.0	0.11	47	1.2	0.08	1.3	0.09
Other leukemias	68	1.9	0.10	2.1	0.12	48	1.2	0.08	1.3	0.09
Mesothelioma	55	1.5	0.09	1.7	0.10	15	0.3	0.04	0.4	0.05
Kaposi Sarcoma	12	0.4	0.05	0.4	0.05	-	-	-	-	-
Ill-defined & Unknown	671	17.6	0.31	20.7	0.36	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	271	7.5	0.21	8.4	0.23	550	13.6	0.27	15.5	0.30
Breast (<i>in situ</i>)	8	0.2	0.03	0.3	0.04	994	24.2	0.36	28.7	0.41

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	14,661	413.6	1.56	490.6	1.83	14,157	377.2	1.47	439.0	1.68
Oral Cavity & Pharynx	524	14.7	0.29	18.1	0.36	191	4.9	0.17	5.9	0.20
Lip	15	0.4	0.05	0.5	0.06	5	0.1	0.03	0.2	0.03
Tongue	194	5.4	0.18	6.6	0.22	65	1.7	0.09	2.0	0.12
Major salivary gland	54	1.6	0.10	1.9	0.11	31	0.9	0.07	1.0	0.08
Floor of mouth	21	0.6	0.06	0.7	0.07	9	0.2	0.03	0.3	0.04
Gum & other mouth	47	1.3	0.09	1.6	0.11	36	0.9	0.07	1.1	0.08
Nasopharynx	13	0.4	0.05	0.5	0.06	6	0.2	0.03	0.2	0.04
Oropharynx	24	0.7	0.06	0.8	0.08	8	0.2	0.03	0.2	0.04
Hypopharynx	20	0.6	0.06	0.7	0.07	6	0.2	0.03	0.2	0.04
Digestive System	2,950	83.2	0.70	100.1	0.83	2,174	55.2	0.55	65.2	0.64
Esophagus	269	7.4	0.20	8.9	0.25	69	1.7	0.10	2.0	0.11
Stomach	236	6.8	0.20	8.0	0.23	135	3.5	0.14	4.1	0.16
Small intestine	71	2.0	0.11	2.4	0.13	69	1.8	0.10	2.1	0.12
Colon excl. rectum	873	25.1	0.39	29.7	0.45	826	21.1	0.34	24.6	0.39
Rectum & rectosigmoid	430	12.5	0.28	15.1	0.33	271	7.3	0.21	8.7	0.24
Anus, anal canal & anorectum	34	1.0	0.08	1.2	0.09	72	1.8	0.10	2.3	0.12
Liver	384	10.4	0.24	13.3	0.31	132	3.3	0.13	4.0	0.16
Gallbladder	19	0.5	0.05	0.6	0.07	43	1.1	0.07	1.3	0.09
Pancreas	489	13.5	0.28	16.2	0.33	410	10.0	0.22	11.8	0.26
Respiratory System	2,071	56.9	0.57	67.5	0.67	1,885	45.6	0.48	53.8	0.56
Larynx	136	3.7	0.14	4.6	0.18	32	0.8	0.07	1.0	0.08
Lung & bronchus	1,897	52.0	0.54	61.7	0.64	1,831	44.2	0.47	52.2	0.55
Bones & Joints	39	1.2	0.09	1.3	0.10	26	0.8	0.08	0.8	0.07
Soft Tissue (incl. heart)	126	3.8	0.16	4.3	0.17	84	2.4	0.12	2.7	0.13
Skin (excl. basal & sq.)	1,262	36.4	0.47	42.6	0.54	694	19.4	0.34	22.2	0.39
Melanomas of the skin	1,199	34.6	0.46	40.5	0.53	664	18.6	0.34	21.3	0.38
Breast (excl. <i>in situ</i>)	44	1.2	0.09	1.5	0.10	4,338	117.3	0.83	137.8	0.96
Female Genital System	-	-	-	-	-	1,590	43.7	0.51	51.3	0.59
Cervix uteri	-	-	-	-	-	199	6.8	0.22	7.2	0.23
Uterus Corpus	-	-	-	-	-	825	21.7	0.35	26.3	0.42
Uterus, NOS ¹	-	-	-	-	-	40	1.1	0.08	1.3	0.09
Ovary	-	-	-	-	-	392	10.6	0.25	12.4	0.29
Male Genital System	3,102	84.0	0.69	102.3	0.83	-	-	-	-	-
Prostate	2,918	77.5	0.65	95.7	0.80	-	-	-	-	-
Testis	155	5.7	0.21	5.6	0.20	-	-	-	-	-
Penis	22	0.6	0.06	0.8	0.07	-	-	-	-	-
Urinary System	1,945	55.0	0.57	64.8	0.66	751	19.3	0.33	22.5	0.37
Bladder (incl. <i>in situ</i>)	1,177	32.9	0.43	38.7	0.51	325	7.9	0.20	9.3	0.24
Kidney & renal pelvis	729	20.9	0.36	24.8	0.42	406	10.8	0.25	12.6	0.29
Ureter	27	0.8	0.07	0.9	0.08	15	0.4	0.04	0.4	0.05
Eye & Orbit	26	0.8	0.07	0.9	0.08	27	0.7	0.07	0.9	0.08
Brain & Other CNS ¹	241	7.4	0.22	8.3	0.24	184	5.2	0.18	5.7	0.19
Brain	227	6.9	0.21	7.8	0.23	169	4.7	0.17	5.2	0.18
Endocrine System	241	7.7	0.23	8.6	0.25	669	22.1	0.40	23.8	0.42
Thyroid gland	216	6.9	0.22	7.7	0.24	653	21.6	0.39	23.3	0.41
Lymphomas	721	21.3	0.36	24.4	0.41	566	15.1	0.29	17.3	0.33
Hodgkin Lymphoma	75	2.5	0.13	2.6	0.14	60	2.0	0.12	2.1	0.12
Non-Hodgkin Lymphoma	646	18.8	0.34	21.8	0.39	506	13.1	0.27	15.2	0.31
Multiple Myeloma	216	6.1	0.19	7.2	0.22	151	3.7	0.14	4.4	0.16
Leukemias	467	14.1	0.30	15.7	0.33	316	8.9	0.23	9.7	0.25
Acute lymphocytic	61	2.2	0.13	2.0	0.12	45	1.6	0.11	1.5	0.10
Chronic lymphocytic	128	3.6	0.15	4.3	0.17	77	1.9	0.10	2.3	0.12
Acute myeloid	153	4.5	0.17	5.1	0.19	109	3.0	0.13	3.3	0.15
Chronic myeloid	61	1.8	0.11	2.1	0.12	41	1.1	0.08	1.3	0.09
Other leukemias	63	1.9	0.11	2.2	0.12	44	1.3	0.09	1.4	0.09
Mesothelioma	52	1.5	0.09	1.7	0.11	15	0.4	0.04	0.4	0.05
Kaposi Sarcoma	8	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	627	17.9	0.32	21.1	0.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	247	7.6	0.22	8.5	0.25	493	13.8	0.29	15.7	0.32
Breast (<i>in situ</i>)	7	0.2	0.04	0.2	0.04	896	24.6	0.38	29.2	0.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

ARIZONA

II-24 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	487	383.2	8.56	459.8	10.05	448	323.5	7.10	380.3	8.25
Oral Cavity & Pharynx	9	7.1	1.09	8.2	1.24	3	2.0	0.52	2.6	0.67
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.0	0.64	2.2	0.68	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.8	0.35	0.9	0.37	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	102	79.8	3.89	96.2	4.58	88	66.2	3.27	78.1	3.81
Esophagus	4	4.2	1.03	4.9	1.17	2	1.6	0.47	2.0	0.60
Stomach	12	10.4	1.42	12.2	1.62	7	5.6	0.96	6.3	1.06
Small intestine	5	3.0	0.66	3.7	0.79	4	2.9	0.67	3.2	0.74
Colon excl. rectum	26	21.4	2.07	25.5	2.41	34	25.9	2.05	30.7	2.40
Rectum & rectosigmoid	13	9.1	1.21	10.7	1.41	8	6.2	1.00	7.4	1.18
Anus, anal canal & anorectum	-	-	-	-	-	2	1.1	0.37	1.4	0.47
Liver	16	12.5	1.51	15.6	1.82	6	4.2	0.81	5.0	0.95
Gallbladder	-	-	-	-	-	2	1.4	0.49	1.6	0.55
Pancreas	18	14.4	1.67	17.5	1.97	19	14.9	1.59	17.6	1.85
Respiratory System	75	66.3	3.77	78.3	4.35	52	39.8	2.56	47.9	3.01
Larynx	7	5.4	0.98	6.5	1.13	2	1.0	0.34	1.3	0.45
Lung & bronchus	67	60.1	3.62	70.8	4.17	51	38.7	2.54	46.5	2.97
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	5	3.5	0.75	3.9	0.83	3	2.0	0.56	2.2	0.63
Skin (excl. basal & sq.)	3	1.8	0.50	2.0	0.56	3	2.7	0.67	3.2	0.79
Melanomas of the skin	2	1.6	0.47	1.8	0.54	3	2.2	0.61	2.6	0.71
Breast (excl. <i>in situ</i>)	-	-	-	-	-	146	102.2	3.91	120.4	4.55
Female Genital System	-	-	-	-	-	53	37.7	2.39	44.2	2.78
Cervix uteri	-	-	-	-	-	9	5.6	0.85	6.3	0.96
Uterus Corpus	-	-	-	-	-	27	19.5	1.73	23.4	2.05
Uterus, NOS ¹	-	-	-	-	-	3	2.1	0.56	2.5	0.66
Ovary	-	-	-	-	-	11	8.5	1.17	9.8	1.34
Male Genital System	154	115.1	4.51	143.0	5.44	-	-	-	-	-
Prostate	151	113.5	4.48	141.3	5.41	-	-	-	-	-
Testis	2	0.8	0.28	0.8	0.26	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	48	39.6	2.87	47.3	3.37	21	15.6	1.57	18.7	1.86
Bladder (incl. <i>in situ</i>)	14	14.6	1.92	17.3	2.24	8	6.6	1.08	7.8	1.26
Kidney & renal pelvis	33	24.4	2.09	29.4	2.47	13	8.5	1.10	10.2	1.32
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	3.8	0.76	4.3	0.86	4	3.1	0.69	3.4	0.76
Brain	6	3.7	0.75	4.2	0.86	4	2.7	0.63	3.0	0.70
Endocrine System	7	4.5	0.82	5.1	0.93	21	13.7	1.38	15.1	1.52
Thyroid gland	6	4.0	0.78	4.5	0.88	20	13.4	1.36	14.7	1.50
Lymphomas	27	19.1	1.84	21.8	2.09	14	10.0	1.24	11.2	1.40
Hodgkin Lymphoma	7	3.8	0.67	4.0	0.71	3	1.9	0.50	1.9	0.51
Non-Hodgkin Lymphoma	20	15.3	1.72	17.8	1.97	-	-	-	-	-
Multiple Myeloma	16	12.7	1.56	15.4	1.84	12	8.5	1.16	10.3	1.38
Leukemias	12	9.7	1.43	10.8	1.61	10	7.4	1.10	8.3	1.25
Acute lymphocytic	1	0.6	0.24	0.6	0.25	-	-	-	-	-
Chronic lymphocytic	2	2.1	0.63	2.4	0.73	2	1.7	0.54	1.9	0.62
Acute myeloid	6	4.4	0.93	4.9	1.04	4	3.0	0.69	3.3	0.77
Chronic myeloid	2	1.7	0.64	1.9	0.72	2	1.6	0.49	1.9	0.59
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	1.2	0.36	1.2	0.35	-	-	-	-	-
Ill-defined & Unknown	19	16.7	1.91	19.8	2.22	16	12.2	1.44	14.2	1.67
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	6.6	1.13	7.4	1.29	19	13.9	1.49	16.4	1.74
Breast (<i>in situ</i>)	-	-	-	-	-	40	28.2	2.04	33.5	2.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	206	223.0	7.38	261.9	8.62	329	243.6	6.21	281.9	7.18
Oral Cavity & Pharynx	8	7.7	1.33	9.1	1.58	6	3.9	0.73	4.6	0.87
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.7	0.62	1.9	0.67	2	1.7	0.50	2.1	0.60
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	2.1	0.79	2.7	0.97	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	58	63.3	3.96	74.3	4.61	55	44.2	2.77	51.6	3.21
Esophagus	4	4.3	1.03	4.8	1.14	1	0.8	0.36	1.1	0.47
Stomach	7	8.4	1.47	9.7	1.69	7	5.0	0.91	5.9	1.06
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	13	14.4	1.90	16.9	2.22	17	14.6	1.63	17.1	1.90
Rectum & rectosigmoid	9	9.5	1.45	11.1	1.69	7	5.2	0.91	6.0	1.05
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	14	15.5	1.96	18.5	2.33	7	6.3	1.07	7.1	1.20
Gallbladder	-	-	-	-	-	1	1.0	0.42	1.2	0.49
Pancreas	6	6.6	1.30	7.8	1.52	8	6.9	1.11	7.9	1.27
Respiratory System	32	36.5	3.06	43.3	3.59	36	29.4	2.29	34.9	2.69
Larynx	2	2.0	0.69	2.3	0.76	-	-	-	-	-
Lung & bronchus	29	33.8	2.97	40.2	3.48	35	28.8	2.27	34.1	2.66
Bones & Joints	1	1.1	0.45	1.2	0.50	-	-	-	-	-
Soft Tissue (incl. heart)	3	3.2	0.90	3.7	1.06	3	2.1	0.53	2.5	0.64
Skin (excl. basal & sq.)	1	1.2	0.47	1.5	0.57	2	1.2	0.43	1.5	0.52
Melanomas of the skin	-	-	-	-	-	1	1.0	0.38	1.2	0.46
Breast (excl. <i>in situ</i>)	-	-	-	-	-	114	80.5	3.44	93.2	3.99
Female Genital System	-	-	-	-	-	38	26.2	1.94	31.3	2.32
Cervix uteri	-	-	-	-	-	6	3.6	0.69	4.3	0.83
Uterus Corpus	-	-	-	-	-	19	13.1	1.36	15.7	1.62
Uterus, NOS ¹	-	-	-	-	-	1	0.8	0.36	1.1	0.46
Ovary	-	-	-	-	-	10	7.3	1.06	8.6	1.25
Male Genital System	40	43.8	3.27	52.7	3.88	-	-	-	-	-
Prostate	38	41.9	3.22	50.8	3.84	-	-	-	-	-
Testis	2	1.3	0.41	1.2	0.40	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	21	23.7	2.46	28.0	2.87	9	7.4	1.16	8.3	1.30
Bladder (incl. <i>in situ</i>)	10	13.0	1.88	14.7	2.12	3	3.0	0.76	3.5	0.86
Kidney & renal pelvis	11	10.5	1.54	13.0	1.90	5	3.9	0.81	4.2	0.89
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	3.5	0.85	3.7	0.93	4	2.6	0.60	3.1	0.71
Brain	4	3.5	0.85	3.7	0.93	4	2.5	0.58	2.9	0.69
Endocrine System	6	5.1	0.93	5.7	1.07	27	18.3	1.61	19.7	1.76
Thyroid gland	5	4.4	0.88	5.0	1.00	26	17.6	1.57	19.1	1.72
Lymphomas	14	14.4	1.86	16.1	2.11	13	9.9	1.27	11.3	1.45
Hodgkin Lymphoma	2	1.9	0.57	2.0	0.62	2	1.1	0.36	1.2	0.40
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	1.9	0.67	2.5	0.86	2	1.7	0.53	1.9	0.60
Leukemias	11	10.2	1.47	11.2	1.65	8	5.9	0.95	6.1	1.00
Acute lymphocytic	2	1.6	0.48	1.4	0.44	2	1.8	0.51	1.5	0.44
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	5	5.0	1.05	5.7	1.20	4	2.7	0.66	3.0	0.73
Chronic myeloid	1	1.4	0.59	1.6	0.70	1	0.8	0.33	0.9	0.36
Other leukemias	1	1.3	0.55	1.2	0.53	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	6.0	1.28	7.0	1.50	11	10.0	1.40	11.4	1.59
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	2.9	0.72	3.0	0.77	15	11.2	1.35	13.0	1.55
Breast (<i>in situ</i>)	-	-	-	-	-	31	21.3	1.75	24.9	2.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	356	292.6	7.54	344.1	8.75	419	269.9	6.09	315.2	7.06
Oral Cavity & Pharynx	11	8.0	1.13	9.8	1.36	5	2.8	0.60	3.3	0.71
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	1.8	0.52	2.3	0.64	2	0.9	0.34	1.2	0.43
Major salivary gland	1	1.0	0.37	1.2	0.47	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	2	1.4	0.45	1.5	0.50	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	116	94.5	4.24	113.0	4.97	91	62.9	3.04	74.2	3.54
Esophagus	8	8.0	1.31	9.1	1.48	2	1.1	0.41	1.3	0.48
Stomach	14	12.4	1.61	14.4	1.84	11	7.3	1.03	8.7	1.21
Small intestine	1	0.9	0.39	1.1	0.45	2	1.5	0.47	1.6	0.49
Colon excl. rectum	25	21.0	2.01	24.6	2.33	24	16.9	1.58	19.8	1.83
Rectum & rectosigmoid	18	13.3	1.50	16.2	1.80	10	6.1	0.89	7.5	1.08
Anus, anal canal & anorectum	-	-	-	-	-	2	1.3	0.39	1.7	0.52
Liver	29	20.9	1.86	26.4	2.29	13	9.2	1.18	10.7	1.35
Gallbladder	2	2.6	0.78	2.8	0.85	7	4.9	0.87	5.7	1.01
Pancreas	11	9.8	1.42	11.6	1.66	12	8.8	1.17	10.3	1.34
Respiratory System	23	22.3	2.22	26.0	2.54	25	17.6	1.63	20.8	1.90
Larynx	2	1.4	0.48	1.8	0.58	-	-	-	-	-
Lung & bronchus	20	20.0	2.12	23.1	2.41	23	16.6	1.58	19.6	1.84
Bones & Joints	2	1.1	0.35	1.3	0.44	2	0.8	0.28	0.8	0.30
Soft Tissue (incl. heart)	5	3.4	0.74	3.7	0.82	4	2.0	0.50	2.3	0.59
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	7	7.1	1.28	8.2	1.46	7	4.7	0.83	5.2	0.91
Breast (excl. <i>in situ</i>)	-	-	-	-	-	91	57.7	2.77	68.2	3.24
Female Genital System	-	-	-	-	-	69	42.0	2.31	48.7	2.67
Cervix uteri	-	-	-	-	-	8	4.4	0.73	4.7	0.79
Uterus Corpus	-	-	-	-	-	41	24.3	1.74	28.2	2.00
Uterus, NOS ²	-	-	-	-	-	2	1.6	0.49	1.9	0.57
Ovary	-	-	-	-	-	16	9.9	1.14	11.7	1.35
Male Genital System	65	57.1	3.45	66.6	3.97	-	-	-	-	-
Prostate	55	51.7	3.36	61.2	3.90	-	-	-	-	-
Testis	10	4.9	0.71	4.7	0.68	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	56	44.0	2.82	51.7	3.27	33	21.1	1.68	24.9	1.97
Bladder (incl. <i>in situ</i>)	8	7.0	1.22	8.2	1.41	3	2.0	0.55	2.3	0.63
Kidney & renal pelvis	48	36.8	2.52	43.3	2.94	31	19.1	1.59	22.6	1.87
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	5	2.8	0.63	3.0	0.69	5	2.8	0.60	3.0	0.66
Brain	4	2.4	0.58	2.6	0.64	4	2.7	0.60	3.0	0.66
Endocrine System	6	4.2	0.79	4.7	0.90	29	16.7	1.40	18.7	1.58
Thyroid gland	5	3.7	0.75	4.2	0.85	28	15.9	1.37	18.0	1.55
Lymphomas	16	12.7	1.52	14.8	1.76	18	12.3	1.33	14.3	1.54
Hodgkin Lymphoma	-	-	-	-	-	1	0.8	0.34	0.8	0.37
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	11	9.3	1.37	11.4	1.63	10	6.6	0.97	7.8	1.13
Leukemias	12	8.1	1.18	8.9	1.33	10	6.0	0.88	6.5	0.97
Acute lymphocytic	4	1.6	0.39	1.3	0.33	3	1.4	0.42	1.3	0.40
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	4	2.8	0.69	3.2	0.81	3	2.0	0.51	2.3	0.59
Chronic myeloid	2	1.0	0.34	1.2	0.41	2	1.0	0.36	1.0	0.35
Other leukemias	2	1.5	0.56	1.7	0.64	2	1.5	0.45	1.8	0.54
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	15	13.7	1.74	16.2	2.02	18	13.1	1.44	15.4	1.68
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	10	7.2	1.11	8.1	1.25	20	12.9	1.36	15.1	1.57
Breast (<i>in situ</i>)	-	-	-	-	-	15	9.3	1.09	11.3	1.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,015	333.8	3.63	395.0	4.23	2,391	319.6	3.05	372.2	3.54
Oral Cavity & Pharynx	46	7.6	0.53	9.0	0.63	28	3.8	0.34	4.4	0.39
Lip	2	0.4	0.14	0.4	0.16	1	0.2	0.07	0.2	0.07
Tongue	14	2.1	0.27	2.5	0.32	7	1.0	0.19	1.2	0.21
Major salivary gland	6	1.0	0.20	1.2	0.23	8	1.1	0.18	1.2	0.21
Floor of mouth	2	0.3	0.10	0.4	0.13	-	-	-	-	-
Gum & other mouth	4	0.9	0.20	1.0	0.22	4	0.5	0.13	0.6	0.14
Nasopharynx	4	0.5	0.13	0.6	0.15	2	0.2	0.07	0.2	0.07
Oropharynx	2	0.3	0.10	0.4	0.12	-	-	-	-	-
Hypopharynx	2	0.3	0.12	0.4	0.14	-	-	-	-	-
Digestive System	574	97.3	1.96	116.8	2.31	425	62.3	1.40	73.5	1.64
Esophagus	27	4.6	0.43	5.6	0.51	7	1.0	0.18	1.1	0.20
Stomach	66	12.1	0.72	14.1	0.83	51	7.4	0.48	8.6	0.56
Small intestine	9	1.5	0.24	1.7	0.27	12	1.6	0.22	1.9	0.26
Colon excl. rectum	154	27.0	1.05	31.9	1.22	134	19.5	0.78	23.1	0.92
Rectum & rectosigmoid	91	14.7	0.75	17.6	0.88	49	6.7	0.44	7.9	0.52
Anus, anal canal & anorectum	3	0.5	0.13	0.5	0.15	6	0.8	0.16	1.0	0.19
Liver	128	19.5	0.82	24.7	1.01	46	6.7	0.46	8.0	0.54
Gallbladder	5	1.1	0.23	1.2	0.26	17	2.4	0.27	2.9	0.32
Pancreas	64	11.3	0.68	13.5	0.80	74	11.5	0.62	13.5	0.72
Respiratory System	195	38.5	1.32	45.0	1.51	168	26.5	0.95	30.9	1.09
Larynx	18	3.4	0.38	4.0	0.44	4	0.6	0.13	0.7	0.15
Lung & bronchus	170	34.3	1.25	40.0	1.43	160	25.4	0.93	29.6	1.07
Bones & Joints	9	0.8	0.14	0.9	0.16	8	0.8	0.13	0.8	0.14
Soft Tissue (incl. heart)	24	3.2	0.33	3.6	0.37	18	2.3	0.25	2.6	0.29
Skin (excl. basal & sq.)	35	5.9	0.49	6.8	0.57	41	5.2	0.37	6.1	0.44
Melanomas of the skin	31	5.1	0.45	6.0	0.52	38	4.8	0.36	5.6	0.42
Breast (excl. <i>in situ</i>)	5	0.8	0.18	0.9	0.21	703	91.9	1.60	108.7	1.88
Female Genital System	-	-	-	-	-	341	42.6	1.07	49.5	1.25
Cervix uteri	-	-	-	-	-	74	8.7	0.46	9.3	0.51
Uterus Corpus	-	-	-	-	-	164	20.5	0.74	24.5	0.88
Uterus, NOS ¹	-	-	-	-	-	10	1.3	0.19	1.5	0.23
Ovary	-	-	-	-	-	78	9.9	0.52	11.5	0.61
Male Genital System	449	71.8	1.64	87.2	1.95	-	-	-	-	-
Prostate	387	65.9	1.60	81.1	1.91	-	-	-	-	-
Testis	56	4.8	0.30	4.8	0.30	-	-	-	-	-
Penis	5	1.0	0.20	1.1	0.24	-	-	-	-	-
Urinary System	249	43.0	1.31	50.8	1.53	145	20.1	0.78	23.6	0.91
Bladder (incl. <i>in situ</i>)	90	18.4	0.92	21.4	1.06	28	4.3	0.38	5.0	0.44
Kidney & renal pelvis	157	24.0	0.92	28.8	1.09	114	15.3	0.66	18.0	0.78
Ureter	2	0.4	0.13	0.4	0.15	2	0.5	0.13	0.5	0.14
Eye & Orbit	3	0.4	0.12	0.4	0.14	4	0.5	0.11	0.5	0.13
Brain & Other CNS ¹	46	5.9	0.43	6.5	0.49	36	4.2	0.33	4.7	0.38
Brain	42	5.5	0.43	6.1	0.48	33	3.9	0.32	4.4	0.37
Endocrine System	48	6.4	0.45	7.1	0.51	191	21.1	0.70	23.1	0.79
Thyroid gland	42	5.6	0.42	6.4	0.49	188	20.8	0.70	22.8	0.78
Lymphomas	119	17.9	0.81	20.5	0.93	110	14.7	0.66	16.9	0.76
Hodgkin Lymphoma	20	2.3	0.26	2.5	0.28	22	2.4	0.24	2.6	0.27
Non-Hodgkin Lymphoma	98	15.5	0.77	18.0	0.89	89	12.3	0.61	14.4	0.71
Multiple Myeloma	43	7.4	0.54	8.7	0.63	26	3.7	0.34	4.3	0.39
Leukemias	84	10.6	0.60	11.5	0.67	66	7.8	0.46	8.5	0.51
Acute lymphocytic	31	2.7	0.23	2.5	0.24	21	1.8	0.18	1.7	0.19
Chronic lymphocytic	9	1.7	0.27	2.0	0.32	7	1.0	0.18	1.2	0.21
Acute myeloid	22	3.3	0.35	3.6	0.40	22	2.8	0.28	3.1	0.32
Chronic myeloid	12	1.4	0.20	1.6	0.22	10	1.3	0.19	1.4	0.22
Other leukemias	10	1.6	0.26	1.8	0.30	7	1.0	0.17	1.1	0.19
Mesothelioma	8	1.6	0.27	1.9	0.31	2	0.3	0.10	0.4	0.11
Kaposi Sarcoma	4	0.4	0.11	0.5	0.13	-	-	-	-	-
Ill-defined & Unknown	76	14.4	0.81	16.9	0.94	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	47	7.2	0.53	8.1	0.60	103	13.7	0.63	15.6	0.72
Breast (<i>in situ</i>)	1	0.2	0.10	0.3	0.12	148	19.0	0.72	22.8	0.86

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

ARIZONA

II-28 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	12,739	431.4	1.78	511.3	2.08	11,862	390.6	1.74	453.8	1.96
Oral Cavity & Pharynx	481	16.6	0.36	20.4	0.43	166	5.3	0.20	6.4	0.23
Lip	14	0.5	0.06	0.6	0.07	4	0.1	0.03	0.2	0.04
Tongue	181	6.2	0.22	7.6	0.26	59	1.9	0.12	2.3	0.14
Major salivary gland	49	1.7	0.11	2.0	0.13	24	0.8	0.08	0.9	0.09
Floor of mouth	19	0.6	0.07	0.8	0.08	8	0.3	0.04	0.3	0.05
Gum & other mouth	43	1.5	0.11	1.8	0.13	33	1.0	0.08	1.2	0.10
Nasopharynx	9	0.3	0.05	0.4	0.06	4	0.2	0.04	0.2	0.04
Oropharynx	22	0.7	0.07	0.9	0.09	7	0.2	0.03	0.2	0.04
Hypopharynx	19	0.6	0.06	0.8	0.08	5	0.2	0.04	0.2	0.04
Digestive System	2,396	80.9	0.77	97.1	0.91	1,764	54.0	0.61	63.7	0.71
Esophagus	244	7.9	0.23	9.5	0.28	62	1.9	0.11	2.3	0.13
Stomach	173	5.8	0.20	6.9	0.24	86	2.6	0.13	3.1	0.15
Small intestine	63	2.2	0.13	2.6	0.15	58	1.8	0.11	2.1	0.13
Colon excl. rectum	724	25.0	0.43	29.5	0.50	698	21.4	0.39	24.9	0.44
Rectum & rectosigmoid	342	12.2	0.31	14.7	0.37	224	7.6	0.25	9.0	0.28
Anus, anal canal & anorectum	31	1.1	0.09	1.3	0.11	67	2.1	0.13	2.6	0.15
Liver	261	8.5	0.24	10.8	0.31	88	2.7	0.13	3.2	0.16
Gallbladder	15	0.5	0.05	0.6	0.07	28	0.8	0.07	0.9	0.08
Pancreas	427	13.9	0.31	16.6	0.37	339	9.7	0.24	11.5	0.29
Respiratory System	1,883	60.3	0.63	71.8	0.75	1,721	49.0	0.54	58.1	0.64
Larynx	118	3.8	0.16	4.7	0.20	28	0.9	0.08	1.1	0.09
Lung & bronchus	1,733	55.3	0.60	65.7	0.72	1,676	47.6	0.53	56.4	0.63
Bones & Joints	31	1.4	0.12	1.4	0.12	18	0.9	0.10	0.8	0.09
Soft Tissue (incl. heart)	103	3.9	0.18	4.4	0.20	66	2.5	0.16	2.7	0.16
Skin (excl. basal & sq.)	1,231	43.3	0.58	50.5	0.66	655	24.1	0.46	27.2	0.50
Melanomas of the skin	1,173	41.3	0.57	48.2	0.65	628	23.3	0.46	26.3	0.49
Breast (excl. <i>in situ</i>)	40	1.3	0.10	1.6	0.12	3,662	123.5	0.99	144.6	1.12
Female Genital System	-	-	-	-	-	1,266	42.9	0.59	50.7	0.67
Cervix uteri	-	-	-	-	-	128	6.0	0.26	6.3	0.26
Uterus Corpus	-	-	-	-	-	671	21.4	0.40	26.2	0.47
Uterus, NOS ¹	-	-	-	-	-	31	1.0	0.09	1.2	0.10
Ovary	-	-	-	-	-	318	10.6	0.29	12.4	0.33
Male Genital System	2,681	87.1	0.78	106.0	0.94	-	-	-	-	-
Prostate	2,555	80.2	0.73	99.0	0.90	-	-	-	-	-
Testis	105	6.1	0.27	6.1	0.27	-	-	-	-	-
Penis	17	0.6	0.06	0.7	0.07	-	-	-	-	-
Urinary System	1,704	56.8	0.64	66.8	0.74	613	18.9	0.36	22.0	0.42
Bladder (incl. <i>in situ</i>)	1,090	35.3	0.49	41.5	0.57	298	8.6	0.23	10.1	0.27
Kidney & renal pelvis	578	20.3	0.40	23.9	0.46	298	9.8	0.28	11.4	0.31
Ureter	25	0.8	0.07	0.9	0.09	13	0.4	0.05	0.4	0.06
Eye & Orbit	24	0.9	0.09	1.0	0.10	23	0.8	0.08	0.9	0.09
Brain & Other CNS ¹	197	8.0	0.27	8.8	0.29	149	5.6	0.23	6.1	0.23
Brain	187	7.4	0.26	8.3	0.28	137	5.0	0.21	5.5	0.22
Endocrine System	196	8.4	0.29	9.3	0.31	486	22.5	0.50	24.1	0.51
Thyroid gland	176	7.5	0.27	8.4	0.29	472	21.9	0.49	23.5	0.50
Lymphomas	605	22.0	0.42	25.2	0.47	461	15.0	0.34	17.3	0.38
Hodgkin Lymphoma	55	2.7	0.17	2.8	0.17	40	1.9	0.15	2.0	0.15
Non-Hodgkin Lymphoma	551	19.3	0.39	22.4	0.44	421	13.1	0.31	15.3	0.35
Multiple Myeloma	176	5.8	0.20	6.9	0.24	126	3.6	0.15	4.3	0.18
Leukemias	387	14.3	0.34	16.1	0.38	253	9.0	0.28	9.8	0.29
Acute lymphocytic	32	1.8	0.15	1.7	0.13	25	1.5	0.15	1.4	0.13
Chronic lymphocytic	119	4.0	0.17	4.7	0.20	71	2.0	0.11	2.4	0.13
Acute myeloid	133	4.8	0.19	5.4	0.22	88	2.9	0.15	3.3	0.17
Chronic myeloid	49	1.8	0.12	2.0	0.13	31	1.1	0.09	1.2	0.10
Other leukemias	54	2.0	0.13	2.3	0.14	37	1.4	0.11	1.5	0.11
Mesothelioma	44	1.5	0.10	1.7	0.11	13	0.4	0.05	0.4	0.06
Kaposi Sarcoma	5	0.3	0.06	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	555	18.7	0.36	21.9	0.42	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	201	8.0	0.27	8.9	0.29	393	14.1	0.35	16.0	0.38
Breast (<i>in situ</i>)	6	0.2	0.04	0.3	0.05	753	26.3	0.47	31.0	0.53

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arizona, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	479	404.3	9.06	485.0	10.63	435	343.5	7.62	403.0	8.83
Oral Cavity & Pharynx	9	7.3	1.15	8.5	1.31	3	2.0	0.55	2.7	0.72
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.0	0.66	2.2	0.70	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	100	84.2	4.12	101.4	4.84	87	70.6	3.51	83.2	4.08
Esophagus	4	4.1	1.04	4.8	1.19	2	1.7	0.51	2.2	0.65
Stomach	12	10.8	1.50	12.6	1.71	7	6.2	1.05	6.9	1.15
Small intestine	5	3.3	0.71	4.0	0.85	4	2.9	0.71	3.2	0.77
Colon excl. rectum	26	22.6	2.19	26.9	2.55	33	27.5	2.20	32.5	2.57
Rectum & rectosigmoid	13	9.8	1.30	11.5	1.51	8	6.7	1.08	7.9	1.26
Anus, anal canal & anorectum	-	-	-	-	-	2	1.2	0.41	1.6	0.52
Liver	16	13.1	1.59	16.4	1.92	6	4.6	0.88	5.5	1.02
Gallbladder	-	-	-	-	-	2	1.5	0.53	1.7	0.59
Pancreas	18	15.3	1.77	18.7	2.09	19	15.7	1.68	18.5	1.96
Respiratory System	74	69.7	3.97	82.3	4.58	50	41.1	2.70	49.5	3.17
Larynx	7	5.7	1.03	6.8	1.20	2	1.0	0.37	1.4	0.49
Lung & bronchus	66	63.2	3.82	74.5	4.40	48	39.9	2.67	47.9	3.13
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	5	3.8	0.81	4.2	0.89	3	2.2	0.62	2.5	0.69
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	1.6	0.50	1.9	0.57	3	2.4	0.66	2.8	0.76
Breast (excl. <i>in situ</i>)	-	-	-	-	-	142	109.0	4.22	128.1	4.89
Female Genital System	-	-	-	-	-	51	39.8	2.56	46.6	2.97
Cervix uteri	-	-	-	-	-	9	6.1	0.94	6.8	1.05
Uterus Corpus	-	-	-	-	-	26	20.3	1.83	24.3	2.16
Uterus, NOS ¹	-	-	-	-	-	3	2.3	0.61	2.7	0.71
Ovary	-	-	-	-	-	11	9.3	1.27	10.7	1.45
Male Genital System	153	122.0	4.78	151.6	5.77	-	-	-	-	-
Prostate	150	120.3	4.75	149.7	5.74	-	-	-	-	-
Testis	2	0.9	0.32	0.9	0.30	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	47	42.0	3.04	50.0	3.57	21	16.5	1.68	19.6	1.98
Bladder (incl. <i>in situ</i>)	14	15.5	2.03	18.3	2.37	8	7.1	1.16	8.4	1.35
Kidney & renal pelvis	32	25.9	2.22	31.0	2.62	12	8.8	1.18	10.5	1.40
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.0	0.81	4.5	0.92	4	3.4	0.76	3.7	0.83
Brain	5	3.9	0.81	4.4	0.92	4	3.0	0.70	3.3	0.77
Endocrine System	7	5.0	0.89	5.6	1.01	20	15.2	1.54	16.6	1.68
Thyroid gland	6	4.4	0.85	4.9	0.95	20	14.9	1.52	16.2	1.65
Lymphomas	26	20.5	1.97	23.3	2.23	14	10.7	1.34	12.0	1.50
Hodgkin Lymphoma	7	4.4	0.76	4.5	0.80	3	1.9	0.51	1.8	0.50
Non-Hodgkin Lymphoma	19	16.1	1.82	18.8	2.09	11	8.9	1.24	10.1	1.41
Multiple Myeloma	16	13.1	1.63	16.0	1.93	11	9.1	1.25	11.0	1.48
Leukemias	11	10.0	1.51	11.3	1.71	10	7.9	1.19	8.9	1.34
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	2.2	0.67	2.6	0.77	2	1.6	0.55	1.9	0.64
Acute myeloid	6	4.8	1.00	5.3	1.11	4	3.3	0.76	3.6	0.83
Chronic myeloid	2	1.6	0.66	1.8	0.76	2	1.8	0.54	2.1	0.64
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	1.4	0.41	1.4	0.40	-	-	-	-	-
Ill-defined & Unknown	18	16.9	1.98	20.1	2.31	15	12.6	1.52	14.6	1.74
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	6.9	1.20	7.8	1.37	19	15.2	1.62	17.8	1.89
Breast (<i>in situ</i>)	-	-	-	-	-	40	30.2	2.20	35.9	2.58

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


ARIZONA

II-30 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,959,549	2,967,726	2,978,407	2,990,410	3,002,997
White	2,398,153	2,401,347	2,405,795	2,410,812	2,418,213
Black	475,932	478,506	481,933	485,464	487,818
American Indian/Alaskan Native (AI/AN)	30,622	31,122	31,663	32,438	33,169
Asian/Pacific Islander (API)	54,842	56,751	59,016	61,696	63,797


All Races Population 2013-2017: 14,899,089
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	204,209	208,773	214,128	220,146	227,004
Non-Hispanic White	2,211,183	2,210,191	2,209,750	2,209,681	2,211,060
Non-Hispanic Black	468,481	470,922	474,209	477,328	479,284

Hispanic/Latino Population, Census 2010: 186,050
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ARKANSAS CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.2	100.8	102.8	105.0	105.5
Missing Race	0.5	0.3	1.2	1.5	1.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.2	0.7	0.5	0.6
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.1	2.3	2.7	2.6	2.3
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.4	Prostate	97.2
Oral Cavity & Pharynx	97.4	Testis	98.9
Esophagus	93.7	Bladder (incl. <i>in situ</i>)	97.5
Stomach	95.4	Kidney & Renal Pelvis	90.1
Colon & Rectum	95.7	Brain & Other CNS ¹	81.3
Liver	61.9	Thyroid	98.8
Pancreas	80.4	Hodgkin Lymphoma	99.0
Lung & Bronchus	89.6	Non-Hodgkin Lymphoma	96.2
Melanomas of the Skin	98.9	Multiple Myeloma	93.2
Female Breast (excl. <i>in situ</i>)	98.0	Leukemias	92.7
Cervix uteri	95.3	Brain & Other CNS ¹ <i>non-malig</i>	37.6
Uterus Corpus & Uterus NOS ¹	98.0	Breast <i>in situ</i>	100.0
Ovary	91.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,012	537.2	2.59	640.7	3.05	7,968	424.8	2.19	497.0	2.52
Oral Cavity & Pharynx	359	21.1	0.51	25.9	0.62	139	7.3	0.28	8.7	0.33
Lip	18	1.1	0.12	1.4	0.14	5	0.3	0.05	0.3	0.06
Tongue	108	6.2	0.28	7.7	0.34	39	2.1	0.15	2.4	0.18
Major salivary gland	30	1.9	0.16	2.2	0.18	19	1.1	0.11	1.2	0.13
Floor of mouth	14	0.8	0.10	1.0	0.12	9	0.5	0.07	0.5	0.08
Gum & other mouth	40	2.4	0.18	2.9	0.21	27	1.3	0.11	1.6	0.14
Nasopharynx	12	0.7	0.10	0.9	0.11	4	0.2	0.05	0.3	0.06
Oropharynx	18	1.1	0.11	1.3	0.14	5	0.2	0.05	0.3	0.06
Hypopharynx	22	1.2	0.12	1.5	0.15	6	0.3	0.06	0.4	0.07
Digestive System	1,720	103.0	1.14	123.8	1.35	1,300	67.1	0.85	79.4	1.00
Esophagus	135	7.8	0.31	9.6	0.37	29	1.5	0.13	1.8	0.15
Stomach	147	8.8	0.33	10.5	0.39	82	4.3	0.22	5.0	0.25
Small intestine	53	3.1	0.20	3.8	0.24	44	2.4	0.17	2.8	0.19
Colon excl. rectum	577	35.3	0.67	41.8	0.79	552	28.6	0.56	33.6	0.65
Rectum & rectosigmoid	262	15.9	0.45	18.9	0.53	175	9.3	0.32	11.1	0.38
Anus, anal canal & anorectum	26	1.6	0.14	1.9	0.17	48	2.6	0.17	3.1	0.20
Liver	194	10.9	0.36	13.7	0.44	61	3.1	0.18	3.7	0.21
Gallbladder	12	0.7	0.09	0.8	0.11	24	1.2	0.11	1.4	0.13
Pancreas	246	14.8	0.43	17.7	0.51	217	10.8	0.33	12.8	0.39
Respiratory System	1,760	103.4	1.13	124.2	1.34	1,308	65.2	0.82	78.1	0.98
Larynx	115	6.6	0.28	8.1	0.34	35	1.8	0.14	2.2	0.17
Lung & bronchus	1,627	95.8	1.08	114.8	1.29	1,259	62.7	0.80	75.1	0.96
Bones & Joints	20	1.3	0.13	1.4	0.14	15	0.9	0.11	0.9	0.11
Soft Tissue (incl. heart)	56	3.6	0.22	4.0	0.24	46	2.7	0.18	2.9	0.19
Skin (excl. basal & sq.)	486	30.4	0.63	35.4	0.73	313	18.0	0.47	20.3	0.52
Melanomas of the skin	454	28.3	0.61	33.0	0.70	294	17.0	0.46	19.1	0.51
Breast (excl. <i>in situ</i>)	21	1.3	0.13	1.5	0.15	2,192	118.2	1.17	139.2	1.35
Female Genital System	-	-	-	-	-	896	49.5	0.77	58.0	0.88
Cervix uteri	-	-	-	-	-	146	9.5	0.36	10.2	0.38
Uterus Corpus	-	-	-	-	-	442	23.2	0.51	28.3	0.61
Uterus, NOS ¹	-	-	-	-	-	17	0.9	0.10	1.0	0.11
Ovary	-	-	-	-	-	204	11.2	0.36	13.0	0.41
Male Genital System	2,107	118.8	1.18	145.5	1.43	-	-	-	-	-
Prostate	2,016	112.4	1.14	139.0	1.40	-	-	-	-	-
Testis	72	5.3	0.28	5.2	0.28	-	-	-	-	-
Penis	18	1.1	0.12	1.3	0.14	-	-	-	-	-
Urinary System	1,038	63.8	0.91	75.2	1.06	430	22.5	0.50	26.3	0.57
Bladder (incl. <i>in situ</i>)	567	35.1	0.67	41.3	0.79	160	8.0	0.29	9.4	0.34
Kidney & renal pelvis	451	27.4	0.59	32.3	0.69	261	14.0	0.40	16.3	0.46
Ureter	14	0.9	0.11	1.0	0.12	6	0.3	0.06	0.4	0.07
Eye & Orbit	14	0.9	0.11	1.0	0.12	11	0.6	0.09	0.7	0.09
Brain & Other CNS ¹	131	8.3	0.33	9.2	0.36	97	5.5	0.26	6.0	0.28
Brain	123	7.7	0.32	8.7	0.35	90	5.0	0.25	5.6	0.27
Endocrine System	114	7.2	0.31	8.1	0.34	290	18.4	0.50	20.0	0.53
Thyroid gland	100	6.3	0.29	7.2	0.32	277	17.6	0.49	19.2	0.52
Lymphomas	398	25.0	0.57	28.7	0.65	329	17.6	0.45	20.1	0.50
Hodgkin Lymphoma	45	3.0	0.21	3.1	0.21	37	2.4	0.18	2.5	0.18
Non-Hodgkin Lymphoma	353	22.0	0.54	25.6	0.62	292	15.2	0.41	17.7	0.47
Multiple Myeloma	137	8.3	0.32	9.8	0.38	112	5.7	0.25	6.7	0.29
Leukemias	296	18.5	0.49	21.1	0.56	209	11.2	0.36	12.7	0.40
Acute lymphocytic	25	1.7	0.15	1.6	0.14	19	1.3	0.14	1.2	0.12
Chronic lymphocytic	118	7.0	0.30	8.4	0.35	74	3.7	0.19	4.3	0.23
Acute myeloid	81	5.2	0.26	5.9	0.30	63	3.4	0.20	3.9	0.22
Chronic myeloid	39	2.5	0.18	2.8	0.20	32	1.8	0.14	2.0	0.16
Other leukemias	32	2.0	0.17	2.4	0.19	21	1.1	0.11	1.2	0.12
Mesothelioma	19	1.2	0.13	1.4	0.14	6	0.3	0.06	0.4	0.07
Kaposi Sarcoma	5	0.4	0.08	0.4	0.08	1	0.1	0.02	0.1	0.03
Ill-defined & Unknown	331	20.6	0.52	24.1	0.60	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	124	8.0	0.33	8.9	0.36	239	13.2	0.40	15.2	0.44
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.04	487	26.7	0.56	31.7	0.65

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	7,651	524.5	2.74	623.9	3.23	6,746	422.4	2.39	493.5	2.74
Oral Cavity & Pharynx	318	21.7	0.56	26.6	0.67	120	7.4	0.31	8.8	0.36
Lip	18	1.2	0.14	1.5	0.16	5	0.3	0.06	0.3	0.07
Tongue	97	6.6	0.31	8.1	0.37	36	2.3	0.18	2.7	0.20
Major salivary gland	27	2.0	0.17	2.3	0.20	14	1.0	0.12	1.1	0.13
Floor of mouth	12	0.8	0.10	0.9	0.12	8	0.5	0.08	0.6	0.10
Gum & other mouth	34	2.4	0.19	2.9	0.22	23	1.3	0.12	1.5	0.14
Nasopharynx	10	0.7	0.11	0.9	0.12	3	0.2	0.05	0.3	0.06
Oropharynx	16	1.1	0.12	1.3	0.15	3	0.2	0.05	0.3	0.06
Hypopharynx	17	1.1	0.12	1.3	0.15	4	0.3	0.06	0.3	0.07
Digestive System	1,444	99.6	1.20	119.4	1.42	1,066	63.9	0.90	75.6	1.06
Esophagus	120	8.0	0.33	9.8	0.40	24	1.4	0.13	1.7	0.16
Stomach	116	7.9	0.34	9.5	0.40	63	3.8	0.22	4.5	0.26
Small intestine	46	3.1	0.21	3.8	0.25	34	2.1	0.17	2.5	0.19
Colon excl. rectum	480	33.8	0.71	39.9	0.82	455	27.4	0.59	32.1	0.68
Rectum & rectosigmoid	224	15.8	0.49	18.8	0.57	144	8.9	0.34	10.7	0.41
Anus, anal canal & anorectum	22	1.5	0.15	1.9	0.18	44	2.8	0.20	3.4	0.23
Liver	158	10.2	0.37	12.9	0.46	50	3.0	0.19	3.5	0.23
Gallbladder	9	0.6	0.09	0.7	0.11	19	1.1	0.12	1.3	0.14
Pancreas	209	14.4	0.45	17.1	0.54	176	10.1	0.35	12.0	0.41
Respiratory System	1,517	101.5	1.19	121.8	1.41	1,159	67.0	0.90	80.2	1.07
Larynx	95	6.2	0.29	7.7	0.36	30	1.8	0.15	2.2	0.18
Lung & bronchus	1,406	94.1	1.14	112.7	1.36	1,117	64.4	0.88	77.0	1.05
Bones & Joints	16	1.3	0.14	1.4	0.15	12	1.0	0.13	1.0	0.13
Soft Tissue (incl. heart)	45	3.4	0.23	3.8	0.26	39	2.6	0.20	2.8	0.21
Skin (excl. basal & sq.)	461	32.9	0.70	38.4	0.81	291	20.0	0.55	22.6	0.60
Melanomas of the skin	433	30.8	0.68	36.1	0.78	276	19.1	0.54	21.5	0.59
Breast (excl. <i>in situ</i>)	15	1.1	0.13	1.3	0.15	1,826	115.4	1.26	136.1	1.45
Female Genital System	-	-	-	-	-	743	49.1	0.84	57.4	0.96
Cervix uteri	-	-	-	-	-	112	9.0	0.40	9.6	0.41
Uterus Corpus	-	-	-	-	-	366	23.1	0.56	27.9	0.67
Uterus, NOS ¹	-	-	-	-	-	12	0.7	0.10	0.9	0.11
Ovary	-	-	-	-	-	177	11.5	0.40	13.3	0.46
Male Genital System	1,653	107.5	1.21	130.7	1.45	-	-	-	-	-
Prostate	1,568	100.1	1.15	123.2	1.40	-	-	-	-	-
Testis	67	6.2	0.34	6.1	0.33	-	-	-	-	-
Penis	16	1.1	0.13	1.3	0.15	-	-	-	-	-
Urinary System	934	65.5	0.98	77.1	1.14	367	22.5	0.54	26.2	0.62
Bladder (incl. <i>in situ</i>)	526	36.8	0.73	43.4	0.86	141	8.2	0.32	9.6	0.37
Kidney & renal pelvis	387	27.2	0.64	32.1	0.74	217	13.8	0.44	16.0	0.50
Ureter	14	1.0	0.12	1.1	0.14	6	0.3	0.06	0.4	0.07
Eye & Orbit	13	1.0	0.12	1.1	0.14	11	0.7	0.10	0.8	0.11
Brain & Other CNS ¹	118	8.8	0.37	9.7	0.41	88	6.1	0.30	6.6	0.32
Brain	111	8.3	0.36	9.2	0.39	81	5.5	0.29	6.0	0.31
Endocrine System	101	7.6	0.35	8.5	0.38	246	19.1	0.57	20.7	0.60
Thyroid gland	89	6.7	0.33	7.6	0.36	236	18.3	0.56	19.9	0.59
Lymphomas	349	25.2	0.62	29.0	0.70	285	17.9	0.49	20.4	0.55
Hodgkin Lymphoma	36	3.0	0.23	3.0	0.23	30	2.4	0.20	2.4	0.20
Non-Hodgkin Lymphoma	313	22.3	0.58	25.9	0.66	256	15.5	0.45	18.0	0.51
Multiple Myeloma	105	7.2	0.32	8.5	0.38	80	4.7	0.24	5.5	0.28
Leukemias	257	18.4	0.53	21.1	0.60	176	11.2	0.39	12.5	0.43
Acute lymphocytic	21	1.8	0.18	1.7	0.16	16	1.4	0.16	1.3	0.14
Chronic lymphocytic	104	7.0	0.31	8.4	0.37	64	3.7	0.21	4.3	0.25
Acute myeloid	72	5.2	0.28	6.0	0.32	54	3.4	0.22	3.9	0.24
Chronic myeloid	32	2.4	0.19	2.7	0.21	27	1.7	0.16	2.0	0.17
Other leukemias	28	2.1	0.18	2.4	0.20	16	0.9	0.11	1.1	0.12
Mesothelioma	18	1.3	0.14	1.5	0.16	6	0.3	0.06	0.4	0.08
Kaposi Sarcoma	4	0.3	0.07	0.3	0.08	1	0.1	0.02	0.1	0.03
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	102	7.8	0.35	8.6	0.38	197	13.0	0.43	14.8	0.48
Breast (<i>in situ</i>)	-	-	-	-	-	398	26.0	0.61	30.8	0.70

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,133	589.1	8.44	713.2	9.89	979	402.7	5.94	476.6	6.88
Oral Cavity & Pharynx	33	15.5	1.27	19.1	1.52	16	6.2	0.71	7.5	0.84
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	9	4.0	0.64	5.0	0.78	2	0.7	0.23	0.9	0.29
Major salivary gland	2	1.0	0.32	1.2	0.40	4	1.7	0.38	2.0	0.42
Floor of mouth	2	0.7	0.25	0.9	0.32	-	-	-	-	-
Gum & other mouth	4	1.9	0.43	2.3	0.51	3	1.2	0.32	1.5	0.38
Nasopharynx	1	0.6	0.24	0.7	0.27	-	-	-	-	-
Oropharynx	2	0.8	0.28	0.9	0.32	1	0.4	0.18	0.6	0.23
Hypopharynx	5	2.5	0.52	3.1	0.62	2	0.6	0.21	0.8	0.27
Digestive System	235	123.4	3.89	149.4	4.55	197	82.8	2.72	98.0	3.16
Esophagus	13	6.2	0.83	7.8	1.01	5	2.1	0.41	2.6	0.49
Stomach	27	15.1	1.38	17.9	1.59	16	6.9	0.79	8.2	0.92
Small intestine	6	2.9	0.58	3.5	0.68	8	3.1	0.51	3.6	0.59
Colon excl. rectum	82	44.1	2.36	53.0	2.74	83	34.8	1.76	41.4	2.04
Rectum & rectosigmoid	31	15.3	1.32	18.7	1.56	23	10.2	0.98	11.7	1.10
Anus, anal canal & anorectum	3	1.6	0.42	1.7	0.44	3	1.1	0.31	1.3	0.37
Liver	29	14.0	1.24	17.7	1.52	8	3.4	0.54	4.0	0.64
Gallbladder	3	1.5	0.45	1.8	0.51	4	1.6	0.38	1.9	0.44
Pancreas	33	18.1	1.54	21.8	1.79	38	16.3	1.22	19.3	1.41
Respiratory System	220	119.1	3.89	144.4	4.55	128	52.3	2.14	63.7	2.54
Larynx	19	9.4	1.05	11.5	1.24	4	1.7	0.38	2.1	0.45
Lung & bronchus	200	109.0	3.73	132.0	4.37	123	50.2	2.10	61.2	2.49
Bones & Joints	3	1.2	0.36	1.2	0.36	2	0.7	0.24	0.7	0.25
Soft Tissue (incl. heart)	9	4.7	0.75	5.1	0.81	6	2.6	0.49	2.8	0.52
Skin (excl. basal & sq.)	7	4.1	0.75	4.4	0.81	5	2.2	0.44	2.5	0.49
Melanomas of the skin	3	1.7	0.49	2.0	0.56	3	1.1	0.31	1.3	0.36
Breast (excl. <i>in situ</i>)	4	2.5	0.59	2.9	0.68	294	120.1	3.23	141.7	3.72
Female Genital System	-	-	-	-	-	121	48.4	2.03	58.0	2.38
Cervix uteri	-	-	-	-	-	24	10.1	0.94	11.4	1.05
Uterus Corpus	-	-	-	-	-	61	23.5	1.39	29.3	1.69
Uterus, NOS ¹	-	-	-	-	-	4	1.6	0.37	1.9	0.44
Ovary	-	-	-	-	-	21	8.8	0.88	10.3	1.02
Male Genital System	383	187.3	4.60	234.2	5.53	-	-	-	-	-
Prostate	378	185.2	4.57	231.9	5.51	-	-	-	-	-
Testis	3	1.2	0.33	1.2	0.33	-	-	-	-	-
Penis	2	0.8	0.32	1.1	0.39	-	-	-	-	-
Urinary System	85	46.9	2.45	55.7	2.83	53	22.5	1.43	26.4	1.64
Bladder (incl. <i>in situ</i>)	31	19.1	1.65	22.5	1.89	15	6.4	0.77	7.6	0.89
Kidney & renal pelvis	53	27.7	1.81	33.0	2.09	38	16.0	1.20	18.7	1.37
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	11	5.5	0.78	6.1	0.85	7	2.9	0.50	3.2	0.54
Brain	10	5.2	0.77	5.8	0.84	7	2.7	0.48	3.0	0.53
Endocrine System	10	4.9	0.73	5.6	0.83	31	12.8	1.06	14.1	1.15
Thyroid gland	8	3.7	0.63	4.4	0.73	28	11.8	1.01	13.0	1.10
Lymphomas	39	20.0	1.54	22.6	1.71	32	13.3	1.09	15.1	1.21
Hodgkin Lymphoma	8	3.5	0.57	3.7	0.60	6	2.3	0.43	2.3	0.43
Non-Hodgkin Lymphoma	31	16.5	1.43	18.9	1.61	26	11.0	1.00	12.7	1.13
Multiple Myeloma	29	16.5	1.50	19.6	1.72	28	11.1	0.97	13.7	1.17
Leukemias	27	14.8	1.39	16.7	1.55	22	8.6	0.84	10.3	1.00
Acute lymphocytic	4	1.4	0.34	1.2	0.32	2	0.8	0.27	0.9	0.28
Chronic lymphocytic	10	6.2	0.95	7.1	1.06	7	2.8	0.48	3.5	0.59
Acute myeloid	7	4.3	0.78	4.9	0.86	7	2.5	0.44	3.0	0.53
Chronic myeloid	4	1.8	0.42	2.2	0.51	3	1.1	0.31	1.3	0.36
Other leukemias	2	1.1	0.35	1.3	0.42	3	1.3	0.34	1.5	0.39
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	0.7	0.27	0.8	0.28	-	-	-	-	-
Ill-defined & Unknown	37	21.0	1.67	24.6	1.91	36	16.0	1.23	18.7	1.40
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	19	10.2	1.11	11.8	1.28	36	14.6	1.12	17.2	1.29
Breast (<i>in situ</i>)	-	-	-	-	-	68	26.6	1.48	32.6	1.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	56	351.4	24.08	415.6	27.75	90	398.9	20.45	457.9	23.26
Oral Cavity & Pharynx	3	12.3	3.50	14.5	4.16	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	16	97.5	12.16	119.2	14.35	16	81.0	9.73	94.2	11.10
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	9.2	4.46	11.2	5.41	2	9.9	3.35	11.2	3.76
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	28.6	6.56	34.3	7.66	6	32.8	6.40	38.3	7.28
Rectum & rectosigmoid	3	14.8	4.65	18.0	5.31	3	13.0	3.55	14.8	4.02
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	29.9	6.54	37.6	7.88	1	9.0	3.76	10.0	4.17
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	7.0	2.76	8.9	3.44	2	8.2	2.90	9.8	3.46
Respiratory System	9	58.9	9.51	70.4	10.90	8	39.8	6.75	47.1	7.78
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	55.5	9.13	66.3	10.45	8	39.8	6.75	47.1	7.78
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	27	115.4	10.74	133.3	12.28
Female Genital System	-	-	-	-	-	14	53.2	6.92	60.3	7.87
Cervix uteri	-	-	-	-	-	4	12.3	2.92	13.2	3.21
Uterus Corpus	-	-	-	-	-	6	22.9	4.54	26.9	5.35
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	14.1	3.77	16.4	4.31
Male Genital System	9	60.2	9.84	73.7	11.50	-	-	-	-	-
Prostate	9	58.9	9.79	71.9	11.41	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	27.9	7.65	32.9	8.94	4	20.0	4.56	23.1	5.25
Bladder (incl. <i>in situ</i>)	2	17.6	6.70	20.7	7.86	2	11.0	3.69	12.1	4.14
Kidney & renal pelvis	2	10.4	3.69	12.2	4.25	2	9.1	2.67	10.9	3.23
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	4.1	1.73	3.8	1.60	6	21.6	4.19	23.9	4.65
Thyroid gland	-	-	-	-	-	6	21.6	4.19	23.9	4.65
Lymphomas	4	23.3	6.65	28.1	7.83	5	21.2	4.54	24.1	5.26
Hodgkin Lymphoma	-	-	-	-	-	1	3.6	1.61	3.8	1.68
Non-Hodgkin Lymphoma	4	23.3	6.65	28.1	7.83	4	17.6	4.25	20.4	4.98
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	3	16.5	5.67	17.8	6.49	3	13.4	3.79	14.7	4.16
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	4.6	2.18	4.4	2.19	2	6.8	2.59	7.4	2.80
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	29.7	7.79	32.6	8.38	2	14.6	4.48	16.3	4.88
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	4	17.4	4.43	20.2	5.11
Breast (<i>in situ</i>)	-	-	-	-	-	7	30.1	5.26	35.1	6.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	155	338.7	14.98	399.8	17.29	171	346.5	14.00	403.1	16.13
Oral Cavity & Pharynx	4	9.8	2.51	12.2	3.00	2	3.6	1.36	4.5	1.60
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	2.9	1.45	3.6	1.74	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	33	64.8	6.22	79.0	7.42	29	71.9	6.93	83.2	7.83
Esophagus	1	3.6	1.62	4.5	1.96	-	-	-	-	-
Stomach	4	10.8	2.92	12.7	3.36	3	5.4	1.70	6.0	1.91
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	11	19.4	3.32	23.6	3.99	9	23.4	4.04	26.8	4.52
Rectum & rectosigmoid	7	9.9	1.98	11.8	2.35	5	10.2	2.46	12.4	2.91
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	6.6	1.46	8.5	1.93	3	7.9	2.29	9.4	2.64
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	4	10.9	3.05	13.1	3.57	4	13.7	3.22	15.6	3.57
Respiratory System	20	50.1	5.87	60.6	6.84	14	40.0	5.29	47.3	6.13
Larynx	2	5.4	2.04	5.9	2.17	-	-	-	-	-
Lung & bronchus	17	43.2	5.46	52.7	6.43	14	39.0	5.24	46.3	6.08
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	5.4	2.14	6.0	2.48	2	2.2	0.80	2.4	0.92
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	3	10.5	2.93	11.3	3.12	3	6.6	2.13	7.5	2.38
Breast (excl. <i>in situ</i>)	-	-	-	-	-	46	90.8	6.84	107.6	8.01
Female Genital System	-	-	-	-	-	26	48.8	5.01	56.8	5.80
Cervix uteri	-	-	-	-	-	9	14.3	2.63	15.8	2.99
Uterus Corpus	-	-	-	-	-	11	21.9	3.36	26.5	4.01
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	9.1	2.22	10.6	2.54
Male Genital System	41	97.3	7.97	115.8	9.16	-	-	-	-	-
Prostate	35	92.3	7.91	110.6	9.10	-	-	-	-	-
Testis	6	4.3	0.83	4.2	0.82	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	16	38.9	5.29	45.6	6.07	8	17.4	3.18	20.8	3.73
Bladder (incl. <i>in situ</i>)	6	18.8	3.93	22.2	4.49	2	5.4	2.00	6.1	2.20
Kidney & renal pelvis	10	20.0	3.55	23.4	4.08	6	11.1	2.28	13.6	2.80
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	4.2	1.18	4.7	1.37	2	2.7	0.86	3.3	1.14
Brain	3	3.2	0.90	3.7	1.11	2	2.6	0.84	3.2	1.13
Endocrine System	3	5.4	1.67	5.6	1.74	17	20.6	2.42	22.1	2.71
Thyroid gland	3	4.8	1.64	5.1	1.71	17	20.2	2.40	21.7	2.70
Lymphomas	9	20.0	3.93	22.6	4.43	6	8.8	1.92	9.8	2.20
Hodgkin Lymphoma	2	1.2	0.44	1.1	0.45	2	1.6	0.57	1.6	0.59
Non-Hodgkin Lymphoma	7	18.8	3.90	21.4	4.41	4	7.2	1.83	8.2	2.12
Multiple Myeloma	2	4.9	1.73	5.7	1.92	2	5.8	1.98	6.9	2.32
Leukemias	9	14.9	3.25	16.2	3.63	8	13.6	2.70	15.3	3.10
Acute lymphocytic	-	-	-	-	-	3	2.2	0.66	2.2	0.73
Chronic lymphocytic	1	3.8	1.85	4.7	2.19	-	-	-	-	-
Acute myeloid	3	4.1	1.57	4.0	1.56	3	6.2	2.08	6.9	2.39
Chronic myeloid	2	5.0	2.09	5.7	2.39	1	1.9	0.72	2.2	0.87
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	9.3	2.28	10.5	2.64	5	13.0	3.02	15.0	3.44
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	2.5	0.84	2.8	1.03	5	9.2	2.28	10.5	2.62
Breast (<i>in situ</i>)	-	-	-	-	-	11	18.5	2.79	21.4	3.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

ARKANSAS

II-38 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7,523	532.4	2.82	633.1	3.31	6,600	427.2	2.47	498.7	2.81
Oral Cavity & Pharynx	314	22.3	0.58	27.2	0.70	118	7.5	0.32	8.9	0.38
Lip	18	1.3	0.14	1.5	0.17	5	0.3	0.06	0.4	0.07
Tongue	97	6.8	0.32	8.4	0.39	36	2.4	0.18	2.8	0.21
Major salivary gland	27	2.0	0.18	2.3	0.20	14	1.0	0.12	1.1	0.14
Floor of mouth	12	0.8	0.11	0.9	0.13	8	0.5	0.09	0.6	0.10
Gum & other mouth	33	2.4	0.19	2.9	0.23	22	1.3	0.12	1.5	0.15
Nasopharynx	10	0.8	0.11	0.9	0.13	3	0.2	0.06	0.3	0.06
Oropharynx	15	1.1	0.13	1.3	0.15	3	0.2	0.05	0.3	0.06
Hypopharynx	16	1.1	0.12	1.4	0.15	4	0.2	0.06	0.3	0.07
Digestive System	1,415	100.8	1.23	120.8	1.45	1,044	64.3	0.93	76.1	1.08
Esophagus	118	8.1	0.34	10.0	0.42	23	1.4	0.13	1.7	0.16
Stomach	113	8.0	0.34	9.5	0.41	60	3.7	0.22	4.4	0.26
Small intestine	46	3.2	0.22	3.9	0.26	33	2.2	0.17	2.5	0.20
Colon excl. rectum	472	34.3	0.73	40.5	0.85	448	27.8	0.61	32.5	0.70
Rectum & rectosigmoid	218	16.0	0.50	19.0	0.58	141	9.0	0.35	10.8	0.42
Anus, anal canal & anorectum	22	1.6	0.16	2.0	0.19	44	2.9	0.21	3.5	0.24
Liver	154	10.3	0.38	13.0	0.47	48	2.9	0.20	3.5	0.23
Gallbladder	9	0.6	0.09	0.7	0.11	19	1.1	0.12	1.3	0.14
Pancreas	205	14.5	0.46	17.3	0.55	173	10.1	0.35	12.0	0.42
Respiratory System	1,501	103.0	1.21	123.6	1.44	1,147	67.8	0.92	81.2	1.09
Larynx	94	6.4	0.30	7.9	0.37	30	1.9	0.16	2.3	0.19
Lung & bronchus	1,392	95.6	1.17	114.4	1.39	1,104	65.2	0.90	78.0	1.07
Bones & Joints	16	1.3	0.15	1.4	0.16	12	1.0	0.14	1.0	0.13
Soft Tissue (incl. heart)	43	3.4	0.24	3.8	0.26	37	2.6	0.20	2.9	0.22
Skin (excl. basal & sq.)	457	33.8	0.73	39.4	0.84	288	20.8	0.58	23.4	0.63
Melanomas of the skin	430	31.7	0.71	37.1	0.81	273	19.9	0.57	22.3	0.62
Breast (excl. <i>in situ</i>)	15	1.1	0.13	1.3	0.16	1,786	116.8	1.30	137.5	1.49
Female Genital System	-	-	-	-	-	720	49.4	0.87	57.8	0.99
Cervix uteri	-	-	-	-	-	105	9.0	0.41	9.5	0.42
Uterus Corpus	-	-	-	-	-	356	23.2	0.58	28.2	0.68
Uterus, NOS ¹	-	-	-	-	-	11	0.7	0.09	0.8	0.11
Ovary	-	-	-	-	-	173	11.7	0.42	13.5	0.47
Male Genital System	1,620	108.5	1.23	132.0	1.48	-	-	-	-	-
Prostate	1,541	101.0	1.17	124.3	1.43	-	-	-	-	-
Testis	62	6.3	0.36	6.3	0.36	-	-	-	-	-
Penis	15	1.1	0.13	1.3	0.15	-	-	-	-	-
Urinary System	921	66.6	1.01	78.3	1.17	361	22.8	0.56	26.5	0.64
Bladder (incl. <i>in situ</i>)	521	37.4	0.75	44.0	0.87	140	8.3	0.32	9.7	0.37
Kidney & renal pelvis	380	27.7	0.66	32.6	0.76	212	13.9	0.45	16.2	0.51
Ureter	14	1.0	0.12	1.1	0.14	6	0.3	0.06	0.4	0.07
Eye & Orbit	13	1.0	0.13	1.1	0.14	11	0.8	0.11	0.8	0.12
Brain & Other CNS ¹	115	9.1	0.40	10.0	0.42	86	6.2	0.32	6.8	0.33
Brain	109	8.6	0.38	9.5	0.41	79	5.6	0.30	6.2	0.32
Endocrine System	98	7.8	0.37	8.7	0.40	231	18.9	0.58	20.6	0.62
Thyroid gland	87	6.9	0.34	7.8	0.38	221	18.1	0.57	19.8	0.61
Lymphomas	342	25.8	0.64	29.5	0.72	280	18.1	0.51	20.7	0.57
Hodgkin Lymphoma	35	3.1	0.24	3.2	0.24	29	2.5	0.22	2.5	0.21
Non-Hodgkin Lymphoma	308	22.7	0.59	26.4	0.68	252	15.6	0.46	18.2	0.52
Multiple Myeloma	102	7.2	0.33	8.6	0.38	79	4.8	0.25	5.5	0.28
Leukemias	249	18.5	0.54	21.2	0.61	169	11.2	0.40	12.4	0.44
Acute lymphocytic	18	1.7	0.18	1.6	0.17	14	1.4	0.17	1.2	0.15
Chronic lymphocytic	103	7.1	0.32	8.6	0.38	63	3.7	0.21	4.4	0.25
Acute myeloid	70	5.2	0.28	6.0	0.32	51	3.4	0.23	3.9	0.25
Chronic myeloid	31	2.4	0.20	2.7	0.22	26	1.8	0.16	2.0	0.18
Other leukemias	28	2.1	0.18	2.4	0.21	15	0.9	0.11	1.0	0.12
Mesothelioma	18	1.3	0.14	1.5	0.16	6	0.3	0.06	0.4	0.08
Kaposi Sarcoma	4	0.3	0.08	0.3	0.08	1	0.1	0.02	0.1	0.03
Ill-defined & Unknown	280	20.5	0.56	24.0	0.65	225	13.7	0.42	15.9	0.49
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	100	8.1	0.37	8.9	0.40	193	13.3	0.45	15.1	0.50
Breast (<i>in situ</i>)	-	-	-	-	-	388	26.2	0.63	31.1	0.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Arkansas, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,129	591.9	8.50	716.6	9.95	975	404.0	5.97	478.1	6.91
Oral Cavity & Pharynx	33	15.6	1.28	19.3	1.53	16	6.2	0.72	7.4	0.84
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	9	4.0	0.65	5.1	0.79	2	0.7	0.23	0.9	0.29
Major salivary gland	2	1.0	0.32	1.3	0.40	4	1.8	0.39	2.0	0.43
Floor of mouth	2	0.7	0.25	0.9	0.32	-	-	-	-	-
Gum & other mouth	4	1.9	0.43	2.3	0.52	3	1.2	0.32	1.5	0.38
Nasopharynx	1	0.6	0.25	0.7	0.28	-	-	-	-	-
Oropharynx	2	0.8	0.28	0.9	0.33	1	0.4	0.19	0.6	0.23
Hypopharynx	5	2.5	0.52	3.1	0.62	2	0.5	0.20	0.7	0.25
Digestive System	234	124.3	3.92	150.4	4.58	195	82.8	2.73	98.0	3.16
Esophagus	13	6.2	0.84	7.9	1.02	5	2.1	0.41	2.6	0.50
Stomach	27	15.3	1.39	18.1	1.60	16	6.9	0.79	8.1	0.92
Small intestine	6	2.9	0.59	3.5	0.69	8	3.1	0.52	3.7	0.59
Colon excl. rectum	82	44.3	2.37	53.3	2.75	83	34.7	1.76	41.3	2.05
Rectum & rectosigmoid	31	15.4	1.33	18.9	1.58	23	10.3	0.98	11.8	1.10
Anus, anal canal & anorectum	3	1.7	0.42	1.8	0.44	3	1.1	0.31	1.3	0.37
Liver	29	14.1	1.25	17.7	1.52	8	3.4	0.54	4.1	0.64
Gallbladder	3	1.5	0.45	1.8	0.52	4	1.6	0.38	1.9	0.45
Pancreas	33	18.3	1.55	22.0	1.80	38	16.3	1.22	19.3	1.42
Respiratory System	219	119.6	3.91	145.0	4.58	128	52.6	2.15	64.1	2.56
Larynx	18	9.4	1.05	11.5	1.24	4	1.7	0.38	2.1	0.46
Lung & bronchus	200	109.5	3.75	132.7	4.39	123	50.4	2.11	61.5	2.51
Bones & Joints	3	1.3	0.36	1.2	0.36	2	0.7	0.24	0.7	0.25
Soft Tissue (incl. heart)	9	4.8	0.76	5.2	0.82	6	2.7	0.49	2.9	0.52
Skin (excl. basal & sq.)	7	4.2	0.76	4.5	0.82	5	2.2	0.44	2.5	0.49
Melanomas of the skin	3	1.7	0.50	2.0	0.57	3	1.1	0.31	1.3	0.36
Breast (excl. <i>in situ</i>)	4	2.5	0.60	2.9	0.69	293	120.6	3.25	142.4	3.74
Female Genital System	-	-	-	-	-	120	48.6	2.05	58.2	2.40
Cervix uteri	-	-	-	-	-	24	10.1	0.95	11.5	1.06
Uterus Corpus	-	-	-	-	-	61	23.6	1.40	29.3	1.69
Uterus, NOS ¹	-	-	-	-	-	4	1.6	0.37	1.9	0.45
Ovary	-	-	-	-	-	21	8.9	0.89	10.4	1.02
Male Genital System	381	188.0	4.63	235.1	5.56	-	-	-	-	-
Prostate	376	185.9	4.60	232.8	5.54	-	-	-	-	-
Testis	3	1.2	0.34	1.2	0.33	-	-	-	-	-
Penis	2	0.8	0.32	1.1	0.39	-	-	-	-	-
Urinary System	85	47.2	2.47	56.0	2.85	53	22.5	1.43	26.5	1.65
Bladder (incl. <i>in situ</i>)	31	19.1	1.66	22.6	1.91	15	6.3	0.76	7.5	0.89
Kidney & renal pelvis	53	27.8	1.82	33.2	2.11	38	16.1	1.21	18.8	1.38
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	11	5.5	0.79	6.0	0.85	7	2.9	0.50	3.2	0.55
Brain	10	5.2	0.77	5.8	0.85	7	2.8	0.48	3.0	0.53
Endocrine System	10	4.8	0.73	5.6	0.83	31	12.9	1.07	14.2	1.16
Thyroid gland	8	3.8	0.64	4.4	0.74	28	11.9	1.02	13.2	1.11
Lymphomas	38	20.0	1.54	22.5	1.71	32	13.4	1.10	15.2	1.22
Hodgkin Lymphoma	8	3.6	0.58	3.7	0.61	6	2.4	0.44	2.4	0.44
Non-Hodgkin Lymphoma	30	16.4	1.42	18.7	1.60	26	11.1	1.01	12.8	1.14
Multiple Myeloma	29	16.7	1.51	19.8	1.73	28	11.2	0.98	13.8	1.17
Leukemias	27	14.8	1.39	16.7	1.55	21	8.5	0.84	10.1	0.99
Acute lymphocytic	4	1.4	0.35	1.3	0.32	2	0.9	0.27	0.9	0.29
Chronic lymphocytic	10	6.3	0.95	7.2	1.07	7	2.8	0.49	3.5	0.60
Acute myeloid	7	4.4	0.79	4.9	0.87	6	2.4	0.43	2.9	0.52
Chronic myeloid	4	1.6	0.38	2.0	0.46	3	1.1	0.30	1.3	0.35
Other leukemias	2	1.1	0.36	1.4	0.43	3	1.4	0.35	1.6	0.39
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	0.7	0.27	0.8	0.28	-	-	-	-	-
Ill-defined & Unknown	37	21.2	1.69	24.8	1.93	36	15.9	1.23	18.6	1.40
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	19	10.3	1.12	11.9	1.29	36	14.7	1.13	17.3	1.30
Breast (<i>in situ</i>)	-	-	-	-	-	68	26.7	1.49	32.7	1.79

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

ARKANSAS


II-40 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	38,280,824	38,625,139	38,953,142	39,209,127	39,399,349
White	28,837,801	29,008,534	29,153,588	29,250,601	29,289,341
Black	2,768,281	2,788,916	2,806,054	2,819,090	2,834,619
American Indian/Alaskan Native (AI/AN)	753,487	758,154	762,754	766,785	772,742
Asian/Pacific Islander (API)	5,921,255	6,069,535	6,230,746	6,372,651	6,502,647

All Races Population 2013-2017: 194,467,581

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	14,672,498	14,870,195	15,060,875	15,241,117	15,395,587
Non-Hispanic White	15,433,120	15,422,046	15,392,312	15,324,439	15,227,539
Non-Hispanic Black	2,395,291	2,409,848	2,420,881	2,428,093	2,437,079

Hispanic/Latino Population, Census 2010: 14,013,719

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

CALIFORNIA CANCER REGISTRY

Initial Operation: 1988
 Population-based Data Available: 1988
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.3	100.1	99.2	97.6	96.6
Missing Race	1.7	1.7	2.1	2.3	2.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	1.4	1.6	1.6	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Prostate	95.7
Oral Cavity & Pharynx	97.9	Testis	98.9
Esophagus	95.6	Bladder (incl. <i>in situ</i>)	97.5
Stomach	96.8	Kidney & Renal Pelvis	89.8
Colon & Rectum	96.5	Brain & Other CNS ¹	86.0
Liver	46.1	Thyroid	99.5
Pancreas	83.9	Hodgkin Lymphoma	98.7
Lung & Bronchus	88.4	Non-Hodgkin Lymphoma	97.2
Melanomas of the Skin	98.9	Multiple Myeloma	89.4
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	92.4
Cervix uteri	97.7	Brain & Other CNS ¹ <i>non-malig</i>	45.4
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	93.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	83,082	432.9	0.69	512.1	0.80	85,518	387.6	0.60	452.3	0.69
Oral Cavity & Pharynx	3,105	15.5	0.13	18.8	0.15	1,255	5.6	0.07	6.6	0.08
Lip	200	1.0	0.03	1.2	0.04	80	0.4	0.02	0.4	0.02
Tongue	1,011	5.0	0.07	6.1	0.09	398	1.8	0.04	2.1	0.05
Major salivary gland	300	1.6	0.04	1.9	0.05	197	0.9	0.03	1.0	0.03
Floor of mouth	93	0.5	0.02	0.6	0.03	54	0.2	0.01	0.3	0.02
Gum & other mouth	282	1.5	0.04	1.8	0.05	222	1.0	0.03	1.1	0.03
Nasopharynx	202	1.0	0.03	1.2	0.04	82	0.4	0.02	0.4	0.02
Oropharynx	133	0.6	0.03	0.8	0.03	36	0.2	0.01	0.2	0.01
Hypopharynx	149	0.8	0.03	0.9	0.03	36	0.2	0.01	0.2	0.01
Digestive System	17,747	92.0	0.32	110.0	0.37	14,224	63.1	0.24	74.5	0.28
Esophagus	1,121	5.8	0.08	7.0	0.09	341	1.5	0.04	1.8	0.04
Stomach	1,816	9.7	0.10	11.4	0.12	1,234	5.6	0.07	6.5	0.08
Small intestine	418	2.2	0.05	2.6	0.06	374	1.7	0.04	2.0	0.05
Colon excl. rectum	5,057	26.7	0.17	31.6	0.20	5,064	22.6	0.14	26.4	0.17
Rectum & rectosigmoid	2,600	13.2	0.12	15.8	0.14	1,884	8.5	0.09	10.1	0.10
Anus, anal canal & anorectum	298	1.5	0.04	1.8	0.05	477	2.1	0.04	2.5	0.05
Liver	2,791	13.5	0.12	16.8	0.14	1,029	4.5	0.06	5.4	0.08
Gallbladder	156	0.9	0.03	1.0	0.04	349	1.5	0.04	1.8	0.04
Pancreas	2,542	13.5	0.12	16.0	0.14	2,401	10.5	0.10	12.4	0.11
Respiratory System	9,398	51.0	0.24	59.9	0.28	8,783	39.0	0.19	45.7	0.22
Larynx	672	3.5	0.06	4.2	0.07	138	0.6	0.02	0.7	0.03
Lung & bronchus	8,507	46.4	0.23	54.4	0.27	8,521	37.8	0.19	44.4	0.22
Bones & Joints	198	1.0	0.03	1.1	0.03	150	0.8	0.03	0.8	0.03
Soft Tissue (incl. heart)	830	4.4	0.07	4.9	0.08	659	3.1	0.06	3.5	0.06
Skin (excl. basal & sq.)	6,278	33.4	0.19	39.2	0.22	4,057	18.5	0.13	21.4	0.15
Melanomas of the skin	5,752	30.4	0.18	35.8	0.21	3,743	17.1	0.13	19.8	0.15
Breast (excl. <i>in situ</i>)	190	1.0	0.03	1.2	0.04	26,599	121.5	0.34	142.9	0.39
Female Genital System	-	-	-	-	-	10,731	48.4	0.21	57.4	0.25
Cervix uteri	-	-	-	-	-	1,456	7.2	0.09	7.8	0.09
Uterus Corpus	-	-	-	-	-	5,688	25.0	0.15	30.5	0.18
Uterus, NOS ¹	-	-	-	-	-	214	1.0	0.03	1.1	0.03
Ovary	-	-	-	-	-	2,471	11.3	0.10	13.2	0.12
Male Genital System	20,162	100.2	0.32	121.6	0.39	-	-	-	-	-
Prostate	18,743	93.0	0.31	114.2	0.38	-	-	-	-	-
Testis	1,215	6.1	0.08	6.1	0.08	-	-	-	-	-
Penis	152	0.8	0.03	1.0	0.03	-	-	-	-	-
Urinary System	9,444	50.7	0.24	59.6	0.28	3,894	17.4	0.13	20.3	0.15
Bladder (incl. <i>in situ</i>)	5,288	29.3	0.18	34.3	0.21	1,573	6.9	0.08	8.1	0.09
Kidney & renal pelvis	3,958	20.3	0.15	24.0	0.17	2,209	10.0	0.10	11.7	0.11
Ureter	108	0.6	0.03	0.7	0.03	70	0.3	0.02	0.4	0.02
Eye & Orbit	192	1.0	0.03	1.1	0.04	163	0.8	0.03	0.8	0.03
Brain & Other CNS ¹	1,365	7.1	0.09	7.9	0.10	1,057	5.0	0.07	5.5	0.08
Brain	1,287	6.6	0.08	7.4	0.09	981	4.6	0.07	5.1	0.07
Endocrine System	1,469	7.5	0.09	8.4	0.10	4,094	20.1	0.14	22.0	0.15
Thyroid gland	1,308	6.6	0.08	7.5	0.09	3,953	19.4	0.14	21.2	0.15
Lymphomas	4,707	24.8	0.17	28.6	0.19	3,744	17.1	0.13	19.6	0.14
Hodgkin Lymphoma	487	2.5	0.05	2.6	0.05	392	1.9	0.04	2.0	0.05
Non-Hodgkin Lymphoma	4,220	22.4	0.16	26.0	0.18	3,352	15.1	0.12	17.6	0.14
Multiple Myeloma	1,418	7.5	0.09	8.9	0.11	1,052	4.7	0.07	5.5	0.08
Leukemias	2,968	15.9	0.13	17.8	0.15	2,094	9.7	0.10	10.7	0.11
Acute lymphocytic	443	2.3	0.05	2.2	0.05	330	1.8	0.04	1.6	0.04
Chronic lymphocytic	946	5.0	0.07	6.0	0.09	586	2.5	0.05	3.0	0.06
Acute myeloid	885	4.8	0.07	5.4	0.08	708	3.3	0.06	3.7	0.06
Chronic myeloid	384	2.1	0.05	2.3	0.05	262	1.2	0.03	1.4	0.04
Other leukemias	310	1.7	0.04	1.9	0.05	207	0.9	0.03	1.1	0.03
Mesothelioma	249	1.4	0.04	1.6	0.05	88	0.4	0.02	0.5	0.02
Kaposi Sarcoma	191	1.0	0.03	1.1	0.04	18	0.1	0.01	0.1	0.01
Ill-defined & Unknown	3,168	17.5	0.14	20.4	0.16	2,855	12.6	0.11	14.6	0.12
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1,559	8.2	0.09	9.3	0.11	3,181	14.6	0.12	16.8	0.13
Breast (<i>in situ</i>)	20	0.1	0.01	0.1	0.01	6,098	27.9	0.16	33.2	0.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	65,939	445.4	0.79	525.8	0.92	67,093	403.8	0.71	470.8	0.82
Oral Cavity & Pharynx	2,561	16.5	0.15	20.2	0.18	980	5.8	0.08	6.8	0.10
Lip	184	1.2	0.04	1.5	0.05	73	0.4	0.02	0.5	0.03
Tongue	887	5.7	0.09	7.0	0.10	325	1.9	0.05	2.3	0.06
Major salivary gland	245	1.7	0.05	2.0	0.06	145	0.9	0.03	1.0	0.04
Floor of mouth	77	0.5	0.03	0.6	0.03	46	0.3	0.02	0.3	0.02
Gum & other mouth	220	1.5	0.05	1.8	0.05	177	1.0	0.04	1.2	0.04
Nasopharynx	69	0.4	0.02	0.5	0.03	30	0.2	0.02	0.2	0.02
Oropharynx	110	0.7	0.03	0.9	0.04	29	0.2	0.01	0.2	0.02
Hypopharynx	120	0.8	0.03	1.0	0.04	29	0.2	0.01	0.2	0.02
Digestive System	13,549	91.0	0.36	108.6	0.42	10,821	63.3	0.28	74.7	0.32
Esophagus	967	6.5	0.10	7.8	0.11	280	1.6	0.04	1.9	0.05
Stomach	1,306	9.0	0.11	10.5	0.13	847	5.1	0.08	5.9	0.09
Small intestine	332	2.3	0.06	2.7	0.07	298	1.8	0.05	2.1	0.05
Colon excl. rectum	3,905	26.8	0.20	31.6	0.23	3,883	22.8	0.17	26.6	0.19
Rectum & rectosigmoid	1,957	12.9	0.13	15.5	0.16	1,412	8.5	0.10	10.1	0.12
Anus, anal canal & anorectum	250	1.6	0.05	2.0	0.06	425	2.4	0.05	3.0	0.07
Liver	1,966	12.2	0.13	15.3	0.16	713	4.1	0.07	4.9	0.08
Gallbladder	118	0.8	0.03	1.0	0.04	275	1.6	0.04	1.9	0.05
Pancreas	2,024	13.8	0.14	16.4	0.16	1,863	10.7	0.11	12.6	0.13
Respiratory System	7,237	50.7	0.27	59.4	0.31	6,994	40.7	0.22	47.7	0.26
Larynx	552	3.7	0.07	4.4	0.08	114	0.7	0.03	0.8	0.03
Lung & bronchus	6,511	45.8	0.26	53.6	0.30	6,785	39.5	0.22	46.3	0.25
Bones & Joints	162	1.1	0.04	1.1	0.04	124	0.8	0.03	0.8	0.03
Soft Tissue (incl. heart)	663	4.6	0.08	5.1	0.09	509	3.2	0.06	3.5	0.07
Skin (excl. basal & sq.)	5,661	39.0	0.24	45.7	0.27	3,538	21.5	0.17	24.9	0.19
Melanomas of the skin	5,217	35.7	0.23	42.0	0.26	3,292	20.1	0.16	23.3	0.18
Breast (excl. <i>in situ</i>)	153	1.1	0.04	1.2	0.05	20,600	125.4	0.40	147.5	0.46
Female Genital System	-	-	-	-	-	8,359	50.4	0.25	59.6	0.29
Cervix uteri	-	-	-	-	-	1,089	7.4	0.10	8.0	0.11
Uterus Corpus	-	-	-	-	-	4,407	25.8	0.18	31.5	0.21
Uterus, NOS ¹	-	-	-	-	-	159	0.9	0.03	1.1	0.04
Ovary	-	-	-	-	-	1,959	11.9	0.12	13.9	0.14
Male Genital System	15,229	98.0	0.36	118.6	0.43	-	-	-	-	-
Prostate	13,999	89.7	0.35	110.1	0.42	-	-	-	-	-
Testis	1,065	7.2	0.10	7.1	0.10	-	-	-	-	-
Penis	129	0.9	0.04	1.0	0.04	-	-	-	-	-
Urinary System	7,920	54.9	0.28	64.5	0.33	3,177	18.7	0.15	21.9	0.18
Bladder (incl. <i>in situ</i>)	4,518	32.2	0.22	37.6	0.25	1,316	7.6	0.09	8.8	0.11
Kidney & renal pelvis	3,239	21.5	0.17	25.5	0.20	1,777	10.7	0.12	12.5	0.13
Ureter	89	0.7	0.03	0.8	0.04	53	0.3	0.02	0.4	0.02
Eye & Orbit	172	1.1	0.04	1.3	0.05	147	0.9	0.03	1.0	0.04
Brain & Other CNS ¹	1,161	7.8	0.10	8.7	0.12	897	5.6	0.09	6.2	0.09
Brain	1,100	7.4	0.10	8.3	0.11	840	5.3	0.08	5.8	0.09
Endocrine System	1,139	7.6	0.10	8.6	0.11	3,096	20.7	0.17	22.6	0.18
Thyroid gland	1,028	6.8	0.10	7.8	0.11	3,001	20.1	0.17	21.9	0.18
Lymphomas	3,815	26.2	0.19	30.1	0.22	2,988	18.0	0.15	20.7	0.17
Hodgkin Lymphoma	396	2.7	0.06	2.8	0.06	321	2.1	0.05	2.2	0.06
Non-Hodgkin Lymphoma	3,419	23.5	0.18	27.3	0.21	2,667	15.9	0.14	18.5	0.16
Multiple Myeloma	1,091	7.5	0.10	8.8	0.12	788	4.6	0.07	5.5	0.09
Leukemias	2,472	17.2	0.16	19.3	0.18	1,710	10.5	0.12	11.6	0.13
Acute lymphocytic	378	2.6	0.06	2.4	0.06	272	1.9	0.05	1.8	0.05
Chronic lymphocytic	812	5.6	0.09	6.6	0.10	507	2.9	0.06	3.4	0.07
Acute myeloid	715	5.1	0.09	5.7	0.10	560	3.4	0.07	3.8	0.07
Chronic myeloid	307	2.1	0.06	2.4	0.06	205	1.3	0.04	1.4	0.04
Other leukemias	260	1.8	0.05	2.1	0.06	166	1.0	0.03	1.1	0.04
Mesothelioma	222	1.6	0.05	1.9	0.06	79	0.5	0.02	0.5	0.03
Kaposi Sarcoma	137	0.9	0.04	1.0	0.04	12	0.1	0.01	0.1	0.01
Ill-defined & Unknown	2,596	18.5	0.17	21.5	0.19	2,274	13.1	0.13	15.1	0.14
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1,228	8.4	0.11	9.5	0.12	2,461	15.1	0.14	17.3	0.16
Breast (<i>in situ</i>)	15	0.1	0.01	0.1	0.01	4,382	26.9	0.19	32.0	0.22

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,399	452.9	2.91	547.4	3.44	5,318	372.7	2.33	439.8	2.71
Oral Cavity & Pharynx	149	11.6	0.45	14.3	0.54	65	4.4	0.25	5.3	0.30
Lip	2	0.2	0.06	0.2	0.07	-	-	-	-	-
Tongue	40	3.1	0.23	3.8	0.28	14	1.0	0.12	1.2	0.14
Major salivary gland	12	1.0	0.14	1.2	0.16	13	0.9	0.11	1.1	0.13
Floor of mouth	8	0.7	0.11	0.8	0.13	3	0.2	0.05	0.2	0.06
Gum & other mouth	15	1.2	0.15	1.4	0.17	13	0.9	0.11	1.1	0.13
Nasopharynx	10	0.8	0.12	0.9	0.13	5	0.3	0.07	0.4	0.08
Oropharynx	13	1.0	0.13	1.3	0.16	4	0.3	0.06	0.4	0.08
Hypopharynx	11	0.9	0.12	1.1	0.15	3	0.2	0.05	0.2	0.06
Digestive System	1,224	103.9	1.40	125.6	1.66	1,032	72.7	1.03	86.6	1.21
Esophagus	46	3.8	0.27	4.6	0.31	24	1.7	0.16	2.0	0.18
Stomach	129	12.0	0.50	14.1	0.58	88	6.4	0.31	7.4	0.36
Small intestine	41	3.6	0.26	4.3	0.31	39	2.7	0.20	3.3	0.23
Colon excl. rectum	371	32.0	0.78	38.3	0.92	393	28.1	0.65	33.1	0.75
Rectum & rectosigmoid	142	11.6	0.46	13.9	0.54	116	8.0	0.34	9.6	0.40
Anus, anal canal & anorectum	28	2.2	0.19	2.6	0.22	27	1.9	0.16	2.3	0.19
Liver	217	16.5	0.52	21.2	0.66	75	4.8	0.26	6.1	0.32
Gallbladder	11	1.0	0.14	1.1	0.16	24	1.7	0.16	2.0	0.19
Pancreas	187	16.5	0.57	19.9	0.67	185	13.0	0.44	15.6	0.51
Respiratory System	730	66.3	1.16	79.1	1.35	651	45.8	0.82	54.9	0.97
Larynx	58	5.0	0.31	6.1	0.37	13	0.9	0.11	1.1	0.13
Lung & bronchus	661	60.4	1.11	72.0	1.29	630	44.3	0.81	53.2	0.95
Bones & Joints	10	0.8	0.11	0.8	0.12	8	0.6	0.09	0.6	0.10
Soft Tissue (incl. heart)	52	4.2	0.27	4.7	0.30	52	3.7	0.23	4.1	0.26
Skin (excl. basal & sq.)	29	2.5	0.22	2.9	0.25	25	1.8	0.16	2.0	0.18
Melanomas of the skin	15	1.4	0.17	1.6	0.19	11	0.8	0.11	0.9	0.12
Breast (excl. <i>in situ</i>)	17	1.5	0.17	1.8	0.20	1,720	120.4	1.32	141.7	1.53
Female Genital System	-	-	-	-	-	663	45.0	0.80	54.1	0.94
Cervix uteri	-	-	-	-	-	95	6.9	0.32	7.6	0.35
Uterus Corpus	-	-	-	-	-	359	23.8	0.57	29.5	0.70
Uterus, NOS ¹	-	-	-	-	-	29	2.0	0.17	2.4	0.20
Ovary	-	-	-	-	-	129	8.9	0.36	10.5	0.42
Male Genital System	1,785	140.3	1.56	175.9	1.90	-	-	-	-	-
Prostate	1,754	138.0	1.55	173.4	1.89	-	-	-	-	-
Testis	21	1.5	0.15	1.5	0.15	-	-	-	-	-
Penis	7	0.6	0.11	0.7	0.13	-	-	-	-	-
Urinary System	505	44.5	0.93	52.9	1.09	262	18.6	0.52	21.9	0.61
Bladder (incl. <i>in situ</i>)	211	20.4	0.66	24.1	0.77	82	6.0	0.30	7.1	0.35
Kidney & renal pelvis	287	23.4	0.65	27.9	0.76	172	12.0	0.42	14.2	0.49
Ureter	2	0.2	0.06	0.2	0.08	3	0.2	0.06	0.2	0.06
Eye & Orbit	3	0.3	0.08	0.3	0.08	4	0.3	0.07	0.3	0.07
Brain & Other CNS ¹	61	4.8	0.28	5.3	0.32	42	2.9	0.20	3.2	0.23
Brain	56	4.3	0.27	4.8	0.30	38	2.6	0.19	2.9	0.21
Endocrine System	57	4.5	0.28	5.1	0.31	153	11.0	0.41	12.2	0.44
Thyroid gland	44	3.5	0.24	4.0	0.28	138	9.9	0.39	11.0	0.42
Lymphomas	229	18.6	0.58	21.3	0.65	197	14.0	0.45	16.0	0.51
Hodgkin Lymphoma	33	2.4	0.19	2.5	0.20	27	1.9	0.17	2.0	0.17
Non-Hodgkin Lymphoma	197	16.3	0.54	18.8	0.62	170	12.1	0.42	14.0	0.48
Multiple Myeloma	170	15.2	0.55	18.1	0.64	131	9.2	0.37	11.0	0.43
Leukemias	152	13.3	0.51	15.1	0.58	115	8.2	0.35	9.3	0.39
Acute lymphocytic	15	1.1	0.13	1.0	0.13	15	1.1	0.12	1.0	0.12
Chronic lymphocytic	50	4.6	0.31	5.5	0.36	29	2.0	0.17	2.5	0.21
Acute myeloid	48	4.3	0.29	4.9	0.33	40	2.9	0.20	3.2	0.23
Chronic myeloid	22	1.9	0.19	2.1	0.21	17	1.2	0.13	1.4	0.15
Other leukemias	16	1.4	0.16	1.6	0.19	14	1.0	0.13	1.2	0.14
Mesothelioma	10	1.1	0.16	1.3	0.18	3	0.2	0.06	0.2	0.06
Kaposi Sarcoma	23	1.6	0.16	1.7	0.17	2	0.1	0.05	0.2	0.05
Ill-defined & Unknown	-	-	-	-	-	192	13.9	0.46	16.2	0.53
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	90	7.6	0.38	8.7	0.43	196	13.9	0.45	16.0	0.51
Breast (<i>in situ</i>)	2	0.1	0.05	0.2	0.06	417	28.5	0.64	34.2	0.75

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, Asian/Pacific Islander (API)

<i>SITES</i>	MALES (API)					FEMALES (API)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	8,502	290.5	1.44	342.2	1.67	11,072	298.0	1.29	347.1	1.48
Oral Cavity & Pharynx	325	10.7	0.27	12.5	0.31	180	4.8	0.16	5.6	0.19
Lip	4	0.1	0.03	0.1	0.03	2	0.1	0.02	0.1	0.02
Tongue	66	2.2	0.12	2.6	0.14	50	1.3	0.09	1.6	0.10
Major salivary gland	35	1.2	0.09	1.3	0.10	35	0.9	0.07	1.1	0.08
Floor of mouth	6	0.2	0.03	0.2	0.04	4	0.1	0.02	0.1	0.03
Gum & other mouth	42	1.4	0.10	1.7	0.12	27	0.7	0.06	0.8	0.07
Nasopharynx	118	3.8	0.16	4.4	0.18	45	1.2	0.08	1.4	0.09
Oropharynx	6	0.2	0.03	0.2	0.04	2	0.1	0.02	0.1	0.02
Hypopharynx	16	0.6	0.06	0.7	0.08	4	0.1	0.02	0.1	0.03
Digestive System	2,632	89.4	0.80	106.8	0.94	2,119	56.8	0.56	66.8	0.65
Esophagus	91	3.1	0.15	3.7	0.18	32	0.8	0.07	1.0	0.08
Stomach	353	12.5	0.30	14.6	0.35	275	7.5	0.20	8.7	0.23
Small intestine	38	1.3	0.10	1.5	0.11	29	0.8	0.07	0.9	0.08
Colon excl. rectum	683	23.2	0.40	27.7	0.48	697	18.6	0.32	21.9	0.37
Rectum & rectosigmoid	422	13.8	0.31	16.7	0.37	300	8.0	0.21	9.5	0.25
Anus, anal canal & anorectum	13	0.4	0.05	0.5	0.06	16	0.4	0.05	0.5	0.06
Liver	548	18.0	0.35	21.9	0.42	219	5.9	0.18	6.9	0.21
Gallbladder	26	0.9	0.08	1.1	0.10	47	1.3	0.08	1.5	0.10
Pancreas	299	10.5	0.28	12.4	0.32	330	8.9	0.22	10.4	0.26
Respiratory System	1,319	46.6	0.59	54.8	0.68	1,036	27.8	0.39	32.7	0.46
Larynx	47	1.6	0.11	1.9	0.13	6	0.2	0.03	0.2	0.04
Lung & bronchus	1,240	43.9	0.57	51.7	0.66	1,012	27.1	0.39	32.0	0.45
Bones & Joints	23	0.8	0.07	0.8	0.08	16	0.5	0.06	0.5	0.06
Soft Tissue (incl. heart)	93	3.1	0.15	3.5	0.16	82	2.3	0.12	2.6	0.13
Skin (excl. basal & sq.)	67	2.3	0.13	2.7	0.15	67	1.8	0.10	2.1	0.11
Melanomas of the skin	38	1.3	0.10	1.5	0.11	44	1.2	0.08	1.4	0.09
Breast (excl. <i>in situ</i>)	17	0.6	0.06	0.7	0.07	3,763	100.6	0.74	118.0	0.86
Female Genital System	-	-	-	-	-	1,484	39.3	0.46	46.6	0.54
Cervix uteri	-	-	-	-	-	233	6.4	0.19	7.1	0.21
Uterus Corpus	-	-	-	-	-	796	20.7	0.33	25.1	0.40
Uterus, NOS ¹	-	-	-	-	-	23	0.6	0.06	0.7	0.07
Ovary	-	-	-	-	-	348	9.4	0.23	11.0	0.26
Male Genital System	1,594	52.5	0.60	63.4	0.71	-	-	-	-	-
Prostate	1,502	49.5	0.58	60.4	0.70	-	-	-	-	-
Testis	71	2.2	0.12	2.2	0.12	-	-	-	-	-
Penis	11	0.4	0.06	0.5	0.06	-	-	-	-	-
Urinary System	793	27.7	0.45	32.6	0.52	364	9.8	0.23	11.4	0.27
Bladder (incl. <i>in situ</i>)	409	14.8	0.33	17.3	0.39	137	3.6	0.14	4.3	0.16
Kidney & renal pelvis	360	12.0	0.29	14.2	0.34	208	5.6	0.18	6.6	0.20
Ureter	16	0.6	0.07	0.7	0.08	13	0.4	0.05	0.4	0.05
Eye & Orbit	11	0.4	0.05	0.4	0.05	9	0.3	0.05	0.3	0.04
Brain & Other CNS ¹	127	4.4	0.18	4.7	0.19	101	2.9	0.13	3.2	0.14
Brain	117	4.0	0.17	4.3	0.18	89	2.6	0.13	2.8	0.13
Endocrine System	241	7.9	0.23	8.9	0.26	743	20.6	0.34	22.7	0.37
Thyroid gland	206	6.7	0.21	7.6	0.24	715	19.8	0.33	21.8	0.37
Lymphomas	531	18.3	0.36	20.9	0.41	447	12.3	0.26	14.0	0.30
Hodgkin Lymphoma	44	1.5	0.10	1.5	0.10	34	1.0	0.08	1.0	0.08
Non-Hodgkin Lymphoma	487	16.8	0.35	19.4	0.40	413	11.3	0.25	12.9	0.29
Multiple Myeloma	133	4.6	0.18	5.5	0.21	111	2.9	0.13	3.5	0.15
Leukemias	262	9.3	0.26	10.1	0.28	217	6.3	0.20	6.8	0.21
Acute lymphocytic	43	1.5	0.10	1.4	0.10	37	1.3	0.10	1.2	0.09
Chronic lymphocytic	38	1.3	0.10	1.5	0.11	24	0.6	0.06	0.8	0.07
Acute myeloid	113	4.0	0.17	4.5	0.19	102	2.9	0.13	3.2	0.14
Chronic myeloid	43	1.5	0.10	1.7	0.11	31	0.9	0.07	1.0	0.08
Other leukemias	25	0.9	0.08	1.0	0.09	23	0.7	0.06	0.7	0.07
Mesothelioma	15	0.5	0.06	0.6	0.07	6	0.2	0.03	0.2	0.03
Kaposi Sarcoma	12	0.4	0.06	0.4	0.06	-	-	-	-	-
Ill-defined & Unknown	308	11.2	0.29	12.9	0.33	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	202	6.9	0.22	7.8	0.25	455	12.3	0.26	14.3	0.30
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	1,146	30.4	0.41	36.2	0.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	310	239.3	6.67	285.9	7.79	337	223.3	5.72	263.6	6.63
Oral Cavity & Pharynx	13	9.0	1.19	10.9	1.41	5	3.6	0.73	4.4	0.86
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.7	0.54	2.1	0.66	1	0.7	0.30	0.9	0.36
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	1.0	0.42	1.2	0.48
Nasopharynx	1	0.8	0.37	1.0	0.46	-	-	-	-	-
Oropharynx	1	1.0	0.39	1.2	0.46	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	89	67.4	3.49	81.7	4.13	63	42.8	2.54	51.5	2.98
Esophagus	7	5.0	0.94	5.8	1.07	2	1.2	0.41	1.6	0.49
Stomach	8	5.5	0.98	6.8	1.19	3	2.5	0.67	2.9	0.77
Small intestine	2	1.9	0.59	2.2	0.68	-	-	-	-	-
Colon excl. rectum	17	14.5	1.72	17.0	1.99	24	16.5	1.59	19.4	1.84
Rectum & rectosigmoid	11	8.1	1.24	10.1	1.50	10	6.0	0.92	7.3	1.08
Anus, anal canal & anorectum	1	0.7	0.28	0.9	0.36	2	0.9	0.35	1.2	0.43
Liver	27	18.1	1.66	22.7	2.01	10	6.3	0.94	7.7	1.11
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	13	10.6	1.46	12.7	1.70	9	6.5	1.03	7.7	1.20
Respiratory System	42	37.5	2.81	44.4	3.25	42	29.4	2.15	35.3	2.52
Larynx	3	2.3	0.65	2.8	0.78	1	1.0	0.40	1.2	0.47
Lung & bronchus	39	35.1	2.73	41.5	3.16	39	27.7	2.09	33.4	2.44
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	2.0	0.60	2.3	0.70	2	1.2	0.41	1.4	0.46
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	8	6.4	1.10	7.7	1.30	7	4.4	0.78	5.2	0.90
Breast (excl. <i>in situ</i>)	-	-	-	-	-	87	54.9	2.75	65.6	3.22
Female Genital System	-	-	-	-	-	49	30.5	2.02	35.6	2.33
Cervix uteri	-	-	-	-	-	10	6.1	0.88	6.5	0.93
Uterus Corpus	-	-	-	-	-	27	16.9	1.52	20.1	1.78
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	9	5.2	0.82	6.3	0.98
Male Genital System	65	47.3	2.88	57.0	3.39	-	-	-	-	-
Prostate	55	42.1	2.76	51.7	3.28	-	-	-	-	-
Testis	8	4.2	0.67	4.1	0.66	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	34	28.3	2.36	33.3	2.72	24	16.3	1.57	19.0	1.80
Bladder (incl. <i>in situ</i>)	16	15.5	1.86	17.8	2.10	5	4.0	0.83	4.9	0.98
Kidney & renal pelvis	18	12.2	1.41	14.9	1.69	18	11.7	1.29	13.4	1.46
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	5	3.3	0.72	3.8	0.85	3	2.1	0.54	2.1	0.56
Brain	5	2.9	0.65	3.4	0.75	3	2.1	0.54	2.1	0.56
Endocrine System	5	3.1	0.71	3.5	0.80	15	9.0	1.10	10.0	1.23
Thyroid gland	5	3.0	0.70	3.4	0.79	14	8.7	1.07	9.6	1.19
Lymphomas	12	8.9	1.26	10.6	1.47	13	8.9	1.17	10.3	1.33
Hodgkin Lymphoma	1	0.8	0.37	0.9	0.42	2	1.0	0.37	1.1	0.41
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	5	3.4	0.77	4.0	0.87	5	3.8	0.81	4.4	0.91
Leukemias	11	7.9	1.18	8.9	1.33	8	5.3	0.90	5.8	1.00
Acute lymphocytic	2	1.0	0.33	0.9	0.31	1	0.7	0.27	0.6	0.24
Chronic lymphocytic	2	1.3	0.48	1.6	0.56	1	0.9	0.39	1.1	0.44
Acute myeloid	3	2.6	0.67	2.9	0.74	3	1.9	0.55	2.2	0.63
Chronic myeloid	2	1.6	0.54	1.9	0.63	1	0.8	0.34	0.9	0.39
Other leukemias	2	1.4	0.55	1.7	0.63	1	0.9	0.40	1.0	0.44
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	15	12.6	1.60	15.0	1.87	12	9.6	1.28	11.3	1.49
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	7	4.6	0.88	5.3	1.01	11	6.7	0.95	7.8	1.11
Breast (<i>in situ</i>)	-	-	-	-	-	19	11.5	1.23	14.0	1.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,732	350.3	1.36	412.5	1.58	18,390	324.7	1.11	379.1	1.29
Oral Cavity & Pharynx	407	8.5	0.20	10.2	0.24	202	3.7	0.12	4.3	0.14
Lip	21	0.5	0.05	0.6	0.06	12	0.2	0.03	0.3	0.04
Tongue	110	2.3	0.10	2.8	0.12	63	1.2	0.07	1.4	0.08
Major salivary gland	51	1.1	0.07	1.3	0.09	43	0.7	0.05	0.8	0.06
Floor of mouth	15	0.3	0.04	0.4	0.05	5	0.1	0.02	0.1	0.02
Gum & other mouth	47	1.0	0.07	1.2	0.09	35	0.7	0.06	0.8	0.06
Nasopharynx	20	0.4	0.04	0.4	0.05	10	0.2	0.02	0.2	0.03
Oropharynx	19	0.4	0.05	0.5	0.06	5	0.1	0.02	0.1	0.02
Hypopharynx	22	0.5	0.05	0.6	0.06	5	0.1	0.02	0.1	0.02
Digestive System	4,276	95.8	0.71	114.6	0.83	3,494	66.2	0.52	78.3	0.61
Esophagus	186	4.5	0.16	5.3	0.18	48	1.0	0.06	1.1	0.08
Stomach	538	12.4	0.26	14.5	0.30	451	8.4	0.18	9.8	0.21
Small intestine	81	1.9	0.10	2.2	0.12	81	1.5	0.08	1.8	0.09
Colon excl. rectum	1,094	24.8	0.36	29.3	0.42	1,078	20.2	0.28	23.8	0.33
Rectum & rectosigmoid	657	13.4	0.25	16.2	0.30	449	7.8	0.17	9.4	0.20
Anus, anal canal & anorectum	47	0.9	0.06	1.1	0.08	69	1.2	0.07	1.5	0.08
Liver	876	18.5	0.30	23.0	0.36	355	7.0	0.17	8.3	0.20
Gallbladder	53	1.4	0.09	1.6	0.10	147	2.9	0.11	3.4	0.13
Pancreas	494	12.1	0.26	14.3	0.30	528	10.6	0.21	12.5	0.25
Respiratory System	1,263	34.2	0.46	39.6	0.52	1,066	21.8	0.31	25.6	0.36
Larynx	133	3.2	0.13	3.8	0.15	23	0.4	0.04	0.5	0.05
Lung & bronchus	1,072	29.9	0.43	34.6	0.49	1,015	20.9	0.30	24.5	0.35
Bones & Joints	74	1.1	0.06	1.1	0.07	54	0.7	0.05	0.8	0.05
Soft Tissue (incl. heart)	207	3.8	0.13	4.3	0.15	194	3.1	0.10	3.4	0.12
Skin (excl. basal & sq.)	282	6.3	0.18	7.4	0.21	351	6.0	0.15	7.0	0.17
Melanomas of the skin	225	5.0	0.16	5.9	0.19	294	5.0	0.14	5.8	0.16
Breast (excl. <i>in situ</i>)	28	0.7	0.06	0.8	0.07	5,414	92.9	0.58	109.6	0.68
Female Genital System	-	-	-	-	-	2,775	46.8	0.41	55.1	0.48
Cervix uteri	-	-	-	-	-	553	8.8	0.17	9.6	0.19
Uterus Corpus	-	-	-	-	-	1,353	22.8	0.29	27.7	0.34
Uterus, NOS ¹	-	-	-	-	-	62	1.1	0.06	1.3	0.07
Ovary	-	-	-	-	-	620	10.6	0.20	12.3	0.23
Male Genital System	4,032	88.9	0.68	106.7	0.79	-	-	-	-	-
Prostate	3,460	81.4	0.66	99.0	0.78	-	-	-	-	-
Testis	503	5.9	0.12	5.8	0.12	-	-	-	-	-
Penis	60	1.3	0.08	1.6	0.10	-	-	-	-	-
Urinary System	1,733	40.5	0.47	47.6	0.54	924	17.0	0.26	19.9	0.30
Bladder (incl. <i>in situ</i>)	614	16.9	0.32	19.7	0.37	205	4.2	0.14	4.9	0.16
Kidney & renal pelvis	1,092	22.7	0.33	27.0	0.39	702	12.4	0.22	14.6	0.25
Ureter	16	0.5	0.06	0.6	0.07	10	0.2	0.03	0.2	0.03
Eye & Orbit	33	0.7	0.06	0.7	0.07	32	0.5	0.04	0.5	0.05
Brain & Other CNS ¹	320	5.6	0.15	6.2	0.17	279	4.4	0.12	4.9	0.14
Brain	297	5.2	0.15	5.8	0.17	256	4.1	0.12	4.5	0.14
Endocrine System	347	6.0	0.16	6.7	0.18	1,309	19.8	0.25	21.9	0.28
Thyroid gland	308	5.3	0.15	6.0	0.17	1,274	19.3	0.25	21.3	0.28
Lymphomas	1,061	22.4	0.34	25.7	0.39	959	17.2	0.26	19.9	0.30
Hodgkin Lymphoma	147	2.3	0.09	2.5	0.10	127	1.8	0.07	1.9	0.08
Non-Hodgkin Lymphoma	914	20.1	0.33	23.2	0.37	832	15.4	0.25	18.0	0.29
Multiple Myeloma	313	7.4	0.20	8.7	0.23	261	5.0	0.14	6.0	0.17
Leukemias	693	12.4	0.24	13.5	0.27	530	8.5	0.17	9.3	0.19
Acute lymphocytic	253	3.1	0.09	2.9	0.09	181	2.3	0.08	2.2	0.08
Chronic lymphocytic	89	2.3	0.11	2.7	0.13	65	1.3	0.07	1.6	0.09
Acute myeloid	194	4.0	0.14	4.4	0.16	174	3.0	0.11	3.4	0.12
Chronic myeloid	91	1.7	0.09	1.9	0.10	62	1.0	0.06	1.2	0.07
Other leukemias	67	1.4	0.08	1.5	0.10	47	0.8	0.06	1.0	0.07
Mesothelioma	55	1.4	0.09	1.7	0.11	19	0.3	0.04	0.4	0.04
Kaposi Sarcoma	73	1.2	0.07	1.3	0.08	7	0.2	0.03	0.2	0.03
Ill-defined & Unknown	533	13.6	0.29	15.7	0.33	522	10.4	0.21	12.1	0.24
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	336	6.3	0.17	7.2	0.20	748	13.1	0.22	15.1	0.26
Breast (<i>in situ</i>)	2	0.0	0.01	0.1	0.02	1,247	21.2	0.27	25.3	0.33

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

CALIFORNIA

II-48 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	50,887	479.7	0.98	566.3	1.13	49,284	433.1	0.93	504.0	1.05
Oral Cavity & Pharynx	2,166	19.9	0.20	24.2	0.24	784	6.7	0.11	7.9	0.13
Lip	163	1.6	0.06	1.9	0.07	61	0.5	0.03	0.6	0.04
Tongue	780	7.1	0.12	8.7	0.14	263	2.3	0.07	2.7	0.08
Major salivary gland	196	1.9	0.06	2.2	0.07	104	0.9	0.04	1.1	0.05
Floor of mouth	62	0.6	0.03	0.7	0.04	40	0.3	0.02	0.4	0.03
Gum & other mouth	174	1.6	0.06	1.9	0.07	143	1.2	0.05	1.4	0.05
Nasopharynx	50	0.5	0.03	0.6	0.04	21	0.2	0.02	0.2	0.02
Oropharynx	92	0.8	0.04	1.0	0.05	24	0.2	0.02	0.2	0.02
Hypopharynx	98	0.9	0.04	1.1	0.05	24	0.2	0.02	0.2	0.02
Digestive System	9,379	87.9	0.42	104.9	0.49	7,425	61.0	0.33	71.8	0.38
Esophagus	785	7.2	0.12	8.6	0.14	233	1.8	0.05	2.2	0.06
Stomach	781	7.4	0.12	8.7	0.14	408	3.3	0.08	3.9	0.09
Small intestine	254	2.4	0.07	2.9	0.08	220	1.9	0.06	2.2	0.07
Colon excl. rectum	2,841	27.4	0.24	32.2	0.27	2,838	23.4	0.21	27.2	0.24
Rectum & rectosigmoid	1,321	12.7	0.16	15.1	0.19	980	8.7	0.13	10.3	0.15
Anus, anal canal & anorectum	204	1.9	0.06	2.3	0.07	358	3.0	0.07	3.6	0.09
Liver	1,108	9.5	0.13	12.0	0.16	369	2.9	0.07	3.6	0.08
Gallbladder	65	0.6	0.04	0.7	0.04	130	1.0	0.04	1.2	0.05
Pancreas	1,540	14.3	0.17	17.0	0.19	1,346	10.6	0.13	12.5	0.16
Respiratory System	6,004	55.8	0.33	65.6	0.38	5,957	47.3	0.28	55.4	0.33
Larynx	422	3.8	0.09	4.6	0.10	92	0.8	0.04	0.9	0.04
Lung & bronchus	5,465	50.8	0.31	59.7	0.36	5,797	45.9	0.28	53.8	0.32
Bones & Joints	90	1.1	0.06	1.1	0.05	71	0.9	0.05	0.9	0.05
Soft Tissue (incl. heart)	462	4.8	0.10	5.4	0.11	322	3.2	0.09	3.5	0.09
Skin (excl. basal & sq.)	5,398	52.2	0.33	61.0	0.37	3,218	30.6	0.26	34.8	0.28
Melanomas of the skin	5,006	48.4	0.32	56.6	0.36	3,023	29.0	0.25	33.0	0.28
Breast (excl. <i>in situ</i>)	125	1.2	0.05	1.4	0.06	15,365	138.7	0.53	162.6	0.60
Female Genital System	-	-	-	-	-	5,668	49.9	0.31	59.3	0.36
Cervix uteri	-	-	-	-	-	553	6.5	0.13	6.9	0.13
Uterus Corpus	-	-	-	-	-	3,097	25.8	0.22	31.8	0.26
Uterus, NOS ¹	-	-	-	-	-	99	0.8	0.04	1.0	0.05
Ovary	-	-	-	-	-	1,354	12.1	0.16	14.2	0.18
Male Genital System	11,551	103.1	0.44	124.9	0.52	-	-	-	-	-
Prostate	10,873	94.3	0.41	116.0	0.50	-	-	-	-	-
Testis	580	7.8	0.15	7.8	0.15	-	-	-	-	-
Penis	70	0.7	0.04	0.8	0.04	-	-	-	-	-
Urinary System	6,237	59.0	0.34	69.3	0.40	2,278	18.6	0.18	21.8	0.21
Bladder (incl. <i>in situ</i>)	3,927	37.1	0.27	43.4	0.31	1,115	8.7	0.12	10.2	0.14
Kidney & renal pelvis	2,175	20.6	0.20	24.4	0.24	1,095	9.4	0.14	11.1	0.15
Ureter	73	0.7	0.04	0.8	0.04	43	0.3	0.02	0.4	0.03
Eye & Orbit	140	1.4	0.05	1.6	0.06	116	1.1	0.05	1.2	0.05
Brain & Other CNS ¹	848	9.1	0.15	10.0	0.16	625	6.4	0.12	6.9	0.13
Brain	809	8.6	0.14	9.5	0.15	590	6.0	0.12	6.5	0.12
Endocrine System	803	8.6	0.14	9.6	0.15	1,828	21.1	0.24	22.8	0.24
Thyroid gland	731	7.7	0.13	8.7	0.15	1,765	20.4	0.23	22.1	0.24
Lymphomas	2,785	27.8	0.25	31.9	0.27	2,063	18.4	0.19	21.0	0.21
Hodgkin Lymphoma	255	3.1	0.09	3.3	0.09	199	2.5	0.09	2.6	0.08
Non-Hodgkin Lymphoma	2,530	24.7	0.23	28.7	0.26	1,865	15.8	0.17	18.4	0.20
Multiple Myeloma	786	7.3	0.12	8.7	0.14	536	4.3	0.09	5.1	0.10
Leukemias	1,797	18.1	0.20	20.5	0.22	1,193	10.7	0.15	11.9	0.16
Acute lymphocytic	130	1.9	0.08	1.7	0.07	96	1.5	0.07	1.3	0.06
Chronic lymphocytic	728	6.7	0.11	8.0	0.13	445	3.5	0.08	4.1	0.09
Acute myeloid	526	5.3	0.11	6.0	0.12	388	3.4	0.08	3.9	0.09
Chronic myeloid	219	2.2	0.07	2.5	0.08	144	1.3	0.05	1.5	0.06
Other leukemias	194	2.0	0.07	2.3	0.07	120	1.0	0.05	1.2	0.05
Mesothelioma	168	1.6	0.06	1.9	0.06	61	0.5	0.03	0.6	0.03
Kaposi Sarcoma	70	0.8	0.04	0.9	0.05	6	0.0	0.01	0.1	0.01
Ill-defined & Unknown	2,077	19.9	0.20	23.2	0.23	1,768	14.0	0.16	16.1	0.18
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	904	9.4	0.15	10.6	0.16	1,739	16.0	0.18	18.3	0.20
Breast (<i>in situ</i>)	13	0.1	0.02	0.1	0.02	3,182	29.9	0.25	35.2	0.29

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
California, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,323	477.8	3.08	577.2	3.64	5,203	394.1	2.50	464.2	2.89
Oral Cavity & Pharynx	148	12.4	0.48	15.3	0.57	64	4.7	0.27	5.7	0.32
Lip	2	0.2	0.06	0.2	0.08	-	-	-	-	-
Tongue	40	3.3	0.24	4.1	0.29	14	1.1	0.13	1.3	0.15
Major salivary gland	12	1.0	0.14	1.3	0.17	13	1.0	0.12	1.1	0.14
Floor of mouth	8	0.7	0.12	0.9	0.14	3	0.2	0.05	0.3	0.07
Gum & other mouth	15	1.3	0.16	1.5	0.18	13	1.0	0.12	1.2	0.14
Nasopharynx	10	0.9	0.13	1.0	0.15	4	0.3	0.07	0.4	0.08
Oropharynx	13	1.1	0.14	1.3	0.17	4	0.3	0.07	0.4	0.09
Hypopharynx	11	0.9	0.13	1.2	0.16	3	0.2	0.05	0.2	0.06
Digestive System	1,207	109.5	1.48	132.4	1.75	1,013	76.5	1.10	91.0	1.28
Esophagus	46	4.1	0.28	4.9	0.33	23	1.8	0.17	2.1	0.19
Stomach	126	12.5	0.52	14.7	0.60	86	6.7	0.33	7.8	0.38
Small intestine	40	3.7	0.28	4.5	0.33	38	2.9	0.21	3.4	0.25
Colon excl. rectum	366	33.8	0.83	40.4	0.97	387	29.6	0.69	34.9	0.79
Rectum & rectosigmoid	140	12.3	0.49	14.8	0.57	114	8.5	0.36	10.1	0.43
Anus, anal canal & anorectum	28	2.3	0.21	2.8	0.24	27	2.0	0.17	2.4	0.21
Liver	215	17.5	0.56	22.4	0.70	72	5.0	0.27	6.4	0.34
Gallbladder	10	1.0	0.15	1.2	0.17	23	1.8	0.17	2.1	0.20
Pancreas	185	17.4	0.60	21.0	0.71	182	13.7	0.46	16.4	0.54
Respiratory System	721	69.6	1.22	83.1	1.42	641	48.0	0.86	57.6	1.02
Larynx	58	5.3	0.33	6.4	0.39	13	0.9	0.12	1.2	0.14
Lung & bronchus	653	63.4	1.17	75.6	1.36	620	46.5	0.85	55.7	1.00
Bones & Joints	10	0.9	0.13	0.9	0.13	8	0.7	0.10	0.7	0.11
Soft Tissue (incl. heart)	50	4.4	0.29	5.0	0.33	50	3.9	0.25	4.4	0.28
Skin (excl. basal & sq.)	28	2.7	0.23	3.0	0.26	24	1.9	0.18	2.2	0.20
Melanomas of the skin	14	1.4	0.18	1.6	0.20	11	0.9	0.12	1.0	0.13
Breast (excl. <i>in situ</i>)	17	1.6	0.18	1.9	0.21	1,680	127.7	1.42	149.9	1.64
Female Genital System	-	-	-	-	-	644	47.4	0.85	56.9	1.00
Cervix uteri	-	-	-	-	-	91	7.3	0.35	8.0	0.38
Uterus Corpus	-	-	-	-	-	351	25.0	0.61	30.9	0.74
Uterus, NOS ¹	-	-	-	-	-	28	2.1	0.18	2.5	0.21
Ovary	-	-	-	-	-	126	9.5	0.39	11.2	0.45
Male Genital System	1,761	147.7	1.65	185.2	2.01	-	-	-	-	-
Prostate	1,731	145.1	1.63	182.4	2.00	-	-	-	-	-
Testis	20	1.6	0.16	1.6	0.16	-	-	-	-	-
Penis	7	0.6	0.11	0.7	0.13	-	-	-	-	-
Urinary System	498	46.9	0.99	55.6	1.15	258	19.6	0.56	23.1	0.65
Bladder (incl. <i>in situ</i>)	208	21.3	0.69	25.2	0.81	82	6.3	0.32	7.4	0.37
Kidney & renal pelvis	282	24.8	0.69	29.5	0.80	169	12.8	0.45	15.1	0.52
Ureter	2	0.2	0.07	0.2	0.08	3	0.2	0.06	0.3	0.07
Eye & Orbit	2	0.3	0.08	0.3	0.08	4	0.3	0.07	0.3	0.08
Brain & Other CNS ¹	59	5.1	0.31	5.6	0.34	41	3.1	0.22	3.5	0.24
Brain	53	4.6	0.29	5.1	0.32	36	2.8	0.21	3.1	0.23
Endocrine System	56	4.8	0.30	5.5	0.34	149	12.0	0.45	13.2	0.48
Thyroid gland	44	3.8	0.26	4.4	0.30	135	10.8	0.43	11.9	0.46
Lymphomas	225	20.0	0.62	22.8	0.70	192	14.9	0.49	16.9	0.55
Hodgkin Lymphoma	31	2.6	0.21	2.7	0.22	26	2.1	0.19	2.2	0.19
Non-Hodgkin Lymphoma	194	17.4	0.58	20.1	0.67	166	12.8	0.45	14.7	0.51
Multiple Myeloma	167	16.0	0.58	19.0	0.68	129	9.7	0.39	11.6	0.46
Leukemias	147	14.0	0.54	16.0	0.61	112	8.7	0.37	9.8	0.42
Acute lymphocytic	14	1.2	0.14	1.1	0.14	14	1.1	0.14	1.1	0.13
Chronic lymphocytic	50	4.9	0.33	5.8	0.38	29	2.1	0.18	2.6	0.22
Acute myeloid	46	4.5	0.31	5.1	0.35	39	3.0	0.22	3.4	0.24
Chronic myeloid	22	2.1	0.20	2.3	0.22	17	1.3	0.14	1.5	0.16
Other leukemias	15	1.4	0.17	1.7	0.20	14	1.1	0.13	1.2	0.15
Mesothelioma	10	1.1	0.17	1.3	0.19	3	0.2	0.07	0.2	0.07
Kaposi Sarcoma	23	1.9	0.18	2.0	0.19	2	0.2	0.05	0.2	0.05
Ill-defined & Unknown	192	19.0	0.65	22.5	0.75	188	14.6	0.48	17.1	0.56
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	90	8.3	0.41	9.3	0.46	191	14.8	0.49	17.0	0.55
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.06	408	30.2	0.68	36.2	0.80

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


CALIFORNIA

II-50 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	21,140,844	21,338,612	21,525,871	21,701,170	21,865,733
White	16,977,873	17,091,271	17,190,925	17,280,538	17,355,688
Black	1,286,023	1,305,259	1,322,823	1,340,526	1,360,115
American Indian/Alaskan Native (AI/AN)	476,952	481,417	485,936	490,348	495,966
Asian/Pacific Islander (API)	2,399,996	2,460,665	2,526,187	2,589,758	2,653,964


All Races Population 2013-2017: 107,572,230
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	8,007,275	8,149,492	8,290,628	8,435,572	8,576,468
Non-Hispanic White	9,681,754	9,664,876	9,635,406	9,592,535	9,541,906
Non-Hispanic Black	1,082,828	1,097,714	1,110,833	1,124,177	1,138,689

Hispanic/Latino Population, Census 2010: 14,013,719
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GREATER CALIFORNIA CANCER REGISTRY

Initial Operation: 1988
 Population-based Data Available: 1988
 Coverage Area: California (excl. GB and Los)

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	96.7	99.5	99.0	96.7	96.4
Missing Race	1.7	1.7	2.3	2.3	2.7
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.6	1.6	2.0	1.8	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Prostate	95.4
Oral Cavity & Pharynx	97.6	Testis	98.7
Esophagus	95.2	Bladder (incl. <i>in situ</i>)	97.1
Stomach	96.3	Kidney & Renal Pelvis	89.8
Colon & Rectum	96.1	Brain & Other CNS ¹	85.6
Liver	45.5	Thyroid	99.3
Pancreas	83.1	Hodgkin Lymphoma	98.3
Lung & Bronchus	87.4	Non-Hodgkin Lymphoma	96.8
Melanomas of the Skin	98.6	Multiple Myeloma	88.2
Female Breast (excl. <i>in situ</i>)	98.9	Leukemias	91.8
Cervix uteri	97.6	Brain & Other CNS ¹ <i>non-malig</i>	43.3
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	91.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	47,754	446.1	0.93	528.0	1.09	48,080	397.2	0.83	463.4	0.95
Oral Cavity & Pharynx	1,856	16.6	0.18	20.2	0.21	717	5.8	0.10	6.9	0.12
Lip	136	1.3	0.05	1.5	0.06	53	0.4	0.03	0.5	0.03
Tongue	610	5.4	0.10	6.6	0.12	229	1.8	0.06	2.2	0.07
Major salivary gland	183	1.8	0.06	2.1	0.07	112	0.9	0.04	1.1	0.05
Floor of mouth	59	0.5	0.03	0.6	0.04	34	0.3	0.02	0.3	0.03
Gum & other mouth	152	1.4	0.05	1.7	0.06	120	1.0	0.04	1.1	0.05
Nasopharynx	91	0.8	0.04	1.0	0.05	34	0.3	0.02	0.3	0.03
Oropharynx	85	0.7	0.04	0.9	0.04	21	0.2	0.02	0.2	0.02
Hypopharynx	88	0.8	0.04	1.0	0.05	21	0.2	0.02	0.2	0.02
Digestive System	9,876	91.8	0.42	109.9	0.50	7,759	62.7	0.32	74.0	0.38
Esophagus	690	6.4	0.11	7.7	0.13	199	1.6	0.05	1.9	0.06
Stomach	912	8.8	0.13	10.3	0.15	602	5.0	0.09	5.8	0.11
Small intestine	239	2.3	0.07	2.7	0.08	207	1.7	0.05	2.0	0.06
Colon excl. rectum	2,791	26.5	0.23	31.4	0.27	2,791	22.7	0.20	26.6	0.23
Rectum & rectosigmoid	1,464	13.4	0.16	16.1	0.19	1,048	8.6	0.12	10.2	0.14
Anus, anal canal & anorectum	154	1.4	0.05	1.7	0.06	303	2.4	0.06	2.9	0.08
Liver	1,588	13.6	0.16	17.1	0.19	564	4.4	0.08	5.4	0.10
Gallbladder	86	0.8	0.04	1.0	0.05	174	1.4	0.05	1.6	0.06
Pancreas	1,447	13.7	0.16	16.3	0.19	1,316	10.5	0.13	12.4	0.15
Respiratory System	5,501	53.2	0.33	62.5	0.38	5,300	42.6	0.27	50.1	0.31
Larynx	391	3.6	0.08	4.3	0.10	89	0.7	0.03	0.9	0.04
Lung & bronchus	4,990	48.4	0.31	56.9	0.36	5,138	41.3	0.26	48.5	0.30
Bones & Joints	109	1.0	0.04	1.1	0.05	88	0.8	0.04	0.8	0.04
Soft Tissue (incl. heart)	457	4.3	0.09	4.9	0.10	363	3.1	0.08	3.5	0.08
Skin (excl. basal & sq.)	3,903	37.3	0.27	43.8	0.32	2,497	20.8	0.19	24.1	0.22
Melanomas of the skin	3,594	34.2	0.26	40.2	0.30	2,320	19.4	0.18	22.5	0.21
Breast (excl. <i>in situ</i>)	109	1.0	0.05	1.2	0.05	14,664	122.0	0.46	143.6	0.53
Female Genital System	-	-	-	-	-	5,869	48.4	0.29	57.2	0.34
Cervix uteri	-	-	-	-	-	824	7.6	0.12	8.2	0.13
Uterus Corpus	-	-	-	-	-	3,079	24.6	0.20	30.0	0.24
Uterus, NOS ¹	-	-	-	-	-	115	0.9	0.04	1.1	0.05
Ovary	-	-	-	-	-	1,348	11.2	0.14	13.1	0.16
Male Genital System	11,437	101.7	0.44	123.3	0.52	-	-	-	-	-
Prostate	10,645	94.3	0.42	115.8	0.50	-	-	-	-	-
Testis	675	6.2	0.11	6.2	0.11	-	-	-	-	-
Penis	90	0.9	0.04	1.0	0.05	-	-	-	-	-
Urinary System	5,535	53.3	0.33	62.6	0.38	2,265	18.4	0.18	21.5	0.20
Bladder (incl. <i>in situ</i>)	3,109	30.9	0.25	36.1	0.29	907	7.2	0.11	8.5	0.13
Kidney & renal pelvis	2,307	21.2	0.20	25.2	0.24	1,296	10.7	0.14	12.5	0.16
Ureter	66	0.7	0.04	0.8	0.04	39	0.3	0.02	0.4	0.03
Eye & Orbit	119	1.1	0.05	1.3	0.05	90	0.8	0.04	0.8	0.04
Brain & Other CNS ¹	786	7.3	0.12	8.1	0.13	613	5.3	0.10	5.8	0.10
Brain	742	6.9	0.12	7.7	0.13	567	4.9	0.09	5.3	0.10
Endocrine System	791	7.3	0.12	8.3	0.13	2,268	20.5	0.20	22.4	0.21
Thyroid gland	704	6.5	0.11	7.4	0.13	2,196	19.9	0.19	21.7	0.21
Lymphomas	2,598	24.7	0.22	28.4	0.25	2,033	16.9	0.17	19.4	0.19
Hodgkin Lymphoma	272	2.5	0.07	2.7	0.07	223	2.0	0.06	2.1	0.06
Non-Hodgkin Lymphoma	2,326	22.2	0.21	25.8	0.24	1,811	14.9	0.16	17.3	0.18
Multiple Myeloma	797	7.5	0.12	9.0	0.14	587	4.7	0.09	5.6	0.10
Leukemias	1,711	16.4	0.18	18.5	0.20	1,200	10.1	0.13	11.2	0.15
Acute lymphocytic	249	2.3	0.07	2.2	0.06	185	1.7	0.06	1.6	0.05
Chronic lymphocytic	564	5.4	0.10	6.4	0.12	352	2.8	0.07	3.3	0.08
Acute myeloid	493	4.8	0.10	5.4	0.11	390	3.3	0.08	3.7	0.08
Chronic myeloid	224	2.2	0.07	2.4	0.07	151	1.3	0.05	1.4	0.05
Other leukemias	181	1.8	0.06	2.0	0.07	123	1.0	0.04	1.2	0.05
Mesothelioma	152	1.5	0.06	1.8	0.07	51	0.4	0.03	0.5	0.03
Kaposi Sarcoma	79	0.8	0.04	0.8	0.04	8	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,938	19.2	0.20	22.3	0.23	1,706	13.7	0.15	15.9	0.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	905	8.6	0.13	9.7	0.15	1,839	15.5	0.16	17.7	0.19
Breast (<i>in situ</i>)	11	0.1	0.01	0.1	0.02	3,214	26.8	0.22	31.9	0.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	40,428	453.1	1.03	535.6	1.20	40,526	408.3	0.93	476.1	1.07
Oral Cavity & Pharynx	1,634	17.6	0.20	21.5	0.24	610	6.0	0.11	7.1	0.13
Lip	125	1.4	0.06	1.7	0.07	48	0.5	0.03	0.6	0.04
Tongue	562	6.0	0.12	7.3	0.14	203	2.0	0.06	2.4	0.08
Major salivary gland	158	1.8	0.07	2.1	0.08	89	0.9	0.04	1.0	0.05
Floor of mouth	52	0.5	0.03	0.7	0.04	30	0.3	0.02	0.4	0.03
Gum & other mouth	129	1.5	0.06	1.7	0.07	104	1.0	0.05	1.2	0.05
Nasopharynx	41	0.4	0.03	0.5	0.04	17	0.2	0.02	0.2	0.02
Oropharynx	74	0.8	0.04	1.0	0.05	17	0.2	0.02	0.2	0.02
Hypopharynx	78	0.8	0.04	1.0	0.05	18	0.2	0.02	0.2	0.02
Digestive System	8,188	91.3	0.46	109.2	0.54	6,411	62.8	0.36	74.0	0.42
Esophagus	632	7.0	0.13	8.4	0.15	175	1.7	0.06	2.0	0.07
Stomach	730	8.4	0.14	9.8	0.16	454	4.5	0.10	5.3	0.11
Small intestine	201	2.3	0.07	2.7	0.09	176	1.8	0.06	2.1	0.07
Colon excl. rectum	2,333	26.7	0.25	31.4	0.29	2,329	22.9	0.22	26.7	0.25
Rectum & rectosigmoid	1,190	13.2	0.17	15.8	0.21	853	8.6	0.13	10.2	0.16
Anus, anal canal & anorectum	137	1.5	0.06	1.8	0.07	279	2.7	0.07	3.3	0.09
Liver	1,232	12.7	0.16	16.0	0.20	429	4.1	0.09	5.0	0.11
Gallbladder	69	0.8	0.04	0.9	0.05	146	1.4	0.05	1.7	0.06
Pancreas	1,239	14.0	0.18	16.6	0.21	1,110	10.6	0.15	12.6	0.17
Respiratory System	4,666	53.7	0.36	63.0	0.42	4,595	44.4	0.30	52.1	0.35
Larynx	343	3.8	0.09	4.5	0.11	79	0.8	0.04	0.9	0.05
Lung & bronchus	4,222	48.8	0.34	57.2	0.40	4,455	43.0	0.29	50.4	0.34
Bones & Joints	94	1.1	0.05	1.1	0.05	77	0.9	0.05	0.9	0.05
Soft Tissue (incl. heart)	385	4.4	0.10	5.0	0.11	302	3.2	0.08	3.5	0.09
Skin (excl. basal & sq.)	3,524	40.3	0.31	47.4	0.36	2,174	22.3	0.22	25.8	0.25
Melanomas of the skin	3,252	37.0	0.30	43.6	0.34	2,031	20.9	0.21	24.2	0.24
Breast (excl. <i>in situ</i>)	94	1.1	0.05	1.3	0.06	12,276	125.1	0.52	147.2	0.60
Female Genital System	-	-	-	-	-	4,911	49.7	0.33	58.8	0.38
Cervix uteri	-	-	-	-	-	660	7.7	0.14	8.3	0.14
Uterus Corpus	-	-	-	-	-	2,573	25.1	0.23	30.7	0.27
Uterus, NOS ¹	-	-	-	-	-	93	0.9	0.04	1.1	0.05
Ovary	-	-	-	-	-	1,147	11.7	0.16	13.6	0.18
Male Genital System	9,234	98.5	0.47	119.2	0.56	-	-	-	-	-
Prostate	8,532	90.3	0.45	110.9	0.54	-	-	-	-	-
Testis	602	7.0	0.13	7.0	0.13	-	-	-	-	-
Penis	79	0.9	0.05	1.1	0.05	-	-	-	-	-
Urinary System	4,896	56.4	0.37	66.1	0.43	1,968	19.4	0.20	22.7	0.23
Bladder (incl. <i>in situ</i>)	2,783	32.8	0.28	38.3	0.33	805	7.7	0.12	9.0	0.14
Kidney & renal pelvis	2,008	22.3	0.23	26.4	0.26	1,111	11.2	0.15	13.1	0.18
Ureter	60	0.7	0.04	0.8	0.05	34	0.3	0.03	0.4	0.03
Eye & Orbit	108	1.2	0.05	1.4	0.06	83	0.9	0.04	1.0	0.05
Brain & Other CNS ¹	698	7.9	0.14	8.8	0.15	544	5.7	0.11	6.3	0.12
Brain	662	7.5	0.13	8.4	0.15	509	5.3	0.11	5.9	0.12
Endocrine System	654	7.4	0.13	8.4	0.15	1,833	20.9	0.22	22.7	0.24
Thyroid gland	590	6.6	0.13	7.6	0.14	1,781	20.3	0.22	22.1	0.24
Lymphomas	2,226	25.5	0.25	29.4	0.28	1,723	17.4	0.19	20.0	0.22
Hodgkin Lymphoma	229	2.6	0.08	2.8	0.08	192	2.2	0.07	2.3	0.07
Non-Hodgkin Lymphoma	1,997	22.9	0.23	26.6	0.27	1,532	15.2	0.18	17.7	0.20
Multiple Myeloma	663	7.5	0.13	8.9	0.16	479	4.7	0.10	5.5	0.11
Leukemias	1,490	17.3	0.20	19.3	0.23	1,038	10.6	0.15	11.7	0.16
Acute lymphocytic	221	2.6	0.08	2.4	0.07	159	1.9	0.07	1.7	0.06
Chronic lymphocytic	495	5.6	0.12	6.7	0.14	314	3.0	0.08	3.5	0.09
Acute myeloid	425	5.0	0.11	5.6	0.12	333	3.4	0.09	3.8	0.09
Chronic myeloid	190	2.2	0.07	2.5	0.08	125	1.3	0.05	1.5	0.06
Other leukemias	160	1.9	0.07	2.1	0.08	107	1.1	0.05	1.2	0.05
Mesothelioma	139	1.7	0.06	1.9	0.07	48	0.5	0.03	0.6	0.04
Kaposi Sarcoma	60	0.7	0.04	0.8	0.04	5	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,674	19.7	0.22	22.9	0.25	1,449	13.9	0.17	16.1	0.19
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	757	8.8	0.15	9.8	0.16	1,529	15.7	0.18	18.0	0.21
Breast (<i>in situ</i>)	9	0.1	0.02	0.1	0.02	2,558	26.3	0.24	31.3	0.28

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,244	442.1	4.51	535.7	5.33	2,050	362.0	3.69	427.6	4.28
Oral Cavity & Pharynx	57	10.4	0.67	12.8	0.80	26	4.5	0.41	5.4	0.48
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	13	2.3	0.30	2.9	0.37	6	0.9	0.18	1.1	0.22
Major salivary gland	5	1.0	0.23	1.2	0.27	6	1.1	0.20	1.3	0.24
Floor of mouth	3	0.6	0.16	0.7	0.19	-	-	-	-	-
Gum & other mouth	5	0.9	0.19	1.1	0.23	5	0.9	0.19	1.1	0.22
Nasopharynx	5	1.0	0.21	1.1	0.23	2	0.3	0.10	0.3	0.12
Oropharynx	6	1.0	0.19	1.2	0.24	2	0.4	0.12	0.4	0.14
Hypopharynx	4	0.7	0.16	0.9	0.20	-	-	-	-	-
Digestive System	502	99.8	2.16	121.2	2.55	382	68.9	1.63	82.3	1.91
Esophagus	16	3.0	0.37	3.7	0.44	8	1.6	0.25	1.9	0.29
Stomach	50	10.9	0.74	12.7	0.85	33	6.1	0.49	7.1	0.56
Small intestine	18	3.7	0.42	4.3	0.48	15	2.7	0.32	3.2	0.37
Colon excl. rectum	155	31.1	1.21	37.5	1.42	144	26.5	1.02	31.3	1.18
Rectum & rectosigmoid	60	11.5	0.73	14.0	0.86	46	7.9	0.54	9.5	0.63
Anus, anal canal & anorectum	8	1.4	0.24	1.7	0.28	11	2.0	0.27	2.3	0.32
Liver	94	16.8	0.82	21.5	1.02	29	4.6	0.40	6.0	0.51
Gallbladder	4	0.8	0.20	1.0	0.22	8	1.5	0.25	1.8	0.29
Pancreas	78	16.6	0.91	20.0	1.07	65	11.9	0.68	14.3	0.80
Respiratory System	285	62.2	1.78	74.4	2.07	243	44.5	1.32	53.3	1.55
Larynx	21	4.3	0.45	5.2	0.54	4	0.7	0.16	0.9	0.20
Lung & bronchus	259	57.0	1.71	68.1	1.99	235	43.1	1.30	51.7	1.52
Bones & Joints	5	0.8	0.17	0.8	0.18	4	0.6	0.13	0.6	0.14
Soft Tissue (incl. heart)	23	4.3	0.44	4.9	0.49	20	3.4	0.35	3.8	0.39
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	6	1.2	0.25	1.4	0.28	6	1.2	0.21	1.3	0.24
Breast (excl. <i>in situ</i>)	8	1.8	0.30	2.1	0.35	680	118.4	2.09	139.4	2.42
Female Genital System	-	-	-	-	-	246	41.4	1.21	49.6	1.43
Cervix uteri	-	-	-	-	-	41	6.9	0.50	7.7	0.55
Uterus Corpus	-	-	-	-	-	126	20.9	0.86	25.9	1.04
Uterus, NOS ¹	-	-	-	-	-	11	1.9	0.26	2.2	0.30
Ovary	-	-	-	-	-	49	8.3	0.55	9.8	0.64
Male Genital System	763	141.2	2.45	176.8	2.97	-	-	-	-	-
Prostate	748	138.9	2.43	174.5	2.96	-	-	-	-	-
Testis	12	1.6	0.21	1.6	0.22	-	-	-	-	-
Penis	2	0.5	0.17	0.6	0.19	-	-	-	-	-
Urinary System	210	43.5	1.45	51.9	1.70	108	19.7	0.88	23.2	1.01
Bladder (incl. <i>in situ</i>)	86	20.0	1.04	23.7	1.21	32	6.3	0.51	7.3	0.58
Kidney & renal pelvis	122	22.9	0.99	27.5	1.17	74	13.0	0.70	15.4	0.81
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.3	0.13	0.4	0.15	2	0.3	0.10	0.3	0.11
Brain & Other CNS ¹	29	5.0	0.45	5.5	0.51	19	3.0	0.32	3.4	0.36
Brain	25	4.3	0.42	4.8	0.47	16	2.6	0.30	2.9	0.33
Endocrine System	25	4.4	0.42	5.0	0.47	66	11.1	0.63	12.5	0.70
Thyroid gland	20	3.6	0.38	4.1	0.43	59	9.9	0.59	11.2	0.66
Lymphomas	93	16.6	0.83	19.0	0.95	75	13.2	0.70	15.1	0.80
Hodgkin Lymphoma	15	2.3	0.27	2.3	0.28	11	1.9	0.26	2.0	0.27
Non-Hodgkin Lymphoma	77	14.3	0.78	16.7	0.90	64	11.4	0.65	13.1	0.75
Multiple Myeloma	68	14.6	0.85	17.4	1.00	53	9.4	0.60	11.4	0.71
Leukemias	66	13.3	0.79	15.1	0.90	42	7.3	0.52	8.2	0.59
Acute lymphocytic	6	1.0	0.18	0.9	0.18	7	1.1	0.18	1.0	0.18
Chronic lymphocytic	22	4.7	0.49	5.5	0.56	10	1.9	0.28	2.3	0.32
Acute myeloid	20	4.0	0.44	4.6	0.49	13	2.1	0.28	2.4	0.31
Chronic myeloid	10	2.1	0.31	2.2	0.33	7	1.2	0.21	1.4	0.24
Other leukemias	7	1.5	0.28	1.8	0.33	5	1.0	0.20	1.1	0.23
Mesothelioma	5	1.2	0.27	1.4	0.32	-	-	-	-	-
Kaposi Sarcoma	6	1.0	0.18	1.0	0.19	-	-	-	-	-
Ill-defined & Unknown	89	19.6	1.01	23.4	1.18	75	14.3	0.76	16.7	0.88
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	44	8.4	0.61	9.4	0.68	83	14.9	0.75	17.0	0.85
Breast (<i>in situ</i>)	-	-	-	-	-	161	27.0	0.98	32.7	1.16

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, Asian/Pacific Islander (API)

<i>SITES</i>	MALES (API)					FEMALES (API)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	3,108	280.0	2.31	329.7	2.69	4,150	292.9	2.06	340.4	2.37
Oral Cavity & Pharynx	118	10.0	0.42	11.8	0.49	61	4.3	0.25	5.0	0.29
Lip	2	0.1	0.05	0.2	0.06	-	-	-	-	-
Tongue	23	2.0	0.19	2.4	0.23	16	1.1	0.13	1.3	0.15
Major salivary gland	14	1.2	0.15	1.4	0.17	13	0.9	0.12	1.0	0.13
Floor of mouth	3	0.2	0.06	0.3	0.08	2	0.1	0.04	0.1	0.05
Gum & other mouth	14	1.3	0.15	1.5	0.18	7	0.5	0.08	0.6	0.10
Nasopharynx	42	3.5	0.24	4.0	0.28	15	1.0	0.12	1.2	0.14
Oropharynx	2	0.2	0.06	0.2	0.07	-	-	-	-	-
Hypopharynx	5	0.4	0.09	0.5	0.11	2	0.1	0.04	0.2	0.05
Digestive System	957	86.0	1.28	102.5	1.50	792	56.9	0.92	66.6	1.06
Esophagus	30	2.7	0.23	3.3	0.27	12	0.8	0.11	1.0	0.13
Stomach	113	10.7	0.46	12.5	0.53	101	7.3	0.33	8.5	0.38
Small intestine	15	1.4	0.16	1.6	0.18	11	0.8	0.11	0.9	0.12
Colon excl. rectum	238	21.4	0.64	25.6	0.75	255	18.2	0.52	21.4	0.60
Rectum & rectosigmoid	161	14.0	0.50	16.7	0.60	111	7.7	0.33	9.2	0.39
Anus, anal canal & anorectum	5	0.4	0.09	0.5	0.10	6	0.4	0.08	0.5	0.09
Liver	218	18.8	0.59	22.9	0.70	89	6.5	0.31	7.6	0.36
Gallbladder	11	1.1	0.15	1.2	0.17	18	1.3	0.14	1.5	0.16
Pancreas	109	10.3	0.45	12.1	0.52	126	9.2	0.37	10.7	0.43
Respiratory System	471	44.2	0.94	52.1	1.09	385	27.7	0.64	32.5	0.74
Larynx	19	1.7	0.18	2.0	0.21	2	0.2	0.05	0.2	0.06
Lung & bronchus	440	41.5	0.91	48.9	1.06	376	27.1	0.63	31.8	0.74
Bones & Joints	8	0.7	0.11	0.7	0.11	6	0.5	0.08	0.5	0.09
Soft Tissue (incl. heart)	35	3.0	0.23	3.4	0.26	32	2.4	0.19	2.6	0.21
Skin (excl. basal & sq.)	27	2.5	0.22	2.9	0.25	26	1.9	0.17	2.1	0.19
Melanomas of the skin	17	1.7	0.18	1.9	0.21	19	1.3	0.14	1.5	0.16
Breast (excl. <i>in situ</i>)	6	0.5	0.10	0.6	0.11	1,369	94.8	1.16	111.1	1.35
Female Genital System	-	-	-	-	-	573	39.3	0.74	46.5	0.87
Cervix uteri	-	-	-	-	-	97	6.9	0.32	7.7	0.35
Uterus Corpus	-	-	-	-	-	302	20.4	0.53	24.6	0.64
Uterus, NOS ¹	-	-	-	-	-	9	0.6	0.09	0.7	0.11
Ovary	-	-	-	-	-	132	9.1	0.36	10.8	0.42
Male Genital System	587	50.8	0.96	61.4	1.15	-	-	-	-	-
Prostate	553	48.0	0.94	58.5	1.12	-	-	-	-	-
Testis	26	2.0	0.18	2.0	0.18	-	-	-	-	-
Penis	5	0.5	0.10	0.5	0.11	-	-	-	-	-
Urinary System	276	25.4	0.70	30.0	0.82	127	9.2	0.37	10.6	0.42
Bladder (incl. <i>in situ</i>)	141	13.7	0.53	15.9	0.61	46	3.3	0.22	3.9	0.26
Kidney & renal pelvis	127	11.0	0.45	13.1	0.53	75	5.4	0.28	6.2	0.32
Ureter	5	0.5	0.10	0.6	0.12	4	0.3	0.07	0.4	0.08
Eye & Orbit	4	0.3	0.08	0.4	0.08	3	0.3	0.07	0.3	0.07
Brain & Other CNS ¹	50	4.3	0.28	4.7	0.30	40	2.9	0.21	3.2	0.23
Brain	46	4.0	0.27	4.3	0.29	34	2.5	0.20	2.7	0.21
Endocrine System	89	7.6	0.37	8.6	0.41	302	21.3	0.55	23.6	0.61
Thyroid gland	75	6.4	0.34	7.2	0.38	290	20.4	0.54	22.6	0.60
Lymphomas	197	17.8	0.58	20.3	0.66	169	12.1	0.42	13.9	0.48
Hodgkin Lymphoma	19	1.5	0.16	1.6	0.17	14	1.0	0.12	1.0	0.12
Non-Hodgkin Lymphoma	179	16.3	0.56	18.7	0.64	156	11.2	0.41	12.8	0.46
Multiple Myeloma	49	4.6	0.30	5.5	0.36	40	2.8	0.20	3.3	0.24
Leukemias	98	8.9	0.41	9.7	0.45	85	6.4	0.31	6.9	0.33
Acute lymphocytic	18	1.5	0.16	1.4	0.15	16	1.3	0.15	1.2	0.13
Chronic lymphocytic	14	1.3	0.16	1.5	0.19	8	0.6	0.09	0.6	0.11
Acute myeloid	42	3.9	0.28	4.3	0.31	40	2.9	0.21	3.2	0.23
Chronic myeloid	15	1.4	0.16	1.5	0.18	14	1.0	0.12	1.1	0.14
Other leukemias	8	0.8	0.12	0.9	0.14	8	0.6	0.10	0.7	0.11
Mesothelioma	6	0.6	0.11	0.7	0.13	2	0.1	0.04	0.1	0.05
Kaposi Sarcoma	5	0.4	0.09	0.4	0.10	-	-	-	-	-
Ill-defined & Unknown	125	12.2	0.50	14.2	0.58	138	10.1	0.39	11.6	0.45
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	79	7.0	0.36	7.9	0.41	181	12.9	0.44	14.9	0.50
Breast (<i>in situ</i>)	-	-	-	-	-	393	26.8	0.61	32.0	0.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	315	243.5	6.73	291.0	7.87	343	227.5	5.77	268.4	6.70
Oral Cavity & Pharynx	13	9.1	1.19	11.1	1.41	6	3.7	0.74	4.5	0.88
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.7	0.54	2.1	0.66	1	0.7	0.30	0.9	0.36
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	1.0	0.42	1.2	0.48
Nasopharynx	1	0.8	0.37	1.0	0.46	-	-	-	-	-
Oropharynx	1	1.0	0.39	1.2	0.46	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	90	68.2	3.52	82.8	4.16	64	43.3	2.55	52.0	2.99
Esophagus	7	5.0	0.94	5.8	1.07	2	1.2	0.41	1.6	0.49
Stomach	8	5.5	0.98	6.8	1.19	3	2.5	0.67	2.9	0.77
Small intestine	3	2.0	0.60	2.3	0.70	-	-	-	-	-
Colon excl. rectum	18	14.8	1.73	17.5	2.00	24	16.5	1.59	19.4	1.84
Rectum & rectosigmoid	11	8.1	1.24	10.1	1.50	10	6.3	0.94	7.6	1.11
Anus, anal canal & anorectum	1	0.7	0.28	0.9	0.36	2	0.9	0.35	1.2	0.43
Liver	27	18.4	1.69	23.1	2.04	10	6.5	0.95	8.0	1.14
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	13	10.7	1.46	12.9	1.70	9	6.5	1.02	7.7	1.19
Respiratory System	43	37.8	2.82	44.7	3.27	42	29.6	2.16	35.6	2.53
Larynx	3	2.3	0.65	2.8	0.78	1	1.0	0.40	1.2	0.47
Lung & bronchus	39	35.4	2.74	41.8	3.17	40	27.9	2.09	33.6	2.45
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	2.0	0.60	2.3	0.70	2	1.2	0.41	1.4	0.46
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	8	6.5	1.10	7.8	1.31	7	4.5	0.79	5.3	0.91
Breast (excl. <i>in situ</i>)	-	-	-	-	-	88	55.9	2.78	66.8	3.26
Female Genital System	-	-	-	-	-	50	31.0	2.04	36.2	2.36
Cervix uteri	-	-	-	-	-	10	6.1	0.88	6.5	0.93
Uterus Corpus	-	-	-	-	-	28	17.5	1.55	20.7	1.80
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	9	5.2	0.82	6.3	0.98
Male Genital System	66	48.4	2.91	58.4	3.43	-	-	-	-	-
Prostate	57	43.2	2.79	53.1	3.32	-	-	-	-	-
Testis	8	4.2	0.67	4.1	0.66	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	35	28.5	2.37	33.5	2.73	24	16.7	1.60	19.4	1.83
Bladder (incl. <i>in situ</i>)	16	15.7	1.87	18.0	2.11	5	4.0	0.83	4.9	0.98
Kidney & renal pelvis	18	12.2	1.41	14.9	1.69	18	12.1	1.32	13.9	1.49
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	5	3.3	0.72	3.8	0.85	3	2.2	0.55	2.3	0.58
Brain	5	2.9	0.65	3.4	0.75	3	2.2	0.55	2.3	0.58
Endocrine System	5	3.1	0.71	3.5	0.80	15	9.3	1.12	10.4	1.25
Thyroid gland	5	3.0	0.70	3.4	0.79	15	9.0	1.09	10.0	1.21
Lymphomas	13	9.1	1.26	10.8	1.48	13	9.2	1.19	10.6	1.35
Hodgkin Lymphoma	1	0.8	0.37	0.9	0.42	2	1.2	0.40	1.3	0.45
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	5	3.7	0.80	4.3	0.91	5	3.8	0.81	4.4	0.91
Leukemias	11	8.0	1.18	9.0	1.32	8	5.3	0.90	5.8	1.00
Acute lymphocytic	2	1.0	0.33	0.9	0.31	1	0.7	0.27	0.6	0.24
Chronic lymphocytic	2	1.4	0.48	1.7	0.54	1	0.9	0.39	1.1	0.44
Acute myeloid	3	2.6	0.67	2.9	0.74	3	1.9	0.55	2.2	0.63
Chronic myeloid	2	1.6	0.54	1.9	0.63	1	0.8	0.34	0.9	0.39
Other leukemias	2	1.4	0.55	1.7	0.63	1	0.9	0.40	1.0	0.44
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	15	13.2	1.66	15.7	1.94	13	10.0	1.31	11.7	1.52
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	7	4.7	0.89	5.4	1.02	12	7.5	1.02	8.7	1.18
Breast (<i>in situ</i>)	-	-	-	-	-	19	11.7	1.24	14.3	1.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,507	358.6	1.90	422.6	2.21	9,752	332.2	1.57	388.1	1.83
Oral Cavity & Pharynx	214	8.5	0.28	10.2	0.33	109	3.9	0.17	4.5	0.20
Lip	11	0.4	0.07	0.5	0.08	6	0.2	0.04	0.3	0.05
Tongue	56	2.2	0.14	2.7	0.17	32	1.1	0.09	1.3	0.11
Major salivary gland	29	1.1	0.10	1.3	0.12	24	0.8	0.08	0.9	0.08
Floor of mouth	8	0.3	0.06	0.4	0.07	4	0.1	0.03	0.2	0.04
Gum & other mouth	24	1.1	0.11	1.3	0.12	19	0.7	0.08	0.9	0.09
Nasopharynx	10	0.3	0.05	0.4	0.06	4	0.1	0.03	0.1	0.03
Oropharynx	11	0.5	0.07	0.6	0.08	3	0.1	0.03	0.1	0.03
Hypopharynx	11	0.5	0.07	0.6	0.08	2	0.1	0.02	0.1	0.03
Digestive System	2,309	97.5	0.99	117.0	1.16	1,778	65.5	0.72	77.5	0.85
Esophagus	97	4.4	0.21	5.2	0.25	27	1.0	0.09	1.2	0.11
Stomach	262	11.7	0.35	13.6	0.40	215	7.7	0.25	9.1	0.29
Small intestine	44	1.9	0.14	2.2	0.16	40	1.5	0.11	1.7	0.13
Colon excl. rectum	582	24.8	0.50	29.5	0.58	550	20.0	0.40	23.5	0.46
Rectum & rectosigmoid	359	13.9	0.36	16.9	0.42	242	8.1	0.24	9.7	0.29
Anus, anal canal & anorectum	22	0.8	0.08	1.0	0.10	37	1.3	0.10	1.6	0.12
Liver	520	20.3	0.43	25.4	0.52	192	7.3	0.24	8.8	0.29
Gallbladder	28	1.4	0.12	1.6	0.14	68	2.6	0.15	3.1	0.17
Pancreas	272	12.6	0.37	14.9	0.43	270	10.7	0.30	12.6	0.35
Respiratory System	672	34.4	0.63	40.0	0.72	595	24.0	0.46	28.3	0.53
Larynx	66	3.0	0.18	3.6	0.21	13	0.5	0.06	0.6	0.07
Lung & bronchus	575	30.4	0.60	35.2	0.68	565	23.0	0.45	27.0	0.52
Bones & Joints	40	1.0	0.08	1.1	0.09	33	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	109	3.8	0.18	4.2	0.20	104	3.2	0.15	3.6	0.17
Skin (excl. basal & sq.)	152	6.5	0.26	7.7	0.30	196	6.4	0.21	7.4	0.25
Melanomas of the skin	120	5.1	0.23	6.0	0.27	167	5.4	0.19	6.3	0.23
Breast (excl. <i>in situ</i>)	16	0.8	0.09	0.9	0.11	2,895	95.7	0.82	112.8	0.97
Female Genital System	-	-	-	-	-	1,409	45.7	0.56	53.8	0.67
Cervix uteri	-	-	-	-	-	297	8.9	0.24	9.8	0.27
Uterus Corpus	-	-	-	-	-	670	21.8	0.39	26.5	0.47
Uterus, NOS ¹	-	-	-	-	-	33	1.1	0.09	1.3	0.11
Ovary	-	-	-	-	-	315	10.4	0.27	12.2	0.32
Male Genital System	2,160	90.8	0.95	108.8	1.11	-	-	-	-	-
Prostate	1,846	83.2	0.93	101.0	1.09	-	-	-	-	-
Testis	276	5.9	0.17	5.9	0.17	-	-	-	-	-
Penis	33	1.4	0.12	1.7	0.14	-	-	-	-	-
Urinary System	961	42.2	0.66	49.6	0.76	503	17.9	0.37	21.0	0.43
Bladder (incl. <i>in situ</i>)	326	17.0	0.45	19.8	0.51	106	4.3	0.19	5.1	0.22
Kidney & renal pelvis	620	24.4	0.47	28.9	0.55	387	13.2	0.31	15.5	0.37
Ureter	9	0.5	0.08	0.6	0.09	6	0.3	0.05	0.3	0.05
Eye & Orbit	19	0.7	0.08	0.8	0.09	17	0.5	0.05	0.5	0.06
Brain & Other CNS ¹	178	5.7	0.21	6.2	0.24	153	4.6	0.18	5.1	0.20
Brain	166	5.3	0.21	5.9	0.23	141	4.3	0.17	4.8	0.20
Endocrine System	187	6.1	0.22	6.9	0.25	727	20.8	0.36	23.0	0.40
Thyroid gland	165	5.4	0.21	6.2	0.24	710	20.3	0.35	22.4	0.40
Lymphomas	562	22.7	0.47	26.0	0.54	497	17.2	0.36	19.8	0.42
Hodgkin Lymphoma	78	2.2	0.13	2.4	0.14	71	1.9	0.11	2.0	0.12
Non-Hodgkin Lymphoma	484	20.4	0.46	23.5	0.52	426	15.3	0.35	17.8	0.40
Multiple Myeloma	176	7.8	0.28	9.2	0.33	143	5.4	0.21	6.4	0.25
Leukemias	378	12.5	0.33	13.6	0.37	290	8.8	0.25	9.6	0.28
Acute lymphocytic	141	3.1	0.13	2.9	0.13	99	2.2	0.11	2.1	0.11
Chronic lymphocytic	47	2.3	0.16	2.7	0.18	39	1.5	0.11	1.8	0.13
Acute myeloid	102	3.9	0.19	4.3	0.22	87	2.8	0.14	3.2	0.16
Chronic myeloid	50	1.8	0.13	2.0	0.14	35	1.1	0.09	1.3	0.10
Other leukemias	38	1.5	0.12	1.7	0.14	29	1.0	0.09	1.2	0.10
Mesothelioma	29	1.4	0.13	1.7	0.15	10	0.4	0.05	0.4	0.06
Kaposi Sarcoma	33	1.0	0.09	1.1	0.10	3	0.1	0.04	0.1	0.04
Ill-defined & Unknown	313	15.2	0.42	17.5	0.48	290	11.4	0.31	13.2	0.36
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	203	7.1	0.25	8.0	0.29	433	14.6	0.33	16.8	0.38
Breast (<i>in situ</i>)	1	0.1	0.02	0.1	0.03	645	21.0	0.38	25.1	0.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	32,302	482.2	1.24	569.9	1.43	31,117	431.2	1.17	501.8	1.31
Oral Cavity & Pharynx	1,427	20.8	0.26	25.4	0.30	504	6.8	0.14	8.1	0.17
Lip	115	1.8	0.08	2.1	0.09	42	0.6	0.04	0.7	0.05
Tongue	508	7.3	0.15	9.0	0.18	171	2.3	0.08	2.8	0.10
Major salivary gland	131	2.0	0.08	2.3	0.09	66	0.9	0.06	1.1	0.06
Floor of mouth	44	0.6	0.04	0.8	0.05	27	0.3	0.03	0.4	0.04
Gum & other mouth	105	1.6	0.07	1.9	0.08	86	1.1	0.06	1.3	0.07
Nasopharynx	31	0.5	0.04	0.6	0.05	13	0.2	0.02	0.2	0.03
Oropharynx	63	0.9	0.05	1.1	0.06	15	0.2	0.02	0.2	0.03
Hypopharynx	67	0.9	0.05	1.1	0.06	16	0.2	0.02	0.2	0.03
Digestive System	5,948	88.4	0.53	105.6	0.62	4,693	60.9	0.42	71.8	0.48
Esophagus	537	7.7	0.15	9.3	0.18	149	1.8	0.07	2.2	0.08
Stomach	475	7.1	0.15	8.4	0.17	245	3.2	0.10	3.8	0.11
Small intestine	158	2.4	0.09	2.8	0.10	138	1.9	0.08	2.2	0.09
Colon excl. rectum	1,772	27.1	0.30	31.9	0.34	1,799	23.5	0.26	27.3	0.30
Rectum & rectosigmoid	846	13.0	0.21	15.5	0.24	622	8.7	0.17	10.3	0.19
Anus, anal canal & anorectum	116	1.8	0.08	2.1	0.09	243	3.2	0.10	3.9	0.11
Liver	726	9.8	0.17	12.5	0.21	244	3.1	0.09	3.7	0.11
Gallbladder	42	0.6	0.05	0.7	0.05	79	1.0	0.05	1.2	0.06
Pancreas	974	14.2	0.21	17.0	0.25	847	10.5	0.17	12.4	0.20
Respiratory System	4,013	58.8	0.42	69.3	0.49	4,017	50.1	0.36	58.8	0.42
Larynx	279	4.0	0.11	4.8	0.13	66	0.9	0.05	1.0	0.06
Lung & bronchus	3,663	53.7	0.40	63.2	0.47	3,906	48.5	0.36	57.0	0.41
Bones & Joints	55	1.1	0.07	1.1	0.07	44	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	279	4.6	0.13	5.2	0.14	201	3.2	0.11	3.5	0.12
Skin (excl. basal & sq.)	3,382	52.0	0.42	60.9	0.47	1,997	30.2	0.33	34.4	0.36
Melanomas of the skin	3,140	48.3	0.40	56.5	0.46	1,880	28.6	0.32	32.6	0.35
Breast (excl. <i>in situ</i>)	78	1.2	0.06	1.4	0.07	9,488	134.4	0.66	157.9	0.75
Female Genital System	-	-	-	-	-	3,545	49.6	0.40	58.8	0.45
Cervix uteri	-	-	-	-	-	372	7.1	0.18	7.6	0.18
Uterus Corpus	-	-	-	-	-	1,926	25.3	0.27	31.2	0.32
Uterus, NOS ¹	-	-	-	-	-	61	0.8	0.05	1.0	0.06
Ovary	-	-	-	-	-	838	11.8	0.19	13.8	0.22
Male Genital System	7,252	102.2	0.55	123.9	0.66	-	-	-	-	-
Prostate	6,853	93.8	0.52	115.4	0.63	-	-	-	-	-
Testis	336	7.5	0.19	7.4	0.18	-	-	-	-	-
Penis	46	0.7	0.05	0.8	0.05	-	-	-	-	-
Urinary System	3,967	59.6	0.43	69.9	0.50	1,482	19.2	0.24	22.5	0.27
Bladder (incl. <i>in situ</i>)	2,470	37.0	0.34	43.3	0.39	702	8.6	0.15	10.1	0.17
Kidney & renal pelvis	1,405	21.1	0.26	25.1	0.30	737	10.1	0.18	11.8	0.20
Ureter	51	0.8	0.05	0.9	0.06	28	0.3	0.03	0.4	0.03
Eye & Orbit	90	1.4	0.07	1.7	0.08	67	1.0	0.06	1.2	0.06
Brain & Other CNS ¹	524	9.0	0.19	9.9	0.20	395	6.3	0.16	6.9	0.16
Brain	500	8.5	0.18	9.4	0.19	371	5.9	0.15	6.4	0.16
Endocrine System	476	8.2	0.18	9.2	0.19	1,132	20.9	0.30	22.6	0.31
Thyroid gland	432	7.3	0.17	8.3	0.18	1,097	20.3	0.29	21.9	0.30
Lymphomas	1,685	26.7	0.30	30.7	0.34	1,244	17.5	0.24	19.9	0.26
Hodgkin Lymphoma	155	3.1	0.12	3.2	0.12	123	2.5	0.11	2.6	0.11
Non-Hodgkin Lymphoma	1,530	23.7	0.28	27.5	0.32	1,121	14.9	0.21	17.4	0.24
Multiple Myeloma	492	7.3	0.15	8.6	0.18	341	4.4	0.11	5.1	0.13
Leukemias	1,122	17.9	0.25	20.4	0.28	756	10.8	0.19	12.0	0.20
Acute lymphocytic	83	1.9	0.10	1.7	0.09	63	1.5	0.09	1.4	0.08
Chronic lymphocytic	451	6.6	0.14	7.9	0.17	278	3.4	0.09	4.0	0.11
Acute myeloid	325	5.2	0.13	5.9	0.15	247	3.5	0.11	3.9	0.11
Chronic myeloid	141	2.3	0.09	2.6	0.10	90	1.3	0.07	1.5	0.07
Other leukemias	122	2.0	0.08	2.3	0.09	78	1.1	0.06	1.2	0.06
Mesothelioma	111	1.7	0.07	2.0	0.08	38	0.5	0.04	0.6	0.04
Kaposi Sarcoma	30	0.6	0.05	0.6	0.05	3	0.0	0.01	0.0	0.01
Ill-defined & Unknown	1,370	20.8	0.26	24.3	0.30	1,168	14.6	0.20	16.9	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	563	9.5	0.19	10.6	0.20	1,114	16.4	0.24	18.6	0.26
Breast (<i>in situ</i>)	8	0.1	0.02	0.1	0.02	1,943	28.5	0.31	33.7	0.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater California, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,211	469.9	4.81	569.1	5.68	2,007	389.5	4.00	459.3	4.63
Oral Cavity & Pharynx	57	11.3	0.72	13.8	0.86	26	4.9	0.45	5.9	0.53
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	13	2.5	0.33	3.2	0.40	6	1.0	0.20	1.3	0.24
Major salivary gland	5	1.1	0.24	1.3	0.29	6	1.2	0.22	1.4	0.26
Floor of mouth	3	0.6	0.17	0.8	0.21	-	-	-	-	-
Gum & other mouth	5	0.9	0.20	1.1	0.25	5	1.0	0.21	1.2	0.24
Nasopharynx	5	1.1	0.23	1.2	0.25	2	0.3	0.12	0.4	0.13
Oropharynx	6	1.0	0.21	1.3	0.26	2	0.4	0.13	0.5	0.15
Hypopharynx	4	0.8	0.17	1.0	0.22	-	-	-	-	-
Digestive System	495	106.1	2.30	128.8	2.72	375	73.8	1.75	88.1	2.05
Esophagus	15	3.2	0.39	3.9	0.47	8	1.7	0.27	2.0	0.32
Stomach	49	11.6	0.79	13.6	0.91	33	6.6	0.53	7.7	0.61
Small intestine	17	3.8	0.44	4.5	0.51	15	2.9	0.34	3.4	0.40
Colon excl. rectum	153	33.0	1.28	39.8	1.52	141	28.4	1.10	33.5	1.27
Rectum & rectosigmoid	59	12.4	0.78	15.0	0.92	45	8.6	0.59	10.2	0.68
Anus, anal canal & anorectum	8	1.5	0.26	1.8	0.30	11	2.1	0.29	2.5	0.34
Liver	93	17.9	0.88	22.9	1.09	28	4.9	0.43	6.3	0.54
Gallbladder	4	0.8	0.20	1.0	0.23	8	1.6	0.26	1.9	0.31
Pancreas	77	17.7	0.97	21.3	1.14	64	12.7	0.73	15.2	0.86
Respiratory System	281	65.8	1.89	78.6	2.20	239	47.3	1.41	56.8	1.66
Larynx	21	4.5	0.48	5.5	0.57	4	0.8	0.18	1.0	0.21
Lung & bronchus	255	60.2	1.81	71.9	2.11	231	45.8	1.39	55.0	1.63
Bones & Joints	5	0.9	0.19	0.9	0.20	4	0.6	0.15	0.6	0.15
Soft Tissue (incl. heart)	22	4.6	0.47	5.2	0.53	19	3.7	0.39	4.1	0.43
Skin (excl. basal & sq.)	10	2.2	0.33	2.5	0.38	11	2.1	0.30	2.4	0.33
Melanomas of the skin	5	1.2	0.26	1.4	0.29	6	1.3	0.24	1.5	0.26
Breast (excl. <i>in situ</i>)	8	2.0	0.33	2.3	0.38	663	127.5	2.28	149.9	2.62
Female Genital System	-	-	-	-	-	240	44.6	1.32	53.4	1.55
Cervix uteri	-	-	-	-	-	40	7.6	0.56	8.4	0.61
Uterus Corpus	-	-	-	-	-	122	22.2	0.92	27.5	1.12
Uterus, NOS ¹	-	-	-	-	-	11	2.0	0.29	2.4	0.33
Ovary	-	-	-	-	-	49	9.1	0.60	10.8	0.70
Male Genital System	752	149.7	2.61	187.5	3.17	-	-	-	-	-
Prostate	739	147.3	2.59	185.0	3.15	-	-	-	-	-
Testis	11	1.7	0.24	1.7	0.24	-	-	-	-	-
Penis	2	0.6	0.18	0.7	0.20	-	-	-	-	-
Urinary System	206	46.1	1.55	55.0	1.81	106	21.2	0.95	25.0	1.09
Bladder (incl. <i>in situ</i>)	85	21.0	1.10	25.0	1.28	32	6.7	0.55	7.8	0.63
Kidney & renal pelvis	119	24.4	1.07	29.2	1.25	72	14.0	0.76	16.6	0.88
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.3	0.14	0.4	0.16	2	0.3	0.11	0.3	0.12
Brain & Other CNS ¹	27	5.3	0.49	5.9	0.55	18	3.3	0.36	3.7	0.40
Brain	24	4.6	0.45	5.1	0.51	15	2.9	0.34	3.1	0.37
Endocrine System	24	4.8	0.45	5.4	0.51	64	12.3	0.70	13.8	0.78
Thyroid gland	19	3.9	0.41	4.4	0.47	57	11.0	0.66	12.3	0.73
Lymphomas	91	18.0	0.90	20.5	1.02	74	14.5	0.78	16.4	0.87
Hodgkin Lymphoma	15	2.6	0.31	2.6	0.31	11	2.2	0.30	2.2	0.31
Non-Hodgkin Lymphoma	76	15.4	0.84	17.9	0.97	62	12.3	0.72	14.2	0.81
Multiple Myeloma	68	15.5	0.91	18.6	1.06	52	10.0	0.64	12.1	0.76
Leukemias	64	14.1	0.85	16.1	0.96	40	7.9	0.57	8.9	0.64
Acute lymphocytic	5	1.0	0.20	0.9	0.19	6	1.1	0.20	1.1	0.20
Chronic lymphocytic	22	5.0	0.52	5.9	0.60	10	2.0	0.30	2.4	0.34
Acute myeloid	19	4.2	0.46	4.9	0.52	12	2.4	0.31	2.6	0.34
Chronic myeloid	10	2.3	0.34	2.5	0.36	7	1.4	0.23	1.6	0.27
Other leukemias	7	1.6	0.30	1.9	0.35	5	1.0	0.21	1.2	0.24
Mesothelioma	5	1.2	0.28	1.5	0.33	-	-	-	-	-
Kaposi Sarcoma	6	1.1	0.20	1.2	0.21	-	-	-	-	-
Ill-defined & Unknown	88	20.9	1.08	24.9	1.26	73	15.1	0.81	17.6	0.94
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	44	9.1	0.66	10.2	0.74	81	16.1	0.83	18.3	0.92
Breast (<i>in situ</i>)	-	-	-	-	-	157	28.8	1.06	34.9	1.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


GREATER BAY AREA CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	7,141,875	7,238,119	7,330,234	7,387,417	7,414,857
White	4,570,125	4,603,595	4,627,456	4,627,786	4,605,495
Black	505,076	505,844	506,846	505,833	505,225
American Indian/Alaskan Native (AI/AN)	105,704	105,774	106,014	105,855	105,971
Asian/Pacific Islander (API)	1,960,970	2,022,906	2,089,918	2,147,943	2,198,166

All Races Population 2013-2017: 36,512,502

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	1,844,913	1,867,828	1,887,604	1,900,804	1,906,648
Non-Hispanic White	2,937,397	2,949,531	2,955,528	2,943,856	2,917,237
Non-Hispanic Black	447,976	448,250	448,608	447,160	445,913

Hispanic/Latino Population, Census 2010: 1,763,285

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GREATER BAY AREA CANCER REGISTRY

Initial Operation: 1973
 Population-based Data Available: 1988
 Coverage Area: County

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.8	109.7	109.0	108.0	108.6
Missing Race	1.3	1.2	1.3	2.0	2.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.8	1.2	1.0	1.0	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.5	Prostate	96.0
Oral Cavity & Pharynx	98.8	Testis	99.4
Esophagus	96.6	Bladder (incl. <i>in situ</i>)	98.1
Stomach	97.5	Kidney & Renal Pelvis	88.4
Colon & Rectum	96.7	Brain & Other CNS ¹	86.2
Liver	40.0	Thyroid	99.6
Pancreas	85.7	Hodgkin Lymphoma	99.3
Lung & Bronchus	88.8	Non-Hodgkin Lymphoma	97.8
Melanomas of the Skin	99.3	Multiple Myeloma	92.1
Female Breast (excl. <i>in situ</i>)	99.2	Leukemias	92.0
Cervix uteri	97.5	Brain & Other CNS ¹ <i>non-malig</i>	43.8
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	94.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	16,186	430.7	1.55	508.9	1.80	16,644	386.9	1.37	451.2	1.57
Oral Cavity & Pharynx	588	15.0	0.28	18.1	0.34	259	5.9	0.17	7.0	0.20
Lip	29	0.8	0.07	0.9	0.08	13	0.3	0.04	0.3	0.04
Tongue	188	4.7	0.16	5.8	0.19	82	1.9	0.09	2.2	0.11
Major salivary gland	55	1.5	0.09	1.7	0.11	39	0.9	0.07	1.1	0.08
Floor of mouth	14	0.4	0.04	0.4	0.05	11	0.2	0.03	0.3	0.04
Gum & other mouth	61	1.7	0.10	2.0	0.11	50	1.1	0.07	1.3	0.08
Nasopharynx	61	1.6	0.09	1.8	0.11	25	0.6	0.06	0.7	0.06
Oropharynx	23	0.6	0.05	0.7	0.07	8	0.2	0.03	0.2	0.03
Hypopharynx	25	0.6	0.06	0.8	0.07	8	0.2	0.03	0.2	0.03
Digestive System	3,448	90.8	0.71	108.7	0.83	2,731	62.0	0.54	73.0	0.63
Esophagus	210	5.6	0.18	6.7	0.21	74	1.7	0.09	1.9	0.10
Stomach	350	9.6	0.23	11.2	0.27	243	5.6	0.16	6.5	0.19
Small intestine	86	2.3	0.11	2.7	0.13	72	1.6	0.09	2.0	0.10
Colon excl. rectum	958	25.7	0.38	30.4	0.44	968	22.1	0.32	25.8	0.37
Rectum & rectosigmoid	491	12.5	0.26	15.1	0.31	341	7.9	0.19	9.3	0.23
Anus, anal canal & anorectum	65	1.6	0.09	2.0	0.11	80	1.8	0.09	2.2	0.11
Liver	580	14.3	0.27	17.9	0.33	196	4.4	0.14	5.2	0.17
Gallbladder	30	0.8	0.07	1.0	0.08	65	1.4	0.08	1.7	0.10
Pancreas	495	13.4	0.28	16.0	0.32	478	10.7	0.22	12.6	0.26
Respiratory System	1,755	48.8	0.53	57.2	0.62	1,637	37.2	0.42	43.5	0.48
Larynx	120	3.2	0.13	3.8	0.16	21	0.5	0.05	0.6	0.06
Lung & bronchus	1,593	44.5	0.51	52.1	0.59	1,595	36.2	0.41	42.4	0.48
Bones & Joints	38	1.1	0.08	1.1	0.08	25	0.6	0.06	0.7	0.06
Soft Tissue (incl. heart)	164	4.5	0.16	5.0	0.18	125	3.0	0.12	3.4	0.14
Skin (excl. basal & sq.)	1,396	37.8	0.46	44.2	0.53	926	21.7	0.33	25.1	0.37
Melanomas of the skin	1,277	34.3	0.44	40.2	0.51	860	20.2	0.31	23.4	0.36
Breast (excl. <i>in situ</i>)	37	1.0	0.08	1.2	0.09	5,378	126.4	0.79	148.2	0.91
Female Genital System	-	-	-	-	-	2,027	46.7	0.47	55.5	0.55
Cervix uteri	-	-	-	-	-	226	5.7	0.17	6.2	0.18
Uterus Corpus	-	-	-	-	-	1,140	25.6	0.35	31.3	0.42
Uterus, NOS ¹	-	-	-	-	-	25	0.6	0.05	0.7	0.06
Ovary	-	-	-	-	-	461	10.9	0.23	12.7	0.27
Male Genital System	3,925	99.3	0.73	120.8	0.87	-	-	-	-	-
Prostate	3,657	92.2	0.70	113.6	0.84	-	-	-	-	-
Testis	231	6.0	0.18	6.1	0.18	-	-	-	-	-
Penis	27	0.8	0.07	0.9	0.08	-	-	-	-	-
Urinary System	1,761	48.2	0.53	56.6	0.61	703	15.9	0.27	18.7	0.32
Bladder (incl. <i>in situ</i>)	1,010	28.4	0.41	33.3	0.47	305	6.8	0.18	8.0	0.21
Kidney & renal pelvis	715	18.8	0.32	22.1	0.37	375	8.6	0.20	10.1	0.24
Ureter	22	0.7	0.06	0.8	0.07	14	0.3	0.04	0.4	0.04
Eye & Orbit	39	1.0	0.08	1.2	0.09	33	0.8	0.06	0.9	0.07
Brain & Other CNS ¹	271	7.3	0.20	8.1	0.22	198	4.9	0.16	5.3	0.17
Brain	254	6.8	0.20	7.6	0.21	185	4.5	0.15	5.0	0.17
Endocrine System	291	7.6	0.20	8.4	0.22	721	18.3	0.31	19.9	0.33
Thyroid gland	255	6.6	0.19	7.4	0.21	689	17.5	0.30	19.0	0.33
Lymphomas	977	26.4	0.39	30.3	0.44	769	18.1	0.30	20.7	0.34
Hodgkin Lymphoma	98	2.6	0.12	2.8	0.13	73	1.9	0.10	2.0	0.10
Non-Hodgkin Lymphoma	879	23.7	0.37	27.5	0.42	696	16.2	0.28	18.7	0.32
Multiple Myeloma	285	7.7	0.21	9.1	0.24	202	4.6	0.15	5.4	0.17
Leukemias	574	16.0	0.31	17.9	0.34	373	9.0	0.21	10.0	0.23
Acute lymphocytic	70	2.0	0.11	1.9	0.10	53	1.6	0.10	1.4	0.09
Chronic lymphocytic	199	5.4	0.18	6.4	0.20	111	2.5	0.11	3.0	0.13
Acute myeloid	179	5.1	0.17	5.7	0.19	131	3.1	0.12	3.5	0.14
Chronic myeloid	69	1.9	0.10	2.2	0.12	45	1.1	0.07	1.2	0.08
Other leukemias	56	1.6	0.09	1.8	0.11	32	0.8	0.06	0.8	0.07
Mesothelioma	47	1.4	0.09	1.6	0.10	18	0.4	0.05	0.5	0.05
Kaposi Sarcoma	45	1.2	0.08	1.3	0.09	5	0.1	0.02	0.1	0.03
Ill-defined & Unknown	547	15.6	0.30	18.0	0.35	513	11.4	0.23	13.2	0.26
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	321	8.6	0.22	9.9	0.25	644	15.1	0.27	17.5	0.31
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.03	1,371	32.5	0.40	38.4	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	11,598	461.8	1.96	544.4	2.28	11,578	419.2	1.79	488.1	2.05
Oral Cavity & Pharynx	432	16.3	0.36	19.9	0.43	165	5.7	0.21	6.9	0.24
Lip	27	1.1	0.09	1.3	0.11	11	0.4	0.06	0.5	0.06
Tongue	156	5.8	0.21	7.2	0.26	54	1.9	0.12	2.3	0.14
Major salivary gland	38	1.6	0.12	1.8	0.13	24	0.9	0.08	1.0	0.09
Floor of mouth	11	0.4	0.06	0.5	0.07	8	0.3	0.04	0.3	0.05
Gum & other mouth	42	1.7	0.12	2.0	0.14	34	1.1	0.09	1.3	0.10
Nasopharynx	11	0.4	0.06	0.5	0.07	3	0.1	0.03	0.1	0.04
Oropharynx	18	0.7	0.07	0.8	0.09	6	0.2	0.04	0.2	0.04
Hypopharynx	18	0.7	0.07	0.8	0.09	6	0.2	0.04	0.2	0.04
Digestive System	2,248	88.6	0.86	105.8	1.00	1,807	63.1	0.68	74.3	0.79
Esophagus	159	6.3	0.23	7.5	0.27	57	1.9	0.12	2.3	0.14
Stomach	206	8.3	0.27	9.7	0.31	135	4.8	0.19	5.6	0.22
Small intestine	62	2.5	0.14	2.9	0.17	53	1.9	0.12	2.2	0.14
Colon excl. rectum	646	26.1	0.47	30.7	0.54	655	23.1	0.42	26.8	0.48
Rectum & rectosigmoid	314	12.1	0.31	14.5	0.37	216	7.8	0.24	9.3	0.28
Anus, anal canal & anorectum	52	2.0	0.13	2.4	0.15	69	2.3	0.13	2.9	0.16
Liver	324	11.8	0.30	14.8	0.37	108	3.7	0.16	4.5	0.19
Gallbladder	18	0.7	0.08	0.9	0.09	43	1.5	0.10	1.7	0.12
Pancreas	349	14.1	0.35	16.7	0.40	327	11.1	0.28	13.1	0.33
Respiratory System	1,121	46.5	0.64	54.3	0.73	1,130	39.3	0.53	45.8	0.61
Larynx	88	3.5	0.17	4.2	0.20	16	0.5	0.06	0.7	0.07
Lung & bronchus	1,003	41.7	0.60	48.7	0.69	1,102	38.3	0.53	44.6	0.61
Bones & Joints	29	1.3	0.11	1.3	0.11	18	0.7	0.08	0.8	0.08
Soft Tissue (incl. heart)	120	5.0	0.21	5.6	0.23	82	3.1	0.16	3.5	0.17
Skin (excl. basal & sq.)	1,273	51.5	0.66	60.2	0.76	824	30.5	0.49	35.1	0.55
Melanomas of the skin	1,175	47.3	0.63	55.4	0.73	774	28.7	0.48	33.1	0.54
Breast (excl. <i>in situ</i>)	28	1.1	0.10	1.3	0.11	3,676	135.4	1.03	158.6	1.18
Female Genital System	-	-	-	-	-	1,387	49.8	0.61	59.2	0.72
Cervix uteri	-	-	-	-	-	146	6.2	0.23	6.5	0.24
Uterus Corpus	-	-	-	-	-	774	26.9	0.44	33.0	0.53
Uterus, NOS ¹	-	-	-	-	-	16	0.5	0.06	0.6	0.07
Ovary	-	-	-	-	-	322	11.8	0.30	13.8	0.35
Male Genital System	2,743	103.5	0.91	125.6	1.08	-	-	-	-	-
Prostate	2,524	94.4	0.86	116.3	1.04	-	-	-	-	-
Testis	192	8.0	0.26	8.0	0.26	-	-	-	-	-
Penis	20	0.8	0.09	1.0	0.10	-	-	-	-	-
Urinary System	1,350	55.2	0.69	64.7	0.79	510	17.8	0.36	20.9	0.42
Bladder (incl. <i>in situ</i>)	804	33.5	0.54	39.2	0.62	233	7.9	0.24	9.3	0.28
Kidney & renal pelvis	521	20.6	0.41	24.2	0.48	262	9.4	0.27	11.1	0.31
Ureter	16	0.7	0.08	0.8	0.09	9	0.3	0.04	0.3	0.05
Eye & Orbit	34	1.4	0.11	1.6	0.12	29	1.1	0.09	1.2	0.10
Brain & Other CNS ¹	209	8.5	0.27	9.5	0.29	151	5.9	0.22	6.5	0.24
Brain	197	8.0	0.26	8.9	0.29	143	5.5	0.21	6.1	0.23
Endocrine System	196	7.8	0.26	8.7	0.28	455	18.8	0.40	20.4	0.43
Thyroid gland	176	7.0	0.24	7.8	0.26	438	18.1	0.40	19.7	0.42
Lymphomas	714	29.0	0.50	33.4	0.56	553	20.2	0.40	23.2	0.44
Hodgkin Lymphoma	73	3.0	0.16	3.2	0.17	55	2.3	0.14	2.4	0.15
Non-Hodgkin Lymphoma	641	26.0	0.47	30.2	0.54	498	17.9	0.37	20.7	0.42
Multiple Myeloma	194	7.9	0.26	9.3	0.30	131	4.5	0.18	5.4	0.21
Leukemias	435	18.2	0.40	20.4	0.44	276	10.2	0.28	11.4	0.31
Acute lymphocytic	51	2.3	0.15	2.1	0.13	34	1.6	0.13	1.5	0.11
Chronic lymphocytic	167	6.8	0.24	8.0	0.28	92	3.1	0.15	3.7	0.18
Acute myeloid	125	5.4	0.22	6.0	0.24	93	3.4	0.16	3.8	0.18
Chronic myeloid	48	2.0	0.13	2.3	0.15	34	1.2	0.10	1.4	0.11
Other leukemias	43	1.8	0.12	2.0	0.14	23	0.8	0.08	0.9	0.09
Mesothelioma	39	1.7	0.12	1.9	0.14	15	0.5	0.06	0.6	0.07
Kaposi Sarcoma	33	1.3	0.10	1.5	0.12	3	0.1	0.03	0.1	0.03
Ill-defined & Unknown	400	16.9	0.39	19.6	0.44	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	223	9.0	0.28	10.3	0.31	423	15.6	0.35	17.9	0.39
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.03	824	31.1	0.50	36.5	0.57

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,161	488.6	6.75	590.0	7.94	1,093	392.5	5.43	463.9	6.30
Oral Cavity & Pharynx	33	13.4	1.10	16.2	1.29	12	4.3	0.56	5.2	0.66
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	8	3.2	0.53	3.9	0.63	3	1.0	0.28	1.2	0.33
Major salivary gland	3	1.4	0.39	1.6	0.43	2	0.9	0.26	1.0	0.28
Floor of mouth	2	0.8	0.27	0.9	0.31	-	-	-	-	-
Gum & other mouth	4	1.7	0.40	1.9	0.46	2	0.8	0.24	0.9	0.28
Nasopharynx	2	0.8	0.25	0.9	0.28	-	-	-	-	-
Oropharynx	3	1.0	0.27	1.3	0.34	1	0.4	0.16	0.5	0.20
Hypopharynx	2	1.1	0.32	1.3	0.37	-	-	-	-	-
Digestive System	275	116.3	3.30	141.1	3.90	222	80.0	2.46	95.0	2.86
Esophagus	13	5.7	0.73	6.9	0.86	6	2.3	0.43	2.7	0.48
Stomach	29	13.4	1.18	15.9	1.37	19	7.0	0.74	8.3	0.85
Small intestine	10	4.4	0.65	5.3	0.77	8	2.7	0.44	3.4	0.54
Colon excl. rectum	73	31.5	1.74	37.4	2.01	87	31.5	1.54	37.1	1.79
Rectum & rectosigmoid	29	12.0	1.05	14.7	1.24	22	7.9	0.77	9.4	0.89
Anus, anal canal & anorectum	7	2.5	0.44	3.0	0.53	7	2.6	0.45	3.1	0.52
Liver	56	21.3	1.34	27.4	1.67	16	5.3	0.60	6.7	0.75
Gallbladder	3	1.6	0.42	1.9	0.48	5	1.9	0.38	2.3	0.44
Pancreas	42	18.4	1.34	22.1	1.57	40	14.2	1.03	17.0	1.22
Respiratory System	161	73.2	2.72	87.0	3.15	139	48.9	1.90	58.9	2.25
Larynx	15	6.8	0.84	8.2	0.98	3	1.2	0.29	1.4	0.35
Lung & bronchus	144	65.6	2.58	77.9	2.98	133	46.9	1.86	56.6	2.20
Bones & Joints	1	0.6	0.24	0.6	0.22	2	0.7	0.22	0.8	0.26
Soft Tissue (incl. heart)	9	3.7	0.58	4.3	0.65	12	4.2	0.56	4.8	0.63
Skin (excl. basal & sq.)	8	3.5	0.59	3.9	0.66	4	1.4	0.32	1.6	0.37
Melanomas of the skin	4	1.7	0.43	2.0	0.50	1	0.5	0.20	0.6	0.23
Breast (excl. <i>in situ</i>)	3	1.4	0.39	1.6	0.43	338	122.5	3.05	144.1	3.52
Female Genital System	-	-	-	-	-	138	48.0	1.87	58.0	2.22
Cervix uteri	-	-	-	-	-	13	5.2	0.66	5.5	0.68
Uterus Corpus	-	-	-	-	-	81	27.6	1.40	34.3	1.70
Uterus, NOS ¹	-	-	-	-	-	4	1.3	0.31	1.6	0.37
Ovary	-	-	-	-	-	28	10.2	0.88	12.1	1.02
Male Genital System	374	145.2	3.52	182.7	4.31	-	-	-	-	-
Prostate	367	142.6	3.49	179.8	4.28	-	-	-	-	-
Testis	4	1.5	0.34	1.5	0.34	-	-	-	-	-
Penis	2	0.7	0.24	0.8	0.30	-	-	-	-	-
Urinary System	109	48.1	2.16	57.1	2.51	59	21.1	1.25	25.1	1.46
Bladder (incl. <i>in situ</i>)	42	20.3	1.47	24.0	1.70	18	6.6	0.70	7.8	0.82
Kidney & renal pelvis	65	26.9	1.56	32.1	1.82	39	13.8	1.01	16.4	1.18
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	12	4.5	0.62	5.2	0.71	8	2.8	0.46	3.1	0.51
Brain	11	4.3	0.60	4.9	0.68	7	2.6	0.45	2.9	0.49
Endocrine System	9	3.5	0.54	4.1	0.63	22	8.4	0.81	9.3	0.88
Thyroid gland	7	2.5	0.45	3.0	0.52	19	7.3	0.76	8.0	0.82
Lymphomas	53	22.0	1.41	24.9	1.57	44	16.3	1.12	18.6	1.26
Hodgkin Lymphoma	7	2.8	0.47	2.9	0.49	5	2.1	0.42	2.2	0.43
Non-Hodgkin Lymphoma	46	19.2	1.33	22.0	1.50	39	14.1	1.04	16.4	1.18
Multiple Myeloma	37	16.3	1.26	19.3	1.46	25	9.1	0.84	10.7	0.96
Leukemias	31	14.2	1.19	16.1	1.33	23	8.5	0.80	9.7	0.90
Acute lymphocytic	2	1.0	0.29	0.9	0.25	3	1.0	0.29	1.0	0.28
Chronic lymphocytic	11	4.9	0.70	5.9	0.82	7	2.5	0.43	3.1	0.52
Acute myeloid	11	5.2	0.74	5.9	0.83	9	3.3	0.50	3.7	0.56
Chronic myeloid	4	1.7	0.38	2.0	0.44	2	0.9	0.26	1.0	0.29
Other leukemias	3	1.4	0.38	1.5	0.40	2	0.7	0.24	0.8	0.27
Mesothelioma	3	1.6	0.45	1.8	0.50	-	-	-	-	-
Kaposi Sarcoma	5	2.1	0.43	2.2	0.44	-	-	-	-	-
Ill-defined & Unknown	39	18.7	1.40	21.6	1.59	42	15.4	1.08	18.1	1.25
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	18	8.0	0.87	9.3	0.99	42	15.3	1.08	18.0	1.24
Breast (<i>in situ</i>)	-	-	-	-	-	85	29.4	1.46	35.7	1.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,967	305.9	2.56	360.2	2.98	3,710	303.1	2.26	353.7	2.61
Oral Cavity & Pharynx	116	11.4	0.48	13.4	0.56	79	6.4	0.33	7.5	0.38
Lip	1	0.1	0.05	0.1	0.06	1	0.1	0.04	0.1	0.05
Tongue	22	2.2	0.21	2.6	0.25	23	1.9	0.18	2.2	0.21
Major salivary gland	13	1.2	0.16	1.4	0.18	13	1.0	0.13	1.2	0.15
Floor of mouth	1	0.1	0.06	0.2	0.06	2	0.2	0.05	0.2	0.06
Gum & other mouth	15	1.5	0.18	1.8	0.21	13	1.1	0.14	1.3	0.16
Nasopharynx	47	4.6	0.30	5.3	0.35	21	1.7	0.17	2.0	0.19
Oropharynx	2	0.2	0.07	0.3	0.08	-	-	-	-	-
Hypopharynx	4	0.5	0.10	0.6	0.12	1	0.1	0.04	0.1	0.05
Digestive System	883	89.8	1.38	107.8	1.63	675	55.2	0.96	64.9	1.12
Esophagus	37	3.7	0.28	4.6	0.34	10	0.8	0.12	1.0	0.14
Stomach	112	12.0	0.52	14.1	0.60	85	7.1	0.35	8.2	0.40
Small intestine	13	1.4	0.17	1.6	0.20	11	0.9	0.12	1.0	0.14
Colon excl. rectum	225	22.9	0.70	27.4	0.82	216	17.5	0.54	20.7	0.63
Rectum & rectosigmoid	137	13.3	0.52	16.2	0.62	97	7.9	0.36	9.3	0.43
Anus, anal canal & anorectum	5	0.5	0.10	0.6	0.12	4	0.3	0.07	0.4	0.09
Liver	192	19.1	0.63	23.3	0.76	70	5.8	0.32	6.7	0.36
Gallbladder	9	1.0	0.15	1.1	0.17	16	1.3	0.15	1.5	0.17
Pancreas	102	10.7	0.49	12.7	0.57	109	9.0	0.39	10.5	0.45
Respiratory System	461	49.4	1.05	58.1	1.22	361	29.5	0.70	34.9	0.82
Larynx	13	1.3	0.17	1.6	0.20	1	0.1	0.04	0.1	0.05
Lung & bronchus	437	47.0	1.03	55.3	1.19	354	28.9	0.70	34.1	0.81
Bones & Joints	8	0.8	0.13	0.8	0.13	4	0.4	0.09	0.4	0.09
Soft Tissue (incl. heart)	30	3.0	0.25	3.4	0.28	27	2.3	0.20	2.6	0.22
Skin (excl. basal & sq.)	24	2.5	0.23	2.9	0.26	25	2.0	0.19	2.3	0.21
Melanomas of the skin	11	1.1	0.15	1.3	0.18	15	1.3	0.15	1.4	0.16
Breast (excl. <i>in situ</i>)	6	0.6	0.11	0.7	0.13	1,299	105.5	1.32	123.9	1.54
Female Genital System	-	-	-	-	-	477	38.4	0.80	45.7	0.94
Cervix uteri	-	-	-	-	-	63	5.1	0.29	5.8	0.33
Uterus Corpus	-	-	-	-	-	270	21.4	0.59	26.1	0.71
Uterus, NOS ¹	-	-	-	-	-	5	0.4	0.09	0.5	0.10
Ovary	-	-	-	-	-	106	8.8	0.38	10.1	0.44
Male Genital System	584	58.9	1.11	70.9	1.32	-	-	-	-	-
Prostate	551	55.7	1.09	67.6	1.29	-	-	-	-	-
Testis	27	2.5	0.22	2.5	0.21	-	-	-	-	-
Penis	4	0.5	0.10	0.5	0.12	-	-	-	-	-
Urinary System	273	28.7	0.79	33.6	0.92	121	9.8	0.41	11.6	0.47
Bladder (incl. <i>in situ</i>)	142	15.5	0.59	18.1	0.68	47	3.8	0.25	4.5	0.30
Kidney & renal pelvis	124	12.3	0.51	14.6	0.59	68	5.5	0.30	6.5	0.36
Ureter	6	0.6	0.12	0.7	0.14	4	0.4	0.08	0.4	0.09
Eye & Orbit	4	0.4	0.09	0.4	0.10	3	0.3	0.08	0.3	0.08
Brain & Other CNS ¹	48	5.0	0.33	5.4	0.35	36	3.2	0.24	3.4	0.26
Brain	44	4.5	0.31	4.8	0.33	33	2.9	0.23	3.1	0.24
Endocrine System	82	8.0	0.40	8.9	0.45	229	19.1	0.57	20.9	0.62
Thyroid gland	69	6.6	0.36	7.5	0.41	218	18.1	0.56	19.8	0.61
Lymphomas	192	19.7	0.65	22.4	0.73	155	12.9	0.47	14.7	0.53
Hodgkin Lymphoma	17	1.6	0.18	1.7	0.19	12	1.1	0.14	1.1	0.14
Non-Hodgkin Lymphoma	175	18.1	0.62	20.7	0.71	143	11.8	0.45	13.6	0.51
Multiple Myeloma	52	5.3	0.34	6.4	0.40	44	3.6	0.24	4.3	0.29
Leukemias	96	10.3	0.48	11.3	0.52	69	6.2	0.34	6.7	0.36
Acute lymphocytic	14	1.5	0.18	1.4	0.17	14	1.6	0.19	1.4	0.17
Chronic lymphocytic	17	1.7	0.19	2.0	0.22	10	0.8	0.12	1.0	0.14
Acute myeloid	41	4.5	0.32	5.0	0.35	30	2.5	0.21	2.8	0.23
Chronic myeloid	15	1.6	0.19	1.8	0.21	9	0.7	0.11	0.8	0.13
Other leukemias	9	1.0	0.15	1.1	0.16	6	0.6	0.11	0.6	0.11
Mesothelioma	5	0.6	0.12	0.7	0.13	2	0.2	0.05	0.2	0.06
Kaposi Sarcoma	5	0.5	0.10	0.5	0.11	-	-	-	-	-
Ill-defined & Unknown	100	11.1	0.50	12.7	0.57	101	8.2	0.37	9.5	0.42
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	75	7.6	0.40	8.7	0.46	169	13.8	0.48	16.1	0.56
Breast (<i>in situ</i>)	-	-	-	-	-	443	35.8	0.77	42.6	0.91

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,050	365.9	3.96	430.7	4.58	2,353	336.5	3.21	392.8	3.74
Oral Cavity & Pharynx	55	9.1	0.60	10.9	0.71	26	4.0	0.37	4.7	0.42
Lip	3	0.5	0.14	0.6	0.16	2	0.3	0.11	0.4	0.12
Tongue	14	2.3	0.30	2.8	0.36	9	1.3	0.20	1.5	0.24
Major salivary gland	7	1.3	0.24	1.5	0.28	6	0.9	0.17	1.0	0.19
Floor of mouth	3	0.5	0.16	0.6	0.18	-	-	-	-	-
Gum & other mouth	5	0.9	0.19	1.0	0.21	5	0.8	0.17	1.0	0.20
Nasopharynx	2	0.3	0.10	0.3	0.11	-	-	-	-	-
Oropharynx	3	0.4	0.13	0.5	0.15	-	-	-	-	-
Hypopharynx	2	0.4	0.12	0.4	0.14	-	-	-	-	-
Digestive System	537	96.0	2.02	114.6	2.35	463	71.3	1.53	84.1	1.79
Esophagus	24	4.6	0.45	5.4	0.52	8	1.2	0.20	1.5	0.24
Stomach	68	12.6	0.74	14.7	0.85	60	9.0	0.54	10.5	0.62
Small intestine	12	2.2	0.31	2.5	0.35	11	1.8	0.25	2.1	0.28
Colon excl. rectum	137	24.7	1.03	29.0	1.19	144	22.1	0.85	25.8	0.98
Rectum & rectosigmoid	76	11.9	0.67	14.4	0.79	52	7.2	0.46	8.7	0.55
Anus, anal canal & anorectum	6	0.9	0.18	1.1	0.21	11	1.6	0.22	1.9	0.26
Liver	112	18.9	0.86	23.6	1.04	48	7.7	0.52	9.2	0.60
Gallbladder	5	1.1	0.23	1.2	0.27	17	2.7	0.30	3.3	0.36
Pancreas	63	12.7	0.77	15.0	0.88	73	11.9	0.64	14.1	0.75
Respiratory System	176	39.1	1.40	45.2	1.59	143	23.4	0.90	27.6	1.04
Larynx	18	3.3	0.38	3.9	0.44	2	0.3	0.10	0.4	0.12
Lung & bronchus	151	34.6	1.33	40.0	1.51	139	22.8	0.89	26.9	1.03
Bones & Joints	10	1.1	0.16	1.1	0.17	5	0.6	0.12	0.6	0.13
Soft Tissue (incl. heart)	29	4.3	0.40	4.8	0.45	22	2.8	0.27	3.1	0.32
Skin (excl. basal & sq.)	51	9.0	0.62	10.5	0.71	60	8.3	0.50	9.5	0.57
Melanomas of the skin	43	7.4	0.56	8.6	0.64	53	7.3	0.47	8.4	0.54
Breast (excl. <i>in situ</i>)	4	0.7	0.17	0.8	0.20	700	97.4	1.69	114.3	1.99
Female Genital System	-	-	-	-	-	336	45.8	1.15	54.3	1.37
Cervix uteri	-	-	-	-	-	63	7.9	0.46	8.6	0.51
Uterus Corpus	-	-	-	-	-	173	23.9	0.84	29.2	1.02
Uterus, NOS ¹	-	-	-	-	-	4	0.5	0.12	0.6	0.15
Ovary	-	-	-	-	-	70	9.7	0.53	11.3	0.63
Male Genital System	522	91.3	1.95	110.0	2.28	-	-	-	-	-
Prostate	448	83.7	1.90	102.1	2.24	-	-	-	-	-
Testis	65	6.0	0.34	6.0	0.35	-	-	-	-	-
Penis	8	1.5	0.25	1.7	0.29	-	-	-	-	-
Urinary System	227	43.4	1.40	51.0	1.61	116	17.2	0.74	20.3	0.87
Bladder (incl. <i>in situ</i>)	93	20.3	1.00	23.6	1.15	30	4.9	0.41	5.6	0.47
Kidney & renal pelvis	131	22.1	0.94	26.2	1.10	84	12.0	0.60	14.4	0.72
Ureter	3	0.8	0.21	0.9	0.24	-	-	-	-	-
Eye & Orbit	5	0.8	0.18	0.9	0.21	4	0.5	0.12	0.6	0.14
Brain & Other CNS ¹	40	5.9	0.47	6.5	0.53	35	4.3	0.34	4.7	0.38
Brain	36	5.4	0.46	6.0	0.51	31	3.9	0.33	4.3	0.37
Endocrine System	44	5.6	0.42	6.1	0.46	145	17.5	0.67	19.2	0.75
Thyroid gland	40	5.2	0.41	5.7	0.45	141	16.9	0.65	18.5	0.73
Lymphomas	143	23.6	0.97	27.3	1.12	133	19.3	0.78	22.3	0.90
Hodgkin Lymphoma	23	2.9	0.30	3.0	0.32	17	2.0	0.23	2.1	0.24
Non-Hodgkin Lymphoma	120	20.7	0.93	24.3	1.07	117	17.3	0.74	20.2	0.86
Multiple Myeloma	39	7.5	0.58	8.8	0.67	29	4.7	0.40	5.5	0.46
Leukemias	91	13.6	0.73	15.0	0.82	65	8.5	0.50	9.2	0.55
Acute lymphocytic	30	2.9	0.24	2.7	0.24	21	2.1	0.21	2.0	0.22
Chronic lymphocytic	14	2.9	0.38	3.4	0.44	7	1.2	0.20	1.4	0.23
Acute myeloid	28	4.5	0.43	5.0	0.49	24	3.4	0.32	3.8	0.37
Chronic myeloid	12	2.0	0.29	2.3	0.33	9	1.3	0.20	1.4	0.23
Other leukemias	8	1.4	0.24	1.6	0.28	4	0.5	0.12	0.6	0.14
Mesothelioma	7	1.6	0.29	1.8	0.33	2	0.3	0.11	0.4	0.11
Kaposi Sarcoma	9	1.1	0.18	1.2	0.21	1	0.2	0.10	0.3	0.11
Ill-defined & Unknown	62	12.3	0.76	14.2	0.87	65	10.4	0.59	12.0	0.68
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	41	6.2	0.48	7.1	0.55	100	13.8	0.64	15.9	0.74
Breast (<i>in situ</i>)	-	-	-	-	-	175	23.9	0.83	28.5	0.99

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

Greater Bay Area

II-68 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,618	481.5	2.27	567.2	2.61	9,295	436.4	2.14	507.4	2.41
Oral Cavity & Pharynx	379	18.1	0.43	22.1	0.51	140	6.2	0.25	7.5	0.29
Lip	24	1.2	0.11	1.4	0.13	9	0.4	0.07	0.5	0.08
Tongue	143	6.7	0.26	8.3	0.31	46	2.1	0.14	2.5	0.17
Major salivary gland	31	1.6	0.13	1.9	0.15	18	0.9	0.10	1.0	0.11
Floor of mouth	8	0.4	0.06	0.5	0.07	7	0.3	0.05	0.4	0.07
Gum & other mouth	37	1.8	0.14	2.2	0.16	29	1.2	0.10	1.4	0.12
Nasopharynx	9	0.5	0.07	0.5	0.08	2	0.1	0.04	0.1	0.04
Oropharynx	15	0.7	0.08	0.9	0.10	5	0.2	0.05	0.3	0.05
Hypopharynx	16	0.7	0.08	0.9	0.10	5	0.2	0.04	0.3	0.05
Digestive System	1,723	85.3	0.95	101.8	1.10	1,357	59.5	0.76	70.1	0.87
Esophagus	135	6.5	0.26	7.8	0.30	49	2.1	0.14	2.4	0.16
Stomach	139	7.0	0.27	8.2	0.31	77	3.3	0.17	3.8	0.20
Small intestine	50	2.5	0.16	3.0	0.19	42	1.9	0.14	2.3	0.16
Colon excl. rectum	512	26.2	0.53	30.8	0.61	514	22.9	0.48	26.6	0.54
Rectum & rectosigmoid	240	12.0	0.36	14.4	0.42	167	7.9	0.29	9.3	0.33
Anus, anal canal & anorectum	46	2.3	0.15	2.8	0.18	58	2.5	0.15	3.1	0.19
Liver	214	9.7	0.30	12.2	0.38	62	2.6	0.15	3.2	0.18
Gallbladder	13	0.7	0.08	0.8	0.10	27	1.1	0.10	1.3	0.11
Pancreas	287	14.2	0.38	16.9	0.45	254	10.7	0.31	12.6	0.36
Respiratory System	949	47.6	0.71	55.6	0.81	990	42.6	0.62	49.5	0.72
Larynx	71	3.5	0.19	4.2	0.22	14	0.6	0.08	0.7	0.09
Lung & bronchus	854	42.8	0.67	50.0	0.77	966	41.5	0.61	48.3	0.71
Bones & Joints	19	1.3	0.14	1.3	0.13	13	0.8	0.11	0.8	0.10
Soft Tissue (incl. heart)	92	5.0	0.24	5.7	0.27	61	3.0	0.19	3.4	0.20
Skin (excl. basal & sq.)	1,225	62.7	0.83	73.1	0.94	768	38.7	0.67	44.1	0.73
Melanomas of the skin	1,136	58.1	0.79	67.7	0.90	725	36.9	0.65	42.0	0.72
Breast (excl. <i>in situ</i>)	24	1.2	0.11	1.4	0.13	2,997	144.8	1.25	169.3	1.42
Female Genital System	-	-	-	-	-	1,063	48.8	0.70	58.4	0.82
Cervix uteri	-	-	-	-	-	85	5.2	0.26	5.5	0.27
Uterus Corpus	-	-	-	-	-	607	26.6	0.50	32.8	0.61
Uterus, NOS ¹	-	-	-	-	-	12	0.5	0.07	0.6	0.08
Ovary	-	-	-	-	-	254	12.0	0.36	14.1	0.41
Male Genital System	2,253	106.3	1.03	129.0	1.22	-	-	-	-	-
Prostate	2,105	96.5	0.96	119.1	1.17	-	-	-	-	-
Testis	130	8.8	0.35	8.8	0.35	-	-	-	-	-
Penis	12	0.6	0.09	0.7	0.10	-	-	-	-	-
Urinary System	1,127	56.9	0.78	66.6	0.89	396	17.1	0.40	20.2	0.47
Bladder (incl. <i>in situ</i>)	713	36.1	0.62	42.2	0.71	203	8.5	0.27	9.9	0.32
Kidney & renal pelvis	392	19.6	0.46	23.0	0.52	179	8.2	0.29	9.6	0.33
Ureter	13	0.7	0.08	0.8	0.10	8	0.3	0.05	0.4	0.06
Eye & Orbit	30	1.5	0.13	1.8	0.15	25	1.2	0.11	1.4	0.13
Brain & Other CNS ¹	169	9.5	0.34	10.5	0.36	117	6.3	0.28	7.0	0.30
Brain	162	9.1	0.34	10.0	0.36	111	6.0	0.28	6.6	0.29
Endocrine System	154	8.6	0.33	9.5	0.35	313	18.9	0.51	20.5	0.53
Thyroid gland	137	7.6	0.30	8.4	0.32	301	18.2	0.50	19.7	0.52
Lymphomas	575	30.3	0.59	34.8	0.65	425	20.4	0.47	23.2	0.52
Hodgkin Lymphoma	51	3.2	0.21	3.4	0.21	39	2.6	0.20	2.6	0.20
Non-Hodgkin Lymphoma	524	27.1	0.55	31.4	0.62	387	17.8	0.43	20.6	0.48
Multiple Myeloma	157	7.8	0.29	9.2	0.33	102	4.4	0.20	5.2	0.23
Leukemias	348	18.6	0.46	21.1	0.51	213	10.0	0.33	11.3	0.36
Acute lymphocytic	23	1.7	0.17	1.6	0.15	14	1.2	0.15	1.0	0.12
Chronic lymphocytic	154	7.7	0.28	9.1	0.33	85	3.6	0.18	4.3	0.21
Acute myeloid	98	5.3	0.25	6.0	0.27	70	3.3	0.19	3.7	0.21
Chronic myeloid	37	2.0	0.15	2.2	0.16	25	1.2	0.11	1.4	0.13
Other leukemias	36	1.9	0.15	2.2	0.17	19	0.8	0.09	0.9	0.10
Mesothelioma	32	1.7	0.14	1.9	0.15	13	0.6	0.07	0.6	0.08
Kaposi Sarcoma	24	1.3	0.13	1.5	0.14	2	0.1	0.03	0.1	0.03
Ill-defined & Unknown	341	17.7	0.44	20.4	0.50	301	12.7	0.35	14.7	0.39
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	182	9.7	0.33	11.0	0.37	326	15.8	0.42	18.1	0.46
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	655	33.1	0.61	38.6	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Greater Bay Area, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,147	510.3	7.08	615.7	8.32	1,071	409.9	5.74	483.2	6.63
Oral Cavity & Pharynx	33	14.2	1.16	17.0	1.36	12	4.5	0.60	5.4	0.70
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	8	3.3	0.56	4.1	0.66	3	1.1	0.30	1.3	0.35
Major salivary gland	3	1.5	0.41	1.7	0.46	2	0.9	0.29	1.0	0.30
Floor of mouth	2	0.8	0.29	1.0	0.33	-	-	-	-	-
Gum & other mouth	4	1.8	0.43	2.1	0.48	2	0.8	0.25	1.0	0.29
Nasopharynx	2	0.8	0.27	1.0	0.31	-	-	-	-	-
Oropharynx	3	1.0	0.29	1.3	0.36	1	0.4	0.17	0.5	0.21
Hypopharynx	2	1.1	0.34	1.3	0.39	-	-	-	-	-
Digestive System	272	121.6	3.46	147.4	4.09	217	82.7	2.58	98.1	2.99
Esophagus	13	6.0	0.77	7.2	0.90	6	2.4	0.46	2.7	0.50
Stomach	28	14.0	1.23	16.6	1.43	19	7.2	0.77	8.5	0.89
Small intestine	10	4.6	0.68	5.5	0.80	7	2.7	0.45	3.3	0.55
Colon excl. rectum	72	32.8	1.82	39.0	2.10	85	32.7	1.62	38.4	1.87
Rectum & rectosigmoid	29	12.7	1.10	15.4	1.31	22	8.3	0.82	9.8	0.94
Anus, anal canal & anorectum	6	2.6	0.47	3.1	0.56	7	2.8	0.48	3.3	0.56
Liver	56	22.5	1.41	28.9	1.76	15	5.4	0.63	6.8	0.78
Gallbladder	3	1.7	0.44	2.0	0.50	5	1.9	0.40	2.3	0.46
Pancreas	41	19.2	1.40	22.9	1.64	39	14.8	1.08	17.7	1.27
Respiratory System	159	76.3	2.84	90.7	3.30	136	50.5	1.98	60.9	2.34
Larynx	15	7.2	0.88	8.6	1.03	3	1.2	0.31	1.5	0.37
Lung & bronchus	143	68.4	2.69	81.2	3.12	131	48.5	1.94	58.5	2.30
Bones & Joints	1	0.7	0.27	0.6	0.25	2	0.8	0.25	0.9	0.28
Soft Tissue (incl. heart)	9	3.9	0.61	4.5	0.69	11	4.4	0.60	5.0	0.67
Skin (excl. basal & sq.)	7	3.6	0.61	4.0	0.68	4	1.5	0.35	1.7	0.40
Melanomas of the skin	3	1.7	0.43	2.0	0.50	1	0.6	0.22	0.6	0.24
Breast (excl. <i>in situ</i>)	3	1.5	0.41	1.7	0.46	331	128.6	3.24	150.7	3.72
Female Genital System	-	-	-	-	-	134	50.0	1.98	60.1	2.33
Cervix uteri	-	-	-	-	-	13	5.6	0.72	5.9	0.74
Uterus Corpus	-	-	-	-	-	80	28.6	1.47	35.4	1.78
Uterus, NOS ¹	-	-	-	-	-	3	1.2	0.31	1.5	0.37
Ovary	-	-	-	-	-	28	10.7	0.93	12.6	1.07
Male Genital System	369	151.3	3.68	190.4	4.51	-	-	-	-	-
Prostate	363	148.5	3.65	187.3	4.47	-	-	-	-	-
Testis	4	1.7	0.39	1.7	0.39	-	-	-	-	-
Penis	2	0.7	0.25	0.9	0.31	-	-	-	-	-
Urinary System	108	50.2	2.27	59.6	2.63	59	22.1	1.32	26.3	1.54
Bladder (incl. <i>in situ</i>)	42	21.1	1.53	24.8	1.77	18	6.9	0.74	8.2	0.86
Kidney & renal pelvis	64	28.3	1.65	33.7	1.92	38	14.5	1.08	17.2	1.25
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	11	4.7	0.65	5.4	0.73	8	3.1	0.51	3.4	0.56
Brain	10	4.4	0.63	5.0	0.71	7	2.9	0.50	3.1	0.53
Endocrine System	9	3.8	0.59	4.5	0.67	22	9.1	0.89	10.0	0.95
Thyroid gland	7	2.7	0.48	3.2	0.56	19	7.9	0.83	8.6	0.89
Lymphomas	52	23.3	1.50	26.3	1.66	43	17.2	1.20	19.5	1.33
Hodgkin Lymphoma	7	3.0	0.52	3.0	0.52	5	2.4	0.47	2.5	0.47
Non-Hodgkin Lymphoma	45	20.3	1.41	23.2	1.58	38	14.8	1.10	17.1	1.24
Multiple Myeloma	36	16.8	1.32	20.0	1.53	24	9.4	0.87	11.0	1.00
Leukemias	30	14.6	1.24	16.6	1.39	22	8.7	0.85	9.9	0.94
Acute lymphocytic	2	1.1	0.32	0.9	0.28	2	1.1	0.33	1.0	0.30
Chronic lymphocytic	11	5.2	0.74	6.2	0.86	7	2.7	0.45	3.3	0.55
Acute myeloid	10	5.2	0.76	5.9	0.85	8	3.2	0.51	3.6	0.57
Chronic myeloid	4	1.8	0.41	2.1	0.47	2	1.0	0.28	1.1	0.31
Other leukemias	3	1.4	0.40	1.5	0.42	2	0.8	0.26	0.8	0.28
Mesothelioma	3	1.7	0.47	1.9	0.53	-	-	-	-	-
Kaposi Sarcoma	5	2.3	0.48	2.4	0.49	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	42	16.2	1.14	19.0	1.31
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	18	8.5	0.92	9.8	1.05	42	16.2	1.15	19.0	1.32
Breast (<i>in situ</i>)	-	-	-	-	-	83	31.0	1.56	37.5	1.84

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	9,998,105	10,048,408	10,097,037	10,120,540	10,118,759
White	7,289,803	7,313,668	7,335,207	7,342,277	7,328,158
Black	977,182	977,813	976,385	972,731	969,279
American Indian/Alaskan Native (AI/AN)	170,831	170,963	170,804	170,582	170,805
Asian/Pacific Islander (API)	1,560,289	1,585,964	1,614,641	1,634,950	1,650,517

All Races Population 2013-2017: 50,382,849

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	4,820,310	4,852,875	4,882,643	4,904,741	4,912,471
Non-Hispanic White	2,813,969	2,807,639	2,801,378	2,788,048	2,768,396
Non-Hispanic Black	864,487	863,884	861,440	856,756	852,477

Hispanic/Latino Population, Census 2010: 4,687,889

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

LOS ANGELES CANCER REGISTRY

Initial Operation: 1970
 Population-based Data Available: 1972
 Coverage Area: County

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	93.8	95.4	93.8	93.3	90.0
Missing Race	2.0	2.2	2.0	2.3	2.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	1.2	1.1	1.5	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Prostate	96.2
Oral Cavity & Pharynx	98.1	Testis	99.2
Esophagus	95.7	Bladder (incl. <i>in situ</i>)	98.3
Stomach	97.2	Kidney & Renal Pelvis	91.0
Colon & Rectum	97.1	Brain & Other CNS ¹	86.8
Liver	53.1	Thyroid	99.7
Pancreas	84.5	Hodgkin Lymphoma	99.2
Lung & Bronchus	90.6	Non-Hodgkin Lymphoma	97.8
Melanomas of the Skin	99.6	Multiple Myeloma	90.1
Female Breast (excl. <i>in situ</i>)	99.2	Leukemias	94.4
Cervix uteri	98.0	Brain & Other CNS ¹ <i>non-malig</i>	52.5
Uterus Corpus & Uterus NOS ¹	99.0	Breast <i>in situ</i>	100.0
Ovary	94.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	19,144	404.8	1.34	478.5	1.56	20,795	367.7	1.16	429.1	1.34
Oral Cavity & Pharynx	661	13.3	0.24	16.1	0.28	280	4.9	0.13	5.8	0.15
Lip	35	0.7	0.06	0.9	0.07	14	0.2	0.03	0.3	0.03
Tongue	213	4.3	0.13	5.2	0.16	87	1.5	0.07	1.8	0.09
Major salivary gland	62	1.3	0.08	1.5	0.09	47	0.8	0.06	1.0	0.06
Floor of mouth	20	0.4	0.04	0.5	0.05	9	0.2	0.02	0.2	0.03
Gum & other mouth	68	1.4	0.08	1.7	0.09	52	0.9	0.06	1.1	0.07
Nasopharynx	50	1.0	0.07	1.2	0.07	23	0.4	0.04	0.5	0.04
Oropharynx	26	0.5	0.05	0.6	0.06	8	0.1	0.02	0.2	0.03
Hypopharynx	37	0.8	0.06	0.9	0.07	7	0.1	0.02	0.2	0.03
Digestive System	4,423	93.5	0.64	111.4	0.76	3,734	64.8	0.48	76.5	0.56
Esophagus	221	4.7	0.15	5.6	0.17	69	1.2	0.07	1.4	0.08
Stomach	555	12.0	0.23	14.1	0.27	389	6.9	0.16	8.0	0.18
Small intestine	93	2.0	0.09	2.3	0.11	95	1.6	0.08	2.0	0.09
Colon excl. rectum	1,308	28.1	0.36	33.1	0.41	1,304	22.6	0.28	26.6	0.33
Rectum & rectosigmoid	645	13.1	0.24	15.8	0.28	495	8.6	0.18	10.3	0.21
Anus, anal canal & anorectum	79	1.6	0.08	1.9	0.10	94	1.6	0.07	2.0	0.09
Liver	623	12.5	0.23	15.4	0.28	269	4.6	0.13	5.5	0.15
Gallbladder	41	0.9	0.07	1.1	0.07	110	1.9	0.08	2.3	0.10
Pancreas	600	13.0	0.24	15.4	0.28	606	10.5	0.19	12.3	0.22
Respiratory System	2,142	47.7	0.47	56.0	0.55	1,846	32.3	0.34	38.0	0.40
Larynx	161	3.4	0.12	4.1	0.14	28	0.5	0.04	0.6	0.05
Lung & bronchus	1,925	43.1	0.45	50.6	0.52	1,789	31.3	0.34	36.8	0.39
Bones & Joints	51	1.1	0.07	1.1	0.07	37	0.7	0.05	0.7	0.05
Soft Tissue (incl. heart)	210	4.4	0.14	4.9	0.15	172	3.1	0.11	3.5	0.12
Skin (excl. basal & sq.)	979	21.2	0.31	24.8	0.36	634	11.2	0.20	12.9	0.23
Melanomas of the skin	882	18.9	0.29	22.2	0.34	563	10.0	0.19	11.5	0.22
Breast (excl. <i>in situ</i>)	44	0.9	0.06	1.1	0.08	6,557	116.6	0.65	137.1	0.76
Female Genital System	-	-	-	-	-	2,834	49.9	0.43	58.9	0.50
Cervix uteri	-	-	-	-	-	407	7.6	0.17	8.3	0.19
Uterus Corpus	-	-	-	-	-	1,469	25.4	0.30	30.8	0.36
Uterus, NOS ¹	-	-	-	-	-	74	1.3	0.07	1.5	0.08
Ovary	-	-	-	-	-	662	11.7	0.21	13.7	0.24
Male Genital System	4,801	97.3	0.64	118.1	0.77	-	-	-	-	-
Prostate	4,442	90.3	0.62	111.1	0.75	-	-	-	-	-
Testis	309	5.9	0.15	5.8	0.15	-	-	-	-	-
Penis	36	0.8	0.06	0.9	0.07	-	-	-	-	-
Urinary System	2,149	46.8	0.46	55.1	0.54	926	16.2	0.24	19.0	0.28
Bladder (incl. <i>in situ</i>)	1,170	26.4	0.35	31.0	0.41	361	6.2	0.15	7.3	0.17
Kidney & renal pelvis	936	19.3	0.29	22.9	0.34	538	9.5	0.19	11.1	0.22
Ureter	20	0.5	0.05	0.5	0.05	17	0.3	0.03	0.3	0.04
Eye & Orbit	34	0.7	0.06	0.8	0.06	39	0.7	0.05	0.8	0.06
Brain & Other CNS ¹	308	6.4	0.17	7.1	0.18	247	4.5	0.13	5.0	0.14
Brain	291	6.0	0.16	6.7	0.18	229	4.2	0.13	4.6	0.14
Endocrine System	387	7.7	0.18	8.8	0.20	1,106	20.6	0.28	22.6	0.31
Thyroid gland	349	6.9	0.17	7.9	0.19	1,068	19.9	0.28	21.8	0.30
Lymphomas	1,132	24.0	0.33	27.6	0.37	941	16.7	0.25	19.2	0.28
Hodgkin Lymphoma	117	2.3	0.10	2.5	0.10	96	1.8	0.08	1.9	0.09
Non-Hodgkin Lymphoma	1,015	21.6	0.31	25.1	0.36	846	14.9	0.23	17.4	0.27
Multiple Myeloma	336	7.3	0.18	8.6	0.21	263	4.5	0.13	5.4	0.15
Leukemias	684	14.7	0.26	16.3	0.28	520	9.5	0.19	10.4	0.21
Acute lymphocytic	124	2.6	0.10	2.4	0.10	92	1.9	0.09	1.7	0.08
Chronic lymphocytic	183	3.9	0.13	4.7	0.16	123	2.1	0.09	2.5	0.10
Acute myeloid	214	4.7	0.15	5.3	0.16	187	3.4	0.11	3.8	0.12
Chronic myeloid	91	1.9	0.09	2.2	0.10	66	1.2	0.07	1.3	0.07
Other leukemias	72	1.5	0.08	1.8	0.09	52	0.9	0.06	1.1	0.07
Mesothelioma	51	1.2	0.07	1.4	0.09	19	0.3	0.04	0.4	0.04
Kaposi Sarcoma	68	1.4	0.08	1.5	0.08	5	0.1	0.02	0.1	0.02
Ill-defined & Unknown	684	15.3	0.27	17.9	0.31	635	11.0	0.20	12.7	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	333	6.9	0.17	7.9	0.20	698	12.4	0.21	14.4	0.24
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.02	1,513	26.9	0.31	32.0	0.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	13,913	412.7	1.61	486.3	1.86	14,984	381.5	1.42	445.0	1.63
Oral Cavity & Pharynx	495	14.0	0.29	17.0	0.34	206	5.2	0.17	6.1	0.19
Lip	32	0.9	0.08	1.1	0.09	14	0.3	0.04	0.4	0.05
Tongue	169	4.7	0.17	5.8	0.20	68	1.7	0.09	2.0	0.11
Major salivary gland	48	1.5	0.10	1.7	0.11	32	0.8	0.07	1.0	0.08
Floor of mouth	14	0.4	0.05	0.5	0.06	7	0.2	0.03	0.2	0.04
Gum & other mouth	49	1.4	0.09	1.7	0.11	39	1.0	0.07	1.1	0.08
Nasopharynx	18	0.5	0.05	0.6	0.06	11	0.3	0.04	0.3	0.04
Oropharynx	19	0.5	0.05	0.7	0.07	6	0.1	0.03	0.2	0.03
Hypopharynx	24	0.7	0.07	0.9	0.08	5	0.1	0.03	0.2	0.03
Digestive System	3,112	92.1	0.76	109.5	0.89	2,602	65.1	0.58	76.8	0.68
Esophagus	176	5.3	0.18	6.3	0.21	48	1.2	0.08	1.4	0.09
Stomach	370	11.1	0.27	13.0	0.31	258	6.6	0.19	7.6	0.21
Small intestine	69	2.1	0.11	2.4	0.13	69	1.7	0.09	2.1	0.11
Colon excl. rectum	926	27.9	0.42	32.8	0.49	900	22.5	0.34	26.3	0.40
Rectum & rectosigmoid	453	12.9	0.28	15.4	0.33	342	8.6	0.21	10.3	0.25
Anus, anal canal & anorectum	61	1.7	0.10	2.0	0.12	77	1.9	0.10	2.3	0.12
Liver	409	11.4	0.26	14.1	0.31	176	4.4	0.15	5.2	0.18
Gallbladder	31	1.0	0.08	1.1	0.09	86	2.1	0.10	2.5	0.12
Pancreas	435	13.3	0.29	15.7	0.34	427	10.6	0.23	12.5	0.27
Respiratory System	1,450	45.8	0.55	53.4	0.63	1,269	32.2	0.41	37.6	0.48
Larynx	121	3.6	0.15	4.3	0.18	19	0.5	0.05	0.6	0.06
Lung & bronchus	1,286	40.9	0.52	47.7	0.60	1,228	31.2	0.40	36.4	0.47
Bones & Joints	39	1.1	0.08	1.1	0.08	29	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	158	4.6	0.17	5.2	0.19	125	3.3	0.13	3.6	0.15
Skin (excl. basal & sq.)	865	26.3	0.41	30.8	0.47	540	13.7	0.27	15.8	0.31
Melanomas of the skin	790	23.8	0.39	28.0	0.45	487	12.4	0.26	14.3	0.29
Breast (excl. <i>in situ</i>)	32	1.0	0.08	1.1	0.09	4,647	119.1	0.79	140.3	0.92
Female Genital System	-	-	-	-	-	2,060	52.3	0.52	61.8	0.61
Cervix uteri	-	-	-	-	-	283	7.6	0.21	8.3	0.22
Uterus Corpus	-	-	-	-	-	1,060	26.5	0.37	32.2	0.44
Uterus, NOS ¹	-	-	-	-	-	50	1.2	0.08	1.5	0.09
Ovary	-	-	-	-	-	490	12.5	0.26	14.6	0.30
Male Genital System	3,251	92.5	0.75	111.7	0.88	-	-	-	-	-
Prostate	2,941	84.3	0.71	103.4	0.86	-	-	-	-	-
Testis	271	7.0	0.19	6.9	0.19	-	-	-	-	-
Penis	30	0.9	0.08	1.1	0.09	-	-	-	-	-
Urinary System	1,673	51.1	0.57	60.1	0.66	699	17.6	0.30	20.6	0.35
Bladder (incl. <i>in situ</i>)	932	29.6	0.44	34.7	0.51	278	6.9	0.19	8.1	0.22
Kidney & renal pelvis	710	20.5	0.35	24.3	0.41	404	10.3	0.23	12.1	0.27
Ureter	14	0.4	0.05	0.5	0.06	11	0.3	0.04	0.3	0.04
Eye & Orbit	29	0.8	0.07	1.0	0.08	35	0.9	0.07	1.0	0.08
Brain & Other CNS ¹	255	7.3	0.21	8.2	0.23	202	5.2	0.17	5.8	0.18
Brain	241	6.9	0.20	7.7	0.23	188	4.9	0.16	5.4	0.18
Endocrine System	288	7.9	0.21	9.0	0.24	807	21.5	0.34	23.6	0.37
Thyroid gland	263	7.2	0.20	8.2	0.23	781	20.8	0.34	22.8	0.37
Lymphomas	874	25.8	0.40	29.7	0.46	711	18.0	0.31	20.8	0.35
Hodgkin Lymphoma	94	2.6	0.12	2.8	0.13	74	1.9	0.10	2.0	0.11
Non-Hodgkin Lymphoma	780	23.2	0.38	27.0	0.44	637	16.1	0.29	18.8	0.34
Multiple Myeloma	234	7.1	0.21	8.4	0.25	179	4.5	0.15	5.3	0.18
Leukemias	547	16.3	0.32	18.1	0.35	396	10.3	0.23	11.2	0.25
Acute lymphocytic	106	3.0	0.13	2.7	0.12	79	2.2	0.11	2.1	0.11
Chronic lymphocytic	150	4.5	0.17	5.4	0.20	100	2.4	0.11	2.9	0.13
Acute myeloid	166	5.1	0.18	5.7	0.20	134	3.5	0.14	3.9	0.15
Chronic myeloid	69	2.1	0.11	2.3	0.13	47	1.2	0.08	1.4	0.09
Other leukemias	57	1.7	0.10	1.9	0.12	36	0.9	0.07	1.0	0.08
Mesothelioma	44	1.4	0.10	1.6	0.11	16	0.4	0.05	0.5	0.05
Kaposi Sarcoma	44	1.2	0.09	1.3	0.09	3	0.1	0.02	0.1	0.02
Ill-defined & Unknown	521	16.4	0.33	19.1	0.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	248	7.2	0.21	8.2	0.24	509	13.0	0.26	15.1	0.30
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.03	999	25.6	0.37	30.6	0.43

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,994	447.0	4.64	538.5	5.48	2,175	373.8	3.65	440.0	4.23
Oral Cavity & Pharynx	60	12.2	0.73	15.3	0.90	27	4.4	0.38	5.4	0.47
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	19	3.8	0.40	4.9	0.50	6	1.0	0.19	1.2	0.22
Major salivary gland	4	0.8	0.18	0.9	0.22	5	0.7	0.16	0.9	0.19
Floor of mouth	3	0.7	0.17	0.9	0.22	1	0.2	0.08	0.3	0.10
Gum & other mouth	7	1.5	0.26	1.7	0.29	6	0.9	0.18	1.2	0.22
Nasopharynx	3	0.6	0.17	0.8	0.20	2	0.4	0.12	0.4	0.13
Oropharynx	5	1.0	0.22	1.3	0.26	1	0.2	0.08	0.2	0.10
Hypopharynx	5	0.9	0.20	1.2	0.26	2	0.3	0.10	0.4	0.12
Digestive System	447	101.9	2.23	122.2	2.63	428	72.7	1.59	86.5	1.87
Esophagus	17	3.8	0.42	4.5	0.50	9	1.5	0.23	1.9	0.27
Stomach	51	12.4	0.80	14.5	0.93	36	6.2	0.47	7.2	0.54
Small intestine	13	3.0	0.39	3.6	0.46	16	2.8	0.31	3.3	0.36
Colon excl. rectum	143	33.4	1.29	39.5	1.51	162	28.0	1.00	32.9	1.15
Rectum & rectosigmoid	53	11.6	0.74	13.8	0.86	47	7.9	0.52	9.6	0.63
Anus, anal canal & anorectum	13	2.9	0.37	3.4	0.43	9	1.4	0.22	1.8	0.27
Liver	67	13.6	0.77	17.4	0.96	30	4.8	0.40	6.0	0.49
Gallbladder	3	0.8	0.20	1.0	0.23	11	1.8	0.25	2.1	0.29
Pancreas	67	15.5	0.88	18.7	1.04	80	13.5	0.68	16.1	0.81
Respiratory System	285	67.3	1.85	80.2	2.16	270	45.5	1.26	54.4	1.48
Larynx	22	4.9	0.49	6.0	0.58	5	0.9	0.17	1.1	0.21
Lung & bronchus	259	61.4	1.77	73.2	2.07	262	44.3	1.24	52.9	1.46
Bones & Joints	4	0.9	0.21	0.9	0.21	3	0.5	0.15	0.5	0.14
Soft Tissue (incl. heart)	19	4.3	0.46	4.7	0.49	20	3.7	0.38	4.1	0.41
Skin (excl. basal & sq.)	11	2.5	0.35	2.9	0.39	10	1.9	0.27	2.0	0.29
Melanomas of the skin	6	1.4	0.26	1.5	0.30	3	0.6	0.16	0.7	0.17
Breast (excl. <i>in situ</i>)	6	1.3	0.24	1.6	0.29	702	121.3	2.09	142.7	2.41
Female Genital System	-	-	-	-	-	279	47.0	1.28	56.4	1.51
Cervix uteri	-	-	-	-	-	41	7.6	0.54	8.4	0.59
Uterus Corpus	-	-	-	-	-	152	24.9	0.92	30.7	1.11
Uterus, NOS ¹	-	-	-	-	-	15	2.4	0.29	2.9	0.34
Ovary	-	-	-	-	-	52	8.9	0.56	10.5	0.65
Male Genital System	649	137.0	2.49	171.4	3.04	-	-	-	-	-
Prostate	639	134.7	2.46	169.0	3.02	-	-	-	-	-
Testis	6	1.4	0.25	1.3	0.24	-	-	-	-	-
Penis	3	0.6	0.18	0.7	0.20	-	-	-	-	-
Urinary System	187	43.9	1.49	51.8	1.72	95	16.3	0.76	19.1	0.88
Bladder (incl. <i>in situ</i>)	83	20.6	1.05	24.5	1.23	32	5.5	0.44	6.4	0.51
Kidney & renal pelvis	101	22.4	1.03	26.3	1.19	60	10.3	0.61	12.1	0.70
Ureter	-	-	-	-	-	1	0.2	0.09	0.2	0.10
Eye & Orbit	-	-	-	-	-	2	0.3	0.11	0.3	0.11
Brain & Other CNS ¹	21	4.6	0.46	5.0	0.50	16	2.8	0.32	3.2	0.36
Brain	20	4.3	0.45	4.8	0.49	15	2.6	0.30	2.9	0.34
Endocrine System	23	4.9	0.48	5.7	0.54	65	12.3	0.70	13.3	0.74
Thyroid gland	18	3.9	0.42	4.5	0.48	60	11.4	0.67	12.3	0.71
Lymphomas	84	19.0	0.96	21.8	1.09	78	13.6	0.70	15.6	0.80
Hodgkin Lymphoma	10	2.2	0.32	2.3	0.34	10	1.9	0.27	1.9	0.28
Non-Hodgkin Lymphoma	74	16.8	0.90	19.5	1.04	68	11.8	0.65	13.7	0.75
Multiple Myeloma	65	15.2	0.88	18.1	1.02	54	9.1	0.56	10.8	0.66
Leukemias	55	12.8	0.80	14.6	0.91	51	9.0	0.57	10.1	0.64
Acute lymphocytic	7	1.4	0.25	1.4	0.25	6	1.2	0.23	1.1	0.20
Chronic lymphocytic	17	4.3	0.48	5.1	0.56	12	1.9	0.26	2.4	0.31
Acute myeloid	17	4.1	0.45	4.7	0.51	19	3.3	0.34	3.7	0.38
Chronic myeloid	8	1.8	0.30	2.0	0.33	8	1.4	0.22	1.6	0.25
Other leukemias	6	1.3	0.24	1.5	0.28	7	1.2	0.21	1.4	0.24
Mesothelioma	3	0.8	0.21	0.8	0.23	-	-	-	-	-
Kaposi Sarcoma	11	2.4	0.32	2.5	0.33	-	-	-	-	-
Ill-defined & Unknown	65	15.9	0.91	18.8	1.06	75	13.0	0.68	15.1	0.78
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	28	6.4	0.57	7.4	0.64	70	12.2	0.66	14.2	0.76
Breast (<i>in situ</i>)	-	-	-	-	-	172	29.5	1.02	34.9	1.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,428	286.5	2.65	337.8	3.08	3,212	299.6	2.42	349.3	2.77
Oral Cavity & Pharynx	91	10.9	0.52	12.5	0.59	40	3.8	0.28	4.3	0.31
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	21	2.4	0.24	2.9	0.28	11	1.0	0.14	1.2	0.16
Major salivary gland	9	1.1	0.17	1.2	0.18	9	0.9	0.13	1.0	0.15
Floor of mouth	1	0.1	0.06	0.2	0.07	-	-	-	-	-
Gum & other mouth	13	1.5	0.19	1.7	0.22	6	0.5	0.10	0.6	0.12
Nasopharynx	28	3.4	0.30	3.9	0.33	10	1.0	0.14	1.1	0.16
Oropharynx	1	0.1	0.06	0.2	0.07	-	-	-	-	-
Hypopharynx	7	0.9	0.15	1.0	0.17	-	-	-	-	-
Digestive System	793	93.1	1.51	111.0	1.77	652	58.5	1.04	69.2	1.22
Esophagus	24	2.8	0.26	3.4	0.31	10	0.9	0.13	1.0	0.15
Stomach	128	15.3	0.62	18.0	0.71	89	8.0	0.39	9.4	0.45
Small intestine	9	1.1	0.16	1.3	0.19	8	0.7	0.11	0.8	0.13
Colon excl. rectum	219	25.6	0.79	30.7	0.93	226	20.2	0.61	23.9	0.72
Rectum & rectosigmoid	124	14.3	0.59	17.3	0.70	92	8.4	0.40	10.1	0.47
Anus, anal canal & anorectum	3	0.4	0.10	0.4	0.11	6	0.5	0.10	0.6	0.11
Liver	138	15.9	0.62	19.2	0.73	60	5.3	0.31	6.3	0.37
Gallbladder	6	0.8	0.14	0.9	0.16	14	1.2	0.15	1.5	0.18
Pancreas	89	10.6	0.51	12.5	0.60	95	8.5	0.40	10.0	0.46
Respiratory System	388	46.3	1.07	54.7	1.25	290	26.0	0.69	30.7	0.81
Larynx	15	1.8	0.21	2.2	0.25	3	0.2	0.06	0.3	0.07
Lung & bronchus	364	43.5	1.04	51.3	1.21	282	25.2	0.68	29.9	0.80
Bones & Joints	7	0.9	0.16	0.9	0.16	5	0.6	0.13	0.6	0.12
Soft Tissue (incl. heart)	28	3.4	0.29	3.8	0.32	23	2.3	0.22	2.6	0.24
Skin (excl. basal & sq.)	16	2.0	0.22	2.2	0.25	16	1.5	0.17	1.7	0.19
Melanomas of the skin	10	1.1	0.17	1.3	0.19	10	0.9	0.13	1.1	0.15
Breast (excl. <i>in situ</i>)	5	0.6	0.12	0.8	0.14	1,094	103.0	1.42	120.6	1.64
Female Genital System	-	-	-	-	-	434	40.7	0.89	48.0	1.04
Cervix uteri	-	-	-	-	-	72	7.2	0.39	8.0	0.42
Uterus Corpus	-	-	-	-	-	223	20.4	0.62	24.7	0.74
Uterus, NOS ¹	-	-	-	-	-	9	0.8	0.13	1.0	0.15
Ovary	-	-	-	-	-	109	10.4	0.46	12.1	0.52
Male Genital System	422	47.4	1.05	57.5	1.26	-	-	-	-	-
Prostate	398	44.5	1.02	54.5	1.23	-	-	-	-	-
Testis	18	2.2	0.24	2.2	0.23	-	-	-	-	-
Penis	2	0.3	0.09	0.3	0.10	-	-	-	-	-
Urinary System	244	29.1	0.85	34.4	0.99	116	10.6	0.45	12.4	0.52
Bladder (incl. <i>in situ</i>)	126	15.3	0.62	18.0	0.72	44	3.9	0.27	4.6	0.31
Kidney & renal pelvis	109	12.8	0.56	15.1	0.65	65	6.0	0.34	7.1	0.39
Ureter	6	0.7	0.13	0.8	0.15	5	0.4	0.09	0.5	0.10
Eye & Orbit	3	0.4	0.10	0.4	0.10	2	0.3	0.09	0.3	0.08
Brain & Other CNS ¹	29	3.6	0.31	3.9	0.33	25	2.7	0.25	2.9	0.26
Brain	27	3.4	0.30	3.7	0.32	23	2.4	0.24	2.6	0.24
Endocrine System	70	8.2	0.45	9.4	0.51	212	21.4	0.67	23.6	0.73
Thyroid gland	62	7.3	0.42	8.4	0.48	207	20.8	0.66	23.0	0.72
Lymphomas	142	17.0	0.65	19.7	0.74	123	11.7	0.48	13.3	0.54
Hodgkin Lymphoma	9	1.1	0.17	1.2	0.18	9	1.0	0.15	1.0	0.15
Non-Hodgkin Lymphoma	133	15.9	0.63	18.5	0.72	114	10.7	0.46	12.3	0.52
Multiple Myeloma	32	3.8	0.31	4.6	0.36	27	2.3	0.20	2.9	0.25
Leukemias	68	8.5	0.47	9.4	0.51	62	6.4	0.38	7.0	0.40
Acute lymphocytic	10	1.5	0.21	1.4	0.19	7	1.0	0.17	0.9	0.15
Chronic lymphocytic	7	0.8	0.14	1.0	0.17	6	0.5	0.10	0.7	0.12
Acute myeloid	30	3.6	0.30	4.1	0.34	32	3.2	0.26	3.6	0.28
Chronic myeloid	12	1.6	0.20	1.7	0.22	9	0.9	0.14	1.0	0.15
Other leukemias	8	1.0	0.17	1.1	0.18	8	0.8	0.13	0.9	0.14
Mesothelioma	3	0.4	0.10	0.5	0.12	2	0.2	0.06	0.2	0.07
Kaposi Sarcoma	3	0.4	0.10	0.3	0.10	-	-	-	-	-
Ill-defined & Unknown	83	10.2	0.51	11.8	0.58	88	7.9	0.38	9.1	0.44
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	49	5.8	0.38	6.6	0.43	106	9.9	0.44	11.5	0.50
Breast (<i>in situ</i>)	-	-	-	-	-	311	29.2	0.76	34.5	0.88

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,175	331.9	2.24	390.4	2.59	6,286	310.1	1.80	361.8	2.09
Oral Cavity & Pharynx	138	8.3	0.34	10.1	0.40	68	3.4	0.19	4.0	0.22
Lip	7	0.5	0.09	0.6	0.11	4	0.2	0.05	0.2	0.06
Tongue	40	2.3	0.18	2.9	0.21	22	1.1	0.11	1.3	0.13
Major salivary gland	14	0.9	0.12	1.1	0.13	14	0.7	0.08	0.7	0.09
Floor of mouth	5	0.3	0.07	0.4	0.08	-	-	-	-	-
Gum & other mouth	17	1.1	0.12	1.3	0.14	12	0.6	0.08	0.7	0.10
Nasopharynx	8	0.5	0.08	0.5	0.09	5	0.2	0.05	0.3	0.05
Oropharynx	5	0.3	0.07	0.4	0.08	1	0.1	0.03	0.1	0.03
Hypopharynx	9	0.6	0.10	0.7	0.11	2	0.1	0.03	0.1	0.04
Digestive System	1,430	93.2	1.19	110.8	1.38	1,253	65.4	0.85	77.4	0.99
Esophagus	65	4.5	0.27	5.4	0.31	14	0.8	0.09	0.9	0.11
Stomach	208	13.6	0.46	15.8	0.52	176	9.1	0.32	10.6	0.36
Small intestine	24	1.7	0.17	2.0	0.19	29	1.5	0.13	1.8	0.15
Colon excl. rectum	375	24.5	0.61	29.1	0.71	383	19.8	0.47	23.4	0.54
Rectum & rectosigmoid	222	13.2	0.43	15.9	0.51	155	7.6	0.28	9.1	0.33
Anus, anal canal & anorectum	19	1.0	0.12	1.2	0.14	21	1.0	0.10	1.3	0.12
Liver	245	15.6	0.48	19.1	0.57	115	6.3	0.27	7.4	0.31
Gallbladder	21	1.5	0.16	1.7	0.18	62	3.3	0.19	3.9	0.23
Pancreas	159	11.1	0.42	13.1	0.49	185	9.9	0.34	11.8	0.39
Respiratory System	415	32.0	0.75	37.0	0.85	328	18.3	0.46	21.3	0.53
Larynx	50	3.5	0.24	4.2	0.27	7	0.4	0.06	0.4	0.07
Lung & bronchus	346	27.5	0.70	31.7	0.79	311	17.5	0.45	20.4	0.52
Bones & Joints	24	1.1	0.11	1.1	0.11	16	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	69	3.7	0.22	4.1	0.25	67	3.1	0.17	3.4	0.19
Skin (excl. basal & sq.)	78	5.1	0.28	5.9	0.32	95	4.7	0.22	5.4	0.25
Melanomas of the skin	63	4.0	0.24	4.8	0.29	74	3.6	0.19	4.2	0.22
Breast (excl. <i>in situ</i>)	8	0.6	0.09	0.7	0.11	1,819	87.4	0.94	103.1	1.10
Female Genital System	-	-	-	-	-	1,030	48.8	0.70	57.2	0.82
Cervix uteri	-	-	-	-	-	193	8.8	0.29	9.7	0.32
Uterus Corpus	-	-	-	-	-	511	24.1	0.49	28.9	0.58
Uterus, NOS ¹	-	-	-	-	-	25	1.2	0.11	1.4	0.13
Ovary	-	-	-	-	-	235	11.1	0.33	13.0	0.39
Male Genital System	1,350	85.0	1.11	102.2	1.31	-	-	-	-	-
Prostate	1,166	77.7	1.08	94.7	1.28	-	-	-	-	-
Testis	162	5.9	0.21	5.8	0.21	-	-	-	-	-
Penis	19	1.2	0.13	1.4	0.16	-	-	-	-	-
Urinary System	545	36.7	0.76	43.4	0.88	305	15.6	0.41	18.3	0.48
Bladder (incl. <i>in situ</i>)	195	15.5	0.52	18.0	0.60	69	3.9	0.21	4.5	0.25
Kidney & renal pelvis	341	20.5	0.54	24.5	0.63	230	11.4	0.35	13.4	0.40
Ureter	4	0.4	0.08	0.4	0.10	3	0.2	0.05	0.2	0.05
Eye & Orbit	9	0.6	0.10	0.6	0.11	11	0.5	0.07	0.5	0.08
Brain & Other CNS ¹	102	5.3	0.26	5.9	0.29	91	4.2	0.20	4.6	0.23
Brain	96	5.0	0.25	5.6	0.28	83	3.9	0.20	4.2	0.22
Endocrine System	116	5.8	0.26	6.6	0.30	436	19.1	0.42	21.3	0.47
Thyroid gland	103	5.1	0.24	5.8	0.28	424	18.6	0.41	20.6	0.46
Lymphomas	356	21.5	0.56	24.8	0.64	328	16.6	0.42	19.2	0.49
Hodgkin Lymphoma	46	2.2	0.16	2.3	0.17	39	1.6	0.12	1.7	0.13
Non-Hodgkin Lymphoma	310	19.3	0.53	22.4	0.61	289	15.0	0.40	17.5	0.47
Multiple Myeloma	99	6.7	0.33	7.9	0.37	88	4.6	0.23	5.5	0.27
Leukemias	224	11.8	0.39	12.7	0.43	176	8.1	0.28	8.8	0.31
Acute lymphocytic	83	3.2	0.16	3.0	0.16	62	2.5	0.14	2.4	0.14
Chronic lymphocytic	28	2.0	0.18	2.4	0.21	18	1.0	0.11	1.2	0.13
Acute myeloid	64	3.9	0.24	4.3	0.27	64	3.1	0.18	3.5	0.21
Chronic myeloid	29	1.5	0.14	1.7	0.16	18	0.8	0.09	0.9	0.10
Other leukemias	21	1.2	0.13	1.3	0.14	14	0.7	0.09	0.8	0.10
Mesothelioma	19	1.4	0.15	1.7	0.18	6	0.3	0.06	0.4	0.07
Kaposi Sarcoma	31	1.5	0.13	1.6	0.14	2	0.1	0.04	0.2	0.05
Ill-defined & Unknown	159	11.6	0.45	13.5	0.51	167	9.1	0.32	10.5	0.37
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	91	5.1	0.26	5.9	0.30	215	10.7	0.33	12.3	0.38
Breast (<i>in situ</i>)	-	-	-	-	-	427	20.4	0.45	24.5	0.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

Los Angeles

II-78 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,965	469.3	2.28	553.1	2.63	8,869	437.0	2.19	508.4	2.48
Oral Cavity & Pharynx	360	18.3	0.44	22.4	0.53	140	6.8	0.27	8.0	0.31
Lip	25	1.3	0.12	1.5	0.14	10	0.5	0.07	0.5	0.08
Tongue	130	6.6	0.26	8.0	0.32	46	2.2	0.15	2.6	0.18
Major salivary gland	34	1.8	0.14	2.1	0.16	19	1.0	0.11	1.1	0.12
Floor of mouth	10	0.5	0.07	0.6	0.08	6	0.3	0.05	0.3	0.06
Gum & other mouth	31	1.6	0.13	2.0	0.16	27	1.3	0.12	1.5	0.13
Nasopharynx	10	0.6	0.09	0.6	0.09	6	0.3	0.06	0.4	0.07
Oropharynx	14	0.7	0.08	0.9	0.10	5	0.2	0.05	0.3	0.06
Hypopharynx	15	0.8	0.09	0.9	0.11	3	0.1	0.04	0.2	0.04
Digestive System	1,708	89.1	0.99	105.7	1.15	1,375	62.6	0.79	73.7	0.92
Esophagus	113	5.8	0.25	6.9	0.29	35	1.5	0.12	1.8	0.14
Stomach	167	8.8	0.31	10.3	0.36	86	3.9	0.20	4.6	0.23
Small intestine	46	2.3	0.16	2.8	0.19	40	1.8	0.13	2.2	0.16
Colon excl. rectum	557	29.8	0.58	34.7	0.66	525	23.9	0.49	27.8	0.56
Rectum & rectosigmoid	235	12.5	0.37	14.8	0.43	191	9.5	0.32	11.2	0.37
Anus, anal canal & anorectum	42	2.1	0.15	2.6	0.18	57	2.7	0.16	3.3	0.20
Liver	168	8.1	0.29	10.2	0.35	63	2.8	0.17	3.4	0.20
Gallbladder	10	0.6	0.08	0.6	0.09	24	1.0	0.10	1.2	0.11
Pancreas	279	14.4	0.39	17.0	0.46	245	10.6	0.32	12.5	0.37
Respiratory System	1,043	54.0	0.76	63.5	0.88	950	42.3	0.63	49.6	0.73
Larynx	72	3.6	0.19	4.3	0.23	12	0.6	0.07	0.7	0.09
Lung & bronchus	947	49.2	0.73	57.6	0.84	925	41.0	0.62	48.2	0.72
Bones & Joints	16	1.1	0.13	1.1	0.13	13	0.9	0.13	0.9	0.12
Soft Tissue (incl. heart)	91	5.1	0.25	5.8	0.27	59	3.3	0.21	3.6	0.22
Skin (excl. basal & sq.)	792	42.1	0.69	49.2	0.79	453	23.4	0.52	26.6	0.58
Melanomas of the skin	731	38.8	0.66	45.4	0.75	419	22.0	0.51	24.9	0.56
Breast (excl. <i>in situ</i>)	24	1.2	0.12	1.5	0.13	2,879	146.9	1.29	172.3	1.47
Female Genital System	-	-	-	-	-	1,060	52.3	0.75	62.6	0.88
Cervix uteri	-	-	-	-	-	96	6.0	0.29	6.4	0.30
Uterus Corpus	-	-	-	-	-	564	26.9	0.53	33.2	0.64
Uterus, NOS ¹	-	-	-	-	-	26	1.2	0.11	1.4	0.13
Ovary	-	-	-	-	-	262	13.2	0.38	15.4	0.44
Male Genital System	2,045	102.6	1.04	124.1	1.23	-	-	-	-	-
Prostate	1,915	93.6	0.97	115.1	1.18	-	-	-	-	-
Testis	114	8.1	0.35	8.0	0.34	-	-	-	-	-
Penis	12	0.6	0.08	0.7	0.10	-	-	-	-	-
Urinary System	1,143	59.7	0.81	70.2	0.93	400	18.0	0.42	21.2	0.49
Bladder (incl. <i>in situ</i>)	744	38.6	0.64	45.3	0.75	210	9.1	0.29	10.6	0.34
Kidney & renal pelvis	378	20.0	0.47	23.5	0.54	179	8.5	0.30	10.1	0.34
Ureter	10	0.5	0.07	0.6	0.09	7	0.3	0.05	0.4	0.06
Eye & Orbit	20	1.1	0.11	1.3	0.13	24	1.2	0.12	1.4	0.14
Brain & Other CNS ¹	155	9.0	0.34	10.0	0.36	114	6.5	0.30	7.0	0.31
Brain	147	8.5	0.33	9.5	0.35	107	6.1	0.29	6.6	0.30
Endocrine System	174	10.1	0.36	11.3	0.39	382	24.2	0.59	26.1	0.61
Thyroid gland	161	9.3	0.34	10.5	0.37	368	23.4	0.57	25.2	0.60
Lymphomas	524	28.9	0.59	33.1	0.65	394	19.3	0.46	22.3	0.52
Hodgkin Lymphoma	49	3.2	0.22	3.4	0.22	37	2.5	0.20	2.6	0.20
Non-Hodgkin Lymphoma	475	25.7	0.54	29.7	0.61	357	16.8	0.42	19.7	0.48
Multiple Myeloma	137	7.1	0.28	8.4	0.32	92	4.2	0.20	5.0	0.24
Leukemias	327	18.2	0.47	20.6	0.51	224	11.3	0.37	12.5	0.39
Acute lymphocytic	24	2.1	0.20	1.9	0.17	18	1.5	0.18	1.4	0.15
Chronic lymphocytic	123	6.2	0.26	7.5	0.30	82	3.6	0.18	4.3	0.22
Acute myeloid	103	5.6	0.25	6.4	0.28	71	3.4	0.20	3.8	0.21
Chronic myeloid	41	2.3	0.16	2.5	0.18	30	1.6	0.14	1.8	0.15
Other leukemias	36	2.0	0.16	2.3	0.17	22	1.1	0.11	1.2	0.12
Mesothelioma	25	1.3	0.12	1.5	0.14	10	0.5	0.07	0.5	0.08
Kaposi Sarcoma	16	1.0	0.11	1.1	0.12	1	0.1	0.02	0.1	0.02
Ill-defined & Unknown	365	19.3	0.46	22.5	0.53	299	13.1	0.36	15.1	0.40
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	159	9.0	0.33	10.2	0.36	299	15.1	0.42	17.4	0.46
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	584	31.0	0.60	36.7	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Los Angeles, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,965	470.2	4.91	566.5	5.80	2,125	390.9	3.87	459.6	4.47
Oral Cavity & Pharynx	59	13.0	0.78	16.2	0.95	26	4.6	0.41	5.7	0.50
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	19	4.0	0.43	5.1	0.53	6	1.1	0.20	1.3	0.24
Major salivary gland	4	0.8	0.19	1.0	0.24	4	0.8	0.16	0.9	0.20
Floor of mouth	3	0.7	0.18	1.0	0.24	1	0.2	0.09	0.3	0.11
Gum & other mouth	6	1.6	0.28	1.8	0.31	6	1.0	0.19	1.2	0.23
Nasopharynx	3	0.7	0.18	0.8	0.21	2	0.4	0.11	0.4	0.14
Oropharynx	5	1.1	0.23	1.3	0.27	1	0.2	0.08	0.3	0.11
Hypopharynx	5	1.0	0.21	1.3	0.27	2	0.3	0.11	0.4	0.13
Digestive System	440	106.8	2.36	128.2	2.77	421	76.0	1.68	90.4	1.97
Esophagus	17	4.0	0.45	4.8	0.53	9	1.6	0.24	1.9	0.29
Stomach	49	12.6	0.83	14.8	0.96	35	6.5	0.50	7.5	0.57
Small intestine	13	3.2	0.41	3.8	0.48	16	3.0	0.33	3.5	0.39
Colon excl. rectum	141	35.2	1.37	41.6	1.59	160	29.3	1.05	34.4	1.22
Rectum & rectosigmoid	52	12.3	0.79	14.5	0.91	46	8.3	0.56	10.1	0.66
Anus, anal canal & anorectum	13	3.2	0.40	3.7	0.46	9	1.4	0.22	1.9	0.29
Liver	66	14.3	0.81	18.3	1.02	29	5.0	0.42	6.3	0.52
Gallbladder	3	0.9	0.22	1.0	0.25	11	1.9	0.26	2.3	0.31
Pancreas	66	16.3	0.93	19.6	1.10	79	14.1	0.72	16.8	0.85
Respiratory System	281	70.4	1.94	84.1	2.28	266	47.4	1.32	56.7	1.56
Larynx	22	5.1	0.51	6.3	0.61	5	0.9	0.18	1.1	0.22
Lung & bronchus	256	64.3	1.86	76.7	2.18	258	46.1	1.30	55.2	1.54
Bones & Joints	4	1.0	0.23	1.0	0.23	3	0.6	0.17	0.6	0.16
Soft Tissue (incl. heart)	19	4.6	0.49	5.0	0.53	20	3.9	0.41	4.4	0.44
Skin (excl. basal & sq.)	11	2.7	0.38	3.1	0.42	10	2.0	0.30	2.2	0.31
Melanomas of the skin	6	1.5	0.28	1.6	0.31	3	0.7	0.17	0.8	0.18
Breast (excl. <i>in situ</i>)	6	1.3	0.25	1.6	0.30	685	127.2	2.22	149.3	2.56
Female Genital System	-	-	-	-	-	270	48.9	1.36	58.5	1.59
Cervix uteri	-	-	-	-	-	39	7.9	0.58	8.7	0.62
Uterus Corpus	-	-	-	-	-	149	25.9	0.97	32.0	1.17
Uterus, NOS ¹	-	-	-	-	-	14	2.5	0.30	3.0	0.36
Ovary	-	-	-	-	-	50	9.3	0.60	10.9	0.69
Male Genital System	640	143.8	2.63	180.0	3.22	-	-	-	-	-
Prostate	630	141.3	2.60	177.4	3.19	-	-	-	-	-
Testis	6	1.5	0.29	1.4	0.26	-	-	-	-	-
Penis	3	0.7	0.19	0.8	0.22	-	-	-	-	-
Urinary System	184	45.9	1.57	54.2	1.82	93	16.9	0.80	19.9	0.92
Bladder (incl. <i>in situ</i>)	82	21.4	1.09	25.4	1.28	32	5.7	0.46	6.7	0.53
Kidney & renal pelvis	99	23.7	1.10	27.8	1.26	58	10.8	0.65	12.6	0.74
Ureter	-	-	-	-	-	1	0.2	0.09	0.3	0.11
Eye & Orbit	-	-	-	-	-	2	0.3	0.12	0.3	0.12
Brain & Other CNS ¹	20	5.0	0.51	5.4	0.54	15	2.9	0.34	3.3	0.38
Brain	19	4.7	0.49	5.1	0.52	14	2.6	0.33	3.0	0.36
Endocrine System	23	5.3	0.52	6.2	0.59	63	13.2	0.76	14.2	0.80
Thyroid gland	18	4.2	0.46	4.9	0.52	58	12.1	0.73	13.1	0.77
Lymphomas	83	20.4	1.03	23.4	1.17	75	14.2	0.75	16.3	0.84
Hodgkin Lymphoma	10	2.4	0.35	2.6	0.37	9	2.0	0.30	2.1	0.30
Non-Hodgkin Lymphoma	73	18.0	0.97	20.8	1.11	65	12.2	0.69	14.2	0.79
Multiple Myeloma	64	16.0	0.93	19.0	1.08	53	9.5	0.59	11.2	0.69
Leukemias	54	13.6	0.85	15.5	0.97	50	9.5	0.62	10.7	0.68
Acute lymphocytic	6	1.5	0.28	1.5	0.27	5	1.2	0.25	1.1	0.22
Chronic lymphocytic	17	4.5	0.50	5.3	0.59	12	2.0	0.27	2.5	0.33
Acute myeloid	17	4.3	0.48	5.0	0.55	18	3.5	0.37	3.9	0.41
Chronic myeloid	8	1.9	0.32	2.1	0.35	8	1.4	0.24	1.7	0.27
Other leukemias	6	1.3	0.25	1.6	0.30	7	1.3	0.23	1.5	0.26
Mesothelioma	3	0.8	0.22	0.9	0.24	-	-	-	-	-
Kaposi Sarcoma	11	2.7	0.36	2.8	0.38	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	73	13.5	0.72	15.7	0.82
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	28	6.9	0.61	7.9	0.69	69	12.8	0.71	14.9	0.81
Breast (<i>in situ</i>)	-	-	-	-	-	168	30.9	1.09	36.5	1.26

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	5,270,482	5,351,218	5,452,107	5,540,921	5,615,902
White	4,712,954	4,776,771	4,857,107	4,928,406	4,988,145
Black	266,464	274,465	282,993	290,285	296,017
American Indian/Alaskan Native (AI/AN)	98,212	99,839	102,287	104,502	106,564
Asian/Pacific Islander (API)	192,852	200,143	209,720	217,728	225,176


All Races Population 2013-2017: 27,230,630
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	1,109,836	1,132,659	1,159,917	1,184,706	1,209,285
Non-Hispanic White	3,709,893	3,753,372	3,809,738	3,859,018	3,896,921
Non-Hispanic Black	233,335	240,352	247,501	253,887	258,674

Hispanic/Latino Population, Census 2010: 1,038,687
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

COLORADO CANCER REGISTRY

Initial Operation: 1968
Population-based Data Available: 1988
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	98.1	99.3	99.2	97.7	98.4
Missing Race	1.4	0.6	0.8	1.0	2.2
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.4	0.5	0.1	0.1	0.3
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.3	2.3	1.8	2.1	2.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Prostate	95.5
Oral Cavity & Pharynx	97.5	Testis	99.2
Esophagus	93.8	Bladder (incl. <i>in situ</i>)	97.2
Stomach	95.7	Kidney & Renal Pelvis	88.4
Colon & Rectum	95.3	Brain & Other CNS ¹	81.2
Liver	44.3	Thyroid	99.3
Pancreas	83.1	Hodgkin Lymphoma	97.6
Lung & Bronchus	84.9	Non-Hodgkin Lymphoma	96.6
Melanomas of the Skin	99.3	Multiple Myeloma	89.1
Female Breast (excl. <i>in situ</i>)	98.4	Leukemias	87.8
Cervix uteri	96.7	Brain & Other CNS ¹ <i>non-malig</i>	35.8
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	92.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11,481	419.4	1.82	495.9	2.11	11,752	388.5	1.64	451.4	1.87
Oral Cavity & Pharynx	465	15.9	0.34	19.5	0.41	183	5.8	0.20	7.0	0.23
Lip	26	1.0	0.09	1.2	0.11	13	0.4	0.05	0.5	0.06
Tongue	151	5.0	0.19	6.2	0.23	63	2.0	0.11	2.4	0.14
Major salivary gland	40	1.6	0.12	1.8	0.13	26	0.8	0.08	1.0	0.09
Floor of mouth	17	0.5	0.06	0.7	0.07	9	0.3	0.04	0.3	0.05
Gum & other mouth	41	1.5	0.11	1.8	0.13	32	1.1	0.09	1.2	0.10
Nasopharynx	16	0.6	0.07	0.7	0.07	8	0.2	0.04	0.3	0.05
Oropharynx	18	0.6	0.07	0.8	0.08	5	0.1	0.03	0.2	0.04
Hypopharynx	15	0.5	0.06	0.7	0.08	6	0.2	0.03	0.2	0.04
Digestive System	2,307	84.3	0.82	100.4	0.95	1,735	56.9	0.63	66.9	0.72
Esophagus	212	7.8	0.25	9.3	0.29	44	1.4	0.10	1.7	0.11
Stomach	201	7.6	0.25	8.9	0.29	103	3.4	0.15	4.0	0.18
Small intestine	71	2.7	0.15	3.1	0.17	60	2.0	0.12	2.3	0.14
Colon excl. rectum	662	25.1	0.45	29.4	0.52	667	22.2	0.39	25.8	0.45
Rectum & rectosigmoid	334	11.8	0.30	14.2	0.35	230	7.6	0.23	9.0	0.27
Anus, anal canal & anorectum	32	1.1	0.09	1.3	0.11	70	2.1	0.11	2.6	0.14
Liver	307	10.1	0.27	12.7	0.33	93	2.9	0.14	3.5	0.17
Gallbladder	15	0.6	0.07	0.7	0.09	38	1.3	0.09	1.5	0.11
Pancreas	354	13.1	0.33	15.7	0.38	295	9.5	0.25	11.3	0.30
Respiratory System	1,282	49.0	0.64	57.7	0.74	1,255	41.2	0.53	48.3	0.61
Larynx	110	3.9	0.17	4.7	0.20	29	0.9	0.08	1.1	0.09
Lung & bronchus	1,143	44.1	0.61	51.9	0.70	1,207	39.6	0.52	46.4	0.60
Bones & Joints	37	1.3	0.10	1.4	0.11	22	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	100	3.8	0.17	4.2	0.19	75	2.6	0.14	2.9	0.15
Skin (excl. basal & sq.)	799	29.8	0.49	34.8	0.56	580	19.5	0.37	22.2	0.42
Melanomas of the skin	747	27.6	0.47	32.3	0.54	541	18.2	0.36	20.7	0.40
Breast (excl. <i>in situ</i>)	27	1.0	0.09	1.2	0.10	3,875	127.6	0.94	149.5	1.08
Female Genital System	-	-	-	-	-	1,363	43.8	0.54	52.0	0.63
Cervix uteri	-	-	-	-	-	174	6.2	0.22	6.7	0.23
Uterus Corpus	-	-	-	-	-	728	22.4	0.38	27.6	0.46
Uterus, NOS ¹	-	-	-	-	-	4	0.1	0.03	0.2	0.04
Ovary	-	-	-	-	-	311	10.4	0.27	12.0	0.31
Male Genital System	2,911	99.3	0.86	120.8	1.02	-	-	-	-	-
Prostate	2,727	92.7	0.83	114.1	0.99	-	-	-	-	-
Testis	160	5.7	0.20	5.6	0.20	-	-	-	-	-
Penis	19	0.7	0.08	0.8	0.09	-	-	-	-	-
Urinary System	1,341	51.1	0.65	60.0	0.75	556	18.3	0.36	21.3	0.41
Bladder (incl. <i>in situ</i>)	802	31.7	0.52	37.0	0.60	238	7.8	0.23	9.1	0.27
Kidney & renal pelvis	509	18.2	0.37	21.5	0.43	305	10.1	0.26	11.7	0.30
Ureter	19	0.8	0.08	0.9	0.10	9	0.3	0.04	0.3	0.05
Eye & Orbit	32	1.2	0.10	1.3	0.11	28	0.9	0.08	1.0	0.09
Brain & Other CNS ¹	208	7.6	0.24	8.4	0.26	162	5.6	0.20	6.1	0.22
Brain	195	7.1	0.23	7.9	0.26	149	5.1	0.19	5.6	0.21
Endocrine System	242	8.5	0.25	9.6	0.28	640	22.8	0.41	24.5	0.44
Thyroid gland	220	7.7	0.24	8.8	0.27	622	22.2	0.41	23.8	0.43
Lymphomas	631	23.6	0.44	27.0	0.49	479	16.1	0.34	18.4	0.38
Hodgkin Lymphoma	77	2.8	0.14	2.9	0.15	55	2.0	0.12	2.1	0.12
Non-Hodgkin Lymphoma	554	20.8	0.41	24.0	0.47	424	14.1	0.31	16.3	0.36
Multiple Myeloma	217	8.1	0.25	9.5	0.30	143	4.6	0.18	5.5	0.21
Leukemias	444	17.0	0.37	19.4	0.42	300	10.2	0.27	11.4	0.30
Acute lymphocytic	42	1.6	0.11	1.4	0.10	33	1.3	0.10	1.1	0.09
Chronic lymphocytic	158	5.9	0.22	7.1	0.26	91	2.9	0.14	3.5	0.16
Acute myeloid	123	4.8	0.20	5.4	0.22	104	3.6	0.16	4.0	0.18
Chronic myeloid	57	2.2	0.13	2.4	0.15	35	1.2	0.09	1.4	0.10
Other leukemias	64	2.6	0.15	3.0	0.17	37	1.2	0.09	1.4	0.10
Mesothelioma	34	1.4	0.11	1.6	0.13	11	0.4	0.05	0.4	0.06
Kaposi Sarcoma	10	0.4	0.05	0.4	0.05	-	-	-	-	-
Ill-defined & Unknown	395	16.2	0.38	18.7	0.43	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	300	11.3	0.30	12.8	0.34	603	20.3	0.38	23.2	0.43
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.03	862	28.3	0.44	33.5	0.51

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	10,474	413.4	1.88	488.3	2.17	10,899	391.8	1.72	455.0	1.96
Oral Cavity & Pharynx	433	16.0	0.36	19.6	0.43	171	5.9	0.21	7.1	0.24
Lip	26	1.1	0.10	1.2	0.11	13	0.5	0.06	0.5	0.07
Tongue	144	5.2	0.20	6.4	0.24	58	2.0	0.12	2.4	0.14
Major salivary gland	37	1.6	0.12	1.8	0.13	24	0.8	0.08	1.0	0.09
Floor of mouth	15	0.5	0.06	0.7	0.08	8	0.3	0.04	0.3	0.05
Gum & other mouth	39	1.5	0.11	1.8	0.13	30	1.1	0.09	1.3	0.10
Nasopharynx	10	0.4	0.06	0.5	0.06	6	0.2	0.04	0.2	0.04
Oropharynx	17	0.6	0.07	0.8	0.08	4	0.1	0.03	0.2	0.04
Hypopharynx	14	0.5	0.07	0.6	0.08	6	0.2	0.04	0.2	0.04
Digestive System	2,097	82.7	0.84	98.5	0.98	1,575	55.9	0.65	65.6	0.74
Esophagus	203	8.0	0.26	9.5	0.30	40	1.4	0.10	1.7	0.12
Stomach	180	7.3	0.25	8.6	0.29	86	3.1	0.15	3.6	0.17
Small intestine	66	2.7	0.15	3.1	0.17	55	2.0	0.12	2.3	0.14
Colon excl. rectum	600	24.6	0.47	28.8	0.54	609	22.0	0.41	25.5	0.46
Rectum & rectosigmoid	301	11.6	0.31	13.9	0.36	207	7.4	0.24	8.7	0.27
Anus, anal canal & anorectum	29	1.1	0.09	1.3	0.11	66	2.1	0.12	2.7	0.15
Liver	263	9.3	0.27	11.8	0.33	77	2.6	0.14	3.2	0.16
Gallbladder	14	0.6	0.08	0.7	0.09	34	1.2	0.10	1.4	0.11
Pancreas	330	13.2	0.34	15.7	0.39	275	9.6	0.26	11.3	0.31
Respiratory System	1,187	48.7	0.66	57.3	0.76	1,173	41.4	0.55	48.5	0.64
Larynx	102	3.9	0.18	4.7	0.21	28	1.0	0.08	1.2	0.10
Lung & bronchus	1,060	43.8	0.63	51.4	0.72	1,127	39.8	0.54	46.6	0.62
Bones & Joints	33	1.4	0.11	1.4	0.11	19	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	92	3.8	0.18	4.2	0.20	67	2.6	0.14	2.8	0.15
Skin (excl. basal & sq.)	792	31.8	0.52	37.1	0.60	571	21.1	0.40	24.0	0.45
Melanomas of the skin	743	29.7	0.50	34.7	0.58	536	19.8	0.39	22.5	0.44
Breast (excl. <i>in situ</i>)	26	1.0	0.10	1.2	0.11	3,603	129.2	0.99	151.3	1.13
Female Genital System	-	-	-	-	-	1,258	44.0	0.57	52.3	0.66
Cervix uteri	-	-	-	-	-	156	6.2	0.23	6.7	0.24
Uterus Corpus	-	-	-	-	-	669	22.4	0.40	27.5	0.48
Uterus, NOS ¹	-	-	-	-	-	4	0.1	0.03	0.2	0.04
Ovary	-	-	-	-	-	292	10.6	0.28	12.3	0.32
Male Genital System	2,523	93.0	0.86	112.9	1.02	-	-	-	-	-
Prostate	2,355	86.2	0.83	106.0	0.99	-	-	-	-	-
Testis	146	5.9	0.22	5.8	0.22	-	-	-	-	-
Penis	17	0.7	0.08	0.8	0.09	-	-	-	-	-
Urinary System	1,245	51.0	0.67	59.9	0.77	511	18.2	0.37	21.2	0.42
Bladder (incl. <i>in situ</i>)	748	31.6	0.54	37.0	0.62	219	7.7	0.24	9.0	0.27
Kidney & renal pelvis	468	18.1	0.39	21.4	0.45	280	10.0	0.28	11.6	0.31
Ureter	18	0.8	0.09	0.9	0.10	8	0.3	0.05	0.3	0.05
Eye & Orbit	29	1.2	0.10	1.3	0.11	27	1.0	0.09	1.1	0.10
Brain & Other CNS ¹	196	7.8	0.26	8.6	0.28	153	5.8	0.22	6.3	0.23
Brain	184	7.3	0.25	8.1	0.27	142	5.3	0.21	5.9	0.22
Endocrine System	225	8.7	0.26	9.8	0.30	583	23.1	0.44	24.8	0.46
Thyroid gland	206	7.9	0.25	9.0	0.28	568	22.5	0.43	24.2	0.46
Lymphomas	583	23.6	0.45	27.1	0.51	446	16.3	0.35	18.6	0.40
Hodgkin Lymphoma	69	2.8	0.15	2.9	0.16	49	2.0	0.13	2.1	0.13
Non-Hodgkin Lymphoma	514	20.9	0.43	24.1	0.49	397	14.3	0.33	16.5	0.37
Multiple Myeloma	195	7.8	0.26	9.2	0.30	126	4.4	0.18	5.2	0.21
Leukemias	412	17.1	0.39	19.5	0.44	281	10.4	0.29	11.6	0.31
Acute lymphocytic	37	1.6	0.12	1.4	0.11	30	1.3	0.11	1.2	0.10
Chronic lymphocytic	150	6.0	0.23	7.2	0.27	87	3.0	0.15	3.6	0.17
Acute myeloid	114	4.8	0.21	5.4	0.23	99	3.7	0.17	4.1	0.19
Chronic myeloid	51	2.1	0.14	2.4	0.15	32	1.2	0.10	1.3	0.11
Other leukemias	61	2.6	0.16	3.1	0.18	34	1.2	0.09	1.4	0.11
Mesothelioma	31	1.4	0.12	1.6	0.13	11	0.4	0.05	0.4	0.06
Kaposi Sarcoma	7	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	368	16.2	0.39	18.7	0.45	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	277	11.4	0.32	12.9	0.35	550	20.1	0.39	23.0	0.44
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	792	28.4	0.46	33.6	0.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	428	431.8	10.44	518.7	12.22	357	338.1	8.27	398.5	9.63
Oral Cavity & Pharynx	15	14.2	1.85	17.2	2.21	3	2.8	0.70	3.5	0.86
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	4.4	1.04	5.4	1.25	-	-	-	-	-
Major salivary gland	1	1.4	0.63	1.7	0.75	1	1.0	0.40	1.1	0.45
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.5	0.67	1.9	0.81	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	97	100.9	5.14	121.2	6.02	67	64.5	3.65	77.1	4.30
Esophagus	4	5.2	1.27	5.8	1.42	2	1.7	0.57	2.0	0.67
Stomach	10	12.1	1.91	14.3	2.21	4	3.7	0.86	4.6	1.05
Small intestine	3	2.9	0.79	3.4	0.90	3	2.6	0.69	3.4	0.87
Colon excl. rectum	30	31.9	2.93	37.7	3.39	23	22.8	2.20	26.6	2.53
Rectum & rectosigmoid	14	13.2	1.81	15.7	2.14	10	8.8	1.29	10.5	1.53
Anus, anal canal & anorectum	1	1.2	0.49	1.5	0.60	2	1.6	0.53	2.2	0.70
Liver	18	16.2	1.87	20.8	2.32	6	5.6	1.09	6.6	1.26
Gallbladder	-	-	-	-	-	2	2.6	0.78	3.0	0.89
Pancreas	13	13.0	1.79	15.9	2.11	10	10.2	1.47	12.6	1.76
Respiratory System	50	58.2	4.08	69.1	4.70	39	39.1	2.89	46.4	3.35
Larynx	4	4.2	1.03	5.1	1.17	-	-	-	-	-
Lung & bronchus	44	52.2	3.90	61.8	4.49	37	37.5	2.84	44.5	3.30
Bones & Joints	2	1.3	0.51	1.4	0.54	1	1.1	0.46	1.1	0.46
Soft Tissue (incl. heart)	4	3.5	0.85	3.7	0.92	4	2.9	0.71	3.1	0.78
Skin (excl. basal & sq.)	2	1.9	0.60	2.1	0.68	1	1.2	0.50	1.4	0.58
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	121	113.2	4.74	133.7	5.53
Female Genital System	-	-	-	-	-	42	40.3	2.86	48.3	3.37
Cervix uteri	-	-	-	-	-	6	5.7	1.05	6.5	1.18
Uterus Corpus	-	-	-	-	-	24	22.5	2.12	27.5	2.54
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	7.2	1.24	8.2	1.40
Male Genital System	142	132.6	5.53	166.7	6.69	-	-	-	-	-
Prostate	140	131.0	5.50	165.1	6.67	-	-	-	-	-
Testis	2	1.0	0.36	0.9	0.33	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	39	40.5	3.19	47.5	3.67	16	15.5	1.81	17.8	2.06
Bladder (incl. <i>in situ</i>)	16	17.8	2.21	20.7	2.52	4	4.7	1.04	5.4	1.16
Kidney & renal pelvis	23	21.6	2.23	25.6	2.60	11	10.6	1.47	12.2	1.68
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	4.4	1.00	4.9	1.15	3	2.6	0.64	2.5	0.65
Brain	5	4.2	0.99	4.6	1.12	3	2.2	0.60	2.2	0.62
Endocrine System	6	5.1	1.02	5.7	1.15	17	14.2	1.58	15.7	1.75
Thyroid gland	4	3.8	0.89	4.4	1.01	16	13.2	1.52	14.6	1.68
Lymphomas	21	17.9	1.90	20.4	2.16	14	12.3	1.54	14.6	1.82
Hodgkin Lymphoma	3	2.4	0.61	2.3	0.61	2	1.7	0.51	1.6	0.51
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	16	17.9	2.26	20.8	2.56	11	10.3	1.45	12.6	1.74
Leukemias	12	12.7	1.86	14.1	2.07	8	7.5	1.23	8.1	1.36
Acute lymphocytic	-	-	-	-	-	2	1.2	0.41	1.0	0.38
Chronic lymphocytic	3	3.6	1.02	4.4	1.18	1	1.4	0.56	1.7	0.64
Acute myeloid	5	5.3	1.23	5.7	1.37	2	2.3	0.71	2.5	0.79
Chronic myeloid	2	1.5	0.60	1.6	0.66	1	1.4	0.54	1.6	0.61
Other leukemias	2	1.9	0.69	2.0	0.73	1	1.2	0.49	1.3	0.55
Mesothelioma	2	1.8	0.70	2.1	0.76	-	-	-	-	-
Kaposi Sarcoma	2	1.0	0.36	1.0	0.37	-	-	-	-	-
Ill-defined & Unknown	13	16.8	2.30	19.5	2.66	10	10.6	1.54	12.6	1.79
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	10	9.6	1.52	10.9	1.74	22	21.5	2.12	25.0	2.44
Breast (<i>in situ</i>)	-	-	-	-	-	28	25.1	2.18	30.8	2.62

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	177	264.5	9.47	311.5	11.09	259	266.3	7.63	307.9	8.80
Oral Cavity & Pharynx	7	9.0	1.58	10.3	1.82	5	5.5	1.10	6.6	1.29
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	2	1.5	0.56	1.9	0.68
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	4	4.9	1.14	5.2	1.24	1	1.3	0.50	1.7	0.63
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	56	81.6	5.14	97.9	6.10	53	59.6	3.77	70.2	4.37
Esophagus	2	3.3	1.05	4.0	1.25	1	1.4	0.58	1.7	0.69
Stomach	7	10.8	1.91	13.2	2.30	10	11.2	1.65	13.0	1.90
Small intestine	-	-	-	-	-	1	1.3	0.51	1.7	0.63
Colon excl. rectum	16	23.0	2.75	27.0	3.20	16	17.3	2.02	20.4	2.35
Rectum & rectosigmoid	9	11.9	1.88	14.1	2.23	8	8.1	1.33	9.7	1.59
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	13	18.4	2.38	22.5	2.89	6	6.6	1.25	8.0	1.49
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	5	7.6	1.63	9.3	1.96	6	6.8	1.31	7.9	1.50
Respiratory System	25	42.4	4.02	50.5	4.73	25	30.1	2.74	34.8	3.12
Larynx	1	2.3	0.98	2.6	1.06	-	-	-	-	-
Lung & bronchus	23	39.0	3.87	46.6	4.56	25	29.9	2.74	34.5	3.11
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.9	0.97	3.4	1.15	2	1.8	0.65	2.1	0.76
Skin (excl. basal & sq.)	-	-	-	-	-	3	2.8	0.77	3.0	0.84
Melanomas of the skin	-	-	-	-	-	2	1.7	0.54	1.9	0.63
Breast (excl. <i>in situ</i>)	-	-	-	-	-	81	78.8	4.00	92.5	4.70
Female Genital System	-	-	-	-	-	31	29.6	2.43	35.3	2.90
Cervix uteri	-	-	-	-	-	5	4.3	0.92	4.5	0.97
Uterus Corpus	-	-	-	-	-	16	15.1	1.70	18.8	2.12
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	8	8.5	1.34	10.2	1.60
Male Genital System	29	43.5	3.84	52.5	4.56	-	-	-	-	-
Prostate	26	40.7	3.74	49.5	4.45	-	-	-	-	-
Testis	2	2.2	0.77	2.3	0.85	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	14	22.1	2.82	26.1	3.31	8	9.9	1.57	11.4	1.78
Bladder (incl. <i>in situ</i>)	7	12.2	2.19	14.3	2.56	3	4.5	1.11	5.0	1.22
Kidney & renal pelvis	7	9.5	1.74	11.4	2.06	4	4.7	1.04	5.6	1.22
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	5.5	1.26	5.4	1.28	4	4.2	0.93	4.1	0.94
Brain	4	5.1	1.23	5.1	1.26	4	3.8	0.89	3.8	0.92
Endocrine System	6	7.3	1.33	8.4	1.55	23	19.8	1.88	21.2	2.05
Thyroid gland	5	6.1	1.22	7.0	1.41	22	19.5	1.86	20.8	2.04
Lymphomas	12	18.9	2.59	21.1	2.91	8	8.3	1.38	9.2	1.53
Hodgkin Lymphoma	2	2.1	0.74	2.1	0.79	2	1.3	0.47	1.3	0.46
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	3	5.4	1.40	6.7	1.69	3	2.8	0.79	3.2	0.90
Leukemias	8	12.0	2.04	13.0	2.27	5	4.3	0.92	4.9	1.05
Acute lymphocytic	2	2.4	0.69	1.9	0.56	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	3	5.3	1.42	5.9	1.59	2	1.9	0.58	2.2	0.69
Chronic myeloid	1	1.7	0.74	2.0	0.86	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	10.1	1.96	11.9	2.31	7	8.1	1.43	9.0	1.59
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	8.8	1.60	10.1	1.88	17	17.9	1.98	20.5	2.27
Breast (<i>in situ</i>)	-	-	-	-	-	26	25.2	2.23	30.1	2.66

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6	198.8	41.01	227.5	46.21	9	304.9	48.48	352.0	55.08
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	1	53.8	21.61	61.5	23.96	2	70.3	23.94	83.0	28.05
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	55.3	24.03	59.4	25.27	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	1	55.3	24.03	59.4	25.27	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	89.7	27.40	100.5	30.24
Female Genital System	-	-	-	-	-	1	40.7	16.37	49.7	19.41
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	35.5	15.54	43.2	18.31
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.
¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)
² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,221	364.1	5.11	431.0	5.96	1,452	361.5	4.42	422.3	5.16
Oral Cavity & Pharynx	35	9.9	0.81	11.9	0.96	16	4.3	0.50	5.2	0.59
Lip	1	0.6	0.23	0.6	0.25	-	-	-	-	-
Tongue	9	2.5	0.40	3.0	0.47	5	1.2	0.25	1.5	0.31
Major salivary gland	2	0.6	0.21	0.7	0.22	3	0.7	0.20	0.8	0.23
Floor of mouth	1	0.3	0.11	0.4	0.15	-	-	-	-	-
Gum & other mouth	5	1.4	0.32	1.7	0.38	4	1.1	0.27	1.3	0.30
Nasopharynx	3	0.7	0.22	0.8	0.25	-	-	-	-	-
Oropharynx	1	0.4	0.16	0.4	0.18	-	-	-	-	-
Hypopharynx	3	1.0	0.26	1.2	0.32	-	-	-	-	-
Digestive System	369	111.7	2.83	134.4	3.33	262	70.6	2.03	83.8	2.38
Esophagus	21	6.4	0.68	7.7	0.80	4	1.2	0.26	1.5	0.32
Stomach	40	13.2	1.02	15.6	1.18	28	7.5	0.65	8.6	0.75
Small intestine	9	2.6	0.43	3.1	0.50	8	2.2	0.36	2.5	0.41
Colon excl. rectum	94	29.3	1.48	34.8	1.73	95	25.6	1.22	30.4	1.43
Rectum & rectosigmoid	54	14.7	0.96	17.8	1.14	30	7.6	0.64	9.1	0.76
Anus, anal canal & anorectum	3	0.7	0.20	0.8	0.23	3	0.8	0.22	1.0	0.26
Liver	84	23.2	1.21	29.3	1.49	27	7.3	0.65	8.8	0.77
Gallbladder	3	1.5	0.38	1.8	0.45	9	2.5	0.38	2.9	0.44
Pancreas	39	12.8	0.99	15.0	1.14	38	10.7	0.80	12.7	0.94
Respiratory System	122	43.2	1.88	50.5	2.16	120	35.7	1.50	41.6	1.73
Larynx	15	4.5	0.56	5.5	0.67	2	0.5	0.16	0.7	0.21
Lung & bronchus	103	37.7	1.77	43.9	2.03	115	34.5	1.48	40.1	1.70
Bones & Joints	5	0.9	0.20	1.0	0.21	4	0.8	0.18	0.9	0.21
Soft Tissue (incl. heart)	16	4.0	0.50	4.6	0.58	14	3.2	0.41	3.7	0.47
Skin (excl. basal & sq.)	17	4.7	0.57	5.4	0.66	30	6.8	0.57	7.9	0.67
Melanomas of the skin	14	4.1	0.53	4.7	0.61	26	5.7	0.51	6.6	0.60
Breast (excl. <i>in situ</i>)	-	-	-	-	-	440	106.3	2.34	125.6	2.76
Female Genital System	-	-	-	-	-	187	43.0	1.45	50.7	1.72
Cervix uteri	-	-	-	-	-	41	8.7	0.63	9.5	0.70
Uterus Corpus	-	-	-	-	-	90	20.6	0.99	25.2	1.22
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	39	9.2	0.69	10.8	0.81
Male Genital System	266	78.3	2.34	94.2	2.76	-	-	-	-	-
Prostate	229	71.5	2.27	87.2	2.69	-	-	-	-	-
Testis	32	4.8	0.39	4.7	0.38	-	-	-	-	-
Penis	5	1.9	0.40	2.2	0.46	-	-	-	-	-
Urinary System	143	43.5	1.77	51.6	2.06	84	21.6	1.10	25.5	1.29
Bladder (incl. <i>in situ</i>)	51	18.3	1.23	21.4	1.41	16	4.7	0.55	5.4	0.63
Kidney & renal pelvis	90	24.6	1.25	29.4	1.48	66	16.3	0.93	19.2	1.10
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.4	0.15	0.5	0.18	3	0.6	0.17	0.7	0.19
Brain & Other CNS ¹	25	5.8	0.58	6.3	0.66	21	4.6	0.49	5.0	0.55
Brain	22	5.2	0.56	5.8	0.64	19	4.2	0.46	4.6	0.53
Endocrine System	30	6.4	0.56	7.3	0.65	116	23.9	1.03	26.1	1.14
Thyroid gland	26	5.8	0.54	6.5	0.61	113	23.4	1.02	25.5	1.13
Lymphomas	72	20.0	1.17	22.9	1.35	59	15.0	0.92	17.2	1.05
Hodgkin Lymphoma	14	3.1	0.43	3.4	0.48	9	1.7	0.26	1.8	0.28
Non-Hodgkin Lymphoma	58	16.8	1.09	19.5	1.26	50	13.3	0.88	15.4	1.01
Multiple Myeloma	24	7.6	0.75	8.9	0.87	18	5.0	0.54	5.9	0.63
Leukemias	46	11.1	0.84	12.5	0.97	40	8.8	0.67	9.6	0.76
Acute lymphocytic	13	1.9	0.24	1.7	0.24	11	1.7	0.24	1.6	0.23
Chronic lymphocytic	7	2.2	0.41	2.7	0.49	7	2.0	0.35	2.4	0.42
Acute myeloid	15	3.8	0.50	4.3	0.58	12	2.6	0.37	2.9	0.42
Chronic myeloid	7	1.6	0.31	1.9	0.37	6	1.3	0.25	1.4	0.29
Other leukemias	5	1.7	0.37	1.9	0.42	4	1.1	0.26	1.3	0.31
Mesothelioma	3	1.3	0.34	1.6	0.40	-	-	-	-	-
Kaposi Sarcoma	2	0.5	0.16	0.5	0.17	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	37	10.8	0.82	12.5	0.96
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	38	10.1	0.83	11.3	0.94	76	18.9	1.02	21.6	1.16
Breast (<i>in situ</i>)	-	-	-	-	-	93	22.0	1.04	26.3	1.24

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

COLORADO

II-88 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,349	421.3	2.03	497.0	2.34	9,558	397.0	1.88	460.5	2.13
Oral Cavity & Pharynx	401	17.0	0.39	20.8	0.47	156	6.2	0.23	7.4	0.27
Lip	24	1.1	0.11	1.3	0.12	12	0.5	0.07	0.6	0.07
Tongue	135	5.6	0.22	6.9	0.27	54	2.2	0.14	2.6	0.16
Major salivary gland	35	1.7	0.13	1.9	0.15	21	0.8	0.09	1.0	0.10
Floor of mouth	14	0.6	0.07	0.7	0.09	8	0.3	0.05	0.4	0.06
Gum & other mouth	34	1.6	0.12	1.9	0.14	26	1.1	0.10	1.2	0.11
Nasopharynx	8	0.3	0.06	0.4	0.07	5	0.2	0.04	0.3	0.05
Oropharynx	16	0.7	0.08	0.8	0.09	3	0.1	0.03	0.2	0.04
Hypopharynx	11	0.5	0.07	0.6	0.08	6	0.2	0.04	0.3	0.05
Digestive System	1,756	79.2	0.88	94.1	1.02	1,336	54.1	0.68	63.4	0.78
Esophagus	184	8.1	0.28	9.7	0.33	36	1.4	0.11	1.7	0.13
Stomach	142	6.5	0.25	7.7	0.29	60	2.4	0.15	2.8	0.17
Small intestine	58	2.7	0.16	3.1	0.19	47	1.9	0.13	2.3	0.15
Colon excl. rectum	513	24.1	0.49	28.2	0.57	524	21.6	0.44	24.9	0.49
Rectum & rectosigmoid	252	11.2	0.33	13.4	0.38	179	7.5	0.26	8.8	0.30
Anus, anal canal & anorectum	26	1.2	0.10	1.4	0.12	63	2.3	0.14	2.9	0.17
Liver	188	7.6	0.26	9.6	0.32	53	2.1	0.13	2.5	0.15
Gallbladder	11	0.5	0.07	0.6	0.08	26	1.1	0.09	1.2	0.11
Pancreas	294	13.2	0.36	15.8	0.42	239	9.4	0.28	11.1	0.32
Respiratory System	1,074	49.5	0.70	58.2	0.81	1,062	42.3	0.60	49.5	0.69
Larynx	88	3.8	0.19	4.6	0.22	26	1.0	0.09	1.2	0.11
Lung & bronchus	964	44.6	0.67	52.5	0.77	1,020	40.6	0.58	47.6	0.67
Bones & Joints	29	1.4	0.12	1.5	0.13	16	0.8	0.09	0.8	0.09
Soft Tissue (incl. heart)	77	3.7	0.20	4.1	0.22	55	2.5	0.16	2.7	0.17
Skin (excl. basal & sq.)	775	35.8	0.60	41.6	0.68	542	23.7	0.47	26.8	0.52
Melanomas of the skin	729	33.5	0.58	39.0	0.66	511	22.3	0.46	25.3	0.51
Breast (excl. <i>in situ</i>)	25	1.2	0.11	1.3	0.12	3,193	132.7	1.09	155.2	1.24
Female Genital System	-	-	-	-	-	1,088	43.8	0.62	52.1	0.71
Cervix uteri	-	-	-	-	-	119	5.8	0.25	6.2	0.25
Uterus Corpus	-	-	-	-	-	590	22.4	0.43	27.7	0.51
Uterus, NOS ¹	-	-	-	-	-	4	0.1	0.03	0.2	0.04
Ovary	-	-	-	-	-	255	10.7	0.31	12.5	0.35
Male Genital System	2,281	95.3	0.93	115.7	1.10	-	-	-	-	-
Prostate	2,147	88.4	0.89	108.7	1.07	-	-	-	-	-
Testis	118	6.1	0.26	6.1	0.25	-	-	-	-	-
Penis	12	0.5	0.07	0.6	0.08	-	-	-	-	-
Urinary System	1,113	51.8	0.72	60.8	0.83	434	17.5	0.39	20.5	0.44
Bladder (incl. <i>in situ</i>)	701	33.3	0.58	39.0	0.67	205	8.1	0.26	9.5	0.30
Kidney & renal pelvis	385	17.2	0.41	20.2	0.47	219	9.0	0.28	10.5	0.32
Ureter	17	0.8	0.09	1.0	0.11	7	0.3	0.05	0.3	0.06
Eye & Orbit	28	1.3	0.12	1.5	0.13	24	1.0	0.10	1.2	0.11
Brain & Other CNS ¹	172	8.2	0.29	9.0	0.31	132	6.0	0.24	6.6	0.26
Brain	163	7.7	0.28	8.5	0.30	123	5.5	0.23	6.1	0.25
Endocrine System	197	9.1	0.30	10.3	0.33	477	23.1	0.49	24.7	0.51
Thyroid gland	181	8.3	0.29	9.4	0.32	464	22.5	0.48	24.1	0.50
Lymphomas	516	24.3	0.50	27.8	0.56	391	16.6	0.39	18.8	0.43
Hodgkin Lymphoma	56	2.8	0.17	3.0	0.18	40	2.1	0.15	2.1	0.15
Non-Hodgkin Lymphoma	460	21.5	0.47	24.8	0.53	351	14.5	0.36	16.7	0.40
Multiple Myeloma	172	7.7	0.27	9.2	0.32	110	4.3	0.19	5.1	0.22
Leukemias	369	17.7	0.43	20.2	0.48	244	10.5	0.31	11.8	0.34
Acute lymphocytic	25	1.4	0.13	1.3	0.12	20	1.2	0.13	1.1	0.11
Chronic lymphocytic	143	6.5	0.25	7.7	0.29	80	3.1	0.16	3.7	0.19
Acute myeloid	100	4.8	0.22	5.5	0.25	87	3.8	0.19	4.3	0.21
Chronic myeloid	45	2.2	0.15	2.5	0.17	27	1.2	0.10	1.3	0.11
Other leukemias	56	2.8	0.17	3.2	0.20	30	1.2	0.10	1.4	0.12
Mesothelioma	28	1.4	0.12	1.6	0.14	10	0.4	0.06	0.5	0.07
Kaposi Sarcoma	5	0.3	0.06	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	330	16.4	0.42	19.0	0.48	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	241	11.5	0.34	13.1	0.38	482	20.5	0.43	23.4	0.48
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	705	29.5	0.52	34.9	0.59

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Colorado, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	422	448.6	10.86	538.3	12.71	349	353.7	8.71	415.8	10.11
Oral Cavity & Pharynx	15	14.9	1.93	18.0	2.31	3	2.9	0.73	3.5	0.89
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	4.7	1.09	5.7	1.31	-	-	-	-	-
Major salivary gland	1	1.5	0.67	1.8	0.79	1	1.0	0.44	1.2	0.49
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.6	0.71	2.0	0.85	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	95	104.3	5.33	125.1	6.25	66	67.6	3.84	80.6	4.51
Esophagus	4	5.4	1.33	6.1	1.49	2	1.8	0.61	2.1	0.72
Stomach	10	12.6	1.99	14.9	2.31	4	3.9	0.90	4.9	1.11
Small intestine	3	3.1	0.83	3.6	0.95	3	2.8	0.73	3.6	0.93
Colon excl. rectum	29	33.0	3.04	39.0	3.52	23	24.0	2.32	27.8	2.66
Rectum & rectosigmoid	13	13.5	1.89	15.9	2.21	10	9.3	1.37	11.1	1.62
Anus, anal canal & anorectum	1	1.3	0.52	1.6	0.63	2	1.7	0.55	2.3	0.74
Liver	18	16.7	1.94	21.4	2.41	6	5.9	1.15	7.0	1.33
Gallbladder	-	-	-	-	-	2	2.5	0.78	2.9	0.89
Pancreas	13	13.2	1.83	16.2	2.16	10	10.6	1.53	13.0	1.84
Respiratory System	49	60.1	4.24	71.2	4.87	38	40.4	3.01	48.0	3.50
Larynx	4	4.4	1.07	5.3	1.22	-	-	-	-	-
Lung & bronchus	43	53.8	4.05	63.6	4.65	36	38.6	2.95	45.9	3.43
Bones & Joints	2	1.4	0.55	1.5	0.58	1	1.2	0.51	1.2	0.51
Soft Tissue (incl. heart)	4	3.7	0.90	4.0	0.97	3	2.9	0.73	3.1	0.80
Skin (excl. basal & sq.)	2	2.1	0.64	2.3	0.72	1	1.3	0.53	1.5	0.61
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	119	119.1	5.02	140.3	5.83
Female Genital System	-	-	-	-	-	42	42.2	3.01	50.6	3.55
Cervix uteri	-	-	-	-	-	6	6.0	1.11	6.8	1.24
Uterus Corpus	-	-	-	-	-	24	23.6	2.23	29.0	2.68
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	7.4	1.30	8.5	1.46
Male Genital System	141	137.6	5.74	173.1	6.95	-	-	-	-	-
Prostate	138	135.9	5.71	171.3	6.92	-	-	-	-	-
Testis	2	1.1	0.41	1.0	0.37	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	38	41.8	3.32	49.1	3.82	16	16.4	1.92	18.8	2.17
Bladder (incl. <i>in situ</i>)	15	18.4	2.29	21.3	2.61	4	4.8	1.08	5.5	1.20
Kidney & renal pelvis	22	22.4	2.33	26.5	2.71	11	11.4	1.57	13.1	1.79
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	4.6	1.06	5.1	1.20	3	2.9	0.73	2.8	0.72
Brain	4	4.3	1.04	4.8	1.17	3	2.5	0.68	2.4	0.68
Endocrine System	6	5.5	1.08	6.1	1.22	16	14.9	1.71	16.2	1.86
Thyroid gland	4	4.1	0.94	4.7	1.07	15	13.9	1.65	15.1	1.79
Lymphomas	20	18.8	1.99	21.3	2.26	13	12.9	1.62	15.1	1.89
Hodgkin Lymphoma	3	2.5	0.66	2.5	0.65	2	1.9	0.59	1.9	0.58
Non-Hodgkin Lymphoma	17	16.3	1.88	18.8	2.16	11	10.9	1.51	13.2	1.80
Multiple Myeloma	16	18.7	2.35	21.8	2.67	11	10.7	1.52	13.1	1.82
Leukemias	12	13.5	1.95	14.9	2.17	8	8.0	1.32	8.6	1.45
Acute lymphocytic	-	-	-	-	-	1	1.2	0.46	1.1	0.41
Chronic lymphocytic	3	3.8	1.06	4.6	1.23	1	1.5	0.59	1.8	0.68
Acute myeloid	5	5.6	1.30	6.0	1.44	2	2.5	0.75	2.7	0.84
Chronic myeloid	2	1.6	0.63	1.8	0.69	1	1.5	0.58	1.7	0.65
Other leukemias	-	-	-	-	-	1	1.3	0.53	1.4	0.59
Mesothelioma	2	1.9	0.73	2.1	0.79	-	-	-	-	-
Kaposi Sarcoma	1	1.0	0.39	1.0	0.39	-	-	-	-	-
Ill-defined & Unknown	13	17.6	2.40	20.4	2.77	10	10.4	1.56	12.5	1.82
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	10	10.0	1.60	11.4	1.82	21	21.8	2.20	25.5	2.54
Breast (<i>in situ</i>)	-	-	-	-	-	28	26.4	2.31	32.3	2.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


COLORADO

II-90 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	3,594,915	3,594,783	3,587,509	3,578,674	3,573,880
White	2,974,036	2,962,888	2,945,568	2,928,842	2,914,682
Black	433,928	438,519	443,495	447,715	453,203
American Indian/Alaskan Native (AI/AN)	21,628	22,045	22,397	22,622	23,027
Asian/Pacific Islander (API)	165,323	171,331	176,049	179,495	182,968


All Races Population 2013-2017: 17,929,761
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	524,596	537,096	548,284	560,132	573,610
Non-Hispanic White	2,532,118	2,510,380	2,483,949	2,457,116	2,432,361
Non-Hispanic Black	370,923	374,026	377,324	380,181	383,445

Hispanic/Latino Population, Census 2010: 479,087
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

CONNECTICUT CANCER REGISTRY

Initial Operation: 1935
 Population-based Data Available: 1935
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	118.5	116.9	115.7	114.5	115.4
Missing Race	0.9	0.7	1.1	1.2	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.8	0.6	0.4	0.6	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.5	Prostate	98.0
Oral Cavity & Pharynx	99.4	Testis	99.8
Esophagus	97.2	Bladder (incl. <i>in situ</i>)	99.1
Stomach	98.4	Kidney & Renal Pelvis	94.8
Colon & Rectum	97.4	Brain & Other CNS ¹	89.6
Liver	67.9	Thyroid	99.7
Pancreas	90.3	Hodgkin Lymphoma	98.8
Lung & Bronchus	92.5	Non-Hodgkin Lymphoma	96.9
Melanomas of the Skin	99.8	Multiple Myeloma	93.0
Female Breast (excl. <i>in situ</i>)	99.3	Leukemias	84.8
Cervix uteri	99.3	Brain & Other CNS ¹ <i>non-malig</i>	56.0
Uterus Corpus & Uterus NOS ¹	99.1	Breast <i>in situ</i>	100.0
Ovary	96.5		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,321	504.9	2.28	598.3	2.65	10,694	449.9	2.02	523.0	2.29
Oral Cavity & Pharynx	370	17.3	0.41	21.1	0.49	175	7.2	0.25	8.5	0.29
Lip	9	0.5	0.07	0.5	0.08	7	0.3	0.05	0.3	0.05
Tongue	123	5.7	0.23	7.0	0.28	55	2.3	0.14	2.7	0.17
Major salivary gland	28	1.5	0.13	1.7	0.14	27	1.2	0.11	1.4	0.12
Floor of mouth	16	0.7	0.08	0.9	0.10	8	0.3	0.05	0.4	0.06
Gum & other mouth	44	2.1	0.15	2.6	0.17	37	1.4	0.11	1.7	0.12
Nasopharynx	13	0.6	0.08	0.7	0.09	6	0.3	0.05	0.3	0.06
Oropharynx	19	0.9	0.09	1.1	0.11	6	0.3	0.05	0.3	0.06
Hypopharynx	25	1.2	0.11	1.4	0.13	6	0.2	0.04	0.3	0.05
Digestive System	1,965	96.3	1.00	114.5	1.16	1,592	63.4	0.74	74.6	0.85
Esophagus	168	8.1	0.29	9.7	0.34	50	1.9	0.12	2.3	0.15
Stomach	223	11.1	0.34	13.1	0.39	130	5.3	0.22	6.1	0.24
Small intestine	54	2.8	0.17	3.2	0.19	54	2.3	0.14	2.7	0.16
Colon excl. rectum	539	27.1	0.53	31.7	0.61	573	22.8	0.44	26.4	0.50
Rectum & rectosigmoid	265	13.1	0.37	15.5	0.43	201	8.3	0.27	9.9	0.32
Anus, anal canal & anorectum	30	1.5	0.12	1.7	0.14	53	2.1	0.13	2.6	0.16
Liver	243	10.9	0.32	13.7	0.40	70	2.7	0.15	3.3	0.18
Gallbladder	14	0.7	0.09	0.8	0.10	30	1.2	0.10	1.4	0.12
Pancreas	317	15.5	0.40	18.4	0.47	309	11.9	0.31	14.1	0.36
Respiratory System	1,459	71.9	0.86	85.2	1.00	1,456	57.8	0.69	68.3	0.81
Larynx	122	5.7	0.24	7.0	0.28	33	1.3	0.10	1.6	0.13
Lung & bronchus	1,314	65.0	0.82	76.9	0.95	1,407	55.8	0.68	65.9	0.79
Bones & Joints	20	1.1	0.12	1.1	0.11	16	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	80	4.2	0.22	4.7	0.24	63	2.9	0.17	3.2	0.18
Skin (excl. basal & sq.)	562	28.3	0.55	33.1	0.63	403	17.5	0.41	20.0	0.45
Melanomas of the skin	517	25.9	0.52	30.3	0.60	376	16.4	0.39	18.7	0.44
Breast (excl. <i>in situ</i>)	30	1.5	0.12	1.8	0.14	3,263	140.5	1.14	164.2	1.30
Female Genital System	-	-	-	-	-	1,233	51.3	0.68	61.0	0.78
Cervix uteri	-	-	-	-	-	118	6.1	0.26	6.4	0.27
Uterus Corpus	-	-	-	-	-	712	28.7	0.49	35.0	0.59
Uterus, NOS ¹	-	-	-	-	-	23	0.9	0.09	1.1	0.10
Ovary	-	-	-	-	-	256	10.7	0.31	12.6	0.36
Male Genital System	2,579	119.0	1.07	145.5	1.29	-	-	-	-	-
Prostate	2,447	111.3	1.03	137.6	1.25	-	-	-	-	-
Testis	108	6.4	0.28	6.5	0.28	-	-	-	-	-
Penis	19	0.9	0.10	1.1	0.12	-	-	-	-	-
Urinary System	1,361	67.9	0.84	80.0	0.97	566	22.9	0.45	26.7	0.51
Bladder (incl. <i>in situ</i>)	867	44.0	0.68	51.5	0.79	293	11.4	0.31	13.3	0.35
Kidney & renal pelvis	460	22.2	0.48	26.4	0.55	251	10.7	0.31	12.4	0.35
Ureter	17	0.9	0.10	1.0	0.11	14	0.5	0.06	0.6	0.07
Eye & Orbit	17	0.9	0.10	1.0	0.11	19	0.9	0.09	1.0	0.10
Brain & Other CNS ¹	158	8.2	0.30	9.2	0.33	124	5.8	0.24	6.3	0.26
Brain	151	7.8	0.29	8.7	0.32	117	5.4	0.24	5.9	0.25
Endocrine System	205	10.7	0.34	11.9	0.37	546	28.0	0.56	30.1	0.58
Thyroid gland	187	9.7	0.33	10.9	0.36	532	27.4	0.55	29.4	0.57
Lymphomas	582	30.0	0.57	34.2	0.64	472	19.9	0.43	22.9	0.48
Hodgkin Lymphoma	68	3.8	0.21	4.0	0.22	52	2.8	0.18	2.9	0.18
Non-Hodgkin Lymphoma	514	26.2	0.53	30.3	0.60	421	17.1	0.39	20.1	0.44
Multiple Myeloma	188	9.3	0.31	11.0	0.36	143	5.8	0.22	6.9	0.26
Leukemias	346	17.8	0.44	20.2	0.49	281	11.8	0.33	13.4	0.36
Acute lymphocytic	29	1.7	0.14	1.6	0.14	26	1.5	0.14	1.4	0.12
Chronic lymphocytic	142	7.0	0.27	8.3	0.31	108	4.1	0.18	4.9	0.21
Acute myeloid	95	4.9	0.23	5.6	0.26	82	3.5	0.18	3.9	0.20
Chronic myeloid	42	2.3	0.16	2.5	0.17	38	1.6	0.12	1.9	0.14
Other leukemias	38	2.0	0.15	2.2	0.16	26	1.1	0.10	1.2	0.11
Mesothelioma	31	1.6	0.13	1.9	0.15	7	0.3	0.05	0.3	0.06
Kaposi Sarcoma	10	0.6	0.08	0.6	0.08	2	0.1	0.02	0.1	0.02
Ill-defined & Unknown	357	18.5	0.45	21.4	0.51	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	155	8.1	0.30	9.1	0.33	316	13.9	0.37	15.8	0.40
Breast (<i>in situ</i>)	6	0.3	0.05	0.3	0.06	967	43.4	0.65	50.5	0.73

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	9,091	501.2	2.42	592.5	2.79	9,407	453.5	2.20	526.9	2.48
Oral Cavity & Pharynx	332	17.6	0.45	21.5	0.53	157	7.4	0.28	8.7	0.32
Lip	8	0.5	0.08	0.6	0.09	6	0.3	0.05	0.3	0.06
Tongue	115	6.0	0.26	7.4	0.31	51	2.5	0.16	2.9	0.18
Major salivary gland	25	1.5	0.14	1.7	0.15	23	1.2	0.12	1.3	0.13
Floor of mouth	15	0.7	0.09	0.9	0.11	7	0.3	0.06	0.4	0.07
Gum & other mouth	36	2.0	0.15	2.4	0.18	33	1.4	0.12	1.7	0.13
Nasopharynx	9	0.5	0.08	0.6	0.09	4	0.2	0.05	0.2	0.05
Oropharynx	16	0.9	0.10	1.1	0.12	6	0.3	0.05	0.3	0.06
Hypopharynx	22	1.1	0.11	1.4	0.13	6	0.2	0.05	0.3	0.06
Digestive System	1,705	94.1	1.05	111.5	1.21	1,366	61.4	0.78	72.0	0.89
Esophagus	155	8.4	0.31	10.0	0.36	44	1.9	0.13	2.3	0.16
Stomach	187	10.4	0.35	12.2	0.40	104	4.7	0.22	5.5	0.25
Small intestine	44	2.6	0.18	2.9	0.20	44	2.1	0.15	2.5	0.17
Colon excl. rectum	469	26.5	0.56	31.0	0.64	501	22.5	0.47	26.0	0.53
Rectum & rectosigmoid	226	12.8	0.39	15.0	0.45	169	8.0	0.29	9.5	0.33
Anus, anal canal & anorectum	27	1.5	0.13	1.8	0.15	48	2.2	0.15	2.7	0.18
Liver	201	10.1	0.33	12.8	0.40	56	2.5	0.15	2.9	0.18
Gallbladder	11	0.7	0.09	0.7	0.10	23	1.1	0.10	1.2	0.11
Pancreas	284	15.5	0.42	18.4	0.49	274	11.8	0.33	14.0	0.39
Respiratory System	1,311	72.0	0.91	85.3	1.06	1,329	59.4	0.75	70.1	0.87
Larynx	105	5.6	0.25	6.8	0.30	30	1.3	0.11	1.6	0.14
Lung & bronchus	1,185	65.2	0.87	77.1	1.01	1,287	57.5	0.73	67.8	0.86
Bones & Joints	18	1.2	0.13	1.2	0.13	13	0.8	0.11	0.8	0.10
Soft Tissue (incl. heart)	69	4.1	0.23	4.6	0.25	53	2.8	0.18	3.1	0.19
Skin (excl. basal & sq.)	538	30.4	0.60	35.6	0.69	380	19.3	0.47	21.9	0.51
Melanomas of the skin	495	28.0	0.58	32.7	0.66	356	18.1	0.46	20.6	0.50
Breast (excl. <i>in situ</i>)	26	1.4	0.13	1.7	0.15	2,853	141.8	1.25	165.7	1.41
Female Genital System	-	-	-	-	-	1,073	51.4	0.73	61.0	0.85
Cervix uteri	-	-	-	-	-	95	6.0	0.29	6.3	0.29
Uterus Corpus	-	-	-	-	-	623	28.8	0.53	35.1	0.64
Uterus, NOS ¹	-	-	-	-	-	18	0.8	0.09	1.0	0.10
Ovary	-	-	-	-	-	228	10.8	0.33	12.8	0.39
Male Genital System	2,168	113.1	1.12	137.7	1.33	-	-	-	-	-
Prostate	2,047	104.4	1.06	128.8	1.28	-	-	-	-	-
Testis	100	7.5	0.34	7.5	0.34	-	-	-	-	-
Penis	16	0.9	0.10	1.1	0.12	-	-	-	-	-
Urinary System	1,247	69.5	0.90	81.7	1.04	511	23.2	0.48	27.1	0.55
Bladder (incl. <i>in situ</i>)	818	46.0	0.73	53.8	0.85	273	11.9	0.33	13.9	0.38
Kidney & renal pelvis	398	21.8	0.50	25.9	0.58	217	10.5	0.33	12.2	0.38
Ureter	16	1.0	0.11	1.1	0.12	13	0.5	0.07	0.6	0.08
Eye & Orbit	16	0.9	0.11	1.1	0.12	18	1.0	0.11	1.1	0.12
Brain & Other CNS ¹	142	8.5	0.33	9.5	0.36	109	6.0	0.27	6.5	0.28
Brain	136	8.1	0.32	9.1	0.35	103	5.6	0.26	6.1	0.27
Endocrine System	180	11.0	0.38	12.2	0.41	456	28.5	0.63	30.5	0.65
Thyroid gland	166	10.1	0.37	11.3	0.40	445	27.9	0.63	29.9	0.64
Lymphomas	518	30.3	0.61	34.6	0.68	421	20.2	0.46	23.3	0.52
Hodgkin Lymphoma	55	3.7	0.23	3.8	0.23	42	2.8	0.20	2.9	0.20
Non-Hodgkin Lymphoma	463	26.6	0.57	30.7	0.64	379	17.4	0.42	20.5	0.48
Multiple Myeloma	154	8.5	0.31	10.1	0.37	112	5.1	0.23	6.1	0.26
Leukemias	310	17.9	0.47	20.4	0.52	252	12.1	0.36	13.7	0.40
Acute lymphocytic	24	1.7	0.16	1.6	0.15	22	1.5	0.15	1.4	0.14
Chronic lymphocytic	130	7.0	0.28	8.4	0.33	101	4.3	0.20	5.1	0.23
Acute myeloid	85	4.9	0.24	5.6	0.27	74	3.6	0.20	4.1	0.22
Chronic myeloid	36	2.2	0.17	2.5	0.18	32	1.6	0.13	1.8	0.15
Other leukemias	35	2.1	0.16	2.3	0.18	23	1.1	0.11	1.2	0.12
Mesothelioma	30	1.7	0.14	2.0	0.16	6	0.3	0.05	0.3	0.06
Kaposi Sarcoma	7	0.5	0.09	0.5	0.09	2	0.1	0.02	0.1	0.03
Ill-defined & Unknown	321	18.5	0.47	21.4	0.54	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	136	8.2	0.33	9.2	0.35	276	14.2	0.41	16.1	0.44
Breast (<i>in situ</i>)	4	0.3	0.06	0.3	0.06	830	43.8	0.71	50.8	0.80

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	812	501.7	8.39	604.3	9.89	825	376.6	5.97	442.6	6.95
Oral Cavity & Pharynx	23	13.3	1.32	16.3	1.60	10	4.6	0.65	5.3	0.76
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	2.5	0.55	3.1	0.68	2	0.9	0.31	1.1	0.36
Major salivary gland	3	1.7	0.50	1.8	0.54	2	1.0	0.30	1.2	0.34
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	3	1.5	0.45	1.8	0.53	2	0.8	0.28	0.9	0.32
Nasopharynx	2	0.9	0.34	1.0	0.40	1	0.5	0.22	0.6	0.24
Oropharynx	2	1.0	0.32	1.3	0.42	-	-	-	-	-
Hypopharynx	3	1.7	0.52	2.1	0.61	-	-	-	-	-
Digestive System	176	110.5	3.98	133.9	4.72	160	74.0	2.67	88.4	3.15
Esophagus	11	7.1	1.01	8.7	1.22	4	2.0	0.43	2.4	0.52
Stomach	25	17.8	1.71	20.8	1.97	18	8.9	0.95	10.2	1.08
Small intestine	9	5.2	0.83	6.3	0.98	8	3.4	0.56	4.1	0.67
Colon excl. rectum	46	30.0	2.11	35.6	2.47	52	24.1	1.52	28.7	1.79
Rectum & rectosigmoid	24	14.6	1.42	17.5	1.67	18	8.1	0.88	9.6	1.03
Anus, anal canal & anorectum	1	0.7	0.25	0.9	0.33	4	1.8	0.40	2.1	0.47
Liver	27	15.0	1.35	19.6	1.71	9	3.8	0.56	5.0	0.74
Gallbladder	2	1.3	0.44	1.6	0.54	5	2.4	0.48	3.1	0.59
Pancreas	24	15.3	1.47	18.6	1.75	28	13.7	1.17	16.1	1.36
Respiratory System	114	79.0	3.51	93.4	4.06	99	46.1	2.12	55.1	2.50
Larynx	13	7.4	0.99	9.3	1.21	3	1.5	0.37	1.9	0.47
Lung & bronchus	100	70.6	3.36	83.1	3.86	93	43.7	2.07	52.3	2.44
Bones & Joints	1	0.6	0.23	0.6	0.23	3	1.1	0.31	1.1	0.32
Soft Tissue (incl. heart)	8	4.2	0.72	4.6	0.80	6	2.8	0.50	3.2	0.57
Skin (excl. basal & sq.)	3	1.7	0.45	2.0	0.52	4	1.9	0.43	2.1	0.47
Melanomas of the skin	2	1.1	0.38	1.3	0.42	2	1.0	0.33	1.1	0.35
Breast (excl. <i>in situ</i>)	4	2.3	0.59	2.7	0.68	261	117.0	3.29	137.2	3.83
Female Genital System	-	-	-	-	-	106	46.9	2.08	56.7	2.48
Cervix uteri	-	-	-	-	-	15	6.8	0.80	7.7	0.90
Uterus Corpus	-	-	-	-	-	59	25.8	1.53	32.1	1.88
Uterus, NOS ¹	-	-	-	-	-	4	1.8	0.40	2.1	0.47
Ovary	-	-	-	-	-	18	8.0	0.87	9.3	1.00
Male Genital System	284	166.9	4.68	207.9	5.67	-	-	-	-	-
Prostate	279	164.3	4.64	205.0	5.63	-	-	-	-	-
Testis	3	1.2	0.33	1.2	0.35	-	-	-	-	-
Penis	2	1.1	0.42	1.3	0.48	-	-	-	-	-
Urinary System	73	47.1	2.64	55.9	3.08	37	17.7	1.32	20.2	1.49
Bladder (incl. <i>in situ</i>)	28	21.6	1.94	25.3	2.25	15	7.3	0.85	8.6	1.00
Kidney & renal pelvis	43	23.6	1.69	28.4	1.99	21	9.7	0.97	10.7	1.07
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	9	5.1	0.78	5.5	0.84	7	3.3	0.56	3.7	0.62
Brain	9	4.7	0.73	5.0	0.79	7	3.1	0.54	3.5	0.61
Endocrine System	12	6.4	0.87	7.1	0.97	39	17.2	1.25	19.0	1.38
Thyroid gland	9	4.5	0.71	5.0	0.78	36	16.2	1.22	17.9	1.34
Lymphomas	35	20.5	1.66	23.3	1.86	28	12.8	1.11	14.3	1.24
Hodgkin Lymphoma	7	4.1	0.72	4.3	0.77	5	2.2	0.44	2.2	0.45
Non-Hodgkin Lymphoma	28	16.5	1.49	19.0	1.70	22	10.5	1.01	12.1	1.15
Multiple Myeloma	28	17.3	1.54	20.4	1.77	25	11.5	1.06	13.6	1.24
Leukemias	19	12.3	1.36	13.9	1.52	18	8.8	0.94	9.8	1.04
Acute lymphocytic	2	1.0	0.30	1.2	0.35	2	0.8	0.26	0.8	0.27
Chronic lymphocytic	5	3.5	0.74	4.0	0.84	4	2.0	0.44	2.4	0.52
Acute myeloid	6	4.0	0.79	4.5	0.89	5	2.7	0.52	3.0	0.58
Chronic myeloid	4	2.4	0.60	2.7	0.68	5	2.3	0.49	2.5	0.52
Other leukemias	2	1.3	0.46	1.4	0.48	2	1.0	0.31	1.2	0.37
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	0.7	0.29	0.8	0.32	-	-	-	-	-
Ill-defined & Unknown	20	13.5	1.43	15.7	1.64	22	10.5	1.02	12.3	1.19
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	10	5.5	0.84	6.4	0.98	21	9.3	0.93	10.8	1.08
Breast (<i>in situ</i>)	-	-	-	-	-	86	37.7	1.85	45.1	2.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, Asian/Pacific Islander (API)**

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	132	219.6	9.32	260.9	11.01	195	255.3	8.66	294.9	10.02
Oral Cavity & Pharynx	7	10.2	1.80	13.2	2.33	4	5.7	1.29	7.0	1.57
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	2	2.4	0.81	3.1	1.00
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	4	5.2	1.24	7.1	1.68	-	-	-	-	-
Nasopharynx	1	1.3	0.54	1.4	0.60	1	1.3	0.54	1.7	0.71
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	39	63.8	4.92	75.7	5.78	29	44.8	3.96	53.0	4.62
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	7	11.9	2.12	13.6	2.40	4	5.1	1.29	6.1	1.51
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	10	16.6	2.52	20.4	3.06	8	11.9	2.06	13.8	2.36
Rectum & rectosigmoid	5	6.8	1.34	8.1	1.63	5	6.5	1.34	7.9	1.61
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	12.9	2.13	15.3	2.48	3	5.0	1.37	6.1	1.65
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	4	7.6	1.85	9.0	2.18	4	6.1	1.49	7.2	1.74
Respiratory System	15	27.0	3.38	33.0	4.05	15	23.5	2.91	26.8	3.30
Larynx	1	2.3	1.01	2.8	1.17	-	-	-	-	-
Lung & bronchus	14	23.9	3.13	29.3	3.76	14	22.5	2.86	25.7	3.24
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	2	2.2	0.71	2.7	0.88
Skin (excl. basal & sq.)	-	-	-	-	-	2	2.6	0.92	3.0	1.05
Melanomas of the skin	-	-	-	-	-	2	2.4	0.89	2.8	1.03
Breast (excl. <i>in situ</i>)	-	-	-	-	-	74	90.9	4.92	105.3	5.71
Female Genital System	-	-	-	-	-	21	26.3	2.69	30.5	3.15
Cervix uteri	-	-	-	-	-	3	3.5	0.95	4.0	1.10
Uterus Corpus	-	-	-	-	-	10	11.5	1.71	14.0	2.10
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	9.0	1.66	9.8	1.84
Male Genital System	25	43.1	4.11	51.7	4.85	-	-	-	-	-
Prostate	24	41.2	4.01	49.5	4.71	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	13	23.5	3.25	27.9	3.86	5	5.9	1.23	7.2	1.51
Bladder (incl. <i>in situ</i>)	6	12.9	2.58	15.4	3.07	1	1.8	0.68	2.1	0.81
Kidney & renal pelvis	7	10.7	1.98	12.5	2.34	3	3.9	1.00	4.8	1.24
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	3.3	0.99	3.5	1.10	4	4.1	1.02	4.4	1.10
Brain	2	3.0	0.96	3.2	1.06	3	3.5	0.95	3.7	1.02
Endocrine System	5	6.9	1.44	8.1	1.75	22	23.8	2.34	25.9	2.60
Thyroid gland	5	6.4	1.40	7.7	1.73	22	23.6	2.33	25.7	2.59
Lymphomas	9	15.0	2.52	17.3	2.97	7	8.9	1.65	10.3	1.91
Hodgkin Lymphoma	2	2.0	0.82	2.3	0.93	1	1.3	0.50	1.5	0.60
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	3.4	1.23	4.1	1.47	2	2.4	0.91	2.7	1.04
Leukemias	5	8.0	1.78	8.8	2.00	3	3.5	0.97	4.0	1.11
Acute lymphocytic	1	1.6	0.61	1.6	0.65	-	-	-	-	-
Chronic lymphocytic	1	2.2	0.94	2.5	1.08	-	-	-	-	-
Acute myeloid	-	-	-	-	-	2	2.2	0.81	2.3	0.86
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	9.4	1.90	11.0	2.20	6	9.5	1.88	10.9	2.16
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	6.2	1.50	7.2	1.78	8	10.3	1.75	11.8	2.02
Breast (<i>in situ</i>)	-	-	-	-	-	26	31.2	2.82	36.1	3.28

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11	145.8	21.34	172.5	24.77	13	132.4	17.08	160.6	20.52
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	25.8	8.27	33.0	10.34	2	22.8	7.52	26.9	8.73
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	23.5	8.40	28.7	9.80	2	20.5	6.65	26.2	8.35
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	23.5	8.40	28.7	9.80	2	20.5	6.65	26.2	8.35
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	4	46.8	10.36	57.1	12.55
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	36.3	12.36	42.1	14.18	-	-	-	-	-
Prostate	2	34.1	12.18	40.3	14.06	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	1	17.1	7.25	19.3	8.21	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	2	14.7	5.22	18.9	6.76

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	697	462.0	8.78	550.7	10.26	844	424.4	6.92	492.8	8.04
Oral Cavity & Pharynx	24	14.9	1.50	17.9	1.77	13	6.5	0.86	7.3	0.98
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.1	0.70	3.8	0.82	3	1.8	0.47	1.9	0.51
Major salivary gland	2	1.3	0.50	1.4	0.56	3	1.4	0.37	1.4	0.41
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	3	1.9	0.54	2.4	0.66	2	1.1	0.37	1.2	0.41
Nasopharynx	2	0.7	0.28	0.8	0.32	-	-	-	-	-
Oropharynx	2	1.8	0.56	2.0	0.64	-	-	-	-	-
Hypopharynx	3	1.9	0.55	2.3	0.63	-	-	-	-	-
Digestive System	184	121.4	4.46	146.1	5.23	142	77.0	3.06	90.5	3.58
Esophagus	7	5.4	0.98	6.4	1.14	3	2.4	0.59	2.7	0.67
Stomach	24	16.7	1.70	19.8	1.99	16	8.6	1.01	10.1	1.18
Small intestine	4	2.8	0.71	3.0	0.76	5	2.5	0.53	2.9	0.63
Colon excl. rectum	48	33.7	2.45	39.3	2.82	45	23.8	1.68	27.4	1.94
Rectum & rectosigmoid	26	14.7	1.44	17.9	1.71	19	9.4	1.00	11.5	1.22
Anus, anal canal & anorectum	3	2.1	0.56	2.5	0.68	6	3.1	0.62	3.6	0.72
Liver	43	26.2	1.93	33.5	2.39	12	6.9	0.94	8.3	1.11
Gallbladder	2	1.7	0.60	1.9	0.66	4	2.1	0.49	2.5	0.58
Pancreas	16	11.3	1.38	13.5	1.61	22	12.2	1.25	14.6	1.48
Respiratory System	83	62.7	3.39	74.2	3.90	71	42.1	2.35	50.1	2.74
Larynx	11	7.3	1.06	8.7	1.21	2	0.9	0.29	1.1	0.35
Lung & bronchus	68	53.8	3.18	63.8	3.68	67	40.3	2.31	47.9	2.69
Bones & Joints	2	0.8	0.24	0.9	0.27	3	1.0	0.28	0.9	0.29
Soft Tissue (incl. heart)	8	3.6	0.62	4.0	0.73	4	1.7	0.39	2.0	0.47
Skin (excl. basal & sq.)	-	-	-	-	-	13	6.6	0.89	7.5	1.01
Melanomas of the skin	9	6.5	1.12	7.9	1.34	10	5.0	0.77	5.7	0.88
Breast (excl. <i>in situ</i>)	-	-	-	-	-	252	121.6	3.60	142.3	4.21
Female Genital System	-	-	-	-	-	109	52.0	2.35	60.2	2.72
Cervix uteri	-	-	-	-	-	22	9.3	0.93	9.7	1.00
Uterus Corpus	-	-	-	-	-	59	28.5	1.75	34.0	2.07
Uterus, NOS ¹	-	-	-	-	-	2	0.9	0.33	1.1	0.37
Ovary	-	-	-	-	-	19	9.1	1.00	10.4	1.14
Male Genital System	169	109.9	4.15	134.9	4.94	-	-	-	-	-
Prostate	153	103.5	4.08	128.2	4.87	-	-	-	-	-
Testis	13	4.6	0.59	4.4	0.57	-	-	-	-	-
Penis	3	1.8	0.52	2.2	0.64	-	-	-	-	-
Urinary System	68	49.7	3.01	58.6	3.48	40	21.2	1.59	25.1	1.88
Bladder (incl. <i>in situ</i>)	35	29.8	2.47	34.7	2.82	14	8.5	1.07	10.0	1.25
Kidney & renal pelvis	31	18.2	1.62	22.0	1.93	25	12.0	1.14	14.3	1.36
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.7	0.25	0.8	0.32	-	-	-	-	-
Brain & Other CNS ¹	13	6.7	0.96	7.5	1.10	13	6.0	0.82	6.5	0.89
Brain	13	6.3	0.91	7.1	1.05	12	5.7	0.80	6.1	0.88
Endocrine System	18	8.1	0.93	9.2	1.09	80	32.1	1.66	34.8	1.85
Thyroid gland	16	7.4	0.90	8.4	1.05	79	31.7	1.65	34.5	1.84
Lymphomas	48	27.5	2.07	31.6	2.38	46	23.6	1.65	27.5	1.92
Hodgkin Lymphoma	10	3.9	0.62	4.1	0.67	7	2.8	0.50	2.9	0.54
Non-Hodgkin Lymphoma	38	23.6	1.97	27.5	2.29	39	20.9	1.57	24.6	1.84
Multiple Myeloma	14	10.5	1.40	12.5	1.64	14	8.1	1.03	9.4	1.17
Leukemias	25	14.2	1.50	16.2	1.72	23	10.8	1.08	12.2	1.24
Acute lymphocytic	6	2.2	0.48	2.1	0.50	7	2.4	0.45	2.5	0.48
Chronic lymphocytic	4	2.8	0.69	3.2	0.80	4	2.5	0.57	3.1	0.67
Acute myeloid	9	5.5	0.97	6.5	1.12	6	3.1	0.60	3.5	0.68
Chronic myeloid	4	2.0	0.54	2.3	0.64	3	1.3	0.32	1.6	0.41
Other leukemias	3	1.7	0.54	2.0	0.64	3	1.4	0.41	1.6	0.46
Mesothelioma	2	2.3	0.76	2.6	0.86	-	-	-	-	-
Kaposi Sarcoma	2	1.2	0.42	1.2	0.43	-	-	-	-	-
Ill-defined & Unknown	24	20.0	2.04	23.1	2.34	22	13.4	1.36	15.5	1.56
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	7.3	1.02	8.5	1.18	35	17.0	1.36	19.4	1.57
Breast (<i>in situ</i>)	-	-	-	-	-	82	37.8	1.94	44.3	2.28

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

CONNECTICUT

II-98 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,526	507.8	2.55	599.7	2.93	8,720	458.9	2.36	532.9	2.64
Oral Cavity & Pharynx	311	18.0	0.47	21.9	0.56	147	7.5	0.30	8.8	0.34
Lip	8	0.5	0.08	0.6	0.09	6	0.3	0.06	0.4	0.07
Tongue	111	6.3	0.28	7.8	0.33	48	2.5	0.18	3.0	0.20
Major salivary gland	23	1.4	0.14	1.6	0.15	21	1.2	0.13	1.3	0.14
Floor of mouth	14	0.8	0.10	1.0	0.12	7	0.3	0.06	0.4	0.07
Gum & other mouth	34	2.0	0.16	2.4	0.19	32	1.4	0.12	1.7	0.14
Nasopharynx	8	0.5	0.08	0.6	0.09	4	0.2	0.05	0.2	0.05
Oropharynx	14	0.8	0.10	1.0	0.12	5	0.3	0.05	0.3	0.06
Hypopharynx	19	1.1	0.11	1.3	0.14	5	0.2	0.05	0.3	0.06
Digestive System	1,551	92.3	1.08	109.3	1.25	1,249	60.2	0.81	70.6	0.92
Esophagus	148	8.6	0.33	10.3	0.38	41	1.9	0.14	2.3	0.16
Stomach	166	9.8	0.35	11.7	0.41	90	4.4	0.22	5.1	0.25
Small intestine	40	2.5	0.18	2.9	0.21	41	2.1	0.16	2.5	0.18
Colon excl. rectum	430	26.3	0.59	30.7	0.67	464	22.2	0.49	25.7	0.56
Rectum & rectosigmoid	205	12.8	0.42	14.9	0.47	155	8.0	0.31	9.6	0.35
Anus, anal canal & anorectum	25	1.5	0.14	1.8	0.16	43	2.1	0.15	2.6	0.18
Liver	165	9.0	0.32	11.3	0.40	46	2.2	0.15	2.6	0.18
Gallbladder	9	0.6	0.09	0.7	0.10	20	0.9	0.10	1.1	0.11
Pancreas	269	15.7	0.44	18.7	0.51	255	11.7	0.34	13.8	0.40
Respiratory System	1,238	72.5	0.94	85.9	1.10	1,268	60.8	0.79	71.8	0.92
Larynx	96	5.4	0.26	6.6	0.31	28	1.3	0.12	1.6	0.14
Lung & bronchus	1,125	65.9	0.90	78.0	1.05	1,229	58.8	0.77	69.4	0.90
Bones & Joints	16	1.3	0.15	1.3	0.15	11	0.8	0.12	0.8	0.11
Soft Tissue (incl. heart)	63	4.1	0.25	4.7	0.27	50	2.9	0.20	3.2	0.21
Skin (excl. basal & sq.)	530	32.7	0.66	38.0	0.75	368	20.9	0.53	23.6	0.57
Melanomas of the skin	488	30.1	0.63	35.0	0.72	347	19.9	0.52	22.4	0.56
Breast (excl. <i>in situ</i>)	25	1.4	0.13	1.7	0.16	2,650	145.0	1.35	169.2	1.51
Female Genital System	-	-	-	-	-	987	51.1	0.77	61.0	0.89
Cervix uteri	-	-	-	-	-	78	5.6	0.31	5.9	0.31
Uterus Corpus	-	-	-	-	-	578	28.8	0.56	35.2	0.67
Uterus, NOS ¹	-	-	-	-	-	17	0.8	0.09	0.9	0.11
Ovary	-	-	-	-	-	212	10.9	0.36	13.0	0.41
Male Genital System	2,040	115.0	1.18	139.8	1.39	-	-	-	-	-
Prostate	1,933	105.7	1.10	130.3	1.33	-	-	-	-	-
Testis	89	8.2	0.40	8.2	0.39	-	-	-	-	-
Penis	13	0.8	0.10	1.0	0.12	-	-	-	-	-
Urinary System	1,190	71.0	0.95	83.5	1.09	477	23.4	0.51	27.3	0.57
Bladder (incl. <i>in situ</i>)	789	47.1	0.77	55.2	0.88	260	12.1	0.35	14.2	0.40
Kidney & renal pelvis	373	22.2	0.54	26.4	0.62	197	10.4	0.35	12.1	0.40
Ureter	15	0.9	0.11	1.1	0.12	12	0.5	0.07	0.6	0.08
Eye & Orbit	15	1.0	0.12	1.1	0.13	17	1.1	0.13	1.2	0.13
Brain & Other CNS ¹	131	8.8	0.36	9.8	0.39	98	6.2	0.31	6.7	0.31
Brain	126	8.4	0.35	9.4	0.38	93	5.7	0.29	6.2	0.30
Endocrine System	165	11.5	0.43	12.8	0.45	393	28.5	0.70	30.5	0.71
Thyroid gland	153	10.6	0.41	11.8	0.44	382	27.8	0.69	29.7	0.70
Lymphomas	481	30.8	0.66	35.1	0.72	384	20.1	0.49	23.2	0.55
Hodgkin Lymphoma	49	3.9	0.26	4.0	0.26	37	2.9	0.23	3.0	0.23
Non-Hodgkin Lymphoma	433	26.9	0.60	31.1	0.67	348	17.2	0.44	20.2	0.50
Multiple Myeloma	143	8.5	0.33	10.1	0.38	102	5.0	0.23	6.0	0.27
Leukemias	290	18.3	0.50	20.8	0.55	232	12.1	0.39	13.7	0.42
Acute lymphocytic	19	1.6	0.18	1.6	0.16	17	1.5	0.17	1.4	0.15
Chronic lymphocytic	127	7.4	0.30	8.9	0.35	96	4.4	0.21	5.3	0.25
Acute myeloid	78	4.9	0.26	5.5	0.28	68	3.6	0.21	4.1	0.23
Chronic myeloid	33	2.2	0.18	2.5	0.19	29	1.6	0.14	1.8	0.15
Other leukemias	33	2.2	0.18	2.4	0.19	21	1.1	0.11	1.2	0.13
Mesothelioma	29	1.7	0.15	2.0	0.17	6	0.3	0.06	0.4	0.07
Kaposi Sarcoma	5	0.4	0.08	0.4	0.08	2	0.0	0.02	0.1	0.02
Ill-defined & Unknown	302	18.5	0.49	21.4	0.55	280	13.0	0.37	15.0	0.42
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	125	8.5	0.36	9.4	0.38	247	14.0	0.44	15.9	0.47
Breast (<i>in situ</i>)	4	0.2	0.06	0.3	0.07	763	45.0	0.78	52.0	0.86

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Connecticut, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	792	533.1	8.99	642.2	10.60	797	399.0	6.43	468.0	7.45
Oral Cavity & Pharynx	23	14.4	1.43	17.7	1.74	10	4.8	0.70	5.6	0.81
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	2.7	0.60	3.4	0.74	2	1.0	0.33	1.2	0.39
Major salivary gland	3	1.8	0.53	1.9	0.58	2	1.1	0.33	1.2	0.37
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	3	1.7	0.49	2.0	0.58	2	0.9	0.31	1.0	0.35
Nasopharynx	2	1.0	0.37	1.2	0.44	-	-	-	-	-
Oropharynx	2	1.0	0.34	1.3	0.45	-	-	-	-	-
Hypopharynx	3	1.9	0.56	2.3	0.66	-	-	-	-	-
Digestive System	171	117.3	4.27	142.0	5.06	155	77.7	2.84	92.9	3.35
Esophagus	11	7.5	1.08	9.2	1.30	4	2.2	0.47	2.6	0.56
Stomach	24	19.0	1.84	22.2	2.12	18	9.3	1.01	10.7	1.14
Small intestine	9	5.7	0.91	6.8	1.06	7	3.6	0.60	4.3	0.71
Colon excl. rectum	45	31.4	2.24	37.4	2.63	51	25.4	1.62	30.2	1.91
Rectum & rectosigmoid	24	15.7	1.54	18.7	1.80	17	8.4	0.94	9.8	1.08
Anus, anal canal & anorectum	1	0.7	0.29	1.0	0.37	4	2.0	0.45	2.4	0.52
Liver	26	15.7	1.44	20.3	1.82	9	4.0	0.60	5.3	0.79
Gallbladder	2	1.4	0.47	1.8	0.59	5	2.5	0.51	3.2	0.63
Pancreas	24	16.4	1.58	19.9	1.88	28	14.2	1.23	16.9	1.44
Respiratory System	112	83.7	3.75	99.0	4.34	95	48.0	2.24	57.4	2.65
Larynx	12	8.0	1.07	10.0	1.30	3	1.5	0.38	2.0	0.49
Lung & bronchus	98	74.6	3.57	87.9	4.12	90	45.5	2.19	54.5	2.58
Bones & Joints	1	0.6	0.26	0.6	0.26	3	1.3	0.37	1.3	0.37
Soft Tissue (incl. heart)	7	4.5	0.78	4.9	0.87	6	3.1	0.56	3.5	0.63
Skin (excl. basal & sq.)	3	1.8	0.48	2.1	0.56	4	2.1	0.48	2.3	0.52
Melanomas of the skin	2	1.2	0.41	1.3	0.45	2	1.1	0.36	1.2	0.38
Breast (excl. <i>in situ</i>)	4	2.5	0.64	3.0	0.74	252	125.0	3.58	146.0	4.13
Female Genital System	-	-	-	-	-	102	49.6	2.23	59.9	2.66
Cervix uteri	-	-	-	-	-	15	7.4	0.88	8.3	0.98
Uterus Corpus	-	-	-	-	-	57	26.9	1.62	33.6	2.00
Uterus, NOS ¹	-	-	-	-	-	4	1.9	0.44	2.3	0.52
Ovary	-	-	-	-	-	17	8.6	0.94	9.9	1.08
Male Genital System	277	176.5	4.99	220.3	6.07	-	-	-	-	-
Prostate	272	173.7	4.96	217.2	6.03	-	-	-	-	-
Testis	2	1.3	0.37	1.3	0.39	-	-	-	-	-
Penis	2	1.2	0.46	1.4	0.52	-	-	-	-	-
Urinary System	72	50.7	2.84	60.2	3.32	37	19.1	1.43	21.7	1.61
Bladder (incl. <i>in situ</i>)	28	23.0	2.08	27.0	2.41	15	7.9	0.92	9.3	1.07
Kidney & renal pelvis	42	25.7	1.84	30.8	2.17	20	10.4	1.06	11.5	1.16
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	9	5.6	0.86	6.0	0.92	7	3.4	0.59	3.8	0.66
Brain	8	5.1	0.81	5.4	0.87	6	3.1	0.57	3.5	0.64
Endocrine System	11	6.8	0.95	7.6	1.05	36	18.2	1.37	20.2	1.50
Thyroid gland	8	4.9	0.77	5.4	0.85	34	17.3	1.34	19.0	1.46
Lymphomas	34	22.0	1.79	24.9	2.01	27	13.8	1.21	15.4	1.34
Hodgkin Lymphoma	7	4.4	0.79	4.6	0.84	5	2.6	0.52	2.6	0.52
Non-Hodgkin Lymphoma	27	17.6	1.61	20.3	1.82	22	11.1	1.09	12.8	1.24
Multiple Myeloma	27	18.0	1.62	21.3	1.88	24	12.0	1.12	14.3	1.31
Leukemias	18	13.2	1.46	14.7	1.64	18	9.4	1.01	10.5	1.12
Acute lymphocytic	2	1.2	0.35	1.3	0.39	2	0.8	0.30	0.8	0.29
Chronic lymphocytic	5	3.6	0.79	4.1	0.89	4	2.2	0.48	2.6	0.56
Acute myeloid	6	4.5	0.87	5.0	0.97	5	2.9	0.57	3.2	0.63
Chronic myeloid	4	2.6	0.66	3.0	0.74	5	2.5	0.54	2.7	0.57
Other leukemias	2	1.3	0.47	1.3	0.49	2	0.9	0.31	1.1	0.38
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	0.8	0.32	0.9	0.35	-	-	-	-	-
Ill-defined & Unknown	20	14.5	1.53	16.8	1.75	21	10.9	1.08	12.7	1.26
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	5.8	0.90	6.8	1.05	20	9.8	1.00	11.5	1.15
Breast (<i>in situ</i>)	-	-	-	-	-	83	40.2	2.00	47.9	2.36

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


CONNECTICUT

II-100 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	923,638	932,596	941,413	949,216	957,078
White	666,100	670,059	673,247	676,272	679,733
Black	214,629	218,157	221,959	225,576	228,990
American Indian/Alaskan Native (AI/AN)	6,612	6,651	6,694	6,753	6,959
Asian/Pacific Islander (API)	36,297	37,729	39,513	40,615	41,396


All Races Population 2013-2017: 4,703,941
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	79,554	81,508	83,596	85,789	88,702
Non-Hispanic White	601,361	603,718	605,286	606,515	607,622
Non-Hispanic Black	204,266	207,510	210,990	214,322	217,425

Hispanic/Latino Population, Census 2010: 73,221
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

DELAWARE CANCER REGISTRY

Initial Operation: 1972
Population-based Data Available: 1980
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.5	109.8	112.4	106.0	98.0
Missing Race	0.3	0.1	0.1	0.0	0.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.1	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.7	1.0	1.1	0.9	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Prostate	98.0
Oral Cavity & Pharynx	98.9	Testis	100.0
Esophagus	97.6	Bladder (incl. <i>in situ</i>)	99.0
Stomach	95.6	Kidney & Renal Pelvis	88.9
Colon & Rectum	96.8	Brain & Other CNS ¹	84.3
Liver	54.7	Thyroid	99.6
Pancreas	86.1	Hodgkin Lymphoma	99.3
Lung & Bronchus	88.7	Non-Hodgkin Lymphoma	97.1
Melanomas of the Skin	99.7	Multiple Myeloma	88.5
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	87.2
Cervix uteri	98.5	Brain & Other CNS ¹ <i>non-malig</i>	56.4
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	99.9
Ovary	93.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,982	537.5	4.52	639.0	5.30	2,852	453.1	3.94	528.0	4.48
Oral Cavity & Pharynx	110	19.5	0.86	23.9	1.03	42	6.7	0.48	7.7	0.54
Lip	2	0.3	0.12	0.4	0.13	-	-	-	-	-
Tongue	36	6.3	0.49	7.7	0.58	11	1.7	0.25	2.0	0.28
Major salivary gland	10	1.9	0.28	2.2	0.33	9	1.5	0.24	1.7	0.25
Floor of mouth	6	0.9	0.17	1.2	0.22	2	0.3	0.10	0.4	0.12
Gum & other mouth	12	2.3	0.30	2.7	0.35	7	1.2	0.21	1.4	0.23
Nasopharynx	3	0.6	0.15	0.6	0.17	-	-	-	-	-
Oropharynx	5	0.9	0.18	1.1	0.21	2	0.3	0.10	0.4	0.12
Hypopharynx	6	1.0	0.19	1.3	0.23	1	0.2	0.09	0.2	0.09
Digestive System	559	101.7	1.97	121.5	2.33	428	65.7	1.46	77.3	1.69
Esophagus	49	9.0	0.59	10.6	0.69	10	1.6	0.22	1.8	0.25
Stomach	48	8.8	0.59	10.4	0.68	30	4.5	0.38	5.4	0.45
Small intestine	18	3.2	0.35	3.9	0.41	18	3.0	0.33	3.4	0.36
Colon excl. rectum	167	31.3	1.11	36.6	1.28	157	24.6	0.91	28.4	1.03
Rectum & rectosigmoid	68	12.8	0.71	15.2	0.83	51	8.1	0.52	9.6	0.61
Anus, anal canal & anorectum	8	1.4	0.24	1.7	0.28	15	2.3	0.27	2.8	0.33
Liver	73	12.3	0.66	15.6	0.82	25	3.6	0.33	4.4	0.40
Gallbladder	5	0.9	0.19	1.1	0.22	10	1.4	0.21	1.7	0.25
Pancreas	94	16.8	0.79	20.2	0.95	81	12.1	0.61	14.3	0.72
Respiratory System	456	82.2	1.76	97.2	2.06	430	63.0	1.38	75.3	1.64
Larynx	33	5.7	0.45	7.0	0.55	13	1.8	0.23	2.3	0.29
Lung & bronchus	416	75.3	1.69	88.7	1.97	415	60.8	1.36	72.5	1.61
Bones & Joints	4	0.9	0.20	0.9	0.19	4	0.8	0.19	0.8	0.18
Soft Tissue (incl. heart)	17	3.3	0.37	3.7	0.41	17	3.0	0.35	3.3	0.36
Skin (excl. basal & sq.)	221	41.2	1.27	48.1	1.47	143	23.6	0.92	27.1	1.03
Melanomas of the skin	209	38.8	1.24	45.3	1.42	135	22.3	0.90	25.6	1.00
Breast (excl. <i>in situ</i>)	7	1.2	0.21	1.5	0.25	836	134.7	2.17	157.8	2.48
Female Genital System	-	-	-	-	-	342	54.3	1.37	64.3	1.58
Cervix uteri	-	-	-	-	-	40	7.8	0.58	8.2	0.59
Uterus Corpus	-	-	-	-	-	190	28.9	0.97	35.2	1.16
Uterus, NOS ¹	-	-	-	-	-	11	1.7	0.24	2.1	0.28
Ovary	-	-	-	-	-	69	10.9	0.61	12.8	0.70
Male Genital System	776	130.8	2.15	160.9	2.61	-	-	-	-	-
Prostate	748	124.5	2.08	154.4	2.55	-	-	-	-	-
Testis	22	5.2	0.50	5.2	0.49	-	-	-	-	-
Penis	4	0.8	0.18	0.9	0.20	-	-	-	-	-
Urinary System	364	67.5	1.62	79.2	1.88	143	21.9	0.84	25.5	0.97
Bladder (incl. <i>in situ</i>)	226	42.2	1.28	49.5	1.49	66	9.7	0.54	11.4	0.63
Kidney & renal pelvis	129	23.5	0.95	27.6	1.10	74	11.7	0.63	13.6	0.72
Ureter	5	1.1	0.21	1.2	0.24	3	0.4	0.11	0.5	0.13
Eye & Orbit	-	-	-	-	-	2	0.4	0.13	0.3	0.12
Brain & Other CNS ¹	36	7.1	0.54	7.9	0.59	32	5.7	0.47	6.2	0.49
Brain	33	6.4	0.51	7.2	0.57	29	5.1	0.44	5.6	0.47
Endocrine System	41	7.9	0.57	8.9	0.63	131	26.0	1.06	27.7	1.09
Thyroid gland	35	6.8	0.53	7.8	0.59	127	25.2	1.04	26.9	1.08
Lymphomas	145	27.8	1.06	31.7	1.19	121	19.4	0.82	22.2	0.92
Hodgkin Lymphoma	16	3.4	0.39	3.5	0.39	12	2.6	0.34	2.6	0.33
Non-Hodgkin Lymphoma	129	24.5	0.99	28.3	1.13	108	16.8	0.75	19.7	0.85
Multiple Myeloma	47	8.6	0.57	10.1	0.66	41	6.2	0.44	7.4	0.52
Leukemias	91	17.3	0.84	19.6	0.93	57	9.1	0.56	10.4	0.62
Acute lymphocytic	8	1.8	0.29	1.7	0.27	-	-	-	-	-
Chronic lymphocytic	30	5.5	0.46	6.6	0.54	19	2.8	0.29	3.3	0.35
Acute myeloid	28	5.3	0.47	6.0	0.52	21	3.3	0.33	3.7	0.37
Chronic myeloid	11	2.2	0.31	2.5	0.33	7	1.0	0.19	1.3	0.22
Other leukemias	13	2.4	0.31	2.8	0.36	5	0.7	0.15	0.8	0.18
Mesothelioma	12	2.2	0.30	2.5	0.33	2	0.3	0.10	0.4	0.12
Kaposi Sarcoma	3	0.6	0.16	0.6	0.17	-	-	-	-	-
Ill-defined & Unknown	93	17.6	0.83	20.5	0.96	80	12.2	0.62	14.2	0.72
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	35	6.5	0.51	7.5	0.58	66	11.4	0.66	12.8	0.71
Breast (<i>in situ</i>)	-	-	-	-	-	199	32.8	1.09	38.8	1.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,403	537.1	5.06	636.3	5.89	2,270	462.8	4.61	538.8	5.20
Oral Cavity & Pharynx	95	21.2	1.01	26.3	1.22	35	6.8	0.55	8.1	0.63
Lip	2	0.4	0.15	0.5	0.16	-	-	-	-	-
Tongue	32	7.2	0.59	8.7	0.70	9	1.9	0.29	2.2	0.33
Major salivary gland	8	2.0	0.32	2.3	0.37	7	1.3	0.24	1.5	0.27
Floor of mouth	5	1.0	0.20	1.3	0.26	2	0.3	0.13	0.4	0.15
Gum & other mouth	10	2.3	0.32	2.8	0.39	6	1.3	0.25	1.5	0.27
Nasopharynx	1	0.3	0.13	0.4	0.16	-	-	-	-	-
Oropharynx	5	1.0	0.22	1.2	0.26	2	0.3	0.11	0.4	0.14
Hypopharynx	6	1.1	0.22	1.4	0.27	-	-	-	-	-
Digestive System	436	98.4	2.17	117.3	2.55	324	63.2	1.64	73.7	1.88
Esophagus	44	9.9	0.68	11.7	0.80	10	1.8	0.27	2.1	0.31
Stomach	36	8.1	0.62	9.6	0.73	21	4.2	0.43	4.8	0.48
Small intestine	14	2.9	0.37	3.6	0.44	13	2.7	0.36	3.1	0.40
Colon excl. rectum	131	30.4	1.23	35.5	1.41	120	23.8	1.02	27.3	1.14
Rectum & rectosigmoid	54	12.7	0.81	15.1	0.94	41	8.4	0.62	9.9	0.71
Anus, anal canal & anorectum	6	1.4	0.26	1.6	0.30	12	2.4	0.32	3.0	0.39
Liver	51	10.8	0.69	13.6	0.86	16	3.0	0.35	3.6	0.41
Gallbladder	4	0.8	0.20	0.9	0.23	7	1.2	0.23	1.5	0.26
Pancreas	75	16.4	0.86	19.7	1.03	61	11.2	0.66	13.1	0.77
Respiratory System	381	83.9	1.97	99.3	2.30	357	65.1	1.58	77.9	1.88
Larynx	27	5.8	0.51	7.2	0.63	10	1.8	0.26	2.3	0.33
Lung & bronchus	349	76.8	1.88	90.6	2.20	344	62.8	1.55	75.1	1.84
Bones & Joints	3	1.0	0.25	1.0	0.25	3	1.0	0.25	1.0	0.24
Soft Tissue (incl. heart)	13	3.2	0.42	3.6	0.45	12	2.8	0.39	3.1	0.41
Skin (excl. basal & sq.)	218	50.3	1.58	58.6	1.81	136	29.7	1.22	34.0	1.34
Melanomas of the skin	207	47.8	1.54	55.6	1.76	130	28.5	1.20	32.5	1.31
Breast (excl. <i>in situ</i>)	5	1.1	0.22	1.4	0.27	648	134.3	2.51	157.4	2.85
Female Genital System	-	-	-	-	-	271	55.7	1.61	66.1	1.85
Cervix uteri	-	-	-	-	-	29	7.8	0.69	8.3	0.71
Uterus Corpus	-	-	-	-	-	153	30.2	1.16	36.9	1.37
Uterus, NOS ¹	-	-	-	-	-	6	1.2	0.23	1.4	0.26
Ovary	-	-	-	-	-	57	11.6	0.73	13.6	0.83
Male Genital System	556	116.3	2.27	141.8	2.73	-	-	-	-	-
Prostate	530	108.3	2.15	133.7	2.63	-	-	-	-	-
Testis	21	6.9	0.69	6.9	0.68	-	-	-	-	-
Penis	4	0.8	0.21	1.0	0.23	-	-	-	-	-
Urinary System	312	70.8	1.84	82.9	2.13	116	22.6	0.99	26.2	1.12
Bladder (incl. <i>in situ</i>)	203	45.8	1.47	53.7	1.71	56	10.1	0.62	11.9	0.73
Kidney & renal pelvis	101	23.0	1.07	27.0	1.22	57	11.9	0.75	13.7	0.83
Ureter	5	1.2	0.24	1.4	0.28	3	0.5	0.13	0.5	0.15
Eye & Orbit	-	-	-	-	-	1	0.5	0.19	0.4	0.17
Brain & Other CNS ¹	32	8.2	0.68	9.1	0.73	26	6.1	0.56	6.6	0.59
Brain	30	7.6	0.65	8.4	0.70	25	5.5	0.53	6.1	0.57
Endocrine System	32	8.1	0.68	9.2	0.74	100	27.1	1.29	29.0	1.33
Thyroid gland	28	7.2	0.64	8.3	0.70	96	26.3	1.27	28.1	1.31
Lymphomas	120	28.4	1.20	32.6	1.35	100	20.3	0.97	23.3	1.07
Hodgkin Lymphoma	10	3.0	0.43	3.0	0.43	9	2.8	0.43	2.8	0.42
Non-Hodgkin Lymphoma	110	25.4	1.12	29.6	1.28	90	17.5	0.86	20.5	0.99
Multiple Myeloma	32	7.3	0.60	8.5	0.68	26	4.8	0.43	5.7	0.51
Leukemias	77	18.2	0.97	20.7	1.08	46	9.6	0.68	10.7	0.73
Acute lymphocytic	6	1.9	0.35	1.8	0.33	4	1.3	0.31	1.1	0.26
Chronic lymphocytic	27	6.0	0.53	7.2	0.63	16	2.9	0.34	3.4	0.40
Acute myeloid	23	5.5	0.52	6.2	0.58	17	3.5	0.40	3.9	0.44
Chronic myeloid	9	2.2	0.35	2.5	0.37	5	1.1	0.23	1.3	0.27
Other leukemias	11	2.6	0.37	3.0	0.42	4	0.8	0.18	0.9	0.21
Mesothelioma	11	2.5	0.34	2.7	0.38	2	0.4	0.13	0.5	0.16
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	78	17.9	0.93	20.9	1.07	68	12.8	0.73	15.0	0.83
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	26	6.1	0.56	7.1	0.64	50	11.6	0.78	12.9	0.84
Breast (<i>in situ</i>)	-	-	-	-	-	149	32.6	1.28	38.4	1.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	504	558.0	11.78	673.2	13.90	506	431.3	8.82	504.9	10.14
Oral Cavity & Pharynx	10	11.2	1.71	12.9	1.94	5	4.9	0.97	5.2	1.02
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.8	0.85	3.3	1.01	1	1.1	0.47	1.2	0.48
Major salivary gland	-	-	-	-	-	2	2.1	0.64	2.1	0.65
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	105	117.7	5.45	142.8	6.46	94	80.1	3.81	96.3	4.49
Esophagus	3	4.2	1.09	5.0	1.29	-	-	-	-	-
Stomach	9	10.5	1.65	12.7	1.96	7	5.9	1.03	7.3	1.24
Small intestine	4	4.7	1.09	5.6	1.28	5	4.5	0.92	5.2	1.05
Colon excl. rectum	33	39.5	3.27	46.8	3.81	34	29.8	2.35	35.0	2.70
Rectum & rectosigmoid	12	13.3	1.80	15.9	2.10	9	7.5	1.14	9.1	1.36
Anus, anal canal & anorectum	2	1.8	0.61	2.2	0.73	2	2.0	0.58	2.4	0.69
Liver	19	18.2	1.95	23.8	2.48	8	6.3	1.04	8.0	1.29
Gallbladder	1	2.0	0.76	2.1	0.79	2	1.8	0.55	2.3	0.70
Pancreas	16	17.6	2.12	21.5	2.52	19	16.8	1.77	20.3	2.09
Respiratory System	68	82.2	4.74	96.6	5.46	68	59.7	3.34	70.5	3.87
Larynx	5	6.2	1.26	7.4	1.46	2	1.5	0.48	1.9	0.62
Lung & bronchus	61	74.2	4.51	87.2	5.20	66	58.1	3.31	68.3	3.81
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.0	1.02	4.5	1.15	4	3.6	0.79	3.9	0.85
Skin (excl. basal & sq.)	2	2.1	0.80	2.5	0.94	3	2.9	0.72	3.3	0.81
Melanomas of the skin	-	-	-	-	-	2	1.5	0.52	1.7	0.58
Breast (excl. <i>in situ</i>)	2	2.1	0.77	2.4	0.87	163	135.6	4.88	159.4	5.62
Female Genital System	-	-	-	-	-	61	52.1	3.06	61.0	3.51
Cervix uteri	-	-	-	-	-	10	8.9	1.31	9.3	1.34
Uterus Corpus	-	-	-	-	-	32	26.4	2.16	31.9	2.55
Uterus, NOS ¹	-	-	-	-	-	5	3.5	0.72	4.5	0.92
Ovary	-	-	-	-	-	10	8.1	1.20	9.6	1.40
Male Genital System	200	204.6	6.79	256.1	8.27	-	-	-	-	-
Prostate	198	202.8	6.75	254.0	8.24	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	46	54.5	3.82	64.6	4.43	26	22.0	2.00	26.1	2.33
Bladder (incl. <i>in situ</i>)	20	25.9	2.77	30.8	3.24	9	8.4	1.25	9.8	1.45
Kidney & renal pelvis	26	27.7	2.56	32.7	2.96	16	13.3	1.54	15.8	1.79
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	2.8	0.71	3.1	0.79	5	4.4	0.88	4.8	0.96
Brain	2	1.9	0.57	2.2	0.69	4	3.7	0.81	4.0	0.88
Endocrine System	6	6.1	1.15	6.9	1.30	22	19.2	1.88	20.1	1.93
Thyroid gland	4	4.4	0.97	5.0	1.09	21	18.5	1.84	19.5	1.91
Lymphomas	19	21.4	2.29	23.4	2.47	18	15.4	1.66	17.5	1.87
Hodgkin Lymphoma	4	4.0	0.92	4.2	0.97	3	2.4	0.65	2.5	0.66
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	14	15.4	1.94	18.5	2.28	14	12.3	1.50	14.7	1.75
Leukemias	11	13.0	1.86	14.5	2.09	10	8.2	1.20	9.6	1.40
Acute lymphocytic	1	1.1	0.47	1.0	0.40	2	1.6	0.51	1.6	0.51
Chronic lymphocytic	3	3.3	0.99	4.0	1.17	3	2.6	0.68	3.1	0.80
Acute myeloid	3	3.9	1.05	4.4	1.18	3	2.6	0.71	3.1	0.84
Chronic myeloid	2	2.3	0.76	2.5	0.82	1	0.9	0.36	1.3	0.50
Other leukemias	2	2.3	0.76	2.7	0.87	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	1.6	0.58	1.7	0.61	-	-	-	-	-
Ill-defined & Unknown	12	17.3	2.37	20.6	2.80	11	10.4	1.42	12.0	1.62
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	7.4	1.31	8.1	1.42	13	11.2	1.42	12.9	1.60
Breast (<i>in situ</i>)	-	-	-	-	-	44	36.2	2.51	42.9	2.91

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	40	267.3	19.74	308.3	22.89	46	245.2	16.64	280.6	19.13
Oral Cavity & Pharynx	4	22.9	5.33	27.2	6.36	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	8.3	3.18	10.3	3.97	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	10	69.1	10.08	79.8	11.69	6	31.8	6.21	37.9	7.30
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	10.7	3.83	12.0	4.28	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	8.7	3.33	9.2	3.55	-	-	-	-	-
Rectum & rectosigmoid	2	13.3	4.74	16.0	5.70	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	11.9	3.81	13.8	4.46	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	11.5	4.33	13.4	5.09	1	8.7	3.41	10.6	4.06
Respiratory System	4	32.1	7.62	37.3	8.91	4	25.6	5.86	31.4	7.08
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	29.5	7.40	34.5	8.69	4	22.9	5.48	27.8	6.59
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	17	90.2	9.95	104.3	11.51
Female Genital System	-	-	-	-	-	6	27.9	5.39	31.3	6.14
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	3	16.6	4.27	18.1	4.74
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	7.3	2.58	8.6	3.11
Male Genital System	9	64.6	9.69	76.0	11.36	-	-	-	-	-
Prostate	9	63.7	9.65	75.3	11.34	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	18.6	4.85	20.8	5.47	2	8.5	3.09	9.9	3.53
Bladder (incl. <i>in situ</i>)	2	11.1	3.76	11.7	4.02	-	-	-	-	-
Kidney & renal pelvis	1	7.5	3.07	9.1	3.71	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	6	26.5	5.18	27.3	5.48
Thyroid gland	-	-	-	-	-	6	26.5	5.18	27.3	5.48
Lymphomas	3	19.8	5.59	23.1	6.56	2	11.5	3.58	13.5	4.20
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	16.7	5.29	19.2	6.13	2	10.8	3.51	12.8	4.13
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	9.6	3.48	9.4	3.49	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	11.2	4.02	13.0	4.67	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	12.0	3.82	14.3	4.60	2	8.1	2.86	8.5	3.05
Breast (<i>in situ</i>)	-	-	-	-	-	6	28.7	5.50	34.4	6.58

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	83	427.7	23.97	501.9	27.60	90	380.2	19.55	444.6	22.84
Oral Cavity & Pharynx	3	12.6	3.86	14.8	4.47	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	19	102.5	11.70	120.4	13.40	17	82.0	9.65	96.9	11.21
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	14.7	4.54	17.2	5.18	2	9.5	3.25	11.2	3.77
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	6	26.3	5.51	31.0	6.38	6	33.3	6.54	38.7	7.42
Rectum & rectosigmoid	3	11.7	3.36	14.2	4.10	2	9.3	3.01	11.3	3.63
Anus, anal canal & anorectum	-	-	-	-	-	1	4.8	2.05	6.0	2.55
Liver	4	26.2	6.13	30.8	6.96	1	6.3	2.72	7.5	3.10
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	13.7	4.85	15.2	5.29	2	7.6	2.67	8.7	3.05
Respiratory System	6	35.9	7.20	42.5	8.33	6	28.0	5.55	34.3	6.63
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	32.9	7.03	38.3	8.05	5	25.6	5.24	31.5	6.29
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	3.4	1.45	4.3	1.91	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	9.1	3.51	10.6	4.03	2	6.8	2.51	8.1	3.07
Breast (excl. <i>in situ</i>)	-	-	-	-	-	25	105.8	10.33	123.5	12.02
Female Genital System	-	-	-	-	-	13	53.1	6.97	61.8	8.16
Cervix uteri	-	-	-	-	-	2	4.8	1.75	4.9	1.87
Uterus Corpus	-	-	-	-	-	8	32.5	5.54	39.2	6.67
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	8.3	2.74	9.4	3.10
Male Genital System	25	126.4	12.75	151.5	14.79	-	-	-	-	-
Prostate	21	117.6	12.49	142.7	14.56	-	-	-	-	-
Testis	3	6.5	1.65	6.5	1.73	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	7	45.0	8.61	51.8	9.78	5	22.6	4.87	26.8	5.71
Bladder (incl. <i>in situ</i>)	4	29.2	7.15	33.9	8.24	1	7.4	2.92	8.9	3.46
Kidney & renal pelvis	3	13.9	4.39	15.9	4.92	3	15.2	3.90	17.9	4.55
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	7.0	2.61	7.8	2.97	2	5.2	2.14	5.2	2.22
Brain	2	5.3	2.35	5.8	2.61	-	-	-	-	-
Endocrine System	1	4.4	1.76	5.6	2.34	9	27.5	4.16	30.6	4.88
Thyroid gland	1	4.1	1.73	5.4	2.33	9	27.2	4.15	30.4	4.87
Lymphomas	6	29.2	6.07	33.2	6.91	4	19.8	4.64	22.7	5.32
Hodgkin Lymphoma	2	4.2	1.48	4.8	1.80	-	-	-	-	-
Non-Hodgkin Lymphoma	5	25.0	5.89	28.4	6.68	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	5	21.2	5.14	23.8	5.97	4	11.8	3.14	14.0	3.83
Acute lymphocytic	2	4.5	1.58	4.7	1.92	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	8.6	3.62	9.5	4.09	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	16.3	5.10	19.0	5.93	1	5.8	2.66	6.6	3.08
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	5.6	2.36	6.3	2.82	4	13.0	3.41	15.3	4.09
Breast (<i>in situ</i>)	-	-	-	-	-	8	30.0	4.85	36.2	5.95

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

DELAWARE

II-108 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,342	545.8	5.25	646.2	6.09	2,202	469.9	4.82	546.3	5.40
Oral Cavity & Pharynx	93	21.7	1.06	26.9	1.27	34	7.1	0.58	8.4	0.67
Lip	2	0.4	0.16	0.5	0.17	-	-	-	-	-
Tongue	31	7.5	0.63	9.1	0.74	9	1.9	0.31	2.3	0.35
Major salivary gland	7	1.9	0.32	2.2	0.37	7	1.4	0.26	1.6	0.29
Floor of mouth	5	1.0	0.21	1.3	0.27	2	0.4	0.13	0.5	0.16
Gum & other mouth	10	2.2	0.32	2.8	0.40	6	1.4	0.27	1.5	0.29
Nasopharynx	1	0.4	0.14	0.4	0.17	-	-	-	-	-
Oropharynx	5	1.1	0.24	1.3	0.28	2	0.3	0.12	0.4	0.15
Hypopharynx	5	1.1	0.23	1.4	0.28	-	-	-	-	-
Digestive System	421	99.0	2.23	118.0	2.62	311	62.9	1.69	73.4	1.92
Esophagus	44	10.3	0.71	12.1	0.83	9	1.8	0.28	2.1	0.31
Stomach	34	8.1	0.64	9.5	0.75	20	4.0	0.42	4.6	0.48
Small intestine	13	2.9	0.38	3.6	0.45	12	2.8	0.39	3.2	0.42
Colon excl. rectum	126	30.6	1.26	35.7	1.45	115	23.8	1.06	27.2	1.17
Rectum & rectosigmoid	51	12.7	0.84	15.1	0.97	39	8.4	0.64	10.0	0.74
Anus, anal canal & anorectum	5	1.3	0.26	1.5	0.30	11	2.3	0.32	2.9	0.40
Liver	48	10.6	0.71	13.4	0.88	15	3.0	0.36	3.6	0.42
Gallbladder	3	0.8	0.20	0.9	0.23	6	1.2	0.22	1.4	0.26
Pancreas	74	16.6	0.88	20.0	1.05	59	11.2	0.67	13.1	0.78
Respiratory System	376	85.7	2.03	101.4	2.38	352	66.4	1.63	79.4	1.93
Larynx	27	5.9	0.53	7.4	0.65	10	1.8	0.27	2.3	0.34
Lung & bronchus	344	78.4	1.94	92.4	2.26	340	64.0	1.60	76.6	1.89
Bones & Joints	3	0.9	0.25	0.9	0.24	3	0.8	0.25	0.9	0.24
Soft Tissue (incl. heart)	12	3.1	0.42	3.5	0.46	12	3.0	0.43	3.2	0.44
Skin (excl. basal & sq.)	216	52.4	1.67	61.0	1.90	135	31.3	1.32	35.6	1.43
Melanomas of the skin	205	49.8	1.63	57.9	1.85	129	30.0	1.29	34.1	1.40
Breast (excl. <i>in situ</i>)	5	1.1	0.21	1.3	0.26	631	137.0	2.63	160.3	2.96
Female Genital System	-	-	-	-	-	260	56.2	1.68	66.6	1.91
Cervix uteri	-	-	-	-	-	28	8.1	0.74	8.6	0.76
Uterus Corpus	-	-	-	-	-	147	30.2	1.19	36.9	1.40
Uterus, NOS ¹	-	-	-	-	-	6	1.3	0.24	1.5	0.27
Ovary	-	-	-	-	-	55	11.8	0.76	13.8	0.86
Male Genital System	540	117.2	2.33	143.0	2.80	-	-	-	-	-
Prostate	517	109.4	2.20	135.0	2.69	-	-	-	-	-
Testis	18	6.8	0.74	6.8	0.72	-	-	-	-	-
Penis	3	0.8	0.20	0.9	0.22	-	-	-	-	-
Urinary System	307	72.2	1.91	84.6	2.20	112	22.8	1.03	26.3	1.15
Bladder (incl. <i>in situ</i>)	199	46.5	1.51	54.5	1.75	55	10.3	0.65	12.1	0.75
Kidney & renal pelvis	99	23.8	1.13	27.8	1.28	54	11.9	0.79	13.6	0.86
Ureter	5	1.2	0.25	1.4	0.28	3	0.5	0.14	0.5	0.15
Eye & Orbit	-	-	-	-	-	1	0.6	0.22	0.5	0.20
Brain & Other CNS ¹	30	8.4	0.73	9.2	0.76	25	6.0	0.59	6.6	0.62
Brain	29	7.7	0.69	8.6	0.74	24	5.6	0.57	6.2	0.59
Endocrine System	31	8.8	0.76	9.8	0.80	93	27.6	1.38	29.4	1.41
Thyroid gland	28	7.7	0.71	8.7	0.76	90	26.8	1.36	28.6	1.39
Lymphomas	116	28.8	1.26	33.0	1.40	96	20.4	1.01	23.4	1.11
Hodgkin Lymphoma	9	2.9	0.46	3.0	0.46	9	2.9	0.47	2.9	0.45
Non-Hodgkin Lymphoma	107	25.8	1.17	30.0	1.33	87	17.5	0.89	20.5	1.02
Multiple Myeloma	31	7.5	0.62	8.7	0.71	25	4.8	0.45	5.8	0.53
Leukemias	72	18.0	1.00	20.5	1.10	43	9.4	0.70	10.5	0.75
Acute lymphocytic	5	1.6	0.35	1.6	0.33	3	1.3	0.34	1.1	0.28
Chronic lymphocytic	27	6.1	0.55	7.3	0.65	15	2.9	0.34	3.4	0.40
Acute myeloid	22	5.3	0.53	6.0	0.59	16	3.4	0.41	3.8	0.45
Chronic myeloid	9	2.3	0.38	2.6	0.40	5	1.1	0.25	1.3	0.28
Other leukemias	10	2.6	0.39	3.0	0.43	4	0.7	0.17	0.9	0.21
Mesothelioma	10	2.5	0.35	2.8	0.39	2	0.4	0.14	0.5	0.16
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	76	18.2	0.96	21.2	1.11	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	24	5.9	0.58	7.0	0.66	47	11.7	0.83	13.0	0.88
Breast (<i>in situ</i>)	-	-	-	-	-	142	32.8	1.33	38.5	1.50

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Delaware, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	498	563.6	11.96	680.1	14.12	498	435.8	8.98	509.7	10.30
Oral Cavity & Pharynx	10	11.5	1.75	13.2	1.99	5	4.9	0.98	5.2	1.03
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.8	0.87	3.4	1.03	1	1.2	0.49	1.2	0.50
Major salivary gland	-	-	-	-	-	2	1.9	0.62	2.0	0.64
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	105	120.2	5.57	145.9	6.60	93	81.1	3.88	97.5	4.56
Esophagus	3	4.3	1.11	5.2	1.32	-	-	-	-	-
Stomach	9	10.8	1.69	13.0	2.00	7	6.1	1.05	7.4	1.27
Small intestine	4	4.8	1.11	5.8	1.31	5	4.6	0.95	5.3	1.07
Colon excl. rectum	33	40.4	3.34	47.8	3.89	34	30.4	2.40	35.6	2.76
Rectum & rectosigmoid	12	13.6	1.84	16.3	2.15	9	7.4	1.15	9.0	1.36
Anus, anal canal & anorectum	2	1.8	0.63	2.2	0.75	2	1.9	0.58	2.2	0.68
Liver	19	18.4	1.98	24.2	2.53	8	6.4	1.05	8.1	1.31
Gallbladder	1	2.0	0.77	2.1	0.80	2	1.8	0.56	2.3	0.71
Pancreas	16	18.0	2.17	22.0	2.58	19	17.0	1.80	20.5	2.12
Respiratory System	67	83.4	4.82	98.1	5.55	67	60.3	3.39	71.2	3.92
Larynx	5	6.3	1.28	7.6	1.49	2	1.5	0.49	2.0	0.63
Lung & bronchus	61	75.3	4.58	88.4	5.28	65	58.6	3.35	69.1	3.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.1	1.05	4.6	1.18	4	3.7	0.82	4.0	0.88
Skin (excl. basal & sq.)	2	2.1	0.81	2.5	0.95	3	3.0	0.75	3.4	0.83
Melanomas of the skin	-	-	-	-	-	2	1.6	0.53	1.8	0.60
Breast (excl. <i>in situ</i>)	2	2.1	0.78	2.4	0.89	160	136.9	4.97	160.7	5.72
Female Genital System	-	-	-	-	-	61	53.1	3.13	62.2	3.59
Cervix uteri	-	-	-	-	-	10	9.1	1.34	9.5	1.38
Uterus Corpus	-	-	-	-	-	32	27.0	2.20	32.6	2.60
Uterus, NOS ¹	-	-	-	-	-	5	3.6	0.74	4.6	0.94
Ovary	-	-	-	-	-	9	8.2	1.22	9.6	1.42
Male Genital System	196	205.2	6.87	256.9	8.38	-	-	-	-	-
Prostate	194	203.3	6.83	254.8	8.34	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	46	55.4	3.88	65.6	4.51	25	21.5	2.00	25.5	2.32
Bladder (incl. <i>in situ</i>)	20	26.0	2.79	31.0	3.27	9	8.0	1.23	9.3	1.42
Kidney & renal pelvis	26	28.4	2.62	33.5	3.03	15	13.2	1.55	15.7	1.80
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	2.6	0.69	2.9	0.79	5	4.6	0.92	5.0	1.00
Brain	2	1.8	0.56	2.1	0.69	4	3.8	0.84	4.2	0.91
Endocrine System	6	6.3	1.19	7.1	1.34	21	19.5	1.94	20.3	1.98
Thyroid gland	4	4.6	1.00	5.2	1.12	20	18.7	1.90	19.6	1.95
Lymphomas	19	21.6	2.33	23.6	2.52	18	15.8	1.72	17.9	1.91
Hodgkin Lymphoma	4	4.2	0.96	4.4	1.00	3	2.4	0.67	2.4	0.66
Non-Hodgkin Lymphoma	15	17.4	2.12	19.2	2.31	15	13.4	1.58	15.5	1.79
Multiple Myeloma	14	15.3	1.96	18.4	2.31	14	12.6	1.53	15.0	1.78
Leukemias	11	12.7	1.84	14.2	2.06	9	7.9	1.19	9.3	1.39
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	2.9	0.91	3.5	1.06	3	2.4	0.67	2.9	0.79
Acute myeloid	3	4.0	1.07	4.5	1.21	3	2.6	0.73	3.1	0.85
Chronic myeloid	2	2.4	0.79	2.6	0.85	1	0.8	0.34	1.2	0.47
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	1.5	0.57	1.6	0.60	-	-	-	-	-
Ill-defined & Unknown	12	17.5	2.41	20.8	2.84	11	10.5	1.45	12.1	1.64
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	7.6	1.35	8.4	1.46	13	11.4	1.45	13.1	1.63
Breast (<i>in situ</i>)	-	-	-	-	-	43	36.5	2.56	43.2	2.96

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

DELAWARE


II-110 Incidence – Non-Hispanic Black

DISTRICT OF COLUMBIA CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	650,431	662,513	675,254	686,575	695,691
White	286,632	294,588	303,348	311,809	319,646
Black	330,644	333,604	335,916	337,225	337,125
American Indian/Alaskan Native (AI/AN)	4,663	4,782	4,881	5,048	5,123
Asian/Pacific Islander (API)	28,492	29,539	31,109	32,493	33,797


All Races Population 2013-2017: 3,370,464
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	66,886	69,697	72,747	75,139	77,044
Non-Hispanic White	235,852	241,493	247,740	254,199	260,282
Non-Hispanic Black	319,217	321,791	323,752	324,864	324,651

Hispanic/Latino Population, Census 2010: 54,749
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

DISTRICT OF COLUMBIA CANCER REGISTRY

Initial Operation: 1987
 Population-based Data Available: 1987
 Coverage Area: District of Columbia

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.7	101.2	89.0	88.4	92.0
Missing Race	2.8	1.5	2.5	3.6	4.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.8	0.9
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.3	0.8	0.6	3.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.5	Prostate	96.7
Oral Cavity & Pharynx	96.6	Testis	98.0
Esophagus	91.9	Bladder (incl. <i>in situ</i>)	97.8
Stomach	95.7	Kidney & Renal Pelvis	90.5
Colon & Rectum	95.8	Brain & Other CNS ¹	90.8
Liver	57.4	Thyroid	99.4
Pancreas	86.2	Hodgkin Lymphoma	99.0
Lung & Bronchus	88.6	Non-Hodgkin Lymphoma	97.2
Melanomas of the Skin	98.9	Multiple Myeloma	92.6
Female Breast (excl. <i>in situ</i>)	98.7	Leukemias	91.5
Cervix uteri	93.5	Brain & Other CNS ¹ <i>non-malig</i>	52.5
Uterus Corpus & Uterus NOS ¹	96.4	Breast <i>in situ</i>	100.0
Ovary	91.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,327	452.8	5.74	541.6	6.76	1,509	417.8	4.94	490.5	5.74
Oral Cavity & Pharynx	49	17.1	1.12	20.3	1.31	22	5.9	0.58	7.0	0.68
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	14	4.8	0.59	5.8	0.70	5	1.5	0.30	1.7	0.34
Major salivary gland	5	1.8	0.37	2.0	0.41	6	1.6	0.31	1.8	0.34
Floor of mouth	2	0.7	0.22	0.8	0.25	-	-	-	-	-
Gum & other mouth	6	2.1	0.41	2.5	0.47	3	0.8	0.20	0.9	0.25
Nasopharynx	4	1.4	0.32	1.6	0.35	1	0.3	0.14	0.4	0.16
Oropharynx	3	1.2	0.30	1.4	0.35	2	0.5	0.17	0.7	0.22
Hypopharynx	5	1.7	0.36	2.0	0.42	-	-	-	-	-
Digestive System	314	107.3	2.79	129.7	3.32	281	76.9	2.10	91.8	2.48
Esophagus	16	5.6	0.65	6.8	0.77	9	2.2	0.35	2.8	0.43
Stomach	34	11.8	0.94	14.3	1.12	22	6.2	0.61	7.2	0.70
Small intestine	11	3.8	0.52	4.4	0.61	12	3.4	0.45	4.0	0.52
Colon excl. rectum	82	28.7	1.47	33.8	1.70	100	27.1	1.24	32.2	1.46
Rectum & rectosigmoid	36	12.2	0.94	14.5	1.10	33	9.4	0.75	11.0	0.87
Anus, anal canal & anorectum	12	4.1	0.53	4.8	0.62	11	2.8	0.40	3.6	0.50
Liver	55	16.8	1.04	21.9	1.34	20	5.2	0.53	6.5	0.66
Gallbladder	4	1.4	0.32	1.7	0.38	6	1.7	0.32	2.0	0.36
Pancreas	51	18.3	1.18	21.9	1.38	51	14.0	0.89	16.7	1.06
Respiratory System	159	55.6	2.04	67.3	2.41	172	46.7	1.62	56.8	1.95
Larynx	13	4.5	0.58	5.6	0.69	6	1.6	0.30	2.0	0.37
Lung & bronchus	141	49.8	1.93	60.1	2.28	164	44.5	1.58	54.2	1.91
Bones & Joints	4	1.4	0.32	1.4	0.32	4	1.0	0.25	1.0	0.24
Soft Tissue (incl. heart)	12	3.9	0.53	4.3	0.58	9	2.4	0.37	2.6	0.41
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	43	14.9	1.05	17.1	1.20	26	6.9	0.62	7.5	0.68
Breast (excl. <i>in situ</i>)	7	2.5	0.43	2.8	0.49	489	139.4	2.89	162.2	3.33
Female Genital System	-	-	-	-	-	199	55.0	1.78	65.6	2.11
Cervix uteri	-	-	-	-	-	31	8.8	0.73	9.7	0.80
Uterus Corpus	-	-	-	-	-	105	28.5	1.27	35.2	1.55
Uterus, NOS ¹	-	-	-	-	-	6	1.7	0.31	2.1	0.39
Ovary	-	-	-	-	-	43	12.1	0.84	14.0	0.97
Male Genital System	397	133.0	3.08	162.9	3.70	-	-	-	-	-
Prostate	375	127.4	3.03	157.2	3.66	-	-	-	-	-
Testis	20	5.1	0.54	5.2	0.54	-	-	-	-	-
Penis	1	0.4	0.15	0.4	0.18	-	-	-	-	-
Urinary System	111	38.8	1.70	46.6	2.00	63	17.1	0.99	20.4	1.16
Bladder (incl. <i>in situ</i>)	56	20.4	1.26	24.2	1.47	27	7.4	0.65	8.7	0.75
Kidney & renal pelvis	52	17.3	1.10	21.1	1.32	34	9.2	0.73	11.1	0.87
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.4	0.15	0.4	0.15	1	0.4	0.15	0.4	0.17
Brain & Other CNS ¹	19	6.2	0.65	6.7	0.71	13	3.8	0.49	4.2	0.52
Brain	18	5.7	0.63	6.2	0.68	11	3.2	0.45	3.6	0.49
Endocrine System	28	8.3	0.74	9.5	0.84	74	19.9	1.08	22.2	1.20
Thyroid gland	24	7.2	0.68	8.2	0.78	72	19.3	1.06	21.5	1.18
Lymphomas	65	22.0	1.26	25.1	1.43	55	14.8	0.92	16.9	1.05
Hodgkin Lymphoma	9	2.8	0.43	2.9	0.45	11	2.7	0.38	2.8	0.40
Non-Hodgkin Lymphoma	56	19.2	1.19	22.1	1.36	44	12.1	0.84	14.1	0.97
Multiple Myeloma	30	10.7	0.91	12.8	1.06	30	8.2	0.69	9.8	0.81
Leukemias	32	11.1	0.92	12.4	1.01	22	6.3	0.62	6.9	0.66
Acute lymphocytic	-	-	-	-	-	4	1.0	0.26	1.0	0.24
Chronic lymphocytic	9	3.0	0.48	3.7	0.57	5	1.4	0.29	1.6	0.33
Acute myeloid	9	3.1	0.49	3.6	0.55	9	2.5	0.39	2.6	0.41
Chronic myeloid	5	1.5	0.32	1.8	0.38	3	0.9	0.23	1.0	0.26
Other leukemias	4	1.4	0.33	1.6	0.38	2	0.5	0.16	0.6	0.19
Mesothelioma	2	0.9	0.27	0.9	0.28	-	-	-	-	-
Kaposi Sarcoma	8	2.2	0.36	2.4	0.39	-	-	-	-	-
Ill-defined & Unknown	44	15.7	1.09	18.2	1.25	43	11.5	0.81	13.5	0.94
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	25	9.0	0.83	10.0	0.92	48	13.4	0.89	15.6	1.02
Breast (<i>in situ</i>)	1	0.5	0.17	0.6	0.21	137	40.4	1.58	47.4	1.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	418	334.5	7.67	393.1	8.93	442	344.6	7.68	398.7	8.89
Oral Cavity & Pharynx	20	16.2	1.69	19.2	1.99	7	5.5	0.96	6.2	1.08
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	7	5.7	1.00	6.5	1.15	3	2.1	0.62	2.4	0.69
Major salivary gland	3	2.1	0.61	2.5	0.72	2	1.3	0.42	1.4	0.47
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	3	2.7	0.72	3.2	0.84	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	1	1.1	0.46	1.3	0.54	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	79	65.5	3.42	77.8	4.02	62	49.5	2.93	58.1	3.42
Esophagus	5	4.0	0.87	4.6	0.98	2	1.6	0.54	1.9	0.66
Stomach	10	8.3	1.22	10.2	1.48	4	3.0	0.72	3.4	0.82
Small intestine	3	2.1	0.59	2.5	0.72	1	1.2	0.45	1.4	0.53
Colon excl. rectum	20	16.2	1.69	18.9	1.96	21	16.5	1.68	19.3	1.96
Rectum & rectosigmoid	10	7.5	1.12	9.1	1.34	8	6.4	1.04	7.5	1.23
Anus, anal canal & anorectum	5	3.5	0.72	4.5	0.93	2	1.9	0.57	2.5	0.73
Liver	7	5.7	0.99	7.1	1.22	2	1.4	0.49	1.8	0.61
Gallbladder	-	-	-	-	-	1	1.2	0.47	1.4	0.53
Pancreas	14	13.8	1.67	15.5	1.86	14	11.5	1.43	13.3	1.65
Respiratory System	32	28.2	2.30	33.3	2.68	37	30.6	2.34	35.8	2.70
Larynx	2	1.8	0.60	2.1	0.68	-	-	-	-	-
Lung & bronchus	28	24.8	2.16	29.4	2.52	36	29.8	2.31	34.8	2.67
Bones & Joints	2	1.1	0.40	1.1	0.41	2	1.6	0.53	1.7	0.55
Soft Tissue (incl. heart)	5	3.1	0.67	3.5	0.78	3	2.7	0.68	2.9	0.75
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	29	22.9	1.99	26.3	2.29	18	11.5	1.36	12.5	1.49
Breast (excl. <i>in situ</i>)	2	1.9	0.60	2.0	0.68	164	130.7	4.73	152.2	5.53
Female Genital System	-	-	-	-	-	52	41.4	2.67	49.2	3.17
Cervix uteri	-	-	-	-	-	7	4.6	0.84	5.1	0.96
Uterus Corpus	-	-	-	-	-	25	20.1	1.86	24.7	2.27
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	15	12.3	1.45	14.5	1.71
Male Genital System	117	90.0	3.88	108.5	4.64	-	-	-	-	-
Prostate	101	82.4	3.77	100.6	4.53	-	-	-	-	-
Testis	15	7.0	0.87	7.1	0.90	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	41	34.9	2.52	41.3	2.94	16	12.9	1.52	15.1	1.75
Bladder (incl. <i>in situ</i>)	25	21.8	2.02	25.6	2.33	7	5.3	0.95	6.2	1.10
Kidney & renal pelvis	14	11.4	1.41	13.7	1.68	8	7.1	1.15	8.3	1.33
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	1	0.9	0.39	1.1	0.47
Brain & Other CNS ¹	10	7.5	1.15	8.1	1.22	5	3.5	0.76	3.9	0.86
Brain	10	7.2	1.12	7.9	1.21	4	3.3	0.74	3.7	0.82
Endocrine System	15	9.5	1.21	10.6	1.34	34	22.0	1.86	24.2	2.08
Thyroid gland	13	8.0	1.08	8.9	1.22	34	21.6	1.84	23.8	2.06
Lymphomas	27	21.3	1.98	24.0	2.22	19	14.0	1.53	15.8	1.73
Hodgkin Lymphoma	5	2.8	0.61	3.0	0.68	4	2.1	0.51	2.0	0.50
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	8	6.5	1.09	7.9	1.30	5	4.1	0.84	4.8	0.98
Leukemias	15	11.6	1.44	12.9	1.59	6	5.1	1.01	5.4	1.02
Acute lymphocytic	4	3.0	0.75	2.6	0.65	1	1.2	0.56	1.1	0.48
Chronic lymphocytic	4	3.0	0.71	3.8	0.89	2	1.2	0.42	1.4	0.49
Acute myeloid	3	2.8	0.72	3.3	0.83	2	2.0	0.65	1.9	0.63
Chronic myeloid	3	1.9	0.59	2.1	0.65	-	-	-	-	-
Other leukemias	1	0.9	0.38	1.1	0.45	-	-	-	-	-
Mesothelioma	1	1.4	0.55	1.5	0.57	-	-	-	-	-
Kaposi Sarcoma	1	0.8	0.33	0.9	0.39	-	-	-	-	-
Ill-defined & Unknown	13	11.1	1.42	12.8	1.65	10	7.7	1.13	8.9	1.31
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	11	8.9	1.25	9.8	1.39	14	10.4	1.32	11.9	1.51
Breast (<i>in situ</i>)	-	-	-	-	-	48	40.7	2.68	48.3	3.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	795	500.2	8.21	603.7	9.67	952	434.2	6.51	513.1	7.52
Oral Cavity & Pharynx	27	16.9	1.52	20.1	1.77	13	5.7	0.74	6.9	0.87
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	3.8	0.70	4.7	0.85	2	1.0	0.30	1.2	0.35
Major salivary gland	2	1.3	0.42	1.4	0.45	3	1.5	0.41	1.7	0.43
Floor of mouth	1	0.9	0.35	1.1	0.40	-	-	-	-	-
Gum & other mouth	2	1.5	0.46	1.7	0.52	2	0.9	0.27	1.2	0.35
Nasopharynx	3	2.0	0.53	2.2	0.57	-	-	-	-	-
Oropharynx	2	1.3	0.43	1.5	0.48	2	0.7	0.25	0.9	0.33
Hypopharynx	4	2.7	0.61	3.3	0.73	-	-	-	-	-
Digestive System	216	135.6	4.28	164.2	5.05	200	88.0	2.87	105.7	3.39
Esophagus	10	6.5	0.94	8.0	1.13	6	2.6	0.47	3.3	0.58
Stomach	21	14.1	1.41	16.7	1.63	16	7.4	0.86	8.6	0.97
Small intestine	8	5.1	0.84	5.9	0.96	10	4.6	0.68	5.4	0.78
Colon excl. rectum	54	36.2	2.26	42.7	2.61	73	31.8	1.72	38.0	2.02
Rectum & rectosigmoid	22	14.7	1.44	17.3	1.65	21	10.1	1.02	11.7	1.16
Anus, anal canal & anorectum	8	5.3	0.89	5.9	0.97	7	3.1	0.54	4.0	0.68
Liver	46	25.1	1.71	32.9	2.19	16	6.8	0.77	8.6	0.97
Gallbladder	3	2.0	0.53	2.4	0.62	5	2.0	0.42	2.3	0.48
Pancreas	34	21.2	1.68	26.0	2.00	35	15.2	1.17	18.5	1.40
Respiratory System	121	75.9	3.20	92.2	3.79	130	56.2	2.25	69.0	2.73
Larynx	11	6.5	0.92	8.2	1.12	5	2.4	0.47	2.9	0.57
Lung & bronchus	108	68.6	3.05	83.0	3.60	124	53.1	2.19	65.3	2.65
Bones & Joints	2	1.6	0.47	1.6	0.47	-	-	-	-	-
Soft Tissue (incl. heart)	7	4.4	0.80	4.9	0.87	5	2.5	0.51	2.8	0.55
Skin (excl. basal & sq.)	2	1.4	0.42	1.6	0.49	4	1.9	0.47	2.1	0.49
Melanomas of the skin	1	0.9	0.35	1.1	0.41	2	0.8	0.31	0.9	0.34
Breast (excl. <i>in situ</i>)	5	3.2	0.67	3.7	0.76	290	137.4	3.75	159.7	4.24
Female Genital System	-	-	-	-	-	127	57.8	2.37	69.0	2.77
Cervix uteri	-	-	-	-	-	19	9.6	1.03	10.7	1.11
Uterus Corpus	-	-	-	-	-	70	30.7	1.69	37.7	2.03
Uterus, NOS ¹	-	-	-	-	-	5	2.3	0.47	2.9	0.58
Ovary	-	-	-	-	-	24	11.2	1.06	13.0	1.20
Male Genital System	236	144.1	4.35	178.1	5.23	-	-	-	-	-
Prostate	232	141.5	4.30	175.4	5.20	-	-	-	-	-
Testis	3	2.3	0.60	2.3	0.59	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	63	39.7	2.32	48.0	2.74	45	19.6	1.36	23.4	1.59
Bladder (incl. <i>in situ</i>)	26	17.3	1.56	20.7	1.83	19	8.2	0.86	9.7	1.00
Kidney & renal pelvis	36	22.0	1.70	26.8	2.02	24	10.8	1.02	13.1	1.20
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	4.5	0.76	5.0	0.83	7	3.6	0.63	3.9	0.66
Brain	7	4.0	0.70	4.4	0.78	6	2.6	0.52	3.0	0.58
Endocrine System	10	6.3	0.91	7.5	1.06	31	15.4	1.29	17.6	1.42
Thyroid gland	9	5.3	0.84	6.4	0.98	30	14.7	1.26	16.8	1.39
Lymphomas	32	20.6	1.69	23.9	1.91	29	13.7	1.18	15.7	1.32
Hodgkin Lymphoma	4	2.4	0.59	2.6	0.62	5	2.6	0.52	2.8	0.56
Non-Hodgkin Lymphoma	-	-	-	-	-	24	11.1	1.06	12.9	1.20
Multiple Myeloma	20	13.3	1.38	15.6	1.59	24	10.4	0.98	12.5	1.16
Leukemias	15	9.8	1.18	11.1	1.33	14	6.4	0.80	7.2	0.88
Acute lymphocytic	1	0.9	0.36	0.7	0.27	2	1.2	0.36	1.2	0.34
Chronic lymphocytic	5	3.2	0.69	3.7	0.78	2	1.0	0.30	1.2	0.37
Acute myeloid	4	3.0	0.66	3.5	0.75	5	2.2	0.44	2.6	0.52
Chronic myeloid	2	1.0	0.34	1.4	0.45	3	1.5	0.41	1.6	0.43
Other leukemias	2	1.6	0.50	1.8	0.56	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	5	3.0	0.62	3.1	0.64	-	-	-	-	-
Ill-defined & Unknown	29	19.3	1.66	22.3	1.88	32	14.1	1.16	16.4	1.32
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	8.6	1.12	9.7	1.23	29	13.6	1.17	15.9	1.34
Breast (<i>in situ</i>)	-	-	-	-	-	77	37.2	1.96	43.7	2.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	27	356.1	33.02	426.8	39.01	38	295.8	22.97	341.9	26.82
Oral Cavity & Pharynx	2	23.5	7.85	29.2	9.79	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	9	121.3	19.84	146.0	23.19	6	49.8	9.63	57.7	11.14
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	20.4	8.14	25.5	9.79	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	24.6	8.96	30.5	10.72	2	10.7	4.17	13.0	5.08
Rectum & rectosigmoid	2	21.5	8.47	23.2	9.08	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	15.9	6.90	19.4	8.15	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	27.6	10.11	31.6	11.31	-	-	-	-	-
Respiratory System	4	59.8	14.28	69.5	16.39	3	25.8	7.32	32.8	9.12
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	54.4	13.65	64.1	15.80	3	25.8	7.32	32.8	9.12
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	13	98.8	12.77	112.7	14.86
Female Genital System	-	-	-	-	-	5	36.2	7.67	42.4	9.10
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	14.4	4.95	17.8	6.14
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	12.8	4.39	14.6	5.09
Male Genital System	6	78.4	15.18	96.9	18.41	-	-	-	-	-
Prostate	5	65.9	13.67	84.7	17.19	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	26.1	8.49	32.5	10.62	1	12.4	5.14	14.4	5.96
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	4	26.1	6.17	29.7	7.29
Thyroid gland	-	-	-	-	-	4	24.0	5.94	27.9	7.15
Lymphomas	1	19.6	7.87	20.7	8.29	2	13.5	5.05	15.0	5.75
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	1	11.1	4.82	12.8	5.58
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	21.4	6.32	26.3	7.61
Breast (<i>in situ</i>)	-	-	-	-	-	4	31.5	7.04	35.4	8.20

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	59	304.7	21.35	356.5	24.39	70	274.9	15.71	312.6	18.00
Oral Cavity & Pharynx	2	10.8	3.77	13.2	4.37	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	15	83.2	11.21	99.2	13.00	13	55.1	7.37	61.9	8.31
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	3	17.8	5.01	22.0	6.01	2	7.1	2.67	8.2	3.08
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	19.2	5.11	22.1	5.77	3	13.5	3.76	15.2	4.22
Rectum & rectosigmoid	2	9.3	3.37	11.5	3.97	2	8.2	2.78	9.0	3.14
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	7.6	3.54	9.3	4.17	1	4.8	1.97	6.0	2.47
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	16.7	6.01	18.2	6.60	1	6.0	2.63	6.3	2.84
Respiratory System	5	26.5	6.23	31.5	7.13	3	16.1	4.23	19.4	4.98
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	23.9	6.03	28.2	6.84	3	15.4	4.16	18.5	4.90
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	1	3.8	1.65	4.2	1.97
Skin (excl. basal & sq.)	1	7.4	3.42	8.5	3.93	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	1	4.4	1.85	4.7	2.03
Breast (excl. <i>in situ</i>)	-	-	-	-	-	21	82.0	8.37	94.7	9.73
Female Genital System	-	-	-	-	-	8	30.0	5.08	34.0	5.83
Cervix uteri	-	-	-	-	-	3	10.2	2.61	11.2	2.98
Uterus Corpus	-	-	-	-	-	3	11.6	3.31	13.1	3.68
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	6.6	2.39	8.0	2.91
Male Genital System	14	75.7	10.75	91.3	12.48	-	-	-	-	-
Prostate	11	68.1	10.46	83.1	12.19	-	-	-	-	-
Testis	3	5.9	1.72	6.3	1.89	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	17.7	5.67	20.4	6.38	2	9.6	2.97	11.3	3.49
Bladder (incl. <i>in situ</i>)	1	11.0	4.86	12.5	5.47	-	-	-	-	-
Kidney & renal pelvis	2	6.7	2.92	7.9	3.27	1	5.8	2.32	7.1	2.87
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	2	7.8	2.94	7.7	2.94	8	23.5	3.97	26.6	4.64
Thyroid gland	2	6.8	2.84	6.5	2.79	7	21.9	3.78	24.5	4.39
Lymphomas	6	30.2	6.96	33.5	7.66	5	20.3	4.34	22.8	4.91
Hodgkin Lymphoma	2	5.9	2.81	6.2	2.95	-	-	-	-	-
Non-Hodgkin Lymphoma	4	24.3	6.37	27.2	7.07	-	-	-	-	-
Multiple Myeloma	2	9.2	3.08	11.6	3.86	-	-	-	-	-
Leukemias	4	16.4	4.43	18.5	5.10	1	4.4	1.94	3.9	1.76
Acute lymphocytic	2	6.3	2.94	6.1	3.28	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	3.8	1.57	4.5	1.95	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	10.2	4.43	11.3	4.86	3	15.6	4.03	17.8	4.58
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.6	1.66	4.8	1.80	3	14.2	3.97	15.0	4.21
Breast (<i>in situ</i>)	-	-	-	-	-	9	32.0	4.96	36.1	5.68

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

District of Columbia

II-118 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	380	345.5	8.26	406.1	9.62	398	365.7	8.63	424.2	10.00
Oral Cavity & Pharynx	18	17.2	1.84	20.3	2.17	7	5.8	1.07	6.7	1.21
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	7	6.4	1.13	7.4	1.30	2	2.3	0.71	2.6	0.79
Major salivary gland	2	2.2	0.65	2.7	0.79	2	1.3	0.43	1.5	0.50
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	3	2.8	0.78	3.3	0.90	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	69	64.2	3.57	76.2	4.21	55	50.6	3.19	60.0	3.77
Esophagus	4	4.2	0.94	4.7	1.05	2	1.8	0.62	2.2	0.75
Stomach	8	7.3	1.21	8.9	1.47	3	2.4	0.68	2.7	0.79
Small intestine	2	1.9	0.61	2.3	0.74	1	1.1	0.48	1.4	0.60
Colon excl. rectum	18	16.4	1.80	19.0	2.08	20	17.8	1.88	20.9	2.20
Rectum & rectosigmoid	8	7.4	1.18	8.9	1.42	7	6.8	1.17	8.1	1.40
Anus, anal canal & anorectum	5	3.8	0.81	5.0	1.06	2	2.3	0.69	2.9	0.87
Liver	6	5.4	1.02	6.9	1.27	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	13	13.2	1.70	14.9	1.91	13	12.6	1.62	14.7	1.88
Respiratory System	29	28.8	2.44	34.1	2.85	35	33.1	2.61	38.7	3.02
Larynx	2	2.1	0.66	2.4	0.76	-	-	-	-	-
Lung & bronchus	26	25.3	2.28	30.0	2.68	34	32.4	2.58	37.8	2.98
Bones & Joints	1	1.0	0.44	1.1	0.44	2	1.7	0.58	1.8	0.61
Soft Tissue (incl. heart)	4	3.5	0.77	4.0	0.90	2	2.1	0.67	2.2	0.73
Skin (excl. basal & sq.)	-	-	-	-	-	18	13.8	1.60	14.9	1.75
Melanomas of the skin	29	25.4	2.21	29.0	2.53	17	12.8	1.56	13.9	1.70
Breast (excl. <i>in situ</i>)	2	2.1	0.67	2.3	0.75	150	142.5	5.41	165.9	6.32
Female Genital System	-	-	-	-	-	47	44.9	3.04	53.4	3.60
Cervix uteri	-	-	-	-	-	5	4.0	0.86	4.5	1.00
Uterus Corpus	-	-	-	-	-	24	22.7	2.15	27.9	2.63
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	14	13.3	1.65	15.5	1.93
Male Genital System	109	94.8	4.20	114.6	5.05	-	-	-	-	-
Prostate	95	87.1	4.07	106.8	4.93	-	-	-	-	-
Testis	13	7.0	0.95	7.0	0.97	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	39	37.2	2.72	44.1	3.20	14	13.5	1.67	15.6	1.92
Bladder (incl. <i>in situ</i>)	24	23.4	2.18	27.6	2.54	6	5.4	1.02	6.4	1.19
Kidney & renal pelvis	13	12.0	1.53	14.3	1.81	8	7.5	1.27	8.6	1.45
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	1	1.1	0.48	1.4	0.56
Brain & Other CNS ¹	9	8.7	1.43	9.2	1.44	4	4.0	0.92	4.5	0.99
Brain	9	8.2	1.36	8.9	1.41	4	3.8	0.90	4.2	0.95
Endocrine System	14	10.1	1.36	11.4	1.52	30	23.0	2.16	25.2	2.38
Thyroid gland	12	8.3	1.14	9.5	1.35	29	22.8	2.14	25.0	2.37
Lymphomas	22	20.8	2.11	23.5	2.35	15	13.2	1.61	15.0	1.83
Hodgkin Lymphoma	3	2.3	0.61	2.5	0.69	3	1.8	0.50	1.7	0.46
Non-Hodgkin Lymphoma	19	18.6	2.02	21.0	2.25	12	11.4	1.53	13.2	1.77
Multiple Myeloma	6	6.1	1.13	7.3	1.34	5	4.4	0.95	5.3	1.12
Leukemias	12	11.2	1.55	12.4	1.68	5	5.1	1.11	5.6	1.15
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	3	3.0	0.74	3.8	0.94	2	1.4	0.49	1.6	0.57
Acute myeloid	3	2.8	0.80	3.2	0.87	2	2.5	0.89	2.4	0.81
Chronic myeloid	2	2.0	0.64	2.2	0.71	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	1.4	0.57	1.4	0.58	-	-	-	-	-
Kaposi Sarcoma	1	1.0	0.40	1.1	0.47	-	-	-	-	-
Ill-defined & Unknown	12	11.3	1.52	13.1	1.76	8	7.0	1.17	8.2	1.36
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	10	9.3	1.38	10.3	1.53	12	10.6	1.46	12.1	1.67
Breast (<i>in situ</i>)	-	-	-	-	-	43	43.8	3.07	52.4	3.67

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
District of Columbia, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	790	507.5	8.36	612.3	9.83	944	439.5	6.64	519.4	7.65
Oral Cavity & Pharynx	26	17.2	1.55	20.5	1.80	13	5.9	0.76	7.1	0.89
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	3.8	0.71	4.8	0.87	2	1.0	0.31	1.2	0.36
Major salivary gland	2	1.2	0.42	1.3	0.44	3	1.6	0.43	1.7	0.44
Floor of mouth	1	0.9	0.36	1.1	0.41	-	-	-	-	-
Gum & other mouth	2	1.5	0.47	1.7	0.53	2	0.9	0.28	1.2	0.36
Nasopharynx	3	2.1	0.55	2.2	0.59	-	-	-	-	-
Oropharynx	2	1.3	0.43	1.5	0.49	2	0.7	0.26	0.9	0.34
Hypopharynx	4	2.8	0.62	3.3	0.74	-	-	-	-	-
Digestive System	214	137.2	4.35	166.2	5.13	198	89.2	2.93	107.1	3.45
Esophagus	10	6.7	0.96	8.2	1.15	6	2.6	0.47	3.2	0.58
Stomach	21	14.3	1.43	16.9	1.65	16	7.5	0.88	8.8	0.99
Small intestine	8	5.3	0.87	6.0	0.98	10	4.7	0.70	5.5	0.80
Colon excl. rectum	54	36.3	2.29	42.9	2.65	72	32.3	1.75	38.6	2.06
Rectum & rectosigmoid	22	14.8	1.47	17.4	1.67	21	10.3	1.04	11.9	1.18
Anus, anal canal & anorectum	7	5.3	0.89	5.9	0.98	7	3.2	0.56	4.1	0.70
Liver	46	25.6	1.75	33.4	2.23	16	6.9	0.79	8.7	0.98
Gallbladder	3	1.9	0.53	2.3	0.61	4	1.9	0.41	2.2	0.48
Pancreas	34	21.7	1.71	26.6	2.04	35	15.5	1.19	18.8	1.43
Respiratory System	120	76.7	3.25	93.3	3.85	130	57.0	2.29	70.0	2.77
Larynx	11	6.7	0.94	8.4	1.14	5	2.4	0.48	3.0	0.58
Lung & bronchus	107	69.3	3.10	83.9	3.65	123	53.9	2.22	66.2	2.69
Bones & Joints	2	1.6	0.48	1.7	0.49	-	-	-	-	-
Soft Tissue (incl. heart)	7	4.6	0.82	5.0	0.89	5	2.6	0.52	2.9	0.57
Skin (excl. basal & sq.)	-	-	-	-	-	3	1.8	0.47	2.0	0.48
Melanomas of the skin	1	0.9	0.36	1.1	0.42	1	0.7	0.29	0.8	0.31
Breast (excl. <i>in situ</i>)	5	3.2	0.68	3.8	0.78	288	139.1	3.82	161.6	4.32
Female Genital System	-	-	-	-	-	126	58.9	2.43	70.2	2.82
Cervix uteri	-	-	-	-	-	18	9.7	1.06	10.7	1.13
Uterus Corpus	-	-	-	-	-	70	31.2	1.72	38.4	2.07
Uterus, NOS ¹	-	-	-	-	-	5	2.4	0.48	3.0	0.59
Ovary	-	-	-	-	-	24	11.5	1.09	13.3	1.23
Male Genital System	234	145.9	4.42	180.4	5.32	-	-	-	-	-
Prostate	230	143.2	4.37	177.6	5.28	-	-	-	-	-
Testis	3	2.4	0.62	2.4	0.61	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	62	40.4	2.37	48.9	2.79	44	19.6	1.37	23.5	1.61
Bladder (incl. <i>in situ</i>)	26	17.5	1.58	20.9	1.86	19	8.2	0.87	9.7	1.01
Kidney & renal pelvis	36	22.5	1.75	27.4	2.06	24	10.8	1.03	13.1	1.22
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	4.7	0.79	5.1	0.86	7	3.8	0.65	4.0	0.68
Brain	7	4.1	0.73	4.5	0.80	6	2.7	0.53	3.1	0.59
Endocrine System	10	6.4	0.94	7.6	1.09	31	15.6	1.32	17.7	1.44
Thyroid gland	9	5.5	0.86	6.5	1.01	29	14.9	1.29	17.0	1.42
Lymphomas	32	21.2	1.74	24.5	1.96	29	14.0	1.21	16.0	1.35
Hodgkin Lymphoma	4	2.5	0.61	2.7	0.64	5	2.7	0.54	2.9	0.57
Non-Hodgkin Lymphoma	28	18.7	1.62	21.8	1.85	24	11.3	1.08	13.1	1.22
Multiple Myeloma	20	13.6	1.41	16.0	1.62	23	10.4	0.99	12.5	1.18
Leukemias	14	9.9	1.20	11.3	1.35	14	6.4	0.81	7.2	0.89
Acute lymphocytic	1	1.0	0.38	0.8	0.29	-	-	-	-	-
Chronic lymphocytic	5	3.2	0.70	3.8	0.80	2	1.0	0.31	1.3	0.37
Acute myeloid	4	3.0	0.67	3.5	0.76	5	2.1	0.43	2.5	0.51
Chronic myeloid	2	1.1	0.34	1.4	0.46	3	1.5	0.43	1.6	0.44
Other leukemias	2	1.5	0.50	1.7	0.55	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	5	3.1	0.65	3.2	0.67	-	-	-	-	-
Ill-defined & Unknown	29	19.6	1.69	22.7	1.91	31	13.9	1.16	16.2	1.32
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	8.8	1.15	9.9	1.26	29	13.9	1.20	16.3	1.37
Breast (<i>in situ</i>)	-	-	-	-	-	77	37.7	1.99	44.3	2.29

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	19,563,166	19,860,330	20,224,249	20,629,982	20,976,812
White	15,469,854	15,678,062	15,944,691	16,242,093	16,489,706
Black	3,389,052	3,455,611	3,527,043	3,604,523	3,674,436
American Indian/Alaskan Native (AI/AN)	105,670	107,900	110,839	113,783	116,771
Asian/Pacific Islander (API)	598,590	618,757	641,676	669,583	695,899


All Races Population 2013-2017: 101,254,539
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	4,657,941	4,810,901	4,989,264	5,187,276	5,373,742
Non-Hispanic White	11,151,982	11,221,535	11,327,199	11,445,464	11,524,173
Non-Hispanic Black	3,135,490	3,190,694	3,248,644	3,311,235	3,367,498

Hispanic/Latino Population, Census 2010: 4,223,806
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

FLORIDA CANCER REGISTRY

Initial Operation: 1981
 Population-based Data Available: 1981
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.8	108.7	110.2	107.5	103.0
Missing Race	1.5	1.8	2.4	3.5	2.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	1.4	1.5	1.5	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Prostate	94.5
Oral Cavity & Pharynx	96.0	Testis	97.8
Esophagus	94.1	Bladder (incl. <i>in situ</i>)	97.2
Stomach	96.3	Kidney & Renal Pelvis	89.5
Colon & Rectum	96.1	Brain & Other CNS ¹	84.5
Liver	69.4	Thyroid	99.3
Pancreas	85.2	Hodgkin Lymphoma	99.0
Lung & Bronchus	89.7	Non-Hodgkin Lymphoma	97.9
Melanomas of the Skin	98.8	Multiple Myeloma	96.0
Female Breast (excl. <i>in situ</i>)	98.2	Leukemias	95.8
Cervix uteri	97.1	Brain & Other CNS ¹ <i>non-malig</i>	38.1
Uterus Corpus & Uterus NOS ¹	98.5	Breast <i>in situ</i>	100.0
Ovary	92.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	65,331	499.1	0.89	593.6	1.05	61,222	425.9	0.81	497.4	0.92
Oral Cavity & Pharynx	2,804	21.6	0.19	26.6	0.23	990	6.8	0.10	8.2	0.12
Lip	58	0.5	0.03	0.6	0.03	17	0.1	0.01	0.1	0.01
Tongue	921	7.0	0.11	8.7	0.13	302	2.1	0.06	2.5	0.07
Major salivary gland	202	1.6	0.05	1.9	0.06	127	0.9	0.04	1.1	0.04
Floor of mouth	118	0.9	0.04	1.1	0.05	56	0.4	0.02	0.5	0.03
Gum & other mouth	233	1.8	0.05	2.2	0.06	180	1.2	0.04	1.4	0.05
Nasopharynx	95	0.8	0.04	0.9	0.04	40	0.3	0.02	0.4	0.03
Oropharynx	206	1.6	0.05	2.0	0.06	50	0.3	0.02	0.4	0.03
Hypopharynx	168	1.3	0.04	1.6	0.05	39	0.3	0.02	0.3	0.02
Digestive System	11,988	91.6	0.38	110.3	0.46	9,300	61.3	0.30	72.6	0.35
Esophagus	1,021	7.6	0.11	9.2	0.13	276	1.7	0.05	2.1	0.06
Stomach	1,008	7.8	0.11	9.2	0.13	606	4.1	0.08	4.7	0.09
Small intestine	300	2.3	0.06	2.8	0.07	257	1.8	0.05	2.1	0.06
Colon excl. rectum	3,768	29.2	0.22	34.6	0.26	3,653	24.1	0.19	28.3	0.21
Rectum & rectosigmoid	1,584	12.5	0.14	15.1	0.17	1,084	7.6	0.11	9.1	0.13
Anus, anal canal & anorectum	234	1.9	0.06	2.3	0.07	420	2.9	0.07	3.5	0.08
Liver	1,469	10.8	0.13	13.7	0.16	492	3.2	0.07	3.9	0.08
Gallbladder	95	0.7	0.03	0.8	0.04	183	1.2	0.04	1.4	0.05
Pancreas	1,920	14.5	0.15	17.3	0.18	1,724	10.9	0.12	12.9	0.14
Respiratory System	9,982	74.1	0.34	89.0	0.40	8,303	52.3	0.26	62.6	0.31
Larynx	858	6.4	0.10	7.9	0.12	185	1.2	0.04	1.5	0.05
Lung & bronchus	8,976	66.5	0.32	79.7	0.38	8,029	50.5	0.26	60.3	0.31
Bones & Joints	145	1.4	0.05	1.4	0.05	103	0.9	0.04	0.9	0.04
Soft Tissue (incl. heart)	477	4.0	0.08	4.5	0.09	383	3.0	0.07	3.3	0.08
Skin (excl. basal & sq.)	4,659	36.2	0.24	42.3	0.28	2,652	19.1	0.17	22.0	0.20
Melanomas of the skin	4,285	33.3	0.23	39.0	0.27	2,467	17.9	0.17	20.5	0.19
Breast (excl. <i>in situ</i>)	157	1.2	0.04	1.4	0.05	16,451	118.3	0.43	138.8	0.50
Female Genital System	-	-	-	-	-	6,793	48.8	0.28	57.7	0.32
Cervix uteri	-	-	-	-	-	1,001	8.9	0.13	9.7	0.14
Uterus Corpus	-	-	-	-	-	3,484	23.7	0.19	29.0	0.22
Uterus, NOS ¹	-	-	-	-	-	140	1.0	0.04	1.1	0.04
Ovary	-	-	-	-	-	1,567	11.1	0.13	13.1	0.15
Male Genital System	13,599	99.7	0.39	121.8	0.47	-	-	-	-	-
Prostate	13,024	93.9	0.37	115.9	0.46	-	-	-	-	-
Testis	447	4.8	0.10	4.8	0.10	-	-	-	-	-
Penis	102	0.8	0.04	1.0	0.04	-	-	-	-	-
Urinary System	7,015	53.3	0.29	62.9	0.34	2,826	18.6	0.16	21.8	0.19
Bladder (incl. <i>in situ</i>)	4,335	32.4	0.22	38.0	0.26	1,320	8.2	0.10	9.7	0.12
Kidney & renal pelvis	2,527	19.8	0.18	23.5	0.21	1,424	9.9	0.12	11.6	0.14
Ureter	104	0.8	0.03	0.9	0.04	57	0.3	0.02	0.4	0.02
Eye & Orbit	110	0.9	0.04	1.0	0.04	92	0.7	0.04	0.8	0.04
Brain & Other CNS ¹	874	7.5	0.12	8.3	0.13	689	5.4	0.10	5.9	0.10
Brain	827	7.1	0.11	7.9	0.12	640	5.0	0.09	5.5	0.10
Endocrine System	804	7.1	0.12	8.0	0.13	2,146	19.1	0.19	20.7	0.20
Thyroid gland	714	6.3	0.11	7.1	0.12	2,068	18.5	0.19	20.0	0.20
Lymphomas	3,921	31.8	0.23	36.3	0.26	3,261	23.0	0.19	26.4	0.21
Hodgkin Lymphoma	379	3.6	0.09	3.8	0.09	310	2.9	0.08	3.0	0.08
Non-Hodgkin Lymphoma	3,542	28.2	0.22	32.5	0.25	2,951	20.1	0.17	23.4	0.20
Multiple Myeloma	1,310	9.9	0.12	11.8	0.15	1,024	6.6	0.10	7.9	0.11
Leukemias	2,844	22.7	0.20	25.9	0.22	2,082	14.6	0.15	16.5	0.17
Acute lymphocytic	223	2.3	0.07	2.2	0.07	162	1.6	0.06	1.5	0.05
Chronic lymphocytic	1,090	8.2	0.11	9.7	0.13	752	4.7	0.08	5.6	0.09
Acute myeloid	742	5.9	0.10	6.7	0.11	565	4.1	0.08	4.6	0.09
Chronic myeloid	393	3.2	0.07	3.6	0.08	288	2.1	0.06	2.4	0.06
Other leukemias	396	3.2	0.07	3.6	0.08	314	2.2	0.06	2.5	0.06
Mesothelioma	174	1.3	0.04	1.5	0.05	58	0.4	0.02	0.4	0.03
Kaposi Sarcoma	91	0.9	0.04	0.9	0.04	15	0.1	0.01	0.1	0.01
Ill-defined & Unknown	4,378	33.8	0.23	39.4	0.27	4,054	26.6	0.20	30.8	0.22
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1,116	9.4	0.13	10.6	0.14	2,319	16.7	0.16	19.1	0.18
Breast (<i>in situ</i>)	15	0.1	0.01	0.1	0.02	3,693	27.1	0.21	32.0	0.24

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	55,796	490.4	0.95	582.6	1.12	51,779	424.5	0.89	495.7	1.01
Oral Cavity & Pharynx	2,499	22.5	0.21	27.8	0.25	870	7.1	0.11	8.5	0.13
Lip	56	0.5	0.03	0.6	0.04	16	0.1	0.01	0.1	0.02
Tongue	845	7.5	0.12	9.3	0.15	275	2.3	0.06	2.7	0.08
Major salivary gland	179	1.6	0.05	1.9	0.06	101	0.9	0.04	1.0	0.05
Floor of mouth	111	1.0	0.04	1.2	0.05	51	0.4	0.03	0.5	0.03
Gum & other mouth	200	1.8	0.06	2.2	0.07	158	1.2	0.04	1.4	0.05
Nasopharynx	67	0.6	0.04	0.8	0.04	28	0.3	0.02	0.3	0.03
Oropharynx	179	1.6	0.06	2.0	0.07	44	0.4	0.02	0.4	0.03
Hypopharynx	141	1.2	0.05	1.5	0.06	34	0.3	0.02	0.3	0.03
Digestive System	10,124	89.0	0.41	107.1	0.48	7,687	58.9	0.32	69.7	0.37
Esophagus	923	7.9	0.12	9.6	0.14	232	1.7	0.05	2.0	0.06
Stomach	786	6.9	0.11	8.2	0.13	450	3.5	0.08	4.1	0.09
Small intestine	247	2.2	0.06	2.6	0.08	205	1.7	0.06	2.0	0.06
Colon excl. rectum	3,147	28.0	0.23	33.2	0.27	3,032	23.1	0.20	27.1	0.23
Rectum & rectosigmoid	1,338	12.3	0.16	14.9	0.19	910	7.6	0.12	9.1	0.14
Anus, anal canal & anorectum	199	1.9	0.06	2.3	0.07	380	3.1	0.07	3.8	0.09
Liver	1,222	10.4	0.14	13.3	0.17	388	2.9	0.07	3.6	0.08
Gallbladder	74	0.6	0.03	0.7	0.04	136	1.0	0.04	1.2	0.05
Pancreas	1,673	14.3	0.16	17.1	0.19	1,444	10.5	0.13	12.4	0.15
Respiratory System	8,818	74.6	0.36	89.6	0.43	7,492	54.6	0.29	65.5	0.35
Larynx	744	6.5	0.11	8.0	0.13	165	1.3	0.05	1.6	0.06
Lung & bronchus	7,944	66.9	0.34	80.2	0.41	7,255	52.7	0.28	63.1	0.34
Bones & Joints	119	1.4	0.06	1.5	0.06	83	0.9	0.05	0.9	0.05
Soft Tissue (incl. heart)	405	4.0	0.09	4.5	0.10	310	2.9	0.08	3.2	0.09
Skin (excl. basal & sq.)	4,426	39.5	0.27	46.2	0.32	2,482	21.5	0.21	24.7	0.23
Melanomas of the skin	4,077	36.5	0.26	42.8	0.30	2,320	20.3	0.20	23.3	0.23
Breast (excl. <i>in situ</i>)	129	1.1	0.04	1.3	0.05	13,752	117.0	0.48	137.4	0.54
Female Genital System	-	-	-	-	-	5,570	48.0	0.31	56.6	0.35
Cervix uteri	-	-	-	-	-	766	8.7	0.15	9.3	0.15
Uterus Corpus	-	-	-	-	-	2,847	23.1	0.20	28.2	0.24
Uterus, NOS ¹	-	-	-	-	-	102	0.8	0.04	1.0	0.05
Ovary	-	-	-	-	-	1,338	11.3	0.15	13.3	0.17
Male Genital System	10,586	89.6	0.40	109.0	0.48	-	-	-	-	-
Prostate	10,086	83.2	0.37	102.4	0.46	-	-	-	-	-
Testis	394	5.5	0.13	5.4	0.12	-	-	-	-	-
Penis	86	0.8	0.04	0.9	0.05	-	-	-	-	-
Urinary System	6,224	53.8	0.31	63.5	0.37	2,431	18.6	0.18	21.8	0.21
Bladder (incl. <i>in situ</i>)	3,918	33.0	0.24	38.8	0.28	1,160	8.3	0.11	9.8	0.13
Kidney & renal pelvis	2,164	19.6	0.20	23.3	0.23	1,197	9.8	0.14	11.5	0.15
Ureter	99	0.8	0.04	1.0	0.04	53	0.4	0.02	0.4	0.03
Eye & Orbit	99	1.0	0.05	1.1	0.05	83	0.8	0.04	0.9	0.04
Brain & Other CNS ¹	775	8.0	0.14	8.9	0.15	599	5.7	0.11	6.3	0.12
Brain	736	7.6	0.13	8.4	0.14	557	5.3	0.11	5.8	0.11
Endocrine System	699	7.5	0.13	8.3	0.14	1,795	20.2	0.23	21.7	0.24
Thyroid gland	631	6.8	0.13	7.6	0.14	1,736	19.6	0.22	21.1	0.23
Lymphomas	3,393	31.7	0.25	36.4	0.29	2,738	22.6	0.21	26.0	0.23
Hodgkin Lymphoma	308	3.6	0.10	3.8	0.10	241	2.8	0.09	3.0	0.09
Non-Hodgkin Lymphoma	3,085	28.1	0.23	32.6	0.27	2,498	19.8	0.19	23.0	0.21
Multiple Myeloma	1,010	8.7	0.12	10.3	0.15	738	5.5	0.09	6.5	0.11
Leukemias	2,490	23.0	0.21	26.2	0.24	1,761	14.6	0.17	16.4	0.18
Acute lymphocytic	186	2.5	0.08	2.3	0.08	135	1.8	0.07	1.6	0.07
Chronic lymphocytic	971	8.3	0.12	9.8	0.14	655	4.7	0.09	5.6	0.10
Acute myeloid	657	6.0	0.11	6.9	0.12	475	4.0	0.09	4.5	0.10
Chronic myeloid	336	3.1	0.08	3.6	0.09	243	2.0	0.06	2.3	0.07
Other leukemias	341	3.1	0.08	3.6	0.09	253	2.1	0.06	2.4	0.07
Mesothelioma	164	1.4	0.05	1.6	0.06	54	0.4	0.03	0.5	0.03
Kaposi Sarcoma	63	0.7	0.04	0.8	0.04	10	0.1	0.01	0.1	0.01
Ill-defined & Unknown	3,774	32.9	0.25	38.5	0.28	3,323	25.1	0.21	29.0	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	940	9.3	0.14	10.5	0.16	1,903	16.2	0.18	18.5	0.20
Breast (<i>in situ</i>)	13	0.1	0.01	0.1	0.02	3,037	26.7	0.23	31.6	0.27

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,450	461.9	2.71	555.8	3.20	6,486	370.6	2.10	434.9	2.43
Oral Cavity & Pharynx	201	13.6	0.45	16.6	0.54	83	4.6	0.23	5.5	0.27
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	45	3.1	0.22	3.8	0.26	18	1.0	0.11	1.2	0.13
Major salivary gland	15	1.1	0.13	1.2	0.15	19	1.1	0.11	1.3	0.13
Floor of mouth	6	0.4	0.08	0.5	0.10	3	0.2	0.04	0.2	0.05
Gum & other mouth	22	1.5	0.15	1.8	0.17	15	0.8	0.10	1.0	0.12
Nasopharynx	18	1.2	0.13	1.3	0.15	8	0.4	0.07	0.5	0.08
Oropharynx	19	1.2	0.13	1.6	0.16	5	0.3	0.06	0.3	0.07
Hypopharynx	22	1.6	0.16	2.0	0.20	4	0.2	0.05	0.3	0.06
Digestive System	1,373	100.1	1.28	120.4	1.51	1,217	70.6	0.92	84.0	1.08
Esophagus	66	4.8	0.28	5.8	0.33	34	1.9	0.15	2.3	0.18
Stomach	168	13.1	0.48	15.5	0.56	117	7.0	0.29	8.1	0.34
Small intestine	43	3.1	0.22	3.8	0.27	42	2.4	0.17	2.9	0.20
Colon excl. rectum	472	35.0	0.76	41.8	0.89	473	27.4	0.58	32.6	0.67
Rectum & rectosigmoid	165	11.6	0.42	14.0	0.50	122	7.0	0.29	8.3	0.34
Anus, anal canal & anorectum	27	1.8	0.16	2.1	0.18	28	1.6	0.14	1.9	0.16
Liver	181	11.6	0.40	14.8	0.50	76	4.1	0.22	5.1	0.26
Gallbladder	15	1.3	0.15	1.4	0.17	37	2.1	0.16	2.6	0.19
Pancreas	184	14.0	0.49	16.6	0.57	221	13.1	0.40	15.5	0.47
Respiratory System	870	65.0	1.04	78.4	1.23	602	34.8	0.65	41.7	0.76
Larynx	88	6.3	0.32	7.7	0.38	16	0.9	0.10	1.1	0.12
Lung & bronchus	770	57.9	0.99	69.8	1.16	574	33.2	0.63	39.9	0.75
Bones & Joints	18	1.1	0.12	1.2	0.13	16	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	53	3.6	0.23	4.0	0.26	56	3.2	0.19	3.4	0.21
Skin (excl. basal & sq.)	33	2.5	0.20	2.8	0.23	28	1.6	0.14	1.8	0.16
Melanomas of the skin	21	1.7	0.17	1.9	0.19	15	0.9	0.10	1.0	0.12
Breast (excl. <i>in situ</i>)	20	1.5	0.16	1.8	0.18	1,901	107.4	1.12	126.1	1.30
Female Genital System	-	-	-	-	-	926	51.7	0.78	61.5	0.91
Cervix uteri	-	-	-	-	-	183	10.5	0.35	11.7	0.39
Uterus Corpus	-	-	-	-	-	493	27.0	0.56	33.0	0.67
Uterus, NOS ¹	-	-	-	-	-	31	1.7	0.14	2.1	0.17
Ovary	-	-	-	-	-	154	8.9	0.33	10.3	0.37
Male Genital System	2,186	149.4	1.50	185.7	1.81	-	-	-	-	-
Prostate	2,150	147.1	1.49	183.2	1.80	-	-	-	-	-
Testis	20	1.2	0.12	1.2	0.12	-	-	-	-	-
Penis	12	0.9	0.11	1.0	0.14	-	-	-	-	-
Urinary System	452	34.3	0.76	40.5	0.89	264	15.4	0.43	18.0	0.50
Bladder (incl. <i>in situ</i>)	175	15.0	0.53	17.5	0.62	80	4.9	0.25	5.8	0.29
Kidney & renal pelvis	270	18.8	0.54	22.4	0.63	179	10.2	0.35	11.9	0.40
Ureter	3	0.2	0.05	0.2	0.07	2	0.1	0.04	0.2	0.05
Eye & Orbit	6	0.3	0.06	0.3	0.06	6	0.3	0.06	0.3	0.06
Brain & Other CNS ¹	72	4.8	0.26	5.2	0.29	63	3.5	0.20	3.7	0.21
Brain	66	4.4	0.25	4.8	0.28	58	3.2	0.19	3.4	0.21
Endocrine System	62	4.1	0.24	4.6	0.27	229	12.8	0.38	14.4	0.43
Thyroid gland	46	3.1	0.21	3.5	0.24	213	11.9	0.37	13.4	0.41
Lymphomas	319	21.9	0.58	24.7	0.65	295	16.9	0.45	19.1	0.50
Hodgkin Lymphoma	48	2.9	0.19	3.1	0.20	43	2.3	0.16	2.4	0.17
Non-Hodgkin Lymphoma	271	19.0	0.54	21.6	0.61	252	14.5	0.42	16.7	0.47
Multiple Myeloma	230	17.5	0.55	20.9	0.64	226	13.3	0.40	15.7	0.47
Leukemias	215	15.5	0.50	17.6	0.57	187	10.8	0.36	12.1	0.40
Acute lymphocytic	24	1.4	0.14	1.4	0.14	20	1.1	0.11	1.1	0.11
Chronic lymphocytic	59	4.6	0.28	5.4	0.33	43	2.6	0.18	3.0	0.21
Acute myeloid	63	4.5	0.27	5.1	0.31	60	3.5	0.20	3.9	0.23
Chronic myeloid	36	2.5	0.20	2.9	0.23	28	1.6	0.14	1.8	0.15
Other leukemias	33	2.4	0.20	2.8	0.23	36	2.0	0.15	2.4	0.18
Mesothelioma	7	0.5	0.10	0.6	0.11	2	0.1	0.04	0.2	0.05
Kaposi Sarcoma	21	1.3	0.13	1.4	0.14	3	0.2	0.04	0.2	0.05
Ill-defined & Unknown	311	24.8	0.67	29.1	0.77	380	22.6	0.53	26.2	0.61
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	127	9.3	0.39	10.6	0.44	301	17.5	0.46	20.1	0.52
Breast (<i>in situ</i>)	2	0.1	0.04	0.2	0.05	467	26.1	0.55	31.1	0.65

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	623	226.6	4.23	266.3	4.95	872	238.4	3.71	275.9	4.26
Oral Cavity & Pharynx	32	11.1	0.91	13.4	1.09	14	3.9	0.47	4.5	0.54
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	8	2.8	0.46	3.4	0.54	3	0.9	0.22	1.0	0.25
Major salivary gland	2	0.7	0.23	0.9	0.29	3	0.8	0.22	1.0	0.25
Floor of mouth	-	-	-	-	-	1	0.3	0.12	0.4	0.15
Gum & other mouth	5	1.7	0.35	2.2	0.44	3	0.9	0.24	1.0	0.27
Nasopharynx	8	2.5	0.40	2.8	0.46	2	0.6	0.18	0.6	0.19
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	0.8	0.28	0.9	0.33	-	-	-	-	-
Digestive System	164	59.1	2.14	70.2	2.53	138	39.4	1.55	45.9	1.79
Esophagus	7	2.6	0.44	3.0	0.50	3	1.0	0.25	1.2	0.29
Stomach	20	7.0	0.73	8.4	0.87	16	4.6	0.53	5.4	0.61
Small intestine	2	0.8	0.25	1.0	0.32	3	0.8	0.23	0.9	0.27
Colon excl. rectum	46	17.0	1.17	19.9	1.36	45	13.0	0.90	15.0	1.03
Rectum & rectosigmoid	30	10.5	0.89	12.4	1.05	20	5.6	0.58	6.6	0.67
Anus, anal canal & anorectum	1	0.5	0.21	0.5	0.22	1	0.4	0.14	0.4	0.16
Liver	30	10.5	0.89	12.6	1.06	14	4.4	0.54	5.1	0.62
Gallbladder	2	0.7	0.24	0.8	0.27	3	0.9	0.22	1.1	0.28
Pancreas	17	6.4	0.73	7.8	0.88	21	5.9	0.60	6.9	0.69
Respiratory System	89	32.9	1.64	39.4	1.94	80	23.3	1.20	27.2	1.39
Larynx	6	2.1	0.40	2.6	0.49	-	-	-	-	-
Lung & bronchus	80	30.0	1.57	35.7	1.86	78	22.6	1.19	26.4	1.37
Bones & Joints	3	1.0	0.27	1.0	0.30	2	0.6	0.19	0.6	0.20
Soft Tissue (incl. heart)	5	1.7	0.37	1.9	0.41	9	2.4	0.38	2.6	0.41
Skin (excl. basal & sq.)	6	2.1	0.42	2.5	0.49	4	1.2	0.27	1.4	0.31
Melanomas of the skin	4	1.6	0.37	1.9	0.43	3	0.9	0.23	1.1	0.27
Breast (excl. <i>in situ</i>)	2	0.6	0.21	0.7	0.25	295	77.4	2.06	90.1	2.38
Female Genital System	-	-	-	-	-	114	29.5	1.27	34.6	1.47
Cervix uteri	-	-	-	-	-	20	5.2	0.53	5.6	0.57
Uterus Corpus	-	-	-	-	-	56	14.1	0.86	17.1	1.03
Uterus, NOS ¹	-	-	-	-	-	3	0.8	0.23	0.9	0.25
Ovary	-	-	-	-	-	30	7.9	0.66	9.2	0.77
Male Genital System	120	42.3	1.78	51.0	2.13	-	-	-	-	-
Prostate	114	40.4	1.75	49.0	2.10	-	-	-	-	-
Testis	5	1.5	0.30	1.5	0.30	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	52	19.8	1.29	22.9	1.48	22	6.7	0.65	7.7	0.75
Bladder (incl. <i>in situ</i>)	25	10.2	0.96	11.9	1.11	7	2.4	0.41	2.8	0.46
Kidney & renal pelvis	25	9.2	0.84	10.5	0.97	14	4.0	0.49	4.6	0.56
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	2.7	0.44	3.0	0.50	8	2.2	0.36	2.3	0.38
Brain	7	2.5	0.43	2.8	0.49	7	2.0	0.34	2.1	0.36
Endocrine System	15	4.7	0.55	5.4	0.64	59	15.7	0.93	17.2	1.02
Thyroid gland	13	4.0	0.51	4.7	0.60	57	15.2	0.91	16.7	1.00
Lymphomas	45	15.9	1.11	18.1	1.25	45	12.6	0.87	14.6	1.00
Hodgkin Lymphoma	5	1.6	0.34	1.8	0.38	3	1.0	0.25	0.9	0.24
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	15	5.6	0.69	6.7	0.82	13	3.4	0.44	4.1	0.52
Leukemias	27	9.9	0.88	10.6	0.95	26	7.0	0.64	8.1	0.73
Acute lymphocytic	-	-	-	-	-	3	0.7	0.21	0.8	0.21
Chronic lymphocytic	5	2.0	0.40	2.2	0.44	4	1.0	0.25	1.2	0.30
Acute myeloid	7	2.5	0.44	2.8	0.49	12	3.3	0.44	3.8	0.49
Chronic myeloid	6	2.0	0.38	2.3	0.42	4	0.9	0.23	1.1	0.27
Other leukemias	3	1.5	0.39	1.7	0.46	4	1.0	0.25	1.2	0.29
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	0.4	0.15	0.4	0.17	-	-	-	-	-
Ill-defined & Unknown	40	16.3	1.22	18.9	1.42	42	12.6	0.90	14.4	1.03
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	15	5.6	0.68	6.5	0.80	45	12.7	0.87	14.5	0.98
Breast (<i>in situ</i>)	-	-	-	-	-	79	20.4	1.05	24.0	1.22

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

FLORIDA

II-126 Incidence – API

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	19	189.1	20.84	228.4	24.61	22	198.3	19.57	223.6	21.80
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	36.9	8.69	48.4	11.18	5	42.1	9.08	50.5	10.74
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	2	19.2	6.32	23.2	7.51
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	21.2	7.57	24.9	8.61	2	18.0	6.16	20.5	6.92
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	1	15.5	6.26	18.1	7.01	2	18.0	6.16	20.5	6.92
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	8	68.3	11.40	78.9	12.95
Female Genital System	-	-	-	-	-	3	28.3	7.40	28.9	7.47
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	16.6	5.60	17.7	5.90
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	46.3	10.37	57.0	12.40	-	-	-	-	-
Prostate	4	45.0	10.28	55.6	12.32	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	20.9	7.02	24.4	8.26	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	16.7	5.62	19.3	6.52	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	1	11.9	5.12	13.7	5.79	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	1	11.9	5.12	13.7	5.79	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	13.2	5.32	16.7	6.43	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	1	11.6	4.83	13.0	5.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, Hispanic/Latino, All Races

<i>SITES</i>	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	8,947	426.1	2.05	503.8	2.42	9,628	361.2	1.65	421.2	1.93
Oral Cavity & Pharynx	335	15.2	0.38	18.5	0.46	133	4.9	0.19	5.8	0.23
Lip	5	0.3	0.05	0.3	0.06	1	0.0	0.02	0.1	0.02
Tongue	105	4.7	0.21	5.8	0.25	41	1.5	0.11	1.8	0.13
Major salivary gland	22	1.0	0.10	1.2	0.12	22	0.8	0.08	1.0	0.09
Floor of mouth	15	0.7	0.08	0.8	0.10	4	0.1	0.03	0.2	0.04
Gum & other mouth	34	1.6	0.13	2.0	0.15	27	1.0	0.09	1.2	0.10
Nasopharynx	16	0.7	0.08	0.9	0.10	6	0.2	0.04	0.3	0.05
Oropharynx	24	1.1	0.10	1.3	0.12	5	0.2	0.03	0.2	0.04
Hypopharynx	18	0.8	0.09	1.0	0.11	3	0.1	0.03	0.1	0.04
Digestive System	1,934	92.2	0.95	110.3	1.13	1,655	61.7	0.68	72.7	0.80
Esophagus	100	4.8	0.22	5.8	0.26	28	1.0	0.09	1.3	0.11
Stomach	203	9.7	0.31	11.4	0.36	153	5.7	0.21	6.6	0.24
Small intestine	44	2.1	0.14	2.4	0.17	44	1.7	0.11	2.0	0.13
Colon excl. rectum	640	30.9	0.56	36.7	0.66	663	24.7	0.43	29.0	0.51
Rectum & rectosigmoid	266	12.3	0.34	14.7	0.41	186	6.9	0.23	8.2	0.27
Anus, anal canal & anorectum	30	1.4	0.11	1.6	0.13	68	2.5	0.14	3.0	0.17
Liver	262	12.0	0.34	15.0	0.42	103	3.8	0.17	4.6	0.20
Gallbladder	16	0.8	0.09	1.0	0.11	40	1.5	0.11	1.8	0.13
Pancreas	278	13.6	0.37	16.2	0.44	270	10.1	0.28	11.8	0.32
Respiratory System	1,168	58.1	0.77	69.0	0.91	774	28.8	0.47	34.4	0.55
Larynx	129	6.0	0.24	7.4	0.30	19	0.7	0.07	0.9	0.09
Lung & bronchus	1,014	51.0	0.73	60.3	0.85	741	27.6	0.46	32.9	0.54
Bones & Joints	31	1.3	0.11	1.3	0.11	21	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	89	4.0	0.19	4.5	0.22	81	3.1	0.15	3.4	0.17
Skin (excl. basal & sq.)	166	7.9	0.28	9.3	0.33	146	5.5	0.20	6.3	0.23
Melanomas of the skin	143	6.8	0.26	8.0	0.31	129	4.8	0.19	5.6	0.22
Breast (excl. <i>in situ</i>)	21	1.0	0.10	1.2	0.12	2,691	100.9	0.87	118.8	1.03
Female Genital System	-	-	-	-	-	1,261	46.9	0.59	55.7	0.71
Cervix uteri	-	-	-	-	-	247	9.4	0.27	10.5	0.30
Uterus Corpus	-	-	-	-	-	628	23.1	0.41	28.3	0.51
Uterus, NOS ¹	-	-	-	-	-	29	1.1	0.09	1.3	0.11
Ovary	-	-	-	-	-	273	10.2	0.28	12.0	0.33
Male Genital System	2,184	102.5	1.00	124.1	1.20	-	-	-	-	-
Prostate	2,041	96.8	0.97	118.2	1.18	-	-	-	-	-
Testis	114	4.3	0.18	4.3	0.18	-	-	-	-	-
Penis	24	1.1	0.10	1.3	0.12	-	-	-	-	-
Urinary System	878	43.1	0.66	50.6	0.77	413	15.4	0.34	18.1	0.40
Bladder (incl. <i>in situ</i>)	456	23.6	0.50	27.5	0.58	156	5.8	0.21	6.9	0.25
Kidney & renal pelvis	404	18.6	0.42	22.0	0.50	246	9.2	0.26	10.8	0.31
Ureter	13	0.6	0.08	0.8	0.10	7	0.3	0.05	0.3	0.05
Eye & Orbit	16	0.7	0.08	0.8	0.09	13	0.5	0.06	0.5	0.07
Brain & Other CNS ¹	155	6.9	0.25	7.6	0.28	137	5.3	0.20	5.7	0.22
Brain	144	6.4	0.24	7.1	0.27	123	4.7	0.19	5.1	0.21
Endocrine System	185	7.9	0.26	8.9	0.30	640	24.6	0.44	27.0	0.48
Thyroid gland	165	7.0	0.25	8.0	0.28	624	24.0	0.43	26.4	0.48
Lymphomas	644	29.6	0.53	33.8	0.61	592	22.4	0.41	25.7	0.47
Hodgkin Lymphoma	90	3.8	0.18	4.0	0.19	76	3.0	0.15	3.1	0.16
Non-Hodgkin Lymphoma	554	25.9	0.50	29.9	0.58	516	19.4	0.38	22.6	0.45
Multiple Myeloma	182	8.9	0.30	10.6	0.35	165	6.1	0.21	7.3	0.26
Leukemias	388	18.1	0.42	20.3	0.47	348	13.3	0.32	14.8	0.36
Acute lymphocytic	73	3.0	0.16	2.8	0.15	52	2.1	0.13	2.0	0.13
Chronic lymphocytic	98	4.8	0.22	5.7	0.26	80	3.0	0.15	3.5	0.18
Acute myeloid	110	5.2	0.23	6.0	0.26	114	4.3	0.18	4.9	0.20
Chronic myeloid	58	2.7	0.16	3.1	0.19	50	1.9	0.12	2.2	0.14
Other leukemias	49	2.3	0.15	2.7	0.17	52	2.0	0.12	2.2	0.14
Mesothelioma	14	0.7	0.09	0.8	0.10	7	0.2	0.04	0.3	0.05
Kaposi Sarcoma	25	1.1	0.10	1.2	0.11	1	0.1	0.02	0.1	0.02
Ill-defined & Unknown	533	26.8	0.53	31.0	0.61	550	20.6	0.39	23.7	0.45
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	197	9.1	0.29	10.2	0.34	451	17.0	0.36	19.5	0.41
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	655	24.6	0.43	29.1	0.51

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

FLORIDA

II-128 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	47,693	513.0	1.11	609.5	1.29	43,024	447.6	1.07	522.1	1.21
Oral Cavity & Pharynx	2,194	24.8	0.25	30.7	0.30	747	7.8	0.14	9.4	0.16
Lip	51	0.6	0.04	0.7	0.05	14	0.1	0.02	0.2	0.02
Tongue	749	8.3	0.14	10.3	0.17	236	2.5	0.08	3.0	0.09
Major salivary gland	160	1.7	0.06	2.0	0.07	81	0.9	0.05	1.0	0.05
Floor of mouth	96	1.1	0.05	1.4	0.06	48	0.5	0.04	0.6	0.04
Gum & other mouth	169	1.9	0.07	2.3	0.08	133	1.3	0.05	1.5	0.06
Nasopharynx	52	0.6	0.04	0.8	0.05	22	0.3	0.03	0.3	0.03
Oropharynx	157	1.8	0.07	2.2	0.08	39	0.4	0.03	0.5	0.04
Hypopharynx	125	1.4	0.06	1.7	0.07	30	0.3	0.03	0.4	0.03
Digestive System	8,371	90.1	0.46	108.6	0.55	6,186	59.4	0.37	70.3	0.43
Esophagus	832	8.6	0.14	10.5	0.17	206	1.9	0.06	2.3	0.07
Stomach	605	6.4	0.12	7.7	0.14	316	3.0	0.08	3.5	0.09
Small intestine	207	2.3	0.08	2.7	0.09	166	1.7	0.07	2.0	0.08
Colon excl. rectum	2,564	28.1	0.26	33.2	0.30	2,425	23.1	0.23	27.0	0.26
Rectum & rectosigmoid	1,099	12.8	0.18	15.4	0.22	742	8.0	0.15	9.5	0.17
Anus, anal canal & anorectum	172	2.0	0.07	2.5	0.09	316	3.3	0.09	4.1	0.11
Liver	986	10.2	0.15	13.1	0.19	297	2.9	0.08	3.5	0.10
Gallbladder	59	0.6	0.04	0.7	0.04	101	0.9	0.04	1.1	0.05
Pancreas	1,419	14.7	0.18	17.5	0.21	1,195	10.7	0.15	12.7	0.17
Respiratory System	7,732	79.0	0.41	95.1	0.50	6,779	61.3	0.35	73.5	0.42
Larynx	625	6.7	0.13	8.3	0.15	148	1.5	0.06	1.9	0.07
Lung & bronchus	7,001	71.0	0.39	85.2	0.47	6,571	59.1	0.34	70.9	0.41
Bones & Joints	90	1.5	0.08	1.5	0.07	64	1.0	0.06	1.0	0.06
Soft Tissue (incl. heart)	326	4.1	0.11	4.6	0.12	236	2.9	0.10	3.2	0.10
Skin (excl. basal & sq.)	4,271	47.3	0.35	55.1	0.39	2,349	27.0	0.28	30.7	0.31
Melanomas of the skin	3,943	43.9	0.33	51.3	0.38	2,202	25.6	0.28	29.1	0.30
Breast (excl. <i>in situ</i>)	110	1.2	0.05	1.4	0.06	11,309	123.4	0.58	144.5	0.65
Female Genital System	-	-	-	-	-	4,417	49.0	0.37	57.6	0.41
Cervix uteri	-	-	-	-	-	544	8.8	0.19	9.3	0.19
Uterus Corpus	-	-	-	-	-	2,275	23.3	0.24	28.4	0.28
Uterus, NOS ¹	-	-	-	-	-	76	0.8	0.05	0.9	0.05
Ovary	-	-	-	-	-	1,083	11.7	0.18	13.7	0.20
Male Genital System	8,657	89.2	0.45	108.4	0.54	-	-	-	-	-
Prostate	8,283	82.1	0.41	101.2	0.51	-	-	-	-	-
Testis	294	6.2	0.17	6.1	0.16	-	-	-	-	-
Penis	64	0.7	0.04	0.8	0.05	-	-	-	-	-
Urinary System	5,428	56.7	0.36	67.0	0.42	2,059	19.6	0.21	23.0	0.24
Bladder (incl. <i>in situ</i>)	3,506	35.2	0.27	41.5	0.32	1,021	8.9	0.13	10.6	0.15
Kidney & renal pelvis	1,797	20.3	0.23	24.1	0.26	974	10.1	0.16	11.8	0.18
Ureter	87	0.9	0.04	1.0	0.05	46	0.4	0.03	0.5	0.03
Eye & Orbit	84	1.0	0.05	1.2	0.06	71	0.9	0.05	1.0	0.06
Brain & Other CNS ¹	632	8.6	0.17	9.4	0.18	475	6.0	0.14	6.5	0.14
Brain	603	8.1	0.16	9.0	0.17	446	5.5	0.14	6.1	0.14
Endocrine System	530	7.6	0.16	8.4	0.17	1,200	18.8	0.27	20.1	0.27
Thyroid gland	480	6.9	0.15	7.6	0.16	1,155	18.2	0.27	19.4	0.27
Lymphomas	2,795	32.3	0.29	37.0	0.33	2,201	23.0	0.25	26.4	0.27
Hodgkin Lymphoma	223	3.6	0.12	3.8	0.12	172	2.9	0.11	3.0	0.11
Non-Hodgkin Lymphoma	2,573	28.7	0.27	33.2	0.31	2,030	20.1	0.22	23.4	0.25
Multiple Myeloma	846	8.8	0.14	10.4	0.17	590	5.4	0.11	6.4	0.12
Leukemias	2,139	24.0	0.25	27.5	0.28	1,447	14.9	0.20	16.9	0.21
Acute lymphocytic	120	2.2	0.10	2.1	0.09	87	1.7	0.09	1.5	0.08
Chronic lymphocytic	881	9.0	0.14	10.8	0.17	582	5.2	0.10	6.1	0.12
Acute myeloid	558	6.2	0.13	7.1	0.14	373	3.9	0.10	4.4	0.11
Chronic myeloid	283	3.2	0.09	3.7	0.10	198	2.1	0.07	2.4	0.08
Other leukemias	297	3.4	0.09	3.9	0.11	207	2.1	0.07	2.4	0.08
Mesothelioma	151	1.5	0.06	1.7	0.06	48	0.4	0.03	0.5	0.04
Kaposi Sarcoma	41	0.6	0.05	0.7	0.05	9	0.1	0.01	0.1	0.02
Ill-defined & Unknown	3,294	34.8	0.28	40.7	0.33	2,837	26.7	0.25	30.9	0.28
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	765	9.7	0.17	10.9	0.18	1,500	16.5	0.22	18.7	0.23
Breast (<i>in situ</i>)	11	0.1	0.02	0.1	0.02	2,436	27.6	0.28	32.6	0.31

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Florida, 2013-2017, Non-Hispanic Black

<i>SITES</i>	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	6,187	474.3	2.84	570.7	3.35	6,215	379.7	2.20	445.2	2.54
Oral Cavity & Pharynx	190	13.9	0.47	16.9	0.56	79	4.7	0.24	5.6	0.28
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	42	3.1	0.23	3.8	0.27	18	1.0	0.11	1.3	0.14
Major salivary gland	15	1.1	0.13	1.2	0.15	18	1.1	0.12	1.3	0.13
Floor of mouth	6	0.4	0.09	0.5	0.10	3	0.2	0.04	0.2	0.05
Gum & other mouth	20	1.5	0.15	1.8	0.18	14	0.8	0.10	1.0	0.12
Nasopharynx	17	1.2	0.14	1.4	0.16	7	0.4	0.07	0.5	0.08
Oropharynx	19	1.3	0.14	1.6	0.17	5	0.3	0.06	0.3	0.07
Hypopharynx	21	1.7	0.17	2.0	0.21	4	0.2	0.05	0.3	0.06
Digestive System	1,316	102.6	1.34	123.3	1.57	1,166	72.1	0.96	85.7	1.13
Esophagus	64	4.9	0.29	6.0	0.34	33	2.0	0.16	2.4	0.19
Stomach	162	13.5	0.50	16.0	0.59	111	7.1	0.31	8.3	0.35
Small intestine	42	3.2	0.23	3.9	0.28	40	2.4	0.18	2.9	0.21
Colon excl. rectum	452	35.9	0.80	42.8	0.93	456	28.2	0.60	33.5	0.71
Rectum & rectosigmoid	160	12.0	0.45	14.5	0.53	117	7.1	0.30	8.5	0.35
Anus, anal canal & anorectum	26	1.8	0.17	2.2	0.19	27	1.7	0.15	1.9	0.17
Liver	173	11.8	0.42	15.1	0.53	72	4.2	0.22	5.2	0.27
Gallbladder	15	1.3	0.16	1.5	0.18	35	2.1	0.17	2.6	0.20
Pancreas	175	14.2	0.51	16.9	0.59	211	13.4	0.42	15.8	0.49
Respiratory System	840	67.1	1.09	80.9	1.29	578	35.5	0.67	42.7	0.80
Larynx	84	6.4	0.33	7.8	0.39	15	0.9	0.10	1.0	0.12
Lung & bronchus	744	59.8	1.04	72.2	1.22	552	33.9	0.66	40.8	0.78
Bones & Joints	17	1.1	0.12	1.2	0.13	15	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	49	3.6	0.24	4.0	0.27	53	3.2	0.20	3.5	0.22
Skin (excl. basal & sq.)	32	2.5	0.21	2.8	0.23	28	1.7	0.15	1.9	0.16
Melanomas of the skin	20	1.7	0.18	2.0	0.20	15	0.9	0.11	1.1	0.12
Breast (excl. <i>in situ</i>)	19	1.6	0.17	1.8	0.19	1,823	110.2	1.18	129.4	1.36
Female Genital System	-	-	-	-	-	890	53.2	0.81	63.1	0.95
Cervix uteri	-	-	-	-	-	174	10.7	0.37	11.9	0.41
Uterus Corpus	-	-	-	-	-	474	27.7	0.58	33.8	0.70
Uterus, NOS ¹	-	-	-	-	-	30	1.8	0.15	2.2	0.18
Ovary	-	-	-	-	-	150	9.2	0.34	10.7	0.39
Male Genital System	2,100	153.3	1.57	190.7	1.90	-	-	-	-	-
Prostate	2,069	151.1	1.56	188.3	1.89	-	-	-	-	-
Testis	17	1.1	0.12	1.1	0.12	-	-	-	-	-
Penis	12	0.9	0.12	1.0	0.14	-	-	-	-	-
Urinary System	435	35.3	0.80	41.7	0.93	254	15.8	0.45	18.5	0.52
Bladder (incl. <i>in situ</i>)	167	15.2	0.56	17.8	0.64	77	5.0	0.26	5.9	0.30
Kidney & renal pelvis	262	19.6	0.57	23.3	0.66	172	10.5	0.37	12.2	0.42
Ureter	3	0.2	0.06	0.2	0.07	2	0.1	0.04	0.2	0.05
Eye & Orbit	5	0.3	0.06	0.3	0.06	5	0.3	0.06	0.3	0.07
Brain & Other CNS ¹	68	4.9	0.28	5.2	0.30	59	3.5	0.21	3.8	0.22
Brain	62	4.5	0.27	4.9	0.29	54	3.2	0.20	3.5	0.21
Endocrine System	59	4.2	0.25	4.7	0.28	216	13.0	0.40	14.6	0.45
Thyroid gland	44	3.1	0.22	3.6	0.25	202	12.1	0.39	13.6	0.43
Lymphomas	306	22.7	0.61	25.5	0.68	280	17.1	0.47	19.4	0.52
Hodgkin Lymphoma	47	3.0	0.20	3.2	0.22	41	2.4	0.17	2.5	0.18
Non-Hodgkin Lymphoma	259	19.7	0.57	22.3	0.64	239	14.7	0.44	16.8	0.49
Multiple Myeloma	222	18.1	0.57	21.6	0.67	220	13.8	0.42	16.3	0.49
Leukemias	202	15.7	0.52	17.8	0.59	177	10.9	0.37	12.3	0.42
Acute lymphocytic	22	1.5	0.15	1.4	0.14	19	1.1	0.12	1.1	0.11
Chronic lymphocytic	57	4.7	0.30	5.6	0.34	41	2.6	0.19	3.1	0.22
Acute myeloid	58	4.5	0.28	5.1	0.32	56	3.5	0.21	3.9	0.23
Chronic myeloid	34	2.5	0.20	2.9	0.24	26	1.6	0.14	1.8	0.16
Other leukemias	31	2.4	0.21	2.8	0.24	35	2.1	0.16	2.5	0.19
Mesothelioma	6	0.5	0.10	0.6	0.12	2	0.1	0.04	0.2	0.05
Kaposi Sarcoma	20	1.3	0.14	1.4	0.15	3	0.2	0.05	0.2	0.05
Ill-defined & Unknown	300	25.6	0.70	30.0	0.81	368	23.3	0.56	27.1	0.64
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	121	9.5	0.41	10.8	0.46	286	17.8	0.48	20.4	0.54
Breast (<i>in situ</i>)	2	0.1	0.05	0.2	0.06	449	26.9	0.58	32.0	0.68

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


FLORIDA

II-130 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	9,973,326	10,069,001	10,181,111	10,304,763	10,413,055
White	6,303,171	6,330,279	6,365,811	6,404,929	6,436,223
Black	3,212,389	3,265,278	3,323,014	3,383,693	3,442,098
American Indian/Alaskan Native (AI/AN)	55,676	56,338	57,214	58,869	59,973
Asian/Pacific Islander (API)	402,090	417,106	435,072	457,272	474,761


All Races Population 2013-2017: 50,941,256
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	899,266	916,840	941,767	971,126	997,780
Non-Hispanic White	5,540,269	5,553,636	5,568,806	5,584,026	5,593,528
Non-Hispanic Black	3,121,668	3,171,589	3,226,061	3,283,231	3,337,974

Hispanic/Latino Population, Census 2010: 853,689
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GEORGIA CANCER REGISTRY

Initial Operation: 1995
Population-based Data Available: 1995
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.0	108.4	107.3	107.9	107.7
Missing Race	0.2	0.1	0.2	0.4	0.2
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	1.9	1.3	1.3	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Prostate	96.8
Oral Cavity & Pharynx	97.5	Testis	98.8
Esophagus	95.2	Bladder (incl. <i>in situ</i>)	97.1
Stomach	95.6	Kidney & Renal Pelvis	86.4
Colon & Rectum	96.1	Brain & Other CNS ¹	84.7
Liver	51.3	Thyroid	99.2
Pancreas	83.1	Hodgkin Lymphoma	98.9
Lung & Bronchus	87.6	Non-Hodgkin Lymphoma	96.4
Melanomas of the Skin	99.5	Multiple Myeloma	83.4
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	89.3
Cervix uteri	97.3	Brain & Other CNS ¹ <i>non-malig</i>	36.5
Uterus Corpus & Uterus NOS ¹	98.5	Breast <i>in situ</i>	100.0
Ovary	92.5		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	25,945	532.1	1.54	634.1	1.81	24,469	421.4	1.23	492.5	1.41
Oral Cavity & Pharynx	1,008	19.5	0.28	23.9	0.34	406	6.9	0.16	8.2	0.18
Lip	32	0.7	0.06	0.8	0.07	12	0.2	0.03	0.2	0.03
Tongue	309	5.8	0.15	7.2	0.19	114	1.9	0.08	2.3	0.10
Major salivary gland	90	2.0	0.10	2.4	0.12	58	1.0	0.06	1.2	0.07
Floor of mouth	45	0.8	0.06	1.1	0.07	19	0.3	0.03	0.4	0.04
Gum & other mouth	103	2.1	0.10	2.5	0.11	90	1.6	0.08	1.8	0.09
Nasopharynx	42	0.8	0.06	0.9	0.07	19	0.4	0.04	0.4	0.04
Oropharynx	55	1.0	0.06	1.3	0.08	14	0.2	0.03	0.3	0.03
Hypopharynx	67	1.3	0.07	1.6	0.09	18	0.3	0.03	0.4	0.04
Digestive System	4,974	101.4	0.67	121.7	0.79	3,908	66.9	0.49	79.2	0.57
Esophagus	378	7.6	0.18	9.2	0.22	103	1.7	0.08	2.1	0.09
Stomach	417	8.7	0.20	10.4	0.23	268	4.7	0.13	5.5	0.15
Small intestine	158	3.2	0.12	3.8	0.14	145	2.5	0.09	2.9	0.11
Colon excl. rectum	1,575	32.9	0.39	39.0	0.45	1,491	25.7	0.30	30.2	0.35
Rectum & rectosigmoid	788	15.6	0.26	18.8	0.31	572	9.8	0.19	11.6	0.22
Anus, anal canal & anorectum	99	2.0	0.09	2.3	0.11	140	2.3	0.09	2.8	0.11
Liver	598	11.1	0.21	14.1	0.26	198	3.3	0.11	4.0	0.13
Gallbladder	35	0.8	0.06	0.9	0.07	73	1.2	0.07	1.5	0.08
Pancreas	707	14.9	0.26	17.8	0.31	677	11.6	0.20	13.7	0.24
Respiratory System	4,140	86.9	0.63	103.9	0.74	3,120	52.6	0.43	62.7	0.50
Larynx	336	6.6	0.17	8.1	0.20	80	1.3	0.07	1.6	0.08
Lung & bronchus	3,745	79.0	0.60	94.4	0.71	2,999	50.6	0.42	60.3	0.49
Bones & Joints	57	1.1	0.07	1.2	0.07	46	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	187	3.9	0.13	4.3	0.15	157	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	1,796	38.4	0.42	44.9	0.49	1,221	21.6	0.28	24.6	0.32
Melanomas of the skin	1,683	35.8	0.41	41.9	0.47	1,144	20.3	0.27	23.0	0.31
Breast (excl. <i>in situ</i>)	68	1.4	0.08	1.7	0.09	7,398	126.8	0.67	149.0	0.78
Female Genital System	-	-	-	-	-	2,790	47.4	0.41	55.9	0.47
Cervix uteri	-	-	-	-	-	419	7.8	0.17	8.4	0.18
Uterus Corpus	-	-	-	-	-	1,422	23.2	0.28	28.4	0.34
Uterus, NOS ¹	-	-	-	-	-	36	0.6	0.05	0.7	0.05
Ovary	-	-	-	-	-	634	11.0	0.20	12.8	0.23
Male Genital System	6,757	129.7	0.73	159.1	0.88	-	-	-	-	-
Prostate	6,491	124.2	0.72	153.5	0.87	-	-	-	-	-
Testis	210	4.3	0.13	4.3	0.13	-	-	-	-	-
Penis	43	0.9	0.07	1.1	0.08	-	-	-	-	-
Urinary System	2,653	57.3	0.52	67.5	0.61	1,176	20.1	0.27	23.7	0.31
Bladder (incl. <i>in situ</i>)	1,427	32.5	0.40	38.1	0.47	445	7.7	0.16	9.0	0.19
Kidney & renal pelvis	1,160	23.2	0.32	27.7	0.37	694	11.8	0.20	13.9	0.24
Ureter	30	0.7	0.06	0.8	0.07	21	0.4	0.04	0.4	0.04
Eye & Orbit	43	0.9	0.06	1.0	0.07	42	0.7	0.05	0.8	0.06
Brain & Other CNS ¹	345	7.1	0.18	7.8	0.19	288	5.2	0.14	5.6	0.15
Brain	328	6.7	0.17	7.5	0.19	269	4.8	0.13	5.3	0.14
Endocrine System	356	7.2	0.17	8.0	0.19	1,020	18.6	0.27	20.3	0.29
Thyroid gland	311	6.3	0.16	7.0	0.18	979	17.9	0.26	19.5	0.28
Lymphomas	1,191	25.0	0.34	28.6	0.38	969	17.0	0.25	19.5	0.28
Hodgkin Lymphoma	135	2.7	0.11	2.9	0.11	113	2.2	0.09	2.2	0.09
Non-Hodgkin Lymphoma	1,055	22.3	0.32	25.7	0.36	856	14.9	0.23	17.3	0.26
Multiple Myeloma	488	10.3	0.22	12.2	0.25	433	7.4	0.16	8.8	0.19
Leukemias	862	18.7	0.30	21.3	0.34	650	11.6	0.21	13.0	0.23
Acute lymphocytic	74	1.5	0.08	1.4	0.08	61	1.2	0.07	1.1	0.06
Chronic lymphocytic	331	7.2	0.18	8.5	0.22	222	3.8	0.12	4.5	0.14
Acute myeloid	238	5.2	0.16	5.9	0.18	202	3.6	0.12	4.0	0.13
Chronic myeloid	126	2.7	0.11	3.1	0.13	94	1.7	0.08	1.9	0.09
Other leukemias	93	2.1	0.10	2.4	0.11	71	1.3	0.07	1.4	0.08
Mesothelioma	48	1.1	0.08	1.3	0.09	14	0.2	0.03	0.3	0.03
Kaposi Sarcoma	69	1.4	0.08	1.4	0.08	3	0.1	0.02	0.1	0.02
Ill-defined & Unknown	904	20.7	0.32	24.0	0.37	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	455	9.7	0.21	10.9	0.24	978	17.2	0.25	19.7	0.28
Breast (<i>in situ</i>)	10	0.2	0.03	0.2	0.03	1,698	28.9	0.32	34.1	0.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	18,592	530.3	1.80	628.9	2.10	17,242	439.0	1.53	511.9	1.76
Oral Cavity & Pharynx	796	21.5	0.35	26.5	0.43	300	7.5	0.20	8.8	0.23
Lip	29	0.9	0.08	1.0	0.09	12	0.3	0.04	0.3	0.05
Tongue	262	6.9	0.20	8.6	0.24	91	2.3	0.11	2.7	0.13
Major salivary gland	73	2.3	0.12	2.6	0.14	34	0.9	0.07	1.0	0.08
Floor of mouth	34	0.9	0.07	1.1	0.09	15	0.4	0.04	0.4	0.05
Gum & other mouth	73	2.1	0.11	2.5	0.13	69	1.7	0.09	2.0	0.11
Nasopharynx	19	0.5	0.05	0.6	0.06	11	0.3	0.04	0.3	0.04
Oropharynx	43	1.1	0.08	1.4	0.10	10	0.2	0.04	0.3	0.04
Hypopharynx	46	1.2	0.08	1.5	0.10	11	0.3	0.04	0.3	0.04
Digestive System	3,385	96.2	0.76	115.1	0.90	2,547	63.1	0.57	74.6	0.66
Esophagus	279	7.7	0.21	9.4	0.25	68	1.7	0.09	2.0	0.11
Stomach	247	7.1	0.21	8.5	0.24	152	3.9	0.14	4.5	0.16
Small intestine	105	3.0	0.13	3.5	0.16	82	2.0	0.10	2.4	0.12
Colon excl. rectum	1,070	31.2	0.44	36.9	0.51	973	24.3	0.35	28.4	0.41
Rectum & rectosigmoid	550	15.4	0.30	18.5	0.36	375	9.6	0.23	11.3	0.26
Anus, anal canal & anorectum	63	1.8	0.10	2.1	0.12	111	2.7	0.12	3.4	0.14
Liver	386	10.2	0.24	12.8	0.30	124	3.0	0.12	3.6	0.15
Gallbladder	19	0.6	0.06	0.7	0.07	44	1.1	0.07	1.3	0.09
Pancreas	504	14.5	0.30	17.2	0.35	441	10.6	0.23	12.7	0.27
Respiratory System	3,073	87.8	0.73	104.7	0.86	2,406	57.8	0.53	68.9	0.63
Larynx	221	6.1	0.19	7.4	0.23	59	1.4	0.08	1.7	0.10
Lung & bronchus	2,806	80.4	0.70	95.8	0.82	2,319	55.6	0.52	66.3	0.62
Bones & Joints	40	1.2	0.09	1.3	0.09	31	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	134	4.0	0.16	4.5	0.18	97	2.6	0.12	2.9	0.13
Skin (excl. basal & sq.)	1,753	51.3	0.57	60.1	0.65	1,171	31.8	0.43	36.0	0.47
Melanomas of the skin	1,655	48.2	0.55	56.5	0.63	1,115	30.4	0.42	34.4	0.46
Breast (excl. <i>in situ</i>)	46	1.3	0.09	1.5	0.10	4,985	126.8	0.82	149.2	0.95
Female Genital System	-	-	-	-	-	1,881	48.4	0.51	56.9	0.59
Cervix uteri	-	-	-	-	-	266	8.1	0.23	8.6	0.24
Uterus Corpus	-	-	-	-	-	943	23.1	0.35	28.3	0.41
Uterus, NOS ¹	-	-	-	-	-	19	0.5	0.05	0.6	0.06
Ovary	-	-	-	-	-	449	11.5	0.25	13.4	0.28
Male Genital System	4,119	110.5	0.79	134.1	0.95	-	-	-	-	-
Prostate	3,899	103.4	0.76	126.9	0.92	-	-	-	-	-
Testis	181	5.9	0.20	5.9	0.20	-	-	-	-	-
Penis	31	0.9	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,088	61.5	0.62	72.5	0.72	834	20.7	0.33	24.3	0.38
Bladder (incl. <i>in situ</i>)	1,218	36.8	0.49	43.2	0.57	339	8.2	0.20	9.7	0.24
Kidney & renal pelvis	815	23.0	0.37	27.3	0.43	467	11.8	0.25	13.8	0.29
Ureter	26	0.8	0.07	0.9	0.08	18	0.4	0.05	0.5	0.05
Eye & Orbit	38	1.1	0.08	1.3	0.09	36	1.0	0.07	1.1	0.08
Brain & Other CNS ¹	274	8.2	0.23	9.0	0.25	223	6.1	0.19	6.7	0.20
Brain	262	7.8	0.22	8.6	0.24	209	5.7	0.18	6.3	0.19
Endocrine System	279	8.2	0.23	9.2	0.25	734	21.6	0.37	23.3	0.39
Thyroid gland	249	7.3	0.21	8.2	0.23	709	20.9	0.36	22.6	0.38
Lymphomas	879	26.1	0.40	29.8	0.46	711	18.2	0.31	20.9	0.35
Hodgkin Lymphoma	86	2.7	0.13	2.8	0.14	71	2.2	0.12	2.3	0.12
Non-Hodgkin Lymphoma	793	23.4	0.38	27.0	0.44	640	16.0	0.29	18.6	0.33
Multiple Myeloma	276	8.1	0.22	9.5	0.26	206	5.1	0.16	5.9	0.19
Leukemias	665	20.1	0.36	22.8	0.40	475	12.4	0.26	13.9	0.29
Acute lymphocytic	54	1.8	0.11	1.6	0.10	42	1.3	0.09	1.2	0.09
Chronic lymphocytic	264	7.7	0.22	9.2	0.26	177	4.3	0.15	5.1	0.17
Acute myeloid	179	5.4	0.19	6.2	0.21	140	3.7	0.14	4.1	0.16
Chronic myeloid	93	2.8	0.14	3.2	0.15	66	1.7	0.10	2.0	0.11
Other leukemias	73	2.3	0.12	2.6	0.14	50	1.3	0.08	1.5	0.09
Mesothelioma	42	1.3	0.09	1.5	0.11	12	0.3	0.04	0.3	0.04
Kaposi Sarcoma	20	0.6	0.06	0.7	0.07	-	-	-	-	-
Ill-defined & Unknown	686	21.3	0.38	24.7	0.43	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	326	9.8	0.25	11.1	0.28	646	17.0	0.31	19.3	0.34
Breast (<i>in situ</i>)	6	0.2	0.03	0.2	0.04	1,086	27.9	0.39	32.9	0.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

GEORGIA

II-134 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,792	559.6	3.37	675.3	3.96	6,611	400.0	2.28	469.4	2.63
Oral Cavity & Pharynx	184	13.7	0.49	16.8	0.58	94	5.5	0.26	6.6	0.31
Lip	2	0.2	0.05	0.2	0.06	-	-	-	-	-
Tongue	41	3.1	0.23	3.8	0.28	19	1.1	0.12	1.3	0.14
Major salivary gland	15	1.1	0.15	1.3	0.17	22	1.2	0.12	1.4	0.14
Floor of mouth	10	0.8	0.12	1.0	0.14	4	0.2	0.05	0.3	0.06
Gum & other mouth	22	1.7	0.18	2.1	0.21	19	1.1	0.12	1.4	0.14
Nasopharynx	16	1.2	0.14	1.4	0.16	7	0.4	0.07	0.4	0.08
Oropharynx	12	0.8	0.11	1.0	0.14	4	0.2	0.05	0.3	0.06
Hypopharynx	20	1.5	0.17	1.9	0.20	6	0.4	0.07	0.5	0.08
Digestive System	1,429	117.9	1.55	142.7	1.83	1,257	78.1	1.02	92.7	1.19
Esophagus	91	7.5	0.39	9.2	0.46	31	1.8	0.15	2.3	0.18
Stomach	148	13.0	0.54	15.6	0.63	103	6.6	0.30	7.8	0.35
Small intestine	50	4.1	0.29	4.9	0.33	61	3.7	0.22	4.4	0.26
Colon excl. rectum	462	39.2	0.91	46.9	1.06	486	30.2	0.64	35.8	0.74
Rectum & rectosigmoid	206	16.0	0.55	19.4	0.64	177	10.4	0.36	12.5	0.43
Anus, anal canal & anorectum	35	2.5	0.20	2.8	0.22	27	1.6	0.14	1.9	0.17
Liver	183	12.8	0.46	16.7	0.57	61	3.6	0.22	4.4	0.26
Gallbladder	15	1.5	0.20	1.8	0.23	27	1.7	0.16	2.1	0.18
Pancreas	187	16.9	0.62	20.3	0.73	224	14.7	0.46	17.3	0.53
Respiratory System	1,017	90.5	1.42	109.0	1.65	667	41.9	0.76	50.2	0.88
Larynx	111	8.9	0.41	10.9	0.49	21	1.2	0.13	1.5	0.15
Lung & bronchus	893	80.5	1.35	96.8	1.57	634	40.0	0.74	47.9	0.86
Bones & Joints	14	0.9	0.13	1.0	0.13	13	0.7	0.09	0.7	0.10
Soft Tissue (incl. heart)	46	3.6	0.26	3.9	0.29	54	3.3	0.21	3.6	0.23
Skin (excl. basal & sq.)	26	2.1	0.21	2.4	0.24	33	1.9	0.16	2.2	0.18
Melanomas of the skin	13	1.1	0.16	1.4	0.19	15	0.9	0.11	1.1	0.13
Breast (excl. <i>in situ</i>)	21	1.8	0.20	2.1	0.23	2,213	130.2	1.28	152.9	1.48
Female Genital System	-	-	-	-	-	826	48.5	0.78	57.5	0.91
Cervix uteri	-	-	-	-	-	135	8.0	0.31	8.7	0.34
Uterus Corpus	-	-	-	-	-	443	25.3	0.56	31.1	0.67
Uterus, NOS ¹	-	-	-	-	-	17	1.0	0.11	1.2	0.14
Ovary	-	-	-	-	-	163	9.9	0.36	11.5	0.41
Male Genital System	2,504	196.4	1.93	243.5	2.30	-	-	-	-	-
Prostate	2,464	193.3	1.91	240.3	2.29	-	-	-	-	-
Testis	23	1.6	0.15	1.5	0.15	-	-	-	-	-
Penis	11	1.1	0.17	1.3	0.20	-	-	-	-	-
Urinary System	520	45.4	0.99	53.8	1.15	323	20.2	0.52	23.9	0.61
Bladder (incl. <i>in situ</i>)	184	19.0	0.70	22.3	0.81	98	6.8	0.32	7.9	0.36
Kidney & renal pelvis	326	25.5	0.69	30.4	0.80	217	13.0	0.41	15.4	0.48
Ureter	3	0.3	0.08	0.3	0.09	2	0.1	0.04	0.2	0.05
Eye & Orbit	4	0.3	0.08	0.4	0.09	4	0.3	0.06	0.3	0.06
Brain & Other CNS ¹	61	4.5	0.28	4.9	0.30	59	3.5	0.21	3.7	0.22
Brain	57	4.1	0.27	4.5	0.29	53	3.2	0.20	3.4	0.21
Endocrine System	57	4.3	0.27	4.8	0.31	234	13.4	0.40	14.9	0.44
Thyroid gland	44	3.4	0.24	3.8	0.28	220	12.5	0.39	14.0	0.43
Lymphomas	282	21.5	0.63	24.4	0.71	233	14.0	0.42	15.9	0.48
Hodgkin Lymphoma	46	3.0	0.21	3.3	0.22	39	2.2	0.16	2.3	0.17
Non-Hodgkin Lymphoma	236	18.5	0.59	21.2	0.67	194	11.8	0.39	13.6	0.45
Multiple Myeloma	203	18.4	0.65	21.8	0.75	222	14.2	0.44	16.6	0.51
Leukemias	174	15.3	0.59	17.5	0.67	156	9.7	0.36	10.9	0.40
Acute lymphocytic	17	1.0	0.12	1.0	0.12	14	0.8	0.10	0.7	0.09
Chronic lymphocytic	61	5.7	0.36	6.7	0.42	40	2.7	0.20	3.2	0.23
Acute myeloid	52	4.6	0.32	5.2	0.37	56	3.4	0.21	3.8	0.23
Chronic myeloid	28	2.5	0.24	2.8	0.27	27	1.6	0.14	1.9	0.16
Other leukemias	16	1.5	0.19	1.7	0.22	19	1.2	0.13	1.3	0.14
Mesothelioma	4	0.5	0.11	0.6	0.14	2	0.1	0.04	0.1	0.05
Kaposi Sarcoma	49	3.1	0.20	3.1	0.20	2	0.2	0.05	0.2	0.04
Ill-defined & Unknown	197	19.4	0.70	22.6	0.80	220	14.4	0.45	16.6	0.51
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	112	9.5	0.45	10.8	0.51	297	18.3	0.49	21.0	0.56
Breast (<i>in situ</i>)	4	0.3	0.07	0.3	0.08	557	32.2	0.63	38.2	0.73

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	434	286.4	6.84	338.0	8.01	526	272.1	5.69	315.6	6.60
Oral Cavity & Pharynx	26	15.2	1.48	18.2	1.76	11	5.8	0.81	6.5	0.92
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.0	0.67	3.7	0.82	4	2.1	0.47	2.4	0.54
Major salivary gland	3	1.7	0.52	1.9	0.56	2	1.0	0.30	1.1	0.34
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	7	4.2	0.78	5.1	0.94	3	1.6	0.46	1.8	0.52
Nasopharynx	6	2.6	0.50	3.2	0.62	2	0.8	0.26	0.9	0.28
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	1.1	0.47	1.3	0.58	-	-	-	-	-
Digestive System	142	93.1	3.88	111.3	4.58	96	55.2	2.73	65.6	3.20
Esophagus	6	4.0	0.85	4.8	1.01	2	1.2	0.37	1.6	0.49
Stomach	21	14.5	1.58	17.1	1.83	13	7.8	1.05	9.0	1.21
Small intestine	3	1.5	0.45	1.7	0.51	1	0.9	0.37	1.1	0.43
Colon excl. rectum	35	22.9	1.91	26.9	2.22	30	17.3	1.52	20.6	1.79
Rectum & rectosigmoid	27	16.3	1.56	20.1	1.90	17	8.2	0.96	10.0	1.16
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	28	18.0	1.71	22.2	2.06	12	6.6	0.91	7.8	1.06
Gallbladder	1	0.9	0.39	1.2	0.47	2	1.3	0.44	1.6	0.51
Pancreas	14	10.0	1.31	11.6	1.49	11	7.5	1.09	8.8	1.28
Respiratory System	43	31.8	2.44	37.7	2.87	41	24.2	1.83	28.7	2.13
Larynx	3	1.9	0.53	2.2	0.61	-	-	-	-	-
Lung & bronchus	38	29.1	2.36	34.6	2.78	39	23.4	1.80	27.6	2.08
Bones & Joints	3	1.3	0.37	1.5	0.43	2	0.9	0.28	0.9	0.27
Soft Tissue (incl. heart)	6	3.1	0.64	3.6	0.75	4	1.7	0.40	1.8	0.43
Skin (excl. basal & sq.)	4	2.2	0.50	2.5	0.57	2	1.0	0.31	1.1	0.35
Melanomas of the skin	2	1.3	0.40	1.6	0.46	2	0.7	0.28	0.8	0.30
Breast (excl. <i>in situ</i>)	1	0.8	0.31	0.9	0.37	180	87.3	3.06	101.7	3.57
Female Genital System	-	-	-	-	-	69	34.1	1.94	40.5	2.30
Cervix uteri	-	-	-	-	-	14	6.6	0.81	7.6	0.93
Uterus Corpus	-	-	-	-	-	30	14.4	1.25	17.5	1.50
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	21	10.9	1.13	12.8	1.33
Male Genital System	80	55.5	3.01	66.3	3.53	-	-	-	-	-
Prostate	76	53.7	2.98	64.5	3.50	-	-	-	-	-
Testis	3	1.4	0.35	1.4	0.34	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	34	24.1	2.09	28.6	2.45	15	9.4	1.20	11.1	1.40
Bladder (incl. <i>in situ</i>)	19	14.6	1.73	17.4	2.04	5	3.5	0.76	4.2	0.90
Kidney & renal pelvis	15	8.6	1.07	10.2	1.25	8	4.9	0.82	5.7	0.96
Ureter	-	-	-	-	-	1	1.0	0.41	1.1	0.47
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.0	0.65	4.1	0.68	6	3.1	0.58	3.3	0.63
Brain	7	3.7	0.62	3.7	0.65	6	3.0	0.58	3.2	0.62
Endocrine System	18	9.1	1.04	10.0	1.17	46	19.9	1.35	21.8	1.51
Thyroid gland	16	8.1	0.98	9.0	1.12	44	19.1	1.31	20.7	1.45
Lymphomas	25	14.9	1.46	17.2	1.69	20	11.4	1.23	12.5	1.36
Hodgkin Lymphoma	2	1.1	0.31	1.0	0.29	2	1.0	0.28	0.9	0.25
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	8	5.8	1.03	6.7	1.17	5	2.5	0.55	3.0	0.65
Leukemias	19	11.5	1.33	13.2	1.54	15	7.8	0.96	8.4	1.07
Acute lymphocytic	2	1.0	0.30	0.9	0.28	5	2.5	0.52	2.4	0.52
Chronic lymphocytic	4	3.1	0.80	3.7	0.95	3	1.6	0.50	2.0	0.60
Acute myeloid	6	3.3	0.63	3.8	0.72	5	2.6	0.54	2.8	0.59
Chronic myeloid	4	2.2	0.54	2.5	0.62	-	-	-	-	-
Other leukemias	3	1.9	0.60	2.2	0.70	1	0.7	0.29	0.8	0.33
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	17	12.1	1.51	14.1	1.77	12	7.1	1.02	8.1	1.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	7.6	1.02	8.4	1.15	30	16.7	1.45	18.9	1.63
Breast (<i>in situ</i>)	-	-	-	-	-	50	23.2	1.51	26.5	1.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

GEORGIA

II-136 Incidence – API

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	746	396.8	8.12	465.6	9.31	890	376.5	6.46	438.2	7.50
Oral Cavity & Pharynx	19	8.6	1.08	10.8	1.30	10	4.6	0.75	5.4	0.87
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.0	0.68	3.7	0.81	4	2.0	0.52	2.4	0.61
Major salivary gland	1	0.3	0.12	0.3	0.15	2	0.4	0.16	0.5	0.21
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.2	0.42	1.5	0.50	3	1.1	0.37	1.3	0.43
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	0.6	0.28	0.7	0.32	-	-	-	-	-
Digestive System	168	90.9	3.85	108.3	4.46	145	73.9	3.07	86.2	3.53
Esophagus	11	7.2	1.19	8.7	1.41	2	1.5	0.47	1.7	0.52
Stomach	20	10.6	1.35	12.7	1.58	17	7.1	0.89	8.3	1.04
Small intestine	5	2.5	0.62	3.0	0.70	4	2.1	0.52	2.6	0.63
Colon excl. rectum	47	25.3	2.04	29.4	2.33	50	24.3	1.74	28.3	2.01
Rectum & rectosigmoid	28	12.2	1.29	14.9	1.52	20	9.5	1.06	11.2	1.21
Anus, anal canal & anorectum	2	1.2	0.43	1.4	0.46	5	2.8	0.62	3.2	0.69
Liver	26	13.3	1.39	16.4	1.63	13	7.2	0.99	8.4	1.13
Gallbladder	1	0.9	0.40	1.0	0.45	5	2.6	0.57	3.0	0.64
Pancreas	20	11.7	1.40	13.9	1.62	18	10.7	1.24	12.3	1.41
Respiratory System	70	46.5	2.96	54.8	3.38	55	31.2	2.04	36.8	2.34
Larynx	8	4.2	0.81	5.2	0.95	-	-	-	-	-
Lung & bronchus	59	41.3	2.82	48.5	3.21	53	30.6	2.02	36.0	2.32
Bones & Joints	6	1.1	0.21	1.1	0.23	4	1.2	0.31	1.3	0.36
Soft Tissue (incl. heart)	11	3.9	0.67	4.2	0.73	8	2.6	0.48	2.8	0.55
Skin (excl. basal & sq.)	18	10.0	1.33	11.5	1.51	20	8.8	1.04	9.9	1.15
Melanomas of the skin	16	8.7	1.24	10.2	1.42	17	7.4	0.93	8.3	1.03
Breast (excl. <i>in situ</i>)	2	0.9	0.40	1.0	0.43	269	108.2	3.32	127.4	3.90
Female Genital System	-	-	-	-	-	125	46.7	2.11	54.6	2.48
Cervix uteri	-	-	-	-	-	35	10.1	0.83	11.0	0.95
Uterus Corpus	-	-	-	-	-	53	21.9	1.50	26.1	1.77
Uterus, NOS ¹	-	-	-	-	-	2	0.6	0.25	0.7	0.29
Ovary	-	-	-	-	-	29	11.1	1.04	13.2	1.24
Male Genital System	187	101.6	3.96	121.6	4.57	-	-	-	-	-
Prostate	160	96.4	3.94	116.4	4.54	-	-	-	-	-
Testis	24	4.2	0.38	4.0	0.37	-	-	-	-	-
Penis	3	0.7	0.21	0.9	0.27	-	-	-	-	-
Urinary System	75	47.4	2.99	55.0	3.39	36	17.3	1.46	20.5	1.70
Bladder (incl. <i>in situ</i>)	29	23.7	2.25	27.2	2.56	9	5.2	0.85	6.1	0.98
Kidney & renal pelvis	43	21.6	1.84	25.4	2.08	26	11.5	1.14	13.7	1.35
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.3	0.15	0.4	0.18	2	0.7	0.26	0.8	0.31
Brain & Other CNS ¹	20	7.2	0.99	7.9	1.12	16	5.1	0.69	5.5	0.77
Brain	19	6.9	0.97	7.6	1.10	15	4.9	0.68	5.3	0.76
Endocrine System	18	6.2	0.86	6.9	0.95	80	23.3	1.29	26.2	1.52
Thyroid gland	14	5.2	0.79	6.0	0.89	79	22.9	1.28	25.7	1.51
Lymphomas	56	22.5	1.80	26.3	2.10	47	19.7	1.49	22.9	1.73
Hodgkin Lymphoma	9	2.6	0.54	2.8	0.61	9	2.3	0.39	2.4	0.43
Non-Hodgkin Lymphoma	47	19.9	1.72	23.5	2.01	39	17.5	1.44	20.5	1.67
Multiple Myeloma	17	9.7	1.25	11.2	1.39	14	7.4	0.96	8.9	1.13
Leukemias	45	18.1	1.71	19.7	1.89	32	11.7	1.15	12.7	1.28
Acute lymphocytic	17	3.1	0.46	2.9	0.46	11	2.3	0.36	2.2	0.38
Chronic lymphocytic	7	5.2	1.05	5.9	1.15	4	2.1	0.55	2.5	0.63
Acute myeloid	9	4.5	0.87	5.0	0.96	10	4.1	0.71	4.5	0.78
Chronic myeloid	7	3.2	0.74	3.6	0.82	5	1.5	0.39	1.7	0.43
Other leukemias	5	2.0	0.56	2.3	0.66	4	1.7	0.48	1.9	0.54
Mesothelioma	2	1.5	0.57	1.5	0.61	1	0.6	0.25	0.6	0.28
Kaposi Sarcoma	4	1.3	0.39	1.4	0.45	-	-	-	-	-
Ill-defined & Unknown	28	19.2	2.04	22.0	2.35	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	18	6.6	0.96	7.7	1.13	40	16.8	1.37	19.5	1.59
Breast (<i>in situ</i>)	-	-	-	-	-	64	24.5	1.52	28.9	1.79

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

GEORGIA

II-138 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17,921	538.6	1.86	638.6	2.17	16,463	443.6	1.60	516.8	1.82
Oral Cavity & Pharynx	779	22.4	0.37	27.5	0.45	291	7.6	0.21	9.1	0.24
Lip	28	0.9	0.08	1.0	0.09	12	0.3	0.04	0.4	0.05
Tongue	257	7.2	0.21	8.9	0.25	88	2.3	0.11	2.7	0.13
Major salivary gland	72	2.4	0.13	2.7	0.15	33	0.9	0.08	1.0	0.08
Floor of mouth	34	0.9	0.08	1.2	0.09	14	0.4	0.04	0.4	0.05
Gum & other mouth	71	2.1	0.12	2.5	0.14	66	1.7	0.10	2.0	0.11
Nasopharynx	19	0.5	0.06	0.6	0.07	10	0.3	0.04	0.3	0.05
Oropharynx	42	1.2	0.08	1.5	0.10	10	0.3	0.04	0.3	0.05
Hypopharynx	44	1.2	0.08	1.5	0.10	11	0.3	0.04	0.4	0.05
Digestive System	3,234	97.0	0.79	116.0	0.93	2,420	62.8	0.59	74.2	0.68
Esophagus	270	7.8	0.22	9.5	0.26	66	1.7	0.09	2.0	0.11
Stomach	229	6.9	0.21	8.2	0.25	137	3.6	0.14	4.2	0.16
Small intestine	100	3.0	0.14	3.6	0.16	79	2.1	0.11	2.5	0.12
Colon excl. rectum	1,029	31.7	0.46	37.4	0.53	929	24.2	0.36	28.4	0.42
Rectum & rectosigmoid	525	15.7	0.32	18.8	0.37	357	9.7	0.24	11.5	0.27
Anus, anal canal & anorectum	61	1.8	0.11	2.2	0.13	107	2.8	0.12	3.4	0.15
Liver	363	10.1	0.24	12.7	0.30	113	2.8	0.12	3.4	0.15
Gallbladder	18	0.6	0.06	0.7	0.07	38	0.9	0.07	1.2	0.08
Pancreas	486	14.6	0.31	17.4	0.36	425	10.6	0.23	12.7	0.28
Respiratory System	3,010	89.6	0.75	106.9	0.89	2,357	58.9	0.55	70.3	0.65
Larynx	215	6.2	0.19	7.6	0.23	58	1.5	0.09	1.8	0.11
Lung & bronchus	2,752	82.1	0.72	97.8	0.85	2,271	56.6	0.54	67.6	0.64
Bones & Joints	34	1.2	0.09	1.2	0.10	27	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	124	4.0	0.17	4.5	0.18	91	2.7	0.13	2.9	0.14
Skin (excl. basal & sq.)	1,736	54.0	0.60	63.0	0.69	1,152	34.1	0.47	38.3	0.51
Melanomas of the skin	1,640	50.8	0.58	59.3	0.67	1,098	32.7	0.46	36.6	0.50
Breast (excl. <i>in situ</i>)	44	1.3	0.09	1.6	0.11	4,757	128.2	0.86	150.7	0.99
Female Genital System	-	-	-	-	-	1,772	48.4	0.53	56.9	0.61
Cervix uteri	-	-	-	-	-	235	8.0	0.24	8.4	0.25
Uterus Corpus	-	-	-	-	-	898	23.3	0.36	28.4	0.43
Uterus, NOS ¹	-	-	-	-	-	18	0.5	0.05	0.6	0.06
Ovary	-	-	-	-	-	424	11.4	0.26	13.3	0.29
Male Genital System	3,954	111.3	0.82	135.2	0.97	-	-	-	-	-
Prostate	3,761	104.1	0.78	127.8	0.95	-	-	-	-	-
Testis	157	6.1	0.22	6.0	0.22	-	-	-	-	-
Penis	29	0.9	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,020	62.3	0.64	73.4	0.75	803	21.0	0.34	24.6	0.39
Bladder (incl. <i>in situ</i>)	1,192	37.4	0.50	43.9	0.58	331	8.4	0.21	9.9	0.24
Kidney & renal pelvis	776	23.2	0.38	27.5	0.45	445	11.9	0.26	13.9	0.30
Ureter	25	0.8	0.07	0.9	0.08	18	0.4	0.05	0.5	0.06
Eye & Orbit	36	1.1	0.09	1.3	0.10	34	1.0	0.08	1.1	0.08
Brain & Other CNS ¹	256	8.3	0.24	9.2	0.26	208	6.2	0.20	6.8	0.21
Brain	244	7.9	0.23	8.8	0.25	195	5.8	0.19	6.3	0.20
Endocrine System	263	8.5	0.24	9.5	0.26	659	21.4	0.39	23.0	0.41
Thyroid gland	236	7.6	0.23	8.5	0.25	635	20.6	0.38	22.2	0.40
Lymphomas	828	26.2	0.42	30.0	0.47	672	18.2	0.32	20.8	0.36
Hodgkin Lymphoma	78	2.7	0.14	2.9	0.15	64	2.3	0.13	2.3	0.13
Non-Hodgkin Lymphoma	751	23.5	0.40	27.1	0.45	608	15.9	0.30	18.6	0.34
Multiple Myeloma	263	8.0	0.23	9.5	0.27	195	5.0	0.16	5.8	0.19
Leukemias	623	19.9	0.37	22.8	0.42	445	12.2	0.27	13.8	0.30
Acute lymphocytic	39	1.5	0.11	1.4	0.10	32	1.2	0.10	1.1	0.09
Chronic lymphocytic	258	7.9	0.23	9.4	0.27	174	4.4	0.15	5.2	0.18
Acute myeloid	171	5.5	0.19	6.2	0.22	131	3.6	0.15	4.1	0.16
Chronic myeloid	87	2.9	0.14	3.2	0.16	61	1.7	0.10	2.0	0.11
Other leukemias	68	2.3	0.13	2.6	0.14	47	1.3	0.09	1.5	0.10
Mesothelioma	41	1.3	0.09	1.5	0.11	11	0.3	0.04	0.3	0.04
Kaposi Sarcoma	16	0.6	0.06	0.6	0.07	-	-	-	-	-
Ill-defined & Unknown	660	21.5	0.39	24.9	0.44	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	309	10.1	0.26	11.3	0.29	609	17.1	0.32	19.4	0.36
Breast (<i>in situ</i>)	6	0.2	0.03	0.2	0.04	1,033	28.1	0.41	33.3	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Georgia, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,739	563.3	3.40	679.7	3.99	6,525	400.8	2.30	470.3	2.65
Oral Cavity & Pharynx	182	13.8	0.49	16.9	0.59	93	5.5	0.26	6.6	0.31
Lip	2	0.2	0.05	0.2	0.06	-	-	-	-	-
Tongue	41	3.1	0.24	3.8	0.28	18	1.1	0.12	1.3	0.14
Major salivary gland	15	1.2	0.15	1.3	0.17	21	1.3	0.12	1.5	0.14
Floor of mouth	10	0.8	0.12	1.0	0.14	4	0.2	0.05	0.3	0.06
Gum & other mouth	22	1.7	0.18	2.1	0.21	18	1.1	0.12	1.4	0.15
Nasopharynx	16	1.2	0.14	1.4	0.16	7	0.4	0.07	0.4	0.08
Oropharynx	12	0.9	0.12	1.1	0.14	4	0.2	0.05	0.3	0.06
Hypopharynx	20	1.6	0.17	1.9	0.20	6	0.4	0.07	0.5	0.08
Digestive System	1,417	118.6	1.57	143.5	1.84	1,243	78.3	1.03	93.0	1.20
Esophagus	90	7.5	0.39	9.2	0.46	31	1.8	0.15	2.3	0.19
Stomach	147	13.1	0.54	15.7	0.64	102	6.6	0.31	7.8	0.35
Small intestine	50	4.1	0.29	4.9	0.33	60	3.7	0.22	4.4	0.26
Colon excl. rectum	458	39.4	0.92	47.1	1.07	482	30.4	0.64	35.9	0.75
Rectum & rectosigmoid	204	16.1	0.55	19.5	0.65	175	10.4	0.36	12.5	0.43
Anus, anal canal & anorectum	35	2.6	0.20	2.8	0.22	26	1.6	0.14	1.9	0.16
Liver	182	12.9	0.46	16.8	0.58	60	3.6	0.22	4.4	0.26
Gallbladder	15	1.5	0.20	1.8	0.23	27	1.7	0.16	2.1	0.18
Pancreas	186	17.0	0.62	20.5	0.73	223	14.7	0.46	17.4	0.53
Respiratory System	1,013	91.2	1.43	109.9	1.67	661	42.1	0.76	50.4	0.89
Larynx	110	8.9	0.42	11.0	0.49	20	1.2	0.13	1.5	0.15
Lung & bronchus	889	81.1	1.36	97.6	1.58	629	40.2	0.75	48.1	0.87
Bones & Joints	14	1.0	0.13	1.0	0.14	13	0.7	0.09	0.8	0.10
Soft Tissue (incl. heart)	45	3.6	0.26	4.0	0.29	53	3.3	0.21	3.6	0.23
Skin (excl. basal & sq.)	25	2.1	0.21	2.4	0.24	33	2.0	0.16	2.2	0.18
Melanomas of the skin	13	1.2	0.17	1.4	0.19	15	0.9	0.11	1.1	0.13
Breast (excl. <i>in situ</i>)	21	1.9	0.20	2.2	0.23	2,181	130.4	1.29	153.0	1.49
Female Genital System	-	-	-	-	-	815	48.5	0.79	57.5	0.92
Cervix uteri	-	-	-	-	-	132	8.0	0.32	8.7	0.35
Uterus Corpus	-	-	-	-	-	438	25.3	0.56	31.1	0.67
Uterus, NOS ¹	-	-	-	-	-	16	1.0	0.11	1.2	0.14
Ovary	-	-	-	-	-	160	9.9	0.36	11.5	0.41
Male Genital System	2,487	197.6	1.94	245.1	2.33	-	-	-	-	-
Prostate	2,447	194.5	1.93	241.8	2.31	-	-	-	-	-
Testis	23	1.6	0.15	1.6	0.15	-	-	-	-	-
Penis	11	1.1	0.17	1.3	0.20	-	-	-	-	-
Urinary System	516	45.6	1.00	54.1	1.16	319	20.3	0.53	23.9	0.61
Bladder (incl. <i>in situ</i>)	182	19.0	0.70	22.2	0.81	98	6.8	0.32	7.9	0.37
Kidney & renal pelvis	323	25.7	0.70	30.7	0.81	214	13.0	0.41	15.4	0.48
Ureter	3	0.3	0.08	0.3	0.09	2	0.1	0.04	0.2	0.05
Eye & Orbit	4	0.3	0.09	0.4	0.10	4	0.3	0.06	0.3	0.06
Brain & Other CNS ¹	60	4.5	0.28	4.9	0.31	58	3.6	0.21	3.7	0.23
Brain	55	4.1	0.27	4.5	0.30	52	3.2	0.20	3.4	0.22
Endocrine System	56	4.3	0.28	4.8	0.31	232	13.5	0.40	15.1	0.45
Thyroid gland	43	3.4	0.25	3.8	0.28	218	12.6	0.39	14.1	0.43
Lymphomas	279	21.7	0.64	24.6	0.72	226	13.9	0.43	15.8	0.48
Hodgkin Lymphoma	46	3.1	0.21	3.3	0.23	37	2.2	0.16	2.3	0.17
Non-Hodgkin Lymphoma	233	18.6	0.60	21.3	0.68	189	11.7	0.39	13.5	0.45
Multiple Myeloma	200	18.5	0.65	21.9	0.75	218	14.1	0.44	16.6	0.51
Leukemias	172	15.5	0.59	17.6	0.68	154	9.8	0.36	11.0	0.40
Acute lymphocytic	16	1.0	0.12	1.0	0.12	13	0.8	0.10	0.7	0.09
Chronic lymphocytic	61	5.8	0.37	6.8	0.42	40	2.7	0.20	3.2	0.23
Acute myeloid	52	4.7	0.33	5.3	0.37	55	3.4	0.21	3.8	0.24
Chronic myeloid	27	2.4	0.24	2.8	0.27	27	1.6	0.15	1.9	0.17
Other leukemias	16	1.5	0.19	1.8	0.23	19	1.2	0.13	1.3	0.14
Mesothelioma	4	0.5	0.12	0.6	0.14	2	0.1	0.04	0.1	0.05
Kaposi Sarcoma	49	3.2	0.21	3.2	0.21	2	0.2	0.05	0.2	0.05
Ill-defined & Unknown	196	19.5	0.70	22.7	0.81	218	14.5	0.45	16.7	0.52
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	111	9.6	0.45	10.9	0.51	294	18.4	0.50	21.1	0.56
Breast (<i>in situ</i>)	4	0.3	0.07	0.3	0.08	549	32.3	0.64	38.3	0.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


GEORGIA

II-140 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,408,453	1,414,862	1,422,484	1,428,105	1,424,203
White	352,019	355,175	358,214	360,843	360,604
Black	39,387	40,484	41,750	42,865	43,251
American Indian/Alaskan Native (AI/AN)	6,379	6,534	6,609	6,546	6,494
Asian/Pacific Islander (API)	1,010,668	1,012,669	1,015,911	1,017,851	1,013,854


All Races Population 2013-2017: 7,098,107
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	132,765	136,594	139,917	142,934	144,148
Non-Hispanic White	306,200	307,661	309,056	309,923	308,871
Non-Hispanic Black	34,167	35,106	36,254	37,271	37,524

Hispanic/Latino Population, Census 2010: 120,842
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

HAWAII CANCER REGISTRY

Initial Operation: 1960
Population-based Data Available: 1960
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	112.4	108.0	108.3	110.9	114.8
Missing Race	0.8	2.1	0.3	1.4	1.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.1	1.2	1.3	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Prostate	96.2
Oral Cavity & Pharynx	97.7	Testis	98.6
Esophagus	96.6	Bladder (incl. <i>in situ</i>)	97.1
Stomach	96.1	Kidney & Renal Pelvis	93.9
Colon & Rectum	96.8	Brain & Other CNS ¹	85.2
Liver	60.5	Thyroid	99.4
Pancreas	80.7	Hodgkin Lymphoma	99.1
Lung & Bronchus	89.2	Non-Hodgkin Lymphoma	97.8
Melanomas of the Skin	99.6	Multiple Myeloma	89.5
Female Breast (excl. <i>in situ</i>)	99.3	Leukemias	91.7
Cervix uteri	98.4	Brain & Other CNS ¹ <i>non-malig</i>	40.1
Uterus Corpus & Uterus NOS ¹	99.4	Breast <i>in situ</i>	100.0
Ovary	94.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,650	437.7	3.33	517.3	3.86	3,634	406.4	3.15	474.9	3.60
Oral Cavity & Pharynx	158	18.8	0.69	22.7	0.82	73	8.1	0.44	9.5	0.51
Lip	6	0.7	0.14	0.8	0.16	2	0.2	0.06	0.2	0.08
Tongue	51	6.0	0.38	7.2	0.46	26	2.9	0.26	3.4	0.31
Major salivary gland	15	1.8	0.22	2.1	0.25	14	1.7	0.21	1.9	0.23
Floor of mouth	7	0.8	0.14	1.0	0.17	2	0.3	0.08	0.3	0.09
Gum & other mouth	13	1.6	0.20	1.9	0.24	14	1.5	0.19	1.7	0.21
Nasopharynx	17	2.2	0.25	2.5	0.28	6	0.7	0.13	0.9	0.16
Oropharynx	5	0.6	0.12	0.8	0.15	-	-	-	-	-
Hypopharynx	12	1.4	0.19	1.7	0.22	3	0.3	0.08	0.3	0.10
Digestive System	884	106.0	1.64	126.9	1.93	659	69.0	1.25	81.2	1.45
Esophagus	52	6.2	0.39	7.4	0.46	13	1.3	0.16	1.6	0.20
Stomach	92	11.3	0.54	13.2	0.62	63	6.3	0.37	7.5	0.43
Small intestine	19	2.2	0.24	2.7	0.28	15	1.7	0.20	2.0	0.23
Colon excl. rectum	236	28.5	0.85	34.1	1.00	226	23.9	0.75	27.9	0.85
Rectum & rectosigmoid	155	18.8	0.69	22.7	0.82	103	11.8	0.54	13.8	0.62
Anus, anal canal & anorectum	7	0.8	0.14	1.1	0.17	13	1.3	0.17	1.7	0.21
Liver	126	14.6	0.60	18.0	0.72	49	4.9	0.32	5.9	0.38
Gallbladder	9	1.1	0.17	1.4	0.20	10	1.1	0.15	1.2	0.18
Pancreas	130	15.5	0.63	18.3	0.72	120	12.1	0.51	14.2	0.60
Respiratory System	521	62.3	1.25	73.7	1.46	367	37.3	0.90	44.3	1.05
Larynx	32	3.6	0.29	4.4	0.36	5	0.5	0.10	0.6	0.13
Lung & bronchus	477	57.3	1.20	67.5	1.40	357	36.3	0.88	43.0	1.04
Bones & Joints	7	1.0	0.17	1.0	0.17	5	0.8	0.15	0.8	0.15
Soft Tissue (incl. heart)	33	4.2	0.33	4.7	0.37	25	2.8	0.27	3.2	0.29
Skin (excl. basal & sq.)	261	31.4	0.90	36.8	1.03	151	17.3	0.66	20.1	0.74
Melanomas of the skin	239	28.8	0.86	33.7	0.98	139	16.1	0.64	18.7	0.72
Breast (excl. <i>in situ</i>)	8	0.8	0.14	1.0	0.17	1,214	138.9	1.86	164.3	2.15
Female Genital System	-	-	-	-	-	461	54.1	1.18	63.6	1.35
Cervix uteri	-	-	-	-	-	49	6.8	0.45	7.3	0.47
Uterus Corpus	-	-	-	-	-	279	32.1	0.89	38.5	1.05
Uterus, NOS ¹	-	-	-	-	-	4	0.5	0.11	0.6	0.13
Ovary	-	-	-	-	-	85	10.1	0.51	11.7	0.58
Male Genital System	822	95.1	1.52	113.8	1.79	-	-	-	-	-
Prostate	771	88.2	1.46	106.7	1.73	-	-	-	-	-
Testis	42	5.9	0.42	5.9	0.41	-	-	-	-	-
Penis	5	0.6	0.12	0.7	0.15	-	-	-	-	-
Urinary System	374	45.5	1.08	53.4	1.25	134	14.1	0.57	16.7	0.66
Bladder (incl. <i>in situ</i>)	204	24.8	0.80	29.0	0.92	55	5.4	0.34	6.4	0.40
Kidney & renal pelvis	160	19.3	0.70	22.8	0.81	75	8.4	0.45	9.8	0.51
Ureter	6	0.8	0.14	0.9	0.16	3	0.3	0.07	0.3	0.09
Eye & Orbit	7	0.9	0.15	1.0	0.16	4	0.5	0.12	0.6	0.13
Brain & Other CNS ¹	38	5.0	0.37	5.5	0.40	29	3.5	0.30	3.8	0.32
Brain	36	4.6	0.35	5.1	0.39	26	3.1	0.28	3.4	0.31
Endocrine System	61	8.1	0.48	8.9	0.52	169	23.0	0.82	24.7	0.86
Thyroid gland	53	7.1	0.45	7.9	0.49	162	22.2	0.81	23.8	0.85
Lymphomas	176	21.6	0.75	25.0	0.85	133	14.7	0.60	16.9	0.67
Hodgkin Lymphoma	14	1.8	0.23	2.0	0.24	9	1.2	0.19	1.3	0.19
Non-Hodgkin Lymphoma	162	19.8	0.71	23.1	0.82	124	13.5	0.57	15.6	0.64
Multiple Myeloma	55	6.5	0.40	7.8	0.48	42	4.4	0.31	5.2	0.36
Leukemias	108	13.7	0.60	15.3	0.67	73	8.5	0.46	9.2	0.49
Acute lymphocytic	11	1.6	0.22	1.5	0.21	13	1.8	0.24	1.7	0.21
Chronic lymphocytic	23	2.7	0.25	3.2	0.30	15	1.5	0.18	1.8	0.21
Acute myeloid	40	5.2	0.37	5.8	0.41	29	3.3	0.29	3.7	0.32
Chronic myeloid	21	2.5	0.26	2.9	0.29	11	1.2	0.17	1.4	0.19
Other leukemias	13	1.7	0.21	1.8	0.23	6	0.6	0.13	0.7	0.13
Mesothelioma	6	0.8	0.14	0.9	0.16	1	0.1	0.06	0.1	0.06
Kaposi Sarcoma	4	0.6	0.13	0.6	0.14	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	93	9.3	0.45	10.7	0.51
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	61	7.7	0.45	8.7	0.50	130	14.7	0.61	16.7	0.67
Breast (<i>in situ</i>)	1	0.1	0.06	0.2	0.07	301	35.3	0.95	41.9	1.10

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,330	507.5	6.70	594.3	7.60	1,026	461.6	7.06	530.5	7.76
Oral Cavity & Pharynx	74	26.8	1.50	32.6	1.76	21	9.6	1.02	10.8	1.11
Lip	3	1.5	0.39	1.7	0.44	-	-	-	-	-
Tongue	28	9.9	0.90	11.9	1.05	8	3.6	0.61	4.1	0.67
Major salivary gland	7	2.7	0.50	3.2	0.58	4	2.0	0.52	2.0	0.51
Floor of mouth	4	1.4	0.33	1.8	0.41	-	-	-	-	-
Gum & other mouth	5	1.8	0.41	2.2	0.47	4	1.7	0.42	1.9	0.46
Nasopharynx	2	0.7	0.26	0.8	0.28	-	-	-	-	-
Oropharynx	4	1.0	0.26	1.4	0.34	-	-	-	-	-
Hypopharynx	4	1.2	0.29	1.5	0.34	-	-	-	-	-
Digestive System	241	90.4	2.81	107.9	3.24	157	67.5	2.61	79.0	2.94
Esophagus	18	7.0	0.79	8.3	0.91	6	2.3	0.47	2.7	0.54
Stomach	16	6.3	0.74	7.4	0.84	8	3.2	0.56	3.8	0.65
Small intestine	5	1.9	0.41	2.3	0.48	3	1.4	0.36	1.6	0.43
Colon excl. rectum	68	26.8	1.58	31.7	1.80	57	25.6	1.64	29.5	1.83
Rectum & rectosigmoid	38	14.7	1.15	17.5	1.33	25	11.5	1.12	13.4	1.25
Anus, anal canal & anorectum	5	1.6	0.35	1.9	0.42	9	3.4	0.55	4.4	0.68
Liver	33	10.7	0.90	13.5	1.09	10	3.4	0.52	4.3	0.63
Gallbladder	2	0.7	0.25	0.8	0.27	2	0.8	0.28	0.9	0.30
Pancreas	39	14.5	1.11	17.2	1.27	29	12.1	1.08	14.0	1.20
Respiratory System	151	56.4	2.20	66.4	2.52	103	42.2	2.01	49.5	2.28
Larynx	16	5.6	0.68	6.9	0.80	3	0.9	0.26	1.1	0.32
Lung & bronchus	131	49.1	2.05	57.7	2.35	98	40.7	1.98	47.6	2.24
Bones & Joints	2	0.9	0.29	1.0	0.32	-	-	-	-	-
Soft Tissue (incl. heart)	10	4.4	0.70	4.8	0.73	6	3.1	0.67	3.1	0.62
Skin (excl. basal & sq.)	217	86.6	2.82	99.8	3.16	117	53.5	2.44	60.7	2.63
Melanomas of the skin	206	82.0	2.74	94.3	3.06	112	51.0	2.38	58.0	2.57
Breast (excl. <i>in situ</i>)	3	0.9	0.27	1.1	0.33	315	143.4	3.97	166.0	4.39
Female Genital System	-	-	-	-	-	120	53.8	2.40	62.4	2.67
Cervix uteri	-	-	-	-	-	13	7.3	0.99	7.6	0.99
Uterus Corpus	-	-	-	-	-	61	24.8	1.55	29.9	1.79
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	28	13.6	1.26	15.4	1.37
Male Genital System	268	95.6	2.81	113.7	3.24	-	-	-	-	-
Prostate	249	86.3	2.62	104.1	3.08	-	-	-	-	-
Testis	17	8.2	0.96	8.2	0.93	-	-	-	-	-
Penis	2	0.8	0.26	0.9	0.30	-	-	-	-	-
Urinary System	151	58.9	2.29	68.7	2.60	37	15.4	1.23	18.2	1.40
Bladder (incl. <i>in situ</i>)	94	37.6	1.85	43.5	2.10	18	7.5	0.84	8.9	0.97
Kidney & renal pelvis	54	20.0	1.30	23.6	1.49	17	7.4	0.87	8.8	0.99
Ureter	2	0.7	0.24	0.8	0.28	-	-	-	-	-
Eye & Orbit	5	1.9	0.42	2.1	0.46	2	1.1	0.36	1.3	0.41
Brain & Other CNS ¹	19	8.4	0.97	9.0	0.98	11	5.8	0.87	6.2	0.87
Brain	18	8.0	0.96	8.6	0.96	11	5.5	0.85	5.9	0.84
Endocrine System	17	7.1	0.84	7.8	0.88	36	20.3	1.64	21.3	1.65
Thyroid gland	16	6.8	0.81	7.5	0.86	35	20.0	1.63	21.0	1.64
Lymphomas	64	25.3	1.53	29.0	1.69	41	18.4	1.42	20.9	1.53
Hodgkin Lymphoma	7	2.9	0.52	3.0	0.53	3	2.2	0.58	2.1	0.55
Non-Hodgkin Lymphoma	57	22.4	1.44	25.9	1.60	-	-	-	-	-
Multiple Myeloma	21	8.1	0.84	9.7	0.99	10	4.4	0.67	5.1	0.74
Leukemias	38	15.0	1.18	17.2	1.31	23	11.6	1.20	12.7	1.24
Acute lymphocytic	2	1.0	0.35	1.0	0.33	2	1.6	0.51	1.4	0.44
Chronic lymphocytic	14	4.9	0.63	5.8	0.74	8	3.2	0.55	3.8	0.63
Acute myeloid	12	5.0	0.69	5.6	0.75	7	3.9	0.71	4.3	0.74
Chronic myeloid	6	2.3	0.44	2.6	0.50	4	1.9	0.47	2.1	0.51
Other leukemias	4	2.0	0.45	2.2	0.49	2	1.1	0.38	1.2	0.36
Mesothelioma	2	0.9	0.29	1.0	0.32	-	-	-	-	-
Kaposi Sarcoma	2	1.0	0.32	1.0	0.33	-	-	-	-	-
Ill-defined & Unknown	46	18.8	1.34	21.6	1.48	26	10.7	1.02	12.5	1.14
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	17	7.3	0.84	8.0	0.90	30	14.9	1.34	16.4	1.40
Breast (<i>in situ</i>)	-	-	-	-	-	61	27.8	1.76	32.4	1.95

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	61	456.5	30.15	556.1	35.41	28	322.9	29.91	381.7	34.68
Oral Cavity & Pharynx	1	10.0	4.79	11.0	5.11	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	14	109.1	14.86	134.7	17.53	3	41.3	10.98	51.2	13.27
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	11.2	4.93	12.3	5.25	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	31.4	8.28	38.6	9.71	1	20.2	8.94	22.9	10.08
Rectum & rectosigmoid	2	12.5	4.80	15.6	5.59	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	21.0	6.25	27.0	7.51	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	13.4	5.01	16.8	6.16	-	-	-	-	-
Respiratory System	5	49.4	10.99	59.1	12.73	3	54.1	14.25	60.0	15.36
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	44.2	10.72	52.0	12.28	3	54.1	14.25	60.0	15.36
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	10	99.2	14.98	118.7	17.86
Female Genital System	-	-	-	-	-	4	39.8	10.20	48.9	12.24
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	19.6	7.42	24.2	9.00
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	15.4	6.33	19.5	7.59
Male Genital System	24	168.2	17.08	212.1	20.61	-	-	-	-	-
Prostate	23	162.5	16.68	206.0	20.19	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	53.1	11.37	60.3	12.87	1	20.6	8.33	23.3	9.07
Bladder (incl. <i>in situ</i>)	3	34.4	9.61	39.6	10.99	-	-	-	-	-
Kidney & renal pelvis	3	17.8	5.99	19.2	6.53	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	2	15.6	5.15	18.2	5.86	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	14.5	5.03	16.8	5.69	-	-	-	-	-
Multiple Myeloma	2	15.7	4.97	19.7	6.09	1	12.9	5.46	16.2	6.79
Leukemias	2	12.4	4.90	15.3	5.92	1	9.5	4.56	10.7	5.32
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	10.7	5.13	12.0	5.97	1	19.0	8.52	21.6	9.55
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	7.6	3.27	8.0	3.48	1	15.3	6.34	16.1	6.62
Breast (<i>in situ</i>)	-	-	-	-	-	2	25.2	8.09	30.1	9.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,180	394.7	3.84	467.7	4.51	2,511	384.7	3.56	452.5	4.14
Oral Cavity & Pharynx	79	14.7	0.75	17.5	0.88	50	7.6	0.50	9.0	0.59
Lip	2	0.3	0.12	0.4	0.13	-	-	-	-	-
Tongue	22	4.0	0.38	4.8	0.46	17	2.6	0.29	3.2	0.35
Major salivary gland	8	1.4	0.24	1.6	0.26	10	1.6	0.23	1.8	0.26
Floor of mouth	3	0.5	0.12	0.6	0.17	1	0.2	0.09	0.3	0.10
Gum & other mouth	8	1.5	0.24	1.8	0.29	10	1.5	0.21	1.7	0.25
Nasopharynx	15	2.9	0.35	3.4	0.39	6	1.0	0.18	1.2	0.22
Oropharynx	2	0.3	0.11	0.4	0.14	-	-	-	-	-
Hypopharynx	8	1.5	0.24	1.8	0.28	1	0.2	0.08	0.3	0.10
Digestive System	620	112.2	2.05	134.7	2.44	489	69.2	1.46	81.6	1.71
Esophagus	32	5.9	0.47	7.0	0.56	7	1.0	0.16	1.2	0.20
Stomach	73	13.2	0.70	15.6	0.82	54	7.2	0.46	8.5	0.54
Small intestine	13	2.4	0.30	2.9	0.35	12	1.8	0.24	2.1	0.28
Colon excl. rectum	163	29.5	1.05	35.5	1.25	165	23.6	0.86	27.6	1.00
Rectum & rectosigmoid	113	20.6	0.89	25.2	1.07	75	11.7	0.63	13.8	0.73
Anus, anal canal & anorectum	2	0.4	0.12	0.5	0.16	3	0.5	0.12	0.6	0.15
Liver	90	16.1	0.77	19.6	0.93	39	5.3	0.39	6.3	0.47
Gallbladder	7	1.3	0.22	1.6	0.26	8	1.2	0.19	1.4	0.22
Pancreas	87	15.6	0.76	18.4	0.89	89	12.0	0.59	14.1	0.69
Respiratory System	362	65.1	1.55	77.1	1.82	256	35.3	1.02	42.2	1.21
Larynx	14	2.5	0.30	3.0	0.36	2	0.3	0.10	0.4	0.13
Lung & bronchus	340	61.2	1.51	72.4	1.77	251	34.6	1.00	41.3	1.19
Bones & Joints	4	0.9	0.19	0.8	0.19	4	0.8	0.18	0.8	0.18
Soft Tissue (incl. heart)	22	4.2	0.40	4.7	0.45	19	2.9	0.31	3.5	0.36
Skin (excl. basal & sq.)	27	4.7	0.41	5.6	0.49	16	2.4	0.28	2.8	0.32
Melanomas of the skin	17	3.0	0.33	3.6	0.39	10	1.6	0.24	1.8	0.27
Breast (excl. <i>in situ</i>)	5	0.8	0.17	1.0	0.20	875	138.3	2.16	165.0	2.54
Female Genital System	-	-	-	-	-	329	54.1	1.38	64.0	1.60
Cervix uteri	-	-	-	-	-	34	6.3	0.50	6.9	0.54
Uterus Corpus	-	-	-	-	-	212	34.6	1.09	41.6	1.29
Uterus, NOS ¹	-	-	-	-	-	3	0.5	0.13	0.6	0.15
Ovary	-	-	-	-	-	54	9.1	0.57	10.5	0.65
Male Genital System	501	89.0	1.81	106.6	2.14	-	-	-	-	-
Prostate	475	83.5	1.74	100.9	2.08	-	-	-	-	-
Testis	22	4.7	0.46	4.6	0.45	-	-	-	-	-
Penis	3	0.4	0.13	0.5	0.15	-	-	-	-	-
Urinary System	212	38.5	1.20	45.4	1.40	94	13.6	0.65	16.0	0.76
Bladder (incl. <i>in situ</i>)	104	18.5	0.83	21.8	0.96	35	4.7	0.36	5.5	0.43
Kidney & renal pelvis	101	18.7	0.85	22.0	0.99	56	8.6	0.53	10.0	0.61
Ureter	4	0.8	0.17	0.9	0.20	2	0.3	0.08	0.3	0.10
Eye & Orbit	2	0.4	0.12	0.4	0.13	2	0.3	0.10	0.3	0.10
Brain & Other CNS ¹	18	3.4	0.37	3.8	0.40	17	2.7	0.31	3.1	0.34
Brain	16	3.1	0.35	3.5	0.39	15	2.3	0.28	2.6	0.31
Endocrine System	43	8.6	0.60	9.6	0.66	129	24.0	0.97	26.1	1.04
Thyroid gland	36	7.3	0.55	8.1	0.61	123	23.0	0.95	24.9	1.02
Lymphomas	106	19.5	0.86	22.7	0.99	90	13.4	0.66	15.4	0.75
Hodgkin Lymphoma	6	1.3	0.23	1.4	0.24	5	1.0	0.19	1.0	0.20
Non-Hodgkin Lymphoma	100	18.2	0.83	21.3	0.96	84	12.5	0.63	14.3	0.72
Multiple Myeloma	31	5.5	0.45	6.6	0.54	30	4.2	0.35	5.0	0.42
Leukemias	65	12.4	0.69	13.7	0.76	47	7.2	0.49	7.8	0.53
Acute lymphocytic	9	1.9	0.28	1.8	0.26	-	-	-	-	-
Chronic lymphocytic	7	1.1	0.20	1.4	0.24	6	0.7	0.13	0.8	0.16
Acute myeloid	28	5.3	0.46	5.9	0.51	21	3.2	0.33	3.6	0.36
Chronic myeloid	14	2.5	0.31	2.9	0.35	7	1.0	0.18	1.2	0.21
Other leukemias	8	1.5	0.25	1.7	0.27	3	0.5	0.13	0.5	0.14
Mesothelioma	4	0.7	0.17	0.8	0.19	-	-	-	-	-
Kaposi Sarcoma	1	0.3	0.11	0.3	0.12	-	-	-	-	-
Ill-defined & Unknown	78	14.0	0.72	16.4	0.84	63	8.4	0.50	9.7	0.57
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	41	7.5	0.54	8.6	0.61	93	13.8	0.68	15.9	0.76
Breast (<i>in situ</i>)	-	-	-	-	-	233	37.8	1.14	45.2	1.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	171	557.0	21.94	652.1	25.25	208	541.1	18.10	632.1	20.84
Oral Cavity & Pharynx	6	17.6	3.59	20.9	4.18	2	4.8	1.54	6.0	1.88
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	6.5	2.05	7.4	2.28	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	41	138.9	11.11	166.7	12.97	39	111.0	8.57	130.5	9.85
Esophagus	2	7.0	2.55	8.1	2.91	1	3.0	1.32	3.8	1.58
Stomach	3	14.6	3.90	16.6	4.43	3	10.7	2.75	12.3	3.14
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	12	39.8	6.01	47.2	6.99	12	34.4	4.81	40.2	5.53
Rectum & rectosigmoid	5	13.1	3.24	16.4	3.93	6	15.9	2.98	19.3	3.53
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	29.0	5.21	35.7	6.21	4	11.2	2.76	12.7	3.03
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	7	18.4	3.38	23.1	4.06	8	23.5	4.02	27.6	4.60
Respiratory System	29	112.5	10.55	129.4	12.04	25	77.9	7.43	90.4	8.44
Larynx	2	4.1	1.51	5.2	1.87	-	-	-	-	-
Lung & bronchus	26	107.6	10.43	123.1	11.87	24	76.3	7.35	88.6	8.37
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	2	3.3	1.29	3.6	1.42
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	5	13.2	3.39	16.1	4.12	6	13.2	2.65	15.6	3.11
Breast (excl. <i>in situ</i>)	-	-	-	-	-	65	160.8	9.42	190.6	11.01
Female Genital System	-	-	-	-	-	26	64.3	6.02	75.8	7.00
Cervix uteri	-	-	-	-	-	4	8.4	1.94	9.3	2.16
Uterus Corpus	-	-	-	-	-	14	34.3	4.36	40.6	5.05
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	11.3	2.70	13.1	3.13
Male Genital System	34	103.7	9.01	122.5	10.35	-	-	-	-	-
Prostate	30	96.9	8.75	114.8	10.04	-	-	-	-	-
Testis	3	4.0	1.10	4.4	1.25	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	20	66.0	7.49	76.4	8.50	7	20.4	3.63	23.9	4.18
Bladder (incl. <i>in situ</i>)	10	36.6	5.85	41.8	6.57	3	7.8	2.18	9.4	2.56
Kidney & renal pelvis	9	27.7	4.57	32.7	5.29	4	11.7	2.78	13.4	3.14
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	6.7	2.15	7.3	2.38	3	5.1	1.50	5.6	1.69
Brain	2	6.3	2.13	7.0	2.37	2	3.7	1.30	4.2	1.47
Endocrine System	2	3.6	1.14	4.1	1.34	11	23.1	3.41	24.8	3.73
Thyroid gland	1	2.3	0.90	2.5	1.02	11	23.1	3.41	24.8	3.73
Lymphomas	11	34.4	5.27	39.4	5.96	8	20.8	3.63	24.5	4.21
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	1	2.5	1.03	3.5	1.42	2	7.2	2.23	8.6	2.59
Leukemias	7	20.3	3.94	22.7	4.44	6	12.1	2.69	13.2	2.99
Acute lymphocytic	1	1.5	0.65	1.3	0.62	2	2.1	0.82	1.8	0.79
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	3	9.2	2.66	10.2	2.89	2	3.8	1.49	4.6	1.82
Chronic myeloid	-	-	-	-	-	1	3.4	1.50	3.6	1.56
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	23.6	4.90	27.4	5.65	5	14.0	3.02	16.1	3.43
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	5	12.3	3.21	13.9	3.70	7	19.8	3.61	22.1	4.09
Breast (<i>in situ</i>)	-	-	-	-	-	13	29.4	3.77	36.1	4.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

HAWAII

II-148 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,235	507.2	7.02	592.9	7.91	923	456.4	7.48	523.0	8.14
Oral Cavity & Pharynx	70	27.4	1.59	33.2	1.86	20	10.1	1.11	11.4	1.20
Lip	3	1.6	0.42	1.8	0.46	-	-	-	-	-
Tongue	26	10.0	0.95	12.0	1.11	8	3.9	0.67	4.4	0.73
Major salivary gland	6	2.8	0.53	3.3	0.61	3	1.9	0.56	1.9	0.54
Floor of mouth	4	1.5	0.36	1.9	0.44	-	-	-	-	-
Gum & other mouth	5	1.9	0.44	2.3	0.50	4	1.8	0.45	2.1	0.50
Nasopharynx	2	0.7	0.28	0.8	0.31	-	-	-	-	-
Oropharynx	3	1.0	0.27	1.4	0.35	-	-	-	-	-
Hypopharynx	4	1.1	0.28	1.4	0.34	-	-	-	-	-
Digestive System	218	88.3	2.91	105.0	3.33	138	64.7	2.68	75.5	3.01
Esophagus	17	6.7	0.79	8.0	0.92	5	2.3	0.49	2.7	0.56
Stomach	15	5.9	0.74	7.0	0.85	6	2.8	0.54	3.3	0.61
Small intestine	4	1.9	0.44	2.3	0.51	3	1.4	0.39	1.7	0.45
Colon excl. rectum	61	26.2	1.65	30.9	1.86	51	25.3	1.72	28.9	1.89
Rectum & rectosigmoid	36	15.2	1.24	18.0	1.41	21	11.0	1.17	12.6	1.29
Anus, anal canal & anorectum	5	1.7	0.38	2.1	0.45	9	3.4	0.56	4.4	0.70
Liver	29	9.6	0.86	12.3	1.06	8	2.7	0.46	3.5	0.58
Gallbladder	2	0.8	0.27	0.8	0.29	2	0.8	0.29	0.8	0.30
Pancreas	35	14.1	1.15	16.4	1.30	25	11.6	1.11	13.3	1.24
Respiratory System	136	54.0	2.23	63.6	2.54	91	40.5	2.05	47.5	2.32
Larynx	15	5.7	0.71	7.0	0.84	3	0.9	0.28	1.2	0.34
Lung & bronchus	117	46.5	2.06	54.7	2.36	87	38.9	2.02	45.5	2.28
Bones & Joints	2	1.0	0.33	1.2	0.36	-	-	-	-	-
Soft Tissue (incl. heart)	9	4.5	0.77	4.9	0.77	5	3.0	0.74	3.0	0.67
Skin (excl. basal & sq.)	213	91.9	3.04	105.7	3.39	112	57.1	2.70	64.5	2.88
Melanomas of the skin	202	87.2	2.96	100.1	3.29	107	54.8	2.66	61.9	2.83
Breast (excl. <i>in situ</i>)	3	1.0	0.29	1.2	0.35	283	142.3	4.22	164.0	4.62
Female Genital System	-	-	-	-	-	107	51.9	2.48	60.6	2.77
Cervix uteri	-	-	-	-	-	10	6.6	1.02	7.0	1.02
Uterus Corpus	-	-	-	-	-	54	23.7	1.57	28.9	1.85
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	25	13.6	1.33	15.4	1.44
Male Genital System	249	95.2	2.93	113.1	3.36	-	-	-	-	-
Prostate	231	85.1	2.69	103.0	3.16	-	-	-	-	-
Testis	15	8.8	1.10	8.8	1.06	-	-	-	-	-
Penis	2	0.8	0.27	0.9	0.32	-	-	-	-	-
Urinary System	139	58.1	2.36	67.6	2.67	33	15.1	1.28	17.9	1.45
Bladder (incl. <i>in situ</i>)	88	37.5	1.91	43.4	2.16	17	7.3	0.86	8.6	0.98
Kidney & renal pelvis	49	19.4	1.36	22.9	1.53	16	7.4	0.92	8.8	1.05
Ureter	2	0.7	0.25	0.9	0.29	-	-	-	-	-
Eye & Orbit	5	2.1	0.47	2.3	0.50	2	1.2	0.41	1.5	0.46
Brain & Other CNS ¹	17	8.6	1.09	9.1	1.06	10	5.8	0.97	6.0	0.93
Brain	16	8.2	1.07	8.7	1.04	10	5.7	0.97	5.9	0.92
Endocrine System	16	7.6	0.93	8.3	0.97	30	19.6	1.77	20.5	1.76
Thyroid gland	15	7.2	0.89	7.9	0.94	29	19.3	1.76	20.1	1.74
Lymphomas	58	25.1	1.62	28.7	1.76	36	18.5	1.53	20.7	1.63
Hodgkin Lymphoma	6	3.1	0.57	3.2	0.58	3	2.5	0.70	2.5	0.65
Non-Hodgkin Lymphoma	52	22.1	1.51	25.4	1.66	33	16.0	1.36	18.3	1.50
Multiple Myeloma	20	8.3	0.89	9.9	1.03	9	4.1	0.66	4.7	0.73
Leukemias	34	14.7	1.23	16.8	1.34	21	11.3	1.28	12.4	1.31
Acute lymphocytic	2	1.0	0.39	0.9	0.36	1	1.3	0.53	1.2	0.46
Chronic lymphocytic	13	5.0	0.66	6.0	0.77	7	3.0	0.55	3.5	0.63
Acute myeloid	10	4.5	0.70	5.1	0.75	7	4.2	0.83	4.6	0.83
Chronic myeloid	6	2.3	0.46	2.6	0.52	3	1.5	0.42	1.8	0.48
Other leukemias	4	1.9	0.47	2.1	0.51	2	1.3	0.43	1.3	0.41
Mesothelioma	1	0.7	0.26	0.7	0.29	-	-	-	-	-
Kaposi Sarcoma	1	0.5	0.21	0.6	0.26	-	-	-	-	-
Ill-defined & Unknown	42	18.3	1.36	21.1	1.52	24	10.5	1.06	12.2	1.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	14	6.5	0.85	7.2	0.90	26	13.6	1.34	15.1	1.40
Breast (<i>in situ</i>)	-	-	-	-	-	56	28.9	1.93	33.3	2.10

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Hawaii, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	59	471.5	31.49	574.3	36.98	27	344.6	32.75	408.5	38.12
Oral Cavity & Pharynx	1	10.7	5.11	11.8	5.46	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	14	110.7	15.31	136.4	18.05	3	44.9	12.41	55.1	14.85
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	12.0	5.26	13.1	5.60	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	33.7	8.85	41.4	10.38	1	23.2	10.31	26.4	11.63
Rectum & rectosigmoid	2	12.2	4.99	14.8	5.68	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	21.3	6.56	27.3	7.86	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	14.4	5.32	18.0	6.55	-	-	-	-	-
Respiratory System	5	52.1	11.67	62.4	13.52	3	56.8	15.52	63.3	16.79
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	47.0	11.38	55.3	13.04	3	56.8	15.52	63.3	16.79
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	9	107.1	16.49	128.0	19.66
Female Genital System	-	-	-	-	-	4	42.9	11.36	52.7	13.62
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	22.3	8.47	27.5	10.27
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	15.1	6.76	19.2	8.08
Male Genital System	24	171.1	17.61	216.4	21.30	-	-	-	-	-
Prostate	23	165.0	17.17	209.9	20.84	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	55.6	12.04	62.9	13.60	1	23.1	9.32	26.1	10.16
Bladder (incl. <i>in situ</i>)	3	36.5	10.20	42.1	11.66	-	-	-	-	-
Kidney & renal pelvis	3	18.0	6.31	19.3	6.83	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	2	16.6	5.44	19.3	6.20	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	16.7	5.28	21.1	6.49	1	14.5	6.11	18.2	7.63
Leukemias	2	13.2	5.19	16.3	6.28	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	11.6	5.48	13.0	6.35	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	7.7	3.44	8.0	3.66	1	15.0	6.76	15.7	7.02
Breast (<i>in situ</i>)	-	-	-	-	-	2	24.2	8.58	29.7	10.22

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


HAWAII

II-150 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,611,530	1,631,479	1,651,523	1,682,930	1,718,904
White	1,533,598	1,551,023	1,567,780	1,595,320	1,628,135
Black	17,475	18,273	19,137	20,250	21,248
American Indian/Alaskan Native (AI/AN)	31,868	32,535	33,402	34,191	34,797
Asian/Pacific Islander (API)	28,589	29,648	31,204	33,169	34,724


All Races Population 2013-2017: 8,296,366
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	191,577	196,561	202,082	209,112	216,125
Non-Hispanic White	1,358,859	1,371,925	1,383,969	1,405,138	1,431,531
Non-Hispanic Black	14,347	15,034	15,782	16,696	17,558

Hispanic/Latino Population, Census 2010: 175,901
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

IDAHO CANCER REGISTRY

Initial Operation: 1969
Population-based Data Available: 1970
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.5	103.5	106.7	104.3	100.0
Missing Race	1.2	0.9	0.4	0.3	1.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.4	2.2	2.3	1.7	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.0	Prostate	95.8
Oral Cavity & Pharynx	97.9	Testis	99.6
Esophagus	93.6	Bladder (incl. <i>in situ</i>)	95.8
Stomach	95.1	Kidney & Renal Pelvis	83.7
Colon & Rectum	95.0	Brain & Other CNS ¹	82.4
Liver	46.2	Thyroid	99.5
Pancreas	77.5	Hodgkin Lymphoma	99.5
Lung & Bronchus	81.5	Non-Hodgkin Lymphoma	95.5
Melanomas of the Skin	99.3	Multiple Myeloma	83.7
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	86.2
Cervix uteri	98.1	Brain & Other CNS ¹ <i>non-malig</i>	46.1
Uterus Corpus & Uterus NOS ¹	98.1	Breast <i>in situ</i>	100.0
Ovary	89.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,239	473.1	3.34	558.2	3.89	3,960	419.5	3.06	488.1	3.50
Oral Cavity & Pharynx	165	17.8	0.64	21.7	0.76	68	7.1	0.40	8.4	0.46
Lip	24	2.8	0.26	3.3	0.30	7	0.7	0.12	0.8	0.14
Tongue	50	5.3	0.35	6.5	0.42	20	2.1	0.22	2.5	0.25
Major salivary gland	16	1.9	0.22	2.2	0.24	11	1.2	0.17	1.4	0.19
Floor of mouth	6	0.6	0.11	0.7	0.14	2	0.2	0.07	0.3	0.08
Gum & other mouth	15	1.7	0.20	2.0	0.24	13	1.3	0.17	1.5	0.19
Nasopharynx	4	0.4	0.10	0.5	0.12	-	-	-	-	-
Oropharynx	7	0.7	0.12	0.9	0.15	2	0.2	0.06	0.2	0.07
Hypopharynx	6	0.6	0.11	0.7	0.13	2	0.2	0.07	0.3	0.08
Digestive System	796	88.8	1.45	106.1	1.70	603	62.2	1.16	73.4	1.35
Esophagus	78	8.5	0.44	10.2	0.53	16	1.6	0.18	1.9	0.21
Stomach	64	7.2	0.41	8.5	0.49	34	3.6	0.28	4.2	0.33
Small intestine	23	2.6	0.25	3.0	0.28	20	2.1	0.21	2.4	0.24
Colon excl. rectum	227	26.2	0.80	30.7	0.93	221	23.2	0.72	26.9	0.82
Rectum & rectosigmoid	120	13.2	0.56	16.0	0.66	79	8.4	0.44	10.0	0.51
Anus, anal canal & anorectum	6	0.7	0.13	0.9	0.15	29	2.9	0.25	3.6	0.30
Liver	91	9.1	0.44	11.6	0.55	28	2.8	0.24	3.4	0.29
Gallbladder	7	0.9	0.15	1.0	0.17	11	1.0	0.15	1.3	0.17
Pancreas	140	15.8	0.61	18.7	0.72	120	12.2	0.51	14.3	0.59
Respiratory System	524	58.9	1.18	69.4	1.38	464	47.1	1.00	55.4	1.16
Larynx	34	3.6	0.28	4.4	0.34	8	0.9	0.14	1.0	0.16
Lung & bronchus	480	54.3	1.14	63.7	1.32	451	45.7	0.98	53.8	1.14
Bones & Joints	9	1.1	0.16	1.2	0.17	7	0.8	0.14	0.8	0.14
Soft Tissue (incl. heart)	30	3.6	0.30	4.0	0.33	29	3.3	0.28	3.5	0.30
Skin (excl. basal & sq.)	310	35.5	0.93	41.7	1.07	223	24.9	0.77	28.1	0.85
Melanomas of the skin	294	33.6	0.90	39.4	1.04	211	23.7	0.75	26.7	0.83
Breast (excl. <i>in situ</i>)	9	1.0	0.16	1.2	0.18	1,191	126.7	1.69	148.8	1.95
Female Genital System	-	-	-	-	-	444	46.6	1.02	55.3	1.19
Cervix uteri	-	-	-	-	-	52	6.5	0.42	6.9	0.43
Uterus Corpus	-	-	-	-	-	242	24.5	0.73	29.9	0.87
Uterus, NOS ¹	-	-	-	-	-	7	0.7	0.11	0.8	0.14
Ovary	-	-	-	-	-	104	10.9	0.49	12.9	0.57
Male Genital System	1,068	113.2	1.59	136.1	1.89	-	-	-	-	-
Prostate	1,005	105.3	1.52	128.2	1.83	-	-	-	-	-
Testis	53	6.9	0.43	6.8	0.42	-	-	-	-	-
Penis	6	0.8	0.14	0.8	0.15	-	-	-	-	-
Urinary System	529	60.4	1.21	71.1	1.40	207	21.1	0.67	24.9	0.78
Bladder (incl. <i>in situ</i>)	314	36.2	0.94	42.4	1.09	89	8.9	0.43	10.5	0.50
Kidney & renal pelvis	199	22.2	0.72	26.4	0.85	112	11.7	0.51	13.7	0.58
Ureter	8	1.0	0.16	1.2	0.19	4	0.4	0.09	0.4	0.10
Eye & Orbit	11	1.1	0.15	1.3	0.18	6	0.6	0.12	0.7	0.13
Brain & Other CNS ¹	79	9.1	0.47	10.1	0.52	51	5.8	0.37	6.3	0.40
Brain	74	8.5	0.45	9.5	0.50	48	5.3	0.35	5.8	0.38
Endocrine System	73	8.6	0.46	9.4	0.50	189	22.9	0.77	24.8	0.81
Thyroid gland	66	7.8	0.44	8.6	0.48	185	22.4	0.76	24.2	0.80
Lymphomas	223	25.7	0.79	29.3	0.89	171	18.2	0.64	20.9	0.72
Hodgkin Lymphoma	22	2.7	0.26	2.7	0.26	18	2.2	0.23	2.3	0.24
Non-Hodgkin Lymphoma	201	23.0	0.74	26.6	0.85	153	16.0	0.59	18.6	0.68
Multiple Myeloma	71	8.1	0.44	9.5	0.51	50	5.1	0.33	6.0	0.38
Leukemias	176	20.4	0.70	23.2	0.80	121	13.0	0.54	14.6	0.60
Acute lymphocytic	20	2.3	0.23	2.2	0.22	11	1.3	0.18	1.2	0.17
Chronic lymphocytic	68	7.5	0.42	9.0	0.50	47	4.9	0.32	5.7	0.37
Acute myeloid	47	5.5	0.37	6.2	0.42	33	3.6	0.29	4.0	0.32
Chronic myeloid	27	3.1	0.28	3.6	0.32	15	1.6	0.19	1.8	0.21
Other leukemias	16	1.9	0.22	2.2	0.25	15	1.6	0.19	1.8	0.21
Mesothelioma	17	2.1	0.23	2.4	0.26	5	0.6	0.11	0.7	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	71	8.4	0.46	9.3	0.50	144	15.6	0.60	17.8	0.67
Breast (<i>in situ</i>)	-	-	-	-	-	212	23.4	0.74	27.3	0.85

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	4,093	470.2	3.37	554.6	3.93	3,828	419.3	3.12	487.8	3.56
Oral Cavity & Pharynx	159	17.7	0.64	21.5	0.77	65	7.0	0.40	8.3	0.46
Lip	23	2.7	0.26	3.1	0.30	7	0.7	0.12	0.8	0.14
Tongue	48	5.2	0.35	6.4	0.42	19	2.1	0.22	2.5	0.26
Major salivary gland	16	1.9	0.22	2.2	0.25	11	1.2	0.17	1.4	0.19
Floor of mouth	6	0.6	0.12	0.8	0.15	2	0.3	0.08	0.3	0.09
Gum & other mouth	14	1.6	0.19	1.9	0.23	12	1.3	0.17	1.5	0.19
Nasopharynx	3	0.4	0.09	0.4	0.11	-	-	-	-	-
Oropharynx	6	0.6	0.11	0.8	0.14	2	0.2	0.07	0.2	0.08
Hypopharynx	6	0.6	0.11	0.7	0.14	2	0.2	0.06	0.2	0.07
Digestive System	769	88.2	1.46	105.4	1.72	582	61.9	1.18	73.0	1.37
Esophagus	75	8.5	0.45	10.1	0.53	16	1.6	0.18	1.9	0.22
Stomach	61	7.1	0.42	8.5	0.49	32	3.5	0.28	4.1	0.33
Small intestine	22	2.6	0.25	3.0	0.29	20	2.1	0.21	2.4	0.25
Colon excl. rectum	220	26.0	0.81	30.6	0.94	214	23.2	0.73	26.9	0.83
Rectum & rectosigmoid	116	13.3	0.57	16.0	0.67	76	8.4	0.44	10.0	0.52
Anus, anal canal & anorectum	6	0.7	0.13	0.9	0.16	28	2.9	0.25	3.6	0.31
Liver	84	8.7	0.43	11.0	0.54	25	2.6	0.23	3.1	0.28
Gallbladder	7	0.9	0.15	1.0	0.17	11	1.1	0.15	1.3	0.18
Pancreas	139	16.0	0.62	19.0	0.73	117	12.1	0.51	14.3	0.60
Respiratory System	510	58.8	1.19	69.3	1.39	452	47.1	1.01	55.5	1.18
Larynx	32	3.5	0.28	4.3	0.34	8	0.9	0.14	1.0	0.16
Lung & bronchus	469	54.2	1.15	63.7	1.34	439	45.7	0.99	53.8	1.16
Bones & Joints	9	1.1	0.17	1.2	0.18	7	0.8	0.15	0.8	0.14
Soft Tissue (incl. heart)	29	3.5	0.30	4.0	0.34	28	3.3	0.29	3.6	0.30
Skin (excl. basal & sq.)	309	36.6	0.96	42.9	1.11	221	25.6	0.80	28.9	0.88
Melanomas of the skin	294	34.6	0.93	40.6	1.07	211	24.5	0.78	27.6	0.86
Breast (excl. <i>in situ</i>)	9	1.0	0.16	1.2	0.19	1,150	126.6	1.72	148.7	1.98
Female Genital System	-	-	-	-	-	428	46.6	1.04	55.3	1.21
Cervix uteri	-	-	-	-	-	49	6.4	0.42	6.8	0.44
Uterus Corpus	-	-	-	-	-	234	24.5	0.74	30.0	0.89
Uterus, NOS ¹	-	-	-	-	-	7	0.7	0.12	0.8	0.14
Ovary	-	-	-	-	-	100	10.9	0.50	12.9	0.58
Male Genital System	1,011	110.4	1.59	132.6	1.89	-	-	-	-	-
Prostate	951	102.3	1.52	124.5	1.83	-	-	-	-	-
Testis	51	7.0	0.45	6.9	0.43	-	-	-	-	-
Penis	6	0.8	0.14	0.9	0.15	-	-	-	-	-
Urinary System	512	60.0	1.22	70.6	1.42	200	21.0	0.68	24.8	0.79
Bladder (incl. <i>in situ</i>)	307	36.3	0.95	42.5	1.10	86	8.7	0.43	10.4	0.51
Kidney & renal pelvis	190	21.7	0.72	25.8	0.85	109	11.7	0.52	13.7	0.59
Ureter	8	1.1	0.17	1.2	0.19	4	0.4	0.09	0.5	0.10
Eye & Orbit	10	1.1	0.16	1.3	0.19	6	0.7	0.13	0.7	0.14
Brain & Other CNS ¹	77	9.2	0.48	10.2	0.53	49	5.7	0.37	6.2	0.40
Brain	72	8.6	0.47	9.6	0.51	45	5.2	0.36	5.8	0.39
Endocrine System	70	8.5	0.47	9.4	0.51	179	22.6	0.78	24.5	0.83
Thyroid gland	64	7.8	0.45	8.6	0.49	174	22.1	0.77	23.9	0.82
Lymphomas	215	25.6	0.80	29.2	0.90	166	18.2	0.65	21.0	0.73
Hodgkin Lymphoma	21	2.7	0.27	2.7	0.27	18	2.2	0.24	2.3	0.25
Non-Hodgkin Lymphoma	195	22.9	0.75	26.5	0.86	149	16.0	0.60	18.6	0.69
Multiple Myeloma	69	8.0	0.44	9.4	0.51	49	5.1	0.33	6.0	0.39
Leukemias	172	20.6	0.72	23.4	0.81	117	13.0	0.55	14.6	0.61
Acute lymphocytic	19	2.3	0.24	2.2	0.23	11	1.3	0.19	1.2	0.17
Chronic lymphocytic	66	7.6	0.43	9.0	0.50	46	4.9	0.33	5.8	0.38
Acute myeloid	46	5.6	0.38	6.4	0.43	31	3.5	0.29	4.0	0.32
Chronic myeloid	26	3.1	0.28	3.6	0.32	14	1.6	0.19	1.8	0.21
Other leukemias	15	1.9	0.22	2.2	0.26	15	1.6	0.19	1.9	0.22
Mesothelioma	17	2.1	0.23	2.4	0.27	5	0.6	0.11	0.7	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	67	8.2	0.46	9.2	0.51	139	15.8	0.62	17.9	0.69
Breast (<i>in situ</i>)	-	-	-	-	-	205	23.5	0.76	27.4	0.87

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17	437.9	62.16	522.9	71.68	9	265.1	45.51	310.1	52.29
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	94.3	32.73	112.0	38.10	2	50.0	19.43	63.3	23.28
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	67.4	25.40	80.5	28.88	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	67.4	25.40	80.5	28.88	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	83.6	25.91	97.7	29.98
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	6	139.7	28.56	167.1	32.11	-	-	-	-	-
Prostate	6	139.7	28.56	167.1	32.11	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	35.1	20.53	43.3	23.99	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	28	301.0	27.88	357.6	32.42	42	292.7	20.90	337.7	23.95
Oral Cavity & Pharynx	1	11.1	4.79	13.3	5.81	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	8	85.8	15.07	102.4	17.52	6	46.7	8.62	53.5	9.74
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	13.5	6.08	17.3	7.51	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	22.7	7.99	25.6	8.63	2	10.7	3.57	12.4	4.18
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	19.3	6.98	24.5	8.59	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	1	10.8	4.14	12.9	4.92
Respiratory System	4	47.6	12.12	56.8	13.78	4	29.8	6.87	34.5	7.87
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	44.7	11.94	52.5	13.44	4	29.8	6.87	34.5	7.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	14	89.1	11.04	107.0	13.20
Female Genital System	-	-	-	-	-	5	36.7	7.33	42.2	8.40
Cervix uteri	-	-	-	-	-	1	7.9	3.33	8.8	3.76
Uterus Corpus	-	-	-	-	-	2	12.4	3.96	15.1	4.80
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	10.7	3.86	12.5	4.55
Male Genital System	5	54.5	11.46	68.3	13.90	-	-	-	-	-
Prostate	5	53.2	11.39	67.2	13.86	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	4	50.3	11.87	58.6	13.59	2	12.2	4.63	12.8	4.82
Bladder (incl. <i>in situ</i>)	2	25.7	8.73	30.9	10.24	-	-	-	-	-
Kidney & renal pelvis	2	24.5	8.04	27.7	8.94	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	1	11.1	4.42	12.1	4.77
Brain	-	-	-	-	-	1	9.8	4.22	10.7	4.55
Endocrine System	-	-	-	-	-	4	21.6	5.10	23.6	5.65
Thyroid gland	-	-	-	-	-	3	20.4	4.97	22.0	5.42
Lymphomas	2	17.2	6.44	19.2	7.43	1	8.6	3.65	8.9	3.95
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	15.8	6.28	18.1	7.34	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	2	12.2	4.53	13.6	5.04
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	1	7.1	2.89	8.8	3.60
Breast (<i>in situ</i>)	-	-	-	-	-	3	18.1	5.17	21.0	6.00

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	20	347.2	37.52	412.7	43.86	29	464.7	41.20	536.8	47.18
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	7	113.5	21.33	143.1	25.95	6	96.7	19.67	115.8	23.45
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	42.6	13.68	53.4	16.46	2	42.8	14.30	52.4	17.36
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	34.4	10.69	45.4	13.62	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	39.5	13.39	45.8	15.15	5	92.1	18.95	101.9	20.83
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	37.4	13.21	42.4	14.78	5	88.8	18.66	99.2	20.66
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	9	138.2	21.57	162.4	24.84
Female Genital System	-	-	-	-	-	3	36.7	10.51	41.6	11.68
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	24.1	8.81	26.1	9.39
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	79.0	17.76	93.9	20.81	-	-	-	-	-
Prostate	4	70.7	17.07	85.1	20.18	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	51.2	15.58	56.8	17.53	2	29.5	10.32	34.3	11.88
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	37.5	13.89	42.4	15.92	1	19.9	8.49	23.2	9.94
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	16.1	6.67	17.3	7.18
Thyroid gland	-	-	-	-	-	1	16.1	6.67	17.3	7.18
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	158	347.4	14.52	406.2	16.69	189	351.2	12.70	412.2	14.84
Oral Cavity & Pharynx	3	6.7	1.92	8.2	2.27	3	5.3	1.58	5.9	1.77
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	1	2.5	1.07	2.8	1.19
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	38	83.5	6.92	99.8	8.05	30	60.2	5.37	72.7	6.38
Esophagus	2	4.0	1.56	4.4	1.66	-	-	-	-	-
Stomach	3	5.8	1.63	7.0	1.89	4	7.3	1.86	8.8	2.22
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	9	19.2	3.26	22.6	3.78	8	14.2	2.46	17.5	2.99
Rectum & rectosigmoid	7	15.2	2.86	18.2	3.36	5	9.8	2.19	11.6	2.59
Anus, anal canal & anorectum	-	-	-	-	-	2	2.9	1.13	3.7	1.40
Liver	8	16.0	2.74	20.2	3.31	3	8.1	2.19	9.3	2.46
Gallbladder	-	-	-	-	-	1	2.8	1.14	3.7	1.43
Pancreas	5	15.2	3.32	17.8	3.81	4	9.0	2.05	10.8	2.44
Respiratory System	15	43.4	5.49	49.4	6.15	14	35.8	4.60	42.0	5.28
Larynx	1	3.3	1.52	3.8	1.70	-	-	-	-	-
Lung & bronchus	14	38.9	5.20	44.4	5.84	14	35.4	4.58	41.4	5.26
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.5	1.77	5.3	2.06	2	2.9	1.12	2.9	1.16
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	3	6.0	1.94	6.8	2.22	5	7.4	1.60	8.9	1.96
Breast (excl. <i>in situ</i>)	-	-	-	-	-	56	102.6	6.66	119.9	7.76
Female Genital System	-	-	-	-	-	29	48.4	4.43	58.5	5.40
Cervix uteri	-	-	-	-	-	6	8.9	1.60	10.3	1.95
Uterus Corpus	-	-	-	-	-	13	22.0	2.85	27.5	3.58
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	11.2	2.31	13.3	2.72
Male Genital System	35	77.4	6.80	91.2	7.82	-	-	-	-	-
Prostate	29	71.8	6.72	85.7	7.74	-	-	-	-	-
Testis	6	4.7	0.87	4.7	0.86	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	19	45.9	5.47	54.3	6.35	9	18.7	3.12	22.0	3.59
Bladder (incl. <i>in situ</i>)	7	19.7	3.81	23.2	4.37	2	6.3	2.02	6.9	2.20
Kidney & renal pelvis	12	24.7	3.78	29.5	4.42	7	12.4	2.38	15.1	2.83
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	5.5	1.83	5.8	2.04	2	2.9	1.11	3.0	1.19
Brain	3	5.5	1.83	5.8	2.04	2	2.9	1.11	3.0	1.19
Endocrine System	6	9.3	2.01	10.4	2.29	16	21.2	2.51	23.4	2.90
Thyroid gland	6	8.8	1.97	9.6	2.22	16	20.9	2.50	23.1	2.89
Lymphomas	13	23.9	3.56	27.1	4.02	9	18.0	3.04	20.9	3.47
Hodgkin Lymphoma	3	2.7	0.87	2.6	0.86	1	2.5	1.18	2.6	1.21
Non-Hodgkin Lymphoma	11	21.1	3.46	24.5	3.93	8	15.5	2.80	18.4	3.26
Multiple Myeloma	3	10.4	2.88	12.1	3.33	-	-	-	-	-
Leukemias	9	14.9	2.74	17.0	3.19	8	14.2	2.66	16.3	3.07
Acute lymphocytic	4	3.0	0.73	3.0	0.88	1	1.1	0.45	1.0	0.43
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	5.6	1.96	6.4	2.23	3	5.9	1.73	7.0	2.02
Chronic myeloid	1	2.1	0.80	2.6	1.05	1	3.3	1.46	3.8	1.67
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	12.3	2.83	14.3	3.20	5	9.8	2.29	11.1	2.59
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	6	9.1	2.07	9.1	2.13	9	16.4	2.76	19.0	3.16
Breast (<i>in situ</i>)	-	-	-	-	-	10	16.8	2.56	19.5	3.02

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

IDAHO

II-158 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,951	478.1	3.50	563.9	4.07	3,651	423.4	3.25	492.2	3.70
Oral Cavity & Pharynx	156	18.4	0.68	22.4	0.81	62	7.1	0.41	8.4	0.48
Lip	22	2.8	0.27	3.2	0.31	6	0.7	0.13	0.8	0.15
Tongue	47	5.5	0.37	6.7	0.44	18	2.1	0.23	2.5	0.27
Major salivary gland	16	2.0	0.23	2.3	0.26	10	1.2	0.18	1.4	0.20
Floor of mouth	6	0.6	0.12	0.8	0.15	2	0.3	0.08	0.3	0.09
Gum & other mouth	14	1.6	0.20	2.0	0.24	12	1.3	0.17	1.5	0.20
Nasopharynx	3	0.4	0.10	0.4	0.11	-	-	-	-	-
Oropharynx	6	0.6	0.12	0.8	0.15	2	0.2	0.06	0.2	0.07
Hypopharynx	5	0.6	0.12	0.7	0.14	2	0.2	0.06	0.2	0.07
Digestive System	734	88.7	1.51	106.1	1.78	554	61.9	1.21	72.9	1.40
Esophagus	74	8.7	0.47	10.5	0.55	16	1.6	0.19	2.0	0.23
Stomach	58	7.1	0.43	8.5	0.50	29	3.3	0.28	3.9	0.32
Small intestine	22	2.6	0.26	3.1	0.30	19	2.1	0.23	2.5	0.26
Colon excl. rectum	211	26.4	0.84	31.1	0.97	207	23.5	0.76	27.2	0.86
Rectum & rectosigmoid	109	13.3	0.59	16.0	0.69	71	8.3	0.46	10.0	0.54
Anus, anal canal & anorectum	6	0.7	0.14	0.9	0.16	27	2.9	0.26	3.6	0.32
Liver	77	8.3	0.44	10.6	0.55	22	2.3	0.23	2.8	0.27
Gallbladder	7	0.8	0.15	1.0	0.17	9	1.0	0.15	1.2	0.17
Pancreas	133	16.1	0.64	19.1	0.75	113	12.2	0.53	14.4	0.61
Respiratory System	496	59.6	1.23	70.3	1.43	438	47.6	1.04	56.1	1.21
Larynx	31	3.6	0.29	4.4	0.36	8	0.9	0.15	1.1	0.17
Lung & bronchus	455	54.9	1.18	64.6	1.37	425	46.2	1.02	54.4	1.19
Bones & Joints	8	1.1	0.18	1.2	0.19	7	0.9	0.17	0.9	0.16
Soft Tissue (incl. heart)	27	3.5	0.31	4.0	0.35	26	3.4	0.30	3.6	0.32
Skin (excl. basal & sq.)	306	38.5	1.01	45.0	1.17	216	27.0	0.86	30.4	0.94
Melanomas of the skin	291	36.4	0.99	42.7	1.13	206	25.9	0.84	29.1	0.92
Breast (excl. <i>in situ</i>)	9	1.1	0.16	1.2	0.19	1,098	127.8	1.79	150.2	2.06
Female Genital System	-	-	-	-	-	402	46.4	1.08	55.1	1.25
Cervix uteri	-	-	-	-	-	43	6.2	0.44	6.6	0.45
Uterus Corpus	-	-	-	-	-	221	24.6	0.77	30.0	0.92
Uterus, NOS ¹	-	-	-	-	-	7	0.7	0.12	0.9	0.15
Ovary	-	-	-	-	-	95	10.9	0.52	12.9	0.60
Male Genital System	981	112.6	1.65	135.3	1.96	-	-	-	-	-
Prostate	927	104.3	1.57	127.1	1.89	-	-	-	-	-
Testis	46	7.3	0.49	7.1	0.47	-	-	-	-	-
Penis	6	0.8	0.14	0.9	0.16	-	-	-	-	-
Urinary System	495	60.7	1.25	71.4	1.46	191	21.1	0.70	24.8	0.81
Bladder (incl. <i>in situ</i>)	300	37.0	0.98	43.3	1.14	83	8.9	0.44	10.6	0.52
Kidney & renal pelvis	180	21.7	0.75	25.7	0.87	102	11.6	0.53	13.5	0.61
Ureter	8	1.1	0.17	1.2	0.20	4	0.4	0.10	0.5	0.11
Eye & Orbit	10	1.2	0.17	1.4	0.20	6	0.7	0.14	0.8	0.15
Brain & Other CNS ¹	74	9.6	0.51	10.6	0.56	47	6.0	0.41	6.5	0.43
Brain	69	8.9	0.49	9.9	0.54	44	5.5	0.39	6.0	0.41
Endocrine System	64	8.5	0.49	9.3	0.53	165	22.9	0.83	24.7	0.87
Thyroid gland	58	7.7	0.47	8.5	0.50	161	22.4	0.82	24.2	0.86
Lymphomas	204	25.7	0.83	29.3	0.93	158	18.3	0.67	21.0	0.76
Hodgkin Lymphoma	18	2.7	0.29	2.7	0.29	16	2.3	0.26	2.4	0.27
Non-Hodgkin Lymphoma	185	23.0	0.78	26.6	0.89	141	16.0	0.62	18.6	0.71
Multiple Myeloma	66	8.0	0.45	9.4	0.52	48	5.2	0.35	6.2	0.40
Leukemias	164	20.7	0.74	23.6	0.84	110	12.9	0.57	14.5	0.63
Acute lymphocytic	15	2.2	0.25	2.1	0.24	9	1.4	0.20	1.3	0.19
Chronic lymphocytic	65	7.8	0.44	9.3	0.52	46	5.1	0.34	5.9	0.40
Acute myeloid	44	5.7	0.39	6.4	0.44	28	3.4	0.30	3.8	0.32
Chronic myeloid	25	3.2	0.30	3.7	0.34	13	1.5	0.19	1.7	0.22
Other leukemias	14	1.9	0.23	2.2	0.26	14	1.6	0.20	1.8	0.22
Mesothelioma	16	2.1	0.24	2.4	0.27	5	0.6	0.12	0.7	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	62	8.2	0.48	9.2	0.53	131	15.9	0.65	18.1	0.72
Breast (<i>in situ</i>)	-	-	-	-	-	196	23.9	0.80	27.8	0.91

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Idaho, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	16	482.8	75.64	580.2	87.22	8	289.8	51.88	341.4	59.99
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	113.9	41.85	134.8	48.46	2	57.8	22.24	73.4	26.81
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	68.1	30.70	82.1	35.16	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	68.1	30.70	82.1	35.16	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	91.2	29.96	106.0	34.49
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	6	146.6	31.52	177.6	35.56	-	-	-	-	-
Prostate	6	146.6	31.52	177.6	35.56	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	43.9	27.30	53.6	31.70	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	12,898,269	12,888,962	12,864,342	12,826,895	12,786,196
White	10,128,846	10,103,128	10,065,313	10,022,077	9,974,052
Black	1,970,414	1,968,515	1,964,475	1,956,138	1,946,635
American Indian/Alaskan Native (AI/AN)	87,087	87,422	87,616	87,735	88,170
Asian/Pacific Islander (API)	711,922	729,897	746,938	760,945	777,339


All Races Population 2013-2017: 64,264,664
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	2,112,880	2,135,257	2,156,185	2,175,890	2,194,301
Non-Hispanic White	8,177,674	8,131,190	8,073,821	8,011,977	7,947,261
Non-Hispanic Black	1,894,157	1,891,233	1,886,301	1,877,222	1,866,879

Hispanic/Latino Population, Census 2010: 2,027,578
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ILLINOIS CANCER REGISTRY

Initial Operation: 1985
Population-based Data Available: 1986
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.4	104.9	106.3	107.3	107.6
Missing Race	0.5	0.6	0.8	0.6	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	2.1	2.1	2.0	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.1	Prostate	97.3
Oral Cavity & Pharynx	98.5	Testis	99.4
Esophagus	96.7	Bladder (incl. <i>in situ</i>)	98.1
Stomach	97.1	Kidney & Renal Pelvis	90.9
Colon & Rectum	96.6	Brain & Other CNS ¹	87.9
Liver	55.3	Thyroid	99.7
Pancreas	86.2	Hodgkin Lymphoma	99.3
Lung & Bronchus	89.2	Non-Hodgkin Lymphoma	97.4
Melanomas of the Skin	99.6	Multiple Myeloma	90.3
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	88.7
Cervix uteri	97.8	Brain & Other CNS ¹ <i>non-malig</i>	43.9
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	93.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	33,844	504.2	1.26	598.4	1.47	34,658	442.0	1.09	516.1	1.25
Oral Cavity & Pharynx	1,298	18.5	0.24	22.5	0.28	536	6.7	0.13	8.0	0.16
Lip	52	0.8	0.05	1.0	0.06	19	0.2	0.02	0.3	0.03
Tongue	403	5.6	0.13	6.9	0.15	168	2.1	0.07	2.5	0.09
Major salivary gland	108	1.7	0.07	2.0	0.08	84	1.1	0.06	1.3	0.06
Floor of mouth	61	0.9	0.05	1.1	0.06	27	0.3	0.03	0.4	0.03
Gum & other mouth	150	2.2	0.08	2.6	0.10	108	1.3	0.06	1.6	0.07
Nasopharynx	53	0.8	0.05	0.9	0.06	23	0.3	0.03	0.3	0.03
Oropharynx	67	0.9	0.05	1.1	0.06	19	0.2	0.02	0.3	0.03
Hypopharynx	84	1.2	0.06	1.5	0.07	21	0.3	0.03	0.3	0.03
Digestive System	6,936	103.9	0.57	123.8	0.67	5,705	70.2	0.43	82.7	0.49
Esophagus	571	8.3	0.16	10.1	0.19	151	1.8	0.07	2.2	0.08
Stomach	638	9.8	0.18	11.5	0.20	416	5.2	0.12	6.0	0.13
Small intestine	209	3.1	0.10	3.7	0.11	188	2.4	0.08	2.8	0.09
Colon excl. rectum	2,208	33.9	0.33	39.9	0.38	2,212	27.2	0.27	31.8	0.31
Rectum & rectosigmoid	1,065	15.6	0.22	18.8	0.26	756	9.6	0.16	11.4	0.19
Anus, anal canal & anorectum	109	1.6	0.07	1.9	0.08	177	2.2	0.08	2.7	0.09
Liver	713	9.9	0.17	12.3	0.21	267	3.2	0.09	3.8	0.11
Gallbladder	58	0.9	0.05	1.1	0.06	144	1.8	0.07	2.1	0.08
Pancreas	1,040	15.7	0.22	18.8	0.26	981	11.8	0.17	14.0	0.20
Respiratory System	5,354	81.1	0.51	96.3	0.59	4,768	58.2	0.38	69.1	0.45
Larynx	433	6.2	0.14	7.6	0.16	116	1.4	0.06	1.7	0.07
Lung & bronchus	4,849	73.8	0.49	87.5	0.57	4,608	56.3	0.38	66.8	0.44
Bones & Joints	68	1.0	0.06	1.1	0.06	54	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	272	4.3	0.12	4.7	0.13	212	2.9	0.09	3.2	0.10
Skin (excl. basal & sq.)	1,774	27.2	0.30	31.8	0.34	1,367	18.4	0.23	20.8	0.25
Melanomas of the skin	1,652	25.2	0.28	29.5	0.33	1,275	17.2	0.22	19.5	0.25
Breast (excl. <i>in situ</i>)	89	1.3	0.06	1.6	0.08	10,269	133.1	0.60	156.4	0.69
Female Genital System	-	-	-	-	-	4,233	53.8	0.38	64.0	0.44
Cervix uteri	-	-	-	-	-	531	7.7	0.15	8.4	0.16
Uterus Corpus	-	-	-	-	-	2,368	29.1	0.27	35.8	0.33
Uterus, NOS ¹	-	-	-	-	-	71	0.9	0.05	1.0	0.05
Ovary	-	-	-	-	-	857	11.0	0.17	12.9	0.20
Male Genital System	8,287	116.2	0.59	142.2	0.70	-	-	-	-	-
Prostate	7,843	109.1	0.57	135.0	0.69	-	-	-	-	-
Testis	382	6.2	0.14	6.1	0.14	-	-	-	-	-
Penis	48	0.8	0.05	0.9	0.06	-	-	-	-	-
Urinary System	4,109	63.0	0.45	74.0	0.52	1,789	22.2	0.24	26.0	0.28
Bladder (incl. <i>in situ</i>)	2,343	36.9	0.35	43.2	0.40	770	9.2	0.15	10.9	0.18
Kidney & renal pelvis	1,681	24.7	0.28	29.3	0.32	969	12.3	0.18	14.4	0.21
Ureter	53	0.9	0.05	1.0	0.06	35	0.4	0.03	0.5	0.04
Eye & Orbit	55	0.8	0.05	0.9	0.06	48	0.6	0.04	0.7	0.05
Brain & Other CNS ¹	487	7.4	0.15	8.2	0.17	391	5.3	0.12	5.8	0.13
Brain	461	7.0	0.15	7.8	0.16	362	4.9	0.12	5.4	0.13
Endocrine System	590	8.9	0.17	10.0	0.19	1,541	22.5	0.26	24.4	0.28
Thyroid gland	533	8.1	0.16	9.1	0.18	1,496	21.9	0.26	23.7	0.28
Lymphomas	1,740	26.9	0.29	30.8	0.33	1,443	18.6	0.22	21.3	0.25
Hodgkin Lymphoma	205	3.2	0.10	3.3	0.11	160	2.4	0.09	2.5	0.09
Non-Hodgkin Lymphoma	1,535	23.7	0.28	27.4	0.32	1,284	16.2	0.21	18.8	0.24
Multiple Myeloma	520	7.8	0.16	9.3	0.18	453	5.5	0.12	6.6	0.14
Leukemias	1,091	17.1	0.24	19.4	0.27	812	10.5	0.17	11.7	0.19
Acute lymphocytic	120	2.0	0.08	1.8	0.07	88	1.4	0.07	1.3	0.06
Chronic lymphocytic	358	5.4	0.13	6.5	0.15	239	2.9	0.09	3.4	0.10
Acute myeloid	352	5.6	0.14	6.4	0.15	294	3.8	0.10	4.3	0.11
Chronic myeloid	137	2.1	0.08	2.5	0.09	108	1.4	0.06	1.6	0.07
Other leukemias	124	2.0	0.08	2.3	0.09	83	1.0	0.05	1.2	0.06
Mesothelioma	97	1.6	0.07	1.9	0.08	39	0.5	0.04	0.6	0.04
Kaposi Sarcoma	33	0.5	0.04	0.6	0.04	5	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,043	16.5	0.23	19.2	0.27	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	602	9.3	0.17	10.5	0.19	1,250	16.5	0.21	18.8	0.24
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.02	2,488	33.0	0.30	38.9	0.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	28,051	503.0	1.38	595.0	1.60	28,486	449.6	1.23	523.8	1.40
Oral Cavity & Pharynx	1,099	18.8	0.26	23.0	0.31	443	6.9	0.15	8.1	0.17
Lip	48	0.9	0.06	1.1	0.07	17	0.3	0.03	0.3	0.03
Tongue	355	6.0	0.15	7.3	0.18	145	2.2	0.09	2.7	0.10
Major salivary gland	90	1.7	0.08	2.0	0.09	65	1.1	0.06	1.2	0.07
Floor of mouth	52	0.9	0.06	1.1	0.07	22	0.3	0.03	0.4	0.04
Gum & other mouth	120	2.1	0.09	2.5	0.10	92	1.4	0.07	1.6	0.08
Nasopharynx	31	0.5	0.04	0.7	0.05	14	0.2	0.03	0.3	0.03
Oropharynx	55	0.9	0.06	1.1	0.07	15	0.2	0.03	0.3	0.03
Hypopharynx	66	1.1	0.06	1.4	0.08	17	0.3	0.03	0.3	0.03
Digestive System	5,614	101.0	0.62	120.1	0.72	4,520	68.0	0.47	79.8	0.54
Esophagus	498	8.7	0.18	10.5	0.21	120	1.7	0.07	2.1	0.09
Stomach	495	9.1	0.19	10.6	0.21	294	4.5	0.12	5.2	0.14
Small intestine	163	3.0	0.11	3.5	0.12	142	2.2	0.09	2.6	0.10
Colon excl. rectum	1,783	32.8	0.36	38.6	0.41	1,771	26.5	0.29	30.9	0.33
Rectum & rectosigmoid	867	15.4	0.24	18.4	0.28	599	9.4	0.18	11.1	0.20
Anus, anal canal & anorectum	87	1.6	0.08	1.8	0.09	153	2.3	0.09	2.9	0.10
Liver	531	9.0	0.18	11.1	0.22	197	2.9	0.10	3.5	0.11
Gallbladder	44	0.8	0.06	1.0	0.07	111	1.7	0.07	1.9	0.08
Pancreas	872	15.8	0.24	18.8	0.29	788	11.5	0.19	13.6	0.22
Respiratory System	4,424	80.1	0.55	94.9	0.64	3,970	59.4	0.43	70.3	0.50
Larynx	345	5.9	0.15	7.2	0.18	91	1.4	0.07	1.7	0.08
Lung & bronchus	4,018	73.1	0.53	86.3	0.61	3,844	57.4	0.42	68.0	0.49
Bones & Joints	55	1.1	0.07	1.1	0.07	46	0.8	0.06	0.9	0.06
Soft Tissue (incl. heart)	220	4.2	0.13	4.7	0.14	164	2.7	0.10	3.0	0.11
Skin (excl. basal & sq.)	1,697	31.2	0.35	36.4	0.40	1,287	21.8	0.28	24.6	0.31
Melanomas of the skin	1,586	29.1	0.33	33.9	0.38	1,207	20.6	0.27	23.2	0.30
Breast (excl. <i>in situ</i>)	70	1.3	0.07	1.5	0.08	8,337	134.1	0.68	157.6	0.78
Female Genital System	-	-	-	-	-	3,437	54.4	0.43	64.7	0.50
Cervix uteri	-	-	-	-	-	400	7.5	0.17	8.1	0.18
Uterus Corpus	-	-	-	-	-	1,932	29.6	0.31	36.3	0.37
Uterus, NOS ¹	-	-	-	-	-	49	0.7	0.05	0.8	0.05
Ovary	-	-	-	-	-	715	11.4	0.20	13.3	0.23
Male Genital System	6,462	109.4	0.62	133.1	0.74	-	-	-	-	-
Prostate	6,059	101.2	0.60	124.8	0.72	-	-	-	-	-
Testis	353	7.3	0.18	7.2	0.17	-	-	-	-	-
Penis	41	0.8	0.06	0.9	0.06	-	-	-	-	-
Urinary System	3,590	65.8	0.50	77.2	0.58	1,522	23.1	0.27	27.1	0.31
Bladder (incl. <i>in situ</i>)	2,125	39.7	0.39	46.4	0.45	681	9.9	0.17	11.7	0.20
Kidney & renal pelvis	1,389	24.7	0.30	29.1	0.35	797	12.6	0.21	14.7	0.24
Ureter	49	1.0	0.06	1.1	0.07	31	0.4	0.04	0.5	0.04
Eye & Orbit	50	0.9	0.06	1.1	0.07	45	0.7	0.05	0.8	0.06
Brain & Other CNS ¹	431	8.1	0.18	8.9	0.19	341	5.8	0.15	6.4	0.16
Brain	410	7.6	0.17	8.5	0.19	317	5.4	0.14	6.0	0.15
Endocrine System	505	9.4	0.19	10.5	0.21	1,278	24.0	0.31	25.9	0.33
Thyroid gland	463	8.6	0.18	9.7	0.20	1,245	23.4	0.31	25.2	0.32
Lymphomas	1,503	28.0	0.33	32.1	0.37	1,228	19.5	0.26	22.3	0.29
Hodgkin Lymphoma	165	3.2	0.11	3.4	0.12	128	2.5	0.10	2.6	0.10
Non-Hodgkin Lymphoma	1,338	24.8	0.31	28.7	0.35	1,100	16.9	0.24	19.7	0.27
Multiple Myeloma	393	7.1	0.16	8.4	0.19	316	4.7	0.12	5.6	0.14
Leukemias	937	17.8	0.26	20.1	0.30	688	11.0	0.19	12.2	0.21
Acute lymphocytic	102	2.1	0.10	2.0	0.09	74	1.5	0.08	1.4	0.07
Chronic lymphocytic	310	5.6	0.15	6.7	0.17	203	3.0	0.10	3.5	0.11
Acute myeloid	302	5.8	0.15	6.5	0.17	249	3.9	0.12	4.4	0.13
Chronic myeloid	113	2.2	0.09	2.5	0.10	89	1.4	0.07	1.6	0.08
Other leukemias	109	2.1	0.09	2.4	0.10	72	1.1	0.06	1.2	0.07
Mesothelioma	92	1.8	0.08	2.1	0.10	37	0.6	0.04	0.6	0.05
Kaposi Sarcoma	19	0.4	0.04	0.4	0.04	4	0.1	0.01	0.1	0.01
Ill-defined & Unknown	888	16.7	0.26	19.4	0.29	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	508	9.5	0.19	10.7	0.21	1,015	16.7	0.24	19.0	0.27
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.02	1,954	32.6	0.34	38.3	0.39

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,472	558.9	3.91	677.3	4.64	4,770	437.6	2.89	516.9	3.36
Oral Cavity & Pharynx	141	17.0	0.67	20.7	0.79	67	6.0	0.33	7.2	0.40
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	34	4.1	0.33	5.1	0.39	15	1.3	0.16	1.6	0.19
Major salivary gland	14	1.7	0.21	1.9	0.23	16	1.5	0.17	1.6	0.19
Floor of mouth	7	0.8	0.14	1.1	0.18	4	0.3	0.08	0.4	0.09
Gum & other mouth	17	2.2	0.25	2.6	0.29	11	1.0	0.13	1.2	0.16
Nasopharynx	10	1.2	0.17	1.4	0.20	5	0.5	0.09	0.5	0.10
Oropharynx	12	1.4	0.19	1.7	0.23	4	0.3	0.07	0.4	0.09
Hypopharynx	15	1.9	0.23	2.4	0.28	3	0.3	0.07	0.4	0.09
Digestive System	1,022	130.4	1.91	157.7	2.26	960	87.7	1.29	104.7	1.51
Esophagus	60	7.5	0.45	9.1	0.54	27	2.4	0.21	2.9	0.25
Stomach	109	14.9	0.67	17.6	0.77	96	8.9	0.41	10.5	0.48
Small intestine	38	4.9	0.37	5.7	0.42	41	3.8	0.27	4.5	0.31
Colon excl. rectum	338	45.0	1.14	53.6	1.34	369	33.9	0.80	40.3	0.94
Rectum & rectosigmoid	136	17.0	0.68	20.6	0.81	114	10.4	0.44	12.4	0.52
Anus, anal canal & anorectum	20	2.3	0.24	2.8	0.28	22	2.0	0.20	2.4	0.23
Liver	131	14.6	0.59	18.9	0.75	50	4.2	0.27	5.3	0.34
Gallbladder	11	1.4	0.20	1.7	0.24	26	2.3	0.21	2.9	0.25
Pancreas	143	18.6	0.73	22.4	0.86	166	15.3	0.54	18.2	0.63
Respiratory System	791	103.7	1.73	124.9	2.03	708	63.8	1.09	77.0	1.30
Larynx	78	9.7	0.51	11.9	0.62	24	2.0	0.19	2.5	0.23
Lung & bronchus	704	93.0	1.64	111.8	1.93	678	61.1	1.07	73.8	1.27
Bones & Joints	8	0.9	0.15	0.9	0.16	6	0.6	0.11	0.6	0.11
Soft Tissue (incl. heart)	35	4.4	0.34	4.7	0.37	39	3.7	0.27	4.1	0.29
Skin (excl. basal & sq.)	12	1.6	0.21	1.8	0.24	17	1.7	0.18	1.8	0.20
Melanomas of the skin	6	0.8	0.15	0.9	0.17	8	0.8	0.13	0.9	0.14
Breast (excl. <i>in situ</i>)	16	2.2	0.25	2.6	0.30	1,468	135.2	1.61	159.4	1.86
Female Genital System	-	-	-	-	-	604	54.7	1.02	65.1	1.19
Cervix uteri	-	-	-	-	-	108	10.4	0.46	11.6	0.50
Uterus Corpus	-	-	-	-	-	325	28.4	0.72	35.0	0.87
Uterus, NOS ¹	-	-	-	-	-	21	1.9	0.19	2.3	0.22
Ovary	-	-	-	-	-	103	9.7	0.43	11.2	0.50
Male Genital System	1,462	172.8	2.11	216.4	2.57	-	-	-	-	-
Prostate	1,440	170.2	2.09	213.6	2.56	-	-	-	-	-
Testis	12	1.4	0.19	1.4	0.18	-	-	-	-	-
Penis	6	0.8	0.16	1.0	0.19	-	-	-	-	-
Urinary System	395	50.8	1.20	60.7	1.40	223	20.5	0.63	24.2	0.73
Bladder (incl. <i>in situ</i>)	152	21.2	0.80	25.1	0.94	69	6.4	0.35	7.6	0.41
Kidney & renal pelvis	237	28.8	0.87	34.6	1.03	147	13.5	0.51	15.9	0.59
Ureter	2	0.3	0.09	0.3	0.10	3	0.3	0.07	0.3	0.08
Eye & Orbit	2	0.3	0.08	0.3	0.09	1	0.1	0.05	0.1	0.05
Brain & Other CNS ¹	40	4.7	0.34	5.2	0.38	34	3.2	0.25	3.4	0.27
Brain	36	4.3	0.33	4.7	0.36	30	2.8	0.23	3.0	0.25
Endocrine System	44	5.3	0.37	6.1	0.42	141	13.4	0.52	15.0	0.57
Thyroid gland	34	4.1	0.33	4.7	0.37	134	12.7	0.50	14.1	0.55
Lymphomas	163	20.1	0.74	22.8	0.83	148	14.0	0.52	15.8	0.58
Hodgkin Lymphoma	29	3.2	0.28	3.4	0.29	22	2.1	0.21	2.2	0.21
Non-Hodgkin Lymphoma	134	16.9	0.68	19.4	0.77	125	11.9	0.48	13.6	0.54
Multiple Myeloma	107	14.2	0.64	16.8	0.74	124	11.4	0.47	13.5	0.55
Leukemias	103	13.2	0.61	15.2	0.70	94	8.7	0.41	10.0	0.46
Acute lymphocytic	10	1.0	0.15	1.0	0.15	8	0.8	0.12	0.8	0.12
Chronic lymphocytic	33	4.4	0.35	5.3	0.42	26	2.4	0.21	2.8	0.25
Acute myeloid	35	4.7	0.37	5.4	0.43	36	3.3	0.25	3.8	0.29
Chronic myeloid	15	1.9	0.23	2.2	0.26	15	1.4	0.16	1.6	0.19
Other leukemias	9	1.2	0.18	1.3	0.21	9	0.9	0.13	1.0	0.14
Mesothelioma	3	0.4	0.11	0.5	0.13	2	0.2	0.06	0.2	0.06
Kaposi Sarcoma	11	1.3	0.17	1.3	0.18	-	-	-	-	-
Ill-defined & Unknown	116	15.7	0.68	18.6	0.79	133	12.5	0.49	14.6	0.57
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	60	7.5	0.45	8.6	0.51	165	15.5	0.55	17.9	0.62
Breast (<i>in situ</i>)	1	0.1	0.06	0.2	0.07	392	35.6	0.82	42.6	0.96

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	840	274.8	4.46	322.2	5.19	1,049	275.7	3.89	320.8	4.51
Oral Cavity & Pharynx	41	12.3	0.89	14.4	1.04	18	4.7	0.51	5.5	0.60
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	10	2.9	0.43	3.4	0.50	5	1.4	0.27	1.6	0.32
Major salivary gland	4	1.1	0.27	1.2	0.31	3	0.7	0.20	0.8	0.22
Floor of mouth	1	0.4	0.15	0.5	0.19	-	-	-	-	-
Gum & other mouth	11	3.1	0.42	3.9	0.53	4	1.2	0.25	1.4	0.30
Nasopharynx	9	2.8	0.42	3.2	0.49	3	0.9	0.22	1.1	0.27
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	0.6	0.22	0.6	0.24	-	-	-	-	-
Digestive System	237	78.1	2.39	92.8	2.81	179	49.3	1.69	58.2	1.98
Esophagus	10	3.2	0.48	3.9	0.58	4	1.1	0.25	1.4	0.31
Stomach	29	9.9	0.86	11.5	0.99	23	6.5	0.63	7.6	0.72
Small intestine	4	1.6	0.34	1.7	0.38	3	0.7	0.19	0.8	0.22
Colon excl. rectum	65	21.4	1.25	25.3	1.47	54	14.8	0.93	17.4	1.08
Rectum & rectosigmoid	44	13.7	0.97	16.4	1.15	32	8.4	0.68	9.9	0.80
Anus, anal canal & anorectum	1	0.4	0.19	0.5	0.23	-	-	-	-	-
Liver	43	13.7	0.98	16.8	1.19	17	4.9	0.54	5.8	0.63
Gallbladder	3	1.0	0.26	1.2	0.31	5	1.4	0.28	1.7	0.33
Pancreas	20	6.9	0.72	8.2	0.86	23	6.5	0.63	7.6	0.73
Respiratory System	120	41.1	1.77	48.5	2.07	76	21.5	1.14	25.2	1.32
Larynx	7	2.2	0.39	2.6	0.46	-	-	-	-	-
Lung & bronchus	110	38.2	1.72	45.1	2.00	73	20.8	1.12	24.4	1.30
Bones & Joints	3	0.8	0.22	0.9	0.24	2	0.6	0.18	0.7	0.20
Soft Tissue (incl. heart)	12	3.6	0.48	4.0	0.54	6	1.8	0.32	1.9	0.35
Skin (excl. basal & sq.)	6	1.9	0.39	2.2	0.45	6	1.6	0.29	1.8	0.33
Melanomas of the skin	3	1.0	0.27	1.2	0.32	4	1.0	0.23	1.1	0.26
Breast (excl. <i>in situ</i>)	2	0.6	0.17	0.7	0.23	387	98.6	2.28	115.3	2.66
Female Genital System	-	-	-	-	-	141	35.5	1.36	42.7	1.63
Cervix uteri	-	-	-	-	-	18	4.6	0.49	5.3	0.57
Uterus Corpus	-	-	-	-	-	78	19.2	0.99	23.8	1.22
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	32	8.4	0.68	9.8	0.78
Male Genital System	171	53.3	1.90	64.1	2.26	-	-	-	-	-
Prostate	162	50.8	1.86	61.6	2.22	-	-	-	-	-
Testis	7	1.9	0.32	1.8	0.30	-	-	-	-	-
Penis	1	0.5	0.19	0.6	0.23	-	-	-	-	-
Urinary System	75	25.7	1.39	29.9	1.60	27	7.7	0.67	9.0	0.78
Bladder (incl. <i>in situ</i>)	38	13.7	1.04	16.0	1.20	10	2.8	0.41	3.3	0.48
Kidney & renal pelvis	35	11.0	0.87	13.0	1.01	16	4.4	0.50	5.2	0.59
Ureter	2	0.6	0.23	0.7	0.26	-	-	-	-	-
Eye & Orbit	1	0.4	0.16	0.4	0.15	-	-	-	-	-
Brain & Other CNS ¹	11	3.4	0.47	3.7	0.51	12	3.5	0.45	3.6	0.47
Brain	10	3.2	0.45	3.4	0.50	12	3.3	0.44	3.4	0.46
Endocrine System	32	9.2	0.74	10.2	0.84	93	23.0	1.08	25.2	1.20
Thyroid gland	28	8.0	0.69	9.1	0.79	91	22.4	1.07	24.6	1.18
Lymphomas	54	18.1	1.16	20.6	1.33	45	12.1	0.83	13.8	0.94
Hodgkin Lymphoma	8	2.4	0.38	2.6	0.42	6	1.5	0.29	1.4	0.28
Non-Hodgkin Lymphoma	46	15.7	1.09	18.0	1.26	39	10.7	0.78	12.4	0.90
Multiple Myeloma	15	5.0	0.62	6.0	0.74	9	2.5	0.39	2.9	0.44
Leukemias	31	10.1	0.85	11.2	0.94	19	5.3	0.56	5.7	0.61
Acute lymphocytic	6	1.7	0.33	1.6	0.32	4	1.2	0.27	1.1	0.25
Chronic lymphocytic	5	1.7	0.36	2.1	0.42	3	0.7	0.21	0.8	0.23
Acute myeloid	14	4.7	0.59	5.2	0.66	8	2.2	0.36	2.5	0.41
Chronic myeloid	4	1.1	0.25	1.2	0.29	3	0.8	0.22	0.9	0.25
Other leukemias	3	1.0	0.26	1.1	0.29	1	0.4	0.15	0.4	0.16
Mesothelioma	2	0.6	0.24	0.8	0.28	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	27	10.4	0.95	11.7	1.07	26	7.6	0.68	8.7	0.79
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	25	7.8	0.73	8.8	0.83	52	13.7	0.87	15.8	1.00
Breast (<i>in situ</i>)	-	-	-	-	-	116	29.4	1.24	34.5	1.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

ILLINOIS

II-166 Incidence – API

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,183	364.4	3.94	430.4	4.57	2,448	348.3	3.36	406.3	3.91
Oral Cavity & Pharynx	59	9.4	0.61	11.3	0.72	30	4.5	0.39	5.3	0.45
Lip	4	0.7	0.20	0.8	0.22	1	0.3	0.10	0.3	0.11
Tongue	16	2.4	0.30	2.9	0.34	9	1.3	0.21	1.5	0.24
Major salivary gland	6	1.1	0.22	1.3	0.25	6	0.8	0.16	0.9	0.18
Floor of mouth	1	0.2	0.09	0.2	0.10	1	0.2	0.08	0.3	0.10
Gum & other mouth	9	1.5	0.25	1.8	0.30	6	1.1	0.21	1.3	0.24
Nasopharynx	2	0.3	0.11	0.4	0.13	2	0.2	0.07	0.2	0.08
Oropharynx	2	0.2	0.09	0.3	0.12	-	-	-	-	-
Hypopharynx	6	1.1	0.22	1.3	0.25	-	-	-	-	-
Digestive System	559	96.1	2.04	115.3	2.39	437	70.3	1.60	82.5	1.85
Esophagus	23	4.1	0.42	4.8	0.49	5	0.8	0.18	1.0	0.21
Stomach	74	13.0	0.76	15.2	0.88	65	10.4	0.61	12.2	0.71
Small intestine	13	1.9	0.27	2.3	0.31	11	1.5	0.22	1.8	0.27
Colon excl. rectum	138	24.3	1.04	28.8	1.21	127	20.2	0.85	23.3	0.98
Rectum & rectosigmoid	93	14.0	0.72	17.2	0.87	62	8.8	0.53	10.6	0.63
Anus, anal canal & anorectum	6	1.0	0.21	1.1	0.24	9	1.4	0.22	1.7	0.26
Liver	97	16.2	0.82	19.9	0.97	37	6.1	0.47	7.2	0.55
Gallbladder	8	1.4	0.25	1.7	0.30	17	2.8	0.32	3.3	0.37
Pancreas	73	13.9	0.81	16.6	0.94	63	11.0	0.65	12.8	0.75
Respiratory System	184	37.1	1.35	43.4	1.54	147	25.3	0.98	29.9	1.14
Larynx	21	3.6	0.39	4.3	0.46	4	0.6	0.14	0.8	0.17
Lung & bronchus	155	32.6	1.28	38.0	1.46	140	24.2	0.96	28.7	1.12
Bones & Joints	10	0.9	0.15	1.0	0.17	7	0.8	0.14	0.8	0.15
Soft Tissue (incl. heart)	28	3.7	0.36	4.1	0.40	21	2.6	0.27	2.8	0.31
Skin (excl. basal & sq.)	35	6.1	0.53	7.0	0.60	39	5.4	0.42	6.2	0.48
Melanomas of the skin	29	5.3	0.49	6.1	0.57	34	4.7	0.39	5.3	0.44
Breast (excl. <i>in situ</i>)	4	0.7	0.18	0.8	0.21	713	97.0	1.71	114.4	2.02
Female Genital System	-	-	-	-	-	381	50.0	1.21	59.4	1.44
Cervix uteri	-	-	-	-	-	78	9.5	0.50	10.6	0.58
Uterus Corpus	-	-	-	-	-	200	26.0	0.86	31.8	1.05
Uterus, NOS ¹	-	-	-	-	-	6	0.8	0.16	1.0	0.19
Ovary	-	-	-	-	-	73	10.1	0.56	11.8	0.66
Male Genital System	581	95.4	1.97	115.2	2.31	-	-	-	-	-
Prostate	499	87.7	1.92	107.5	2.27	-	-	-	-	-
Testis	72	5.8	0.31	5.6	0.31	-	-	-	-	-
Penis	8	1.6	0.28	1.8	0.31	-	-	-	-	-
Urinary System	237	41.5	1.36	48.6	1.56	119	18.3	0.80	21.6	0.93
Bladder (incl. <i>in situ</i>)	80	17.2	0.95	20.0	1.09	31	5.7	0.48	6.6	0.55
Kidney & renal pelvis	154	23.4	0.95	27.7	1.10	86	12.2	0.63	14.5	0.74
Ureter	2	0.6	0.19	0.7	0.21	2	0.3	0.10	0.3	0.12
Eye & Orbit	5	0.6	0.15	0.7	0.17	3	0.4	0.12	0.4	0.12
Brain & Other CNS ¹	48	6.2	0.46	7.1	0.53	35	4.2	0.35	4.7	0.40
Brain	46	5.9	0.45	6.7	0.52	31	3.8	0.34	4.3	0.38
Endocrine System	57	7.0	0.46	7.8	0.53	208	23.5	0.77	25.8	0.86
Thyroid gland	50	6.4	0.45	7.2	0.51	202	22.8	0.75	24.9	0.85
Lymphomas	153	23.4	0.98	26.8	1.11	132	19.6	0.82	22.6	0.94
Hodgkin Lymphoma	28	3.3	0.32	3.6	0.35	19	2.2	0.25	2.3	0.26
Non-Hodgkin Lymphoma	125	20.1	0.92	23.2	1.06	112	17.4	0.78	20.3	0.91
Multiple Myeloma	41	7.3	0.57	8.7	0.66	37	6.2	0.48	7.4	0.56
Leukemias	100	13.1	0.70	14.2	0.79	77	9.7	0.55	10.6	0.62
Acute lymphocytic	35	2.8	0.22	2.5	0.22	25	2.2	0.21	2.1	0.22
Chronic lymphocytic	11	2.1	0.31	2.4	0.35	9	1.8	0.27	2.0	0.30
Acute myeloid	31	4.8	0.45	5.4	0.52	26	3.5	0.34	3.9	0.38
Chronic myeloid	14	2.0	0.28	2.3	0.32	10	1.3	0.19	1.5	0.24
Other leukemias	9	1.5	0.25	1.6	0.27	7	0.9	0.17	1.1	0.20
Mesothelioma	7	1.3	0.26	1.6	0.30	2	0.3	0.09	0.3	0.11
Kaposi Sarcoma	8	1.0	0.18	1.1	0.21	-	-	-	-	-
Ill-defined & Unknown	69	13.6	0.82	15.8	0.94	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	55	7.8	0.55	8.7	0.63	101	13.5	0.64	15.5	0.74
Breast (<i>in situ</i>)	-	-	-	-	-	182	24.2	0.84	28.6	0.99

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

ILLINOIS

II-168 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	25,989	518.5	1.48	613.2	1.71	26,162	461.6	1.34	537.2	1.52
Oral Cavity & Pharynx	1,043	20.1	0.29	24.5	0.34	414	7.2	0.16	8.5	0.19
Lip	44	0.9	0.06	1.1	0.07	15	0.3	0.03	0.3	0.03
Tongue	340	6.4	0.16	7.9	0.19	137	2.4	0.09	2.8	0.11
Major salivary gland	84	1.8	0.09	2.0	0.10	59	1.1	0.07	1.3	0.07
Floor of mouth	51	1.0	0.06	1.2	0.07	21	0.3	0.03	0.4	0.04
Gum & other mouth	112	2.2	0.09	2.6	0.11	86	1.4	0.07	1.7	0.08
Nasopharynx	29	0.6	0.05	0.7	0.06	13	0.2	0.03	0.3	0.03
Oropharynx	53	1.0	0.06	1.2	0.08	14	0.2	0.03	0.3	0.04
Hypopharynx	60	1.1	0.07	1.4	0.08	16	0.3	0.03	0.3	0.04
Digestive System	5,081	101.6	0.65	120.7	0.76	4,105	67.7	0.49	79.5	0.57
Esophagus	476	9.2	0.19	11.1	0.23	115	1.8	0.08	2.2	0.09
Stomach	423	8.5	0.19	10.0	0.22	233	3.9	0.12	4.5	0.13
Small intestine	151	3.1	0.11	3.6	0.13	132	2.3	0.09	2.7	0.11
Colon excl. rectum	1,654	33.8	0.38	39.7	0.44	1,651	27.1	0.31	31.5	0.36
Rectum & rectosigmoid	780	15.6	0.26	18.7	0.30	540	9.5	0.19	11.1	0.22
Anus, anal canal & anorectum	81	1.6	0.08	1.9	0.10	144	2.5	0.10	3.0	0.11
Liver	437	8.2	0.18	10.1	0.22	162	2.7	0.10	3.1	0.11
Gallbladder	36	0.7	0.06	0.9	0.07	96	1.5	0.07	1.8	0.08
Pancreas	802	16.0	0.26	19.0	0.30	728	11.5	0.20	13.7	0.23
Respiratory System	4,251	84.2	0.59	99.9	0.69	3,828	62.5	0.46	74.0	0.54
Larynx	325	6.2	0.16	7.6	0.19	87	1.5	0.07	1.8	0.09
Lung & bronchus	3,872	76.9	0.56	91.0	0.66	3,709	60.4	0.45	71.5	0.53
Bones & Joints	46	1.1	0.07	1.1	0.08	38	0.9	0.07	0.9	0.06
Soft Tissue (incl. heart)	195	4.3	0.14	4.8	0.15	144	2.8	0.11	3.1	0.12
Skin (excl. basal & sq.)	1,665	34.4	0.39	40.0	0.44	1,250	24.7	0.33	27.6	0.36
Melanomas of the skin	1,559	32.2	0.38	37.4	0.43	1,175	23.4	0.32	26.2	0.35
Breast (excl. <i>in situ</i>)	66	1.3	0.07	1.6	0.09	7,657	138.6	0.74	162.6	0.85
Female Genital System	-	-	-	-	-	3,080	54.5	0.46	64.9	0.53
Cervix uteri	-	-	-	-	-	325	7.2	0.19	7.8	0.20
Uterus Corpus	-	-	-	-	-	1,746	29.6	0.33	36.4	0.39
Uterus, NOS ¹	-	-	-	-	-	43	0.7	0.05	0.8	0.06
Ovary	-	-	-	-	-	647	11.6	0.21	13.5	0.24
Male Genital System	5,919	111.4	0.66	135.5	0.79	-	-	-	-	-
Prostate	5,594	102.9	0.63	127.0	0.76	-	-	-	-	-
Testis	285	7.6	0.21	7.5	0.20	-	-	-	-	-
Penis	33	0.7	0.06	0.8	0.06	-	-	-	-	-
Urinary System	3,368	68.2	0.54	80.0	0.62	1,410	23.6	0.29	27.7	0.34
Bladder (incl. <i>in situ</i>)	2,050	41.7	0.42	48.8	0.49	653	10.3	0.19	12.2	0.22
Kidney & renal pelvis	1,245	24.9	0.33	29.4	0.37	716	12.6	0.22	14.7	0.25
Ureter	47	1.0	0.07	1.1	0.07	29	0.5	0.04	0.5	0.04
Eye & Orbit	46	0.9	0.06	1.1	0.07	42	0.8	0.06	0.9	0.06
Brain & Other CNS ¹	384	8.5	0.20	9.3	0.21	308	6.2	0.17	6.7	0.18
Brain	365	8.1	0.20	8.9	0.21	288	5.7	0.16	6.3	0.17
Endocrine System	451	9.9	0.22	11.1	0.23	1,083	24.4	0.35	26.1	0.36
Thyroid gland	415	9.1	0.21	10.2	0.23	1,055	23.8	0.34	25.5	0.36
Lymphomas	1,358	28.6	0.36	32.7	0.40	1,104	19.6	0.28	22.4	0.31
Hodgkin Lymphoma	138	3.4	0.13	3.5	0.13	110	2.7	0.12	2.7	0.12
Non-Hodgkin Lymphoma	1,220	25.2	0.33	29.3	0.38	994	16.9	0.25	19.7	0.28
Multiple Myeloma	354	7.0	0.17	8.4	0.20	281	4.5	0.12	5.4	0.15
Leukemias	841	17.9	0.28	20.3	0.32	615	10.9	0.21	12.2	0.23
Acute lymphocytic	68	1.8	0.10	1.7	0.09	50	1.3	0.09	1.2	0.08
Chronic lymphocytic	300	5.9	0.16	7.1	0.18	195	3.1	0.10	3.7	0.12
Acute myeloid	273	5.8	0.16	6.6	0.18	225	3.9	0.12	4.4	0.14
Chronic myeloid	100	2.1	0.10	2.4	0.11	79	1.5	0.08	1.6	0.08
Other leukemias	100	2.1	0.10	2.5	0.11	66	1.1	0.07	1.3	0.07
Mesothelioma	85	1.8	0.09	2.1	0.10	35	0.6	0.05	0.7	0.05
Kaposi Sarcoma	12	0.3	0.04	0.3	0.04	3	0.1	0.01	0.1	0.01
Ill-defined & Unknown	822	17.0	0.27	19.8	0.31	764	12.2	0.21	14.1	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	455	9.8	0.21	11.0	0.23	919	17.1	0.27	19.4	0.29
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.02	1,783	33.9	0.38	39.7	0.43

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Illinois, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,443	567.0	3.98	687.0	4.72	4,734	443.2	2.94	523.3	3.41
Oral Cavity & Pharynx	140	17.3	0.68	21.1	0.81	67	6.1	0.34	7.3	0.40
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	34	4.2	0.33	5.1	0.40	15	1.3	0.16	1.6	0.19
Major salivary gland	14	1.7	0.21	1.9	0.24	16	1.5	0.17	1.7	0.19
Floor of mouth	7	0.9	0.15	1.1	0.18	4	0.3	0.08	0.4	0.09
Gum & other mouth	17	2.2	0.25	2.6	0.29	11	1.0	0.14	1.2	0.16
Nasopharynx	10	1.2	0.18	1.5	0.21	5	0.5	0.09	0.5	0.11
Oropharynx	12	1.4	0.19	1.8	0.23	3	0.3	0.07	0.4	0.09
Hypopharynx	15	1.9	0.23	2.4	0.28	3	0.3	0.08	0.4	0.09
Digestive System	1,015	132.2	1.94	159.8	2.30	953	88.7	1.31	105.9	1.54
Esophagus	60	7.6	0.46	9.3	0.55	27	2.4	0.21	3.0	0.26
Stomach	109	15.1	0.68	17.8	0.79	95	8.9	0.42	10.5	0.48
Small intestine	38	4.9	0.37	5.8	0.43	41	3.9	0.28	4.6	0.32
Colon excl. rectum	336	45.5	1.16	54.2	1.36	366	34.3	0.81	40.7	0.95
Rectum & rectosigmoid	135	17.3	0.69	20.9	0.82	114	10.6	0.45	12.6	0.53
Anus, anal canal & anorectum	20	2.4	0.25	2.8	0.29	22	2.0	0.20	2.4	0.23
Liver	130	14.7	0.60	19.2	0.76	50	4.3	0.28	5.4	0.34
Gallbladder	11	1.4	0.20	1.7	0.24	26	2.4	0.21	2.9	0.25
Pancreas	142	18.8	0.74	22.7	0.87	165	15.5	0.55	18.4	0.64
Respiratory System	785	104.9	1.75	126.4	2.07	706	64.6	1.11	78.0	1.32
Larynx	78	9.8	0.52	12.1	0.63	23	2.1	0.19	2.6	0.24
Lung & bronchus	699	94.0	1.67	113.1	1.96	676	61.9	1.08	74.8	1.29
Bones & Joints	7	0.9	0.15	0.9	0.16	6	0.6	0.11	0.6	0.11
Soft Tissue (incl. heart)	35	4.5	0.35	4.8	0.38	39	3.8	0.28	4.2	0.30
Skin (excl. basal & sq.)	12	1.6	0.21	1.9	0.24	17	1.7	0.19	1.8	0.20
Melanomas of the skin	6	0.8	0.15	0.9	0.18	8	0.8	0.13	0.9	0.14
Breast (excl. <i>in situ</i>)	16	2.2	0.26	2.7	0.31	1,456	137.0	1.64	161.5	1.90
Female Genital System	-	-	-	-	-	597	55.2	1.03	65.7	1.21
Cervix uteri	-	-	-	-	-	107	10.6	0.47	11.8	0.51
Uterus Corpus	-	-	-	-	-	322	28.6	0.73	35.3	0.88
Uterus, NOS ¹	-	-	-	-	-	21	2.0	0.19	2.3	0.23
Ovary	-	-	-	-	-	102	9.7	0.44	11.3	0.50
Male Genital System	1,454	175.3	2.14	219.6	2.62	-	-	-	-	-
Prostate	1,433	172.7	2.13	216.7	2.60	-	-	-	-	-
Testis	12	1.4	0.19	1.4	0.18	-	-	-	-	-
Penis	6	0.9	0.17	1.0	0.19	-	-	-	-	-
Urinary System	392	51.6	1.22	61.5	1.42	221	20.7	0.63	24.4	0.74
Bladder (incl. <i>in situ</i>)	152	21.5	0.82	25.5	0.95	69	6.5	0.35	7.6	0.41
Kidney & renal pelvis	235	29.3	0.89	35.1	1.04	146	13.7	0.52	16.1	0.60
Ureter	2	0.3	0.09	0.3	0.10	3	0.3	0.07	0.3	0.08
Eye & Orbit	2	0.3	0.08	0.3	0.09	1	0.1	0.05	0.1	0.05
Brain & Other CNS ¹	40	4.9	0.35	5.3	0.39	34	3.3	0.26	3.5	0.27
Brain	36	4.4	0.34	4.8	0.37	30	2.9	0.24	3.1	0.26
Endocrine System	44	5.5	0.38	6.2	0.43	140	13.7	0.53	15.3	0.58
Thyroid gland	34	4.2	0.34	4.8	0.38	133	13.0	0.52	14.4	0.56
Lymphomas	161	20.5	0.75	23.2	0.84	146	14.2	0.54	16.0	0.59
Hodgkin Lymphoma	29	3.3	0.29	3.5	0.30	22	2.2	0.21	2.3	0.22
Non-Hodgkin Lymphoma	132	17.2	0.70	19.7	0.79	124	12.0	0.49	13.7	0.55
Multiple Myeloma	107	14.4	0.65	17.1	0.76	123	11.6	0.47	13.7	0.55
Leukemias	102	13.4	0.62	15.4	0.71	93	8.9	0.42	10.1	0.47
Acute lymphocytic	10	1.1	0.16	1.0	0.16	8	0.8	0.13	0.8	0.12
Chronic lymphocytic	33	4.4	0.36	5.3	0.43	25	2.4	0.22	2.8	0.25
Acute myeloid	35	4.8	0.38	5.5	0.43	36	3.4	0.26	3.9	0.29
Chronic myeloid	15	1.9	0.23	2.2	0.26	15	1.4	0.17	1.6	0.19
Other leukemias	9	1.2	0.19	1.3	0.21	9	0.9	0.13	1.0	0.15
Mesothelioma	3	0.4	0.11	0.5	0.13	2	0.2	0.06	0.2	0.06
Kaposi Sarcoma	11	1.3	0.18	1.4	0.19	-	-	-	-	-
Ill-defined & Unknown	115	15.9	0.69	18.8	0.81	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	60	7.7	0.46	8.7	0.52	164	15.8	0.56	18.2	0.64
Breast (<i>in situ</i>)	1	0.1	0.05	0.2	0.07	389	36.0	0.83	43.1	0.98

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


ILLINOIS

II-170 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,568,367	6,593,533	6,608,296	6,633,344	6,660,082
White	5,726,164	5,735,619	5,736,012	5,741,802	5,751,279
Black	669,431	677,466	684,793	693,691	702,930
American Indian/Alaskan Native (AI/AN)	30,313	30,744	31,069	31,472	32,155
Asian/Pacific Islander (API)	142,459	149,704	156,422	166,379	173,718


All Races Population 2013-2017: 33,063,622
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	419,576	429,100	438,069	449,998	462,346
Non-Hispanic White	5,348,568	5,349,763	5,342,256	5,337,350	5,336,180
Non-Hispanic Black	645,564	652,727	659,362	667,493	675,686

Hispanic/Latino Population, Census 2010: 389,707
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

INDIANA CANCER REGISTRY

Initial Operation: 1987
 Population-based Data Available: 1987
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.2	103.1	105.4	106.1	99.1
Missing Race	0.6	0.5	0.6	0.7	0.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.1	1.2	1.1	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Prostate	96.9
Oral Cavity & Pharynx	98.5	Testis	99.4
Esophagus	97.0	Bladder (incl. <i>in situ</i>)	97.9
Stomach	97.7	Kidney & Renal Pelvis	90.5
Colon & Rectum	97.0	Brain & Other CNS ¹	84.9
Liver	58.7	Thyroid	99.5
Pancreas	87.9	Hodgkin Lymphoma	99.0
Lung & Bronchus	89.8	Non-Hodgkin Lymphoma	97.7
Melanomas of the Skin	99.6	Multiple Myeloma	91.2
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	92.9
Cervix uteri	98.6	Brain & Other CNS ¹ <i>non-malig</i>	37.4
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	93.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17,638	503.6	1.74	596.3	2.03	17,351	430.7	1.50	502.9	1.72
Oral Cavity & Pharynx	714	19.6	0.34	23.8	0.40	269	6.6	0.18	7.8	0.21
Lip	29	0.9	0.08	1.0	0.09	9	0.2	0.03	0.3	0.04
Tongue	225	6.1	0.19	7.5	0.22	84	2.0	0.10	2.4	0.12
Major salivary gland	56	1.7	0.10	2.0	0.12	38	1.0	0.07	1.1	0.08
Floor of mouth	31	0.8	0.07	1.0	0.08	17	0.4	0.04	0.5	0.05
Gum & other mouth	74	2.1	0.11	2.5	0.13	52	1.2	0.08	1.5	0.09
Nasopharynx	22	0.6	0.06	0.7	0.07	9	0.3	0.04	0.3	0.04
Oropharynx	35	0.9	0.07	1.1	0.09	11	0.3	0.04	0.3	0.04
Hypopharynx	35	0.9	0.07	1.2	0.09	9	0.2	0.03	0.3	0.04
Digestive System	3,582	102.1	0.79	121.8	0.92	2,818	67.8	0.59	79.8	0.68
Esophagus	351	9.8	0.24	11.8	0.28	80	1.8	0.09	2.2	0.11
Stomach	294	8.5	0.23	10.0	0.26	155	3.7	0.14	4.4	0.16
Small intestine	102	2.9	0.13	3.5	0.15	88	2.2	0.11	2.6	0.12
Colon excl. rectum	1,136	33.3	0.45	39.2	0.53	1,147	27.6	0.37	32.2	0.43
Rectum & rectosigmoid	548	15.5	0.30	18.5	0.36	394	9.9	0.23	11.6	0.26
Anus, anal canal & anorectum	52	1.5	0.10	1.8	0.11	109	2.6	0.12	3.2	0.14
Liver	361	9.4	0.23	11.8	0.28	109	2.5	0.11	3.1	0.13
Gallbladder	25	0.7	0.07	0.9	0.08	54	1.2	0.08	1.5	0.09
Pancreas	537	15.5	0.31	18.4	0.36	486	11.5	0.24	13.6	0.28
Respiratory System	3,296	94.0	0.75	111.7	0.88	2,691	63.7	0.56	75.9	0.66
Larynx	238	6.4	0.19	7.9	0.23	71	1.7	0.09	2.1	0.11
Lung & bronchus	3,016	86.4	0.72	102.4	0.84	2,596	61.4	0.55	73.2	0.65
Bones & Joints	33	1.0	0.08	1.0	0.08	26	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	117	3.5	0.15	4.0	0.17	97	2.6	0.12	2.8	0.13
Skin (excl. basal & sq.)	974	28.7	0.42	33.5	0.48	729	19.4	0.33	21.9	0.37
Melanomas of the skin	912	26.8	0.41	31.3	0.47	685	18.3	0.32	20.7	0.36
Breast (excl. <i>in situ</i>)	39	1.2	0.08	1.3	0.10	4,915	122.9	0.81	145.0	0.93
Female Genital System	-	-	-	-	-	2,090	52.3	0.53	61.7	0.61
Cervix uteri	-	-	-	-	-	274	8.2	0.23	8.7	0.24
Uterus Corpus	-	-	-	-	-	1,160	28.0	0.38	34.0	0.45
Uterus, NOS ¹	-	-	-	-	-	10	0.2	0.03	0.3	0.04
Ovary	-	-	-	-	-	421	10.4	0.23	12.2	0.27
Male Genital System	3,746	101.4	0.76	123.0	0.91	-	-	-	-	-
Prostate	3,522	94.2	0.73	115.7	0.88	-	-	-	-	-
Testis	186	6.0	0.20	6.0	0.20	-	-	-	-	-
Penis	31	0.9	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,234	65.5	0.64	77.1	0.74	949	23.1	0.34	27.0	0.40
Bladder (incl. <i>in situ</i>)	1,277	38.3	0.49	44.9	0.57	386	9.1	0.21	10.7	0.25
Kidney & renal pelvis	904	25.6	0.39	30.3	0.45	536	13.4	0.27	15.6	0.30
Ureter	34	1.0	0.08	1.2	0.09	18	0.4	0.05	0.5	0.05
Eye & Orbit	36	1.0	0.08	1.2	0.09	29	0.7	0.06	0.8	0.07
Brain & Other CNS ¹	264	7.8	0.22	8.6	0.24	204	5.4	0.17	5.9	0.19
Brain	251	7.4	0.21	8.2	0.23	193	5.1	0.17	5.6	0.18
Endocrine System	244	7.3	0.21	8.0	0.23	653	19.1	0.34	20.5	0.36
Thyroid gland	217	6.5	0.20	7.2	0.22	626	18.4	0.34	19.7	0.35
Lymphomas	864	25.6	0.40	29.3	0.45	714	17.8	0.31	20.4	0.34
Hodgkin Lymphoma	105	3.2	0.14	3.4	0.15	74	2.2	0.12	2.3	0.12
Non-Hodgkin Lymphoma	759	22.3	0.37	25.9	0.42	640	15.6	0.28	18.1	0.32
Multiple Myeloma	284	8.4	0.23	9.8	0.26	228	5.4	0.16	6.4	0.19
Leukemias	589	17.7	0.33	20.1	0.38	415	10.5	0.24	11.7	0.26
Acute lymphocytic	57	1.8	0.10	1.6	0.10	38	1.2	0.09	1.1	0.08
Chronic lymphocytic	210	6.1	0.19	7.3	0.23	128	3.0	0.12	3.6	0.14
Acute myeloid	189	5.7	0.19	6.5	0.22	152	3.9	0.14	4.3	0.16
Chronic myeloid	78	2.4	0.12	2.7	0.14	59	1.5	0.09	1.7	0.10
Other leukemias	55	1.7	0.11	1.9	0.12	38	1.0	0.07	1.1	0.08
Mesothelioma	53	1.7	0.11	1.9	0.12	17	0.4	0.04	0.5	0.05
Kaposi Sarcoma	8	0.2	0.04	0.3	0.04	1	0.0	0.01	0.0	0.01
Ill-defined & Unknown	560	17.0	0.33	19.9	0.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	281	8.3	0.23	9.4	0.25	562	14.4	0.28	16.4	0.31
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	1,071	27.2	0.38	32.2	0.44

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	16,091	502.0	1.82	593.3	2.11	15,833	435.5	1.60	507.7	1.82
Oral Cavity & Pharynx	660	19.8	0.35	24.1	0.42	242	6.6	0.19	7.7	0.23
Lip	25	0.8	0.08	1.0	0.09	8	0.2	0.03	0.2	0.04
Tongue	212	6.3	0.20	7.7	0.24	77	2.1	0.11	2.5	0.13
Major salivary gland	52	1.7	0.11	2.0	0.13	33	0.9	0.07	1.1	0.08
Floor of mouth	29	0.8	0.07	1.0	0.09	16	0.4	0.05	0.5	0.06
Gum & other mouth	65	2.0	0.11	2.4	0.13	47	1.2	0.08	1.4	0.09
Nasopharynx	18	0.5	0.06	0.6	0.07	7	0.2	0.04	0.2	0.04
Oropharynx	32	0.9	0.07	1.1	0.09	9	0.2	0.04	0.3	0.04
Hypopharynx	31	0.9	0.07	1.1	0.09	8	0.2	0.03	0.3	0.04
Digestive System	3,247	101.0	0.82	120.3	0.95	2,536	67.2	0.61	78.8	0.71
Esophagus	333	10.1	0.25	12.2	0.30	71	1.8	0.10	2.2	0.12
Stomach	261	8.2	0.23	9.7	0.27	131	3.5	0.14	4.1	0.16
Small intestine	93	2.9	0.14	3.4	0.16	76	2.1	0.11	2.5	0.13
Colon excl. rectum	1,034	33.0	0.47	38.8	0.55	1,043	27.6	0.39	32.1	0.45
Rectum & rectosigmoid	504	15.5	0.32	18.6	0.37	358	9.9	0.24	11.6	0.28
Anus, anal canal & anorectum	46	1.5	0.10	1.7	0.11	103	2.8	0.13	3.4	0.15
Liver	301	8.7	0.23	10.8	0.28	92	2.3	0.11	2.8	0.13
Gallbladder	20	0.7	0.07	0.8	0.08	47	1.2	0.08	1.4	0.09
Pancreas	493	15.4	0.32	18.3	0.37	436	11.3	0.25	13.3	0.29
Respiratory System	3,064	95.0	0.79	112.7	0.92	2,482	64.5	0.59	76.8	0.69
Larynx	215	6.4	0.20	7.8	0.24	64	1.7	0.10	2.1	0.12
Lung & bronchus	2,810	87.3	0.76	103.5	0.88	2,395	62.2	0.58	74.0	0.68
Bones & Joints	29	1.0	0.08	1.0	0.09	24	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	108	3.6	0.16	4.0	0.18	84	2.5	0.13	2.8	0.14
Skin (excl. basal & sq.)	931	30.0	0.45	34.9	0.52	683	20.5	0.37	23.1	0.40
Melanomas of the skin	875	28.1	0.44	32.7	0.50	644	19.5	0.36	21.8	0.39
Breast (excl. <i>in situ</i>)	33	1.1	0.08	1.2	0.10	4,455	123.5	0.86	145.6	0.99
Female Genital System	-	-	-	-	-	1,917	53.4	0.57	63.0	0.65
Cervix uteri	-	-	-	-	-	243	8.3	0.25	8.8	0.25
Uterus Corpus	-	-	-	-	-	1,067	28.6	0.40	34.7	0.48
Uterus, NOS ¹	-	-	-	-	-	9	0.2	0.03	0.3	0.04
Ovary	-	-	-	-	-	390	10.7	0.25	12.5	0.29
Male Genital System	3,266	96.7	0.78	116.9	0.92	-	-	-	-	-
Prostate	3,054	88.9	0.74	109.0	0.89	-	-	-	-	-
Testis	176	6.7	0.23	6.6	0.22	-	-	-	-	-
Penis	29	1.0	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,081	66.3	0.67	78.0	0.77	875	23.5	0.37	27.4	0.42
Bladder (incl. <i>in situ</i>)	1,209	39.2	0.52	45.9	0.60	359	9.2	0.22	10.9	0.26
Kidney & renal pelvis	820	25.4	0.41	30.1	0.47	490	13.6	0.28	15.8	0.32
Ureter	34	1.1	0.09	1.3	0.10	18	0.4	0.05	0.5	0.06
Eye & Orbit	34	1.1	0.09	1.2	0.10	28	0.8	0.07	0.9	0.08
Brain & Other CNS ¹	248	8.2	0.24	9.0	0.26	188	5.6	0.19	6.1	0.20
Brain	236	7.8	0.23	8.6	0.25	178	5.2	0.18	5.8	0.20
Endocrine System	223	7.4	0.23	8.2	0.25	599	20.0	0.38	21.5	0.40
Thyroid gland	200	6.6	0.22	7.4	0.23	575	19.3	0.37	20.7	0.39
Lymphomas	805	26.1	0.42	29.9	0.48	661	18.3	0.33	20.9	0.37
Hodgkin Lymphoma	95	3.4	0.16	3.5	0.16	66	2.3	0.13	2.3	0.13
Non-Hodgkin Lymphoma	710	22.8	0.39	26.4	0.45	594	16.0	0.30	18.5	0.34
Multiple Myeloma	246	7.9	0.23	9.2	0.27	189	4.9	0.16	5.8	0.19
Leukemias	544	18.0	0.35	20.4	0.40	384	10.9	0.26	12.0	0.28
Acute lymphocytic	51	1.8	0.12	1.7	0.11	36	1.3	0.10	1.2	0.09
Chronic lymphocytic	196	6.2	0.20	7.4	0.24	120	3.1	0.13	3.6	0.15
Acute myeloid	175	5.8	0.20	6.6	0.23	140	3.9	0.15	4.4	0.17
Chronic myeloid	71	2.3	0.13	2.7	0.14	53	1.5	0.10	1.7	0.11
Other leukemias	51	1.8	0.11	2.0	0.13	35	1.0	0.08	1.1	0.08
Mesothelioma	51	1.7	0.11	2.0	0.13	16	0.4	0.05	0.5	0.05
Kaposi Sarcoma	4	0.1	0.03	0.1	0.03	1	0.0	0.01	0.0	0.01
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	252	8.3	0.24	9.4	0.27	502	14.3	0.30	16.3	0.33
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	944	26.6	0.40	31.6	0.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

INDIANA

II-174 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,282	531.1	7.09	641.8	8.36	1,270	402.4	5.18	476.0	6.03
Oral Cavity & Pharynx	38	14.9	1.14	18.0	1.34	18	5.8	0.61	6.7	0.70
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	8	3.3	0.54	3.9	0.63	4	1.3	0.29	1.7	0.36
Major salivary gland	2	1.0	0.33	1.2	0.39	4	1.2	0.28	1.3	0.30
Floor of mouth	2	0.9	0.26	1.0	0.31	-	-	-	-	-
Gum & other mouth	6	2.4	0.47	2.7	0.53	2	0.9	0.25	0.9	0.26
Nasopharynx	3	1.3	0.34	1.4	0.38	1	0.4	0.17	0.5	0.18
Oropharynx	2	0.9	0.25	1.1	0.31	2	0.6	0.19	0.7	0.23
Hypopharynx	4	1.4	0.35	1.8	0.41	-	-	-	-	-
Digestive System	290	122.2	3.43	147.8	4.04	247	79.6	2.32	95.3	2.73
Esophagus	17	6.6	0.78	8.2	0.93	8	2.6	0.42	3.2	0.50
Stomach	29	13.4	1.19	15.6	1.35	19	6.1	0.65	7.3	0.75
Small intestine	9	3.7	0.60	4.6	0.72	11	3.5	0.49	4.2	0.58
Colon excl. rectum	89	38.3	1.93	45.8	2.27	93	30.4	1.44	36.2	1.69
Rectum & rectosigmoid	35	14.6	1.18	17.2	1.37	28	8.9	0.77	10.7	0.91
Anus, anal canal & anorectum	6	2.1	0.41	2.5	0.47	6	2.0	0.36	2.4	0.42
Liver	51	18.1	1.19	23.8	1.52	15	4.5	0.53	5.6	0.65
Gallbladder	4	1.8	0.44	2.2	0.53	6	1.8	0.34	2.2	0.42
Pancreas	40	18.4	1.38	21.7	1.59	47	15.0	1.01	18.1	1.19
Respiratory System	213	92.5	3.03	111.7	3.56	191	61.3	2.04	73.9	2.41
Larynx	21	8.1	0.83	10.1	1.00	6	1.8	0.33	2.3	0.41
Lung & bronchus	190	83.6	2.90	100.7	3.40	184	59.2	2.01	71.3	2.37
Bones & Joints	3	1.0	0.31	1.1	0.33	2	0.4	0.14	0.4	0.14
Soft Tissue (incl. heart)	8	2.9	0.48	3.1	0.52	11	3.3	0.45	3.7	0.51
Skin (excl. basal & sq.)	6	2.5	0.49	2.8	0.55	5	1.7	0.34	2.0	0.38
Melanomas of the skin	2	1.0	0.33	1.2	0.38	3	0.8	0.23	0.9	0.26
Breast (excl. <i>in situ</i>)	5	2.4	0.50	2.7	0.55	394	123.5	2.85	146.6	3.32
Female Genital System	-	-	-	-	-	146	44.7	1.70	53.3	1.99
Cervix uteri	-	-	-	-	-	26	8.1	0.72	8.9	0.79
Uterus Corpus	-	-	-	-	-	80	24.0	1.23	29.5	1.48
Uterus, NOS ¹	-	-	-	-	-	1	0.4	0.15	0.5	0.19
Ovary	-	-	-	-	-	25	8.0	0.73	9.3	0.84
Male Genital System	407	162.7	3.84	202.4	4.63	-	-	-	-	-
Prostate	400	160.4	3.82	199.7	4.61	-	-	-	-	-
Testis	4	1.2	0.27	1.3	0.30	-	-	-	-	-
Penis	2	0.9	0.28	1.0	0.32	-	-	-	-	-
Urinary System	125	53.8	2.31	64.2	2.69	64	20.8	1.19	24.4	1.37
Bladder (incl. <i>in situ</i>)	47	22.5	1.58	26.8	1.84	21	7.2	0.72	8.5	0.83
Kidney & renal pelvis	78	30.9	1.67	37.0	1.96	42	13.1	0.93	15.4	1.08
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	13	4.2	0.56	4.7	0.64	13	3.9	0.50	4.2	0.54
Brain	12	4.0	0.54	4.5	0.62	12	3.7	0.49	3.9	0.52
Endocrine System	13	4.8	0.64	5.3	0.71	37	11.7	0.87	12.8	0.94
Thyroid gland	10	3.7	0.55	4.1	0.61	34	10.7	0.83	11.7	0.90
Lymphomas	49	19.5	1.33	22.1	1.51	42	13.6	0.95	15.3	1.07
Hodgkin Lymphoma	8	2.5	0.40	2.6	0.42	5	1.5	0.30	1.5	0.30
Non-Hodgkin Lymphoma	41	17.0	1.27	19.6	1.45	37	12.0	0.90	13.8	1.03
Multiple Myeloma	36	15.8	1.24	18.8	1.44	36	11.8	0.90	14.0	1.04
Leukemias	36	14.3	1.16	16.7	1.35	25	7.9	0.73	9.1	0.83
Acute lymphocytic	4	1.2	0.27	1.2	0.28	1	0.4	0.16	0.4	0.15
Chronic lymphocytic	11	4.6	0.68	5.7	0.82	6	1.8	0.36	2.2	0.41
Acute myeloid	12	4.7	0.67	5.5	0.78	10	3.1	0.45	3.5	0.52
Chronic myeloid	7	2.7	0.52	3.1	0.59	5	1.7	0.34	2.0	0.40
Other leukemias	3	1.0	0.28	1.1	0.32	3	0.8	0.23	1.0	0.27
Mesothelioma	2	0.8	0.29	0.9	0.32	-	-	-	-	-
Kaposi Sarcoma	3	1.2	0.29	1.2	0.31	-	-	-	-	-
Ill-defined & Unknown	34	15.3	1.26	18.0	1.46	36	12.2	0.93	14.2	1.06
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	22	9.1	0.92	10.4	1.05	48	15.3	1.01	17.9	1.17
Breast (<i>in situ</i>)	-	-	-	-	-	108	33.9	1.49	39.8	1.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	95	231.7	12.33	268.2	14.23	130	226.5	9.58	262.3	11.12
Oral Cavity & Pharynx	4	8.3	2.20	9.7	2.63	3	5.0	1.45	5.9	1.71
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	29	71.6	6.71	84.3	7.75	23	45.4	4.54	54.1	5.34
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	4	9.1	2.33	10.3	2.59	4	7.7	1.87	9.2	2.21
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	17.4	3.10	20.3	3.52	6	11.4	2.28	14.1	2.77
Rectum & rectosigmoid	5	11.2	2.43	13.5	2.87	5	8.3	1.84	9.8	2.13
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	6	13.6	2.77	15.8	3.14	2	3.9	1.28	4.7	1.52
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	8.3	2.49	10.0	2.94	2	5.4	1.66	6.4	1.93
Respiratory System	12	30.3	4.54	36.0	5.34	10	22.4	3.34	26.4	3.88
Larynx	2	3.5	1.28	4.3	1.54	-	-	-	-	-
Lung & bronchus	10	26.2	4.31	31.1	5.08	10	22.1	3.33	26.0	3.86
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	2	2.9	1.01	3.2	1.19	2	3.6	1.20	3.8	1.27
Melanomas of the skin	-	-	-	-	-	1	2.5	1.07	2.7	1.12
Breast (excl. <i>in situ</i>)	-	-	-	-	-	46	76.9	5.41	89.6	6.29
Female Genital System	-	-	-	-	-	17	26.8	3.04	31.2	3.59
Cervix uteri	-	-	-	-	-	3	4.1	1.06	4.6	1.26
Uterus Corpus	-	-	-	-	-	8	11.9	1.91	14.2	2.32
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	8.5	1.86	9.8	2.17
Male Genital System	17	45.7	5.43	51.8	6.02	-	-	-	-	-
Prostate	15	43.7	5.38	49.9	5.97	-	-	-	-	-
Testis	1	1.7	0.67	1.7	0.71	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	18.4	3.93	21.2	4.57	3	6.8	1.90	7.7	2.13
Bladder (incl. <i>in situ</i>)	4	13.9	3.67	15.9	4.26	1	3.6	1.43	4.0	1.57
Kidney & renal pelvis	2	4.5	1.40	5.3	1.66	2	3.3	1.25	3.8	1.44
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	2.5	0.90	2.8	1.09	3	3.5	0.99	3.6	1.05
Brain	2	2.5	0.90	2.8	1.09	3	3.3	0.97	3.4	1.03
Endocrine System	5	8.7	1.94	9.5	2.20	9	12.1	1.84	12.8	2.02
Thyroid gland	4	7.8	1.86	8.4	2.10	9	11.9	1.82	12.5	2.01
Lymphomas	6	11.6	2.57	13.1	2.95	6	8.9	1.77	10.5	2.08
Hodgkin Lymphoma	-	-	-	-	-	2	2.1	0.81	2.2	0.87
Non-Hodgkin Lymphoma	5	10.3	2.49	11.7	2.88	4	6.8	1.58	8.2	1.89
Multiple Myeloma	-	-	-	-	-	1	2.1	0.92	2.3	1.06
Leukemias	6	13.5	3.12	15.2	3.65	4	7.4	1.88	8.3	2.15
Acute lymphocytic	1	1.9	0.71	1.5	0.60	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	6.9	2.43	7.8	2.82	2	2.7	1.09	2.9	1.24
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	11.6	3.11	14.3	3.79	1	3.1	1.24	3.6	1.46
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	3.8	1.10	4.6	1.41	6	11.0	2.08	12.5	2.40
Breast (<i>in situ</i>)	-	-	-	-	-	14	23.7	2.92	28.5	3.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

INDIANA

II-176 Incidence – API

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCD¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2	137.5	41.49	164.1	49.23	2	136.7	44.98	169.6	53.45
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	-	-	-	-	-	-	-	-	-	-
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
 - Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCD¹ – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	325	315.6	9.12	368.7	10.41	380	318.0	8.00	371.2	9.32
Oral Cavity & Pharynx	9	6.9	1.23	8.2	1.43	5	4.6	0.97	5.5	1.15
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.9	0.77	2.3	0.89	-	-	-	-	-
Major salivary gland	-	-	-	-	-	2	1.3	0.46	1.7	0.58
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	84	85.1	4.77	101.1	5.49	62	59.3	3.65	69.9	4.23
Esophagus	5	5.5	1.26	6.5	1.43	1	1.4	0.58	1.6	0.67
Stomach	11	12.0	1.85	14.0	2.12	7	6.3	1.17	7.3	1.35
Small intestine	2	1.4	0.56	1.6	0.65	2	1.6	0.60	1.7	0.65
Colon excl. rectum	23	23.6	2.54	28.1	2.93	21	21.1	2.22	24.9	2.56
Rectum & rectosigmoid	13	11.6	1.65	13.9	1.92	11	9.5	1.37	11.2	1.60
Anus, anal canal & anorectum	-	-	-	-	-	2	1.4	0.55	1.7	0.65
Liver	14	14.5	1.96	17.3	2.25	4	3.9	0.91	4.8	1.12
Gallbladder	-	-	-	-	-	1	1.3	0.53	1.6	0.64
Pancreas	11	11.4	1.76	13.3	2.01	9	8.8	1.44	10.2	1.65
Respiratory System	34	40.3	3.45	46.8	3.86	27	27.9	2.56	33.1	2.96
Larynx	4	4.8	1.17	5.7	1.34	-	-	-	-	-
Lung & bronchus	28	33.9	3.20	39.4	3.57	26	27.2	2.53	32.3	2.93
Bones & Joints	-	-	-	-	-	1	0.5	0.23	0.5	0.27
Soft Tissue (incl. heart)	3	1.9	0.61	2.2	0.73	4	2.7	0.71	3.0	0.82
Skin (excl. basal & sq.)	6	5.0	1.13	5.7	1.26	9	7.1	1.16	8.4	1.37
Melanomas of the skin	5	4.4	1.10	4.9	1.21	8	5.9	1.03	7.1	1.25
Breast (excl. <i>in situ</i>)	-	-	-	-	-	106	90.4	4.25	107.0	4.98
Female Genital System	-	-	-	-	-	64	47.2	2.83	55.3	3.37
Cervix uteri	-	-	-	-	-	19	11.7	1.28	13.0	1.49
Uterus Corpus	-	-	-	-	-	32	23.3	1.96	28.3	2.42
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	10	7.9	1.24	9.0	1.44
Male Genital System	76	73.9	4.34	88.2	5.02	-	-	-	-	-
Prostate	62	67.2	4.22	81.7	4.91	-	-	-	-	-
Testis	12	4.9	0.68	4.6	0.67	-	-	-	-	-
Penis	2	1.7	0.74	1.9	0.78	-	-	-	-	-
Urinary System	39	41.2	3.39	47.6	3.84	21	18.8	2.01	21.5	2.32
Bladder (incl. <i>in situ</i>)	12	16.4	2.32	18.7	2.59	5	5.1	1.07	5.8	1.23
Kidney & renal pelvis	27	24.3	2.45	28.3	2.80	16	13.8	1.71	15.7	1.97
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	9	5.3	0.99	5.9	1.15	4	2.3	0.62	2.4	0.67
Brain	9	5.3	0.99	5.9	1.15	3	2.1	0.61	2.2	0.66
Endocrine System	9	6.3	1.14	7.0	1.29	27	16.6	1.50	18.4	1.74
Thyroid gland	7	5.0	1.02	5.4	1.14	27	16.1	1.46	17.9	1.70
Lymphomas	22	17.8	2.00	20.4	2.29	22	19.0	2.01	22.0	2.32
Hodgkin Lymphoma	3	1.7	0.48	1.8	0.52	4	2.3	0.59	2.5	0.69
Non-Hodgkin Lymphoma	19	16.1	1.94	18.5	2.23	18	16.7	1.92	19.5	2.21
Multiple Myeloma	6	6.4	1.34	7.5	1.52	5	5.2	1.17	6.0	1.32
Leukemias	16	11.6	1.70	12.6	1.91	13	8.2	1.17	8.9	1.36
Acute lymphocytic	6	2.4	0.43	2.2	0.43	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	1	1.5	0.62	1.9	0.74
Acute myeloid	6	5.9	1.33	6.5	1.48	4	2.8	0.68	3.0	0.78
Chronic myeloid	2	1.7	0.64	2.1	0.78	1	0.9	0.35	1.0	0.42
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	2.1	0.84	2.3	0.91	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	9	9.7	1.71	11.1	1.96	7	7.1	1.28	8.1	1.46
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	5.1	1.07	5.6	1.16	16	13.2	1.65	15.3	1.91
Breast (<i>in situ</i>)	-	-	-	-	-	31	24.8	2.12	29.7	2.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

INDIANA

II-178 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,780	507.7	1.86	600.0	2.16	15,469	438.9	1.64	511.5	1.86
Oral Cavity & Pharynx	652	20.2	0.37	24.6	0.43	237	6.6	0.20	7.8	0.23
Lip	25	0.9	0.08	1.0	0.09	7	0.2	0.03	0.2	0.04
Tongue	211	6.5	0.21	7.9	0.25	76	2.1	0.11	2.5	0.13
Major salivary gland	51	1.8	0.11	2.0	0.13	31	0.9	0.08	1.0	0.08
Floor of mouth	29	0.9	0.07	1.1	0.09	15	0.4	0.05	0.5	0.06
Gum & other mouth	65	2.0	0.12	2.4	0.14	47	1.2	0.08	1.5	0.10
Nasopharynx	17	0.5	0.06	0.7	0.07	7	0.2	0.04	0.2	0.04
Oropharynx	31	0.9	0.08	1.2	0.09	9	0.2	0.04	0.3	0.04
Hypopharynx	30	0.9	0.08	1.1	0.09	8	0.2	0.03	0.3	0.04
Digestive System	3,166	101.6	0.83	121.0	0.97	2,476	67.3	0.62	79.0	0.72
Esophagus	329	10.3	0.26	12.4	0.31	69	1.8	0.10	2.2	0.12
Stomach	250	8.0	0.23	9.5	0.27	124	3.4	0.14	3.9	0.16
Small intestine	91	3.0	0.14	3.5	0.16	75	2.1	0.11	2.5	0.13
Colon excl. rectum	1,012	33.4	0.48	39.2	0.56	1,023	27.8	0.40	32.3	0.46
Rectum & rectosigmoid	491	15.7	0.33	18.7	0.38	347	9.9	0.25	11.6	0.28
Anus, anal canal & anorectum	46	1.5	0.10	1.8	0.12	101	2.8	0.13	3.4	0.15
Liver	288	8.5	0.23	10.6	0.28	88	2.3	0.11	2.8	0.13
Gallbladder	20	0.7	0.07	0.8	0.08	46	1.2	0.08	1.4	0.09
Pancreas	482	15.5	0.32	18.4	0.38	428	11.3	0.25	13.4	0.29
Respiratory System	3,031	96.5	0.80	114.5	0.94	2,455	65.4	0.60	77.8	0.71
Larynx	211	6.4	0.20	7.9	0.24	64	1.7	0.10	2.1	0.12
Lung & bronchus	2,784	88.8	0.77	105.2	0.90	2,370	63.0	0.59	75.0	0.69
Bones & Joints	28	1.0	0.09	1.1	0.09	23	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	105	3.7	0.16	4.1	0.18	81	2.5	0.13	2.8	0.14
Skin (excl. basal & sq.)	926	30.9	0.47	35.9	0.53	675	21.2	0.38	23.8	0.42
Melanomas of the skin	871	28.9	0.45	33.7	0.52	637	20.1	0.37	22.5	0.41
Breast (excl. <i>in situ</i>)	33	1.1	0.09	1.3	0.10	4,353	124.6	0.88	146.8	1.01
Female Genital System	-	-	-	-	-	1,856	53.4	0.58	63.0	0.66
Cervix uteri	-	-	-	-	-	226	8.1	0.25	8.6	0.26
Uterus Corpus	-	-	-	-	-	1,037	28.6	0.41	34.8	0.49
Uterus, NOS ¹	-	-	-	-	-	9	0.2	0.04	0.3	0.04
Ovary	-	-	-	-	-	380	10.8	0.26	12.6	0.29
Male Genital System	3,195	97.4	0.79	117.8	0.94	-	-	-	-	-
Prostate	2,996	89.5	0.75	109.8	0.90	-	-	-	-	-
Testis	165	6.8	0.24	6.7	0.23	-	-	-	-	-
Penis	27	0.9	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,043	67.0	0.68	78.8	0.79	854	23.6	0.37	27.5	0.43
Bladder (incl. <i>in situ</i>)	1,198	39.8	0.53	46.7	0.61	353	9.3	0.23	11.0	0.26
Kidney & renal pelvis	794	25.5	0.42	30.1	0.48	475	13.6	0.29	15.8	0.33
Ureter	34	1.1	0.09	1.3	0.10	18	0.5	0.05	0.5	0.06
Eye & Orbit	34	1.1	0.09	1.3	0.10	27	0.8	0.07	0.9	0.08
Brain & Other CNS ¹	240	8.3	0.25	9.2	0.27	184	5.7	0.20	6.3	0.21
Brain	227	7.9	0.24	8.7	0.26	175	5.4	0.19	5.9	0.20
Endocrine System	214	7.5	0.24	8.3	0.25	573	20.2	0.39	21.6	0.41
Thyroid gland	193	6.7	0.22	7.5	0.24	549	19.4	0.39	20.8	0.40
Lymphomas	782	26.3	0.43	30.2	0.49	640	18.3	0.34	20.9	0.37
Hodgkin Lymphoma	92	3.5	0.17	3.6	0.17	63	2.3	0.13	2.4	0.13
Non-Hodgkin Lymphoma	691	22.9	0.40	26.6	0.46	578	16.0	0.31	18.5	0.35
Multiple Myeloma	240	7.9	0.24	9.3	0.27	185	4.9	0.16	5.8	0.19
Leukemias	528	18.1	0.36	20.5	0.40	371	10.8	0.26	12.0	0.28
Acute lymphocytic	45	1.7	0.12	1.6	0.11	31	1.2	0.10	1.1	0.09
Chronic lymphocytic	196	6.4	0.21	7.6	0.24	119	3.1	0.13	3.7	0.15
Acute myeloid	169	5.8	0.20	6.6	0.23	136	3.9	0.16	4.4	0.17
Chronic myeloid	69	2.4	0.13	2.7	0.15	52	1.5	0.10	1.7	0.11
Other leukemias	50	1.8	0.12	2.0	0.13	34	1.0	0.08	1.1	0.08
Mesothelioma	49	1.7	0.11	2.0	0.13	15	0.4	0.05	0.5	0.05
Kaposi Sarcoma	3	0.1	0.03	0.1	0.03	1	0.0	0.01	0.0	0.01
Ill-defined & Unknown	509	17.2	0.35	20.1	0.40	462	12.2	0.26	14.2	0.30
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	246	8.4	0.25	9.5	0.27	487	14.4	0.30	16.3	0.34
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	914	26.7	0.41	31.7	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Indiana, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,279	537.8	7.18	649.8	8.47	1,265	407.1	5.25	481.3	6.10
Oral Cavity & Pharynx	38	15.1	1.15	18.2	1.36	18	5.9	0.63	6.8	0.72
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	8	3.3	0.55	4.0	0.63	4	1.4	0.30	1.7	0.36
Major salivary gland	2	1.0	0.34	1.2	0.40	4	1.3	0.29	1.4	0.31
Floor of mouth	2	0.9	0.27	1.0	0.31	-	-	-	-	-
Gum & other mouth	6	2.4	0.48	2.8	0.54	2	0.9	0.26	0.9	0.27
Nasopharynx	3	1.3	0.34	1.5	0.39	1	0.5	0.17	0.5	0.19
Oropharynx	2	0.9	0.26	1.1	0.31	2	0.6	0.19	0.7	0.23
Hypopharynx	4	1.4	0.35	1.7	0.41	-	-	-	-	-
Digestive System	289	123.6	3.47	149.5	4.09	246	80.4	2.35	96.2	2.76
Esophagus	17	6.7	0.79	8.3	0.94	8	2.6	0.42	3.2	0.51
Stomach	28	13.5	1.20	15.7	1.37	19	6.2	0.66	7.4	0.76
Small intestine	9	3.8	0.61	4.6	0.73	11	3.6	0.50	4.3	0.58
Colon excl. rectum	89	38.6	1.95	46.2	2.29	93	30.6	1.46	36.4	1.70
Rectum & rectosigmoid	34	14.7	1.19	17.4	1.38	28	9.0	0.78	10.8	0.92
Anus, anal canal & anorectum	6	2.2	0.42	2.5	0.48	6	2.0	0.36	2.4	0.43
Liver	51	18.3	1.21	24.1	1.54	15	4.6	0.54	5.7	0.66
Gallbladder	4	1.8	0.45	2.2	0.54	6	1.8	0.34	2.2	0.42
Pancreas	40	18.7	1.40	22.0	1.61	47	15.2	1.02	18.3	1.20
Respiratory System	212	93.6	3.07	113.0	3.60	191	62.0	2.06	74.8	2.44
Larynx	21	8.2	0.84	10.2	1.02	6	1.8	0.33	2.3	0.42
Lung & bronchus	189	84.6	2.94	101.8	3.44	183	59.9	2.03	72.1	2.39
Bones & Joints	3	1.1	0.31	1.1	0.33	1	0.4	0.14	0.4	0.14
Soft Tissue (incl. heart)	8	2.9	0.49	3.1	0.53	11	3.3	0.46	3.8	0.52
Skin (excl. basal & sq.)	6	2.6	0.50	2.9	0.56	5	1.7	0.34	1.9	0.38
Melanomas of the skin	2	1.0	0.33	1.2	0.38	3	0.8	0.23	1.0	0.27
Breast (excl. <i>in situ</i>)	5	2.4	0.51	2.7	0.56	393	125.1	2.89	148.4	3.37
Female Genital System	-	-	-	-	-	144	45.1	1.72	53.7	2.01
Cervix uteri	-	-	-	-	-	26	8.1	0.73	9.0	0.80
Uterus Corpus	-	-	-	-	-	80	24.3	1.24	29.9	1.50
Uterus, NOS ¹	-	-	-	-	-	1	0.4	0.16	0.5	0.19
Ovary	-	-	-	-	-	25	8.1	0.74	9.4	0.85
Male Genital System	406	164.7	3.89	204.8	4.69	-	-	-	-	-
Prostate	399	162.3	3.86	202.1	4.66	-	-	-	-	-
Testis	4	1.2	0.28	1.3	0.31	-	-	-	-	-
Penis	2	0.9	0.29	1.0	0.32	-	-	-	-	-
Urinary System	125	54.6	2.34	65.1	2.73	64	21.0	1.20	24.7	1.39
Bladder (incl. <i>in situ</i>)	47	22.8	1.60	27.1	1.86	21	7.3	0.73	8.5	0.84
Kidney & renal pelvis	77	31.4	1.69	37.5	1.98	42	13.3	0.94	15.6	1.09
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	13	4.3	0.57	4.9	0.65	13	4.0	0.51	4.3	0.55
Brain	12	4.1	0.56	4.6	0.64	12	3.8	0.50	4.0	0.53
Endocrine System	13	4.9	0.65	5.4	0.73	37	11.9	0.89	12.9	0.96
Thyroid gland	10	3.8	0.56	4.2	0.63	34	10.9	0.85	11.8	0.91
Lymphomas	49	19.9	1.36	22.5	1.53	42	13.7	0.97	15.4	1.08
Hodgkin Lymphoma	8	2.6	0.41	2.6	0.43	5	1.6	0.31	1.6	0.31
Non-Hodgkin Lymphoma	41	17.3	1.29	19.9	1.47	37	12.1	0.91	13.9	1.04
Multiple Myeloma	36	16.0	1.26	19.1	1.46	36	11.9	0.91	14.1	1.06
Leukemias	36	14.5	1.17	17.0	1.37	25	8.0	0.74	9.2	0.84
Acute lymphocytic	4	1.3	0.28	1.3	0.29	1	0.4	0.17	0.4	0.16
Chronic lymphocytic	11	4.6	0.69	5.7	0.83	6	1.9	0.36	2.2	0.42
Acute myeloid	12	4.8	0.68	5.6	0.79	10	3.2	0.46	3.6	0.52
Chronic myeloid	7	2.8	0.53	3.2	0.60	5	1.7	0.35	2.0	0.40
Other leukemias	3	1.0	0.29	1.2	0.32	3	0.8	0.23	1.0	0.27
Mesothelioma	2	0.8	0.29	1.0	0.33	-	-	-	-	-
Kaposi Sarcoma	3	1.1	0.29	1.2	0.30	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	36	12.3	0.94	14.3	1.08
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	22	9.2	0.93	10.6	1.07	48	15.5	1.03	18.2	1.19
Breast (<i>in situ</i>)	-	-	-	-	-	108	34.4	1.52	40.5	1.75

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


INDIANA

II-180 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	3,093,078	3,109,504	3,121,460	3,131,785	3,143,637
White	2,880,989	2,886,125	2,888,948	2,890,489	2,892,857
Black	120,505	126,298	131,697	136,798	142,314
American Indian/Alaskan Native (AI/AN)	16,971	17,446	17,859	18,220	18,471
Asian/Pacific Islander (API)	74,613	79,635	82,956	86,278	89,995


All Races Population 2013-2017: 15,599,464
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	168,612	173,364	178,762	184,152	189,284
Non-Hispanic White	2,727,481	2,728,540	2,726,611	2,723,202	2,721,038
Non-Hispanic Black	114,517	120,050	125,141	130,072	135,252

Hispanic/Latino Population, Census 2010: 151,544
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

IOWA CANCER REGISTRY

Initial Operation: 1973
 Population-based Data Available: 1973
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.6	108.3	109.4	111.5	111.1
Missing Race	0.6	0.5	0.5	0.5	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.5	1.7	1.4	1.2	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.6	Prostate	96.8
Oral Cavity & Pharynx	98.9	Testis	98.8
Esophagus	96.8	Bladder (incl. <i>in situ</i>)	97.2
Stomach	98.0	Kidney & Renal Pelvis	90.2
Colon & Rectum	95.7	Brain & Other CNS ¹	84.4
Liver	46.8	Thyroid	99.3
Pancreas	82.8	Hodgkin Lymphoma	99.2
Lung & Bronchus	87.8	Non-Hodgkin Lymphoma	97.5
Melanomas of the Skin	99.7	Multiple Myeloma	91.7
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	94.0
Cervix uteri	98.4	Brain & Other CNS ¹ <i>non-malig</i>	43.3
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	92.1		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,335	523.9	2.48	620.5	2.89	8,838	449.2	2.23	522.7	2.54
Oral Cavity & Pharynx	364	19.9	0.48	24.2	0.57	148	7.2	0.28	8.7	0.33
Lip	40	2.3	0.17	2.7	0.19	10	0.5	0.07	0.5	0.08
Tongue	114	6.1	0.26	7.5	0.32	46	2.3	0.16	2.8	0.19
Major salivary gland	31	1.8	0.15	2.1	0.17	21	1.1	0.11	1.2	0.12
Floor of mouth	15	0.8	0.10	1.0	0.12	5	0.3	0.05	0.3	0.07
Gum & other mouth	40	2.3	0.17	2.7	0.19	35	1.6	0.13	1.9	0.15
Nasopharynx	10	0.5	0.08	0.7	0.09	5	0.2	0.05	0.3	0.06
Oropharynx	14	0.7	0.09	0.9	0.11	4	0.2	0.04	0.2	0.05
Hypopharynx	19	1.0	0.10	1.3	0.13	4	0.2	0.04	0.2	0.05
Digestive System	1,773	100.2	1.09	119.2	1.27	1,444	68.9	0.84	80.6	0.97
Esophagus	187	10.3	0.34	12.4	0.41	41	1.9	0.14	2.3	0.16
Stomach	112	6.4	0.28	7.5	0.32	64	3.1	0.18	3.6	0.21
Small intestine	58	3.2	0.20	3.9	0.23	48	2.4	0.16	2.8	0.18
Colon excl. rectum	585	34.0	0.64	39.8	0.74	631	29.8	0.55	34.3	0.63
Rectum & rectosigmoid	271	15.3	0.43	18.3	0.50	173	9.0	0.32	10.5	0.37
Anus, anal canal & anorectum	25	1.4	0.13	1.7	0.15	53	2.7	0.17	3.3	0.21
Liver	156	8.3	0.30	10.3	0.37	55	2.6	0.16	3.1	0.19
Gallbladder	14	0.8	0.10	1.0	0.11	26	1.2	0.11	1.4	0.13
Pancreas	275	15.5	0.43	18.4	0.50	255	11.6	0.34	13.8	0.39
Respiratory System	1,467	81.8	0.97	97.2	1.14	1,189	56.5	0.75	67.2	0.88
Larynx	113	6.1	0.26	7.4	0.32	28	1.4	0.12	1.7	0.14
Lung & bronchus	1,338	74.7	0.93	88.7	1.09	1,150	54.5	0.74	64.9	0.87
Bones & Joints	17	1.0	0.11	1.1	0.12	12	0.7	0.10	0.7	0.10
Soft Tissue (incl. heart)	69	4.3	0.24	4.6	0.25	49	2.7	0.18	3.0	0.19
Skin (excl. basal & sq.)	590	34.3	0.65	39.9	0.74	468	26.7	0.58	29.6	0.62
Melanomas of the skin	539	31.3	0.62	36.4	0.70	434	25.0	0.56	27.7	0.61
Breast (excl. <i>in situ</i>)	22	1.2	0.12	1.5	0.14	2,465	128.9	1.21	151.4	1.39
Female Genital System	-	-	-	-	-	1,079	54.9	0.78	65.5	0.91
Cervix uteri	-	-	-	-	-	116	7.5	0.32	7.9	0.33
Uterus Corpus	-	-	-	-	-	599	29.4	0.56	36.2	0.67
Uterus, NOS ¹	-	-	-	-	-	15	0.7	0.09	0.8	0.10
Ovary	-	-	-	-	-	211	10.5	0.34	12.5	0.39
Male Genital System	2,186	116.0	1.14	141.7	1.36	-	-	-	-	-
Prostate	2,061	107.7	1.08	133.3	1.32	-	-	-	-	-
Testis	104	7.1	0.32	7.1	0.31	-	-	-	-	-
Penis	18	1.0	0.11	1.2	0.13	-	-	-	-	-
Urinary System	1,140	65.2	0.88	76.5	1.02	458	22.3	0.48	26.0	0.56
Bladder (incl. <i>in situ</i>)	656	37.6	0.67	44.0	0.77	194	8.8	0.29	10.4	0.34
Kidney & renal pelvis	458	26.0	0.56	30.7	0.65	252	12.9	0.38	15.0	0.43
Ureter	12	0.7	0.09	0.8	0.10	7	0.3	0.06	0.4	0.06
Eye & Orbit	25	1.5	0.14	1.7	0.15	22	1.1	0.11	1.3	0.13
Brain & Other CNS ¹	139	8.0	0.31	9.0	0.35	111	6.1	0.27	6.7	0.29
Brain	130	7.5	0.30	8.5	0.34	104	5.7	0.26	6.3	0.28
Endocrine System	140	8.4	0.33	9.5	0.36	347	22.0	0.55	23.5	0.57
Thyroid gland	127	7.7	0.31	8.6	0.35	337	21.5	0.54	23.0	0.57
Lymphomas	498	29.2	0.60	33.4	0.67	389	19.9	0.47	22.7	0.52
Hodgkin Lymphoma	54	3.4	0.21	3.6	0.22	41	2.6	0.19	2.7	0.19
Non-Hodgkin Lymphoma	444	25.8	0.56	29.8	0.64	348	17.3	0.43	20.0	0.49
Multiple Myeloma	159	9.1	0.33	10.7	0.38	117	5.5	0.23	6.5	0.27
Leukemias	373	21.8	0.52	24.8	0.58	248	12.3	0.36	13.9	0.40
Acute lymphocytic	30	2.0	0.16	1.8	0.15	21	1.3	0.13	1.2	0.12
Chronic lymphocytic	148	8.3	0.31	9.9	0.37	94	4.3	0.21	5.2	0.24
Acute myeloid	111	6.5	0.28	7.4	0.32	82	4.1	0.21	4.7	0.23
Chronic myeloid	50	2.9	0.19	3.4	0.21	28	1.4	0.13	1.6	0.14
Other leukemias	35	2.0	0.16	2.4	0.18	22	1.1	0.11	1.2	0.12
Mesothelioma	27	1.6	0.14	1.8	0.16	9	0.5	0.07	0.5	0.08
Kaposi Sarcoma	2	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	168	9.9	0.35	11.2	0.39	330	17.7	0.46	20.2	0.51
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	519	28.1	0.58	33.2	0.66

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	8,993	522.1	2.52	617.8	2.93	8,545	450.3	2.29	523.7	2.59
Oral Cavity & Pharynx	351	19.9	0.49	24.2	0.58	142	7.2	0.28	8.6	0.33
Lip	39	2.3	0.17	2.7	0.20	9	0.4	0.07	0.5	0.08
Tongue	111	6.2	0.27	7.6	0.32	44	2.3	0.16	2.8	0.19
Major salivary gland	29	1.8	0.15	2.0	0.17	21	1.1	0.11	1.3	0.13
Floor of mouth	15	0.8	0.10	1.0	0.12	5	0.3	0.05	0.3	0.07
Gum & other mouth	38	2.2	0.17	2.7	0.19	34	1.6	0.13	1.9	0.15
Nasopharynx	8	0.5	0.07	0.6	0.09	3	0.2	0.04	0.2	0.05
Oropharynx	14	0.7	0.09	0.9	0.11	3	0.2	0.05	0.2	0.05
Hypopharynx	19	1.0	0.11	1.2	0.13	4	0.2	0.04	0.2	0.06
Digestive System	1,701	99.4	1.10	118.2	1.29	1,389	68.2	0.85	79.7	0.98
Esophagus	183	10.4	0.35	12.6	0.42	40	1.9	0.14	2.3	0.16
Stomach	107	6.3	0.28	7.4	0.32	58	2.9	0.18	3.4	0.20
Small intestine	55	3.2	0.20	3.8	0.23	46	2.4	0.16	2.8	0.19
Colon excl. rectum	566	34.0	0.65	39.8	0.75	614	29.8	0.56	34.3	0.64
Rectum & rectosigmoid	261	15.3	0.44	18.2	0.51	165	8.9	0.33	10.5	0.37
Anus, anal canal & anorectum	23	1.4	0.13	1.6	0.15	52	2.7	0.18	3.4	0.21
Liver	139	7.6	0.30	9.4	0.36	49	2.4	0.16	2.8	0.19
Gallbladder	13	0.8	0.10	0.9	0.11	23	1.1	0.10	1.3	0.12
Pancreas	268	15.5	0.43	18.5	0.51	247	11.6	0.34	13.7	0.40
Respiratory System	1,421	81.5	0.99	96.8	1.15	1,160	56.7	0.76	67.4	0.90
Larynx	109	6.1	0.27	7.4	0.32	28	1.4	0.12	1.7	0.15
Lung & bronchus	1,296	74.4	0.94	88.3	1.10	1,121	54.7	0.75	65.0	0.88
Bones & Joints	16	1.0	0.12	1.1	0.12	12	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	66	4.3	0.24	4.7	0.26	49	2.7	0.18	3.1	0.20
Skin (excl. basal & sq.)	566	34.2	0.66	39.7	0.75	452	27.2	0.61	30.1	0.65
Melanomas of the skin	517	31.2	0.63	36.2	0.72	419	25.6	0.59	28.2	0.63
Breast (excl. <i>in situ</i>)	22	1.3	0.13	1.5	0.15	2,390	129.8	1.25	152.3	1.42
Female Genital System	-	-	-	-	-	1,041	54.9	0.80	65.5	0.93
Cervix uteri	-	-	-	-	-	108	7.4	0.34	7.8	0.34
Uterus Corpus	-	-	-	-	-	581	29.5	0.57	36.3	0.68
Uterus, NOS ¹	-	-	-	-	-	14	0.7	0.09	0.8	0.10
Ovary	-	-	-	-	-	205	10.6	0.35	12.6	0.40
Male Genital System	2,088	114.7	1.15	139.9	1.37	-	-	-	-	-
Prostate	1,971	106.1	1.09	131.2	1.33	-	-	-	-	-
Testis	97	7.3	0.34	7.3	0.33	-	-	-	-	-
Penis	17	1.0	0.11	1.2	0.13	-	-	-	-	-
Urinary System	1,110	65.4	0.90	76.8	1.04	440	22.0	0.49	25.8	0.56
Bladder (incl. <i>in situ</i>)	642	37.9	0.68	44.2	0.78	188	8.8	0.30	10.3	0.35
Kidney & renal pelvis	442	26.0	0.57	30.8	0.66	240	12.7	0.38	14.8	0.44
Ureter	12	0.7	0.09	0.8	0.11	7	0.3	0.06	0.4	0.06
Eye & Orbit	24	1.5	0.14	1.7	0.16	22	1.2	0.12	1.4	0.13
Brain & Other CNS ¹	135	8.2	0.33	9.3	0.36	106	6.2	0.28	6.7	0.30
Brain	127	7.7	0.31	8.7	0.35	100	5.8	0.27	6.3	0.29
Endocrine System	135	8.6	0.34	9.6	0.37	330	22.3	0.57	23.8	0.60
Thyroid gland	123	7.8	0.33	8.8	0.36	322	21.8	0.57	23.3	0.59
Lymphomas	480	29.3	0.61	33.5	0.69	378	20.0	0.48	22.8	0.54
Hodgkin Lymphoma	50	3.4	0.22	3.6	0.23	38	2.6	0.20	2.7	0.20
Non-Hodgkin Lymphoma	430	25.9	0.57	29.9	0.65	340	17.4	0.44	20.1	0.50
Multiple Myeloma	154	9.0	0.33	10.6	0.38	111	5.3	0.23	6.3	0.27
Leukemias	361	21.9	0.53	25.0	0.59	240	12.4	0.37	13.9	0.41
Acute lymphocytic	28	2.0	0.17	1.8	0.16	19	1.4	0.14	1.2	0.13
Chronic lymphocytic	144	8.4	0.32	9.9	0.37	92	4.4	0.21	5.2	0.25
Acute myeloid	107	6.5	0.29	7.4	0.32	80	4.1	0.22	4.6	0.24
Chronic myeloid	47	2.9	0.19	3.3	0.22	27	1.4	0.13	1.6	0.14
Other leukemias	34	2.1	0.16	2.4	0.19	22	1.1	0.11	1.2	0.12
Mesothelioma	27	1.6	0.14	1.8	0.16	9	0.5	0.07	0.5	0.08
Kaposi Sarcoma	2	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	162	10.0	0.36	11.3	0.40	315	17.6	0.47	20.0	0.52
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	499	28.2	0.59	33.2	0.68

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	193	574.1	21.33	701.1	25.19	156	441.3	16.81	518.8	19.57
Oral Cavity & Pharynx	6	15.1	3.25	18.6	3.96	2	3.8	1.47	4.9	1.88
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	1	3.2	1.69	3.6	1.93	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	42	131.0	10.38	158.7	12.09	31	89.3	7.56	107.5	8.98
Esophagus	1	6.0	2.61	7.1	3.02	-	-	-	-	-
Stomach	3	9.7	2.89	11.6	3.30	3	7.8	2.05	9.6	2.56
Small intestine	2	6.4	2.34	8.0	2.82	2	4.3	1.55	4.8	1.78
Colon excl. rectum	12	39.9	6.07	47.2	6.94	10	29.6	4.42	35.4	5.21
Rectum & rectosigmoid	5	14.7	3.23	18.2	3.85	4	9.1	2.24	10.9	2.70
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	11	29.0	4.25	37.0	5.22	3	7.6	1.99	9.9	2.58
Gallbladder	-	-	-	-	-	2	4.7	1.78	5.9	2.15
Pancreas	5	17.6	3.92	20.7	4.42	5	16.4	3.46	19.6	4.00
Respiratory System	33	110.2	9.84	133.8	11.47	20	62.9	6.63	76.1	7.79
Larynx	3	10.4	2.93	12.7	3.40	-	-	-	-	-
Lung & bronchus	29	98.5	9.32	119.9	10.88	20	62.0	6.57	75.1	7.74
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.0	1.75	4.6	2.03	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	111.9	8.32	130.5	9.66
Female Genital System	-	-	-	-	-	21	57.6	5.94	69.0	7.05
Cervix uteri	-	-	-	-	-	3	6.4	1.70	7.0	1.94
Uterus Corpus	-	-	-	-	-	11	31.6	4.55	38.7	5.45
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	8.4	2.25	9.9	2.68
Male Genital System	61	177.6	11.41	225.2	13.86	-	-	-	-	-
Prostate	59	174.6	11.32	222.2	13.78	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	16	46.1	6.03	56.2	7.20	11	34.3	4.96	38.6	5.52
Bladder (incl. <i>in situ</i>)	6	18.1	3.84	23.2	4.74	2	9.0	2.79	10.0	3.04
Kidney & renal pelvis	10	26.3	4.51	30.9	5.28	9	25.3	4.10	28.7	4.62
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	2.9	1.12	3.3	1.35	2	4.5	1.47	4.9	1.70
Brain	2	2.9	1.12	3.3	1.35	2	4.0	1.39	4.2	1.55
Endocrine System	2	5.0	1.79	5.6	1.97	7	14.2	2.62	15.5	2.92
Thyroid gland	1	3.4	1.56	3.8	1.69	6	13.5	2.56	14.7	2.85
Lymphomas	11	22.1	3.38	26.2	4.11	7	15.6	2.99	17.2	3.33
Hodgkin Lymphoma	3	4.2	1.22	4.4	1.31	2	4.3	1.52	4.3	1.53
Non-Hodgkin Lymphoma	-	-	-	-	-	4	11.3	2.58	13.0	2.96
Multiple Myeloma	5	14.2	3.41	17.0	4.00	5	17.1	3.44	20.6	4.03
Leukemias	6	18.3	4.09	20.3	4.60	4	9.7	2.45	10.6	2.75
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	5.2	2.09	6.0	2.33	-	-	-	-	-
Acute myeloid	2	8.4	2.92	8.8	3.21	1	2.3	1.00	2.7	1.21
Chronic myeloid	1	4.0	1.90	4.7	2.26	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	23.6	4.95	27.5	5.64	5	14.8	3.21	17.0	3.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	8.2	2.20	9.3	2.49	9	26.6	4.15	30.7	4.74
Breast (<i>in situ</i>)	-	-	-	-	-	11	30.7	4.42	36.1	5.14

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	57	292.0	20.28	348.3	23.89	76	297.7	16.69	347.2	19.33
Oral Cavity & Pharynx	3	15.9	4.41	19.0	5.16	2	8.3	2.93	9.4	3.27
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	5.8	2.55	7.4	3.11	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	1	3.4	1.41	4.3	1.86
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	21	107.6	12.02	129.3	14.09	17	79.1	9.42	91.5	10.74
Esophagus	1	5.9	2.59	7.4	3.09	-	-	-	-	-
Stomach	2	8.2	3.22	9.5	3.74	2	11.5	3.65	13.0	4.12
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	27.5	6.61	33.6	7.93	4	19.9	4.72	22.8	5.34
Rectum & rectosigmoid	3	14.8	3.88	17.9	4.57	3	10.2	3.04	12.2	3.63
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	27.5	5.71	33.4	6.66	3	15.0	4.39	16.8	4.90
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	9.9	3.91	11.3	4.37	2	9.9	3.37	11.6	3.82
Respiratory System	9	59.6	10.10	71.5	11.88	6	28.0	5.56	33.2	6.42
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	57.2	9.81	68.7	11.56	6	27.4	5.53	32.3	6.36
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	25	89.8	8.47	107.3	10.08
Female Genital System	-	-	-	-	-	10	34.1	5.17	39.9	6.09
Cervix uteri	-	-	-	-	-	3	9.1	2.64	10.1	2.97
Uterus Corpus	-	-	-	-	-	5	17.7	3.86	21.4	4.65
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	5.1	1.88	5.6	2.10
Male Genital System	7	34.8	6.43	42.5	7.74	-	-	-	-	-
Prostate	6	33.0	6.39	40.8	7.70	-	-	-	-	-
Testis	1	1.7	0.74	1.7	0.71	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	18.8	5.38	23.6	6.57	2	9.9	3.08	11.4	3.56
Bladder (incl. <i>in situ</i>)	2	11.3	4.52	14.5	5.64	-	-	-	-	-
Kidney & renal pelvis	1	6.8	2.80	7.8	3.15	2	6.0	2.28	6.8	2.63
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	2.9	1.22	2.7	1.21	1	4.5	1.99	5.3	2.29
Brain	1	2.9	1.22	2.7	1.21	1	4.5	1.99	5.3	2.29
Endocrine System	2	7.7	2.33	9.1	2.86	5	13.0	3.01	13.5	3.19
Thyroid gland	2	6.8	2.14	7.9	2.60	4	11.8	2.88	11.9	2.97
Lymphomas	4	17.2	5.16	18.7	5.78	3	10.2	3.22	11.5	3.65
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	3	15.6	5.08	17.3	5.73	2	8.4	3.08	9.6	3.51
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	12.2	4.61	14.0	5.52	2	5.8	2.07	6.0	2.17
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	8.9	3.83	11.0	4.60	2	8.2	2.97	10.1	3.62
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	6.6	3.14	8.2	3.77	3	10.9	3.06	12.8	3.62
Breast (<i>in situ</i>)	-	-	-	-	-	6	20.0	3.55	26.1	4.70

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8	670.8	127.38	827.5	152.16	11	598.7	85.50	731.0	104.20
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	226.4	79.28	286.0	96.45	2	152.4	45.94	182.7	54.30
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	112.1	44.06	139.9	51.62	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	1	103.0	43.10	127.0	49.97	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	144.8	45.57	172.2	54.19
Female Genital System	-	-	-	-	-	2	106.9	32.87	130.6	40.67
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	110.9	43.78	129.6	49.06	-	-	-	-	-
Prostate	1	101.6	42.77	120.7	48.24	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	121	306.1	15.08	364.5	17.47	122	264.9	12.06	309.2	14.15
Oral Cavity & Pharynx	3	8.7	2.55	10.3	2.98	2	5.2	1.97	5.9	2.20
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	33	91.3	8.33	109.0	9.59	18	47.7	5.46	57.4	6.49
Esophagus	2	4.4	1.80	5.0	1.99	-	-	-	-	-
Stomach	4	10.9	2.97	12.9	3.42	2	5.1	1.61	6.6	2.04
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	10	31.5	5.14	36.3	5.76	5	14.3	3.08	16.9	3.59
Rectum & rectosigmoid	3	6.9	2.01	8.7	2.37	3	6.7	1.72	8.1	2.13
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	15.1	3.30	19.2	4.02	2	7.2	2.41	8.2	2.66
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	4	11.6	2.82	13.8	3.28	2	5.9	1.96	7.4	2.43
Respiratory System	9	28.9	5.08	34.1	5.82	8	23.3	4.11	27.8	4.76
Larynx	1	3.1	1.28	3.9	1.57	-	-	-	-	-
Lung & bronchus	7	25.3	4.91	29.6	5.59	7	22.9	4.09	27.2	4.73
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	3.1	1.18	3.3	1.30	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	3.8	1.39	4.7	1.69	2	4.5	1.61	5.0	1.82
Breast (excl. <i>in situ</i>)	-	-	-	-	-	34	70.3	5.82	82.4	6.94
Female Genital System	-	-	-	-	-	21	40.3	4.32	47.5	5.11
Cervix uteri	-	-	-	-	-	6	10.9	2.34	11.7	2.55
Uterus Corpus	-	-	-	-	-	9	18.7	2.97	22.4	3.55
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	6.6	1.67	8.1	2.09
Male Genital System	29	74.8	7.39	90.6	8.58	-	-	-	-	-
Prostate	23	68.0	7.25	83.5	8.45	-	-	-	-	-
Testis	6	5.9	1.07	6.0	1.12	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	13	34.2	4.98	41.5	5.90	5	12.0	2.72	14.3	3.20
Bladder (incl. <i>in situ</i>)	5	15.3	3.44	19.2	4.22	-	-	-	-	-
Kidney & renal pelvis	8	19.0	3.60	22.3	4.12	5	9.2	2.16	11.4	2.71
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	4.5	1.65	5.0	1.88	2	3.4	1.23	4.0	1.52
Brain	2	4.1	1.64	4.6	1.88	2	3.0	1.18	3.6	1.49
Endocrine System	3	6.8	2.14	8.2	2.50	12	20.1	2.81	21.3	3.12
Thyroid gland	2	3.8	1.14	4.8	1.51	12	19.9	2.80	21.2	3.12
Lymphomas	10	21.7	3.99	24.4	4.48	6	16.1	3.31	18.6	3.81
Hodgkin Lymphoma	3	2.7	0.77	2.6	0.78	1	1.6	0.70	1.7	0.77
Non-Hodgkin Lymphoma	7	19.0	3.92	21.8	4.41	5	14.5	3.23	16.9	3.73
Multiple Myeloma	1	3.3	1.41	4.4	1.85	-	-	-	-	-
Leukemias	7	10.2	2.26	11.4	2.67	6	9.7	2.23	11.0	2.63
Acute lymphocytic	4	3.1	0.84	2.9	0.90	2	2.1	0.66	2.0	0.79
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	2.4	1.16	2.7	1.35	3	4.7	1.59	5.7	1.92
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	8.6	2.68	10.1	3.13	3	6.6	2.10	7.4	2.31
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	4.5	1.43	5.3	1.69	6	14.3	2.92	16.6	3.40
Breast (<i>in situ</i>)	-	-	-	-	-	9	18.1	2.95	21.1	3.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

IOWA

II-188 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,877	526.8	2.57	623.1	2.98	8,425	454.0	2.33	527.8	2.64
Oral Cavity & Pharynx	347	20.2	0.50	24.6	0.60	140	7.3	0.29	8.7	0.34
Lip	39	2.4	0.17	2.8	0.20	9	0.5	0.07	0.5	0.08
Tongue	111	6.3	0.28	7.8	0.33	44	2.4	0.17	2.8	0.20
Major salivary gland	28	1.8	0.15	2.0	0.17	20	1.1	0.12	1.3	0.13
Floor of mouth	15	0.9	0.11	1.1	0.12	5	0.3	0.05	0.4	0.07
Gum & other mouth	38	2.3	0.17	2.7	0.20	34	1.6	0.13	1.9	0.15
Nasopharynx	8	0.5	0.08	0.6	0.09	3	0.2	0.05	0.2	0.05
Oropharynx	13	0.7	0.09	0.9	0.11	3	0.2	0.05	0.2	0.06
Hypopharynx	18	1.0	0.11	1.3	0.13	4	0.2	0.05	0.2	0.06
Digestive System	1,669	99.7	1.12	118.4	1.30	1,372	68.6	0.87	80.1	1.00
Esophagus	182	10.5	0.36	12.8	0.43	39	1.9	0.14	2.3	0.17
Stomach	103	6.1	0.28	7.2	0.32	56	2.8	0.18	3.3	0.20
Small intestine	54	3.2	0.20	3.8	0.24	46	2.4	0.17	2.8	0.19
Colon excl. rectum	556	34.1	0.66	39.9	0.76	608	30.0	0.57	34.6	0.65
Rectum & rectosigmoid	258	15.5	0.45	18.5	0.52	162	8.9	0.33	10.5	0.38
Anus, anal canal & anorectum	22	1.4	0.13	1.6	0.15	52	2.8	0.18	3.4	0.22
Liver	134	7.5	0.30	9.3	0.36	47	2.4	0.16	2.8	0.19
Gallbladder	13	0.8	0.10	0.9	0.11	22	1.0	0.10	1.2	0.12
Pancreas	264	15.6	0.44	18.5	0.51	245	11.6	0.35	13.8	0.40
Respiratory System	1,413	82.4	1.00	98.0	1.17	1,153	57.3	0.78	68.1	0.91
Larynx	107	6.1	0.27	7.5	0.32	28	1.4	0.12	1.7	0.15
Lung & bronchus	1,290	75.3	0.96	89.4	1.12	1,114	55.3	0.76	65.7	0.90
Bones & Joints	15	1.1	0.12	1.1	0.12	11	0.8	0.11	0.8	0.11
Soft Tissue (incl. heart)	64	4.4	0.25	4.7	0.26	48	2.8	0.19	3.1	0.21
Skin (excl. basal & sq.)	563	34.9	0.68	40.4	0.77	449	28.1	0.63	30.9	0.67
Melanomas of the skin	515	31.9	0.65	37.0	0.73	417	26.5	0.62	29.1	0.65
Breast (excl. <i>in situ</i>)	21	1.3	0.13	1.5	0.15	2,356	131.0	1.27	153.6	1.45
Female Genital System	-	-	-	-	-	1,020	54.9	0.81	65.5	0.94
Cervix uteri	-	-	-	-	-	102	7.3	0.34	7.7	0.35
Uterus Corpus	-	-	-	-	-	572	29.5	0.57	36.4	0.69
Uterus, NOS ¹	-	-	-	-	-	14	0.7	0.08	0.8	0.10
Ovary	-	-	-	-	-	202	10.7	0.35	12.7	0.41
Male Genital System	2,060	115.5	1.17	140.9	1.40	-	-	-	-	-
Prostate	1,950	106.9	1.10	132.2	1.34	-	-	-	-	-
Testis	91	7.4	0.35	7.3	0.34	-	-	-	-	-
Penis	17	1.0	0.11	1.2	0.13	-	-	-	-	-
Urinary System	1,097	66.0	0.91	77.4	1.05	435	22.2	0.50	26.0	0.57
Bladder (incl. <i>in situ</i>)	637	38.2	0.69	44.6	0.79	187	8.9	0.30	10.5	0.35
Kidney & renal pelvis	434	26.2	0.58	31.0	0.67	235	12.7	0.39	14.8	0.44
Ureter	12	0.7	0.09	0.8	0.11	7	0.3	0.06	0.4	0.07
Eye & Orbit	24	1.6	0.15	1.8	0.16	22	1.2	0.13	1.4	0.14
Brain & Other CNS ¹	133	8.4	0.34	9.5	0.37	104	6.3	0.29	6.8	0.31
Brain	125	7.8	0.33	8.9	0.36	99	5.9	0.28	6.5	0.30
Endocrine System	131	8.7	0.36	9.8	0.38	318	22.4	0.59	23.9	0.61
Thyroid gland	121	8.0	0.34	9.0	0.37	310	21.9	0.58	23.4	0.60
Lymphomas	471	29.4	0.62	33.7	0.70	372	20.2	0.49	23.0	0.55
Hodgkin Lymphoma	47	3.4	0.22	3.6	0.23	37	2.7	0.21	2.7	0.20
Non-Hodgkin Lymphoma	423	26.1	0.58	30.1	0.66	335	17.5	0.45	20.2	0.51
Multiple Myeloma	152	9.1	0.34	10.7	0.39	110	5.4	0.24	6.4	0.28
Leukemias	355	22.0	0.54	25.1	0.60	234	12.3	0.38	13.9	0.42
Acute lymphocytic	25	1.9	0.18	1.7	0.16	17	1.3	0.14	1.1	0.13
Chronic lymphocytic	144	8.5	0.32	10.1	0.38	92	4.4	0.21	5.3	0.25
Acute myeloid	106	6.6	0.29	7.5	0.33	77	4.1	0.22	4.6	0.24
Chronic myeloid	47	2.9	0.20	3.4	0.22	27	1.5	0.13	1.7	0.15
Other leukemias	34	2.1	0.17	2.4	0.19	22	1.1	0.11	1.2	0.12
Mesothelioma	26	1.6	0.14	1.8	0.16	9	0.5	0.08	0.6	0.09
Kaposi Sarcoma	2	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	333	20.4	0.51	23.7	0.58	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	159	10.2	0.37	11.5	0.41	310	17.8	0.48	20.2	0.53
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	490	28.4	0.60	33.5	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Iowa, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	192	585.8	21.76	715.0	25.70	154	448.6	17.12	527.1	19.93
Oral Cavity & Pharynx	6	15.5	3.32	19.0	4.05	2	3.9	1.50	5.0	1.92
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	1	3.3	1.72	3.7	1.96	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	42	133.7	10.59	161.7	12.34	31	90.0	7.66	108.3	9.09
Esophagus	1	6.1	2.66	7.3	3.08	-	-	-	-	-
Stomach	3	9.9	2.94	11.9	3.36	3	8.0	2.11	9.8	2.62
Small intestine	2	6.6	2.40	8.2	2.90	2	4.4	1.59	4.9	1.83
Colon excl. rectum	12	40.8	6.17	48.2	7.07	10	30.4	4.53	36.3	5.34
Rectum & rectosigmoid	5	15.1	3.31	18.7	3.95	3	8.6	2.17	10.3	2.61
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	11	29.7	4.34	37.8	5.33	3	7.9	2.04	10.1	2.65
Gallbladder	-	-	-	-	-	2	4.9	1.82	6.1	2.20
Pancreas	5	18.0	4.01	21.1	4.52	5	16.8	3.53	20.0	4.09
Respiratory System	33	112.6	10.04	136.7	11.70	19	62.7	6.67	76.0	7.86
Larynx	3	10.7	3.00	13.0	3.49	-	-	-	-	-
Lung & bronchus	29	100.6	9.50	122.4	11.10	19	61.8	6.61	75.0	7.80
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.1	1.78	4.7	2.07	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	114.6	8.53	133.7	9.90
Female Genital System	-	-	-	-	-	21	59.2	6.08	70.8	7.22
Cervix uteri	-	-	-	-	-	3	6.6	1.77	7.3	2.01
Uterus Corpus	-	-	-	-	-	11	32.4	4.65	39.7	5.57
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	8.6	2.30	10.2	2.73
Male Genital System	60	180.4	11.62	228.8	14.12	-	-	-	-	-
Prostate	59	177.4	11.53	225.7	14.04	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	16	47.2	6.17	57.5	7.37	11	35.3	5.08	39.7	5.66
Bladder (incl. <i>in situ</i>)	6	18.6	3.94	23.8	4.86	2	9.2	2.85	10.2	3.10
Kidney & renal pelvis	9	26.8	4.62	31.6	5.40	9	26.1	4.21	29.5	4.74
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	3.0	1.16	3.4	1.39	2	4.7	1.51	5.1	1.74
Brain	2	3.0	1.16	3.4	1.39	2	4.2	1.43	4.3	1.58
Endocrine System	2	5.2	1.83	5.8	2.02	7	14.8	2.72	16.1	3.03
Thyroid gland	1	3.5	1.60	3.9	1.73	6	14.0	2.66	15.3	2.95
Lymphomas	10	22.6	3.46	26.7	4.20	6	15.6	3.03	17.3	3.39
Hodgkin Lymphoma	3	4.4	1.27	4.6	1.36	2	3.9	1.46	4.0	1.50
Non-Hodgkin Lymphoma	8	18.2	3.22	22.1	3.97	4	11.7	2.66	13.4	3.04
Multiple Myeloma	5	14.5	3.49	17.4	4.08	5	17.5	3.51	21.0	4.11
Leukemias	6	18.8	4.19	20.8	4.70	4	10.0	2.52	10.9	2.82
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	5.3	2.13	6.1	2.37	-	-	-	-	-
Acute myeloid	2	8.6	2.98	9.0	3.28	1	2.4	1.04	2.8	1.26
Chronic myeloid	1	4.2	1.96	4.9	2.32	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	24.1	5.05	28.1	5.75	5	14.7	3.25	16.7	3.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	8.5	2.26	9.6	2.55	9	27.4	4.26	31.5	4.87
Breast (<i>in situ</i>)	-	-	-	-	-	11	31.5	4.53	37.1	5.26

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,893,510	2,900,896	2,909,502	2,911,263	2,910,689
White	2,560,307	2,562,645	2,565,016	2,563,170	2,561,300
Black	203,229	204,899	206,517	206,678	206,547
American Indian/Alaskan Native (AI/AN)	41,777	41,951	41,984	42,111	42,425
Asian/Pacific Islander (API)	88,197	91,401	95,985	99,304	100,417


All Races Population 2013-2017: 14,525,860
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	322,154	329,187	335,828	341,283	346,375
Non-Hispanic White	2,268,162	2,264,242	2,260,415	2,253,508	2,246,995
Non-Hispanic Black	190,033	191,337	192,678	192,621	192,394

Hispanic/Latino Population, Census 2010: 300,042
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

KANSAS CANCER REGISTRY

Initial Operation: 1968
 Population-based Data Available: 1984
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.5	97.5	100.0	99.4	101.2
Missing Race	1.7	2.6	2.0	2.1	2.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.2	0.2	0.2	0.2	0.3
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.3	Prostate	98.2
Oral Cavity & Pharynx	98.7	Testis	99.1
Esophagus	99.0	Bladder (incl. <i>in situ</i>)	99.0
Stomach	98.6	Kidney & Renal Pelvis	92.5
Colon & Rectum	98.4	Brain & Other CNS ¹	88.6
Liver	65.0	Thyroid	99.4
Pancreas	88.4	Hodgkin Lymphoma	97.4
Lung & Bronchus	90.8	Non-Hodgkin Lymphoma	97.4
Melanomas of the Skin	99.6	Multiple Myeloma	91.8
Female Breast (excl. <i>in situ</i>)	99.3	Leukemias	91.1
Cervix uteri	98.3	Brain & Other CNS ¹ <i>non-malig</i>	39.5
Uterus Corpus & Uterus NOS ¹	99.2	Breast <i>in situ</i>	99.9
Ovary	95.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7,669	493.3	2.58	585.0	3.01	7,296	425.2	2.30	494.8	2.62
Oral Cavity & Pharynx	292	18.1	0.49	22.2	0.58	112	6.3	0.28	7.5	0.32
Lip	16	1.0	0.12	1.2	0.14	5	0.3	0.06	0.4	0.07
Tongue	89	5.4	0.26	6.7	0.32	37	2.0	0.16	2.5	0.19
Major salivary gland	32	2.2	0.17	2.5	0.20	18	1.1	0.12	1.2	0.13
Floor of mouth	11	0.7	0.09	0.8	0.11	6	0.3	0.06	0.4	0.07
Gum & other mouth	31	2.0	0.16	2.4	0.19	19	1.0	0.11	1.2	0.13
Nasopharynx	9	0.6	0.09	0.7	0.10	5	0.3	0.07	0.3	0.07
Oropharynx	16	1.0	0.11	1.2	0.14	5	0.3	0.05	0.3	0.07
Hypopharynx	13	0.8	0.10	1.0	0.12	4	0.2	0.05	0.3	0.06
Digestive System	1,394	89.7	1.10	107.1	1.29	1,091	61.1	0.85	71.8	0.98
Esophagus	127	8.0	0.33	9.7	0.39	29	1.6	0.13	1.9	0.16
Stomach	104	6.7	0.30	8.0	0.35	57	3.2	0.19	3.8	0.23
Small intestine	46	3.0	0.20	3.6	0.24	41	2.5	0.18	2.8	0.20
Colon excl. rectum	455	30.2	0.65	35.5	0.75	457	25.8	0.56	29.8	0.63
Rectum & rectosigmoid	226	14.6	0.45	17.4	0.52	149	8.5	0.32	10.1	0.37
Anus, anal canal & anorectum	19	1.2	0.13	1.5	0.15	36	1.9	0.15	2.4	0.18
Liver	157	9.3	0.34	11.7	0.42	49	2.6	0.17	3.2	0.21
Gallbladder	11	0.7	0.10	0.9	0.12	20	1.1	0.11	1.3	0.13
Pancreas	191	12.3	0.41	14.6	0.48	189	10.4	0.35	12.2	0.40
Respiratory System	1,099	71.3	0.98	84.5	1.15	931	51.3	0.77	61.0	0.90
Larynx	84	5.3	0.26	6.4	0.31	17	1.0	0.11	1.2	0.13
Lung & bronchus	998	64.9	0.94	76.9	1.09	902	49.7	0.75	59.1	0.89
Bones & Joints	16	1.1	0.12	1.1	0.12	14	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	66	4.4	0.25	5.0	0.28	50	3.1	0.20	3.4	0.22
Skin (excl. basal & sq.)	525	34.8	0.70	40.7	0.80	387	24.2	0.57	27.2	0.63
Melanomas of the skin	488	32.2	0.67	37.7	0.77	362	22.8	0.56	25.6	0.61
Breast (excl. <i>in situ</i>)	20	1.3	0.13	1.5	0.16	2,137	126.0	1.26	148.0	1.45
Female Genital System	-	-	-	-	-	829	49.0	0.79	57.7	0.91
Cervix uteri	-	-	-	-	-	107	7.6	0.34	8.0	0.35
Uterus Corpus	-	-	-	-	-	452	25.6	0.56	31.2	0.66
Uterus, NOS ¹	-	-	-	-	-	13	0.8	0.10	0.9	0.11
Ovary	-	-	-	-	-	181	10.8	0.37	12.5	0.42
Male Genital System	1,880	115.6	1.22	140.2	1.45	-	-	-	-	-
Prostate	1,777	108.3	1.18	132.8	1.42	-	-	-	-	-
Testis	88	6.3	0.31	6.3	0.30	-	-	-	-	-
Penis	13	0.9	0.11	1.0	0.13	-	-	-	-	-
Urinary System	950	62.3	0.93	73.5	1.07	403	22.7	0.52	26.6	0.60
Bladder (incl. <i>in situ</i>)	540	36.1	0.71	42.3	0.82	168	9.1	0.32	10.6	0.37
Kidney & renal pelvis	391	24.9	0.58	29.7	0.67	227	13.2	0.40	15.4	0.46
Ureter	11	0.8	0.10	0.9	0.12	7	0.3	0.06	0.4	0.07
Eye & Orbit	14	0.9	0.11	1.1	0.13	11	0.6	0.09	0.7	0.10
Brain & Other CNS ¹	111	7.3	0.32	8.1	0.35	88	5.5	0.27	5.9	0.28
Brain	104	6.8	0.31	7.7	0.34	82	5.1	0.26	5.5	0.27
Endocrine System	133	8.9	0.35	10.0	0.39	357	24.4	0.60	26.4	0.63
Thyroid gland	122	8.2	0.34	9.3	0.38	350	23.9	0.59	25.9	0.62
Lymphomas	400	26.6	0.61	30.6	0.69	311	17.9	0.47	20.6	0.53
Hodgkin Lymphoma	44	3.0	0.21	3.1	0.21	27	1.9	0.17	1.9	0.17
Non-Hodgkin Lymphoma	357	23.6	0.57	27.5	0.66	285	16.0	0.44	18.7	0.50
Multiple Myeloma	125	8.1	0.33	9.7	0.39	97	5.4	0.25	6.4	0.29
Leukemias	300	20.0	0.53	22.8	0.59	190	11.0	0.37	12.4	0.41
Acute lymphocytic	25	1.7	0.15	1.6	0.14	17	1.2	0.13	1.0	0.12
Chronic lymphocytic	125	8.0	0.33	9.6	0.39	71	3.9	0.21	4.6	0.25
Acute myeloid	81	5.5	0.28	6.3	0.31	58	3.4	0.20	3.8	0.23
Chronic myeloid	41	2.9	0.20	3.2	0.22	26	1.5	0.14	1.7	0.16
Other leukemias	28	1.9	0.16	2.2	0.18	18	1.0	0.11	1.2	0.12
Mesothelioma	16	1.1	0.12	1.2	0.14	7	0.4	0.07	0.5	0.08
Kaposi Sarcoma	2	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	126	8.4	0.34	9.5	0.38	253	15.2	0.44	17.4	0.50
Breast (<i>in situ</i>)	2	0.1	0.04	0.1	0.05	425	25.7	0.58	30.4	0.67

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,895	479.2	2.64	567.3	3.07	6,610	418.0	2.39	486.7	2.72
Oral Cavity & Pharynx	269	18.1	0.51	22.2	0.61	100	6.1	0.28	7.2	0.33
Lip	13	0.9	0.12	1.1	0.14	5	0.3	0.06	0.3	0.07
Tongue	84	5.6	0.28	6.9	0.34	34	2.1	0.17	2.5	0.19
Major salivary gland	30	2.1	0.18	2.5	0.20	15	0.9	0.11	1.1	0.13
Floor of mouth	10	0.7	0.10	0.8	0.12	6	0.3	0.06	0.4	0.08
Gum & other mouth	29	2.0	0.17	2.4	0.20	17	1.0	0.11	1.2	0.13
Nasopharynx	7	0.5	0.09	0.6	0.10	4	0.3	0.07	0.3	0.07
Oropharynx	16	1.0	0.12	1.3	0.14	4	0.3	0.06	0.3	0.07
Hypopharynx	12	0.8	0.10	0.9	0.13	3	0.2	0.05	0.2	0.06
Digestive System	1,248	86.8	1.13	103.5	1.32	983	59.3	0.88	69.6	1.01
Esophagus	118	8.1	0.34	9.7	0.40	27	1.6	0.14	1.8	0.16
Stomach	91	6.3	0.30	7.5	0.35	48	2.8	0.19	3.4	0.22
Small intestine	40	2.8	0.20	3.3	0.24	36	2.3	0.18	2.7	0.20
Colon excl. rectum	410	29.4	0.66	34.4	0.76	420	25.6	0.58	29.5	0.66
Rectum & rectosigmoid	207	14.5	0.46	17.3	0.54	131	8.2	0.33	9.6	0.38
Anus, anal canal & anorectum	18	1.2	0.13	1.5	0.16	34	2.0	0.16	2.5	0.20
Liver	130	8.3	0.34	10.5	0.41	39	2.2	0.16	2.8	0.20
Gallbladder	10	0.7	0.10	0.8	0.12	18	1.1	0.12	1.3	0.13
Pancreas	173	11.9	0.42	14.2	0.49	170	10.0	0.35	11.8	0.41
Respiratory System	1,008	70.3	1.01	83.1	1.18	856	50.8	0.79	60.4	0.93
Larynx	75	5.1	0.27	6.2	0.32	15	0.9	0.11	1.1	0.13
Lung & bronchus	918	64.1	0.97	75.7	1.12	831	49.3	0.78	58.6	0.92
Bones & Joints	14	1.1	0.13	1.1	0.13	12	0.9	0.12	1.0	0.12
Soft Tissue (incl. heart)	60	4.3	0.26	5.0	0.29	44	3.0	0.21	3.3	0.22
Skin (excl. basal & sq.)	473	34.0	0.72	39.6	0.82	341	23.5	0.60	26.3	0.65
Melanomas of the skin	438	31.4	0.69	36.6	0.79	320	22.2	0.58	24.9	0.63
Breast (excl. <i>in situ</i>)	17	1.2	0.13	1.4	0.16	1,953	124.9	1.32	147.0	1.51
Female Genital System	-	-	-	-	-	752	48.3	0.82	57.1	0.94
Cervix uteri	-	-	-	-	-	90	7.2	0.35	7.6	0.36
Uterus Corpus	-	-	-	-	-	412	25.4	0.58	31.0	0.69
Uterus, NOS ¹	-	-	-	-	-	11	0.7	0.10	0.8	0.11
Ovary	-	-	-	-	-	167	10.7	0.38	12.5	0.44
Male Genital System	1,613	107.2	1.22	129.7	1.45	-	-	-	-	-
Prostate	1,520	99.6	1.17	122.0	1.41	-	-	-	-	-
Testis	80	6.6	0.34	6.6	0.33	-	-	-	-	-
Penis	12	0.8	0.11	1.0	0.13	-	-	-	-	-
Urinary System	882	62.2	0.96	73.3	1.11	369	22.5	0.54	26.4	0.62
Bladder (incl. <i>in situ</i>)	503	35.9	0.73	42.1	0.84	155	9.0	0.33	10.5	0.38
Kidney & renal pelvis	360	24.9	0.60	29.7	0.70	207	13.1	0.42	15.4	0.48
Ureter	11	0.8	0.11	0.9	0.12	6	0.3	0.06	0.4	0.07
Eye & Orbit	13	0.9	0.11	1.0	0.13	10	0.6	0.10	0.7	0.11
Brain & Other CNS ¹	105	7.6	0.34	8.5	0.37	82	5.7	0.29	6.1	0.30
Brain	99	7.1	0.33	8.0	0.36	77	5.3	0.28	5.7	0.29
Endocrine System	118	8.6	0.37	9.7	0.40	310	23.7	0.62	25.6	0.66
Thyroid gland	108	8.0	0.35	9.0	0.39	304	23.2	0.62	25.2	0.65
Lymphomas	369	26.5	0.63	30.6	0.72	282	17.7	0.49	20.2	0.55
Hodgkin Lymphoma	39	3.0	0.22	3.1	0.23	25	2.0	0.18	2.0	0.18
Non-Hodgkin Lymphoma	330	23.6	0.59	27.5	0.68	258	15.7	0.45	18.2	0.52
Multiple Myeloma	110	7.6	0.33	9.1	0.39	78	4.6	0.24	5.5	0.28
Leukemias	278	20.0	0.55	22.9	0.62	169	10.6	0.38	12.0	0.42
Acute lymphocytic	22	1.7	0.17	1.6	0.15	14	1.1	0.13	1.0	0.12
Chronic lymphocytic	117	8.1	0.34	9.7	0.40	64	3.8	0.22	4.5	0.26
Acute myeloid	75	5.5	0.29	6.2	0.33	52	3.2	0.21	3.7	0.23
Chronic myeloid	38	2.9	0.21	3.2	0.23	22	1.4	0.14	1.6	0.16
Other leukemias	26	1.9	0.17	2.2	0.19	17	1.0	0.11	1.1	0.13
Mesothelioma	16	1.1	0.13	1.3	0.15	7	0.4	0.07	0.5	0.09
Kaposi Sarcoma	2	0.1	0.05	0.1	0.05	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	111	8.1	0.35	9.2	0.39	228	15.0	0.46	17.1	0.52
Breast (<i>in situ</i>)	-	-	-	-	-	380	25.2	0.60	29.7	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	370	507.1	12.78	615.2	15.08	333	405.0	10.16	473.4	11.71
Oral Cavity & Pharynx	9	12.0	1.92	14.3	2.23	6	6.6	1.26	8.0	1.51
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.4	0.84	2.7	0.91	1	1.5	0.59	2.0	0.77
Major salivary gland	-	-	-	-	-	2	2.6	0.81	2.9	0.90
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	81	114.2	6.15	139.3	7.32	61	75.1	4.40	89.2	5.14
Esophagus	6	7.3	1.51	9.3	1.86	2	1.9	0.67	2.3	0.82
Stomach	6	8.3	1.60	10.2	1.93	4	5.1	1.11	6.4	1.36
Small intestine	4	5.6	1.30	6.6	1.48	4	4.5	1.09	5.2	1.23
Colon excl. rectum	26	38.6	3.72	45.8	4.33	20	25.3	2.58	29.5	2.96
Rectum & rectosigmoid	9	12.8	2.03	15.5	2.40	8	9.8	1.60	11.4	1.84
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	14	17.4	2.21	22.7	2.78	7	6.7	1.17	9.2	1.59
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	12	18.9	2.66	22.7	3.14	13	17.3	2.18	20.0	2.47
Respiratory System	62	89.3	5.48	108.0	6.40	47	58.3	3.88	69.7	4.55
Larynx	4	5.1	1.15	6.8	1.52	1	1.6	0.62	2.1	0.78
Lung & bronchus	57	82.9	5.31	99.7	6.16	45	55.1	3.77	66.0	4.43
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.0	0.93	4.3	1.02	2	2.4	0.76	2.5	0.80
Skin (excl. basal & sq.)	2	4.0	1.28	4.7	1.48	-	-	-	-	-
Melanomas of the skin	2	3.3	1.22	3.8	1.40	-	-	-	-	-
Breast (excl. <i>in situ</i>)	2	2.3	0.73	3.0	0.95	102	124.5	5.65	144.7	6.47
Female Genital System	-	-	-	-	-	33	39.9	3.18	46.6	3.65
Cervix uteri	-	-	-	-	-	6	6.7	1.29	7.3	1.40
Uterus Corpus	-	-	-	-	-	19	22.4	2.35	27.1	2.79
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	7.1	1.40	7.6	1.49
Male Genital System	121	158.6	6.92	198.3	8.35	-	-	-	-	-
Prostate	118	154.6	6.84	193.9	8.27	-	-	-	-	-
Testis	2	1.8	0.58	1.9	0.62	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	31	43.6	3.78	52.4	4.43	17	19.9	2.24	23.6	2.63
Bladder (incl. <i>in situ</i>)	13	20.6	2.76	24.5	3.21	5	6.4	1.33	7.3	1.49
Kidney & renal pelvis	18	22.7	2.57	27.4	3.02	11	13.0	1.76	15.8	2.12
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	3.9	0.90	4.1	0.98	3	3.2	0.88	3.2	0.91
Brain	4	3.8	0.89	4.0	0.98	2	2.6	0.79	2.6	0.83
Endocrine System	5	7.1	1.46	8.7	1.73	14	16.2	1.98	17.7	2.14
Thyroid gland	4	5.3	1.22	6.6	1.47	13	15.4	1.93	16.9	2.10
Lymphomas	13	15.4	2.10	17.2	2.36	12	14.3	1.87	16.8	2.16
Hodgkin Lymphoma	3	2.8	0.81	2.7	0.77	1	1.2	0.49	1.2	0.50
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	10	16.7	2.52	19.6	2.89	14	17.2	2.12	20.5	2.48
Leukemias	12	17.3	2.44	19.8	2.76	11	13.7	1.89	14.9	2.06
Acute lymphocytic	1	1.2	0.45	1.1	0.47	1	1.0	0.40	0.8	0.33
Chronic lymphocytic	5	8.6	1.84	9.8	2.07	3	3.8	1.03	4.2	1.13
Acute myeloid	3	4.1	1.17	4.8	1.35	4	4.5	1.09	5.0	1.19
Chronic myeloid	2	2.8	0.94	3.2	1.04	3	3.3	0.93	3.8	1.05
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	17.1	2.54	20.0	2.91	9	11.0	1.65	13.2	1.96
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	11.0	1.93	12.5	2.19	11	13.0	1.81	15.5	2.13
Breast (<i>in situ</i>)	-	-	-	-	-	23	27.6	2.63	33.1	3.09

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	79	288.3	16.32	341.3	19.22	100	262.5	12.48	302.8	14.37
Oral Cavity & Pharynx	4	14.3	3.87	17.4	4.63	1	2.9	1.29	3.5	1.55
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	29	106.2	9.74	126.5	11.47	19	56.0	6.08	66.2	7.04
Esophagus	1	4.6	2.04	5.7	2.40	-	-	-	-	-
Stomach	4	19.6	4.83	23.0	5.68	3	7.5	2.12	8.8	2.42
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	27.4	4.84	32.3	5.66	5	14.1	2.93	16.9	3.43
Rectum & rectosigmoid	4	10.0	2.47	11.7	2.91	4	10.3	2.52	12.8	3.08
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	6	22.0	4.11	27.3	4.96	2	7.1	2.29	8.5	2.64
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	12.2	3.70	14.2	4.30	2	6.3	2.23	6.9	2.44
Respiratory System	10	37.2	5.98	45.0	7.13	11	33.5	4.80	39.8	5.58
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	32.5	5.46	39.6	6.54	11	33.5	4.80	39.8	5.58
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	1	3.8	1.51	3.9	1.62
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	30	74.6	6.36	85.7	7.34
Female Genital System	-	-	-	-	-	12	29.2	3.88	34.2	4.57
Cervix uteri	-	-	-	-	-	2	5.6	1.69	6.8	2.09
Uterus Corpus	-	-	-	-	-	7	15.8	2.86	18.9	3.41
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	7.8	2.00	8.4	2.21
Male Genital System	13	43.6	5.98	51.8	7.01	-	-	-	-	-
Prostate	11	40.1	5.87	48.4	6.92	-	-	-	-	-
Testis	2	3.5	1.14	3.4	1.12	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	23.0	4.65	27.4	5.50	2	6.7	2.20	7.8	2.52
Bladder (incl. <i>in situ</i>)	3	13.8	3.84	16.8	4.63	-	-	-	-	-
Kidney & renal pelvis	3	9.2	2.63	10.6	2.97	1	3.5	1.45	4.1	1.65
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	3	6.9	1.83	7.4	2.06	10	20.4	2.90	22.4	3.28
Thyroid gland	3	6.4	1.78	7.1	2.03	9	18.6	2.76	20.6	3.14
Lymphomas	5	21.4	4.78	24.3	5.50	4	11.3	2.57	12.7	2.88
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	4	10.4	2.51	11.7	2.82
Multiple Myeloma	2	9.4	3.13	11.3	3.68	2	6.1	2.03	6.9	2.30
Leukemias	3	10.5	3.11	12.3	3.70	2	5.5	1.62	6.2	1.85
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	5.8	2.58	6.8	3.08	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	10.5	3.88	12.1	4.59	2	9.4	2.83	10.6	3.21
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	5.4	1.72	5.7	1.86	5	15.9	3.44	17.4	3.71
Breast (<i>in situ</i>)	-	-	-	-	-	7	18.5	3.20	21.6	3.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

KANSAS

II-196 Incidence – API

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	283	361.7	11.05	431.6	12.95	320	347.2	9.46	404.8	11.03
Oral Cavity & Pharynx	7	8.1	1.56	10.0	1.89	5	5.4	1.17	6.6	1.44
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.4	0.95	3.1	1.17	2	1.8	0.61	2.2	0.79
Major salivary gland	-	-	-	-	-	2	1.8	0.69	2.1	0.83
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	70	93.2	5.61	113.3	6.65	48	57.2	3.97	68.3	4.69
Esophagus	3	5.5	1.48	6.6	1.73	-	-	-	-	-
Stomach	9	11.5	1.96	13.8	2.32	4	5.0	1.20	5.7	1.37
Small intestine	3	3.8	1.14	4.8	1.38	2	2.6	0.82	2.9	0.95
Colon excl. rectum	19	27.6	3.15	33.2	3.72	18	21.1	2.40	24.9	2.82
Rectum & rectosigmoid	12	14.7	2.17	17.5	2.54	5	4.8	1.04	6.1	1.33
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	12	13.4	1.92	17.2	2.37	4	5.7	1.29	6.9	1.52
Gallbladder	-	-	-	-	-	3	4.0	1.12	4.8	1.32
Pancreas	7	10.0	1.86	12.3	2.22	7	8.5	1.57	10.2	1.86
Respiratory System	22	34.4	3.69	40.2	4.24	22	32.2	3.26	36.8	3.64
Larynx	3	4.2	1.17	5.0	1.38	-	-	-	-	-
Lung & bronchus	17	29.3	3.47	34.3	3.98	21	31.3	3.22	35.7	3.59
Bones & Joints	2	0.8	0.27	0.6	0.23	-	-	-	-	-
Soft Tissue (incl. heart)	3	2.9	0.93	3.3	1.08	4	3.0	0.74	3.4	0.88
Skin (excl. basal & sq.)	-	-	-	-	-	9	7.9	1.28	9.0	1.52
Melanomas of the skin	4	5.9	1.46	6.9	1.72	7	6.0	1.06	6.9	1.27
Breast (excl. <i>in situ</i>)	-	-	-	-	-	88	94.2	4.79	110.5	5.63
Female Genital System	-	-	-	-	-	46	47.3	3.37	55.9	3.98
Cervix uteri	-	-	-	-	-	11	10.0	1.46	10.8	1.62
Uterus Corpus	-	-	-	-	-	22	23.4	2.40	28.9	2.92
Uterus, NOS ¹	-	-	-	-	-	1	1.2	0.47	1.6	0.61
Ovary	-	-	-	-	-	9	9.8	1.59	11.2	1.81
Male Genital System	73	96.1	5.69	115.4	6.63	-	-	-	-	-
Prostate	61	89.1	5.58	108.1	6.51	-	-	-	-	-
Testis	11	5.8	0.84	5.9	0.90	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	36	47.9	4.07	57.2	4.77	21	24.5	2.61	28.6	3.02
Bladder (incl. <i>in situ</i>)	12	20.0	2.86	23.7	3.32	6	8.7	1.73	9.9	1.93
Kidney & renal pelvis	23	27.7	2.88	33.2	3.41	15	14.7	1.85	17.5	2.22
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.5	1.01	5.1	1.22	7	5.1	1.04	5.3	1.13
Brain	6	4.3	1.01	5.0	1.22	7	4.9	1.03	5.1	1.12
Endocrine System	8	7.6	1.36	9.0	1.62	29	24.8	2.19	28.4	2.60
Thyroid gland	8	7.4	1.35	8.8	1.61	29	24.5	2.18	28.1	2.59
Lymphomas	16	18.6	2.45	21.4	2.80	14	14.5	1.90	16.8	2.22
Hodgkin Lymphoma	3	2.1	0.77	2.2	0.86	2	1.3	0.40	1.2	0.37
Non-Hodgkin Lymphoma	13	16.4	2.32	19.1	2.67	12	13.2	1.86	15.5	2.19
Multiple Myeloma	8	11.6	2.02	13.6	2.32	5	6.2	1.38	7.1	1.56
Leukemias	15	14.1	2.08	15.2	2.32	10	10.2	1.61	11.3	1.84
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	3.3	1.20	3.8	1.37	1	1.9	0.75	2.4	0.91
Acute myeloid	4	4.7	1.21	5.2	1.34	4	4.7	1.19	5.2	1.33
Chronic myeloid	2	2.6	0.95	2.8	1.06	1	1.0	0.42	1.1	0.47
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	14.0	2.20	17.7	2.70	10	13.3	2.02	15.4	2.32
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	6	4.9	1.13	5.6	1.29	14	14.7	1.90	17.1	2.22
Breast (<i>in situ</i>)	-	-	-	-	-	15	15.1	1.83	17.3	2.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

KANSAS

II-198 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,659	488.2	2.75	577.7	3.19	6,333	423.9	2.50	493.1	2.83
Oral Cavity & Pharynx	263	18.8	0.54	23.0	0.64	95	6.1	0.30	7.3	0.34
Lip	13	1.0	0.12	1.1	0.14	5	0.3	0.06	0.4	0.08
Tongue	83	5.8	0.30	7.2	0.36	32	2.1	0.17	2.5	0.20
Major salivary gland	29	2.2	0.19	2.5	0.21	13	0.9	0.11	1.0	0.13
Floor of mouth	10	0.7	0.10	0.9	0.12	5	0.3	0.06	0.4	0.08
Gum & other mouth	28	2.1	0.18	2.5	0.21	17	1.0	0.11	1.2	0.13
Nasopharynx	6	0.5	0.09	0.5	0.10	4	0.3	0.07	0.3	0.08
Oropharynx	15	1.1	0.12	1.3	0.15	4	0.3	0.06	0.3	0.08
Hypopharynx	11	0.8	0.11	1.0	0.13	3	0.2	0.05	0.2	0.06
Digestive System	1,190	87.2	1.16	104.0	1.36	941	59.7	0.91	69.9	1.04
Esophagus	115	8.2	0.35	9.9	0.42	26	1.6	0.14	1.9	0.16
Stomach	84	6.1	0.31	7.3	0.36	44	2.8	0.19	3.3	0.23
Small intestine	38	2.8	0.21	3.4	0.24	34	2.3	0.19	2.7	0.21
Colon excl. rectum	394	29.8	0.69	34.8	0.79	405	25.8	0.60	29.9	0.68
Rectum & rectosigmoid	196	14.6	0.48	17.4	0.56	127	8.4	0.35	9.9	0.40
Anus, anal canal & anorectum	17	1.2	0.14	1.5	0.17	34	2.1	0.17	2.6	0.21
Liver	122	8.3	0.34	10.4	0.42	35	2.1	0.16	2.6	0.20
Gallbladder	9	0.7	0.10	0.8	0.12	16	1.0	0.11	1.1	0.13
Pancreas	166	12.1	0.43	14.4	0.50	164	10.1	0.36	11.8	0.42
Respiratory System	989	72.0	1.05	85.3	1.22	837	51.7	0.82	61.6	0.96
Larynx	72	5.2	0.28	6.3	0.33	15	1.0	0.12	1.2	0.14
Lung & bronchus	903	65.8	1.00	77.8	1.16	812	50.1	0.81	59.7	0.95
Bones & Joints	13	1.1	0.14	1.1	0.14	12	1.0	0.14	1.0	0.13
Soft Tissue (incl. heart)	58	4.4	0.27	5.1	0.30	42	3.0	0.22	3.3	0.24
Skin (excl. basal & sq.)	469	35.7	0.76	41.6	0.86	333	24.8	0.64	27.7	0.69
Melanomas of the skin	434	33.1	0.73	38.5	0.83	313	23.6	0.63	26.3	0.68
Breast (excl. <i>in situ</i>)	17	1.3	0.14	1.5	0.16	1,875	127.0	1.38	149.4	1.57
Female Genital System	-	-	-	-	-	714	48.7	0.86	57.5	0.98
Cervix uteri	-	-	-	-	-	81	7.1	0.37	7.5	0.38
Uterus Corpus	-	-	-	-	-	394	25.7	0.61	31.3	0.72
Uterus, NOS ¹	-	-	-	-	-	10	0.7	0.10	0.8	0.11
Ovary	-	-	-	-	-	159	10.8	0.40	12.7	0.46
Male Genital System	1,555	108.7	1.27	131.5	1.50	-	-	-	-	-
Prostate	1,470	100.8	1.20	123.5	1.45	-	-	-	-	-
Testis	71	6.9	0.37	6.8	0.36	-	-	-	-	-
Penis	11	0.8	0.11	1.0	0.13	-	-	-	-	-
Urinary System	851	63.1	0.99	74.4	1.15	352	22.5	0.56	26.3	0.64
Bladder (incl. <i>in situ</i>)	493	36.7	0.75	43.0	0.87	150	9.0	0.34	10.6	0.40
Kidney & renal pelvis	341	25.0	0.63	29.8	0.73	195	13.0	0.44	15.2	0.50
Ureter	11	0.8	0.12	0.9	0.13	6	0.3	0.06	0.4	0.07
Eye & Orbit	12	0.9	0.12	1.1	0.14	9	0.6	0.10	0.8	0.11
Brain & Other CNS ¹	99	7.9	0.37	8.8	0.40	76	5.7	0.31	6.2	0.32
Brain	93	7.4	0.35	8.2	0.38	71	5.3	0.29	5.7	0.31
Endocrine System	111	8.9	0.39	10.0	0.43	284	23.9	0.67	25.8	0.70
Thyroid gland	102	8.2	0.38	9.2	0.41	278	23.5	0.66	25.3	0.69
Lymphomas	357	27.4	0.67	31.5	0.75	270	17.9	0.51	20.4	0.57
Hodgkin Lymphoma	36	3.2	0.24	3.3	0.25	23	2.0	0.20	2.1	0.20
Non-Hodgkin Lymphoma	321	24.2	0.62	28.2	0.71	247	15.8	0.47	18.4	0.53
Multiple Myeloma	103	7.5	0.34	9.0	0.40	74	4.5	0.24	5.4	0.28
Leukemias	265	20.3	0.57	23.2	0.64	161	10.6	0.39	12.1	0.43
Acute lymphocytic	17	1.6	0.17	1.5	0.16	12	1.1	0.14	1.0	0.13
Chronic lymphocytic	115	8.3	0.36	10.0	0.42	63	3.9	0.23	4.7	0.27
Acute myeloid	71	5.5	0.30	6.3	0.34	49	3.2	0.22	3.6	0.24
Chronic myeloid	36	2.9	0.22	3.2	0.24	21	1.5	0.15	1.6	0.16
Other leukemias	25	2.0	0.18	2.3	0.20	16	1.0	0.12	1.2	0.13
Mesothelioma	15	1.1	0.13	1.3	0.15	6	0.4	0.07	0.5	0.09
Kaposi Sarcoma	1	0.1	0.04	0.1	0.05	-	-	-	-	-
Ill-defined & Unknown	292	21.7	0.58	25.5	0.67	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	106	8.4	0.38	9.5	0.41	216	15.2	0.49	17.3	0.54
Breast (<i>in situ</i>)	-	-	-	-	-	367	25.8	0.63	30.4	0.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kansas, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	368	517.7	13.05	627.9	15.39	329	411.4	10.39	480.3	11.95
Oral Cavity & Pharynx	9	12.4	1.97	14.7	2.29	6	6.8	1.30	8.2	1.55
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.5	0.87	2.8	0.94	1	1.6	0.60	2.1	0.79
Major salivary gland	-	-	-	-	-	2	2.7	0.84	3.0	0.93
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	81	116.7	6.29	142.3	7.47	60	75.8	4.47	90.2	5.23
Esophagus	6	7.5	1.55	9.6	1.90	1	1.6	0.61	2.0	0.77
Stomach	6	8.5	1.64	10.4	1.98	4	5.2	1.13	6.5	1.39
Small intestine	4	5.7	1.34	6.8	1.52	4	4.7	1.14	5.4	1.27
Colon excl. rectum	26	39.6	3.80	46.9	4.43	20	25.4	2.62	29.6	3.01
Rectum & rectosigmoid	9	13.2	2.07	15.9	2.46	8	9.7	1.61	11.4	1.87
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	14	17.6	2.24	22.9	2.82	7	6.9	1.20	9.4	1.63
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	12	19.3	2.72	23.2	3.21	13	17.7	2.22	20.4	2.52
Respiratory System	62	91.0	5.59	109.9	6.52	47	58.7	3.93	70.2	4.61
Larynx	4	5.2	1.18	7.0	1.55	1	1.5	0.61	1.8	0.74
Lung & bronchus	56	84.4	5.41	101.4	6.28	44	55.6	3.82	66.7	4.50
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.2	0.98	4.5	1.06	2	2.3	0.77	2.5	0.81
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	3.3	1.24	3.9	1.43	-	-	-	-	-
Breast (excl. <i>in situ</i>)	2	2.3	0.75	3.1	0.97	99	126.0	5.78	146.0	6.59
Female Genital System	-	-	-	-	-	33	41.0	3.28	47.7	3.74
Cervix uteri	-	-	-	-	-	6	7.0	1.35	7.6	1.46
Uterus Corpus	-	-	-	-	-	19	23.0	2.42	27.8	2.87
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	7.1	1.43	7.6	1.51
Male Genital System	120	161.2	7.05	201.8	8.52	-	-	-	-	-
Prostate	117	157.3	6.97	197.4	8.43	-	-	-	-	-
Testis	2	1.7	0.56	1.8	0.62	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	31	44.7	3.87	53.7	4.53	16	19.9	2.26	23.8	2.67
Bladder (incl. <i>in situ</i>)	13	21.0	2.82	25.0	3.28	5	6.5	1.35	7.4	1.52
Kidney & renal pelvis	18	23.3	2.63	28.1	3.09	11	12.8	1.77	15.8	2.15
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	4.2	0.95	4.3	1.03	3	3.4	0.93	3.3	0.94
Brain	4	4.0	0.94	4.2	1.02	2	2.8	0.83	2.7	0.86
Endocrine System	5	7.3	1.50	8.9	1.77	14	17.1	2.08	18.5	2.24
Thyroid gland	4	5.4	1.25	6.8	1.51	13	16.2	2.03	17.7	2.19
Lymphomas	13	16.0	2.18	17.9	2.44	12	14.8	1.93	17.3	2.23
Hodgkin Lymphoma	3	3.0	0.86	2.8	0.82	1	1.3	0.53	1.3	0.54
Non-Hodgkin Lymphoma	10	13.0	2.00	15.0	2.30	11	13.5	1.86	16.0	2.16
Multiple Myeloma	10	16.9	2.56	19.8	2.94	14	17.2	2.14	20.6	2.51
Leukemias	12	17.5	2.49	20.1	2.82	11	14.2	1.96	15.4	2.13
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	5	8.8	1.88	10.1	2.11	3	3.9	1.05	4.3	1.16
Acute myeloid	3	4.1	1.18	4.8	1.37	4	4.7	1.14	5.1	1.23
Chronic myeloid	2	2.9	0.97	3.3	1.07	3	3.4	0.96	3.9	1.09
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	17.5	2.59	20.5	2.97	9	11.3	1.70	13.6	2.01
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	11.4	1.98	12.9	2.25	11	13.4	1.87	16.0	2.19
Breast (<i>in situ</i>)	-	-	-	-	-	23	28.4	2.71	34.0	3.18

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	4,404,817	4,414,483	4,425,999	4,438,229	4,453,874
White	3,940,990	3,944,571	3,948,390	3,952,527	3,959,505
Black	383,204	386,772	390,633	395,012	400,902
American Indian/Alaskan Native (AI/AN)	13,371	13,612	13,691	14,005	14,008
Asian/Pacific Islander (API)	67,252	69,528	73,285	76,685	79,459


All Races Population 2013-2017: 22,137,402
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	147,845	150,435	153,953	158,783	164,968
Non-Hispanic White	3,810,152	3,811,627	3,812,399	3,812,257	3,813,717
Non-Hispanic Black	373,013	376,381	379,894	383,983	389,284

Hispanic/Latino Population, Census 2010: 132,836
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

KENTUCKY CANCER REGISTRY

Initial Operation: 1991
 Population-based Data Available: 1991
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.0	110.1	110.2	110.0	109.9
Missing Race	0.8	1.1	1.8	1.7	1.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	1.0	0.9	0.8	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.9	Prostate	96.9
Oral Cavity & Pharynx	97.8	Testis	99.3
Esophagus	95.2	Bladder (incl. <i>in situ</i>)	97.9
Stomach	96.6	Kidney & Renal Pelvis	89.4
Colon & Rectum	96.7	Brain & Other CNS ¹	80.7
Liver	47.8	Thyroid	99.4
Pancreas	80.3	Hodgkin Lymphoma	99.0
Lung & Bronchus	86.1	Non-Hodgkin Lymphoma	96.4
Melanomas of the Skin	99.4	Multiple Myeloma	83.3
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	86.6
Cervix uteri	98.2	Brain & Other CNS ¹ <i>non-malig</i>	34.8
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	90.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,939	574.4	2.25	682.6	2.63	13,374	483.3	1.92	563.9	2.20
Oral Cavity & Pharynx	549	21.5	0.42	26.5	0.51	216	7.7	0.24	9.1	0.28
Lip	42	1.8	0.13	2.1	0.15	14	0.5	0.06	0.6	0.07
Tongue	157	6.0	0.22	7.5	0.27	62	2.3	0.13	2.7	0.15
Major salivary gland	36	1.6	0.12	1.9	0.14	28	1.0	0.09	1.2	0.10
Floor of mouth	22	0.9	0.09	1.1	0.10	10	0.4	0.05	0.4	0.06
Gum & other mouth	53	2.2	0.14	2.6	0.16	41	1.5	0.10	1.7	0.12
Nasopharynx	19	0.8	0.08	0.9	0.09	7	0.3	0.05	0.3	0.05
Oropharynx	25	1.0	0.09	1.2	0.11	6	0.2	0.04	0.3	0.05
Hypopharynx	29	1.1	0.09	1.4	0.11	7	0.3	0.04	0.3	0.05
Digestive System	2,721	112.1	0.99	134.1	1.17	2,148	75.5	0.75	89.1	0.87
Esophagus	228	9.0	0.28	10.9	0.33	54	1.9	0.12	2.2	0.14
Stomach	210	8.8	0.28	10.5	0.33	141	4.9	0.19	5.8	0.22
Small intestine	83	3.5	0.18	4.1	0.20	80	2.9	0.15	3.4	0.17
Colon excl. rectum	906	38.2	0.59	45.2	0.68	879	31.1	0.48	36.3	0.55
Rectum & rectosigmoid	443	18.2	0.40	21.7	0.47	291	10.4	0.28	12.5	0.33
Anus, anal canal & anorectum	42	1.8	0.13	2.1	0.14	86	3.0	0.15	3.7	0.18
Liver	301	11.5	0.31	14.4	0.38	99	3.4	0.16	4.1	0.18
Gallbladder	21	0.9	0.09	1.0	0.10	39	1.3	0.10	1.6	0.11
Pancreas	370	15.3	0.37	18.4	0.44	349	12.0	0.29	14.2	0.34
Respiratory System	2,897	119.0	1.02	142.1	1.20	2,372	80.8	0.75	96.8	0.89
Larynx	218	8.7	0.27	10.5	0.32	75	2.6	0.14	3.2	0.17
Lung & bronchus	2,647	109.0	0.98	130.0	1.15	2,277	77.5	0.74	92.7	0.87
Bones & Joints	27	1.2	0.11	1.3	0.11	23	0.9	0.09	1.0	0.09
Soft Tissue (incl. heart)	91	3.9	0.19	4.5	0.21	59	2.3	0.14	2.5	0.15
Skin (excl. basal & sq.)	838	36.2	0.58	42.0	0.66	626	24.4	0.45	27.4	0.49
Melanomas of the skin	782	33.7	0.56	39.1	0.64	590	23.1	0.44	25.9	0.48
Breast (excl. <i>in situ</i>)	23	0.9	0.09	1.1	0.11	3,491	126.7	0.99	149.0	1.14
Female Genital System	-	-	-	-	-	1,464	54.4	0.66	63.3	0.75
Cervix uteri	-	-	-	-	-	217	9.6	0.30	10.1	0.31
Uterus Corpus	-	-	-	-	-	756	26.8	0.45	32.3	0.53
Uterus, NOS ¹	-	-	-	-	-	17	0.6	0.07	0.7	0.08
Ovary	-	-	-	-	-	273	10.1	0.28	11.7	0.32
Male Genital System	2,878	111.4	0.96	136.2	1.15	-	-	-	-	-
Prostate	2,721	104.1	0.92	128.6	1.12	-	-	-	-	-
Testis	119	5.7	0.24	5.7	0.23	-	-	-	-	-
Penis	35	1.5	0.12	1.8	0.14	-	-	-	-	-
Urinary System	1,599	67.9	0.78	79.9	0.91	726	26.0	0.44	30.2	0.51
Bladder (incl. <i>in situ</i>)	892	38.8	0.60	45.6	0.70	288	9.9	0.27	11.6	0.31
Kidney & renal pelvis	672	27.6	0.49	32.5	0.57	420	15.4	0.35	17.9	0.39
Ureter	20	0.9	0.09	1.0	0.10	14	0.5	0.06	0.6	0.07
Eye & Orbit	36	1.5	0.11	1.7	0.13	24	0.9	0.08	1.0	0.09
Brain & Other CNS ¹	202	8.8	0.28	9.6	0.31	165	6.4	0.23	7.0	0.24
Brain	189	8.2	0.27	9.0	0.30	152	5.8	0.22	6.4	0.23
Endocrine System	212	9.0	0.28	10.1	0.31	559	23.6	0.46	25.4	0.48
Thyroid gland	194	8.2	0.27	9.3	0.30	546	23.1	0.46	24.9	0.48
Lymphomas	638	27.5	0.50	31.5	0.57	520	18.8	0.38	21.7	0.43
Hodgkin Lymphoma	66	3.0	0.17	3.2	0.17	49	2.2	0.14	2.3	0.15
Non-Hodgkin Lymphoma	572	24.5	0.47	28.3	0.54	471	16.6	0.35	19.4	0.40
Multiple Myeloma	221	9.4	0.29	11.1	0.34	155	5.4	0.20	6.3	0.23
Leukemias	465	20.2	0.43	23.0	0.48	349	12.7	0.31	14.5	0.35
Acute lymphocytic	36	1.7	0.13	1.5	0.12	29	1.3	0.11	1.2	0.10
Chronic lymphocytic	185	7.9	0.27	9.3	0.31	125	4.2	0.17	5.1	0.20
Acute myeloid	128	5.5	0.23	6.3	0.25	106	4.0	0.18	4.5	0.20
Chronic myeloid	70	3.1	0.17	3.5	0.19	52	2.0	0.13	2.2	0.14
Other leukemias	46	2.0	0.14	2.3	0.16	37	1.3	0.10	1.5	0.11
Mesothelioma	28	1.3	0.11	1.5	0.13	8	0.3	0.04	0.3	0.05
Kaposi Sarcoma	6	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	507	22.4	0.46	26.2	0.53	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	242	10.6	0.31	11.9	0.35	520	19.7	0.40	22.4	0.44
Breast (<i>in situ</i>)	3	0.1	0.03	0.2	0.04	717	26.1	0.45	31.0	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	12,767	568.2	2.32	673.8	2.71	12,374	486.2	2.02	567.0	2.30
Oral Cavity & Pharynx	514	21.8	0.44	26.8	0.53	203	7.8	0.25	9.3	0.30
Lip	39	1.8	0.13	2.1	0.15	13	0.5	0.06	0.6	0.07
Tongue	147	6.1	0.23	7.6	0.28	59	2.3	0.14	2.8	0.16
Major salivary gland	34	1.6	0.13	1.9	0.15	27	1.1	0.10	1.2	0.11
Floor of mouth	20	0.9	0.09	1.1	0.11	10	0.4	0.05	0.4	0.07
Gum & other mouth	50	2.2	0.14	2.6	0.17	38	1.5	0.11	1.7	0.12
Nasopharynx	17	0.7	0.08	0.9	0.09	6	0.3	0.05	0.3	0.05
Oropharynx	25	1.0	0.09	1.3	0.12	6	0.2	0.04	0.3	0.05
Hypopharynx	27	1.1	0.09	1.3	0.12	6	0.3	0.05	0.3	0.05
Digestive System	2,504	111.4	1.03	133.0	1.21	1,953	74.4	0.77	87.7	0.90
Esophagus	217	9.3	0.29	11.2	0.34	47	1.8	0.12	2.1	0.14
Stomach	192	8.7	0.29	10.3	0.34	124	4.7	0.19	5.5	0.22
Small intestine	75	3.4	0.18	4.0	0.21	68	2.8	0.15	3.2	0.17
Colon excl. rectum	834	37.9	0.61	44.8	0.70	806	30.9	0.50	36.0	0.57
Rectum & rectosigmoid	406	18.1	0.42	21.5	0.48	265	10.3	0.29	12.3	0.34
Anus, anal canal & anorectum	38	1.7	0.13	2.0	0.15	80	3.1	0.16	3.7	0.19
Liver	270	11.2	0.31	14.0	0.38	89	3.3	0.16	4.0	0.19
Gallbladder	20	0.9	0.09	1.0	0.11	34	1.3	0.10	1.5	0.12
Pancreas	342	15.3	0.38	18.3	0.45	318	11.8	0.30	14.0	0.35
Respiratory System	2,733	120.2	1.06	143.6	1.25	2,223	81.7	0.79	97.9	0.94
Larynx	203	8.7	0.28	10.6	0.34	69	2.6	0.14	3.2	0.17
Lung & bronchus	2,501	110.2	1.02	131.5	1.19	2,136	78.4	0.77	93.9	0.91
Bones & Joints	25	1.2	0.11	1.3	0.12	21	1.0	0.10	1.0	0.10
Soft Tissue (incl. heart)	84	4.0	0.20	4.5	0.22	53	2.2	0.14	2.4	0.15
Skin (excl. basal & sq.)	812	37.8	0.61	43.9	0.70	605	25.9	0.49	29.0	0.53
Melanomas of the skin	759	35.3	0.59	40.9	0.67	573	24.6	0.48	27.6	0.52
Breast (excl. <i>in situ</i>)	22	1.0	0.10	1.2	0.11	3,221	127.0	1.04	149.4	1.19
Female Genital System	-	-	-	-	-	1,353	55.0	0.70	64.0	0.79
Cervix uteri	-	-	-	-	-	196	9.6	0.32	10.1	0.33
Uterus Corpus	-	-	-	-	-	699	27.1	0.48	32.7	0.56
Uterus, NOS ¹	-	-	-	-	-	14	0.5	0.07	0.6	0.08
Ovary	-	-	-	-	-	255	10.2	0.30	11.9	0.34
Male Genital System	2,405	100.8	0.95	122.7	1.13	-	-	-	-	-
Prostate	2,255	92.9	0.90	114.6	1.09	-	-	-	-	-
Testis	114	6.2	0.26	6.2	0.26	-	-	-	-	-
Penis	34	1.5	0.12	1.9	0.15	-	-	-	-	-
Urinary System	1,507	68.8	0.82	80.9	0.95	673	26.2	0.46	30.4	0.53
Bladder (incl. <i>in situ</i>)	857	39.8	0.63	46.8	0.73	274	10.2	0.28	12.0	0.33
Kidney & renal pelvis	618	27.5	0.51	32.4	0.59	381	15.3	0.36	17.7	0.41
Ureter	19	0.9	0.09	1.0	0.11	13	0.5	0.06	0.6	0.07
Eye & Orbit	35	1.6	0.12	1.8	0.14	24	1.0	0.09	1.1	0.10
Brain & Other CNS ¹	192	9.2	0.30	10.0	0.33	155	6.6	0.25	7.2	0.26
Brain	180	8.5	0.29	9.4	0.32	143	6.0	0.23	6.6	0.25
Endocrine System	200	9.3	0.30	10.5	0.33	508	23.9	0.49	25.6	0.51
Thyroid gland	185	8.6	0.29	9.7	0.32	496	23.3	0.49	25.1	0.51
Lymphomas	599	27.9	0.53	32.0	0.59	489	19.1	0.40	22.2	0.45
Hodgkin Lymphoma	59	3.0	0.18	3.2	0.18	45	2.3	0.15	2.3	0.16
Non-Hodgkin Lymphoma	540	24.8	0.49	28.8	0.56	444	16.9	0.37	19.8	0.42
Multiple Myeloma	193	8.9	0.29	10.4	0.34	132	4.9	0.20	5.8	0.23
Leukemias	432	20.2	0.45	23.1	0.50	320	12.7	0.33	14.4	0.36
Acute lymphocytic	33	1.8	0.14	1.6	0.12	27	1.4	0.12	1.3	0.11
Chronic lymphocytic	171	7.7	0.27	9.2	0.32	113	4.1	0.18	5.0	0.21
Acute myeloid	119	5.5	0.23	6.3	0.26	99	4.0	0.18	4.5	0.20
Chronic myeloid	65	3.1	0.18	3.5	0.20	46	1.9	0.13	2.2	0.14
Other leukemias	44	2.1	0.15	2.4	0.17	34	1.3	0.10	1.5	0.12
Mesothelioma	27	1.3	0.12	1.5	0.13	8	0.3	0.05	0.3	0.05
Kaposi Sarcoma	4	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	226	10.8	0.33	12.1	0.37	472	19.5	0.42	22.2	0.46
Breast (<i>in situ</i>)	3	0.1	0.03	0.2	0.04	651	25.9	0.47	30.7	0.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	797	537.4	9.28	648.6	10.89	824	447.1	7.17	526.3	8.27
Oral Cavity & Pharynx	24	14.6	1.43	18.1	1.72	7	3.9	0.66	4.5	0.75
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	3.9	0.75	4.9	0.91	1	0.7	0.28	0.8	0.32
Major salivary gland	2	1.3	0.42	1.6	0.50	1	0.6	0.27	0.7	0.30
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.7	0.54	2.0	0.61	1	0.7	0.29	0.9	0.33
Nasopharynx	2	0.8	0.27	1.0	0.35	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	1.3	0.41	1.7	0.52	-	-	-	-	-
Digestive System	182	121.3	4.40	148.3	5.22	166	88.7	3.17	106.7	3.74
Esophagus	9	5.8	0.91	7.4	1.13	6	2.8	0.54	3.6	0.67
Stomach	15	11.0	1.40	13.3	1.64	14	7.3	0.91	8.7	1.06
Small intestine	7	5.0	0.92	6.0	1.06	10	4.9	0.74	6.1	0.88
Colon excl. rectum	61	43.6	2.75	52.3	3.21	65	35.1	2.01	42.1	2.35
Rectum & rectosigmoid	25	15.8	1.52	19.3	1.80	18	9.3	1.00	11.3	1.20
Anus, anal canal & anorectum	3	2.2	0.57	2.4	0.63	4	2.1	0.47	2.6	0.57
Liver	27	15.3	1.42	19.9	1.78	8	4.0	0.64	5.0	0.79
Gallbladder	1	1.0	0.41	1.2	0.49	4	2.0	0.48	2.5	0.57
Pancreas	26	16.6	1.60	20.6	1.91	29	15.9	1.37	18.9	1.59
Respiratory System	152	112.2	4.44	134.2	5.14	138	76.6	3.01	91.2	3.51
Larynx	13	9.0	1.20	11.1	1.44	6	3.4	0.62	4.2	0.74
Lung & bronchus	137	101.8	4.24	121.6	4.91	131	73.1	2.95	87.0	3.43
Bones & Joints	2	1.4	0.48	1.6	0.53	-	-	-	-	-
Soft Tissue (incl. heart)	5	3.4	0.71	3.9	0.78	4	2.3	0.51	2.7	0.58
Skin (excl. basal & sq.)	4	2.8	0.66	3.2	0.75	4	2.1	0.48	2.3	0.53
Melanomas of the skin	2	1.8	0.57	2.1	0.66	2	1.2	0.38	1.3	0.42
Breast (excl. <i>in situ</i>)	2	0.9	0.36	1.2	0.46	233	125.0	3.76	147.3	4.34
Female Genital System	-	-	-	-	-	89	47.7	2.33	56.1	2.67
Cervix uteri	-	-	-	-	-	15	8.6	1.00	9.4	1.07
Uterus Corpus	-	-	-	-	-	48	25.1	1.68	30.3	1.97
Uterus, NOS ¹	-	-	-	-	-	3	1.6	0.43	1.9	0.50
Ovary	-	-	-	-	-	14	8.0	0.96	9.2	1.10
Male Genital System	229	146.9	4.71	182.8	5.66	-	-	-	-	-
Prostate	226	144.9	4.68	180.7	5.63	-	-	-	-	-
Testis	3	1.4	0.39	1.3	0.39	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	77	52.4	2.91	62.2	3.37	48	26.0	1.74	30.8	2.01
Bladder (incl. <i>in situ</i>)	26	19.6	1.87	23.4	2.17	10	5.6	0.82	6.6	0.95
Kidney & renal pelvis	49	31.2	2.15	37.1	2.51	37	19.8	1.51	23.5	1.75
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.5	0.75	4.8	0.83	9	4.7	0.73	4.9	0.77
Brain	8	4.2	0.73	4.5	0.80	8	4.1	0.68	4.4	0.74
Endocrine System	8	4.5	0.77	5.1	0.88	37	19.8	1.49	22.4	1.65
Thyroid gland	6	3.4	0.66	3.9	0.75	37	19.5	1.48	22.0	1.63
Lymphomas	32	21.6	1.84	24.4	2.06	23	12.7	1.22	14.3	1.36
Hodgkin Lymphoma	7	3.5	0.63	3.6	0.65	4	2.0	0.48	2.0	0.48
Non-Hodgkin Lymphoma	26	18.1	1.73	20.7	1.96	-	-	-	-	-
Multiple Myeloma	24	17.3	1.71	20.4	1.96	20	11.0	1.15	12.7	1.29
Leukemias	22	14.5	1.51	16.4	1.70	19	10.8	1.13	12.3	1.27
Acute lymphocytic	2	1.0	0.39	1.0	0.41	-	-	-	-	-
Chronic lymphocytic	7	5.8	1.03	6.8	1.18	7	3.6	0.62	4.5	0.76
Acute myeloid	8	4.7	0.82	5.2	0.92	6	3.3	0.65	3.5	0.67
Chronic myeloid	3	1.9	0.49	2.2	0.55	4	2.4	0.52	2.7	0.59
Other leukemias	2	1.0	0.37	1.2	0.43	2	1.3	0.42	1.3	0.44
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	0.7	0.28	0.6	0.26	-	-	-	-	-
Ill-defined & Unknown	23	17.5	1.78	20.4	2.05	26	15.2	1.37	17.2	1.52
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	12	8.1	1.14	9.2	1.29	40	21.7	1.57	25.0	1.77
Breast (<i>in situ</i>)	-	-	-	-	-	57	30.3	1.84	36.0	2.14

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	45	222.3	16.79	258.3	19.37	76	269.4	14.85	307.5	17.03
Oral Cavity & Pharynx	2	7.9	2.65	9.4	3.10	1	5.5	2.28	6.3	2.65
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	15	71.8	9.59	86.6	11.40	13	55.3	7.25	63.3	8.22
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	6.0	2.48	6.8	2.77	2	6.9	2.60	8.2	3.04
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	15.4	4.43	18.6	5.32	4	16.7	4.07	18.3	4.49
Rectum & rectosigmoid	4	20.4	5.41	24.0	6.37	3	9.4	2.76	11.2	3.24
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	17.2	4.60	21.7	5.68	1	5.8	2.47	6.7	2.82
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	7.8	2.95	9.2	3.37	2	7.0	2.47	8.0	2.83
Respiratory System	5	26.2	5.38	29.7	5.98	8	34.6	5.92	39.7	6.65
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	24.6	5.14	28.1	5.76	7	34.0	5.89	38.8	6.60
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	23	73.2	7.20	84.1	8.40
Female Genital System	-	-	-	-	-	10	35.3	5.30	41.3	6.21
Cervix uteri	-	-	-	-	-	2	5.4	1.89	5.7	2.00
Uterus Corpus	-	-	-	-	-	5	15.1	3.32	18.2	3.99
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	10.3	3.08	11.8	3.55
Male Genital System	7	37.4	6.90	44.0	7.99	-	-	-	-	-
Prostate	6	33.7	6.71	40.1	7.80	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	17.1	4.68	19.0	5.16	2	7.1	2.29	8.2	2.60
Bladder (incl. <i>in situ</i>)	2	9.6	3.57	11.3	4.08	-	-	-	-	-
Kidney & renal pelvis	1	7.4	3.03	7.7	3.16	1	4.7	1.94	4.9	2.02
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	2	8.2	3.05	9.0	3.46	7	19.8	3.31	21.9	3.78
Thyroid gland	2	7.7	3.00	8.6	3.43	7	19.5	3.29	21.5	3.76
Lymphomas	2	10.8	3.58	12.2	4.09	3	10.7	2.93	13.1	3.56
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	10.2	3.54	11.8	4.07	3	10.7	2.93	13.1	3.56
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	3	17.6	4.90	19.3	5.49	2	7.3	2.20	7.6	2.36
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	7.4	3.58	8.4	4.18	1	3.7	1.55	4.4	1.88
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	11.2	4.36	12.7	4.93	2	7.3	2.57	7.9	2.94
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	8.9	2.68	10.0	3.06	5	15.7	3.37	17.8	3.92
Breast (<i>in situ</i>)	-	-	-	-	-	6	19.6	3.60	24.4	4.49

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	95	258.8	14.11	307.3	16.47	94	249.0	12.63	290.0	14.83
Oral Cavity & Pharynx	2	5.5	2.10	6.5	2.45	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	26	75.1	7.80	89.7	9.10	16	47.7	5.78	56.0	6.70
Esophagus	1	4.5	2.14	4.7	2.28	-	-	-	-	-
Stomach	3	6.8	2.26	8.1	2.74	2	4.7	1.84	5.0	1.98
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	21.8	4.12	26.6	4.89	6	19.0	3.69	22.4	4.26
Rectum & rectosigmoid	4	8.6	2.56	9.6	2.79	2	6.0	1.80	7.5	2.29
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	12.4	3.22	15.6	3.83	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	11.2	3.07	13.6	3.58	2	7.3	2.36	7.9	2.55
Respiratory System	11	36.1	5.38	44.2	6.41	7	24.8	4.49	29.3	5.18
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	10	32.4	5.14	39.5	6.06	6	23.7	4.42	28.0	5.09
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.4	0.77	2.3	0.79	-	-	-	-	-
Skin (excl. basal & sq.)	2	4.1	1.67	4.9	1.91	1	2.7	1.15	3.1	1.45
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	29	76.4	6.84	90.0	8.15
Female Genital System	-	-	-	-	-	16	36.5	4.38	42.6	5.27
Cervix uteri	-	-	-	-	-	4	6.9	1.72	7.3	1.95
Uterus Corpus	-	-	-	-	-	8	17.9	3.09	21.6	3.85
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	8.3	2.29	9.6	2.64
Male Genital System	20	59.2	6.79	71.6	7.93	-	-	-	-	-
Prostate	17	55.0	6.63	67.2	7.75	-	-	-	-	-
Testis	3	2.9	0.76	2.9	0.79	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	11	27.7	4.41	33.0	5.19	4	10.7	2.70	12.1	3.08
Bladder (incl. <i>in situ</i>)	4	13.8	3.42	16.8	4.02	1	4.9	2.07	5.5	2.28
Kidney & renal pelvis	6	11.9	2.47	14.0	2.96	2	4.9	1.47	5.6	1.81
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	3.1	1.09	3.3	1.32	2	2.4	0.89	2.2	0.85
Brain	2	2.4	1.01	2.6	1.25	1	2.3	0.88	2.1	0.84
Endocrine System	2	3.6	1.17	4.5	1.54	5	8.5	1.80	9.4	2.15
Thyroid gland	2	3.5	1.15	4.3	1.53	5	8.2	1.78	9.2	2.14
Lymphomas	6	13.6	3.21	14.9	3.61	4	11.6	2.81	13.8	3.34
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	5.1	1.71	6.3	2.15	1	3.5	1.44	4.6	1.93
Leukemias	5	11.7	2.98	13.2	3.42	5	9.8	2.41	10.7	2.76
Acute lymphocytic	-	-	-	-	-	2	3.0	1.14	2.7	1.15
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	3	7.8	2.62	9.1	3.01	1	3.8	1.59	4.3	1.80
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	10.3	3.19	11.6	3.57	4	12.5	3.22	13.8	3.56
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	5	9.0	2.39	10.1	2.75	4	8.2	1.92	9.7	2.41
Breast (<i>in situ</i>)	-	-	-	-	-	5	11.6	2.57	13.5	3.04

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

KENTUCKY

II-208 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	12,682	573.0	2.35	679.3	2.74	12,287	489.7	2.04	570.8	2.33
Oral Cavity & Pharynx	513	22.1	0.45	27.2	0.54	203	8.0	0.26	9.4	0.30
Lip	39	1.8	0.13	2.2	0.16	13	0.5	0.06	0.6	0.07
Tongue	147	6.2	0.23	7.7	0.29	59	2.4	0.14	2.8	0.16
Major salivary gland	34	1.7	0.13	1.9	0.15	27	1.1	0.10	1.2	0.11
Floor of mouth	20	0.9	0.09	1.1	0.11	10	0.4	0.05	0.5	0.07
Gum & other mouth	49	2.2	0.14	2.6	0.17	38	1.5	0.11	1.7	0.13
Nasopharynx	17	0.8	0.09	0.9	0.10	6	0.3	0.05	0.3	0.06
Oropharynx	25	1.0	0.10	1.3	0.12	6	0.2	0.04	0.3	0.05
Hypopharynx	26	1.1	0.10	1.3	0.12	6	0.3	0.05	0.3	0.05
Digestive System	2,481	112.0	1.04	133.8	1.22	1,939	74.7	0.78	88.1	0.90
Esophagus	216	9.3	0.29	11.3	0.35	47	1.8	0.12	2.1	0.14
Stomach	190	8.7	0.29	10.3	0.34	123	4.7	0.19	5.5	0.22
Small intestine	74	3.4	0.18	4.0	0.21	68	2.8	0.16	3.2	0.18
Colon excl. rectum	828	38.2	0.61	45.1	0.71	800	31.0	0.50	36.2	0.58
Rectum & rectosigmoid	403	18.3	0.42	21.7	0.49	263	10.4	0.30	12.4	0.35
Anus, anal canal & anorectum	38	1.8	0.13	2.1	0.15	80	3.1	0.16	3.8	0.19
Liver	266	11.2	0.32	14.0	0.39	89	3.4	0.16	4.0	0.19
Gallbladder	20	0.9	0.09	1.0	0.11	34	1.3	0.10	1.5	0.12
Pancreas	339	15.3	0.38	18.4	0.45	315	11.8	0.30	14.0	0.36
Respiratory System	2,723	121.3	1.07	144.9	1.26	2,217	82.4	0.80	98.7	0.94
Larynx	202	8.8	0.29	10.7	0.34	68	2.6	0.14	3.2	0.18
Lung & bronchus	2,492	111.2	1.03	132.7	1.21	2,131	79.0	0.78	94.7	0.92
Bones & Joints	25	1.3	0.12	1.3	0.12	21	1.0	0.10	1.0	0.10
Soft Tissue (incl. heart)	82	4.0	0.20	4.5	0.22	52	2.3	0.15	2.5	0.15
Skin (excl. basal & sq.)	810	38.4	0.62	44.5	0.71	604	26.3	0.50	29.5	0.54
Melanomas of the skin	758	35.9	0.60	41.6	0.69	572	25.1	0.49	28.1	0.53
Breast (excl. <i>in situ</i>)	22	1.0	0.10	1.2	0.11	3,194	127.8	1.05	150.3	1.20
Female Genital System	-	-	-	-	-	1,338	55.3	0.70	64.2	0.79
Cervix uteri	-	-	-	-	-	192	9.7	0.32	10.2	0.33
Uterus Corpus	-	-	-	-	-	691	27.2	0.48	32.8	0.56
Uterus, NOS ¹	-	-	-	-	-	14	0.5	0.07	0.6	0.08
Ovary	-	-	-	-	-	252	10.3	0.30	11.9	0.34
Male Genital System	2,387	101.5	0.96	123.5	1.14	-	-	-	-	-
Prostate	2,240	93.5	0.91	115.2	1.10	-	-	-	-	-
Testis	112	6.4	0.27	6.3	0.27	-	-	-	-	-
Penis	34	1.6	0.12	1.9	0.15	-	-	-	-	-
Urinary System	1,498	69.4	0.83	81.5	0.96	669	26.3	0.47	30.6	0.53
Bladder (incl. <i>in situ</i>)	854	40.1	0.63	47.2	0.74	273	10.3	0.28	12.1	0.33
Kidney & renal pelvis	612	27.8	0.52	32.7	0.60	379	15.5	0.37	17.8	0.41
Ureter	18	0.9	0.09	1.0	0.11	13	0.5	0.06	0.6	0.07
Eye & Orbit	35	1.6	0.12	1.8	0.14	24	1.0	0.09	1.1	0.10
Brain & Other CNS ¹	190	9.3	0.31	10.2	0.33	153	6.7	0.25	7.3	0.27
Brain	178	8.7	0.30	9.5	0.32	142	6.1	0.24	6.7	0.25
Endocrine System	198	9.5	0.31	10.6	0.34	503	24.2	0.50	26.0	0.52
Thyroid gland	183	8.7	0.30	9.8	0.33	492	23.7	0.50	25.5	0.52
Lymphomas	593	28.1	0.53	32.2	0.60	486	19.3	0.40	22.3	0.46
Hodgkin Lymphoma	58	3.1	0.19	3.2	0.19	45	2.3	0.16	2.4	0.16
Non-Hodgkin Lymphoma	535	25.0	0.50	29.0	0.57	440	16.9	0.37	19.9	0.43
Multiple Myeloma	191	8.9	0.30	10.4	0.34	131	4.9	0.20	5.8	0.23
Leukemias	428	20.4	0.46	23.2	0.51	315	12.7	0.33	14.4	0.37
Acute lymphocytic	33	1.8	0.14	1.6	0.13	25	1.3	0.12	1.2	0.11
Chronic lymphocytic	170	7.8	0.28	9.3	0.32	113	4.2	0.18	5.0	0.21
Acute myeloid	116	5.5	0.23	6.3	0.26	97	4.0	0.19	4.5	0.21
Chronic myeloid	65	3.1	0.18	3.5	0.20	46	1.9	0.13	2.2	0.15
Other leukemias	44	2.1	0.15	2.5	0.17	34	1.3	0.10	1.5	0.12
Mesothelioma	26	1.3	0.12	1.5	0.13	8	0.3	0.05	0.3	0.05
Kaposi Sarcoma	4	0.2	0.05	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	475	22.7	0.48	26.6	0.56	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	222	10.8	0.33	12.1	0.37	468	19.7	0.42	22.3	0.47
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.04	647	26.1	0.48	31.0	0.55

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Kentucky, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	795	542.5	9.38	654.8	11.00	822	451.0	7.25	530.7	8.34
Oral Cavity & Pharynx	24	14.8	1.45	18.3	1.74	7	4.0	0.67	4.6	0.76
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	3.9	0.76	5.0	0.92	1	0.7	0.29	0.8	0.32
Major salivary gland	2	1.3	0.43	1.6	0.50	1	0.7	0.27	0.7	0.30
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.7	0.54	2.0	0.62	1	0.8	0.29	0.9	0.34
Nasopharynx	2	0.8	0.28	1.0	0.36	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	1.3	0.42	1.8	0.53	-	-	-	-	-
Digestive System	181	122.5	4.44	149.8	5.27	166	89.6	3.21	107.8	3.77
Esophagus	9	5.7	0.91	7.3	1.14	6	2.8	0.54	3.6	0.67
Stomach	15	11.1	1.41	13.4	1.66	14	7.4	0.92	8.8	1.07
Small intestine	7	5.1	0.93	6.1	1.07	10	5.0	0.74	6.2	0.89
Colon excl. rectum	60	44.0	2.78	52.8	3.24	65	35.5	2.03	42.5	2.38
Rectum & rectosigmoid	25	16.1	1.54	19.6	1.83	18	9.4	1.01	11.5	1.22
Anus, anal canal & anorectum	3	2.3	0.59	2.5	0.64	4	2.1	0.48	2.6	0.58
Liver	27	15.5	1.44	20.1	1.80	8	4.0	0.65	5.1	0.80
Gallbladder	1	1.0	0.41	1.2	0.50	4	2.0	0.48	2.5	0.58
Pancreas	25	16.7	1.61	20.7	1.93	29	16.0	1.38	19.0	1.61
Respiratory System	152	113.2	4.48	135.4	5.19	137	76.9	3.04	91.7	3.53
Larynx	13	9.1	1.22	11.2	1.45	6	3.4	0.62	4.2	0.75
Lung & bronchus	137	102.8	4.28	122.6	4.96	130	73.4	2.97	87.3	3.45
Bones & Joints	2	1.5	0.49	1.6	0.54	-	-	-	-	-
Soft Tissue (incl. heart)	5	3.5	0.72	3.9	0.79	4	2.4	0.51	2.7	0.59
Skin (excl. basal & sq.)	4	2.8	0.67	3.2	0.76	4	2.0	0.48	2.2	0.52
Melanomas of the skin	2	1.8	0.57	2.1	0.66	2	1.1	0.36	1.2	0.40
Breast (excl. <i>in situ</i>)	2	1.0	0.37	1.3	0.47	232	125.9	3.80	148.4	4.38
Female Genital System	-	-	-	-	-	89	48.3	2.36	56.8	2.71
Cervix uteri	-	-	-	-	-	15	8.7	1.02	9.5	1.09
Uterus Corpus	-	-	-	-	-	48	25.4	1.70	30.7	1.99
Uterus, NOS ¹	-	-	-	-	-	3	1.7	0.44	1.9	0.50
Ovary	-	-	-	-	-	14	8.1	0.98	9.3	1.11
Male Genital System	229	148.4	4.75	184.6	5.71	-	-	-	-	-
Prostate	225	146.3	4.73	182.5	5.68	-	-	-	-	-
Testis	3	1.4	0.40	1.4	0.40	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	76	52.6	2.93	62.5	3.40	48	26.3	1.76	31.1	2.03
Bladder (incl. <i>in situ</i>)	26	19.7	1.89	23.5	2.18	10	5.7	0.83	6.7	0.95
Kidney & renal pelvis	49	31.3	2.17	37.2	2.53	37	20.0	1.53	23.8	1.77
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.6	0.77	4.9	0.84	9	4.8	0.74	5.0	0.78
Brain	8	4.3	0.75	4.6	0.81	8	4.2	0.69	4.4	0.74
Endocrine System	8	4.6	0.78	5.2	0.89	37	20.2	1.52	22.8	1.68
Thyroid gland	6	3.4	0.67	3.9	0.76	37	19.9	1.51	22.4	1.66
Lymphomas	32	22.0	1.87	24.8	2.09	22	12.7	1.23	14.3	1.37
Hodgkin Lymphoma	7	3.6	0.65	3.7	0.67	4	2.0	0.49	2.0	0.49
Non-Hodgkin Lymphoma	26	18.3	1.75	21.0	1.98	19	10.7	1.13	12.3	1.28
Multiple Myeloma	24	17.4	1.73	20.5	1.98	20	11.1	1.16	12.8	1.30
Leukemias	21	14.6	1.53	16.6	1.72	19	10.8	1.14	12.3	1.27
Acute lymphocytic	2	1.1	0.40	1.1	0.42	-	-	-	-	-
Chronic lymphocytic	7	5.9	1.04	6.9	1.19	7	3.5	0.62	4.4	0.75
Acute myeloid	8	4.8	0.84	5.3	0.93	6	3.4	0.66	3.5	0.68
Chronic myeloid	3	2.0	0.50	2.2	0.56	4	2.4	0.53	2.8	0.60
Other leukemias	2	1.0	0.36	1.2	0.43	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	1	0.7	0.29	0.6	0.27	-	-	-	-	-
Ill-defined & Unknown	23	17.5	1.79	20.5	2.06	26	15.4	1.38	17.4	1.54
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	12	8.1	1.14	9.2	1.30	40	22.1	1.60	25.3	1.79
Breast (<i>in situ</i>)	-	-	-	-	-	57	30.6	1.87	36.3	2.16

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


KENTUCKY

II-210 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	4,624,577	4,644,204	4,664,851	4,678,215	4,670,818
White	2,970,631	2,978,791	2,987,653	2,991,115	2,980,169
Black	1,529,112	1,538,606	1,547,407	1,555,065	1,557,486
American Indian/Alaskan Native (AI/AN)	38,151	38,815	39,172	39,454	39,864
Asian/Pacific Islander (API)	86,683	87,992	90,619	92,581	93,299


All Races Population 2013-2017: 23,282,665
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	216,632	223,299	230,159	236,359	239,884
Non-Hispanic White	2,786,348	2,789,359	2,792,880	2,791,368	2,777,739
Non-Hispanic Black	1,507,306	1,515,790	1,523,429	1,529,993	1,531,881

Hispanic/Latino Population, Census 2010: 192,560
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

LOUISIANA CANCER REGISTRY

Initial Operation: 1974
Population-based Data Available: 1988
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.1	102.3	103.3	103.9	104.9
Missing Race	0.1	0.0	0.0	0.1	0.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	1.0	1.1	1.0	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Prostate	98.0
Oral Cavity & Pharynx	98.3	Testis	99.8
Esophagus	96.9	Bladder (incl. <i>in situ</i>)	98.5
Stomach	98.3	Kidney & Renal Pelvis	91.1
Colon & Rectum	97.6	Brain & Other CNS ¹	85.8
Liver	55.3	Thyroid	99.8
Pancreas	84.5	Hodgkin Lymphoma	99.1
Lung & Bronchus	89.9	Non-Hodgkin Lymphoma	97.4
Melanomas of the Skin	99.8	Multiple Myeloma	85.6
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	90.8
Cervix uteri	97.9	Brain & Other CNS ¹ <i>non-malig</i>	45.0
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	92.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,494	556.1	2.21	665.7	2.60	11,867	425.6	1.79	498.1	2.06
Oral Cavity & Pharynx	515	20.5	0.42	25.1	0.50	196	7.0	0.23	8.3	0.27
Lip	31	1.3	0.11	1.6	0.13	7	0.2	0.04	0.3	0.05
Tongue	155	6.1	0.23	7.5	0.27	59	2.1	0.13	2.5	0.15
Major salivary gland	35	1.6	0.12	1.8	0.14	27	1.0	0.09	1.1	0.10
Floor of mouth	26	1.0	0.09	1.3	0.11	11	0.4	0.05	0.5	0.06
Gum & other mouth	56	2.3	0.14	2.8	0.17	41	1.5	0.10	1.7	0.12
Nasopharynx	23	0.9	0.09	1.1	0.10	6	0.2	0.04	0.3	0.05
Oropharynx	25	0.9	0.09	1.2	0.11	11	0.4	0.05	0.5	0.06
Hypopharynx	32	1.2	0.10	1.5	0.12	9	0.3	0.05	0.4	0.06
Digestive System	2,751	112.8	0.99	136.4	1.18	2,038	71.5	0.72	84.7	0.84
Esophagus	190	7.7	0.26	9.4	0.31	52	1.7	0.11	2.1	0.13
Stomach	240	10.1	0.30	12.1	0.35	135	4.8	0.19	5.6	0.22
Small intestine	87	3.6	0.18	4.3	0.21	85	3.0	0.15	3.5	0.17
Colon excl. rectum	850	35.8	0.57	42.7	0.66	797	28.1	0.46	33.1	0.53
Rectum & rectosigmoid	427	17.3	0.39	21.0	0.46	293	10.6	0.28	12.6	0.33
Anus, anal canal & anorectum	43	1.7	0.12	2.1	0.14	59	2.1	0.12	2.5	0.15
Liver	411	15.1	0.34	19.4	0.43	109	3.7	0.16	4.5	0.19
Gallbladder	21	0.9	0.09	1.1	0.11	46	1.5	0.10	1.9	0.12
Pancreas	384	16.3	0.39	19.5	0.45	361	12.5	0.30	14.8	0.35
Respiratory System	2,219	92.2	0.91	110.6	1.07	1,645	56.3	0.63	67.4	0.75
Larynx	211	8.4	0.27	10.3	0.32	61	2.1	0.12	2.6	0.15
Lung & bronchus	1,981	82.6	0.86	98.9	1.01	1,565	53.6	0.62	64.1	0.73
Bones & Joints	19	0.8	0.09	0.8	0.09	18	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	106	4.7	0.21	5.3	0.23	76	2.9	0.15	3.2	0.16
Skin (excl. basal & sq.)	618	27.2	0.50	31.5	0.58	383	14.5	0.34	16.4	0.38
Melanomas of the skin	553	24.2	0.47	28.1	0.54	339	12.9	0.32	14.6	0.36
Breast (excl. <i>in situ</i>)	32	1.3	0.11	1.6	0.13	3,484	125.9	0.98	148.3	1.13
Female Genital System	-	-	-	-	-	1,216	44.3	0.59	51.7	0.67
Cervix uteri	-	-	-	-	-	217	9.1	0.29	9.7	0.30
Uterus Corpus	-	-	-	-	-	572	19.8	0.38	24.0	0.45
Uterus, NOS ¹	-	-	-	-	-	20	0.7	0.07	0.8	0.08
Ovary	-	-	-	-	-	267	9.6	0.27	11.2	0.31
Male Genital System	3,544	137.5	1.07	169.3	1.29	-	-	-	-	-
Prostate	3,404	131.2	1.04	162.7	1.26	-	-	-	-	-
Testis	104	4.7	0.21	4.7	0.21	-	-	-	-	-
Penis	30	1.3	0.11	1.5	0.13	-	-	-	-	-
Urinary System	1,497	63.7	0.76	75.3	0.88	680	23.9	0.42	28.2	0.49
Bladder (incl. <i>in situ</i>)	741	32.5	0.55	38.3	0.64	216	7.5	0.23	8.8	0.27
Kidney & renal pelvis	720	29.6	0.51	35.2	0.59	442	15.7	0.34	18.5	0.40
Ureter	20	0.9	0.09	1.0	0.11	11	0.4	0.05	0.4	0.06
Eye & Orbit	19	0.8	0.08	0.9	0.09	15	0.6	0.07	0.6	0.07
Brain & Other CNS ¹	168	7.2	0.26	7.9	0.28	130	4.9	0.20	5.4	0.21
Brain	158	6.8	0.25	7.5	0.27	121	4.5	0.19	5.0	0.20
Endocrine System	194	8.1	0.27	9.2	0.30	537	21.5	0.43	23.5	0.46
Thyroid gland	176	7.3	0.26	8.4	0.29	521	20.9	0.42	22.9	0.45
Lymphomas	613	26.5	0.49	30.4	0.56	503	18.3	0.37	20.9	0.42
Hodgkin Lymphoma	71	3.1	0.17	3.3	0.17	60	2.5	0.15	2.6	0.15
Non-Hodgkin Lymphoma	542	23.3	0.46	27.2	0.53	443	15.9	0.35	18.3	0.39
Multiple Myeloma	234	10.1	0.30	11.9	0.35	191	6.6	0.22	7.9	0.26
Leukemias	409	18.0	0.41	20.4	0.46	307	11.1	0.29	12.6	0.32
Acute lymphocytic	32	1.4	0.11	1.3	0.11	29	1.2	0.10	1.1	0.10
Chronic lymphocytic	160	7.0	0.25	8.2	0.30	107	3.7	0.16	4.3	0.19
Acute myeloid	116	5.1	0.22	5.8	0.25	95	3.5	0.16	4.0	0.18
Chronic myeloid	60	2.6	0.16	3.0	0.17	48	1.8	0.12	2.0	0.13
Other leukemias	40	1.9	0.13	2.0	0.15	28	1.0	0.09	1.1	0.10
Mesothelioma	48	2.2	0.14	2.5	0.17	19	0.6	0.07	0.8	0.08
Kaposi Sarcoma	20	0.9	0.09	1.0	0.10	2	0.1	0.03	0.1	0.03
Ill-defined & Unknown	487	21.7	0.45	25.4	0.52	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	235	10.2	0.31	11.6	0.34	451	16.6	0.36	18.9	0.40
Breast (<i>in situ</i>)	3	0.1	0.03	0.2	0.04	704	25.3	0.44	30.1	0.51

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	9,560	547.2	2.57	651.4	3.01	8,321	432.1	2.19	504.5	2.50
Oral Cavity & Pharynx	395	21.9	0.51	26.9	0.61	151	7.7	0.29	9.1	0.34
Lip	30	1.7	0.15	2.1	0.17	7	0.3	0.06	0.4	0.07
Tongue	127	6.9	0.28	8.5	0.34	49	2.6	0.17	3.1	0.20
Major salivary gland	27	1.7	0.15	1.9	0.17	18	0.9	0.10	1.1	0.12
Floor of mouth	16	0.9	0.11	1.1	0.13	8	0.4	0.07	0.5	0.08
Gum & other mouth	39	2.2	0.17	2.7	0.20	32	1.6	0.13	1.8	0.15
Nasopharynx	14	0.8	0.10	1.0	0.12	4	0.2	0.04	0.2	0.05
Oropharynx	17	0.9	0.10	1.1	0.12	8	0.4	0.06	0.5	0.08
Hypopharynx	19	1.1	0.11	1.3	0.13	5	0.3	0.05	0.3	0.06
Digestive System	1,823	104.1	1.12	125.2	1.33	1,312	65.7	0.84	77.7	0.97
Esophagus	141	7.9	0.30	9.6	0.36	32	1.5	0.12	1.9	0.15
Stomach	141	8.3	0.32	9.8	0.37	71	3.5	0.19	4.2	0.22
Small intestine	56	3.2	0.20	3.9	0.23	48	2.5	0.16	2.9	0.19
Colon excl. rectum	574	33.6	0.64	39.8	0.75	519	26.2	0.53	30.6	0.61
Rectum & rectosigmoid	288	16.4	0.45	19.8	0.53	188	10.0	0.34	11.8	0.39
Anus, anal canal & anorectum	30	1.7	0.14	2.1	0.17	48	2.4	0.16	3.0	0.19
Liver	235	12.4	0.37	15.7	0.46	68	3.3	0.18	4.0	0.22
Gallbladder	13	0.7	0.09	0.9	0.11	27	1.3	0.11	1.5	0.13
Pancreas	273	15.8	0.44	18.8	0.52	241	11.7	0.34	13.8	0.40
Respiratory System	1,518	86.5	1.02	103.3	1.20	1,231	59.8	0.78	71.5	0.92
Larynx	133	7.4	0.29	9.0	0.35	43	2.1	0.15	2.6	0.18
Lung & bronchus	1,365	77.9	0.97	92.9	1.14	1,173	56.8	0.75	67.9	0.89
Bones & Joints	13	0.9	0.11	0.9	0.11	13	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	82	5.1	0.26	5.8	0.29	51	2.8	0.18	3.1	0.20
Skin (excl. basal & sq.)	600	36.0	0.68	41.9	0.77	362	20.5	0.50	23.0	0.55
Melanomas of the skin	545	32.6	0.64	37.9	0.73	329	18.8	0.48	21.1	0.53
Breast (excl. <i>in situ</i>)	19	1.1	0.11	1.3	0.13	2,354	122.9	1.18	145.1	1.35
Female Genital System	-	-	-	-	-	810	43.5	0.71	50.6	0.81
Cervix uteri	-	-	-	-	-	128	8.3	0.34	8.8	0.35
Uterus Corpus	-	-	-	-	-	380	19.4	0.46	23.4	0.54
Uterus, NOS ¹	-	-	-	-	-	8	0.4	0.07	0.5	0.08
Ovary	-	-	-	-	-	191	10.0	0.33	11.6	0.38
Male Genital System	2,276	122.9	1.18	150.1	1.42	-	-	-	-	-
Prostate	2,162	115.2	1.14	142.2	1.38	-	-	-	-	-
Testis	90	6.3	0.30	6.2	0.29	-	-	-	-	-
Penis	19	1.1	0.12	1.3	0.14	-	-	-	-	-
Urinary System	1,197	69.7	0.93	82.4	1.08	498	25.0	0.52	29.4	0.60
Bladder (incl. <i>in situ</i>)	632	37.4	0.68	44.0	0.79	167	8.1	0.29	9.6	0.33
Kidney & renal pelvis	534	30.5	0.61	36.2	0.71	314	16.2	0.42	19.0	0.48
Ureter	19	1.1	0.12	1.3	0.14	9	0.4	0.06	0.5	0.07
Eye & Orbit	17	1.0	0.11	1.1	0.12	13	0.7	0.10	0.8	0.10
Brain & Other CNS ¹	136	8.4	0.33	9.2	0.36	104	5.9	0.27	6.4	0.28
Brain	129	7.9	0.32	8.8	0.35	98	5.5	0.26	6.0	0.28
Endocrine System	154	9.2	0.34	10.5	0.38	401	24.6	0.57	26.9	0.61
Thyroid gland	142	8.5	0.33	9.7	0.37	392	24.1	0.57	26.3	0.60
Lymphomas	470	28.3	0.60	32.6	0.68	378	19.8	0.47	22.5	0.52
Hodgkin Lymphoma	47	3.1	0.21	3.3	0.21	41	2.7	0.19	2.8	0.19
Non-Hodgkin Lymphoma	423	25.2	0.56	29.3	0.64	337	17.1	0.43	19.8	0.49
Multiple Myeloma	137	8.0	0.32	9.5	0.37	96	4.7	0.22	5.6	0.26
Leukemias	315	19.3	0.50	21.9	0.56	231	12.1	0.37	13.6	0.41
Acute lymphocytic	23	1.6	0.16	1.5	0.14	22	1.5	0.15	1.4	0.13
Chronic lymphocytic	129	7.6	0.31	9.0	0.36	88	4.2	0.20	5.0	0.24
Acute myeloid	87	5.3	0.26	6.1	0.30	65	3.4	0.20	3.9	0.22
Chronic myeloid	45	2.7	0.19	3.1	0.21	36	1.9	0.15	2.2	0.17
Other leukemias	30	1.9	0.16	2.1	0.18	20	1.0	0.11	1.1	0.12
Mesothelioma	39	2.3	0.17	2.7	0.19	15	0.7	0.09	0.8	0.10
Kaposi Sarcoma	9	0.6	0.09	0.7	0.10	1	0.1	0.03	0.1	0.03
Ill-defined & Unknown	361	21.9	0.53	25.5	0.61	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	175	10.7	0.37	12.0	0.41	314	16.8	0.44	19.3	0.49
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	460	24.3	0.53	28.8	0.61

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,741	592.4	4.63	717.8	5.45	3,375	421.9	3.34	496.3	3.85
Oral Cavity & Pharynx	113	16.7	0.74	20.7	0.89	42	5.2	0.37	6.2	0.43
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	27	4.0	0.37	5.1	0.45	9	1.1	0.17	1.4	0.20
Major salivary gland	7	1.1	0.20	1.3	0.22	9	1.1	0.17	1.2	0.19
Floor of mouth	9	1.3	0.20	1.7	0.25	2	0.3	0.08	0.3	0.10
Gum & other mouth	15	2.3	0.27	2.8	0.33	8	1.1	0.17	1.3	0.20
Nasopharynx	7	0.9	0.16	1.2	0.20	2	0.2	0.08	0.3	0.09
Oropharynx	8	1.2	0.20	1.5	0.24	3	0.4	0.10	0.5	0.12
Hypopharynx	12	1.8	0.24	2.2	0.29	4	0.4	0.11	0.5	0.12
Digestive System	873	138.1	2.24	168.3	2.65	696	86.9	1.51	103.6	1.77
Esophagus	47	7.4	0.51	9.0	0.61	20	2.4	0.24	2.9	0.29
Stomach	92	15.5	0.78	18.6	0.91	61	7.9	0.46	9.2	0.53
Small intestine	29	4.7	0.42	5.7	0.50	36	4.5	0.34	5.3	0.39
Colon excl. rectum	263	43.2	1.28	51.9	1.49	269	33.7	0.94	40.0	1.10
Rectum & rectosigmoid	129	20.0	0.84	24.3	0.99	99	12.1	0.56	14.5	0.66
Anus, anal canal & anorectum	12	1.9	0.25	2.1	0.28	11	1.4	0.19	1.7	0.22
Liver	159	21.2	0.79	27.8	1.00	36	4.2	0.32	5.2	0.39
Gallbladder	8	1.3	0.23	1.6	0.27	18	2.2	0.24	2.7	0.29
Pancreas	108	18.2	0.84	21.8	0.98	116	14.9	0.64	17.7	0.74
Respiratory System	679	112.5	2.07	135.7	2.42	397	49.2	1.13	59.2	1.34
Larynx	77	12.2	0.66	14.8	0.78	17	2.0	0.22	2.5	0.27
Lung & bronchus	595	99.1	1.95	119.5	2.28	377	46.7	1.11	56.2	1.30
Bones & Joints	5	0.7	0.15	0.7	0.16	5	0.6	0.12	0.6	0.13
Soft Tissue (incl. heart)	22	3.4	0.34	3.7	0.38	23	2.9	0.27	3.1	0.30
Skin (excl. basal & sq.)	14	2.5	0.31	2.8	0.36	18	2.3	0.25	2.6	0.28
Melanomas of the skin	6	1.0	0.21	1.2	0.24	8	1.0	0.17	1.2	0.19
Breast (excl. <i>in situ</i>)	12	1.9	0.27	2.3	0.31	1,083	135.2	1.89	159.0	2.17
Female Genital System	-	-	-	-	-	384	47.4	1.11	55.6	1.28
Cervix uteri	-	-	-	-	-	84	11.2	0.56	12.1	0.59
Uterus Corpus	-	-	-	-	-	182	21.5	0.73	26.3	0.88
Uterus, NOS ¹	-	-	-	-	-	12	1.4	0.19	1.7	0.22
Ovary	-	-	-	-	-	72	8.9	0.48	10.4	0.55
Male Genital System	1,218	183.7	2.50	228.4	3.01	-	-	-	-	-
Prostate	1,194	180.0	2.48	224.4	2.99	-	-	-	-	-
Testis	11	1.7	0.23	1.7	0.23	-	-	-	-	-
Penis	11	1.8	0.26	2.1	0.30	-	-	-	-	-
Urinary System	283	46.5	1.32	55.3	1.53	176	22.1	0.77	26.1	0.89
Bladder (incl. <i>in situ</i>)	101	17.6	0.84	20.9	0.97	47	6.3	0.42	7.3	0.48
Kidney & renal pelvis	178	28.1	1.00	33.5	1.16	123	15.1	0.63	17.9	0.73
Ureter	-	-	-	-	-	1	0.1	0.06	0.2	0.07
Eye & Orbit	2	0.3	0.09	0.3	0.09	2	0.2	0.07	0.2	0.07
Brain & Other CNS ¹	29	4.3	0.38	4.7	0.42	23	2.9	0.28	3.1	0.30
Brain	27	4.1	0.37	4.5	0.41	20	2.6	0.26	2.7	0.28
Endocrine System	35	5.0	0.40	5.9	0.46	121	15.5	0.65	17.0	0.70
Thyroid gland	28	4.2	0.37	4.9	0.42	114	14.6	0.63	16.1	0.68
Lymphomas	133	20.9	0.86	23.9	0.97	115	14.5	0.62	16.5	0.69
Hodgkin Lymphoma	23	3.2	0.31	3.3	0.32	17	2.1	0.24	2.2	0.24
Non-Hodgkin Lymphoma	110	17.7	0.80	20.6	0.92	98	12.4	0.58	14.3	0.65
Multiple Myeloma	95	16.7	0.82	19.6	0.94	93	11.7	0.56	14.0	0.65
Leukemias	88	14.1	0.72	16.1	0.81	71	8.9	0.48	10.1	0.55
Acute lymphocytic	9	1.1	0.17	1.1	0.17	6	0.7	0.13	0.7	0.12
Chronic lymphocytic	29	5.0	0.44	5.9	0.51	18	2.3	0.24	2.7	0.29
Acute myeloid	26	4.4	0.41	4.9	0.45	28	3.6	0.31	4.0	0.34
Chronic myeloid	15	2.2	0.26	2.5	0.30	11	1.4	0.20	1.7	0.22
Other leukemias	9	1.5	0.24	1.7	0.26	7	0.9	0.16	1.1	0.18
Mesothelioma	9	1.9	0.29	2.2	0.34	4	0.5	0.11	0.6	0.13
Kaposi Sarcoma	11	1.7	0.24	1.7	0.25	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	122	15.8	0.66	18.6	0.76
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	56	9.3	0.59	10.6	0.67	129	16.6	0.67	18.9	0.75
Breast (<i>in situ</i>)	2	0.3	0.09	0.3	0.10	234	28.7	0.86	34.2	1.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	107	298.0	13.95	356.4	16.33	115	278.8	12.16	322.5	13.91
Oral Cavity & Pharynx	3	7.6	1.97	8.9	2.28	3	7.8	2.04	9.0	2.36
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	3.2	1.23	3.6	1.37	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	41	106.6	8.01	130.0	9.52	21	55.2	5.72	65.3	6.63
Esophagus	2	3.5	1.24	4.7	1.68	-	-	-	-	-
Stomach	5	11.5	2.38	14.5	2.95	2	4.3	1.51	5.1	1.80
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	9	23.7	3.84	27.8	4.43	4	11.4	2.55	13.6	2.98
Rectum & rectosigmoid	6	17.5	3.32	20.3	3.77	4	10.4	2.48	12.7	2.95
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	13	32.6	4.31	40.8	5.26	4	9.9	2.40	11.7	2.79
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	7.6	2.09	9.7	2.54	4	10.2	2.53	11.8	2.86
Respiratory System	15	45.3	5.65	55.3	6.69	10	28.0	4.17	32.1	4.69
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	15	44.4	5.61	54.2	6.64	10	27.3	4.14	31.1	4.63
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	4.5	1.81	5.1	1.96	1	3.3	1.41	3.3	1.42
Skin (excl. basal & sq.)	2	4.5	1.75	5.4	2.09	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	33	76.3	6.09	88.4	6.98
Female Genital System	-	-	-	-	-	15	33.7	4.00	39.9	4.70
Cervix uteri	-	-	-	-	-	4	8.8	2.05	10.0	2.33
Uterus Corpus	-	-	-	-	-	7	14.2	2.48	17.7	3.07
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	6.2	1.73	7.3	2.02
Male Genital System	17	48.8	5.82	59.3	6.87	-	-	-	-	-
Prostate	16	45.8	5.66	56.4	6.75	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	20.4	3.97	23.6	4.47	3	8.8	2.26	10.3	2.58
Bladder (incl. <i>in situ</i>)	3	10.2	2.84	11.8	3.21	1	3.1	1.34	3.8	1.57
Kidney & renal pelvis	3	9.7	2.74	11.2	3.06	2	5.7	1.82	6.5	2.04
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	3.8	1.36	3.9	1.44	2	5.1	1.62	6.1	1.91
Brain	1	3.0	1.25	2.8	1.19	2	4.7	1.58	5.7	1.88
Endocrine System	4	8.3	2.08	8.5	2.22	11	23.9	3.26	25.8	3.53
Thyroid gland	3	7.8	2.02	8.2	2.19	11	23.9	3.26	25.8	3.53
Lymphomas	6	16.4	3.30	19.2	3.80	6	15.0	2.88	17.2	3.28
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	5	13.9	3.07	16.6	3.58	-	-	-	-	-
Multiple Myeloma	2	4.8	1.91	6.2	2.38	2	4.1	1.52	4.9	1.76
Leukemias	3	9.7	2.59	10.7	2.90	3	7.6	2.05	8.7	2.33
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	4.0	1.76	4.6	2.02	1	3.1	1.29	3.5	1.44
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	14.1	3.10	16.4	3.58	3	7.3	2.09	8.5	2.36
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	7.7	2.24	8.7	2.51	4	9.6	2.30	10.9	2.60
Breast (<i>in situ</i>)	-	-	-	-	-	7	16.3	2.85	18.4	3.20

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4	242.9	53.75	280.5	60.62	5	209.2	44.27	266.4	55.18
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	1	72.5	28.33	87.6	33.34	1	52.4	22.17	66.0	27.14
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	1	62.9	27.05	77.3	32.45	-	-	-	-	-
Prostate	1	62.9	27.05	77.3	32.45	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	250	333.9	10.14	395.3	11.83	247	306.0	8.86	356.4	10.36
Oral Cavity & Pharynx	9	10.2	1.67	12.2	1.96	5	5.8	1.22	7.1	1.49
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	4.4	1.17	5.0	1.32	1	1.6	0.65	1.9	0.77
Major salivary gland	-	-	-	-	-	2	2.1	0.70	2.6	0.89
Floor of mouth	1	1.3	0.50	1.7	0.65	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	55	69.9	4.51	84.6	5.37	42	51.6	3.63	61.2	4.32
Esophagus	2	3.3	1.06	3.8	1.21	-	-	-	-	-
Stomach	7	9.2	1.65	10.5	1.88	5	5.8	1.21	7.0	1.44
Small intestine	-	-	-	-	-	2	3.0	0.91	3.4	1.02
Colon excl. rectum	15	20.1	2.46	23.9	2.87	13	15.9	2.02	18.0	2.31
Rectum & rectosigmoid	9	10.7	1.64	13.2	1.98	6	6.5	1.25	8.2	1.57
Anus, anal canal & anorectum	-	-	-	-	-	1	1.9	0.74	2.3	0.86
Liver	11	13.8	1.94	17.8	2.44	4	4.6	1.07	5.7	1.33
Gallbladder	-	-	-	-	-	1	1.4	0.59	1.9	0.77
Pancreas	6	8.5	1.68	10.2	1.98	6	7.9	1.47	9.2	1.70
Respiratory System	26	36.1	3.39	43.0	3.95	24	32.3	2.97	38.6	3.52
Larynx	4	5.0	1.22	6.2	1.47	1	1.6	0.68	1.9	0.79
Lung & bronchus	21	30.6	3.15	36.4	3.65	23	30.5	2.89	36.3	3.41
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.0	0.70	2.3	0.86	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	4	5.5	1.28	6.3	1.46	5	5.7	1.14	6.5	1.34
Breast (excl. <i>in situ</i>)	-	-	-	-	-	74	92.9	4.90	109.0	5.75
Female Genital System	-	-	-	-	-	31	36.6	2.99	41.8	3.46
Cervix uteri	-	-	-	-	-	10	10.7	1.58	11.2	1.68
Uterus Corpus	-	-	-	-	-	14	16.5	2.02	19.6	2.42
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	6.1	1.24	7.3	1.48
Male Genital System	73	101.1	5.63	121.8	6.62	-	-	-	-	-
Prostate	66	96.0	5.55	116.6	6.55	-	-	-	-	-
Testis	6	3.9	0.75	3.8	0.75	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	27	40.9	3.73	47.3	4.24	12	16.3	2.14	18.4	2.40
Bladder (incl. <i>in situ</i>)	9	16.1	2.45	18.4	2.77	3	4.6	1.19	4.8	1.25
Kidney & renal pelvis	17	23.2	2.68	27.1	3.08	8	10.4	1.68	11.9	1.92
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	5.5	1.20	5.9	1.36	4	4.1	0.99	4.3	1.06
Brain	4	4.8	1.16	5.3	1.32	3	3.7	0.94	3.8	1.01
Endocrine System	6	7.0	1.39	7.9	1.60	15	16.4	1.95	18.3	2.22
Thyroid gland	6	6.6	1.36	7.6	1.58	15	16.2	1.93	18.0	2.20
Lymphomas	14	15.8	2.06	18.3	2.39	14	17.3	2.12	19.8	2.44
Hodgkin Lymphoma	2	1.9	0.66	2.0	0.70	-	-	-	-	-
Non-Hodgkin Lymphoma	12	13.9	1.95	16.3	2.29	-	-	-	-	-
Multiple Myeloma	5	7.3	1.50	8.5	1.73	3	4.5	1.10	5.5	1.34
Leukemias	9	11.3	1.85	12.4	2.06	7	7.4	1.33	8.1	1.50
Acute lymphocytic	2	1.9	0.72	1.9	0.75	2	1.9	0.58	1.8	0.59
Chronic lymphocytic	3	4.1	1.16	4.8	1.33	2	2.1	0.73	2.5	0.89
Acute myeloid	2	2.7	0.94	2.8	1.01	2	2.3	0.75	2.6	0.87
Chronic myeloid	1	1.2	0.57	1.4	0.65	-	-	-	-	-
Other leukemias	1	1.3	0.58	1.4	0.68	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	17.6	2.54	20.3	2.90	10	12.6	1.84	14.9	2.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	9.0	1.71	10.2	1.96	11	12.8	1.79	15.5	2.17
Breast (<i>in situ</i>)	-	-	-	-	-	16	19.8	2.26	24.0	2.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

LOUISIANA

II-218 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,349	556.8	2.65	662.7	3.10	8,104	437.4	2.26	510.5	2.57
Oral Cavity & Pharynx	388	22.4	0.52	27.5	0.63	147	7.8	0.30	9.3	0.35
Lip	30	1.8	0.15	2.2	0.18	7	0.4	0.06	0.4	0.07
Tongue	124	7.1	0.29	8.7	0.35	49	2.7	0.18	3.1	0.20
Major salivary gland	27	1.7	0.15	2.0	0.17	16	0.9	0.10	1.0	0.11
Floor of mouth	15	0.9	0.11	1.1	0.13	8	0.4	0.07	0.5	0.08
Gum & other mouth	39	2.3	0.17	2.8	0.20	31	1.6	0.13	1.9	0.15
Nasopharynx	14	0.8	0.10	1.0	0.12	4	0.2	0.04	0.2	0.05
Oropharynx	16	0.9	0.10	1.1	0.13	7	0.4	0.07	0.5	0.08
Hypopharynx	19	1.1	0.11	1.3	0.13	5	0.3	0.05	0.3	0.07
Digestive System	1,777	105.6	1.15	126.9	1.36	1,275	66.2	0.86	78.2	0.99
Esophagus	139	8.1	0.31	9.8	0.38	31	1.6	0.13	1.9	0.15
Stomach	135	8.2	0.32	9.8	0.38	66	3.4	0.19	4.0	0.22
Small intestine	56	3.3	0.21	4.0	0.24	47	2.5	0.17	2.9	0.19
Colon excl. rectum	561	34.1	0.66	40.4	0.77	508	26.5	0.54	31.0	0.62
Rectum & rectosigmoid	280	16.7	0.46	20.1	0.54	184	10.1	0.35	12.0	0.40
Anus, anal canal & anorectum	29	1.7	0.15	2.1	0.18	46	2.5	0.17	3.0	0.20
Liver	226	12.3	0.38	15.7	0.47	65	3.2	0.18	3.9	0.22
Gallbladder	12	0.7	0.10	0.9	0.11	26	1.2	0.11	1.5	0.13
Pancreas	268	16.1	0.45	19.1	0.53	235	11.8	0.35	14.0	0.41
Respiratory System	1,496	88.4	1.05	105.6	1.23	1,210	60.8	0.80	72.7	0.94
Larynx	129	7.5	0.30	9.2	0.36	42	2.1	0.15	2.7	0.19
Lung & bronchus	1,347	79.7	1.00	95.0	1.17	1,153	57.8	0.77	69.1	0.92
Bones & Joints	12	0.9	0.12	0.9	0.11	13	0.8	0.11	0.9	0.11
Soft Tissue (incl. heart)	81	5.3	0.27	5.9	0.30	50	2.9	0.19	3.2	0.21
Skin (excl. basal & sq.)	595	37.3	0.71	43.3	0.80	357	21.1	0.52	23.8	0.57
Melanomas of the skin	541	33.8	0.67	39.3	0.76	325	19.4	0.51	21.8	0.55
Breast (excl. <i>in situ</i>)	19	1.1	0.12	1.3	0.14	2,289	124.2	1.21	146.6	1.39
Female Genital System	-	-	-	-	-	784	43.8	0.73	51.0	0.83
Cervix uteri	-	-	-	-	-	120	8.3	0.35	8.7	0.36
Uterus Corpus	-	-	-	-	-	368	19.5	0.47	23.5	0.56
Uterus, NOS ¹	-	-	-	-	-	8	0.4	0.07	0.5	0.08
Ovary	-	-	-	-	-	186	10.1	0.35	11.8	0.39
Male Genital System	2,217	124.3	1.21	151.8	1.46	-	-	-	-	-
Prostate	2,109	116.4	1.16	143.8	1.41	-	-	-	-	-
Testis	85	6.5	0.32	6.4	0.31	-	-	-	-	-
Penis	18	1.1	0.12	1.3	0.14	-	-	-	-	-
Urinary System	1,173	71.0	0.95	83.9	1.11	487	25.4	0.53	29.9	0.61
Bladder (incl. <i>in situ</i>)	624	38.2	0.70	44.9	0.82	164	8.2	0.29	9.8	0.34
Kidney & renal pelvis	520	31.0	0.63	36.8	0.73	307	16.4	0.44	19.3	0.50
Ureter	18	1.1	0.12	1.3	0.14	9	0.4	0.07	0.5	0.08
Eye & Orbit	16	1.0	0.12	1.1	0.13	13	0.8	0.10	0.8	0.11
Brain & Other CNS ¹	131	8.5	0.34	9.4	0.37	101	6.0	0.28	6.5	0.29
Brain	125	8.1	0.33	8.9	0.36	95	5.6	0.27	6.1	0.28
Endocrine System	148	9.4	0.36	10.7	0.39	387	25.1	0.60	27.3	0.63
Thyroid gland	137	8.6	0.34	9.9	0.38	379	24.6	0.59	26.8	0.62
Lymphomas	458	28.8	0.62	33.2	0.70	366	19.9	0.48	22.6	0.54
Hodgkin Lymphoma	45	3.2	0.22	3.4	0.23	41	2.8	0.20	2.9	0.21
Non-Hodgkin Lymphoma	413	25.6	0.58	29.8	0.66	325	17.0	0.44	19.7	0.50
Multiple Myeloma	133	8.1	0.32	9.6	0.38	93	4.7	0.22	5.6	0.26
Leukemias	308	19.7	0.52	22.3	0.58	226	12.3	0.38	13.9	0.42
Acute lymphocytic	21	1.7	0.16	1.5	0.15	20	1.5	0.15	1.4	0.14
Chronic lymphocytic	128	7.8	0.32	9.2	0.37	87	4.3	0.21	5.1	0.25
Acute myeloid	85	5.4	0.27	6.2	0.30	64	3.5	0.20	4.0	0.23
Chronic myeloid	44	2.8	0.20	3.2	0.22	36	2.0	0.16	2.3	0.17
Other leukemias	30	2.0	0.17	2.2	0.18	20	1.0	0.11	1.2	0.12
Mesothelioma	38	2.3	0.17	2.7	0.20	15	0.7	0.09	0.9	0.10
Kaposi Sarcoma	8	0.6	0.09	0.6	0.10	1	0.1	0.03	0.1	0.03
Ill-defined & Unknown	351	22.1	0.54	25.8	0.62	292	14.8	0.40	17.4	0.46
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	169	10.8	0.38	12.2	0.42	305	17.1	0.46	19.5	0.51
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	445	24.5	0.54	29.0	0.62

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Louisiana, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,724	595.8	4.67	721.9	5.49	3,361	424.1	3.36	498.7	3.87
Oral Cavity & Pharynx	113	16.9	0.75	20.9	0.90	42	5.3	0.37	6.2	0.43
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	27	4.0	0.37	5.1	0.45	9	1.1	0.17	1.3	0.20
Major salivary gland	7	1.2	0.20	1.3	0.22	9	1.1	0.17	1.2	0.19
Floor of mouth	9	1.3	0.20	1.7	0.25	2	0.3	0.09	0.3	0.10
Gum & other mouth	15	2.3	0.28	2.8	0.33	8	1.1	0.17	1.3	0.20
Nasopharynx	7	0.9	0.16	1.2	0.20	2	0.2	0.08	0.3	0.09
Oropharynx	8	1.2	0.20	1.5	0.25	3	0.4	0.10	0.5	0.12
Hypopharynx	12	1.8	0.24	2.2	0.29	4	0.5	0.11	0.5	0.13
Digestive System	870	139.0	2.26	169.5	2.67	693	87.3	1.52	104.1	1.78
Esophagus	47	7.5	0.52	9.1	0.61	19	2.4	0.25	2.9	0.30
Stomach	91	15.7	0.79	18.8	0.92	61	7.9	0.47	9.3	0.54
Small intestine	29	4.8	0.42	5.8	0.50	35	4.4	0.34	5.2	0.40
Colon excl. rectum	262	43.4	1.29	52.2	1.50	268	33.9	0.95	40.3	1.11
Rectum & rectosigmoid	129	20.1	0.84	24.5	1.00	98	12.1	0.56	14.6	0.66
Anus, anal canal & anorectum	12	1.9	0.25	2.1	0.28	11	1.4	0.19	1.7	0.22
Liver	158	21.4	0.80	28.0	1.01	36	4.2	0.32	5.2	0.39
Gallbladder	8	1.4	0.23	1.6	0.27	18	2.2	0.24	2.7	0.29
Pancreas	107	18.3	0.85	21.9	0.99	116	15.0	0.64	17.8	0.74
Respiratory System	677	113.1	2.09	136.5	2.44	395	49.3	1.14	59.4	1.34
Larynx	77	12.2	0.66	14.9	0.79	17	2.0	0.22	2.5	0.27
Lung & bronchus	593	99.7	1.97	120.3	2.30	374	46.8	1.11	56.4	1.31
Bones & Joints	5	0.7	0.15	0.8	0.16	5	0.6	0.12	0.6	0.13
Soft Tissue (incl. heart)	21	3.4	0.35	3.7	0.39	23	2.9	0.28	3.2	0.30
Skin (excl. basal & sq.)	14	2.5	0.32	2.9	0.36	18	2.4	0.26	2.7	0.28
Melanomas of the skin	6	1.0	0.21	1.2	0.24	8	1.0	0.17	1.2	0.19
Breast (excl. <i>in situ</i>)	12	1.9	0.27	2.3	0.31	1,079	135.9	1.90	159.9	2.19
Female Genital System	-	-	-	-	-	383	47.6	1.12	55.9	1.29
Cervix uteri	-	-	-	-	-	83	11.3	0.57	12.1	0.60
Uterus Corpus	-	-	-	-	-	182	21.6	0.74	26.5	0.88
Uterus, NOS ¹	-	-	-	-	-	12	1.4	0.19	1.7	0.23
Ovary	-	-	-	-	-	72	9.0	0.49	10.5	0.56
Male Genital System	1,212	184.6	2.52	229.5	3.04	-	-	-	-	-
Prostate	1,188	180.8	2.50	225.4	3.01	-	-	-	-	-
Testis	11	1.7	0.23	1.7	0.23	-	-	-	-	-
Penis	11	1.8	0.26	2.2	0.30	-	-	-	-	-
Urinary System	282	46.7	1.33	55.5	1.54	175	22.2	0.77	26.2	0.89
Bladder (incl. <i>in situ</i>)	101	17.7	0.85	21.0	0.98	47	6.3	0.42	7.3	0.48
Kidney & renal pelvis	177	28.3	1.01	33.6	1.17	122	15.2	0.63	18.0	0.74
Ureter	-	-	-	-	-	1	0.1	0.06	0.2	0.07
Eye & Orbit	2	0.3	0.09	0.3	0.09	2	0.2	0.07	0.2	0.07
Brain & Other CNS ¹	29	4.4	0.39	4.8	0.43	23	2.9	0.28	3.1	0.30
Brain	27	4.2	0.38	4.5	0.41	20	2.6	0.26	2.7	0.28
Endocrine System	34	5.1	0.41	6.0	0.47	121	15.6	0.65	17.2	0.70
Thyroid gland	28	4.2	0.37	4.9	0.43	114	14.7	0.63	16.2	0.68
Lymphomas	132	21.1	0.87	24.1	0.98	115	14.6	0.63	16.6	0.70
Hodgkin Lymphoma	23	3.2	0.31	3.3	0.32	17	2.2	0.24	2.3	0.25
Non-Hodgkin Lymphoma	110	17.9	0.81	20.8	0.93	97	12.5	0.58	14.3	0.65
Multiple Myeloma	94	16.7	0.82	19.6	0.94	93	11.8	0.56	14.1	0.66
Leukemias	87	14.1	0.73	16.1	0.82	70	8.9	0.49	10.2	0.55
Acute lymphocytic	8	1.1	0.17	1.1	0.18	6	0.7	0.13	0.7	0.13
Chronic lymphocytic	29	5.0	0.45	5.9	0.52	18	2.3	0.25	2.7	0.29
Acute myeloid	26	4.4	0.41	5.0	0.46	28	3.6	0.31	4.0	0.34
Chronic myeloid	14	2.1	0.26	2.5	0.30	11	1.4	0.20	1.7	0.23
Other leukemias	9	1.5	0.24	1.7	0.26	7	0.9	0.16	1.1	0.18
Mesothelioma	9	1.9	0.30	2.2	0.34	4	0.5	0.11	0.6	0.13
Kaposi Sarcoma	11	1.7	0.25	1.7	0.26	-	-	-	-	-
Ill-defined & Unknown	120	21.7	0.95	25.5	1.10	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	56	9.4	0.60	10.7	0.67	129	16.7	0.67	19.0	0.76
Breast (<i>in situ</i>)	2	0.3	0.09	0.3	0.10	233	28.8	0.87	34.4	1.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


LOUISIANA

II-220 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,328,196	1,330,760	1,328,484	1,331,370	1,335,063
White	1,278,635	1,279,072	1,276,041	1,277,074	1,279,536
Black	22,249	23,489	24,000	25,186	25,910
American Indian/Alaskan Native (AI/AN)	10,720	10,883	10,994	11,168	11,354
Asian/Pacific Islander (API)	16,592	17,316	17,449	17,942	18,263


All Races Population 2013-2017: 6,653,873
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	19,174	20,171	20,652	21,318	22,143
Non-Hispanic White	1,261,722	1,261,378	1,257,940	1,258,430	1,260,221
Non-Hispanic Black	21,040	22,209	22,672	23,827	24,457

Hispanic/Latino Population, Census 2010: 16,935
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MAINE CANCER REGISTRY

Initial Operation: 1983
 Population-based Data Available: 1983
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.7	111.1	109.0	110.4	107.9
Missing Race	0.3	0.6	0.5	0.4	0.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.1	2.1	2.0	2.1	2.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.2	Prostate	95.7
Oral Cavity & Pharynx	98.1	Testis	99.0
Esophagus	96.3	Bladder (incl. <i>in situ</i>)	97.0
Stomach	97.7	Kidney & Renal Pelvis	87.8
Colon & Rectum	95.6	Brain & Other CNS ¹	84.2
Liver	59.7	Thyroid	99.5
Pancreas	86.4	Hodgkin Lymphoma	98.6
Lung & Bronchus	84.0	Non-Hodgkin Lymphoma	96.9
Melanomas of the Skin	99.3	Multiple Myeloma	82.9
Female Breast (excl. <i>in situ</i>)	98.7	Leukemias	86.2
Cervix uteri	99.5	Brain & Other CNS ¹ <i>non-malig</i>	51.8
Uterus Corpus & Uterus NOS ¹	99.1	Breast <i>in situ</i>	99.9
Ovary	93.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,398	500.5	3.50	592.7	4.05	4,419	458.9	3.26	533.5	3.66
Oral Cavity & Pharynx	181	20.1	0.70	24.5	0.83	71	7.3	0.41	8.5	0.46
Lip	15	1.9	0.22	2.2	0.25	6	0.5	0.10	0.6	0.12
Tongue	55	5.9	0.37	7.3	0.45	17	1.8	0.21	2.1	0.23
Major salivary gland	10	1.2	0.18	1.4	0.20	9	1.0	0.16	1.1	0.17
Floor of mouth	12	1.3	0.17	1.6	0.21	3	0.3	0.08	0.4	0.10
Gum & other mouth	17	2.0	0.22	2.4	0.26	16	1.6	0.18	1.8	0.21
Nasopharynx	7	0.8	0.15	0.9	0.16	2	0.2	0.08	0.2	0.08
Oropharynx	9	1.0	0.16	1.2	0.18	3	0.4	0.10	0.4	0.11
Hypopharynx	10	1.2	0.17	1.4	0.20	3	0.3	0.09	0.4	0.10
Digestive System	800	91.4	1.50	109.0	1.75	649	63.7	1.17	75.0	1.34
Esophagus	105	11.7	0.53	14.1	0.62	26	2.5	0.22	2.9	0.26
Stomach	63	7.2	0.42	8.4	0.48	40	3.9	0.28	4.6	0.33
Small intestine	28	3.3	0.29	3.9	0.33	27	2.7	0.25	3.3	0.29
Colon excl. rectum	229	27.0	0.83	31.9	0.96	253	25.4	0.75	29.3	0.84
Rectum & rectosigmoid	119	13.7	0.58	16.4	0.68	80	8.1	0.42	9.6	0.49
Anus, anal canal & anorectum	13	1.6	0.20	1.8	0.23	27	2.6	0.24	3.3	0.29
Liver	77	8.1	0.43	10.1	0.52	17	1.6	0.18	1.9	0.21
Gallbladder	4	0.5	0.11	0.6	0.13	11	1.1	0.15	1.2	0.17
Pancreas	127	14.3	0.59	17.0	0.68	122	11.5	0.48	13.7	0.56
Respiratory System	782	87.4	1.44	104.2	1.69	704	68.3	1.18	80.6	1.37
Larynx	54	5.9	0.37	7.2	0.44	19	1.8	0.20	2.3	0.24
Lung & bronchus	717	80.3	1.38	95.6	1.62	679	65.8	1.16	77.6	1.35
Bones & Joints	5	0.8	0.17	0.8	0.16	5	0.7	0.15	0.8	0.15
Soft Tissue (incl. heart)	29	3.7	0.32	4.2	0.35	24	3.0	0.29	3.2	0.30
Skin (excl. basal & sq.)	271	32.0	0.90	37.4	1.03	229	26.2	0.83	29.5	0.90
Melanomas of the skin	248	29.1	0.86	34.2	0.98	212	24.5	0.80	27.6	0.87
Breast (excl. <i>in situ</i>)	13	1.4	0.18	1.7	0.22	1,203	127.4	1.74	148.6	1.96
Female Genital System	-	-	-	-	-	537	54.6	1.11	65.4	1.28
Cervix uteri	-	-	-	-	-	44	5.9	0.43	6.3	0.43
Uterus Corpus	-	-	-	-	-	317	30.6	0.80	37.9	0.97
Uterus, NOS ¹	-	-	-	-	-	8	0.8	0.13	0.9	0.15
Ovary	-	-	-	-	-	89	9.4	0.47	10.9	0.53
Male Genital System	911	96.8	1.49	117.5	1.76	-	-	-	-	-
Prostate	856	88.1	1.38	108.6	1.68	-	-	-	-	-
Testis	41	7.1	0.51	7.0	0.49	-	-	-	-	-
Penis	12	1.4	0.19	1.6	0.21	-	-	-	-	-
Urinary System	598	68.5	1.29	80.8	1.50	248	24.6	0.73	28.8	0.83
Bladder (incl. <i>in situ</i>)	397	45.9	1.06	53.8	1.22	122	11.6	0.48	13.7	0.56
Kidney & renal pelvis	188	21.2	0.72	25.3	0.84	121	12.5	0.54	14.6	0.61
Ureter	7	0.8	0.14	0.9	0.16	4	0.3	0.08	0.4	0.09
Eye & Orbit	12	1.5	0.20	1.7	0.22	8	1.0	0.16	1.1	0.17
Brain & Other CNS ¹	70	9.0	0.50	9.9	0.54	55	6.6	0.43	7.1	0.44
Brain	68	8.6	0.49	9.6	0.53	51	6.2	0.42	6.7	0.43
Endocrine System	76	9.9	0.54	11.1	0.57	175	23.3	0.84	25.1	0.87
Thyroid gland	70	8.9	0.51	10.1	0.55	169	22.4	0.82	24.2	0.85
Lymphomas	236	28.7	0.87	32.8	0.97	185	19.5	0.68	22.2	0.75
Hodgkin Lymphoma	23	3.3	0.33	3.5	0.33	20	2.8	0.30	2.9	0.30
Non-Hodgkin Lymphoma	213	25.4	0.81	29.3	0.91	165	16.7	0.61	19.3	0.68
Multiple Myeloma	63	7.1	0.41	8.5	0.48	55	5.2	0.33	6.1	0.37
Leukemias	154	18.5	0.70	21.1	0.77	109	11.5	0.53	13.0	0.57
Acute lymphocytic	10	1.8	0.25	1.6	0.22	10	1.6	0.25	1.5	0.21
Chronic lymphocytic	69	7.7	0.43	9.2	0.50	47	4.4	0.29	5.3	0.35
Acute myeloid	42	5.0	0.36	5.7	0.40	30	3.2	0.27	3.6	0.30
Chronic myeloid	18	2.2	0.24	2.5	0.27	12	1.4	0.19	1.5	0.20
Other leukemias	15	1.9	0.23	2.1	0.25	10	0.9	0.14	1.1	0.16
Mesothelioma	20	2.5	0.26	2.9	0.29	5	0.5	0.10	0.6	0.12
Kaposi Sarcoma	2	0.2	0.09	0.3	0.09	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	54	6.9	0.44	7.7	0.48	89	9.9	0.50	11.3	0.55
Breast (<i>in situ</i>)	-	-	-	-	-	271	29.4	0.84	34.6	0.96

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	4,304	499.5	3.53	591.1	4.08	4,331	458.7	3.30	533.3	3.70
Oral Cavity & Pharynx	178	20.1	0.70	24.6	0.84	69	7.3	0.42	8.6	0.47
Lip	15	1.8	0.22	2.1	0.25	6	0.5	0.10	0.6	0.12
Tongue	54	6.0	0.38	7.4	0.46	17	1.8	0.22	2.1	0.24
Major salivary gland	10	1.2	0.18	1.4	0.20	9	1.0	0.17	1.1	0.18
Floor of mouth	12	1.3	0.18	1.6	0.22	3	0.3	0.08	0.4	0.10
Gum & other mouth	17	1.9	0.22	2.3	0.26	16	1.6	0.18	1.8	0.21
Nasopharynx	6	0.7	0.14	0.8	0.16	2	0.2	0.08	0.2	0.08
Oropharynx	9	1.0	0.16	1.2	0.18	3	0.4	0.10	0.4	0.11
Hypopharynx	10	1.2	0.17	1.4	0.20	3	0.3	0.08	0.4	0.10
Digestive System	783	91.2	1.51	108.7	1.76	634	63.5	1.18	74.7	1.35
Esophagus	104	11.8	0.53	14.2	0.63	25	2.4	0.23	2.9	0.26
Stomach	61	7.1	0.42	8.4	0.49	38	3.7	0.28	4.4	0.32
Small intestine	28	3.4	0.30	3.9	0.34	27	2.8	0.25	3.3	0.29
Colon excl. rectum	224	26.9	0.83	31.8	0.96	249	25.5	0.76	29.4	0.85
Rectum & rectosigmoid	116	13.6	0.59	16.4	0.69	76	7.9	0.42	9.4	0.49
Anus, anal canal & anorectum	13	1.6	0.20	1.9	0.23	27	2.7	0.24	3.3	0.29
Liver	72	7.8	0.42	9.7	0.51	16	1.6	0.18	1.9	0.21
Gallbladder	4	0.5	0.11	0.6	0.12	11	1.1	0.15	1.2	0.17
Pancreas	125	14.4	0.60	17.1	0.69	120	11.5	0.48	13.6	0.57
Respiratory System	770	87.6	1.45	104.4	1.70	694	68.5	1.20	80.8	1.39
Larynx	53	5.9	0.37	7.1	0.44	19	1.9	0.20	2.3	0.24
Lung & bronchus	707	80.6	1.40	95.9	1.63	669	66.0	1.17	77.7	1.36
Bones & Joints	5	0.8	0.17	0.8	0.16	5	0.7	0.16	0.7	0.15
Soft Tissue (incl. heart)	28	3.7	0.33	4.2	0.36	23	2.9	0.29	3.1	0.30
Skin (excl. basal & sq.)	260	31.3	0.90	36.6	1.03	213	24.8	0.81	28.0	0.88
Melanomas of the skin	238	28.5	0.86	33.4	0.98	197	23.1	0.79	26.1	0.86
Breast (excl. <i>in situ</i>)	13	1.4	0.18	1.7	0.22	1,182	127.9	1.77	149.1	1.98
Female Genital System	-	-	-	-	-	529	54.9	1.13	65.8	1.30
Cervix uteri	-	-	-	-	-	43	5.9	0.43	6.3	0.44
Uterus Corpus	-	-	-	-	-	313	30.9	0.81	38.2	0.98
Uterus, NOS ¹	-	-	-	-	-	8	0.8	0.13	0.9	0.15
Ovary	-	-	-	-	-	88	9.5	0.48	11.0	0.54
Male Genital System	884	95.8	1.50	116.2	1.77	-	-	-	-	-
Prostate	830	86.9	1.39	107.2	1.68	-	-	-	-	-
Testis	40	7.3	0.53	7.2	0.51	-	-	-	-	-
Penis	11	1.4	0.19	1.6	0.22	-	-	-	-	-
Urinary System	590	68.8	1.31	81.1	1.51	246	24.8	0.74	29.1	0.85
Bladder (incl. <i>in situ</i>)	392	46.1	1.07	54.0	1.24	121	11.7	0.49	13.8	0.57
Kidney & renal pelvis	186	21.3	0.73	25.5	0.85	119	12.6	0.55	14.7	0.62
Ureter	7	0.8	0.14	0.9	0.16	4	0.3	0.08	0.4	0.09
Eye & Orbit	12	1.4	0.19	1.6	0.22	8	1.0	0.16	1.1	0.17
Brain & Other CNS ¹	70	9.1	0.52	10.1	0.55	54	6.7	0.44	7.2	0.45
Brain	67	8.7	0.51	9.7	0.54	50	6.2	0.42	6.7	0.43
Endocrine System	75	10.1	0.55	11.2	0.59	170	23.4	0.86	25.1	0.88
Thyroid gland	69	9.1	0.52	10.3	0.56	164	22.5	0.84	24.3	0.87
Lymphomas	231	28.7	0.88	32.8	0.98	181	19.5	0.69	22.2	0.76
Hodgkin Lymphoma	22	3.4	0.34	3.6	0.34	19	2.9	0.31	2.9	0.31
Non-Hodgkin Lymphoma	209	25.3	0.81	29.3	0.92	162	16.6	0.61	19.3	0.69
Multiple Myeloma	62	7.1	0.42	8.4	0.49	54	5.2	0.33	6.1	0.38
Leukemias	151	18.6	0.71	21.2	0.78	108	11.7	0.54	13.2	0.58
Acute lymphocytic	10	1.8	0.26	1.6	0.23	10	1.7	0.26	1.5	0.23
Chronic lymphocytic	68	7.7	0.43	9.2	0.51	47	4.4	0.30	5.4	0.36
Acute myeloid	42	5.0	0.36	5.7	0.40	30	3.2	0.28	3.6	0.30
Chronic myeloid	17	2.2	0.25	2.5	0.27	12	1.4	0.20	1.6	0.21
Other leukemias	14	1.9	0.23	2.1	0.25	10	0.9	0.14	1.1	0.17
Mesothelioma	20	2.5	0.26	2.9	0.29	5	0.5	0.11	0.6	0.12
Kaposi Sarcoma	2	0.3	0.09	0.3	0.09	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	51	6.7	0.44	7.5	0.48	87	9.8	0.51	11.2	0.55
Breast (<i>in situ</i>)	-	-	-	-	-	266	29.4	0.86	34.6	0.97

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	25	361.8	37.05	444.1	44.34	18	300.2	33.45	361.4	41.17
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	82.3	15.77	103.6	19.62	4	71.3	16.95	90.4	21.51
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	13.3	5.55	15.4	6.55	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	25.6	8.21	34.0	11.04	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	4	71.4	17.68	92.1	21.71	2	26.5	9.80	30.6	11.62
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	59.8	15.66	77.8	19.29	2	26.5	9.80	30.6	11.62
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	80.0	16.37	94.1	19.93
Female Genital System	-	-	-	-	-	3	51.4	14.27	62.8	17.62
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	27.6	10.73	35.0	13.33
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	7	112.4	20.78	136.9	24.33	-	-	-	-	-
Prostate	7	110.9	20.73	135.4	24.29	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	31.9	12.36	36.6	14.25	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	1	17.8	8.11	20.2	8.92	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	1	16.8	8.05	19.2	8.87	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	1	21.0	10.26	23.8	11.88	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13	240.7	33.45	291.3	39.62	22	249.5	25.13	295.0	29.70
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	70.4	16.83	87.2	20.55	5	54.8	11.76	68.7	14.49
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	2	20.0	7.66	23.6	9.00
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	23.2	9.23	30.4	11.83	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	3	41.3	11.48	50.2	13.87
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	3	41.3	11.48	50.2	13.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	52.4	10.37	61.5	12.25
Female Genital System	-	-	-	-	-	2	23.0	7.01	25.7	7.94
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	14.5	5.57	18.6	7.10
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	22.8	8.17	29.2	10.46	-	-	-	-	-
Prostate	1	20.7	7.90	27.2	10.27	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	39.9	14.30	49.4	17.34	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	3	25.4	7.06	30.4	8.51
Thyroid gland	-	-	-	-	-	3	25.4	7.06	30.4	8.51
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	2	19.5	6.18	22.5	7.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	14	570.1	80.23	700.6	95.86	16	562.5	67.40	662.4	77.98
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	166.2	54.54	192.8	63.81	2	97.2	32.48	113.7	37.76
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	4	123.9	32.53	162.0	40.69	3	119.7	30.90	147.8	37.06
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	117.3	31.86	153.8	39.85	3	112.8	30.12	138.9	35.96
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	6	192.2	37.40	226.6	43.16
Female Genital System	-	-	-	-	-	1	38.9	16.41	49.2	20.41
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	134.5	33.92	164.3	40.15	-	-	-	-	-
Prostate	3	126.0	32.83	154.9	39.03	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malignant)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17	280.4	32.98	331.9	38.31	19	276.5	29.20	327.3	34.43
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	75.2	17.06	90.9	20.09	3	51.4	13.69	57.6	15.27
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	1	18.5	7.78	20.7	8.78
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	28.9	10.68	36.4	13.09	2	23.5	8.51	26.8	9.65
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	28.9	10.68	36.4	13.09	2	23.5	8.51	26.8	9.65
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	7	98.0	17.15	118.5	20.64
Female Genital System	-	-	-	-	-	2	29.9	8.86	40.1	11.83
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	21.8	7.30	30.6	10.26
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	59.4	14.63	73.1	17.57	-	-	-	-	-
Prostate	3	56.6	14.49	70.4	17.46	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	50.7	14.47	57.4	16.17	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	2	41.5	13.68	46.2	15.07	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	21.1	7.14	24.1	8.38
Thyroid gland	-	-	-	-	-	2	21.1	7.14	24.1	8.38
Lymphomas	1	21.2	9.19	22.5	9.71	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MAINE

II-228 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,291	501.0	3.55	592.8	4.10	4,314	460.3	3.32	535.0	3.73
Oral Cavity & Pharynx	177	20.2	0.71	24.7	0.84	69	7.3	0.42	8.6	0.47
Lip	14	1.8	0.22	2.1	0.25	6	0.6	0.11	0.7	0.12
Tongue	54	6.0	0.38	7.4	0.46	17	1.8	0.22	2.1	0.24
Major salivary gland	10	1.2	0.18	1.4	0.20	9	1.0	0.17	1.1	0.18
Floor of mouth	12	1.3	0.18	1.6	0.22	3	0.3	0.08	0.4	0.10
Gum & other mouth	17	1.9	0.22	2.4	0.26	16	1.5	0.18	1.8	0.21
Nasopharynx	6	0.7	0.14	0.8	0.16	2	0.2	0.08	0.2	0.08
Oropharynx	9	1.0	0.16	1.2	0.19	3	0.4	0.10	0.4	0.11
Hypopharynx	10	1.2	0.17	1.4	0.20	3	0.3	0.08	0.4	0.10
Digestive System	780	91.3	1.52	108.9	1.77	632	63.6	1.18	74.8	1.36
Esophagus	103	11.7	0.53	14.2	0.63	25	2.4	0.23	2.9	0.26
Stomach	61	7.1	0.42	8.4	0.49	38	3.8	0.28	4.5	0.33
Small intestine	28	3.4	0.30	3.9	0.34	27	2.8	0.26	3.3	0.29
Colon excl. rectum	224	27.0	0.84	31.9	0.97	248	25.6	0.76	29.5	0.86
Rectum & rectosigmoid	116	13.7	0.59	16.4	0.69	76	7.9	0.43	9.5	0.50
Anus, anal canal & anorectum	13	1.6	0.21	1.9	0.23	27	2.7	0.24	3.3	0.29
Liver	72	7.8	0.42	9.7	0.52	16	1.6	0.18	1.9	0.21
Gallbladder	4	0.5	0.11	0.6	0.12	10	1.0	0.15	1.2	0.17
Pancreas	124	14.4	0.60	17.0	0.69	119	11.5	0.49	13.7	0.57
Respiratory System	769	88.0	1.46	104.8	1.71	692	68.7	1.20	81.1	1.40
Larynx	53	5.9	0.37	7.2	0.44	19	1.9	0.20	2.3	0.25
Lung & bronchus	706	80.9	1.40	96.3	1.64	668	66.2	1.18	78.0	1.37
Bones & Joints	5	0.8	0.18	0.8	0.16	5	0.7	0.16	0.7	0.15
Soft Tissue (incl. heart)	28	3.8	0.33	4.2	0.36	23	2.9	0.29	3.2	0.30
Skin (excl. basal & sq.)	260	31.5	0.91	36.8	1.04	213	25.0	0.82	28.2	0.89
Melanomas of the skin	238	28.7	0.87	33.6	0.99	197	23.3	0.80	26.3	0.86
Breast (excl. <i>in situ</i>)	13	1.4	0.18	1.7	0.22	1,176	128.2	1.78	149.4	1.99
Female Genital System	-	-	-	-	-	527	55.1	1.14	66.0	1.31
Cervix uteri	-	-	-	-	-	42	5.9	0.44	6.3	0.44
Uterus Corpus	-	-	-	-	-	312	31.0	0.82	38.3	0.98
Uterus, NOS ¹	-	-	-	-	-	8	0.8	0.13	0.9	0.15
Ovary	-	-	-	-	-	87	9.5	0.48	11.1	0.54
Male Genital System	880	96.0	1.50	116.4	1.78	-	-	-	-	-
Prostate	827	87.1	1.39	107.3	1.69	-	-	-	-	-
Testis	40	7.4	0.54	7.2	0.51	-	-	-	-	-
Penis	11	1.4	0.19	1.6	0.22	-	-	-	-	-
Urinary System	588	68.9	1.31	81.3	1.52	245	24.9	0.75	29.2	0.85
Bladder (incl. <i>in situ</i>)	390	46.1	1.07	54.1	1.24	121	11.7	0.49	13.8	0.57
Kidney & renal pelvis	185	21.4	0.73	25.6	0.85	119	12.7	0.56	14.8	0.62
Ureter	7	0.8	0.14	0.9	0.16	4	0.3	0.08	0.4	0.09
Eye & Orbit	12	1.4	0.19	1.7	0.22	8	1.0	0.17	1.1	0.17
Brain & Other CNS ¹	69	9.2	0.52	10.1	0.55	53	6.7	0.45	7.2	0.45
Brain	67	8.8	0.51	9.8	0.54	50	6.2	0.43	6.7	0.44
Endocrine System	75	10.1	0.56	11.3	0.59	169	23.5	0.87	25.2	0.89
Thyroid gland	69	9.2	0.53	10.3	0.57	162	22.6	0.85	24.3	0.87
Lymphomas	230	28.8	0.89	32.9	0.99	181	19.6	0.70	22.3	0.76
Hodgkin Lymphoma	22	3.5	0.34	3.6	0.35	19	2.9	0.32	3.0	0.31
Non-Hodgkin Lymphoma	208	25.3	0.82	29.3	0.92	162	16.7	0.62	19.4	0.70
Multiple Myeloma	61	7.1	0.42	8.4	0.49	54	5.2	0.33	6.2	0.38
Leukemias	151	18.7	0.71	21.3	0.79	108	11.7	0.55	13.3	0.59
Acute lymphocytic	10	1.8	0.27	1.6	0.23	10	1.7	0.26	1.5	0.23
Chronic lymphocytic	68	7.7	0.43	9.3	0.51	47	4.4	0.30	5.4	0.36
Acute myeloid	42	5.1	0.36	5.8	0.41	29	3.2	0.28	3.6	0.30
Chronic myeloid	17	2.2	0.25	2.5	0.28	12	1.5	0.20	1.6	0.21
Other leukemias	14	1.9	0.24	2.1	0.26	10	1.0	0.14	1.1	0.17
Mesothelioma	20	2.5	0.26	2.9	0.30	5	0.5	0.11	0.6	0.12
Kaposi Sarcoma	2	0.3	0.09	0.3	0.10	-	-	-	-	-
Ill-defined & Unknown	171	20.8	0.73	24.3	0.84	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	51	6.7	0.44	7.5	0.48	87	9.9	0.51	11.3	0.56
Breast (<i>in situ</i>)	-	-	-	-	-	266	29.7	0.86	34.9	0.98

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maine, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	24	376.4	38.96	461.2	46.56	17	311.0	35.08	372.9	42.94
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	86.7	16.60	109.2	20.66	4	75.9	18.03	96.2	22.85
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	14.0	5.83	16.1	6.87	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	27.0	8.66	35.9	11.65	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	4	73.0	18.63	93.5	22.73	2	28.2	10.38	32.4	12.26
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	60.7	16.46	78.4	20.13	2	28.2	10.38	32.4	12.26
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	81.1	16.94	94.6	20.42
Female Genital System	-	-	-	-	-	3	50.4	14.54	61.0	17.77
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	24.9	10.48	31.4	12.93
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	7	115.6	21.66	140.7	25.35	-	-	-	-	-
Prostate	7	114.0	21.60	139.2	25.30	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	33.7	13.19	38.7	15.19	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	1	18.8	8.58	21.3	9.42	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	5,923,704	5,958,165	5,986,717	6,004,692	6,024,891
White	3,644,697	3,647,588	3,644,059	3,637,481	3,632,537
Black	1,849,408	1,869,391	1,889,067	1,904,132	1,919,108
American Indian/Alaskan Native (AI/AN)	38,031	38,870	39,964	40,709	41,521
Asian/Pacific Islander (API)	391,568	402,316	413,627	422,370	431,725

All Races Population 2013-2017: 29,898,169

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	528,786	550,405	569,594	588,325	607,798
Non-Hispanic White	3,212,225	3,197,168	3,178,308	3,156,267	3,135,342
Non-Hispanic Black	1,785,542	1,803,155	1,820,446	1,833,384	1,846,021

Hispanic/Latino Population, Census 2010: 470,632

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MARYLAND CANCER REGISTRY

Initial Operation: 1982
 Population-based Data Available: 1992
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.4	101.3	107.0	105.5	104.0
Missing Race	0.2	0.2	0.2	0.4	0.3
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.3	0.2	0.2	0.7	0.8
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.9	2.6	2.7	2.9	3.5
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.9	Prostate	96.9
Oral Cavity & Pharynx	97.8	Testis	98.8
Esophagus	94.8	Bladder (incl. <i>in situ</i>)	96.8
Stomach	95.5	Kidney & Renal Pelvis	90.3
Colon & Rectum	95.0	Brain & Other CNS ¹	86.6
Liver	53.7	Thyroid	99.5
Pancreas	85.8	Hodgkin Lymphoma	96.9
Lung & Bronchus	87.9	Non-Hodgkin Lymphoma	95.5
Melanomas of the Skin	99.4	Multiple Myeloma	86.6
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	84.0
Cervix uteri	96.5	Brain & Other CNS ¹ <i>non-malig</i>	49.7
Uterus Corpus & Uterus NOS ¹	98.3	Breast <i>in situ</i>	100.0
Ovary	92.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,375	493.8	1.84	587.5	2.14	15,868	428.0	1.56	499.5	1.78
Oral Cavity & Pharynx	552	16.8	0.33	20.6	0.39	234	6.2	0.19	7.3	0.22
Lip	13	0.4	0.05	0.5	0.06	6	0.1	0.03	0.2	0.03
Tongue	187	5.6	0.19	6.9	0.23	82	2.2	0.11	2.6	0.13
Major salivary gland	46	1.6	0.11	1.8	0.12	36	1.0	0.08	1.1	0.09
Floor of mouth	19	0.6	0.06	0.7	0.07	10	0.3	0.04	0.3	0.04
Gum & other mouth	63	2.0	0.12	2.4	0.14	46	1.2	0.08	1.4	0.09
Nasopharynx	22	0.7	0.07	0.8	0.08	10	0.3	0.04	0.3	0.05
Oropharynx	32	1.0	0.08	1.2	0.09	11	0.3	0.04	0.3	0.05
Hypopharynx	35	1.1	0.08	1.3	0.10	8	0.2	0.03	0.2	0.04
Digestive System	2,920	94.5	0.81	112.5	0.94	2,467	65.2	0.60	76.8	0.70
Esophagus	223	7.3	0.22	8.7	0.26	72	1.9	0.10	2.2	0.12
Stomach	275	9.1	0.25	10.7	0.29	191	5.1	0.17	6.0	0.19
Small intestine	92	2.9	0.14	3.5	0.16	86	2.3	0.11	2.7	0.13
Colon excl. rectum	847	28.3	0.45	33.2	0.52	934	24.9	0.37	29.1	0.43
Rectum & rectosigmoid	388	12.3	0.29	14.6	0.33	301	8.1	0.21	9.6	0.25
Anus, anal canal & anorectum	46	1.5	0.10	1.7	0.12	79	2.0	0.10	2.5	0.12
Liver	409	12.0	0.27	15.0	0.33	138	3.5	0.14	4.3	0.16
Gallbladder	24	0.8	0.08	1.0	0.09	48	1.2	0.08	1.5	0.10
Pancreas	474	15.6	0.33	18.5	0.38	454	11.9	0.25	14.0	0.30
Respiratory System	2,096	69.1	0.70	81.8	0.81	2,045	53.4	0.54	63.3	0.63
Larynx	155	4.8	0.18	5.9	0.21	41	1.0	0.07	1.3	0.09
Lung & bronchus	1,898	62.9	0.67	74.3	0.77	1,980	51.7	0.53	61.3	0.62
Bones & Joints	36	1.2	0.09	1.3	0.10	28	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	121	4.1	0.17	4.6	0.19	100	2.9	0.13	3.2	0.14
Skin (excl. basal & sq.)	1,012	33.8	0.49	39.4	0.56	705	19.7	0.34	22.4	0.38
Melanomas of the skin	953	31.7	0.47	37.1	0.54	660	18.4	0.33	21.0	0.37
Breast (excl. <i>in situ</i>)	52	1.7	0.11	2.0	0.13	4,903	132.9	0.87	155.9	1.00
Female Genital System	-	-	-	-	-	1,910	50.6	0.53	60.2	0.62
Cervix uteri	-	-	-	-	-	220	6.6	0.21	7.2	0.22
Uterus Corpus	-	-	-	-	-	1,049	26.8	0.38	32.8	0.45
Uterus, NOS ¹	-	-	-	-	-	41	1.1	0.08	1.3	0.09
Ovary	-	-	-	-	-	404	10.8	0.25	12.8	0.29
Male Genital System	4,349	130.0	0.91	160.3	1.10	-	-	-	-	-
Prostate	4,195	124.7	0.89	154.8	1.08	-	-	-	-	-
Testis	131	4.6	0.18	4.6	0.18	-	-	-	-	-
Penis	16	0.6	0.07	0.7	0.07	-	-	-	-	-
Urinary System	1,680	56.4	0.63	66.3	0.73	748	19.9	0.33	23.2	0.38
Bladder (incl. <i>in situ</i>)	993	34.4	0.50	40.3	0.58	330	8.6	0.22	10.1	0.25
Kidney & renal pelvis	643	20.5	0.37	24.2	0.43	397	10.7	0.25	12.5	0.28
Ureter	23	0.8	0.08	0.9	0.09	14	0.4	0.04	0.4	0.05
Eye & Orbit	21	0.7	0.07	0.8	0.08	18	0.5	0.06	0.6	0.06
Brain & Other CNS ¹	219	7.3	0.22	8.0	0.24	180	5.2	0.18	5.7	0.19
Brain	207	6.8	0.22	7.6	0.24	166	4.8	0.17	5.3	0.18
Endocrine System	245	8.0	0.24	8.9	0.26	720	21.8	0.37	23.6	0.40
Thyroid gland	216	7.1	0.22	7.9	0.24	693	21.0	0.37	22.8	0.39
Lymphomas	733	24.4	0.42	28.1	0.47	646	17.8	0.32	20.4	0.36
Hodgkin Lymphoma	86	2.9	0.14	3.1	0.15	77	2.5	0.13	2.6	0.13
Non-Hodgkin Lymphoma	647	21.5	0.39	25.0	0.44	569	15.3	0.29	17.8	0.34
Multiple Myeloma	279	9.2	0.25	10.9	0.30	261	6.8	0.19	8.1	0.23
Leukemias	472	16.0	0.34	18.1	0.38	370	10.2	0.24	11.5	0.27
Acute lymphocytic	48	1.7	0.11	1.6	0.10	37	1.2	0.09	1.2	0.09
Chronic lymphocytic	165	5.5	0.20	6.6	0.23	118	3.0	0.13	3.6	0.15
Acute myeloid	144	4.9	0.19	5.6	0.21	123	3.4	0.14	3.9	0.16
Chronic myeloid	58	1.9	0.12	2.2	0.13	51	1.4	0.09	1.6	0.10
Other leukemias	56	1.9	0.12	2.2	0.13	40	1.1	0.08	1.2	0.09
Mesothelioma	34	1.2	0.10	1.4	0.11	15	0.4	0.05	0.5	0.05
Kaposi Sarcoma	17	0.6	0.06	0.6	0.07	3	0.1	0.03	0.1	0.03
Ill-defined & Unknown	537	18.7	0.37	21.8	0.43	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	260	8.7	0.25	9.9	0.28	513	14.0	0.28	16.2	0.32
Breast (<i>in situ</i>)	6	0.2	0.03	0.2	0.04	1,162	31.8	0.43	37.5	0.49

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	10,656	497.1	2.21	588.3	2.57	10,714	445.6	2.00	518.8	2.27
Oral Cavity & Pharynx	428	19.1	0.42	23.3	0.51	169	6.9	0.24	8.1	0.28
Lip	11	0.5	0.07	0.6	0.08	5	0.2	0.04	0.2	0.04
Tongue	158	6.8	0.25	8.5	0.30	64	2.6	0.15	3.1	0.18
Major salivary gland	36	1.8	0.14	2.0	0.15	20	0.9	0.09	1.0	0.10
Floor of mouth	14	0.7	0.08	0.8	0.09	8	0.3	0.05	0.4	0.06
Gum & other mouth	45	2.0	0.14	2.5	0.17	34	1.3	0.10	1.5	0.12
Nasopharynx	10	0.5	0.07	0.6	0.08	4	0.2	0.04	0.2	0.05
Oropharynx	25	1.1	0.10	1.3	0.12	8	0.3	0.05	0.4	0.06
Hypopharynx	21	1.0	0.10	1.2	0.11	6	0.3	0.05	0.3	0.05
Digestive System	1,900	89.3	0.94	105.9	1.09	1,545	61.7	0.73	72.2	0.83
Esophagus	179	8.3	0.29	9.9	0.33	50	1.9	0.13	2.3	0.15
Stomach	165	7.8	0.28	9.2	0.32	94	3.8	0.18	4.4	0.21
Small intestine	55	2.5	0.16	3.0	0.19	48	2.0	0.13	2.3	0.15
Colon excl. rectum	547	26.5	0.52	30.9	0.60	608	24.4	0.46	28.2	0.52
Rectum & rectosigmoid	268	12.6	0.35	14.9	0.41	189	7.9	0.27	9.3	0.31
Anus, anal canal & anorectum	28	1.3	0.11	1.5	0.13	59	2.3	0.14	2.9	0.17
Liver	221	9.5	0.29	11.9	0.36	74	2.9	0.16	3.4	0.18
Gallbladder	15	0.7	0.09	0.8	0.10	25	0.9	0.09	1.1	0.10
Pancreas	325	15.3	0.39	18.1	0.45	287	11.2	0.31	13.2	0.35
Respiratory System	1,502	70.5	0.83	83.3	0.97	1,462	57.1	0.68	67.5	0.80
Larynx	105	4.7	0.21	5.8	0.25	28	1.1	0.09	1.4	0.12
Lung & bronchus	1,366	64.3	0.80	75.8	0.92	1,417	55.3	0.67	65.4	0.78
Bones & Joints	24	1.3	0.12	1.3	0.12	18	0.9	0.10	1.0	0.10
Soft Tissue (incl. heart)	85	4.2	0.21	4.7	0.23	63	2.9	0.17	3.2	0.18
Skin (excl. basal & sq.)	980	46.8	0.69	54.7	0.79	671	29.7	0.54	33.8	0.59
Melanomas of the skin	932	44.4	0.67	51.9	0.77	638	28.4	0.53	32.3	0.58
Breast (excl. <i>in situ</i>)	31	1.5	0.12	1.7	0.14	3,175	134.0	1.11	157.4	1.26
Female Genital System	-	-	-	-	-	1,259	52.1	0.68	61.8	0.79
Cervix uteri	-	-	-	-	-	129	6.5	0.27	7.0	0.28
Uterus Corpus	-	-	-	-	-	694	27.6	0.48	33.7	0.58
Uterus, NOS ¹	-	-	-	-	-	17	0.7	0.08	0.8	0.09
Ovary	-	-	-	-	-	278	11.5	0.32	13.6	0.37
Male Genital System	2,580	112.7	1.02	137.7	1.22	-	-	-	-	-
Prostate	2,454	105.6	0.98	130.5	1.18	-	-	-	-	-
Testis	110	6.3	0.27	6.3	0.27	-	-	-	-	-
Penis	11	0.6	0.08	0.6	0.09	-	-	-	-	-
Urinary System	1,294	61.8	0.79	72.6	0.91	516	20.7	0.42	24.1	0.48
Bladder (incl. <i>in situ</i>)	821	39.6	0.63	46.5	0.73	246	9.5	0.28	11.1	0.32
Kidney & renal pelvis	437	20.3	0.45	24.0	0.52	254	10.6	0.31	12.3	0.35
Ureter	19	1.0	0.10	1.1	0.11	11	0.4	0.06	0.5	0.07
Eye & Orbit	18	0.9	0.10	1.0	0.11	15	0.7	0.08	0.8	0.09
Brain & Other CNS ¹	163	8.1	0.29	9.0	0.32	135	6.1	0.25	6.8	0.26
Brain	156	7.7	0.29	8.6	0.31	126	5.6	0.24	6.3	0.25
Endocrine System	172	8.6	0.30	9.6	0.33	475	24.1	0.52	26.0	0.54
Thyroid gland	157	7.9	0.29	8.8	0.32	461	23.4	0.51	25.2	0.53
Lymphomas	541	26.2	0.52	30.3	0.59	450	18.9	0.41	21.7	0.46
Hodgkin Lymphoma	55	3.0	0.18	3.1	0.19	46	2.5	0.17	2.5	0.17
Non-Hodgkin Lymphoma	486	23.3	0.48	27.2	0.56	404	16.4	0.38	19.1	0.43
Multiple Myeloma	155	7.4	0.27	8.7	0.32	125	4.9	0.20	5.8	0.23
Leukemias	354	17.6	0.43	19.9	0.48	260	10.8	0.31	12.2	0.34
Acute lymphocytic	30	1.8	0.15	1.6	0.13	26	1.4	0.13	1.3	0.12
Chronic lymphocytic	133	6.3	0.25	7.5	0.29	92	3.5	0.17	4.2	0.20
Acute myeloid	107	5.3	0.24	6.0	0.26	83	3.5	0.18	3.9	0.20
Chronic myeloid	41	2.0	0.14	2.3	0.16	33	1.4	0.11	1.6	0.13
Other leukemias	43	2.1	0.15	2.4	0.17	26	1.1	0.10	1.2	0.11
Mesothelioma	29	1.5	0.12	1.7	0.14	12	0.5	0.07	0.6	0.07
Kaposi Sarcoma	5	0.3	0.05	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	173	8.6	0.30	9.8	0.33	328	13.9	0.36	16.0	0.40
Breast (<i>in situ</i>)	4	0.2	0.04	0.2	0.05	704	30.8	0.54	36.3	0.62

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,062	515.4	3.87	622.5	4.56	4,310	402.6	2.82	474.0	3.26
Oral Cavity & Pharynx	103	12.5	0.59	15.2	0.70	52	4.8	0.31	5.6	0.35
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	24	3.0	0.30	3.7	0.35	12	1.0	0.14	1.3	0.17
Major salivary gland	9	1.1	0.17	1.3	0.20	14	1.3	0.16	1.5	0.18
Floor of mouth	4	0.5	0.11	0.6	0.14	2	0.2	0.06	0.2	0.07
Gum & other mouth	13	1.6	0.21	1.9	0.25	9	0.9	0.14	1.0	0.15
Nasopharynx	8	0.9	0.15	1.0	0.17	5	0.5	0.09	0.5	0.10
Oropharynx	8	0.9	0.15	1.1	0.19	3	0.3	0.07	0.3	0.08
Hypopharynx	12	1.5	0.20	1.8	0.24	2	0.1	0.04	0.2	0.06
Digestive System	856	110.5	1.81	133.2	2.13	781	73.6	1.21	87.6	1.42
Esophagus	38	5.2	0.40	6.3	0.48	20	1.9	0.19	2.3	0.23
Stomach	79	11.0	0.59	13.0	0.69	75	7.1	0.38	8.5	0.44
Small intestine	32	4.3	0.36	5.1	0.42	35	3.4	0.26	3.9	0.30
Colon excl. rectum	259	35.0	1.05	41.4	1.21	286	27.1	0.74	32.2	0.86
Rectum & rectosigmoid	96	12.2	0.59	14.5	0.69	87	8.2	0.40	9.6	0.46
Anus, anal canal & anorectum	17	2.0	0.23	2.3	0.26	18	1.6	0.17	2.0	0.21
Liver	161	17.7	0.66	22.8	0.82	52	4.5	0.29	5.6	0.35
Gallbladder	8	1.1	0.18	1.3	0.21	18	1.7	0.18	2.1	0.22
Pancreas	128	17.0	0.72	20.4	0.84	147	14.2	0.54	16.9	0.63
Respiratory System	523	71.6	1.50	85.6	1.75	527	49.9	1.00	59.7	1.18
Larynx	46	5.8	0.41	7.2	0.49	12	1.1	0.15	1.4	0.17
Lung & bronchus	468	64.8	1.44	77.2	1.67	509	48.2	0.99	57.8	1.16
Bones & Joints	10	1.1	0.16	1.1	0.17	6	0.6	0.12	0.7	0.12
Soft Tissue (incl. heart)	30	3.9	0.34	4.3	0.37	32	2.9	0.24	3.3	0.26
Skin (excl. basal & sq.)	19	2.6	0.29	3.0	0.32	17	1.7	0.18	1.9	0.21
Melanomas of the skin	10	1.5	0.23	1.7	0.25	8	0.7	0.12	0.8	0.14
Breast (excl. <i>in situ</i>)	19	2.6	0.29	3.0	0.32	1,448	133.4	1.61	156.5	1.85
Female Genital System	-	-	-	-	-	536	48.1	0.96	57.8	1.13
Cervix uteri	-	-	-	-	-	71	6.6	0.36	7.5	0.40
Uterus Corpus	-	-	-	-	-	300	26.1	0.70	32.3	0.84
Uterus, NOS ¹	-	-	-	-	-	22	2.0	0.20	2.4	0.23
Ovary	-	-	-	-	-	97	8.9	0.42	10.6	0.48
Male Genital System	1,587	188.6	2.25	235.0	2.72	-	-	-	-	-
Prostate	1,569	186.4	2.23	232.7	2.70	-	-	-	-	-
Testis	12	1.4	0.18	1.4	0.18	-	-	-	-	-
Penis	4	0.6	0.15	0.7	0.17	-	-	-	-	-
Urinary System	331	44.9	1.18	53.2	1.37	204	19.5	0.63	22.8	0.72
Bladder (incl. <i>in situ</i>)	142	21.3	0.86	25.0	0.99	73	7.3	0.39	8.5	0.45
Kidney & renal pelvis	183	22.7	0.80	27.1	0.93	127	11.8	0.48	13.9	0.55
Ureter	2	0.3	0.11	0.4	0.13	2	0.2	0.07	0.3	0.08
Eye & Orbit	3	0.3	0.10	0.4	0.11	1	0.1	0.05	0.1	0.04
Brain & Other CNS ¹	38	4.7	0.35	5.1	0.39	32	3.2	0.26	3.4	0.27
Brain	36	4.4	0.34	4.8	0.38	29	2.9	0.25	3.1	0.26
Endocrine System	50	6.3	0.42	7.1	0.46	161	15.1	0.54	16.8	0.60
Thyroid gland	39	5.0	0.37	5.6	0.42	151	14.2	0.53	15.8	0.58
Lymphomas	151	18.7	0.72	21.3	0.81	160	15.1	0.55	17.3	0.62
Hodgkin Lymphoma	26	3.0	0.27	3.1	0.28	26	2.6	0.23	2.7	0.24
Non-Hodgkin Lymphoma	125	15.7	0.67	18.2	0.76	133	12.5	0.50	14.6	0.57
Multiple Myeloma	113	15.5	0.70	18.3	0.81	128	12.2	0.50	14.5	0.58
Leukemias	93	12.2	0.61	14.0	0.69	88	8.4	0.41	9.6	0.46
Acute lymphocytic	11	1.2	0.16	1.2	0.16	6	0.7	0.12	0.6	0.11
Chronic lymphocytic	28	3.9	0.35	4.7	0.42	23	2.2	0.21	2.6	0.24
Acute myeloid	28	3.7	0.34	4.3	0.38	33	3.1	0.25	3.5	0.28
Chronic myeloid	14	1.8	0.23	2.1	0.26	13	1.2	0.15	1.4	0.18
Other leukemias	12	1.6	0.22	1.7	0.25	12	1.2	0.16	1.4	0.18
Mesothelioma	3	0.6	0.14	0.6	0.16	2	0.2	0.06	0.2	0.07
Kaposi Sarcoma	11	1.3	0.18	1.4	0.19	2	0.2	0.07	0.2	0.06
Ill-defined & Unknown	121	17.5	0.77	20.9	0.90	134	13.6	0.54	15.8	0.61
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	67	9.1	0.53	10.3	0.59	147	14.0	0.53	16.3	0.61
Breast (<i>in situ</i>)	2	0.3	0.09	0.3	0.10	375	33.9	0.80	40.3	0.94

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	479	272.7	5.79	321.0	6.77	625	283.8	5.19	328.7	5.98
Oral Cavity & Pharynx	18	9.6	1.03	11.4	1.22	11	5.0	0.68	6.0	0.81
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	2.4	0.52	2.8	0.61	4	2.1	0.45	2.4	0.52
Major salivary gland	-	-	-	-	-	2	0.8	0.28	1.0	0.33
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	5	2.5	0.54	3.0	0.65	2	1.0	0.30	1.2	0.38
Nasopharynx	4	1.8	0.42	2.0	0.47	1	0.6	0.23	0.7	0.26
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	0.9	0.34	1.1	0.39	-	-	-	-	-
Digestive System	131	74.4	3.02	88.1	3.55	105	50.1	2.25	59.3	2.63
Esophagus	4	2.5	0.56	3.1	0.68	1	0.6	0.26	0.7	0.30
Stomach	22	13.6	1.34	15.9	1.55	16	7.7	0.88	9.2	1.04
Small intestine	3	1.8	0.44	2.1	0.53	2	1.0	0.30	1.1	0.33
Colon excl. rectum	33	18.7	1.51	22.3	1.78	28	13.6	1.17	16.0	1.37
Rectum & rectosigmoid	19	9.8	1.03	11.8	1.23	19	8.5	0.91	10.2	1.07
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	24	13.1	1.25	15.5	1.47	10	4.8	0.71	5.6	0.83
Gallbladder	-	-	-	-	-	3	1.6	0.42	1.9	0.48
Pancreas	17	10.0	1.14	11.8	1.33	16	8.2	0.93	9.5	1.07
Respiratory System	58	35.9	2.19	42.3	2.56	48	23.2	1.54	27.2	1.78
Larynx	3	1.4	0.39	1.7	0.49	-	-	-	-	-
Lung & bronchus	54	33.5	2.12	39.4	2.47	46	22.5	1.52	26.4	1.75
Bones & Joints	1	0.7	0.31	0.7	0.33	2	1.1	0.35	1.1	0.35
Soft Tissue (incl. heart)	4	2.4	0.54	2.6	0.57	4	1.7	0.39	1.8	0.43
Skin (excl. basal & sq.)	4	2.6	0.58	2.9	0.65	4	1.8	0.43	2.1	0.50
Melanomas of the skin	4	2.1	0.52	2.4	0.58	2	1.1	0.33	1.4	0.40
Breast (excl. <i>in situ</i>)	1	0.8	0.30	0.8	0.31	214	93.1	2.89	108.8	3.37
Female Genital System	-	-	-	-	-	82	35.6	1.79	42.0	2.11
Cervix uteri	-	-	-	-	-	12	5.3	0.70	5.9	0.78
Uterus Corpus	-	-	-	-	-	41	17.4	1.24	21.1	1.50
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	23	9.8	0.94	11.4	1.09
Male Genital System	118	64.2	2.73	78.3	3.28	-	-	-	-	-
Prostate	113	61.8	2.68	75.8	3.23	-	-	-	-	-
Testis	3	1.4	0.36	1.3	0.36	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	44	26.2	1.85	30.7	2.16	21	10.1	1.02	11.7	1.18
Bladder (incl. <i>in situ</i>)	25	16.1	1.51	18.9	1.76	9	4.5	0.70	5.2	0.81
Kidney & renal pelvis	17	9.0	1.00	10.6	1.18	11	5.1	0.70	5.9	0.82
Ureter	1	0.9	0.36	1.0	0.40	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	1	0.5	0.22	0.5	0.21
Brain & Other CNS ¹	12	6.1	0.81	6.8	0.91	8	3.6	0.59	3.9	0.65
Brain	11	5.6	0.78	6.3	0.88	7	3.1	0.55	3.4	0.60
Endocrine System	18	9.1	0.97	10.1	1.09	66	28.5	1.59	30.9	1.74
Thyroid gland	16	8.0	0.92	8.7	1.01	64	27.6	1.56	29.9	1.70
Lymphomas	28	16.4	1.43	18.5	1.62	25	12.0	1.10	13.3	1.23
Hodgkin Lymphoma	4	1.9	0.43	2.0	0.46	3	1.2	0.34	1.2	0.35
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	7	3.8	0.68	4.6	0.82	5	2.4	0.48	3.0	0.57
Leukemias	15	8.5	1.03	9.4	1.15	13	5.9	0.75	6.3	0.81
Acute lymphocytic	2	1.2	0.36	1.2	0.37	2	1.0	0.32	0.9	0.29
Chronic lymphocytic	2	1.7	0.49	1.8	0.54	-	-	-	-	-
Acute myeloid	7	4.1	0.72	4.8	0.84	5	2.5	0.49	2.7	0.54
Chronic myeloid	2	0.9	0.31	0.9	0.32	3	1.2	0.32	1.3	0.36
Other leukemias	1	0.7	0.28	0.8	0.31	2	0.9	0.30	1.0	0.33
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	17	10.7	1.23	12.3	1.42	17	9.0	1.00	10.3	1.14
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	7.3	0.92	8.4	1.06	27	12.3	1.07	14.3	1.24
Breast (<i>in situ</i>)	-	-	-	-	-	67	28.5	1.57	33.0	1.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	312	230.8	7.07	269.9	8.09	403	227.1	5.52	263.3	6.39
Oral Cavity & Pharynx	7	5.0	1.04	5.8	1.17	4	2.4	0.57	2.7	0.66
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.2	0.46	1.4	0.53	1	0.7	0.32	0.8	0.36
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	2	0.9	0.34	1.1	0.41
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	82	60.3	3.57	71.4	4.13	70	46.0	2.65	53.3	3.04
Esophagus	2	2.0	0.63	2.4	0.76	-	-	-	-	-
Stomach	19	13.4	1.68	15.6	1.93	12	7.0	0.98	8.0	1.13
Small intestine	2	1.5	0.58	1.6	0.65	-	-	-	-	-
Colon excl. rectum	21	14.4	1.71	17.3	2.00	21	13.2	1.40	15.5	1.63
Rectum & rectosigmoid	11	6.6	1.08	7.5	1.22	8	4.4	0.77	5.2	0.91
Anus, anal canal & anorectum	-	-	-	-	-	1	0.8	0.34	0.9	0.39
Liver	12	9.8	1.48	11.9	1.73	7	5.0	0.91	5.9	1.05
Gallbladder	-	-	-	-	-	3	2.1	0.59	2.4	0.66
Pancreas	9	8.7	1.49	10.3	1.72	13	9.2	1.23	10.5	1.38
Respiratory System	22	22.4	2.42	25.7	2.72	23	16.2	1.61	19.5	1.88
Larynx	2	1.7	0.64	2.0	0.74	-	-	-	-	-
Lung & bronchus	18	19.5	2.27	22.4	2.55	22	15.6	1.58	18.7	1.85
Bones & Joints	2	0.8	0.24	0.8	0.27	-	-	-	-	-
Soft Tissue (incl. heart)	5	2.1	0.54	2.3	0.60	3	1.4	0.40	1.5	0.43
Skin (excl. basal & sq.)	-	-	-	-	-	6	3.4	0.67	3.9	0.78
Melanomas of the skin	5	4.0	1.01	4.3	1.12	5	2.7	0.61	3.2	0.71
Breast (excl. <i>in situ</i>)	-	-	-	-	-	123	66.8	2.90	78.4	3.40
Female Genital System	-	-	-	-	-	67	34.5	2.05	40.3	2.41
Cervix uteri	-	-	-	-	-	18	8.3	0.94	8.9	1.04
Uterus Corpus	-	-	-	-	-	28	14.7	1.32	18.0	1.61
Uterus, NOS ¹	-	-	-	-	-	2	1.1	0.41	1.2	0.47
Ovary	-	-	-	-	-	13	6.3	0.85	7.4	1.01
Male Genital System	83	66.2	3.76	80.3	4.38	-	-	-	-	-
Prostate	74	62.3	3.68	76.4	4.30	-	-	-	-	-
Testis	7	2.4	0.48	2.3	0.48	-	-	-	-	-
Penis	2	1.5	0.63	1.6	0.67	-	-	-	-	-
Urinary System	26	23.1	2.36	26.7	2.66	16	10.2	1.25	11.7	1.41
Bladder (incl. <i>in situ</i>)	13	14.0	1.96	15.9	2.17	5	3.9	0.83	4.4	0.92
Kidney & renal pelvis	13	8.6	1.27	10.3	1.49	10	5.8	0.89	6.6	1.02
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	11	5.0	0.88	5.3	0.96	8	4.3	0.76	4.7	0.84
Brain	11	4.8	0.87	5.2	0.96	7	3.8	0.70	4.0	0.76
Endocrine System	8	4.2	0.84	4.7	0.94	35	15.3	1.22	16.8	1.39
Thyroid gland	6	2.9	0.65	3.4	0.74	35	15.1	1.22	16.6	1.38
Lymphomas	26	16.0	1.72	18.3	1.96	18	9.8	1.15	11.3	1.33
Hodgkin Lymphoma	3	1.3	0.42	1.3	0.45	2	1.0	0.28	1.0	0.31
Non-Hodgkin Lymphoma	23	14.7	1.67	17.0	1.91	15	8.8	1.11	10.3	1.29
Multiple Myeloma	5	3.4	0.85	4.0	0.99	5	3.0	0.64	3.9	0.81
Leukemias	16	6.9	1.04	7.1	1.13	13	6.2	0.88	6.6	0.97
Acute lymphocytic	8	2.4	0.48	2.1	0.46	5	2.0	0.43	2.0	0.47
Chronic lymphocytic	1	1.0	0.47	1.3	0.56	2	1.2	0.45	1.4	0.51
Acute myeloid	4	2.5	0.68	2.7	0.76	4	1.9	0.48	2.0	0.53
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	9.7	1.58	11.3	1.81	10	6.6	1.00	7.7	1.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	3.8	0.77	4.3	0.88	17	9.5	1.10	11.1	1.30
Breast (<i>in situ</i>)	-	-	-	-	-	27	13.6	1.22	16.4	1.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MARYLAND

II-238 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,435	515.9	2.33	610.0	2.69	10,439	465.6	2.15	540.8	2.41
Oral Cavity & Pharynx	423	20.1	0.45	24.6	0.54	166	7.2	0.26	8.5	0.30
Lip	11	0.6	0.08	0.7	0.09	5	0.2	0.04	0.2	0.04
Tongue	156	7.2	0.27	8.9	0.32	63	2.8	0.16	3.3	0.19
Major salivary gland	35	1.9	0.15	2.1	0.16	20	1.0	0.10	1.1	0.11
Floor of mouth	14	0.7	0.08	0.8	0.10	8	0.4	0.06	0.4	0.07
Gum & other mouth	45	2.2	0.15	2.6	0.17	33	1.3	0.11	1.6	0.12
Nasopharynx	10	0.5	0.07	0.6	0.08	4	0.2	0.04	0.2	0.05
Oropharynx	24	1.1	0.11	1.4	0.13	8	0.3	0.05	0.4	0.06
Hypopharynx	20	1.0	0.10	1.2	0.12	6	0.3	0.05	0.3	0.06
Digestive System	1,838	91.4	0.98	108.4	1.14	1,496	63.4	0.77	74.1	0.87
Esophagus	177	8.7	0.30	10.4	0.35	50	2.0	0.13	2.4	0.15
Stomach	152	7.5	0.28	8.9	0.33	87	3.7	0.19	4.3	0.21
Small intestine	54	2.7	0.17	3.2	0.20	48	2.1	0.14	2.5	0.16
Colon excl. rectum	530	27.3	0.54	31.8	0.62	592	25.3	0.49	29.1	0.55
Rectum & rectosigmoid	260	13.1	0.38	15.5	0.43	185	8.3	0.29	9.8	0.33
Anus, anal canal & anorectum	28	1.4	0.12	1.6	0.14	58	2.4	0.15	3.0	0.18
Liver	211	9.6	0.30	12.0	0.37	68	2.9	0.16	3.4	0.19
Gallbladder	14	0.7	0.09	0.8	0.10	23	0.9	0.09	1.1	0.10
Pancreas	318	15.7	0.41	18.6	0.47	277	11.4	0.32	13.3	0.36
Respiratory System	1,487	73.1	0.87	86.4	1.01	1,445	59.4	0.72	70.2	0.84
Larynx	104	4.9	0.22	6.0	0.27	28	1.2	0.10	1.4	0.12
Lung & bronchus	1,354	66.6	0.83	78.6	0.96	1,402	57.5	0.70	68.0	0.82
Bones & Joints	22	1.4	0.14	1.4	0.13	18	1.0	0.12	1.1	0.12
Soft Tissue (incl. heart)	81	4.3	0.22	4.9	0.25	61	3.1	0.19	3.3	0.20
Skin (excl. basal & sq.)	975	49.7	0.74	57.9	0.84	667	32.4	0.60	36.6	0.65
Melanomas of the skin	928	47.2	0.72	55.0	0.81	634	31.0	0.59	35.0	0.63
Breast (excl. <i>in situ</i>)	31	1.5	0.13	1.8	0.15	3,096	140.6	1.19	164.8	1.35
Female Genital System	-	-	-	-	-	1,212	53.6	0.72	63.7	0.83
Cervix uteri	-	-	-	-	-	116	6.4	0.28	6.9	0.29
Uterus Corpus	-	-	-	-	-	673	28.5	0.51	34.8	0.61
Uterus, NOS ¹	-	-	-	-	-	17	0.7	0.08	0.9	0.10
Ovary	-	-	-	-	-	270	12.0	0.34	14.1	0.39
Male Genital System	2,528	116.7	1.07	142.5	1.28	-	-	-	-	-
Prostate	2,408	108.7	1.01	134.4	1.23	-	-	-	-	-
Testis	105	7.3	0.32	7.2	0.32	-	-	-	-	-
Penis	10	0.5	0.08	0.6	0.09	-	-	-	-	-
Urinary System	1,276	64.0	0.82	75.3	0.95	505	21.5	0.45	25.1	0.51
Bladder (incl. <i>in situ</i>)	812	40.9	0.66	48.0	0.76	243	9.8	0.29	11.5	0.34
Kidney & renal pelvis	429	21.3	0.48	25.1	0.55	247	11.1	0.33	12.8	0.37
Ureter	19	1.0	0.10	1.1	0.12	10	0.4	0.06	0.5	0.07
Eye & Orbit	18	1.0	0.11	1.1	0.12	15	0.8	0.09	0.8	0.10
Brain & Other CNS ¹	156	8.6	0.32	9.4	0.34	129	6.5	0.27	7.1	0.28
Brain	148	8.1	0.31	9.0	0.33	121	5.9	0.26	6.5	0.27
Endocrine System	166	9.3	0.34	10.3	0.36	453	25.8	0.57	27.6	0.59
Thyroid gland	153	8.6	0.33	9.5	0.35	438	25.0	0.57	26.8	0.58
Lymphomas	522	27.1	0.55	31.3	0.62	437	19.7	0.44	22.5	0.49
Hodgkin Lymphoma	53	3.3	0.21	3.4	0.21	44	2.7	0.19	2.8	0.19
Non-Hodgkin Lymphoma	469	23.9	0.51	27.9	0.58	393	17.0	0.40	19.8	0.45
Multiple Myeloma	152	7.6	0.28	9.0	0.33	121	5.0	0.21	5.9	0.24
Leukemias	341	18.2	0.46	20.5	0.50	251	11.2	0.34	12.7	0.37
Acute lymphocytic	24	1.7	0.16	1.6	0.14	22	1.4	0.14	1.3	0.13
Chronic lymphocytic	132	6.6	0.26	7.8	0.31	91	3.7	0.18	4.3	0.21
Acute myeloid	103	5.5	0.25	6.2	0.27	81	3.6	0.19	4.1	0.21
Chronic myeloid	41	2.2	0.16	2.5	0.17	32	1.5	0.12	1.7	0.14
Other leukemias	41	2.2	0.16	2.5	0.18	25	1.1	0.10	1.2	0.11
Mesothelioma	29	1.5	0.13	1.7	0.14	11	0.5	0.07	0.6	0.08
Kaposi Sarcoma	4	0.3	0.06	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	386	20.0	0.47	23.2	0.53	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	168	9.0	0.32	10.2	0.36	317	14.4	0.38	16.6	0.43
Breast (<i>in situ</i>)	4	0.2	0.04	0.2	0.05	688	32.7	0.59	38.3	0.66

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Maryland, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,044	521.7	3.92	630.0	4.61	4,287	408.0	2.87	480.1	3.30
Oral Cavity & Pharynx	102	12.7	0.60	15.5	0.71	51	4.9	0.31	5.7	0.36
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	24	3.1	0.30	3.7	0.36	12	1.1	0.14	1.3	0.17
Major salivary gland	9	1.1	0.18	1.4	0.21	14	1.3	0.16	1.5	0.18
Floor of mouth	4	0.5	0.12	0.6	0.14	2	0.2	0.06	0.2	0.07
Gum & other mouth	13	1.6	0.21	2.0	0.26	9	0.9	0.14	1.0	0.15
Nasopharynx	8	0.9	0.16	1.1	0.18	5	0.5	0.10	0.5	0.11
Oropharynx	8	0.9	0.16	1.1	0.19	3	0.3	0.07	0.3	0.08
Hypopharynx	12	1.5	0.21	1.8	0.24	2	0.1	0.04	0.2	0.06
Digestive System	853	111.9	1.84	134.8	2.16	777	74.5	1.23	88.6	1.43
Esophagus	38	5.2	0.41	6.3	0.48	20	1.9	0.19	2.3	0.23
Stomach	79	11.1	0.60	13.2	0.70	75	7.2	0.38	8.5	0.45
Small intestine	32	4.3	0.37	5.1	0.42	35	3.4	0.27	4.0	0.31
Colon excl. rectum	257	35.4	1.06	41.9	1.23	285	27.5	0.75	32.6	0.87
Rectum & rectosigmoid	96	12.4	0.60	14.7	0.70	87	8.3	0.41	9.7	0.47
Anus, anal canal & anorectum	17	2.1	0.23	2.4	0.26	18	1.6	0.18	2.0	0.21
Liver	161	18.0	0.66	23.1	0.83	52	4.6	0.29	5.7	0.36
Gallbladder	8	1.1	0.18	1.3	0.21	18	1.7	0.18	2.1	0.22
Pancreas	128	17.2	0.73	20.7	0.85	147	14.3	0.55	17.0	0.63
Respiratory System	521	72.4	1.52	86.5	1.77	524	50.4	1.01	60.4	1.19
Larynx	46	5.9	0.42	7.3	0.50	12	1.1	0.15	1.4	0.18
Lung & bronchus	467	65.5	1.45	78.0	1.69	507	48.7	1.00	58.4	1.17
Bones & Joints	10	1.1	0.16	1.1	0.17	6	0.7	0.12	0.7	0.12
Soft Tissue (incl. heart)	30	4.0	0.35	4.4	0.38	32	3.0	0.25	3.4	0.27
Skin (excl. basal & sq.)	19	2.6	0.29	3.0	0.33	17	1.7	0.19	1.9	0.21
Melanomas of the skin	10	1.5	0.23	1.7	0.26	7	0.7	0.12	0.8	0.14
Breast (excl. <i>in situ</i>)	19	2.6	0.29	3.0	0.33	1,439	135.3	1.64	158.7	1.88
Female Genital System	-	-	-	-	-	532	48.7	0.97	58.5	1.14
Cervix uteri	-	-	-	-	-	70	6.7	0.37	7.6	0.41
Uterus Corpus	-	-	-	-	-	298	26.4	0.71	32.7	0.85
Uterus, NOS ¹	-	-	-	-	-	21	2.0	0.20	2.4	0.23
Ovary	-	-	-	-	-	96	9.0	0.42	10.7	0.49
Male Genital System	1,579	190.6	2.27	237.6	2.75	-	-	-	-	-
Prostate	1,561	188.4	2.26	235.2	2.74	-	-	-	-	-
Testis	12	1.4	0.18	1.4	0.18	-	-	-	-	-
Penis	4	0.6	0.15	0.7	0.17	-	-	-	-	-
Urinary System	330	45.3	1.19	53.7	1.39	203	19.7	0.64	23.1	0.73
Bladder (incl. <i>in situ</i>)	141	21.4	0.86	25.1	1.00	73	7.4	0.40	8.6	0.46
Kidney & renal pelvis	183	23.1	0.81	27.5	0.94	126	11.9	0.49	14.0	0.56
Ureter	2	0.3	0.11	0.4	0.13	2	0.2	0.07	0.3	0.08
Eye & Orbit	3	0.3	0.10	0.4	0.11	1	0.1	0.06	0.1	0.05
Brain & Other CNS ¹	38	4.8	0.36	5.2	0.40	32	3.3	0.27	3.5	0.28
Brain	36	4.5	0.35	4.9	0.38	29	3.0	0.25	3.2	0.27
Endocrine System	50	6.4	0.42	7.2	0.47	160	15.3	0.56	17.1	0.61
Thyroid gland	39	5.1	0.38	5.7	0.42	150	14.4	0.54	16.0	0.59
Lymphomas	151	19.0	0.73	21.7	0.83	159	15.4	0.56	17.6	0.63
Hodgkin Lymphoma	26	3.1	0.28	3.2	0.29	26	2.7	0.24	2.8	0.24
Non-Hodgkin Lymphoma	125	15.9	0.68	18.5	0.77	133	12.7	0.51	14.8	0.58
Multiple Myeloma	113	15.7	0.71	18.6	0.82	128	12.3	0.50	14.7	0.59
Leukemias	92	12.4	0.62	14.2	0.70	88	8.5	0.42	9.7	0.47
Acute lymphocytic	11	1.2	0.17	1.2	0.17	6	0.7	0.13	0.7	0.12
Chronic lymphocytic	28	4.0	0.36	4.8	0.42	23	2.2	0.21	2.6	0.25
Acute myeloid	28	3.8	0.34	4.3	0.39	33	3.1	0.25	3.6	0.28
Chronic myeloid	14	1.8	0.23	2.1	0.27	13	1.3	0.16	1.5	0.18
Other leukemias	12	1.6	0.22	1.8	0.25	12	1.2	0.16	1.4	0.18
Mesothelioma	3	0.6	0.14	0.6	0.16	2	0.2	0.06	0.2	0.07
Kaposi Sarcoma	11	1.3	0.18	1.4	0.19	2	0.2	0.07	0.2	0.07
Ill-defined & Unknown	121	17.7	0.78	21.1	0.91	134	13.8	0.55	15.9	0.62
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	67	9.2	0.54	10.5	0.60	146	14.2	0.54	16.4	0.61
Breast (<i>in situ</i>)	2	0.3	0.09	0.3	0.10	373	34.4	0.82	40.8	0.95

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


MARYLAND

II-240 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,713,944	6,763,652	6,795,891	6,826,022	6,863,246
White	5,649,581	5,664,543	5,665,850	5,662,896	5,665,376
Black	592,331	608,777	623,668	639,117	654,566
American Indian/Alaskan Native (AI/AN)	37,408	37,961	38,569	39,093	39,955
Asian/Pacific Islander (API)	434,624	452,371	467,804	484,916	503,349


All Races Population 2013-2017: 33,962,755
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	710,829	737,290	762,852	787,645	815,726
Non-Hispanic White	5,083,438	5,077,345	5,058,270	5,035,693	5,016,207
Non-Hispanic Black	481,688	493,658	504,487	515,841	526,535

Hispanic/Latino Population, Census 2010: 627,654
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MASSACHUSETTS CANCER REGISTRY

Initial Operation: 1982
Population-based Data Available: 1982
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.6	104.7	108.6	109.9	104.4
Missing Race	1.4	1.2	2.0	1.7	2.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.6	2.4	2.3	1.7	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Prostate	96.7
Oral Cavity & Pharynx	98.4	Testis	99.9
Esophagus	96.9	Bladder (incl. <i>in situ</i>)	98.1
Stomach	96.9	Kidney & Renal Pelvis	93.1
Colon & Rectum	96.4	Brain & Other CNS ¹	87.9
Liver	53.8	Thyroid	99.7
Pancreas	86.6	Hodgkin Lymphoma	99.4
Lung & Bronchus	88.0	Non-Hodgkin Lymphoma	97.5
Melanomas of the Skin	99.6	Multiple Myeloma	92.8
Female Breast (excl. <i>in situ</i>)	99.1	Leukemias	86.7
Cervix uteri	99.0	Brain & Other CNS ¹ <i>non-malig</i>	57.0
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	94.2		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17,967	483.3	1.66	572.5	1.92	19,424	443.1	1.47	516.3	1.67
Oral Cavity & Pharynx	690	17.7	0.31	21.6	0.37	316	7.0	0.18	8.3	0.21
Lip	20	0.6	0.06	0.6	0.07	14	0.3	0.04	0.3	0.04
Tongue	217	5.5	0.17	6.7	0.21	94	2.1	0.10	2.5	0.12
Major salivary gland	53	1.5	0.09	1.7	0.11	46	1.1	0.07	1.2	0.08
Floor of mouth	35	0.9	0.07	1.1	0.08	17	0.4	0.04	0.5	0.05
Gum & other mouth	78	2.1	0.11	2.5	0.13	66	1.4	0.08	1.7	0.09
Nasopharynx	31	0.8	0.07	1.0	0.08	13	0.3	0.04	0.4	0.04
Oropharynx	33	0.8	0.06	1.0	0.08	7	0.2	0.03	0.2	0.03
Hypopharynx	45	1.1	0.08	1.4	0.09	10	0.2	0.03	0.3	0.04
Digestive System	3,532	95.8	0.74	113.6	0.86	2,869	62.9	0.54	73.5	0.62
Esophagus	345	9.2	0.23	11.0	0.27	105	2.2	0.10	2.6	0.12
Stomach	343	9.5	0.23	11.1	0.27	201	4.5	0.15	5.2	0.16
Small intestine	97	2.6	0.12	3.1	0.14	83	1.9	0.09	2.2	0.11
Colon excl. rectum	977	27.1	0.40	31.8	0.46	1,045	22.9	0.33	26.5	0.37
Rectum & rectosigmoid	472	12.8	0.27	15.1	0.31	370	8.5	0.20	9.9	0.23
Anus, anal canal & anorectum	62	1.6	0.10	2.0	0.11	100	2.2	0.10	2.7	0.12
Liver	444	11.2	0.25	13.9	0.30	125	2.7	0.11	3.2	0.13
Gallbladder	29	0.8	0.07	0.9	0.08	70	1.5	0.08	1.8	0.10
Pancreas	549	14.9	0.29	17.7	0.34	553	11.8	0.23	13.9	0.27
Respiratory System	2,643	72.0	0.64	85.2	0.75	2,815	61.1	0.53	72.2	0.61
Larynx	205	5.3	0.17	6.5	0.20	54	1.2	0.07	1.4	0.09
Lung & bronchus	2,394	65.5	0.61	77.3	0.71	2,732	59.2	0.52	70.1	0.60
Bones & Joints	36	1.0	0.08	1.1	0.08	29	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	134	3.8	0.15	4.3	0.17	104	2.6	0.12	2.8	0.12
Skin (excl. basal & sq.)	1,091	30.3	0.42	35.3	0.48	857	20.1	0.32	23.0	0.36
Melanomas of the skin	997	27.6	0.40	32.2	0.46	797	18.7	0.31	21.5	0.34
Breast (excl. <i>in situ</i>)	52	1.4	0.09	1.7	0.10	5,921	137.9	0.83	161.6	0.95
Female Genital System	-	-	-	-	-	2,220	49.8	0.49	59.7	0.57
Cervix uteri	-	-	-	-	-	197	5.2	0.17	5.6	0.18
Uterus Corpus	-	-	-	-	-	1,297	28.3	0.36	34.8	0.43
Uterus, NOS ¹	-	-	-	-	-	31	0.7	0.05	0.8	0.06
Ovary	-	-	-	-	-	458	10.4	0.22	12.3	0.26
Male Genital System	4,370	109.8	0.76	135.0	0.92	-	-	-	-	-
Prostate	4,133	102.6	0.73	127.6	0.89	-	-	-	-	-
Testis	194	6.0	0.20	6.0	0.19	-	-	-	-	-
Penis	35	1.0	0.08	1.2	0.09	-	-	-	-	-
Urinary System	2,272	62.8	0.60	73.7	0.70	980	21.6	0.32	25.4	0.37
Bladder (incl. <i>in situ</i>)	1,374	38.7	0.48	45.2	0.55	494	10.6	0.22	12.5	0.25
Kidney & renal pelvis	846	22.6	0.36	26.7	0.41	455	10.4	0.22	12.2	0.26
Ureter	31	0.9	0.07	1.0	0.08	18	0.4	0.04	0.4	0.05
Eye & Orbit	38	1.1	0.08	1.2	0.09	31	0.8	0.06	0.9	0.07
Brain & Other CNS ¹	288	8.2	0.22	9.0	0.24	240	6.0	0.18	6.5	0.19
Brain	276	7.8	0.22	8.7	0.23	226	5.6	0.17	6.1	0.18
Endocrine System	399	11.3	0.26	12.5	0.28	1,062	28.3	0.40	30.7	0.42
Thyroid gland	366	10.3	0.25	11.5	0.27	1,035	27.6	0.40	30.0	0.42
Lymphomas	945	26.4	0.39	30.2	0.44	792	18.2	0.30	20.9	0.34
Hodgkin Lymphoma	103	3.0	0.13	3.1	0.14	93	2.6	0.12	2.6	0.12
Non-Hodgkin Lymphoma	842	23.4	0.37	27.1	0.42	699	15.6	0.27	18.2	0.31
Multiple Myeloma	302	8.2	0.22	9.7	0.25	237	5.1	0.15	6.1	0.18
Leukemias	552	15.6	0.30	17.7	0.34	414	9.6	0.22	10.7	0.24
Acute lymphocytic	47	1.5	0.10	1.4	0.09	44	1.4	0.10	1.2	0.08
Chronic lymphocytic	193	5.2	0.17	6.2	0.20	126	2.7	0.11	3.2	0.13
Acute myeloid	174	4.9	0.17	5.6	0.19	143	3.3	0.13	3.7	0.14
Chronic myeloid	78	2.2	0.12	2.5	0.13	53	1.2	0.08	1.4	0.09
Other leukemias	61	1.7	0.10	2.0	0.11	47	1.0	0.07	1.2	0.08
Mesothelioma	64	1.9	0.11	2.1	0.12	22	0.5	0.05	0.6	0.05
Kaposi Sarcoma	21	0.6	0.06	0.7	0.07	4	0.1	0.02	0.1	0.02
Ill-defined & Unknown	536	15.4	0.30	17.9	0.35	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	246	6.9	0.20	7.8	0.22	485	11.5	0.24	13.2	0.27
Breast (<i>in situ</i>)	6	0.2	0.03	0.2	0.04	1,634	39.6	0.45	46.2	0.51

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	15,928	480.3	1.75	567.9	2.02	17,360	447.6	1.59	521.4	1.80
Oral Cavity & Pharynx	626	18.0	0.33	22.0	0.40	285	7.1	0.20	8.4	0.23
Lip	18	0.6	0.06	0.7	0.07	13	0.3	0.04	0.4	0.05
Tongue	204	5.8	0.19	7.1	0.22	87	2.2	0.11	2.6	0.13
Major salivary gland	47	1.5	0.10	1.7	0.11	39	1.0	0.08	1.2	0.09
Floor of mouth	32	0.9	0.07	1.1	0.09	17	0.4	0.04	0.5	0.06
Gum & other mouth	71	2.1	0.11	2.5	0.14	58	1.4	0.08	1.6	0.10
Nasopharynx	16	0.5	0.06	0.6	0.06	9	0.2	0.03	0.3	0.04
Oropharynx	31	0.8	0.07	1.1	0.09	6	0.2	0.03	0.2	0.03
Hypopharynx	41	1.1	0.08	1.4	0.10	10	0.2	0.03	0.3	0.04
Digestive System	3,084	93.6	0.77	110.8	0.90	2,525	61.8	0.57	72.2	0.65
Esophagus	323	9.6	0.24	11.5	0.29	97	2.3	0.11	2.7	0.12
Stomach	282	8.7	0.24	10.1	0.27	160	3.9	0.15	4.6	0.16
Small intestine	81	2.5	0.13	2.9	0.15	71	1.8	0.10	2.1	0.11
Colon excl. rectum	864	26.9	0.42	31.4	0.48	940	23.0	0.35	26.6	0.40
Rectum & rectosigmoid	413	12.7	0.29	14.9	0.33	322	8.4	0.22	9.8	0.25
Anus, anal canal & anorectum	56	1.7	0.10	2.0	0.12	92	2.3	0.11	2.8	0.13
Liver	356	10.1	0.25	12.4	0.30	97	2.3	0.11	2.8	0.13
Gallbladder	25	0.8	0.07	0.9	0.08	59	1.4	0.09	1.6	0.10
Pancreas	496	15.0	0.31	17.8	0.36	496	11.7	0.24	13.8	0.28
Respiratory System	2,416	73.0	0.68	86.3	0.79	2,622	63.4	0.57	74.9	0.66
Larynx	188	5.4	0.18	6.6	0.22	50	1.2	0.08	1.5	0.09
Lung & bronchus	2,190	66.4	0.65	78.3	0.75	2,547	61.5	0.56	72.7	0.65
Bones & Joints	31	1.1	0.09	1.1	0.09	24	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	116	3.7	0.16	4.2	0.18	89	2.5	0.13	2.8	0.13
Skin (excl. basal & sq.)	982	30.7	0.45	35.6	0.51	762	20.5	0.35	23.4	0.39
Melanomas of the skin	899	28.0	0.43	32.6	0.49	710	19.3	0.34	22.0	0.38
Breast (excl. <i>in situ</i>)	46	1.4	0.09	1.6	0.11	5,307	140.3	0.90	164.4	1.02
Female Genital System	-	-	-	-	-	1,969	50.0	0.52	59.9	0.61
Cervix uteri	-	-	-	-	-	154	4.9	0.19	5.3	0.19
Uterus Corpus	-	-	-	-	-	1,162	28.6	0.39	35.2	0.47
Uterus, NOS ¹	-	-	-	-	-	26	0.6	0.06	0.8	0.07
Ovary	-	-	-	-	-	409	10.5	0.24	12.4	0.28
Male Genital System	3,688	104.1	0.79	127.4	0.94	-	-	-	-	-
Prostate	3,474	96.2	0.75	119.4	0.91	-	-	-	-	-
Testis	179	6.8	0.23	6.7	0.23	-	-	-	-	-
Penis	30	1.0	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,115	65.1	0.65	76.3	0.75	893	22.1	0.34	25.9	0.39
Bladder (incl. <i>in situ</i>)	1,302	40.5	0.51	47.3	0.59	465	11.1	0.24	13.0	0.27
Kidney & renal pelvis	764	23.0	0.38	27.2	0.44	401	10.3	0.24	12.1	0.27
Ureter	29	0.9	0.08	1.1	0.09	17	0.4	0.04	0.5	0.05
Eye & Orbit	35	1.1	0.08	1.2	0.09	29	0.8	0.07	0.9	0.08
Brain & Other CNS ¹	265	8.6	0.24	9.5	0.26	216	6.2	0.20	6.8	0.21
Brain	254	8.2	0.24	9.1	0.26	205	5.9	0.19	6.4	0.20
Endocrine System	348	11.4	0.28	12.6	0.30	887	28.1	0.44	30.3	0.46
Thyroid gland	321	10.5	0.27	11.7	0.29	864	27.4	0.44	29.6	0.45
Lymphomas	858	27.1	0.43	31.0	0.48	712	18.6	0.33	21.3	0.36
Hodgkin Lymphoma	90	3.1	0.15	3.3	0.15	83	2.8	0.14	2.9	0.14
Non-Hodgkin Lymphoma	768	24.0	0.40	27.8	0.45	629	15.8	0.29	18.4	0.33
Multiple Myeloma	257	7.8	0.22	9.2	0.26	191	4.6	0.15	5.5	0.18
Leukemias	496	15.8	0.33	18.0	0.36	365	9.6	0.24	10.7	0.26
Acute lymphocytic	38	1.5	0.11	1.4	0.10	36	1.4	0.11	1.2	0.09
Chronic lymphocytic	178	5.4	0.19	6.4	0.22	116	2.7	0.12	3.2	0.14
Acute myeloid	160	5.1	0.18	5.8	0.21	125	3.3	0.14	3.7	0.15
Chronic myeloid	67	2.2	0.12	2.5	0.13	47	1.2	0.08	1.4	0.09
Other leukemias	54	1.7	0.11	2.0	0.12	42	1.0	0.07	1.2	0.08
Mesothelioma	61	2.0	0.12	2.3	0.13	21	0.5	0.05	0.6	0.06
Kaposi Sarcoma	13	0.4	0.05	0.5	0.06	2	0.0	0.01	0.1	0.02
Ill-defined & Unknown	491	15.6	0.32	18.1	0.37	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	212	6.8	0.22	7.7	0.24	413	11.2	0.26	12.8	0.29
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.04	1,443	40.2	0.49	46.9	0.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,021	453.1	6.82	548.0	8.03	1,053	367.1	5.16	429.9	5.99
Oral Cavity & Pharynx	29	12.8	1.13	15.1	1.30	12	3.9	0.51	4.9	0.63
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	7	3.7	0.66	4.2	0.74	2	0.5	0.17	0.6	0.22
Major salivary gland	2	1.0	0.31	1.1	0.34	3	0.9	0.24	1.1	0.29
Floor of mouth	2	0.8	0.30	1.0	0.33	-	-	-	-	-
Gum & other mouth	3	1.5	0.38	1.7	0.44	4	1.1	0.27	1.4	0.34
Nasopharynx	3	1.3	0.36	1.4	0.39	1	0.5	0.18	0.6	0.22
Oropharynx	2	0.7	0.25	0.9	0.30	-	-	-	-	-
Hypopharynx	2	0.9	0.30	1.2	0.36	-	-	-	-	-
Digestive System	244	110.9	3.42	133.3	4.01	198	70.8	2.30	83.5	2.68
Esophagus	12	5.4	0.76	6.4	0.89	6	2.0	0.38	2.4	0.45
Stomach	33	16.9	1.42	20.3	1.66	23	8.6	0.82	10.0	0.94
Small intestine	10	3.8	0.57	4.6	0.68	8	2.7	0.44	3.4	0.54
Colon excl. rectum	71	33.2	1.90	40.0	2.23	63	22.7	1.30	26.7	1.51
Rectum & rectosigmoid	27	11.8	1.08	13.8	1.24	25	8.3	0.76	10.1	0.92
Anus, anal canal & anorectum	4	1.4	0.34	1.6	0.39	5	1.7	0.35	1.9	0.40
Liver	39	15.1	1.14	19.1	1.42	13	4.5	0.56	5.4	0.67
Gallbladder	1	0.6	0.24	0.7	0.28	8	3.0	0.49	3.4	0.55
Pancreas	32	15.6	1.32	18.5	1.52	34	12.5	0.98	14.5	1.12
Respiratory System	119	57.8	2.55	69.0	2.96	112	40.1	1.74	48.2	2.05
Larynx	10	4.2	0.63	5.1	0.75	4	1.1	0.27	1.4	0.34
Lung & bronchus	106	52.4	2.45	62.4	2.83	107	38.4	1.70	46.2	2.01
Bones & Joints	2	0.9	0.27	1.0	0.30	3	1.0	0.25	1.1	0.27
Soft Tissue (incl. heart)	8	3.6	0.61	3.9	0.66	7	2.5	0.41	2.7	0.46
Skin (excl. basal & sq.)	4	1.6	0.36	1.8	0.43	6	2.0	0.39	2.1	0.41
Melanomas of the skin	-	-	-	-	-	2	0.6	0.22	0.7	0.24
Breast (excl. <i>in situ</i>)	4	1.9	0.46	2.2	0.53	337	116.1	2.88	134.9	3.32
Female Genital System	-	-	-	-	-	134	45.6	1.80	54.8	2.14
Cervix uteri	-	-	-	-	-	22	7.8	0.75	8.8	0.85
Uterus Corpus	-	-	-	-	-	74	25.2	1.34	30.9	1.62
Uterus, NOS ¹	-	-	-	-	-	3	1.0	0.28	1.3	0.33
Ovary	-	-	-	-	-	23	7.7	0.72	9.2	0.87
Male Genital System	381	161.6	3.96	202.6	4.80	-	-	-	-	-
Prostate	373	158.6	3.92	199.4	4.77	-	-	-	-	-
Testis	4	1.2	0.28	1.2	0.28	-	-	-	-	-
Penis	3	1.4	0.41	1.6	0.45	-	-	-	-	-
Urinary System	76	34.9	1.92	41.3	2.22	48	17.1	1.12	20.2	1.31
Bladder (incl. <i>in situ</i>)	31	15.8	1.35	18.6	1.56	15	5.7	0.67	6.7	0.78
Kidney & renal pelvis	43	18.6	1.35	22.1	1.56	32	10.9	0.88	12.9	1.03
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	2.9	0.47	3.2	0.54	11	3.7	0.50	3.9	0.54
Brain	7	2.5	0.43	2.8	0.50	11	3.5	0.49	3.7	0.53
Endocrine System	13	5.0	0.64	5.4	0.70	61	20.2	1.17	22.8	1.32
Thyroid gland	11	4.2	0.59	4.6	0.65	59	19.5	1.15	22.0	1.30
Lymphomas	44	17.9	1.30	20.6	1.49	39	13.4	0.98	15.5	1.14
Hodgkin Lymphoma	8	2.8	0.46	3.1	0.51	5	1.7	0.34	1.9	0.37
Non-Hodgkin Lymphoma	36	15.1	1.22	17.6	1.40	33	11.6	0.92	13.6	1.07
Multiple Myeloma	31	14.3	1.22	17.2	1.43	35	12.8	1.00	14.9	1.14
Leukemias	26	11.4	1.10	13.0	1.25	23	7.8	0.75	8.8	0.85
Acute lymphocytic	3	1.0	0.23	0.9	0.23	2	0.7	0.20	0.5	0.16
Chronic lymphocytic	6	2.9	0.55	3.6	0.66	4	1.5	0.33	1.7	0.38
Acute myeloid	6	2.9	0.58	3.3	0.65	9	3.1	0.47	3.6	0.54
Chronic myeloid	6	2.7	0.53	3.1	0.60	4	1.4	0.32	1.7	0.37
Other leukemias	4	1.9	0.48	2.1	0.54	3	1.1	0.30	1.3	0.34
Mesothelioma	1	0.9	0.37	1.1	0.43	-	-	-	-	-
Kaposi Sarcoma	5	2.3	0.49	2.5	0.53	1	0.4	0.19	0.5	0.19
Ill-defined & Unknown	24	12.2	1.21	14.4	1.42	25	9.5	0.86	10.8	0.97
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	17	7.8	0.93	8.7	1.03	36	12.6	0.96	14.8	1.11
Breast (<i>in situ</i>)	-	-	-	-	-	101	34.3	1.55	40.5	1.81

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	489	301.8	6.42	355.3	7.50	600	291.3	5.50	338.3	6.40
Oral Cavity & Pharynx	25	13.8	1.28	16.3	1.51	13	6.6	0.84	7.6	0.97
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	2.1	0.49	2.4	0.57	4	2.2	0.48	2.7	0.59
Major salivary gland	2	1.2	0.36	1.5	0.44	2	0.9	0.29	1.0	0.34
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.0	0.35	1.2	0.41	3	1.5	0.42	1.6	0.45
Nasopharynx	12	6.1	0.81	7.4	0.99	2	1.1	0.32	1.2	0.35
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	1.0	0.42	1.2	0.49	-	-	-	-	-
Digestive System	145	91.2	3.55	108.7	4.18	102	54.6	2.50	63.8	2.90
Esophagus	8	5.2	0.86	6.3	1.03	2	1.1	0.35	1.2	0.38
Stomach	20	12.6	1.33	14.5	1.51	13	6.9	0.88	7.7	1.00
Small intestine	3	2.1	0.55	2.5	0.65	1	0.6	0.25	0.7	0.29
Colon excl. rectum	30	20.0	1.70	23.6	1.99	31	16.4	1.37	19.1	1.59
Rectum & rectosigmoid	22	12.0	1.21	14.6	1.46	15	7.7	0.91	8.9	1.05
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	37	22.7	1.75	27.6	2.09	12	6.5	0.87	7.8	1.02
Gallbladder	3	1.9	0.54	2.0	0.58	1	0.7	0.27	0.9	0.35
Pancreas	14	8.8	1.10	10.6	1.30	15	8.3	0.99	9.9	1.16
Respiratory System	81	54.7	2.84	64.8	3.32	60	33.3	1.98	39.3	2.31
Larynx	2	1.2	0.40	1.3	0.46	-	-	-	-	-
Lung & bronchus	77	52.3	2.79	62.1	3.26	58	32.4	1.96	38.2	2.28
Bones & Joints	2	0.9	0.30	0.9	0.32	2	1.0	0.32	1.1	0.36
Soft Tissue (incl. heart)	6	3.3	0.66	3.7	0.75	5	2.4	0.51	2.5	0.55
Skin (excl. basal & sq.)	3	1.7	0.43	1.9	0.48	4	1.7	0.38	1.9	0.45
Melanomas of the skin	2	0.8	0.27	0.9	0.31	2	0.7	0.24	0.9	0.30
Breast (excl. <i>in situ</i>)	2	1.2	0.40	1.4	0.47	201	93.3	3.02	108.4	3.53
Female Genital System	-	-	-	-	-	70	32.4	1.78	39.0	2.14
Cervix uteri	-	-	-	-	-	14	5.9	0.72	6.9	0.87
Uterus Corpus	-	-	-	-	-	34	15.5	1.21	19.0	1.49
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	16	7.9	0.91	9.3	1.07
Male Genital System	90	56.7	2.78	68.7	3.31	-	-	-	-	-
Prostate	84	53.5	2.71	65.3	3.23	-	-	-	-	-
Testis	3	1.4	0.35	1.4	0.35	-	-	-	-	-
Penis	2	1.3	0.46	1.6	0.54	-	-	-	-	-
Urinary System	38	24.7	1.89	28.7	2.18	14	7.4	0.92	8.9	1.09
Bladder (incl. <i>in situ</i>)	20	14.2	1.50	16.3	1.71	4	2.2	0.50	2.6	0.60
Kidney & renal pelvis	17	9.6	1.09	11.4	1.30	9	4.5	0.71	5.4	0.85
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	9	4.0	0.63	4.4	0.71	8	3.9	0.62	4.0	0.65
Brain	8	3.7	0.60	4.1	0.68	7	3.3	0.57	3.5	0.61
Endocrine System	26	12.2	1.13	13.3	1.25	64	26.8	1.53	29.5	1.72
Thyroid gland	23	10.6	1.05	11.6	1.17	63	25.9	1.50	28.7	1.70
Lymphomas	25	14.3	1.37	16.2	1.56	24	11.1	1.06	13.0	1.25
Hodgkin Lymphoma	3	1.3	0.35	1.3	0.38	3	1.0	0.27	1.1	0.30
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	6	4.0	0.74	4.7	0.86	5	3.0	0.60	3.5	0.69
Leukemias	16	9.2	1.07	10.1	1.20	14	6.4	0.80	7.0	0.89
Acute lymphocytic	3	1.6	0.40	1.4	0.37	3	1.3	0.34	1.1	0.29
Chronic lymphocytic	2	1.3	0.41	1.6	0.49	2	1.2	0.38	1.4	0.45
Acute myeloid	5	3.3	0.66	3.5	0.73	6	2.9	0.54	3.3	0.62
Chronic myeloid	3	1.7	0.45	1.9	0.51	-	-	-	-	-
Other leukemias	2	1.4	0.42	1.7	0.52	1	0.5	0.22	0.6	0.27
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	13	8.9	1.15	10.5	1.34	13	7.2	0.91	8.4	1.07
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	5.4	0.85	6.1	0.97	20	10.1	1.03	11.5	1.18
Breast (<i>in situ</i>)	-	-	-	-	-	70	32.0	1.74	37.5	2.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8	100.4	16.88	126.4	20.96	10	143.6	21.50	168.3	24.56
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	1	19.1	7.48	24.8	9.61	2	24.9	9.15	29.5	10.60
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	19.9	8.37	22.3	9.17	1	23.7	9.19	26.7	10.21
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	1	19.9	8.37	22.3	9.17	1	23.7	9.19	26.7	10.21
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	4	52.1	12.49	62.3	14.55
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	27.2	7.97	35.8	10.56	-	-	-	-	-
Prostate	2	21.4	7.23	29.5	9.88	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	716	356.4	6.73	424.8	7.85	838	307.2	5.03	357.7	5.85
Oral Cavity & Pharynx	26	13.2	1.28	16.0	1.51	14	5.3	0.68	6.2	0.79
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	7	4.0	0.74	4.9	0.89	4	1.4	0.36	1.6	0.40
Major salivary gland	3	1.3	0.42	1.5	0.46	1	0.5	0.20	0.5	0.21
Floor of mouth	2	1.0	0.31	1.3	0.40	-	-	-	-	-
Gum & other mouth	2	1.0	0.36	1.2	0.42	4	1.8	0.41	2.1	0.48
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	3	1.6	0.44	1.8	0.49	-	-	-	-	-
Digestive System	173	88.9	3.41	106.0	3.97	133	53.0	2.17	62.1	2.52
Esophagus	6	3.1	0.62	3.8	0.73	1	0.5	0.20	0.7	0.25
Stomach	29	15.7	1.47	18.1	1.67	17	6.6	0.76	7.7	0.87
Small intestine	4	2.1	0.49	2.5	0.57	4	1.3	0.30	1.6	0.38
Colon excl. rectum	42	22.5	1.77	26.4	2.04	41	16.0	1.19	18.4	1.36
Rectum & rectosigmoid	21	9.5	1.05	11.1	1.19	17	6.5	0.74	7.5	0.85
Anus, anal canal & anorectum	3	1.4	0.41	1.8	0.52	6	2.0	0.40	2.5	0.48
Liver	36	17.2	1.41	21.6	1.70	11	4.8	0.69	5.7	0.80
Gallbladder	2	1.1	0.41	1.2	0.45	5	1.9	0.40	2.3	0.48
Pancreas	18	10.2	1.22	12.0	1.41	20	8.5	0.90	10.0	1.03
Respiratory System	79	46.0	2.58	54.5	2.98	62	26.8	1.61	31.7	1.86
Larynx	14	7.3	0.96	8.9	1.15	1	0.5	0.20	0.6	0.23
Lung & bronchus	63	38.0	2.37	44.9	2.73	59	25.8	1.58	30.6	1.83
Bones & Joints	3	0.7	0.20	0.8	0.24	2	0.7	0.23	0.7	0.24
Soft Tissue (incl. heart)	7	3.0	0.59	3.4	0.67	8	2.2	0.38	2.5	0.43
Skin (excl. basal & sq.)	7	2.9	0.57	3.3	0.67	9	3.3	0.51	3.8	0.60
Melanomas of the skin	3	1.7	0.47	2.0	0.55	8	2.9	0.49	3.3	0.56
Breast (excl. <i>in situ</i>)	2	1.1	0.39	1.3	0.46	253	90.3	2.66	106.3	3.12
Female Genital System	-	-	-	-	-	115	40.5	1.78	48.0	2.11
Cervix uteri	-	-	-	-	-	25	8.4	0.80	8.9	0.87
Uterus Corpus	-	-	-	-	-	58	20.8	1.27	25.5	1.55
Uterus, NOS ¹	-	-	-	-	-	2	1.0	0.31	1.2	0.36
Ovary	-	-	-	-	-	18	5.9	0.64	7.2	0.79
Male Genital System	204	100.7	3.47	124.6	4.15	-	-	-	-	-
Prostate	189	97.0	3.44	120.7	4.12	-	-	-	-	-
Testis	12	2.6	0.35	2.6	0.36	-	-	-	-	-
Penis	3	1.0	0.31	1.2	0.36	-	-	-	-	-
Urinary System	70	35.8	2.15	42.1	2.48	37	14.6	1.15	16.9	1.33
Bladder (incl. <i>in situ</i>)	32	18.5	1.64	21.7	1.88	11	5.0	0.72	5.9	0.84
Kidney & renal pelvis	36	16.0	1.31	19.0	1.53	25	9.2	0.88	10.5	1.01
Ureter	1	0.8	0.38	1.0	0.43	-	-	-	-	-
Eye & Orbit	2	0.7	0.29	0.7	0.32	-	-	-	-	-
Brain & Other CNS ¹	16	5.0	0.66	5.2	0.71	14	4.5	0.58	4.9	0.65
Brain	15	4.8	0.66	5.0	0.71	12	4.0	0.55	4.4	0.62
Endocrine System	19	6.7	0.75	7.8	0.88	89	26.7	1.32	29.4	1.48
Thyroid gland	17	6.0	0.71	6.9	0.84	88	26.1	1.29	28.7	1.45
Lymphomas	51	23.0	1.68	26.3	1.93	48	17.9	1.24	20.5	1.42
Hodgkin Lymphoma	9	3.0	0.54	3.3	0.62	10	3.1	0.46	3.3	0.52
Non-Hodgkin Lymphoma	42	20.0	1.60	23.1	1.83	37	14.8	1.15	17.2	1.33
Multiple Myeloma	14	6.9	0.92	8.3	1.08	16	6.5	0.76	7.9	0.90
Leukemias	23	9.8	1.10	10.7	1.22	22	7.5	0.79	8.4	0.90
Acute lymphocytic	7	1.5	0.27	1.4	0.27	6	1.3	0.25	1.2	0.24
Chronic lymphocytic	4	2.3	0.56	2.6	0.62	4	1.5	0.37	1.8	0.45
Acute myeloid	6	3.5	0.72	3.8	0.78	7	2.7	0.49	3.0	0.56
Chronic myeloid	3	1.3	0.38	1.4	0.43	3	1.2	0.31	1.4	0.36
Other leukemias	3	1.3	0.42	1.4	0.48	2	0.8	0.28	1.0	0.33
Mesothelioma	1	1.1	0.47	1.3	0.52	-	-	-	-	-
Kaposi Sarcoma	2	1.0	0.30	1.1	0.34	-	-	-	-	-
Ill-defined & Unknown	16	9.9	1.24	11.2	1.39	16	6.6	0.80	7.6	0.92
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	15	5.7	0.76	6.7	0.91	28	9.8	0.87	11.1	1.01
Breast (<i>in situ</i>)	-	-	-	-	-	76	26.6	1.42	31.6	1.68

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MASSACHUSETTS

II-248 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,214	482.3	1.80	569.6	2.08	16,558	452.5	1.66	526.8	1.87
Oral Cavity & Pharynx	601	18.2	0.34	22.3	0.41	272	7.2	0.20	8.5	0.24
Lip	18	0.6	0.06	0.7	0.07	13	0.3	0.04	0.4	0.05
Tongue	197	6.0	0.20	7.3	0.23	83	2.3	0.12	2.7	0.13
Major salivary gland	43	1.4	0.10	1.6	0.11	38	1.1	0.09	1.3	0.09
Floor of mouth	30	0.9	0.07	1.1	0.09	16	0.4	0.05	0.5	0.06
Gum & other mouth	69	2.2	0.12	2.6	0.14	55	1.4	0.09	1.6	0.10
Nasopharynx	15	0.5	0.06	0.6	0.07	8	0.2	0.04	0.3	0.04
Oropharynx	30	0.9	0.07	1.1	0.09	6	0.1	0.03	0.2	0.03
Hypopharynx	38	1.1	0.08	1.4	0.10	10	0.2	0.03	0.3	0.04
Digestive System	2,920	92.9	0.79	110.0	0.92	2,405	61.8	0.59	72.2	0.67
Esophagus	313	9.7	0.25	11.6	0.30	94	2.3	0.11	2.8	0.13
Stomach	256	8.2	0.24	9.6	0.27	145	3.7	0.15	4.3	0.16
Small intestine	79	2.5	0.13	3.0	0.15	68	1.8	0.10	2.2	0.12
Colon excl. rectum	825	26.9	0.43	31.5	0.49	903	23.2	0.36	26.8	0.41
Rectum & rectosigmoid	394	12.8	0.30	15.0	0.34	308	8.5	0.23	9.9	0.26
Anus, anal canal & anorectum	52	1.6	0.10	2.0	0.12	87	2.3	0.11	2.8	0.14
Liver	327	9.7	0.25	12.0	0.30	88	2.2	0.11	2.7	0.13
Gallbladder	23	0.7	0.07	0.9	0.08	54	1.3	0.09	1.6	0.10
Pancreas	476	15.0	0.32	17.8	0.37	476	11.7	0.25	13.9	0.29
Respiratory System	2,331	73.3	0.70	86.7	0.81	2,538	64.2	0.59	75.9	0.68
Larynx	175	5.3	0.18	6.5	0.22	48	1.2	0.08	1.5	0.10
Lung & bronchus	2,119	66.8	0.66	78.8	0.77	2,467	62.3	0.58	73.7	0.67
Bones & Joints	29	1.1	0.10	1.1	0.10	21	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	110	3.8	0.17	4.3	0.18	83	2.5	0.13	2.8	0.14
Skin (excl. basal & sq.)	960	31.6	0.47	36.7	0.53	738	21.3	0.37	24.3	0.41
Melanomas of the skin	881	28.9	0.45	33.6	0.51	689	20.1	0.36	22.9	0.40
Breast (excl. <i>in situ</i>)	44	1.4	0.10	1.6	0.11	5,089	143.3	0.95	167.7	1.07
Female Genital System	-	-	-	-	-	1,855	49.8	0.54	59.7	0.63
Cervix uteri	-	-	-	-	-	132	4.6	0.19	4.9	0.19
Uterus Corpus	-	-	-	-	-	1,102	28.7	0.40	35.3	0.48
Uterus, NOS ¹	-	-	-	-	-	24	0.6	0.06	0.7	0.07
Ovary	-	-	-	-	-	391	10.6	0.25	12.6	0.29
Male Genital System	3,498	103.8	0.81	126.9	0.97	-	-	-	-	-
Prostate	3,295	95.4	0.76	118.4	0.93	-	-	-	-	-
Testis	168	7.3	0.26	7.2	0.25	-	-	-	-	-
Penis	29	1.0	0.08	1.1	0.09	-	-	-	-	-
Urinary System	2,036	65.6	0.67	76.8	0.77	858	22.3	0.36	26.1	0.41
Bladder (incl. <i>in situ</i>)	1,260	40.8	0.53	47.6	0.60	451	11.3	0.25	13.2	0.28
Kidney & renal pelvis	729	23.2	0.40	27.4	0.46	380	10.4	0.25	12.2	0.28
Ureter	28	0.9	0.08	1.1	0.09	17	0.4	0.05	0.5	0.05
Eye & Orbit	34	1.1	0.09	1.3	0.10	28	0.9	0.08	1.0	0.08
Brain & Other CNS ¹	248	8.7	0.26	9.6	0.27	202	6.3	0.21	6.8	0.22
Brain	239	8.3	0.25	9.2	0.27	192	5.9	0.21	6.5	0.21
Endocrine System	326	11.7	0.30	12.9	0.32	805	28.1	0.47	30.2	0.48
Thyroid gland	302	10.7	0.29	11.9	0.31	785	27.4	0.46	29.5	0.48
Lymphomas	814	27.3	0.44	31.2	0.49	671	18.6	0.34	21.3	0.38
Hodgkin Lymphoma	82	3.2	0.16	3.3	0.16	74	2.8	0.15	2.9	0.15
Non-Hodgkin Lymphoma	732	24.1	0.41	27.9	0.46	597	15.8	0.30	18.4	0.34
Multiple Myeloma	246	7.8	0.23	9.2	0.26	179	4.5	0.15	5.3	0.18
Leukemias	472	15.9	0.34	18.1	0.37	346	9.6	0.25	10.8	0.27
Acute lymphocytic	33	1.4	0.12	1.3	0.11	32	1.3	0.11	1.2	0.10
Chronic lymphocytic	172	5.5	0.19	6.5	0.22	112	2.8	0.12	3.3	0.14
Acute myeloid	152	5.1	0.19	5.8	0.21	118	3.3	0.14	3.7	0.16
Chronic myeloid	64	2.2	0.13	2.5	0.14	44	1.2	0.09	1.4	0.10
Other leukemias	51	1.7	0.11	2.0	0.12	39	1.0	0.08	1.1	0.08
Mesothelioma	60	2.0	0.12	2.3	0.13	21	0.5	0.05	0.6	0.06
Kaposi Sarcoma	11	0.4	0.05	0.4	0.06	2	0.0	0.01	0.0	0.02
Ill-defined & Unknown	475	15.8	0.33	18.3	0.38	446	10.9	0.24	12.6	0.27
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	200	6.9	0.23	7.7	0.25	391	11.3	0.27	12.9	0.30
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.04	1,377	41.3	0.52	48.0	0.59

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Massachusetts, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	928	474.8	7.47	575.7	8.82	954	389.8	5.75	455.7	6.65
Oral Cavity & Pharynx	25	12.8	1.21	14.9	1.38	12	4.3	0.58	5.4	0.71
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	3.4	0.68	3.9	0.75	1	0.5	0.18	0.6	0.24
Major salivary gland	2	1.1	0.36	1.3	0.40	3	1.0	0.27	1.2	0.33
Floor of mouth	1	0.8	0.30	0.9	0.34	-	-	-	-	-
Gum & other mouth	3	1.6	0.43	1.8	0.48	3	1.2	0.31	1.6	0.39
Nasopharynx	3	1.5	0.42	1.7	0.46	1	0.5	0.21	0.7	0.25
Oropharynx	2	0.8	0.29	1.0	0.35	-	-	-	-	-
Hypopharynx	2	0.9	0.33	1.1	0.39	-	-	-	-	-
Digestive System	222	116.1	3.74	140.1	4.40	180	74.7	2.54	87.7	2.95
Esophagus	11	5.8	0.86	6.9	0.99	5	2.0	0.41	2.4	0.49
Stomach	29	17.0	1.52	20.5	1.78	22	9.5	0.92	10.8	1.05
Small intestine	9	3.9	0.62	4.8	0.74	8	3.0	0.50	3.7	0.60
Colon excl. rectum	64	34.0	2.05	41.2	2.43	58	24.0	1.44	28.2	1.67
Rectum & rectosigmoid	27	13.3	1.23	15.6	1.41	23	8.9	0.84	10.8	1.02
Anus, anal canal & anorectum	4	1.6	0.39	1.9	0.45	4	1.8	0.40	2.1	0.45
Liver	35	15.6	1.24	19.8	1.54	12	4.6	0.61	5.5	0.73
Gallbladder	1	0.7	0.28	0.8	0.33	8	3.4	0.56	3.9	0.63
Pancreas	31	17.1	1.48	20.3	1.71	30	12.7	1.07	14.7	1.22
Respiratory System	109	60.8	2.79	72.9	3.25	104	43.1	1.93	51.9	2.28
Larynx	8	4.2	0.68	5.1	0.80	4	1.3	0.31	1.7	0.40
Lung & bronchus	99	55.6	2.69	66.5	3.12	99	41.2	1.89	49.6	2.24
Bones & Joints	2	1.0	0.31	1.1	0.35	3	1.1	0.29	1.1	0.31
Soft Tissue (incl. heart)	7	3.6	0.65	3.9	0.70	6	2.6	0.47	2.8	0.51
Skin (excl. basal & sq.)	4	1.6	0.41	1.9	0.47	5	2.2	0.44	2.3	0.46
Melanomas of the skin	-	-	-	-	-	1	0.6	0.25	0.7	0.26
Breast (excl. <i>in situ</i>)	4	2.2	0.54	2.6	0.61	302	122.8	3.21	142.6	3.69
Female Genital System	-	-	-	-	-	123	49.0	2.02	58.8	2.39
Cervix uteri	-	-	-	-	-	21	8.5	0.85	9.6	0.96
Uterus Corpus	-	-	-	-	-	67	26.7	1.48	32.7	1.79
Uterus, NOS ¹	-	-	-	-	-	3	1.2	0.32	1.5	0.38
Ovary	-	-	-	-	-	22	8.6	0.83	10.2	0.98
Male Genital System	350	171.5	4.37	215.3	5.31	-	-	-	-	-
Prostate	345	168.8	4.34	212.5	5.27	-	-	-	-	-
Testis	3	1.2	0.32	1.2	0.32	-	-	-	-	-
Penis	2	1.2	0.41	1.4	0.46	-	-	-	-	-
Urinary System	68	36.3	2.11	43.1	2.44	45	18.4	1.25	21.7	1.46
Bladder (incl. <i>in situ</i>)	27	15.8	1.46	18.8	1.69	14	6.1	0.74	7.2	0.86
Kidney & renal pelvis	40	19.9	1.50	23.6	1.74	29	11.8	0.99	14.0	1.16
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	3.3	0.54	3.6	0.61	10	4.2	0.59	4.4	0.62
Brain	7	2.7	0.49	3.1	0.56	10	3.9	0.57	4.1	0.60
Endocrine System	11	5.1	0.71	5.6	0.78	54	21.1	1.31	23.8	1.47
Thyroid gland	9	4.3	0.65	4.7	0.72	52	20.4	1.28	22.9	1.44
Lymphomas	39	18.1	1.38	21.0	1.59	34	13.9	1.08	16.1	1.25
Hodgkin Lymphoma	8	3.2	0.54	3.4	0.58	5	1.8	0.38	2.0	0.41
Non-Hodgkin Lymphoma	31	14.9	1.27	17.5	1.48	30	12.1	1.01	14.2	1.18
Multiple Myeloma	27	14.5	1.32	17.5	1.55	31	13.5	1.10	15.6	1.25
Leukemias	24	12.1	1.21	13.8	1.37	20	8.2	0.83	9.2	0.93
Acute lymphocytic	3	1.1	0.28	1.0	0.26	2	0.8	0.24	0.6	0.20
Chronic lymphocytic	6	3.0	0.60	3.7	0.72	4	1.6	0.37	1.8	0.42
Acute myeloid	5	2.9	0.60	3.3	0.69	8	3.2	0.52	3.7	0.59
Chronic myeloid	6	3.2	0.62	3.6	0.70	3	1.3	0.32	1.6	0.39
Other leukemias	3	2.0	0.51	2.2	0.58	3	1.3	0.35	1.5	0.40
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	5	2.4	0.55	2.5	0.58	-	-	-	-	-
Ill-defined & Unknown	21	12.6	1.30	15.0	1.54	23	10.1	0.95	11.6	1.08
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	8.7	1.06	9.8	1.17	34	13.8	1.08	16.2	1.25
Breast (<i>in situ</i>)	-	-	-	-	-	91	36.2	1.73	42.7	2.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


MASSACHUSETTS

II-250 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	9,913,349	9,930,589	9,932,573	9,951,890	9,976,447
White	8,034,681	8,036,981	8,026,930	8,029,342	8,037,423
Black	1,486,926	1,488,498	1,488,675	1,490,668	1,493,472
American Indian/Alaskan Native (AI/AN)	88,111	88,909	89,512	90,313	91,379
Asian/Pacific Islander (API)	303,631	316,201	327,456	341,567	354,173


All Races Population 2013-2017: 49,704,848
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	468,148	477,479	486,127	497,841	508,526
Non-Hispanic White	7,627,496	7,621,872	7,604,494	7,596,608	7,595,764
Non-Hispanic Black	1,450,916	1,451,643	1,451,072	1,452,346	1,454,164

Hispanic/Latino Population, Census 2010: 436,358
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MICHIGAN CANCER REGISTRY

Initial Operation: 1981
Population-based Data Available: 1985
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.5	100.3	101.4	103.3	99.6
Missing Race	0.8	1.0	0.6	1.3	1.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.2	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	2.0	1.4	1.6	1.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.7	Prostate	97.7
Oral Cavity & Pharynx	98.0	Testis	99.2
Esophagus	94.3	Bladder (incl. <i>in situ</i>)	97.7
Stomach	96.1	Kidney & Renal Pelvis	91.5
Colon & Rectum	96.1	Brain & Other CNS ¹	85.7
Liver	59.6	Thyroid	99.6
Pancreas	83.1	Hodgkin Lymphoma	99.0
Lung & Bronchus	88.3	Non-Hodgkin Lymphoma	96.7
Melanomas of the Skin	99.0	Multiple Myeloma	92.6
Female Breast (excl. <i>in situ</i>)	98.7	Leukemias	90.4
Cervix uteri	98.1	Brain & Other CNS ¹ <i>non-malig</i>	44.7
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	92.1		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	27,762	487.9	1.35	578.8	1.57	26,981	421.7	1.19	492.1	1.35
Oral Cavity & Pharynx	1,036	17.6	0.25	21.4	0.30	428	6.6	0.15	7.8	0.17
Lip	32	0.6	0.05	0.7	0.06	13	0.2	0.02	0.2	0.03
Tongue	340	5.7	0.14	7.0	0.17	120	1.9	0.08	2.2	0.09
Major salivary gland	81	1.5	0.08	1.8	0.09	66	1.1	0.06	1.2	0.07
Floor of mouth	49	0.8	0.05	1.0	0.06	25	0.4	0.03	0.5	0.04
Gum & other mouth	110	2.0	0.09	2.3	0.10	100	1.5	0.07	1.7	0.08
Nasopharynx	40	0.7	0.05	0.8	0.06	13	0.2	0.03	0.2	0.03
Oropharynx	48	0.8	0.05	1.0	0.06	15	0.2	0.02	0.3	0.03
Hypopharynx	65	1.1	0.06	1.3	0.07	18	0.3	0.03	0.3	0.04
Digestive System	5,304	93.7	0.59	111.6	0.69	4,255	64.0	0.45	75.3	0.52
Esophagus	530	9.1	0.18	11.0	0.22	142	2.1	0.08	2.5	0.09
Stomach	460	8.4	0.18	9.8	0.21	262	4.0	0.11	4.6	0.13
Small intestine	164	2.9	0.10	3.4	0.12	140	2.2	0.08	2.5	0.10
Colon excl. rectum	1,587	29.0	0.33	34.0	0.39	1,641	24.9	0.28	28.9	0.32
Rectum & rectosigmoid	751	13.3	0.22	15.8	0.26	551	8.6	0.17	10.2	0.20
Anus, anal canal & anorectum	71	1.3	0.07	1.5	0.08	147	2.2	0.09	2.7	0.10
Liver	579	9.3	0.18	11.6	0.22	210	3.1	0.10	3.7	0.11
Gallbladder	42	0.8	0.05	0.9	0.06	79	1.2	0.06	1.4	0.07
Pancreas	870	15.3	0.24	18.2	0.28	817	11.9	0.19	14.1	0.22
Respiratory System	4,502	78.8	0.54	94.0	0.63	4,015	59.1	0.43	70.5	0.50
Larynx	357	5.9	0.14	7.3	0.17	101	1.5	0.07	1.9	0.08
Lung & bronchus	4,085	71.8	0.52	85.4	0.60	3,873	56.9	0.42	67.9	0.49
Bones & Joints	58	1.1	0.07	1.2	0.07	41	0.7	0.05	0.8	0.05
Soft Tissue (incl. heart)	200	3.8	0.12	4.2	0.14	159	2.7	0.10	3.0	0.11
Skin (excl. basal & sq.)	1,482	27.2	0.33	31.7	0.37	1,110	18.9	0.26	21.2	0.29
Melanomas of the skin	1,331	24.3	0.31	28.4	0.35	1,004	17.2	0.25	19.3	0.28
Breast (excl. <i>in situ</i>)	82	1.4	0.07	1.7	0.09	7,708	122.6	0.65	143.6	0.74
Female Genital System	-	-	-	-	-	3,321	51.9	0.42	61.6	0.48
Cervix uteri	-	-	-	-	-	344	6.7	0.17	7.1	0.17
Uterus Corpus	-	-	-	-	-	1,878	28.1	0.30	34.3	0.36
Uterus, NOS ¹	-	-	-	-	-	63	1.0	0.06	1.1	0.06
Ovary	-	-	-	-	-	685	10.8	0.19	12.7	0.22
Male Genital System	6,877	113.2	0.63	138.3	0.75	-	-	-	-	-
Prostate	6,554	106.3	0.60	131.3	0.73	-	-	-	-	-
Testis	272	5.9	0.16	5.9	0.16	-	-	-	-	-
Penis	39	0.7	0.05	0.8	0.06	-	-	-	-	-
Urinary System	3,423	62.0	0.49	72.8	0.56	1,426	21.4	0.26	25.2	0.30
Bladder (incl. <i>in situ</i>)	2,065	38.0	0.38	44.5	0.44	657	9.5	0.17	11.2	0.20
Kidney & renal pelvis	1,271	22.4	0.29	26.4	0.33	725	11.3	0.19	13.2	0.22
Ureter	46	0.8	0.06	1.0	0.07	31	0.4	0.04	0.5	0.04
Eye & Orbit	55	1.0	0.06	1.1	0.07	42	0.7	0.05	0.8	0.05
Brain & Other CNS ¹	410	7.7	0.18	8.5	0.19	313	5.4	0.14	5.8	0.15
Brain	387	7.3	0.17	8.1	0.18	291	4.9	0.13	5.4	0.14
Endocrine System	390	7.3	0.17	8.2	0.19	1,054	20.0	0.29	21.5	0.30
Thyroid gland	348	6.5	0.16	7.3	0.18	1,019	19.4	0.28	20.8	0.29
Lymphomas	1,436	26.7	0.32	30.5	0.36	1,185	18.7	0.25	21.5	0.28
Hodgkin Lymphoma	149	3.0	0.11	3.1	0.12	117	2.3	0.10	2.3	0.10
Non-Hodgkin Lymphoma	1,287	23.7	0.30	27.3	0.34	1,068	16.4	0.23	19.1	0.26
Multiple Myeloma	478	8.6	0.18	10.1	0.21	370	5.5	0.13	6.5	0.15
Leukemias	956	17.8	0.26	20.3	0.30	679	10.8	0.19	12.2	0.21
Acute lymphocytic	84	1.7	0.09	1.6	0.08	60	1.2	0.07	1.1	0.07
Chronic lymphocytic	354	6.3	0.15	7.5	0.18	222	3.2	0.10	3.8	0.12
Acute myeloid	295	5.5	0.15	6.3	0.17	232	3.7	0.11	4.2	0.12
Chronic myeloid	122	2.3	0.10	2.6	0.11	106	1.7	0.08	2.0	0.09
Other leukemias	101	1.9	0.09	2.2	0.10	60	0.9	0.06	1.1	0.06
Mesothelioma	86	1.7	0.08	1.9	0.09	28	0.4	0.04	0.5	0.04
Kaposi Sarcoma	18	0.4	0.04	0.4	0.04	4	0.1	0.01	0.1	0.01
Ill-defined & Unknown	970	17.9	0.26	20.9	0.30	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	409	7.7	0.18	8.7	0.19	840	13.7	0.22	15.5	0.24
Breast (<i>in situ</i>)	10	0.2	0.03	0.2	0.03	1,976	32.0	0.34	37.7	0.38

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	23,479	476.4	1.43	563.5	1.66	22,863	423.1	1.31	492.5	1.48
Oral Cavity & Pharynx	908	17.8	0.27	21.7	0.32	364	6.5	0.16	7.8	0.18
Lip	31	0.7	0.05	0.8	0.06	13	0.2	0.03	0.3	0.03
Tongue	308	5.9	0.16	7.3	0.19	106	2.0	0.09	2.3	0.10
Major salivary gland	71	1.6	0.09	1.8	0.10	54	1.0	0.07	1.2	0.07
Floor of mouth	45	0.8	0.06	1.1	0.07	21	0.4	0.04	0.5	0.04
Gum & other mouth	95	1.9	0.09	2.3	0.11	87	1.5	0.07	1.8	0.09
Nasopharynx	27	0.5	0.05	0.7	0.06	9	0.2	0.03	0.2	0.03
Oropharynx	40	0.7	0.05	0.9	0.07	13	0.2	0.03	0.3	0.03
Hypopharynx	52	1.0	0.06	1.2	0.08	12	0.2	0.03	0.3	0.03
Digestive System	4,380	89.2	0.62	106.0	0.72	3,475	61.2	0.48	71.8	0.55
Esophagus	474	9.3	0.20	11.3	0.23	119	2.0	0.08	2.4	0.10
Stomach	365	7.6	0.18	8.9	0.21	191	3.4	0.11	3.9	0.13
Small intestine	127	2.6	0.11	3.1	0.12	108	2.0	0.09	2.3	0.10
Colon excl. rectum	1,315	27.7	0.35	32.4	0.40	1,355	24.0	0.30	27.8	0.34
Rectum & rectosigmoid	627	12.9	0.24	15.3	0.28	458	8.5	0.19	10.1	0.21
Anus, anal canal & anorectum	56	1.2	0.07	1.4	0.08	132	2.4	0.10	2.9	0.11
Liver	431	8.1	0.18	10.0	0.22	152	2.6	0.10	3.1	0.11
Gallbladder	32	0.7	0.06	0.8	0.06	64	1.1	0.06	1.3	0.07
Pancreas	735	14.8	0.25	17.6	0.29	672	11.4	0.20	13.5	0.23
Respiratory System	3,847	77.0	0.57	91.7	0.67	3,429	59.0	0.46	70.2	0.54
Larynx	296	5.6	0.15	7.0	0.18	79	1.4	0.07	1.7	0.09
Lung & bronchus	3,501	70.3	0.55	83.6	0.64	3,317	57.0	0.45	67.8	0.53
Bones & Joints	50	1.2	0.08	1.3	0.08	35	0.8	0.06	0.8	0.06
Soft Tissue (incl. heart)	165	3.7	0.13	4.1	0.14	128	2.6	0.11	2.8	0.11
Skin (excl. basal & sq.)	1,374	29.1	0.36	33.8	0.41	1,014	20.8	0.31	23.3	0.33
Melanomas of the skin	1,244	26.3	0.34	30.6	0.39	928	19.3	0.30	21.5	0.32
Breast (excl. <i>in situ</i>)	68	1.4	0.08	1.6	0.09	6,513	122.7	0.71	143.7	0.81
Female Genital System	-	-	-	-	-	2,847	52.8	0.46	62.6	0.53
Cervix uteri	-	-	-	-	-	273	6.6	0.19	7.0	0.19
Uterus Corpus	-	-	-	-	-	1,619	28.7	0.33	35.1	0.39
Uterus, NOS ¹	-	-	-	-	-	47	0.8	0.06	1.0	0.07
Ovary	-	-	-	-	-	597	11.2	0.21	13.1	0.24
Male Genital System	5,473	104.2	0.65	126.6	0.77	-	-	-	-	-
Prostate	5,177	96.4	0.61	118.7	0.74	-	-	-	-	-
Testis	252	6.9	0.20	6.8	0.19	-	-	-	-	-
Penis	33	0.7	0.06	0.8	0.06	-	-	-	-	-
Urinary System	3,039	63.1	0.53	74.0	0.61	1,225	21.6	0.29	25.3	0.33
Bladder (incl. <i>in situ</i>)	1,901	39.8	0.42	46.6	0.48	584	9.8	0.19	11.6	0.22
Kidney & renal pelvis	1,059	21.7	0.31	25.5	0.35	601	11.1	0.21	12.9	0.24
Ureter	42	0.9	0.06	1.0	0.07	29	0.5	0.04	0.6	0.05
Eye & Orbit	51	1.1	0.07	1.2	0.08	39	0.8	0.06	0.9	0.06
Brain & Other CNS ¹	373	8.3	0.20	9.2	0.21	277	5.6	0.16	6.2	0.17
Brain	354	7.8	0.19	8.7	0.21	259	5.2	0.15	5.8	0.16
Endocrine System	342	7.7	0.19	8.5	0.21	899	21.2	0.33	22.6	0.34
Thyroid gland	309	6.9	0.18	7.7	0.20	871	20.5	0.33	21.9	0.34
Lymphomas	1,257	27.0	0.35	30.9	0.39	1,025	19.0	0.28	21.9	0.31
Hodgkin Lymphoma	124	3.0	0.12	3.2	0.13	97	2.4	0.11	2.4	0.11
Non-Hodgkin Lymphoma	1,133	24.0	0.33	27.7	0.37	929	16.7	0.25	19.5	0.29
Multiple Myeloma	373	7.7	0.18	9.0	0.21	265	4.6	0.13	5.4	0.15
Leukemias	842	18.1	0.29	20.6	0.32	578	10.8	0.21	12.2	0.23
Acute lymphocytic	74	1.9	0.10	1.8	0.09	49	1.3	0.08	1.2	0.08
Chronic lymphocytic	311	6.3	0.16	7.5	0.19	192	3.2	0.11	3.9	0.13
Acute myeloid	264	5.7	0.16	6.5	0.18	199	3.7	0.12	4.2	0.14
Chronic myeloid	103	2.2	0.10	2.6	0.11	87	1.7	0.09	1.9	0.09
Other leukemias	91	2.0	0.09	2.3	0.11	50	0.9	0.06	1.0	0.07
Mesothelioma	83	1.8	0.09	2.1	0.10	26	0.4	0.04	0.5	0.05
Kaposi Sarcoma	9	0.2	0.03	0.2	0.03	2	0.0	0.01	0.0	0.01
Ill-defined & Unknown	845	17.9	0.28	20.9	0.32	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	346	7.6	0.19	8.5	0.21	681	13.2	0.24	14.9	0.26
Breast (<i>in situ</i>)	8	0.2	0.03	0.2	0.03	1,618	31.5	0.37	37.0	0.42

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,319	539.6	4.40	651.7	5.18	3,310	411.7	3.28	487.2	3.81
Oral Cavity & Pharynx	101	15.6	0.72	19.0	0.86	48	6.0	0.40	7.1	0.46
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	3.5	0.34	4.3	0.41	11	1.4	0.19	1.6	0.22
Major salivary gland	8	1.2	0.20	1.4	0.23	10	1.2	0.18	1.4	0.20
Floor of mouth	4	0.5	0.13	0.7	0.16	2	0.3	0.09	0.4	0.10
Gum & other mouth	11	1.8	0.26	2.2	0.30	7	0.9	0.15	1.0	0.17
Nasopharynx	8	1.2	0.19	1.4	0.22	2	0.2	0.08	0.3	0.09
Oropharynx	8	1.2	0.20	1.5	0.24	2	0.2	0.08	0.3	0.09
Hypopharynx	12	2.0	0.26	2.4	0.31	6	0.7	0.14	0.8	0.16
Digestive System	772	126.8	2.15	153.2	2.53	668	82.0	1.45	98.7	1.72
Esophagus	44	6.9	0.49	8.6	0.59	21	2.6	0.25	3.1	0.30
Stomach	76	13.6	0.73	15.9	0.83	59	7.4	0.44	8.7	0.51
Small intestine	33	5.4	0.45	6.5	0.52	29	3.4	0.29	4.2	0.35
Colon excl. rectum	230	39.1	1.21	46.5	1.41	249	31.1	0.90	37.0	1.05
Rectum & rectosigmoid	97	15.6	0.74	18.7	0.87	74	8.9	0.47	10.8	0.57
Anus, anal canal & anorectum	14	2.2	0.27	2.6	0.31	13	1.6	0.20	1.9	0.24
Liver	127	18.0	0.74	23.6	0.95	47	5.4	0.36	6.8	0.44
Gallbladder	8	1.5	0.24	1.8	0.29	13	1.6	0.21	2.0	0.25
Pancreas	118	20.4	0.88	24.2	1.02	128	15.6	0.63	19.0	0.75
Respiratory System	562	96.1	1.91	115.1	2.23	494	60.5	1.25	73.3	1.48
Larynx	54	8.6	0.55	10.6	0.66	20	2.3	0.24	2.9	0.29
Lung & bronchus	501	86.4	1.82	103.3	2.11	469	57.4	1.22	69.6	1.44
Bones & Joints	6	0.8	0.15	0.8	0.16	4	0.6	0.12	0.5	0.12
Soft Tissue (incl. heart)	27	4.2	0.38	4.7	0.42	24	3.0	0.28	3.4	0.31
Skin (excl. basal & sq.)	11	1.9	0.26	2.1	0.29	19	2.4	0.25	2.7	0.28
Melanomas of the skin	5	0.8	0.17	1.0	0.20	8	1.0	0.16	1.1	0.18
Breast (excl. <i>in situ</i>)	13	2.3	0.29	2.7	0.34	979	123.1	1.80	144.9	2.08
Female Genital System	-	-	-	-	-	382	46.5	1.09	55.7	1.28
Cervix uteri	-	-	-	-	-	56	7.5	0.46	8.1	0.49
Uterus Corpus	-	-	-	-	-	213	25.1	0.79	31.0	0.95
Uterus, NOS ¹	-	-	-	-	-	14	1.7	0.21	2.1	0.25
Ovary	-	-	-	-	-	67	8.2	0.46	9.8	0.54
Male Genital System	1,066	163.4	2.34	204.0	2.84	-	-	-	-	-
Prostate	1,050	160.9	2.32	201.3	2.82	-	-	-	-	-
Testis	11	1.6	0.23	1.7	0.23	-	-	-	-	-
Penis	4	0.7	0.17	0.9	0.20	-	-	-	-	-
Urinary System	301	50.7	1.37	60.2	1.59	173	21.6	0.75	25.6	0.87
Bladder (incl. <i>in situ</i>)	119	21.8	0.94	25.7	1.08	61	7.8	0.46	9.1	0.52
Kidney & renal pelvis	176	27.9	0.98	33.3	1.14	108	13.3	0.59	15.8	0.69
Ureter	2	0.4	0.11	0.4	0.13	-	-	-	-	-
Eye & Orbit	2	0.3	0.09	0.3	0.10	2	0.2	0.08	0.2	0.08
Brain & Other CNS ¹	27	4.1	0.37	4.5	0.40	26	3.4	0.30	3.5	0.31
Brain	24	3.7	0.35	4.1	0.39	23	2.9	0.28	3.1	0.29
Endocrine System	31	5.1	0.43	5.9	0.49	111	14.3	0.62	16.0	0.68
Thyroid gland	25	4.1	0.39	4.8	0.44	104	13.5	0.61	15.1	0.67
Lymphomas	130	21.4	0.88	24.3	0.99	119	14.9	0.63	17.1	0.71
Hodgkin Lymphoma	21	3.2	0.32	3.2	0.32	16	2.1	0.24	2.1	0.24
Non-Hodgkin Lymphoma	110	18.2	0.82	21.1	0.93	103	12.9	0.58	15.0	0.67
Multiple Myeloma	91	15.9	0.78	18.8	0.91	96	12.3	0.57	14.4	0.66
Leukemias	76	13.2	0.71	14.9	0.80	70	8.9	0.49	10.1	0.55
Acute lymphocytic	6	0.8	0.14	0.7	0.13	7	0.9	0.16	0.9	0.15
Chronic lymphocytic	27	4.8	0.43	5.7	0.50	17	2.1	0.24	2.5	0.28
Acute myeloid	23	4.1	0.40	4.6	0.44	26	3.5	0.31	3.9	0.34
Chronic myeloid	13	2.2	0.29	2.5	0.32	12	1.5	0.20	1.7	0.22
Other leukemias	7	1.3	0.23	1.6	0.27	7	0.9	0.16	1.1	0.18
Mesothelioma	2	0.5	0.15	0.5	0.16	2	0.2	0.08	0.3	0.09
Kaposi Sarcoma	8	1.2	0.20	1.2	0.19	1	0.2	0.07	0.2	0.07
Ill-defined & Unknown	92	16.2	0.80	19.4	0.94	92	11.6	0.55	13.6	0.64
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	49	8.2	0.55	9.3	0.62	127	16.4	0.67	18.6	0.75
Breast (<i>in situ</i>)	2	0.4	0.11	0.5	0.14	287	35.5	0.96	42.4	1.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	277	253.3	7.33	295.4	8.53	350	252.2	6.30	292.3	7.31
Oral Cavity & Pharynx	12	8.7	1.20	10.0	1.40	7	4.6	0.81	5.5	0.97
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.3	0.82	3.9	0.96	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.9	0.40	1.1	0.45	3	1.7	0.48	2.2	0.60
Nasopharynx	4	2.4	0.57	2.6	0.63	1	1.0	0.40	1.1	0.43
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	75	69.5	3.87	82.0	4.54	56	45.3	2.85	53.0	3.30
Esophagus	4	3.4	0.82	4.1	0.96	-	-	-	-	-
Stomach	12	11.8	1.60	13.6	1.83	9	7.7	1.21	9.1	1.41
Small intestine	2	1.6	0.58	1.7	0.64	-	-	-	-	-
Colon excl. rectum	20	18.7	2.05	22.0	2.39	17	13.7	1.56	15.7	1.79
Rectum & rectosigmoid	12	11.0	1.51	13.4	1.83	9	6.9	1.07	8.5	1.30
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	10	7.7	1.17	9.2	1.40	5	4.6	0.94	5.2	1.03
Gallbladder	-	-	-	-	-	1	1.0	0.38	1.2	0.44
Pancreas	7	7.6	1.37	8.8	1.59	8	6.7	1.14	7.8	1.30
Respiratory System	32	33.3	2.82	38.9	3.28	34	28.5	2.28	33.2	2.63
Larynx	2	1.8	0.57	2.1	0.67	-	-	-	-	-
Lung & bronchus	29	30.2	2.71	35.4	3.16	32	27.2	2.23	31.7	2.57
Bones & Joints	1	1.3	0.57	1.5	0.65	1	0.7	0.30	0.8	0.34
Soft Tissue (incl. heart)	4	3.0	0.73	3.3	0.84	3	2.0	0.54	2.1	0.58
Skin (excl. basal & sq.)	3	2.3	0.69	2.6	0.82	4	2.8	0.68	3.3	0.80
Melanomas of the skin	-	-	-	-	-	3	2.2	0.63	2.7	0.75
Breast (excl. <i>in situ</i>)	-	-	-	-	-	122	82.8	3.45	97.0	4.05
Female Genital System	-	-	-	-	-	46	30.7	2.09	35.7	2.46
Cervix uteri	-	-	-	-	-	6	3.8	0.72	4.3	0.83
Uterus Corpus	-	-	-	-	-	22	14.8	1.45	17.5	1.72
Uterus, NOS ¹	-	-	-	-	-	1	1.0	0.38	1.1	0.44
Ovary	-	-	-	-	-	12	8.2	1.11	9.4	1.30
Male Genital System	65	57.9	3.41	69.2	4.01	-	-	-	-	-
Prostate	60	55.1	3.35	66.5	3.97	-	-	-	-	-
Testis	4	1.9	0.46	1.9	0.45	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	26	25.2	2.37	29.3	2.75	7	6.2	1.07	7.1	1.22
Bladder (incl. <i>in situ</i>)	12	12.9	1.81	14.8	2.08	3	3.2	0.83	3.6	0.93
Kidney & renal pelvis	13	11.5	1.48	13.5	1.74	4	2.5	0.60	3.0	0.71
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	3.4	0.83	3.5	0.89	6	4.2	0.78	4.5	0.85
Brain	4	3.4	0.83	3.5	0.89	6	3.8	0.74	4.1	0.80
Endocrine System	12	8.8	1.22	9.8	1.38	27	16.3	1.45	18.4	1.67
Thyroid gland	10	7.2	1.10	8.2	1.27	26	15.7	1.41	17.7	1.62
Lymphomas	19	16.4	1.85	18.9	2.14	16	12.0	1.40	13.6	1.59
Hodgkin Lymphoma	1	0.8	0.31	0.8	0.31	2	1.1	0.34	1.1	0.37
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	5	5.5	1.11	6.1	1.21	3	2.0	0.55	2.6	0.70
Leukemias	10	8.3	1.31	9.1	1.47	9	6.3	0.99	6.5	1.05
Acute lymphocytic	2	1.4	0.42	1.2	0.37	2	1.1	0.38	1.0	0.33
Chronic lymphocytic	2	1.9	0.62	2.3	0.75	-	-	-	-	-
Acute myeloid	4	3.8	0.95	4.2	1.08	3	2.1	0.58	2.2	0.62
Chronic myeloid	-	-	-	-	-	2	1.4	0.50	1.5	0.54
Other leukemias	-	-	-	-	-	1	0.8	0.35	0.9	0.38
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	8	7.7	1.31	9.0	1.54	8	7.2	1.18	8.3	1.37
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	6	4.6	0.90	5.3	1.04	15	10.8	1.29	12.5	1.50
Breast (<i>in situ</i>)	-	-	-	-	-	36	23.7	1.82	27.3	2.11

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	100	524.0	25.62	627.6	29.89	102	482.2	22.46	568.5	25.96
Oral Cavity & Pharynx	2	10.3	3.03	12.4	3.61	3	16.1	4.25	18.7	4.81
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	27	138.4	12.82	164.9	14.86	17	78.1	8.94	93.0	10.40
Esophagus	3	14.9	3.91	18.4	4.66	-	-	-	-	-
Stomach	1	7.6	3.06	9.0	3.55	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	45.4	7.75	51.2	8.60	5	24.6	5.00	29.1	5.80
Rectum & rectosigmoid	4	20.1	4.61	23.3	5.26	3	12.4	3.52	13.2	3.69
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	18.0	4.33	23.4	5.40	2	8.9	2.99	11.1	3.64
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	5	23.7	5.41	29.4	6.47	3	16.0	4.16	19.7	4.96
Respiratory System	24	128.5	12.69	156.1	14.96	26	130.4	11.96	154.1	13.81
Larynx	3	11.4	3.34	14.8	4.17	-	-	-	-	-
Lung & bronchus	22	117.1	12.25	141.2	14.37	26	128.3	11.89	151.2	13.70
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	3	21.2	6.20	26.5	7.58	1	5.0	2.06	5.7	2.35
Melanomas of the skin	3	19.8	6.12	24.4	7.43	1	5.0	2.06	5.7	2.35
Breast (excl. <i>in situ</i>)	-	-	-	-	-	24	109.1	10.36	131.1	12.16
Female Genital System	-	-	-	-	-	9	41.9	6.43	48.7	7.33
Cervix uteri	-	-	-	-	-	1	6.4	2.45	7.1	2.69
Uterus Corpus	-	-	-	-	-	5	24.3	4.86	28.1	5.49
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	8.6	3.16	9.6	3.56
Male Genital System	16	81.9	9.89	99.0	11.52	-	-	-	-	-
Prostate	15	76.2	9.64	92.9	11.28	-	-	-	-	-
Testis	1	4.9	2.02	5.0	2.08	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	11	62.1	8.95	73.7	10.31	6	31.3	5.93	37.3	6.95
Bladder (incl. <i>in situ</i>)	4	27.6	6.46	32.6	7.44	3	12.7	3.75	15.7	4.53
Kidney & renal pelvis	7	34.5	6.19	41.2	7.15	3	17.1	4.33	19.7	4.93
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	1	7.4	2.95	7.9	3.19	-	-	-	-	-
Brain	1	7.4	2.95	7.9	3.19	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	10.6	3.30	11.1	3.42
Thyroid gland	-	-	-	-	-	2	10.6	3.30	11.1	3.42
Lymphomas	4	20.1	5.01	22.9	5.59	5	21.7	4.67	25.0	5.28
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	3	18.7	4.90	21.2	5.46	4	17.4	4.23	20.7	4.90
Multiple Myeloma	2	14.6	4.90	17.4	5.68	1	7.4	3.19	8.9	3.75
Leukemias	2	10.9	3.58	13.5	4.34	2	8.9	2.92	9.7	3.11
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	23.1	5.45	27.7	6.39	2	11.8	3.80	14.6	4.61
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	1	6.3	2.73	6.8	2.85	3	14.3	3.94	15.0	4.06
Breast (<i>in situ</i>)	-	-	-	-	-	9	41.7	6.34	48.3	7.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	437	341.7	8.11	404.0	9.38	443	293.6	6.57	345.2	7.70
Oral Cavity & Pharynx	15	10.7	1.33	13.2	1.59	5	3.0	0.63	3.7	0.80
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.7	0.75	4.6	0.92	2	1.4	0.44	1.9	0.57
Major salivary gland	2	1.1	0.44	1.3	0.50	1	0.6	0.26	0.7	0.31
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.8	0.29	1.0	0.37	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	109	88.7	4.18	105.5	4.84	81	57.9	3.02	69.2	3.56
Esophagus	5	3.9	0.80	4.9	0.99	3	2.2	0.62	2.5	0.70
Stomach	11	11.4	1.64	12.6	1.79	7	4.6	0.82	5.6	0.99
Small intestine	2	0.9	0.32	1.2	0.43	2	1.1	0.35	1.3	0.43
Colon excl. rectum	27	21.4	2.03	25.4	2.36	22	15.8	1.57	18.9	1.86
Rectum & rectosigmoid	16	11.5	1.44	14.0	1.70	13	8.5	1.12	10.1	1.33
Anus, anal canal & anorectum	2	1.5	0.50	1.7	0.58	1	1.1	0.44	1.3	0.49
Liver	23	18.2	1.86	22.1	2.16	8	6.1	1.02	7.2	1.17
Gallbladder	-	-	-	-	-	2	1.9	0.56	2.3	0.67
Pancreas	15	13.6	1.70	16.2	1.96	17	12.5	1.42	15.2	1.68
Respiratory System	44	39.5	2.90	46.5	3.32	44	34.2	2.42	40.6	2.80
Larynx	4	2.8	0.68	3.4	0.81	2	1.3	0.50	1.5	0.55
Lung & bronchus	38	35.6	2.78	41.7	3.18	41	31.9	2.33	37.9	2.71
Bones & Joints	1	0.9	0.37	1.0	0.42	-	-	-	-	-
Soft Tissue (incl. heart)	4	2.1	0.56	2.2	0.60	4	2.3	0.55	2.6	0.64
Skin (excl. basal & sq.)	-	-	-	-	-	10	6.5	0.97	7.6	1.13
Melanomas of the skin	7	6.1	1.15	7.0	1.29	8	5.1	0.83	6.2	1.00
Breast (excl. <i>in situ</i>)	1	1.2	0.53	1.4	0.63	117	74.1	3.19	87.5	3.78
Female Genital System	-	-	-	-	-	72	44.4	2.45	52.1	2.89
Cervix uteri	-	-	-	-	-	16	8.9	1.02	9.7	1.15
Uterus Corpus	-	-	-	-	-	35	22.0	1.73	26.9	2.10
Uterus, NOS ¹	-	-	-	-	-	1	0.8	0.32	1.0	0.40
Ovary	-	-	-	-	-	14	8.5	1.08	9.8	1.26
Male Genital System	100	76.7	3.77	93.2	4.44	-	-	-	-	-
Prostate	88	72.0	3.71	88.7	4.40	-	-	-	-	-
Testis	11	4.1	0.58	4.0	0.56	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	56	44.8	2.98	52.6	3.43	23	16.7	1.62	19.4	1.88
Bladder (incl. <i>in situ</i>)	23	20.4	2.07	24.4	2.41	6	4.7	0.92	5.6	1.07
Kidney & renal pelvis	31	23.1	2.07	26.7	2.35	17	11.5	1.32	13.3	1.51
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.4	0.15	0.3	0.12	-	-	-	-	-
Brain & Other CNS ¹	8	4.5	0.83	5.0	0.92	5	2.8	0.63	3.0	0.70
Brain	7	4.2	0.82	4.6	0.90	4	2.5	0.61	2.7	0.67
Endocrine System	10	5.9	0.95	6.8	1.11	27	14.4	1.30	15.6	1.45
Thyroid gland	8	5.3	0.92	6.0	1.06	26	14.0	1.29	15.2	1.43
Lymphomas	33	25.6	2.24	29.0	2.53	21	14.4	1.48	16.8	1.71
Hodgkin Lymphoma	4	1.9	0.46	2.0	0.51	3	1.3	0.37	1.3	0.38
Non-Hodgkin Lymphoma	29	23.7	2.19	27.1	2.47	19	13.1	1.43	15.5	1.67
Multiple Myeloma	11	8.6	1.24	10.7	1.49	7	5.3	0.96	6.4	1.13
Leukemias	20	11.7	1.38	12.6	1.53	13	7.1	0.96	8.2	1.13
Acute lymphocytic	6	2.3	0.43	2.2	0.46	-	-	-	-	-
Chronic lymphocytic	3	2.3	0.69	2.7	0.78	2	1.7	0.55	2.0	0.64
Acute myeloid	6	3.9	0.81	4.3	0.92	5	2.4	0.52	2.7	0.63
Chronic myeloid	3	1.8	0.55	2.0	0.61	2	1.1	0.39	1.3	0.45
Other leukemias	2	1.4	0.55	1.3	0.56	-	-	-	-	-
Mesothelioma	1	1.2	0.50	1.5	0.59	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	14	12.3	1.58	14.4	1.83	14	9.9	1.24	11.7	1.46
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	4.7	0.87	5.4	1.01	18	10.9	1.24	12.9	1.47
Breast (<i>in situ</i>)	-	-	-	-	-	39	24.9	1.84	29.4	2.17

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MICHIGAN

II-258 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	23,100	480.4	1.46	568.2	1.69	22,472	427.2	1.34	496.9	1.51
Oral Cavity & Pharynx	894	18.0	0.28	21.9	0.33	359	6.6	0.16	7.9	0.19
Lip	30	0.7	0.05	0.8	0.06	13	0.2	0.03	0.3	0.03
Tongue	303	6.0	0.16	7.4	0.19	104	2.0	0.09	2.4	0.10
Major salivary gland	69	1.6	0.09	1.8	0.10	53	1.0	0.07	1.2	0.07
Floor of mouth	44	0.8	0.06	1.1	0.07	21	0.4	0.04	0.5	0.05
Gum & other mouth	93	1.9	0.09	2.3	0.11	87	1.5	0.08	1.8	0.09
Nasopharynx	27	0.6	0.05	0.7	0.06	9	0.2	0.03	0.2	0.03
Oropharynx	40	0.8	0.06	1.0	0.07	13	0.2	0.03	0.3	0.04
Hypopharynx	52	1.0	0.07	1.3	0.08	12	0.2	0.03	0.3	0.03
Digestive System	4,283	89.4	0.63	106.2	0.73	3,404	61.4	0.49	71.9	0.56
Esophagus	469	9.4	0.20	11.4	0.24	117	2.0	0.09	2.4	0.10
Stomach	355	7.5	0.18	8.8	0.21	185	3.4	0.12	3.9	0.13
Small intestine	125	2.7	0.11	3.1	0.13	107	2.0	0.09	2.3	0.10
Colon excl. rectum	1,291	27.9	0.36	32.6	0.41	1,336	24.2	0.31	28.0	0.35
Rectum & rectosigmoid	613	12.9	0.24	15.4	0.28	447	8.5	0.19	10.1	0.22
Anus, anal canal & anorectum	55	1.2	0.07	1.4	0.08	131	2.4	0.10	2.9	0.12
Liver	411	7.9	0.18	9.8	0.22	146	2.6	0.10	3.0	0.11
Gallbladder	31	0.7	0.06	0.8	0.06	61	1.1	0.06	1.2	0.07
Pancreas	721	14.8	0.25	17.7	0.30	656	11.4	0.20	13.4	0.24
Respiratory System	3,808	77.9	0.58	92.8	0.68	3,391	59.6	0.47	70.9	0.55
Larynx	292	5.7	0.15	7.0	0.19	78	1.4	0.07	1.7	0.09
Lung & bronchus	3,467	71.1	0.55	84.5	0.65	3,281	57.5	0.46	68.5	0.54
Bones & Joints	49	1.2	0.08	1.3	0.08	34	0.8	0.06	0.8	0.06
Soft Tissue (incl. heart)	161	3.7	0.14	4.1	0.15	125	2.6	0.11	2.9	0.12
Skin (excl. basal & sq.)	1,367	29.8	0.37	34.6	0.42	1,006	21.5	0.32	23.9	0.35
Melanomas of the skin	1,238	26.9	0.35	31.3	0.40	921	19.9	0.31	22.1	0.33
Breast (excl. <i>in situ</i>)	67	1.4	0.08	1.6	0.09	6,408	124.1	0.73	145.3	0.83
Female Genital System	-	-	-	-	-	2,783	53.0	0.47	62.9	0.54
Cervix uteri	-	-	-	-	-	260	6.5	0.19	6.9	0.19
Uterus Corpus	-	-	-	-	-	1,588	28.8	0.34	35.2	0.40
Uterus, NOS ¹	-	-	-	-	-	45	0.8	0.06	1.0	0.07
Ovary	-	-	-	-	-	586	11.2	0.22	13.2	0.25
Male Genital System	5,392	105.1	0.66	127.8	0.78	-	-	-	-	-
Prostate	5,106	97.1	0.62	119.7	0.75	-	-	-	-	-
Testis	242	7.0	0.21	7.0	0.20	-	-	-	-	-
Penis	33	0.7	0.06	0.8	0.07	-	-	-	-	-
Urinary System	2,991	63.5	0.53	74.5	0.62	1,204	21.7	0.29	25.4	0.33
Bladder (incl. <i>in situ</i>)	1,879	40.2	0.42	47.0	0.49	579	9.9	0.19	11.8	0.22
Kidney & renal pelvis	1,034	21.7	0.31	25.5	0.36	586	11.1	0.21	12.9	0.24
Ureter	42	0.9	0.06	1.0	0.07	28	0.5	0.04	0.6	0.05
Eye & Orbit	49	1.0	0.07	1.2	0.08	38	0.8	0.06	0.9	0.07
Brain & Other CNS ¹	366	8.5	0.21	9.3	0.22	272	5.8	0.17	6.3	0.17
Brain	347	8.0	0.20	8.8	0.21	255	5.4	0.16	5.9	0.17
Endocrine System	333	7.8	0.20	8.6	0.21	874	21.5	0.34	22.9	0.35
Thyroid gland	302	7.0	0.19	7.8	0.20	847	20.9	0.34	22.3	0.35
Lymphomas	1,229	27.2	0.36	31.0	0.40	1,007	19.2	0.28	22.1	0.32
Hodgkin Lymphoma	122	3.1	0.13	3.2	0.13	94	2.4	0.12	2.5	0.12
Non-Hodgkin Lymphoma	1,107	24.1	0.33	27.8	0.38	913	16.8	0.26	19.6	0.29
Multiple Myeloma	362	7.6	0.18	9.0	0.21	260	4.6	0.13	5.4	0.15
Leukemias	826	18.2	0.29	20.8	0.33	566	10.9	0.22	12.3	0.24
Acute lymphocytic	68	1.9	0.10	1.8	0.10	47	1.3	0.09	1.2	0.08
Chronic lymphocytic	309	6.4	0.17	7.6	0.20	190	3.3	0.11	3.9	0.13
Acute myeloid	258	5.7	0.16	6.5	0.18	194	3.7	0.13	4.2	0.14
Chronic myeloid	101	2.3	0.10	2.6	0.12	86	1.7	0.09	1.9	0.10
Other leukemias	90	2.0	0.10	2.3	0.11	49	0.9	0.06	1.1	0.07
Mesothelioma	81	1.8	0.09	2.1	0.11	26	0.5	0.04	0.5	0.05
Kaposi Sarcoma	9	0.2	0.03	0.2	0.04	2	0.0	0.01	0.0	0.01
Ill-defined & Unknown	833	18.1	0.29	21.1	0.33	711	12.5	0.22	14.5	0.25
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	339	7.8	0.20	8.7	0.21	666	13.3	0.24	15.1	0.27
Breast (<i>in situ</i>)	8	0.2	0.03	0.2	0.03	1,585	31.8	0.38	37.3	0.43

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Michigan, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,306	542.8	4.44	655.4	5.22	3,295	414.4	3.31	490.3	3.84
Oral Cavity & Pharynx	101	15.8	0.73	19.2	0.87	48	6.1	0.40	7.1	0.46
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	3.6	0.35	4.4	0.41	11	1.4	0.19	1.7	0.23
Major salivary gland	8	1.2	0.20	1.4	0.23	10	1.3	0.19	1.4	0.20
Floor of mouth	4	0.6	0.13	0.7	0.16	2	0.3	0.09	0.4	0.11
Gum & other mouth	11	1.9	0.26	2.2	0.30	7	0.9	0.15	1.0	0.18
Nasopharynx	8	1.2	0.20	1.4	0.23	2	0.2	0.09	0.3	0.09
Oropharynx	8	1.2	0.20	1.5	0.24	2	0.2	0.08	0.3	0.09
Hypopharynx	12	2.0	0.26	2.4	0.31	6	0.7	0.14	0.8	0.16
Digestive System	771	127.8	2.16	154.4	2.55	665	82.4	1.47	99.2	1.73
Esophagus	44	7.0	0.49	8.7	0.60	21	2.6	0.26	3.1	0.31
Stomach	76	13.8	0.74	16.0	0.84	58	7.4	0.44	8.7	0.51
Small intestine	33	5.5	0.45	6.6	0.53	29	3.4	0.30	4.2	0.36
Colon excl. rectum	229	39.4	1.22	46.8	1.42	248	31.3	0.91	37.2	1.06
Rectum & rectosigmoid	97	15.7	0.75	18.8	0.88	73	8.9	0.48	10.9	0.57
Anus, anal canal & anorectum	14	2.3	0.28	2.6	0.32	13	1.6	0.20	1.9	0.24
Liver	127	18.1	0.75	23.7	0.96	46	5.4	0.37	6.8	0.45
Gallbladder	8	1.5	0.24	1.8	0.29	13	1.7	0.21	2.0	0.25
Pancreas	118	20.6	0.89	24.4	1.03	127	15.7	0.64	19.0	0.76
Respiratory System	561	96.7	1.92	115.8	2.24	492	60.9	1.26	73.7	1.49
Larynx	54	8.7	0.56	10.7	0.66	20	2.3	0.24	2.9	0.30
Lung & bronchus	500	86.9	1.83	103.9	2.13	467	57.8	1.23	70.0	1.45
Bones & Joints	6	0.8	0.16	0.8	0.16	4	0.6	0.12	0.6	0.12
Soft Tissue (incl. heart)	27	4.2	0.38	4.7	0.42	24	3.0	0.28	3.4	0.31
Skin (excl. basal & sq.)	11	1.9	0.26	2.1	0.29	19	2.4	0.26	2.7	0.28
Melanomas of the skin	5	0.8	0.18	1.0	0.20	8	1.0	0.16	1.1	0.18
Breast (excl. <i>in situ</i>)	13	2.2	0.29	2.7	0.35	975	124.0	1.82	146.0	2.10
Female Genital System	-	-	-	-	-	380	46.8	1.10	56.0	1.29
Cervix uteri	-	-	-	-	-	55	7.4	0.46	8.1	0.49
Uterus Corpus	-	-	-	-	-	213	25.3	0.80	31.2	0.96
Uterus, NOS ¹	-	-	-	-	-	14	1.8	0.22	2.1	0.25
Ovary	-	-	-	-	-	66	8.2	0.46	9.9	0.54
Male Genital System	1,060	164.1	2.36	204.8	2.86	-	-	-	-	-
Prostate	1,045	161.5	2.34	202.1	2.84	-	-	-	-	-
Testis	11	1.6	0.23	1.7	0.24	-	-	-	-	-
Penis	4	0.7	0.17	0.9	0.20	-	-	-	-	-
Urinary System	299	50.9	1.38	60.4	1.60	172	21.7	0.76	25.7	0.88
Bladder (incl. <i>in situ</i>)	119	22.0	0.95	25.9	1.09	61	7.8	0.46	9.2	0.53
Kidney & renal pelvis	175	27.9	0.99	33.3	1.15	107	13.4	0.59	15.9	0.69
Ureter	2	0.4	0.11	0.4	0.13	-	-	-	-	-
Eye & Orbit	2	0.3	0.09	0.3	0.10	2	0.2	0.08	0.2	0.08
Brain & Other CNS ¹	27	4.1	0.37	4.5	0.41	26	3.4	0.30	3.6	0.32
Brain	24	3.8	0.36	4.1	0.39	23	3.0	0.28	3.1	0.30
Endocrine System	31	5.2	0.43	6.0	0.49	110	14.5	0.63	16.1	0.69
Thyroid gland	25	4.1	0.39	4.9	0.45	104	13.7	0.62	15.3	0.68
Lymphomas	130	21.6	0.89	24.5	0.99	119	15.1	0.64	17.3	0.72
Hodgkin Lymphoma	21	3.2	0.33	3.3	0.33	16	2.1	0.24	2.2	0.25
Non-Hodgkin Lymphoma	109	18.4	0.82	21.3	0.94	103	13.0	0.59	15.2	0.67
Multiple Myeloma	91	16.0	0.79	18.9	0.91	95	12.3	0.58	14.4	0.67
Leukemias	76	13.3	0.72	15.0	0.80	69	9.0	0.49	10.1	0.55
Acute lymphocytic	6	0.8	0.15	0.7	0.13	7	0.9	0.16	0.8	0.14
Chronic lymphocytic	27	4.8	0.44	5.7	0.50	17	2.1	0.24	2.6	0.28
Acute myeloid	23	4.1	0.41	4.6	0.45	26	3.5	0.31	4.0	0.35
Chronic myeloid	13	2.2	0.29	2.5	0.32	12	1.5	0.20	1.7	0.23
Other leukemias	7	1.3	0.23	1.6	0.27	7	0.9	0.16	1.1	0.18
Mesothelioma	2	0.5	0.15	0.5	0.16	2	0.2	0.08	0.3	0.09
Kaposi Sarcoma	8	1.3	0.20	1.2	0.20	1	0.2	0.07	0.2	0.07
Ill-defined & Unknown	91	16.2	0.80	19.4	0.94	91	11.6	0.56	13.6	0.64
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	49	8.2	0.55	9.4	0.62	125	16.4	0.67	18.7	0.75
Breast (<i>in situ</i>)	2	0.4	0.11	0.5	0.14	286	35.8	0.97	42.8	1.14

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

MICHIGAN


II-260 Incidence – Non-Hispanic Black

METROPOLITAN DETROIT CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	3,873,083	3,877,883	3,874,523	3,879,960	3,884,422
White	2,677,110	2,675,901	2,667,758	2,664,609	2,660,618
Black	1,000,520	998,647	996,571	995,858	996,206
American Indian/Alaskan Native (AI/AN)	21,170	21,246	21,262	21,347	21,503
Asian/Pacific Islander (API)	174,283	182,089	188,932	198,146	206,095


All Races Population 2013-2017: 19,389,871
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	165,493	168,470	171,399	175,529	179,172
Non-Hispanic White	2,533,363	2,529,465	2,518,775	2,511,749	2,504,619
Non-Hispanic Black	986,276	984,161	981,774	980,904	980,885

Hispanic/Latino Population, Census 2010: 156,275
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

METROPOLITAN DETROIT CANCER REGISTRY

Initial Operation: 1973
 Population-based Data Available: 1973
 Coverage Area: County

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.6	111.5	111.0	113.4	109.2
Missing Race	0.3	0.3	0.1	0.1	0.8
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	1.2	1.3	1.3	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.0	Prostate	98.6
Oral Cavity & Pharynx	98.9	Testis	99.4
Esophagus	97.0	Bladder (incl. <i>in situ</i>)	98.5
Stomach	97.3	Kidney & Renal Pelvis	92.0
Colon & Rectum	97.0	Brain & Other CNS ¹	88.9
Liver	58.3	Thyroid	99.6
Pancreas	85.4	Hodgkin Lymphoma	99.7
Lung & Bronchus	90.3	Non-Hodgkin Lymphoma	98.5
Melanomas of the Skin	99.7	Multiple Myeloma	94.3
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	96.0
Cervix uteri	98.2	Brain & Other CNS ¹ <i>non-malig</i>	40.5
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	94.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11,484	547.2	2.36	650.1	2.74	11,476	457.8	1.97	535.0	2.25
Oral Cavity & Pharynx	432	19.7	0.44	23.9	0.52	173	6.8	0.24	8.1	0.28
Lip	11	0.5	0.07	0.6	0.09	5	0.2	0.04	0.2	0.04
Tongue	133	5.9	0.24	7.3	0.28	45	1.7	0.12	2.1	0.14
Major salivary gland	34	1.8	0.14	2.0	0.16	29	1.2	0.10	1.4	0.12
Floor of mouth	20	0.9	0.09	1.1	0.11	9	0.4	0.05	0.4	0.06
Gum & other mouth	46	2.2	0.15	2.6	0.17	37	1.4	0.11	1.7	0.12
Nasopharynx	20	0.9	0.10	1.1	0.11	6	0.3	0.05	0.3	0.05
Oropharynx	21	0.9	0.09	1.1	0.11	7	0.2	0.04	0.3	0.05
Hypopharynx	30	1.4	0.12	1.7	0.14	9	0.4	0.06	0.4	0.06
Digestive System	2,247	107.1	1.04	127.9	1.22	1,893	72.3	0.76	85.7	0.89
Esophagus	193	9.0	0.30	10.8	0.35	59	2.2	0.13	2.6	0.15
Stomach	200	9.9	0.32	11.6	0.37	132	5.0	0.20	5.9	0.23
Small intestine	73	3.5	0.19	4.1	0.22	65	2.5	0.14	3.0	0.17
Colon excl. rectum	667	32.9	0.59	38.7	0.68	709	27.3	0.47	32.0	0.54
Rectum & rectosigmoid	316	14.8	0.38	17.7	0.45	250	9.9	0.29	11.7	0.33
Anus, anal canal & anorectum	35	1.7	0.13	2.0	0.15	58	2.2	0.13	2.7	0.16
Liver	266	11.4	0.32	14.4	0.40	97	3.6	0.17	4.4	0.20
Gallbladder	18	0.9	0.09	1.0	0.11	35	1.3	0.10	1.5	0.12
Pancreas	361	17.3	0.42	20.7	0.49	369	13.8	0.33	16.4	0.39
Respiratory System	1,771	85.5	0.94	101.6	1.09	1,705	64.9	0.72	77.2	0.84
Larynx	145	6.4	0.25	7.9	0.30	43	1.6	0.11	2.0	0.14
Lung & bronchus	1,603	78.0	0.90	92.4	1.04	1,644	62.6	0.70	74.4	0.83
Bones & Joints	25	1.3	0.12	1.4	0.13	14	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	80	4.0	0.21	4.5	0.23	70	3.0	0.17	3.3	0.18
Skin (excl. basal & sq.)	520	26.0	0.53	30.2	0.60	388	16.5	0.39	18.7	0.43
Melanomas of the skin	463	23.0	0.49	26.8	0.56	342	14.6	0.37	16.5	0.40
Breast (excl. <i>in situ</i>)	33	1.6	0.13	1.9	0.15	3,288	133.5	1.07	156.4	1.23
Female Genital System	-	-	-	-	-	1,380	54.7	0.68	65.2	0.79
Cervix uteri	-	-	-	-	-	142	6.7	0.26	7.2	0.27
Uterus Corpus	-	-	-	-	-	771	29.4	0.49	36.1	0.59
Uterus, NOS ¹	-	-	-	-	-	23	0.9	0.09	1.1	0.10
Ovary	-	-	-	-	-	293	11.7	0.32	13.8	0.36
Male Genital System	3,020	134.9	1.13	165.2	1.36	-	-	-	-	-
Prostate	2,898	128.2	1.10	158.3	1.33	-	-	-	-	-
Testis	101	5.6	0.25	5.6	0.25	-	-	-	-	-
Penis	15	0.8	0.09	0.9	0.11	-	-	-	-	-
Urinary System	1,359	66.7	0.84	78.5	0.96	576	22.3	0.43	26.1	0.49
Bladder (incl. <i>in situ</i>)	796	40.1	0.65	47.0	0.75	270	10.2	0.28	11.9	0.33
Kidney & renal pelvis	529	24.9	0.50	29.5	0.58	292	11.6	0.31	13.6	0.36
Ureter	18	0.9	0.10	1.1	0.11	9	0.3	0.05	0.4	0.06
Eye & Orbit	20	1.0	0.10	1.1	0.11	14	0.6	0.08	0.7	0.08
Brain & Other CNS ¹	152	7.6	0.28	8.5	0.31	121	5.3	0.22	5.7	0.23
Brain	142	7.1	0.28	8.0	0.30	110	4.9	0.21	5.2	0.23
Endocrine System	184	9.1	0.31	10.2	0.34	517	24.3	0.49	26.3	0.52
Thyroid gland	167	8.3	0.30	9.3	0.32	502	23.6	0.49	25.6	0.51
Lymphomas	588	29.4	0.56	33.6	0.63	499	20.1	0.42	23.2	0.47
Hodgkin Lymphoma	66	3.4	0.19	3.6	0.20	49	2.5	0.16	2.5	0.16
Non-Hodgkin Lymphoma	522	26.0	0.52	30.0	0.59	450	17.7	0.38	20.7	0.44
Multiple Myeloma	212	10.4	0.33	12.2	0.38	181	7.0	0.24	8.2	0.28
Leukemias	420	21.1	0.47	24.2	0.53	304	12.3	0.33	13.9	0.36
Acute lymphocytic	33	1.8	0.14	1.7	0.13	21	1.1	0.11	1.0	0.10
Chronic lymphocytic	170	8.2	0.29	9.8	0.34	107	4.0	0.18	4.8	0.21
Acute myeloid	117	6.1	0.26	6.9	0.29	103	4.2	0.19	4.7	0.21
Chronic myeloid	62	3.1	0.18	3.6	0.20	48	2.0	0.13	2.3	0.15
Other leukemias	37	1.9	0.14	2.2	0.16	25	1.0	0.09	1.1	0.10
Mesothelioma	30	1.7	0.14	1.9	0.16	10	0.4	0.06	0.5	0.06
Kaposi Sarcoma	14	0.8	0.09	0.8	0.10	3	0.1	0.03	0.1	0.03
Ill-defined & Unknown	378	19.3	0.46	22.5	0.52	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	188	9.5	0.32	10.7	0.35	434	17.8	0.40	20.3	0.44
Breast (<i>in situ</i>)	4	0.2	0.04	0.2	0.05	868	35.6	0.56	42.1	0.64

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	8,651	543.4	2.70	642.8	3.12	8,571	472.2	2.38	549.2	2.69
Oral Cavity & Pharynx	340	20.3	0.51	24.8	0.60	130	6.9	0.28	8.2	0.33
Lip	10	0.6	0.09	0.7	0.11	4	0.2	0.05	0.2	0.05
Tongue	111	6.5	0.28	8.0	0.34	35	1.9	0.15	2.3	0.17
Major salivary gland	28	1.9	0.17	2.2	0.19	21	1.2	0.12	1.4	0.14
Floor of mouth	17	1.0	0.11	1.2	0.13	8	0.4	0.07	0.5	0.08
Gum & other mouth	35	2.2	0.17	2.6	0.20	29	1.5	0.13	1.7	0.15
Nasopharynx	11	0.7	0.09	0.8	0.11	4	0.2	0.06	0.3	0.06
Oropharynx	14	0.8	0.10	1.0	0.12	5	0.2	0.05	0.3	0.06
Hypopharynx	21	1.2	0.13	1.5	0.15	4	0.2	0.05	0.3	0.06
Digestive System	1,595	100.2	1.16	119.1	1.34	1,317	68.3	0.87	80.3	1.01
Esophagus	157	9.5	0.35	11.5	0.41	41	2.0	0.15	2.4	0.17
Stomach	136	8.8	0.35	10.3	0.40	81	4.2	0.22	4.9	0.25
Small intestine	46	2.9	0.20	3.4	0.23	42	2.3	0.16	2.7	0.19
Colon excl. rectum	467	30.3	0.64	35.5	0.74	500	25.9	0.54	30.2	0.61
Rectum & rectosigmoid	231	14.4	0.44	17.2	0.51	180	9.9	0.35	11.7	0.40
Anus, anal canal & anorectum	23	1.4	0.14	1.7	0.16	46	2.4	0.17	3.0	0.20
Liver	163	9.5	0.34	11.8	0.41	56	2.8	0.17	3.4	0.21
Gallbladder	10	0.7	0.10	0.7	0.11	24	1.1	0.11	1.3	0.13
Pancreas	268	16.8	0.47	20.0	0.55	259	13.0	0.37	15.3	0.43
Respiratory System	1,323	83.2	1.05	98.7	1.22	1,291	66.5	0.85	78.8	0.99
Larynx	102	5.9	0.27	7.3	0.33	28	1.5	0.13	1.8	0.16
Lung & bronchus	1,203	76.2	1.01	90.1	1.17	1,251	64.4	0.83	76.2	0.97
Bones & Joints	19	1.4	0.14	1.5	0.15	10	0.7	0.10	0.7	0.10
Soft Tissue (incl. heart)	58	3.9	0.24	4.4	0.26	48	2.9	0.20	3.1	0.21
Skin (excl. basal & sq.)	497	32.5	0.67	37.8	0.76	362	21.8	0.54	24.5	0.59
Melanomas of the skin	448	29.1	0.64	34.0	0.72	327	20.0	0.52	22.4	0.56
Breast (excl. <i>in situ</i>)	22	1.4	0.14	1.7	0.16	2,425	136.5	1.29	159.5	1.47
Female Genital System	-	-	-	-	-	1,044	57.4	0.83	68.4	0.96
Cervix uteri	-	-	-	-	-	96	6.6	0.32	7.1	0.33
Uterus Corpus	-	-	-	-	-	584	31.0	0.59	38.0	0.71
Uterus, NOS ¹	-	-	-	-	-	14	0.7	0.09	0.9	0.10
Ovary	-	-	-	-	-	229	12.7	0.39	14.9	0.45
Male Genital System	2,107	124.5	1.25	151.4	1.49	-	-	-	-	-
Prostate	2,002	116.2	1.20	143.0	1.44	-	-	-	-	-
Testis	89	7.2	0.35	7.2	0.34	-	-	-	-	-
Penis	11	0.7	0.10	0.8	0.12	-	-	-	-	-
Urinary System	1,105	70.8	0.98	83.2	1.13	433	22.8	0.51	26.7	0.58
Bladder (incl. <i>in situ</i>)	694	45.1	0.79	52.9	0.90	216	10.9	0.34	12.8	0.39
Kidney & renal pelvis	383	24.0	0.57	28.2	0.65	206	11.3	0.37	13.2	0.42
Ureter	16	1.1	0.12	1.2	0.14	8	0.4	0.06	0.5	0.07
Eye & Orbit	18	1.1	0.12	1.3	0.14	12	0.7	0.10	0.8	0.10
Brain & Other CNS ¹	127	8.5	0.35	9.6	0.38	94	5.7	0.28	6.2	0.29
Brain	120	8.1	0.34	9.0	0.37	88	5.3	0.27	5.8	0.28
Endocrine System	148	10.1	0.39	11.2	0.41	404	28.0	0.65	30.0	0.68
Thyroid gland	138	9.4	0.37	10.4	0.40	394	27.4	0.65	29.4	0.67
Lymphomas	474	31.4	0.67	36.0	0.74	392	21.7	0.51	25.0	0.57
Hodgkin Lymphoma	48	3.6	0.24	3.8	0.24	37	2.8	0.21	2.8	0.21
Non-Hodgkin Lymphoma	426	27.9	0.62	32.2	0.70	356	18.9	0.47	22.2	0.53
Multiple Myeloma	137	8.7	0.34	10.3	0.40	102	5.3	0.24	6.2	0.28
Leukemias	345	22.8	0.57	26.1	0.63	236	13.1	0.40	14.8	0.44
Acute lymphocytic	28	2.2	0.19	2.1	0.18	15	1.2	0.14	1.1	0.13
Chronic lymphocytic	139	8.7	0.34	10.4	0.40	87	4.4	0.22	5.2	0.25
Acute myeloid	97	6.6	0.31	7.5	0.34	80	4.5	0.24	5.1	0.26
Chronic myeloid	49	3.3	0.22	3.7	0.24	36	2.1	0.16	2.3	0.18
Other leukemias	31	2.0	0.17	2.4	0.19	18	1.0	0.11	1.1	0.12
Mesothelioma	28	2.0	0.17	2.2	0.19	9	0.4	0.07	0.5	0.08
Kaposi Sarcoma	6	0.4	0.08	0.5	0.09	1	0.1	0.02	0.1	0.03
Ill-defined & Unknown	301	20.0	0.53	23.2	0.60	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	141	9.5	0.37	10.7	0.41	315	17.6	0.47	20.1	0.52
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.06	619	36.0	0.67	42.3	0.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,535	588.5	5.47	709.6	6.42	2,599	438.8	3.95	519.4	4.58
Oral Cavity & Pharynx	80	18.2	0.95	21.8	1.11	38	6.4	0.47	7.6	0.55
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	19	4.1	0.44	5.0	0.52	8	1.4	0.22	1.6	0.26
Major salivary gland	5	1.2	0.24	1.4	0.29	7	1.3	0.21	1.4	0.24
Floor of mouth	3	0.7	0.18	0.9	0.22	2	0.3	0.10	0.3	0.12
Gum & other mouth	9	2.1	0.33	2.4	0.38	5	0.9	0.17	1.1	0.21
Nasopharynx	6	1.4	0.26	1.6	0.29	2	0.3	0.11	0.3	0.11
Oropharynx	6	1.4	0.27	1.8	0.32	2	0.3	0.10	0.4	0.12
Hypopharynx	9	2.2	0.34	2.6	0.39	4	0.8	0.17	0.9	0.19
Digestive System	593	138.7	2.67	167.5	3.14	527	87.3	1.74	105.2	2.06
Esophagus	32	7.3	0.60	9.0	0.72	17	2.7	0.31	3.4	0.37
Stomach	54	13.8	0.87	16.0	0.99	44	7.4	0.51	8.7	0.59
Small intestine	26	6.0	0.56	7.2	0.65	23	3.7	0.35	4.5	0.42
Colon excl. rectum	184	45.1	1.55	53.3	1.80	195	33.0	1.08	39.2	1.26
Rectum & rectosigmoid	74	17.0	0.92	20.5	1.08	61	10.0	0.58	12.2	0.70
Anus, anal canal & anorectum	11	2.6	0.36	3.1	0.41	12	1.9	0.26	2.4	0.31
Liver	96	19.3	0.92	25.2	1.16	36	5.6	0.43	7.1	0.53
Gallbladder	7	1.6	0.30	2.0	0.35	10	1.6	0.24	2.0	0.29
Pancreas	88	21.1	1.05	25.2	1.22	101	16.7	0.76	20.3	0.91
Respiratory System	417	101.1	2.33	120.8	2.70	383	63.2	1.48	76.7	1.76
Larynx	40	9.2	0.68	11.2	0.80	15	2.3	0.28	2.9	0.35
Lung & bronchus	372	90.8	2.21	108.3	2.56	363	60.0	1.45	72.7	1.72
Bones & Joints	5	1.0	0.22	1.0	0.22	3	0.6	0.16	0.6	0.15
Soft Tissue (incl. heart)	19	4.3	0.46	4.8	0.51	20	3.3	0.34	3.8	0.38
Skin (excl. basal & sq.)	7	1.6	0.28	1.9	0.32	15	2.6	0.31	2.9	0.34
Melanomas of the skin	3	0.7	0.19	0.9	0.22	6	1.0	0.19	1.1	0.21
Breast (excl. <i>in situ</i>)	10	2.3	0.35	2.8	0.41	772	132.0	2.18	155.2	2.51
Female Genital System	-	-	-	-	-	298	49.3	1.31	59.1	1.54
Cervix uteri	-	-	-	-	-	42	7.6	0.54	8.3	0.58
Uterus Corpus	-	-	-	-	-	167	26.6	0.95	32.7	1.14
Uterus, NOS ¹	-	-	-	-	-	9	1.5	0.23	1.8	0.27
Ovary	-	-	-	-	-	54	9.1	0.57	11.0	0.67
Male Genital System	827	181.3	2.94	225.9	3.56	-	-	-	-	-
Prostate	815	178.3	2.92	222.6	3.54	-	-	-	-	-
Testis	8	1.9	0.31	2.0	0.31	-	-	-	-	-
Penis	4	0.9	0.22	1.1	0.26	-	-	-	-	-
Urinary System	224	53.9	1.69	63.9	1.95	132	22.4	0.90	26.4	1.03
Bladder (incl. <i>in situ</i>)	87	22.8	1.14	26.7	1.31	49	8.4	0.55	9.8	0.63
Kidney & renal pelvis	132	30.1	1.22	35.9	1.42	81	13.5	0.69	16.1	0.80
Ureter	2	0.4	0.15	0.5	0.17	-	-	-	-	-
Eye & Orbit	2	0.5	0.15	0.5	0.16	2	0.3	0.11	0.3	0.11
Brain & Other CNS ¹	19	4.3	0.45	4.7	0.50	22	3.9	0.39	4.1	0.40
Brain	17	3.8	0.43	4.2	0.48	19	3.5	0.36	3.6	0.37
Endocrine System	27	6.4	0.58	7.4	0.65	89	15.9	0.77	17.8	0.85
Thyroid gland	22	5.3	0.53	6.2	0.60	85	15.1	0.75	17.0	0.83
Lymphomas	99	23.4	1.09	26.5	1.22	91	15.8	0.76	18.1	0.85
Hodgkin Lymphoma	16	3.7	0.42	3.8	0.43	11	1.9	0.27	2.0	0.28
Non-Hodgkin Lymphoma	83	19.7	1.01	22.7	1.14	81	13.8	0.71	16.1	0.81
Multiple Myeloma	69	17.0	0.96	20.0	1.10	76	12.9	0.68	15.3	0.79
Leukemias	60	15.0	0.90	17.1	1.01	57	10.0	0.60	11.3	0.67
Acute lymphocytic	4	0.8	0.18	0.7	0.17	5	0.9	0.19	0.8	0.17
Chronic lymphocytic	23	5.8	0.56	6.9	0.65	16	2.6	0.30	3.1	0.35
Acute myeloid	17	4.5	0.50	5.0	0.55	20	3.6	0.36	4.0	0.41
Chronic myeloid	11	2.8	0.38	3.1	0.42	10	1.8	0.26	2.1	0.29
Other leukemias	5	1.1	0.25	1.4	0.30	-	-	-	-	-
Mesothelioma	2	0.5	0.17	0.6	0.19	1	0.3	0.10	0.3	0.12
Kaposi Sarcoma	7	1.7	0.30	1.7	0.29	1	0.2	0.10	0.2	0.10
Ill-defined & Unknown	69	17.3	0.98	20.6	1.14	72	12.4	0.67	14.5	0.77
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	40	9.7	0.71	11.0	0.80	106	18.7	0.83	21.2	0.93
Breast (<i>in situ</i>)	1	0.3	0.12	0.4	0.15	220	37.1	1.15	44.2	1.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	189	269.0	9.39	313.9	10.92	222	263.2	8.25	304.5	9.56
Oral Cavity & Pharynx	8	10.5	1.72	12.0	1.99	4	4.3	0.96	5.3	1.19
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	3.9	1.18	4.5	1.35	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.5	0.65	1.7	0.73	2	2.4	0.73	3.0	0.90
Nasopharynx	2	2.3	0.69	2.4	0.75	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	47	66.1	4.67	78.2	5.49	37	48.8	3.78	57.3	4.40
Esophagus	3	3.8	1.10	4.5	1.27	-	-	-	-	-
Stomach	9	12.9	2.13	15.1	2.49	6	8.4	1.61	10.1	1.91
Small intestine	1	1.7	0.71	1.7	0.72	-	-	-	-	-
Colon excl. rectum	13	18.6	2.51	21.7	2.91	10	13.1	1.92	15.2	2.22
Rectum & rectosigmoid	7	9.0	1.64	11.3	2.03	6	7.4	1.42	8.9	1.70
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	6.1	1.29	7.4	1.57	3	4.7	1.28	5.3	1.43
Gallbladder	-	-	-	-	-	1	1.3	0.55	1.6	0.66
Pancreas	4	6.8	1.58	7.9	1.83	6	8.3	1.60	9.6	1.82
Respiratory System	21	33.9	3.58	40.2	4.20	20	26.9	2.85	31.3	3.27
Larynx	2	2.3	0.82	2.5	0.91	-	-	-	-	-
Lung & bronchus	19	31.0	3.43	36.9	4.04	19	25.5	2.79	29.6	3.20
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.9	0.87	3.1	0.93	2	2.5	0.78	2.4	0.75
Skin (excl. basal & sq.)	2	2.5	0.99	2.8	1.14	2	2.5	0.85	2.8	0.97
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	77	86.2	4.52	101.2	5.32
Female Genital System	-	-	-	-	-	30	33.1	2.80	38.6	3.29
Cervix uteri	-	-	-	-	-	3	3.6	1.00	3.8	1.10
Uterus Corpus	-	-	-	-	-	16	16.9	1.95	20.3	2.35
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	8	9.2	1.51	10.7	1.77
Male Genital System	50	70.2	4.70	83.5	5.51	-	-	-	-	-
Prostate	47	66.9	4.62	80.2	5.45	-	-	-	-	-
Testis	3	2.6	0.71	2.5	0.70	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	19	27.7	3.05	32.2	3.53	5	7.3	1.55	8.1	1.73
Bladder (incl. <i>in situ</i>)	9	14.2	2.33	16.4	2.68	3	4.7	1.33	5.1	1.46
Kidney & renal pelvis	10	12.7	1.91	14.9	2.24	2	2.6	0.80	2.9	0.92
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	5.5	1.35	5.8	1.46	3	3.3	0.84	3.7	0.94
Brain	4	5.5	1.35	5.8	1.46	3	2.9	0.78	3.2	0.88
Endocrine System	8	8.9	1.50	9.8	1.68	19	19.4	2.03	21.5	2.31
Thyroid gland	6	7.0	1.31	7.9	1.50	18	18.5	1.96	20.4	2.22
Lymphomas	10	11.8	1.67	13.7	1.97	10	12.3	1.79	14.1	2.05
Hodgkin Lymphoma	-	-	-	-	-	2	1.6	0.58	1.7	0.61
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	5	7.0	1.50	7.6	1.61	2	2.6	0.84	3.3	1.03
Leukemias	7	10.2	1.92	11.4	2.17	5	6.0	1.23	6.1	1.28
Acute lymphocytic	2	1.7	0.62	1.5	0.57	-	-	-	-	-
Chronic lymphocytic	2	2.7	0.95	3.3	1.13	-	-	-	-	-
Acute myeloid	2	3.8	1.32	4.3	1.51	1	1.4	0.55	1.4	0.55
Chronic myeloid	-	-	-	-	-	1	1.7	0.73	1.7	0.76
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	6.9	1.56	8.1	1.84	5	6.8	1.47	7.7	1.67
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	5.4	1.28	6.1	1.44	10	12.7	1.85	14.4	2.11
Breast (<i>in situ</i>)	-	-	-	-	-	22	24.3	2.37	28.2	2.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	215	475.4	15.97	562.8	18.49	249	444.8	13.26	519.8	15.42
Oral Cavity & Pharynx	9	16.8	2.77	20.3	3.28	3	5.3	1.51	6.1	1.70
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	6.4	1.65	8.0	2.03	-	-	-	-	-
Major salivary gland	-	-	-	-	-	1	2.5	1.01	2.6	1.08
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	48	110.4	7.85	130.1	9.01	43	82.9	5.90	97.6	6.87
Esophagus	2	4.5	1.47	5.6	1.78	-	-	-	-	-
Stomach	5	14.0	3.01	15.9	3.35	4	7.8	1.80	9.2	2.10
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	13	31.2	4.21	36.5	4.84	12	24.0	3.28	27.7	3.74
Rectum & rectosigmoid	6	13.0	2.55	15.1	2.90	7	12.5	2.14	15.0	2.56
Anus, anal canal & anorectum	1	3.1	1.32	3.6	1.50	1	2.6	1.11	2.9	1.23
Liver	9	19.1	3.09	23.7	3.66	3	5.3	1.48	6.4	1.76
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	7	16.9	3.20	19.7	3.62	9	17.9	2.78	21.3	3.24
Respiratory System	24	61.1	6.02	72.3	6.92	23	49.2	4.76	58.2	5.48
Larynx	1	2.9	1.17	3.7	1.48	-	-	-	-	-
Lung & bronchus	22	56.4	5.82	66.4	6.67	22	46.5	4.59	55.3	5.32
Bones & Joints	1	2.5	1.05	2.7	1.15	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.0	1.52	4.4	1.65	2	3.5	1.07	3.8	1.22
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	4	8.8	2.27	9.9	2.50	4	7.1	1.58	8.6	1.91
Breast (excl. <i>in situ</i>)	-	-	-	-	-	71	123.4	6.83	145.2	8.01
Female Genital System	-	-	-	-	-	37	62.4	4.79	73.4	5.64
Cervix uteri	-	-	-	-	-	8	11.4	1.90	12.6	2.14
Uterus Corpus	-	-	-	-	-	18	29.0	3.21	35.7	3.93
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	13.0	2.24	14.9	2.57
Male Genital System	50	108.3	7.39	132.7	8.78	-	-	-	-	-
Prostate	47	103.4	7.29	127.5	8.68	-	-	-	-	-
Testis	4	4.3	1.02	4.4	1.08	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	27	63.0	6.00	73.9	6.91	12	23.3	3.18	26.6	3.58
Bladder (incl. <i>in situ</i>)	14	35.7	4.63	42.3	5.36	3	6.6	1.76	7.5	1.97
Kidney & renal pelvis	12	25.9	3.68	30.1	4.23	9	16.7	2.65	19.1	2.99
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	6.9	1.82	7.8	2.01	3	4.8	1.35	4.9	1.43
Brain	4	6.8	1.81	7.6	2.00	3	4.6	1.34	4.7	1.42
Endocrine System	5	7.2	1.63	8.1	1.89	17	24.0	2.71	25.7	2.97
Thyroid gland	5	7.0	1.62	7.9	1.89	17	23.6	2.69	25.2	2.94
Lymphomas	17	38.6	4.63	44.9	5.31	13	21.7	2.85	25.5	3.35
Hodgkin Lymphoma	1	1.6	0.62	1.7	0.70	2	3.3	1.05	3.4	1.11
Non-Hodgkin Lymphoma	16	37.0	4.59	43.2	5.26	11	18.4	2.65	22.1	3.16
Multiple Myeloma	6	11.7	2.28	14.9	2.81	3	6.7	1.65	8.4	2.05
Leukemias	10	16.2	2.59	17.5	2.89	7	12.2	2.19	14.1	2.53
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	5.8	1.81	6.6	2.02	3	5.3	1.54	6.1	1.74
Acute myeloid	1	2.1	0.81	2.5	1.00	2	3.7	1.17	4.3	1.36
Chronic myeloid	2	4.0	1.36	4.5	1.54	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	15.0	2.94	18.0	3.45	8	16.0	2.64	19.0	3.09
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	6.5	1.77	7.7	2.06	10	16.1	2.40	19.1	2.90
Breast (<i>in situ</i>)	-	-	-	-	-	18	32.5	3.55	38.5	4.16

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

Metropolitan Detroit

II-268 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,461	546.2	2.74	646.0	3.17	8,345	473.2	2.43	550.2	2.74
Oral Cavity & Pharynx	332	20.4	0.52	24.9	0.61	127	6.9	0.29	8.3	0.33
Lip	10	0.6	0.10	0.8	0.11	4	0.2	0.04	0.2	0.05
Tongue	108	6.5	0.29	7.9	0.34	35	1.9	0.15	2.3	0.18
Major salivary gland	27	1.9	0.17	2.2	0.19	20	1.2	0.12	1.3	0.14
Floor of mouth	16	1.0	0.11	1.2	0.13	8	0.4	0.07	0.5	0.08
Gum & other mouth	35	2.2	0.17	2.6	0.20	29	1.5	0.13	1.8	0.15
Nasopharynx	11	0.7	0.09	0.8	0.11	4	0.2	0.06	0.3	0.06
Oropharynx	14	0.8	0.10	1.0	0.12	4	0.2	0.05	0.3	0.06
Hypopharynx	21	1.3	0.13	1.6	0.15	4	0.2	0.05	0.3	0.06
Digestive System	1,552	100.0	1.17	118.9	1.36	1,279	68.0	0.88	79.9	1.02
Esophagus	155	9.6	0.36	11.6	0.42	40	2.0	0.15	2.5	0.18
Stomach	132	8.7	0.35	10.2	0.40	78	4.1	0.22	4.8	0.25
Small intestine	45	2.9	0.20	3.4	0.23	41	2.3	0.16	2.7	0.19
Colon excl. rectum	455	30.3	0.65	35.5	0.75	490	26.0	0.55	30.3	0.63
Rectum & rectosigmoid	226	14.5	0.45	17.3	0.52	174	9.8	0.35	11.6	0.40
Anus, anal canal & anorectum	22	1.4	0.14	1.7	0.16	45	2.4	0.17	3.0	0.20
Liver	155	9.2	0.34	11.4	0.41	53	2.8	0.17	3.3	0.21
Gallbladder	10	0.6	0.10	0.7	0.11	23	1.1	0.11	1.3	0.13
Pancreas	261	16.8	0.48	20.0	0.56	251	12.9	0.37	15.2	0.43
Respiratory System	1,301	83.9	1.07	99.4	1.24	1,271	67.0	0.86	79.4	1.01
Larynx	101	6.0	0.27	7.4	0.33	27	1.5	0.13	1.8	0.16
Lung & bronchus	1,183	76.8	1.03	90.7	1.19	1,232	64.9	0.85	76.8	0.99
Bones & Joints	18	1.4	0.15	1.4	0.15	10	0.7	0.11	0.7	0.10
Soft Tissue (incl. heart)	56	4.0	0.24	4.5	0.27	46	2.9	0.20	3.2	0.21
Skin (excl. basal & sq.)	493	33.2	0.69	38.5	0.78	358	22.5	0.56	25.2	0.61
Melanomas of the skin	445	29.8	0.65	34.7	0.74	323	20.6	0.54	23.0	0.58
Breast (excl. <i>in situ</i>)	22	1.4	0.14	1.7	0.16	2,361	136.9	1.32	160.0	1.50
Female Genital System	-	-	-	-	-	1,010	57.1	0.84	68.1	0.97
Cervix uteri	-	-	-	-	-	90	6.5	0.32	6.9	0.33
Uterus Corpus	-	-	-	-	-	568	30.9	0.60	38.0	0.72
Uterus, NOS ¹	-	-	-	-	-	13	0.7	0.09	0.8	0.11
Ovary	-	-	-	-	-	222	12.6	0.40	14.8	0.45
Male Genital System	2,066	125.4	1.27	152.4	1.51	-	-	-	-	-
Prostate	1,964	116.9	1.21	143.8	1.46	-	-	-	-	-
Testis	86	7.4	0.36	7.4	0.36	-	-	-	-	-
Penis	10	0.7	0.10	0.8	0.12	-	-	-	-	-
Urinary System	1,080	71.0	1.00	83.4	1.14	422	22.7	0.51	26.6	0.59
Bladder (incl. <i>in situ</i>)	681	45.3	0.80	53.1	0.92	213	11.0	0.35	12.9	0.40
Kidney & renal pelvis	372	23.9	0.58	28.2	0.66	198	11.2	0.37	13.1	0.42
Ureter	16	1.1	0.12	1.2	0.14	8	0.4	0.07	0.5	0.08
Eye & Orbit	17	1.1	0.12	1.3	0.14	12	0.7	0.10	0.8	0.11
Brain & Other CNS ¹	124	8.7	0.36	9.7	0.39	91	5.7	0.29	6.3	0.30
Brain	117	8.2	0.35	9.1	0.38	85	5.3	0.28	5.8	0.29
Endocrine System	144	10.2	0.40	11.3	0.42	387	28.1	0.67	30.1	0.69
Thyroid gland	133	9.5	0.38	10.5	0.41	378	27.5	0.67	29.4	0.69
Lymphomas	459	31.5	0.68	35.9	0.76	381	21.7	0.52	24.9	0.58
Hodgkin Lymphoma	47	3.7	0.25	3.9	0.25	35	2.8	0.22	2.8	0.22
Non-Hodgkin Lymphoma	412	27.8	0.63	32.1	0.71	346	18.9	0.47	22.1	0.54
Multiple Myeloma	132	8.6	0.35	10.2	0.40	99	5.3	0.25	6.2	0.28
Leukemias	336	22.9	0.58	26.2	0.64	229	13.2	0.41	14.8	0.45
Acute lymphocytic	25	2.1	0.19	2.0	0.18	14	1.2	0.15	1.1	0.13
Chronic lymphocytic	138	8.8	0.34	10.5	0.40	84	4.3	0.22	5.2	0.26
Acute myeloid	96	6.7	0.32	7.6	0.35	78	4.5	0.24	5.1	0.26
Chronic myeloid	47	3.2	0.22	3.7	0.24	35	2.1	0.17	2.4	0.18
Other leukemias	31	2.1	0.17	2.5	0.20	18	1.0	0.11	1.1	0.12
Mesothelioma	27	2.0	0.17	2.2	0.19	9	0.4	0.07	0.5	0.08
Kaposi Sarcoma	6	0.4	0.08	0.5	0.09	1	0.1	0.02	0.1	0.03
Ill-defined & Unknown	296	20.2	0.54	23.4	0.61	252	13.2	0.39	15.2	0.44
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	138	9.7	0.38	10.9	0.42	306	17.7	0.48	20.2	0.53
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.06	603	36.2	0.69	42.5	0.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Metropolitan Detroit, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,520	588.5	5.49	709.7	6.44	2,586	439.6	3.97	520.3	4.60
Oral Cavity & Pharynx	80	18.3	0.95	22.0	1.12	38	6.4	0.48	7.6	0.56
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	19	4.2	0.45	5.0	0.53	8	1.4	0.22	1.6	0.26
Major salivary gland	5	1.2	0.25	1.4	0.29	7	1.2	0.21	1.4	0.24
Floor of mouth	3	0.7	0.18	0.9	0.22	2	0.3	0.10	0.3	0.12
Gum & other mouth	9	2.1	0.33	2.5	0.38	5	0.9	0.17	1.1	0.21
Nasopharynx	6	1.4	0.26	1.6	0.30	2	0.3	0.11	0.3	0.11
Oropharynx	6	1.4	0.27	1.8	0.32	2	0.3	0.10	0.4	0.12
Hypopharynx	9	2.2	0.34	2.6	0.39	4	0.8	0.17	0.9	0.19
Digestive System	591	139.0	2.68	167.9	3.15	524	87.2	1.75	105.2	2.07
Esophagus	32	7.3	0.60	9.0	0.72	17	2.7	0.30	3.4	0.37
Stomach	54	13.9	0.88	16.1	1.00	43	7.3	0.51	8.6	0.59
Small intestine	26	6.0	0.56	7.3	0.65	23	3.7	0.36	4.5	0.43
Colon excl. rectum	183	45.1	1.56	53.4	1.80	195	33.1	1.09	39.3	1.27
Rectum & rectosigmoid	74	17.0	0.92	20.5	1.08	61	10.0	0.59	12.2	0.70
Anus, anal canal & anorectum	11	2.7	0.36	3.1	0.41	12	1.9	0.26	2.4	0.31
Liver	95	19.3	0.92	25.2	1.17	36	5.6	0.43	7.1	0.53
Gallbladder	7	1.6	0.30	2.0	0.35	10	1.6	0.24	2.0	0.29
Pancreas	88	21.2	1.06	25.3	1.23	101	16.6	0.76	20.2	0.91
Respiratory System	415	101.2	2.33	120.9	2.71	381	63.3	1.49	76.8	1.77
Larynx	40	9.3	0.69	11.3	0.81	15	2.4	0.28	3.0	0.35
Lung & bronchus	370	90.8	2.21	108.3	2.57	362	60.1	1.45	72.8	1.72
Bones & Joints	5	1.0	0.22	1.1	0.22	3	0.7	0.16	0.6	0.16
Soft Tissue (incl. heart)	19	4.3	0.46	4.8	0.51	19	3.3	0.34	3.8	0.38
Skin (excl. basal & sq.)	7	1.6	0.28	1.9	0.32	14	2.5	0.31	2.8	0.33
Melanomas of the skin	3	0.7	0.19	0.9	0.22	5	0.9	0.19	1.1	0.20
Breast (excl. <i>in situ</i>)	10	2.3	0.35	2.8	0.41	768	132.2	2.19	155.5	2.52
Female Genital System	-	-	-	-	-	296	49.4	1.32	59.2	1.54
Cervix uteri	-	-	-	-	-	41	7.5	0.54	8.3	0.58
Uterus Corpus	-	-	-	-	-	166	26.7	0.95	32.8	1.14
Uterus, NOS ¹	-	-	-	-	-	9	1.5	0.24	1.8	0.27
Ovary	-	-	-	-	-	54	9.1	0.57	11.0	0.67
Male Genital System	822	181.2	2.95	225.8	3.57	-	-	-	-	-
Prostate	810	178.1	2.92	222.5	3.54	-	-	-	-	-
Testis	8	2.0	0.31	2.0	0.32	-	-	-	-	-
Penis	4	0.9	0.23	1.1	0.26	-	-	-	-	-
Urinary System	223	54.0	1.69	64.0	1.96	132	22.4	0.90	26.4	1.04
Bladder (incl. <i>in situ</i>)	86	22.7	1.14	26.7	1.31	49	8.4	0.55	9.8	0.63
Kidney & renal pelvis	132	30.1	1.22	36.0	1.42	80	13.5	0.69	16.0	0.81
Ureter	2	0.4	0.15	0.5	0.17	-	-	-	-	-
Eye & Orbit	2	0.5	0.15	0.5	0.16	2	0.3	0.11	0.3	0.11
Brain & Other CNS ¹	18	4.2	0.45	4.6	0.50	22	4.0	0.39	4.2	0.40
Brain	16	3.8	0.43	4.2	0.48	19	3.5	0.37	3.7	0.38
Endocrine System	27	6.5	0.58	7.5	0.66	89	16.1	0.78	17.9	0.85
Thyroid gland	22	5.4	0.53	6.3	0.61	85	15.3	0.76	17.1	0.83
Lymphomas	98	23.3	1.10	26.4	1.22	91	15.9	0.76	18.3	0.86
Hodgkin Lymphoma	16	3.8	0.43	3.8	0.43	11	2.0	0.27	2.0	0.28
Non-Hodgkin Lymphoma	82	19.6	1.01	22.6	1.14	81	14.0	0.71	16.2	0.81
Multiple Myeloma	68	16.9	0.96	19.9	1.10	75	12.9	0.68	15.3	0.79
Leukemias	59	14.8	0.90	16.9	1.01	57	10.0	0.61	11.4	0.68
Acute lymphocytic	3	0.7	0.18	0.6	0.16	5	1.0	0.20	0.9	0.18
Chronic lymphocytic	23	5.7	0.56	6.8	0.65	16	2.6	0.30	3.2	0.36
Acute myeloid	17	4.5	0.50	5.0	0.56	20	3.6	0.37	4.1	0.41
Chronic myeloid	11	2.8	0.39	3.1	0.43	10	1.8	0.26	2.1	0.29
Other leukemias	4	1.1	0.25	1.3	0.29	6	1.1	0.20	1.2	0.22
Mesothelioma	2	0.5	0.17	0.6	0.19	1	0.3	0.10	0.3	0.12
Kaposi Sarcoma	7	1.8	0.30	1.7	0.29	1	0.2	0.10	0.2	0.10
Ill-defined & Unknown	68	17.2	0.98	20.5	1.14	72	12.4	0.67	14.4	0.77
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	40	9.8	0.72	11.1	0.80	105	18.7	0.84	21.2	0.93
Breast (<i>in situ</i>)	1	0.3	0.12	0.4	0.15	220	37.3	1.16	44.5	1.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	5,413,693	5,451,522	5,482,503	5,523,409	5,568,155
White	4,723,103	4,735,926	4,741,713	4,754,167	4,773,182
Black	346,332	360,541	375,156	392,487	408,369
American Indian/Alaskan Native (AI/AN)	82,580	83,582	84,890	85,948	86,967
Asian/Pacific Islander (API)	261,678	271,473	280,744	290,807	299,637


All Races Population 2013-2017: 27,439,282
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	270,754	277,430	284,791	292,508	301,006
Non-Hispanic White	4,488,128	4,495,531	4,495,524	4,501,604	4,513,443
Non-Hispanic Black	332,360	346,069	360,202	377,018	392,253

Hispanic/Latino Population, Census 2010: 250,258
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MINNESOTA CANCER REGISTRY

Initial Operation: 1988
 Population-based Data Available: 1988
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.4	110.2	116.3	115.4	115.3
Missing Race	0.5	0.6	0.8	0.6	1.2
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.6	2.0	2.5	0.8	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.0	Prostate	97.7
Oral Cavity & Pharynx	99.0	Testis	99.7
Esophagus	97.7	Bladder (incl. <i>in situ</i>)	98.1
Stomach	97.8	Kidney & Renal Pelvis	91.3
Colon & Rectum	96.3	Brain & Other CNS ¹	88.2
Liver	56.6	Thyroid	99.5
Pancreas	88.7	Hodgkin Lymphoma	99.4
Lung & Bronchus	89.8	Non-Hodgkin Lymphoma	98.2
Melanomas of the Skin	99.8	Multiple Myeloma	93.3
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	94.0
Cervix uteri	98.0	Brain & Other CNS ¹ <i>non-malig</i>	58.2
Uterus Corpus & Uterus NOS ¹	99.0	Breast <i>in situ</i>	100.0
Ovary	94.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	15,130	503.6	1.88	595.9	2.18	14,634	443.0	1.69	515.1	1.92
Oral Cavity & Pharynx	552	17.5	0.34	21.4	0.41	251	7.4	0.21	8.7	0.25
Lip	48	1.7	0.11	2.0	0.13	19	0.6	0.06	0.7	0.07
Tongue	176	5.5	0.19	6.8	0.23	74	2.2	0.12	2.6	0.14
Major salivary gland	42	1.5	0.10	1.7	0.12	37	1.1	0.09	1.3	0.10
Floor of mouth	28	0.9	0.08	1.1	0.09	15	0.5	0.05	0.5	0.06
Gum & other mouth	56	1.9	0.11	2.2	0.13	57	1.6	0.10	1.9	0.11
Nasopharynx	18	0.6	0.07	0.7	0.07	6	0.2	0.03	0.2	0.04
Oropharynx	24	0.7	0.07	0.9	0.08	6	0.2	0.03	0.2	0.04
Hypopharynx	31	1.0	0.08	1.2	0.10	7	0.2	0.03	0.3	0.04
Digestive System	2,748	92.3	0.81	109.4	0.94	2,196	64.2	0.63	75.1	0.72
Esophagus	248	8.1	0.24	9.8	0.28	67	1.9	0.11	2.3	0.13
Stomach	233	7.9	0.24	9.3	0.27	124	3.7	0.15	4.3	0.17
Small intestine	91	3.1	0.15	3.6	0.17	76	2.3	0.12	2.7	0.14
Colon excl. rectum	838	29.0	0.46	33.8	0.53	884	25.9	0.40	29.8	0.45
Rectum & rectosigmoid	408	13.6	0.31	16.1	0.36	265	8.1	0.23	9.5	0.26
Anus, anal canal & anorectum	31	1.0	0.08	1.2	0.10	73	2.1	0.11	2.6	0.14
Liver	294	9.1	0.25	11.3	0.30	96	2.8	0.13	3.3	0.15
Gallbladder	22	0.8	0.07	0.9	0.08	44	1.3	0.09	1.5	0.10
Pancreas	444	15.1	0.33	17.8	0.38	409	11.7	0.27	13.8	0.31
Respiratory System	2,005	67.4	0.69	79.8	0.80	1,859	53.9	0.57	63.8	0.67
Larynx	150	4.7	0.18	5.8	0.21	38	1.1	0.08	1.4	0.10
Lung & bronchus	1,822	61.5	0.66	72.7	0.77	1,803	52.2	0.56	61.8	0.65
Bones & Joints	32	1.1	0.09	1.2	0.09	17	0.6	0.07	0.6	0.07
Soft Tissue (incl. heart)	123	4.3	0.18	4.8	0.20	97	3.2	0.15	3.4	0.16
Skin (excl. basal & sq.)	1,199	41.0	0.54	47.7	0.62	911	29.6	0.45	33.3	0.50
Melanomas of the skin	1,099	37.4	0.52	43.6	0.59	851	27.8	0.44	31.3	0.48
Breast (excl. <i>in situ</i>)	29	1.0	0.08	1.2	0.10	4,311	132.5	0.93	155.2	1.07
Female Genital System	-	-	-	-	-	1,784	53.2	0.58	63.4	0.68
Cervix uteri	-	-	-	-	-	154	5.5	0.21	5.8	0.21
Uterus Corpus	-	-	-	-	-	1,055	30.5	0.43	37.4	0.52
Uterus, NOS ¹	-	-	-	-	-	17	0.5	0.05	0.6	0.06
Ovary	-	-	-	-	-	339	10.2	0.26	12.0	0.29
Male Genital System	3,745	117.0	0.88	142.9	1.05	-	-	-	-	-
Prostate	3,524	108.8	0.84	134.4	1.02	-	-	-	-	-
Testis	182	6.9	0.23	6.9	0.23	-	-	-	-	-
Penis	28	1.0	0.09	1.2	0.10	-	-	-	-	-
Urinary System	1,828	62.3	0.67	73.3	0.77	716	21.0	0.36	24.6	0.41
Bladder (incl. <i>in situ</i>)	1,064	37.0	0.52	43.3	0.60	324	9.2	0.24	10.8	0.27
Kidney & renal pelvis	724	23.9	0.41	28.3	0.47	370	11.1	0.27	13.0	0.31
Ureter	20	0.7	0.07	0.8	0.08	14	0.4	0.05	0.5	0.05
Eye & Orbit	25	0.9	0.08	1.0	0.09	25	0.7	0.07	0.9	0.08
Brain & Other CNS ¹	242	8.4	0.25	9.2	0.27	184	6.1	0.21	6.5	0.22
Brain	231	8.0	0.24	8.8	0.26	169	5.5	0.20	6.0	0.21
Endocrine System	225	7.7	0.24	8.7	0.26	557	19.7	0.39	21.1	0.40
Thyroid gland	204	7.0	0.22	7.9	0.25	538	19.1	0.38	20.4	0.40
Lymphomas	855	29.5	0.46	33.8	0.52	649	19.6	0.35	22.5	0.40
Hodgkin Lymphoma	94	3.4	0.16	3.6	0.17	65	2.4	0.13	2.4	0.14
Non-Hodgkin Lymphoma	761	26.1	0.43	30.3	0.49	583	17.3	0.33	20.1	0.38
Multiple Myeloma	256	8.6	0.25	10.2	0.29	180	5.2	0.18	6.1	0.21
Leukemias	631	21.9	0.40	25.1	0.45	401	12.1	0.28	13.6	0.31
Acute lymphocytic	44	1.6	0.11	1.5	0.10	39	1.5	0.11	1.3	0.10
Chronic lymphocytic	273	9.2	0.26	10.9	0.30	144	4.1	0.16	4.8	0.18
Acute myeloid	176	6.1	0.21	7.0	0.24	135	4.1	0.16	4.6	0.18
Chronic myeloid	84	3.0	0.15	3.4	0.17	52	1.6	0.10	1.8	0.11
Other leukemias	55	2.0	0.12	2.2	0.14	31	0.9	0.08	1.0	0.08
Mesothelioma	55	2.0	0.12	2.3	0.14	20	0.6	0.06	0.7	0.07
Kaposi Sarcoma	10	0.4	0.06	0.4	0.06	-	-	-	-	-
Ill-defined & Unknown	570	20.4	0.39	23.5	0.44	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	239	8.2	0.24	9.3	0.27	403	12.7	0.29	14.4	0.32
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.03	960	30.2	0.45	35.7	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	14,067	500.0	1.94	591.0	2.24	13,619	444.4	1.77	516.1	2.00
Oral Cavity & Pharynx	511	17.3	0.35	21.2	0.42	231	7.3	0.22	8.7	0.26
Lip	46	1.7	0.12	2.0	0.13	18	0.6	0.06	0.6	0.07
Tongue	166	5.5	0.20	6.8	0.24	70	2.3	0.13	2.7	0.14
Major salivary gland	39	1.4	0.11	1.7	0.12	33	1.1	0.09	1.3	0.10
Floor of mouth	26	0.9	0.08	1.1	0.10	13	0.4	0.05	0.5	0.06
Gum & other mouth	52	1.8	0.12	2.2	0.14	55	1.6	0.10	1.9	0.12
Nasopharynx	12	0.4	0.05	0.5	0.06	4	0.1	0.03	0.1	0.03
Oropharynx	23	0.7	0.07	0.9	0.09	5	0.2	0.03	0.2	0.04
Hypopharynx	27	0.9	0.08	1.1	0.10	6	0.2	0.03	0.2	0.04
Digestive System	2,499	89.6	0.82	106.1	0.95	2,008	62.4	0.65	72.9	0.74
Esophagus	238	8.2	0.24	9.9	0.29	60	1.8	0.11	2.1	0.12
Stomach	205	7.4	0.24	8.7	0.27	105	3.3	0.15	3.9	0.17
Small intestine	85	3.0	0.15	3.6	0.18	73	2.3	0.13	2.8	0.15
Colon excl. rectum	778	28.8	0.47	33.5	0.54	828	25.8	0.42	29.6	0.47
Rectum & rectosigmoid	371	13.3	0.32	15.7	0.37	239	7.8	0.24	9.3	0.27
Anus, anal canal & anorectum	28	1.0	0.09	1.2	0.10	68	2.1	0.12	2.6	0.14
Liver	229	7.6	0.23	9.4	0.28	74	2.3	0.12	2.7	0.14
Gallbladder	20	0.7	0.07	0.8	0.09	38	1.1	0.08	1.3	0.10
Pancreas	418	15.0	0.34	17.8	0.39	381	11.5	0.27	13.6	0.31
Respiratory System	1,867	66.4	0.70	78.6	0.82	1,736	53.4	0.59	63.1	0.68
Larynx	137	4.6	0.18	5.7	0.22	34	1.1	0.08	1.3	0.10
Lung & bronchus	1,699	60.7	0.67	71.6	0.78	1,686	51.8	0.58	61.2	0.67
Bones & Joints	29	1.2	0.10	1.2	0.10	16	0.6	0.07	0.6	0.07
Soft Tissue (incl. heart)	114	4.4	0.19	4.8	0.20	89	3.2	0.16	3.5	0.17
Skin (excl. basal & sq.)	1,163	42.7	0.58	49.6	0.65	875	31.6	0.50	35.3	0.54
Melanomas of the skin	1,069	39.1	0.55	45.5	0.63	823	29.9	0.49	33.4	0.53
Breast (excl. <i>in situ</i>)	27	1.0	0.08	1.1	0.10	4,048	134.2	0.98	157.2	1.12
Female Genital System	-	-	-	-	-	1,654	53.1	0.61	63.3	0.70
Cervix uteri	-	-	-	-	-	128	5.2	0.22	5.5	0.22
Uterus Corpus	-	-	-	-	-	986	30.6	0.45	37.5	0.54
Uterus, NOS ¹	-	-	-	-	-	15	0.4	0.05	0.5	0.06
Ovary	-	-	-	-	-	319	10.4	0.27	12.2	0.31
Male Genital System	3,450	115.0	0.90	140.2	1.07	-	-	-	-	-
Prostate	3,244	106.1	0.85	131.1	1.03	-	-	-	-	-
Testis	170	7.5	0.26	7.5	0.26	-	-	-	-	-
Penis	27	1.0	0.09	1.2	0.10	-	-	-	-	-
Urinary System	1,732	62.6	0.69	73.7	0.80	670	21.0	0.38	24.5	0.43
Bladder (incl. <i>in situ</i>)	1,025	37.5	0.54	43.9	0.62	308	9.3	0.24	10.9	0.28
Kidney & renal pelvis	670	23.7	0.42	28.1	0.49	342	11.1	0.28	12.9	0.32
Ureter	19	0.7	0.08	0.8	0.09	13	0.4	0.05	0.4	0.06
Eye & Orbit	24	0.9	0.08	1.0	0.09	23	0.7	0.07	0.9	0.08
Brain & Other CNS ¹	225	8.6	0.26	9.5	0.28	170	6.3	0.23	6.7	0.23
Brain	215	8.2	0.26	9.1	0.28	157	5.7	0.21	6.2	0.22
Endocrine System	206	7.8	0.25	8.8	0.28	497	19.9	0.42	21.3	0.43
Thyroid gland	189	7.1	0.24	8.1	0.26	479	19.3	0.41	20.6	0.42
Lymphomas	797	29.6	0.48	34.0	0.54	606	19.8	0.37	22.7	0.42
Hodgkin Lymphoma	85	3.5	0.17	3.7	0.18	60	2.5	0.15	2.6	0.15
Non-Hodgkin Lymphoma	712	26.1	0.45	30.3	0.51	546	17.3	0.34	20.1	0.39
Multiple Myeloma	234	8.4	0.25	9.9	0.29	164	5.0	0.18	5.9	0.21
Leukemias	594	22.1	0.42	25.3	0.47	368	12.0	0.29	13.5	0.32
Acute lymphocytic	38	1.7	0.12	1.6	0.11	32	1.4	0.12	1.3	0.10
Chronic lymphocytic	257	9.2	0.26	10.9	0.31	134	4.0	0.16	4.7	0.18
Acute myeloid	168	6.2	0.22	7.2	0.25	125	4.1	0.17	4.6	0.19
Chronic myeloid	80	3.0	0.16	3.4	0.17	48	1.6	0.11	1.8	0.12
Other leukemias	52	2.0	0.13	2.3	0.14	30	0.9	0.08	1.1	0.09
Mesothelioma	53	2.0	0.13	2.3	0.14	19	0.6	0.06	0.7	0.07
Kaposi Sarcoma	6	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	536	20.3	0.40	23.4	0.45	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	218	8.2	0.25	9.2	0.28	367	12.6	0.31	14.3	0.34
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.04	894	30.6	0.48	36.1	0.55

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	508	535.5	12.61	648.6	14.73	434	399.5	9.36	474.6	11.02
Oral Cavity & Pharynx	15	14.8	2.07	17.5	2.36	8	6.8	1.16	8.2	1.41
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	4.3	1.11	5.0	1.22	2	1.6	0.62	2.0	0.78
Major salivary gland	1	1.7	0.81	2.0	0.91	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	2.2	0.76	2.7	0.92	2	2.1	0.70	2.5	0.81
Nasopharynx	2	1.0	0.35	1.2	0.42	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	1.8	0.79	2.2	0.95	-	-	-	-	-
Digestive System	122	132.6	6.40	159.0	7.39	85	86.3	4.55	103.5	5.36
Esophagus	5	6.1	1.54	6.8	1.65	5	5.2	1.12	6.1	1.28
Stomach	12	13.8	2.14	16.3	2.45	6	6.5	1.29	7.7	1.51
Small intestine	4	3.5	0.94	4.0	1.04	1	1.0	0.44	1.3	0.54
Colon excl. rectum	30	31.9	3.14	38.2	3.67	26	25.1	2.41	30.7	2.90
Rectum & rectosigmoid	15	14.9	2.09	17.8	2.41	11	10.1	1.52	11.8	1.75
Anus, anal canal & anorectum	2	1.3	0.50	1.6	0.59	3	3.3	0.85	4.0	1.01
Liver	35	36.5	3.23	45.3	3.80	10	11.2	1.69	13.6	1.97
Gallbladder	-	-	-	-	-	2	2.0	0.69	2.5	0.84
Pancreas	14	16.9	2.38	20.1	2.71	15	15.7	1.99	18.7	2.33
Respiratory System	70	83.5	5.24	101.6	6.10	54	57.8	3.78	70.5	4.48
Larynx	7	6.0	1.20	7.7	1.44	3	2.7	0.76	3.4	0.94
Lung & bronchus	62	76.6	5.09	92.8	5.91	51	54.3	3.68	66.1	4.35
Bones & Joints	1	0.6	0.24	0.6	0.22	-	-	-	-	-
Soft Tissue (incl. heart)	5	2.7	0.63	2.9	0.72	3	2.1	0.66	2.2	0.73
Skin (excl. basal & sq.)	4	3.3	0.98	3.9	1.15	5	3.7	0.80	4.1	0.90
Melanomas of the skin	-	-	-	-	-	2	1.6	0.55	1.8	0.62
Breast (excl. <i>in situ</i>)	2	1.5	0.56	1.7	0.64	123	106.5	4.62	125.7	5.44
Female Genital System	-	-	-	-	-	58	53.7	3.40	64.5	4.02
Cervix uteri	-	-	-	-	-	10	7.9	1.22	9.0	1.39
Uterus Corpus	-	-	-	-	-	33	32.2	2.67	39.8	3.21
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	9	7.7	1.29	8.7	1.47
Male Genital System	157	160.1	6.59	201.6	7.92	-	-	-	-	-
Prostate	154	158.3	6.58	199.6	7.91	-	-	-	-	-
Testis	2	1.2	0.35	1.2	0.35	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	46	52.6	4.13	62.5	4.77	21	19.8	2.09	23.9	2.48
Bladder (incl. <i>in situ</i>)	16	22.9	2.94	26.9	3.35	5	5.6	1.16	6.9	1.38
Kidney & renal pelvis	29	28.0	2.82	33.6	3.31	15	12.7	1.60	15.5	1.93
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	5.5	1.06	6.0	1.17	6	3.4	0.66	3.6	0.74
Brain	7	5.3	1.05	5.9	1.17	5	2.9	0.62	3.2	0.72
Endocrine System	8	7.1	1.32	8.4	1.54	23	16.1	1.59	18.0	1.83
Thyroid gland	7	5.8	1.17	6.9	1.40	22	15.5	1.56	17.3	1.79
Lymphomas	26	24.6	2.65	28.5	3.08	16	14.6	1.82	17.0	2.10
Hodgkin Lymphoma	4	2.5	0.55	2.6	0.61	2	1.7	0.61	1.8	0.64
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	11	11.8	1.80	14.4	2.10	7	7.5	1.36	8.9	1.57
Leukemias	13	13.7	2.06	15.7	2.31	9	6.2	1.05	6.8	1.23
Acute lymphocytic	2	1.3	0.62	1.4	0.72	3	1.8	0.53	1.7	0.54
Chronic lymphocytic	4	5.4	1.34	6.4	1.50	1	1.6	0.66	2.1	0.81
Acute myeloid	4	4.5	1.12	5.1	1.24	2	1.0	0.37	1.1	0.45
Chronic myeloid	2	2.0	0.84	2.2	0.96	2	1.3	0.45	1.6	0.55
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	3	2.3	0.68	2.4	0.72	-	-	-	-	-
Ill-defined & Unknown	15	17.3	2.39	20.5	2.78	13	14.1	1.91	16.7	2.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	8.1	1.39	9.8	1.69	13	10.8	1.51	12.5	1.74
Breast (<i>in situ</i>)	-	-	-	-	-	28	23.9	2.11	29.5	2.58

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	217	297.2	10.03	349.7	11.67	287	291.1	8.22	336.7	9.57
Oral Cavity & Pharynx	12	12.7	1.77	15.5	2.17	6	6.0	1.20	7.0	1.40
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.1	0.67	2.6	0.86	-	-	-	-	-
Major salivary gland	1	1.3	0.51	1.7	0.67	2	1.8	0.61	2.2	0.75
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	4	4.9	1.11	5.6	1.29	1	1.5	0.59	2.0	0.76
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	1.8	0.80	2.2	0.95	-	-	-	-	-
Digestive System	73	101.7	5.83	121.7	6.86	60	71.0	4.35	82.7	5.04
Esophagus	3	4.5	1.24	5.5	1.51	-	-	-	-	-
Stomach	10	15.5	2.43	18.8	2.88	10	11.4	1.77	12.9	2.01
Small intestine	1	1.8	0.78	2.1	0.92	-	-	-	-	-
Colon excl. rectum	15	20.7	2.60	24.1	3.00	16	18.4	2.21	21.5	2.57
Rectum & rectosigmoid	12	13.5	1.88	16.4	2.29	9	10.7	1.64	12.6	1.92
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	20	26.5	2.82	32.4	3.37	7	8.6	1.55	10.1	1.79
Gallbladder	-	-	-	-	-	4	4.3	1.07	5.2	1.25
Pancreas	7	11.3	2.07	13.1	2.37	6	8.5	1.58	9.5	1.75
Respiratory System	33	53.2	4.46	62.7	5.14	25	29.8	2.82	35.4	3.29
Larynx	1	2.1	0.89	2.4	1.00	-	-	-	-	-
Lung & bronchus	32	50.9	4.36	60.1	5.03	24	29.1	2.80	34.7	3.27
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	1.4	0.45	1.3	0.44	3	1.8	0.51	1.7	0.51
Skin (excl. basal & sq.)	2	2.0	0.76	2.3	0.86	2	2.1	0.71	2.3	0.77
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	82	78.2	4.02	91.9	4.79
Female Genital System	-	-	-	-	-	38	33.0	2.54	37.9	2.98
Cervix uteri	-	-	-	-	-	10	8.2	1.25	9.3	1.46
Uterus Corpus	-	-	-	-	-	18	15.3	1.66	17.7	1.97
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	4.8	0.93	5.6	1.12
Male Genital System	33	49.8	4.20	59.3	4.88	-	-	-	-	-
Prostate	29	46.9	4.14	56.4	4.82	-	-	-	-	-
Testis	3	1.9	0.47	1.7	0.43	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	14	21.3	2.85	25.0	3.31	8	10.0	1.65	11.6	1.88
Bladder (incl. <i>in situ</i>)	7	13.2	2.35	15.4	2.72	3	4.3	1.11	5.0	1.27
Kidney & renal pelvis	6	7.2	1.47	8.6	1.74	4	4.7	1.08	5.5	1.25
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	4.1	0.82	4.4	0.98	4	3.4	0.79	3.6	0.88
Brain	5	3.7	0.78	4.1	0.94	4	3.4	0.79	3.6	0.88
Endocrine System	6	5.8	1.16	6.4	1.33	25	20.0	1.90	21.5	2.12
Thyroid gland	4	3.6	0.84	3.7	0.92	25	19.2	1.84	20.6	2.06
Lymphomas	14	18.5	2.46	21.3	2.83	11	11.2	1.63	13.0	1.92
Hodgkin Lymphoma	2	1.7	0.68	1.8	0.78	1	1.0	0.44	1.0	0.44
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	4	5.1	1.28	6.0	1.49	4	5.0	1.14	6.0	1.34
Leukemias	9	8.0	1.34	8.3	1.47	11	9.2	1.39	10.2	1.60
Acute lymphocytic	3	2.0	0.49	1.6	0.40	3	1.9	0.55	1.8	0.57
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	2.3	0.73	2.5	0.83	6	5.0	1.05	5.7	1.23
Chronic myeloid	2	1.7	0.73	1.7	0.80	1	1.5	0.64	1.7	0.72
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	8	12.7	2.31	14.4	2.65	8	10.0	1.69	11.4	1.93
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	7.1	1.35	7.7	1.51	15	14.5	1.78	17.2	2.14
Breast (<i>in situ</i>)	-	-	-	-	-	22	21.6	2.13	25.7	2.55

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	238	437.4	15.72	515.4	18.03	278	428.8	13.35	501.8	15.47
Oral Cavity & Pharynx	7	11.7	2.43	14.1	2.84	4	7.5	2.02	8.4	2.24
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	3.6	1.52	4.0	1.66	2	3.7	1.51	3.9	1.54
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	59	112.3	8.06	131.8	9.16	53	95.5	6.68	113.3	7.77
Esophagus	2	5.1	1.73	6.2	1.97	-	-	-	-	-
Stomach	8	13.2	2.68	15.6	3.16	7	10.2	2.05	11.8	2.36
Small intestine	2	3.5	1.25	4.2	1.44	2	2.0	0.71	2.5	0.92
Colon excl. rectum	14	27.1	4.07	31.3	4.60	17	29.8	3.71	35.8	4.39
Rectum & rectosigmoid	9	13.5	2.58	16.0	2.94	7	10.2	2.00	12.0	2.33
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	12	26.6	4.13	31.4	4.64	4	7.9	1.93	9.8	2.29
Gallbladder	-	-	-	-	-	2	5.8	1.87	6.5	2.02
Pancreas	8	14.3	2.80	16.7	3.18	8	16.7	2.90	19.3	3.32
Respiratory System	25	58.5	6.03	69.4	6.91	17	37.5	4.42	43.4	4.99
Larynx	3	6.3	1.95	8.0	2.32	-	-	-	-	-
Lung & bronchus	21	50.2	5.62	59.3	6.42	16	36.4	4.38	42.1	4.93
Bones & Joints	1	0.8	0.37	0.9	0.48	-	-	-	-	-
Soft Tissue (incl. heart)	3	4.7	1.70	5.6	2.06	4	3.4	0.79	3.8	0.99
Skin (excl. basal & sq.)	-	-	-	-	-	10	12.9	2.15	14.9	2.51
Melanomas of the skin	5	8.4	2.03	10.0	2.39	9	11.4	2.02	13.2	2.36
Breast (excl. <i>in situ</i>)	-	-	-	-	-	71	101.4	6.07	121.0	7.20
Female Genital System	-	-	-	-	-	41	58.9	4.70	69.9	5.52
Cervix uteri	-	-	-	-	-	9	10.7	1.86	11.7	2.11
Uterus Corpus	-	-	-	-	-	21	28.6	3.19	34.6	3.83
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	8.9	1.81	10.9	2.18
Male Genital System	52	101.6	7.55	121.9	8.72	-	-	-	-	-
Prostate	43	95.3	7.45	115.2	8.61	-	-	-	-	-
Testis	8	4.6	0.73	4.5	0.73	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	27	52.1	5.48	60.8	6.27	14	21.2	2.97	24.9	3.45
Bladder (incl. <i>in situ</i>)	10	25.1	4.08	28.8	4.59	4	8.5	2.12	9.5	2.35
Kidney & renal pelvis	16	24.4	3.32	29.1	3.92	10	12.8	2.09	15.3	2.53
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	4.6	1.17	4.8	1.28	4	4.4	1.29	4.5	1.39
Brain	4	4.1	1.13	4.3	1.23	4	4.1	1.27	4.3	1.38
Endocrine System	7	6.5	1.26	7.2	1.48	21	21.7	2.40	24.5	2.80
Thyroid gland	7	6.2	1.25	7.0	1.48	21	21.4	2.39	24.2	2.79
Lymphomas	18	30.8	4.10	36.7	4.80	17	27.3	3.50	31.4	3.98
Hodgkin Lymphoma	3	2.6	0.78	3.0	0.97	2	2.6	1.07	2.8	1.21
Non-Hodgkin Lymphoma	15	28.2	4.03	33.7	4.70	15	24.8	3.33	28.6	3.80
Multiple Myeloma	6	11.2	2.40	13.8	2.81	4	7.4	1.86	8.4	2.08
Leukemias	14	18.5	3.09	20.6	3.46	10	12.4	2.17	14.0	2.50
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	3	7.3	2.12	8.6	2.45	2	3.3	1.22	4.1	1.46
Acute myeloid	3	5.6	1.88	6.0	2.06	4	6.2	1.65	7.1	1.87
Chronic myeloid	2	1.5	0.54	1.9	0.75	1	1.1	0.51	1.3	0.61
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	12.0	2.93	13.2	3.19	8	16.1	2.97	18.1	3.29
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	5.3	1.40	6.2	1.64	10	12.4	2.13	14.1	2.43
Breast (<i>in situ</i>)	-	-	-	-	-	20	29.6	3.31	35.9	3.94

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MINNESOTA

II-278 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,850	501.7	1.96	592.8	2.27	13,367	445.5	1.80	517.1	2.03
Oral Cavity & Pharynx	504	17.4	0.36	21.4	0.43	228	7.3	0.23	8.7	0.26
Lip	46	1.7	0.12	2.0	0.13	18	0.6	0.06	0.7	0.07
Tongue	164	5.6	0.20	6.9	0.24	68	2.2	0.13	2.7	0.15
Major salivary gland	38	1.4	0.11	1.7	0.12	33	1.1	0.09	1.3	0.10
Floor of mouth	26	0.9	0.08	1.1	0.10	13	0.4	0.05	0.5	0.06
Gum & other mouth	51	1.8	0.12	2.2	0.14	54	1.7	0.10	2.0	0.12
Nasopharynx	11	0.4	0.05	0.5	0.06	4	0.1	0.03	0.1	0.03
Oropharynx	22	0.7	0.07	0.9	0.09	5	0.2	0.03	0.2	0.04
Hypopharynx	26	0.9	0.08	1.1	0.10	6	0.2	0.03	0.2	0.04
Digestive System	2,446	89.3	0.83	105.7	0.96	1,960	61.9	0.65	72.3	0.74
Esophagus	236	8.2	0.25	10.0	0.29	59	1.8	0.11	2.2	0.13
Stomach	198	7.2	0.24	8.5	0.27	99	3.1	0.15	3.7	0.17
Small intestine	82	3.0	0.15	3.6	0.18	71	2.3	0.13	2.8	0.15
Colon excl. rectum	767	28.9	0.48	33.7	0.55	813	25.7	0.42	29.5	0.47
Rectum & rectosigmoid	364	13.3	0.32	15.7	0.37	233	7.8	0.24	9.2	0.27
Anus, anal canal & anorectum	28	1.0	0.09	1.2	0.10	67	2.1	0.12	2.6	0.15
Liver	218	7.3	0.23	9.1	0.28	70	2.2	0.12	2.6	0.14
Gallbladder	19	0.7	0.07	0.8	0.08	36	1.1	0.08	1.3	0.10
Pancreas	411	15.0	0.34	17.7	0.39	374	11.5	0.27	13.5	0.32
Respiratory System	1,844	66.6	0.71	78.7	0.82	1,720	53.7	0.59	63.4	0.69
Larynx	134	4.6	0.18	5.6	0.22	33	1.1	0.09	1.3	0.10
Lung & bronchus	1,679	60.8	0.68	71.8	0.79	1,671	52.0	0.58	61.5	0.68
Bones & Joints	28	1.2	0.10	1.2	0.11	15	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	111	4.4	0.19	4.9	0.21	85	3.2	0.16	3.5	0.17
Skin (excl. basal & sq.)	1,158	43.5	0.59	50.5	0.67	865	32.3	0.52	36.1	0.56
Melanomas of the skin	1,064	39.9	0.56	46.3	0.64	814	30.7	0.51	34.2	0.54
Breast (excl. <i>in situ</i>)	26	1.0	0.09	1.1	0.10	3,983	135.0	1.00	158.1	1.14
Female Genital System	-	-	-	-	-	1,618	53.0	0.61	63.2	0.71
Cervix uteri	-	-	-	-	-	121	5.1	0.22	5.4	0.22
Uterus Corpus	-	-	-	-	-	968	30.5	0.45	37.5	0.54
Uterus, NOS ¹	-	-	-	-	-	15	0.4	0.05	0.5	0.06
Ovary	-	-	-	-	-	313	10.5	0.28	12.2	0.31
Male Genital System	3,401	115.4	0.91	140.7	1.08	-	-	-	-	-
Prostate	3,203	106.3	0.86	131.5	1.04	-	-	-	-	-
Testis	162	7.7	0.28	7.7	0.27	-	-	-	-	-
Penis	26	1.0	0.09	1.2	0.10	-	-	-	-	-
Urinary System	1,707	62.7	0.70	73.8	0.80	658	21.0	0.38	24.5	0.43
Bladder (incl. <i>in situ</i>)	1,016	37.7	0.54	44.1	0.62	305	9.3	0.25	10.9	0.28
Kidney & renal pelvis	655	23.7	0.43	28.1	0.49	333	11.0	0.28	12.9	0.32
Ureter	19	0.7	0.08	0.8	0.09	13	0.4	0.05	0.4	0.06
Eye & Orbit	23	0.9	0.09	1.0	0.09	23	0.7	0.07	0.9	0.08
Brain & Other CNS ¹	220	8.7	0.27	9.6	0.29	166	6.3	0.23	6.8	0.24
Brain	211	8.3	0.26	9.2	0.28	154	5.8	0.22	6.3	0.23
Endocrine System	200	7.8	0.26	8.8	0.28	478	20.0	0.43	21.3	0.44
Thyroid gland	183	7.1	0.24	8.1	0.27	461	19.4	0.42	20.6	0.43
Lymphomas	781	29.7	0.49	34.0	0.55	590	19.6	0.38	22.5	0.42
Hodgkin Lymphoma	83	3.6	0.18	3.7	0.18	59	2.6	0.16	2.6	0.16
Non-Hodgkin Lymphoma	698	26.1	0.45	30.3	0.52	532	17.1	0.34	19.9	0.39
Multiple Myeloma	230	8.4	0.25	9.9	0.29	161	4.9	0.18	5.9	0.21
Leukemias	581	22.0	0.42	25.3	0.47	360	12.0	0.30	13.4	0.32
Acute lymphocytic	32	1.5	0.12	1.4	0.11	29	1.4	0.12	1.3	0.11
Chronic lymphocytic	254	9.2	0.27	10.9	0.31	132	4.0	0.16	4.7	0.19
Acute myeloid	165	6.2	0.22	7.2	0.25	122	4.0	0.17	4.6	0.19
Chronic myeloid	78	3.0	0.16	3.5	0.18	47	1.6	0.11	1.8	0.12
Other leukemias	52	2.0	0.13	2.3	0.14	30	0.9	0.08	1.1	0.09
Mesothelioma	52	2.1	0.13	2.3	0.14	19	0.6	0.06	0.7	0.07
Kaposi Sarcoma	6	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	531	20.4	0.40	23.5	0.46	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	214	8.3	0.26	9.4	0.29	358	12.7	0.32	14.3	0.34
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.04	877	30.8	0.49	36.3	0.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Minnesota, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	505	546.2	12.89	661.7	15.07	429	404.2	9.51	479.9	11.18
Oral Cavity & Pharynx	15	15.2	2.13	18.0	2.42	8	6.9	1.19	8.4	1.44
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	4.4	1.14	5.1	1.25	2	1.6	0.64	2.1	0.79
Major salivary gland	1	1.8	0.84	2.1	0.93	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	2.3	0.78	2.8	0.94	2	2.2	0.71	2.5	0.83
Nasopharynx	2	1.1	0.37	1.2	0.43	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	1.9	0.81	2.3	0.97	-	-	-	-	-
Digestive System	121	134.7	6.52	161.7	7.54	84	87.2	4.62	104.6	5.44
Esophagus	5	6.3	1.58	7.0	1.69	5	5.3	1.14	6.2	1.31
Stomach	12	14.2	2.20	16.7	2.51	6	6.6	1.32	7.9	1.53
Small intestine	4	3.6	0.97	4.1	1.07	1	1.1	0.45	1.3	0.56
Colon excl. rectum	29	32.1	3.18	38.6	3.73	25	25.1	2.44	30.5	2.93
Rectum & rectosigmoid	15	15.3	2.15	18.3	2.48	11	10.4	1.55	12.0	1.79
Anus, anal canal & anorectum	1	1.2	0.50	1.5	0.60	3	3.3	0.87	4.0	1.03
Liver	34	37.3	3.31	46.3	3.90	10	11.5	1.72	13.9	2.01
Gallbladder	-	-	-	-	-	2	2.0	0.70	2.5	0.86
Pancreas	14	16.8	2.37	20.0	2.71	14	15.6	1.99	18.8	2.35
Respiratory System	70	84.8	5.35	103.2	6.23	54	59.0	3.86	72.0	4.57
Larynx	7	6.2	1.23	7.9	1.48	3	2.7	0.78	3.5	0.96
Lung & bronchus	62	77.7	5.19	94.2	6.04	51	55.4	3.75	67.5	4.43
Bones & Joints	1	0.5	0.21	0.5	0.20	-	-	-	-	-
Soft Tissue (incl. heart)	5	2.8	0.65	3.0	0.74	3	2.1	0.67	2.2	0.75
Skin (excl. basal & sq.)	4	3.4	1.00	4.0	1.18	5	3.8	0.82	4.2	0.92
Melanomas of the skin	-	-	-	-	-	2	1.6	0.56	1.9	0.64
Breast (excl. <i>in situ</i>)	2	1.5	0.57	1.7	0.65	122	107.7	4.70	127.2	5.53
Female Genital System	-	-	-	-	-	57	54.0	3.44	64.9	4.07
Cervix uteri	-	-	-	-	-	9	7.9	1.24	9.0	1.41
Uterus Corpus	-	-	-	-	-	32	32.1	2.68	39.7	3.23
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	9	7.9	1.32	8.9	1.51
Male Genital System	157	163.9	6.76	206.3	8.12	-	-	-	-	-
Prostate	154	162.0	6.74	204.3	8.10	-	-	-	-	-
Testis	2	1.2	0.36	1.2	0.36	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	46	54.1	4.24	64.2	4.90	21	20.1	2.12	24.3	2.52
Bladder (incl. <i>in situ</i>)	16	23.5	3.02	27.6	3.44	5	5.8	1.18	7.0	1.40
Kidney & renal pelvis	29	28.7	2.89	34.5	3.39	14	12.9	1.63	15.7	1.96
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	5.3	1.03	5.8	1.14	6	3.6	0.68	3.7	0.77
Brain	7	5.1	1.02	5.7	1.14	5	3.0	0.64	3.3	0.74
Endocrine System	8	7.3	1.35	8.6	1.58	22	16.1	1.61	18.0	1.86
Thyroid gland	7	5.9	1.20	7.1	1.43	22	15.6	1.58	17.3	1.81
Lymphomas	26	25.3	2.72	29.3	3.17	16	14.6	1.82	16.9	2.10
Hodgkin Lymphoma	4	2.6	0.57	2.7	0.63	2	1.8	0.62	1.9	0.65
Non-Hodgkin Lymphoma	22	22.8	2.66	26.6	3.10	13	12.8	1.71	15.1	1.99
Multiple Myeloma	11	11.8	1.84	14.4	2.14	7	7.7	1.39	9.1	1.60
Leukemias	13	13.9	2.10	15.9	2.36	9	6.2	1.07	6.7	1.23
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	4	5.4	1.36	6.3	1.52	1	1.5	0.66	1.9	0.79
Acute myeloid	4	4.6	1.15	5.3	1.27	2	1.1	0.38	1.2	0.46
Chronic myeloid	2	2.1	0.87	2.3	0.99	2	1.4	0.47	1.6	0.56
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	3	2.4	0.70	2.5	0.74	-	-	-	-	-
Ill-defined & Unknown	15	17.8	2.45	21.0	2.86	13	14.0	1.91	16.6	2.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	8.3	1.43	10.1	1.73	12	10.7	1.51	12.4	1.75
Breast (<i>in situ</i>)	-	-	-	-	-	27	24.0	2.14	29.6	2.61

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

MINNESOTA


II-280 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,988,797	2,990,623	2,988,693	2,988,298	2,989,663
White	1,803,766	1,800,357	1,794,758	1,790,911	1,788,864
Black	1,133,488	1,137,447	1,139,893	1,142,910	1,145,377
American Indian/Alaskan Native (AI/AN)	18,252	18,504	18,732	18,961	19,244
Asian/Pacific Islander (API)	33,291	34,315	35,310	35,516	36,178

All Races Population 2013-2017: 14,946,074

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	86,349	88,865	91,065	93,296	96,680
Non-Hispanic White	1,732,416	1,727,180	1,720,144	1,714,833	1,709,872
Non-Hispanic Black	1,123,411	1,126,859	1,128,754	1,131,235	1,133,379

Hispanic/Latino Population, Census 2010: 81,481

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MISSISSIPPI CANCER REGISTRY

Initial Operation: 1996
Population-based Data Available: 2003
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	98.1	101.4	100.5	104.2	103.5
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	1.0	1.2	0.9	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Prostate	97.8
Oral Cavity & Pharynx	97.9	Testis	99.3
Esophagus	96.2	Bladder (incl. <i>in situ</i>)	98.4
Stomach	97.8	Kidney & Renal Pelvis	89.9
Colon & Rectum	97.3	Brain & Other CNS ¹	85.4
Liver	61.4	Thyroid	99.7
Pancreas	83.4	Hodgkin Lymphoma	98.6
Lung & Bronchus	91.6	Non-Hodgkin Lymphoma	97.0
Melanomas of the Skin	99.6	Multiple Myeloma	90.0
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	88.3
Cervix uteri	98.2	Brain & Other CNS ¹ <i>non-malig</i>	42.2
Uterus Corpus & Uterus NOS ¹	99.0	Breast <i>in situ</i>	100.0
Ovary	93.1		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,648	547.4	2.72	656.8	3.21	7,589	414.2	2.18	485.4	2.51
Oral Cavity & Pharynx	339	20.8	0.52	25.6	0.63	130	7.0	0.28	8.4	0.33
Lip	12	0.8	0.11	1.0	0.13	2	0.1	0.03	0.1	0.04
Tongue	92	5.6	0.27	6.9	0.32	35	1.9	0.14	2.3	0.17
Major salivary gland	26	1.8	0.16	2.0	0.18	20	1.1	0.12	1.3	0.13
Floor of mouth	15	0.9	0.11	1.1	0.13	6	0.3	0.06	0.4	0.07
Gum & other mouth	41	2.5	0.18	3.1	0.22	24	1.3	0.12	1.5	0.14
Nasopharynx	15	0.9	0.11	1.1	0.13	7	0.4	0.07	0.4	0.08
Oropharynx	24	1.5	0.14	1.8	0.17	6	0.3	0.06	0.4	0.07
Hypopharynx	30	1.7	0.15	2.2	0.18	7	0.4	0.06	0.5	0.08
Digestive System	1,785	113.1	1.24	136.9	1.47	1,404	74.5	0.91	88.5	1.06
Esophagus	129	7.9	0.32	9.7	0.39	35	1.8	0.14	2.2	0.17
Stomach	140	9.0	0.35	10.8	0.41	94	5.1	0.24	6.0	0.28
Small intestine	57	3.7	0.22	4.4	0.26	57	3.1	0.19	3.6	0.22
Colon excl. rectum	630	40.6	0.75	48.7	0.88	589	31.3	0.59	37.0	0.69
Rectum & rectosigmoid	254	15.9	0.46	19.2	0.55	179	9.7	0.33	11.7	0.39
Anus, anal canal & anorectum	23	1.5	0.15	1.8	0.17	46	2.5	0.17	3.0	0.20
Liver	213	12.5	0.39	15.9	0.49	67	3.5	0.19	4.2	0.23
Gallbladder	10	0.7	0.10	0.8	0.11	23	1.2	0.11	1.4	0.13
Pancreas	262	17.1	0.49	20.4	0.58	235	12.2	0.36	14.4	0.42
Respiratory System	1,687	107.3	1.21	128.9	1.43	1,166	60.0	0.80	72.2	0.95
Larynx	142	8.5	0.33	10.6	0.40	32	1.7	0.13	2.1	0.17
Lung & bronchus	1,526	97.6	1.15	116.8	1.36	1,122	57.7	0.78	69.4	0.93
Bones & Joints	16	1.1	0.12	1.1	0.13	14	0.8	0.10	0.9	0.11
Soft Tissue (incl. heart)	59	4.0	0.24	4.5	0.27	48	2.8	0.19	3.1	0.20
Skin (excl. basal & sq.)	381	25.5	0.60	29.8	0.69	252	14.6	0.42	16.5	0.47
Melanomas of the skin	351	23.5	0.58	27.4	0.66	236	13.7	0.41	15.5	0.45
Breast (excl. <i>in situ</i>)	22	1.4	0.14	1.7	0.16	2,134	118.0	1.18	138.9	1.35
Female Genital System	-	-	-	-	-	832	46.3	0.74	54.2	0.85
Cervix uteri	-	-	-	-	-	147	9.4	0.36	10.1	0.37
Uterus Corpus	-	-	-	-	-	405	21.4	0.49	26.1	0.58
Uterus, NOS ¹	-	-	-	-	-	18	1.0	0.10	1.1	0.12
Ovary	-	-	-	-	-	172	9.5	0.33	11.1	0.38
Male Genital System	2,233	132.7	1.29	163.8	1.57	-	-	-	-	-
Prostate	2,164	127.7	1.26	158.7	1.54	-	-	-	-	-
Testis	53	4.0	0.25	3.9	0.24	-	-	-	-	-
Penis	14	0.9	0.11	1.1	0.13	-	-	-	-	-
Urinary System	917	60.4	0.92	71.4	1.07	437	23.6	0.52	27.7	0.60
Bladder (incl. <i>in situ</i>)	457	31.0	0.67	36.5	0.78	135	7.0	0.27	8.2	0.32
Kidney & renal pelvis	446	28.3	0.62	33.7	0.72	292	16.1	0.43	18.8	0.50
Ureter	10	0.8	0.11	0.9	0.13	5	0.3	0.05	0.3	0.06
Eye & Orbit	17	1.2	0.13	1.3	0.14	15	0.8	0.10	0.9	0.11
Brain & Other CNS ¹	107	7.1	0.32	7.9	0.35	88	5.1	0.25	5.6	0.27
Brain	102	6.8	0.31	7.6	0.34	83	4.8	0.24	5.2	0.26
Endocrine System	89	5.9	0.29	6.6	0.32	264	16.6	0.47	18.0	0.50
Thyroid gland	77	5.2	0.27	5.8	0.30	250	15.7	0.46	17.1	0.49
Lymphomas	345	23.2	0.57	26.6	0.65	290	16.1	0.43	18.4	0.49
Hodgkin Lymphoma	40	2.7	0.19	2.9	0.21	33	2.1	0.17	2.2	0.17
Non-Hodgkin Lymphoma	305	20.5	0.54	23.7	0.62	257	14.0	0.40	16.2	0.46
Multiple Myeloma	145	9.3	0.36	11.1	0.42	124	6.5	0.27	7.8	0.31
Leukemias	232	15.5	0.47	17.6	0.53	169	9.5	0.33	10.6	0.37
Acute lymphocytic	22	1.5	0.14	1.3	0.13	18	1.2	0.13	1.1	0.12
Chronic lymphocytic	83	5.3	0.27	6.3	0.32	51	2.6	0.17	3.1	0.20
Acute myeloid	68	4.6	0.26	5.3	0.29	59	3.4	0.20	3.8	0.22
Chronic myeloid	38	2.7	0.20	3.0	0.22	24	1.3	0.13	1.5	0.14
Other leukemias	22	1.5	0.15	1.7	0.17	18	0.9	0.10	1.1	0.12
Mesothelioma	19	1.4	0.15	1.6	0.17	7	0.4	0.07	0.5	0.08
Kaposi Sarcoma	6	0.5	0.09	0.5	0.09	-	-	-	-	-
Ill-defined & Unknown	249	16.9	0.50	20.0	0.58	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	123	8.3	0.35	9.4	0.39	247	13.9	0.41	15.9	0.45
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.06	450	24.7	0.54	29.5	0.63

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	5,864	530.9	3.18	632.4	3.74	5,138	424.3	2.76	495.3	3.16
Oral Cavity & Pharynx	248	22.1	0.65	27.2	0.78	95	7.6	0.36	9.2	0.43
Lip	11	1.1	0.14	1.3	0.17	2	0.1	0.04	0.1	0.05
Tongue	73	6.5	0.35	8.0	0.42	30	2.4	0.20	2.9	0.24
Major salivary gland	18	1.8	0.19	2.0	0.22	13	1.0	0.13	1.2	0.15
Floor of mouth	9	0.7	0.11	0.9	0.14	4	0.3	0.07	0.3	0.08
Gum & other mouth	29	2.6	0.22	3.2	0.27	17	1.4	0.16	1.6	0.17
Nasopharynx	9	0.8	0.13	1.0	0.15	3	0.3	0.07	0.3	0.08
Oropharynx	15	1.4	0.16	1.7	0.19	4	0.3	0.07	0.4	0.09
Hypopharynx	19	1.5	0.16	1.9	0.20	4	0.3	0.07	0.4	0.09
Digestive System	1,160	105.0	1.42	126.6	1.68	878	68.9	1.08	81.5	1.25
Esophagus	84	7.3	0.36	8.9	0.44	21	1.6	0.16	1.9	0.19
Stomach	78	7.1	0.37	8.5	0.44	47	3.8	0.26	4.4	0.29
Small intestine	32	2.9	0.24	3.5	0.28	34	2.8	0.22	3.3	0.26
Colon excl. rectum	399	36.9	0.85	43.9	1.00	362	28.2	0.69	33.0	0.79
Rectum & rectosigmoid	165	15.0	0.54	18.1	0.64	117	9.8	0.42	11.7	0.49
Anus, anal canal & anorectum	18	1.7	0.18	2.0	0.22	34	2.8	0.23	3.4	0.27
Liver	153	12.9	0.48	16.5	0.60	44	3.4	0.24	4.2	0.28
Gallbladder	6	0.6	0.11	0.7	0.13	13	1.1	0.13	1.2	0.15
Pancreas	179	16.3	0.56	19.5	0.66	148	11.1	0.42	13.2	0.49
Respiratory System	1,146	102.3	1.38	122.2	1.63	871	65.9	1.02	79.1	1.22
Larynx	81	7.1	0.36	8.8	0.44	22	1.8	0.17	2.2	0.21
Lung & bronchus	1,050	93.8	1.32	111.7	1.56	841	63.4	1.00	76.1	1.19
Bones & Joints	12	1.2	0.16	1.3	0.17	10	0.9	0.14	1.0	0.14
Soft Tissue (incl. heart)	42	4.2	0.30	4.7	0.33	29	2.7	0.23	2.9	0.25
Skin (excl. basal & sq.)	372	35.1	0.84	41.1	0.97	241	22.1	0.67	24.9	0.73
Melanomas of the skin	345	32.6	0.81	38.1	0.93	230	21.3	0.66	23.9	0.72
Breast (excl. <i>in situ</i>)	13	1.2	0.16	1.4	0.18	1,387	115.9	1.46	136.4	1.67
Female Genital System	-	-	-	-	-	536	46.9	0.95	54.5	1.08
Cervix uteri	-	-	-	-	-	84	9.0	0.46	9.6	0.48
Uterus Corpus	-	-	-	-	-	257	21.3	0.62	25.7	0.73
Uterus, NOS ¹	-	-	-	-	-	8	0.7	0.11	0.8	0.12
Ovary	-	-	-	-	-	121	10.3	0.44	11.9	0.49
Male Genital System	1,288	110.3	1.41	134.2	1.69	-	-	-	-	-
Prostate	1,233	103.9	1.35	127.6	1.64	-	-	-	-	-
Testis	44	5.4	0.37	5.3	0.36	-	-	-	-	-
Penis	10	0.9	0.13	1.1	0.16	-	-	-	-	-
Urinary System	702	64.9	1.12	76.8	1.31	295	23.8	0.65	28.0	0.74
Bladder (incl. <i>in situ</i>)	384	35.6	0.83	41.9	0.97	105	7.8	0.35	9.3	0.42
Kidney & renal pelvis	306	28.1	0.74	33.5	0.87	183	15.5	0.54	18.0	0.61
Ureter	10	1.0	0.14	1.1	0.17	4	0.3	0.07	0.4	0.08
Eye & Orbit	16	1.6	0.18	1.8	0.20	13	1.1	0.15	1.3	0.16
Brain & Other CNS ¹	84	8.3	0.42	9.3	0.46	66	6.1	0.35	6.6	0.37
Brain	82	8.1	0.41	9.0	0.45	63	5.8	0.34	6.3	0.36
Endocrine System	70	6.9	0.38	7.7	0.42	181	19.0	0.66	20.3	0.69
Thyroid gland	63	6.3	0.37	7.0	0.40	175	18.4	0.65	19.7	0.68
Lymphomas	259	24.8	0.71	28.6	0.80	206	17.0	0.55	19.4	0.62
Hodgkin Lymphoma	25	2.6	0.24	2.8	0.25	20	2.1	0.22	2.2	0.22
Non-Hodgkin Lymphoma	234	22.2	0.67	25.8	0.76	186	14.9	0.50	17.2	0.58
Multiple Myeloma	80	7.3	0.37	8.6	0.44	55	4.1	0.25	4.9	0.30
Leukemias	168	16.1	0.57	18.3	0.64	121	10.1	0.43	11.4	0.47
Acute lymphocytic	17	1.9	0.22	1.8	0.19	12	1.3	0.18	1.2	0.16
Chronic lymphocytic	61	5.4	0.32	6.5	0.38	39	2.9	0.21	3.5	0.26
Acute myeloid	48	4.5	0.30	5.2	0.34	42	3.7	0.27	4.1	0.29
Chronic myeloid	26	2.5	0.23	2.9	0.26	15	1.2	0.14	1.4	0.16
Other leukemias	17	1.7	0.18	2.0	0.21	13	1.0	0.13	1.1	0.15
Mesothelioma	16	1.6	0.18	1.8	0.20	6	0.5	0.10	0.6	0.11
Kaposi Sarcoma	2	0.2	0.07	0.3	0.08	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	87	8.6	0.42	9.7	0.47	161	13.8	0.51	15.7	0.57
Breast (<i>in situ</i>)	2	0.1	0.05	0.2	0.07	277	23.5	0.66	27.9	0.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,719	587.9	5.44	714.7	6.42	2,376	401.0	3.78	473.1	4.38
Oral Cavity & Pharynx	87	17.0	0.86	20.9	1.03	34	5.5	0.43	6.7	0.51
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	18	3.4	0.37	4.2	0.45	5	0.8	0.17	1.0	0.20
Major salivary gland	8	1.7	0.29	1.9	0.31	8	1.3	0.21	1.4	0.23
Floor of mouth	6	1.2	0.23	1.5	0.28	2	0.3	0.08	0.3	0.11
Gum & other mouth	11	2.3	0.32	2.8	0.39	6	1.0	0.19	1.3	0.23
Nasopharynx	6	1.2	0.23	1.4	0.27	3	0.6	0.14	0.6	0.16
Oropharynx	9	1.6	0.25	2.0	0.31	1	0.2	0.09	0.3	0.11
Hypopharynx	11	2.2	0.31	2.7	0.37	3	0.5	0.13	0.6	0.15
Digestive System	607	132.8	2.61	161.7	3.08	509	86.3	1.76	103.3	2.06
Esophagus	44	9.0	0.65	11.4	0.80	13	2.1	0.27	2.6	0.33
Stomach	58	13.3	0.85	16.1	1.00	45	7.8	0.53	9.3	0.62
Small intestine	25	5.5	0.54	6.5	0.62	22	3.8	0.37	4.5	0.42
Colon excl. rectum	227	50.2	1.62	60.9	1.91	222	37.5	1.16	44.9	1.36
Rectum & rectosigmoid	88	18.7	0.96	22.8	1.14	59	9.6	0.57	11.7	0.69
Anus, anal canal & anorectum	6	1.1	0.22	1.3	0.24	11	1.9	0.26	2.2	0.30
Liver	56	10.6	0.67	13.5	0.82	20	3.3	0.34	4.0	0.40
Gallbladder	4	0.8	0.20	1.0	0.24	8	1.5	0.23	1.7	0.27
Pancreas	81	19.0	1.03	22.8	1.20	85	14.9	0.74	17.7	0.87
Respiratory System	534	121.0	2.54	146.8	2.99	286	48.1	1.31	58.3	1.55
Larynx	60	12.1	0.76	15.2	0.92	10	1.5	0.22	2.0	0.28
Lung & bronchus	470	107.9	2.42	130.4	2.83	273	46.1	1.29	55.8	1.52
Bones & Joints	4	0.8	0.18	0.9	0.19	4	0.7	0.16	0.7	0.16
Soft Tissue (incl. heart)	16	3.4	0.42	3.8	0.46	18	3.0	0.32	3.3	0.35
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	5	1.3	0.27	1.4	0.30	5	0.9	0.18	1.0	0.21
Breast (excl. <i>in situ</i>)	9	2.0	0.34	2.5	0.39	728	121.8	2.07	143.6	2.39
Female Genital System	-	-	-	-	-	286	47.4	1.29	56.0	1.49
Cervix uteri	-	-	-	-	-	61	10.4	0.61	11.5	0.66
Uterus Corpus	-	-	-	-	-	145	23.3	0.89	28.6	1.07
Uterus, NOS ¹	-	-	-	-	-	10	1.6	0.24	2.0	0.28
Ovary	-	-	-	-	-	48	8.3	0.55	9.7	0.63
Male Genital System	928	189.6	2.98	236.9	3.60	-	-	-	-	-
Prostate	915	186.9	2.96	234.1	3.58	-	-	-	-	-
Testis	8	1.7	0.27	1.6	0.26	-	-	-	-	-
Penis	4	1.0	0.24	1.1	0.26	-	-	-	-	-
Urinary System	209	47.6	1.59	56.4	1.83	138	24.0	0.94	28.0	1.08
Bladder (incl. <i>in situ</i>)	70	17.5	1.02	20.8	1.18	30	5.3	0.44	6.2	0.51
Kidney & renal pelvis	137	29.6	1.21	35.1	1.39	105	18.3	0.82	21.3	0.93
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	2	0.3	0.09	0.3	0.11
Brain & Other CNS ¹	21	4.3	0.45	4.8	0.50	21	3.6	0.36	3.9	0.39
Brain	19	3.9	0.43	4.3	0.47	18	3.1	0.34	3.4	0.36
Endocrine System	17	3.8	0.43	4.4	0.49	78	13.1	0.68	14.5	0.74
Thyroid gland	13	3.0	0.39	3.5	0.44	70	11.7	0.64	13.1	0.70
Lymphomas	84	17.7	0.92	20.1	1.04	80	13.8	0.71	15.7	0.80
Hodgkin Lymphoma	15	2.8	0.34	3.0	0.36	13	2.1	0.26	2.1	0.27
Non-Hodgkin Lymphoma	68	14.8	0.85	17.1	0.97	67	11.7	0.66	13.6	0.75
Multiple Myeloma	64	14.7	0.89	17.6	1.03	69	11.8	0.65	14.1	0.76
Leukemias	61	14.1	0.87	15.9	0.97	47	8.3	0.55	9.2	0.61
Acute lymphocytic	4	0.7	0.15	0.6	0.13	7	1.1	0.19	1.0	0.18
Chronic lymphocytic	22	5.1	0.53	6.1	0.62	11	2.1	0.28	2.4	0.32
Acute myeloid	19	4.5	0.50	5.0	0.55	17	2.9	0.32	3.2	0.36
Chronic myeloid	12	2.9	0.39	3.2	0.43	8	1.3	0.22	1.5	0.25
Other leukemias	4	0.9	0.22	1.0	0.24	5	0.9	0.18	1.0	0.21
Mesothelioma	4	1.0	0.26	1.2	0.29	-	-	-	-	-
Kaposi Sarcoma	4	0.9	0.22	0.9	0.22	-	-	-	-	-
Ill-defined & Unknown	61	15.0	0.93	17.7	1.07	65	11.5	0.65	13.4	0.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	34	7.9	0.65	9.0	0.73	83	14.3	0.72	16.3	0.81
Breast (<i>in situ</i>)	1	0.2	0.09	0.3	0.12	167	27.3	0.97	32.9	1.14

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	33	283.1	23.85	341.7	28.13	49	301.7	20.52	354.3	23.80
Oral Cavity & Pharynx	2	10.6	3.78	14.0	4.95	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	9	78.7	12.73	94.2	14.97	8	57.9	9.62	69.6	11.38
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	18.9	6.13	22.6	7.10	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	11.8	4.26	14.0	5.06	2	14.7	4.51	17.5	5.24
Rectum & rectosigmoid	-	-	-	-	-	1	8.3	3.74	10.7	4.68
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	20.5	6.64	24.4	7.91	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	1	9.6	3.94	12.0	4.79
Respiratory System	5	45.1	9.69	53.2	11.03	7	53.6	9.50	62.5	10.90
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	43.8	9.61	51.4	10.89	7	53.6	9.50	62.5	10.90
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	15	80.1	9.66	96.6	11.47
Female Genital System	-	-	-	-	-	6	34.4	6.80	41.2	8.05
Cervix uteri	-	-	-	-	-	2	10.8	3.81	12.9	4.46
Uterus Corpus	-	-	-	-	-	1	7.8	3.20	10.4	4.16
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	12.2	4.13	14.1	4.75
Male Genital System	8	65.3	11.44	79.4	13.53	-	-	-	-	-
Prostate	7	63.0	11.32	77.0	13.41	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	23.7	7.48	28.4	8.77	2	12.8	4.22	14.4	4.64
Bladder (incl. <i>in situ</i>)	1	16.1	6.62	19.0	7.69	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	2	10.8	3.99	11.8	4.24
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	9.9	4.36	9.9	4.42	4	21.9	4.99	24.4	5.53
Thyroid gland	1	9.9	4.36	9.9	4.42	4	20.0	4.60	22.5	5.19
Lymphomas	2	13.6	4.79	17.1	5.94	3	17.3	4.98	20.0	5.74
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	13.6	4.79	17.1	5.94	2	15.3	4.78	17.4	5.43
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	15.0	5.66	18.1	6.85	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	10.7	4.83	13.7	5.92	1	8.5	3.71	9.6	4.18
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	12.4	4.18	14.1	4.60
Breast (<i>in situ</i>)	-	-	-	-	-	5	28.6	6.09	32.4	6.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	14	568.2	79.68	673.5	92.68	17	523.6	62.09	623.0	73.88
Oral Cavity & Pharynx	1	46.0	18.84	55.8	21.86	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	239.6	51.39	283.6	59.09	7	211.0	37.53	249.5	44.09
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	66.5	28.65	76.8	32.90	3	81.5	23.18	98.0	27.55
Rectum & rectosigmoid	-	-	-	-	-	1	29.9	12.39	32.3	14.01
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	70.8	26.94	82.3	29.98	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	53.0	16.82	68.9	21.87
Female Genital System	-	-	-	-	-	3	90.7	27.15	107.2	32.37
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	52.4	22.81	59.4	26.63
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	69.4	27.53	89.1	34.55	-	-	-	-	-
Prostate	2	66.0	27.32	85.5	34.37	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	73.4	25.32	83.1	28.48	2	56.5	22.90	67.4	27.63
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	50.4	20.34	59.4	24.02	1	39.1	14.85	46.4	17.90
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	56	224.9	15.41	268.4	18.19	49	200.9	13.82	231.4	16.04
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	14	50.4	6.84	61.1	8.20	9	42.1	6.67	50.4	7.91
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	18.1	4.30	21.5	4.99	1	6.3	2.70	6.9	2.90
Rectum & rectosigmoid	3	9.9	2.56	11.9	3.21	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	7.8	2.85	9.6	3.38	2	9.3	3.21	11.0	3.80
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	7.7	2.97	9.3	3.50	-	-	-	-	-
Respiratory System	6	28.0	5.51	34.3	6.58	5	29.7	5.90	34.6	6.75
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	6	26.6	5.41	32.5	6.44	5	28.8	5.83	33.4	6.65
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	2.3	0.97	2.4	1.05	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	6.8	2.90	7.6	3.32	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	12	48.8	6.67	56.0	7.73
Female Genital System	-	-	-	-	-	6	21.7	3.96	24.2	4.63
Cervix uteri	-	-	-	-	-	2	5.7	1.86	6.1	2.10
Uterus Corpus	-	-	-	-	-	4	13.0	3.14	14.8	3.72
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	16	75.5	9.34	89.9	10.86	-	-	-	-	-
Prostate	13	69.9	9.19	83.5	10.67	-	-	-	-	-
Testis	2	4.0	1.22	4.2	1.32	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	22.3	5.17	26.6	6.11	2	6.5	2.36	8.2	2.93
Bladder (incl. <i>in situ</i>)	2	10.8	3.74	13.1	4.46	-	-	-	-	-
Kidney & renal pelvis	2	8.5	2.81	10.1	3.38	1	5.8	2.23	7.0	2.67
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	3.6	2.01	4.0	2.31	2	6.0	2.21	7.0	2.68
Brain	1	3.6	2.01	4.0	2.31	2	5.7	2.19	6.8	2.67
Endocrine System	-	-	-	-	-	4	11.4	2.84	12.3	3.16
Thyroid gland	-	-	-	-	-	3	9.0	2.41	10.0	2.78
Lymphomas	3	9.4	2.98	11.5	3.61	3	11.6	3.54	13.1	3.99
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	5.4	2.21	6.0	2.49	2	6.0	2.17	6.9	2.59
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	10.7	3.38	13.2	4.13	1	4.9	2.23	5.7	2.60
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	4.8	2.22	5.8	2.68	2	9.8	3.03	11.2	3.48
Breast (<i>in situ</i>)	-	-	-	-	-	3	10.5	2.90	11.8	3.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MISSISSIPPI

II-288 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,813	536.3	3.23	638.7	3.80	5,095	428.0	2.81	499.5	3.20
Oral Cavity & Pharynx	247	22.5	0.66	27.6	0.80	95	7.7	0.37	9.2	0.43
Lip	11	1.1	0.15	1.3	0.17	2	0.1	0.04	0.1	0.05
Tongue	73	6.6	0.36	8.1	0.43	30	2.4	0.21	2.9	0.25
Major salivary gland	18	1.8	0.19	2.0	0.22	12	1.0	0.13	1.2	0.15
Floor of mouth	9	0.7	0.11	0.9	0.14	4	0.3	0.07	0.4	0.08
Gum & other mouth	29	2.7	0.23	3.3	0.27	17	1.4	0.16	1.6	0.18
Nasopharynx	9	0.8	0.13	1.0	0.15	3	0.3	0.07	0.3	0.08
Oropharynx	15	1.4	0.16	1.7	0.20	4	0.3	0.07	0.4	0.09
Hypopharynx	19	1.6	0.17	2.0	0.21	4	0.3	0.07	0.4	0.09
Digestive System	1,148	105.9	1.44	127.6	1.71	871	69.4	1.09	81.9	1.27
Esophagus	84	7.4	0.37	9.0	0.44	20	1.6	0.16	1.9	0.19
Stomach	77	7.2	0.38	8.5	0.44	46	3.7	0.26	4.3	0.29
Small intestine	32	3.0	0.24	3.5	0.28	34	2.8	0.23	3.3	0.26
Colon excl. rectum	395	37.3	0.86	44.3	1.01	361	28.6	0.70	33.4	0.80
Rectum & rectosigmoid	162	15.0	0.55	18.1	0.65	116	9.9	0.43	11.8	0.50
Anus, anal canal & anorectum	18	1.7	0.19	2.0	0.22	34	2.9	0.23	3.5	0.27
Liver	151	13.1	0.49	16.6	0.61	42	3.3	0.24	4.0	0.28
Gallbladder	6	0.6	0.11	0.7	0.13	13	1.0	0.13	1.2	0.15
Pancreas	178	16.5	0.57	19.7	0.67	148	11.2	0.42	13.3	0.50
Respiratory System	1,140	103.5	1.40	123.5	1.66	867	66.4	1.03	79.8	1.23
Larynx	81	7.2	0.37	9.0	0.45	22	1.8	0.18	2.2	0.21
Lung & bronchus	1,044	94.8	1.34	112.9	1.58	836	63.9	1.01	76.7	1.21
Bones & Joints	11	1.2	0.16	1.2	0.17	10	1.0	0.15	1.0	0.15
Soft Tissue (incl. heart)	41	4.2	0.30	4.7	0.33	29	2.7	0.24	2.9	0.25
Skin (excl. basal & sq.)	370	35.7	0.86	41.8	0.98	240	22.6	0.69	25.4	0.75
Melanomas of the skin	344	33.1	0.82	38.7	0.95	229	21.7	0.68	24.4	0.74
Breast (excl. <i>in situ</i>)	13	1.2	0.16	1.4	0.18	1,377	117.0	1.48	137.6	1.70
Female Genital System	-	-	-	-	-	530	47.2	0.97	54.9	1.09
Cervix uteri	-	-	-	-	-	82	9.1	0.47	9.6	0.48
Uterus Corpus	-	-	-	-	-	253	21.3	0.63	25.8	0.74
Uterus, NOS ¹	-	-	-	-	-	8	0.7	0.11	0.8	0.13
Ovary	-	-	-	-	-	120	10.4	0.45	12.0	0.50
Male Genital System	1,274	111.0	1.43	135.0	1.71	-	-	-	-	-
Prostate	1,222	104.5	1.36	128.4	1.66	-	-	-	-	-
Testis	42	5.5	0.38	5.4	0.37	-	-	-	-	-
Penis	10	0.9	0.13	1.1	0.16	-	-	-	-	-
Urinary System	697	65.6	1.14	77.7	1.33	293	24.1	0.66	28.3	0.76
Bladder (incl. <i>in situ</i>)	382	35.9	0.84	42.3	0.98	104	7.9	0.36	9.4	0.42
Kidney & renal pelvis	304	28.5	0.76	34.0	0.88	182	15.6	0.55	18.2	0.62
Ureter	9	0.9	0.14	1.1	0.16	4	0.3	0.07	0.4	0.08
Eye & Orbit	16	1.6	0.19	1.8	0.21	13	1.2	0.15	1.3	0.17
Brain & Other CNS ¹	83	8.4	0.43	9.4	0.47	64	6.1	0.36	6.6	0.38
Brain	81	8.2	0.42	9.1	0.46	62	5.8	0.35	6.4	0.37
Endocrine System	69	7.1	0.40	7.9	0.43	178	19.2	0.68	20.6	0.70
Thyroid gland	62	6.4	0.38	7.1	0.41	172	18.7	0.67	20.0	0.69
Lymphomas	257	25.1	0.72	28.9	0.82	204	17.0	0.56	19.5	0.63
Hodgkin Lymphoma	25	2.7	0.25	2.9	0.26	19	2.1	0.22	2.2	0.23
Non-Hodgkin Lymphoma	232	22.4	0.68	26.0	0.78	184	14.9	0.51	17.3	0.58
Multiple Myeloma	79	7.4	0.38	8.7	0.44	54	4.1	0.25	4.9	0.30
Leukemias	167	16.3	0.58	18.5	0.65	119	10.2	0.44	11.4	0.48
Acute lymphocytic	16	2.0	0.23	1.8	0.20	11	1.3	0.18	1.2	0.17
Chronic lymphocytic	61	5.5	0.33	6.6	0.38	39	2.9	0.22	3.5	0.26
Acute myeloid	48	4.6	0.30	5.3	0.35	41	3.7	0.27	4.1	0.29
Chronic myeloid	26	2.6	0.24	2.9	0.26	15	1.2	0.15	1.4	0.16
Other leukemias	17	1.6	0.18	1.9	0.21	12	1.0	0.13	1.1	0.15
Mesothelioma	16	1.6	0.18	1.8	0.21	6	0.5	0.10	0.6	0.11
Kaposi Sarcoma	2	0.2	0.07	0.3	0.08	-	-	-	-	-
Ill-defined & Unknown	183	17.6	0.60	20.7	0.70	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	86	8.7	0.44	9.8	0.48	159	13.9	0.52	15.8	0.58
Breast (<i>in situ</i>)	2	0.1	0.05	0.2	0.07	274	23.6	0.67	28.1	0.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Mississippi, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,716	591.7	5.48	719.3	6.46	2,372	402.8	3.80	475.2	4.40
Oral Cavity & Pharynx	87	17.2	0.87	21.1	1.04	34	5.5	0.44	6.7	0.52
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	18	3.4	0.37	4.3	0.45	5	0.8	0.17	1.0	0.20
Major salivary gland	8	1.7	0.29	1.9	0.32	8	1.3	0.21	1.4	0.23
Floor of mouth	6	1.2	0.23	1.5	0.28	2	0.3	0.09	0.3	0.11
Gum & other mouth	11	2.3	0.33	2.8	0.39	6	1.0	0.19	1.2	0.23
Nasopharynx	6	1.2	0.23	1.4	0.27	3	0.6	0.14	0.6	0.16
Oropharynx	9	1.6	0.25	2.0	0.31	1	0.2	0.09	0.3	0.11
Hypopharynx	11	2.2	0.32	2.7	0.38	3	0.5	0.13	0.6	0.15
Digestive System	607	133.7	2.63	162.7	3.10	508	86.6	1.77	103.7	2.07
Esophagus	44	9.1	0.66	11.5	0.80	13	2.1	0.27	2.6	0.33
Stomach	58	13.4	0.85	16.2	1.01	45	7.8	0.53	9.4	0.63
Small intestine	25	5.6	0.54	6.6	0.62	22	3.9	0.38	4.5	0.43
Colon excl. rectum	226	50.5	1.63	61.3	1.92	221	37.7	1.16	45.1	1.37
Rectum & rectosigmoid	87	18.8	0.97	22.9	1.15	59	9.6	0.58	11.8	0.69
Anus, anal canal & anorectum	6	1.2	0.22	1.3	0.24	11	1.9	0.26	2.2	0.30
Liver	56	10.6	0.67	13.6	0.83	20	3.3	0.34	4.0	0.40
Gallbladder	4	0.8	0.20	1.0	0.24	8	1.4	0.23	1.7	0.27
Pancreas	81	19.1	1.04	22.9	1.21	84	14.9	0.75	17.7	0.87
Respiratory System	534	121.8	2.56	147.8	3.01	285	48.3	1.32	58.5	1.56
Larynx	59	12.2	0.76	15.3	0.93	10	1.5	0.22	2.0	0.28
Lung & bronchus	470	108.7	2.44	131.4	2.85	272	46.3	1.29	56.0	1.53
Bones & Joints	4	0.8	0.19	0.9	0.19	4	0.7	0.16	0.7	0.16
Soft Tissue (incl. heart)	16	3.5	0.42	3.8	0.47	18	3.0	0.32	3.3	0.35
Skin (excl. basal & sq.)	8	1.8	0.31	2.0	0.35	10	1.7	0.25	1.9	0.28
Melanomas of the skin	5	1.3	0.27	1.4	0.30	5	0.9	0.18	1.0	0.20
Breast (excl. <i>in situ</i>)	9	2.1	0.34	2.5	0.39	727	122.4	2.08	144.2	2.41
Female Genital System	-	-	-	-	-	286	47.7	1.29	56.3	1.50
Cervix uteri	-	-	-	-	-	61	10.5	0.61	11.5	0.67
Uterus Corpus	-	-	-	-	-	145	23.4	0.90	28.7	1.07
Uterus, NOS ¹	-	-	-	-	-	10	1.6	0.24	2.0	0.29
Ovary	-	-	-	-	-	48	8.3	0.55	9.7	0.63
Male Genital System	926	190.7	3.01	238.3	3.62	-	-	-	-	-
Prostate	914	188.0	2.98	235.5	3.61	-	-	-	-	-
Testis	8	1.7	0.28	1.6	0.26	-	-	-	-	-
Penis	4	1.0	0.24	1.1	0.26	-	-	-	-	-
Urinary System	209	48.0	1.60	56.9	1.85	138	24.1	0.94	28.2	1.08
Bladder (incl. <i>in situ</i>)	70	17.6	1.03	20.9	1.19	30	5.3	0.45	6.2	0.52
Kidney & renal pelvis	137	29.8	1.22	35.3	1.40	105	18.4	0.82	21.4	0.94
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	2	0.3	0.09	0.3	0.11
Brain & Other CNS ¹	21	4.4	0.45	4.9	0.50	21	3.7	0.36	3.9	0.39
Brain	19	3.9	0.43	4.4	0.48	18	3.2	0.34	3.4	0.36
Endocrine System	17	3.8	0.44	4.4	0.50	77	13.1	0.68	14.5	0.74
Thyroid gland	13	3.0	0.39	3.5	0.45	70	11.8	0.65	13.1	0.71
Lymphomas	83	17.8	0.93	20.2	1.04	80	13.9	0.71	15.8	0.80
Hodgkin Lymphoma	15	2.9	0.34	3.0	0.36	13	2.1	0.27	2.2	0.28
Non-Hodgkin Lymphoma	68	14.9	0.86	17.2	0.98	67	11.8	0.66	13.6	0.75
Multiple Myeloma	64	14.8	0.89	17.7	1.04	69	11.9	0.66	14.2	0.77
Leukemias	61	14.2	0.87	16.0	0.98	47	8.3	0.56	9.2	0.61
Acute lymphocytic	4	0.7	0.15	0.6	0.13	7	1.1	0.19	1.0	0.18
Chronic lymphocytic	22	5.1	0.53	6.1	0.63	11	2.1	0.28	2.4	0.32
Acute myeloid	19	4.5	0.50	5.1	0.55	17	2.9	0.33	3.2	0.36
Chronic myeloid	12	2.9	0.40	3.2	0.43	8	1.4	0.23	1.5	0.25
Other leukemias	4	0.9	0.22	1.0	0.24	5	0.9	0.19	1.0	0.21
Mesothelioma	4	1.0	0.26	1.2	0.29	-	-	-	-	-
Kaposi Sarcoma	4	1.0	0.22	0.9	0.22	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	64	11.5	0.66	13.4	0.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	34	7.9	0.65	9.0	0.74	83	14.3	0.72	16.3	0.81
Breast (<i>in situ</i>)	1	0.2	0.09	0.3	0.12	167	27.4	0.97	33.0	1.15

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


MISSISSIPPI

II-290 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,040,658	6,056,293	6,071,745	6,087,203	6,108,612
White	5,119,014	5,124,801	5,130,022	5,137,228	5,148,193
Black	750,945	755,573	760,133	764,501	768,378
American Indian/Alaskan Native (AI/AN)	40,817	41,716	42,402	43,110	43,958
Asian/Pacific Islander (API)	129,882	134,203	139,188	142,364	148,083


All Races Population 2013-2017: 30,364,511
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	230,347	236,411	242,786	249,399	256,271
Non-Hispanic White	4,916,334	4,917,184	4,916,898	4,918,545	4,923,498
Non-Hispanic Black	736,636	740,679	744,744	748,617	752,174

Hispanic/Latino Population, Census 2010: 212,470
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MISSOURI CANCER REGISTRY

Initial Operation: 1972
Population-based Data Available: 1985
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.9	102.7	103.5	101.6	104.1
Missing Race	0.2	0.2	0.2	0.2	0.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.3	2.4	2.5	2.4	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.6	Prostate	96.9
Oral Cavity & Pharynx	97.7	Testis	99.2
Esophagus	93.4	Bladder (incl. <i>in situ</i>)	97.9
Stomach	96.7	Kidney & Renal Pelvis	89.6
Colon & Rectum	96.1	Brain & Other CNS ¹	86.5
Liver	53.0	Thyroid	99.4
Pancreas	83.3	Hodgkin Lymphoma	99.1
Lung & Bronchus	86.2	Non-Hodgkin Lymphoma	96.3
Melanomas of the Skin	98.9	Multiple Myeloma	89.9
Female Breast (excl. <i>in situ</i>)	98.5	Leukemias	89.6
Cervix uteri	97.7	Brain & Other CNS ¹ <i>non-malig</i>	38.7
Uterus Corpus & Uterus NOS ¹	98.5	Breast <i>in situ</i>	100.0
Ovary	92.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	16,717	490.3	1.74	583.1	2.03	16,722	431.9	1.54	505.2	1.77
Oral Cavity & Pharynx	692	19.6	0.34	24.1	0.41	258	6.5	0.19	7.8	0.22
Lip	24	0.7	0.07	0.9	0.08	9	0.2	0.03	0.3	0.04
Tongue	216	6.0	0.19	7.5	0.23	76	1.9	0.10	2.3	0.12
Major salivary gland	52	1.6	0.10	1.8	0.12	34	0.9	0.07	1.0	0.08
Floor of mouth	29	0.8	0.06	1.0	0.08	15	0.4	0.04	0.5	0.05
Gum & other mouth	72	2.1	0.12	2.5	0.13	55	1.4	0.08	1.6	0.10
Nasopharynx	23	0.7	0.07	0.8	0.08	13	0.3	0.04	0.4	0.05
Oropharynx	42	1.1	0.08	1.4	0.10	8	0.2	0.03	0.2	0.04
Hypopharynx	42	1.1	0.08	1.4	0.10	9	0.2	0.03	0.3	0.04
Digestive System	3,345	98.7	0.78	117.9	0.92	2,612	65.0	0.59	76.6	0.68
Esophagus	307	8.9	0.23	10.7	0.28	81	1.9	0.10	2.3	0.12
Stomach	260	7.8	0.22	9.2	0.26	137	3.5	0.14	4.0	0.16
Small intestine	97	2.8	0.13	3.4	0.15	91	2.3	0.11	2.8	0.13
Colon excl. rectum	1,065	32.5	0.45	38.1	0.53	1,069	26.7	0.38	31.0	0.43
Rectum & rectosigmoid	492	14.5	0.30	17.4	0.35	328	8.5	0.22	10.1	0.25
Anus, anal canal & anorectum	54	1.6	0.10	1.9	0.12	106	2.7	0.12	3.3	0.14
Liver	381	10.3	0.24	13.0	0.30	122	3.0	0.12	3.6	0.15
Gallbladder	26	0.8	0.07	0.9	0.08	47	1.1	0.07	1.3	0.09
Pancreas	503	14.8	0.30	17.7	0.36	447	10.8	0.23	12.8	0.27
Respiratory System	3,133	91.4	0.75	109.1	0.88	2,700	65.5	0.57	78.5	0.68
Larynx	235	6.6	0.20	8.1	0.24	69	1.7	0.09	2.1	0.12
Lung & bronchus	2,858	83.6	0.71	99.5	0.84	2,609	63.2	0.56	75.7	0.67
Bones & Joints	34	1.1	0.08	1.2	0.09	26	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	121	3.8	0.16	4.2	0.17	93	2.6	0.12	2.8	0.13
Skin (excl. basal & sq.)	865	26.3	0.41	30.7	0.47	586	16.5	0.32	18.5	0.35
Melanomas of the skin	810	24.6	0.40	28.7	0.45	553	15.7	0.31	17.6	0.34
Breast (excl. <i>in situ</i>)	38	1.2	0.09	1.4	0.10	4,951	130.5	0.86	153.5	0.99
Female Genital System	-	-	-	-	-	1,901	49.8	0.53	58.8	0.61
Cervix uteri	-	-	-	-	-	253	8.0	0.23	8.6	0.24
Uterus Corpus	-	-	-	-	-	1,039	26.0	0.37	31.7	0.44
Uterus, NOS ¹	-	-	-	-	-	31	0.8	0.06	0.9	0.07
Ovary	-	-	-	-	-	374	9.9	0.24	11.5	0.27
Male Genital System	3,554	98.0	0.75	120.2	0.91	-	-	-	-	-
Prostate	3,364	91.4	0.72	113.5	0.88	-	-	-	-	-
Testis	156	5.5	0.20	5.5	0.20	-	-	-	-	-
Penis	26	0.8	0.07	0.9	0.08	-	-	-	-	-
Urinary System	2,056	61.7	0.62	72.8	0.72	907	22.7	0.35	26.7	0.40
Bladder (incl. <i>in situ</i>)	1,151	35.1	0.47	41.1	0.55	346	8.3	0.20	9.8	0.24
Kidney & renal pelvis	861	25.3	0.40	30.1	0.46	530	13.6	0.27	16.0	0.31
Ureter	29	0.9	0.07	1.0	0.09	23	0.5	0.05	0.6	0.06
Eye & Orbit	37	1.1	0.09	1.3	0.10	25	0.7	0.06	0.8	0.07
Brain & Other CNS ¹	253	7.9	0.23	8.7	0.25	205	5.8	0.19	6.3	0.20
Brain	241	7.5	0.22	8.3	0.24	190	5.3	0.18	5.8	0.19
Endocrine System	225	7.1	0.22	7.9	0.24	589	18.1	0.35	19.6	0.37
Thyroid gland	202	6.3	0.21	7.1	0.23	569	17.5	0.34	19.0	0.36
Lymphomas	844	25.7	0.41	29.7	0.46	693	17.9	0.31	20.6	0.35
Hodgkin Lymphoma	92	3.0	0.14	3.2	0.15	76	2.4	0.13	2.5	0.13
Non-Hodgkin Lymphoma	752	22.7	0.38	26.5	0.44	616	15.5	0.29	18.1	0.33
Multiple Myeloma	282	8.4	0.23	9.9	0.27	211	5.2	0.16	6.1	0.19
Leukemias	584	18.0	0.34	20.6	0.38	408	10.7	0.25	12.1	0.27
Acute lymphocytic	45	1.5	0.10	1.4	0.10	36	1.2	0.09	1.1	0.08
Chronic lymphocytic	207	6.1	0.19	7.3	0.23	131	3.1	0.13	3.8	0.15
Acute myeloid	179	5.6	0.19	6.4	0.22	137	3.7	0.15	4.1	0.16
Chronic myeloid	77	2.4	0.13	2.7	0.14	51	1.4	0.09	1.6	0.10
Other leukemias	75	2.4	0.12	2.7	0.14	52	1.3	0.08	1.5	0.09
Mesothelioma	42	1.3	0.09	1.5	0.11	14	0.4	0.05	0.4	0.05
Kaposi Sarcoma	8	0.3	0.04	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	604	18.7	0.35	21.8	0.40	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	284	9.0	0.24	10.1	0.27	605	16.2	0.31	18.6	0.34
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	1,025	27.3	0.40	32.4	0.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	14,862	485.7	1.82	576.6	2.13	14,719	432.4	1.66	505.2	1.89
Oral Cavity & Pharynx	634	20.1	0.37	24.7	0.44	232	6.6	0.20	8.0	0.24
Lip	23	0.8	0.07	0.9	0.09	9	0.2	0.04	0.3	0.04
Tongue	204	6.4	0.21	7.9	0.25	70	2.0	0.11	2.5	0.13
Major salivary gland	47	1.6	0.11	1.9	0.12	29	0.9	0.08	1.0	0.09
Floor of mouth	26	0.8	0.07	1.0	0.09	13	0.4	0.05	0.5	0.06
Gum & other mouth	66	2.2	0.12	2.5	0.14	50	1.4	0.09	1.6	0.10
Nasopharynx	18	0.6	0.06	0.7	0.07	10	0.3	0.04	0.4	0.05
Oropharynx	36	1.1	0.08	1.4	0.10	7	0.2	0.03	0.2	0.04
Hypopharynx	35	1.1	0.08	1.3	0.10	8	0.2	0.03	0.3	0.04
Digestive System	2,904	95.5	0.81	113.9	0.95	2,232	62.6	0.61	73.6	0.71
Esophagus	287	9.2	0.25	11.2	0.30	69	1.9	0.10	2.2	0.12
Stomach	219	7.3	0.23	8.6	0.26	108	3.1	0.14	3.6	0.16
Small intestine	80	2.6	0.13	3.1	0.16	74	2.2	0.12	2.5	0.13
Colon excl. rectum	941	31.9	0.48	37.4	0.55	936	26.3	0.40	30.5	0.45
Rectum & rectosigmoid	440	14.5	0.32	17.4	0.37	278	8.3	0.23	9.7	0.27
Anus, anal canal & anorectum	45	1.5	0.10	1.8	0.12	96	2.8	0.13	3.4	0.16
Liver	295	8.9	0.24	11.2	0.29	95	2.6	0.12	3.1	0.15
Gallbladder	21	0.7	0.07	0.8	0.08	37	1.0	0.07	1.1	0.09
Pancreas	432	14.1	0.31	16.8	0.36	380	10.3	0.24	12.2	0.28
Respiratory System	2,794	90.2	0.78	107.5	0.92	2,407	65.8	0.61	78.8	0.73
Larynx	202	6.3	0.20	7.8	0.25	59	1.7	0.10	2.1	0.12
Lung & bronchus	2,558	82.7	0.75	98.4	0.88	2,327	63.5	0.60	76.0	0.71
Bones & Joints	30	1.1	0.09	1.2	0.10	23	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	105	3.7	0.17	4.2	0.18	78	2.5	0.13	2.7	0.14
Skin (excl. basal & sq.)	843	28.6	0.45	33.3	0.52	565	18.5	0.37	20.7	0.40
Melanomas of the skin	791	26.8	0.44	31.3	0.50	537	17.7	0.36	19.7	0.39
Breast (excl. <i>in situ</i>)	32	1.1	0.09	1.3	0.10	4,330	129.9	0.92	153.0	1.06
Female Genital System	-	-	-	-	-	1,680	50.4	0.57	59.4	0.66
Cervix uteri	-	-	-	-	-	211	7.9	0.25	8.4	0.26
Uterus Corpus	-	-	-	-	-	922	26.3	0.40	32.1	0.48
Uterus, NOS ¹	-	-	-	-	-	24	0.7	0.06	0.8	0.07
Ovary	-	-	-	-	-	336	10.1	0.26	11.8	0.29
Male Genital System	3,033	93.4	0.78	114.1	0.93	-	-	-	-	-
Prostate	2,858	86.3	0.74	106.8	0.90	-	-	-	-	-
Testis	145	6.1	0.23	6.1	0.23	-	-	-	-	-
Penis	23	0.8	0.07	0.9	0.09	-	-	-	-	-
Urinary System	1,881	62.6	0.66	73.7	0.77	796	22.6	0.37	26.5	0.43
Bladder (incl. <i>in situ</i>)	1,076	36.1	0.50	42.2	0.58	309	8.4	0.22	9.8	0.25
Kidney & renal pelvis	764	25.1	0.42	29.9	0.49	459	13.5	0.29	15.8	0.33
Ureter	28	0.9	0.08	1.1	0.09	21	0.6	0.06	0.7	0.06
Eye & Orbit	34	1.2	0.09	1.4	0.10	23	0.7	0.07	0.8	0.08
Brain & Other CNS ¹	232	8.2	0.25	9.1	0.27	187	6.1	0.21	6.6	0.22
Brain	221	7.8	0.24	8.6	0.26	174	5.6	0.20	6.2	0.21
Endocrine System	204	7.3	0.24	8.2	0.26	518	18.8	0.39	20.3	0.40
Thyroid gland	186	6.7	0.23	7.5	0.25	502	18.2	0.38	19.7	0.40
Lymphomas	770	26.2	0.43	30.3	0.49	622	18.3	0.34	20.9	0.38
Hodgkin Lymphoma	81	3.1	0.16	3.2	0.16	66	2.4	0.14	2.5	0.14
Non-Hodgkin Lymphoma	689	23.1	0.40	27.0	0.46	556	15.8	0.31	18.4	0.35
Multiple Myeloma	235	7.8	0.23	9.2	0.27	163	4.5	0.16	5.3	0.19
Leukemias	533	18.3	0.36	21.0	0.41	363	10.9	0.27	12.2	0.29
Acute lymphocytic	39	1.6	0.12	1.5	0.11	31	1.2	0.10	1.2	0.09
Chronic lymphocytic	190	6.2	0.20	7.4	0.24	118	3.2	0.13	3.8	0.16
Acute myeloid	165	5.7	0.20	6.6	0.23	122	3.7	0.16	4.2	0.17
Chronic myeloid	69	2.4	0.13	2.8	0.15	44	1.4	0.10	1.5	0.11
Other leukemias	69	2.4	0.13	2.8	0.15	48	1.3	0.09	1.5	0.10
Mesothelioma	41	1.4	0.10	1.6	0.11	13	0.4	0.05	0.4	0.05
Kaposi Sarcoma	5	0.2	0.04	0.2	0.04	-	-	-	-	-
Ill-defined & Unknown	552	18.8	0.37	22.0	0.42	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	246	8.8	0.26	9.8	0.28	516	15.7	0.32	18.1	0.36
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.02	871	26.6	0.42	31.6	0.49

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,582	546.0	6.53	659.9	7.69	1,691	436.2	4.85	516.6	5.64
Oral Cavity & Pharynx	50	16.2	1.07	19.6	1.27	21	5.1	0.51	6.2	0.61
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	10	3.1	0.47	3.9	0.57	5	1.2	0.24	1.4	0.30
Major salivary gland	4	1.5	0.35	1.7	0.39	4	0.9	0.21	1.1	0.26
Floor of mouth	2	0.7	0.21	0.9	0.26	2	0.4	0.15	0.6	0.18
Gum & other mouth	5	1.5	0.32	1.8	0.39	3	0.7	0.19	0.8	0.22
Nasopharynx	4	1.4	0.32	1.5	0.34	2	0.5	0.16	0.6	0.18
Oropharynx	6	1.9	0.38	2.3	0.44	-	-	-	-	-
Hypopharynx	6	2.0	0.38	2.4	0.44	1	0.4	0.15	0.4	0.17
Digestive System	371	130.2	3.22	157.6	3.79	331	85.8	2.15	102.4	2.53
Esophagus	17	6.1	0.70	7.5	0.83	11	2.8	0.38	3.5	0.47
Stomach	33	12.5	1.03	14.9	1.20	24	6.4	0.59	7.6	0.69
Small intestine	15	5.0	0.62	6.1	0.73	16	4.3	0.49	5.1	0.56
Colon excl. rectum	104	38.1	1.77	45.4	2.07	116	30.4	1.29	36.1	1.50
Rectum & rectosigmoid	42	14.7	1.07	17.5	1.25	40	10.2	0.73	12.4	0.87
Anus, anal canal & anorectum	7	2.2	0.39	2.6	0.45	9	2.4	0.37	2.9	0.43
Liver	71	21.6	1.21	27.7	1.50	22	5.3	0.52	6.5	0.63
Gallbladder	4	1.5	0.36	1.7	0.42	9	2.5	0.37	3.0	0.43
Pancreas	63	23.3	1.39	28.0	1.63	62	16.1	0.93	19.3	1.10
Respiratory System	304	110.7	3.02	133.0	3.53	261	66.8	1.89	80.9	2.25
Larynx	30	10.1	0.88	12.3	1.03	9	2.1	0.32	2.8	0.41
Lung & bronchus	270	99.1	2.87	118.9	3.35	250	64.2	1.86	77.7	2.21
Bones & Joints	3	0.7	0.20	0.8	0.23	3	0.7	0.19	0.7	0.19
Soft Tissue (incl. heart)	12	3.8	0.51	4.2	0.57	13	3.4	0.42	3.8	0.47
Skin (excl. basal & sq.)	4	1.6	0.37	1.7	0.41	4	1.0	0.23	1.1	0.26
Melanomas of the skin	2	1.0	0.31	1.1	0.35	2	0.4	0.16	0.5	0.18
Breast (excl. <i>in situ</i>)	5	2.0	0.43	2.3	0.50	526	136.3	2.72	160.4	3.14
Female Genital System	-	-	-	-	-	181	46.0	1.56	54.7	1.82
Cervix uteri	-	-	-	-	-	34	8.9	0.70	9.9	0.77
Uterus Corpus	-	-	-	-	-	99	24.5	1.13	29.9	1.35
Uterus, NOS ¹	-	-	-	-	-	6	1.5	0.28	1.9	0.34
Ovary	-	-	-	-	-	30	7.6	0.64	8.9	0.74
Male Genital System	468	151.0	3.29	189.1	4.00	-	-	-	-	-
Prostate	459	147.7	3.26	185.6	3.96	-	-	-	-	-
Testis	6	1.8	0.34	1.8	0.34	-	-	-	-	-
Penis	3	1.0	0.31	1.2	0.36	-	-	-	-	-
Urinary System	140	51.1	2.06	60.6	2.39	97	25.0	1.16	29.8	1.36
Bladder (incl. <i>in situ</i>)	55	22.1	1.42	25.9	1.64	30	7.9	0.65	9.5	0.77
Kidney & renal pelvis	83	28.0	1.45	33.5	1.70	64	16.5	0.94	19.6	1.10
Ureter	1	0.5	0.22	0.6	0.24	-	-	-	-	-
Eye & Orbit	2	0.5	0.18	0.6	0.19	1	0.3	0.12	0.2	0.10
Brain & Other CNS ¹	16	5.1	0.60	5.5	0.66	14	3.5	0.42	3.7	0.45
Brain	15	4.8	0.59	5.2	0.65	12	3.1	0.40	3.2	0.42
Endocrine System	14	4.5	0.56	5.2	0.64	49	12.7	0.83	14.5	0.93
Thyroid gland	10	3.4	0.49	4.0	0.58	46	11.8	0.79	13.5	0.90
Lymphomas	61	19.9	1.20	22.9	1.37	60	15.4	0.91	17.8	1.04
Hodgkin Lymphoma	10	2.7	0.41	2.9	0.42	10	2.6	0.38	2.6	0.38
Non-Hodgkin Lymphoma	51	17.1	1.13	20.0	1.30	50	12.8	0.83	15.2	0.96
Multiple Myeloma	43	16.3	1.18	19.4	1.37	45	12.0	0.81	14.2	0.94
Leukemias	41	14.8	1.10	16.9	1.24	36	9.3	0.71	10.7	0.81
Acute lymphocytic	3	0.9	0.22	0.8	0.20	3	0.7	0.18	0.7	0.18
Chronic lymphocytic	15	5.3	0.65	6.4	0.77	11	3.0	0.40	3.6	0.47
Acute myeloid	12	4.6	0.63	5.1	0.69	12	3.1	0.41	3.6	0.47
Chronic myeloid	6	2.2	0.40	2.4	0.45	6	1.6	0.31	1.7	0.32
Other leukemias	4	1.9	0.42	2.1	0.48	4	1.0	0.23	1.2	0.27
Mesothelioma	1	0.7	0.27	0.8	0.31	-	-	-	-	-
Kaposi Sarcoma	3	0.7	0.20	0.8	0.22	-	-	-	-	-
Ill-defined & Unknown	43	16.3	1.19	19.0	1.37	48	12.8	0.84	15.1	0.98
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	28	10.2	0.92	11.7	1.05	73	19.4	1.03	22.2	1.17
Breast (<i>in situ</i>)	-	-	-	-	-	130	33.5	1.34	39.7	1.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, Asian/Pacific Islander (API)**

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	103	243.1	11.58	286.2	13.60	165	278.3	10.15	324.4	11.83
Oral Cavity & Pharynx	3	7.0	1.84	8.5	2.25	3	5.9	1.56	6.9	1.83
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	34	82.7	6.75	96.8	7.88	29	55.2	4.79	65.2	5.60
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	4	9.7	2.42	10.9	2.76	4	7.4	1.77	8.8	2.06
Small intestine	1	3.5	1.40	4.1	1.62	-	-	-	-	-
Colon excl. rectum	10	24.1	3.69	27.5	4.22	9	18.0	2.79	21.0	3.24
Rectum & rectosigmoid	3	8.6	2.31	10.4	2.79	5	9.2	1.85	11.2	2.25
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	19.1	3.08	22.2	3.56	4	6.9	1.67	8.2	1.94
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	4	8.8	2.01	10.5	2.37	4	7.4	1.82	8.5	2.06
Respiratory System	17	44.9	5.19	53.0	6.08	15	28.4	3.47	34.6	4.13
Larynx	2	4.2	1.60	5.3	1.93	-	-	-	-	-
Lung & bronchus	15	38.3	4.77	45.2	5.57	15	28.1	3.45	34.4	4.12
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	2	4.1	1.60	4.5	1.78	2	2.3	0.89	2.4	0.97
Melanomas of the skin	-	-	-	-	-	1	1.8	0.67	1.7	0.66
Breast (excl. <i>in situ</i>)	-	-	-	-	-	59	94.2	5.68	110.2	6.67
Female Genital System	-	-	-	-	-	22	32.4	3.18	38.1	3.77
Cervix uteri	-	-	-	-	-	5	7.0	1.41	7.5	1.55
Uterus Corpus	-	-	-	-	-	9	12.9	1.99	15.8	2.45
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	8.7	1.63	10.4	1.98
Male Genital System	16	38.3	4.60	46.2	5.48	-	-	-	-	-
Prostate	15	36.4	4.49	44.3	5.37	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	9	19.4	3.11	24.0	3.80	6	12.6	2.36	14.6	2.71
Bladder (incl. <i>in situ</i>)	4	10.4	2.44	13.0	2.99	3	7.2	1.88	8.5	2.17
Kidney & renal pelvis	4	8.1	1.81	9.9	2.22	2	4.1	1.21	4.7	1.38
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	4.7	1.47	4.8	1.58	1	1.8	0.70	2.0	0.76
Brain	2	4.4	1.45	4.6	1.56	1	1.5	0.63	1.6	0.69
Endocrine System	3	5.3	1.47	5.7	1.66	11	16.9	2.31	18.1	2.51
Thyroid gland	3	5.0	1.45	5.5	1.64	11	16.9	2.31	18.1	2.51
Lymphomas	7	12.2	2.20	14.8	2.72	6	10.2	1.87	12.5	2.28
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	5.1	1.81	6.2	2.15	-	-	-	-	-
Leukemias	2	4.6	1.76	5.0	2.03	3	4.6	1.17	4.5	1.18
Acute lymphocytic	-	-	-	-	-	1	1.9	0.72	1.6	0.60
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	1	2.2	0.82	2.3	0.91
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	9.8	2.54	11.3	2.93	5	10.9	2.24	12.1	2.51
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	7.6	2.09	8.9	2.40	7	11.6	2.05	13.6	2.40
Breast (<i>in situ</i>)	-	-	-	-	-	15	23.5	2.79	27.3	3.24

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

MISSOURI

II-296 Incidence – API

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	170	271.0	10.46	319.1	12.10	191	276.3	9.53	321.2	11.06
Oral Cavity & Pharynx	5	8.7	1.90	9.6	2.06	2	3.0	0.95	3.8	1.20
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.5	0.96	3.1	1.16	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	42	68.7	5.21	82.2	6.10	30	47.9	4.13	55.6	4.74
Esophagus	3	5.0	1.44	5.7	1.64	-	-	-	-	-
Stomach	6	8.6	1.76	10.5	2.15	3	4.4	1.24	5.0	1.41
Small intestine	-	-	-	-	-	1	1.7	0.74	2.0	0.87
Colon excl. rectum	10	17.6	2.75	19.9	3.08	11	18.3	2.57	21.2	2.95
Rectum & rectosigmoid	9	12.3	2.04	15.0	2.46	5	7.7	1.59	8.8	1.82
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	12.9	2.17	16.8	2.69	2	2.7	1.01	3.1	1.15
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	7.3	1.90	8.2	2.08	4	6.1	1.50	7.1	1.73
Respiratory System	19	36.4	4.10	42.4	4.64	19	33.3	3.58	38.9	4.09
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	17	33.4	3.96	38.9	4.47	18	32.7	3.55	38.2	4.05
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.5	0.99	2.6	1.04	3	3.3	1.05	3.6	1.15
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	4	6.2	1.61	7.2	1.86	2	2.7	0.90	3.4	1.14
Breast (excl. <i>in situ</i>)	-	-	-	-	-	52	75.1	4.92	87.5	5.72
Female Genital System	-	-	-	-	-	28	36.6	3.27	43.6	3.93
Cervix uteri	-	-	-	-	-	6	8.1	1.55	9.1	1.77
Uterus Corpus	-	-	-	-	-	14	18.3	2.24	22.0	2.74
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	7.0	1.52	8.5	1.82
Male Genital System	38	60.3	4.87	72.9	5.72	-	-	-	-	-
Prostate	31	54.7	4.78	67.2	5.63	-	-	-	-	-
Testis	7	5.1	0.87	5.1	0.87	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	22	34.3	3.65	41.2	4.31	12	18.0	2.49	21.4	2.92
Bladder (incl. <i>in situ</i>)	8	15.2	2.59	18.8	3.11	2	3.0	1.06	3.5	1.22
Kidney & renal pelvis	13	18.4	2.52	21.6	2.92	9	13.4	2.11	16.2	2.51
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	4.4	0.95	4.8	1.14	3	2.9	0.80	3.1	0.92
Brain	5	4.3	0.95	4.7	1.13	3	2.7	0.79	2.9	0.91
Endocrine System	3	4.0	1.17	4.6	1.32	16	17.6	2.08	19.1	2.36
Thyroid gland	3	3.2	1.02	3.7	1.14	16	17.4	2.07	18.9	2.35
Lymphomas	10	17.4	2.81	19.3	3.12	9	13.1	2.04	15.9	2.46
Hodgkin Lymphoma	2	1.3	0.51	1.4	0.61	2	1.9	0.73	2.2	0.86
Non-Hodgkin Lymphoma	9	16.1	2.77	17.9	3.07	8	11.2	1.91	13.7	2.30
Multiple Myeloma	3	4.8	1.32	5.5	1.54	2	3.1	1.09	3.7	1.25
Leukemias	7	8.2	1.58	9.3	1.91	7	8.2	1.59	8.8	1.74
Acute lymphocytic	3	2.1	0.58	2.0	0.59	2	1.5	0.50	1.6	0.58
Chronic lymphocytic	-	-	-	-	-	1	2.6	1.05	2.9	1.13
Acute myeloid	2	2.5	0.96	2.8	1.13	3	3.4	0.95	3.6	1.06
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	2.7	1.17	3.2	1.33	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	10.8	2.26	12.3	2.57	5	8.7	1.84	9.9	2.08
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	5	6.2	1.47	7.2	1.71	10	13.8	2.06	15.7	2.38
Breast (<i>in situ</i>)	-	-	-	-	-	14	20.2	2.52	23.7	2.95

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MISSOURI

II-298 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	14,733	490.6	1.85	582.3	2.16	14,564	436.6	1.69	509.8	1.92
Oral Cavity & Pharynx	630	20.3	0.37	25.0	0.45	230	6.7	0.20	8.0	0.24
Lip	23	0.8	0.08	0.9	0.09	9	0.2	0.04	0.3	0.04
Tongue	203	6.5	0.21	8.0	0.25	70	2.1	0.12	2.5	0.14
Major salivary gland	46	1.6	0.11	1.9	0.12	28	0.9	0.08	1.0	0.09
Floor of mouth	26	0.8	0.07	1.0	0.09	13	0.4	0.05	0.5	0.06
Gum & other mouth	66	2.2	0.12	2.6	0.14	50	1.4	0.09	1.6	0.10
Nasopharynx	18	0.6	0.07	0.7	0.08	10	0.3	0.04	0.4	0.05
Oropharynx	36	1.1	0.08	1.4	0.10	7	0.2	0.03	0.3	0.04
Hypopharynx	35	1.1	0.08	1.4	0.10	8	0.2	0.03	0.3	0.04
Digestive System	2,871	96.2	0.82	114.8	0.97	2,207	63.0	0.62	74.0	0.72
Esophagus	285	9.3	0.25	11.3	0.30	69	1.9	0.10	2.2	0.12
Stomach	214	7.3	0.23	8.5	0.26	106	3.1	0.14	3.6	0.16
Small intestine	79	2.7	0.14	3.1	0.16	73	2.2	0.12	2.6	0.14
Colon excl. rectum	934	32.3	0.48	37.8	0.56	927	26.4	0.40	30.7	0.46
Rectum & rectosigmoid	434	14.6	0.32	17.5	0.38	274	8.3	0.24	9.8	0.27
Anus, anal canal & anorectum	45	1.5	0.10	1.8	0.12	95	2.8	0.13	3.4	0.16
Liver	288	8.9	0.24	11.2	0.30	94	2.6	0.12	3.2	0.15
Gallbladder	21	0.7	0.07	0.8	0.08	36	1.0	0.07	1.1	0.09
Pancreas	429	14.3	0.31	17.0	0.37	377	10.4	0.25	12.3	0.29
Respiratory System	2,779	91.1	0.79	108.6	0.93	2,390	66.4	0.62	79.4	0.74
Larynx	201	6.4	0.21	7.9	0.25	59	1.7	0.10	2.1	0.12
Lung & bronchus	2,545	83.6	0.76	99.4	0.89	2,311	64.1	0.61	76.6	0.72
Bones & Joints	30	1.2	0.10	1.2	0.10	23	0.8	0.08	0.9	0.08
Soft Tissue (incl. heart)	104	3.8	0.17	4.2	0.19	76	2.5	0.13	2.7	0.14
Skin (excl. basal & sq.)	839	29.1	0.46	33.9	0.53	563	19.0	0.38	21.1	0.41
Melanomas of the skin	788	27.3	0.45	31.8	0.51	535	18.2	0.37	20.2	0.40
Breast (excl. <i>in situ</i>)	32	1.1	0.09	1.3	0.10	4,288	131.3	0.94	154.6	1.08
Female Genital System	-	-	-	-	-	1,660	50.9	0.59	60.0	0.67
Cervix uteri	-	-	-	-	-	207	8.0	0.26	8.5	0.27
Uterus Corpus	-	-	-	-	-	911	26.5	0.41	32.3	0.49
Uterus, NOS ¹	-	-	-	-	-	24	0.7	0.06	0.8	0.08
Ovary	-	-	-	-	-	332	10.2	0.26	11.9	0.30
Male Genital System	3,005	94.2	0.79	115.1	0.94	-	-	-	-	-
Prostate	2,836	87.0	0.74	107.7	0.91	-	-	-	-	-
Testis	140	6.2	0.24	6.1	0.23	-	-	-	-	-
Penis	23	0.8	0.08	0.9	0.09	-	-	-	-	-
Urinary System	1,864	63.1	0.67	74.3	0.78	786	22.7	0.38	26.6	0.43
Bladder (incl. <i>in situ</i>)	1,069	36.4	0.51	42.6	0.59	307	8.4	0.22	9.9	0.26
Kidney & renal pelvis	755	25.3	0.42	30.1	0.49	452	13.5	0.30	15.9	0.34
Ureter	27	0.9	0.08	1.1	0.09	21	0.6	0.06	0.7	0.06
Eye & Orbit	34	1.2	0.10	1.4	0.11	23	0.7	0.07	0.8	0.08
Brain & Other CNS ¹	228	8.4	0.26	9.2	0.27	184	6.2	0.21	6.7	0.22
Brain	218	7.9	0.25	8.8	0.27	172	5.7	0.21	6.2	0.22
Endocrine System	202	7.5	0.24	8.3	0.26	506	18.9	0.40	20.4	0.41
Thyroid gland	184	6.8	0.23	7.6	0.25	491	18.3	0.39	19.8	0.41
Lymphomas	761	26.5	0.44	30.6	0.50	613	18.4	0.35	21.1	0.39
Hodgkin Lymphoma	79	3.1	0.16	3.3	0.17	64	2.5	0.14	2.6	0.15
Non-Hodgkin Lymphoma	682	23.3	0.41	27.3	0.47	549	15.9	0.31	18.5	0.36
Multiple Myeloma	232	7.8	0.24	9.2	0.27	162	4.5	0.16	5.3	0.19
Leukemias	528	18.5	0.37	21.2	0.42	358	11.0	0.27	12.3	0.30
Acute lymphocytic	37	1.6	0.12	1.5	0.11	30	1.2	0.11	1.2	0.10
Chronic lymphocytic	190	6.2	0.21	7.5	0.24	117	3.2	0.14	3.9	0.16
Acute myeloid	164	5.8	0.21	6.6	0.23	120	3.7	0.16	4.2	0.17
Chronic myeloid	68	2.5	0.14	2.8	0.15	44	1.4	0.10	1.6	0.11
Other leukemias	69	2.5	0.14	2.9	0.15	48	1.4	0.09	1.5	0.10
Mesothelioma	39	1.4	0.10	1.6	0.11	13	0.4	0.05	0.4	0.06
Kaposi Sarcoma	5	0.2	0.04	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	547	19.0	0.37	22.2	0.43	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	243	8.9	0.26	10.0	0.29	509	15.9	0.33	18.2	0.37
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.02	860	26.8	0.43	31.9	0.49

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Missouri, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,577	549.5	6.58	664.1	7.75	1,685	438.5	4.88	519.1	5.68
Oral Cavity & Pharynx	50	16.2	1.08	19.7	1.27	21	5.2	0.52	6.2	0.62
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	10	3.1	0.47	3.9	0.57	5	1.2	0.25	1.4	0.30
Major salivary gland	4	1.5	0.35	1.7	0.39	4	0.9	0.22	1.2	0.27
Floor of mouth	2	0.7	0.21	0.9	0.27	2	0.4	0.15	0.6	0.19
Gum & other mouth	5	1.5	0.32	1.8	0.40	3	0.7	0.19	0.8	0.22
Nasopharynx	4	1.4	0.32	1.5	0.34	2	0.5	0.16	0.6	0.18
Oropharynx	6	1.9	0.38	2.3	0.44	-	-	-	-	-
Hypopharynx	6	2.0	0.38	2.4	0.45	1	0.4	0.15	0.4	0.17
Digestive System	370	131.0	3.24	158.4	3.82	330	86.2	2.17	103.0	2.54
Esophagus	17	6.2	0.71	7.6	0.84	11	2.8	0.38	3.5	0.47
Stomach	33	12.6	1.04	15.0	1.21	24	6.5	0.60	7.7	0.70
Small intestine	15	5.1	0.63	6.1	0.74	16	4.2	0.49	5.0	0.56
Colon excl. rectum	104	38.2	1.79	45.5	2.08	116	30.6	1.30	36.2	1.51
Rectum & rectosigmoid	42	14.8	1.08	17.6	1.26	40	10.3	0.74	12.5	0.88
Anus, anal canal & anorectum	7	2.2	0.40	2.6	0.46	9	2.5	0.37	3.0	0.43
Liver	70	21.7	1.21	27.8	1.51	22	5.3	0.52	6.6	0.63
Gallbladder	4	1.5	0.36	1.7	0.42	9	2.5	0.37	3.0	0.44
Pancreas	63	23.5	1.40	28.3	1.65	62	16.2	0.94	19.4	1.11
Respiratory System	304	111.5	3.05	134.0	3.56	261	67.2	1.90	81.5	2.27
Larynx	30	10.2	0.88	12.4	1.04	9	2.2	0.32	2.8	0.41
Lung & bronchus	269	99.8	2.90	119.7	3.38	250	64.6	1.87	78.3	2.22
Bones & Joints	3	0.7	0.20	0.8	0.23	3	0.7	0.19	0.7	0.20
Soft Tissue (incl. heart)	12	3.8	0.51	4.3	0.58	13	3.4	0.43	3.8	0.47
Skin (excl. basal & sq.)	4	1.6	0.37	1.8	0.41	4	1.0	0.24	1.2	0.26
Melanomas of the skin	2	1.0	0.31	1.2	0.36	2	0.4	0.16	0.5	0.18
Breast (excl. <i>in situ</i>)	5	2.0	0.43	2.3	0.50	523	136.9	2.74	161.1	3.16
Female Genital System	-	-	-	-	-	180	46.1	1.57	54.8	1.83
Cervix uteri	-	-	-	-	-	33	9.0	0.71	9.9	0.77
Uterus Corpus	-	-	-	-	-	98	24.6	1.14	30.0	1.36
Uterus, NOS ¹	-	-	-	-	-	6	1.5	0.28	1.9	0.34
Ovary	-	-	-	-	-	29	7.6	0.64	8.9	0.74
Male Genital System	467	151.7	3.31	190.0	4.03	-	-	-	-	-
Prostate	457	148.4	3.28	186.5	3.99	-	-	-	-	-
Testis	6	1.8	0.35	1.8	0.34	-	-	-	-	-
Penis	2	1.0	0.30	1.2	0.35	-	-	-	-	-
Urinary System	139	51.4	2.07	61.0	2.41	97	25.1	1.17	30.0	1.37
Bladder (incl. <i>in situ</i>)	54	22.1	1.43	26.0	1.65	30	7.9	0.65	9.5	0.78
Kidney & renal pelvis	83	28.3	1.47	33.8	1.71	64	16.6	0.95	19.7	1.11
Ureter	1	0.5	0.22	0.6	0.24	-	-	-	-	-
Eye & Orbit	2	0.5	0.18	0.6	0.19	1	0.3	0.12	0.2	0.10
Brain & Other CNS ¹	16	5.1	0.61	5.5	0.67	14	3.5	0.43	3.7	0.46
Brain	15	4.8	0.59	5.3	0.65	12	3.1	0.41	3.3	0.43
Endocrine System	14	4.5	0.56	5.2	0.65	49	12.8	0.83	14.5	0.94
Thyroid gland	10	3.4	0.49	4.0	0.58	45	11.8	0.80	13.5	0.90
Lymphomas	61	20.1	1.22	23.1	1.39	60	15.5	0.92	17.9	1.04
Hodgkin Lymphoma	10	2.8	0.41	2.9	0.43	10	2.6	0.38	2.6	0.38
Non-Hodgkin Lymphoma	51	17.3	1.15	20.2	1.32	50	13.0	0.84	15.3	0.97
Multiple Myeloma	43	16.4	1.19	19.5	1.38	45	12.1	0.82	14.3	0.95
Leukemias	41	14.9	1.11	17.0	1.25	36	9.4	0.72	10.7	0.81
Acute lymphocytic	3	0.9	0.23	0.8	0.21	3	0.7	0.18	0.7	0.18
Chronic lymphocytic	15	5.3	0.66	6.5	0.78	11	2.9	0.40	3.5	0.47
Acute myeloid	12	4.6	0.63	5.1	0.69	12	3.1	0.41	3.6	0.47
Chronic myeloid	6	2.2	0.41	2.5	0.45	6	1.6	0.32	1.7	0.33
Other leukemias	4	1.9	0.42	2.2	0.48	4	1.0	0.23	1.2	0.27
Mesothelioma	1	0.7	0.28	0.8	0.32	-	-	-	-	-
Kaposi Sarcoma	3	0.7	0.20	0.8	0.22	-	-	-	-	-
Ill-defined & Unknown	43	16.5	1.20	19.2	1.38	48	12.7	0.84	15.0	0.98
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	28	10.3	0.93	11.9	1.06	72	19.1	1.03	22.1	1.17
Breast (<i>in situ</i>)	-	-	-	-	-	130	33.8	1.36	39.9	1.57

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


MISSOURI

II-300 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,013,564	1,021,891	1,030,503	1,040,863	1,053,090
White	921,882	928,453	935,562	944,041	954,366
Black	8,754	8,977	9,273	9,642	10,069
American Indian/Alaskan Native (AI/AN)	73,063	74,183	75,031	75,929	76,956
Asian/Pacific Islander (API)	9,865	10,278	10,637	11,251	11,699


All Races Population 2013-2017: 5,159,911
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	33,907	35,635	37,356	38,895	40,849
Non-Hispanic White	895,015	900,363	906,251	913,541	922,200
Non-Hispanic Black	7,880	8,067	8,319	8,657	9,038

Hispanic/Latino Population, Census 2010: 28,565
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MONTANA CANCER REGISTRY

Initial Operation: 1979
 Population-based Data Available: 1979
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.2	106.0	107.7	110.9	108.1
Missing Race	0.5	0.6	0.5	0.7	1.3
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.1	1.8	2.1	1.2	1.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.5	Prostate	95.6
Oral Cavity & Pharynx	97.4	Testis	100.0
Esophagus	94.5	Bladder (incl. <i>in situ</i>)	97.9
Stomach	97.6	Kidney & Renal Pelvis	89.7
Colon & Rectum	95.8	Brain & Other CNS ¹	81.2
Liver	55.9	Thyroid	99.5
Pancreas	80.7	Hodgkin Lymphoma	98.4
Lung & Bronchus	86.6	Non-Hodgkin Lymphoma	96.7
Melanomas of the Skin	99.7	Multiple Myeloma	89.6
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	87.5
Cervix uteri	97.3	Brain & Other CNS ¹ <i>non-malig</i>	43.7
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	91.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,208	490.5	4.02	580.5	4.66	2,888	435.4	3.80	506.5	4.29
Oral Cavity & Pharynx	114	17.3	0.75	21.0	0.90	43	6.4	0.46	7.5	0.53
Lip	8	1.3	0.21	1.5	0.24	2	0.3	0.08	0.3	0.10
Tongue	35	5.2	0.41	6.3	0.48	15	2.3	0.28	2.7	0.32
Major salivary gland	10	1.5	0.22	1.8	0.26	5	0.8	0.17	1.0	0.19
Floor of mouth	5	0.7	0.16	0.9	0.18	3	0.4	0.10	0.5	0.13
Gum & other mouth	15	2.3	0.27	2.7	0.32	6	0.9	0.17	1.1	0.19
Nasopharynx	2	0.4	0.11	0.4	0.13	-	-	-	-	-
Oropharynx	5	0.9	0.18	1.1	0.21	2	0.3	0.09	0.4	0.12
Hypopharynx	5	0.7	0.15	0.9	0.19	1	0.2	0.08	0.3	0.10
Digestive System	586	90.7	1.74	107.9	2.03	426	61.6	1.39	72.6	1.60
Esophagus	56	8.5	0.53	10.2	0.62	13	1.8	0.23	2.1	0.27
Stomach	43	6.7	0.47	7.9	0.55	23	3.3	0.32	3.9	0.38
Small intestine	19	2.8	0.30	3.4	0.35	15	2.1	0.26	2.5	0.30
Colon excl. rectum	190	30.0	1.01	35.5	1.17	166	24.2	0.88	28.3	1.00
Rectum & rectosigmoid	93	14.6	0.71	17.5	0.83	54	8.2	0.52	9.8	0.60
Anus, anal canal & anorectum	8	1.3	0.21	1.5	0.25	18	2.6	0.29	3.2	0.35
Liver	62	8.8	0.52	10.9	0.63	18	2.5	0.27	3.0	0.32
Gallbladder	3	0.5	0.13	0.6	0.15	9	1.3	0.20	1.5	0.23
Pancreas	87	13.3	0.66	15.7	0.77	79	11.0	0.57	12.9	0.66
Respiratory System	384	58.9	1.38	69.3	1.61	401	56.2	1.28	66.3	1.50
Larynx	30	4.5	0.38	5.5	0.45	7	1.0	0.19	1.2	0.22
Lung & bronchus	347	53.3	1.31	62.5	1.52	391	54.7	1.26	64.6	1.48
Bones & Joints	6	1.0	0.19	1.2	0.21	8	1.5	0.25	1.5	0.24
Soft Tissue (incl. heart)	18	3.0	0.32	3.4	0.36	19	3.2	0.35	3.4	0.36
Skin (excl. basal & sq.)	222	35.6	1.11	41.3	1.26	162	26.3	0.98	29.9	1.08
Melanomas of the skin	196	31.4	1.05	36.4	1.18	149	24.4	0.95	27.8	1.04
Breast (excl. <i>in situ</i>)	10	1.6	0.24	1.8	0.27	845	128.5	2.08	150.9	2.37
Female Genital System	-	-	-	-	-	324	49.0	1.29	57.7	1.46
Cervix uteri	-	-	-	-	-	37	6.8	0.53	7.4	0.55
Uterus Corpus	-	-	-	-	-	187	27.0	0.93	32.5	1.08
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	73	11.3	0.62	13.2	0.70
Male Genital System	892	126.9	1.96	154.0	2.34	-	-	-	-	-
Prostate	850	118.3	1.87	145.5	2.26	-	-	-	-	-
Testis	34	7.2	0.57	6.9	0.54	-	-	-	-	-
Penis	6	1.0	0.19	1.2	0.21	-	-	-	-	-
Urinary System	383	59.5	1.41	69.9	1.62	154	22.4	0.84	26.2	0.96
Bladder (incl. <i>in situ</i>)	232	36.1	1.09	42.5	1.27	73	10.1	0.55	12.0	0.64
Kidney & renal pelvis	144	22.2	0.87	26.1	0.99	78	11.9	0.63	13.6	0.70
Ureter	6	0.9	0.18	1.1	0.21	1	0.2	0.08	0.2	0.09
Eye & Orbit	7	1.1	0.20	1.2	0.22	7	1.0	0.19	1.2	0.22
Brain & Other CNS ¹	51	8.3	0.55	9.5	0.61	38	6.4	0.49	7.0	0.52
Brain	48	7.8	0.53	9.0	0.59	36	6.0	0.47	6.7	0.50
Endocrine System	49	8.6	0.57	9.5	0.62	114	21.4	0.94	22.8	0.97
Thyroid gland	45	7.7	0.54	8.7	0.59	108	20.5	0.92	21.9	0.95
Lymphomas	155	25.2	0.94	28.8	1.05	115	17.5	0.76	19.9	0.84
Hodgkin Lymphoma	14	2.6	0.33	2.7	0.33	11	2.1	0.28	2.1	0.29
Non-Hodgkin Lymphoma	141	22.6	0.88	26.1	1.00	104	15.4	0.70	17.8	0.79
Multiple Myeloma	56	8.7	0.54	10.2	0.62	36	5.0	0.38	6.0	0.45
Leukemias	123	19.7	0.82	22.8	0.93	72	10.9	0.60	12.3	0.66
Acute lymphocytic	7	1.4	0.24	1.3	0.22	6	1.1	0.22	1.0	0.19
Chronic lymphocytic	59	9.1	0.54	10.9	0.64	32	4.4	0.36	5.3	0.42
Acute myeloid	27	4.3	0.38	4.9	0.43	20	3.1	0.33	3.6	0.36
Chronic myeloid	15	2.6	0.31	2.9	0.34	8	1.2	0.21	1.4	0.23
Other leukemias	15	2.4	0.29	2.8	0.33	6	0.9	0.18	1.1	0.19
Mesothelioma	14	2.3	0.28	2.7	0.33	4	0.7	0.16	0.8	0.17
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	121	17.4	0.74	20.1	0.83
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	54	9.1	0.58	10.3	0.63	100	15.7	0.74	18.1	0.83
Breast (<i>in situ</i>)	-	-	-	-	-	172	27.2	0.98	32.0	1.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	3,024	483.9	4.09	572.7	4.74	2,702	430.2	3.90	500.7	4.40
Oral Cavity & Pharynx	107	17.1	0.77	20.9	0.92	39	6.1	0.46	7.3	0.53
Lip	8	1.3	0.21	1.6	0.25	2	0.2	0.08	0.3	0.09
Tongue	34	5.3	0.42	6.4	0.50	14	2.3	0.29	2.7	0.33
Major salivary gland	10	1.5	0.23	1.8	0.27	5	0.7	0.17	0.9	0.18
Floor of mouth	4	0.7	0.15	0.8	0.18	3	0.4	0.10	0.5	0.13
Gum & other mouth	13	2.1	0.27	2.5	0.31	6	0.9	0.16	1.0	0.19
Nasopharynx	2	0.4	0.12	0.5	0.13	-	-	-	-	-
Oropharynx	5	1.0	0.19	1.1	0.22	2	0.3	0.10	0.4	0.13
Hypopharynx	4	0.7	0.15	0.8	0.18	1	0.2	0.07	0.2	0.09
Digestive System	542	87.7	1.75	104.5	2.04	397	60.5	1.42	71.2	1.63
Esophagus	53	8.4	0.53	10.1	0.63	12	1.8	0.24	2.1	0.28
Stomach	39	6.3	0.47	7.4	0.54	20	3.1	0.32	3.7	0.38
Small intestine	18	2.8	0.31	3.3	0.36	14	2.2	0.27	2.6	0.31
Colon excl. rectum	176	29.0	1.01	34.4	1.18	155	23.8	0.90	27.8	1.02
Rectum & rectosigmoid	85	14.1	0.72	16.8	0.83	49	7.9	0.53	9.3	0.61
Anus, anal canal & anorectum	8	1.3	0.22	1.6	0.26	18	2.7	0.30	3.4	0.36
Liver	54	8.2	0.51	10.1	0.62	16	2.3	0.27	2.8	0.32
Gallbladder	3	0.5	0.13	0.6	0.16	8	1.2	0.19	1.4	0.23
Pancreas	83	13.3	0.68	15.6	0.78	75	10.9	0.58	12.9	0.68
Respiratory System	362	57.7	1.40	67.9	1.62	371	54.5	1.30	64.4	1.51
Larynx	28	4.4	0.38	5.3	0.46	6	1.0	0.19	1.2	0.22
Lung & bronchus	327	52.2	1.33	61.3	1.54	362	53.1	1.28	62.7	1.49
Bones & Joints	6	1.1	0.20	1.2	0.22	7	1.4	0.25	1.4	0.25
Soft Tissue (incl. heart)	18	3.2	0.35	3.6	0.38	16	3.0	0.36	3.2	0.36
Skin (excl. basal & sq.)	208	35.0	1.13	40.6	1.28	151	26.0	1.01	29.7	1.11
Melanomas of the skin	182	30.7	1.06	35.6	1.20	138	24.2	0.98	27.5	1.08
Breast (excl. <i>in situ</i>)	9	1.7	0.25	1.9	0.28	795	128.1	2.15	150.4	2.45
Female Genital System	-	-	-	-	-	301	48.0	1.31	56.6	1.49
Cervix uteri	-	-	-	-	-	34	6.7	0.55	7.2	0.57
Uterus Corpus	-	-	-	-	-	173	26.3	0.94	31.8	1.10
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	69	11.2	0.63	13.1	0.72
Male Genital System	842	125.4	2.00	152.2	2.38	-	-	-	-	-
Prostate	803	116.6	1.89	143.5	2.30	-	-	-	-	-
Testis	31	7.3	0.60	7.1	0.57	-	-	-	-	-
Penis	6	1.0	0.20	1.2	0.22	-	-	-	-	-
Urinary System	365	58.9	1.43	69.2	1.65	143	21.8	0.86	25.5	0.97
Bladder (incl. <i>in situ</i>)	227	36.7	1.12	43.2	1.30	71	10.4	0.57	12.3	0.66
Kidney & renal pelvis	130	21.0	0.86	24.6	0.98	69	11.1	0.63	12.8	0.70
Ureter	6	0.9	0.18	1.1	0.21	1	0.2	0.07	0.2	0.08
Eye & Orbit	7	1.2	0.22	1.3	0.23	7	1.1	0.20	1.3	0.24
Brain & Other CNS ¹	48	8.4	0.57	9.7	0.63	36	6.5	0.51	7.2	0.54
Brain	46	8.0	0.55	9.2	0.62	34	6.1	0.49	6.7	0.53
Endocrine System	47	8.6	0.59	9.6	0.64	107	21.8	0.99	23.3	1.03
Thyroid gland	42	7.7	0.56	8.7	0.61	102	20.8	0.97	22.3	1.01
Lymphomas	147	25.1	0.97	28.8	1.08	111	17.6	0.78	20.1	0.87
Hodgkin Lymphoma	13	2.7	0.36	2.7	0.35	11	2.1	0.30	2.2	0.30
Non-Hodgkin Lymphoma	135	22.4	0.90	26.0	1.02	100	15.5	0.72	17.9	0.82
Multiple Myeloma	53	8.6	0.55	10.1	0.63	35	5.1	0.40	6.0	0.46
Leukemias	119	19.9	0.85	23.1	0.96	68	10.8	0.62	12.3	0.68
Acute lymphocytic	6	1.3	0.25	1.2	0.23	5	1.2	0.25	1.1	0.21
Chronic lymphocytic	58	9.3	0.56	11.1	0.66	32	4.5	0.37	5.4	0.43
Acute myeloid	26	4.3	0.39	5.0	0.44	18	3.0	0.33	3.4	0.36
Chronic myeloid	14	2.6	0.32	2.9	0.35	8	1.3	0.22	1.5	0.24
Other leukemias	14	2.5	0.30	2.9	0.34	5	0.8	0.17	1.0	0.19
Mesothelioma	14	2.4	0.28	2.8	0.34	4	0.6	0.15	0.7	0.17
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	115	17.2	0.75	19.9	0.85
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	52	9.3	0.61	10.4	0.66	94	15.8	0.78	18.1	0.86
Breast (<i>in situ</i>)	-	-	-	-	-	163	27.4	1.02	32.3	1.16

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	503.7	85.51	583.9	97.44	4	183.4	44.86	214.6	53.03
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	110.3	39.42	122.2	42.40	-	-	-	-	-
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	60.0	24.63	73.0	30.06
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	194.5	50.77	230.2	58.87	-	-	-	-	-
Prostate	3	187.6	50.29	224.4	58.57	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	43.9	21.21	54.9	25.15	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	293.0	46.18	360.4	55.93	16	311.9	36.36	346.7	40.01
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	92.1	25.27	112.9	30.43	2	43.0	14.18	46.3	15.24
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	29.2	12.47	39.7	17.12	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	44.0	19.22	54.5	23.00	2	43.0	14.22	48.6	15.62
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	2	37.8	13.24	43.2	14.64
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	6	110.8	20.61	128.4	23.51
Female Genital System	-	-	-	-	-	2	31.8	11.63	32.8	11.98
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	2	49.5	18.26	66.5	24.09	-	-	-	-	-
Prostate	2	49.5	18.26	66.5	24.09	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	1	25.7	10.94	28.9	12.13
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	2	31.3	11.50	33.3	12.11

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	106	548.0	26.76	650.1	30.92	118	509.8	22.19	592.7	25.40
Oral Cavity & Pharynx	4	20.7	5.19	24.8	6.10	2	10.0	3.15	11.7	3.59
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	28	146.0	14.02	173.9	16.21	21	92.1	9.46	110.1	11.01
Esophagus	2	9.9	3.30	11.7	3.78	-	-	-	-	-
Stomach	4	14.3	3.43	17.8	4.23	1	5.7	2.25	7.0	2.67
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	45.7	8.32	53.9	9.68	9	39.3	6.07	46.8	7.03
Rectum & rectosigmoid	6	32.0	6.61	37.1	7.39	4	15.7	3.87	19.4	4.67
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	20.2	4.82	24.4	5.52	1	3.6	1.50	4.8	2.06
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	14.3	4.56	17.6	5.36	3	15.4	4.25	17.8	4.85
Respiratory System	15	84.5	10.65	99.8	12.09	18	90.5	10.18	105.8	11.73
Larynx	1	5.2	2.01	7.0	2.64	-	-	-	-	-
Lung & bronchus	14	78.0	10.38	91.5	11.72	17	87.9	10.06	102.8	11.59
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	2	7.2	2.65	8.1	3.04
Skin (excl. basal & sq.)	2	10.6	3.60	13.3	4.35	-	-	-	-	-
Melanomas of the skin	2	8.6	3.40	10.3	3.97	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	32	134.6	11.19	160.3	13.07
Female Genital System	-	-	-	-	-	15	59.1	7.20	68.6	8.22
Cervix uteri	-	-	-	-	-	2	5.9	2.13	6.1	2.21
Uterus Corpus	-	-	-	-	-	8	31.7	5.21	38.3	6.18
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	13.2	3.46	15.1	3.86
Male Genital System	25	117.5	11.66	143.8	13.94	-	-	-	-	-
Prostate	23	109.8	11.39	136.4	13.73	-	-	-	-	-
Testis	2	7.1	2.45	6.5	2.19	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	13	71.4	10.27	85.3	12.06	8	35.5	5.69	40.2	6.34
Bladder (incl. <i>in situ</i>)	3	21.1	6.42	25.5	7.61	1	5.3	2.08	6.7	2.55
Kidney & renal pelvis	10	50.3	8.02	59.8	9.36	7	30.2	5.30	33.5	5.81
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	2	8.3	3.10	9.6	3.48	2	4.8	1.73	5.1	1.88
Brain	2	7.5	2.99	8.6	3.31	2	4.8	1.73	5.1	1.88
Endocrine System	2	7.8	2.64	8.6	2.91	5	18.5	3.89	19.8	4.14
Thyroid gland	2	6.7	2.41	7.7	2.76	4	17.2	3.78	18.0	3.95
Lymphomas	5	28.3	6.31	31.3	6.87	3	14.8	3.76	15.2	3.92
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	5	26.5	6.16	29.3	6.71	3	13.6	3.67	14.0	3.83
Multiple Myeloma	2	9.1	3.19	10.8	3.67	1	5.4	2.16	6.9	2.63
Leukemias	3	15.0	4.43	17.3	5.01	3	9.8	2.80	11.4	3.20
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	1	4.9	1.96	5.6	2.21
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	26.8	6.02	29.2	6.50	4	16.9	4.14	18.2	4.42
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	-	-	-	-	-	3	12.8	3.40	14.5	3.82
Breast (<i>in situ</i>)	-	-	-	-	-	6	23.5	4.62	27.3	5.24

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	39	412.2	32.81	489.2	37.82	45	390.1	27.41	456.4	31.73
Oral Cavity & Pharynx	2	14.5	5.40	18.3	6.60	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	10	105.1	16.17	126.3	18.88	7	62.6	11.20	75.9	13.25
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	26.2	8.43	31.6	9.99	2	16.6	5.37	20.8	6.62
Rectum & rectosigmoid	3	27.5	8.07	34.7	9.74	1	13.9	5.51	16.2	6.31
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	17.4	5.71	21.8	7.08	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	17.2	7.07	19.2	7.79	1	13.7	5.34	16.0	6.15
Respiratory System	2	27.4	9.01	31.3	9.92	4	42.1	9.57	49.2	11.01
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	25.9	8.89	29.1	9.67	4	40.6	9.46	48.1	10.95
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	4	31.2	7.00	36.8	8.33
Breast (excl. <i>in situ</i>)	-	-	-	-	-	13	109.6	14.33	127.8	16.50
Female Genital System	-	-	-	-	-	5	39.9	8.83	44.5	9.83
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	24.0	7.24	26.8	7.99
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	9.5	4.11	11.3	4.90
Male Genital System	9	87.3	14.48	108.7	17.38	-	-	-	-	-
Prostate	8	86.1	14.42	107.6	17.35	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	58.5	12.11	69.0	13.89	2	18.4	6.36	21.5	7.36
Bladder (incl. <i>in situ</i>)	2	19.1	6.88	23.3	8.15	-	-	-	-	-
Kidney & renal pelvis	4	39.4	9.97	45.6	11.25	1	14.7	5.76	17.0	6.63
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	1	7.1	3.12	7.4	3.47
Brain	-	-	-	-	-	1	6.5	3.06	6.9	3.44
Endocrine System	-	-	-	-	-	2	15.0	4.90	18.0	5.82
Thyroid gland	-	-	-	-	-	2	13.6	4.72	15.9	5.46
Lymphomas	2	24.6	8.28	28.8	9.51	2	16.6	5.49	19.4	6.46
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	22.6	8.10	24.2	8.73	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	23.3	9.52	24.5	10.02	2	22.2	6.99	27.0	8.28
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	15.6	6.54	18.1	7.62	1	10.2	4.25	11.9	4.96
Breast (<i>in situ</i>)	-	-	-	-	-	1	8.6	3.54	10.8	4.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

MONTANA

II-308 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,988	484.9	4.13	573.8	4.78	2,661	430.3	3.94	500.7	4.45
Oral Cavity & Pharynx	106	17.2	0.78	20.9	0.93	39	6.1	0.46	7.3	0.54
Lip	8	1.3	0.22	1.6	0.26	2	0.2	0.08	0.3	0.09
Tongue	34	5.3	0.43	6.5	0.51	14	2.4	0.30	2.8	0.34
Major salivary gland	9	1.5	0.23	1.8	0.27	5	0.8	0.17	0.9	0.19
Floor of mouth	4	0.7	0.15	0.8	0.18	3	0.4	0.10	0.5	0.13
Gum & other mouth	13	2.1	0.27	2.5	0.32	6	0.9	0.17	1.0	0.19
Nasopharynx	2	0.4	0.12	0.5	0.14	-	-	-	-	-
Oropharynx	5	1.0	0.19	1.2	0.23	2	0.3	0.09	0.3	0.12
Hypopharynx	4	0.7	0.15	0.8	0.18	1	0.2	0.07	0.2	0.09
Digestive System	532	87.4	1.76	104.0	2.05	390	60.4	1.43	71.0	1.64
Esophagus	53	8.4	0.54	10.1	0.63	12	1.8	0.24	2.1	0.28
Stomach	38	6.3	0.47	7.4	0.55	20	3.1	0.32	3.7	0.38
Small intestine	18	2.8	0.31	3.3	0.36	14	2.2	0.28	2.7	0.32
Colon excl. rectum	174	29.0	1.02	34.4	1.19	153	23.9	0.91	27.8	1.03
Rectum & rectosigmoid	82	13.9	0.72	16.6	0.84	48	7.8	0.53	9.2	0.61
Anus, anal canal & anorectum	8	1.3	0.22	1.6	0.26	18	2.7	0.30	3.3	0.37
Liver	52	7.9	0.51	9.9	0.62	16	2.3	0.27	2.8	0.32
Gallbladder	3	0.5	0.13	0.6	0.16	8	1.2	0.20	1.4	0.23
Pancreas	81	13.2	0.68	15.6	0.79	73	10.8	0.58	12.8	0.68
Respiratory System	360	58.1	1.41	68.3	1.64	368	54.6	1.31	64.6	1.53
Larynx	28	4.4	0.39	5.4	0.46	6	1.0	0.20	1.3	0.23
Lung & bronchus	325	52.5	1.34	61.6	1.55	359	53.2	1.29	62.9	1.50
Bones & Joints	6	1.1	0.21	1.2	0.23	7	1.4	0.25	1.4	0.25
Soft Tissue (incl. heart)	17	3.1	0.34	3.5	0.38	16	3.1	0.37	3.3	0.37
Skin (excl. basal & sq.)	207	35.4	1.15	41.0	1.30	147	25.8	1.02	29.4	1.12
Melanomas of the skin	182	31.1	1.08	36.1	1.22	134	23.9	0.99	27.2	1.08
Breast (excl. <i>in situ</i>)	9	1.6	0.25	1.9	0.28	783	128.2	2.18	150.4	2.47
Female Genital System	-	-	-	-	-	297	48.1	1.33	56.8	1.51
Cervix uteri	-	-	-	-	-	33	6.7	0.56	7.2	0.57
Uterus Corpus	-	-	-	-	-	171	26.4	0.95	31.9	1.11
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	68	11.2	0.64	13.2	0.73
Male Genital System	834	126.0	2.02	152.9	2.40	-	-	-	-	-
Prostate	795	117.0	1.91	143.9	2.32	-	-	-	-	-
Testis	31	7.5	0.62	7.3	0.59	-	-	-	-	-
Penis	6	1.1	0.20	1.2	0.22	-	-	-	-	-
Urinary System	359	58.8	1.44	69.0	1.66	141	21.9	0.86	25.6	0.98
Bladder (incl. <i>in situ</i>)	225	36.9	1.13	43.3	1.31	70	10.4	0.58	12.4	0.67
Kidney & renal pelvis	127	20.8	0.87	24.3	0.99	68	11.1	0.64	12.7	0.71
Ureter	6	0.9	0.18	1.1	0.21	1	0.2	0.08	0.2	0.09
Eye & Orbit	6	1.2	0.22	1.3	0.23	7	1.1	0.21	1.4	0.24
Brain & Other CNS ¹	48	8.5	0.58	9.8	0.65	35	6.4	0.52	7.1	0.55
Brain	45	8.0	0.56	9.2	0.63	33	6.0	0.50	6.7	0.53
Endocrine System	46	8.6	0.60	9.6	0.65	105	22.0	1.02	23.5	1.05
Thyroid gland	42	7.8	0.57	8.8	0.62	100	21.0	0.99	22.5	1.03
Lymphomas	145	25.2	0.98	28.9	1.09	109	17.6	0.79	20.1	0.88
Hodgkin Lymphoma	13	2.8	0.37	2.8	0.36	10	2.1	0.30	2.2	0.31
Non-Hodgkin Lymphoma	133	22.5	0.91	26.1	1.03	98	15.5	0.73	17.9	0.82
Multiple Myeloma	52	8.6	0.55	10.1	0.64	34	5.0	0.39	6.0	0.46
Leukemias	116	19.8	0.86	23.0	0.97	67	10.9	0.63	12.4	0.69
Acute lymphocytic	5	1.3	0.25	1.2	0.23	5	1.3	0.26	1.1	0.22
Chronic lymphocytic	58	9.3	0.57	11.2	0.67	31	4.5	0.37	5.4	0.44
Acute myeloid	25	4.2	0.39	4.8	0.44	18	3.0	0.34	3.4	0.37
Chronic myeloid	14	2.6	0.32	2.9	0.35	8	1.3	0.22	1.5	0.25
Other leukemias	14	2.5	0.31	2.9	0.35	5	0.8	0.17	0.9	0.19
Mesothelioma	14	2.3	0.28	2.8	0.34	4	0.6	0.15	0.7	0.17
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	50	9.2	0.61	10.3	0.66	93	15.9	0.79	18.2	0.87
Breast (<i>in situ</i>)	-	-	-	-	-	162	27.7	1.04	32.6	1.18

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Montana, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	548.0	93.92	632.9	106.34	3	155.7	43.17	180.0	50.18
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	122.9	44.66	135.4	47.52	-	-	-	-	-
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	66.1	27.18	80.4	33.13
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	206.6	54.38	244.2	62.91	-	-	-	-	-
Prostate	3	198.9	53.83	237.7	62.57	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	46.7	22.48	58.3	26.66	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


MONTANA

II-310 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,865,414	1,879,522	1,891,507	1,905,924	1,917,575
White	1,691,137	1,698,224	1,704,506	1,711,982	1,719,194
Black	102,336	104,963	107,011	109,589	111,208
American Indian/Alaskan Native (AI/AN)	28,051	29,030	29,959	30,802	31,288
Asian/Pacific Islander (API)	43,890	47,305	50,031	53,551	55,885


All Races Population 2013-2017: 9,459,942
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	186,026	191,187	196,668	203,340	209,812
Non-Hispanic White	1,525,320	1,528,393	1,530,134	1,531,956	1,533,304
Non-Hispanic Black	96,253	98,585	100,459	102,724	104,089

Hispanic/Latino Population, Census 2010: 167,405
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEBRASKA CANCER REGISTRY

Initial Operation: 1987
Population-based Data Available: 1987
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.6	105.0	108.1	107.7	108.8
Missing Race	0.7	0.7	0.7	0.5	1.2
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.9	1.5	1.2	1.4	1.3
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.9	Prostate	97.7
Oral Cavity & Pharynx	98.6	Testis	99.1
Esophagus	94.4	Bladder (incl. <i>in situ</i>)	98.1
Stomach	96.9	Kidney & Renal Pelvis	92.4
Colon & Rectum	96.8	Brain & Other CNS ¹	84.4
Liver	63.0	Thyroid	99.4
Pancreas	87.4	Hodgkin Lymphoma	98.3
Lung & Bronchus	90.7	Non-Hodgkin Lymphoma	96.8
Melanomas of the Skin	99.7	Multiple Myeloma	90.8
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	91.6
Cervix uteri	96.4	Brain & Other CNS ¹ <i>non-malig</i>	44.3
Uterus Corpus & Uterus NOS ¹	99.4	Breast <i>in situ</i>	100.0
Ovary	91.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,109	501.9	3.21	595.1	3.74	4,853	433.6	2.88	504.5	3.28
Oral Cavity & Pharynx	195	18.8	0.62	22.9	0.74	78	6.8	0.36	8.0	0.41
Lip	18	1.9	0.20	2.2	0.23	8	0.7	0.11	0.8	0.13
Tongue	56	5.3	0.32	6.4	0.39	22	2.0	0.20	2.4	0.23
Major salivary gland	18	1.9	0.20	2.2	0.23	12	1.1	0.14	1.2	0.16
Floor of mouth	7	0.7	0.12	0.8	0.14	4	0.3	0.08	0.4	0.09
Gum & other mouth	23	2.2	0.21	2.7	0.25	18	1.5	0.17	1.8	0.19
Nasopharynx	7	0.7	0.12	0.8	0.13	3	0.3	0.08	0.3	0.08
Oropharynx	11	1.0	0.13	1.2	0.17	2	0.2	0.05	0.2	0.07
Hypopharynx	11	1.0	0.14	1.3	0.17	3	0.3	0.07	0.3	0.09
Digestive System	960	95.3	1.41	113.1	1.64	780	66.6	1.10	77.9	1.27
Esophagus	84	8.1	0.41	9.8	0.48	21	1.7	0.17	2.0	0.20
Stomach	74	7.4	0.39	8.7	0.46	37	3.2	0.24	3.7	0.28
Small intestine	30	3.0	0.26	3.5	0.29	24	2.2	0.20	2.6	0.23
Colon excl. rectum	326	32.7	0.83	38.6	0.96	331	28.0	0.71	32.3	0.81
Rectum & rectosigmoid	154	15.2	0.56	18.2	0.66	109	9.8	0.44	11.5	0.50
Anus, anal canal & anorectum	13	1.3	0.17	1.6	0.19	27	2.4	0.21	2.9	0.25
Liver	81	7.5	0.38	9.3	0.46	26	2.1	0.19	2.6	0.23
Gallbladder	10	1.0	0.15	1.2	0.17	17	1.4	0.16	1.6	0.18
Pancreas	149	15.0	0.56	17.6	0.65	134	11.3	0.45	13.2	0.52
Respiratory System	716	71.0	1.21	84.0	1.41	624	52.9	0.97	62.8	1.14
Larynx	51	4.7	0.30	5.8	0.37	15	1.3	0.16	1.6	0.18
Lung & bronchus	657	65.4	1.17	77.3	1.35	600	50.8	0.95	60.3	1.11
Bones & Joints	9	0.9	0.14	1.0	0.14	8	0.8	0.13	0.8	0.12
Soft Tissue (incl. heart)	44	4.6	0.32	5.1	0.35	25	2.4	0.22	2.6	0.23
Skin (excl. basal & sq.)	315	32.1	0.83	37.2	0.94	266	26.1	0.75	29.0	0.80
Melanomas of the skin	288	29.2	0.79	34.0	0.90	252	24.8	0.73	27.5	0.78
Breast (excl. <i>in situ</i>)	17	1.6	0.18	1.9	0.21	1,405	127.2	1.57	150.3	1.82
Female Genital System	-	-	-	-	-	563	51.1	1.00	60.3	1.15
Cervix uteri	-	-	-	-	-	72	7.8	0.43	8.4	0.45
Uterus Corpus	-	-	-	-	-	310	27.1	0.71	33.1	0.85
Uterus, NOS ¹	-	-	-	-	-	5	0.4	0.09	0.5	0.11
Ovary	-	-	-	-	-	115	10.6	0.46	12.2	0.51
Male Genital System	1,340	125.1	1.56	152.7	1.87	-	-	-	-	-
Prostate	1,263	116.7	1.50	144.1	1.82	-	-	-	-	-
Testis	64	7.1	0.40	7.0	0.39	-	-	-	-	-
Penis	11	1.1	0.15	1.3	0.18	-	-	-	-	-
Urinary System	604	60.6	1.13	71.4	1.31	251	21.5	0.63	25.2	0.72
Bladder (incl. <i>in situ</i>)	343	35.0	0.86	40.9	0.99	110	8.8	0.39	10.4	0.45
Kidney & renal pelvis	247	24.1	0.70	28.8	0.82	135	12.2	0.49	14.1	0.55
Ureter	8	0.9	0.14	1.0	0.16	4	0.4	0.08	0.4	0.09
Eye & Orbit	12	1.1	0.15	1.3	0.18	10	0.9	0.13	1.0	0.15
Brain & Other CNS ¹	81	8.2	0.41	9.1	0.46	62	5.9	0.35	6.4	0.36
Brain	76	7.6	0.40	8.6	0.44	58	5.4	0.33	5.9	0.35
Endocrine System	81	8.3	0.42	9.2	0.46	218	23.0	0.72	24.8	0.76
Thyroid gland	72	7.4	0.40	8.3	0.44	210	22.3	0.71	24.0	0.75
Lymphomas	277	28.2	0.78	32.5	0.88	222	19.5	0.60	22.6	0.69
Hodgkin Lymphoma	33	3.6	0.28	3.7	0.29	24	2.5	0.23	2.6	0.24
Non-Hodgkin Lymphoma	243	24.7	0.72	28.7	0.83	197	17.0	0.56	20.0	0.65
Multiple Myeloma	80	8.1	0.41	9.5	0.48	55	4.6	0.28	5.5	0.34
Leukemias	180	18.1	0.62	20.7	0.70	123	11.0	0.46	12.2	0.50
Acute lymphocytic	18	1.9	0.20	1.8	0.19	13	1.4	0.18	1.2	0.15
Chronic lymphocytic	64	6.3	0.36	7.5	0.42	38	3.1	0.23	3.7	0.27
Acute myeloid	55	5.6	0.34	6.4	0.39	44	3.9	0.27	4.4	0.30
Chronic myeloid	23	2.3	0.22	2.6	0.25	14	1.3	0.16	1.4	0.17
Other leukemias	20	2.0	0.21	2.3	0.23	15	1.3	0.16	1.4	0.17
Mesothelioma	12	1.3	0.17	1.5	0.19	4	0.4	0.08	0.4	0.10
Kaposi Sarcoma	2	0.2	0.07	0.2	0.06	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	159	12.9	0.47	14.9	0.54
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	73	7.4	0.40	8.3	0.44	146	13.9	0.53	15.5	0.58
Breast (<i>in situ</i>)	2	0.2	0.06	0.2	0.07	289	27.0	0.74	32.0	0.85

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	4,783	495.8	3.28	587.1	3.82	4,575	434.7	2.99	505.2	3.40
Oral Cavity & Pharynx	184	18.7	0.64	22.8	0.76	74	6.9	0.37	8.1	0.43
Lip	17	1.8	0.21	2.1	0.23	8	0.7	0.12	0.8	0.13
Tongue	53	5.3	0.33	6.5	0.40	21	2.1	0.21	2.4	0.24
Major salivary gland	17	1.9	0.20	2.2	0.23	12	1.1	0.15	1.3	0.17
Floor of mouth	7	0.7	0.12	0.8	0.14	3	0.3	0.08	0.4	0.09
Gum & other mouth	22	2.2	0.22	2.7	0.26	17	1.5	0.17	1.7	0.19
Nasopharynx	5	0.5	0.11	0.6	0.13	3	0.3	0.08	0.3	0.08
Oropharynx	10	0.9	0.14	1.2	0.17	2	0.2	0.06	0.2	0.07
Hypopharynx	11	1.0	0.15	1.3	0.18	3	0.3	0.08	0.4	0.09
Digestive System	887	92.9	1.43	110.2	1.66	729	65.7	1.13	76.6	1.29
Esophagus	81	8.2	0.42	10.0	0.50	20	1.7	0.18	2.0	0.21
Stomach	67	7.1	0.39	8.3	0.46	33	3.0	0.24	3.5	0.28
Small intestine	27	2.9	0.26	3.3	0.29	22	2.1	0.21	2.5	0.24
Colon excl. rectum	304	32.1	0.84	37.9	0.98	314	28.0	0.73	32.2	0.83
Rectum & rectosigmoid	146	15.3	0.58	18.2	0.68	102	9.7	0.45	11.4	0.52
Anus, anal canal & anorectum	12	1.2	0.17	1.5	0.19	26	2.4	0.22	2.9	0.26
Liver	64	6.2	0.36	7.8	0.44	21	1.8	0.18	2.2	0.22
Gallbladder	9	1.0	0.15	1.1	0.17	15	1.3	0.15	1.5	0.17
Pancreas	140	14.9	0.58	17.4	0.66	126	11.1	0.46	12.9	0.52
Respiratory System	680	70.5	1.23	83.5	1.44	587	52.3	0.99	62.0	1.16
Larynx	45	4.4	0.30	5.4	0.36	14	1.3	0.16	1.5	0.18
Lung & bronchus	626	65.2	1.19	77.1	1.38	565	50.3	0.97	59.6	1.14
Bones & Joints	9	0.9	0.14	1.0	0.15	7	0.8	0.14	0.7	0.13
Soft Tissue (incl. heart)	40	4.5	0.32	5.0	0.36	23	2.4	0.23	2.5	0.24
Skin (excl. basal & sq.)	303	32.7	0.86	37.9	0.98	252	26.7	0.79	29.5	0.85
Melanomas of the skin	278	29.9	0.82	34.7	0.94	238	25.4	0.77	28.1	0.83
Breast (excl. <i>in situ</i>)	16	1.6	0.18	1.9	0.22	1,336	128.8	1.64	152.0	1.89
Female Genital System	-	-	-	-	-	534	51.8	1.05	61.0	1.20
Cervix uteri	-	-	-	-	-	66	7.9	0.45	8.3	0.46
Uterus Corpus	-	-	-	-	-	294	27.4	0.74	33.4	0.88
Uterus, NOS ¹	-	-	-	-	-	5	0.5	0.10	0.6	0.11
Ovary	-	-	-	-	-	111	10.9	0.48	12.5	0.54
Male Genital System	1,228	120.9	1.58	147.3	1.89	-	-	-	-	-
Prostate	1,153	111.7	1.50	138.0	1.83	-	-	-	-	-
Testis	62	7.8	0.45	7.6	0.44	-	-	-	-	-
Penis	11	1.1	0.16	1.3	0.18	-	-	-	-	-
Urinary System	575	60.6	1.15	71.3	1.34	234	21.2	0.64	24.8	0.74
Bladder (incl. <i>in situ</i>)	333	35.4	0.88	41.5	1.02	105	8.8	0.40	10.4	0.46
Kidney & renal pelvis	228	23.6	0.72	28.0	0.84	123	11.9	0.50	13.8	0.56
Ureter	8	0.9	0.15	1.0	0.16	4	0.4	0.08	0.4	0.09
Eye & Orbit	11	1.1	0.16	1.4	0.18	9	0.9	0.14	1.1	0.16
Brain & Other CNS ¹	78	8.4	0.44	9.3	0.48	59	6.1	0.37	6.5	0.39
Brain	73	7.8	0.42	8.8	0.46	55	5.6	0.35	6.1	0.37
Endocrine System	76	8.5	0.45	9.4	0.48	202	23.3	0.76	25.0	0.80
Thyroid gland	67	7.5	0.42	8.4	0.46	195	22.5	0.75	24.2	0.79
Lymphomas	263	28.4	0.80	32.7	0.91	209	19.4	0.62	22.6	0.71
Hodgkin Lymphoma	31	3.7	0.30	3.8	0.31	21	2.3	0.23	2.4	0.24
Non-Hodgkin Lymphoma	231	24.8	0.74	28.8	0.85	188	17.1	0.58	20.2	0.67
Multiple Myeloma	75	7.9	0.42	9.3	0.48	49	4.2	0.28	5.1	0.33
Leukemias	169	18.1	0.64	20.7	0.71	116	11.0	0.48	12.3	0.52
Acute lymphocytic	17	2.0	0.22	1.9	0.21	12	1.5	0.20	1.3	0.17
Chronic lymphocytic	61	6.3	0.37	7.5	0.43	37	3.1	0.24	3.7	0.28
Acute myeloid	51	5.4	0.35	6.3	0.40	41	3.8	0.28	4.4	0.31
Chronic myeloid	21	2.3	0.23	2.6	0.25	13	1.3	0.17	1.5	0.18
Other leukemias	19	2.1	0.22	2.4	0.24	13	1.3	0.16	1.4	0.17
Mesothelioma	12	1.3	0.17	1.5	0.19	4	0.4	0.09	0.4	0.10
Kaposi Sarcoma	1	0.2	0.07	0.2	0.07	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	151	12.8	0.48	14.8	0.55
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	67	7.3	0.41	8.3	0.45	134	13.5	0.55	15.2	0.60
Breast (<i>in situ</i>)	1	0.2	0.06	0.2	0.06	269	26.9	0.76	31.9	0.88

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	193	595.2	20.99	718.7	24.63	160	421.8	15.41	499.7	18.07
Oral Cavity & Pharynx	6	15.7	3.08	19.6	3.79	2	4.1	1.40	5.1	1.75
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	3.4	1.30	4.3	1.65	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	3.6	1.63	4.0	1.87	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	44	140.7	10.35	168.3	12.08	30	80.4	6.79	97.1	8.09
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	4	13.6	3.21	15.9	3.66	2	5.3	1.64	6.6	2.03
Small intestine	2	7.9	2.46	9.4	2.86	2	4.4	1.50	5.1	1.74
Colon excl. rectum	14	44.1	5.82	52.4	6.75	9	25.6	3.91	30.6	4.59
Rectum & rectosigmoid	5	14.7	3.14	17.4	3.66	5	12.5	2.63	15.0	3.12
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	21.9	3.72	28.2	4.60	2	5.2	1.71	6.5	2.08
Gallbladder	-	-	-	-	-	2	4.3	1.56	5.3	1.87
Pancreas	7	26.2	4.80	31.0	5.59	5	15.7	3.11	18.6	3.62
Respiratory System	25	86.0	8.44	102.5	9.75	27	74.1	6.58	89.3	7.78
Larynx	3	9.4	2.49	11.6	2.96	-	-	-	-	-
Lung & bronchus	22	76.6	8.06	91.0	9.29	26	71.7	6.49	86.4	7.67
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	3.8	1.30	4.5	1.61	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	1	3.1	1.31	3.5	1.46
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	42	110.0	7.79	131.2	9.20
Female Genital System	-	-	-	-	-	17	44.7	4.98	52.7	5.82
Cervix uteri	-	-	-	-	-	4	10.2	2.34	11.4	2.64
Uterus Corpus	-	-	-	-	-	9	22.7	3.52	27.2	4.16
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	6.3	1.97	7.2	2.26
Male Genital System	69	203.9	11.87	253.4	14.24	-	-	-	-	-
Prostate	68	203.2	11.86	252.6	14.23	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	21	62.7	6.74	75.1	7.80	10	28.4	4.10	33.4	4.76
Bladder (incl. <i>in situ</i>)	5	20.6	4.29	23.5	4.78	4	10.9	2.64	12.4	2.95
Kidney & renal pelvis	15	42.1	5.21	51.6	6.17	7	17.0	3.09	20.3	3.69
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	2.4	0.92	2.5	1.03	2	3.7	1.21	4.5	1.53
Brain	1	2.1	0.87	2.1	0.98	2	3.5	1.19	4.3	1.52
Endocrine System	2	7.5	2.38	8.4	2.61	6	15.6	2.90	17.5	3.26
Thyroid gland	2	7.0	2.34	7.7	2.52	6	14.9	2.82	16.8	3.19
Lymphomas	7	20.0	3.63	24.0	4.31	9	20.2	3.24	23.2	3.72
Hodgkin Lymphoma	-	-	-	-	-	3	5.4	1.44	5.8	1.58
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	4	14.2	3.26	16.4	3.72	6	16.0	3.12	18.6	3.56
Leukemias	4	11.4	2.86	13.2	3.27	3	7.4	1.95	8.2	2.19
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	2.6	1.08	3.5	1.44	-	-	-	-	-
Acute myeloid	-	-	-	-	-	2	3.4	1.24	4.0	1.51
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	16.3	4.03	19.3	4.73	4	11.0	2.53	12.2	2.84
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.3	1.34	4.9	1.58	8	20.9	3.36	23.6	3.81
Breast (<i>in situ</i>)	-	-	-	-	-	10	27.7	3.98	33.7	4.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	38	326.7	26.60	379.2	30.52	45	248.7	17.80	291.7	20.82
Oral Cavity & Pharynx	2	11.8	3.65	14.1	4.53	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	12	104.5	14.71	121.7	16.82	9	59.1	9.24	70.9	10.90
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	11.0	4.76	13.4	5.43	1	6.0	2.48	7.8	3.18
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	22.9	7.15	27.8	8.54	3	17.5	5.18	20.4	5.98
Rectum & rectosigmoid	1	8.3	3.78	10.0	4.40	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	37.8	8.74	43.5	10.04	2	12.7	4.55	15.0	5.32
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	2	10.5	3.95	12.4	4.54
Respiratory System	6	64.7	12.83	72.0	14.18	4	26.0	6.22	30.9	7.24
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	5	58.9	12.15	66.2	13.59	3	22.0	5.68	26.1	6.60
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	12	62.8	8.38	74.5	9.98
Female Genital System	-	-	-	-	-	4	22.6	5.39	27.5	6.47
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	13.4	4.25	16.1	5.02
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	7	68.6	12.65	82.0	14.71	-	-	-	-	-
Prostate	7	66.7	12.56	79.6	14.59	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	19.6	7.12	23.9	8.49	2	10.1	3.59	12.0	4.33
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	2	9.1	3.45	10.7	4.12
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	5.8	2.28	5.8	2.36	-	-	-	-	-
Brain	1	5.8	2.28	5.8	2.36	-	-	-	-	-
Endocrine System	1	6.2	2.41	6.6	2.73	6	25.5	5.07	26.8	5.51
Thyroid gland	1	6.2	2.41	6.6	2.73	6	25.5	5.07	26.8	5.51
Lymphomas	2	19.6	6.81	23.1	7.99	2	9.7	3.74	11.0	4.25
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	18.8	6.77	22.4	7.97	1	9.0	3.66	10.3	4.20
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	9.2	3.80	9.5	4.01	2	10.7	3.89	12.2	4.39
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	1	7.8	3.09	9.6	3.68
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	8.8	4.11	11.5	5.24	2	10.9	3.68	12.8	4.40
Breast (<i>in situ</i>)	-	-	-	-	-	5	25.4	5.45	26.8	5.81

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	20	389.2	45.69	480.1	54.29	23	371.0	39.58	438.4	45.45
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	7	125.8	22.78	160.2	27.81	5	92.7	22.12	107.9	24.98
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	37.7	14.27	43.2	15.80	2	54.2	19.12	62.6	21.43
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	51.9	13.88	68.3	17.63	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	69.4	23.45	82.5	27.41	3	68.2	18.93	79.2	21.02
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	50.6	21.16	61.5	25.14	3	68.2	18.93	79.2	21.02
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	7	92.6	16.88	113.6	20.47
Female Genital System	-	-	-	-	-	2	34.8	12.17	39.6	13.62
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	50.2	13.93	63.4	17.06	-	-	-	-	-
Prostate	3	45.7	13.55	58.8	16.72	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	41.5	14.76	52.2	17.67	2	23.0	7.30	27.6	9.01
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	24.5	8.21	33.7	11.41	2	23.0	7.30	27.6	9.01
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	38.0	15.14	43.5	17.15	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	21.9	10.33	22.8	10.75	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malignant)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	152	353.3	15.35	419.4	17.81	169	356.0	13.84	416.4	16.14
Oral Cavity & Pharynx	3	6.5	1.99	8.2	2.48	2	3.8	1.40	4.4	1.66
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	36	86.8	7.73	103.2	8.89	28	69.1	6.45	81.8	7.50
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	4	9.0	2.32	11.0	2.80	3	6.9	2.08	7.8	2.36
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	9	23.9	4.23	27.3	4.76	10	25.3	3.96	30.4	4.68
Rectum & rectosigmoid	7	13.5	2.67	16.5	3.09	4	7.8	1.93	9.2	2.23
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	7	15.3	3.13	18.5	3.62	3	7.2	1.95	9.0	2.39
Gallbladder	1	4.4	1.88	5.3	2.24	-	-	-	-	-
Pancreas	4	10.3	2.85	11.7	3.14	4	11.9	2.81	13.9	3.22
Respiratory System	13	39.5	5.44	46.1	6.16	14	40.5	5.16	48.1	5.99
Larynx	1	3.1	1.34	4.1	1.62	-	-	-	-	-
Lung & bronchus	12	36.3	5.27	42.0	5.94	14	38.9	5.07	46.0	5.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	3.2	1.33	3.7	1.62	2	2.8	1.14	2.9	1.26
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	1	2.6	1.28	3.1	1.58	4	6.4	1.60	8.0	2.06
Breast (excl. <i>in situ</i>)	-	-	-	-	-	46	96.3	7.03	113.2	8.21
Female Genital System	-	-	-	-	-	24	46.2	4.71	54.9	5.64
Cervix uteri	-	-	-	-	-	7	12.9	2.59	14.2	2.90
Uterus Corpus	-	-	-	-	-	11	21.2	3.08	26.3	3.85
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	8.2	1.90	9.5	2.25
Male Genital System	35	87.8	7.65	106.0	8.90	-	-	-	-	-
Prostate	30	82.0	7.52	99.8	8.77	-	-	-	-	-
Testis	5	5.2	1.34	5.2	1.35	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	17	40.7	5.14	49.8	6.15	7	17.4	3.23	19.5	3.59
Bladder (incl. <i>in situ</i>)	7	19.3	3.87	23.9	4.67	2	4.3	1.64	5.1	1.89
Kidney & renal pelvis	11	21.4	3.39	26.0	4.00	6	12.8	2.75	14.0	3.02
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	9.6	2.44	10.6	2.75	3	3.9	1.17	4.2	1.33
Brain	5	8.7	2.32	9.7	2.62	3	3.6	1.13	3.8	1.30
Endocrine System	6	10.0	2.13	11.9	2.56	15	19.4	2.40	20.1	2.63
Thyroid gland	6	9.4	2.11	11.4	2.55	15	19.3	2.40	20.0	2.63
Lymphomas	12	26.1	4.23	29.2	4.75	8	18.3	3.17	22.5	3.79
Hodgkin Lymphoma	3	2.9	0.85	3.0	0.93	1	1.6	0.74	2.0	0.97
Non-Hodgkin Lymphoma	9	23.2	4.14	26.2	4.66	7	16.7	3.08	20.5	3.66
Multiple Myeloma	4	10.3	2.81	12.3	3.34	3	6.7	1.89	8.0	2.20
Leukemias	10	18.7	3.46	21.0	3.96	5	8.6	2.07	9.2	2.29
Acute lymphocytic	5	4.6	1.19	4.7	1.31	3	2.9	0.99	2.6	0.96
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	3	7.3	2.36	8.3	2.69	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	1	3.0	1.63	3.6	1.96	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	8.7	2.08	11.0	2.61	5	13.4	2.91	16.1	3.47
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	6.0	2.02	6.8	2.25	8	12.8	2.39	13.9	2.64
Breast (<i>in situ</i>)	-	-	-	-	-	7	14.8	2.75	16.9	3.11

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEBRASKA

II-318 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,644	502.8	3.39	595.2	3.93	4,422	440.0	3.11	510.8	3.51
Oral Cavity & Pharynx	181	19.4	0.67	23.6	0.79	73	7.0	0.39	8.3	0.44
Lip	17	1.9	0.21	2.2	0.24	8	0.7	0.12	0.9	0.14
Tongue	53	5.5	0.35	6.7	0.42	21	2.1	0.22	2.5	0.25
Major salivary gland	17	1.9	0.21	2.2	0.24	12	1.1	0.15	1.3	0.18
Floor of mouth	7	0.7	0.13	0.9	0.15	3	0.3	0.08	0.3	0.09
Gum & other mouth	22	2.3	0.23	2.8	0.27	17	1.6	0.18	1.8	0.20
Nasopharynx	5	0.6	0.12	0.6	0.13	3	0.3	0.08	0.3	0.08
Oropharynx	10	1.0	0.14	1.2	0.18	2	0.2	0.06	0.3	0.08
Hypopharynx	11	1.1	0.15	1.4	0.19	3	0.3	0.08	0.4	0.10
Digestive System	855	93.4	1.47	110.6	1.70	704	65.7	1.16	76.6	1.32
Esophagus	80	8.5	0.43	10.3	0.52	19	1.7	0.18	2.1	0.21
Stomach	64	6.9	0.40	8.2	0.46	30	2.8	0.24	3.3	0.27
Small intestine	26	3.0	0.27	3.4	0.30	21	2.1	0.21	2.5	0.24
Colon excl. rectum	296	32.5	0.87	38.4	1.00	306	28.3	0.76	32.5	0.85
Rectum & rectosigmoid	139	15.4	0.60	18.3	0.70	98	9.8	0.46	11.5	0.53
Anus, anal canal & anorectum	12	1.3	0.17	1.5	0.20	25	2.5	0.23	3.0	0.28
Liver	58	5.9	0.35	7.3	0.43	18	1.6	0.17	2.0	0.21
Gallbladder	8	0.9	0.15	1.0	0.17	14	1.2	0.15	1.5	0.18
Pancreas	137	15.1	0.59	17.7	0.68	122	11.0	0.46	12.9	0.53
Respiratory System	667	71.6	1.27	84.9	1.48	573	52.8	1.01	62.6	1.19
Larynx	44	4.5	0.31	5.5	0.38	14	1.3	0.17	1.6	0.19
Lung & bronchus	615	66.2	1.22	78.3	1.42	552	50.7	0.99	60.2	1.16
Bones & Joints	8	1.0	0.15	1.0	0.16	7	0.8	0.15	0.8	0.14
Soft Tissue (incl. heart)	39	4.6	0.34	5.1	0.37	21	2.3	0.24	2.5	0.25
Skin (excl. basal & sq.)	301	34.3	0.91	39.6	1.03	247	28.3	0.85	31.0	0.90
Melanomas of the skin	276	31.4	0.87	36.3	0.99	235	27.0	0.83	29.6	0.88
Breast (excl. <i>in situ</i>)	15	1.6	0.19	1.9	0.22	1,295	130.8	1.71	154.3	1.96
Female Genital System	-	-	-	-	-	512	52.2	1.09	61.4	1.24
Cervix uteri	-	-	-	-	-	60	7.8	0.47	8.2	0.48
Uterus Corpus	-	-	-	-	-	285	27.7	0.76	33.7	0.91
Uterus, NOS ¹	-	-	-	-	-	4	0.4	0.09	0.5	0.11
Ovary	-	-	-	-	-	107	11.0	0.50	12.7	0.56
Male Genital System	1,198	122.9	1.63	149.7	1.94	-	-	-	-	-
Prostate	1,127	113.2	1.54	140.0	1.87	-	-	-	-	-
Testis	58	8.2	0.49	8.1	0.48	-	-	-	-	-
Penis	10	1.1	0.16	1.3	0.19	-	-	-	-	-
Urinary System	558	61.2	1.19	72.0	1.37	228	21.4	0.66	25.1	0.76
Bladder (incl. <i>in situ</i>)	327	35.9	0.91	42.0	1.04	104	8.9	0.40	10.6	0.47
Kidney & renal pelvis	218	23.7	0.74	28.1	0.86	118	11.9	0.51	13.8	0.58
Ureter	8	0.9	0.15	1.0	0.17	4	0.3	0.08	0.4	0.09
Eye & Orbit	11	1.2	0.17	1.4	0.20	9	1.0	0.15	1.1	0.17
Brain & Other CNS ¹	73	8.5	0.46	9.4	0.50	56	6.2	0.39	6.6	0.40
Brain	68	7.8	0.44	8.8	0.48	52	5.7	0.37	6.2	0.39
Endocrine System	70	8.5	0.47	9.4	0.50	188	23.4	0.80	25.2	0.83
Thyroid gland	62	7.5	0.44	8.4	0.48	181	22.6	0.79	24.4	0.82
Lymphomas	252	28.7	0.83	32.9	0.93	201	19.7	0.65	22.7	0.73
Hodgkin Lymphoma	29	3.8	0.32	3.9	0.33	19	2.4	0.25	2.5	0.26
Non-Hodgkin Lymphoma	223	24.9	0.77	29.0	0.87	182	17.2	0.60	20.2	0.69
Multiple Myeloma	71	7.8	0.42	9.2	0.49	46	4.1	0.28	5.0	0.33
Leukemias	159	17.9	0.65	20.5	0.73	112	11.1	0.50	12.3	0.53
Acute lymphocytic	13	1.7	0.22	1.6	0.20	10	1.4	0.20	1.2	0.17
Chronic lymphocytic	60	6.4	0.38	7.7	0.45	36	3.2	0.24	3.8	0.29
Acute myeloid	49	5.4	0.35	6.3	0.40	40	3.9	0.29	4.4	0.32
Chronic myeloid	21	2.3	0.24	2.7	0.27	13	1.3	0.18	1.5	0.19
Other leukemias	18	2.1	0.22	2.3	0.25	13	1.3	0.17	1.4	0.18
Mesothelioma	12	1.3	0.17	1.5	0.20	4	0.4	0.09	0.4	0.10
Kaposi Sarcoma	1	0.2	0.08	0.2	0.08	-	-	-	-	-
Ill-defined & Unknown	172	18.8	0.65	22.2	0.76	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	65	7.7	0.44	8.6	0.48	127	13.5	0.57	15.1	0.61
Breast (<i>in situ</i>)	1	0.2	0.06	0.2	0.07	263	27.6	0.80	32.7	0.92

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nebraska, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	191	612.5	21.65	739.1	25.38	159	431.7	15.83	510.3	18.53
Oral Cavity & Pharynx	6	16.3	3.19	20.3	3.92	2	4.3	1.46	5.3	1.81
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	3.6	1.36	4.5	1.71	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	3.7	1.69	4.2	1.93	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	44	144.9	10.68	173.3	12.45	29	81.5	6.94	98.1	8.25
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	4	14.1	3.32	16.5	3.79	2	5.5	1.69	6.9	2.10
Small intestine	2	8.2	2.54	9.7	2.95	2	4.6	1.56	5.2	1.80
Colon excl. rectum	14	45.7	6.02	54.2	6.98	9	25.4	3.96	30.3	4.63
Rectum & rectosigmoid	5	14.4	3.14	17.1	3.67	5	12.5	2.67	14.8	3.14
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	22.6	3.84	29.1	4.75	2	5.4	1.75	6.7	2.14
Gallbladder	-	-	-	-	-	2	4.5	1.61	5.4	1.92
Pancreas	7	27.1	4.96	32.1	5.77	5	16.2	3.20	19.1	3.72
Respiratory System	25	88.9	8.72	105.9	10.07	27	76.3	6.77	92.0	8.00
Larynx	3	9.7	2.58	12.0	3.07	-	-	-	-	-
Lung & bronchus	22	79.2	8.33	94.0	9.59	26	73.7	6.67	89.0	7.88
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	3.9	1.35	4.7	1.66	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	1	3.2	1.36	3.6	1.52
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	41	112.4	8.01	133.8	9.43
Female Genital System	-	-	-	-	-	17	45.8	5.12	53.8	5.97
Cervix uteri	-	-	-	-	-	4	10.6	2.44	11.9	2.74
Uterus Corpus	-	-	-	-	-	9	23.0	3.61	27.4	4.23
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	6.4	2.02	7.4	2.32
Male Genital System	68	209.6	12.24	260.3	14.67	-	-	-	-	-
Prostate	68	208.8	12.23	259.4	14.66	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	21	65.0	6.98	77.8	8.07	10	28.9	4.20	33.7	4.86
Bladder (incl. <i>in situ</i>)	5	21.3	4.43	24.3	4.93	3	10.7	2.67	12.1	2.95
Kidney & renal pelvis	15	43.7	5.40	53.5	6.39	7	17.6	3.19	21.0	3.80
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	2.1	0.87	1.9	0.85	2	3.9	1.27	4.7	1.59
Brain	-	-	-	-	-	2	3.6	1.24	4.5	1.57
Endocrine System	2	7.7	2.46	8.7	2.70	6	16.2	3.00	18.2	3.37
Thyroid gland	2	7.3	2.42	8.0	2.61	6	15.5	2.93	17.5	3.30
Lymphomas	7	20.4	3.75	24.6	4.45	9	21.0	3.36	24.1	3.85
Hodgkin Lymphoma	-	-	-	-	-	3	5.7	1.52	6.1	1.66
Non-Hodgkin Lymphoma	-	-	-	-	-	6	15.3	3.00	17.9	3.48
Multiple Myeloma	4	14.7	3.38	16.9	3.85	5	15.9	3.16	18.5	3.61
Leukemias	4	10.9	2.83	12.7	3.25	3	7.8	2.03	8.6	2.28
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	2.7	1.12	3.6	1.49	-	-	-	-	-
Acute myeloid	-	-	-	-	-	2	3.6	1.29	4.2	1.57
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	16.8	4.16	19.9	4.88	4	11.4	2.61	12.6	2.93
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.5	1.41	5.1	1.65	8	21.1	3.44	24.0	3.91
Breast (<i>in situ</i>)	-	-	-	-	-	10	27.8	4.03	33.9	4.84

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NEBRASKA

II-320 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,776,972	2,819,012	2,868,666	2,919,772	2,972,405
White	2,183,424	2,205,398	2,231,363	2,256,906	2,282,813
Black	277,043	286,739	299,176	313,185	327,516
American Indian/Alaskan Native (AI/AN)	52,135	53,556	54,898	56,424	57,899
Asian/Pacific Islander (API)	264,370	273,319	283,229	293,257	304,177


All Races Population 2013-2017: 14,356,827
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	763,765	783,052	807,635	831,270	854,886
Non-Hispanic White	1,492,352	1,497,558	1,502,306	1,507,548	1,513,160
Non-Hispanic Black	248,356	257,100	268,032	280,636	293,470

Hispanic/Latino Population, Census 2010: 716,501
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEVADA CANCER REGISTRY

Initial Operation: 1979
Population-based Data Available: 1995
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	No	Yes	No
Completeness of Case Ascertainment	93.0	89.1	85.3	89.3	82.6
Missing Race	0.3	0.4	0.3	0.3	1.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.1	0.2	0.0	0.9
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	4.6	1.9	2.6	2.6	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Prostate	96.2
Oral Cavity & Pharynx	97.1	Testis	98.4
Esophagus	93.7	Bladder (incl. <i>in situ</i>)	98.2
Stomach	96.2	Kidney & Renal Pelvis	91.3
Colon & Rectum	95.0	Brain & Other CNS ¹	83.6
Liver	61.6	Thyroid	99.6
Pancreas	83.5	Hodgkin Lymphoma	98.8
Lung & Bronchus	87.8	Non-Hodgkin Lymphoma	96.4
Melanomas of the Skin	98.5	Multiple Myeloma	91.2
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	91.2
Cervix uteri	97.5	Brain & Other CNS ¹ <i>non-malig</i>	40.1
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	91.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,421	405.6	2.34	480.1	2.74	6,287	379.6	2.19	442.6	2.52
Oral Cavity & Pharynx	255	15.5	0.45	18.8	0.54	99	5.8	0.27	6.9	0.31
Lip	15	1.0	0.12	1.2	0.14	5	0.3	0.06	0.4	0.07
Tongue	88	5.3	0.26	6.4	0.31	36	2.1	0.16	2.5	0.19
Major salivary gland	24	1.7	0.16	1.9	0.18	12	0.8	0.10	0.9	0.11
Floor of mouth	8	0.5	0.07	0.6	0.10	5	0.3	0.06	0.3	0.07
Gum & other mouth	18	1.1	0.12	1.3	0.14	14	0.8	0.10	1.0	0.12
Nasopharynx	12	0.8	0.10	0.9	0.11	6	0.3	0.07	0.4	0.08
Oropharynx	16	1.0	0.11	1.2	0.13	5	0.3	0.06	0.3	0.07
Hypopharynx	12	0.7	0.09	0.9	0.12	4	0.2	0.05	0.3	0.06
Digestive System	1,328	83.6	1.06	100.4	1.26	989	59.0	0.86	69.9	1.00
Esophagus	118	7.2	0.31	8.8	0.37	28	1.6	0.14	1.9	0.17
Stomach	102	6.6	0.30	7.9	0.36	67	4.1	0.23	4.8	0.26
Small intestine	31	2.0	0.16	2.3	0.19	24	1.5	0.14	1.7	0.16
Colon excl. rectum	421	27.3	0.61	32.3	0.72	377	22.8	0.54	26.8	0.62
Rectum & rectosigmoid	210	13.0	0.41	15.8	0.49	140	8.3	0.32	10.0	0.38
Anus, anal canal & anorectum	22	1.4	0.14	1.6	0.16	36	2.0	0.15	2.5	0.19
Liver	160	9.4	0.34	11.8	0.42	58	3.4	0.20	4.0	0.24
Gallbladder	10	0.6	0.09	0.7	0.11	17	1.0	0.11	1.2	0.13
Pancreas	197	12.4	0.41	14.9	0.49	189	11.1	0.37	13.2	0.43
Respiratory System	911	58.4	0.89	68.9	1.05	906	53.0	0.80	62.5	0.94
Larynx	61	3.7	0.22	4.4	0.26	15	0.8	0.10	1.0	0.12
Lung & bronchus	838	53.9	0.86	63.6	1.01	881	51.6	0.79	60.8	0.93
Bones & Joints	19	1.3	0.14	1.3	0.14	12	0.8	0.11	0.8	0.11
Soft Tissue (incl. heart)	60	3.9	0.23	4.4	0.26	44	2.8	0.19	3.1	0.21
Skin (excl. basal & sq.)	352	22.9	0.56	26.9	0.66	210	12.9	0.41	15.0	0.47
Melanomas of the skin	331	21.6	0.55	25.3	0.64	198	12.1	0.39	14.1	0.45
Breast (excl. <i>in situ</i>)	21	1.3	0.14	1.6	0.16	1,835	110.3	1.18	129.6	1.36
Female Genital System	-	-	-	-	-	723	43.7	0.75	51.1	0.86
Cervix uteri	-	-	-	-	-	130	8.9	0.36	9.4	0.37
Uterus Corpus	-	-	-	-	-	351	20.2	0.49	24.5	0.59
Uterus, NOS ¹	-	-	-	-	-	15	0.9	0.10	1.1	0.12
Ovary	-	-	-	-	-	170	10.3	0.36	12.1	0.42
Male Genital System	1,536	91.5	1.07	110.8	1.29	-	-	-	-	-
Prostate	1,445	85.1	1.03	104.3	1.25	-	-	-	-	-
Testis	76	5.4	0.28	5.4	0.28	-	-	-	-	-
Penis	12	0.8	0.11	1.0	0.13	-	-	-	-	-
Urinary System	788	51.1	0.84	60.1	0.98	338	20.1	0.50	23.6	0.58
Bladder (incl. <i>in situ</i>)	482	32.0	0.68	37.6	0.79	152	9.1	0.33	10.6	0.39
Kidney & renal pelvis	291	18.1	0.49	21.4	0.57	176	10.5	0.36	12.3	0.42
Ureter	7	0.5	0.08	0.5	0.09	7	0.4	0.07	0.5	0.08
Eye & Orbit	15	1.0	0.12	1.2	0.14	10	0.6	0.09	0.7	0.10
Brain & Other CNS ¹	113	7.3	0.32	8.1	0.35	86	5.3	0.26	5.9	0.29
Brain	109	7.1	0.31	7.8	0.34	82	5.1	0.26	5.6	0.28
Endocrine System	121	7.8	0.32	8.7	0.36	359	23.9	0.58	25.9	0.62
Thyroid gland	111	7.1	0.31	8.0	0.34	349	23.2	0.57	25.2	0.61
Lymphomas	293	19.2	0.52	22.1	0.59	230	13.9	0.42	16.1	0.48
Hodgkin Lymphoma	26	1.8	0.16	1.9	0.17	24	1.7	0.15	1.7	0.16
Non-Hodgkin Lymphoma	267	17.4	0.49	20.2	0.57	205	12.3	0.39	14.4	0.45
Multiple Myeloma	90	5.8	0.28	6.8	0.33	66	3.9	0.22	4.6	0.26
Leukemias	223	15.0	0.46	16.8	0.51	147	9.4	0.35	10.4	0.38
Acute lymphocytic	25	1.9	0.17	1.7	0.15	18	1.4	0.14	1.2	0.13
Chronic lymphocytic	71	4.5	0.25	5.4	0.30	45	2.7	0.19	3.2	0.21
Acute myeloid	67	4.6	0.26	5.2	0.29	48	3.0	0.20	3.4	0.22
Chronic myeloid	24	1.6	0.15	1.8	0.16	18	1.1	0.12	1.3	0.14
Other leukemias	36	2.5	0.19	2.7	0.21	18	1.2	0.13	1.3	0.14
Mesothelioma	17	1.1	0.13	1.3	0.15	6	0.4	0.07	0.4	0.08
Kaposi Sarcoma	11	0.8	0.10	0.8	0.11	-	-	-	-	-
Ill-defined & Unknown	267	17.9	0.51	21.0	0.59	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	96	6.4	0.30	7.3	0.34	203	12.4	0.40	14.4	0.46
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.06	352	20.8	0.51	24.8	0.60

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	5,472	414.8	2.58	490.5	3.02	5,150	389.7	2.49	454.2	2.86
Oral Cavity & Pharynx	224	16.4	0.50	20.0	0.61	84	6.2	0.31	7.3	0.36
Lip	15	1.2	0.14	1.4	0.17	5	0.4	0.08	0.4	0.09
Tongue	80	5.7	0.29	7.0	0.35	31	2.3	0.19	2.7	0.22
Major salivary gland	21	1.8	0.18	2.0	0.20	10	0.8	0.12	0.9	0.13
Floor of mouth	7	0.5	0.08	0.7	0.11	4	0.3	0.07	0.3	0.08
Gum & other mouth	15	1.1	0.13	1.3	0.16	12	0.9	0.11	1.0	0.14
Nasopharynx	7	0.6	0.10	0.6	0.11	4	0.3	0.06	0.3	0.07
Oropharynx	14	0.9	0.12	1.2	0.15	4	0.3	0.06	0.3	0.08
Hypopharynx	11	0.8	0.11	1.0	0.13	3	0.2	0.06	0.3	0.07
Digestive System	1,075	81.1	1.14	97.5	1.35	789	58.6	0.95	69.4	1.12
Esophagus	104	7.6	0.35	9.2	0.41	25	1.8	0.16	2.2	0.20
Stomach	77	5.9	0.31	7.0	0.37	48	3.6	0.24	4.3	0.28
Small intestine	25	1.9	0.18	2.2	0.20	20	1.6	0.16	1.8	0.18
Colon excl. rectum	340	26.4	0.66	31.3	0.77	300	22.6	0.60	26.4	0.69
Rectum & rectosigmoid	169	12.6	0.45	15.3	0.53	116	8.7	0.37	10.4	0.44
Anus, anal canal & anorectum	19	1.5	0.15	1.8	0.18	31	2.2	0.18	2.7	0.22
Liver	122	8.6	0.36	10.7	0.44	40	2.9	0.21	3.4	0.25
Gallbladder	7	0.5	0.09	0.6	0.11	14	1.1	0.13	1.2	0.15
Pancreas	166	12.5	0.45	15.1	0.53	155	11.2	0.41	13.4	0.49
Respiratory System	776	59.1	0.98	69.8	1.15	773	55.7	0.91	65.7	1.07
Larynx	53	3.8	0.24	4.5	0.28	13	0.9	0.12	1.2	0.14
Lung & bronchus	712	54.5	0.94	64.2	1.10	751	54.2	0.90	63.8	1.05
Bones & Joints	15	1.3	0.16	1.4	0.16	10	0.9	0.13	0.9	0.13
Soft Tissue (incl. heart)	50	4.0	0.26	4.5	0.29	32	2.5	0.20	2.8	0.22
Skin (excl. basal & sq.)	343	26.8	0.67	31.4	0.77	201	15.6	0.51	18.2	0.58
Melanomas of the skin	323	25.3	0.65	29.7	0.75	191	14.8	0.49	17.3	0.56
Breast (excl. <i>in situ</i>)	17	1.3	0.15	1.6	0.17	1,473	111.2	1.33	130.7	1.54
Female Genital System	-	-	-	-	-	583	44.5	0.85	52.1	0.97
Cervix uteri	-	-	-	-	-	101	9.0	0.41	9.5	0.42
Uterus Corpus	-	-	-	-	-	286	20.7	0.56	25.2	0.67
Uterus, NOS ¹	-	-	-	-	-	11	0.8	0.11	1.0	0.13
Ovary	-	-	-	-	-	136	10.4	0.41	12.2	0.47
Male Genital System	1,287	92.0	1.18	111.1	1.41	-	-	-	-	-
Prostate	1,205	84.7	1.12	103.6	1.36	-	-	-	-	-
Testis	68	6.2	0.34	6.2	0.33	-	-	-	-	-
Penis	11	0.9	0.13	1.1	0.15	-	-	-	-	-
Urinary System	697	53.9	0.94	63.5	1.10	287	21.3	0.58	25.0	0.67
Bladder (incl. <i>in situ</i>)	443	34.8	0.76	40.8	0.89	136	10.0	0.39	11.7	0.45
Kidney & renal pelvis	241	18.1	0.54	21.4	0.63	142	10.6	0.41	12.4	0.47
Ureter	7	0.5	0.10	0.6	0.11	7	0.5	0.09	0.6	0.10
Eye & Orbit	14	1.2	0.14	1.3	0.16	9	0.7	0.11	0.8	0.12
Brain & Other CNS ¹	99	7.8	0.36	8.6	0.39	73	5.7	0.31	6.4	0.34
Brain	95	7.5	0.36	8.4	0.39	70	5.4	0.30	6.1	0.33
Endocrine System	103	8.1	0.37	9.1	0.40	281	24.4	0.67	26.3	0.71
Thyroid gland	95	7.5	0.35	8.4	0.39	273	23.6	0.66	25.5	0.70
Lymphomas	251	19.9	0.58	22.9	0.66	190	14.5	0.48	16.7	0.55
Hodgkin Lymphoma	22	1.9	0.19	2.0	0.19	19	1.7	0.18	1.8	0.18
Non-Hodgkin Lymphoma	229	18.0	0.55	20.9	0.63	172	12.8	0.45	14.9	0.51
Multiple Myeloma	74	5.7	0.30	6.7	0.36	49	3.6	0.23	4.2	0.27
Leukemias	195	15.9	0.52	17.7	0.58	123	9.9	0.41	10.8	0.44
Acute lymphocytic	21	2.0	0.20	1.8	0.17	16	1.5	0.17	1.3	0.15
Chronic lymphocytic	64	4.8	0.28	5.9	0.33	39	3.0	0.22	3.4	0.24
Acute myeloid	57	4.6	0.28	5.2	0.32	38	3.0	0.23	3.4	0.25
Chronic myeloid	21	1.7	0.17	1.9	0.19	14	1.1	0.14	1.3	0.15
Other leukemias	32	2.7	0.22	2.9	0.24	15	1.2	0.15	1.4	0.16
Mesothelioma	14	1.2	0.14	1.3	0.16	5	0.4	0.08	0.4	0.09
Kaposi Sarcoma	8	0.7	0.11	0.7	0.12	-	-	-	-	-
Ill-defined & Unknown	230	18.3	0.56	21.5	0.65	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	78	6.3	0.33	7.2	0.37	160	12.3	0.44	14.3	0.51
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.07	265	19.8	0.56	23.6	0.66

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

NEVADA

II-324 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	438	378.4	8.59	454.4	10.18	437	330.8	7.28	390.0	8.51
Oral Cavity & Pharynx	15	12.9	1.54	15.3	1.81	6	4.5	0.82	5.5	0.99
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.9	0.89	4.6	1.03	2	1.2	0.42	1.4	0.51
Major salivary gland	2	1.6	0.55	1.7	0.61	1	0.9	0.39	1.1	0.47
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	0.8	0.31	1.0	0.41
Nasopharynx	2	1.4	0.46	1.6	0.53	-	-	-	-	-
Oropharynx	2	1.5	0.49	1.9	0.60	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	100	86.8	4.11	105.0	4.89	80	61.7	3.18	73.5	3.74
Esophagus	6	4.4	0.85	5.6	1.07	1	0.9	0.37	1.1	0.45
Stomach	9	7.8	1.26	9.4	1.49	7	5.5	0.99	6.6	1.17
Small intestine	4	3.2	0.77	3.8	0.89	2	1.7	0.52	2.0	0.59
Colon excl. rectum	38	34.0	2.64	40.4	3.09	32	24.6	2.00	29.1	2.34
Rectum & rectosigmoid	11	9.1	1.32	11.1	1.59	8	6.5	1.04	7.4	1.18
Anus, anal canal & anorectum	-	-	-	-	-	3	2.2	0.58	2.6	0.68
Liver	14	10.9	1.38	14.0	1.74	6	4.1	0.78	5.1	0.97
Gallbladder	-	-	-	-	-	1	1.1	0.44	1.3	0.52
Pancreas	15	12.9	1.57	15.5	1.86	16	12.5	1.43	15.1	1.71
Respiratory System	60	55.4	3.38	66.1	3.97	60	48.1	2.87	57.6	3.39
Larynx	5	4.1	0.89	4.8	1.01	-	-	-	-	-
Lung & bronchus	55	51.1	3.26	61.2	3.83	58	46.7	2.84	56.0	3.35
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	3.0	0.68	3.4	0.77	5	3.2	0.68	3.6	0.76
Skin (excl. basal & sq.)	2	1.4	0.48	1.7	0.60	3	2.3	0.62	2.5	0.69
Melanomas of the skin	1	1.0	0.43	1.3	0.54	2	1.4	0.51	1.6	0.59
Breast (excl. <i>in situ</i>)	2	2.0	0.62	2.6	0.79	141	104.6	4.03	122.7	4.69
Female Genital System	-	-	-	-	-	50	36.5	2.36	43.5	2.80
Cervix uteri	-	-	-	-	-	10	7.6	1.06	8.0	1.12
Uterus Corpus	-	-	-	-	-	23	16.2	1.56	20.1	1.92
Uterus, NOS ¹	-	-	-	-	-	2	1.2	0.40	1.4	0.49
Ovary	-	-	-	-	-	11	8.8	1.20	10.5	1.42
Male Genital System	133	109.3	4.46	136.6	5.46	-	-	-	-	-
Prostate	131	108.0	4.44	135.2	5.44	-	-	-	-	-
Testis	1	0.9	0.36	0.9	0.33	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	45	42.3	2.99	49.1	3.45	23	17.5	1.68	21.0	1.99
Bladder (incl. <i>in situ</i>)	19	21.4	2.31	24.6	2.64	7	5.5	0.98	6.5	1.15
Kidney & renal pelvis	25	20.5	1.89	24.1	2.20	16	12.0	1.37	14.4	1.63
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	5.2	0.96	5.7	1.08	6	4.0	0.77	4.4	0.86
Brain	7	5.1	0.95	5.5	1.06	5	3.8	0.75	4.1	0.83
Endocrine System	4	2.5	0.60	2.7	0.66	13	9.4	1.16	10.6	1.31
Thyroid gland	2	1.7	0.52	1.9	0.56	13	8.8	1.12	10.0	1.27
Lymphomas	18	15.9	1.81	18.0	2.06	15	10.9	1.32	12.6	1.53
Hodgkin Lymphoma	2	1.7	0.48	1.8	0.53	3	1.8	0.46	2.1	0.56
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	11	9.8	1.43	11.6	1.67	8	6.3	1.03	7.5	1.22
Leukemias	14	11.6	1.50	13.1	1.70	9	6.9	1.07	7.8	1.22
Acute lymphocytic	2	1.3	0.44	1.0	0.37	-	-	-	-	-
Chronic lymphocytic	4	3.5	0.86	4.2	1.02	2	2.0	0.63	2.4	0.75
Acute myeloid	4	3.7	0.86	4.1	0.97	3	2.4	0.62	2.7	0.72
Chronic myeloid	1	1.0	0.40	1.2	0.46	2	1.4	0.46	1.6	0.52
Other leukemias	2	2.1	0.65	2.5	0.75	-	-	-	-	-
Mesothelioma	2	1.7	0.68	2.2	0.84	-	-	-	-	-
Kaposi Sarcoma	3	1.5	0.43	1.6	0.46	-	-	-	-	-
Ill-defined & Unknown	17	16.2	1.90	18.8	2.20	17	13.9	1.55	16.3	1.80
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	6.0	1.12	7.0	1.29	19	14.0	1.49	16.1	1.72
Breast (<i>in situ</i>)	-	-	-	-	-	27	20.6	1.82	24.2	2.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, Asian/Pacific Islander (API)**

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	305	237.6	6.39	279.7	7.47	492	271.2	5.65	315.7	6.49
Oral Cavity & Pharynx	9	6.2	0.98	7.5	1.17	6	3.2	0.59	4.0	0.71
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.4	0.51	1.6	0.58	3	1.3	0.37	1.5	0.43
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	2	1.6	0.50	2.0	0.60	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	94	74.5	3.61	88.4	4.26	82	46.4	2.39	54.4	2.77
Esophagus	5	3.3	0.71	3.9	0.82	-	-	-	-	-
Stomach	11	9.4	1.35	11.3	1.61	10	5.6	0.84	6.7	0.98
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	26	21.8	2.01	25.7	2.36	32	18.1	1.49	21.2	1.73
Rectum & rectosigmoid	22	16.1	1.59	19.0	1.87	10	5.3	0.78	6.3	0.91
Anus, anal canal & anorectum	-	-	-	-	-	1	0.6	0.28	0.8	0.35
Liver	13	10.7	1.37	12.7	1.61	9	4.9	0.77	5.6	0.87
Gallbladder	2	1.1	0.38	1.5	0.50	-	-	-	-	-
Pancreas	9	7.2	1.10	8.6	1.29	12	7.2	0.97	8.5	1.13
Respiratory System	50	40.6	2.71	48.2	3.19	52	29.5	1.89	34.6	2.20
Larynx	2	1.1	0.38	1.3	0.47	-	-	-	-	-
Lung & bronchus	48	39.5	2.68	46.7	3.15	52	29.4	1.89	34.5	2.20
Bones & Joints	2	1.5	0.50	1.4	0.47	-	-	-	-	-
Soft Tissue (incl. heart)	3	2.5	0.62	2.8	0.69	6	3.1	0.60	3.5	0.68
Skin (excl. basal & sq.)	2	2.0	0.59	2.2	0.65	3	2.0	0.50	2.3	0.56
Melanomas of the skin	2	1.6	0.54	1.7	0.59	3	1.6	0.45	1.8	0.49
Breast (excl. <i>in situ</i>)	-	-	-	-	-	162	87.0	3.15	102.2	3.65
Female Genital System	-	-	-	-	-	65	34.8	1.97	40.4	2.26
Cervix uteri	-	-	-	-	-	12	7.1	0.91	7.6	0.97
Uterus Corpus	-	-	-	-	-	29	14.7	1.24	17.7	1.47
Uterus, NOS ¹	-	-	-	-	-	2	1.0	0.33	1.2	0.38
Ovary	-	-	-	-	-	19	10.5	1.11	12.1	1.26
Male Genital System	65	48.3	2.80	57.7	3.31	-	-	-	-	-
Prostate	63	46.8	2.76	56.0	3.27	-	-	-	-	-
Testis	2	1.5	0.46	1.5	0.48	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	26	19.7	1.79	23.5	2.10	17	9.7	1.08	11.3	1.24
Bladder (incl. <i>in situ</i>)	11	8.3	1.20	9.9	1.41	6	3.3	0.65	3.8	0.75
Kidney & renal pelvis	16	11.3	1.32	13.4	1.55	11	6.1	0.84	7.2	0.97
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	2.9	0.64	3.3	0.73	4	2.3	0.56	2.3	0.55
Brain	4	2.6	0.60	3.1	0.71	3	2.0	0.54	2.1	0.52
Endocrine System	11	8.1	1.14	9.0	1.27	48	27.4	1.80	30.3	1.97
Thyroid gland	9	7.3	1.10	8.0	1.21	48	27.1	1.79	30.0	1.96
Lymphomas	14	11.3	1.39	13.2	1.61	16	9.0	1.04	10.5	1.20
Hodgkin Lymphoma	-	-	-	-	-	1	0.8	0.35	0.8	0.33
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	1.7	0.52	2.1	0.61	6	3.1	0.60	3.9	0.72
Leukemias	8	7.1	1.18	7.7	1.31	9	5.4	0.84	6.1	0.92
Acute lymphocytic	1	1.1	0.41	1.0	0.38	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	4	3.9	0.90	4.2	1.01	5	2.7	0.57	3.2	0.67
Chronic myeloid	-	-	-	-	-	2	0.8	0.30	1.0	0.34
Other leukemias	-	-	-	-	-	1	0.8	0.36	0.9	0.37
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	11	9.7	1.38	11.2	1.60	13	7.4	0.96	8.8	1.13
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	5.2	0.90	6.0	1.03	16	8.8	1.02	10.1	1.15
Breast (<i>in situ</i>)	-	-	-	-	-	44	22.5	1.56	26.8	1.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

NEVADA

II-326 Incidence – API

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	52	265.0	18.03	311.6	20.86	62	262.0	15.60	311.8	18.28
Oral Cavity & Pharynx	2	7.1	2.41	8.1	2.74	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	14	66.3	8.57	79.7	9.99	12	52.9	7.26	63.7	8.57
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	5.2	2.18	6.4	2.62	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	27.3	6.02	30.6	6.63	4	16.7	4.08	20.8	4.93
Rectum & rectosigmoid	2	9.6	3.32	11.7	3.91	1	4.3	1.64	5.9	2.25
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	12.7	3.14	16.7	4.09	1	6.4	2.70	7.4	3.14
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	6.7	2.77	8.2	3.31	2	9.8	3.15	11.4	3.60
Respiratory System	7	40.9	7.45	47.5	8.49	7	35.3	6.07	41.8	7.07
Larynx	1	7.4	3.40	8.9	4.03	-	-	-	-	-
Lung & bronchus	6	32.7	6.57	38.0	7.44	7	33.2	5.87	39.3	6.83
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	17	71.0	8.05	84.5	9.41
Female Genital System	-	-	-	-	-	8	28.9	4.73	34.6	5.58
Cervix uteri	-	-	-	-	-	2	9.1	2.64	10.5	3.04
Uterus Corpus	-	-	-	-	-	4	13.0	3.11	15.5	3.67
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	12	57.0	8.01	68.7	9.48	-	-	-	-	-
Prostate	10	51.4	7.75	62.8	9.25	-	-	-	-	-
Testis	2	5.7	2.02	5.9	2.11	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	33.3	6.79	39.4	7.97	5	18.7	4.06	23.1	4.88
Bladder (incl. <i>in situ</i>)	2	12.5	4.25	15.1	5.05	2	8.2	2.90	9.9	3.36
Kidney & renal pelvis	4	20.7	5.30	24.3	6.17	3	10.5	2.85	13.2	3.53
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	1	6.0	2.44	6.5	2.59	-	-	-	-	-
Brain	1	6.0	2.44	6.5	2.59	-	-	-	-	-
Endocrine System	1	5.1	2.14	5.7	2.36	4	15.9	3.79	18.3	4.38
Thyroid gland	1	5.1	2.14	5.7	2.36	4	14.4	3.51	16.6	4.02
Lymphomas	2	11.2	3.79	13.0	4.35	2	8.7	2.54	10.0	2.93
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	11.2	3.79	13.0	4.35	1	5.1	1.93	6.3	2.39
Multiple Myeloma	-	-	-	-	-	1	5.6	2.42	6.4	2.72
Leukemias	2	13.4	4.68	15.1	5.34	1	5.3	2.31	6.0	2.55
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	15.8	4.83	17.7	5.44	2	11.2	3.44	13.2	4.08
Selected tumors (non-invasive)	-	-	-	-	-	2	7.7	2.54	8.8	2.89
Brain & Other CNS ² (non-malig)	-	-	-	-	-	3	12.6	3.17	16.2	3.95
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	632	292.2	5.92	343.2	6.86	768	289.6	5.04	336.6	5.86
Oral Cavity & Pharynx	19	9.1	1.07	10.7	1.23	7	2.9	0.52	3.4	0.60
Lip	2	0.8	0.35	1.0	0.42	-	-	-	-	-
Tongue	5	2.4	0.56	2.7	0.62	2	0.9	0.30	1.0	0.33
Major salivary gland	2	1.5	0.51	1.7	0.58	2	0.7	0.21	0.8	0.25
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	2	0.6	0.19	0.6	0.22	-	-	-	-	-
Oropharynx	1	0.6	0.22	0.7	0.28	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	154	72.2	2.94	86.1	3.43	132	55.5	2.32	65.4	2.70
Esophagus	8	4.1	0.73	4.9	0.86	3	1.4	0.41	1.6	0.47
Stomach	17	8.4	1.04	10.0	1.21	18	6.6	0.76	7.8	0.89
Small intestine	3	1.4	0.40	1.6	0.45	3	1.2	0.35	1.4	0.41
Colon excl. rectum	49	23.5	1.71	27.9	1.99	44	17.8	1.29	20.9	1.51
Rectum & rectosigmoid	23	9.2	0.96	11.1	1.13	19	7.1	0.78	8.8	0.95
Anus, anal canal & anorectum	2	0.8	0.35	1.0	0.43	3	1.1	0.31	1.4	0.38
Liver	26	12.0	1.17	14.6	1.38	10	4.9	0.72	5.6	0.81
Gallbladder	2	0.9	0.34	1.0	0.36	3	1.7	0.43	1.9	0.50
Pancreas	18	9.1	1.07	10.8	1.24	23	10.5	1.05	12.5	1.22
Respiratory System	53	30.5	2.06	35.4	2.35	55	26.0	1.67	30.4	1.92
Larynx	5	2.8	0.63	3.3	0.71	1	0.5	0.20	0.6	0.26
Lung & bronchus	45	26.9	1.95	31.1	2.22	52	25.0	1.64	29.3	1.89
Bones & Joints	4	0.9	0.20	0.9	0.22	3	1.1	0.32	1.3	0.37
Soft Tissue (incl. heart)	12	4.6	0.71	5.2	0.80	5	1.9	0.39	2.1	0.46
Skin (excl. basal & sq.)	9	4.1	0.70	4.7	0.80	-	-	-	-	-
Melanomas of the skin	8	3.5	0.65	4.1	0.75	11	4.3	0.61	5.0	0.71
Breast (excl. <i>in situ</i>)	3	1.2	0.36	1.3	0.41	218	78.8	2.53	93.0	2.99
Female Genital System	-	-	-	-	-	109	37.8	1.73	43.7	2.02
Cervix uteri	-	-	-	-	-	30	9.2	0.79	9.8	0.86
Uterus Corpus	-	-	-	-	-	50	17.6	1.18	21.1	1.41
Uterus, NOS ¹	-	-	-	-	-	2	0.7	0.25	0.9	0.30
Ovary	-	-	-	-	-	21	7.9	0.83	9.2	0.97
Male Genital System	166	76.8	2.99	92.1	3.50	-	-	-	-	-
Prostate	140	70.5	2.92	85.6	3.44	-	-	-	-	-
Testis	23	5.2	0.49	5.2	0.52	-	-	-	-	-
Penis	2	0.9	0.33	1.1	0.40	-	-	-	-	-
Urinary System	67	34.0	2.10	40.2	2.43	43	17.4	1.27	20.3	1.47
Bladder (incl. <i>in situ</i>)	28	17.1	1.58	20.1	1.83	13	6.3	0.83	7.3	0.94
Kidney & renal pelvis	37	16.4	1.35	19.5	1.58	30	11.0	0.96	12.9	1.12
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.5	0.23	0.6	0.27	-	-	-	-	-
Brain & Other CNS ¹	15	5.3	0.71	5.7	0.79	12	4.4	0.62	4.8	0.71
Brain	14	5.1	0.71	5.6	0.78	12	4.3	0.61	4.7	0.70
Endocrine System	15	5.0	0.67	5.4	0.75	80	23.3	1.21	25.8	1.38
Thyroid gland	14	4.6	0.65	5.0	0.73	79	23.0	1.21	25.5	1.38
Lymphomas	39	14.7	1.24	17.0	1.43	33	12.7	1.08	14.5	1.23
Hodgkin Lymphoma	7	2.0	0.39	2.0	0.42	4	1.0	0.25	1.1	0.26
Non-Hodgkin Lymphoma	32	12.8	1.17	14.9	1.37	28	11.6	1.05	13.4	1.20
Multiple Myeloma	11	5.6	0.85	6.6	0.99	9	3.7	0.61	4.4	0.72
Leukemias	30	10.6	1.07	11.3	1.18	25	8.7	0.87	9.5	0.97
Acute lymphocytic	9	2.2	0.38	2.0	0.38	6	1.5	0.28	1.4	0.30
Chronic lymphocytic	4	2.5	0.61	3.0	0.71	4	2.0	0.47	2.3	0.52
Acute myeloid	6	2.5	0.52	2.7	0.57	9	3.2	0.53	3.7	0.62
Chronic myeloid	4	1.2	0.32	1.3	0.33	3	1.2	0.33	1.3	0.36
Other leukemias	6	2.1	0.50	2.2	0.56	3	0.8	0.26	0.9	0.28
Mesothelioma	2	1.1	0.36	1.3	0.40	-	-	-	-	-
Kaposi Sarcoma	3	0.8	0.21	0.9	0.23	-	-	-	-	-
Ill-defined & Unknown	29	15.1	1.40	17.6	1.62	23	10.6	1.06	12.2	1.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	11	4.7	0.75	5.4	0.87	31	11.4	1.00	13.3	1.16
Breast (<i>in situ</i>)	-	-	-	-	-	45	15.5	1.08	18.9	1.32

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEVADA

II-328 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,910	440.5	2.93	520.7	3.41	4,465	414.7	2.93	482.6	3.32
Oral Cavity & Pharynx	207	18.1	0.59	22.1	0.70	77	7.1	0.38	8.3	0.43
Lip	14	1.3	0.17	1.5	0.19	5	0.4	0.10	0.5	0.10
Tongue	77	6.5	0.35	8.0	0.42	29	2.6	0.23	3.2	0.27
Major salivary gland	19	1.9	0.19	2.2	0.22	8	0.9	0.15	1.0	0.15
Floor of mouth	6	0.5	0.09	0.7	0.13	4	0.3	0.08	0.4	0.09
Gum & other mouth	15	1.3	0.16	1.6	0.19	11	1.0	0.14	1.2	0.16
Nasopharynx	5	0.5	0.11	0.6	0.12	3	0.3	0.08	0.3	0.09
Oropharynx	12	1.0	0.13	1.2	0.16	3	0.3	0.07	0.4	0.09
Hypopharynx	10	0.8	0.12	1.0	0.15	3	0.3	0.07	0.3	0.08
Digestive System	946	84.0	1.27	101.1	1.50	673	59.6	1.07	70.8	1.25
Esophagus	98	8.4	0.39	10.1	0.47	23	1.9	0.19	2.3	0.22
Stomach	62	5.6	0.33	6.6	0.39	32	2.8	0.23	3.3	0.27
Small intestine	23	2.1	0.21	2.5	0.24	18	1.6	0.18	1.9	0.21
Colon excl. rectum	298	27.2	0.73	32.4	0.86	262	23.5	0.68	27.5	0.78
Rectum & rectosigmoid	150	13.5	0.51	16.3	0.61	100	9.3	0.44	11.1	0.51
Anus, anal canal & anorectum	18	1.6	0.18	2.0	0.21	28	2.4	0.21	3.0	0.26
Liver	100	8.3	0.38	10.4	0.47	32	2.7	0.22	3.3	0.27
Gallbladder	6	0.5	0.10	0.6	0.11	11	0.9	0.13	1.1	0.15
Pancreas	150	13.2	0.50	15.9	0.59	133	11.3	0.45	13.5	0.53
Respiratory System	731	63.7	1.09	75.3	1.28	725	60.9	1.04	72.0	1.21
Larynx	48	4.0	0.26	4.8	0.32	12	1.0	0.14	1.3	0.17
Lung & bronchus	674	58.8	1.04	69.5	1.23	705	59.3	1.02	70.0	1.20
Bones & Joints	12	1.5	0.21	1.5	0.20	7	0.9	0.16	0.9	0.16
Soft Tissue (incl. heart)	40	4.1	0.30	4.5	0.33	28	2.7	0.25	3.0	0.27
Skin (excl. basal & sq.)	334	31.5	0.81	36.8	0.92	190	19.2	0.66	22.0	0.74
Melanomas of the skin	316	29.8	0.78	34.8	0.90	180	18.2	0.64	20.9	0.72
Breast (excl. <i>in situ</i>)	15	1.4	0.17	1.6	0.19	1,279	119.7	1.58	140.4	1.80
Female Genital System	-	-	-	-	-	485	46.2	1.00	54.2	1.13
Cervix uteri	-	-	-	-	-	74	9.0	0.50	9.6	0.51
Uterus Corpus	-	-	-	-	-	242	21.3	0.65	26.0	0.77
Uterus, NOS ¹	-	-	-	-	-	10	0.8	0.13	1.0	0.15
Ovary	-	-	-	-	-	117	11.0	0.48	13.0	0.55
Male Genital System	1,137	95.3	1.31	115.1	1.56	-	-	-	-	-
Prostate	1,079	87.5	1.22	107.3	1.49	-	-	-	-	-
Testis	47	6.7	0.45	6.5	0.43	-	-	-	-	-
Penis	9	0.9	0.14	1.0	0.16	-	-	-	-	-
Urinary System	635	57.4	1.06	67.5	1.23	247	21.8	0.65	25.6	0.74
Bladder (incl. <i>in situ</i>)	417	37.5	0.85	44.0	0.99	124	10.7	0.44	12.6	0.51
Kidney & renal pelvis	206	18.8	0.62	22.1	0.71	114	10.3	0.46	12.1	0.52
Ureter	6	0.6	0.11	0.7	0.12	7	0.6	0.10	0.7	0.11
Eye & Orbit	13	1.3	0.18	1.5	0.19	8	0.8	0.14	0.9	0.15
Brain & Other CNS ¹	85	8.9	0.46	9.7	0.49	63	6.6	0.41	7.2	0.42
Brain	82	8.6	0.45	9.4	0.48	60	6.2	0.39	6.8	0.41
Endocrine System	89	9.1	0.46	10.2	0.50	209	25.4	0.84	27.1	0.86
Thyroid gland	82	8.4	0.44	9.4	0.48	202	24.4	0.82	26.2	0.84
Lymphomas	215	20.8	0.67	23.9	0.75	161	15.0	0.56	17.2	0.63
Hodgkin Lymphoma	16	1.9	0.23	2.0	0.23	15	2.1	0.25	2.1	0.25
Non-Hodgkin Lymphoma	200	18.9	0.63	21.9	0.71	145	12.9	0.50	15.1	0.57
Multiple Myeloma	63	5.7	0.33	6.7	0.39	42	3.6	0.26	4.3	0.30
Leukemias	167	16.9	0.62	18.9	0.67	100	10.2	0.49	11.1	0.51
Acute lymphocytic	13	2.2	0.28	1.8	0.23	10	1.7	0.25	1.4	0.21
Chronic lymphocytic	60	5.3	0.31	6.4	0.38	36	3.2	0.25	3.6	0.28
Acute myeloid	51	5.1	0.34	5.7	0.37	31	3.0	0.26	3.4	0.28
Chronic myeloid	17	1.8	0.20	2.0	0.22	12	1.1	0.15	1.3	0.17
Other leukemias	26	2.6	0.24	2.9	0.26	13	1.2	0.17	1.4	0.18
Mesothelioma	12	1.2	0.15	1.3	0.17	4	0.4	0.09	0.5	0.10
Kaposi Sarcoma	5	0.6	0.12	0.6	0.13	-	-	-	-	-
Ill-defined & Unknown	205	19.1	0.62	22.4	0.72	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	69	6.9	0.40	7.8	0.43	134	12.6	0.52	14.6	0.58
Breast (<i>in situ</i>)	2	0.2	0.06	0.3	0.07	226	21.1	0.67	25.0	0.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nevada, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	433	392.0	8.90	470.7	10.54	430	344.9	7.64	406.3	8.92
Oral Cavity & Pharynx	15	12.8	1.52	15.2	1.77	6	4.6	0.85	5.6	1.02
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.7	0.84	4.4	0.97	2	1.2	0.44	1.5	0.54
Major salivary gland	2	1.7	0.58	1.8	0.64	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	0.8	0.32	1.1	0.43
Nasopharynx	2	1.5	0.49	1.7	0.56	-	-	-	-	-
Oropharynx	2	1.6	0.52	2.0	0.63	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	100	90.8	4.29	109.7	5.10	78	63.6	3.31	75.7	3.89
Esophagus	6	4.6	0.89	5.9	1.12	1	0.9	0.39	1.2	0.48
Stomach	9	8.2	1.31	9.8	1.55	7	5.8	1.04	6.9	1.23
Small intestine	4	3.4	0.81	4.0	0.94	2	1.8	0.54	2.1	0.63
Colon excl. rectum	37	35.4	2.74	41.9	3.21	31	25.2	2.08	29.8	2.43
Rectum & rectosigmoid	11	9.6	1.38	11.7	1.66	8	6.6	1.08	7.5	1.22
Anus, anal canal & anorectum	-	-	-	-	-	3	2.1	0.57	2.6	0.69
Liver	14	11.4	1.44	14.7	1.82	6	4.3	0.82	5.4	1.02
Gallbladder	-	-	-	-	-	1	1.2	0.45	1.4	0.54
Pancreas	15	13.5	1.64	16.3	1.95	16	12.9	1.49	15.6	1.78
Respiratory System	60	57.0	3.47	68.2	4.09	59	49.5	2.97	59.2	3.51
Larynx	5	4.3	0.93	5.0	1.06	-	-	-	-	-
Lung & bronchus	55	52.5	3.34	63.0	3.95	57	48.0	2.93	57.6	3.47
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	2.9	0.70	3.2	0.78	5	3.5	0.73	3.8	0.82
Skin (excl. basal & sq.)	2	1.3	0.49	1.6	0.60	3	2.4	0.65	2.5	0.71
Melanomas of the skin	-	-	-	-	-	1	1.3	0.52	1.5	0.59
Breast (excl. <i>in situ</i>)	2	2.1	0.65	2.7	0.82	139	109.7	4.26	128.6	4.94
Female Genital System	-	-	-	-	-	49	38.2	2.50	45.4	2.94
Cervix uteri	-	-	-	-	-	10	8.1	1.15	8.6	1.21
Uterus Corpus	-	-	-	-	-	23	17.0	1.65	21.1	2.01
Uterus, NOS ¹	-	-	-	-	-	2	1.2	0.41	1.4	0.50
Ovary	-	-	-	-	-	11	8.9	1.24	10.7	1.47
Male Genital System	132	113.5	4.63	141.8	5.68	-	-	-	-	-
Prostate	130	112.0	4.61	140.2	5.65	-	-	-	-	-
Testis	1	1.0	0.40	1.0	0.37	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	45	43.4	3.08	50.4	3.55	23	18.3	1.76	21.9	2.08
Bladder (incl. <i>in situ</i>)	19	21.4	2.33	24.6	2.68	7	5.7	1.02	6.8	1.19
Kidney & renal pelvis	25	21.7	1.99	25.4	2.32	16	12.5	1.44	15.1	1.71
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	5.5	1.02	6.0	1.14	6	4.2	0.82	4.6	0.91
Brain	7	5.4	1.01	5.8	1.12	5	4.0	0.80	4.3	0.88
Endocrine System	3	2.6	0.64	2.8	0.71	13	10.2	1.26	11.4	1.41
Thyroid gland	2	1.9	0.56	2.0	0.60	13	9.6	1.21	10.8	1.37
Lymphomas	18	16.6	1.88	18.8	2.15	14	11.5	1.40	13.3	1.61
Hodgkin Lymphoma	2	1.8	0.53	1.9	0.57	3	1.9	0.50	2.3	0.61
Non-Hodgkin Lymphoma	15	14.8	1.81	16.9	2.07	11	9.5	1.30	11.0	1.49
Multiple Myeloma	11	10.2	1.49	12.1	1.74	8	6.6	1.08	7.9	1.28
Leukemias	13	12.1	1.56	13.6	1.77	9	7.2	1.12	8.1	1.27
Acute lymphocytic	2	1.2	0.42	0.9	0.33	-	-	-	-	-
Chronic lymphocytic	4	3.6	0.89	4.4	1.06	2	2.1	0.65	2.6	0.79
Acute myeloid	4	3.9	0.90	4.4	1.02	3	2.5	0.66	2.9	0.75
Chronic myeloid	1	1.1	0.43	1.3	0.49	2	1.4	0.46	1.5	0.52
Other leukemias	2	2.2	0.68	2.6	0.78	-	-	-	-	-
Mesothelioma	2	1.8	0.70	2.3	0.87	-	-	-	-	-
Kaposi Sarcoma	3	1.7	0.47	1.8	0.51	-	-	-	-	-
Ill-defined & Unknown	17	16.7	1.95	19.4	2.26	17	14.4	1.62	16.9	1.88
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	6.3	1.16	7.3	1.34	18	14.6	1.57	16.9	1.80
Breast (<i>in situ</i>)	-	-	-	-	-	27	21.5	1.91	25.3	2.22

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NEVADA

II-330 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,326,408	1,333,223	1,336,294	1,342,373	1,349,767
White	1,261,933	1,266,241	1,266,523	1,269,565	1,274,836
Black	22,723	23,528	24,545	25,912	27,014
American Indian/Alaskan Native (AI/AN)	4,791	4,845	4,894	5,008	5,113
Asian/Pacific Islander (API)	36,961	38,609	40,332	41,888	42,804


All Races Population 2013-2017: 6,688,065
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	41,865	43,548	45,546	47,821	50,332
Non-Hispanic White	1,225,421	1,228,362	1,226,915	1,228,141	1,231,334
Non-Hispanic Black	19,232	19,781	20,559	21,601	22,418

Hispanic/Latino Population, Census 2010: 36,704
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW HAMPSHIRE CANCER REGISTRY

Initial Operation: 1986
 Population-based Data Available: 1987
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.2	111.9	110.8	109.1	104.3
Missing Race	1.4	1.4	1.0	1.5	1.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.4	1.0	1.1	1.4	1.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.8	Prostate	96.2
Oral Cavity & Pharynx	98.8	Testis	100.0
Esophagus	97.8	Bladder (incl. <i>in situ</i>)	98.2
Stomach	96.1	Kidney & Renal Pelvis	91.6
Colon & Rectum	96.7	Brain & Other CNS ¹	92.8
Liver	53.0	Thyroid	99.5
Pancreas	86.8	Hodgkin Lymphoma	98.5
Lung & Bronchus	85.6	Non-Hodgkin Lymphoma	97.3
Melanomas of the Skin	99.6	Multiple Myeloma	92.4
Female Breast (excl. <i>in situ</i>)	99.1	Leukemias	85.3
Cervix uteri	98.3	Brain & Other CNS ¹ <i>non-malig</i>	45.7
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	92.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,170	511.6	3.68	604.2	4.24	4,142	463.9	3.36	540.8	3.80
Oral Cavity & Pharynx	155	18.1	0.68	22.0	0.80	58	6.2	0.38	7.5	0.44
Lip	5	0.7	0.14	0.8	0.16	3	0.3	0.08	0.4	0.10
Tongue	53	6.2	0.39	7.4	0.46	19	2.1	0.22	2.5	0.26
Major salivary gland	8	1.1	0.18	1.2	0.19	5	0.6	0.13	0.6	0.13
Floor of mouth	7	0.8	0.13	0.9	0.16	4	0.5	0.11	0.6	0.13
Gum & other mouth	14	1.7	0.21	2.1	0.25	11	1.1	0.16	1.4	0.19
Nasopharynx	5	0.6	0.13	0.7	0.14	-	-	-	-	-
Oropharynx	10	1.1	0.17	1.4	0.20	2	0.2	0.07	0.2	0.08
Hypopharynx	9	0.9	0.15	1.2	0.18	4	0.4	0.09	0.5	0.11
Digestive System	754	92.7	1.57	109.9	1.81	558	60.8	1.20	71.1	1.36
Esophagus	95	11.5	0.55	13.7	0.64	24	2.4	0.23	2.9	0.27
Stomach	61	7.4	0.44	8.8	0.51	32	3.5	0.29	4.1	0.33
Small intestine	25	3.0	0.28	3.5	0.32	18	2.1	0.22	2.4	0.25
Colon excl. rectum	213	27.5	0.87	32.0	0.99	217	23.6	0.75	27.4	0.84
Rectum & rectosigmoid	117	14.5	0.62	17.1	0.72	73	8.1	0.44	9.6	0.51
Anus, anal canal & anorectum	12	1.4	0.19	1.7	0.23	22	2.3	0.23	2.9	0.28
Liver	78	8.8	0.46	10.9	0.56	18	2.0	0.21	2.3	0.24
Gallbladder	6	0.8	0.15	0.9	0.17	14	1.6	0.19	1.8	0.21
Pancreas	111	13.3	0.59	15.8	0.68	103	11.1	0.51	13.0	0.58
Respiratory System	593	73.5	1.40	86.7	1.62	602	63.6	1.19	75.8	1.39
Larynx	41	4.9	0.36	5.9	0.42	11	1.1	0.15	1.4	0.19
Lung & bronchus	542	67.2	1.34	79.3	1.54	585	61.8	1.17	73.6	1.37
Bones & Joints	7	1.0	0.18	1.1	0.18	4	0.7	0.15	0.7	0.14
Soft Tissue (incl. heart)	29	4.1	0.35	4.4	0.37	22	2.7	0.27	3.0	0.29
Skin (excl. basal & sq.)	324	41.0	1.06	47.8	1.21	249	29.2	0.87	33.3	0.96
Melanomas of the skin	304	38.3	1.02	44.7	1.16	234	27.7	0.85	31.6	0.93
Breast (excl. <i>in situ</i>)	12	1.5	0.20	1.8	0.24	1,283	144.7	1.89	169.6	2.14
Female Genital System	-	-	-	-	-	475	51.5	1.10	61.6	1.28
Cervix uteri	-	-	-	-	-	35	4.7	0.38	5.1	0.39
Uterus Corpus	-	-	-	-	-	288	30.3	0.83	37.0	0.98
Uterus, NOS ¹	-	-	-	-	-	10	1.1	0.16	1.4	0.19
Ovary	-	-	-	-	-	91	10.0	0.49	11.9	0.56
Male Genital System	1,046	117.9	1.69	144.1	2.01	-	-	-	-	-
Prostate	991	109.2	1.60	135.3	1.94	-	-	-	-	-
Testis	44	7.2	0.50	7.2	0.48	-	-	-	-	-
Penis	7	0.9	0.15	1.0	0.18	-	-	-	-	-
Urinary System	535	68.0	1.36	79.5	1.56	220	23.9	0.75	28.1	0.85
Bladder (incl. <i>in situ</i>)	352	45.4	1.12	53.0	1.28	117	12.5	0.53	14.7	0.61
Kidney & renal pelvis	174	21.4	0.76	25.0	0.86	95	10.5	0.50	12.3	0.57
Ureter	7	0.9	0.15	1.0	0.18	6	0.6	0.11	0.8	0.14
Eye & Orbit	8	1.0	0.16	1.1	0.18	8	0.9	0.15	1.1	0.17
Brain & Other CNS ¹	66	8.8	0.51	9.6	0.54	51	6.2	0.41	6.9	0.44
Brain	62	8.3	0.49	9.0	0.52	48	5.8	0.40	6.5	0.43
Endocrine System	66	8.7	0.50	9.7	0.54	171	23.7	0.85	25.2	0.87
Thyroid gland	59	7.8	0.48	8.7	0.51	166	23.1	0.84	24.6	0.86
Lymphomas	218	28.4	0.89	32.5	1.00	175	19.9	0.70	23.0	0.78
Hodgkin Lymphoma	22	3.2	0.32	3.3	0.32	18	2.6	0.29	2.7	0.29
Non-Hodgkin Lymphoma	197	25.2	0.83	29.1	0.94	158	17.3	0.64	20.3	0.73
Multiple Myeloma	59	7.5	0.45	8.7	0.52	45	4.6	0.32	5.6	0.38
Leukemias	137	18.0	0.72	20.4	0.79	86	10.4	0.53	11.4	0.56
Acute lymphocytic	10	1.7	0.24	1.6	0.22	8	1.3	0.22	1.2	0.19
Chronic lymphocytic	54	6.8	0.43	8.0	0.49	30	3.3	0.27	3.8	0.31
Acute myeloid	38	5.0	0.37	5.7	0.42	26	3.2	0.29	3.5	0.31
Chronic myeloid	17	2.3	0.26	2.6	0.28	11	1.3	0.18	1.5	0.20
Other leukemias	17	2.3	0.26	2.5	0.28	11	1.4	0.19	1.5	0.20
Mesothelioma	14	1.9	0.24	2.2	0.27	3	0.3	0.09	0.4	0.10
Kaposi Sarcoma	3	0.3	0.10	0.4	0.11	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	133	14.4	0.58	16.4	0.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	58	7.6	0.47	8.5	0.51	121	14.1	0.60	16.2	0.67
Breast (<i>in situ</i>)	-	-	-	-	-	312	36.0	0.95	42.3	1.08

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	4,033	508.6	3.73	600.4	4.28	4,016	463.2	3.42	539.8	3.86
Oral Cavity & Pharynx	152	18.3	0.69	22.3	0.82	56	6.2	0.39	7.4	0.45
Lip	5	0.7	0.15	0.8	0.16	3	0.3	0.08	0.4	0.10
Tongue	52	6.3	0.41	7.5	0.47	19	2.1	0.23	2.5	0.26
Major salivary gland	7	1.0	0.18	1.1	0.19	4	0.6	0.14	0.6	0.14
Floor of mouth	7	0.7	0.13	0.9	0.16	4	0.5	0.11	0.6	0.13
Gum & other mouth	14	1.8	0.22	2.2	0.26	11	1.2	0.16	1.4	0.19
Nasopharynx	4	0.5	0.13	0.6	0.14	-	-	-	-	-
Oropharynx	10	1.1	0.17	1.4	0.20	1	0.1	0.06	0.2	0.06
Hypopharynx	9	1.0	0.15	1.2	0.19	4	0.4	0.09	0.5	0.11
Digestive System	728	92.3	1.59	109.2	1.83	543	60.9	1.22	71.2	1.38
Esophagus	93	11.5	0.55	13.7	0.64	23	2.4	0.23	3.0	0.28
Stomach	58	7.2	0.44	8.6	0.51	30	3.5	0.29	4.0	0.33
Small intestine	24	3.0	0.28	3.5	0.33	18	2.1	0.23	2.4	0.26
Colon excl. rectum	208	27.7	0.89	32.1	1.01	211	23.6	0.76	27.4	0.85
Rectum & rectosigmoid	113	14.4	0.63	17.0	0.72	71	8.1	0.45	9.6	0.52
Anus, anal canal & anorectum	12	1.5	0.20	1.8	0.23	22	2.4	0.23	3.0	0.28
Liver	74	8.5	0.46	10.6	0.56	18	1.9	0.21	2.3	0.24
Gallbladder	6	0.8	0.15	0.9	0.17	13	1.6	0.20	1.7	0.22
Pancreas	108	13.3	0.60	15.8	0.69	101	11.2	0.51	13.0	0.59
Respiratory System	580	73.6	1.41	86.9	1.63	590	63.8	1.20	76.1	1.41
Larynx	40	5.0	0.36	6.0	0.43	11	1.1	0.16	1.4	0.19
Lung & bronchus	530	67.2	1.35	79.3	1.56	573	62.0	1.19	73.9	1.39
Bones & Joints	7	1.1	0.19	1.1	0.19	4	0.6	0.15	0.6	0.14
Soft Tissue (incl. heart)	28	4.0	0.35	4.3	0.37	21	2.7	0.28	3.0	0.29
Skin (excl. basal & sq.)	302	39.2	1.05	45.8	1.20	227	27.7	0.87	31.5	0.95
Melanomas of the skin	283	36.5	1.01	42.7	1.15	214	26.2	0.85	29.8	0.93
Breast (excl. <i>in situ</i>)	12	1.6	0.21	1.9	0.24	1,255	146.1	1.94	171.1	2.19
Female Genital System	-	-	-	-	-	459	51.3	1.12	61.4	1.30
Cervix uteri	-	-	-	-	-	34	4.7	0.39	5.0	0.40
Uterus Corpus	-	-	-	-	-	278	30.1	0.84	36.7	0.99
Uterus, NOS ¹	-	-	-	-	-	10	1.1	0.16	1.4	0.19
Ovary	-	-	-	-	-	89	10.0	0.50	11.9	0.57
Male Genital System	1,003	116.1	1.70	141.9	2.03	-	-	-	-	-
Prostate	950	107.1	1.60	132.9	1.95	-	-	-	-	-
Testis	43	7.5	0.52	7.5	0.51	-	-	-	-	-
Penis	6	0.9	0.16	1.0	0.18	-	-	-	-	-
Urinary System	524	68.3	1.38	79.8	1.58	215	23.9	0.75	28.1	0.86
Bladder (incl. <i>in situ</i>)	345	45.5	1.13	53.2	1.30	115	12.5	0.54	14.8	0.62
Kidney & renal pelvis	169	21.6	0.78	25.2	0.88	91	10.4	0.51	12.2	0.58
Ureter	7	0.9	0.16	1.0	0.18	6	0.6	0.11	0.8	0.14
Eye & Orbit	7	1.0	0.17	1.1	0.18	8	0.9	0.15	1.0	0.17
Brain & Other CNS ¹	63	8.8	0.52	9.6	0.55	50	6.4	0.43	7.0	0.45
Brain	59	8.2	0.50	9.0	0.53	47	5.9	0.41	6.6	0.44
Endocrine System	65	8.9	0.52	9.9	0.56	162	23.6	0.87	25.1	0.89
Thyroid gland	58	8.0	0.50	9.0	0.53	158	23.1	0.87	24.5	0.88
Lymphomas	212	28.6	0.91	32.6	1.01	169	19.8	0.71	22.8	0.79
Hodgkin Lymphoma	21	3.3	0.33	3.4	0.33	17	2.7	0.30	2.7	0.30
Non-Hodgkin Lymphoma	191	25.3	0.85	29.2	0.96	152	17.1	0.64	20.1	0.74
Multiple Myeloma	57	7.4	0.46	8.7	0.52	43	4.5	0.32	5.5	0.38
Leukemias	134	18.2	0.73	20.5	0.80	84	10.4	0.54	11.5	0.57
Acute lymphocytic	10	1.6	0.25	1.6	0.23	7	1.3	0.22	1.2	0.19
Chronic lymphocytic	53	6.8	0.43	8.0	0.50	29	3.2	0.28	3.7	0.31
Acute myeloid	38	5.1	0.38	5.7	0.42	26	3.3	0.31	3.6	0.32
Chronic myeloid	17	2.3	0.26	2.6	0.29	11	1.3	0.18	1.5	0.20
Other leukemias	17	2.3	0.26	2.6	0.29	11	1.4	0.20	1.5	0.21
Mesothelioma	13	1.9	0.24	2.2	0.27	3	0.3	0.09	0.4	0.11
Kaposi Sarcoma	2	0.3	0.10	0.4	0.11	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	128	14.2	0.58	16.1	0.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	56	7.7	0.48	8.6	0.52	116	14.1	0.61	16.1	0.68
Breast (<i>in situ</i>)	-	-	-	-	-	304	36.2	0.97	42.5	1.10

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	28	370.9	36.75	445.0	42.63	18	251.7	29.12	303.2	34.67
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	81.2	16.90	97.2	19.43	3	42.9	11.37	55.9	14.63
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	20.4	7.11	26.6	9.06	1	19.8	7.95	24.9	9.98
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	18.0	8.20	21.3	9.15	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	49.1	13.88	56.5	15.55	1	30.2	11.89	33.9	13.56
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	41.7	12.49	48.5	14.26	1	27.8	11.65	31.9	13.41
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	6	87.3	17.37	104.2	20.33
Female Genital System	-	-	-	-	-	2	21.6	7.27	28.7	9.88
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	11	152.2	24.20	186.0	28.39	-	-	-	-	-
Prostate	11	152.2	24.20	186.0	28.39	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	34.1	11.89	41.8	14.17	2	28.4	10.36	34.1	12.12
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	15.0	5.43	19.4	7.05	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	1	11.0	5.05	12.6	5.68	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	1	11.0	5.05	12.6	5.68	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	25.0	9.61	28.5	10.79
Breast (<i>in situ</i>)	-	-	-	-	-	2	25.3	9.18	27.5	9.86

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	30	256.0	23.77	298.2	27.41	44	265.8	19.68	315.1	23.20
Oral Cavity & Pharynx	1	9.5	3.99	11.0	4.52	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	8	68.6	12.01	84.7	14.44	6	46.7	9.40	57.0	11.35
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	2	16.4	5.70	20.0	6.85
Rectum & rectosigmoid	2	13.6	4.42	17.4	5.60	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	16.1	6.05	18.2	6.77	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	38.2	10.27	44.2	11.77	5	38.7	8.28	44.9	9.40
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	38.2	10.27	44.2	11.77	5	38.7	8.28	44.9	9.40
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	16	84.4	9.99	101.2	11.97
Female Genital System	-	-	-	-	-	7	35.2	6.43	42.3	7.79
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	4	24.5	5.55	29.8	6.77
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	6	54.3	10.44	64.7	12.20	-	-	-	-	-
Prostate	6	49.4	10.06	59.8	11.86	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	21.6	7.44	26.7	9.02	1	13.0	5.32	13.6	5.72
Bladder (incl. <i>in situ</i>)	1	15.5	6.72	19.4	8.20	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	4	18.2	4.58	20.3	5.12
Thyroid gland	-	-	-	-	-	3	14.6	3.67	17.0	4.39
Lymphomas	2	14.8	5.51	15.2	5.59	2	8.2	2.98	10.5	3.78
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	1	12.7	5.37	13.0	5.44	1	7.2	2.81	9.4	3.62
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	13.2	5.33	13.9	5.79	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	2	10.3	3.85	11.8	4.42
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	1	8.7	3.91	10.7	4.62	2	18.3	5.76	21.6	6.61
Breast (<i>in situ</i>)	-	-	-	-	-	4	22.6	4.86	26.7	5.85

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	41	349.1	27.93	412.9	32.23	44	290.8	21.08	333.9	24.22
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	10	86.8	13.75	103.8	16.03	4	28.8	6.69	34.9	8.06
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	16.8	6.65	20.3	7.68	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	17.6	6.22	19.2	6.91	1	8.3	3.70	9.3	4.18
Rectum & rectosigmoid	2	13.5	4.85	16.8	5.98	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	13.2	5.17	15.9	6.01	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	5	45.5	10.69	53.0	12.02	4	35.5	8.18	40.3	9.12
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	39.2	9.70	46.1	11.03	4	34.4	8.10	38.7	8.99
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	15	92.1	11.33	108.7	13.41
Female Genital System	-	-	-	-	-	4	30.8	7.10	35.2	8.01
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	3	17.4	5.14	21.1	6.16
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	13	99.9	14.10	120.5	16.68	-	-	-	-	-
Prostate	10	90.4	13.81	111.4	16.46	-	-	-	-	-
Testis	2	8.5	2.65	7.8	2.41	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	29.2	8.65	33.9	9.59	1	7.4	3.06	10.0	4.12
Bladder (incl. <i>in situ</i>)	2	17.8	7.30	20.3	7.85	-	-	-	-	-
Kidney & renal pelvis	1	11.4	4.64	13.7	5.51	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	4.9	2.09	5.2	2.45	2	6.4	2.32	6.0	2.24
Brain	1	4.9	2.09	5.2	2.45	2	6.4	2.32	6.0	2.24
Endocrine System	2	13.8	5.54	16.0	6.43	5	29.2	6.03	30.1	6.33
Thyroid gland	1	9.7	4.52	11.5	5.41	5	29.2	6.03	30.1	6.33
Lymphomas	2	20.6	7.39	22.7	7.98	3	22.6	6.37	25.9	7.19
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	1	8.3	3.96	9.1	4.48	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	13.7	5.87	17.1	7.16	2	14.0	5.09	16.3	5.92
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	3	16.3	4.73	18.1	5.33
Breast (<i>in situ</i>)	-	-	-	-	-	3	16.8	4.34	20.9	5.59

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEW HAMPSHIRE

II-338 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,000	511.2	3.77	603.3	4.33	3,981	466.1	3.47	543.2	3.91
Oral Cavity & Pharynx	152	18.5	0.70	22.5	0.83	55	6.2	0.39	7.4	0.45
Lip	5	0.7	0.15	0.8	0.17	3	0.3	0.08	0.4	0.10
Tongue	52	6.3	0.41	7.6	0.48	18	2.1	0.23	2.5	0.26
Major salivary gland	7	1.0	0.18	1.2	0.20	4	0.6	0.14	0.6	0.14
Floor of mouth	7	0.8	0.13	0.9	0.16	4	0.5	0.11	0.6	0.13
Gum & other mouth	14	1.8	0.22	2.2	0.26	11	1.2	0.16	1.4	0.19
Nasopharynx	4	0.5	0.13	0.6	0.14	-	-	-	-	-
Oropharynx	10	1.1	0.17	1.4	0.20	1	0.1	0.06	0.2	0.07
Hypopharynx	8	1.0	0.15	1.2	0.19	4	0.4	0.09	0.5	0.12
Digestive System	721	92.6	1.61	109.6	1.85	539	61.4	1.23	71.7	1.40
Esophagus	92	11.5	0.56	13.8	0.65	23	2.4	0.23	3.0	0.28
Stomach	57	7.2	0.44	8.5	0.51	30	3.5	0.30	4.0	0.33
Small intestine	24	3.0	0.29	3.5	0.33	18	2.1	0.23	2.5	0.27
Colon excl. rectum	206	27.8	0.90	32.2	1.02	210	23.8	0.77	27.6	0.87
Rectum & rectosigmoid	111	14.5	0.64	17.1	0.73	70	8.2	0.46	9.7	0.53
Anus, anal canal & anorectum	11	1.5	0.20	1.8	0.24	22	2.4	0.24	3.0	0.29
Liver	72	8.4	0.46	10.5	0.56	17	1.9	0.22	2.3	0.25
Gallbladder	6	0.8	0.16	0.9	0.17	13	1.5	0.20	1.7	0.22
Pancreas	107	13.4	0.60	15.9	0.70	100	11.3	0.52	13.1	0.59
Respiratory System	576	73.8	1.42	87.2	1.65	586	64.1	1.22	76.5	1.42
Larynx	40	5.0	0.37	6.0	0.43	11	1.1	0.16	1.4	0.20
Lung & bronchus	526	67.4	1.36	79.6	1.57	570	62.3	1.20	74.3	1.40
Bones & Joints	7	1.1	0.20	1.1	0.19	3	0.6	0.14	0.6	0.14
Soft Tissue (incl. heart)	28	4.1	0.36	4.4	0.38	21	2.7	0.28	3.0	0.30
Skin (excl. basal & sq.)	301	39.6	1.06	46.3	1.21	227	28.1	0.89	32.0	0.97
Melanomas of the skin	282	36.9	1.02	43.2	1.17	213	26.7	0.87	30.3	0.94
Breast (excl. <i>in situ</i>)	12	1.6	0.21	1.9	0.25	1,242	147.0	1.96	172.1	2.21
Female Genital System	-	-	-	-	-	456	51.7	1.14	61.9	1.31
Cervix uteri	-	-	-	-	-	33	4.7	0.39	5.1	0.40
Uterus Corpus	-	-	-	-	-	276	30.3	0.85	37.0	1.01
Uterus, NOS ¹	-	-	-	-	-	10	1.1	0.17	1.4	0.20
Ovary	-	-	-	-	-	88	10.1	0.50	12.0	0.58
Male Genital System	993	116.2	1.71	142.1	2.04	-	-	-	-	-
Prostate	942	107.3	1.61	133.1	1.96	-	-	-	-	-
Testis	41	7.4	0.53	7.4	0.52	-	-	-	-	-
Penis	6	0.8	0.15	1.0	0.18	-	-	-	-	-
Urinary System	521	68.9	1.40	80.4	1.60	214	24.1	0.76	28.3	0.88
Bladder (incl. <i>in situ</i>)	344	45.8	1.14	53.6	1.31	115	12.7	0.55	14.9	0.63
Kidney & renal pelvis	168	21.8	0.79	25.4	0.89	91	10.5	0.52	12.3	0.58
Ureter	7	0.9	0.16	1.0	0.18	6	0.6	0.12	0.8	0.14
Eye & Orbit	7	1.0	0.17	1.1	0.19	8	0.9	0.15	1.0	0.17
Brain & Other CNS ¹	62	8.9	0.53	9.7	0.56	48	6.3	0.43	7.0	0.46
Brain	59	8.3	0.51	9.1	0.54	45	5.8	0.41	6.6	0.44
Endocrine System	63	9.0	0.53	9.9	0.57	158	23.5	0.89	25.0	0.91
Thyroid gland	57	8.1	0.51	9.0	0.54	154	23.0	0.88	24.5	0.90
Lymphomas	210	28.8	0.93	32.9	1.03	168	19.9	0.72	22.9	0.80
Hodgkin Lymphoma	21	3.4	0.35	3.5	0.35	17	2.7	0.31	2.8	0.31
Non-Hodgkin Lymphoma	190	25.4	0.86	29.4	0.97	151	17.2	0.65	20.1	0.74
Multiple Myeloma	56	7.4	0.46	8.7	0.53	43	4.5	0.32	5.5	0.38
Leukemias	133	18.3	0.74	20.7	0.81	83	10.6	0.55	11.6	0.58
Acute lymphocytic	9	1.6	0.25	1.6	0.23	7	1.3	0.23	1.2	0.20
Chronic lymphocytic	53	6.9	0.44	8.1	0.51	29	3.2	0.28	3.8	0.32
Acute myeloid	37	5.1	0.39	5.8	0.43	26	3.4	0.31	3.7	0.33
Chronic myeloid	17	2.3	0.27	2.6	0.29	11	1.3	0.18	1.5	0.20
Other leukemias	17	2.3	0.27	2.6	0.29	11	1.4	0.20	1.5	0.21
Mesothelioma	13	1.9	0.24	2.2	0.27	3	0.3	0.09	0.4	0.11
Kaposi Sarcoma	2	0.3	0.10	0.4	0.11	-	-	-	-	-
Ill-defined & Unknown	141	19.2	0.75	22.2	0.85	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	55	7.8	0.49	8.7	0.53	114	14.0	0.62	16.0	0.68
Breast (<i>in situ</i>)	-	-	-	-	-	302	36.7	0.99	43.1	1.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Hampshire, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	26	381.7	39.03	460.3	45.31	17	281.2	33.60	336.6	39.68
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	82.1	17.82	99.5	20.69	3	46.8	12.82	60.2	16.25
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	22.8	7.90	29.7	10.08	1	23.0	9.21	28.8	11.53
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	45.7	13.57	52.8	14.97	1	36.7	14.48	41.2	16.48
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	37.5	11.82	43.9	13.31	1	33.7	14.16	38.7	16.30
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	94.7	19.57	112.4	22.74
Female Genital System	-	-	-	-	-	2	24.9	8.38	33.0	11.30
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	10	157.3	25.87	192.1	30.27	-	-	-	-	-
Prostate	10	157.3	25.87	192.1	30.27	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	38.2	13.28	46.8	15.81	2	33.6	12.38	40.4	14.46
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	16.9	6.11	21.9	7.92	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	1	12.5	5.66	14.3	6.39	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	29.1	11.19	33.2	12.51
Breast (<i>in situ</i>)	-	-	-	-	-	1	21.6	9.69	23.4	10.29

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	8,858,362	8,866,780	8,870,869	8,874,516	8,888,543
White	6,597,334	6,580,875	6,558,216	6,537,395	6,521,957
Black	1,364,487	1,373,866	1,381,914	1,387,999	1,394,738
American Indian/Alaskan Native (AI/AN)	60,439	61,025	61,584	61,874	63,063
Asian/Pacific Islander (API)	836,102	851,014	869,155	887,248	908,785


All Races Population 2013-2017: 44,359,070
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	1,670,491	1,702,805	1,733,370	1,764,567	1,800,000
Non-Hispanic White	5,174,070	5,132,956	5,087,341	5,041,747	4,998,098
Non-Hispanic Black	1,184,348	1,187,286	1,188,908	1,189,926	1,191,533

Hispanic/Latino Population, Census 2010: 1,555,144
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW JERSEY CANCER REGISTRY

Initial Operation: 1979
 Population-based Data Available: 1979
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.6	111.1	111.7	110.9	111.3
Missing Race	1.5	1.5	1.5	1.6	2.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	1.5	1.6	1.1	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.5	Prostate	98.3
Oral Cavity & Pharynx	97.9	Testis	99.5
Esophagus	94.7	Bladder (incl. <i>in situ</i>)	98.5
Stomach	96.6	Kidney & Renal Pelvis	91.8
Colon & Rectum	96.8	Brain & Other CNS ¹	87.3
Liver	59.1	Thyroid	99.4
Pancreas	85.3	Hodgkin Lymphoma	98.9
Lung & Bronchus	89.4	Non-Hodgkin Lymphoma	97.2
Melanomas of the Skin	99.5	Multiple Myeloma	92.0
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	91.5
Cervix uteri	97.6	Brain & Other CNS ¹ <i>non-malig</i>	42.6
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	94.2		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	25,464	530.5	1.52	628.4	1.77	26,226	458.8	1.30	534.0	1.49
Oral Cavity & Pharynx	842	16.8	0.27	20.4	0.32	362	6.2	0.15	7.3	0.17
Lip	24	0.5	0.05	0.6	0.06	15	0.2	0.03	0.3	0.03
Tongue	255	5.0	0.14	6.1	0.17	112	1.9	0.08	2.3	0.10
Major salivary gland	91	2.0	0.09	2.3	0.11	61	1.1	0.07	1.2	0.07
Floor of mouth	32	0.6	0.05	0.8	0.06	16	0.3	0.03	0.3	0.04
Gum & other mouth	104	2.2	0.10	2.6	0.11	76	1.3	0.07	1.5	0.08
Nasopharynx	39	0.8	0.06	0.9	0.07	16	0.3	0.04	0.3	0.04
Oropharynx	43	0.8	0.06	1.0	0.07	15	0.2	0.03	0.3	0.03
Hypopharynx	45	0.9	0.06	1.1	0.07	11	0.2	0.02	0.2	0.03
Digestive System	4,911	102.6	0.67	122.0	0.78	4,160	69.8	0.50	81.9	0.57
Esophagus	360	7.4	0.18	8.9	0.21	110	1.8	0.08	2.1	0.09
Stomach	503	10.7	0.22	12.6	0.25	344	5.9	0.15	6.9	0.17
Small intestine	146	3.0	0.11	3.6	0.13	128	2.2	0.09	2.6	0.10
Colon excl. rectum	1,492	31.8	0.38	37.4	0.44	1,554	26.2	0.31	30.4	0.35
Rectum & rectosigmoid	730	15.0	0.25	17.9	0.30	566	9.7	0.19	11.5	0.22
Anus, anal canal & anorectum	66	1.3	0.08	1.6	0.09	131	2.2	0.09	2.7	0.11
Liver	545	10.6	0.21	13.2	0.25	176	2.9	0.10	3.5	0.12
Gallbladder	45	1.0	0.07	1.2	0.08	94	1.5	0.07	1.8	0.08
Pancreas	768	16.2	0.27	19.2	0.31	787	12.9	0.21	15.2	0.24
Respiratory System	3,152	67.2	0.55	79.2	0.63	3,209	53.3	0.43	63.0	0.50
Larynx	264	5.4	0.15	6.5	0.18	60	1.0	0.06	1.2	0.07
Lung & bronchus	2,836	60.8	0.52	71.4	0.60	3,113	51.7	0.42	61.1	0.49
Bones & Joints	53	1.2	0.07	1.2	0.08	46	1.0	0.07	1.0	0.07
Soft Tissue (incl. heart)	199	4.4	0.14	4.9	0.16	162	3.0	0.11	3.4	0.12
Skin (excl. basal & sq.)	1,480	31.6	0.38	37.0	0.43	1,058	19.0	0.27	21.9	0.30
Melanomas of the skin	1,360	28.9	0.36	34.0	0.41	975	17.6	0.26	20.2	0.29
Breast (excl. <i>in situ</i>)	72	1.5	0.08	1.8	0.09	7,668	136.6	0.72	159.7	0.82
Female Genital System	-	-	-	-	-	3,284	56.8	0.46	67.8	0.53
Cervix uteri	-	-	-	-	-	382	7.7	0.18	8.4	0.19
Uterus Corpus	-	-	-	-	-	1,834	30.6	0.33	37.7	0.40
Uterus, NOS ¹	-	-	-	-	-	80	1.4	0.07	1.6	0.08
Ovary	-	-	-	-	-	679	11.8	0.21	13.9	0.24
Male Genital System	7,030	138.4	0.76	169.1	0.91	-	-	-	-	-
Prostate	6,723	131.3	0.73	161.7	0.89	-	-	-	-	-
Testis	253	6.0	0.17	6.0	0.17	-	-	-	-	-
Penis	40	0.9	0.06	1.0	0.07	-	-	-	-	-
Urinary System	3,014	64.4	0.54	75.7	0.62	1,328	22.3	0.28	26.2	0.32
Bladder (incl. <i>in situ</i>)	1,841	40.2	0.43	47.1	0.49	646	10.5	0.19	12.4	0.22
Kidney & renal pelvis	1,101	22.6	0.31	26.7	0.36	635	11.0	0.20	12.9	0.23
Ureter	38	0.9	0.06	1.0	0.07	29	0.5	0.04	0.5	0.05
Eye & Orbit	34	0.8	0.06	0.8	0.06	33	0.6	0.05	0.7	0.05
Brain & Other CNS ¹	371	8.1	0.19	8.9	0.21	302	5.8	0.15	6.3	0.16
Brain	353	7.7	0.19	8.5	0.20	284	5.4	0.15	6.0	0.16
Endocrine System	510	10.9	0.22	12.2	0.24	1,421	29.2	0.36	31.7	0.38
Thyroid gland	466	9.9	0.21	11.1	0.23	1,374	28.3	0.35	30.7	0.37
Lymphomas	1,370	29.7	0.37	33.9	0.41	1,192	21.3	0.28	24.2	0.32
Hodgkin Lymphoma	158	3.5	0.13	3.8	0.13	132	2.9	0.12	3.0	0.12
Non-Hodgkin Lymphoma	1,212	26.1	0.34	30.2	0.39	1,059	18.3	0.26	21.2	0.29
Multiple Myeloma	434	9.1	0.20	10.8	0.23	360	6.0	0.15	7.2	0.17
Leukemias	917	20.0	0.30	22.8	0.34	693	12.3	0.22	13.8	0.24
Acute lymphocytic	82	2.0	0.10	1.8	0.09	74	1.7	0.09	1.6	0.08
Chronic lymphocytic	370	7.8	0.18	9.3	0.22	255	4.1	0.12	4.9	0.14
Acute myeloid	243	5.4	0.16	6.1	0.18	205	3.6	0.12	4.1	0.13
Chronic myeloid	123	2.8	0.11	3.1	0.13	81	1.5	0.08	1.6	0.08
Other leukemias	99	2.2	0.10	2.5	0.11	78	1.4	0.07	1.5	0.08
Mesothelioma	83	1.9	0.10	2.2	0.11	33	0.6	0.04	0.6	0.05
Kaposi Sarcoma	32	0.7	0.06	0.8	0.06	5	0.1	0.02	0.1	0.02
Ill-defined & Unknown	958	21.2	0.31	24.6	0.36	910	14.8	0.23	17.2	0.26
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	444	9.7	0.21	10.9	0.23	893	16.0	0.25	18.3	0.28
Breast (<i>in situ</i>)	8	0.2	0.03	0.2	0.03	2,245	41.2	0.40	48.3	0.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	20,757	537.5	1.71	634.9	1.98	21,347	475.1	1.52	552.1	1.72
Oral Cavity & Pharynx	700	17.4	0.30	21.2	0.36	297	6.4	0.17	7.6	0.20
Lip	22	0.6	0.06	0.7	0.07	13	0.3	0.03	0.3	0.04
Tongue	222	5.4	0.17	6.7	0.20	96	2.1	0.10	2.5	0.11
Major salivary gland	77	2.1	0.11	2.4	0.12	48	1.1	0.08	1.3	0.08
Floor of mouth	26	0.6	0.06	0.8	0.07	14	0.3	0.04	0.4	0.04
Gum & other mouth	77	2.0	0.10	2.4	0.12	59	1.2	0.08	1.4	0.09
Nasopharynx	25	0.7	0.06	0.8	0.07	10	0.2	0.03	0.3	0.04
Oropharynx	34	0.8	0.06	1.0	0.08	12	0.3	0.03	0.3	0.04
Hypopharynx	35	0.9	0.07	1.0	0.08	9	0.2	0.03	0.2	0.03
Digestive System	3,961	102.5	0.75	121.6	0.87	3,291	68.9	0.56	80.6	0.64
Esophagus	315	8.0	0.21	9.6	0.24	88	1.8	0.09	2.1	0.10
Stomach	383	10.0	0.23	11.8	0.27	239	5.2	0.16	5.9	0.18
Small intestine	113	2.9	0.13	3.4	0.15	93	2.0	0.10	2.3	0.11
Colon excl. rectum	1,213	32.1	0.42	37.6	0.49	1,251	26.2	0.35	30.3	0.39
Rectum & rectosigmoid	586	15.1	0.29	18.0	0.33	448	9.7	0.21	11.5	0.25
Anus, anal canal & anorectum	53	1.3	0.08	1.6	0.10	111	2.4	0.11	2.9	0.13
Liver	407	9.9	0.22	12.2	0.27	129	2.6	0.11	3.1	0.13
Gallbladder	35	1.0	0.07	1.1	0.08	67	1.3	0.07	1.6	0.09
Pancreas	644	16.7	0.30	19.8	0.35	646	13.1	0.24	15.3	0.27
Respiratory System	2,658	69.3	0.61	81.6	0.71	2,746	56.8	0.50	67.0	0.58
Larynx	220	5.5	0.17	6.7	0.20	45	0.9	0.06	1.1	0.08
Lung & bronchus	2,399	62.8	0.59	73.7	0.68	2,672	55.2	0.49	65.1	0.57
Bones & Joints	42	1.3	0.09	1.3	0.09	35	1.0	0.08	1.0	0.08
Soft Tissue (incl. heart)	166	4.6	0.17	5.2	0.18	128	3.1	0.13	3.4	0.14
Skin (excl. basal & sq.)	1,397	36.9	0.45	43.2	0.52	984	22.9	0.34	26.3	0.38
Melanomas of the skin	1,292	34.1	0.43	39.9	0.50	916	21.5	0.33	24.6	0.37
Breast (excl. <i>in situ</i>)	58	1.5	0.09	1.8	0.11	6,100	139.5	0.83	163.1	0.95
Female Genital System	-	-	-	-	-	2,646	58.7	0.53	69.9	0.62
Cervix uteri	-	-	-	-	-	280	7.7	0.22	8.3	0.22
Uterus Corpus	-	-	-	-	-	1,497	31.9	0.38	39.3	0.46
Uterus, NOS ¹	-	-	-	-	-	57	1.2	0.08	1.4	0.09
Ovary	-	-	-	-	-	551	12.2	0.24	14.4	0.28
Male Genital System	5,249	129.0	0.82	156.9	0.97	-	-	-	-	-
Prostate	4,985	120.5	0.78	148.2	0.94	-	-	-	-	-
Testis	220	7.3	0.22	7.3	0.22	-	-	-	-	-
Penis	33	0.9	0.07	1.0	0.08	-	-	-	-	-
Urinary System	2,604	68.4	0.61	80.3	0.71	1,120	23.5	0.33	27.6	0.38
Bladder (incl. <i>in situ</i>)	1,631	43.3	0.49	50.6	0.56	563	11.3	0.22	13.3	0.26
Kidney & renal pelvis	910	23.4	0.36	27.7	0.41	518	11.4	0.23	13.4	0.27
Ureter	36	1.0	0.07	1.1	0.08	26	0.5	0.05	0.6	0.05
Eye & Orbit	30	0.8	0.07	0.9	0.08	29	0.7	0.06	0.8	0.07
Brain & Other CNS ¹	310	8.6	0.22	9.5	0.24	253	6.3	0.19	6.9	0.20
Brain	297	8.2	0.22	9.1	0.24	239	5.9	0.18	6.5	0.19
Endocrine System	428	11.8	0.26	13.3	0.29	1,131	31.4	0.44	34.0	0.46
Thyroid gland	394	10.9	0.25	12.2	0.28	1,099	30.6	0.43	33.2	0.45
Lymphomas	1,166	31.7	0.43	36.2	0.48	996	22.5	0.33	25.6	0.37
Hodgkin Lymphoma	126	3.8	0.15	4.0	0.16	102	3.1	0.14	3.1	0.14
Non-Hodgkin Lymphoma	1,040	27.9	0.40	32.2	0.45	894	19.4	0.30	22.5	0.34
Multiple Myeloma	328	8.5	0.21	10.1	0.25	250	5.2	0.15	6.2	0.18
Leukemias	750	20.4	0.34	23.2	0.38	562	12.6	0.25	14.1	0.27
Acute lymphocytic	66	2.2	0.12	2.0	0.11	55	1.7	0.11	1.6	0.10
Chronic lymphocytic	298	7.7	0.20	9.2	0.24	209	4.2	0.13	5.0	0.16
Acute myeloid	205	5.6	0.18	6.4	0.20	169	3.8	0.14	4.3	0.15
Chronic myeloid	97	2.7	0.13	3.1	0.14	65	1.5	0.09	1.7	0.10
Other leukemias	83	2.3	0.11	2.6	0.13	64	1.4	0.08	1.6	0.09
Mesothelioma	78	2.2	0.11	2.5	0.13	29	0.6	0.05	0.7	0.06
Kaposi Sarcoma	21	0.6	0.06	0.7	0.07	3	0.1	0.02	0.1	0.02
Ill-defined & Unknown	810	21.9	0.35	25.4	0.40	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	353	9.8	0.24	11.0	0.26	707	16.2	0.29	18.5	0.32
Breast (<i>in situ</i>)	6	0.1	0.03	0.2	0.03	1,750	41.9	0.47	49.2	0.53

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,836	515.1	4.57	621.4	5.40	3,102	410.2	3.34	481.9	3.88
Oral Cavity & Pharynx	75	12.8	0.69	15.7	0.83	36	4.7	0.36	5.5	0.41
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	15	2.7	0.32	3.3	0.39	8	1.0	0.16	1.2	0.20
Major salivary gland	7	1.2	0.22	1.5	0.26	8	1.1	0.18	1.2	0.19
Floor of mouth	3	0.5	0.14	0.7	0.18	-	-	-	-	-
Gum & other mouth	8	1.5	0.24	1.8	0.29	8	1.1	0.17	1.3	0.20
Nasopharynx	6	0.9	0.17	1.1	0.21	3	0.5	0.12	0.5	0.12
Oropharynx	7	1.2	0.21	1.5	0.26	1	0.2	0.06	0.2	0.08
Hypopharynx	8	1.4	0.24	1.7	0.28	2	0.2	0.07	0.3	0.09
Digestive System	605	111.2	2.14	134.2	2.53	605	80.4	1.48	95.4	1.74
Esophagus	31	5.8	0.50	7.0	0.58	17	2.2	0.24	2.7	0.29
Stomach	67	13.6	0.79	16.1	0.92	61	8.2	0.48	9.7	0.56
Small intestine	24	4.2	0.40	5.1	0.48	28	3.8	0.32	4.4	0.37
Colon excl. rectum	193	36.0	1.22	42.9	1.43	220	29.7	0.91	34.8	1.05
Rectum & rectosigmoid	76	13.8	0.75	16.5	0.88	70	9.1	0.50	10.8	0.58
Anus, anal canal & anorectum	10	1.6	0.24	2.0	0.28	16	2.1	0.24	2.5	0.28
Liver	87	14.0	0.70	18.2	0.89	32	4.0	0.32	5.0	0.40
Gallbladder	7	1.3	0.24	1.6	0.28	18	2.4	0.26	2.9	0.30
Pancreas	88	16.4	0.83	19.8	0.98	108	14.4	0.63	17.2	0.74
Respiratory System	355	70.2	1.76	83.5	2.05	359	47.2	1.13	56.9	1.35
Larynx	34	6.2	0.50	7.5	0.59	13	1.6	0.20	2.0	0.25
Lung & bronchus	314	62.9	1.67	74.6	1.95	343	45.2	1.11	54.5	1.32
Bones & Joints	6	0.9	0.18	0.9	0.19	6	0.8	0.15	0.8	0.15
Soft Tissue (incl. heart)	20	3.3	0.35	3.7	0.39	23	3.0	0.28	3.3	0.31
Skin (excl. basal & sq.)	14	2.4	0.31	2.7	0.35	14	2.0	0.23	2.2	0.26
Melanomas of the skin	6	1.2	0.23	1.5	0.27	7	1.0	0.16	1.1	0.18
Breast (excl. <i>in situ</i>)	10	2.0	0.29	2.3	0.33	975	128.2	1.86	150.2	2.16
Female Genital System	-	-	-	-	-	416	53.6	1.19	64.4	1.42
Cervix uteri	-	-	-	-	-	75	10.1	0.53	11.3	0.59
Uterus Corpus	-	-	-	-	-	218	27.4	0.84	34.0	1.03
Uterus, NOS ¹	-	-	-	-	-	19	2.5	0.26	3.0	0.30
Ovary	-	-	-	-	-	71	9.2	0.50	10.9	0.58
Male Genital System	1,091	189.8	2.70	234.6	3.25	-	-	-	-	-
Prostate	1,075	187.1	2.68	231.6	3.23	-	-	-	-	-
Testis	10	1.6	0.23	1.7	0.24	-	-	-	-	-
Penis	5	0.9	0.20	1.1	0.23	-	-	-	-	-
Urinary System	236	44.2	1.36	52.5	1.59	135	18.0	0.70	21.3	0.82
Bladder (incl. <i>in situ</i>)	101	21.2	1.00	24.9	1.16	48	6.5	0.43	7.7	0.50
Kidney & renal pelvis	131	22.3	0.91	26.7	1.07	83	11.0	0.54	12.9	0.64
Ureter	1	0.2	0.10	0.3	0.12	1	0.2	0.06	0.2	0.08
Eye & Orbit	1	0.2	0.09	0.2	0.10	2	0.3	0.09	0.3	0.08
Brain & Other CNS ¹	31	5.3	0.44	5.7	0.49	28	3.8	0.33	4.1	0.35
Brain	28	4.8	0.42	5.3	0.47	27	3.6	0.32	3.9	0.34
Endocrine System	30	5.0	0.42	5.8	0.49	128	17.1	0.69	19.0	0.75
Thyroid gland	25	4.1	0.38	4.8	0.44	118	15.9	0.66	17.5	0.72
Lymphomas	112	19.6	0.87	22.7	1.00	114	15.4	0.65	17.3	0.73
Hodgkin Lymphoma	20	3.0	0.31	3.3	0.34	22	2.9	0.29	3.0	0.29
Non-Hodgkin Lymphoma	92	16.6	0.81	19.4	0.94	93	12.4	0.59	14.3	0.67
Multiple Myeloma	78	14.7	0.78	17.8	0.93	87	11.7	0.57	13.8	0.66
Leukemias	73	13.7	0.76	15.8	0.87	67	9.2	0.51	10.2	0.56
Acute lymphocytic	5	0.8	0.17	0.8	0.16	10	1.4	0.20	1.4	0.19
Chronic lymphocytic	24	4.7	0.46	5.7	0.54	16	2.2	0.25	2.5	0.28
Acute myeloid	23	4.3	0.43	5.0	0.49	22	3.1	0.30	3.4	0.33
Chronic myeloid	14	2.6	0.33	3.0	0.38	9	1.2	0.18	1.4	0.21
Other leukemias	7	1.2	0.22	1.4	0.25	10	1.4	0.20	1.5	0.22
Mesothelioma	3	0.7	0.18	0.8	0.21	3	0.4	0.11	0.5	0.12
Kaposi Sarcoma	8	1.2	0.20	1.3	0.22	2	0.3	0.09	0.3	0.10
Ill-defined & Unknown	88	17.9	0.91	21.2	1.06	102	14.1	0.63	16.3	0.72
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	48	8.6	0.58	9.8	0.66	106	14.3	0.63	16.3	0.71
Breast (<i>in situ</i>)	2	0.3	0.11	0.4	0.13	265	34.2	0.95	40.6	1.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,012	277.2	4.13	323.9	4.79	1,257	283.0	3.67	328.3	4.25
Oral Cavity & Pharynx	51	13.0	0.86	15.5	1.01	23	5.3	0.51	6.1	0.58
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	13	3.3	0.43	3.9	0.50	6	1.4	0.26	1.7	0.30
Major salivary gland	5	1.4	0.29	1.7	0.35	3	0.5	0.15	0.6	0.18
Floor of mouth	1	0.3	0.12	0.4	0.14	-	-	-	-	-
Gum & other mouth	15	3.9	0.48	4.7	0.57	7	1.6	0.29	1.9	0.33
Nasopharynx	7	1.7	0.29	1.9	0.32	3	0.7	0.17	0.7	0.19
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	0.7	0.21	0.8	0.25	-	-	-	-	-
Digestive System	275	76.0	2.18	89.8	2.55	198	48.4	1.59	56.7	1.85
Esophagus	12	3.3	0.46	3.9	0.52	5	1.2	0.25	1.3	0.29
Stomach	46	13.0	0.92	15.3	1.07	34	8.1	0.64	9.3	0.74
Small intestine	5	1.5	0.30	1.7	0.34	3	0.7	0.18	0.8	0.22
Colon excl. rectum	66	17.7	1.03	20.8	1.20	62	15.0	0.89	17.8	1.04
Rectum & rectosigmoid	51	12.8	0.84	15.4	1.00	33	7.6	0.61	9.0	0.72
Anus, anal canal & anorectum	1	0.3	0.12	0.4	0.15	3	0.7	0.19	0.9	0.23
Liver	43	12.0	0.88	14.4	1.04	13	3.2	0.41	3.7	0.47
Gallbladder	3	1.0	0.28	1.2	0.33	7	1.6	0.29	1.9	0.34
Pancreas	31	9.4	0.81	11.0	0.94	28	7.1	0.62	8.2	0.71
Respiratory System	120	35.6	1.54	41.4	1.78	86	21.5	1.07	25.3	1.25
Larynx	7	1.9	0.35	2.2	0.40	1	0.4	0.16	0.5	0.18
Lung & bronchus	108	32.5	1.48	37.8	1.71	83	20.5	1.04	24.2	1.22
Bones & Joints	4	0.9	0.21	1.0	0.23	3	0.7	0.19	0.7	0.17
Soft Tissue (incl. heart)	9	2.2	0.36	2.5	0.40	7	1.6	0.27	1.7	0.30
Skin (excl. basal & sq.)	7	1.8	0.33	2.1	0.38	5	1.4	0.27	1.5	0.29
Melanomas of the skin	5	1.2	0.28	1.5	0.33	3	0.9	0.22	1.0	0.25
Breast (excl. <i>in situ</i>)	2	0.6	0.20	0.8	0.25	483	103.5	2.15	121.1	2.51
Female Genital System	-	-	-	-	-	166	35.4	1.26	42.6	1.50
Cervix uteri	-	-	-	-	-	22	4.9	0.48	5.6	0.55
Uterus Corpus	-	-	-	-	-	85	17.2	0.85	21.6	1.06
Uterus, NOS ¹	-	-	-	-	-	3	0.6	0.16	0.7	0.19
Ovary	-	-	-	-	-	48	10.7	0.70	12.3	0.81
Male Genital System	241	64.7	1.95	77.7	2.31	-	-	-	-	-
Prostate	230	61.9	1.92	74.7	2.27	-	-	-	-	-
Testis	10	2.1	0.31	2.2	0.32	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	89	25.0	1.26	29.1	1.46	38	9.1	0.68	10.5	0.79
Bladder (incl. <i>in situ</i>)	47	14.1	0.98	16.4	1.13	13	3.7	0.46	4.1	0.52
Kidney & renal pelvis	40	10.3	0.77	12.1	0.90	22	4.8	0.47	5.6	0.55
Ureter	1	0.4	0.16	0.5	0.18	2	0.5	0.18	0.6	0.20
Eye & Orbit	1	0.3	0.11	0.3	0.11	2	0.5	0.15	0.4	0.14
Brain & Other CNS ¹	23	5.7	0.56	6.1	0.61	16	3.8	0.44	4.0	0.46
Brain	22	5.5	0.55	5.8	0.60	15	3.5	0.42	3.7	0.45
Endocrine System	40	9.1	0.65	9.7	0.70	111	22.9	0.98	24.7	1.07
Thyroid gland	36	8.0	0.61	8.6	0.66	107	21.9	0.96	23.7	1.04
Lymphomas	58	15.4	0.95	17.4	1.08	47	10.9	0.73	12.4	0.83
Hodgkin Lymphoma	6	1.5	0.27	1.6	0.29	6	1.4	0.26	1.4	0.26
Non-Hodgkin Lymphoma	52	13.9	0.91	15.8	1.04	41	9.5	0.68	11.0	0.79
Multiple Myeloma	17	4.9	0.57	5.8	0.66	13	3.1	0.40	3.7	0.46
Leukemias	37	10.4	0.80	11.3	0.89	27	6.7	0.59	7.2	0.64
Acute lymphocytic	-	-	-	-	-	7	1.7	0.29	1.5	0.25
Chronic lymphocytic	7	2.0	0.35	2.3	0.41	4	1.1	0.25	1.3	0.29
Acute myeloid	12	3.5	0.48	3.9	0.55	11	2.7	0.38	3.0	0.43
Chronic myeloid	6	1.6	0.31	1.8	0.36	3	0.6	0.17	0.7	0.20
Other leukemias	4	1.3	0.30	1.5	0.35	2	0.6	0.19	0.7	0.22
Mesothelioma	2	0.6	0.20	0.7	0.23	-	-	-	-	-
Kaposi Sarcoma	1	0.3	0.14	0.3	0.15	-	-	-	-	-
Ill-defined & Unknown	35	10.7	0.87	12.6	1.02	31	8.3	0.69	9.5	0.79
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	28	7.1	0.62	7.8	0.69	47	10.7	0.72	12.3	0.82
Breast (<i>in situ</i>)	-	-	-	-	-	177	37.5	1.28	43.5	1.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,395	426.7	4.24	504.7	4.93	2,707	377.2	3.34	437.8	3.87
Oral Cavity & Pharynx	70	11.5	0.66	13.8	0.78	34	4.7	0.38	5.5	0.44
Lip	2	0.3	0.10	0.3	0.12	2	0.2	0.08	0.3	0.09
Tongue	18	3.1	0.35	3.7	0.41	10	1.3	0.20	1.6	0.23
Major salivary gland	6	1.2	0.23	1.4	0.26	9	1.2	0.18	1.4	0.21
Floor of mouth	2	0.4	0.13	0.4	0.13	-	-	-	-	-
Gum & other mouth	10	1.8	0.26	2.2	0.32	4	0.7	0.15	0.8	0.17
Nasopharynx	6	0.9	0.17	1.1	0.21	3	0.4	0.10	0.4	0.12
Oropharynx	6	0.9	0.19	1.2	0.23	1	0.2	0.07	0.2	0.09
Hypopharynx	3	0.5	0.15	0.6	0.17	-	-	-	-	-
Digestive System	554	100.4	2.07	119.7	2.43	483	71.9	1.51	84.3	1.75
Esophagus	23	4.5	0.45	5.4	0.52	9	1.5	0.23	1.7	0.26
Stomach	78	14.2	0.78	16.8	0.91	65	9.4	0.54	10.9	0.62
Small intestine	17	3.1	0.36	3.6	0.43	14	2.0	0.24	2.3	0.28
Colon excl. rectum	162	29.8	1.14	35.2	1.33	159	23.9	0.87	27.7	1.00
Rectum & rectosigmoid	79	13.0	0.71	15.7	0.84	61	8.5	0.50	10.3	0.60
Anus, anal canal & anorectum	7	1.1	0.20	1.3	0.24	19	2.7	0.29	3.2	0.34
Liver	80	13.6	0.73	16.9	0.89	31	4.8	0.40	5.6	0.46
Gallbladder	6	1.3	0.25	1.5	0.28	15	2.3	0.27	2.8	0.32
Pancreas	66	13.1	0.78	15.3	0.89	77	12.0	0.63	14.2	0.73
Respiratory System	220	44.6	1.44	52.3	1.65	190	29.5	0.98	34.9	1.15
Larynx	27	5.1	0.47	6.1	0.55	5	0.7	0.14	0.8	0.17
Lung & bronchus	188	38.7	1.35	45.3	1.55	182	28.3	0.96	33.4	1.12
Bones & Joints	9	1.0	0.16	1.0	0.16	7	0.9	0.15	1.0	0.17
Soft Tissue (incl. heart)	23	3.3	0.33	3.6	0.36	24	3.0	0.29	3.2	0.31
Skin (excl. basal & sq.)	34	5.9	0.49	6.8	0.57	35	4.9	0.38	5.6	0.43
Melanomas of the skin	25	4.4	0.43	5.1	0.49	29	4.0	0.34	4.6	0.39
Breast (excl. <i>in situ</i>)	4	0.7	0.18	0.8	0.20	806	109.5	1.77	128.0	2.06
Female Genital System	-	-	-	-	-	386	51.8	1.21	60.8	1.42
Cervix uteri	-	-	-	-	-	86	11.0	0.54	11.9	0.59
Uterus Corpus	-	-	-	-	-	183	24.3	0.82	29.8	1.00
Uterus, NOS ¹	-	-	-	-	-	10	1.4	0.20	1.6	0.23
Ovary	-	-	-	-	-	73	10.0	0.54	11.8	0.63
Male Genital System	725	128.7	2.30	156.1	2.71	-	-	-	-	-
Prostate	670	121.8	2.25	148.9	2.66	-	-	-	-	-
Testis	43	4.4	0.30	4.3	0.30	-	-	-	-	-
Penis	12	2.4	0.34	2.8	0.39	-	-	-	-	-
Urinary System	246	46.5	1.44	54.6	1.67	125	18.1	0.75	21.2	0.87
Bladder (incl. <i>in situ</i>)	119	26.0	1.14	30.3	1.31	42	6.7	0.47	7.8	0.55
Kidney & renal pelvis	123	19.5	0.85	23.3	1.00	79	10.8	0.56	12.6	0.65
Ureter	2	0.5	0.16	0.6	0.17	2	0.3	0.10	0.4	0.12
Eye & Orbit	3	0.4	0.12	0.4	0.13	4	0.5	0.11	0.5	0.13
Brain & Other CNS ¹	49	6.9	0.48	7.6	0.54	36	4.5	0.35	5.0	0.39
Brain	47	6.7	0.48	7.4	0.54	34	4.3	0.34	4.8	0.38
Endocrine System	52	6.9	0.46	7.8	0.53	229	27.6	0.83	30.4	0.92
Thyroid gland	47	6.3	0.44	7.1	0.50	222	26.8	0.81	29.4	0.91
Lymphomas	166	27.5	1.05	31.5	1.21	142	19.9	0.77	22.8	0.88
Hodgkin Lymphoma	23	2.9	0.29	3.1	0.31	22	2.6	0.25	2.7	0.27
Non-Hodgkin Lymphoma	143	24.6	1.01	28.4	1.17	120	17.3	0.73	20.1	0.84
Multiple Myeloma	48	9.1	0.64	11.0	0.75	40	5.9	0.43	7.1	0.51
Leukemias	98	15.7	0.78	17.4	0.88	79	10.7	0.56	11.7	0.62
Acute lymphocytic	23	2.5	0.25	2.4	0.24	21	2.3	0.23	2.2	0.23
Chronic lymphocytic	19	3.9	0.43	4.5	0.48	13	2.0	0.26	2.3	0.30
Acute myeloid	28	4.6	0.43	5.2	0.49	23	3.3	0.32	3.6	0.36
Chronic myeloid	15	2.3	0.29	2.5	0.32	11	1.5	0.21	1.7	0.24
Other leukemias	13	2.4	0.33	2.7	0.37	11	1.6	0.22	1.8	0.25
Mesothelioma	5	1.1	0.22	1.3	0.26	3	0.5	0.12	0.6	0.14
Kaposi Sarcoma	9	1.3	0.21	1.3	0.22	-	-	-	-	-
Ill-defined & Unknown	79	15.4	0.85	17.9	0.98	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	49	7.3	0.52	8.2	0.59	109	14.6	0.64	16.8	0.74
Breast (<i>in situ</i>)	-	-	-	-	-	245	31.8	0.93	37.6	1.09

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEW JERSEY

II-348 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	18,652	553.8	1.87	653.5	2.15	18,942	491.0	1.70	570.4	1.91
Oral Cavity & Pharynx	637	18.3	0.34	22.3	0.40	267	6.7	0.19	7.9	0.22
Lip	20	0.6	0.06	0.7	0.07	11	0.3	0.04	0.3	0.04
Tongue	206	5.8	0.19	7.2	0.23	87	2.2	0.11	2.6	0.13
Major salivary gland	71	2.2	0.12	2.5	0.14	41	1.1	0.09	1.3	0.09
Floor of mouth	24	0.7	0.06	0.8	0.08	13	0.3	0.04	0.4	0.05
Gum & other mouth	68	2.0	0.11	2.4	0.13	56	1.3	0.09	1.6	0.10
Nasopharynx	19	0.6	0.06	0.7	0.07	7	0.2	0.04	0.2	0.04
Oropharynx	29	0.8	0.07	1.0	0.08	11	0.3	0.04	0.3	0.04
Hypopharynx	32	0.9	0.07	1.1	0.09	8	0.2	0.03	0.2	0.04
Digestive System	3,453	102.3	0.80	121.2	0.93	2,858	68.1	0.60	79.7	0.69
Esophagus	293	8.5	0.23	10.1	0.27	79	1.8	0.09	2.1	0.11
Stomach	312	9.2	0.24	10.9	0.28	180	4.3	0.15	5.0	0.17
Small intestine	98	2.9	0.14	3.4	0.16	82	2.0	0.11	2.4	0.12
Colon excl. rectum	1,063	32.3	0.46	37.7	0.52	1,106	26.4	0.38	30.5	0.43
Rectum & rectosigmoid	514	15.4	0.32	18.3	0.36	393	9.9	0.24	11.8	0.27
Anus, anal canal & anorectum	47	1.4	0.09	1.7	0.11	93	2.3	0.11	2.9	0.14
Liver	334	9.3	0.23	11.4	0.28	102	2.4	0.11	2.8	0.13
Gallbladder	29	0.9	0.08	1.0	0.09	55	1.2	0.08	1.4	0.09
Pancreas	583	17.0	0.32	20.2	0.38	575	13.1	0.25	15.4	0.30
Respiratory System	2,456	72.2	0.67	85.0	0.77	2,573	60.6	0.55	71.4	0.64
Larynx	195	5.6	0.18	6.8	0.22	41	1.0	0.07	1.2	0.09
Lung & bronchus	2,227	65.5	0.63	77.0	0.73	2,507	58.9	0.54	69.5	0.63
Bones & Joints	34	1.2	0.10	1.3	0.10	28	1.0	0.09	1.0	0.09
Soft Tissue (incl. heart)	146	4.8	0.19	5.3	0.20	109	3.1	0.14	3.4	0.15
Skin (excl. basal & sq.)	1,366	41.7	0.52	48.7	0.59	953	26.8	0.42	30.5	0.46
Melanomas of the skin	1,269	38.7	0.50	45.1	0.57	890	25.3	0.41	28.7	0.45
Breast (excl. <i>in situ</i>)	55	1.6	0.10	1.9	0.12	5,381	144.8	0.94	169.1	1.06
Female Genital System	-	-	-	-	-	2,301	59.2	0.58	70.8	0.68
Cervix uteri	-	-	-	-	-	202	6.9	0.23	7.4	0.24
Uterus Corpus	-	-	-	-	-	1,336	32.9	0.42	40.6	0.51
Uterus, NOS ¹	-	-	-	-	-	48	1.2	0.08	1.4	0.09
Ovary	-	-	-	-	-	485	12.5	0.27	14.8	0.31
Male Genital System	4,655	131.0	0.88	159.3	1.05	-	-	-	-	-
Prostate	4,439	121.7	0.83	149.9	1.01	-	-	-	-	-
Testis	183	8.2	0.28	8.2	0.27	-	-	-	-	-
Penis	23	0.7	0.07	0.8	0.08	-	-	-	-	-
Urinary System	2,382	71.0	0.67	83.3	0.77	1,010	24.1	0.36	28.4	0.41
Bladder (incl. <i>in situ</i>)	1,523	45.3	0.53	53.0	0.61	525	11.9	0.24	14.1	0.28
Kidney & renal pelvis	800	23.9	0.39	28.2	0.45	449	11.4	0.26	13.4	0.29
Ureter	34	1.0	0.08	1.2	0.09	24	0.5	0.05	0.6	0.06
Eye & Orbit	28	0.9	0.08	1.0	0.09	25	0.7	0.07	0.8	0.08
Brain & Other CNS ¹	267	8.9	0.26	9.8	0.27	222	6.8	0.22	7.4	0.23
Brain	255	8.4	0.25	9.4	0.26	210	6.3	0.21	6.9	0.22
Endocrine System	382	13.1	0.32	14.6	0.34	933	32.6	0.51	35.2	0.53
Thyroid gland	353	12.1	0.30	13.5	0.33	907	31.9	0.51	34.3	0.52
Lymphomas	1,018	32.4	0.47	36.9	0.52	872	23.0	0.38	26.1	0.41
Hodgkin Lymphoma	106	4.1	0.19	4.3	0.19	83	3.2	0.17	3.3	0.17
Non-Hodgkin Lymphoma	913	28.3	0.43	32.6	0.49	789	19.8	0.34	22.8	0.38
Multiple Myeloma	284	8.3	0.23	9.9	0.26	213	5.0	0.16	6.0	0.19
Leukemias	664	20.8	0.37	23.7	0.41	492	12.7	0.28	14.3	0.30
Acute lymphocytic	45	1.9	0.13	1.8	0.12	36	1.5	0.12	1.4	0.11
Chronic lymphocytic	282	8.2	0.22	9.8	0.26	198	4.5	0.15	5.4	0.18
Acute myeloid	179	5.6	0.20	6.4	0.22	148	3.9	0.15	4.3	0.17
Chronic myeloid	86	2.7	0.14	3.1	0.15	56	1.5	0.10	1.7	0.11
Other leukemias	72	2.3	0.12	2.6	0.14	53	1.3	0.09	1.5	0.10
Mesothelioma	73	2.3	0.12	2.6	0.14	26	0.6	0.06	0.7	0.06
Kaposi Sarcoma	13	0.5	0.06	0.5	0.06	2	0.1	0.02	0.1	0.02
Ill-defined & Unknown	739	22.5	0.38	26.1	0.43	677	15.1	0.28	17.6	0.31
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	310	10.3	0.27	11.5	0.30	616	16.6	0.32	18.9	0.35
Breast (<i>in situ</i>)	5	0.2	0.03	0.2	0.04	1,533	44.1	0.53	51.6	0.60

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Jersey, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,749	550.9	4.94	664.6	5.84	2,978	432.1	3.60	507.0	4.16
Oral Cavity & Pharynx	73	13.8	0.75	16.9	0.91	33	4.8	0.38	5.7	0.44
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	15	2.8	0.34	3.5	0.42	8	1.1	0.18	1.3	0.21
Major salivary gland	7	1.3	0.23	1.6	0.28	7	1.2	0.19	1.3	0.21
Floor of mouth	3	0.6	0.15	0.8	0.20	-	-	-	-	-
Gum & other mouth	8	1.5	0.26	1.9	0.31	8	1.1	0.18	1.3	0.21
Nasopharynx	6	1.0	0.19	1.2	0.23	3	0.5	0.13	0.5	0.13
Oropharynx	7	1.3	0.24	1.6	0.28	1	0.2	0.07	0.2	0.08
Hypopharynx	7	1.5	0.26	1.8	0.31	2	0.2	0.08	0.3	0.10
Digestive System	586	118.8	2.31	143.4	2.74	580	84.0	1.58	99.6	1.85
Esophagus	30	6.2	0.53	7.5	0.63	16	2.3	0.25	2.8	0.31
Stomach	64	14.4	0.85	17.0	0.99	59	8.6	0.51	10.1	0.59
Small intestine	23	4.5	0.44	5.4	0.52	27	4.0	0.35	4.6	0.40
Colon excl. rectum	189	38.8	1.33	46.2	1.55	212	31.0	0.97	36.4	1.12
Rectum & rectosigmoid	73	14.6	0.81	17.5	0.95	68	9.7	0.54	11.5	0.63
Anus, anal canal & anorectum	10	1.8	0.27	2.1	0.31	16	2.2	0.26	2.6	0.30
Liver	84	14.9	0.76	19.3	0.96	29	4.0	0.33	5.0	0.41
Gallbladder	7	1.4	0.26	1.7	0.30	17	2.5	0.27	2.9	0.31
Pancreas	85	17.6	0.90	21.3	1.06	103	15.0	0.67	17.9	0.79
Respiratory System	348	75.0	1.90	89.5	2.21	350	49.9	1.21	60.2	1.44
Larynx	34	6.6	0.54	8.1	0.64	13	1.8	0.22	2.2	0.27
Lung & bronchus	308	67.2	1.80	79.9	2.10	334	47.7	1.18	57.5	1.41
Bones & Joints	5	1.0	0.20	1.0	0.21	6	0.9	0.17	0.9	0.17
Soft Tissue (incl. heart)	19	3.6	0.38	3.9	0.42	21	3.1	0.31	3.4	0.33
Skin (excl. basal & sq.)	14	2.7	0.34	3.0	0.38	14	2.0	0.25	2.3	0.28
Melanomas of the skin	6	1.3	0.25	1.6	0.29	7	1.0	0.17	1.1	0.20
Breast (excl. <i>in situ</i>)	10	2.1	0.31	2.4	0.36	938	135.9	2.02	159.0	2.32
Female Genital System	-	-	-	-	-	400	56.4	1.28	67.8	1.52
Cervix uteri	-	-	-	-	-	70	10.5	0.57	11.8	0.63
Uterus Corpus	-	-	-	-	-	211	28.8	0.90	35.7	1.10
Uterus, NOS ¹	-	-	-	-	-	19	2.7	0.28	3.2	0.33
Ovary	-	-	-	-	-	68	9.8	0.54	11.6	0.63
Male Genital System	1,058	202.6	2.91	250.4	3.51	-	-	-	-	-
Prostate	1,043	199.7	2.89	247.3	3.49	-	-	-	-	-
Testis	10	1.9	0.27	1.9	0.27	-	-	-	-	-
Penis	4	0.8	0.20	1.0	0.24	-	-	-	-	-
Urinary System	229	47.5	1.48	56.4	1.72	131	19.0	0.75	22.5	0.88
Bladder (incl. <i>in situ</i>)	97	22.5	1.07	26.5	1.24	46	6.9	0.46	8.1	0.53
Kidney & renal pelvis	128	24.1	0.99	28.9	1.17	81	11.6	0.59	13.7	0.68
Ureter	1	0.3	0.11	0.3	0.13	1	0.2	0.07	0.2	0.08
Eye & Orbit	1	0.2	0.10	0.3	0.11	2	0.3	0.11	0.3	0.10
Brain & Other CNS ¹	29	5.7	0.49	6.2	0.53	25	3.8	0.35	4.1	0.37
Brain	27	5.2	0.47	5.6	0.51	23	3.5	0.33	3.9	0.36
Endocrine System	29	5.3	0.46	6.1	0.53	119	17.9	0.75	19.8	0.81
Thyroid gland	23	4.4	0.42	5.0	0.48	109	16.4	0.72	18.1	0.78
Lymphomas	106	20.8	0.95	24.1	1.09	107	15.9	0.70	17.9	0.78
Hodgkin Lymphoma	19	3.2	0.34	3.5	0.37	20	3.1	0.32	3.2	0.32
Non-Hodgkin Lymphoma	88	17.6	0.88	20.6	1.02	87	12.8	0.63	14.7	0.71
Multiple Myeloma	76	15.7	0.85	19.0	1.01	86	12.6	0.61	14.8	0.71
Leukemias	70	14.7	0.83	16.8	0.94	64	9.7	0.55	10.7	0.60
Acute lymphocytic	5	0.9	0.20	0.8	0.18	9	1.4	0.22	1.4	0.21
Chronic lymphocytic	23	5.0	0.49	6.0	0.58	15	2.3	0.27	2.7	0.30
Acute myeloid	22	4.7	0.47	5.3	0.53	21	3.3	0.32	3.6	0.35
Chronic myeloid	13	2.8	0.36	3.2	0.41	9	1.3	0.20	1.5	0.23
Other leukemias	6	1.2	0.24	1.4	0.27	9	1.4	0.21	1.6	0.23
Mesothelioma	3	0.7	0.20	0.8	0.23	3	0.4	0.11	0.4	0.12
Kaposi Sarcoma	7	1.3	0.22	1.5	0.25	2	0.3	0.10	0.3	0.10
Ill-defined & Unknown	86	19.4	0.99	22.8	1.15	100	15.0	0.68	17.3	0.78
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	47	9.3	0.64	10.6	0.72	102	15.1	0.68	17.2	0.76
Breast (<i>in situ</i>)	2	0.3	0.12	0.4	0.14	255	36.4	1.03	43.1	1.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NEW JERSEY

II-350 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,092,792	2,090,342	2,090,211	2,092,789	2,093,395
White	1,759,009	1,752,534	1,747,690	1,746,612	1,744,608
Black	60,794	61,472	62,202	63,024	63,708
American Indian/Alaskan Native (AI/AN)	230,817	233,817	236,921	239,187	240,543
Asian/Pacific Islander (API)	42,172	42,519	43,398	43,966	44,536


All Races Population 2013-2017: 10,459,529
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	995,337	1,001,625	1,009,169	1,016,563	1,022,174
Non-Hispanic White	833,766	823,254	812,871	806,386	799,606
Non-Hispanic Black	43,758	44,154	44,617	45,086	45,517

Hispanic/Latino Population, Census 2010: 953,403
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW MEXICO CANCER REGISTRY

Initial Operation: 1966
Population-based Data Available: 1969
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	No	Yes	Yes	Yes	No
Completeness of Case Ascertainment	86.8	94.1	94.4	91.6	88.0
Missing Race	0.4	1.0	1.1	1.0	2.5
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.2	0.1	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	4.3	1.7	3.7	1.4	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Prostate	95.8
Oral Cavity & Pharynx	96.7	Testis	99.1
Esophagus	91.8	Bladder (incl. <i>in situ</i>)	96.8
Stomach	95.1	Kidney & Renal Pelvis	90.4
Colon & Rectum	95.5	Brain & Other CNS ¹	87.3
Liver	58.6	Thyroid	99.4
Pancreas	80.8	Hodgkin Lymphoma	96.9
Lung & Bronchus	83.9	Non-Hodgkin Lymphoma	96.0
Melanomas of the Skin	99.1	Multiple Myeloma	91.2
Female Breast (excl. <i>in situ</i>)	98.4	Leukemias	93.0
Cervix uteri	97.1	Brain & Other CNS ¹ <i>non-malig</i>	53.8
Uterus Corpus & Uterus NOS ¹	98.2	Breast <i>in situ</i>	100.0
Ovary	92.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,605	391.5	2.65	463.7	3.09	4,705	365.7	2.47	426.6	2.82
Oral Cavity & Pharynx	162	13.6	0.49	16.5	0.58	59	4.5	0.27	5.3	0.31
Lip	10	0.9	0.13	1.1	0.15	2	0.2	0.05	0.2	0.06
Tongue	49	3.9	0.26	4.9	0.32	21	1.5	0.15	1.9	0.19
Major salivary gland	19	1.8	0.18	2.0	0.21	9	0.8	0.12	0.9	0.13
Floor of mouth	5	0.5	0.09	0.5	0.11	2	0.1	0.05	0.2	0.05
Gum & other mouth	15	1.3	0.15	1.5	0.18	11	0.9	0.12	0.9	0.13
Nasopharynx	7	0.6	0.10	0.7	0.12	1	0.1	0.04	0.1	0.04
Oropharynx	10	0.8	0.12	1.0	0.14	3	0.2	0.06	0.3	0.07
Hypopharynx	10	0.8	0.12	1.0	0.14	2	0.1	0.04	0.1	0.05
Digestive System	1,052	89.2	1.26	107.2	1.49	781	58.6	0.97	69.4	1.12
Esophagus	83	6.9	0.35	8.3	0.41	15	1.1	0.13	1.3	0.15
Stomach	94	8.3	0.39	9.6	0.45	65	5.0	0.29	5.8	0.33
Small intestine	24	2.1	0.20	2.5	0.23	20	1.5	0.16	1.8	0.18
Colon excl. rectum	280	24.2	0.66	28.8	0.78	281	21.3	0.58	25.1	0.68
Rectum & rectosigmoid	155	13.3	0.49	16.0	0.58	106	8.2	0.37	9.8	0.43
Anus, anal canal & anorectum	13	1.1	0.14	1.4	0.17	22	1.7	0.16	2.0	0.19
Liver	186	14.9	0.50	18.7	0.62	64	4.7	0.27	5.5	0.31
Gallbladder	11	0.9	0.13	1.1	0.15	21	1.6	0.16	1.9	0.19
Pancreas	151	12.7	0.47	15.3	0.56	136	9.9	0.39	11.8	0.46
Respiratory System	572	49.1	0.94	57.8	1.09	492	35.8	0.74	42.1	0.86
Larynx	49	4.0	0.26	4.9	0.32	13	0.9	0.12	1.2	0.15
Lung & bronchus	510	43.9	0.89	51.5	1.03	472	34.3	0.72	40.4	0.84
Bones & Joints	11	1.1	0.15	1.1	0.15	11	1.0	0.14	1.0	0.14
Soft Tissue (incl. heart)	40	3.7	0.27	4.1	0.29	32	2.7	0.22	3.1	0.24
Skin (excl. basal & sq.)	257	22.2	0.64	26.1	0.74	178	14.0	0.49	16.2	0.55
Melanomas of the skin	235	20.2	0.60	23.8	0.70	160	12.5	0.46	14.6	0.52
Breast (excl. <i>in situ</i>)	12	1.0	0.14	1.2	0.16	1,438	111.8	1.37	132.1	1.58
Female Genital System	-	-	-	-	-	610	48.3	0.91	56.5	1.04
Cervix uteri	-	-	-	-	-	84	8.2	0.41	8.6	0.42
Uterus Corpus	-	-	-	-	-	304	23.1	0.62	27.9	0.72
Uterus, NOS ¹	-	-	-	-	-	13	1.0	0.12	1.2	0.15
Ovary	-	-	-	-	-	152	11.8	0.44	13.8	0.51
Male Genital System	1,124	90.5	1.24	109.5	1.48	-	-	-	-	-
Prostate	1,046	82.8	1.17	101.8	1.42	-	-	-	-	-
Testis	65	6.6	0.37	6.5	0.36	-	-	-	-	-
Penis	11	0.9	0.13	1.1	0.15	-	-	-	-	-
Urinary System	517	44.9	0.91	52.8	1.05	236	18.1	0.54	21.0	0.62
Bladder (incl. <i>in situ</i>)	281	24.4	0.67	28.8	0.78	91	6.7	0.32	7.8	0.37
Kidney & renal pelvis	224	19.4	0.60	22.9	0.69	140	11.0	0.43	12.8	0.49
Ureter	7	0.6	0.10	0.7	0.12	4	0.3	0.07	0.4	0.08
Eye & Orbit	9	0.8	0.13	0.9	0.13	7	0.6	0.09	0.7	0.11
Brain & Other CNS ¹	69	6.0	0.33	6.8	0.37	56	4.6	0.29	5.1	0.31
Brain	66	5.8	0.33	6.6	0.37	51	4.1	0.27	4.6	0.29
Endocrine System	95	8.5	0.40	9.7	0.45	262	24.1	0.69	26.2	0.73
Thyroid gland	86	7.7	0.38	8.8	0.43	255	23.5	0.69	25.5	0.72
Lymphomas	228	20.1	0.61	23.1	0.69	196	15.1	0.50	17.5	0.56
Hodgkin Lymphoma	32	2.9	0.24	3.2	0.26	19	1.8	0.18	1.8	0.19
Non-Hodgkin Lymphoma	196	17.1	0.56	19.9	0.64	177	13.4	0.46	15.6	0.53
Multiple Myeloma	82	7.2	0.36	8.4	0.42	57	4.3	0.26	5.0	0.30
Leukemias	180	16.2	0.55	18.2	0.61	139	11.1	0.43	12.4	0.47
Acute lymphocytic	20	2.0	0.20	1.8	0.18	18	1.8	0.19	1.6	0.17
Chronic lymphocytic	64	5.5	0.31	6.4	0.37	45	3.3	0.22	3.9	0.26
Acute myeloid	48	4.3	0.29	4.9	0.32	44	3.4	0.24	3.9	0.26
Chronic myeloid	27	2.5	0.22	2.8	0.24	19	1.6	0.17	1.8	0.18
Other leukemias	21	2.0	0.20	2.3	0.23	13	1.0	0.13	1.2	0.15
Mesothelioma	12	1.1	0.14	1.2	0.16	4	0.3	0.07	0.3	0.08
Kaposi Sarcoma	3	0.4	0.09	0.4	0.09	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	145	10.8	0.41	12.6	0.47
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	68	6.2	0.34	6.9	0.38	144	11.8	0.46	13.4	0.51
Breast (<i>in situ</i>)	1	0.1	0.05	0.1	0.05	260	20.5	0.59	24.5	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	4,127	391.4	2.80	464.0	3.27	4,203	371.7	2.68	433.1	3.04
Oral Cavity & Pharynx	151	14.1	0.53	17.2	0.63	55	4.7	0.30	5.6	0.34
Lip	9	0.9	0.14	1.1	0.16	2	0.2	0.05	0.2	0.06
Tongue	47	4.3	0.29	5.3	0.35	20	1.7	0.17	2.0	0.21
Major salivary gland	18	1.8	0.20	2.1	0.22	8	0.8	0.13	0.9	0.14
Floor of mouth	5	0.5	0.10	0.5	0.11	2	0.1	0.05	0.2	0.06
Gum & other mouth	13	1.2	0.15	1.5	0.18	10	0.9	0.13	1.0	0.14
Nasopharynx	6	0.5	0.10	0.7	0.12	-	-	-	-	-
Oropharynx	10	0.9	0.13	1.1	0.15	3	0.2	0.06	0.3	0.08
Hypopharynx	9	0.9	0.13	1.0	0.15	2	0.1	0.04	0.1	0.05
Digestive System	925	87.5	1.32	105.3	1.57	676	57.3	1.02	67.7	1.18
Esophagus	78	7.1	0.37	8.5	0.44	14	1.1	0.14	1.3	0.16
Stomach	80	7.8	0.40	9.1	0.46	52	4.5	0.29	5.2	0.33
Small intestine	22	2.1	0.21	2.5	0.24	17	1.4	0.16	1.7	0.19
Colon excl. rectum	247	23.9	0.70	28.5	0.82	244	20.9	0.62	24.6	0.72
Rectum & rectosigmoid	135	13.0	0.52	15.7	0.61	93	8.1	0.39	9.7	0.46
Anus, anal canal & anorectum	13	1.2	0.16	1.5	0.19	21	1.8	0.18	2.2	0.21
Liver	159	14.4	0.52	18.1	0.65	52	4.3	0.28	5.1	0.32
Gallbladder	9	0.9	0.13	1.0	0.16	16	1.4	0.16	1.7	0.19
Pancreas	137	12.7	0.50	15.3	0.59	124	10.2	0.42	12.1	0.49
Respiratory System	534	50.5	1.00	59.6	1.17	463	37.8	0.80	44.4	0.93
Larynx	44	4.1	0.28	5.0	0.34	12	1.0	0.13	1.2	0.16
Lung & bronchus	479	45.4	0.95	53.4	1.10	444	36.2	0.78	42.5	0.91
Bones & Joints	10	1.2	0.17	1.2	0.17	10	1.0	0.15	1.1	0.16
Soft Tissue (incl. heart)	34	3.5	0.28	4.0	0.31	28	2.7	0.24	3.1	0.26
Skin (excl. basal & sq.)	240	23.2	0.69	27.3	0.80	164	14.6	0.54	17.0	0.60
Melanomas of the skin	220	21.2	0.66	25.0	0.76	149	13.3	0.51	15.5	0.58
Breast (excl. <i>in situ</i>)	11	1.0	0.15	1.2	0.17	1,307	115.9	1.50	136.9	1.73
Female Genital System	-	-	-	-	-	527	47.5	0.97	55.8	1.11
Cervix uteri	-	-	-	-	-	71	8.2	0.46	8.6	0.46
Uterus Corpus	-	-	-	-	-	260	22.4	0.65	27.1	0.76
Uterus, NOS ¹	-	-	-	-	-	10	0.9	0.12	1.1	0.15
Ovary	-	-	-	-	-	132	11.7	0.47	13.7	0.54
Male Genital System	985	88.4	1.29	107.1	1.54	-	-	-	-	-
Prostate	919	80.6	1.22	99.2	1.48	-	-	-	-	-
Testis	54	6.7	0.41	6.5	0.40	-	-	-	-	-
Penis	10	1.0	0.14	1.1	0.16	-	-	-	-	-
Urinary System	464	44.7	0.95	52.7	1.11	207	17.9	0.58	20.8	0.66
Bladder (incl. <i>in situ</i>)	266	25.4	0.71	30.0	0.83	84	6.8	0.34	8.0	0.40
Kidney & renal pelvis	186	18.2	0.62	21.4	0.71	118	10.6	0.46	12.3	0.52
Ureter	7	0.7	0.11	0.8	0.13	4	0.3	0.07	0.4	0.08
Eye & Orbit	7	0.7	0.13	0.8	0.14	7	0.6	0.11	0.7	0.12
Brain & Other CNS ¹	64	6.4	0.37	7.3	0.41	50	4.8	0.32	5.3	0.34
Brain	62	6.1	0.36	7.0	0.40	47	4.4	0.30	4.9	0.33
Endocrine System	84	8.8	0.44	10.0	0.49	231	25.2	0.78	27.3	0.81
Thyroid gland	77	8.0	0.42	9.1	0.47	225	24.7	0.77	26.6	0.81
Lymphomas	209	20.7	0.66	23.9	0.75	173	15.1	0.53	17.5	0.60
Hodgkin Lymphoma	29	3.1	0.27	3.4	0.28	18	1.9	0.21	2.0	0.21
Non-Hodgkin Lymphoma	180	17.6	0.60	20.5	0.69	156	13.2	0.49	15.5	0.56
Multiple Myeloma	72	6.9	0.37	8.2	0.44	47	3.9	0.27	4.6	0.31
Leukemias	161	16.4	0.59	18.4	0.66	123	11.2	0.47	12.4	0.51
Acute lymphocytic	17	2.0	0.22	1.8	0.20	15	1.8	0.21	1.6	0.19
Chronic lymphocytic	57	5.4	0.33	6.4	0.38	40	3.2	0.23	3.9	0.28
Acute myeloid	44	4.4	0.31	5.0	0.34	39	3.5	0.26	4.0	0.29
Chronic myeloid	24	2.5	0.24	2.8	0.26	17	1.6	0.18	1.8	0.20
Other leukemias	19	2.0	0.21	2.4	0.24	12	1.1	0.15	1.3	0.17
Mesothelioma	11	1.1	0.15	1.2	0.17	4	0.3	0.08	0.4	0.09
Kaposi Sarcoma	2	0.2	0.08	0.2	0.08	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	130	10.9	0.44	12.6	0.50
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	59	6.2	0.37	6.9	0.40	123	11.6	0.49	13.2	0.54
Breast (<i>in situ</i>)	1	0.1	0.05	0.2	0.06	235	21.2	0.65	25.2	0.75

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	91	361.2	18.28	436.4	21.54	64	272.9	15.65	323.0	18.26
Oral Cavity & Pharynx	2	7.1	2.36	8.7	2.79	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	18	74.3	8.50	91.6	10.20	13	56.2	7.19	66.8	8.39
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	7.2	2.45	9.1	2.93	2	6.8	2.43	8.4	2.98
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	20.2	4.21	24.5	4.99	5	22.0	4.51	25.9	5.22
Rectum & rectosigmoid	1	4.8	2.15	5.8	2.60	1	5.7	2.36	6.5	2.66
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	10.7	2.65	14.3	3.47	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	16.3	4.29	19.4	4.99	2	9.3	3.00	10.8	3.43
Respiratory System	14	65.9	8.44	76.4	9.62	8	36.3	5.87	42.8	6.79
Larynx	1	3.9	1.63	5.2	2.13	-	-	-	-	-
Lung & bronchus	12	60.5	8.20	69.8	9.32	8	35.7	5.84	41.8	6.71
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	5.5	2.30	5.7	2.54	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	19	79.0	8.36	94.2	9.82
Female Genital System	-	-	-	-	-	6	24.4	4.71	28.0	5.32
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	3	13.9	3.53	15.5	3.89
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	7.2	2.59	8.5	3.03
Male Genital System	33	116.0	9.60	146.2	11.73	-	-	-	-	-
Prostate	32	113.1	9.49	143.3	11.63	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	38.1	6.33	44.4	7.27	3	12.6	3.25	15.7	3.99
Bladder (incl. <i>in situ</i>)	4	22.0	5.26	24.6	5.94	-	-	-	-	-
Kidney & renal pelvis	5	16.1	3.52	19.8	4.19	2	7.9	2.43	10.2	3.14
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	4.0	1.67	4.8	1.97	3	10.5	2.99	11.3	3.20
Thyroid gland	1	4.0	1.67	4.8	1.97	2	9.2	2.82	9.4	2.88
Lymphomas	4	13.7	3.21	15.7	3.63	3	10.4	2.84	12.6	3.47
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	3	11.9	3.03	14.1	3.50	2	7.0	2.39	9.1	3.05
Multiple Myeloma	2	8.4	2.64	9.6	2.94	3	10.9	2.96	14.1	3.78
Leukemias	2	8.1	2.69	9.6	3.17	3	12.6	3.43	14.4	3.89
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	1	5.9	2.46	6.5	2.68
Acute myeloid	-	-	-	-	-	1	5.0	2.07	6.2	2.54
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	13.0	3.58	15.4	4.11	3	12.9	3.50	15.0	4.02
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	3	11.3	3.06	13.7	3.71
Breast (<i>in situ</i>)	-	-	-	-	-	4	15.2	3.55	18.6	4.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	52	331.4	21.74	387.9	25.08	69	287.7	15.89	336.4	18.36
Oral Cavity & Pharynx	2	9.7	3.55	11.2	4.02	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	13	88.8	11.47	104.1	13.27	11	47.2	6.61	54.8	7.58
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	10.1	3.78	12.4	4.57	1	6.1	2.54	6.6	2.74
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	20.1	5.66	23.1	6.43	3	14.1	3.64	16.5	4.20
Rectum & rectosigmoid	2	10.2	3.59	12.0	4.29	1	5.5	2.28	6.2	2.58
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	24.3	6.13	27.5	6.87	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	11.5	4.09	14.2	4.91	2	9.2	2.73	11.6	3.37
Respiratory System	6	38.1	7.53	45.5	8.80	9	37.9	6.03	46.0	7.11
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	29.0	6.72	34.3	7.75	8	37.3	6.00	45.1	7.05
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	2	8.5	3.03	10.0	3.57	-	-	-	-	-
Melanomas of the skin	1	7.4	2.83	9.1	3.46	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	20	81.3	8.21	95.6	9.56
Female Genital System	-	-	-	-	-	9	32.7	5.10	39.3	6.06
Cervix uteri	-	-	-	-	-	2	7.7	2.46	8.4	2.69
Uterus Corpus	-	-	-	-	-	5	19.0	3.90	23.7	4.77
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	4.6	1.95	5.5	2.30
Male Genital System	15	93.1	11.43	111.8	13.42	-	-	-	-	-
Prostate	14	88.7	11.22	107.8	13.27	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	4	25.6	6.05	29.3	6.83	3	14.9	3.81	17.0	4.34
Bladder (incl. <i>in situ</i>)	2	13.4	4.75	15.7	5.39	2	7.6	2.78	9.3	3.32
Kidney & renal pelvis	2	12.2	3.74	13.7	4.21	1	6.3	2.41	6.7	2.59
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	1	5.4	2.27	5.7	2.35
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	2	9.0	3.01	10.2	3.45	5	20.3	4.03	22.1	4.38
Thyroid gland	2	7.8	2.77	9.2	3.32	5	20.3	4.03	22.1	4.38
Lymphomas	3	15.7	4.64	17.9	5.22	4	18.7	4.21	21.8	4.83
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	14.3	4.53	16.4	5.11	4	16.2	3.94	19.1	4.58
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	3	18.8	5.36	21.1	6.00	2	9.9	2.93	11.8	3.45
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	1	5.2	2.19	5.9	2.45
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	11.4	4.12	12.6	4.51	2	8.6	2.92	9.8	3.30
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1	5.5	2.27	6.2	2.61	2	9.6	2.81	11.0	3.18
Breast (<i>in situ</i>)	-	-	-	-	-	6	21.3	4.07	25.5	4.85

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	235	314.8	9.82	366.6	11.31	293	293.0	7.82	341.6	9.03
Oral Cavity & Pharynx	5	6.7	1.38	7.8	1.59	2	1.7	0.59	2.2	0.73
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	85	114.3	5.91	135.0	6.86	72	73.4	3.97	87.4	4.67
Esophagus	2	3.5	1.07	4.0	1.22	-	-	-	-	-
Stomach	10	14.8	2.18	17.2	2.50	9	9.1	1.42	10.4	1.61
Small intestine	1	2.0	0.78	2.1	0.81	2	2.0	0.64	2.4	0.76
Colon excl. rectum	21	28.4	2.93	33.4	3.39	25	25.4	2.34	30.3	2.75
Rectum & rectosigmoid	15	18.8	2.26	22.5	2.65	10	9.6	1.41	11.2	1.63
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	18	21.7	2.42	26.5	2.87	10	10.0	1.46	12.0	1.73
Gallbladder	1	2.4	0.95	2.7	1.07	4	3.8	0.89	4.6	1.07
Pancreas	9	14.2	2.30	16.6	2.66	6	6.6	1.21	8.0	1.44
Respiratory System	14	22.1	2.81	25.2	3.17	10	10.7	1.56	12.5	1.79
Larynx	1	1.7	0.66	1.9	0.73	-	-	-	-	-
Lung & bronchus	11	18.9	2.65	21.4	3.00	9	10.3	1.53	12.0	1.76
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.7	1.21	5.1	1.35	3	3.2	0.83	3.5	0.89
Skin (excl. basal & sq.)	4	5.6	1.31	6.5	1.49	6	6.0	1.12	6.7	1.24
Melanomas of the skin	3	4.5	1.18	5.4	1.38	4	4.1	0.92	4.8	1.06
Breast (excl. <i>in situ</i>)	-	-	-	-	-	70	68.3	3.73	81.0	4.35
Female Genital System	-	-	-	-	-	56	55.4	3.37	63.8	3.84
Cervix uteri	-	-	-	-	-	9	9.0	1.38	9.6	1.47
Uterus Corpus	-	-	-	-	-	28	26.7	2.29	31.3	2.66
Uterus, NOS ²	-	-	-	-	-	2	1.9	0.64	2.0	0.68
Ovary	-	-	-	-	-	14	14.1	1.72	16.5	1.98
Male Genital System	44	60.1	4.34	70.7	5.03	-	-	-	-	-
Prostate	37	53.0	4.18	63.5	4.89	-	-	-	-	-
Testis	7	6.3	1.09	6.2	1.06	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	35	46.3	3.72	54.9	4.35	18	17.9	1.94	20.8	2.24
Bladder (incl. <i>in situ</i>)	6	9.6	1.91	11.2	2.22	3	3.5	0.86	4.1	1.01
Kidney & renal pelvis	29	36.8	3.20	43.7	3.74	14	14.4	1.74	16.7	1.99
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	3	3.6	1.08	3.7	1.15	3	3.1	0.76	3.2	0.81
Brain	3	3.6	1.08	3.7	1.15	3	2.4	0.69	2.6	0.74
Endocrine System	6	5.7	1.11	6.8	1.33	19	17.5	1.84	20.1	2.11
Thyroid gland	5	4.9	1.02	6.2	1.28	18	16.8	1.80	19.3	2.06
Lymphomas	8	10.1	1.66	11.4	1.87	12	12.9	1.69	14.9	1.92
Hodgkin Lymphoma	1	1.8	0.74	2.1	0.87	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	6	10.2	1.90	11.7	2.16	6	5.9	1.12	6.8	1.28
Leukemias	8	8.9	1.54	9.4	1.64	8	7.6	1.23	8.4	1.37
Acute lymphocytic	2	2.0	0.58	1.8	0.54	3	2.4	0.65	2.7	0.75
Chronic lymphocytic	1	2.2	0.88	2.4	0.92	1	1.2	0.53	1.5	0.61
Acute myeloid	2	1.9	0.74	2.1	0.79	2	1.6	0.55	1.7	0.60
Chronic myeloid	2	2.0	0.69	2.2	0.77	2	1.9	0.63	2.0	0.67
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	10	12.0	1.86	13.6	2.11	7	8.1	1.37	9.1	1.52
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	5	6.7	1.39	7.4	1.55	13	13.6	1.70	15.4	1.91
Breast (<i>in situ</i>)	-	-	-	-	-	12	11.3	1.49	13.6	1.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,478	352.2	4.22	417.2	4.94	1,675	348.5	3.86	405.9	4.45
Oral Cavity & Pharynx	42	9.9	0.70	11.9	0.83	21	4.5	0.44	5.2	0.51
Lip	2	0.6	0.16	0.6	0.19	-	-	-	-	-
Tongue	12	2.7	0.36	3.3	0.43	7	1.5	0.24	1.8	0.30
Major salivary gland	4	1.2	0.26	1.3	0.28	4	0.8	0.19	0.9	0.22
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	4	1.0	0.23	1.2	0.27	4	0.9	0.21	1.0	0.22
Nasopharynx	3	0.6	0.16	0.7	0.20	-	-	-	-	-
Oropharynx	3	0.6	0.16	0.7	0.20	1	0.3	0.11	0.3	0.13
Hypopharynx	3	0.7	0.20	0.8	0.23	-	-	-	-	-
Digestive System	445	105.3	2.30	127.1	2.73	325	67.6	1.70	80.1	1.99
Esophagus	25	6.0	0.55	7.2	0.65	4	0.8	0.18	0.9	0.21
Stomach	44	11.1	0.77	13.0	0.89	36	7.6	0.57	8.8	0.66
Small intestine	11	2.6	0.35	3.1	0.41	8	1.6	0.26	1.9	0.30
Colon excl. rectum	106	25.6	1.14	30.6	1.35	113	23.3	1.00	27.7	1.17
Rectum & rectosigmoid	66	15.5	0.88	18.6	1.04	42	8.6	0.60	10.5	0.72
Anus, anal canal & anorectum	4	0.9	0.20	1.1	0.25	6	1.2	0.22	1.5	0.27
Liver	104	23.0	1.03	28.7	1.27	32	6.6	0.53	7.8	0.62
Gallbladder	6	1.4	0.28	1.7	0.33	10	2.2	0.30	2.6	0.36
Pancreas	56	13.6	0.84	16.4	1.00	52	10.9	0.69	12.9	0.80
Respiratory System	156	40.1	1.48	47.0	1.71	131	28.1	1.11	32.5	1.27
Larynx	16	3.9	0.44	4.7	0.53	3	0.7	0.17	0.8	0.20
Lung & bronchus	136	35.4	1.40	41.4	1.61	125	26.8	1.09	31.0	1.24
Bones & Joints	6	1.3	0.24	1.3	0.26	6	1.2	0.22	1.2	0.23
Soft Tissue (incl. heart)	16	3.8	0.43	4.2	0.48	14	2.8	0.34	3.1	0.38
Skin (excl. basal & sq.)	23	5.4	0.51	6.3	0.60	27	5.6	0.49	6.6	0.56
Melanomas of the skin	19	4.3	0.45	5.1	0.53	23	4.6	0.44	5.4	0.51
Breast (excl. <i>in situ</i>)	3	0.7	0.19	0.9	0.23	501	103.6	2.10	122.4	2.45
Female Genital System	-	-	-	-	-	224	46.3	1.40	53.9	1.62
Cervix uteri	-	-	-	-	-	41	8.9	0.63	9.4	0.66
Uterus Corpus	-	-	-	-	-	102	20.7	0.93	24.9	1.11
Uterus, NOS ¹	-	-	-	-	-	5	1.1	0.21	1.3	0.25
Ovary	-	-	-	-	-	54	11.1	0.69	13.0	0.80
Male Genital System	345	79.4	1.97	95.8	2.34	-	-	-	-	-
Prostate	306	71.3	1.88	87.5	2.26	-	-	-	-	-
Testis	34	6.6	0.52	6.5	0.50	-	-	-	-	-
Penis	5	1.4	0.27	1.6	0.32	-	-	-	-	-
Urinary System	158	38.3	1.40	45.3	1.64	92	19.3	0.91	22.6	1.06
Bladder (incl. <i>in situ</i>)	65	16.9	0.96	19.8	1.12	24	5.1	0.47	6.0	0.55
Kidney & renal pelvis	90	20.5	0.99	24.4	1.17	66	13.7	0.76	16.1	0.89
Ureter	2	0.5	0.16	0.6	0.19	1	0.3	0.12	0.3	0.13
Eye & Orbit	2	0.5	0.17	0.6	0.19	2	0.4	0.13	0.5	0.15
Brain & Other CNS ¹	23	5.3	0.50	5.8	0.56	18	3.7	0.39	4.1	0.44
Brain	21	4.9	0.49	5.5	0.55	17	3.5	0.38	3.9	0.43
Endocrine System	38	8.5	0.63	9.6	0.71	120	25.2	1.05	27.4	1.13
Thyroid gland	35	7.8	0.60	9.0	0.69	117	24.7	1.04	26.8	1.12
Lymphomas	80	18.7	0.97	21.7	1.11	71	14.6	0.79	16.9	0.90
Hodgkin Lymphoma	14	3.0	0.37	3.3	0.41	9	1.8	0.27	1.9	0.29
Non-Hodgkin Lymphoma	66	15.8	0.89	18.3	1.03	62	12.8	0.74	15.0	0.86
Multiple Myeloma	27	6.7	0.59	7.8	0.68	23	4.8	0.46	5.6	0.53
Leukemias	59	13.7	0.83	15.0	0.91	45	9.2	0.62	10.2	0.69
Acute lymphocytic	12	2.3	0.30	2.1	0.29	10	1.8	0.27	1.7	0.25
Chronic lymphocytic	13	3.1	0.40	3.6	0.46	11	2.3	0.32	2.8	0.37
Acute myeloid	17	4.1	0.46	4.5	0.51	16	3.1	0.36	3.6	0.41
Chronic myeloid	10	2.3	0.34	2.5	0.38	5	1.1	0.22	1.2	0.24
Other leukemias	7	2.0	0.33	2.2	0.38	4	0.8	0.19	0.9	0.21
Mesothelioma	3	0.9	0.23	1.1	0.27	2	0.5	0.15	0.6	0.17
Kaposi Sarcoma	1	0.3	0.13	0.3	0.13	-	-	-	-	-
Ill-defined & Unknown	52	13.4	0.86	15.5	0.98	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	26	6.1	0.55	6.8	0.62	58	12.0	0.72	13.8	0.82
Breast (<i>in situ</i>)	-	-	-	-	-	92	18.9	0.89	22.7	1.06

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEW MEXICO

II-358 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,704	413.9	3.77	490.4	4.35	2,584	384.9	3.76	448.3	4.18
Oral Cavity & Pharynx	109	16.6	0.75	20.4	0.90	35	4.7	0.38	5.7	0.45
Lip	7	1.1	0.20	1.3	0.23	2	0.2	0.08	0.3	0.09
Tongue	36	5.3	0.42	6.7	0.52	13	1.8	0.24	2.2	0.28
Major salivary gland	14	2.1	0.26	2.4	0.30	5	0.7	0.17	0.8	0.18
Floor of mouth	4	0.7	0.16	0.8	0.18	-	-	-	-	-
Gum & other mouth	9	1.3	0.20	1.6	0.24	7	0.9	0.16	1.0	0.18
Nasopharynx	3	0.4	0.12	0.5	0.14	-	-	-	-	-
Oropharynx	7	1.1	0.21	1.3	0.23	1	0.2	0.07	0.2	0.08
Hypopharynx	6	1.0	0.18	1.2	0.22	-	-	-	-	-
Digestive System	494	75.7	1.61	90.6	1.88	363	50.9	1.30	59.9	1.48
Esophagus	53	7.7	0.49	9.2	0.58	10	1.3	0.19	1.5	0.23
Stomach	37	5.6	0.43	6.5	0.49	19	2.7	0.30	3.2	0.34
Small intestine	11	1.8	0.26	2.1	0.29	10	1.4	0.23	1.6	0.24
Colon excl. rectum	145	23.2	0.92	27.4	1.05	136	19.5	0.81	22.7	0.92
Rectum & rectosigmoid	71	11.4	0.65	13.7	0.75	53	7.9	0.54	9.4	0.61
Anus, anal canal & anorectum	9	1.4	0.23	1.8	0.28	15	2.2	0.28	2.7	0.32
Liver	59	8.3	0.50	10.6	0.63	21	2.9	0.31	3.4	0.35
Gallbladder	3	0.6	0.15	0.7	0.17	6	0.9	0.18	1.0	0.19
Pancreas	82	12.1	0.63	14.5	0.74	73	9.6	0.53	11.4	0.62
Respiratory System	382	56.6	1.33	66.9	1.56	335	43.5	1.11	51.6	1.30
Larynx	29	4.3	0.38	5.2	0.45	9	1.2	0.19	1.5	0.24
Lung & bronchus	347	51.1	1.26	60.2	1.48	322	41.8	1.08	49.5	1.27
Bones & Joints	5	1.0	0.23	1.0	0.22	4	0.8	0.21	0.8	0.19
Soft Tissue (incl. heart)	19	3.2	0.35	3.7	0.39	15	2.5	0.33	2.8	0.35
Skin (excl. basal & sq.)	219	35.0	1.13	40.8	1.28	137	22.2	0.96	25.3	1.03
Melanomas of the skin	203	32.4	1.09	37.8	1.23	127	20.7	0.93	23.6	1.00
Breast (excl. <i>in situ</i>)	8	1.3	0.21	1.5	0.24	820	121.3	2.09	143.5	2.37
Female Genital System	-	-	-	-	-	314	47.9	1.35	56.6	1.51
Cervix uteri	-	-	-	-	-	32	7.5	0.66	7.8	0.65
Uterus Corpus	-	-	-	-	-	165	23.6	0.91	28.7	1.05
Uterus, NOS ¹	-	-	-	-	-	5	0.7	0.15	0.9	0.18
Ovary	-	-	-	-	-	81	11.9	0.65	14.1	0.74
Male Genital System	658	94.2	1.72	114.5	2.05	-	-	-	-	-
Prostate	629	86.8	1.60	107.0	1.95	-	-	-	-	-
Testis	22	6.5	0.63	6.4	0.61	-	-	-	-	-
Penis	5	0.7	0.14	0.8	0.17	-	-	-	-	-
Urinary System	311	47.4	1.26	55.9	1.46	119	16.9	0.75	19.5	0.83
Bladder (incl. <i>in situ</i>)	203	30.1	0.97	35.5	1.14	61	7.9	0.47	9.3	0.55
Kidney & renal pelvis	100	16.2	0.78	19.0	0.89	55	8.5	0.57	9.7	0.62
Ureter	5	0.8	0.16	0.9	0.18	3	0.3	0.10	0.4	0.11
Eye & Orbit	5	1.0	0.23	1.1	0.22	5	0.6	0.14	0.8	0.16
Brain & Other CNS ¹	42	7.3	0.55	8.4	0.60	32	5.8	0.53	6.3	0.53
Brain	41	7.1	0.54	8.3	0.60	30	5.1	0.47	5.6	0.49
Endocrine System	49	9.3	0.66	10.5	0.70	116	25.2	1.17	27.1	1.19
Thyroid gland	44	8.3	0.62	9.5	0.67	112	24.6	1.16	26.5	1.18
Lymphomas	132	22.1	0.93	25.4	1.02	104	15.6	0.76	17.9	0.83
Hodgkin Lymphoma	16	3.6	0.43	3.8	0.44	9	2.1	0.35	2.1	0.34
Non-Hodgkin Lymphoma	116	18.5	0.82	21.6	0.92	96	13.6	0.68	15.8	0.76
Multiple Myeloma	46	7.0	0.48	8.2	0.56	25	3.4	0.34	4.0	0.38
Leukemias	104	17.3	0.82	19.6	0.89	78	12.5	0.72	13.8	0.75
Acute lymphocytic	5	1.5	0.31	1.3	0.27	5	1.7	0.36	1.5	0.30
Chronic lymphocytic	45	6.8	0.47	8.0	0.55	29	3.8	0.33	4.5	0.39
Acute myeloid	28	4.5	0.41	5.2	0.45	24	3.7	0.38	4.1	0.41
Chronic myeloid	14	2.5	0.33	2.8	0.35	12	2.0	0.30	2.2	0.30
Other leukemias	12	2.0	0.26	2.3	0.30	8	1.3	0.21	1.5	0.25
Mesothelioma	8	1.1	0.19	1.3	0.21	1	0.2	0.07	0.2	0.08
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	35	6.6	0.55	7.2	0.58	67	10.6	0.64	12.1	0.71
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.09	146	23.3	0.96	27.4	1.08

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Mexico, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	89	400.8	20.52	484.0	24.16	61	325.2	19.09	382.5	22.00
Oral Cavity & Pharynx	2	8.0	2.66	9.7	3.11	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	18	81.0	9.47	99.9	11.36	12	65.0	8.61	76.9	9.97
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	8.0	2.70	10.1	3.24	2	8.3	2.98	10.2	3.64
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	23.0	4.82	27.8	5.69	4	23.8	5.20	28.1	6.00
Rectum & rectosigmoid	-	-	-	-	-	1	7.1	2.94	8.1	3.33
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	12.0	2.97	15.9	3.88	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	18.3	4.86	21.8	5.66	2	10.9	3.53	12.7	4.04
Respiratory System	14	71.7	9.32	82.8	10.60	8	42.6	6.88	50.3	7.97
Larynx	1	4.3	1.80	5.7	2.35	-	-	-	-	-
Lung & bronchus	12	65.4	9.04	75.2	10.25	8	41.9	6.84	49.1	7.89
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	6.1	2.72	6.4	3.00	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	18	95.2	10.38	112.5	12.00
Female Genital System	-	-	-	-	-	5	30.2	6.02	34.1	6.60
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	3	16.7	4.47	18.3	4.72
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	8.9	3.24	10.7	3.79
Male Genital System	33	129.8	10.79	163.5	13.18	-	-	-	-	-
Prostate	32	126.2	10.64	159.9	13.05	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	42.7	7.21	49.7	8.31	3	15.4	3.94	19.0	4.79
Bladder (incl. <i>in situ</i>)	4	24.3	5.99	27.2	6.81	-	-	-	-	-
Kidney & renal pelvis	5	18.4	4.01	22.5	4.76	2	9.8	3.00	12.5	3.80
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	4.6	1.94	5.5	2.25	2	12.6	3.94	13.2	4.04
Thyroid gland	1	4.6	1.94	5.5	2.25	2	11.0	3.76	10.9	3.68
Lymphomas	4	16.2	3.78	18.4	4.19	3	13.2	3.61	15.7	4.24
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	8.5	2.82	10.0	3.20	3	13.2	3.61	17.1	4.60
Leukemias	2	9.6	3.13	11.2	3.62	3	13.9	3.92	16.0	4.48
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	1	6.2	2.56	7.7	3.15
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	14.5	3.98	17.1	4.57	3	14.9	4.05	17.4	4.67
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	3	13.1	3.68	15.7	4.40
Breast (<i>in situ</i>)	-	-	-	-	-	4	18.3	4.45	22.1	5.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

NEW MEXICO


II-360 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	19,628,043	19,656,330	19,661,411	19,641,589	19,590,719
White	14,110,914	14,084,671	14,040,860	13,980,911	13,908,492
Black	3,608,469	3,622,359	3,632,146	3,637,096	3,634,378
American Indian/Alaskan Native (AI/AN)	221,116	222,093	222,758	223,449	223,829
Asian/Pacific Islander (API)	1,687,544	1,727,207	1,765,647	1,800,133	1,824,020

All Races Population 2013-2017: 98,178,092

Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹


Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	3,604,850	3,645,148	3,683,100	3,713,815	3,731,762
Non-Hispanic White	11,363,329	11,307,495	11,235,872	11,155,056	11,070,695
Non-Hispanic Black	2,965,236	2,970,253	2,971,425	2,968,234	2,960,636

Hispanic/Latino Population, Census 2010: 3,416,922

Distribution of Hispanic/Latino Populations²



**% Hispanic/Latino of Total Population
By Census Year²**



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW YORK CANCER REGISTRY

Initial Operation: 1940
Population-based Data Available: 1976
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	113.1	114.1	115.8	116.8	115.5
Missing Race	0.6	0.7	0.8	1.0	1.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.8	0.9	1.1	0.8	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.2	Prostate	98.0
Oral Cavity & Pharynx	98.6	Testis	99.5
Esophagus	97.0	Bladder (incl. <i>in situ</i>)	98.3
Stomach	97.7	Kidney & Renal Pelvis	91.1
Colon & Rectum	96.7	Brain & Other CNS ¹	85.9
Liver	57.7	Thyroid	99.7
Pancreas	86.2	Hodgkin Lymphoma	99.3
Lung & Bronchus	89.9	Non-Hodgkin Lymphoma	97.8
Melanomas of the Skin	99.7	Multiple Myeloma	92.4
Female Breast (excl. <i>in situ</i>)	99.2	Leukemias	92.8
Cervix uteri	98.6	Brain & Other CNS ¹ <i>non-malig</i>	39.4
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	93.7		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	55,956	531.6	1.03	629.9	1.20	57,193	456.3	0.88	531.4	1.00
Oral Cavity & Pharynx	1,802	16.7	0.18	20.1	0.21	828	6.5	0.10	7.7	0.12
Lip	65	0.6	0.04	0.7	0.04	35	0.3	0.02	0.3	0.02
Tongue	558	5.1	0.10	6.2	0.12	242	1.9	0.06	2.3	0.07
Major salivary gland	171	1.7	0.06	2.0	0.07	137	1.1	0.04	1.3	0.05
Floor of mouth	77	0.7	0.04	0.9	0.04	39	0.3	0.02	0.4	0.03
Gum & other mouth	208	2.0	0.06	2.3	0.07	172	1.3	0.05	1.5	0.05
Nasopharynx	123	1.2	0.05	1.4	0.06	47	0.4	0.03	0.5	0.03
Oropharynx	94	0.8	0.04	1.0	0.05	28	0.2	0.02	0.3	0.02
Hypopharynx	116	1.1	0.05	1.3	0.05	32	0.2	0.02	0.3	0.02
Digestive System	10,956	104.5	0.46	124.3	0.53	9,097	69.5	0.33	81.7	0.39
Esophagus	815	7.6	0.12	9.2	0.14	269	2.0	0.06	2.4	0.07
Stomach	1,226	11.9	0.15	14.0	0.18	816	6.3	0.10	7.4	0.12
Small intestine	336	3.2	0.08	3.8	0.09	290	2.3	0.06	2.7	0.07
Colon excl. rectum	3,105	30.4	0.25	35.6	0.29	3,274	25.0	0.20	29.1	0.23
Rectum & rectosigmoid	1,509	14.3	0.17	17.0	0.20	1,139	9.0	0.12	10.7	0.14
Anus, anal canal & anorectum	201	1.9	0.06	2.3	0.07	309	2.4	0.06	2.9	0.07
Liver	1,400	12.5	0.15	15.5	0.19	465	3.5	0.07	4.2	0.09
Gallbladder	111	1.1	0.05	1.3	0.05	232	1.8	0.05	2.1	0.06
Pancreas	1,692	16.2	0.18	19.3	0.21	1,695	12.6	0.14	14.8	0.16
Respiratory System	7,598	73.0	0.38	86.5	0.45	7,348	55.4	0.29	65.8	0.35
Larynx	611	5.7	0.10	6.9	0.12	161	1.2	0.04	1.5	0.05
Lung & bronchus	6,863	66.2	0.36	78.3	0.42	7,099	53.4	0.29	63.5	0.34
Bones & Joints	125	1.3	0.05	1.3	0.05	102	1.0	0.04	1.0	0.04
Soft Tissue (incl. heart)	438	4.4	0.10	4.9	0.10	345	3.0	0.07	3.3	0.08
Skin (excl. basal & sq.)	2,683	26.4	0.23	30.7	0.27	1,946	16.0	0.17	18.2	0.19
Melanomas of the skin	2,420	23.7	0.22	27.6	0.25	1,762	14.5	0.16	16.6	0.18
Breast (excl. <i>in situ</i>)	155	1.5	0.05	1.8	0.06	16,238	132.8	0.48	155.4	0.55
Female Genital System	-	-	-	-	-	7,163	56.9	0.31	67.7	0.36
Cervix uteri	-	-	-	-	-	859	7.8	0.12	8.6	0.13
Uterus Corpus	-	-	-	-	-	4,034	31.1	0.22	38.0	0.27
Uterus, NOS ¹	-	-	-	-	-	125	1.0	0.04	1.1	0.05
Ovary	-	-	-	-	-	1,495	12.1	0.14	14.1	0.16
Male Genital System	14,697	132.0	0.50	161.5	0.60	-	-	-	-	-
Prostate	14,016	125.0	0.48	154.3	0.59	-	-	-	-	-
Testis	562	5.9	0.11	5.9	0.11	-	-	-	-	-
Penis	93	0.9	0.04	1.1	0.05	-	-	-	-	-
Urinary System	6,665	64.8	0.36	76.3	0.42	2,854	21.8	0.19	25.7	0.22
Bladder (incl. <i>in situ</i>)	4,022	39.9	0.29	46.6	0.33	1,381	10.2	0.13	12.0	0.15
Kidney & renal pelvis	2,496	23.5	0.22	27.9	0.25	1,387	11.0	0.14	12.9	0.16
Ureter	86	0.9	0.04	1.0	0.05	54	0.4	0.03	0.5	0.03
Eye & Orbit	97	0.9	0.04	1.1	0.05	94	0.8	0.04	0.9	0.04
Brain & Other CNS ¹	798	7.9	0.13	8.7	0.14	643	5.6	0.10	6.1	0.11
Brain	746	7.4	0.12	8.2	0.13	594	5.1	0.10	5.6	0.10
Endocrine System	1,171	11.5	0.15	12.8	0.17	3,206	29.9	0.24	32.4	0.26
Thyroid gland	1,054	10.3	0.15	11.6	0.16	3,100	29.0	0.24	31.4	0.25
Lymphomas	3,034	29.9	0.25	34.1	0.28	2,605	21.0	0.19	24.0	0.21
Hodgkin Lymphoma	344	3.5	0.09	3.7	0.09	311	3.0	0.08	3.1	0.08
Non-Hodgkin Lymphoma	2,690	26.3	0.23	30.5	0.26	2,293	18.0	0.17	21.0	0.20
Multiple Myeloma	1,065	10.2	0.14	12.1	0.17	889	6.8	0.10	8.0	0.12
Leukemias	2,172	21.5	0.21	24.6	0.24	1,599	12.7	0.15	14.4	0.16
Acute lymphocytic	177	1.9	0.07	1.8	0.06	132	1.4	0.05	1.3	0.05
Chronic lymphocytic	921	8.8	0.13	10.5	0.16	627	4.6	0.08	5.5	0.10
Acute myeloid	581	5.8	0.11	6.6	0.12	476	3.8	0.08	4.3	0.09
Chronic myeloid	274	2.7	0.07	3.1	0.08	207	1.7	0.05	1.9	0.06
Other leukemias	220	2.2	0.07	2.5	0.08	158	1.2	0.05	1.4	0.05
Mesothelioma	145	1.5	0.06	1.7	0.06	53	0.4	0.03	0.5	0.03
Kaposi Sarcoma	125	1.3	0.05	1.4	0.06	20	0.2	0.02	0.2	0.02
Ill-defined & Unknown	2,228	22.3	0.22	25.9	0.25	2,163	16.1	0.16	18.5	0.18
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1,097	10.9	0.15	12.3	0.17	2,224	18.1	0.18	20.7	0.20
Breast (<i>in situ</i>)	16	0.2	0.02	0.2	0.02	4,984	42.3	0.28	49.5	0.32

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	44,086	539.2	1.17	637.1	1.36	44,818	476.3	1.05	554.2	1.19
Oral Cavity & Pharynx	1,465	17.5	0.21	21.2	0.25	649	6.7	0.12	7.9	0.14
Lip	60	0.7	0.04	0.9	0.05	33	0.3	0.03	0.4	0.03
Tongue	482	5.7	0.12	6.9	0.14	197	2.0	0.07	2.5	0.08
Major salivary gland	140	1.8	0.07	2.1	0.08	100	1.1	0.05	1.2	0.06
Floor of mouth	65	0.8	0.04	0.9	0.05	33	0.3	0.03	0.4	0.03
Gum & other mouth	166	2.0	0.07	2.4	0.08	138	1.4	0.05	1.6	0.06
Nasopharynx	51	0.6	0.04	0.7	0.05	21	0.2	0.02	0.3	0.03
Oropharynx	76	0.9	0.05	1.1	0.06	21	0.2	0.02	0.3	0.03
Hypopharynx	87	1.0	0.05	1.3	0.06	26	0.3	0.02	0.3	0.03
Digestive System	8,239	100.9	0.51	119.8	0.59	6,785	67.8	0.38	79.5	0.44
Esophagus	686	8.2	0.14	9.9	0.17	213	2.1	0.07	2.5	0.08
Stomach	832	10.3	0.16	12.1	0.19	526	5.3	0.11	6.3	0.12
Small intestine	250	3.1	0.09	3.6	0.10	209	2.2	0.07	2.6	0.08
Colon excl. rectum	2,387	29.9	0.28	35.0	0.32	2,513	25.0	0.23	29.0	0.26
Rectum & rectosigmoid	1,147	14.1	0.19	16.8	0.22	849	9.0	0.14	10.6	0.17
Anus, anal canal & anorectum	152	1.8	0.07	2.2	0.08	252	2.6	0.08	3.2	0.09
Liver	916	10.5	0.16	13.0	0.19	296	2.9	0.08	3.5	0.09
Gallbladder	74	0.9	0.05	1.1	0.06	153	1.5	0.06	1.8	0.07
Pancreas	1,362	16.6	0.21	19.7	0.24	1,312	12.6	0.16	14.8	0.19
Respiratory System	6,147	75.1	0.44	88.9	0.51	6,128	60.4	0.35	71.7	0.42
Larynx	484	5.8	0.12	7.0	0.14	125	1.3	0.05	1.6	0.06
Lung & bronchus	5,563	68.1	0.42	80.4	0.48	5,934	58.4	0.35	69.3	0.41
Bones & Joints	97	1.4	0.06	1.4	0.06	76	1.0	0.05	1.0	0.05
Soft Tissue (incl. heart)	345	4.5	0.11	5.0	0.12	257	3.0	0.09	3.2	0.09
Skin (excl. basal & sq.)	2,566	32.2	0.29	37.6	0.33	1,824	20.4	0.22	23.2	0.25
Melanomas of the skin	2,335	29.3	0.28	34.2	0.32	1,675	18.9	0.22	21.4	0.24
Breast (excl. <i>in situ</i>)	122	1.5	0.06	1.8	0.07	12,536	137.7	0.57	161.2	0.65
Female Genital System	-	-	-	-	-	5,416	57.8	0.36	68.7	0.42
Cervix uteri	-	-	-	-	-	549	7.1	0.14	7.6	0.15
Uterus Corpus	-	-	-	-	-	3,090	32.0	0.27	39.1	0.32
Uterus, NOS ¹	-	-	-	-	-	71	0.7	0.04	0.8	0.04
Ovary	-	-	-	-	-	1,174	12.7	0.17	14.8	0.20
Male Genital System	10,605	123.2	0.55	149.9	0.65	-	-	-	-	-
Prostate	10,022	114.7	0.52	141.3	0.63	-	-	-	-	-
Testis	492	7.3	0.15	7.3	0.15	-	-	-	-	-
Penis	71	0.9	0.05	1.1	0.06	-	-	-	-	-
Urinary System	5,707	70.7	0.43	83.1	0.49	2,363	23.8	0.23	27.9	0.26
Bladder (incl. <i>in situ</i>)	3,591	44.8	0.34	52.4	0.39	1,201	11.6	0.15	13.6	0.18
Kidney & renal pelvis	1,988	24.3	0.25	28.8	0.29	1,093	11.5	0.16	13.5	0.19
Ureter	79	1.0	0.05	1.2	0.06	47	0.5	0.03	0.5	0.03
Eye & Orbit	83	1.1	0.05	1.2	0.06	84	1.0	0.05	1.1	0.05
Brain & Other CNS ¹	670	8.8	0.16	9.7	0.17	534	6.3	0.13	6.9	0.13
Brain	631	8.2	0.15	9.1	0.16	497	5.8	0.12	6.4	0.13
Endocrine System	928	12.2	0.18	13.6	0.20	2,361	31.2	0.30	33.6	0.31
Thyroid gland	844	11.1	0.18	12.4	0.19	2,288	30.3	0.29	32.7	0.31
Lymphomas	2,480	31.6	0.29	36.2	0.33	2,104	22.5	0.23	25.8	0.26
Hodgkin Lymphoma	265	3.7	0.10	3.9	0.11	237	3.2	0.10	3.3	0.10
Non-Hodgkin Lymphoma	2,215	27.9	0.27	32.3	0.31	1,867	19.3	0.21	22.5	0.24
Multiple Myeloma	758	9.3	0.15	11.0	0.18	586	5.8	0.11	6.9	0.13
Leukemias	1,830	23.3	0.25	26.6	0.28	1,301	13.6	0.18	15.5	0.20
Acute lymphocytic	140	2.1	0.08	2.0	0.08	103	1.5	0.07	1.4	0.06
Chronic lymphocytic	815	9.9	0.16	11.8	0.19	548	5.3	0.10	6.3	0.12
Acute myeloid	477	6.1	0.13	7.0	0.14	371	3.9	0.10	4.4	0.11
Chronic myeloid	220	2.8	0.09	3.2	0.10	159	1.7	0.06	1.9	0.07
Other leukemias	178	2.3	0.08	2.6	0.09	120	1.2	0.05	1.4	0.06
Mesothelioma	130	1.7	0.07	1.9	0.08	47	0.5	0.03	0.5	0.04
Kaposi Sarcoma	76	1.0	0.05	1.1	0.06	14	0.1	0.02	0.1	0.02
Ill-defined & Unknown	1,839	23.4	0.25	27.1	0.28	1,753	16.7	0.19	19.3	0.21
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	850	11.1	0.17	12.5	0.19	1,711	18.7	0.21	21.3	0.24
Breast (<i>in situ</i>)	12	0.1	0.02	0.2	0.02	3,729	43.5	0.33	50.8	0.38

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7,933	527.5	2.77	635.7	3.27	8,252	392.0	1.96	460.6	2.27
Oral Cavity & Pharynx	185	11.9	0.41	14.3	0.48	102	4.8	0.22	5.7	0.25
Lip	1	0.1	0.03	0.1	0.04	-	-	-	-	-
Tongue	44	2.8	0.20	3.4	0.24	21	1.0	0.10	1.1	0.11
Major salivary gland	16	1.0	0.11	1.2	0.13	23	1.1	0.11	1.3	0.12
Floor of mouth	8	0.5	0.08	0.6	0.10	5	0.2	0.04	0.3	0.05
Gum & other mouth	20	1.4	0.14	1.6	0.16	21	1.0	0.10	1.2	0.11
Nasopharynx	19	1.1	0.12	1.3	0.14	7	0.3	0.06	0.4	0.06
Oropharynx	14	0.9	0.12	1.1	0.14	6	0.3	0.05	0.3	0.06
Hypopharynx	22	1.5	0.15	1.8	0.17	6	0.3	0.05	0.3	0.06
Digestive System	1,718	117.2	1.32	140.7	1.56	1,609	76.0	0.86	90.1	1.01
Esophagus	87	6.3	0.31	7.5	0.37	43	2.0	0.14	2.4	0.17
Stomach	208	15.1	0.49	17.8	0.57	179	8.6	0.29	10.0	0.34
Small intestine	67	4.7	0.26	5.5	0.31	62	2.9	0.17	3.5	0.20
Colon excl. rectum	482	34.0	0.72	40.3	0.84	545	25.8	0.50	30.5	0.59
Rectum & rectosigmoid	216	14.4	0.46	17.1	0.54	185	8.7	0.29	10.4	0.34
Anus, anal canal & anorectum	43	2.7	0.19	3.1	0.22	49	2.3	0.15	2.7	0.18
Liver	282	17.1	0.47	21.7	0.59	103	4.6	0.21	5.8	0.25
Gallbladder	25	1.9	0.17	2.2	0.20	59	2.7	0.16	3.3	0.19
Pancreas	237	16.2	0.49	19.6	0.58	289	13.8	0.37	16.3	0.43
Respiratory System	960	67.0	1.01	80.3	1.19	862	40.2	0.62	48.4	0.74
Larynx	94	6.3	0.31	7.7	0.36	30	1.3	0.11	1.7	0.14
Lung & bronchus	849	59.6	0.96	71.3	1.12	819	38.2	0.61	46.0	0.72
Bones & Joints	17	1.0	0.11	1.0	0.12	17	0.9	0.10	0.9	0.09
Soft Tissue (incl. heart)	60	3.9	0.23	4.3	0.26	61	3.0	0.17	3.3	0.19
Skin (excl. basal & sq.)	34	2.3	0.19	2.6	0.21	40	2.0	0.14	2.2	0.16
Melanomas of the skin	15	1.1	0.13	1.2	0.15	19	0.9	0.10	1.1	0.11
Breast (excl. <i>in situ</i>)	27	1.8	0.17	2.2	0.19	2,503	119.6	1.09	140.3	1.26
Female Genital System	-	-	-	-	-	1,196	55.7	0.73	66.7	0.86
Cervix uteri	-	-	-	-	-	202	9.9	0.32	11.2	0.35
Uterus Corpus	-	-	-	-	-	663	30.1	0.53	37.0	0.64
Uterus, NOS ¹	-	-	-	-	-	47	2.2	0.15	2.6	0.17
Ovary	-	-	-	-	-	196	9.3	0.30	10.9	0.35
Male Genital System	3,091	196.7	1.65	244.1	1.99	-	-	-	-	-
Prostate	3,039	193.5	1.63	240.7	1.98	-	-	-	-	-
Testis	34	2.0	0.16	1.9	0.15	-	-	-	-	-
Penis	15	1.0	0.12	1.2	0.14	-	-	-	-	-
Urinary System	620	42.7	0.80	50.9	0.94	356	16.9	0.41	19.8	0.47
Bladder (incl. <i>in situ</i>)	254	19.1	0.56	22.5	0.65	130	6.2	0.25	7.3	0.29
Kidney & renal pelvis	356	22.9	0.56	27.6	0.67	214	10.1	0.31	11.9	0.36
Ureter	3	0.3	0.07	0.3	0.08	4	0.2	0.04	0.2	0.05
Eye & Orbit	6	0.3	0.07	0.4	0.07	5	0.3	0.05	0.3	0.05
Brain & Other CNS ¹	75	4.7	0.25	5.1	0.27	64	3.2	0.18	3.4	0.19
Brain	68	4.3	0.24	4.7	0.26	57	2.9	0.17	3.1	0.18
Endocrine System	87	5.6	0.28	6.2	0.31	352	17.3	0.42	19.3	0.46
Thyroid gland	68	4.4	0.25	4.9	0.27	332	16.4	0.41	18.3	0.45
Lymphomas	338	22.0	0.56	25.1	0.63	339	16.4	0.41	18.7	0.45
Hodgkin Lymphoma	55	3.3	0.21	3.5	0.22	56	2.8	0.17	2.9	0.18
Non-Hodgkin Lymphoma	283	18.7	0.52	21.6	0.59	284	13.6	0.37	15.7	0.42
Multiple Myeloma	241	16.9	0.51	20.1	0.59	255	12.1	0.34	14.3	0.40
Leukemias	194	13.3	0.45	15.2	0.51	190	9.3	0.30	10.4	0.34
Acute lymphocytic	20	1.2	0.12	1.1	0.12	15	0.8	0.09	0.7	0.09
Chronic lymphocytic	56	4.0	0.25	4.8	0.29	49	2.3	0.15	2.7	0.17
Acute myeloid	63	4.4	0.26	5.0	0.29	69	3.4	0.18	3.8	0.20
Chronic myeloid	31	2.0	0.17	2.3	0.20	30	1.5	0.12	1.7	0.14
Other leukemias	24	1.7	0.16	1.9	0.18	27	1.3	0.12	1.5	0.13
Mesothelioma	9	0.8	0.11	0.9	0.13	3	0.2	0.04	0.2	0.05
Kaposi Sarcoma	33	2.0	0.16	2.2	0.17	4	0.2	0.05	0.2	0.05
Ill-defined & Unknown	238	17.2	0.52	20.1	0.60	292	14.0	0.37	16.3	0.43
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	137	9.2	0.37	10.6	0.42	308	14.9	0.38	17.2	0.44
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.06	769	36.5	0.60	43.3	0.70

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,824	356.6	3.12	419.6	3.62	3,162	333.5	2.70	386.3	3.11
Oral Cavity & Pharynx	127	15.0	0.61	17.6	0.71	65	6.9	0.39	8.0	0.45
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	25	2.9	0.27	3.5	0.32	21	2.3	0.23	2.6	0.26
Major salivary gland	12	1.5	0.20	1.7	0.22	12	1.2	0.17	1.4	0.18
Floor of mouth	4	0.4	0.10	0.5	0.12	1	0.1	0.06	0.2	0.07
Gum & other mouth	19	2.3	0.25	2.8	0.30	10	1.2	0.16	1.3	0.19
Nasopharynx	51	5.9	0.38	6.7	0.42	17	1.7	0.18	2.0	0.22
Oropharynx	3	0.4	0.11	0.5	0.13	-	-	-	-	-
Hypopharynx	6	0.7	0.15	0.9	0.17	-	-	-	-	-
Digestive System	852	107.0	1.71	127.4	2.00	581	63.7	1.21	75.1	1.41
Esophagus	37	4.7	0.36	5.7	0.42	10	1.2	0.17	1.4	0.19
Stomach	168	21.7	0.78	25.7	0.91	98	10.7	0.49	12.5	0.57
Small intestine	14	1.9	0.23	2.2	0.27	14	1.4	0.17	1.7	0.21
Colon excl. rectum	191	24.1	0.81	28.6	0.95	169	18.5	0.65	21.8	0.76
Rectum & rectosigmoid	125	15.1	0.63	18.1	0.74	83	8.7	0.44	10.3	0.51
Anus, anal canal & anorectum	4	0.5	0.12	0.6	0.14	3	0.3	0.08	0.4	0.10
Liver	173	20.6	0.73	24.9	0.86	58	6.4	0.38	7.6	0.45
Gallbladder	9	1.3	0.20	1.5	0.24	17	1.8	0.21	2.2	0.24
Pancreas	81	10.5	0.55	12.4	0.63	82	9.3	0.47	11.0	0.55
Respiratory System	439	58.4	1.30	69.0	1.51	313	34.3	0.89	40.7	1.04
Larynx	25	3.0	0.28	3.8	0.34	3	0.3	0.08	0.4	0.10
Lung & bronchus	408	54.6	1.26	64.4	1.46	305	33.4	0.88	39.8	1.03
Bones & Joints	7	0.9	0.15	0.9	0.15	6	0.6	0.12	0.6	0.11
Soft Tissue (incl. heart)	26	3.2	0.29	3.5	0.32	20	2.1	0.22	2.3	0.23
Skin (excl. basal & sq.)	20	2.6	0.27	3.0	0.31	18	2.0	0.21	2.2	0.23
Melanomas of the skin	12	1.7	0.22	1.9	0.25	10	1.1	0.15	1.2	0.18
Breast (excl. <i>in situ</i>)	5	0.7	0.15	0.8	0.17	961	99.0	1.45	114.9	1.67
Female Genital System	-	-	-	-	-	418	42.7	0.95	50.3	1.11
Cervix uteri	-	-	-	-	-	81	8.4	0.43	9.5	0.47
Uterus Corpus	-	-	-	-	-	210	21.2	0.66	25.5	0.79
Uterus, NOS ¹	-	-	-	-	-	5	0.5	0.11	0.6	0.13
Ovary	-	-	-	-	-	100	10.2	0.47	12.0	0.54
Male Genital System	537	65.5	1.32	79.1	1.55	-	-	-	-	-
Prostate	511	62.6	1.29	76.1	1.53	-	-	-	-	-
Testis	20	2.1	0.21	2.1	0.21	-	-	-	-	-
Penis	5	0.7	0.14	0.8	0.16	-	-	-	-	-
Urinary System	243	31.7	0.95	37.2	1.10	97	10.6	0.49	12.4	0.57
Bladder (incl. <i>in situ</i>)	132	18.3	0.74	21.4	0.86	36	4.1	0.31	4.8	0.36
Kidney & renal pelvis	105	12.6	0.57	14.9	0.66	57	6.0	0.37	7.0	0.42
Ureter	3	0.4	0.11	0.5	0.13	3	0.4	0.09	0.4	0.11
Eye & Orbit	4	0.5	0.11	0.5	0.12	3	0.4	0.09	0.3	0.09
Brain & Other CNS ¹	41	4.9	0.35	5.3	0.38	35	3.9	0.30	4.2	0.32
Brain	37	4.4	0.33	4.8	0.36	32	3.5	0.29	3.8	0.31
Endocrine System	123	14.1	0.58	15.8	0.65	368	36.7	0.87	40.2	0.95
Thyroid gland	111	12.6	0.54	14.1	0.61	356	35.4	0.85	38.7	0.93
Lymphomas	151	19.2	0.72	21.8	0.82	112	12.1	0.52	13.8	0.59
Hodgkin Lymphoma	16	1.9	0.22	2.0	0.23	11	1.2	0.16	1.2	0.17
Non-Hodgkin Lymphoma	135	17.3	0.69	19.8	0.78	101	10.9	0.50	12.5	0.57
Multiple Myeloma	44	5.6	0.39	6.8	0.46	29	3.1	0.26	3.7	0.31
Leukemias	91	11.6	0.56	12.9	0.63	65	7.1	0.40	7.9	0.45
Acute lymphocytic	14	1.7	0.21	1.6	0.19	10	1.1	0.17	1.1	0.16
Chronic lymphocytic	17	2.2	0.25	2.6	0.29	9	1.0	0.15	1.2	0.17
Acute myeloid	35	4.6	0.36	5.1	0.40	29	3.1	0.27	3.6	0.30
Chronic myeloid	13	1.6	0.21	1.9	0.24	9	1.0	0.15	1.2	0.17
Other leukemias	11	1.5	0.21	1.7	0.24	7	0.8	0.13	0.9	0.15
Mesothelioma	5	0.6	0.13	0.7	0.15	1	0.2	0.06	0.2	0.07
Kaposi Sarcoma	4	0.6	0.13	0.6	0.14	-	-	-	-	-
Ill-defined & Unknown	104	14.5	0.67	16.8	0.76	70	8.2	0.44	9.3	0.50
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	77	9.4	0.50	10.7	0.56	145	15.3	0.58	17.9	0.67
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.08	389	40.0	0.92	46.2	1.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	63	360.4	21.63	431.6	25.41	65	313.1	17.71	367.5	20.59
Oral Cavity & Pharynx	3	16.5	4.10	21.3	5.22	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	6.6	2.55	8.4	3.22	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	13	69.9	9.16	84.7	10.88	13	62.9	7.91	76.5	9.48
Esophagus	1	8.2	3.28	9.5	3.64	-	-	-	-	-
Stomach	1	6.4	2.75	8.0	3.40	1	6.1	2.56	7.4	3.08
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	16.7	4.70	19.9	5.51	6	27.4	5.19	33.4	6.24
Rectum & rectosigmoid	2	9.4	3.29	10.8	3.79	1	5.2	2.15	6.5	2.67
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	17.9	4.11	23.5	5.31	1	5.4	2.28	7.0	2.85
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	1	7.1	2.74	8.0	3.05
Respiratory System	9	60.9	9.58	71.0	11.01	11	54.5	7.42	66.0	8.87
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	57.9	9.41	67.3	10.80	10	50.1	7.15	60.6	8.54
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	1	8.0	3.22	9.2	3.80	2	8.9	2.84	10.4	3.31
Melanomas of the skin	1	8.0	3.22	9.2	3.80	1	5.3	2.18	6.1	2.52
Breast (excl. <i>in situ</i>)	-	-	-	-	-	16	78.2	8.91	89.3	10.09
Female Genital System	-	-	-	-	-	8	36.5	6.01	42.2	6.91
Cervix uteri	-	-	-	-	-	2	8.9	3.01	9.5	3.23
Uterus Corpus	-	-	-	-	-	3	15.8	3.91	18.8	4.59
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	6.6	2.54	7.8	2.95
Male Genital System	17	91.5	10.47	112.0	12.46	-	-	-	-	-
Prostate	16	87.3	10.30	107.8	12.32	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	9	54.5	8.87	63.8	10.18	3	15.8	3.92	19.6	4.78
Bladder (incl. <i>in situ</i>)	3	23.4	6.04	27.1	6.89	-	-	-	-	-
Kidney & renal pelvis	5	31.2	6.50	36.7	7.49	2	11.2	3.29	13.5	3.89
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	6.4	2.64	6.8	2.81	3	13.5	3.52	14.1	3.69
Thyroid gland	-	-	-	-	-	3	13.5	3.52	14.1	3.69
Lymphomas	2	8.2	2.76	9.6	3.23	3	16.1	4.12	18.8	4.76
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	7.3	2.62	8.8	3.13	3	15.3	4.04	17.7	4.64
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	15.8	4.89	18.6	5.73	1	5.4	2.26	5.9	2.45
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	12.0	4.10	14.9	4.96	2	8.0	2.89	9.4	3.35
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	1	5.0	2.05	5.4	2.27	2	10.1	2.96	11.8	3.46
Breast (<i>in situ</i>)	-	-	-	-	-	6	27.7	5.03	34.3	6.17

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, Hispanic/Latino, All Races

<i>SITES</i>	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	5,628	442.9	2.80	526.3	3.29	6,301	370.6	2.12	432.2	2.46
Oral Cavity & Pharynx	177	13.3	0.47	16.1	0.56	84	5.0	0.25	5.9	0.29
Lip	3	0.3	0.07	0.3	0.09	3	0.2	0.05	0.2	0.05
Tongue	47	3.6	0.24	4.3	0.29	24	1.4	0.13	1.7	0.15
Major salivary gland	15	1.0	0.12	1.2	0.14	16	0.9	0.11	1.1	0.12
Floor of mouth	7	0.6	0.10	0.7	0.12	4	0.2	0.06	0.3	0.06
Gum & other mouth	21	1.7	0.17	2.0	0.20	19	1.2	0.12	1.3	0.14
Nasopharynx	14	1.0	0.12	1.2	0.15	4	0.2	0.05	0.3	0.06
Oropharynx	13	1.0	0.13	1.3	0.16	3	0.2	0.05	0.2	0.06
Hypopharynx	15	1.2	0.15	1.4	0.17	3	0.2	0.05	0.2	0.06
Digestive System	1,392	111.6	1.42	133.4	1.67	1,154	70.0	0.93	82.6	1.09
Esophagus	67	5.6	0.33	6.7	0.38	23	1.4	0.14	1.7	0.16
Stomach	191	15.6	0.54	18.3	0.62	152	9.2	0.34	10.8	0.39
Small intestine	36	2.8	0.22	3.2	0.25	33	2.0	0.16	2.3	0.18
Colon excl. rectum	355	29.3	0.74	34.5	0.86	350	21.3	0.51	25.0	0.60
Rectum & rectosigmoid	183	13.9	0.49	16.6	0.57	140	8.2	0.31	9.7	0.37
Anus, anal canal & anorectum	29	2.1	0.18	2.4	0.21	43	2.5	0.17	3.1	0.21
Liver	274	20.6	0.59	25.7	0.72	109	6.6	0.29	7.9	0.34
Gallbladder	19	1.6	0.18	1.9	0.21	51	3.1	0.20	3.7	0.23
Pancreas	166	13.9	0.51	16.6	0.60	173	10.8	0.37	12.7	0.43
Respiratory System	601	52.1	1.00	61.6	1.16	498	30.3	0.62	36.3	0.73
Larynx	76	6.3	0.34	7.6	0.40	21	1.2	0.12	1.5	0.14
Lung & bronchus	506	44.6	0.93	52.7	1.08	469	28.6	0.60	34.2	0.71
Bones & Joints	20	1.1	0.12	1.1	0.12	17	1.0	0.10	1.0	0.11
Soft Tissue (incl. heart)	58	3.9	0.24	4.3	0.27	46	2.6	0.17	2.8	0.19
Skin (excl. basal & sq.)	66	5.3	0.31	6.1	0.36	68	4.0	0.22	4.6	0.25
Melanomas of the skin	53	4.3	0.28	5.0	0.33	53	3.1	0.20	3.6	0.22
Breast (excl. <i>in situ</i>)	10	0.9	0.13	1.0	0.15	1,806	105.0	1.12	123.6	1.31
Female Genital System	-	-	-	-	-	881	50.7	0.77	59.8	0.91
Cervix uteri	-	-	-	-	-	171	9.8	0.34	10.7	0.37
Uterus Corpus	-	-	-	-	-	455	25.9	0.55	31.6	0.67
Uterus, NOS ¹	-	-	-	-	-	14	0.8	0.10	1.0	0.12
Ovary	-	-	-	-	-	177	10.3	0.35	11.9	0.40
Male Genital System	1,645	126.7	1.47	154.9	1.76	-	-	-	-	-
Prostate	1,533	120.5	1.44	148.6	1.73	-	-	-	-	-
Testis	88	4.4	0.21	4.3	0.21	-	-	-	-	-
Penis	20	1.6	0.17	1.8	0.19	-	-	-	-	-
Urinary System	497	41.3	0.88	48.7	1.03	272	16.4	0.45	19.3	0.53
Bladder (incl. <i>in situ</i>)	239	22.2	0.68	26.1	0.78	96	6.1	0.28	7.1	0.33
Kidney & renal pelvis	249	18.2	0.54	21.6	0.64	166	9.7	0.34	11.4	0.40
Ureter	5	0.4	0.09	0.6	0.11	5	0.4	0.07	0.4	0.08
Eye & Orbit	9	0.6	0.09	0.6	0.10	9	0.5	0.08	0.6	0.09
Brain & Other CNS ¹	99	6.6	0.32	7.2	0.36	78	4.4	0.23	4.8	0.25
Brain	92	6.2	0.31	6.8	0.35	71	4.1	0.22	4.4	0.24
Endocrine System	130	8.2	0.34	9.1	0.38	522	29.0	0.57	31.9	0.63
Thyroid gland	113	7.2	0.32	8.0	0.36	509	28.3	0.57	31.0	0.63
Lymphomas	358	26.4	0.67	30.3	0.77	339	19.9	0.49	22.8	0.56
Hodgkin Lymphoma	57	3.4	0.21	3.7	0.23	52	2.9	0.18	3.0	0.19
Non-Hodgkin Lymphoma	300	23.0	0.63	26.6	0.73	287	17.0	0.46	19.8	0.53
Multiple Myeloma	132	11.0	0.45	13.1	0.53	122	7.5	0.31	8.8	0.36
Leukemias	206	15.2	0.51	16.9	0.58	179	10.4	0.35	11.5	0.39
Acute lymphocytic	49	2.6	0.17	2.5	0.17	34	1.8	0.14	1.7	0.14
Chronic lymphocytic	42	3.7	0.27	4.4	0.31	37	2.2	0.17	2.7	0.20
Acute myeloid	61	4.9	0.30	5.4	0.34	63	3.7	0.21	4.2	0.24
Chronic myeloid	35	2.5	0.20	2.8	0.23	27	1.6	0.14	1.8	0.15
Other leukemias	20	1.6	0.17	1.8	0.20	18	1.1	0.11	1.2	0.13
Mesothelioma	8	0.7	0.13	0.9	0.15	7	0.4	0.07	0.5	0.08
Kaposi Sarcoma	31	2.1	0.19	2.4	0.21	3	0.2	0.05	0.2	0.06
Ill-defined & Unknown	190	15.8	0.55	18.5	0.64	213	13.2	0.41	15.2	0.47
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	119	8.6	0.38	9.7	0.43	276	16.2	0.44	18.6	0.51
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.05	625	36.0	0.65	42.4	0.76

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NEW YORK

II-368 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	39,811	554.0	1.28	654.0	1.47	39,919	493.7	1.17	573.9	1.32
Oral Cavity & Pharynx	1,327	18.2	0.23	22.0	0.27	579	6.9	0.14	8.2	0.16
Lip	58	0.8	0.05	1.0	0.06	30	0.3	0.03	0.4	0.03
Tongue	444	6.0	0.13	7.3	0.16	178	2.2	0.08	2.6	0.09
Major salivary gland	130	1.9	0.08	2.2	0.09	87	1.1	0.06	1.3	0.06
Floor of mouth	59	0.8	0.05	1.0	0.06	29	0.3	0.03	0.4	0.04
Gum & other mouth	148	2.1	0.08	2.4	0.09	121	1.4	0.06	1.6	0.07
Nasopharynx	41	0.6	0.04	0.7	0.05	18	0.2	0.03	0.3	0.03
Oropharynx	66	0.9	0.05	1.1	0.06	19	0.2	0.02	0.3	0.03
Hypopharynx	76	1.0	0.05	1.2	0.06	23	0.3	0.03	0.3	0.03
Digestive System	7,130	99.1	0.54	117.6	0.63	5,877	67.3	0.41	78.8	0.47
Esophagus	630	8.5	0.15	10.2	0.18	195	2.2	0.07	2.6	0.08
Stomach	679	9.5	0.17	11.2	0.19	402	4.6	0.11	5.4	0.13
Small intestine	223	3.1	0.10	3.7	0.11	184	2.3	0.08	2.6	0.09
Colon excl. rectum	2,109	30.1	0.30	35.1	0.34	2,244	25.6	0.26	29.6	0.29
Rectum & rectosigmoid	1,002	14.2	0.21	16.8	0.24	740	9.1	0.16	10.7	0.18
Anus, anal canal & anorectum	130	1.8	0.07	2.2	0.09	220	2.6	0.08	3.2	0.10
Liver	695	9.0	0.16	11.2	0.19	208	2.3	0.08	2.8	0.09
Gallbladder	59	0.8	0.05	1.0	0.06	113	1.3	0.06	1.5	0.06
Pancreas	1,229	16.9	0.22	20.1	0.26	1,174	12.8	0.17	15.1	0.20
Respiratory System	5,666	77.8	0.47	92.1	0.55	5,722	64.6	0.39	76.6	0.46
Larynx	424	5.7	0.13	6.9	0.15	111	1.3	0.06	1.6	0.07
Lung & bronchus	5,157	70.8	0.45	83.7	0.52	5,549	62.5	0.39	74.1	0.45
Bones & Joints	82	1.4	0.07	1.4	0.07	64	1.0	0.06	1.1	0.06
Soft Tissue (incl. heart)	300	4.5	0.12	5.1	0.13	221	3.0	0.10	3.3	0.10
Skin (excl. basal & sq.)	2,509	36.1	0.33	41.9	0.38	1,766	23.6	0.27	26.7	0.29
Melanomas of the skin	2,289	32.9	0.32	38.3	0.36	1,629	22.0	0.26	24.8	0.28
Breast (excl. <i>in situ</i>)	115	1.6	0.07	1.9	0.08	11,156	143.8	0.64	168.1	0.73
Female Genital System	-	-	-	-	-	4,739	58.7	0.40	70.0	0.46
Cervix uteri	-	-	-	-	-	420	6.6	0.15	7.1	0.16
Uterus Corpus	-	-	-	-	-	2,745	32.9	0.29	40.3	0.35
Uterus, NOS ¹	-	-	-	-	-	61	0.7	0.04	0.8	0.05
Ovary	-	-	-	-	-	1,033	13.0	0.19	15.2	0.22
Male Genital System	9,480	125.1	0.59	152.2	0.70	-	-	-	-	-
Prostate	8,985	115.9	0.56	142.9	0.68	-	-	-	-	-
Testis	421	8.1	0.18	8.0	0.18	-	-	-	-	-
Penis	56	0.8	0.05	0.9	0.06	-	-	-	-	-
Urinary System	5,317	74.3	0.47	87.4	0.54	2,151	24.9	0.25	29.2	0.29
Bladder (incl. <i>in situ</i>)	3,401	47.4	0.37	55.5	0.43	1,125	12.4	0.17	14.6	0.20
Kidney & renal pelvis	1,795	25.2	0.28	29.9	0.32	964	11.8	0.18	13.9	0.20
Ureter	74	1.0	0.06	1.2	0.06	42	0.5	0.03	0.5	0.04
Eye & Orbit	76	1.1	0.06	1.3	0.07	77	1.1	0.06	1.2	0.06
Brain & Other CNS ¹	590	9.2	0.18	10.1	0.19	471	6.7	0.15	7.3	0.15
Brain	555	8.6	0.17	9.5	0.18	439	6.2	0.14	6.7	0.15
Endocrine System	824	13.1	0.21	14.5	0.23	1,958	31.9	0.34	34.2	0.35
Thyroid gland	754	11.9	0.20	13.3	0.22	1,896	31.0	0.34	33.2	0.35
Lymphomas	2,205	32.5	0.32	37.1	0.36	1,840	22.9	0.25	26.2	0.28
Hodgkin Lymphoma	222	3.9	0.12	4.0	0.12	196	3.3	0.11	3.4	0.11
Non-Hodgkin Lymphoma	1,983	28.6	0.30	33.1	0.33	1,644	19.5	0.23	22.7	0.26
Multiple Myeloma	660	9.1	0.16	10.8	0.19	496	5.6	0.12	6.7	0.14
Leukemias	1,665	24.1	0.27	27.7	0.31	1,160	14.0	0.20	15.9	0.22
Acute lymphocytic	98	1.9	0.09	1.8	0.08	73	1.4	0.08	1.3	0.07
Chronic lymphocytic	785	10.8	0.18	12.8	0.21	520	5.7	0.12	6.8	0.14
Acute myeloid	426	6.2	0.14	7.1	0.15	323	3.9	0.10	4.5	0.11
Chronic myeloid	194	2.8	0.09	3.3	0.11	138	1.7	0.07	2.0	0.08
Other leukemias	163	2.4	0.09	2.7	0.10	106	1.2	0.06	1.4	0.06
Mesothelioma	123	1.8	0.07	2.0	0.08	41	0.5	0.04	0.6	0.04
Kaposi Sarcoma	54	0.8	0.05	0.9	0.06	12	0.1	0.02	0.1	0.02
Ill-defined & Unknown	1,688	24.2	0.27	28.0	0.31	1,588	17.2	0.20	19.9	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	760	11.6	0.20	13.0	0.21	1,503	19.3	0.24	21.9	0.26
Breast (<i>in situ</i>)	11	0.2	0.02	0.2	0.02	3,242	45.0	0.37	52.4	0.42

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New York, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7,081	550.1	3.05	663.4	3.60	7,304	406.0	2.16	476.7	2.50
Oral Cavity & Pharynx	160	12.0	0.44	14.4	0.52	93	5.1	0.24	6.0	0.28
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	38	2.9	0.21	3.5	0.25	19	1.0	0.11	1.2	0.13
Major salivary gland	14	1.0	0.13	1.2	0.15	20	1.2	0.12	1.3	0.13
Floor of mouth	6	0.4	0.08	0.6	0.10	5	0.2	0.05	0.3	0.06
Gum & other mouth	18	1.4	0.16	1.7	0.18	19	1.1	0.11	1.2	0.13
Nasopharynx	16	1.2	0.14	1.3	0.15	7	0.4	0.07	0.4	0.08
Oropharynx	12	0.9	0.13	1.1	0.15	5	0.3	0.06	0.3	0.07
Hypopharynx	19	1.4	0.16	1.7	0.18	5	0.3	0.06	0.3	0.07
Digestive System	1,517	121.0	1.45	145.2	1.71	1,426	78.5	0.94	92.9	1.10
Esophagus	78	6.6	0.35	7.8	0.40	39	2.1	0.15	2.6	0.18
Stomach	182	15.4	0.54	18.2	0.62	159	8.9	0.32	10.3	0.37
Small intestine	61	4.9	0.29	5.8	0.34	57	3.2	0.19	3.8	0.22
Colon excl. rectum	429	35.4	0.80	41.8	0.93	490	27.0	0.55	31.9	0.65
Rectum & rectosigmoid	189	14.8	0.50	17.5	0.58	163	9.0	0.32	10.7	0.38
Anus, anal canal & anorectum	36	2.7	0.20	3.1	0.24	42	2.3	0.16	2.8	0.19
Liver	244	17.3	0.51	22.0	0.64	87	4.5	0.22	5.7	0.27
Gallbladder	23	2.0	0.19	2.4	0.23	49	2.6	0.17	3.2	0.20
Pancreas	212	17.0	0.55	20.5	0.65	260	14.3	0.40	16.9	0.47
Respiratory System	864	70.1	1.11	84.1	1.31	787	42.5	0.69	51.2	0.82
Larynx	82	6.5	0.34	7.9	0.40	24	1.3	0.12	1.6	0.14
Lung & bronchus	767	62.5	1.05	74.8	1.24	751	40.5	0.67	48.9	0.80
Bones & Joints	15	1.1	0.13	1.1	0.13	14	0.9	0.11	0.9	0.10
Soft Tissue (incl. heart)	50	3.9	0.26	4.3	0.28	55	3.2	0.20	3.5	0.21
Skin (excl. basal & sq.)	30	2.4	0.20	2.6	0.22	37	2.1	0.16	2.4	0.18
Melanomas of the skin	12	1.0	0.13	1.1	0.15	18	1.0	0.11	1.2	0.12
Breast (excl. <i>in situ</i>)	24	1.9	0.18	2.3	0.21	2,198	123.4	1.20	144.5	1.38
Female Genital System	-	-	-	-	-	1,068	58.2	0.81	69.7	0.95
Cervix uteri	-	-	-	-	-	175	10.2	0.35	11.5	0.39
Uterus Corpus	-	-	-	-	-	594	31.4	0.59	38.6	0.71
Uterus, NOS ¹	-	-	-	-	-	45	2.5	0.17	2.9	0.20
Ovary	-	-	-	-	-	175	9.7	0.34	11.5	0.39
Male Genital System	2,792	207.1	1.82	257.3	2.21	-	-	-	-	-
Prostate	2,752	204.1	1.81	254.1	2.20	-	-	-	-	-
Testis	26	1.9	0.17	1.9	0.17	-	-	-	-	-
Penis	10	0.8	0.12	1.0	0.14	-	-	-	-	-
Urinary System	558	44.8	0.89	53.4	1.04	316	17.4	0.44	20.5	0.52
Bladder (incl. <i>in situ</i>)	223	19.6	0.61	23.0	0.71	114	6.3	0.27	7.4	0.31
Kidney & renal pelvis	326	24.5	0.63	29.6	0.75	192	10.5	0.35	12.4	0.40
Ureter	3	0.2	0.07	0.3	0.08	3	0.2	0.04	0.2	0.05
Eye & Orbit	6	0.4	0.08	0.4	0.08	4	0.2	0.06	0.2	0.05
Brain & Other CNS ¹	63	4.7	0.27	5.0	0.29	54	3.2	0.20	3.4	0.21
Brain	57	4.3	0.26	4.6	0.28	49	2.9	0.19	3.1	0.20
Endocrine System	75	5.7	0.30	6.3	0.33	297	17.4	0.46	19.4	0.50
Thyroid gland	58	4.4	0.27	5.0	0.30	280	16.4	0.45	18.3	0.49
Lymphomas	289	22.2	0.61	25.4	0.69	291	16.6	0.44	18.9	0.50
Hodgkin Lymphoma	46	3.4	0.23	3.6	0.24	48	3.0	0.19	3.0	0.20
Non-Hodgkin Lymphoma	243	18.8	0.56	21.8	0.64	243	13.7	0.40	15.8	0.45
Multiple Myeloma	218	17.9	0.57	21.2	0.66	231	12.7	0.38	15.1	0.44
Leukemias	170	13.8	0.49	15.8	0.56	167	9.6	0.34	10.8	0.37
Acute lymphocytic	16	1.2	0.13	1.2	0.13	13	0.9	0.11	0.8	0.10
Chronic lymphocytic	50	4.2	0.28	5.0	0.32	44	2.4	0.17	2.8	0.19
Acute myeloid	56	4.6	0.29	5.3	0.33	58	3.4	0.20	3.8	0.22
Chronic myeloid	26	2.1	0.19	2.4	0.21	27	1.6	0.14	1.8	0.15
Other leukemias	21	1.8	0.18	2.0	0.20	25	1.4	0.13	1.6	0.14
Mesothelioma	8	0.8	0.13	0.9	0.14	2	0.1	0.04	0.2	0.05
Kaposi Sarcoma	30	2.2	0.19	2.4	0.20	3	0.2	0.05	0.2	0.05
Ill-defined & Unknown	213	18.0	0.58	21.1	0.67	262	14.5	0.41	16.9	0.47
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	123	9.8	0.41	11.3	0.47	269	15.3	0.42	17.6	0.48
Breast (<i>in situ</i>)	2	0.2	0.06	0.2	0.06	678	37.6	0.66	44.7	0.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NEW YORK

II-370 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	9,843,599	9,933,944	10,033,079	10,156,679	10,270,800
White	7,145,624	7,191,037	7,247,395	7,319,010	7,384,159
Black	2,249,214	2,277,743	2,304,698	2,336,621	2,366,357
American Indian/Alaskan Native (AI/AN)	163,437	165,568	167,930	170,412	172,539
Asian/Pacific Islander (API)	285,324	299,596	313,056	330,636	347,745


All Races Population 2013-2017: 50,238,101
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	859,069	879,061	905,448	934,735	964,994
Non-Hispanic White	6,427,393	6,458,783	6,494,945	6,544,157	6,584,340
Non-Hispanic Black	2,169,267	2,193,918	2,217,099	2,244,641	2,270,929

Hispanic/Latino Population, Census 2010: 800,120
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NORTH CAROLINA CANCER REGISTRY

Initial Operation: 1987
 Population-based Data Available: 1990
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	106.7	105.7	107.7	107.5	105.6
Missing Race	0.2	0.4	0.5	1.3	2.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.2	0.3	0.2	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.4	1.1	0.9	0.7	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.4	Prostate	97.4
Oral Cavity & Pharynx	97.7	Testis	99.4
Esophagus	95.5	Bladder (incl. <i>in situ</i>)	97.8
Stomach	96.7	Kidney & Renal Pelvis	88.8
Colon & Rectum	96.1	Brain & Other CNS ¹	85.7
Liver	54.2	Thyroid	99.5
Pancreas	85.7	Hodgkin Lymphoma	97.2
Lung & Bronchus	87.7	Non-Hodgkin Lymphoma	96.6
Melanomas of the Skin	99.6	Multiple Myeloma	89.7
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	90.5
Cervix uteri	97.3	Brain & Other CNS ¹ <i>non-malig</i>	41.7
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	93.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	28,090	522.2	1.43	621.6	1.68	27,200	431.7	1.20	504.5	1.38
Oral Cavity & Pharynx	1,081	19.3	0.27	23.6	0.32	431	6.8	0.15	8.0	0.17
Lip	34	0.7	0.05	0.8	0.06	17	0.3	0.03	0.3	0.03
Tongue	349	6.1	0.15	7.5	0.18	121	1.9	0.08	2.3	0.09
Major salivary gland	85	1.7	0.09	2.0	0.10	57	0.9	0.06	1.1	0.06
Floor of mouth	55	1.0	0.06	1.2	0.07	20	0.3	0.03	0.4	0.04
Gum & other mouth	105	1.9	0.09	2.3	0.10	100	1.6	0.07	1.8	0.08
Nasopharynx	34	0.6	0.05	0.7	0.06	16	0.3	0.03	0.3	0.03
Oropharynx	66	1.1	0.06	1.4	0.08	19	0.3	0.03	0.4	0.04
Hypopharynx	69	1.2	0.07	1.5	0.08	14	0.2	0.02	0.3	0.03
Digestive System	5,129	95.5	0.61	114.5	0.72	4,124	64.1	0.46	75.6	0.53
Esophagus	414	7.5	0.17	9.1	0.20	102	1.5	0.07	1.9	0.08
Stomach	456	8.6	0.18	10.2	0.22	297	4.7	0.12	5.5	0.14
Small intestine	178	3.3	0.12	3.9	0.13	171	2.7	0.09	3.2	0.11
Colon excl. rectum	1,532	29.3	0.34	34.7	0.40	1,544	24.1	0.28	28.2	0.32
Rectum & rectosigmoid	719	13.3	0.23	15.9	0.27	523	8.5	0.17	9.9	0.20
Anus, anal canal & anorectum	80	1.5	0.08	1.8	0.09	161	2.5	0.09	3.0	0.11
Liver	672	11.6	0.21	14.6	0.26	198	2.9	0.10	3.6	0.12
Gallbladder	44	0.8	0.06	1.0	0.07	78	1.2	0.06	1.4	0.07
Pancreas	797	15.0	0.25	17.9	0.29	759	11.5	0.19	13.6	0.22
Respiratory System	4,856	90.7	0.60	108.1	0.70	3,890	58.6	0.43	69.9	0.50
Larynx	377	6.7	0.16	8.2	0.19	107	1.6	0.07	2.0	0.09
Lung & bronchus	4,418	82.8	0.57	98.5	0.67	3,748	56.4	0.42	67.3	0.49
Bones & Joints	51	1.0	0.07	1.1	0.07	46	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	195	3.9	0.13	4.3	0.14	164	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	1,907	37.0	0.39	43.1	0.45	1,269	21.1	0.27	24.1	0.30
Melanomas of the skin	1,781	34.4	0.38	40.1	0.43	1,195	20.0	0.27	22.7	0.30
Breast (excl. <i>in situ</i>)	65	1.2	0.07	1.5	0.08	8,384	134.0	0.67	157.6	0.78
Female Genital System	-	-	-	-	-	3,047	48.4	0.40	57.2	0.47
Cervix uteri	-	-	-	-	-	380	7.1	0.17	7.6	0.17
Uterus Corpus	-	-	-	-	-	1,606	24.4	0.28	29.8	0.33
Uterus, NOS ¹	-	-	-	-	-	58	0.9	0.06	1.1	0.06
Ovary	-	-	-	-	-	658	10.6	0.19	12.3	0.22
Male Genital System	7,110	123.7	0.67	152.0	0.82	-	-	-	-	-
Prostate	6,808	117.4	0.65	145.6	0.80	-	-	-	-	-
Testis	243	5.1	0.15	5.1	0.15	-	-	-	-	-
Penis	46	0.9	0.06	1.1	0.07	-	-	-	-	-
Urinary System	3,115	60.0	0.50	70.6	0.58	1,378	21.3	0.26	25.1	0.30
Bladder (incl. <i>in situ</i>)	1,763	35.0	0.38	40.9	0.44	578	8.7	0.16	10.3	0.19
Kidney & renal pelvis	1,279	23.5	0.30	27.9	0.35	762	12.0	0.20	14.1	0.23
Ureter	47	1.0	0.06	1.1	0.07	26	0.4	0.04	0.5	0.04
Eye & Orbit	47	0.9	0.06	1.0	0.07	50	0.8	0.05	0.9	0.06
Brain & Other CNS ¹	380	7.4	0.17	8.2	0.19	321	5.5	0.14	6.0	0.15
Brain	360	7.0	0.17	7.8	0.19	300	5.1	0.14	5.6	0.15
Endocrine System	369	7.2	0.17	8.0	0.19	1,018	18.6	0.27	20.2	0.28
Thyroid gland	328	6.4	0.16	7.1	0.18	977	17.9	0.26	19.4	0.28
Lymphomas	1,257	24.4	0.32	28.0	0.36	1,040	16.7	0.24	19.1	0.27
Hodgkin Lymphoma	148	3.0	0.11	3.1	0.12	113	2.1	0.09	2.2	0.09
Non-Hodgkin Lymphoma	1,108	21.4	0.30	24.9	0.34	927	14.6	0.22	16.9	0.25
Multiple Myeloma	494	9.3	0.19	11.1	0.23	428	6.6	0.14	7.7	0.17
Leukemias	952	18.8	0.28	21.3	0.31	676	11.0	0.19	12.3	0.21
Acute lymphocytic	87	1.8	0.09	1.7	0.08	59	1.2	0.07	1.1	0.06
Chronic lymphocytic	371	7.1	0.17	8.4	0.20	245	3.7	0.11	4.4	0.13
Acute myeloid	263	5.2	0.15	5.9	0.17	209	3.4	0.11	3.9	0.12
Chronic myeloid	134	2.7	0.11	3.0	0.12	97	1.6	0.07	1.8	0.08
Other leukemias	97	2.0	0.09	2.3	0.10	66	1.1	0.06	1.2	0.07
Mesothelioma	58	1.2	0.07	1.4	0.08	19	0.3	0.03	0.3	0.04
Kaposi Sarcoma	25	0.5	0.05	0.6	0.05	1	0.0	0.01	0.0	0.01
Ill-defined & Unknown	998	20.1	0.29	23.4	0.34	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	473	9.2	0.19	10.5	0.22	979	16.0	0.24	18.3	0.26
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.02	1,855	29.9	0.32	35.3	0.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	21,779	510.6	1.59	605.4	1.86	21,045	436.8	1.39	509.8	1.59
Oral Cavity & Pharynx	887	20.2	0.31	24.7	0.37	347	7.1	0.18	8.3	0.20
Lip	31	0.8	0.06	0.9	0.07	14	0.3	0.04	0.3	0.04
Tongue	303	6.8	0.18	8.3	0.22	105	2.1	0.10	2.5	0.11
Major salivary gland	68	1.7	0.10	2.0	0.11	41	0.9	0.06	1.0	0.07
Floor of mouth	43	1.0	0.07	1.2	0.08	17	0.3	0.04	0.4	0.04
Gum & other mouth	81	1.9	0.10	2.3	0.11	81	1.6	0.08	1.9	0.09
Nasopharynx	21	0.5	0.05	0.6	0.06	11	0.3	0.04	0.3	0.04
Oropharynx	48	1.1	0.07	1.4	0.09	16	0.3	0.04	0.4	0.05
Hypopharynx	49	1.1	0.07	1.4	0.09	10	0.2	0.03	0.2	0.03
Digestive System	3,841	90.1	0.67	107.8	0.79	2,998	60.4	0.51	71.0	0.59
Esophagus	342	7.8	0.19	9.4	0.23	71	1.4	0.07	1.7	0.09
Stomach	311	7.3	0.19	8.7	0.22	187	3.8	0.13	4.4	0.15
Small intestine	128	3.0	0.12	3.6	0.14	114	2.3	0.10	2.7	0.12
Colon excl. rectum	1,147	27.6	0.37	32.6	0.44	1,138	23.0	0.31	26.8	0.36
Rectum & rectosigmoid	550	13.0	0.25	15.5	0.30	389	8.3	0.19	9.7	0.22
Anus, anal canal & anorectum	60	1.4	0.08	1.7	0.10	135	2.8	0.11	3.4	0.13
Liver	482	10.6	0.22	13.3	0.27	138	2.7	0.10	3.2	0.12
Gallbladder	29	0.7	0.06	0.8	0.07	48	0.9	0.06	1.1	0.07
Pancreas	611	14.3	0.27	17.1	0.31	551	10.7	0.21	12.7	0.24
Respiratory System	3,822	88.9	0.66	105.7	0.77	3,180	61.5	0.50	73.2	0.59
Larynx	275	6.2	0.17	7.6	0.21	81	1.7	0.08	2.0	0.10
Lung & bronchus	3,497	81.5	0.63	96.8	0.74	3,072	59.3	0.49	70.6	0.57
Bones & Joints	38	1.0	0.08	1.0	0.08	37	0.9	0.07	1.0	0.07
Soft Tissue (incl. heart)	154	3.9	0.14	4.3	0.16	121	2.7	0.11	3.0	0.12
Skin (excl. basal & sq.)	1,817	44.1	0.48	51.4	0.55	1,195	26.6	0.36	30.2	0.40
Melanomas of the skin	1,708	41.4	0.46	48.2	0.53	1,136	25.4	0.35	28.9	0.39
Breast (excl. <i>in situ</i>)	47	1.1	0.07	1.3	0.09	6,373	133.6	0.77	157.2	0.89
Female Genital System	-	-	-	-	-	2,323	48.8	0.47	57.6	0.54
Cervix uteri	-	-	-	-	-	259	6.7	0.19	7.1	0.20
Uterus Corpus	-	-	-	-	-	1,217	24.4	0.32	29.8	0.39
Uterus, NOS ¹	-	-	-	-	-	33	0.7	0.05	0.8	0.06
Ovary	-	-	-	-	-	532	11.2	0.23	13.1	0.26
Male Genital System	4,926	108.4	0.71	132.3	0.85	-	-	-	-	-
Prostate	4,667	101.0	0.68	124.8	0.83	-	-	-	-	-
Testis	213	6.3	0.19	6.2	0.19	-	-	-	-	-
Penis	38	0.9	0.07	1.1	0.08	-	-	-	-	-
Urinary System	2,605	62.6	0.56	73.5	0.65	1,062	21.3	0.30	25.0	0.35
Bladder (incl. <i>in situ</i>)	1,557	38.0	0.44	44.4	0.51	477	9.2	0.19	10.9	0.22
Kidney & renal pelvis	982	23.0	0.34	27.2	0.39	554	11.5	0.23	13.5	0.26
Ureter	43	1.1	0.07	1.2	0.09	22	0.4	0.04	0.5	0.05
Eye & Orbit	42	1.0	0.07	1.1	0.08	45	1.0	0.07	1.1	0.08
Brain & Other CNS ¹	316	8.0	0.21	8.8	0.22	263	6.0	0.17	6.6	0.18
Brain	299	7.5	0.20	8.4	0.22	248	5.6	0.17	6.2	0.18
Endocrine System	307	7.8	0.20	8.6	0.22	771	19.6	0.33	21.0	0.34
Thyroid gland	279	7.1	0.19	7.9	0.21	743	18.9	0.32	20.3	0.34
Lymphomas	1,015	24.9	0.36	28.6	0.41	817	17.0	0.27	19.5	0.31
Hodgkin Lymphoma	108	2.9	0.13	3.1	0.13	81	2.2	0.11	2.2	0.11
Non-Hodgkin Lymphoma	907	22.0	0.33	25.6	0.38	736	14.9	0.25	17.3	0.29
Multiple Myeloma	315	7.4	0.19	8.8	0.22	254	5.0	0.14	5.8	0.17
Leukemias	776	19.3	0.32	21.9	0.36	536	11.3	0.23	12.7	0.25
Acute lymphocytic	66	1.9	0.11	1.8	0.10	46	1.3	0.09	1.2	0.08
Chronic lymphocytic	315	7.5	0.19	8.9	0.23	201	3.9	0.12	4.6	0.15
Acute myeloid	208	5.2	0.16	5.9	0.18	163	3.5	0.13	3.9	0.14
Chronic myeloid	106	2.7	0.12	3.0	0.13	72	1.6	0.09	1.8	0.09
Other leukemias	81	2.1	0.11	2.4	0.12	54	1.1	0.07	1.3	0.08
Mesothelioma	54	1.4	0.08	1.6	0.10	16	0.3	0.04	0.4	0.04
Kaposi Sarcoma	11	0.3	0.04	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	808	20.2	0.32	23.4	0.37	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	358	8.9	0.22	10.1	0.24	748	16.0	0.27	18.3	0.30
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.03	1,376	29.5	0.37	34.8	0.42

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,299	547.8	3.61	661.6	4.25	5,183	403.6	2.57	475.4	2.97
Oral Cavity & Pharynx	160	15.1	0.56	18.7	0.68	69	5.3	0.29	6.3	0.34
Lip	1	0.1	0.06	0.2	0.08	2	0.1	0.05	0.2	0.06
Tongue	37	3.5	0.27	4.3	0.32	12	0.9	0.13	1.1	0.15
Major salivary gland	13	1.4	0.18	1.6	0.21	14	1.1	0.13	1.2	0.15
Floor of mouth	10	0.9	0.13	1.2	0.16	3	0.2	0.06	0.3	0.08
Gum & other mouth	18	1.8	0.21	2.3	0.25	16	1.2	0.14	1.5	0.17
Nasopharynx	10	1.0	0.14	1.1	0.16	4	0.3	0.07	0.3	0.08
Oropharynx	15	1.4	0.17	1.8	0.21	3	0.2	0.06	0.3	0.07
Hypopharynx	19	1.7	0.18	2.1	0.22	4	0.3	0.07	0.4	0.08
Digestive System	1,096	114.5	1.66	138.4	1.96	973	76.2	1.12	90.6	1.31
Esophagus	65	6.8	0.41	8.2	0.48	28	2.2	0.19	2.7	0.23
Stomach	120	13.3	0.58	15.7	0.67	92	7.5	0.36	8.7	0.41
Small intestine	45	4.8	0.34	5.6	0.39	52	4.0	0.26	4.8	0.30
Colon excl. rectum	333	36.0	0.95	43.0	1.11	354	27.7	0.67	33.0	0.79
Rectum & rectosigmoid	136	13.5	0.55	16.4	0.65	107	8.4	0.37	9.9	0.43
Anus, anal canal & anorectum	18	1.7	0.19	2.0	0.21	24	1.9	0.18	2.2	0.20
Liver	155	13.7	0.52	17.9	0.66	47	3.4	0.23	4.3	0.28
Gallbladder	13	1.5	0.20	1.8	0.22	25	2.0	0.18	2.4	0.21
Pancreas	166	18.2	0.68	21.8	0.79	188	14.9	0.50	17.7	0.58
Respiratory System	921	100.1	1.59	120.4	1.86	625	48.1	0.88	58.1	1.04
Larynx	92	9.3	0.47	11.5	0.56	24	1.7	0.16	2.2	0.20
Lung & bronchus	819	89.8	1.51	107.7	1.76	594	45.9	0.86	55.3	1.02
Bones & Joints	9	0.9	0.14	0.9	0.15	7	0.6	0.10	0.6	0.10
Soft Tissue (incl. heart)	33	3.3	0.27	3.7	0.30	34	2.8	0.22	3.1	0.24
Skin (excl. basal & sq.)	22	2.4	0.24	2.8	0.28	20	1.6	0.16	1.9	0.19
Melanomas of the skin	10	1.1	0.17	1.3	0.20	10	0.8	0.12	0.9	0.13
Breast (excl. <i>in situ</i>)	15	1.7	0.21	2.0	0.24	1,720	133.2	1.47	156.8	1.70
Female Genital System	-	-	-	-	-	599	45.8	0.86	54.4	1.00
Cervix uteri	-	-	-	-	-	96	7.7	0.36	8.6	0.39
Uterus Corpus	-	-	-	-	-	329	24.4	0.62	29.7	0.74
Uterus, NOS ¹	-	-	-	-	-	23	1.8	0.17	2.1	0.20
Ovary	-	-	-	-	-	98	7.8	0.36	9.0	0.41
Male Genital System	1,841	179.9	2.00	223.7	2.41	-	-	-	-	-
Prostate	1,813	176.9	1.98	220.5	2.40	-	-	-	-	-
Testis	18	1.8	0.19	1.8	0.19	-	-	-	-	-
Penis	8	0.9	0.17	1.1	0.19	-	-	-	-	-
Urinary System	436	47.0	1.08	55.9	1.26	279	21.7	0.60	25.7	0.69
Bladder (incl. <i>in situ</i>)	167	20.0	0.75	23.6	0.87	89	7.0	0.34	8.3	0.40
Kidney & renal pelvis	262	26.3	0.77	31.4	0.90	184	14.2	0.48	16.7	0.55
Ureter	3	0.4	0.10	0.4	0.11	3	0.2	0.06	0.3	0.07
Eye & Orbit	4	0.4	0.09	0.4	0.10	3	0.2	0.06	0.3	0.06
Brain & Other CNS ¹	49	4.7	0.32	5.3	0.36	47	3.8	0.25	4.1	0.27
Brain	46	4.5	0.31	5.0	0.35	42	3.4	0.24	3.6	0.25
Endocrine System	47	4.9	0.33	5.4	0.36	181	14.3	0.49	15.9	0.53
Thyroid gland	36	3.8	0.29	4.2	0.32	169	13.4	0.47	15.0	0.52
Lymphomas	195	19.9	0.67	22.6	0.76	183	14.4	0.49	16.5	0.55
Hodgkin Lymphoma	34	3.2	0.25	3.3	0.26	28	2.2	0.19	2.4	0.20
Non-Hodgkin Lymphoma	162	16.7	0.63	19.3	0.71	155	12.2	0.45	14.2	0.51
Multiple Myeloma	166	18.5	0.69	21.8	0.79	160	12.6	0.46	15.0	0.53
Leukemias	137	14.8	0.61	16.9	0.69	110	8.9	0.39	10.1	0.43
Acute lymphocytic	14	1.1	0.14	1.1	0.14	9	0.7	0.11	0.7	0.11
Chronic lymphocytic	42	4.8	0.36	5.7	0.41	33	2.6	0.21	3.1	0.24
Acute myeloid	45	4.9	0.35	5.6	0.40	42	3.3	0.24	3.8	0.26
Chronic myeloid	23	2.5	0.25	2.8	0.28	19	1.5	0.16	1.7	0.18
Other leukemias	13	1.5	0.20	1.7	0.23	9	0.7	0.11	0.8	0.12
Mesothelioma	3	0.4	0.12	0.5	0.13	2	0.2	0.05	0.2	0.06
Kaposi Sarcoma	12	1.1	0.15	1.1	0.15	-	-	-	-	-
Ill-defined & Unknown	153	18.1	0.71	21.1	0.81	168	13.6	0.48	15.9	0.55
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	91	10.0	0.50	11.5	0.57	196	15.8	0.52	18.0	0.58
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.08	406	30.9	0.70	36.7	0.82

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	216	231.7	7.88	272.1	9.21	328	262.9	6.98	305.3	8.10
Oral Cavity & Pharynx	12	10.5	1.45	12.4	1.70	5	4.7	1.00	5.4	1.14
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.7	0.85	4.1	0.96	2	2.3	0.73	2.6	0.82
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.7	0.55	2.2	0.72	-	-	-	-	-
Nasopharynx	2	1.4	0.52	1.7	0.64	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	62	66.8	4.21	79.9	4.99	58	54.4	3.43	63.5	3.97
Esophagus	2	2.5	0.79	3.1	0.93	-	-	-	-	-
Stomach	10	12.5	1.91	15.1	2.26	8	7.0	1.22	8.1	1.41
Small intestine	2	1.7	0.56	2.2	0.70	2	1.4	0.52	1.6	0.58
Colon excl. rectum	10	10.6	1.70	12.5	2.00	17	15.4	1.79	18.3	2.11
Rectum & rectosigmoid	12	11.4	1.59	14.0	1.94	9	7.4	1.17	8.8	1.37
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	14	14.6	1.95	17.5	2.32	6	5.8	1.12	6.7	1.29
Gallbladder	-	-	-	-	-	2	1.8	0.68	2.1	0.77
Pancreas	7	7.5	1.42	8.7	1.65	8	9.2	1.52	10.6	1.73
Respiratory System	31	35.0	3.11	42.0	3.67	33	31.9	2.66	37.4	3.06
Larynx	2	2.1	0.66	2.5	0.78	-	-	-	-	-
Lung & bronchus	28	32.4	3.03	38.8	3.57	32	30.9	2.62	36.1	3.01
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	1.5	0.57	1.7	0.64	3	2.3	0.65	2.7	0.77
Skin (excl. basal & sq.)	2	1.8	0.56	2.1	0.64	1	0.9	0.43	1.1	0.52
Melanomas of the skin	1	1.1	0.46	1.2	0.53	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	109	79.1	3.56	92.1	4.17
Female Genital System	-	-	-	-	-	41	30.8	2.28	36.6	2.70
Cervix uteri	-	-	-	-	-	8	5.9	0.99	6.5	1.13
Uterus Corpus	-	-	-	-	-	19	13.8	1.50	16.8	1.82
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	11	8.3	1.17	9.9	1.38
Male Genital System	42	46.7	3.46	56.0	4.07	-	-	-	-	-
Prostate	39	45.0	3.42	54.5	4.04	-	-	-	-	-
Testis	2	1.3	0.38	1.2	0.34	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	14	18.5	2.46	21.3	2.83	9	8.2	1.30	9.8	1.52
Bladder (incl. <i>in situ</i>)	9	11.8	2.00	13.5	2.29	3	3.0	0.83	3.6	0.97
Kidney & renal pelvis	5	5.5	1.24	6.4	1.42	5	4.2	0.89	5.1	1.07
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	6.6	1.28	7.1	1.42	3	2.7	0.74	3.1	0.85
Brain	7	6.4	1.27	6.8	1.40	3	2.7	0.74	3.1	0.85
Endocrine System	5	3.4	0.75	3.4	0.76	28	17.8	1.54	19.4	1.72
Thyroid gland	5	2.9	0.66	2.9	0.67	28	17.3	1.52	19.0	1.71
Lymphomas	14	14.0	1.90	15.5	2.15	15	11.6	1.45	13.4	1.69
Hodgkin Lymphoma	2	1.4	0.42	1.4	0.45	1	0.9	0.40	0.9	0.40
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	3	3.8	1.03	4.4	1.20	5	4.6	1.02	5.4	1.18
Leukemias	9	8.1	1.43	9.0	1.64	5	3.9	0.87	4.1	0.94
Acute lymphocytic	2	1.1	0.36	0.9	0.32	2	1.5	0.49	1.3	0.47
Chronic lymphocytic	2	2.1	0.81	2.5	0.97	-	-	-	-	-
Acute myeloid	5	4.5	1.08	5.0	1.24	1	1.0	0.41	1.1	0.44
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	10	12.4	2.07	14.5	2.43	11	9.1	1.33	10.5	1.55
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	9.1	1.51	10.6	1.77	16	13.1	1.59	15.0	1.83
Breast (<i>in situ</i>)	-	-	-	-	-	31	22.2	1.84	26.5	2.20

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	33	408.6	35.04	488.5	41.15	36	375.6	29.34	445.2	34.36
Oral Cavity & Pharynx	1	11.2	4.59	14.7	6.14	1	18.9	7.42	21.5	8.54
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	11	125.9	18.44	152.6	21.98	7	70.8	12.87	83.6	14.97
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	14.5	5.15	18.6	6.57	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	37.9	10.66	45.4	12.76	3	28.0	8.02	31.6	8.97
Rectum & rectosigmoid	2	18.2	5.76	23.3	7.46	1	13.8	5.38	16.4	6.29
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	25.4	7.67	31.7	9.28	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	5	70.4	15.73	81.4	17.93	7	73.8	13.43	90.4	16.07
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	63.8	14.99	74.7	17.26	7	73.8	13.43	90.4	16.07
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	9	100.4	15.16	114.8	17.13
Female Genital System	-	-	-	-	-	4	34.2	7.96	40.8	9.48
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	17.0	5.40	21.5	6.87
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	12.5	4.73	13.7	5.24
Male Genital System	6	71.8	14.42	89.6	17.59	-	-	-	-	-
Prostate	5	66.6	14.10	83.2	17.18	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	64.3	14.19	77.5	16.82	2	26.6	8.02	31.3	9.35
Bladder (incl. <i>in situ</i>)	2	23.0	8.37	28.9	10.12	-	-	-	-	-
Kidney & renal pelvis	3	34.6	10.41	41.8	12.53	2	18.8	6.51	22.2	7.67
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	1	10.8	4.45	14.2	5.80
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	1	10.8	4.45	14.2	5.80
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	21.4	9.14	22.1	9.55	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	3	28.2	8.05	28.2	8.17
Brain & Other CNS ² (non-malig)	-	-	-	-	-	2	18.1	5.75	23.4	7.44
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	454	250.7	6.72	293.3	7.70	529	249.6	5.68	289.3	6.58
Oral Cavity & Pharynx	14	7.4	1.14	8.9	1.33	4	2.3	0.60	2.5	0.64
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	2.2	0.64	2.5	0.71	-	-	-	-	-
Major salivary gland	2	1.1	0.50	1.4	0.60	2	1.0	0.41	1.1	0.43
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.1	0.45	1.3	0.56	-	-	-	-	-
Nasopharynx	1	0.6	0.33	0.6	0.38	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	0.4	0.16	0.5	0.22	-	-	-	-	-
Digestive System	106	59.8	3.25	70.7	3.76	87	49.0	2.67	57.2	3.08
Esophagus	5	3.9	0.93	4.5	1.06	1	1.1	0.44	1.3	0.49
Stomach	14	6.6	1.02	7.6	1.16	14	6.9	0.96	7.9	1.11
Small intestine	2	1.1	0.49	1.3	0.59	4	2.1	0.53	2.4	0.62
Colon excl. rectum	26	15.4	1.70	17.6	1.92	24	13.1	1.37	15.2	1.57
Rectum & rectosigmoid	17	8.6	1.16	10.3	1.33	10	5.3	0.85	6.3	0.98
Anus, anal canal & anorectum	2	1.3	0.53	1.6	0.62	2	0.9	0.35	1.1	0.42
Liver	20	10.2	1.21	12.9	1.47	7	4.6	0.85	5.4	0.99
Gallbladder	1	1.2	0.52	1.3	0.58	3	2.0	0.56	2.2	0.61
Pancreas	13	8.3	1.28	9.7	1.47	13	8.2	1.12	9.6	1.30
Respiratory System	41	31.6	2.64	36.6	2.98	34	22.8	1.92	26.8	2.21
Larynx	5	3.5	0.84	4.0	0.94	1	1.1	0.45	1.1	0.47
Lung & bronchus	33	27.4	2.49	31.7	2.81	32	21.5	1.86	25.3	2.15
Bones & Joints	2	0.4	0.13	0.4	0.14	2	0.3	0.12	0.3	0.11
Soft Tissue (incl. heart)	7	2.1	0.47	2.5	0.56	7	2.6	0.53	3.1	0.64
Skin (excl. basal & sq.)	11	5.9	1.02	6.8	1.16	-	-	-	-	-
Melanomas of the skin	9	4.7	0.91	5.4	1.03	6	2.5	0.56	2.9	0.65
Breast (excl. <i>in situ</i>)	2	1.1	0.49	1.3	0.59	149	64.6	2.71	75.7	3.19
Female Genital System	-	-	-	-	-	85	36.3	2.05	42.1	2.38
Cervix uteri	-	-	-	-	-	23	7.5	0.85	7.9	0.93
Uterus Corpus	-	-	-	-	-	36	16.3	1.37	19.7	1.65
Uterus, NOS ¹	-	-	-	-	-	2	1.0	0.37	1.2	0.46
Ovary	-	-	-	-	-	18	7.7	0.93	9.0	1.09
Male Genital System	111	65.5	3.32	78.6	3.83	-	-	-	-	-
Prostate	93	62.0	3.30	75.0	3.81	-	-	-	-	-
Testis	17	3.2	0.35	3.1	0.35	-	-	-	-	-
Penis	1	0.4	0.15	0.4	0.20	-	-	-	-	-
Urinary System	39	25.6	2.28	30.0	2.63	25	14.0	1.42	16.5	1.65
Bladder (incl. <i>in situ</i>)	13	10.2	1.52	12.0	1.76	6	4.2	0.85	4.8	0.95
Kidney & renal pelvis	26	15.1	1.70	17.6	1.94	19	9.6	1.12	11.4	1.33
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.3	0.11	0.3	0.12	-	-	-	-	-
Brain & Other CNS ¹	14	4.6	0.81	5.2	0.95	9	3.5	0.67	3.9	0.76
Brain	13	4.5	0.80	5.1	0.94	8	3.3	0.64	3.6	0.72
Endocrine System	14	4.8	0.80	5.0	0.86	47	14.2	1.06	15.4	1.20
Thyroid gland	12	4.4	0.79	4.7	0.85	46	13.8	1.03	15.0	1.18
Lymphomas	35	16.0	1.65	18.1	1.87	28	14.2	1.41	16.2	1.60
Hodgkin Lymphoma	6	2.0	0.60	2.2	0.70	5	1.9	0.47	2.1	0.52
Non-Hodgkin Lymphoma	29	14.0	1.54	15.9	1.73	23	12.3	1.33	14.1	1.51
Multiple Myeloma	9	5.4	0.98	6.5	1.16	9	4.8	0.83	5.8	0.98
Leukemias	29	9.0	1.12	9.6	1.24	20	8.0	1.02	8.9	1.16
Acute lymphocytic	13	2.2	0.29	2.0	0.29	6	1.6	0.39	1.6	0.43
Chronic lymphocytic	2	1.6	0.57	1.8	0.64	3	2.6	0.68	3.0	0.77
Acute myeloid	7	2.3	0.56	2.5	0.63	6	1.8	0.39	2.0	0.46
Chronic myeloid	4	1.6	0.52	1.7	0.57	3	1.2	0.36	1.3	0.41
Other leukemias	3	1.4	0.50	1.6	0.56	2	0.9	0.37	1.1	0.43
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	2	0.6	0.24	0.6	0.27	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	16	9.8	1.26	11.5	1.46
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	6.2	0.95	7.0	1.11	26	10.9	1.12	12.7	1.32
Breast (<i>in situ</i>)	-	-	-	-	-	30	11.9	1.08	14.1	1.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NORTH CAROLINA

II-378 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	21,435	522.8	1.64	619.5	1.92	20,659	448.3	1.46	522.3	1.65
Oral Cavity & Pharynx	877	20.9	0.32	25.5	0.39	344	7.3	0.18	8.6	0.21
Lip	31	0.8	0.07	0.9	0.08	14	0.3	0.04	0.4	0.04
Tongue	299	7.0	0.19	8.6	0.23	104	2.2	0.10	2.6	0.12
Major salivary gland	68	1.8	0.10	2.0	0.11	40	0.9	0.07	1.0	0.07
Floor of mouth	43	1.0	0.07	1.3	0.09	16	0.3	0.04	0.4	0.05
Gum & other mouth	80	1.9	0.10	2.3	0.12	80	1.6	0.09	1.9	0.10
Nasopharynx	20	0.5	0.05	0.6	0.06	10	0.2	0.03	0.3	0.04
Oropharynx	48	1.1	0.08	1.4	0.09	16	0.4	0.04	0.4	0.05
Hypopharynx	48	1.1	0.07	1.4	0.09	10	0.2	0.03	0.2	0.03
Digestive System	3,762	91.9	0.69	109.8	0.81	2,934	61.3	0.52	72.0	0.60
Esophagus	337	8.0	0.20	9.6	0.24	70	1.4	0.08	1.7	0.09
Stomach	301	7.3	0.19	8.7	0.23	178	3.7	0.13	4.3	0.15
Small intestine	126	3.1	0.13	3.7	0.15	111	2.4	0.10	2.8	0.12
Colon excl. rectum	1,129	28.3	0.39	33.4	0.45	1,121	23.5	0.33	27.3	0.37
Rectum & rectosigmoid	536	13.4	0.27	15.9	0.31	382	8.6	0.21	10.0	0.23
Anus, anal canal & anorectum	58	1.4	0.09	1.7	0.10	134	2.9	0.12	3.5	0.14
Liver	468	10.7	0.23	13.5	0.28	133	2.6	0.11	3.2	0.13
Gallbladder	28	0.7	0.06	0.8	0.07	46	0.9	0.06	1.1	0.07
Pancreas	600	14.6	0.27	17.4	0.32	541	10.8	0.21	12.8	0.25
Respiratory System	3,790	90.9	0.68	108.1	0.80	3,153	62.8	0.51	74.8	0.60
Larynx	271	6.4	0.18	7.8	0.21	80	1.7	0.09	2.1	0.11
Lung & bronchus	3,472	83.3	0.65	99.0	0.76	3,047	60.5	0.50	72.1	0.59
Bones & Joints	36	1.1	0.08	1.1	0.08	36	1.0	0.08	1.0	0.08
Soft Tissue (incl. heart)	148	4.0	0.15	4.4	0.17	116	2.7	0.12	3.0	0.13
Skin (excl. basal & sq.)	1,808	46.0	0.50	53.4	0.57	1,190	28.2	0.39	31.9	0.42
Melanomas of the skin	1,700	43.2	0.48	50.2	0.55	1,132	27.0	0.38	30.5	0.41
Breast (excl. <i>in situ</i>)	46	1.1	0.08	1.4	0.09	6,267	137.5	0.81	161.5	0.93
Female Genital System	-	-	-	-	-	2,260	49.7	0.49	58.6	0.56
Cervix uteri	-	-	-	-	-	243	6.8	0.21	7.2	0.21
Uterus Corpus	-	-	-	-	-	1,189	24.8	0.33	30.3	0.40
Uterus, NOS ¹	-	-	-	-	-	33	0.7	0.06	0.8	0.07
Ovary	-	-	-	-	-	520	11.5	0.24	13.4	0.27
Male Genital System	4,844	110.6	0.73	135.0	0.88	-	-	-	-	-
Prostate	4,600	102.7	0.69	127.0	0.85	-	-	-	-	-
Testis	199	6.7	0.22	6.6	0.21	-	-	-	-	-
Penis	36	0.9	0.07	1.1	0.08	-	-	-	-	-
Urinary System	2,575	64.1	0.58	75.2	0.67	1,044	21.7	0.31	25.5	0.36
Bladder (incl. <i>in situ</i>)	1,547	38.8	0.45	45.4	0.52	473	9.4	0.20	11.1	0.23
Kidney & renal pelvis	962	23.6	0.35	27.9	0.41	541	11.7	0.24	13.7	0.27
Ureter	43	1.1	0.08	1.3	0.09	22	0.4	0.04	0.5	0.05
Eye & Orbit	40	1.0	0.07	1.2	0.08	45	1.1	0.08	1.2	0.08
Brain & Other CNS ¹	304	8.3	0.22	9.1	0.24	258	6.3	0.19	6.9	0.20
Brain	289	7.8	0.21	8.6	0.23	243	5.9	0.18	6.5	0.19
Endocrine System	296	8.1	0.22	9.0	0.24	738	20.3	0.35	21.8	0.36
Thyroid gland	270	7.4	0.21	8.2	0.22	711	19.7	0.35	21.1	0.36
Lymphomas	989	25.5	0.37	29.2	0.42	797	17.3	0.29	19.8	0.32
Hodgkin Lymphoma	103	3.1	0.14	3.2	0.14	77	2.3	0.12	2.3	0.12
Non-Hodgkin Lymphoma	886	22.4	0.35	26.0	0.40	720	15.0	0.26	17.5	0.30
Multiple Myeloma	309	7.5	0.20	8.9	0.23	247	5.0	0.15	5.9	0.17
Leukemias	753	19.7	0.33	22.3	0.37	520	11.5	0.24	12.9	0.26
Acute lymphocytic	55	1.9	0.12	1.7	0.10	42	1.4	0.10	1.2	0.09
Chronic lymphocytic	313	7.7	0.20	9.1	0.23	199	3.9	0.13	4.7	0.15
Acute myeloid	203	5.3	0.17	6.0	0.19	157	3.5	0.13	3.9	0.14
Chronic myeloid	103	2.8	0.13	3.1	0.14	69	1.6	0.09	1.8	0.10
Other leukemias	79	2.1	0.11	2.4	0.12	54	1.2	0.08	1.3	0.08
Mesothelioma	53	1.4	0.09	1.6	0.10	16	0.4	0.04	0.4	0.05
Kaposi Sarcoma	10	0.3	0.05	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	796	20.5	0.33	23.9	0.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	348	9.2	0.23	10.4	0.25	727	16.4	0.29	18.7	0.32
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	1,355	30.5	0.39	35.9	0.44

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Carolina, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,286	554.9	3.66	669.8	4.30	5,165	408.6	2.60	480.9	3.01
Oral Cavity & Pharynx	160	15.4	0.57	18.9	0.69	69	5.4	0.30	6.4	0.35
Lip	1	0.1	0.06	0.2	0.08	2	0.1	0.05	0.2	0.06
Tongue	37	3.5	0.27	4.4	0.33	12	1.0	0.13	1.1	0.15
Major salivary gland	13	1.4	0.18	1.6	0.21	14	1.1	0.14	1.2	0.15
Floor of mouth	10	0.9	0.13	1.2	0.16	3	0.3	0.06	0.3	0.08
Gum & other mouth	18	1.8	0.21	2.3	0.26	16	1.3	0.14	1.5	0.17
Nasopharynx	10	1.0	0.14	1.1	0.16	4	0.3	0.07	0.3	0.08
Oropharynx	15	1.5	0.18	1.8	0.21	3	0.2	0.06	0.3	0.07
Hypopharynx	19	1.7	0.18	2.1	0.22	4	0.3	0.07	0.4	0.08
Digestive System	1,092	116.0	1.69	140.1	1.98	969	77.0	1.13	91.5	1.32
Esophagus	65	6.9	0.41	8.4	0.49	28	2.3	0.20	2.7	0.23
Stomach	119	13.4	0.59	15.8	0.68	92	7.6	0.36	8.8	0.41
Small intestine	45	4.9	0.35	5.7	0.40	52	4.1	0.26	4.8	0.30
Colon excl. rectum	332	36.5	0.96	43.6	1.13	352	28.0	0.68	33.3	0.80
Rectum & rectosigmoid	135	13.7	0.56	16.6	0.66	107	8.5	0.37	10.0	0.44
Anus, anal canal & anorectum	18	1.8	0.19	2.0	0.22	24	1.9	0.18	2.2	0.20
Liver	154	13.8	0.53	18.0	0.67	47	3.5	0.23	4.3	0.28
Gallbladder	13	1.5	0.20	1.8	0.23	25	2.0	0.18	2.4	0.21
Pancreas	166	18.5	0.69	22.1	0.80	188	15.1	0.50	17.9	0.59
Respiratory System	919	101.1	1.61	121.6	1.88	624	48.6	0.89	58.6	1.05
Larynx	92	9.4	0.47	11.6	0.56	24	1.7	0.16	2.2	0.20
Lung & bronchus	817	90.7	1.53	108.9	1.78	593	46.3	0.87	55.8	1.03
Bones & Joints	9	0.9	0.14	0.9	0.15	7	0.6	0.10	0.6	0.10
Soft Tissue (incl. heart)	33	3.4	0.28	3.7	0.30	34	2.8	0.22	3.1	0.24
Skin (excl. basal & sq.)	22	2.4	0.25	2.8	0.28	20	1.6	0.17	1.9	0.19
Melanomas of the skin	10	1.1	0.17	1.3	0.20	10	0.8	0.12	0.9	0.13
Breast (excl. <i>in situ</i>)	15	1.7	0.21	2.0	0.25	1,715	135.1	1.49	158.9	1.72
Female Genital System	-	-	-	-	-	598	46.5	0.87	55.1	1.01
Cervix uteri	-	-	-	-	-	96	7.8	0.37	8.8	0.40
Uterus Corpus	-	-	-	-	-	328	24.7	0.62	30.0	0.74
Uterus, NOS ¹	-	-	-	-	-	22	1.8	0.17	2.1	0.20
Ovary	-	-	-	-	-	98	7.9	0.36	9.2	0.42
Male Genital System	1,838	182.1	2.03	226.4	2.44	-	-	-	-	-
Prostate	1,809	179.0	2.01	223.1	2.43	-	-	-	-	-
Testis	18	1.9	0.20	1.9	0.20	-	-	-	-	-
Penis	8	1.0	0.17	1.1	0.19	-	-	-	-	-
Urinary System	434	47.6	1.10	56.5	1.27	278	22.0	0.60	25.9	0.70
Bladder (incl. <i>in situ</i>)	167	20.2	0.76	23.9	0.88	89	7.1	0.34	8.4	0.40
Kidney & renal pelvis	261	26.6	0.78	31.8	0.91	183	14.4	0.49	16.9	0.56
Ureter	3	0.4	0.10	0.4	0.12	3	0.2	0.06	0.3	0.07
Eye & Orbit	4	0.4	0.10	0.4	0.11	3	0.3	0.07	0.3	0.07
Brain & Other CNS ¹	48	4.9	0.33	5.4	0.36	47	3.9	0.26	4.2	0.28
Brain	45	4.6	0.32	5.1	0.35	41	3.4	0.24	3.7	0.26
Endocrine System	47	5.0	0.34	5.5	0.37	180	14.6	0.50	16.2	0.54
Thyroid gland	36	3.8	0.30	4.3	0.33	169	13.6	0.48	15.2	0.53
Lymphomas	195	20.3	0.69	23.1	0.77	182	14.6	0.50	16.8	0.56
Hodgkin Lymphoma	34	3.3	0.26	3.4	0.27	28	2.3	0.20	2.4	0.21
Non-Hodgkin Lymphoma	161	17.0	0.64	19.6	0.73	154	12.3	0.45	14.3	0.52
Multiple Myeloma	166	18.7	0.70	22.0	0.80	159	12.8	0.46	15.1	0.54
Leukemias	137	15.1	0.62	17.2	0.70	110	9.0	0.39	10.2	0.44
Acute lymphocytic	14	1.2	0.15	1.2	0.14	8	0.7	0.11	0.7	0.11
Chronic lymphocytic	42	4.9	0.36	5.8	0.42	32	2.6	0.21	3.1	0.24
Acute myeloid	45	5.0	0.36	5.7	0.41	41	3.4	0.24	3.8	0.27
Chronic myeloid	23	2.6	0.25	2.9	0.28	19	1.5	0.16	1.7	0.18
Other leukemias	13	1.5	0.20	1.7	0.23	9	0.7	0.11	0.8	0.13
Mesothelioma	3	0.5	0.12	0.5	0.13	2	0.2	0.05	0.2	0.06
Kaposi Sarcoma	12	1.2	0.16	1.2	0.16	-	-	-	-	-
Ill-defined & Unknown	152	18.3	0.72	21.4	0.83	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	91	10.2	0.51	11.7	0.58	196	16.1	0.52	18.2	0.59
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.08	405	31.4	0.71	37.3	0.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NORTH CAROLINA

II-380 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	721,999	737,382	754,022	754,353	755,176
White	653,367	664,650	674,811	671,051	669,116
Black	15,844	18,370	22,590	25,448	27,056
American Indian/Alaskan Native (AI/AN)	42,437	43,421	44,485	44,948	44,943
Asian/Pacific Islander (API)	10,351	10,941	12,136	12,906	14,061


All Races Population 2013-2017: 3,722,932
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	20,627	23,222	26,431	27,605	28,376
Non-Hispanic White	636,694	645,931	653,507	648,915	646,191
Non-Hispanic Black	15,061	17,426	21,477	24,231	25,781

Hispanic/Latino Population, Census 2010: 13,467
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NORTH DAKOTA CANCER REGISTRY

Initial Operation: 1997
 Population-based Data Available: 1997
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	117.3	113.4	108.4	115.0	126.2
Missing Race	2.1	2.0	1.6	1.3	0.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.2	0.7
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	0.7	1.0	0.9	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.1	Prostate	97.7
Oral Cavity & Pharynx	98.7	Testis	98.6
Esophagus	98.1	Bladder (incl. <i>in situ</i>)	98.2
Stomach	97.4	Kidney & Renal Pelvis	88.2
Colon & Rectum	96.8	Brain & Other CNS ¹	81.8
Liver	63.9	Thyroid	100.0
Pancreas	84.5	Hodgkin Lymphoma	100.0
Lung & Bronchus	92.7	Non-Hodgkin Lymphoma	97.9
Melanomas of the Skin	99.7	Multiple Myeloma	88.5
Female Breast (excl. <i>in situ</i>)	98.9	Leukemias	92.0
Cervix uteri	100.0	Brain & Other CNS ¹ <i>non-malig</i>	36.4
Uterus Corpus & Uterus NOS ¹	99.6	Breast <i>in situ</i>	100.0
Ovary	92.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,968	489.6	5.07	578.7	5.87	1,804	430.1	4.72	498.4	5.35
Oral Cavity & Pharynx	76	18.3	0.97	22.3	1.15	32	7.5	0.61	8.8	0.71
Lip	16	4.1	0.47	4.8	0.54	4	0.9	0.22	1.0	0.23
Tongue	17	4.2	0.46	5.1	0.55	9	2.1	0.33	2.4	0.38
Major salivary gland	5	1.4	0.27	1.6	0.30	5	1.3	0.26	1.4	0.29
Floor of mouth	2	0.6	0.17	0.7	0.20	2	0.5	0.16	0.7	0.20
Gum & other mouth	7	1.8	0.29	2.1	0.35	6	1.3	0.24	1.5	0.28
Nasopharynx	2	0.5	0.17	0.5	0.17	-	-	-	-	-
Oropharynx	3	0.8	0.20	0.9	0.24	-	-	-	-	-
Hypopharynx	4	0.9	0.21	1.2	0.26	1	0.3	0.11	0.3	0.14
Digestive System	362	91.4	2.21	108.2	2.56	286	64.6	1.78	75.4	2.04
Esophagus	34	8.3	0.65	10.0	0.77	8	2.0	0.33	2.2	0.36
Stomach	31	8.1	0.67	9.4	0.76	15	3.5	0.42	4.0	0.47
Small intestine	9	2.2	0.35	2.6	0.40	7	1.7	0.30	2.0	0.34
Colon excl. rectum	127	32.2	1.31	37.8	1.51	124	28.0	1.17	32.2	1.32
Rectum & rectosigmoid	65	16.1	0.93	19.3	1.08	44	10.4	0.73	12.3	0.85
Anus, anal canal & anorectum	4	1.0	0.23	1.3	0.28	9	2.2	0.34	2.6	0.39
Liver	24	5.7	0.54	7.1	0.65	7	1.6	0.27	1.9	0.32
Gallbladder	2	0.6	0.19	0.7	0.20	7	1.4	0.26	1.7	0.31
Pancreas	55	13.9	0.86	16.4	0.99	47	10.4	0.70	12.2	0.81
Respiratory System	284	71.8	1.95	84.6	2.26	235	53.5	1.60	63.2	1.87
Larynx	23	5.7	0.55	6.9	0.64	4	0.8	0.20	1.0	0.23
Lung & bronchus	258	65.4	1.86	76.9	2.15	230	52.3	1.58	61.7	1.84
Bones & Joints	2	0.7	0.20	0.7	0.20	2	0.5	0.17	0.5	0.17
Soft Tissue (incl. heart)	13	3.5	0.44	3.9	0.48	9	2.2	0.35	2.4	0.37
Skin (excl. basal & sq.)	108	27.6	1.22	31.8	1.38	-	-	-	-	-
Melanomas of the skin	100	25.6	1.18	29.6	1.33	87	22.7	1.14	25.2	1.23
Breast (excl. <i>in situ</i>)	5	1.5	0.29	1.7	0.33	526	128.6	2.62	150.9	3.00
Female Genital System	-	-	-	-	-	197	47.2	1.57	56.0	1.81
Cervix uteri	-	-	-	-	-	19	5.5	0.58	5.9	0.61
Uterus Corpus	-	-	-	-	-	112	26.2	1.15	32.2	1.37
Uterus, NOS ¹	-	-	-	-	-	2	0.4	0.14	0.4	0.16
Ovary	-	-	-	-	-	41	9.9	0.71	11.5	0.82
Male Genital System	522	122.2	2.46	149.4	2.94	-	-	-	-	-
Prostate	488	113.5	2.36	140.5	2.86	-	-	-	-	-
Testis	29	7.2	0.62	7.2	0.61	-	-	-	-	-
Penis	5	1.3	0.27	1.5	0.30	-	-	-	-	-
Urinary System	234	60.9	1.83	70.6	2.07	88	19.6	0.97	23.0	1.12
Bladder (incl. <i>in situ</i>)	132	34.6	1.38	40.1	1.57	37	8.1	0.62	9.3	0.70
Kidney & renal pelvis	96	24.6	1.16	28.5	1.31	46	10.7	0.73	12.7	0.85
Ureter	4	0.9	0.23	1.1	0.26	3	0.6	0.15	0.7	0.18
Eye & Orbit	3	0.6	0.16	0.7	0.20	2	0.4	0.14	0.5	0.15
Brain & Other CNS ¹	31	7.7	0.64	8.5	0.69	20	5.0	0.52	5.4	0.55
Brain	29	7.1	0.61	8.0	0.68	19	4.7	0.50	5.1	0.54
Endocrine System	35	8.9	0.70	10.1	0.78	99	28.1	1.31	30.1	1.37
Thyroid gland	33	8.5	0.68	9.6	0.76	96	27.4	1.30	29.3	1.36
Lymphomas	101	25.5	1.17	29.5	1.33	79	18.4	0.96	20.9	1.07
Hodgkin Lymphoma	14	3.6	0.45	3.9	0.47	7	2.0	0.34	2.0	0.34
Non-Hodgkin Lymphoma	87	21.9	1.08	25.7	1.24	72	16.4	0.90	18.9	1.02
Multiple Myeloma	30	7.8	0.65	9.1	0.75	22	4.8	0.48	5.7	0.55
Leukemias	81	20.6	1.06	23.6	1.19	53	12.1	0.78	13.5	0.86
Acute lymphocytic	7	1.9	0.33	1.6	0.29	4	1.1	0.25	1.0	0.24
Chronic lymphocytic	36	8.8	0.68	10.6	0.80	22	5.0	0.49	5.7	0.56
Acute myeloid	18	4.5	0.49	5.2	0.56	16	3.7	0.42	4.1	0.47
Chronic myeloid	11	3.0	0.41	3.3	0.44	7	1.5	0.27	1.7	0.31
Other leukemias	10	2.5	0.37	2.9	0.42	3	0.8	0.21	0.9	0.22
Mesothelioma	5	1.2	0.26	1.4	0.29	2	0.4	0.13	0.4	0.16
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	74	19.1	1.02	22.3	1.16	61	13.4	0.80	15.3	0.90
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	25	6.9	0.63	7.6	0.68	49	12.6	0.83	14.1	0.91
Breast (<i>in situ</i>)	-	-	-	-	-	103	26.6	1.23	31.1	1.39

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	1,856	484.0	5.17	571.3	5.97	1,688	424.2	4.85	491.5	5.48
Oral Cavity & Pharynx	71	18.0	0.98	21.8	1.17	32	7.8	0.65	9.2	0.75
Lip	16	4.2	0.48	4.9	0.56	4	1.0	0.24	1.0	0.24
Tongue	16	4.2	0.48	5.1	0.57	9	2.2	0.35	2.6	0.40
Major salivary gland	5	1.4	0.28	1.6	0.31	5	1.3	0.28	1.5	0.31
Floor of mouth	2	0.6	0.18	0.7	0.21	2	0.5	0.17	0.7	0.21
Gum & other mouth	7	1.7	0.30	2.1	0.36	6	1.3	0.25	1.6	0.30
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	3	0.8	0.21	0.9	0.24	-	-	-	-	-
Hypopharynx	4	0.9	0.21	1.1	0.26	-	-	-	-	-
Digestive System	337	88.9	2.23	105.1	2.58	263	62.0	1.79	72.3	2.05
Esophagus	31	7.9	0.65	9.5	0.77	7	1.8	0.32	2.0	0.34
Stomach	29	7.8	0.67	9.0	0.76	14	3.2	0.41	3.7	0.46
Small intestine	8	2.0	0.34	2.4	0.39	6	1.4	0.28	1.7	0.32
Colon excl. rectum	120	31.9	1.34	37.3	1.53	117	27.4	1.19	31.5	1.34
Rectum & rectosigmoid	59	15.6	0.94	18.7	1.09	40	9.9	0.74	11.8	0.86
Anus, anal canal & anorectum	4	1.1	0.24	1.4	0.29	8	2.1	0.35	2.6	0.41
Liver	21	5.2	0.52	6.5	0.63	6	1.5	0.27	1.7	0.31
Gallbladder	2	0.6	0.19	0.7	0.21	6	1.2	0.24	1.5	0.28
Pancreas	52	13.8	0.88	16.3	1.01	44	10.0	0.71	11.7	0.81
Respiratory System	267	70.0	1.96	82.4	2.27	219	51.8	1.61	61.2	1.88
Larynx	21	5.4	0.54	6.5	0.64	4	0.9	0.21	1.0	0.25
Lung & bronchus	243	63.8	1.87	75.0	2.16	213	50.5	1.59	59.7	1.85
Bones & Joints	2	0.7	0.22	0.7	0.22	2	0.5	0.18	0.5	0.18
Soft Tissue (incl. heart)	12	3.4	0.45	3.8	0.49	8	2.1	0.36	2.3	0.37
Skin (excl. basal & sq.)	106	28.8	1.29	33.1	1.45	-	-	-	-	-
Melanomas of the skin	99	26.7	1.24	30.8	1.40	85	23.9	1.23	26.5	1.32
Breast (excl. <i>in situ</i>)	5	1.5	0.31	1.7	0.34	496	128.0	2.71	150.3	3.09
Female Genital System	-	-	-	-	-	183	46.0	1.60	54.7	1.85
Cervix uteri	-	-	-	-	-	15	4.8	0.58	5.1	0.59
Uterus Corpus	-	-	-	-	-	105	25.8	1.18	31.6	1.41
Uterus, NOS ¹	-	-	-	-	-	2	0.3	0.12	0.4	0.14
Ovary	-	-	-	-	-	39	9.8	0.73	11.5	0.84
Male Genital System	491	120.5	2.50	147.2	2.98	-	-	-	-	-
Prostate	460	111.4	2.38	137.9	2.89	-	-	-	-	-
Testis	27	7.7	0.69	7.7	0.67	-	-	-	-	-
Penis	4	1.3	0.27	1.4	0.30	-	-	-	-	-
Urinary System	224	60.7	1.86	70.3	2.11	80	18.7	0.97	22.0	1.12
Bladder (incl. <i>in situ</i>)	129	34.9	1.41	40.4	1.60	35	8.0	0.63	9.3	0.71
Kidney & renal pelvis	89	24.0	1.18	27.9	1.33	41	9.9	0.72	11.7	0.84
Ureter	3	0.9	0.22	1.0	0.26	3	0.6	0.16	0.7	0.19
Eye & Orbit	2	0.5	0.15	0.7	0.20	2	0.5	0.15	0.5	0.16
Brain & Other CNS ¹	30	8.0	0.68	8.9	0.73	19	5.4	0.57	5.8	0.60
Brain	28	7.5	0.65	8.4	0.71	18	5.0	0.54	5.4	0.58
Endocrine System	32	9.0	0.73	10.2	0.81	90	27.8	1.37	29.8	1.42
Thyroid gland	31	8.6	0.71	9.7	0.79	88	27.2	1.36	29.2	1.41
Lymphomas	97	25.7	1.21	29.7	1.36	75	18.2	0.98	20.8	1.10
Hodgkin Lymphoma	14	3.8	0.48	4.0	0.50	7	2.1	0.36	2.1	0.37
Non-Hodgkin Lymphoma	83	21.9	1.11	25.7	1.27	68	16.1	0.92	18.6	1.04
Multiple Myeloma	29	7.8	0.66	9.1	0.76	21	4.9	0.49	5.7	0.57
Leukemias	76	20.5	1.08	23.4	1.21	50	12.2	0.81	13.6	0.89
Acute lymphocytic	6	1.9	0.35	1.6	0.31	4	1.1	0.28	1.1	0.26
Chronic lymphocytic	35	8.9	0.70	10.8	0.82	22	5.2	0.52	5.9	0.58
Acute myeloid	16	4.4	0.49	5.1	0.56	15	3.6	0.44	4.1	0.48
Chronic myeloid	10	2.8	0.41	3.1	0.44	6	1.4	0.28	1.6	0.31
Other leukemias	9	2.5	0.39	2.9	0.43	3	0.9	0.22	0.9	0.23
Mesothelioma	5	1.3	0.27	1.5	0.30	2	0.4	0.14	0.5	0.16
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	69	18.5	1.02	21.5	1.17	58	13.2	0.82	15.0	0.91
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	23	6.9	0.66	7.5	0.70	45	12.1	0.85	13.7	0.93
Breast (<i>in situ</i>)	-	-	-	-	-	97	26.7	1.28	31.2	1.44

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13	292.2	60.26	355.7	69.47	8	251.4	55.60	293.1	63.82
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	82.1	43.41	93.8	47.68	1	38.5	14.75	51.7	20.53
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	49.2	30.38	59.1	35.27
Female Genital System	-	-	-	-	-	2	32.2	11.97	37.2	14.43
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	98.6	23.54	129.1	28.80	-	-	-	-	-
Prostate	5	97.5	23.51	128.1	28.78	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	25.2	10.70	26.9	11.80
Thyroid gland	-	-	-	-	-	1	25.2	10.70	26.9	11.80
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8	291.3	65.91	337.0	72.13	12	330.1	51.86	381.5	60.11
Oral Cavity & Pharynx	1	36.9	14.70	48.4	19.88	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	-	-	-	-	-	2	102.6	35.19	118.5	39.92
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	48.5	23.10	57.3	27.58	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	70.0	19.08	83.3	23.17
Female Genital System	-	-	-	-	-	2	41.8	13.48	51.9	17.59
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	1	38.8	15.94	52.0	21.64	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	3	52.0	19.76	52.4	21.57
Thyroid gland	-	-	-	-	-	3	52.0	19.76	52.4	21.57
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCD¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	54	588.2	40.25	707.8	47.39	59	523.2	32.59	619.6	38.00
Oral Cavity & Pharynx	3	28.8	7.92	34.6	9.23	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	16	173.5	22.28	207.2	26.11	11	101.9	14.53	122.1	17.10
Esophagus	1	13.0	5.15	15.8	6.12	-	-	-	-	-
Stomach	2	23.0	9.81	26.4	11.41	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	48.4	10.78	58.1	12.59	4	31.8	8.10	38.7	9.62
Rectum & rectosigmoid	4	39.9	11.25	48.1	13.41	2	22.5	6.76	25.1	7.48
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	22.8	7.49	27.5	8.76	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	15.5	6.30	18.6	7.42	1	12.1	5.17	15.7	6.57
Respiratory System	11	136.5	20.34	164.1	23.81	11	112.5	16.04	132.9	18.58
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	10	127.1	19.83	152.6	23.21	11	112.5	16.04	132.9	18.58
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	1	11.4	4.39	11.3	4.29
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	15	127.0	15.54	149.2	17.98
Female Genital System	-	-	-	-	-	7	51.2	8.85	62.3	10.69
Cervix uteri	-	-	-	-	-	2	14.6	4.50	18.5	5.66
Uterus Corpus	-	-	-	-	-	3	24.1	6.16	30.7	7.74
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	9	98.8	16.30	123.0	19.73	-	-	-	-	-
Prostate	9	96.0	16.06	120.1	19.51	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	56.9	11.75	66.5	13.46	5	39.1	8.87	48.7	10.76
Bladder (incl. <i>in situ</i>)	1	13.2	5.81	15.9	6.92	-	-	-	-	-
Kidney & renal pelvis	4	40.2	9.62	47.1	11.03	3	24.6	6.17	32.1	7.95
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	14.5	4.96	15.3	5.19
Thyroid gland	-	-	-	-	-	2	13.3	4.82	13.6	4.91
Lymphomas	2	20.0	6.57	24.1	7.85	2	21.1	7.63	23.3	8.68
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	18.5	6.38	21.6	7.46	2	21.1	7.63	23.3	8.68
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	2	17.5	6.06	20.6	7.02	1	12.3	4.95	14.6	5.74
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	26.6	7.81	32.6	9.26	2	21.9	7.25	26.7	8.60
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	1	8.0	3.37	8.5	3.64
Breast (<i>in situ</i>)	-	-	-	-	-	2	13.4	4.58	17.4	5.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCD – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	12	262.3	46.15	315.7	53.04	11	259.0	39.93	289.7	44.60
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	80.9	25.63	97.1	29.28	2	55.0	17.24	68.5	21.21
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	1	26.3	12.35	31.0	14.01
Rectum & rectosigmoid	1	19.6	8.07	27.3	11.53	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	21.4	9.54	28.2	12.76	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	74.3	21.36	76.7	22.66
Female Genital System	-	-	-	-	-	2	35.5	14.56	42.4	16.98
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	67.9	23.16	83.2	27.17	-	-	-	-	-
Prostate	2	65.2	23.11	80.8	27.13	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	37.4	18.94	45.2	22.21	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	20.1	7.67	25.4	10.03	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	17.0	7.26	17.9	7.97
Thyroid gland	-	-	-	-	-	1	17.0	7.26	17.9	7.97
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

NORTH DAKOTA

II-388 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,849	486.9	5.22	574.6	6.02	1,680	427.0	4.91	494.6	5.54
Oral Cavity & Pharynx	71	18.1	0.99	21.9	1.18	31	7.8	0.65	9.1	0.75
Lip	16	4.3	0.49	5.0	0.56	4	1.0	0.24	1.0	0.24
Tongue	16	4.2	0.48	5.1	0.57	9	2.2	0.36	2.6	0.41
Major salivary gland	5	1.4	0.29	1.6	0.32	5	1.3	0.27	1.4	0.30
Floor of mouth	2	0.6	0.18	0.7	0.21	2	0.5	0.17	0.6	0.21
Gum & other mouth	7	1.8	0.30	2.1	0.36	6	1.3	0.25	1.6	0.30
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	3	0.8	0.21	0.9	0.25	-	-	-	-	-
Hypopharynx	3	0.8	0.21	1.1	0.26	-	-	-	-	-
Digestive System	336	89.5	2.25	105.7	2.60	262	62.4	1.81	72.6	2.06
Esophagus	31	8.0	0.66	9.6	0.78	7	1.8	0.32	2.0	0.35
Stomach	28	7.8	0.67	9.0	0.76	14	3.3	0.42	3.7	0.47
Small intestine	8	2.1	0.35	2.4	0.40	6	1.5	0.29	1.7	0.33
Colon excl. rectum	120	32.1	1.35	37.6	1.54	116	27.5	1.20	31.6	1.35
Rectum & rectosigmoid	59	15.8	0.95	18.8	1.10	40	10.0	0.75	11.9	0.87
Anus, anal canal & anorectum	4	1.1	0.24	1.4	0.30	8	2.1	0.35	2.6	0.41
Liver	21	5.2	0.52	6.5	0.63	6	1.4	0.27	1.7	0.31
Gallbladder	2	0.6	0.19	0.7	0.21	6	1.2	0.24	1.5	0.29
Pancreas	52	13.9	0.89	16.3	1.02	44	10.0	0.71	11.7	0.82
Respiratory System	266	70.3	1.97	82.7	2.28	218	52.1	1.62	61.5	1.89
Larynx	21	5.4	0.55	6.6	0.65	4	0.9	0.21	1.0	0.25
Lung & bronchus	242	64.1	1.88	75.3	2.17	213	50.8	1.60	59.9	1.87
Bones & Joints	2	0.8	0.22	0.8	0.22	2	0.5	0.19	0.5	0.19
Soft Tissue (incl. heart)	12	3.4	0.45	3.9	0.50	8	2.2	0.37	2.3	0.37
Skin (excl. basal & sq.)	106	29.2	1.31	33.6	1.47	88	25.1	1.27	27.8	1.36
Melanomas of the skin	99	27.2	1.26	31.3	1.42	85	24.3	1.25	26.9	1.34
Breast (excl. <i>in situ</i>)	5	1.5	0.31	1.7	0.34	494	128.7	2.73	151.2	3.12
Female Genital System	-	-	-	-	-	181	46.3	1.62	55.0	1.87
Cervix uteri	-	-	-	-	-	15	4.9	0.59	5.2	0.60
Uterus Corpus	-	-	-	-	-	104	25.9	1.19	31.8	1.42
Uterus, NOS ¹	-	-	-	-	-	2	0.3	0.12	0.4	0.14
Ovary	-	-	-	-	-	39	9.9	0.74	11.6	0.85
Male Genital System	489	121.2	2.52	147.9	3.01	-	-	-	-	-
Prostate	458	111.8	2.40	138.5	2.91	-	-	-	-	-
Testis	26	7.9	0.71	7.8	0.69	-	-	-	-	-
Penis	4	1.3	0.27	1.4	0.30	-	-	-	-	-
Urinary System	222	60.7	1.87	70.3	2.12	80	18.7	0.98	22.0	1.13
Bladder (incl. <i>in situ</i>)	129	35.1	1.42	40.6	1.61	35	8.1	0.63	9.3	0.72
Kidney & renal pelvis	88	23.9	1.18	27.7	1.34	41	9.9	0.72	11.7	0.84
Ureter	3	0.9	0.22	1.1	0.26	3	0.6	0.16	0.7	0.19
Eye & Orbit	2	0.5	0.16	0.7	0.20	2	0.5	0.15	0.5	0.17
Brain & Other CNS ¹	29	8.1	0.69	8.9	0.74	19	5.3	0.57	5.7	0.60
Brain	28	7.6	0.67	8.5	0.73	18	4.9	0.55	5.3	0.58
Endocrine System	32	9.1	0.74	10.2	0.82	90	28.3	1.40	30.2	1.45
Thyroid gland	31	8.6	0.73	9.8	0.80	87	27.6	1.39	29.6	1.44
Lymphomas	97	26.1	1.23	30.1	1.38	75	18.4	1.00	21.0	1.12
Hodgkin Lymphoma	14	4.0	0.50	4.2	0.51	7	2.1	0.37	2.2	0.38
Non-Hodgkin Lymphoma	83	22.1	1.12	25.9	1.28	68	16.3	0.93	18.8	1.05
Multiple Myeloma	29	7.8	0.66	9.2	0.77	21	4.9	0.49	5.7	0.57
Leukemias	75	20.7	1.10	23.6	1.23	50	12.4	0.82	13.8	0.90
Acute lymphocytic	5	1.9	0.36	1.6	0.31	4	1.2	0.29	1.1	0.26
Chronic lymphocytic	34	8.9	0.70	10.8	0.83	22	5.2	0.52	6.0	0.59
Acute myeloid	16	4.4	0.50	5.1	0.57	15	3.7	0.45	4.1	0.49
Chronic myeloid	10	2.9	0.42	3.2	0.45	6	1.4	0.28	1.6	0.31
Other leukemias	9	2.5	0.39	2.9	0.44	3	0.9	0.22	1.0	0.24
Mesothelioma	5	1.3	0.27	1.5	0.31	2	0.4	0.14	0.5	0.17
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	23	7.0	0.67	7.7	0.72	45	12.3	0.86	13.8	0.94
Breast (<i>in situ</i>)	-	-	-	-	-	97	27.0	1.30	31.5	1.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
North Dakota, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13	300.9	61.92	366.1	71.11	8	259.6	57.37	302.1	65.55
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	84.8	44.98	96.8	49.12	1	39.5	15.15	53.1	21.11
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	49.7	30.46	59.8	35.39
Female Genital System	-	-	-	-	-	2	33.3	12.36	38.4	14.88
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	102.0	24.35	133.6	29.81	-	-	-	-	-
Prostate	5	100.9	24.33	132.5	29.79	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	26.1	11.06	27.8	12.18
Thyroid gland	-	-	-	-	-	1	26.1	11.06	27.8	12.18
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


NORTH DAKOTA

II-390 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹


Race	2013	2014	2015	2016	2017
All Races	11,576,576	11,602,973	11,617,850	11,635,003	11,664,129
White	9,734,422	9,730,868	9,715,761	9,702,670	9,702,563
Black	1,551,109	1,567,387	1,583,768	1,599,613	1,615,089
American Indian/Alaskan Native (AI/AN)	40,721	41,417	41,902	42,534	43,211
Asian/Pacific Islander (API)	250,324	263,301	276,419	290,186	303,266

All Races Population 2013-2017: 58,096,531
Distribution of Population by Race


**Hispanic/Latino Population Counts by Year¹**

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	391,677	404,361	416,855	430,059	444,657
Non-Hispanic White	9,403,518	9,389,756	9,364,574	9,340,697	9,328,343
Non-Hispanic Black	1,508,488	1,522,953	1,537,495	1,551,528	1,565,377

Hispanic/Latino Population, Census 2010: 354,674
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OHIO CANCER REGISTRY

Initial Operation: 1992
Population-based Data Available: 1996
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.3	101.4	103.3	100.8	99.0
Missing Race	1.4	0.9	1.1	1.3	1.5
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.4	3.6	4.0	2.7	2.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.5	Prostate	97.3
Oral Cavity & Pharynx	97.7	Testis	99.5
Esophagus	94.6	Bladder (incl. <i>in situ</i>)	97.7
Stomach	95.7	Kidney & Renal Pelvis	92.1
Colon & Rectum	96.1	Brain & Other CNS ¹	86.0
Liver	57.2	Thyroid	99.6
Pancreas	82.5	Hodgkin Lymphoma	98.3
Lung & Bronchus	89.3	Non-Hodgkin Lymphoma	96.4
Melanomas of the Skin	98.5	Multiple Myeloma	88.2
Female Breast (excl. <i>in situ</i>)	98.5	Leukemias	84.6
Cervix uteri	97.7	Brain & Other CNS ¹ <i>non-malig</i>	51.3
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	93.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	33,071	502.9	1.27	597.1	1.48	33,164	441.3	1.12	515.1	1.28
Oral Cavity & Pharynx	1,243	18.2	0.24	22.2	0.28	511	6.7	0.14	8.0	0.16
Lip	28	0.4	0.04	0.5	0.04	12	0.2	0.02	0.2	0.02
Tongue	431	6.2	0.14	7.6	0.17	158	2.1	0.08	2.5	0.09
Major salivary gland	99	1.6	0.07	1.8	0.08	73	1.0	0.05	1.1	0.06
Floor of mouth	60	0.8	0.05	1.1	0.06	26	0.3	0.03	0.4	0.04
Gum & other mouth	133	2.0	0.08	2.4	0.09	104	1.3	0.06	1.6	0.07
Nasopharynx	42	0.6	0.05	0.8	0.05	17	0.2	0.03	0.3	0.03
Oropharynx	67	0.9	0.05	1.2	0.07	20	0.2	0.03	0.3	0.03
Hypopharynx	68	1.0	0.05	1.2	0.07	22	0.3	0.03	0.3	0.03
Digestive System	6,491	99.1	0.57	118.2	0.66	5,332	67.9	0.43	80.0	0.50
Esophagus	625	9.3	0.17	11.2	0.20	156	1.9	0.07	2.3	0.08
Stomach	574	8.9	0.17	10.5	0.20	327	4.2	0.11	4.9	0.12
Small intestine	205	3.2	0.10	3.7	0.12	180	2.4	0.08	2.8	0.09
Colon excl. rectum	2,073	32.5	0.33	38.3	0.38	2,160	27.5	0.27	32.1	0.31
Rectum & rectosigmoid	963	14.8	0.22	17.6	0.26	679	9.1	0.16	10.7	0.19
Anus, anal canal & anorectum	91	1.4	0.07	1.6	0.08	184	2.4	0.08	2.9	0.10
Liver	661	9.3	0.17	11.6	0.20	235	2.9	0.09	3.5	0.10
Gallbladder	47	0.7	0.05	0.9	0.06	108	1.4	0.06	1.6	0.07
Pancreas	960	14.6	0.22	17.5	0.25	946	11.6	0.17	13.8	0.20
Respiratory System	5,808	88.1	0.53	105.1	0.62	4,870	61.1	0.40	72.9	0.47
Larynx	468	6.8	0.14	8.3	0.17	140	1.8	0.07	2.2	0.08
Lung & bronchus	5,262	80.0	0.51	95.3	0.59	4,687	58.7	0.39	70.0	0.46
Bones & Joints	63	1.1	0.06	1.1	0.06	51	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	241	3.9	0.12	4.4	0.13	200	2.9	0.09	3.2	0.10
Skin (excl. basal & sq.)	1,966	31.2	0.32	36.3	0.37	1,477	21.3	0.26	24.0	0.28
Melanomas of the skin	1,849	29.3	0.31	34.1	0.36	1,389	20.1	0.25	22.7	0.28
Breast (excl. <i>in situ</i>)	74	1.1	0.06	1.3	0.07	9,568	128.9	0.61	151.4	0.70
Female Genital System	-	-	-	-	-	4,046	54.0	0.39	64.2	0.46
Cervix uteri	-	-	-	-	-	481	7.9	0.17	8.4	0.17
Uterus Corpus	-	-	-	-	-	2,291	29.3	0.28	35.9	0.34
Uterus, NOS ¹	-	-	-	-	-	103	1.3	0.06	1.6	0.07
Ovary	-	-	-	-	-	798	10.6	0.17	12.5	0.20
Male Genital System	7,765	110.9	0.58	135.7	0.69	-	-	-	-	-
Prostate	7,389	104.1	0.56	128.8	0.67	-	-	-	-	-
Testis	306	5.7	0.15	5.7	0.15	-	-	-	-	-
Penis	58	0.9	0.06	1.1	0.06	-	-	-	-	-
Urinary System	4,021	62.8	0.45	73.8	0.52	1,755	22.6	0.25	26.5	0.29
Bladder (incl. <i>in situ</i>)	2,415	38.3	0.36	44.8	0.41	766	9.4	0.16	11.1	0.18
Kidney & renal pelvis	1,520	23.1	0.27	27.4	0.32	942	12.6	0.19	14.7	0.22
Ureter	55	0.9	0.05	1.0	0.06	33	0.4	0.03	0.5	0.04
Eye & Orbit	76	1.2	0.06	1.4	0.07	65	0.9	0.05	1.0	0.06
Brain & Other CNS ¹	520	8.4	0.17	9.3	0.18	412	6.0	0.14	6.5	0.15
Brain	492	7.9	0.16	8.8	0.18	384	5.5	0.13	6.1	0.14
Endocrine System	505	8.2	0.17	9.1	0.18	1,461	23.6	0.29	25.4	0.30
Thyroid gland	455	7.4	0.16	8.3	0.17	1,416	22.9	0.28	24.7	0.30
Lymphomas	1,670	26.6	0.30	30.6	0.34	1,349	18.1	0.23	20.7	0.26
Hodgkin Lymphoma	184	3.2	0.11	3.3	0.11	145	2.4	0.09	2.5	0.09
Non-Hodgkin Lymphoma	1,487	23.5	0.28	27.2	0.32	1,204	15.7	0.21	18.2	0.24
Multiple Myeloma	500	7.7	0.16	9.2	0.18	386	4.9	0.11	5.8	0.13
Leukemias	982	15.9	0.23	18.0	0.26	705	9.5	0.17	10.6	0.18
Acute lymphocytic	94	1.7	0.08	1.6	0.07	76	1.3	0.07	1.2	0.06
Chronic lymphocytic	324	5.0	0.13	6.0	0.15	199	2.4	0.08	2.9	0.09
Acute myeloid	309	5.0	0.13	5.7	0.15	252	3.4	0.10	3.8	0.11
Chronic myeloid	128	2.1	0.09	2.4	0.09	88	1.2	0.06	1.4	0.07
Other leukemias	127	2.1	0.09	2.4	0.10	90	1.1	0.06	1.3	0.06
Mesothelioma	112	1.9	0.08	2.1	0.09	33	0.4	0.03	0.5	0.04
Kaposi Sarcoma	20	0.4	0.04	0.4	0.04	3	0.0	0.01	0.0	0.01
Ill-defined & Unknown	1,011	16.2	0.23	18.9	0.27	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	467	7.6	0.16	8.5	0.18	905	12.8	0.20	14.4	0.22
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.02	2,085	28.5	0.29	33.9	0.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	28,779	494.1	1.34	585.3	1.55	29,064	443.5	1.21	516.9	1.38
Oral Cavity & Pharynx	1,133	18.7	0.26	22.9	0.31	456	6.8	0.15	8.1	0.17
Lip	27	0.5	0.04	0.6	0.05	11	0.2	0.02	0.2	0.03
Tongue	403	6.6	0.15	8.1	0.18	147	2.2	0.08	2.6	0.10
Major salivary gland	89	1.6	0.08	1.9	0.09	61	0.9	0.06	1.1	0.06
Floor of mouth	54	0.9	0.05	1.1	0.07	24	0.4	0.03	0.4	0.04
Gum & other mouth	119	2.0	0.09	2.5	0.10	95	1.4	0.07	1.6	0.08
Nasopharynx	33	0.6	0.04	0.7	0.05	14	0.2	0.03	0.3	0.03
Oropharynx	61	1.0	0.06	1.2	0.07	17	0.2	0.03	0.3	0.03
Hypopharynx	58	0.9	0.06	1.2	0.07	17	0.3	0.03	0.3	0.03
Digestive System	5,599	96.5	0.59	114.8	0.69	4,580	66.3	0.45	77.9	0.52
Esophagus	584	9.8	0.19	11.8	0.22	135	1.9	0.07	2.2	0.09
Stomach	476	8.3	0.17	9.8	0.20	254	3.7	0.11	4.3	0.12
Small intestine	171	3.0	0.10	3.5	0.12	148	2.2	0.09	2.6	0.10
Colon excl. rectum	1,796	31.8	0.34	37.3	0.40	1,883	27.2	0.29	31.6	0.33
Rectum & rectosigmoid	844	14.7	0.23	17.4	0.27	587	9.0	0.17	10.6	0.20
Anus, anal canal & anorectum	76	1.3	0.07	1.6	0.08	168	2.5	0.09	3.1	0.11
Liver	512	8.2	0.17	10.2	0.20	186	2.7	0.09	3.2	0.10
Gallbladder	39	0.7	0.05	0.8	0.06	88	1.3	0.06	1.5	0.07
Pancreas	844	14.4	0.23	17.2	0.27	813	11.3	0.18	13.4	0.21
Respiratory System	5,149	87.6	0.56	104.3	0.65	4,300	61.3	0.43	73.1	0.50
Larynx	408	6.7	0.15	8.2	0.18	121	1.8	0.08	2.2	0.09
Lung & bronchus	4,674	79.6	0.53	94.7	0.62	4,142	59.0	0.42	70.2	0.49
Bones & Joints	55	1.1	0.07	1.1	0.07	45	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	210	3.9	0.12	4.4	0.14	167	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	1,796	32.2	0.35	37.3	0.40	1,311	21.9	0.29	24.7	0.31
Melanomas of the skin	1,692	30.3	0.34	35.1	0.38	1,236	20.8	0.28	23.4	0.30
Breast (excl. <i>in situ</i>)	64	1.1	0.06	1.3	0.07	8,365	129.2	0.66	151.8	0.75
Female Genital System	-	-	-	-	-	3,594	55.3	0.43	65.7	0.50
Cervix uteri	-	-	-	-	-	407	7.9	0.18	8.4	0.19
Uterus Corpus	-	-	-	-	-	2,046	30.1	0.31	36.9	0.37
Uterus, NOS ¹	-	-	-	-	-	89	1.3	0.06	1.6	0.08
Ovary	-	-	-	-	-	719	11.0	0.19	12.9	0.22
Male Genital System	6,335	102.3	0.59	124.6	0.70	-	-	-	-	-
Prostate	5,987	94.7	0.56	116.9	0.68	-	-	-	-	-
Testis	286	6.4	0.17	6.4	0.17	-	-	-	-	-
Penis	52	0.9	0.06	1.1	0.07	-	-	-	-	-
Urinary System	3,654	64.0	0.49	75.2	0.56	1,558	22.9	0.27	26.7	0.31
Bladder (incl. <i>in situ</i>)	2,248	39.7	0.38	46.5	0.44	694	9.7	0.17	11.4	0.20
Kidney & renal pelvis	1,327	22.9	0.29	27.1	0.33	823	12.6	0.21	14.7	0.23
Ureter	53	1.0	0.06	1.1	0.07	30	0.4	0.03	0.5	0.04
Eye & Orbit	73	1.3	0.07	1.5	0.08	61	1.0	0.06	1.1	0.07
Brain & Other CNS ¹	468	8.7	0.19	9.6	0.20	370	6.3	0.15	6.8	0.16
Brain	444	8.2	0.18	9.1	0.20	347	5.8	0.15	6.4	0.16
Endocrine System	451	8.5	0.19	9.4	0.20	1,278	24.6	0.32	26.4	0.33
Thyroid gland	412	7.7	0.18	8.6	0.19	1,243	23.9	0.32	25.7	0.33
Lymphomas	1,503	27.1	0.32	31.1	0.36	1,207	18.5	0.25	21.2	0.28
Hodgkin Lymphoma	157	3.2	0.12	3.4	0.12	122	2.4	0.10	2.5	0.10
Non-Hodgkin Lymphoma	1,345	23.9	0.30	27.8	0.34	1,085	16.1	0.23	18.7	0.26
Multiple Myeloma	395	6.8	0.16	8.1	0.18	295	4.2	0.11	5.0	0.13
Leukemias	872	16.0	0.25	18.1	0.28	615	9.6	0.18	10.7	0.20
Acute lymphocytic	84	1.8	0.09	1.7	0.08	67	1.4	0.08	1.3	0.07
Chronic lymphocytic	282	4.8	0.13	5.8	0.16	171	2.3	0.08	2.8	0.10
Acute myeloid	279	5.1	0.14	5.8	0.16	221	3.4	0.11	3.8	0.12
Chronic myeloid	113	2.1	0.09	2.4	0.10	75	1.2	0.07	1.4	0.07
Other leukemias	114	2.1	0.09	2.4	0.10	82	1.2	0.06	1.3	0.07
Mesothelioma	106	1.9	0.09	2.2	0.10	31	0.4	0.04	0.5	0.04
Kaposi Sarcoma	11	0.2	0.03	0.3	0.03	2	0.0	0.01	0.0	0.01
Ill-defined & Unknown	904	16.3	0.25	18.9	0.28	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	406	7.6	0.17	8.5	0.19	772	12.6	0.21	14.2	0.23
Breast (<i>in situ</i>)	5	0.1	0.02	0.1	0.02	1,780	28.2	0.31	33.4	0.36

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,303	513.7	4.20	623.2	4.96	3,351	409.5	3.23	483.9	3.75
Oral Cavity & Pharynx	89	13.1	0.65	15.9	0.77	43	5.2	0.36	6.2	0.42
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	3.3	0.32	4.1	0.39	8	1.0	0.15	1.2	0.19
Major salivary gland	8	1.3	0.22	1.5	0.24	10	1.2	0.18	1.3	0.20
Floor of mouth	4	0.6	0.13	0.7	0.16	2	0.2	0.07	0.3	0.09
Gum & other mouth	10	1.5	0.22	1.9	0.26	7	0.9	0.15	1.0	0.17
Nasopharynx	6	0.9	0.17	0.9	0.18	2	0.2	0.06	0.2	0.07
Oropharynx	6	0.9	0.17	1.1	0.21	3	0.3	0.09	0.4	0.11
Hypopharynx	10	1.6	0.24	2.0	0.28	4	0.4	0.11	0.5	0.12
Digestive System	714	112.3	1.97	136.4	2.34	636	77.3	1.40	92.2	1.64
Esophagus	34	5.1	0.41	6.3	0.49	19	2.2	0.24	2.7	0.28
Stomach	81	13.9	0.72	16.3	0.83	60	7.6	0.45	8.8	0.51
Small intestine	30	4.7	0.40	5.5	0.46	29	3.5	0.30	4.2	0.35
Colon excl. rectum	205	32.8	1.08	39.5	1.27	228	27.7	0.83	33.1	0.98
Rectum & rectosigmoid	86	13.3	0.67	16.2	0.80	71	8.7	0.47	10.3	0.55
Anus, anal canal & anorectum	14	2.0	0.25	2.4	0.29	15	1.8	0.21	2.2	0.25
Liver	126	17.3	0.72	22.5	0.91	43	4.7	0.33	6.0	0.41
Gallbladder	7	1.2	0.22	1.4	0.25	18	2.1	0.23	2.5	0.27
Pancreas	102	16.8	0.78	20.1	0.91	120	14.6	0.61	17.4	0.71
Respiratory System	603	98.9	1.89	118.9	2.21	524	63.1	1.26	76.4	1.49
Larynx	55	8.6	0.55	10.5	0.65	18	2.1	0.23	2.6	0.28
Lung & bronchus	540	89.0	1.80	107.0	2.10	501	60.3	1.23	73.0	1.46
Bones & Joints	6	0.8	0.15	0.9	0.17	5	0.5	0.12	0.6	0.12
Soft Tissue (incl. heart)	26	4.0	0.36	4.3	0.39	27	3.3	0.29	3.6	0.32
Skin (excl. basal & sq.)	10	1.5	0.23	1.8	0.26	12	1.5	0.20	1.7	0.22
Melanomas of the skin	4	0.6	0.15	0.8	0.18	5	0.6	0.13	0.7	0.14
Breast (excl. <i>in situ</i>)	8	1.4	0.22	1.6	0.25	1,035	127.5	1.81	150.5	2.10
Female Genital System	-	-	-	-	-	373	45.1	1.07	53.6	1.25
Cervix uteri	-	-	-	-	-	61	7.9	0.46	8.6	0.50
Uterus Corpus	-	-	-	-	-	205	24.1	0.77	29.5	0.92
Uterus, NOS ¹	-	-	-	-	-	12	1.5	0.20	1.8	0.23
Ovary	-	-	-	-	-	62	7.6	0.44	8.9	0.51
Male Genital System	1,080	158.5	2.26	199.2	2.75	-	-	-	-	-
Prostate	1,065	156.0	2.24	196.5	2.73	-	-	-	-	-
Testis	10	1.5	0.21	1.4	0.21	-	-	-	-	-
Penis	5	0.9	0.20	1.1	0.23	-	-	-	-	-
Urinary System	296	48.2	1.31	57.3	1.53	169	20.6	0.73	24.3	0.84
Bladder (incl. <i>in situ</i>)	118	20.8	0.90	24.6	1.04	57	6.9	0.42	8.2	0.49
Kidney & renal pelvis	174	26.7	0.94	31.8	1.10	108	13.3	0.59	15.5	0.67
Ureter	2	0.3	0.10	0.4	0.12	2	0.3	0.07	0.3	0.10
Eye & Orbit	2	0.2	0.07	0.2	0.08	3	0.3	0.09	0.3	0.09
Brain & Other CNS ¹	39	5.4	0.40	6.0	0.45	32	4.0	0.32	4.2	0.34
Brain	36	5.0	0.39	5.6	0.44	29	3.6	0.30	3.8	0.32
Endocrine System	39	5.8	0.43	6.7	0.49	137	17.6	0.69	19.5	0.75
Thyroid gland	31	4.5	0.38	5.3	0.44	129	16.5	0.67	18.5	0.73
Lymphomas	127	19.9	0.83	22.7	0.93	110	13.5	0.59	15.7	0.67
Hodgkin Lymphoma	21	3.0	0.30	3.1	0.31	19	2.4	0.25	2.5	0.26
Non-Hodgkin Lymphoma	106	17.0	0.77	19.6	0.88	91	11.1	0.53	13.1	0.62
Multiple Myeloma	92	15.2	0.74	18.1	0.86	83	10.3	0.51	12.2	0.60
Leukemias	71	11.4	0.64	13.0	0.72	64	7.8	0.44	8.9	0.50
Acute lymphocytic	7	0.8	0.15	0.8	0.14	6	0.7	0.13	0.7	0.13
Chronic lymphocytic	24	4.2	0.40	4.9	0.46	16	1.9	0.22	2.4	0.26
Acute myeloid	21	3.4	0.34	3.9	0.39	25	3.2	0.29	3.6	0.32
Chronic myeloid	10	1.7	0.25	1.8	0.27	9	1.1	0.17	1.3	0.19
Other leukemias	8	1.3	0.22	1.6	0.25	7	0.9	0.15	1.0	0.17
Mesothelioma	5	1.1	0.22	1.3	0.25	2	0.3	0.08	0.3	0.09
Kaposi Sarcoma	6	0.9	0.17	0.9	0.17	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	94	11.5	0.54	13.6	0.63
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	45	7.0	0.49	7.9	0.55	110	13.7	0.60	15.6	0.67
Breast (<i>in situ</i>)	-	-	-	-	-	258	31.4	0.89	37.6	1.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	209	230.3	7.67	270.8	8.99	278	235.7	6.62	273.6	7.67
Oral Cavity & Pharynx	9	9.3	1.46	10.8	1.71	6	4.7	0.90	5.3	1.03
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	2.6	0.74	3.0	0.85	2	1.9	0.60	2.2	0.67
Major salivary gland	2	1.5	0.55	1.6	0.60	1	1.0	0.40	1.1	0.46
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	2.1	0.76	2.6	0.93	-	-	-	-	-
Nasopharynx	2	1.8	0.59	2.0	0.67	1	0.9	0.36	0.9	0.39
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	60	63.9	3.96	77.0	4.73	44	41.0	2.89	48.7	3.40
Esophagus	3	3.9	1.14	4.7	1.37	1	1.2	0.50	1.4	0.60
Stomach	9	10.0	1.60	11.8	1.85	6	5.4	1.01	6.5	1.19
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	14	15.4	2.01	18.7	2.41	14	12.8	1.60	15.1	1.87
Rectum & rectosigmoid	11	10.8	1.60	12.9	1.92	5	4.6	0.92	5.6	1.12
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	12	11.4	1.55	13.9	1.87	3	3.1	0.80	3.9	0.98
Gallbladder	-	-	-	-	-	2	1.7	0.58	2.0	0.69
Pancreas	7	7.6	1.34	9.2	1.59	7	7.0	1.27	8.1	1.45
Respiratory System	30	38.0	3.37	45.0	3.96	30	30.1	2.59	35.0	2.96
Larynx	2	2.6	0.89	3.1	1.05	-	-	-	-	-
Lung & bronchus	26	33.6	3.16	40.0	3.72	29	29.2	2.55	34.0	2.91
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	2.0	0.61	2.4	0.74	3	2.1	0.61	2.1	0.63
Skin (excl. basal & sq.)	2	1.5	0.55	1.8	0.66	2	1.9	0.59	2.2	0.71
Melanomas of the skin	-	-	-	-	-	1	1.1	0.45	1.4	0.56
Breast (excl. <i>in situ</i>)	-	-	-	-	-	96	77.2	3.64	89.8	4.24
Female Genital System	-	-	-	-	-	38	29.6	2.21	36.0	2.69
Cervix uteri	-	-	-	-	-	4	3.3	0.74	4.1	0.91
Uterus Corpus	-	-	-	-	-	19	14.9	1.53	18.3	1.89
Uterus, NOS ¹	-	-	-	-	-	1	1.3	0.52	1.6	0.61
Ovary	-	-	-	-	-	10	8.1	1.16	9.5	1.37
Male Genital System	44	48.5	3.41	57.8	4.01	-	-	-	-	-
Prostate	41	45.4	3.32	54.6	3.92	-	-	-	-	-
Testis	3	1.7	0.47	1.7	0.48	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	17	21.9	2.58	25.4	2.99	7	6.1	1.12	7.3	1.32
Bladder (incl. <i>in situ</i>)	9	13.3	2.08	15.1	2.37	3	3.4	0.88	3.9	1.01
Kidney & renal pelvis	7	7.7	1.41	9.2	1.69	3	2.3	0.61	2.9	0.76
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	4	3.5	0.89	3.6	0.97	2	2.0	0.62	1.9	0.62
Brain	4	3.3	0.86	3.4	0.93	2	1.8	0.59	1.7	0.60
Endocrine System	7	6.4	1.09	7.2	1.27	25	18.1	1.67	19.6	1.84
Thyroid gland	7	5.6	1.02	6.4	1.19	24	17.8	1.66	19.2	1.82
Lymphomas	11	11.6	1.66	13.1	1.87	11	10.1	1.42	11.7	1.65
Hodgkin Lymphoma	1	0.9	0.37	0.9	0.36	1	0.7	0.28	0.7	0.28
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	4	5.1	1.24	5.9	1.43	1	1.6	0.63	1.8	0.67
Leukemias	11	9.7	1.42	10.8	1.64	7	5.3	0.96	5.5	1.02
Acute lymphocytic	2	1.5	0.47	1.3	0.39	2	1.1	0.40	1.0	0.36
Chronic lymphocytic	2	1.5	0.56	2.0	0.71	-	-	-	-	-
Acute myeloid	4	3.5	0.78	3.9	0.89	3	2.2	0.56	2.3	0.60
Chronic myeloid	2	2.0	0.71	2.3	0.83	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	6	7.3	1.47	8.4	1.70	5	5.0	1.06	5.8	1.22
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	7	6.7	1.25	7.9	1.51	11	9.0	1.25	9.9	1.40
Breast (<i>in situ</i>)	-	-	-	-	-	30	24.0	1.99	28.1	2.33

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	326	305.2	8.38	361.8	9.72	325	255.3	6.64	298.3	7.76
Oral Cavity & Pharynx	8	6.4	1.13	8.2	1.39	4	2.8	0.67	3.4	0.80
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.7	0.58	2.1	0.72	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	84	79.1	4.24	94.9	4.96	57	48.0	2.96	56.7	3.46
Esophagus	6	5.8	1.17	6.9	1.36	-	-	-	-	-
Stomach	8	8.5	1.45	9.7	1.63	8	6.1	1.02	7.2	1.20
Small intestine	2	1.6	0.45	1.9	0.58	2	1.7	0.58	1.8	0.63
Colon excl. rectum	22	21.5	2.27	25.4	2.63	19	15.6	1.68	18.5	1.98
Rectum & rectosigmoid	13	11.6	1.58	14.0	1.87	8	6.6	1.07	7.6	1.23
Anus, anal canal & anorectum	1	1.2	0.54	1.4	0.60	2	1.4	0.50	1.7	0.57
Liver	18	14.7	1.68	18.8	2.09	4	3.4	0.76	4.3	0.96
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	9	8.7	1.42	10.5	1.66	10	8.7	1.30	10.4	1.53
Respiratory System	38	41.9	3.29	49.5	3.78	28	25.3	2.21	30.1	2.58
Larynx	4	3.4	0.89	4.3	1.06	-	-	-	-	-
Lung & bronchus	33	37.6	3.15	44.2	3.60	27	24.6	2.18	29.2	2.54
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	1.6	0.52	1.9	0.62	3	2.2	0.58	2.4	0.68
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	5	4.9	1.03	5.7	1.17	5	4.5	0.92	5.2	1.07
Breast (excl. <i>in situ</i>)	1	1.1	0.48	1.3	0.58	84	65.9	3.33	76.7	3.88
Female Genital System	-	-	-	-	-	50	38.2	2.50	45.5	2.98
Cervix uteri	-	-	-	-	-	9	6.4	0.97	7.3	1.14
Uterus Corpus	-	-	-	-	-	25	19.6	1.79	23.6	2.16
Uterus, NOS ¹	-	-	-	-	-	1	1.1	0.42	1.3	0.52
Ovary	-	-	-	-	-	10	7.7	1.13	9.0	1.33
Male Genital System	81	77.4	4.21	93.2	4.89	-	-	-	-	-
Prostate	73	72.8	4.13	88.2	4.81	-	-	-	-	-
Testis	6	2.8	0.52	2.9	0.56	-	-	-	-	-
Penis	2	1.8	0.64	2.0	0.71	-	-	-	-	-
Urinary System	37	35.2	2.85	41.6	3.30	17	13.4	1.53	16.0	1.82
Bladder (incl. <i>in situ</i>)	16	18.1	2.19	21.4	2.52	5	4.5	0.95	5.3	1.10
Kidney & renal pelvis	21	16.6	1.78	19.6	2.08	12	8.6	1.17	10.4	1.42
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	0.9	0.49	0.9	0.53	-	-	-	-	-
Brain & Other CNS ¹	8	5.2	1.01	5.9	1.14	6	3.6	0.70	4.1	0.83
Brain	7	4.9	1.00	5.6	1.12	6	3.5	0.69	4.0	0.82
Endocrine System	6	4.1	0.85	4.3	0.92	25	15.7	1.46	16.9	1.62
Thyroid gland	6	3.6	0.76	3.8	0.84	24	15.6	1.46	16.8	1.62
Lymphomas	23	19.6	2.05	22.7	2.37	16	12.9	1.53	15.0	1.77
Hodgkin Lymphoma	4	2.4	0.60	2.6	0.66	2	1.5	0.48	1.7	0.57
Non-Hodgkin Lymphoma	19	17.2	1.96	20.1	2.28	14	11.5	1.45	13.3	1.67
Multiple Myeloma	4	5.0	1.15	5.8	1.30	6	4.4	0.86	5.4	1.04
Leukemias	15	11.3	1.55	12.5	1.75	8	5.9	1.02	6.3	1.12
Acute lymphocytic	4	1.7	0.49	1.5	0.49	-	-	-	-	-
Chronic lymphocytic	2	2.1	0.76	2.3	0.80	1	1.3	0.51	1.6	0.59
Acute myeloid	6	5.2	1.10	6.0	1.28	1	0.8	0.36	0.9	0.40
Chronic myeloid	1	0.8	0.36	0.9	0.41	2	1.5	0.54	1.6	0.57
Other leukemias	2	1.5	0.50	1.8	0.61	-	-	-	-	-
Mesothelioma	1	1.7	0.71	1.9	0.80	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	9	9.1	1.51	10.8	1.76	12	10.2	1.41	11.9	1.63
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	5.7	1.08	6.2	1.21	11	7.3	1.06	8.4	1.23
Breast (<i>in situ</i>)	-	-	-	-	-	19	14.0	1.49	16.7	1.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

OHIO

II-398 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	28,539	498.5	1.36	590.3	1.57	28,819	447.9	1.23	521.9	1.40
Oral Cavity & Pharynx	1,127	19.0	0.26	23.2	0.31	453	6.9	0.15	8.2	0.18
Lip	27	0.5	0.04	0.6	0.05	11	0.2	0.02	0.2	0.03
Tongue	401	6.7	0.15	8.2	0.18	146	2.2	0.09	2.7	0.10
Major salivary gland	89	1.6	0.08	1.9	0.09	60	1.0	0.06	1.1	0.06
Floor of mouth	54	0.9	0.05	1.1	0.07	24	0.4	0.04	0.4	0.04
Gum & other mouth	119	2.1	0.09	2.5	0.10	95	1.4	0.07	1.7	0.08
Nasopharynx	33	0.6	0.05	0.7	0.05	14	0.2	0.03	0.3	0.03
Oropharynx	60	1.0	0.06	1.2	0.07	17	0.2	0.03	0.3	0.03
Hypopharynx	57	0.9	0.06	1.2	0.07	17	0.3	0.03	0.3	0.04
Digestive System	5,537	97.1	0.60	115.4	0.70	4,536	66.7	0.46	78.3	0.53
Esophagus	580	9.9	0.19	11.9	0.22	135	1.9	0.08	2.3	0.09
Stomach	471	8.3	0.18	9.8	0.20	249	3.7	0.11	4.3	0.12
Small intestine	169	3.0	0.11	3.5	0.12	147	2.3	0.09	2.7	0.10
Colon excl. rectum	1,780	32.0	0.35	37.6	0.40	1,868	27.4	0.29	31.8	0.34
Rectum & rectosigmoid	834	14.8	0.24	17.6	0.27	581	9.1	0.18	10.7	0.20
Anus, anal canal & anorectum	75	1.3	0.07	1.6	0.08	166	2.5	0.09	3.1	0.11
Liver	500	8.1	0.17	10.1	0.20	183	2.7	0.09	3.2	0.11
Gallbladder	39	0.7	0.05	0.8	0.06	87	1.3	0.06	1.5	0.07
Pancreas	836	14.5	0.23	17.3	0.27	805	11.4	0.18	13.5	0.22
Respiratory System	5,119	88.3	0.57	105.3	0.66	4,276	61.9	0.43	73.7	0.51
Larynx	405	6.8	0.15	8.3	0.19	121	1.8	0.08	2.2	0.09
Lung & bronchus	4,647	80.3	0.54	95.6	0.63	4,118	59.5	0.42	70.9	0.50
Bones & Joints	55	1.1	0.07	1.2	0.07	44	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	208	4.0	0.13	4.4	0.14	164	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	1,791	32.7	0.36	37.9	0.40	1,307	22.4	0.29	25.2	0.32
Melanomas of the skin	1,688	30.7	0.34	35.7	0.39	1,232	21.3	0.29	23.9	0.31
Breast (excl. <i>in situ</i>)	63	1.1	0.06	1.3	0.07	8,304	130.6	0.67	153.4	0.77
Female Genital System	-	-	-	-	-	3,556	55.7	0.44	66.2	0.50
Cervix uteri	-	-	-	-	-	399	8.0	0.19	8.5	0.19
Uterus Corpus	-	-	-	-	-	2,027	30.3	0.31	37.2	0.37
Uterus, NOS ¹	-	-	-	-	-	88	1.3	0.07	1.6	0.08
Ovary	-	-	-	-	-	712	11.0	0.19	13.0	0.22
Male Genital System	6,279	103.0	0.60	125.5	0.71	-	-	-	-	-
Prostate	5,935	95.3	0.57	117.6	0.69	-	-	-	-	-
Testis	283	6.6	0.18	6.6	0.18	-	-	-	-	-
Penis	50	0.9	0.06	1.1	0.07	-	-	-	-	-
Urinary System	3,624	64.5	0.49	75.8	0.57	1,546	23.1	0.27	27.0	0.31
Bladder (incl. <i>in situ</i>)	2,234	40.0	0.39	46.9	0.45	690	9.8	0.17	11.5	0.20
Kidney & renal pelvis	1,310	23.0	0.29	27.2	0.34	815	12.7	0.21	14.8	0.24
Ureter	52	1.0	0.06	1.1	0.07	30	0.4	0.03	0.5	0.04
Eye & Orbit	72	1.3	0.07	1.5	0.08	60	1.0	0.06	1.1	0.07
Brain & Other CNS ¹	464	8.9	0.19	9.8	0.20	367	6.4	0.16	6.9	0.16
Brain	440	8.3	0.18	9.3	0.20	343	5.9	0.15	6.5	0.16
Endocrine System	447	8.6	0.19	9.6	0.20	1,259	24.9	0.33	26.7	0.34
Thyroid gland	407	7.8	0.18	8.8	0.20	1,224	24.2	0.32	26.0	0.34
Lymphomas	1,487	27.3	0.33	31.4	0.37	1,195	18.7	0.25	21.4	0.28
Hodgkin Lymphoma	155	3.3	0.12	3.4	0.12	120	2.5	0.11	2.6	0.11
Non-Hodgkin Lymphoma	1,332	24.1	0.30	28.0	0.35	1,074	16.2	0.23	18.8	0.26
Multiple Myeloma	393	6.9	0.16	8.2	0.19	290	4.2	0.11	4.9	0.13
Leukemias	860	16.1	0.25	18.2	0.28	609	9.7	0.18	10.8	0.20
Acute lymphocytic	80	1.8	0.09	1.7	0.09	64	1.4	0.08	1.3	0.07
Chronic lymphocytic	280	4.9	0.13	5.9	0.16	170	2.4	0.08	2.8	0.10
Acute myeloid	275	5.1	0.14	5.8	0.16	220	3.5	0.11	3.9	0.12
Chronic myeloid	112	2.1	0.09	2.4	0.10	74	1.2	0.07	1.4	0.07
Other leukemias	113	2.2	0.09	2.5	0.10	81	1.2	0.06	1.4	0.07
Mesothelioma	105	2.0	0.09	2.2	0.10	30	0.4	0.04	0.5	0.04
Kaposi Sarcoma	11	0.2	0.03	0.3	0.03	2	0.0	0.01	0.0	0.01
Ill-defined & Unknown	897	16.4	0.25	19.1	0.29	821	11.6	0.19	13.5	0.21
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	401	7.7	0.18	8.6	0.19	765	12.8	0.22	14.3	0.24
Breast (<i>in situ</i>)	5	0.1	0.02	0.1	0.02	1,768	28.5	0.32	33.8	0.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ohio, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,294	518.7	4.24	629.2	5.01	3,342	414.1	3.27	489.1	3.80
Oral Cavity & Pharynx	88	13.2	0.66	16.1	0.78	43	5.2	0.36	6.2	0.43
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	3.4	0.33	4.2	0.39	8	1.0	0.16	1.2	0.19
Major salivary gland	8	1.3	0.22	1.5	0.25	10	1.2	0.18	1.4	0.20
Floor of mouth	4	0.6	0.14	0.8	0.17	2	0.2	0.07	0.3	0.09
Gum & other mouth	10	1.5	0.22	1.9	0.26	7	0.9	0.15	1.1	0.18
Nasopharynx	6	0.9	0.17	0.9	0.18	1	0.2	0.06	0.2	0.07
Oropharynx	6	0.9	0.17	1.1	0.21	3	0.4	0.10	0.4	0.11
Hypopharynx	10	1.6	0.24	2.0	0.29	4	0.5	0.11	0.5	0.13
Digestive System	713	113.3	1.99	137.7	2.36	634	78.1	1.41	93.1	1.66
Esophagus	33	5.1	0.42	6.3	0.50	19	2.3	0.24	2.8	0.29
Stomach	81	13.9	0.73	16.4	0.84	60	7.7	0.45	8.8	0.51
Small intestine	30	4.7	0.40	5.6	0.47	28	3.6	0.31	4.2	0.35
Colon excl. rectum	205	33.2	1.09	40.0	1.28	228	28.0	0.84	33.5	0.99
Rectum & rectosigmoid	86	13.5	0.68	16.4	0.81	70	8.8	0.48	10.4	0.55
Anus, anal canal & anorectum	14	2.0	0.25	2.4	0.29	15	1.8	0.21	2.2	0.26
Liver	126	17.5	0.73	22.7	0.92	43	4.8	0.33	6.1	0.42
Gallbladder	7	1.2	0.22	1.4	0.25	17	2.1	0.23	2.6	0.27
Pancreas	102	16.9	0.79	20.3	0.92	120	14.8	0.62	17.6	0.72
Respiratory System	602	99.8	1.91	120.0	2.24	523	63.6	1.27	77.1	1.51
Larynx	54	8.7	0.55	10.6	0.65	18	2.1	0.23	2.6	0.28
Lung & bronchus	539	89.8	1.82	107.9	2.13	500	60.9	1.24	73.7	1.48
Bones & Joints	6	0.8	0.15	0.9	0.17	5	0.6	0.12	0.6	0.12
Soft Tissue (incl. heart)	26	4.1	0.37	4.4	0.40	27	3.4	0.30	3.7	0.32
Skin (excl. basal & sq.)	10	1.6	0.23	1.8	0.26	12	1.5	0.20	1.7	0.22
Melanomas of the skin	4	0.6	0.15	0.8	0.18	5	0.7	0.13	0.8	0.15
Breast (excl. <i>in situ</i>)	8	1.4	0.22	1.6	0.25	1,032	129.0	1.84	152.2	2.12
Female Genital System	-	-	-	-	-	372	45.6	1.08	54.2	1.26
Cervix uteri	-	-	-	-	-	61	8.0	0.47	8.8	0.51
Uterus Corpus	-	-	-	-	-	205	24.4	0.78	29.9	0.94
Uterus, NOS ¹	-	-	-	-	-	12	1.5	0.20	1.7	0.23
Ovary	-	-	-	-	-	62	7.7	0.45	9.0	0.51
Male Genital System	1,077	159.8	2.28	200.9	2.78	-	-	-	-	-
Prostate	1,062	157.4	2.26	198.3	2.76	-	-	-	-	-
Testis	9	1.4	0.21	1.4	0.21	-	-	-	-	-
Penis	5	0.9	0.20	1.1	0.23	-	-	-	-	-
Urinary System	296	48.8	1.33	58.0	1.54	168	20.9	0.73	24.6	0.85
Bladder (incl. <i>in situ</i>)	118	21.0	0.91	24.8	1.05	57	6.9	0.42	8.3	0.49
Kidney & renal pelvis	174	27.0	0.96	32.2	1.11	108	13.5	0.59	15.7	0.68
Ureter	2	0.3	0.10	0.4	0.12	2	0.3	0.07	0.3	0.10
Eye & Orbit	2	0.2	0.07	0.2	0.08	3	0.4	0.10	0.3	0.09
Brain & Other CNS ¹	38	5.5	0.41	6.0	0.46	32	4.0	0.32	4.3	0.34
Brain	36	5.1	0.39	5.6	0.44	29	3.6	0.31	3.8	0.33
Endocrine System	39	5.8	0.43	6.8	0.50	137	17.9	0.70	19.9	0.76
Thyroid gland	31	4.6	0.38	5.4	0.44	129	16.8	0.68	18.8	0.74
Lymphomas	127	20.2	0.84	22.9	0.94	110	13.7	0.59	15.9	0.68
Hodgkin Lymphoma	21	3.0	0.30	3.2	0.32	19	2.4	0.25	2.6	0.27
Non-Hodgkin Lymphoma	106	17.2	0.78	19.7	0.89	91	11.2	0.54	13.3	0.63
Multiple Myeloma	92	15.4	0.75	18.3	0.87	83	10.4	0.52	12.3	0.61
Leukemias	71	11.6	0.65	13.2	0.73	64	7.9	0.45	9.1	0.51
Acute lymphocytic	7	0.9	0.15	0.8	0.15	6	0.7	0.14	0.7	0.13
Chronic lymphocytic	24	4.2	0.40	5.0	0.47	16	1.9	0.22	2.4	0.26
Acute myeloid	21	3.4	0.35	4.0	0.40	25	3.2	0.29	3.6	0.32
Chronic myeloid	10	1.7	0.25	1.9	0.27	9	1.1	0.17	1.3	0.20
Other leukemias	8	1.4	0.22	1.6	0.25	7	0.9	0.15	1.0	0.17
Mesothelioma	5	1.1	0.23	1.3	0.25	2	0.3	0.08	0.3	0.10
Kaposi Sarcoma	6	1.0	0.18	1.0	0.18	-	-	-	-	-
Ill-defined & Unknown	88	15.2	0.77	18.1	0.89	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	45	7.1	0.49	8.0	0.55	109	13.8	0.61	15.8	0.68
Breast (<i>in situ</i>)	-	-	-	-	-	257	31.7	0.91	38.0	1.06

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	3,853,205	3,878,367	3,909,831	3,926,769	3,932,640
White	3,021,238	3,032,869	3,047,980	3,054,560	3,053,544
Black	335,045	339,287	344,739	348,054	350,613
American Indian/Alaskan Native (AI/AN)	404,229	409,194	414,445	418,879	421,435
Asian/Pacific Islander (API)	92,693	97,017	102,667	105,276	107,048


All Races Population 2013-2017: 19,500,812
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	371,162	383,293	396,412	409,485	419,270
Non-Hispanic White	2,709,984	2,711,944	2,716,682	2,712,738	2,703,541
Non-Hispanic Black	319,253	323,110	328,007	330,734	332,812

Hispanic/Latino Population, Census 2010: 332,007
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OKLAHOMA CANCER REGISTRY

Initial Operation: 1997
 Population-based Data Available: 1997
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	95.3	100.9	97.5	95.2	91.2
Missing Race	0.5	0.7	1.1	0.7	1.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.3	3.4	2.7	2.4	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.7	Prostate	96.2
Oral Cavity & Pharynx	96.3	Testis	97.8
Esophagus	93.5	Bladder (incl. <i>in situ</i>)	97.4
Stomach	94.7	Kidney & Renal Pelvis	89.6
Colon & Rectum	95.4	Brain & Other CNS ¹	82.4
Liver	50.7	Thyroid	99.0
Pancreas	79.6	Hodgkin Lymphoma	98.5
Lung & Bronchus	85.5	Non-Hodgkin Lymphoma	95.9
Melanomas of the Skin	98.9	Multiple Myeloma	89.1
Female Breast (excl. <i>in situ</i>)	97.8	Leukemias	87.4
Cervix uteri	96.8	Brain & Other CNS ¹ <i>non-malig</i>	40.2
Uterus Corpus & Uterus NOS ¹	98.0	Breast <i>in situ</i>	100.0
Ovary	90.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,204	490.8	2.22	583.6	2.61	9,807	421.2	1.95	492.3	2.24
Oral Cavity & Pharynx	412	19.4	0.44	23.7	0.53	159	6.7	0.24	7.9	0.28
Lip	44	2.2	0.15	2.6	0.18	16	0.7	0.07	0.8	0.09
Tongue	124	5.8	0.24	7.1	0.28	45	1.9	0.13	2.3	0.15
Major salivary gland	43	2.2	0.15	2.6	0.18	24	1.1	0.10	1.2	0.11
Floor of mouth	14	0.6	0.08	0.8	0.10	5	0.2	0.04	0.2	0.05
Gum & other mouth	33	1.6	0.12	1.9	0.15	29	1.2	0.11	1.4	0.12
Nasopharynx	15	0.7	0.09	0.9	0.10	9	0.4	0.06	0.4	0.07
Oropharynx	20	0.9	0.09	1.1	0.11	6	0.3	0.05	0.3	0.06
Hypopharynx	17	0.7	0.08	0.9	0.10	4	0.1	0.03	0.2	0.04
Digestive System	2,009	96.4	0.98	115.6	1.16	1,570	65.5	0.76	77.4	0.88
Esophagus	164	7.6	0.27	9.3	0.33	39	1.6	0.12	1.9	0.14
Stomach	156	7.7	0.28	9.1	0.33	95	4.0	0.19	4.7	0.22
Small intestine	56	2.6	0.16	3.2	0.19	54	2.3	0.14	2.7	0.17
Colon excl. rectum	667	33.0	0.58	38.7	0.68	642	26.9	0.49	31.5	0.56
Rectum & rectosigmoid	315	15.2	0.39	18.1	0.46	215	9.2	0.29	11.0	0.34
Anus, anal canal & anorectum	30	1.4	0.12	1.7	0.14	64	2.7	0.16	3.2	0.18
Liver	267	11.8	0.33	15.0	0.41	99	4.0	0.18	4.8	0.22
Gallbladder	16	0.8	0.09	0.9	0.11	28	1.1	0.10	1.4	0.12
Pancreas	261	12.6	0.36	15.1	0.42	260	10.5	0.30	12.5	0.35
Respiratory System	1,840	87.7	0.93	104.9	1.10	1,468	59.4	0.70	71.0	0.83
Larynx	129	5.9	0.24	7.2	0.29	42	1.8	0.13	2.1	0.15
Lung & bronchus	1,683	80.5	0.90	96.1	1.06	1,413	57.1	0.69	68.3	0.82
Bones & Joints	22	1.1	0.11	1.2	0.11	19	1.0	0.10	1.0	0.10
Soft Tissue (incl. heart)	68	3.5	0.19	3.8	0.21	53	2.4	0.15	2.6	0.16
Skin (excl. basal & sq.)	633	31.8	0.58	37.1	0.67	390	17.8	0.42	20.0	0.46
Melanomas of the skin	592	29.7	0.56	34.7	0.64	361	16.5	0.40	18.6	0.44
Breast (excl. <i>in situ</i>)	24	1.2	0.11	1.4	0.13	2,827	122.7	1.06	144.6	1.23
Female Genital System	-	-	-	-	-	1,084	47.9	0.67	56.0	0.77
Cervix uteri	-	-	-	-	-	176	9.2	0.32	9.7	0.33
Uterus Corpus	-	-	-	-	-	523	22.1	0.44	26.8	0.53
Uterus, NOS ¹	-	-	-	-	-	21	0.9	0.09	1.1	0.10
Ovary	-	-	-	-	-	265	11.5	0.32	13.4	0.37
Male Genital System	2,189	100.2	0.98	122.2	1.18	-	-	-	-	-
Prostate	2,068	93.8	0.94	115.6	1.14	-	-	-	-	-
Testis	99	5.3	0.24	5.3	0.24	-	-	-	-	-
Penis	18	0.9	0.10	1.1	0.11	-	-	-	-	-
Urinary System	1,223	60.6	0.79	71.4	0.92	541	22.6	0.45	26.7	0.52
Bladder (incl. <i>in situ</i>)	674	34.0	0.60	39.9	0.69	186	7.6	0.25	9.0	0.30
Kidney & renal pelvis	528	25.5	0.51	30.2	0.59	340	14.5	0.36	17.1	0.42
Ureter	13	0.7	0.09	0.8	0.10	10	0.4	0.06	0.5	0.07
Eye & Orbit	18	0.9	0.10	1.0	0.11	13	0.6	0.07	0.7	0.08
Brain & Other CNS ¹	154	7.5	0.28	8.4	0.31	126	5.7	0.23	6.2	0.25
Brain	148	7.2	0.27	8.1	0.30	120	5.4	0.23	6.0	0.25
Endocrine System	144	7.2	0.27	8.0	0.30	403	20.0	0.46	21.6	0.49
Thyroid gland	129	6.5	0.26	7.3	0.29	388	19.3	0.45	20.9	0.48
Lymphomas	473	23.5	0.49	27.1	0.56	412	17.8	0.40	20.3	0.45
Hodgkin Lymphoma	50	2.5	0.16	2.7	0.17	43	2.2	0.15	2.2	0.15
Non-Hodgkin Lymphoma	423	21.0	0.47	24.4	0.54	369	15.6	0.37	18.1	0.43
Multiple Myeloma	163	7.9	0.28	9.5	0.34	121	5.0	0.21	5.8	0.24
Leukemias	360	18.1	0.44	20.6	0.49	256	11.1	0.32	12.5	0.35
Acute lymphocytic	31	1.6	0.13	1.5	0.12	28	1.4	0.12	1.3	0.11
Chronic lymphocytic	135	6.6	0.26	7.9	0.31	85	3.4	0.17	4.1	0.20
Acute myeloid	102	5.2	0.23	5.9	0.26	80	3.5	0.18	3.9	0.20
Chronic myeloid	50	2.6	0.17	2.9	0.19	35	1.6	0.12	1.8	0.14
Other leukemias	41	2.1	0.15	2.4	0.17	27	1.1	0.10	1.3	0.11
Mesothelioma	25	1.3	0.12	1.4	0.13	6	0.3	0.05	0.3	0.06
Kaposi Sarcoma	8	0.4	0.07	0.4	0.07	-	-	-	-	-
Ill-defined & Unknown	438	22.0	0.48	25.8	0.56	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	162	8.1	0.29	9.2	0.33	313	14.1	0.37	16.1	0.41
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.03	478	21.0	0.44	25.0	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	8,383	470.5	2.35	559.0	2.75	8,028	408.0	2.11	477.1	2.42
Oral Cavity & Pharynx	351	19.4	0.47	23.7	0.57	135	6.7	0.26	7.9	0.31
Lip	41	2.4	0.17	2.8	0.20	15	0.7	0.08	0.8	0.10
Tongue	108	5.9	0.26	7.2	0.31	39	1.9	0.14	2.3	0.17
Major salivary gland	37	2.1	0.16	2.5	0.19	20	1.1	0.11	1.2	0.12
Floor of mouth	13	0.7	0.09	0.9	0.11	4	0.2	0.05	0.2	0.05
Gum & other mouth	28	1.5	0.13	1.9	0.16	24	1.2	0.11	1.4	0.13
Nasopharynx	12	0.7	0.09	0.8	0.10	5	0.3	0.06	0.3	0.06
Oropharynx	15	0.8	0.10	1.0	0.12	6	0.3	0.05	0.4	0.07
Hypopharynx	12	0.7	0.08	0.8	0.11	3	0.1	0.03	0.2	0.05
Digestive System	1,600	89.8	1.03	107.4	1.21	1,250	61.2	0.80	72.3	0.93
Esophagus	141	7.6	0.29	9.3	0.35	31	1.5	0.12	1.8	0.14
Stomach	119	6.8	0.29	8.0	0.33	70	3.4	0.19	4.0	0.22
Small intestine	45	2.5	0.17	3.0	0.20	43	2.2	0.15	2.6	0.18
Colon excl. rectum	535	30.9	0.61	36.2	0.71	516	25.3	0.51	29.6	0.59
Rectum & rectosigmoid	253	14.3	0.41	17.1	0.48	173	8.8	0.31	10.5	0.36
Anus, anal canal & anorectum	24	1.4	0.13	1.7	0.15	58	3.0	0.18	3.5	0.21
Liver	191	9.9	0.33	12.6	0.41	69	3.3	0.18	4.0	0.22
Gallbladder	12	0.7	0.09	0.8	0.10	20	1.0	0.10	1.1	0.12
Pancreas	215	12.1	0.38	14.4	0.44	212	10.0	0.31	11.8	0.37
Respiratory System	1,546	84.9	0.98	101.7	1.17	1,235	58.3	0.75	69.8	0.90
Larynx	105	5.5	0.25	6.9	0.30	34	1.7	0.14	2.1	0.16
Lung & bronchus	1,420	78.2	0.94	93.5	1.12	1,190	56.0	0.74	67.1	0.88
Bones & Joints	16	1.0	0.12	1.1	0.12	14	0.9	0.11	0.9	0.11
Soft Tissue (incl. heart)	55	3.4	0.21	3.7	0.22	39	2.2	0.16	2.4	0.17
Skin (excl. basal & sq.)	569	33.2	0.64	38.8	0.73	340	18.6	0.47	20.9	0.52
Melanomas of the skin	534	31.1	0.62	36.4	0.71	317	17.4	0.46	19.6	0.50
Breast (excl. <i>in situ</i>)	20	1.1	0.12	1.4	0.14	2,310	118.6	1.15	140.1	1.33
Female Genital System	-	-	-	-	-	872	46.1	0.73	54.0	0.83
Cervix uteri	-	-	-	-	-	133	8.7	0.35	9.2	0.36
Uterus Corpus	-	-	-	-	-	422	21.2	0.48	25.8	0.57
Uterus, NOS ¹	-	-	-	-	-	16	0.8	0.09	0.9	0.10
Ovary	-	-	-	-	-	216	11.0	0.35	13.0	0.40
Male Genital System	1,713	91.6	1.01	111.5	1.21	-	-	-	-	-
Prostate	1,615	85.0	0.96	104.7	1.17	-	-	-	-	-
Testis	79	5.5	0.28	5.5	0.28	-	-	-	-	-
Penis	16	0.9	0.11	1.1	0.12	-	-	-	-	-
Urinary System	1,031	59.2	0.84	69.6	0.98	442	21.8	0.48	25.7	0.56
Bladder (incl. <i>in situ</i>)	602	34.8	0.64	40.8	0.75	161	7.6	0.27	9.0	0.32
Kidney & renal pelvis	410	23.3	0.53	27.6	0.61	269	13.6	0.39	16.1	0.45
Ureter	12	0.7	0.10	0.9	0.11	9	0.4	0.06	0.5	0.07
Eye & Orbit	16	0.9	0.11	1.1	0.12	11	0.6	0.08	0.7	0.09
Brain & Other CNS ¹	127	7.6	0.31	8.5	0.34	108	6.0	0.27	6.5	0.29
Brain	121	7.2	0.30	8.1	0.33	104	5.7	0.26	6.3	0.28
Endocrine System	118	7.2	0.31	8.0	0.33	323	19.9	0.52	21.6	0.54
Thyroid gland	109	6.6	0.29	7.4	0.32	312	19.3	0.51	20.9	0.54
Lymphomas	396	23.2	0.53	26.7	0.61	345	17.5	0.44	20.1	0.49
Hodgkin Lymphoma	39	2.4	0.18	2.6	0.19	33	2.2	0.17	2.2	0.17
Non-Hodgkin Lymphoma	358	20.8	0.50	24.2	0.58	312	15.4	0.40	17.9	0.46
Multiple Myeloma	128	7.2	0.29	8.6	0.34	90	4.3	0.21	5.1	0.24
Leukemias	298	17.5	0.46	20.0	0.52	210	10.7	0.34	12.1	0.38
Acute lymphocytic	21	1.4	0.14	1.3	0.13	19	1.3	0.14	1.2	0.12
Chronic lymphocytic	117	6.6	0.28	7.8	0.33	76	3.5	0.18	4.3	0.22
Acute myeloid	85	5.0	0.25	5.7	0.28	64	3.3	0.19	3.7	0.21
Chronic myeloid	40	2.4	0.18	2.7	0.19	28	1.5	0.13	1.7	0.14
Other leukemias	35	2.1	0.16	2.4	0.19	23	1.1	0.11	1.3	0.12
Mesothelioma	22	1.3	0.12	1.4	0.14	5	0.3	0.05	0.3	0.06
Kaposi Sarcoma	6	0.4	0.08	0.4	0.08	-	-	-	-	-
Ill-defined & Unknown	371	21.5	0.51	25.4	0.59	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	133	7.9	0.32	9.0	0.35	255	13.7	0.40	15.6	0.45
Breast (<i>in situ</i>)	-	-	-	-	-	386	20.3	0.48	24.1	0.56

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	638	521.5	10.06	629.1	11.80	571	391.8	7.57	460.7	8.74
Oral Cavity & Pharynx	16	12.8	1.53	15.3	1.78	6	3.7	0.72	4.4	0.84
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.7	0.80	4.4	0.93	1	1.0	0.40	1.2	0.46
Major salivary gland	3	2.5	0.74	2.8	0.82	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.9	0.40	1.0	0.44	-	-	-	-	-
Nasopharynx	-	-	-	-	-	1	0.8	0.30	1.0	0.39
Oropharynx	1	1.1	0.42	1.3	0.50	-	-	-	-	-
Hypopharynx	2	1.1	0.40	1.4	0.51	-	-	-	-	-
Digestive System	134	108.1	4.57	131.0	5.39	110	75.9	3.34	90.7	3.92
Esophagus	6	4.6	0.93	5.7	1.10	3	1.7	0.47	2.2	0.61
Stomach	15	13.3	1.68	15.5	1.92	9	6.0	0.95	7.1	1.09
Small intestine	4	3.7	0.84	4.4	0.96	5	3.6	0.73	4.3	0.84
Colon excl. rectum	44	37.0	2.74	44.3	3.22	42	30.3	2.14	35.3	2.46
Rectum & rectosigmoid	19	15.0	1.66	17.9	1.93	13	8.7	1.09	10.8	1.33
Anus, anal canal & anorectum	3	2.4	0.70	2.8	0.81	3	2.2	0.57	2.5	0.64
Liver	20	13.3	1.37	17.4	1.75	7	4.3	0.75	5.5	0.94
Gallbladder	1	1.4	0.60	1.7	0.73	2	1.9	0.55	2.1	0.62
Pancreas	18	14.8	1.73	18.1	2.04	19	13.1	1.40	16.0	1.68
Respiratory System	106	92.9	4.37	110.2	5.03	76	52.9	2.81	63.5	3.29
Larynx	9	7.3	1.18	8.7	1.38	2	1.5	0.44	1.9	0.55
Lung & bronchus	96	83.7	4.14	99.1	4.76	74	51.4	2.77	61.5	3.24
Bones & Joints	-	-	-	-	-	2	1.5	0.46	1.5	0.47
Soft Tissue (incl. heart)	4	2.8	0.67	3.1	0.74	5	3.4	0.70	3.8	0.78
Skin (excl. basal & sq.)	2	1.6	0.54	1.8	0.62	3	2.0	0.53	2.3	0.60
Melanomas of the skin	1	1.0	0.47	1.3	0.56	2	1.3	0.44	1.5	0.49
Breast (excl. <i>in situ</i>)	2	2.1	0.65	2.5	0.76	179	122.2	4.21	142.7	4.83
Female Genital System	-	-	-	-	-	63	42.4	2.46	50.4	2.87
Cervix uteri	-	-	-	-	-	10	7.0	1.01	7.6	1.10
Uterus Corpus	-	-	-	-	-	35	22.8	1.78	28.1	2.13
Uterus, NOS ¹	-	-	-	-	-	3	1.9	0.53	2.1	0.59
Ovary	-	-	-	-	-	12	8.3	1.11	9.7	1.27
Male Genital System	215	167.1	5.52	208.1	6.64	-	-	-	-	-
Prostate	212	164.9	5.49	205.8	6.61	-	-	-	-	-
Testis	2	1.7	0.51	1.6	0.50	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	57	51.2	3.32	60.7	3.86	31	21.7	1.80	25.7	2.09
Bladder (incl. <i>in situ</i>)	22	21.6	2.27	25.6	2.63	10	7.5	1.09	8.9	1.26
Kidney & renal pelvis	35	28.5	2.35	33.8	2.74	21	14.0	1.43	16.6	1.66
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	4.5	0.84	5.0	0.93	5	2.9	0.62	3.4	0.72
Brain	7	4.5	0.84	5.0	0.93	5	2.9	0.62	3.4	0.72
Endocrine System	7	4.7	0.87	5.5	0.99	20	13.4	1.37	15.0	1.51
Thyroid gland	5	3.2	0.67	3.6	0.76	19	12.8	1.34	14.3	1.48
Lymphomas	26	20.1	1.89	23.3	2.16	20	13.6	1.41	15.1	1.55
Hodgkin Lymphoma	4	2.6	0.60	2.7	0.62	4	2.3	0.54	2.4	0.55
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	17	14.7	1.73	17.8	2.03	17	12.2	1.36	14.4	1.58
Leukemias	21	17.8	1.91	20.6	2.18	13	9.4	1.18	10.6	1.33
Acute lymphocytic	-	-	-	-	-	3	1.5	0.43	1.6	0.48
Chronic lymphocytic	7	5.9	1.09	7.5	1.34	3	2.7	0.66	3.0	0.75
Acute myeloid	6	5.7	1.12	6.5	1.25	4	3.0	0.66	3.4	0.75
Chronic myeloid	4	3.5	0.80	3.8	0.86	1	0.9	0.35	1.0	0.38
Other leukemias	2	2.2	0.71	2.4	0.78	2	1.3	0.47	1.5	0.52
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	21	18.8	2.02	21.9	2.32	20	14.2	1.46	16.9	1.70
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	11	8.5	1.22	9.7	1.39	21	14.4	1.43	16.2	1.60
Breast (<i>in situ</i>)	-	-	-	-	-	35	23.2	1.81	28.0	2.13

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	96	334.1	16.99	392.6	19.69	134	329.0	13.49	381.5	15.57
Oral Cavity & Pharynx	3	13.0	3.43	14.4	3.82	2	5.2	1.62	5.9	1.84
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	32	109.6	9.66	129.1	11.23	28	77.2	6.97	92.0	8.20
Esophagus	2	8.1	2.89	9.2	3.24	-	-	-	-	-
Stomach	4	14.4	3.41	17.9	4.10	4	9.6	2.33	11.4	2.74
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	9	30.6	5.11	35.0	5.85	10	28.5	4.41	34.3	5.26
Rectum & rectosigmoid	4	12.2	3.10	14.4	3.59	4	11.0	2.58	13.1	3.02
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	29.0	4.97	34.8	5.85	3	8.6	2.34	10.2	2.76
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	8.2	2.75	9.3	3.12	4	9.9	2.42	12.0	2.86
Respiratory System	14	50.0	6.72	60.0	7.87	14	37.7	4.80	44.1	5.50
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	12	45.8	6.46	54.8	7.55	14	37.7	4.80	44.1	5.50
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	3.2	1.35	3.5	1.50	1	3.9	1.57	4.0	1.70
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	90.4	6.61	105.1	7.66
Female Genital System	-	-	-	-	-	21	48.3	5.00	56.2	5.79
Cervix uteri	-	-	-	-	-	5	11.3	2.38	12.6	2.72
Uterus Corpus	-	-	-	-	-	8	19.5	3.14	23.1	3.68
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	14.5	2.70	17.1	3.15
Male Genital System	14	49.7	6.34	60.3	7.51	-	-	-	-	-
Prostate	14	48.9	6.32	59.6	7.49	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	31.7	5.51	37.7	6.38	3	9.4	2.50	11.1	2.89
Bladder (incl. <i>in situ</i>)	3	12.7	3.63	15.0	4.22	1	4.8	1.88	5.4	2.09
Kidney & renal pelvis	5	16.8	3.82	20.4	4.52	1	3.4	1.39	4.4	1.76
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	5.1	1.55	5.7	1.83	2	3.2	1.23	3.6	1.38
Brain	2	5.1	1.55	5.7	1.83	2	3.2	1.23	3.6	1.38
Endocrine System	3	8.7	2.42	9.9	2.71	7	15.7	2.87	16.3	3.12
Thyroid gland	3	8.2	2.38	9.5	2.68	7	15.4	2.86	16.0	3.11
Lymphomas	7	22.9	4.51	25.5	5.04	6	14.7	2.83	17.4	3.28
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	1	3.8	1.78	4.8	2.17	-	-	-	-	-
Leukemias	5	14.7	3.48	16.8	4.03	4	9.5	2.20	9.9	2.36
Acute lymphocytic	-	-	-	-	-	1	2.1	0.86	2.0	0.86
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	6.8	2.28	8.2	2.76	2	4.4	1.56	4.5	1.69
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	15.4	4.03	18.3	4.71	3	7.6	2.07	9.3	2.49
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	7.4	2.24	8.3	2.58	4	10.8	2.45	12.2	2.76
Breast (<i>in situ</i>)	-	-	-	-	-	9	21.1	3.27	24.3	3.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	912	626.3	10.02	742.4	11.71	958	548.4	8.17	639.3	9.42
Oral Cavity & Pharynx	37	23.2	1.83	28.1	2.17	13	7.4	0.95	8.7	1.11
Lip	3	2.3	0.70	2.6	0.81	-	-	-	-	-
Tongue	9	5.5	0.86	6.7	1.02	4	2.2	0.49	2.7	0.61
Major salivary gland	3	2.3	0.65	2.6	0.75	2	1.2	0.41	1.4	0.48
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.5	0.44	1.8	0.53	2	1.3	0.37	1.5	0.43
Nasopharynx	2	1.1	0.35	1.4	0.45	-	-	-	-	-
Oropharynx	3	2.0	0.53	2.5	0.62	-	-	-	-	-
Hypopharynx	3	1.6	0.47	2.0	0.55	-	-	-	-	-
Digestive System	223	150.9	4.88	182.6	5.79	171	100.4	3.56	118.8	4.15
Esophagus	15	10.0	1.23	12.4	1.49	4	2.6	0.59	3.1	0.68
Stomach	15	12.2	1.51	14.4	1.76	13	7.2	0.93	8.3	1.06
Small intestine	5	3.4	0.73	4.2	0.87	4	2.5	0.57	2.8	0.64
Colon excl. rectum	73	51.6	2.95	61.9	3.48	70	41.4	2.29	49.0	2.68
Rectum & rectosigmoid	35	22.3	1.79	26.6	2.10	23	12.8	1.24	15.0	1.43
Anus, anal canal & anorectum	3	1.8	0.49	2.3	0.60	2	1.3	0.38	1.6	0.47
Liver	43	26.0	1.88	32.9	2.32	19	10.8	1.15	13.1	1.37
Gallbladder	2	1.9	0.64	2.3	0.76	4	2.3	0.54	2.8	0.65
Pancreas	23	15.9	1.58	19.1	1.86	24	14.8	1.40	17.4	1.62
Respiratory System	168	121.6	4.50	143.7	5.21	138	81.0	3.18	96.6	3.72
Larynx	14	8.9	1.13	11.1	1.37	4	2.5	0.55	3.0	0.65
Lung & bronchus	151	110.9	4.33	130.4	4.99	133	77.7	3.12	92.7	3.65
Bones & Joints	4	2.4	0.59	2.6	0.65	2	1.0	0.33	1.0	0.35
Soft Tissue (incl. heart)	6	4.2	0.81	4.5	0.89	5	3.1	0.62	3.4	0.67
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	32	21.5	1.81	24.7	2.06	19	11.4	1.21	12.2	1.29
Breast (excl. <i>in situ</i>)	1	0.9	0.40	1.1	0.45	272	153.2	4.26	179.7	4.93
Female Genital System	-	-	-	-	-	113	62.7	2.70	72.5	3.09
Cervix uteri	-	-	-	-	-	24	13.2	1.24	14.1	1.32
Uterus Corpus	-	-	-	-	-	52	28.4	1.81	33.7	2.11
Uterus, NOS ²	-	-	-	-	-	2	1.1	0.36	1.2	0.40
Ovary	-	-	-	-	-	27	15.1	1.34	17.7	1.55
Male Genital System	168	110.9	4.12	134.1	4.87	-	-	-	-	-
Prostate	152	102.6	4.00	125.4	4.77	-	-	-	-	-
Testis	14	7.0	0.87	7.1	0.88	-	-	-	-	-
Penis	2	1.0	0.39	1.3	0.48	-	-	-	-	-
Urinary System	116	82.5	3.71	97.4	4.32	59	33.4	2.00	39.6	2.34
Bladder (incl. <i>in situ</i>)	41	34.0	2.56	39.3	2.94	12	6.9	0.94	8.3	1.11
Kidney & renal pelvis	74	47.8	2.65	57.3	3.14	47	26.1	1.76	30.7	2.04
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	2	0.8	0.31	0.9	0.36
Brain & Other CNS ²	16	9.1	1.13	10.1	1.27	10	5.2	0.78	5.8	0.87
Brain	16	9.1	1.13	10.1	1.27	9	4.8	0.74	5.3	0.83
Endocrine System	14	8.3	1.10	9.2	1.24	44	24.0	1.66	26.1	1.80
Thyroid gland	11	7.0	1.01	7.9	1.14	42	22.9	1.61	25.0	1.76
Lymphomas	40	27.8	2.16	31.9	2.48	35	20.5	1.60	23.2	1.79
Hodgkin Lymphoma	5	2.8	0.59	3.0	0.64	4	1.7	0.40	1.9	0.44
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	15	11.5	1.44	13.6	1.68	12	7.1	0.96	8.3	1.10
Leukemias	30	19.9	1.79	22.5	2.05	24	13.2	1.27	14.6	1.42
Acute lymphocytic	6	2.9	0.58	2.9	0.62	5	2.0	0.43	1.9	0.42
Chronic lymphocytic	8	6.0	1.04	7.1	1.20	4	2.6	0.59	3.1	0.68
Acute myeloid	8	5.8	0.98	6.5	1.11	8	4.6	0.75	5.2	0.86
Chronic myeloid	5	3.3	0.76	3.8	0.88	5	2.9	0.61	3.3	0.69
Other leukemias	3	1.8	0.51	2.1	0.58	2	1.1	0.38	1.2	0.42
Mesothelioma	2	1.3	0.48	1.6	0.55	-	-	-	-	-
Kaposi Sarcoma	1	0.7	0.27	0.7	0.30	-	-	-	-	-
Ill-defined & Unknown	36	27.4	2.20	31.6	2.51	35	21.3	1.67	24.8	1.93
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	14	9.4	1.26	10.7	1.45	29	17.2	1.46	19.1	1.62
Breast (<i>in situ</i>)	-	-	-	-	-	42	22.6	1.60	27.2	1.89

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	272	327.8	10.67	385.0	12.27	343	358.9	9.79	420.9	11.44
Oral Cavity & Pharynx	9	10.4	1.85	12.2	2.12	5	4.5	0.99	5.4	1.18
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	3.6	1.15	4.1	1.30	1	1.1	0.43	1.4	0.57
Major salivary gland	1	1.8	0.85	2.0	0.90	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	0.8	0.34	0.9	0.41
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	69	79.0	4.97	94.8	5.78	56	68.7	4.59	80.9	5.29
Esophagus	3	4.3	1.32	5.0	1.48	-	-	-	-	-
Stomach	6	6.9	1.47	8.3	1.73	6	7.5	1.54	8.4	1.71
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	21	24.4	2.82	28.5	3.22	20	24.8	2.82	27.9	3.15
Rectum & rectosigmoid	12	13.7	2.04	16.4	2.40	6	6.1	1.22	7.4	1.47
Anus, anal canal & anorectum	-	-	-	-	-	2	2.2	0.85	2.6	0.95
Liver	12	12.3	1.72	15.6	2.12	7	8.5	1.53	10.8	1.87
Gallbladder	1	2.0	0.84	2.3	0.93	1	1.2	0.51	1.5	0.62
Pancreas	9	11.1	1.94	13.6	2.30	9	12.9	2.09	15.4	2.41
Respiratory System	28	43.0	4.14	50.7	4.74	22	31.8	3.26	37.4	3.74
Larynx	3	3.9	1.21	4.4	1.34	-	-	-	-	-
Lung & bronchus	24	37.8	3.91	44.8	4.49	21	30.7	3.23	36.2	3.70
Bones & Joints	1	0.6	0.24	0.5	0.22	2	1.0	0.38	1.1	0.44
Soft Tissue (incl. heart)	5	3.3	0.84	3.5	0.90	3	2.5	0.77	2.8	0.87
Skin (excl. basal & sq.)	-	-	-	-	-	9	10.2	1.76	12.0	2.07
Melanomas of the skin	5	5.9	1.42	6.9	1.63	7	8.0	1.54	9.3	1.80
Breast (excl. <i>in situ</i>)	-	-	-	-	-	95	96.1	4.84	114.5	5.76
Female Genital System	-	-	-	-	-	55	51.4	3.46	60.6	4.11
Cervix uteri	-	-	-	-	-	16	11.7	1.41	12.6	1.59
Uterus Corpus	-	-	-	-	-	22	22.2	2.30	27.4	2.81
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	13	12.8	1.78	15.5	2.15
Male Genital System	57	70.6	4.96	83.6	5.71	-	-	-	-	-
Prostate	45	63.9	4.83	76.7	5.59	-	-	-	-	-
Testis	11	4.7	0.66	4.6	0.68	-	-	-	-	-
Penis	1	1.2	0.62	1.3	0.65	-	-	-	-	-
Urinary System	34	49.1	4.43	56.8	5.04	17	18.5	2.20	22.0	2.60
Bladder (incl. <i>in situ</i>)	12	22.3	3.24	25.7	3.70	4	5.9	1.38	6.9	1.58
Kidney & renal pelvis	21	25.4	2.91	29.5	3.32	12	11.6	1.64	13.9	1.97
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.2	0.77	4.7	0.92	8	5.3	1.09	6.0	1.31
Brain	8	4.2	0.77	4.7	0.92	7	5.2	1.08	5.9	1.31
Endocrine System	5	3.7	0.86	4.4	1.03	24	17.9	1.78	19.8	2.06
Thyroid gland	4	3.2	0.82	3.9	0.99	24	17.5	1.76	19.3	2.03
Lymphomas	16	17.9	2.46	20.9	2.79	18	20.7	2.50	23.7	2.83
Hodgkin Lymphoma	3	2.3	0.76	2.4	0.81	3	1.5	0.50	1.5	0.51
Non-Hodgkin Lymphoma	13	15.7	2.34	18.5	2.67	16	19.2	2.45	22.2	2.78
Multiple Myeloma	5	6.4	1.49	7.6	1.74	5	6.3	1.35	7.4	1.58
Leukemias	14	12.0	1.96	13.0	2.20	12	10.2	1.58	11.3	1.85
Acute lymphocytic	-	-	-	-	-	3	1.3	0.35	1.1	0.30
Chronic lymphocytic	1	2.3	1.05	2.6	1.22	1	1.5	0.71	1.8	0.85
Acute myeloid	3	2.8	1.01	3.0	1.11	5	4.5	1.03	5.1	1.22
Chronic myeloid	4	3.6	1.01	4.1	1.10	2	1.2	0.46	1.5	0.58
Other leukemias	-	-	-	-	-	1	1.7	0.78	1.8	0.88
Mesothelioma	1	2.2	1.00	2.6	1.16	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	12	16.3	2.54	18.8	2.91	11	13.2	2.00	15.3	2.32
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	5	4.3	1.09	4.7	1.23	11	13.4	2.05	14.9	2.27
Breast (<i>in situ</i>)	-	-	-	-	-	19	18.1	2.02	21.0	2.36

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

OKLAHOMA

II-408 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8,178	480.0	2.43	570.2	2.85	7,750	412.2	2.19	481.8	2.50
Oral Cavity & Pharynx	344	20.0	0.50	24.4	0.60	131	6.8	0.28	8.0	0.32
Lip	41	2.5	0.18	2.9	0.20	15	0.7	0.09	0.9	0.10
Tongue	106	6.1	0.27	7.5	0.33	38	2.0	0.15	2.3	0.17
Major salivary gland	36	2.2	0.16	2.5	0.19	20	1.1	0.12	1.3	0.13
Floor of mouth	13	0.7	0.09	0.9	0.11	4	0.2	0.05	0.2	0.05
Gum & other mouth	27	1.5	0.13	1.9	0.16	24	1.2	0.12	1.4	0.13
Nasopharynx	12	0.7	0.10	0.8	0.11	5	0.3	0.06	0.3	0.06
Oropharynx	15	0.8	0.10	1.0	0.12	5	0.3	0.05	0.3	0.07
Hypopharynx	12	0.7	0.09	0.9	0.11	3	0.1	0.04	0.2	0.05
Digestive System	1,551	91.2	1.06	109.0	1.25	1,205	61.4	0.82	72.5	0.95
Esophagus	139	7.9	0.31	9.6	0.37	31	1.5	0.13	1.8	0.15
Stomach	114	6.8	0.29	8.0	0.34	65	3.3	0.19	3.9	0.22
Small intestine	44	2.6	0.18	3.1	0.21	43	2.3	0.16	2.7	0.19
Colon excl. rectum	520	31.5	0.63	36.8	0.73	500	25.4	0.53	29.8	0.61
Rectum & rectosigmoid	244	14.5	0.43	17.4	0.50	168	9.0	0.32	10.7	0.38
Anus, anal canal & anorectum	23	1.4	0.13	1.7	0.16	56	3.1	0.19	3.6	0.22
Liver	183	10.0	0.34	12.7	0.42	63	3.1	0.18	3.8	0.22
Gallbladder	11	0.6	0.09	0.7	0.10	19	0.9	0.10	1.1	0.11
Pancreas	209	12.3	0.39	14.6	0.46	205	10.0	0.32	11.8	0.37
Respiratory System	1,524	86.8	1.01	104.1	1.20	1,218	59.5	0.78	71.2	0.93
Larynx	103	5.7	0.25	7.0	0.31	34	1.8	0.14	2.1	0.17
Lung & bronchus	1,401	79.9	0.97	95.6	1.15	1,173	57.1	0.76	68.4	0.91
Bones & Joints	15	1.0	0.12	1.1	0.13	13	0.9	0.12	0.9	0.11
Soft Tissue (incl. heart)	53	3.5	0.22	3.8	0.23	38	2.2	0.17	2.4	0.18
Skin (excl. basal & sq.)	564	34.5	0.67	40.3	0.77	333	19.4	0.50	21.8	0.55
Melanomas of the skin	529	32.3	0.65	37.8	0.74	311	18.2	0.49	20.4	0.53
Breast (excl. <i>in situ</i>)	20	1.2	0.12	1.4	0.14	2,229	119.8	1.19	141.5	1.37
Female Genital System	-	-	-	-	-	829	46.1	0.76	54.0	0.86
Cervix uteri	-	-	-	-	-	121	8.6	0.37	9.1	0.37
Uterus Corpus	-	-	-	-	-	405	21.3	0.50	25.9	0.59
Uterus, NOS ¹	-	-	-	-	-	15	0.8	0.09	0.9	0.11
Ovary	-	-	-	-	-	206	11.1	0.36	13.0	0.41
Male Genital System	1,670	93.1	1.04	113.4	1.25	-	-	-	-	-
Prostate	1,582	86.4	0.99	106.5	1.21	-	-	-	-	-
Testis	71	5.7	0.31	5.7	0.30	-	-	-	-	-
Penis	15	0.9	0.11	1.1	0.12	-	-	-	-	-
Urinary System	1,003	59.9	0.87	70.6	1.01	428	22.0	0.50	25.9	0.57
Bladder (incl. <i>in situ</i>)	593	35.4	0.66	41.5	0.77	157	7.7	0.28	9.1	0.33
Kidney & renal pelvis	393	23.5	0.55	27.8	0.63	259	13.8	0.40	16.2	0.46
Ureter	12	0.7	0.10	0.8	0.11	8	0.4	0.06	0.5	0.07
Eye & Orbit	15	1.0	0.11	1.1	0.13	11	0.6	0.09	0.7	0.10
Brain & Other CNS ¹	122	7.9	0.33	8.8	0.36	102	6.0	0.28	6.6	0.30
Brain	116	7.5	0.32	8.3	0.35	98	5.7	0.27	6.3	0.29
Endocrine System	114	7.6	0.33	8.4	0.36	303	20.2	0.55	21.8	0.57
Thyroid gland	106	7.0	0.32	7.8	0.34	291	19.5	0.54	21.1	0.56
Lymphomas	383	23.7	0.56	27.3	0.63	332	17.7	0.45	20.2	0.51
Hodgkin Lymphoma	37	2.6	0.20	2.8	0.20	32	2.3	0.19	2.4	0.19
Non-Hodgkin Lymphoma	346	21.1	0.52	24.6	0.60	300	15.3	0.41	17.9	0.47
Multiple Myeloma	124	7.2	0.30	8.6	0.35	86	4.2	0.21	5.0	0.24
Leukemias	288	17.8	0.48	20.3	0.54	201	10.7	0.36	12.1	0.39
Acute lymphocytic	18	1.4	0.15	1.3	0.14	17	1.3	0.15	1.2	0.13
Chronic lymphocytic	115	6.8	0.29	8.0	0.34	75	3.6	0.19	4.3	0.23
Acute myeloid	83	5.1	0.26	5.8	0.29	61	3.3	0.20	3.7	0.22
Chronic myeloid	37	2.4	0.18	2.7	0.20	26	1.5	0.14	1.6	0.15
Other leukemias	35	2.1	0.17	2.5	0.19	22	1.1	0.11	1.2	0.12
Mesothelioma	21	1.3	0.13	1.4	0.14	5	0.3	0.06	0.3	0.06
Kaposi Sarcoma	5	0.4	0.08	0.4	0.08	-	-	-	-	-
Ill-defined & Unknown	363	21.9	0.53	25.8	0.61	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	129	8.2	0.33	9.3	0.37	245	13.9	0.42	15.9	0.47
Breast (<i>in situ</i>)	-	-	-	-	-	371	20.4	0.50	24.2	0.58

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oklahoma, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	635	529.7	10.23	638.8	12.01	565	395.5	7.67	464.6	8.85
Oral Cavity & Pharynx	16	13.1	1.56	15.6	1.81	5	3.5	0.71	4.2	0.84
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.8	0.82	4.5	0.95	1	1.1	0.41	1.2	0.47
Major salivary gland	3	2.5	0.76	2.8	0.84	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.9	0.41	1.1	0.46	-	-	-	-	-
Nasopharynx	-	-	-	-	-	1	0.8	0.31	1.0	0.40
Oropharynx	1	1.1	0.43	1.3	0.51	-	-	-	-	-
Hypopharynx	2	1.1	0.41	1.4	0.51	-	-	-	-	-
Digestive System	133	110.1	4.65	133.4	5.49	109	76.2	3.37	91.1	3.96
Esophagus	6	4.5	0.93	5.6	1.11	3	1.8	0.48	2.3	0.62
Stomach	15	13.5	1.71	15.8	1.96	8	6.0	0.95	7.1	1.10
Small intestine	4	3.7	0.85	4.5	0.98	5	3.6	0.73	4.2	0.84
Colon excl. rectum	44	37.8	2.79	45.3	3.28	42	30.7	2.17	35.8	2.49
Rectum & rectosigmoid	19	15.2	1.69	18.1	1.96	13	8.7	1.10	10.8	1.34
Anus, anal canal & anorectum	3	2.4	0.72	2.8	0.83	3	2.3	0.58	2.6	0.65
Liver	20	13.5	1.40	17.8	1.78	7	4.4	0.76	5.6	0.95
Gallbladder	1	1.4	0.61	1.8	0.74	2	1.9	0.56	2.2	0.63
Pancreas	18	15.1	1.76	18.4	2.08	18	12.8	1.39	15.6	1.67
Respiratory System	105	94.1	4.44	111.5	5.11	75	53.1	2.83	63.7	3.32
Larynx	9	7.3	1.20	8.7	1.39	2	1.5	0.44	1.9	0.56
Lung & bronchus	95	84.8	4.21	100.4	4.84	73	51.5	2.79	61.7	3.27
Bones & Joints	-	-	-	-	-	2	1.5	0.48	1.6	0.49
Soft Tissue (incl. heart)	4	2.8	0.69	3.1	0.76	5	3.4	0.71	3.7	0.78
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	1	1.1	0.49	1.3	0.57	2	1.3	0.43	1.4	0.49
Breast (excl. <i>in situ</i>)	2	2.0	0.65	2.3	0.75	177	124.1	4.29	144.5	4.90
Female Genital System	-	-	-	-	-	63	43.0	2.51	51.1	2.91
Cervix uteri	-	-	-	-	-	10	7.2	1.05	7.9	1.13
Uterus Corpus	-	-	-	-	-	35	23.3	1.81	28.6	2.17
Uterus, NOS ¹	-	-	-	-	-	2	1.7	0.51	2.0	0.57
Ovary	-	-	-	-	-	12	8.4	1.12	9.8	1.28
Male Genital System	214	169.7	5.62	211.3	6.75	-	-	-	-	-
Prostate	211	167.3	5.58	208.9	6.72	-	-	-	-	-
Testis	2	1.7	0.53	1.7	0.51	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	57	52.3	3.38	61.9	3.94	31	22.0	1.83	26.1	2.12
Bladder (incl. <i>in situ</i>)	22	22.0	2.31	26.1	2.68	10	7.6	1.10	9.0	1.27
Kidney & renal pelvis	35	29.1	2.40	34.5	2.80	21	14.3	1.45	16.9	1.69
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.6	0.86	5.0	0.95	5	2.9	0.63	3.3	0.72
Brain	6	4.6	0.86	5.0	0.95	5	2.9	0.63	3.3	0.72
Endocrine System	6	4.7	0.88	5.4	1.00	20	13.9	1.41	15.4	1.55
Thyroid gland	5	3.2	0.69	3.6	0.77	19	13.2	1.38	14.7	1.52
Lymphomas	26	20.4	1.93	23.7	2.20	19	13.6	1.43	15.1	1.56
Hodgkin Lymphoma	4	2.8	0.62	2.8	0.64	4	2.4	0.57	2.5	0.58
Non-Hodgkin Lymphoma	22	17.7	1.83	20.9	2.11	15	11.2	1.31	12.6	1.45
Multiple Myeloma	17	15.0	1.76	18.1	2.07	17	12.2	1.38	14.5	1.59
Leukemias	21	18.2	1.95	21.0	2.22	13	9.4	1.20	10.7	1.35
Acute lymphocytic	-	-	-	-	-	3	1.6	0.45	1.7	0.50
Chronic lymphocytic	7	6.0	1.12	7.6	1.37	3	2.7	0.67	3.1	0.76
Acute myeloid	6	5.8	1.14	6.6	1.27	4	3.0	0.68	3.5	0.77
Chronic myeloid	4	3.6	0.82	3.8	0.87	1	0.9	0.36	1.0	0.39
Other leukemias	-	-	-	-	-	2	1.2	0.44	1.4	0.51
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	20	18.7	2.04	21.9	2.35	20	14.4	1.48	17.1	1.71
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	11	8.7	1.25	9.9	1.43	21	14.6	1.46	16.4	1.62
Breast (<i>in situ</i>)	-	-	-	-	-	35	23.6	1.84	28.5	2.17

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	3,922,908	3,964,106	4,016,918	4,091,404	4,146,592
White	3,536,348	3,564,163	3,603,809	3,658,193	3,699,129
Black	101,554	105,058	108,554	113,442	117,252
American Indian/Alaskan Native (AI/AN)	85,168	86,483	88,075	90,034	91,698
Asian/Pacific Islander (API)	199,838	208,402	216,480	229,735	238,513


All Races Population 2013-2017: 20,141,928
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	481,312	493,287	506,668	523,144	540,313
Non-Hispanic White	3,107,624	3,124,875	3,152,771	3,192,793	3,218,399
Non-Hispanic Black	88,855	91,981	95,077	99,438	102,808

Hispanic/Latino Population, Census 2010: 450,062
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OREGON CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.2	103.9	102.5	98.0	97.8
Missing Race	0.4	1.3	0.7	1.1	1.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.6	4.3	2.5	2.0	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.7	Prostate	95.9
Oral Cavity & Pharynx	97.6	Testis	99.7
Esophagus	92.6	Bladder (incl. <i>in situ</i>)	97.5
Stomach	95.8	Kidney & Renal Pelvis	90.6
Colon & Rectum	95.0	Brain & Other CNS ¹	85.2
Liver	40.2	Thyroid	99.5
Pancreas	81.4	Hodgkin Lymphoma	97.9
Lung & Bronchus	83.0	Non-Hodgkin Lymphoma	96.1
Melanomas of the Skin	99.0	Multiple Myeloma	87.4
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	90.2
Cervix uteri	96.0	Brain & Other CNS ¹ <i>non-malig</i>	55.9
Uterus Corpus & Uterus NOS ¹	98.2	Breast <i>in situ</i>	100.0
Ovary	91.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,835	460.2	2.04	545.2	2.37	10,716	417.7	1.87	487.2	2.14
Oral Cavity & Pharynx	442	18.2	0.40	22.2	0.48	181	6.9	0.24	8.2	0.28
Lip	20	0.9	0.09	1.0	0.10	9	0.3	0.05	0.4	0.06
Tongue	159	6.5	0.24	7.9	0.28	62	2.4	0.14	2.9	0.16
Major salivary gland	30	1.3	0.11	1.6	0.13	24	1.0	0.09	1.1	0.10
Floor of mouth	19	0.7	0.08	0.9	0.09	10	0.4	0.05	0.5	0.07
Gum & other mouth	42	1.8	0.13	2.1	0.15	35	1.3	0.10	1.6	0.12
Nasopharynx	14	0.6	0.08	0.7	0.09	5	0.2	0.04	0.2	0.05
Oropharynx	20	0.8	0.08	1.0	0.10	8	0.3	0.04	0.3	0.05
Hypopharynx	19	0.8	0.08	0.9	0.10	6	0.2	0.04	0.3	0.05
Digestive System	2,164	91.8	0.91	110.1	1.07	1,638	62.0	0.71	73.0	0.82
Esophagus	202	8.5	0.27	10.1	0.32	53	1.9	0.12	2.3	0.14
Stomach	173	7.4	0.26	8.8	0.30	92	3.6	0.18	4.1	0.20
Small intestine	60	2.6	0.15	3.1	0.18	54	2.1	0.13	2.5	0.15
Colon excl. rectum	575	25.4	0.49	29.9	0.56	600	22.9	0.43	26.7	0.49
Rectum & rectosigmoid	313	13.4	0.35	16.1	0.41	201	7.9	0.26	9.3	0.30
Anus, anal canal & anorectum	35	1.5	0.12	1.8	0.14	74	2.8	0.15	3.4	0.18
Liver	329	12.4	0.31	15.9	0.40	98	3.5	0.16	4.3	0.20
Gallbladder	18	0.8	0.09	1.0	0.10	34	1.2	0.10	1.5	0.12
Pancreas	353	15.1	0.37	17.9	0.43	317	11.7	0.30	13.8	0.35
Respiratory System	1,495	63.8	0.76	75.5	0.89	1,407	51.9	0.63	61.1	0.74
Larynx	97	3.9	0.18	4.8	0.22	21	0.8	0.08	0.9	0.09
Lung & bronchus	1,370	58.7	0.73	69.3	0.85	1,371	50.6	0.63	59.5	0.73
Bones & Joints	24	1.2	0.11	1.2	0.11	15	0.7	0.09	0.7	0.08
Soft Tissue (incl. heart)	84	3.8	0.19	4.3	0.21	70	2.9	0.16	3.2	0.17
Skin (excl. basal & sq.)	786	34.4	0.56	40.2	0.65	602	24.7	0.47	28.2	0.52
Melanomas of the skin	749	32.7	0.55	38.3	0.63	572	23.5	0.46	26.8	0.51
Breast (excl. <i>in situ</i>)	27	1.2	0.10	1.4	0.12	3,204	125.5	1.03	148.0	1.19
Female Genital System	-	-	-	-	-	1,322	51.4	0.66	61.1	0.76
Cervix uteri	-	-	-	-	-	145	7.0	0.27	7.4	0.28
Uterus Corpus	-	-	-	-	-	731	27.2	0.47	33.5	0.56
Uterus, NOS ¹	-	-	-	-	-	27	1.0	0.09	1.2	0.11
Ovary	-	-	-	-	-	301	11.8	0.32	13.8	0.36
Male Genital System	2,542	101.1	0.92	122.6	1.10	-	-	-	-	-
Prostate	2,386	93.3	0.88	114.6	1.06	-	-	-	-	-
Testis	132	6.8	0.27	6.7	0.26	-	-	-	-	-
Penis	18	0.8	0.09	0.9	0.10	-	-	-	-	-
Urinary System	1,376	60.0	0.74	70.6	0.86	521	19.6	0.40	23.1	0.46
Bladder (incl. <i>in situ</i>)	835	36.8	0.58	43.2	0.68	238	8.7	0.26	10.3	0.30
Kidney & renal pelvis	512	21.8	0.45	25.9	0.52	268	10.4	0.29	12.2	0.34
Ureter	20	0.9	0.09	1.0	0.10	11	0.4	0.05	0.5	0.06
Eye & Orbit	33	1.4	0.11	1.7	0.13	26	1.1	0.10	1.2	0.11
Brain & Other CNS ¹	191	8.7	0.29	9.6	0.32	140	6.0	0.24	6.5	0.25
Brain	185	8.4	0.28	9.3	0.31	131	5.6	0.23	6.0	0.24
Endocrine System	175	8.0	0.28	8.9	0.30	447	20.8	0.46	22.3	0.48
Thyroid gland	157	7.2	0.26	8.0	0.29	432	20.2	0.45	21.6	0.47
Lymphomas	568	25.2	0.49	29.0	0.55	458	18.0	0.39	20.6	0.44
Hodgkin Lymphoma	50	2.4	0.15	2.5	0.16	46	2.3	0.15	2.3	0.15
Non-Hodgkin Lymphoma	518	22.8	0.46	26.5	0.53	412	15.7	0.36	18.3	0.41
Multiple Myeloma	161	7.0	0.25	8.3	0.30	116	4.3	0.18	5.1	0.21
Leukemias	371	16.8	0.40	19.0	0.45	252	10.0	0.29	11.2	0.32
Acute lymphocytic	36	1.9	0.15	1.7	0.13	26	1.4	0.13	1.2	0.11
Chronic lymphocytic	137	6.0	0.23	7.0	0.27	88	3.1	0.15	3.8	0.18
Acute myeloid	117	5.2	0.22	6.0	0.25	85	3.4	0.17	3.8	0.19
Chronic myeloid	38	1.7	0.13	2.0	0.15	31	1.2	0.10	1.4	0.11
Other leukemias	42	2.0	0.14	2.3	0.16	22	0.9	0.08	1.0	0.09
Mesothelioma	36	1.6	0.13	1.9	0.14	9	0.3	0.05	0.4	0.06
Kaposi Sarcoma	8	0.4	0.07	0.4	0.07	-	-	-	-	-
Ill-defined & Unknown	352	15.7	0.38	18.3	0.44	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	161	7.3	0.26	8.2	0.29	284	11.7	0.32	13.3	0.36
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	633	25.4	0.47	30.1	0.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	10,138	459.2	2.10	543.7	2.45	10,052	421.4	1.96	491.2	2.23
Oral Cavity & Pharynx	418	18.4	0.42	22.5	0.50	170	6.9	0.25	8.3	0.29
Lip	19	0.9	0.09	1.0	0.10	9	0.3	0.05	0.4	0.06
Tongue	152	6.6	0.25	8.1	0.30	60	2.5	0.15	3.0	0.17
Major salivary gland	28	1.3	0.12	1.6	0.13	22	1.0	0.10	1.1	0.11
Floor of mouth	18	0.7	0.08	0.9	0.10	10	0.4	0.06	0.5	0.07
Gum & other mouth	39	1.8	0.13	2.1	0.15	34	1.4	0.11	1.6	0.13
Nasopharynx	10	0.4	0.07	0.5	0.08	3	0.1	0.03	0.1	0.04
Oropharynx	19	0.8	0.08	1.0	0.11	7	0.2	0.04	0.3	0.05
Hypopharynx	19	0.8	0.09	1.0	0.10	6	0.2	0.05	0.3	0.05
Digestive System	2,004	90.7	0.93	108.8	1.10	1,514	61.2	0.73	72.0	0.84
Esophagus	194	8.6	0.29	10.4	0.34	50	2.0	0.13	2.3	0.15
Stomach	156	7.2	0.26	8.5	0.31	79	3.4	0.18	3.8	0.20
Small intestine	57	2.6	0.16	3.1	0.19	52	2.1	0.14	2.5	0.16
Colon excl. rectum	540	25.5	0.50	30.0	0.58	562	22.8	0.45	26.6	0.51
Rectum & rectosigmoid	289	13.3	0.36	16.0	0.43	184	7.8	0.27	9.2	0.31
Anus, anal canal & anorectum	33	1.6	0.13	1.8	0.15	72	2.9	0.16	3.5	0.19
Liver	290	11.6	0.31	15.0	0.40	85	3.2	0.16	3.9	0.19
Gallbladder	17	0.8	0.09	0.9	0.10	30	1.1	0.10	1.4	0.11
Pancreas	332	15.0	0.38	17.8	0.44	295	11.6	0.31	13.7	0.36
Respiratory System	1,398	63.2	0.78	74.8	0.91	1,329	52.2	0.66	61.4	0.76
Larynx	93	4.0	0.19	4.9	0.23	20	0.8	0.08	0.9	0.10
Lung & bronchus	1,279	58.0	0.74	68.4	0.87	1,296	50.8	0.65	59.8	0.75
Bones & Joints	21	1.2	0.12	1.2	0.12	14	0.8	0.10	0.8	0.09
Soft Tissue (incl. heart)	78	3.8	0.20	4.3	0.22	66	3.0	0.17	3.3	0.18
Skin (excl. basal & sq.)	769	36.0	0.60	42.0	0.69	585	26.2	0.51	29.8	0.56
Melanomas of the skin	733	34.2	0.58	40.1	0.67	556	25.0	0.50	28.4	0.55
Breast (excl. <i>in situ</i>)	25	1.2	0.11	1.4	0.13	3,007	126.8	1.08	149.5	1.24
Female Genital System	-	-	-	-	-	1,241	52.0	0.69	61.8	0.80
Cervix uteri	-	-	-	-	-	132	7.0	0.28	7.5	0.29
Uterus Corpus	-	-	-	-	-	690	27.7	0.49	34.0	0.59
Uterus, NOS ¹	-	-	-	-	-	25	1.0	0.09	1.2	0.11
Ovary	-	-	-	-	-	282	11.9	0.33	13.9	0.38
Male Genital System	2,338	99.0	0.94	120.0	1.12	-	-	-	-	-
Prostate	2,193	90.8	0.89	111.7	1.08	-	-	-	-	-
Testis	124	7.2	0.29	7.1	0.29	-	-	-	-	-
Penis	16	0.8	0.09	0.9	0.10	-	-	-	-	-
Urinary System	1,306	60.4	0.77	71.1	0.89	491	19.8	0.41	23.2	0.48
Bladder (incl. <i>in situ</i>)	794	37.0	0.60	43.4	0.70	223	8.6	0.26	10.2	0.31
Kidney & renal pelvis	484	22.1	0.46	26.2	0.54	253	10.6	0.31	12.4	0.35
Ureter	18	0.8	0.09	1.0	0.10	10	0.4	0.06	0.5	0.06
Eye & Orbit	32	1.5	0.12	1.7	0.14	26	1.1	0.10	1.3	0.11
Brain & Other CNS ¹	179	8.8	0.30	9.8	0.33	134	6.3	0.26	6.7	0.26
Brain	173	8.5	0.30	9.5	0.33	125	5.8	0.24	6.3	0.25
Endocrine System	164	8.1	0.29	9.0	0.32	399	20.6	0.48	22.0	0.50
Thyroid gland	147	7.3	0.28	8.2	0.30	387	20.0	0.47	21.4	0.49
Lymphomas	532	25.3	0.50	29.1	0.57	432	18.3	0.41	20.9	0.46
Hodgkin Lymphoma	46	2.4	0.16	2.5	0.17	43	2.3	0.16	2.3	0.16
Non-Hodgkin Lymphoma	487	22.9	0.48	26.5	0.54	390	15.9	0.37	18.6	0.43
Multiple Myeloma	152	7.0	0.26	8.3	0.31	110	4.3	0.19	5.1	0.22
Leukemias	349	16.9	0.42	19.1	0.46	238	10.3	0.31	11.4	0.34
Acute lymphocytic	32	1.9	0.15	1.7	0.14	24	1.5	0.14	1.3	0.12
Chronic lymphocytic	130	6.0	0.24	7.0	0.28	85	3.2	0.16	3.9	0.19
Acute myeloid	111	5.3	0.23	6.1	0.26	79	3.5	0.18	3.9	0.20
Chronic myeloid	36	1.7	0.13	2.0	0.15	30	1.3	0.11	1.4	0.12
Other leukemias	41	2.0	0.14	2.3	0.16	20	0.9	0.09	1.0	0.10
Mesothelioma	34	1.7	0.13	1.9	0.15	9	0.3	0.05	0.4	0.06
Kaposi Sarcoma	7	0.4	0.07	0.4	0.07	-	-	-	-	-
Ill-defined & Unknown	331	15.6	0.39	18.3	0.46	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	149	7.3	0.28	8.2	0.30	260	11.6	0.34	13.2	0.37
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	583	25.3	0.49	30.0	0.57

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

OREGON

II-414 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	187	497.8	18.42	597.8	21.30	134	376.6	15.08	444.7	17.61
Oral Cavity & Pharynx	4	8.7	2.19	10.3	2.52	2	5.3	1.82	5.6	1.95
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	41	107.9	8.42	130.1	9.75	25	73.7	6.78	87.9	7.95
Esophagus	1	3.6	1.48	4.1	1.62	-	-	-	-	-
Stomach	5	11.5	2.58	13.9	2.99	2	5.9	1.90	6.7	2.17
Small intestine	-	-	-	-	-	1	2.9	1.19	3.5	1.47
Colon excl. rectum	9	25.4	4.38	29.6	4.91	8	24.5	3.91	28.6	4.53
Rectum & rectosigmoid	4	9.2	2.39	11.5	2.91	2	5.9	1.77	7.6	2.25
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	12	28.9	4.01	37.0	4.93	2	6.8	2.15	8.0	2.46
Gallbladder	-	-	-	-	-	1	3.6	1.53	4.4	1.82
Pancreas	7	21.5	4.11	24.8	4.59	5	15.7	3.13	19.3	3.76
Respiratory System	28	80.2	7.71	95.5	8.83	18	57.0	6.19	68.2	7.24
Larynx	2	4.9	1.63	6.2	2.00	-	-	-	-	-
Lung & bronchus	25	74.0	7.50	87.7	8.54	18	56.6	6.18	67.5	7.21
Bones & Joints	1	2.2	0.89	2.2	0.92	-	-	-	-	-
Soft Tissue (incl. heart)	1	2.0	0.83	2.2	0.97	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	42	113.7	8.05	134.3	9.43
Female Genital System	-	-	-	-	-	14	38.4	4.69	46.2	5.56
Cervix uteri	-	-	-	-	-	1	4.0	1.54	4.1	1.60
Uterus Corpus	-	-	-	-	-	9	23.0	3.59	29.0	4.42
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	8.0	2.19	9.4	2.53
Male Genital System	62	161.7	10.38	198.8	12.20	-	-	-	-	-
Prostate	60	157.3	10.25	194.0	12.05	-	-	-	-	-
Testis	2	4.1	1.64	4.3	1.81	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	17	42.4	5.14	51.0	5.91	7	20.7	3.63	24.4	4.23
Bladder (incl. <i>in situ</i>)	5	13.8	3.10	16.1	3.44	4	11.2	2.72	13.4	3.20
Kidney & renal pelvis	12	27.0	3.86	32.8	4.52	3	9.1	2.36	10.4	2.69
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	6.8	1.97	8.3	2.37	2	4.0	1.46	4.8	1.75
Brain	3	6.6	1.95	8.1	2.36	-	-	-	-	-
Endocrine System	2	5.7	1.80	6.4	1.97	8	21.0	3.41	22.9	3.74
Thyroid gland	2	3.7	1.45	4.0	1.54	8	19.6	3.32	21.3	3.61
Lymphomas	9	22.0	3.70	25.9	4.22	5	12.9	2.84	14.4	3.20
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	4	11.2	2.69	13.0	3.11
Multiple Myeloma	4	13.1	3.29	15.2	3.76	2	6.5	2.00	7.3	2.23
Leukemias	6	18.8	3.84	21.2	4.29	4	8.9	2.19	11.3	2.76
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	7.3	2.42	8.4	2.71	-	-	-	-	-
Acute myeloid	2	5.5	1.94	6.2	2.11	2	4.5	1.66	5.5	2.03
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	18.5	4.12	22.0	4.82	4	10.5	2.60	13.3	3.18
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.2	1.47	5.0	1.71	4	10.8	2.47	12.9	2.95
Breast (<i>in situ</i>)	-	-	-	-	-	11	29.6	4.07	36.0	4.86

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, Asian/Pacific Islander (API)**

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	230	311.0	9.69	363.2	11.19	320	300.5	7.76	349.2	8.96
Oral Cavity & Pharynx	11	12.0	1.70	13.8	1.98	6	5.1	0.99	5.9	1.15
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	2.7	0.77	3.1	0.88	-	-	-	-	-
Major salivary gland	-	-	-	-	-	1	1.0	0.40	1.2	0.48
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.8	0.71	2.3	0.88	-	-	-	-	-
Nasopharynx	4	4.4	0.96	5.2	1.15	2	1.9	0.61	2.1	0.68
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	74	100.1	5.48	117.6	6.33	69	69.2	3.87	81.8	4.51
Esophagus	3	4.0	1.11	4.6	1.28	-	-	-	-	-
Stomach	9	13.4	2.09	15.7	2.42	9	9.4	1.43	10.6	1.60
Small intestine	2	2.3	0.87	2.9	1.04	-	-	-	-	-
Colon excl. rectum	15	21.3	2.63	24.3	2.93	21	20.7	2.11	24.6	2.46
Rectum & rectosigmoid	13	14.5	1.85	17.6	2.24	9	8.8	1.32	10.4	1.55
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	17	22.0	2.46	26.1	2.87	8	8.5	1.40	10.1	1.62
Gallbladder	1	1.9	0.80	2.0	0.86	2	1.9	0.65	2.3	0.77
Pancreas	8	12.0	2.00	14.1	2.33	11	12.0	1.64	14.3	1.92
Respiratory System	38	54.7	4.19	64.8	4.87	34	35.5	2.80	41.8	3.26
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	36	52.1	4.10	61.7	4.77	33	34.0	2.75	40.1	3.20
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	3.8	1.04	4.2	1.15	2	2.0	0.63	2.1	0.70
Skin (excl. basal & sq.)	-	-	-	-	-	3	2.6	0.68	3.0	0.79
Melanomas of the skin	-	-	-	-	-	2	2.1	0.62	2.4	0.71
Breast (excl. <i>in situ</i>)	-	-	-	-	-	98	87.1	4.05	101.9	4.72
Female Genital System	-	-	-	-	-	38	33.6	2.50	39.9	2.96
Cervix uteri	-	-	-	-	-	7	6.2	1.10	6.6	1.18
Uterus Corpus	-	-	-	-	-	18	14.7	1.59	18.2	1.97
Uterus, NOS ¹	-	-	-	-	-	1	1.3	0.49	1.6	0.61
Ovary	-	-	-	-	-	10	9.1	1.35	10.8	1.58
Male Genital System	39	52.2	3.94	63.2	4.65	-	-	-	-	-
Prostate	36	49.3	3.86	60.1	4.57	-	-	-	-	-
Testis	2	1.8	0.56	1.8	0.56	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	17	23.6	2.74	27.1	3.13	8	7.3	1.23	8.7	1.44
Bladder (incl. <i>in situ</i>)	9	13.7	2.17	15.5	2.43	2	2.3	0.70	2.8	0.84
Kidney & renal pelvis	6	7.9	1.48	9.1	1.72	5	4.9	1.01	5.9	1.17
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	5	5.6	1.14	5.9	1.23	3	2.7	0.75	2.7	0.75
Brain	5	5.3	1.11	5.6	1.21	3	2.7	0.75	2.7	0.75
Endocrine System	7	9.1	1.61	10.2	1.79	30	24.7	2.07	26.8	2.27
Thyroid gland	6	8.1	1.51	8.9	1.67	28	23.4	2.00	25.2	2.19
Lymphomas	15	20.5	2.57	23.3	2.93	11	11.0	1.54	12.4	1.72
Hodgkin Lymphoma	1	1.0	0.42	1.0	0.39	1	0.9	0.36	0.9	0.40
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	3	3.5	1.04	4.1	1.19	3	2.4	0.68	2.7	0.78
Leukemias	8	10.2	1.73	11.0	1.90	7	6.0	1.05	6.6	1.18
Acute lymphocytic	2	2.3	0.67	1.9	0.55	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	3.6	1.11	4.2	1.27	3	3.1	0.77	3.5	0.87
Chronic myeloid	1	1.4	0.55	1.6	0.64	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	9	12.2	1.95	14.1	2.24	10	10.4	1.56	11.7	1.73
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	6	7.8	1.50	8.5	1.69	12	10.8	1.42	12.4	1.64
Breast (<i>in situ</i>)	-	-	-	-	-	27	23.5	2.07	28.0	2.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

OREGON

II-416 Incidence – API

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	115	370.7	17.05	443.6	19.94	131	379.8	15.95	446.6	18.35
Oral Cavity & Pharynx	4	11.4	2.75	14.7	3.40	2	5.2	1.75	6.4	2.07
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	31	95.4	8.34	117.5	9.98	24	72.8	7.25	86.7	8.43
Esophagus	2	7.5	2.59	8.8	2.98	-	-	-	-	-
Stomach	1	3.9	1.92	4.9	2.38	2	4.2	1.63	5.2	1.98
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	25.2	4.54	30.7	5.32	6	20.4	3.85	22.9	4.33
Rectum & rectosigmoid	4	12.6	2.77	14.5	3.15	3	8.8	2.37	10.6	2.77
Anus, anal canal & anorectum	-	-	-	-	-	1	2.6	1.09	3.5	1.44
Liver	8	18.5	3.04	25.1	4.09	3	9.3	2.78	11.5	3.29
Gallbladder	-	-	-	-	-	1	4.2	1.88	5.0	2.20
Pancreas	5	17.3	3.55	20.9	4.18	4	15.5	3.58	17.9	4.03
Respiratory System	23	79.5	8.27	95.8	9.73	21	67.3	7.07	79.6	8.07
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	22	76.4	8.11	92.5	9.58	21	66.1	7.03	77.8	8.01
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	5	16.9	3.63	19.2	4.09	4	11.9	2.79	13.2	3.10
Melanomas of the skin	4	13.8	3.25	15.9	3.72	4	10.8	2.67	12.1	2.98
Breast (excl. <i>in situ</i>)	-	-	-	-	-	34	92.2	7.46	110.1	8.69
Female Genital System	-	-	-	-	-	21	55.1	5.79	65.6	6.80
Cervix uteri	-	-	-	-	-	4	11.3	2.57	12.0	2.75
Uterus Corpus	-	-	-	-	-	10	24.4	3.64	30.2	4.44
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	14.4	3.32	17.0	3.86
Male Genital System	18	54.5	6.16	65.0	7.13	-	-	-	-	-
Prostate	16	48.1	5.90	58.9	6.92	-	-	-	-	-
Testis	2	5.3	1.63	5.1	1.55	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	13	47.0	6.46	55.1	7.44	7	21.7	4.05	25.3	4.59
Bladder (incl. <i>in situ</i>)	6	23.4	4.92	27.8	5.72	2	8.4	2.61	9.4	2.83
Kidney & renal pelvis	7	22.5	4.04	26.2	4.64	4	13.4	3.09	16.0	3.62
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	2	6.2	2.20	6.9	2.44	-	-	-	-	-
Brain	2	6.2	2.20	6.9	2.44	-	-	-	-	-
Endocrine System	-	-	-	-	-	6	15.9	2.94	16.7	3.07
Thyroid gland	-	-	-	-	-	6	15.9	2.94	16.7	3.07
Lymphomas	7	17.4	3.13	20.6	3.73	5	15.1	3.31	18.0	3.88
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	4	13.0	3.14	16.0	3.75
Multiple Myeloma	1	5.9	2.49	7.0	2.94	-	-	-	-	-
Leukemias	3	11.0	2.94	12.3	3.28	2	5.0	1.62	5.6	1.83
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	4.5	2.02	5.3	2.28	-	-	-	-	-
Acute myeloid	2	5.0	1.92	5.5	2.15	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	16.5	3.98	19.9	4.69	3	9.6	2.78	10.6	3.05
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	2	6.0	2.16	6.7	2.33	6	15.6	2.94	17.9	3.33
Breast (<i>in situ</i>)	-	-	-	-	-	6	16.5	3.15	20.2	3.73

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	392	343.9	9.35	405.0	10.75	479	361.3	8.36	423.9	9.74
Oral Cavity & Pharynx	11	8.8	1.35	10.8	1.61	5	4.3	0.91	5.2	1.10
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	3.2	0.89	3.7	1.02	2	1.7	0.54	2.2	0.68
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.0	0.40	1.2	0.47	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	104	91.4	4.75	110.2	5.55	90	76.3	4.01	91.6	4.71
Esophagus	5	5.5	1.28	6.4	1.44	2	2.6	0.82	3.0	0.94
Stomach	13	12.0	1.80	13.9	2.06	10	8.3	1.33	9.3	1.49
Small intestine	2	2.2	0.77	2.6	0.86	3	2.1	0.59	2.8	0.76
Colon excl. rectum	27	23.3	2.40	28.1	2.81	24	19.1	1.96	23.1	2.33
Rectum & rectosigmoid	16	12.8	1.69	15.5	2.01	13	9.7	1.33	11.9	1.60
Anus, anal canal & anorectum	-	-	-	-	-	3	2.1	0.55	2.6	0.71
Liver	21	17.2	1.88	21.7	2.28	9	7.3	1.21	9.3	1.49
Gallbladder	2	1.2	0.49	1.4	0.55	3	2.2	0.68	2.7	0.80
Pancreas	13	12.8	1.85	15.3	2.13	15	14.2	1.83	16.7	2.10
Respiratory System	32	37.1	3.35	43.4	3.80	34	35.1	2.95	40.9	3.35
Larynx	3	2.2	0.68	2.7	0.80	-	-	-	-	-
Lung & bronchus	29	34.2	3.26	39.7	3.68	33	34.7	2.94	40.3	3.33
Bones & Joints	2	0.7	0.21	0.7	0.20	2	1.1	0.39	1.2	0.46
Soft Tissue (incl. heart)	7	5.3	1.11	5.8	1.21	5	3.2	0.77	3.4	0.86
Skin (excl. basal & sq.)	-	-	-	-	-	12	9.0	1.37	10.2	1.52
Melanomas of the skin	7	6.3	1.29	7.0	1.42	11	7.9	1.25	8.9	1.41
Breast (excl. <i>in situ</i>)	-	-	-	-	-	136	99.2	4.20	117.3	4.95
Female Genital System	-	-	-	-	-	69	46.4	2.77	55.6	3.33
Cervix uteri	-	-	-	-	-	13	7.2	0.95	8.0	1.09
Uterus Corpus	-	-	-	-	-	37	25.8	2.05	32.0	2.54
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	15	10.9	1.50	12.5	1.69
Male Genital System	93	83.7	4.50	99.8	5.18	-	-	-	-	-
Prostate	78	78.5	4.45	94.5	5.14	-	-	-	-	-
Testis	14	4.5	0.54	4.3	0.52	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	43	40.9	3.34	48.5	3.88	23	18.8	1.95	22.6	2.32
Bladder (incl. <i>in situ</i>)	17	20.2	2.52	23.7	2.89	5	5.4	1.17	6.2	1.35
Kidney & renal pelvis	25	19.9	2.14	23.9	2.52	17	12.3	1.49	14.9	1.79
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	1.5	0.71	1.7	0.82	-	-	-	-	-
Brain & Other CNS ¹	9	5.7	1.14	6.3	1.27	8	4.7	0.90	5.0	1.01
Brain	9	5.6	1.14	6.2	1.27	8	4.6	0.90	4.9	1.01
Endocrine System	11	7.0	1.15	7.9	1.29	42	21.9	1.68	23.5	1.88
Thyroid gland	10	6.5	1.13	7.4	1.27	40	20.7	1.61	22.3	1.79
Lymphomas	27	20.3	2.16	23.3	2.47	22	16.4	1.77	19.1	2.06
Hodgkin Lymphoma	3	1.5	0.40	1.8	0.52	4	2.1	0.58	2.3	0.66
Non-Hodgkin Lymphoma	24	18.8	2.12	21.5	2.41	19	14.3	1.68	16.8	1.95
Multiple Myeloma	7	6.8	1.38	8.2	1.62	4	4.7	1.09	5.5	1.23
Leukemias	22	13.7	1.76	14.8	1.95	14	8.2	1.16	9.0	1.34
Acute lymphocytic	-	-	-	-	-	6	2.3	0.52	2.2	0.54
Chronic lymphocytic	2	3.0	0.98	3.6	1.12	1	0.9	0.41	1.2	0.53
Acute myeloid	7	5.1	1.16	5.6	1.24	6	3.3	0.67	3.6	0.79
Chronic myeloid	3	2.0	0.65	2.3	0.76	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	1.5	0.69	1.6	0.71	-	-	-	-	-
Kaposi Sarcoma	1	1.0	0.48	1.0	0.56	-	-	-	-	-
Ill-defined & Unknown	9	10.3	1.81	11.7	2.04	11	11.8	1.74	13.4	1.95
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	8	3.9	0.73	4.2	0.81	20	14.1	1.62	15.7	1.82
Breast (<i>in situ</i>)	-	-	-	-	-	28	19.0	1.70	22.5	2.03

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

OREGON

II-418 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,768	465.2	2.18	550.7	2.53	9,589	424.1	2.05	494.0	2.31
Oral Cavity & Pharynx	407	19.0	0.44	23.2	0.52	165	7.1	0.26	8.4	0.30
Lip	18	0.9	0.09	1.0	0.11	8	0.3	0.05	0.4	0.06
Tongue	148	6.8	0.26	8.4	0.31	58	2.6	0.16	3.0	0.18
Major salivary gland	27	1.4	0.12	1.6	0.14	21	1.0	0.10	1.2	0.12
Floor of mouth	17	0.8	0.08	0.9	0.10	10	0.4	0.06	0.5	0.07
Gum & other mouth	38	1.8	0.14	2.1	0.16	33	1.4	0.11	1.6	0.13
Nasopharynx	9	0.5	0.07	0.5	0.08	3	0.1	0.03	0.1	0.04
Oropharynx	19	0.8	0.09	1.1	0.11	7	0.3	0.05	0.3	0.06
Hypopharynx	18	0.8	0.09	1.0	0.11	6	0.2	0.05	0.3	0.06
Digestive System	1,905	90.5	0.96	108.6	1.13	1,428	60.3	0.75	71.0	0.86
Esophagus	189	8.8	0.29	10.5	0.35	48	2.0	0.13	2.3	0.15
Stomach	144	6.9	0.27	8.2	0.31	69	3.0	0.17	3.5	0.19
Small intestine	54	2.7	0.17	3.1	0.19	49	2.1	0.14	2.5	0.16
Colon excl. rectum	515	25.6	0.52	30.1	0.60	540	22.9	0.46	26.6	0.53
Rectum & rectosigmoid	274	13.4	0.38	16.0	0.44	172	7.7	0.28	9.1	0.32
Anus, anal canal & anorectum	32	1.6	0.13	1.9	0.15	69	2.9	0.17	3.6	0.20
Liver	270	11.3	0.32	14.6	0.40	76	3.0	0.16	3.7	0.19
Gallbladder	15	0.8	0.09	0.9	0.10	27	1.1	0.10	1.3	0.11
Pancreas	319	15.1	0.39	17.9	0.46	281	11.5	0.32	13.6	0.37
Respiratory System	1,368	64.4	0.80	76.2	0.93	1,297	52.8	0.67	62.2	0.78
Larynx	90	4.1	0.20	5.0	0.24	19	0.8	0.08	1.0	0.10
Lung & bronchus	1,253	59.0	0.77	69.7	0.89	1,264	51.4	0.66	60.5	0.77
Bones & Joints	19	1.2	0.13	1.2	0.13	12	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	71	3.7	0.21	4.3	0.23	61	3.0	0.19	3.3	0.19
Skin (excl. basal & sq.)	762	37.8	0.63	44.0	0.72	574	27.7	0.55	31.4	0.60
Melanomas of the skin	727	36.0	0.62	42.0	0.71	546	26.6	0.54	30.1	0.59
Breast (excl. <i>in situ</i>)	25	1.2	0.11	1.4	0.13	2,874	128.0	1.13	150.9	1.29
Female Genital System	-	-	-	-	-	1,173	52.0	0.72	61.8	0.83
Cervix uteri	-	-	-	-	-	119	7.0	0.30	7.4	0.31
Uterus Corpus	-	-	-	-	-	653	27.5	0.51	33.8	0.61
Uterus, NOS ¹	-	-	-	-	-	24	1.0	0.10	1.2	0.11
Ovary	-	-	-	-	-	267	11.9	0.34	13.9	0.39
Male Genital System	2,250	100.0	0.98	121.2	1.16	-	-	-	-	-
Prostate	2,120	91.5	0.91	112.6	1.11	-	-	-	-	-
Testis	111	7.5	0.32	7.4	0.32	-	-	-	-	-
Penis	16	0.8	0.09	0.9	0.11	-	-	-	-	-
Urinary System	1,266	61.2	0.79	72.0	0.92	469	19.8	0.43	23.2	0.49
Bladder (incl. <i>in situ</i>)	778	37.6	0.62	44.1	0.72	218	8.7	0.27	10.3	0.32
Kidney & renal pelvis	461	22.3	0.48	26.4	0.56	237	10.5	0.32	12.3	0.37
Ureter	18	0.9	0.09	1.0	0.11	10	0.4	0.06	0.5	0.07
Eye & Orbit	30	1.5	0.13	1.7	0.14	25	1.2	0.11	1.3	0.12
Brain & Other CNS ¹	171	9.2	0.33	10.2	0.35	126	6.5	0.28	6.9	0.28
Brain	166	8.9	0.32	9.9	0.35	118	5.9	0.26	6.4	0.27
Endocrine System	152	8.3	0.32	9.2	0.34	358	20.2	0.51	21.7	0.52
Thyroid gland	137	7.5	0.30	8.3	0.32	347	19.7	0.50	21.1	0.52
Lymphomas	506	25.5	0.53	29.3	0.59	411	18.4	0.43	21.0	0.48
Hodgkin Lymphoma	43	2.6	0.18	2.7	0.19	39	2.5	0.18	2.4	0.18
Non-Hodgkin Lymphoma	463	22.9	0.49	26.7	0.56	372	15.9	0.39	18.5	0.44
Multiple Myeloma	145	7.0	0.27	8.3	0.31	106	4.3	0.20	5.2	0.23
Leukemias	328	16.8	0.43	19.1	0.48	224	10.2	0.33	11.4	0.35
Acute lymphocytic	23	1.6	0.16	1.5	0.14	18	1.3	0.15	1.2	0.13
Chronic lymphocytic	127	6.1	0.25	7.2	0.29	84	3.3	0.17	4.0	0.20
Acute myeloid	104	5.2	0.24	6.0	0.27	74	3.4	0.19	3.8	0.20
Chronic myeloid	33	1.7	0.14	1.9	0.15	29	1.3	0.11	1.5	0.13
Other leukemias	40	2.1	0.15	2.4	0.17	19	0.9	0.09	1.0	0.10
Mesothelioma	33	1.7	0.13	1.9	0.15	9	0.4	0.06	0.4	0.06
Kaposi Sarcoma	5	0.3	0.06	0.3	0.07	-	-	-	-	-
Ill-defined & Unknown	323	15.9	0.41	18.6	0.47	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	141	7.5	0.30	8.4	0.32	240	11.4	0.35	13.0	0.39
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	556	25.7	0.52	30.3	0.59

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Oregon, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	184	523.4	19.36	628.5	22.42	132	400.3	16.06	472.0	18.72
Oral Cavity & Pharynx	4	9.4	2.35	11.0	2.69	2	5.8	1.99	6.2	2.12
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	40	113.3	8.87	136.4	10.27	25	77.9	7.19	92.7	8.42
Esophagus	1	3.9	1.59	4.4	1.74	-	-	-	-	-
Stomach	4	11.5	2.69	13.7	3.08	2	6.3	2.03	7.2	2.30
Small intestine	-	-	-	-	-	1	3.2	1.33	3.9	1.62
Colon excl. rectum	8	26.7	4.61	30.9	5.16	8	25.7	4.14	30.0	4.78
Rectum & rectosigmoid	4	9.8	2.55	12.3	3.11	2	6.5	1.92	8.3	2.44
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	12	30.6	4.24	39.3	5.22	2	6.7	2.21	7.8	2.50
Gallbladder	-	-	-	-	-	1	3.8	1.61	4.6	1.92
Pancreas	7	22.3	4.31	25.7	4.81	5	16.7	3.31	20.5	3.99
Respiratory System	27	82.5	8.01	98.6	9.20	18	59.2	6.44	70.9	7.55
Larynx	2	5.2	1.73	6.6	2.12	-	-	-	-	-
Lung & bronchus	24	76.0	7.79	90.3	8.90	18	58.7	6.42	70.2	7.52
Bones & Joints	1	2.5	1.01	2.4	1.03	-	-	-	-	-
Soft Tissue (incl. heart)	1	2.2	0.93	2.5	1.07	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	42	122.6	8.69	144.4	10.13
Female Genital System	-	-	-	-	-	14	40.6	5.03	49.0	5.95
Cervix uteri	-	-	-	-	-	1	3.8	1.59	4.1	1.68
Uterus Corpus	-	-	-	-	-	9	24.3	3.83	30.6	4.71
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	8.7	2.38	10.3	2.75
Male Genital System	62	171.5	10.96	210.8	12.89	-	-	-	-	-
Prostate	60	166.6	10.81	205.5	12.73	-	-	-	-	-
Testis	2	4.5	1.76	4.7	1.92	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	17	44.8	5.42	53.9	6.25	7	21.4	3.79	25.3	4.43
Bladder (incl. <i>in situ</i>)	5	14.6	3.27	17.0	3.63	3	11.2	2.80	13.5	3.30
Kidney & renal pelvis	11	28.4	4.08	34.7	4.79	3	9.7	2.52	11.1	2.87
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	7.0	2.06	8.4	2.47	2	4.4	1.61	5.3	1.92
Brain	3	6.7	2.04	8.2	2.45	-	-	-	-	-
Endocrine System	2	6.2	1.93	6.9	2.11	8	22.8	3.72	24.9	4.08
Thyroid gland	2	4.0	1.56	4.3	1.65	7	21.3	3.62	23.1	3.94
Lymphomas	9	23.6	3.93	27.8	4.48	5	14.0	3.04	15.5	3.39
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	4	13.9	3.48	16.1	3.99	2	7.0	2.15	7.8	2.40
Leukemias	6	20.0	4.05	22.6	4.52	3	9.0	2.28	11.4	2.86
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	7.7	2.54	8.8	2.85	-	-	-	-	-
Acute myeloid	2	5.9	2.05	6.6	2.24	2	4.8	1.76	5.9	2.15
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	18.1	4.19	21.7	4.94	4	11.2	2.74	14.1	3.37
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.6	1.58	5.5	1.83	4	10.7	2.54	12.6	3.00
Breast (<i>in situ</i>)	-	-	-	-	-	11	31.7	4.37	38.2	5.20

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


OREGON

II-420 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	12,776,621	12,789,101	12,785,759	12,783,538	12,790,447
White	10,730,634	10,711,090	10,680,421	10,647,668	10,624,947
Black	1,563,805	1,578,277	1,590,821	1,604,568	1,617,787
American Indian/Alaskan Native (AI/AN)	51,498	52,754	54,197	55,777	57,119
Asian/Pacific Islander (API)	430,684	446,980	460,320	475,525	490,594


All Races Population 2013-2017: 63,925,466
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	812,300	841,689	870,604	902,531	936,811
Non-Hispanic White	10,092,643	10,051,561	9,999,645	9,943,509	9,894,926
Non-Hispanic Black	1,433,872	1,442,472	1,449,300	1,456,832	1,463,492

Hispanic/Latino Population, Census 2010: 719,660
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

PENNSYLVANIA CANCER REGISTRY

Initial Operation: 1982
 Population-based Data Available: 1985
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.2	108.3	109.2	107.8	106.9
Missing Race	1.4	1.5	1.5	1.6	1.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.7	2.3	2.3	2.5	2.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.9	Prostate	96.9
Oral Cavity & Pharynx	98.2	Testis	99.4
Esophagus	95.9	Bladder (incl. <i>in situ</i>)	98.0
Stomach	97.1	Kidney & Renal Pelvis	89.0
Colon & Rectum	96.0	Brain & Other CNS ¹	82.3
Liver	50.5	Thyroid	99.6
Pancreas	84.8	Hodgkin Lymphoma	98.8
Lung & Bronchus	87.3	Non-Hodgkin Lymphoma	97.1
Melanomas of the Skin	99.5	Multiple Myeloma	90.6
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	89.8
Cervix uteri	98.2	Brain & Other CNS ¹ <i>non-malig</i>	35.1
Uterus Corpus & Uterus NOS ¹	98.7	Breast <i>in situ</i>	100.0
Ovary	92.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	39,560	522.3	1.20	619.2	1.40	40,035	462.2	1.08	538.3	1.23
Oral Cavity & Pharynx	1,401	18.0	0.22	22.0	0.26	604	6.8	0.13	8.1	0.15
Lip	55	0.8	0.05	0.9	0.05	29	0.3	0.03	0.4	0.03
Tongue	443	5.6	0.12	6.9	0.15	187	2.1	0.07	2.5	0.08
Major salivary gland	118	1.6	0.07	1.9	0.08	90	1.1	0.05	1.2	0.06
Floor of mouth	70	0.9	0.05	1.1	0.06	28	0.3	0.03	0.4	0.03
Gum & other mouth	168	2.2	0.08	2.6	0.09	126	1.4	0.06	1.6	0.06
Nasopharynx	49	0.7	0.04	0.8	0.05	24	0.3	0.03	0.4	0.03
Oropharynx	63	0.8	0.04	1.0	0.05	21	0.2	0.02	0.3	0.03
Hypopharynx	93	1.2	0.05	1.4	0.07	21	0.2	0.02	0.3	0.03
Digestive System	7,876	104.0	0.54	124.1	0.63	6,277	68.0	0.40	80.0	0.46
Esophagus	709	9.2	0.16	11.0	0.19	192	2.0	0.07	2.4	0.08
Stomach	665	8.9	0.16	10.5	0.18	362	4.0	0.10	4.6	0.11
Small intestine	223	3.0	0.09	3.5	0.11	199	2.2	0.07	2.7	0.09
Colon excl. rectum	2,372	32.2	0.30	37.8	0.35	2,468	26.5	0.25	30.9	0.28
Rectum & rectosigmoid	1,137	15.2	0.21	18.1	0.24	819	9.4	0.15	11.1	0.18
Anus, anal canal & anorectum	118	1.5	0.07	1.9	0.08	207	2.4	0.08	2.9	0.09
Liver	952	11.6	0.17	14.6	0.21	289	3.1	0.09	3.8	0.10
Gallbladder	60	0.8	0.05	0.9	0.05	128	1.3	0.05	1.6	0.06
Pancreas	1,270	16.7	0.21	19.9	0.25	1,185	12.4	0.17	14.7	0.19
Respiratory System	6,150	80.6	0.47	95.8	0.55	5,471	58.6	0.36	69.8	0.43
Larynx	470	6.0	0.13	7.3	0.15	136	1.5	0.06	1.8	0.07
Lung & bronchus	5,594	73.4	0.45	87.1	0.52	5,273	56.4	0.36	67.2	0.42
Bones & Joints	77	1.2	0.06	1.2	0.06	60	0.8	0.05	0.9	0.05
Soft Tissue (incl. heart)	267	3.8	0.11	4.3	0.12	221	2.8	0.09	3.1	0.09
Skin (excl. basal & sq.)	2,404	32.8	0.31	38.2	0.35	1,724	21.6	0.24	24.4	0.27
Melanomas of the skin	2,223	30.2	0.29	35.3	0.34	1,601	20.2	0.24	22.8	0.26
Breast (excl. <i>in situ</i>)	108	1.4	0.06	1.7	0.07	11,177	132.3	0.59	155.0	0.67
Female Genital System	-	-	-	-	-	4,966	57.4	0.38	68.4	0.44
Cervix uteri	-	-	-	-	-	510	7.3	0.15	7.9	0.16
Uterus Corpus	-	-	-	-	-	2,881	32.1	0.28	39.4	0.33
Uterus, NOS ¹	-	-	-	-	-	48	0.5	0.03	0.6	0.04
Ovary	-	-	-	-	-	1,013	11.8	0.17	13.8	0.20
Male Genital System	8,956	111.3	0.54	136.5	0.65	-	-	-	-	-
Prostate	8,493	103.7	0.51	128.7	0.63	-	-	-	-	-
Testis	381	6.4	0.15	6.4	0.15	-	-	-	-	-
Penis	65	0.9	0.05	1.0	0.06	-	-	-	-	-
Urinary System	5,004	67.4	0.44	79.1	0.50	2,135	23.6	0.24	27.6	0.27
Bladder (incl. <i>in situ</i>)	3,074	41.5	0.34	48.7	0.39	1,012	10.6	0.15	12.5	0.18
Kidney & renal pelvis	1,811	24.2	0.26	28.5	0.30	1,060	12.3	0.18	14.3	0.20
Ureter	73	1.0	0.05	1.2	0.06	43	0.4	0.03	0.5	0.04
Eye & Orbit	76	1.1	0.06	1.2	0.06	71	0.9	0.05	1.0	0.05
Brain & Other CNS ¹	601	8.7	0.16	9.5	0.17	463	5.9	0.13	6.4	0.14
Brain	569	8.2	0.16	9.0	0.17	426	5.3	0.12	5.8	0.13
Endocrine System	750	10.8	0.18	12.1	0.20	2,050	29.8	0.31	32.0	0.32
Thyroid gland	690	9.9	0.18	11.1	0.19	1,990	29.0	0.30	31.2	0.32
Lymphomas	2,070	28.7	0.29	32.9	0.32	1,780	20.7	0.23	23.6	0.26
Hodgkin Lymphoma	240	3.8	0.11	3.9	0.11	185	2.8	0.10	2.9	0.10
Non-Hodgkin Lymphoma	1,830	25.0	0.27	29.0	0.30	1,594	17.9	0.21	20.7	0.24
Multiple Myeloma	646	8.6	0.15	10.2	0.18	521	5.6	0.11	6.7	0.13
Leukemias	1,398	19.4	0.24	22.1	0.27	992	11.6	0.17	13.0	0.19
Acute lymphocytic	112	1.9	0.08	1.7	0.07	91	1.5	0.07	1.4	0.06
Chronic lymphocytic	547	7.2	0.14	8.6	0.17	339	3.5	0.09	4.2	0.10
Acute myeloid	411	5.7	0.13	6.5	0.14	328	3.9	0.10	4.3	0.11
Chronic myeloid	171	2.4	0.08	2.7	0.09	130	1.6	0.06	1.8	0.07
Other leukemias	156	2.2	0.08	2.5	0.09	103	1.1	0.05	1.3	0.06
Mesothelioma	143	2.0	0.08	2.3	0.09	48	0.5	0.03	0.6	0.04
Kaposi Sarcoma	25	0.4	0.04	0.4	0.04	5	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,606	22.0	0.25	25.7	0.29	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	718	10.2	0.17	11.5	0.19	1,487	17.9	0.22	20.4	0.24
Breast (<i>in situ</i>)	12	0.2	0.02	0.2	0.03	2,735	33.9	0.30	39.8	0.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	34,695	512.0	1.26	605.6	1.46	35,246	463.0	1.17	538.4	1.32
Oral Cavity & Pharynx	1,260	18.2	0.24	22.2	0.28	534	6.8	0.14	8.1	0.16
Lip	51	0.8	0.05	0.9	0.06	25	0.3	0.03	0.3	0.03
Tongue	415	6.0	0.13	7.3	0.16	170	2.2	0.08	2.6	0.09
Major salivary gland	105	1.6	0.07	1.9	0.08	78	1.1	0.06	1.2	0.06
Floor of mouth	62	0.9	0.05	1.1	0.06	26	0.3	0.03	0.4	0.03
Gum & other mouth	146	2.1	0.08	2.6	0.10	112	1.3	0.06	1.6	0.07
Nasopharynx	35	0.5	0.04	0.6	0.05	17	0.2	0.03	0.3	0.03
Oropharynx	55	0.8	0.05	1.0	0.06	18	0.2	0.03	0.3	0.03
Hypopharynx	80	1.1	0.06	1.4	0.07	17	0.2	0.02	0.3	0.03
Digestive System	6,868	101.4	0.56	120.5	0.65	5,404	65.6	0.42	77.0	0.48
Esophagus	653	9.4	0.17	11.3	0.20	162	1.9	0.07	2.3	0.08
Stomach	563	8.4	0.16	9.9	0.19	289	3.5	0.10	4.1	0.11
Small intestine	190	2.8	0.09	3.3	0.11	162	2.1	0.08	2.4	0.09
Colon excl. rectum	2,106	31.9	0.32	37.3	0.37	2,177	26.2	0.26	30.4	0.30
Rectum & rectosigmoid	1,018	15.3	0.22	18.1	0.26	698	9.1	0.16	10.7	0.19
Anus, anal canal & anorectum	100	1.5	0.07	1.8	0.08	185	2.4	0.08	2.9	0.10
Liver	719	9.9	0.17	12.3	0.21	215	2.6	0.08	3.1	0.10
Gallbladder	50	0.7	0.05	0.9	0.05	103	1.2	0.05	1.4	0.06
Pancreas	1,142	16.7	0.23	19.8	0.26	1,035	12.1	0.17	14.3	0.20
Respiratory System	5,502	79.8	0.49	94.8	0.57	4,821	58.0	0.38	69.1	0.45
Larynx	415	5.9	0.13	7.2	0.16	119	1.5	0.06	1.8	0.08
Lung & bronchus	5,012	72.7	0.47	86.3	0.55	4,647	55.8	0.38	66.4	0.44
Bones & Joints	69	1.2	0.07	1.3	0.07	53	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	234	3.8	0.11	4.2	0.12	190	2.8	0.10	3.0	0.10
Skin (excl. basal & sq.)	2,189	33.4	0.33	38.9	0.37	1,533	22.2	0.27	25.0	0.29
Melanomas of the skin	2,028	30.9	0.32	36.0	0.36	1,427	20.9	0.26	23.5	0.29
Breast (excl. <i>in situ</i>)	95	1.4	0.07	1.7	0.08	9,901	133.7	0.64	156.6	0.72
Female Genital System	-	-	-	-	-	4,396	58.0	0.41	69.1	0.48
Cervix uteri	-	-	-	-	-	408	7.0	0.16	7.5	0.17
Uterus Corpus	-	-	-	-	-	2,573	32.7	0.30	40.1	0.36
Uterus, NOS ¹	-	-	-	-	-	36	0.4	0.03	0.5	0.04
Ovary	-	-	-	-	-	913	12.1	0.19	14.2	0.22
Male Genital System	7,373	102.7	0.55	125.4	0.66	-	-	-	-	-
Prostate	6,946	94.3	0.52	116.9	0.63	-	-	-	-	-
Testis	353	7.2	0.18	7.2	0.17	-	-	-	-	-
Penis	59	0.9	0.05	1.1	0.06	-	-	-	-	-
Urinary System	4,576	68.4	0.46	80.2	0.53	1,907	23.8	0.26	27.8	0.29
Bladder (incl. <i>in situ</i>)	2,890	43.0	0.36	50.4	0.42	933	11.0	0.17	12.9	0.19
Kidney & renal pelvis	1,573	23.6	0.28	27.8	0.32	916	12.1	0.19	14.1	0.21
Ureter	68	1.0	0.06	1.2	0.06	41	0.5	0.03	0.5	0.04
Eye & Orbit	52	0.8	0.05	0.9	0.06	48	0.7	0.05	0.8	0.05
Brain & Other CNS ¹	539	8.9	0.18	9.8	0.19	420	6.1	0.14	6.7	0.15
Brain	513	8.4	0.17	9.3	0.18	388	5.6	0.14	6.2	0.14
Endocrine System	670	11.1	0.20	12.4	0.22	1,787	30.9	0.35	33.1	0.36
Thyroid gland	623	10.3	0.19	11.5	0.21	1,738	30.1	0.34	32.3	0.35
Lymphomas	1,853	28.9	0.31	33.1	0.35	1,592	20.9	0.25	23.9	0.28
Hodgkin Lymphoma	204	3.8	0.12	3.9	0.12	158	2.9	0.11	2.9	0.11
Non-Hodgkin Lymphoma	1,649	25.1	0.28	29.2	0.32	1,433	18.1	0.22	21.0	0.25
Multiple Myeloma	542	8.0	0.16	9.4	0.18	404	4.8	0.11	5.7	0.13
Leukemias	1,270	19.6	0.25	22.5	0.28	892	11.9	0.19	13.3	0.21
Acute lymphocytic	92	1.8	0.09	1.7	0.08	75	1.5	0.08	1.4	0.07
Chronic lymphocytic	510	7.4	0.15	8.9	0.18	315	3.7	0.10	4.4	0.11
Acute myeloid	373	5.8	0.14	6.6	0.15	295	4.0	0.11	4.5	0.12
Chronic myeloid	154	2.4	0.09	2.8	0.10	116	1.6	0.07	1.8	0.08
Other leukemias	140	2.2	0.08	2.5	0.10	91	1.1	0.06	1.3	0.06
Mesothelioma	135	2.1	0.08	2.4	0.09	44	0.5	0.04	0.6	0.04
Kaposi Sarcoma	14	0.3	0.03	0.3	0.03	3	0.0	0.01	0.0	0.01
Ill-defined & Unknown	1,453	22.1	0.26	25.7	0.30	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	630	10.1	0.19	11.4	0.21	1,292	17.8	0.24	20.3	0.26
Breast (<i>in situ</i>)	10	0.2	0.02	0.2	0.03	2,350	33.5	0.33	39.4	0.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,369	551.9	4.49	668.1	5.31	3,612	443.8	3.37	523.6	3.91
Oral Cavity & Pharynx	99	15.5	0.73	18.8	0.86	49	5.9	0.38	7.0	0.45
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	22	3.5	0.35	4.3	0.42	10	1.1	0.16	1.4	0.20
Major salivary gland	10	1.6	0.24	1.9	0.28	11	1.3	0.18	1.5	0.21
Floor of mouth	5	0.8	0.18	1.0	0.21	2	0.2	0.08	0.3	0.10
Gum & other mouth	11	1.7	0.25	2.1	0.30	8	1.0	0.16	1.2	0.19
Nasopharynx	8	1.2	0.20	1.5	0.23	4	0.5	0.12	0.6	0.13
Oropharynx	7	1.0	0.18	1.2	0.22	2	0.2	0.08	0.3	0.09
Hypopharynx	12	1.9	0.27	2.3	0.31	4	0.4	0.10	0.6	0.13
Digestive System	778	128.3	2.18	156.2	2.58	688	83.9	1.46	100.3	1.72
Esophagus	43	7.1	0.51	8.7	0.61	26	3.2	0.28	3.8	0.34
Stomach	74	13.4	0.73	15.8	0.85	53	6.7	0.42	7.8	0.48
Small intestine	28	4.7	0.42	5.5	0.47	32	4.0	0.32	4.7	0.37
Colon excl. rectum	208	35.8	1.17	42.8	1.37	233	28.5	0.85	34.0	1.00
Rectum & rectosigmoid	79	12.9	0.68	15.5	0.80	82	10.0	0.50	11.9	0.59
Anus, anal canal & anorectum	17	2.5	0.29	3.0	0.33	19	2.2	0.23	2.7	0.28
Liver	185	26.7	0.92	34.8	1.16	55	6.4	0.39	8.0	0.48
Gallbladder	7	1.5	0.26	1.7	0.29	21	2.6	0.26	3.1	0.30
Pancreas	107	18.5	0.85	22.2	0.99	129	15.7	0.63	18.8	0.74
Respiratory System	541	95.1	1.93	114.0	2.26	570	69.3	1.32	83.6	1.57
Larynx	46	7.8	0.54	9.3	0.63	15	1.8	0.21	2.2	0.25
Lung & bronchus	488	86.3	1.85	103.5	2.15	551	67.0	1.30	80.7	1.54
Bones & Joints	4	0.5	0.12	0.5	0.12	4	0.5	0.12	0.6	0.13
Soft Tissue (incl. heart)	22	3.3	0.33	3.7	0.37	22	2.8	0.27	3.1	0.30
Skin (excl. basal & sq.)	14	2.2	0.27	2.5	0.31	14	1.7	0.21	2.0	0.24
Melanomas of the skin	6	1.0	0.19	1.2	0.22	6	0.8	0.14	0.9	0.16
Breast (excl. <i>in situ</i>)	10	1.6	0.25	2.0	0.29	1,018	126.2	1.80	148.2	2.08
Female Genital System	-	-	-	-	-	440	53.2	1.16	63.5	1.36
Cervix uteri	-	-	-	-	-	75	9.6	0.51	10.6	0.55
Uterus Corpus	-	-	-	-	-	246	29.0	0.84	35.8	1.02
Uterus, NOS ¹	-	-	-	-	-	9	1.1	0.17	1.4	0.20
Ovary	-	-	-	-	-	69	8.4	0.46	9.8	0.53
Male Genital System	1,031	159.5	2.34	199.9	2.85	-	-	-	-	-
Prostate	1,014	157.0	2.32	197.3	2.83	-	-	-	-	-
Testis	11	1.6	0.21	1.5	0.21	-	-	-	-	-
Penis	3	0.7	0.18	0.8	0.19	-	-	-	-	-
Urinary System	341	57.8	1.48	68.8	1.72	190	23.3	0.77	27.6	0.90
Bladder (incl. <i>in situ</i>)	133	24.8	1.02	29.5	1.18	60	7.6	0.44	8.9	0.51
Kidney & renal pelvis	203	32.1	1.05	38.1	1.23	125	15.2	0.62	18.1	0.73
Ureter	4	0.7	0.18	0.8	0.19	1	0.2	0.07	0.2	0.08
Eye & Orbit	3	0.3	0.08	0.3	0.08	1	0.2	0.06	0.1	0.06
Brain & Other CNS ¹	37	5.6	0.43	6.0	0.47	30	3.7	0.30	3.9	0.33
Brain	33	4.9	0.40	5.3	0.44	26	3.2	0.28	3.4	0.30
Endocrine System	43	6.4	0.45	7.3	0.51	157	20.0	0.73	22.0	0.79
Thyroid gland	35	5.3	0.41	6.0	0.47	150	19.0	0.71	21.0	0.77
Lymphomas	144	22.3	0.88	25.7	1.00	130	15.9	0.64	18.3	0.72
Hodgkin Lymphoma	26	3.5	0.32	3.7	0.34	20	2.5	0.25	2.6	0.26
Non-Hodgkin Lymphoma	118	18.8	0.81	22.0	0.94	109	13.4	0.59	15.7	0.68
Multiple Myeloma	90	16.0	0.80	19.0	0.92	105	13.2	0.59	15.5	0.68
Leukemias	82	13.5	0.71	15.4	0.81	69	8.4	0.46	9.5	0.52
Acute lymphocytic	11	1.4	0.20	1.3	0.19	7	0.8	0.14	0.8	0.14
Chronic lymphocytic	22	3.9	0.40	4.7	0.47	17	2.0	0.22	2.4	0.26
Acute myeloid	28	4.6	0.42	5.3	0.47	25	3.1	0.28	3.5	0.31
Chronic myeloid	11	1.8	0.26	2.1	0.30	11	1.3	0.19	1.5	0.21
Other leukemias	10	1.8	0.26	2.1	0.31	9	1.1	0.17	1.3	0.20
Mesothelioma	5	1.1	0.22	1.2	0.25	2	0.3	0.09	0.4	0.10
Kaposi Sarcoma	9	1.2	0.19	1.3	0.20	-	-	-	-	-
Ill-defined & Unknown	118	21.7	0.95	25.5	1.09	122	15.1	0.62	17.7	0.72
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	59	9.7	0.60	11.2	0.68	142	17.9	0.69	20.4	0.77
Breast (<i>in situ</i>)	1	0.2	0.09	0.3	0.11	299	36.8	0.97	43.9	1.14

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

**Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, Asian/Pacific Islander (API)**

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	451	277.7	6.27	328.5	7.35	578	281.4	5.46	326.2	6.32
Oral Cavity & Pharynx	21	11.3	1.13	13.2	1.32	12	6.1	0.82	6.9	0.94
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	1.9	0.50	2.1	0.55	4	2.1	0.50	2.5	0.59
Major salivary gland	2	0.9	0.32	1.0	0.36	1	0.7	0.27	0.7	0.29
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	7	3.7	0.64	4.4	0.76	3	1.5	0.43	1.7	0.49
Nasopharynx	5	2.5	0.51	2.8	0.59	3	1.1	0.30	1.3	0.35
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	132	82.9	3.45	99.5	4.08	112	60.7	2.69	71.3	3.13
Esophagus	7	4.4	0.80	5.2	0.94	2	1.2	0.40	1.5	0.49
Stomach	18	11.8	1.31	13.8	1.51	15	8.2	1.00	9.5	1.16
Small intestine	2	1.1	0.32	1.3	0.41	2	1.1	0.36	1.2	0.40
Colon excl. rectum	28	19.4	1.76	23.1	2.07	34	17.8	1.43	20.8	1.67
Rectum & rectosigmoid	21	11.7	1.20	14.2	1.44	22	10.7	1.07	12.9	1.28
Anus, anal canal & anorectum	-	-	-	-	-	1	0.6	0.28	0.8	0.35
Liver	32	17.8	1.48	22.0	1.79	11	6.7	0.93	7.9	1.08
Gallbladder	2	1.1	0.38	1.4	0.46	2	1.3	0.40	1.4	0.44
Pancreas	13	9.3	1.22	11.0	1.42	15	8.5	1.03	9.9	1.19
Respiratory System	64	43.2	2.60	51.4	3.06	54	29.7	1.90	35.1	2.20
Larynx	3	2.1	0.54	2.5	0.63	-	-	-	-	-
Lung & bronchus	58	39.7	2.50	47.3	2.94	52	29.0	1.88	34.3	2.18
Bones & Joints	2	1.0	0.37	1.1	0.43	-	-	-	-	-
Soft Tissue (incl. heart)	4	2.5	0.57	2.8	0.66	4	1.6	0.40	1.9	0.46
Skin (excl. basal & sq.)	3	2.1	0.56	2.5	0.67	5	2.4	0.51	2.6	0.55
Melanomas of the skin	3	1.6	0.50	2.0	0.60	3	1.7	0.43	1.7	0.45
Breast (excl. <i>in situ</i>)	2	1.1	0.39	1.3	0.46	172	79.3	2.79	92.2	3.24
Female Genital System	-	-	-	-	-	78	35.7	1.86	42.5	2.21
Cervix uteri	-	-	-	-	-	14	6.2	0.75	7.1	0.87
Uterus Corpus	-	-	-	-	-	36	16.6	1.26	20.4	1.54
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	23	10.5	1.01	12.3	1.18
Male Genital System	83	50.1	2.61	60.3	3.08	-	-	-	-	-
Prostate	76	47.1	2.55	57.1	3.03	-	-	-	-	-
Testis	6	2.2	0.44	2.3	0.45	-	-	-	-	-
Penis	1	0.6	0.27	0.7	0.30	-	-	-	-	-
Urinary System	37	24.0	1.90	28.6	2.24	17	9.2	1.06	10.7	1.22
Bladder (incl. <i>in situ</i>)	21	14.6	1.55	17.3	1.81	7	4.4	0.75	5.1	0.86
Kidney & renal pelvis	15	8.8	1.07	10.7	1.28	8	4.3	0.70	5.0	0.81
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	1	0.5	0.22	0.5	0.19
Brain & Other CNS ¹	12	6.7	0.93	7.5	1.06	6	2.8	0.52	3.0	0.56
Brain	11	6.2	0.90	7.0	1.04	6	2.5	0.47	2.6	0.50
Endocrine System	21	10.4	1.03	11.4	1.15	62	25.7	1.50	28.3	1.67
Thyroid gland	19	9.0	0.97	9.9	1.08	61	25.0	1.48	27.5	1.65
Lymphomas	25	14.2	1.37	16.4	1.61	24	11.4	1.08	12.9	1.23
Hodgkin Lymphoma	4	1.8	0.39	1.8	0.40	3	1.0	0.27	0.9	0.24
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	9	5.7	0.88	6.8	1.03	4	2.1	0.49	2.4	0.55
Leukemias	16	9.4	1.15	10.4	1.29	12	5.4	0.75	5.9	0.82
Acute lymphocytic	3	1.2	0.33	1.0	0.28	3	1.5	0.40	1.5	0.39
Chronic lymphocytic	2	1.7	0.52	2.0	0.61	-	-	-	-	-
Acute myeloid	6	3.9	0.75	4.3	0.83	5	2.2	0.47	2.6	0.55
Chronic myeloid	3	1.6	0.45	1.9	0.54	2	0.8	0.28	1.0	0.35
Other leukemias	1	1.0	0.42	1.2	0.49	1	0.6	0.25	0.6	0.24
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	18	12.1	1.39	14.4	1.64	14	7.7	0.98	9.0	1.13
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	9.0	1.09	10.7	1.27	26	12.6	1.16	14.7	1.35
Breast (<i>in situ</i>)	-	-	-	-	-	59	26.2	1.56	30.5	1.82

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	868	391.6	6.73	464.5	7.80	961	343.4	5.30	401.2	6.18
Oral Cavity & Pharynx	29	12.1	1.12	14.9	1.36	11	4.3	0.63	5.0	0.72
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	2.6	0.56	3.1	0.67	3	1.7	0.42	1.9	0.47
Major salivary gland	3	1.1	0.31	1.4	0.37	2	0.6	0.20	0.6	0.21
Floor of mouth	2	0.6	0.25	0.8	0.29	-	-	-	-	-
Gum & other mouth	5	2.4	0.53	2.9	0.63	1	0.6	0.23	0.7	0.28
Nasopharynx	2	0.7	0.21	0.9	0.27	-	-	-	-	-
Oropharynx	1	0.6	0.25	0.7	0.31	-	-	-	-	-
Hypopharynx	3	1.3	0.35	1.6	0.43	-	-	-	-	-
Digestive System	221	99.7	3.37	119.9	3.93	156	61.2	2.33	72.8	2.73
Esophagus	11	5.4	0.78	6.4	0.90	3	1.5	0.37	1.7	0.44
Stomach	27	13.4	1.30	15.3	1.45	17	6.7	0.77	7.8	0.89
Small intestine	5	1.8	0.41	2.0	0.47	5	2.0	0.41	2.3	0.48
Colon excl. rectum	56	26.2	1.76	31.1	2.04	48	18.9	1.30	22.5	1.53
Rectum & rectosigmoid	28	11.9	1.12	14.4	1.32	23	8.2	0.81	9.5	0.93
Anus, anal canal & anorectum	4	1.5	0.37	1.8	0.44	8	2.8	0.48	3.5	0.59
Liver	54	21.7	1.45	27.5	1.78	14	5.4	0.69	6.6	0.82
Gallbladder	2	1.5	0.49	1.7	0.56	5	2.2	0.46	2.7	0.54
Pancreas	24	11.2	1.13	13.5	1.32	21	9.2	0.95	10.8	1.10
Respiratory System	97	51.3	2.59	60.2	2.95	67	28.0	1.63	33.3	1.90
Larynx	12	5.7	0.85	6.7	0.97	2	0.9	0.31	1.1	0.34
Lung & bronchus	83	44.9	2.43	52.7	2.77	63	26.7	1.59	31.8	1.86
Bones & Joints	4	0.9	0.22	0.9	0.22	3	0.8	0.24	0.9	0.26
Soft Tissue (incl. heart)	8	2.6	0.49	3.1	0.60	8	2.4	0.42	2.7	0.47
Skin (excl. basal & sq.)	13	6.4	0.91	7.5	1.04	17	5.7	0.66	6.7	0.77
Melanomas of the skin	11	5.5	0.84	6.5	0.97	15	4.9	0.60	5.7	0.71
Breast (excl. <i>in situ</i>)	2	0.7	0.28	0.8	0.32	260	92.2	2.70	108.1	3.16
Female Genital System	-	-	-	-	-	153	52.9	2.02	62.7	2.40
Cervix uteri	-	-	-	-	-	35	10.4	0.83	11.4	0.93
Uterus Corpus	-	-	-	-	-	76	27.1	1.45	33.3	1.76
Uterus, NOS ¹	-	-	-	-	-	1	0.4	0.18	0.5	0.22
Ovary	-	-	-	-	-	27	9.4	0.86	11.1	1.02
Male Genital System	221	99.4	3.33	120.6	3.91	-	-	-	-	-
Prostate	196	92.8	3.25	113.5	3.83	-	-	-	-	-
Testis	20	4.0	0.41	3.9	0.41	-	-	-	-	-
Penis	5	2.5	0.56	3.1	0.67	-	-	-	-	-
Urinary System	91	44.2	2.34	51.8	2.69	44	16.1	1.15	19.0	1.36
Bladder (incl. <i>in situ</i>)	39	23.1	1.81	26.8	2.07	12	4.9	0.68	5.8	0.80
Kidney & renal pelvis	51	20.8	1.46	24.5	1.70	32	10.8	0.91	12.6	1.07
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.7	0.26	0.7	0.30	2	0.5	0.18	0.6	0.22
Brain & Other CNS ¹	19	5.9	0.74	6.6	0.85	17	5.7	0.69	6.3	0.78
Brain	17	5.6	0.74	6.3	0.85	16	5.3	0.66	5.9	0.75
Endocrine System	19	5.7	0.66	6.3	0.75	94	26.6	1.28	28.9	1.43
Thyroid gland	16	5.1	0.64	5.7	0.73	91	25.6	1.26	27.9	1.40
Lymphomas	57	22.6	1.55	25.7	1.75	52	19.3	1.29	22.3	1.48
Hodgkin Lymphoma	11	3.1	0.52	3.4	0.58	10	2.6	0.41	2.9	0.46
Non-Hodgkin Lymphoma	46	19.4	1.45	22.3	1.65	43	16.6	1.22	19.4	1.40
Multiple Myeloma	16	8.0	1.00	9.5	1.14	18	7.2	0.80	8.6	0.94
Leukemias	37	14.4	1.26	16.4	1.44	29	8.7	0.82	9.6	0.92
Acute lymphocytic	11	2.3	0.37	2.3	0.38	8	1.8	0.30	1.6	0.28
Chronic lymphocytic	8	4.2	0.74	5.0	0.86	4	1.8	0.44	2.1	0.51
Acute myeloid	9	3.8	0.69	4.2	0.78	10	2.8	0.44	3.1	0.50
Chronic myeloid	7	2.7	0.51	3.1	0.59	3	1.0	0.29	1.3	0.36
Other leukemias	3	1.5	0.41	1.7	0.49	4	1.3	0.32	1.6	0.38
Mesothelioma	2	1.6	0.51	1.9	0.59	-	-	-	-	-
Kaposi Sarcoma	3	1.2	0.36	1.2	0.38	-	-	-	-	-
Ill-defined & Unknown	28	14.2	1.34	16.6	1.54	29	11.5	1.03	13.3	1.19
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	24	9.5	1.02	10.6	1.15	53	18.0	1.18	21.0	1.39
Breast (<i>in situ</i>)	-	-	-	-	-	78	26.2	1.38	31.0	1.64

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

PENNSYLVANIA

II-428 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	34,051	517.3	1.29	611.4	1.49	34,515	468.2	1.20	544.1	1.35
Oral Cavity & Pharynx	1,237	18.4	0.24	22.5	0.29	525	6.9	0.14	8.2	0.16
Lip	50	0.8	0.05	0.9	0.06	25	0.3	0.03	0.3	0.03
Tongue	410	6.1	0.14	7.4	0.17	168	2.2	0.08	2.7	0.09
Major salivary gland	103	1.6	0.07	1.9	0.08	76	1.1	0.06	1.2	0.07
Floor of mouth	61	0.9	0.05	1.1	0.06	26	0.3	0.03	0.4	0.04
Gum & other mouth	142	2.1	0.08	2.6	0.10	111	1.4	0.06	1.6	0.07
Nasopharynx	34	0.5	0.04	0.6	0.05	16	0.2	0.03	0.3	0.03
Oropharynx	54	0.8	0.05	1.0	0.06	18	0.2	0.03	0.3	0.03
Hypopharynx	78	1.1	0.06	1.4	0.07	17	0.2	0.02	0.3	0.03
Digestive System	6,699	101.7	0.57	120.8	0.66	5,287	65.9	0.43	77.3	0.49
Esophagus	645	9.5	0.17	11.4	0.20	159	1.9	0.07	2.3	0.08
Stomach	541	8.2	0.16	9.8	0.19	276	3.4	0.10	4.0	0.11
Small intestine	187	2.9	0.10	3.4	0.11	159	2.1	0.08	2.5	0.09
Colon excl. rectum	2,064	32.1	0.33	37.6	0.37	2,141	26.4	0.27	30.6	0.31
Rectum & rectosigmoid	995	15.5	0.23	18.3	0.26	681	9.1	0.17	10.7	0.19
Anus, anal canal & anorectum	97	1.5	0.07	1.8	0.08	178	2.4	0.08	2.9	0.10
Liver	679	9.6	0.17	12.0	0.21	206	2.6	0.09	3.1	0.10
Gallbladder	48	0.7	0.05	0.8	0.06	99	1.2	0.05	1.4	0.06
Pancreas	1,121	16.8	0.23	20.0	0.27	1,019	12.2	0.18	14.4	0.21
Respiratory System	5,427	80.6	0.50	95.8	0.58	4,769	58.9	0.39	70.1	0.46
Larynx	407	6.0	0.14	7.2	0.16	118	1.5	0.06	1.9	0.08
Lung & bronchus	4,946	73.5	0.48	87.1	0.56	4,598	56.6	0.38	67.4	0.45
Bones & Joints	66	1.2	0.07	1.3	0.07	52	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	229	3.8	0.12	4.3	0.13	185	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	2,179	34.4	0.34	39.9	0.39	1,520	23.0	0.28	25.9	0.31
Melanomas of the skin	2,019	31.8	0.33	37.0	0.37	1,415	21.7	0.28	24.4	0.30
Breast (excl. <i>in situ</i>)	94	1.4	0.07	1.7	0.08	9,700	135.4	0.65	158.5	0.74
Female Genital System	-	-	-	-	-	4,271	58.1	0.42	69.3	0.49
Cervix uteri	-	-	-	-	-	381	6.8	0.17	7.3	0.17
Uterus Corpus	-	-	-	-	-	2,511	32.9	0.31	40.3	0.37
Uterus, NOS ¹	-	-	-	-	-	35	0.4	0.03	0.5	0.04
Ovary	-	-	-	-	-	891	12.1	0.19	14.3	0.22
Male Genital System	7,221	103.5	0.56	126.3	0.67	-	-	-	-	-
Prostate	6,812	94.9	0.52	117.6	0.64	-	-	-	-	-
Testis	339	7.5	0.19	7.5	0.18	-	-	-	-	-
Penis	55	0.9	0.05	1.0	0.06	-	-	-	-	-
Urinary System	4,504	69.0	0.47	81.0	0.54	1,876	24.0	0.26	28.1	0.30
Bladder (incl. <i>in situ</i>)	2,859	43.5	0.37	51.0	0.43	925	11.2	0.17	13.1	0.20
Kidney & renal pelvis	1,532	23.8	0.28	28.0	0.32	893	12.2	0.19	14.1	0.22
Ureter	68	1.0	0.06	1.2	0.07	40	0.5	0.03	0.5	0.04
Eye & Orbit	50	0.8	0.06	1.0	0.06	47	0.7	0.05	0.8	0.05
Brain & Other CNS ¹	527	9.2	0.19	10.0	0.20	407	6.2	0.15	6.8	0.16
Brain	502	8.7	0.18	9.5	0.19	376	5.6	0.14	6.2	0.15
Endocrine System	657	11.4	0.21	12.7	0.22	1,718	31.4	0.36	33.5	0.37
Thyroid gland	612	10.6	0.20	11.9	0.22	1,670	30.6	0.36	32.7	0.37
Lymphomas	1,811	29.3	0.32	33.5	0.35	1,553	21.1	0.26	24.1	0.28
Hodgkin Lymphoma	197	3.9	0.13	4.0	0.13	152	2.9	0.11	3.0	0.11
Non-Hodgkin Lymphoma	1,615	25.4	0.29	29.4	0.33	1,401	18.2	0.23	21.1	0.26
Multiple Myeloma	528	8.0	0.16	9.4	0.18	391	4.8	0.11	5.7	0.13
Leukemias	1,245	19.9	0.26	22.8	0.29	873	12.0	0.20	13.4	0.21
Acute lymphocytic	86	1.9	0.09	1.7	0.08	71	1.5	0.09	1.4	0.08
Chronic lymphocytic	505	7.5	0.15	9.0	0.18	312	3.7	0.10	4.4	0.12
Acute myeloid	368	5.8	0.14	6.7	0.16	288	4.0	0.11	4.5	0.12
Chronic myeloid	148	2.4	0.09	2.8	0.10	113	1.6	0.07	1.8	0.08
Other leukemias	138	2.2	0.09	2.6	0.10	89	1.1	0.06	1.3	0.06
Mesothelioma	134	2.1	0.08	2.4	0.09	43	0.5	0.04	0.6	0.04
Kaposi Sarcoma	11	0.2	0.03	0.2	0.03	3	0.0	0.01	0.0	0.01
Ill-defined & Unknown	1,433	22.3	0.27	25.9	0.31	1,296	15.4	0.20	17.8	0.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	612	10.2	0.19	11.5	0.21	1,253	17.9	0.24	20.4	0.27
Breast (<i>in situ</i>)	10	0.2	0.02	0.2	0.03	2,287	33.8	0.34	39.7	0.38

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Pennsylvania, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,321	569.8	4.66	689.9	5.50	3,543	455.5	3.49	536.8	4.04
Oral Cavity & Pharynx	98	16.1	0.76	19.6	0.90	48	6.1	0.40	7.3	0.47
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	22	3.6	0.37	4.5	0.44	10	1.2	0.17	1.5	0.21
Major salivary gland	10	1.7	0.25	2.0	0.29	10	1.3	0.19	1.5	0.22
Floor of mouth	5	0.9	0.19	1.1	0.22	2	0.3	0.08	0.3	0.10
Gum & other mouth	11	1.8	0.26	2.2	0.31	8	1.1	0.17	1.2	0.20
Nasopharynx	8	1.3	0.21	1.5	0.24	4	0.6	0.13	0.6	0.14
Oropharynx	7	1.0	0.19	1.3	0.23	2	0.3	0.08	0.3	0.10
Hypopharynx	12	2.0	0.28	2.4	0.32	4	0.5	0.11	0.6	0.13
Digestive System	767	132.4	2.25	161.2	2.67	676	85.9	1.50	102.7	1.77
Esophagus	42	7.3	0.53	9.0	0.63	25	3.2	0.29	3.9	0.34
Stomach	73	13.8	0.76	16.3	0.88	52	6.8	0.43	7.9	0.49
Small intestine	28	4.9	0.43	5.8	0.50	31	4.0	0.33	4.8	0.38
Colon excl. rectum	205	36.9	1.21	44.1	1.42	230	29.3	0.88	34.9	1.03
Rectum & rectosigmoid	78	13.3	0.71	16.0	0.83	81	10.4	0.53	12.3	0.61
Anus, anal canal & anorectum	16	2.6	0.30	3.1	0.35	19	2.3	0.25	2.8	0.29
Liver	182	27.5	0.95	35.8	1.21	54	6.6	0.41	8.2	0.50
Gallbladder	7	1.6	0.27	1.8	0.30	21	2.6	0.26	3.2	0.31
Pancreas	106	19.2	0.88	23.0	1.03	126	16.0	0.65	19.1	0.76
Respiratory System	534	97.9	2.00	117.4	2.33	565	71.2	1.36	85.9	1.62
Larynx	45	7.9	0.55	9.5	0.65	15	1.8	0.21	2.3	0.26
Lung & bronchus	483	88.9	1.91	106.8	2.23	546	68.9	1.34	83.0	1.59
Bones & Joints	3	0.5	0.12	0.5	0.13	4	0.6	0.12	0.6	0.13
Soft Tissue (incl. heart)	21	3.4	0.35	3.8	0.39	22	2.9	0.29	3.2	0.31
Skin (excl. basal & sq.)	13	2.2	0.28	2.5	0.32	14	1.8	0.22	2.1	0.25
Melanomas of the skin	5	0.9	0.19	1.1	0.22	6	0.8	0.15	0.9	0.17
Breast (excl. <i>in situ</i>)	9	1.7	0.26	2.0	0.31	999	130.1	1.88	152.5	2.16
Female Genital System	-	-	-	-	-	430	54.5	1.20	64.9	1.40
Cervix uteri	-	-	-	-	-	73	9.9	0.53	11.0	0.58
Uterus Corpus	-	-	-	-	-	240	29.5	0.87	36.4	1.05
Uterus, NOS ¹	-	-	-	-	-	9	1.2	0.17	1.4	0.21
Ovary	-	-	-	-	-	67	8.7	0.48	10.1	0.55
Male Genital System	1,017	164.7	2.43	206.4	2.95	-	-	-	-	-
Prostate	1,002	162.2	2.41	203.9	2.94	-	-	-	-	-
Testis	11	1.6	0.23	1.6	0.22	-	-	-	-	-
Penis	3	0.7	0.18	0.8	0.19	-	-	-	-	-
Urinary System	336	59.7	1.53	71.1	1.79	185	23.8	0.80	28.1	0.93
Bladder (incl. <i>in situ</i>)	132	25.6	1.05	30.5	1.23	60	7.7	0.45	9.1	0.53
Kidney & renal pelvis	199	33.1	1.10	39.4	1.28	121	15.5	0.64	18.3	0.75
Ureter	3	0.7	0.18	0.8	0.19	1	0.2	0.07	0.2	0.08
Eye & Orbit	3	0.3	0.09	0.3	0.08	1	0.2	0.07	0.2	0.06
Brain & Other CNS ¹	36	5.8	0.45	6.2	0.49	29	3.8	0.32	4.0	0.34
Brain	32	5.1	0.42	5.5	0.46	25	3.2	0.29	3.5	0.32
Endocrine System	42	6.7	0.48	7.7	0.54	149	20.2	0.76	22.3	0.82
Thyroid gland	34	5.5	0.44	6.3	0.49	142	19.3	0.74	21.3	0.80
Lymphomas	141	23.1	0.91	26.6	1.04	126	16.3	0.67	18.7	0.75
Hodgkin Lymphoma	25	3.7	0.34	3.9	0.36	20	2.7	0.27	2.7	0.28
Non-Hodgkin Lymphoma	116	19.4	0.85	22.7	0.97	106	13.7	0.61	16.0	0.70
Multiple Myeloma	90	16.7	0.83	19.7	0.96	104	13.6	0.61	15.9	0.70
Leukemias	79	13.8	0.73	15.7	0.83	67	8.6	0.48	9.8	0.54
Acute lymphocytic	10	1.4	0.21	1.3	0.20	6	0.8	0.14	0.8	0.14
Chronic lymphocytic	22	4.0	0.41	4.8	0.48	16	2.0	0.23	2.4	0.27
Acute myeloid	26	4.7	0.43	5.3	0.48	25	3.2	0.30	3.6	0.33
Chronic myeloid	11	1.9	0.27	2.2	0.31	11	1.4	0.20	1.6	0.22
Other leukemias	10	1.8	0.27	2.2	0.32	9	1.1	0.17	1.3	0.20
Mesothelioma	5	1.1	0.23	1.3	0.26	2	0.3	0.09	0.4	0.11
Kaposi Sarcoma	9	1.3	0.21	1.4	0.21	-	-	-	-	-
Ill-defined & Unknown	116	22.4	0.98	26.4	1.13	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	58	10.1	0.62	11.5	0.71	136	18.1	0.71	20.6	0.79
Breast (<i>in situ</i>)	1	0.2	0.10	0.3	0.11	295	38.2	1.02	45.5	1.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


PENNSYLVANIA

II-430 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,055,122	1,056,017	1,056,173	1,057,063	1,056,486
White	913,968	911,649	908,430	906,086	903,507
Black	90,505	92,424	94,342	96,366	97,995
American Indian/Alaskan Native (AI/AN)	11,386	11,622	12,005	12,284	12,494
Asian/Pacific Islander (API)	39,263	40,322	41,396	42,327	42,490


All Races Population 2013-2017: 5,280,861
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	145,054	149,413	154,169	159,053	163,315
Non-Hispanic White	801,547	796,001	789,363	783,444	777,820
Non-Hispanic Black	66,794	67,907	68,916	70,033	70,845

Hispanic/Latino Population, Census 2010: 130,655
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

RHODE ISLAND CANCER REGISTRY

Initial Operation: 1986
 Population-based Data Available: 1986
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	115.8	114.3	108.5	109.9	99.4
Missing Race	1.2	0.7	0.7	1.0	1.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.6	2.7	2.5	1.9	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Prostate	97.6
Oral Cavity & Pharynx	98.3	Testis	100.0
Esophagus	96.1	Bladder (incl. <i>in situ</i>)	97.6
Stomach	96.9	Kidney & Renal Pelvis	91.0
Colon & Rectum	96.3	Brain & Other CNS ¹	88.1
Liver	58.1	Thyroid	99.9
Pancreas	84.2	Hodgkin Lymphoma	98.9
Lung & Bronchus	88.1	Non-Hodgkin Lymphoma	96.9
Melanomas of the Skin	99.5	Multiple Myeloma	92.9
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	91.9
Cervix uteri	98.5	Brain & Other CNS ¹ <i>non-malig</i>	48.1
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	94.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,906	489.8	4.18	580.2	4.84	3,218	460.4	3.78	536.3	4.29
Oral Cavity & Pharynx	97	15.6	0.73	19.2	0.87	54	7.3	0.46	8.8	0.55
Lip	4	0.6	0.15	0.7	0.18	2	0.2	0.06	0.2	0.08
Tongue	33	5.3	0.42	6.5	0.51	16	2.1	0.25	2.5	0.29
Major salivary gland	9	1.6	0.24	1.9	0.28	8	1.2	0.18	1.4	0.22
Floor of mouth	5	0.9	0.18	1.1	0.21	4	0.5	0.12	0.6	0.14
Gum & other mouth	10	1.6	0.23	2.0	0.28	11	1.5	0.21	1.7	0.24
Nasopharynx	4	0.7	0.17	0.9	0.19	2	0.3	0.09	0.4	0.11
Oropharynx	5	0.7	0.16	0.9	0.19	4	0.5	0.11	0.6	0.14
Hypopharynx	6	1.0	0.19	1.2	0.22	2	0.3	0.09	0.3	0.10
Digestive System	558	94.7	1.84	112.5	2.14	458	62.0	1.35	73.0	1.56
Esophagus	47	7.7	0.52	9.3	0.61	15	2.1	0.25	2.4	0.28
Stomach	65	11.2	0.64	13.2	0.74	37	5.1	0.39	5.8	0.44
Small intestine	19	3.3	0.35	3.9	0.40	15	2.2	0.25	2.5	0.30
Colon excl. rectum	144	25.2	0.96	29.5	1.10	159	21.0	0.77	24.7	0.89
Rectum & rectosigmoid	74	12.7	0.68	15.0	0.79	62	8.9	0.53	10.5	0.61
Anus, anal canal & anorectum	9	1.5	0.24	1.7	0.27	17	2.4	0.27	2.9	0.32
Liver	70	11.1	0.61	13.7	0.73	23	3.2	0.31	3.8	0.35
Gallbladder	5	0.9	0.18	1.0	0.21	12	1.7	0.23	2.0	0.26
Pancreas	91	15.4	0.74	18.3	0.87	82	10.6	0.54	12.6	0.64
Respiratory System	484	82.0	1.71	97.0	1.99	499	67.6	1.39	80.1	1.62
Larynx	35	5.9	0.45	7.1	0.53	10	1.5	0.22	1.8	0.25
Lung & bronchus	444	75.4	1.64	89.1	1.90	486	65.6	1.36	77.7	1.60
Bones & Joints	8	1.5	0.25	1.5	0.24	6	0.9	0.17	0.9	0.18
Soft Tissue (incl. heart)	23	4.0	0.39	4.6	0.43	17	2.6	0.30	2.9	0.32
Skin (excl. basal & sq.)	185	31.9	1.08	37.3	1.23	141	20.7	0.81	23.8	0.91
Melanomas of the skin	170	29.3	1.03	34.3	1.18	130	19.1	0.78	22.0	0.88
Breast (excl. <i>in situ</i>)	10	1.8	0.26	2.1	0.29	940	137.8	2.09	161.6	2.39
Female Genital System	-	-	-	-	-	377	54.2	1.30	64.4	1.50
Cervix uteri	-	-	-	-	-	40	7.0	0.52	7.5	0.54
Uterus Corpus	-	-	-	-	-	210	29.0	0.92	35.6	1.11
Uterus, NOS ¹	-	-	-	-	-	9	1.2	0.18	1.5	0.22
Ovary	-	-	-	-	-	71	10.3	0.57	12.0	0.65
Male Genital System	649	103.4	1.87	126.1	2.22	-	-	-	-	-
Prostate	613	96.5	1.79	118.9	2.16	-	-	-	-	-
Testis	29	5.7	0.48	5.8	0.48	-	-	-	-	-
Penis	5	0.9	0.19	1.1	0.21	-	-	-	-	-
Urinary System	377	64.8	1.53	76.2	1.77	184	25.2	0.87	29.4	0.99
Bladder (incl. <i>in situ</i>)	244	42.4	1.24	49.6	1.43	94	12.3	0.59	14.3	0.68
Kidney & renal pelvis	125	21.0	0.87	24.9	1.00	84	12.1	0.62	14.1	0.70
Ureter	6	1.1	0.19	1.2	0.23	4	0.5	0.12	0.6	0.14
Eye & Orbit	5	0.8	0.18	0.9	0.19	4	0.5	0.12	0.6	0.13
Brain & Other CNS ¹	41	7.1	0.51	8.0	0.57	40	6.3	0.47	6.9	0.49
Brain	39	6.8	0.50	7.7	0.55	37	5.7	0.44	6.3	0.47
Endocrine System	57	9.9	0.61	11.3	0.67	156	27.6	1.03	29.6	1.07
Thyroid gland	52	8.9	0.57	10.3	0.64	152	26.8	1.01	28.8	1.05
Lymphomas	161	28.1	1.02	32.4	1.15	136	19.8	0.79	22.6	0.88
Hodgkin Lymphoma	19	3.4	0.37	3.6	0.38	19	3.3	0.36	3.4	0.36
Non-Hodgkin Lymphoma	142	24.7	0.95	28.8	1.09	117	16.5	0.71	19.2	0.81
Multiple Myeloma	43	7.3	0.51	8.6	0.59	32	4.3	0.35	5.1	0.41
Leukemias	104	18.4	0.83	20.9	0.92	77	11.4	0.61	12.6	0.65
Acute lymphocytic	7	1.4	0.25	1.3	0.23	7	1.3	0.24	1.3	0.22
Chronic lymphocytic	41	6.9	0.49	8.2	0.58	26	3.5	0.32	4.0	0.36
Acute myeloid	28	4.9	0.43	5.6	0.48	23	3.5	0.34	3.8	0.36
Chronic myeloid	15	2.7	0.33	3.0	0.36	11	1.6	0.22	1.8	0.25
Other leukemias	14	2.4	0.30	2.8	0.34	10	1.5	0.23	1.6	0.23
Mesothelioma	11	2.1	0.29	2.4	0.32	3	0.4	0.11	0.4	0.12
Kaposi Sarcoma	3	0.6	0.15	0.7	0.17	-	-	-	-	-
Ill-defined & Unknown	90	15.7	0.76	18.5	0.88	92	11.7	0.57	13.5	0.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	45	7.9	0.54	9.1	0.61	78	11.9	0.63	13.5	0.69
Breast (<i>in situ</i>)	-	-	-	-	-	238	36.1	1.09	42.5	1.25

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,682	491.4	4.37	581.5	5.05	2,981	466.5	4.02	542.9	4.54
Oral Cavity & Pharynx	91	15.9	0.77	19.6	0.92	50	7.4	0.49	8.9	0.57
Lip	4	0.7	0.17	0.8	0.19	1	0.2	0.07	0.2	0.08
Tongue	32	5.5	0.45	6.8	0.54	15	2.2	0.26	2.6	0.31
Major salivary gland	9	1.7	0.26	1.9	0.29	8	1.1	0.19	1.4	0.23
Floor of mouth	4	0.8	0.18	1.0	0.21	3	0.4	0.12	0.5	0.14
Gum & other mouth	9	1.6	0.24	2.0	0.29	10	1.6	0.24	1.8	0.26
Nasopharynx	3	0.6	0.16	0.7	0.18	2	0.3	0.09	0.3	0.11
Oropharynx	4	0.7	0.16	0.9	0.20	4	0.5	0.12	0.7	0.15
Hypopharynx	6	1.0	0.20	1.2	0.23	2	0.3	0.09	0.3	0.10
Digestive System	507	93.1	1.90	110.9	2.22	416	60.8	1.40	71.6	1.61
Esophagus	43	7.7	0.54	9.3	0.64	14	2.1	0.26	2.4	0.29
Stomach	57	10.4	0.63	12.4	0.74	31	4.5	0.38	5.2	0.43
Small intestine	18	3.3	0.36	3.9	0.42	14	2.1	0.26	2.5	0.31
Colon excl. rectum	133	25.1	1.00	29.4	1.15	148	21.1	0.81	24.9	0.94
Rectum & rectosigmoid	68	12.9	0.72	15.1	0.83	55	8.6	0.55	10.1	0.63
Anus, anal canal & anorectum	8	1.5	0.25	1.7	0.28	15	2.4	0.29	2.9	0.34
Liver	61	10.4	0.62	12.9	0.74	21	3.1	0.31	3.6	0.36
Gallbladder	5	0.9	0.19	1.0	0.21	10	1.5	0.22	1.7	0.25
Pancreas	84	15.4	0.77	18.3	0.90	76	10.6	0.57	12.6	0.66
Respiratory System	451	82.7	1.78	97.7	2.07	476	69.5	1.47	82.4	1.71
Larynx	32	5.7	0.46	6.9	0.55	10	1.6	0.24	1.9	0.27
Lung & bronchus	416	76.2	1.71	90.0	1.99	463	67.5	1.44	80.0	1.69
Bones & Joints	7	1.6	0.27	1.6	0.26	5	0.9	0.18	1.0	0.20
Soft Tissue (incl. heart)	21	4.1	0.41	4.6	0.45	17	2.8	0.33	3.1	0.35
Skin (excl. basal & sq.)	174	32.8	1.14	38.2	1.30	130	21.1	0.88	24.2	0.97
Melanomas of the skin	161	30.2	1.10	35.2	1.25	119	19.4	0.84	22.3	0.93
Breast (excl. <i>in situ</i>)	10	1.9	0.27	2.1	0.31	873	140.4	2.23	164.5	2.53
Female Genital System	-	-	-	-	-	346	54.4	1.37	64.7	1.58
Cervix uteri	-	-	-	-	-	34	6.9	0.56	7.3	0.57
Uterus Corpus	-	-	-	-	-	195	29.5	0.98	36.2	1.17
Uterus, NOS ¹	-	-	-	-	-	8	1.1	0.18	1.4	0.22
Ovary	-	-	-	-	-	64	10.1	0.60	11.9	0.68
Male Genital System	587	102.1	1.94	124.0	2.30	-	-	-	-	-
Prostate	553	94.4	1.84	116.1	2.22	-	-	-	-	-
Testis	28	6.4	0.56	6.5	0.55	-	-	-	-	-
Penis	5	0.9	0.19	1.0	0.21	-	-	-	-	-
Urinary System	360	66.8	1.62	78.6	1.86	173	25.7	0.92	29.9	1.04
Bladder (incl. <i>in situ</i>)	236	44.0	1.31	51.6	1.51	90	12.7	0.63	14.8	0.72
Kidney & renal pelvis	116	21.3	0.92	25.3	1.06	77	12.1	0.65	14.1	0.73
Ureter	6	1.1	0.20	1.2	0.23	3	0.5	0.12	0.5	0.14
Eye & Orbit	5	1.0	0.21	1.0	0.22	4	0.5	0.13	0.6	0.15
Brain & Other CNS ¹	38	7.2	0.55	8.2	0.60	38	6.7	0.51	7.3	0.54
Brain	37	7.0	0.54	8.0	0.60	35	6.0	0.48	6.6	0.51
Endocrine System	52	10.1	0.65	11.5	0.72	140	28.3	1.12	30.3	1.16
Thyroid gland	48	9.2	0.62	10.7	0.69	137	27.6	1.11	29.5	1.14
Lymphomas	149	28.4	1.07	32.8	1.21	127	20.3	0.85	23.2	0.94
Hodgkin Lymphoma	17	3.6	0.40	3.8	0.41	17	3.5	0.40	3.6	0.39
Non-Hodgkin Lymphoma	132	24.9	1.00	29.0	1.14	110	16.8	0.75	19.6	0.85
Multiple Myeloma	36	6.5	0.50	7.7	0.58	27	3.9	0.35	4.6	0.41
Leukemias	96	18.7	0.88	21.1	0.97	71	11.6	0.67	12.7	0.70
Acute lymphocytic	6	1.5	0.29	1.4	0.25	6	1.4	0.28	1.3	0.25
Chronic lymphocytic	40	7.2	0.53	8.6	0.61	25	3.6	0.34	4.1	0.38
Acute myeloid	25	4.9	0.45	5.5	0.50	21	3.5	0.37	3.8	0.38
Chronic myeloid	12	2.6	0.34	2.8	0.36	9	1.5	0.23	1.7	0.26
Other leukemias	13	2.4	0.31	2.8	0.35	10	1.6	0.25	1.7	0.26
Mesothelioma	11	2.1	0.30	2.4	0.33	3	0.4	0.11	0.4	0.12
Kaposi Sarcoma	3	0.5	0.14	0.7	0.17	-	-	-	-	-
Ill-defined & Unknown	85	16.0	0.79	18.8	0.92	86	11.8	0.60	13.5	0.68
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	41	8.0	0.57	9.1	0.64	72	12.2	0.68	13.7	0.74
Breast (<i>in situ</i>)	-	-	-	-	-	219	36.8	1.17	43.2	1.32

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	120	369.9	16.36	444.3	19.06	118	307.6	13.01	360.9	15.15
Oral Cavity & Pharynx	3	10.0	2.67	12.2	3.16	3	6.3	1.78	7.9	2.20
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	26	82.2	7.88	96.8	9.03	21	57.1	5.70	67.2	6.62
Esophagus	2	8.6	2.79	9.6	3.03	-	-	-	-	-
Stomach	3	11.5	3.08	12.7	3.33	3	6.1	1.73	7.2	2.02
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	6	21.1	4.04	24.3	4.57	5	14.6	3.00	16.5	3.34
Rectum & rectosigmoid	3	7.0	2.06	8.5	2.42	3	8.3	2.13	9.6	2.42
Anus, anal canal & anorectum	-	-	-	-	-	1	3.1	1.30	3.8	1.57
Liver	3	8.5	2.12	11.4	2.79	1	3.1	1.31	3.9	1.58
Gallbladder	-	-	-	-	-	2	5.4	1.82	6.2	2.08
Pancreas	5	18.4	3.86	21.8	4.45	4	9.3	2.23	11.6	2.76
Respiratory System	20	65.2	7.02	77.5	8.05	14	40.4	4.90	48.4	5.77
Larynx	2	4.3	1.59	5.1	1.85	-	-	-	-	-
Lung & bronchus	18	60.9	6.84	72.4	7.83	14	39.4	4.84	47.3	5.72
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.1	1.63	4.5	1.77	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	99.9	7.26	117.3	8.49
Female Genital System	-	-	-	-	-	12	31.3	4.08	37.9	4.91
Cervix uteri	-	-	-	-	-	2	5.6	1.73	6.8	2.09
Uterus Corpus	-	-	-	-	-	6	16.0	2.91	20.1	3.60
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	3.6	1.39	4.2	1.65
Male Genital System	36	107.0	8.53	134.1	10.30	-	-	-	-	-
Prostate	36	105.3	8.49	132.3	10.25	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	10	31.5	4.96	37.8	5.75	6	16.3	3.15	18.6	3.57
Bladder (incl. <i>in situ</i>)	3	11.9	3.31	14.0	3.78	2	5.6	1.81	7.0	2.22
Kidney & renal pelvis	6	17.4	3.46	21.2	4.01	4	10.7	2.58	11.6	2.80
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	4.2	1.50	4.0	1.51	2	3.6	1.27	4.2	1.52
Brain	1	3.5	1.42	3.5	1.45	2	3.6	1.27	4.2	1.52
Endocrine System	3	8.1	2.44	9.0	2.70	7	15.9	2.77	17.1	3.01
Thyroid gland	2	6.0	1.89	6.6	2.08	6	14.6	2.67	15.9	2.92
Lymphomas	6	17.2	3.48	20.2	4.10	4	9.1	2.16	10.0	2.37
Hodgkin Lymphoma	1	2.4	0.99	2.4	1.03	1	2.6	1.09	2.6	1.07
Non-Hodgkin Lymphoma	5	14.8	3.33	17.9	3.97	3	6.5	1.87	7.4	2.12
Multiple Myeloma	5	14.5	2.98	18.0	3.56	3	9.2	2.44	10.5	2.74
Leukemias	4	11.3	2.75	13.5	3.18	3	7.3	1.94	8.2	2.20
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	3.3	1.34	4.0	1.63	-	-	-	-	-
Chronic myeloid	1	3.6	1.36	4.5	1.72	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	4.7	1.71	5.9	2.06	3	7.9	2.22	9.2	2.57
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	7.5	2.35	8.2	2.54	3	8.0	1.99	9.7	2.42
Breast (<i>in situ</i>)	-	-	-	-	-	10	26.3	3.75	31.8	4.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	30	230.7	20.00	267.5	22.91	47	290.3	19.92	340.8	23.18
Oral Cavity & Pharynx	2	13.5	4.65	15.7	5.32	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	11	83.3	12.23	94.5	13.78	10	70.9	10.55	81.6	11.98
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	11.3	4.64	12.6	4.98	1	10.8	4.32	11.8	4.67
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	22.2	6.57	25.0	7.41	3	18.2	5.26	21.3	6.04
Rectum & rectosigmoid	1	10.0	4.34	11.0	4.83	2	13.3	4.42	15.6	5.21
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	22.0	5.48	25.6	6.37	2	10.7	4.04	12.3	4.58
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	4	33.6	7.49	39.5	8.55	4	26.6	6.29	32.8	7.50
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	27.6	6.58	33.7	7.81	4	26.6	6.29	32.8	7.50
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	1	8.3	3.56	10.9	4.48	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	14	83.4	10.04	99.5	11.95
Female Genital System	-	-	-	-	-	8	48.6	8.28	55.9	9.51
Cervix uteri	-	-	-	-	-	2	9.8	3.36	11.2	3.88
Uterus Corpus	-	-	-	-	-	3	18.8	4.92	23.1	6.00
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	14.4	4.75	15.6	5.20
Male Genital System	4	31.7	7.24	40.1	8.90	-	-	-	-	-
Prostate	4	31.1	7.22	39.4	8.87	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	10.9	3.94	12.3	4.48	1	7.3	3.14	9.0	3.79
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	7.8	3.25	9.0	3.79	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	4	18.8	4.39	22.5	5.37
Thyroid gland	-	-	-	-	-	4	18.8	4.39	22.5	5.37
Lymphomas	2	18.4	5.85	19.4	6.23	1	8.0	3.27	8.5	3.47
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	17.4	5.77	18.6	6.17	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	1	7.9	3.71	8.4	4.19	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	2	11.2	4.32	12.9	4.92
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	3	16.4	4.26	19.9	5.18

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2	408.0	130.69	502.6	158.09	3	505.2	127.38	554.6	137.52
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	-	-	-	-	-	-	-	-	-	-
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	162.0	67.39	195.5	81.28
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	119	316.9	14.74	374.7	17.06	153	296.9	11.48	348.2	13.38
Oral Cavity & Pharynx	4	9.1	2.40	11.5	2.97	2	3.4	1.26	4.2	1.54
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	30	79.4	7.33	93.6	8.47	28	56.3	5.08	66.9	5.98
Esophagus	1	3.0	1.29	3.3	1.43	-	-	-	-	-
Stomach	6	14.7	3.19	17.6	3.70	5	8.9	2.00	10.0	2.23
Small intestine	1	3.3	1.45	3.7	1.60	-	-	-	-	-
Colon excl. rectum	6	18.4	3.73	21.2	4.22	8	15.2	2.62	18.0	3.08
Rectum & rectosigmoid	6	12.7	2.70	14.7	3.11	4	7.3	1.82	8.5	2.09
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	9.0	2.23	11.0	2.68	1	2.3	1.05	2.6	1.19
Gallbladder	-	-	-	-	-	2	3.9	1.31	5.1	1.65
Pancreas	4	11.2	2.94	13.3	3.42	4	8.8	2.08	10.7	2.50
Respiratory System	14	41.2	5.37	49.3	6.23	11	27.6	3.86	32.2	4.42
Larynx	2	4.2	1.65	5.2	2.00	-	-	-	-	-
Lung & bronchus	12	36.6	5.10	43.6	5.89	10	26.4	3.82	30.7	4.36
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	2.0	0.78	2.4	1.02	2	2.5	0.86	3.0	1.11
Skin (excl. basal & sq.)	-	-	-	-	-	1	2.3	1.02	2.7	1.21
Melanomas of the skin	1	5.5	2.28	5.8	2.39	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	45	83.4	5.84	98.3	6.88
Female Genital System	-	-	-	-	-	21	42.1	4.40	49.9	5.13
Cervix uteri	-	-	-	-	-	5	8.8	1.79	10.5	2.14
Uterus Corpus	-	-	-	-	-	11	23.5	3.35	27.9	3.89
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	5.4	1.66	6.0	1.84
Male Genital System	32	90.7	7.98	107.2	9.16	-	-	-	-	-
Prostate	29	86.0	7.82	102.4	8.99	-	-	-	-	-
Testis	2	2.5	0.78	2.4	0.76	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	10	30.0	4.66	35.3	5.36	6	13.4	2.52	15.8	2.93
Bladder (incl. <i>in situ</i>)	4	14.0	3.37	16.1	3.84	1	2.2	0.93	2.8	1.17
Kidney & renal pelvis	6	14.9	3.02	17.8	3.50	5	11.2	2.34	13.0	2.68
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	4.4	1.38	5.5	1.75	4	6.1	1.55	6.8	1.80
Brain	2	4.4	1.38	5.5	1.75	3	5.8	1.52	6.6	1.79
Endocrine System	4	5.6	1.36	6.9	1.76	13	19.9	2.54	22.8	2.96
Thyroid gland	3	5.4	1.33	6.7	1.74	13	19.9	2.54	22.8	2.96
Lymphomas	6	12.2	2.64	14.7	3.16	8	17.0	2.86	19.3	3.23
Hodgkin Lymphoma	-	-	-	-	-	2	2.3	0.83	2.4	0.90
Non-Hodgkin Lymphoma	-	-	-	-	-	7	14.7	2.74	16.9	3.10
Multiple Myeloma	3	8.9	2.58	10.2	2.89	3	6.6	1.73	8.3	2.13
Leukemias	6	13.7	2.93	15.8	3.44	5	8.1	1.87	8.8	2.07
Acute lymphocytic	1	1.9	0.74	2.1	0.90	1	1.5	0.63	1.3	0.56
Chronic lymphocytic	-	-	-	-	-	1	2.9	1.25	3.4	1.42
Acute myeloid	2	3.0	1.35	3.3	1.58	-	-	-	-	-
Chronic myeloid	1	3.6	1.57	4.3	1.87	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	11.7	3.25	14.1	3.86	3	7.7	2.06	8.5	2.28
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	8.4	2.29	9.9	2.69	5	8.4	1.72	9.7	2.05
Breast (<i>in situ</i>)	-	-	-	-	-	17	28.7	3.23	34.5	3.90

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

RHODE ISLAND

II-438 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,571	500.1	4.57	590.9	5.26	2,848	478.6	4.28	555.9	4.80
Oral Cavity & Pharynx	88	16.5	0.82	20.2	0.97	49	7.6	0.52	9.2	0.61
Lip	4	0.7	0.18	0.9	0.21	1	0.2	0.07	0.2	0.09
Tongue	31	5.8	0.48	7.2	0.58	14	2.3	0.28	2.7	0.33
Major salivary gland	8	1.7	0.27	1.9	0.30	7	1.2	0.21	1.4	0.24
Floor of mouth	4	0.8	0.19	1.0	0.22	3	0.4	0.12	0.5	0.14
Gum & other mouth	9	1.7	0.26	2.0	0.31	10	1.6	0.25	1.9	0.27
Nasopharynx	3	0.6	0.17	0.7	0.19	2	0.3	0.09	0.4	0.12
Oropharynx	4	0.8	0.18	1.0	0.22	4	0.5	0.13	0.7	0.16
Hypopharynx	6	1.1	0.21	1.3	0.25	2	0.3	0.09	0.3	0.11
Digestive System	480	93.0	1.96	110.8	2.28	394	60.7	1.44	71.6	1.67
Esophagus	42	8.0	0.56	9.6	0.67	14	2.2	0.28	2.5	0.31
Stomach	52	10.1	0.64	12.1	0.75	28	4.2	0.37	4.9	0.43
Small intestine	17	3.3	0.37	3.9	0.43	13	2.2	0.28	2.6	0.32
Colon excl. rectum	126	25.2	1.04	29.5	1.18	140	20.9	0.83	24.6	0.96
Rectum & rectosigmoid	63	12.5	0.73	14.8	0.84	53	8.8	0.58	10.4	0.66
Anus, anal canal & anorectum	8	1.6	0.27	1.9	0.30	15	2.5	0.31	3.0	0.36
Liver	57	10.3	0.63	12.7	0.76	19	3.0	0.32	3.6	0.37
Gallbladder	4	0.9	0.19	1.0	0.22	8	1.3	0.22	1.5	0.24
Pancreas	80	15.5	0.80	18.5	0.93	72	10.8	0.59	12.7	0.69
Respiratory System	440	84.7	1.85	100.1	2.15	466	71.9	1.54	85.2	1.80
Larynx	30	5.8	0.48	7.0	0.57	9	1.6	0.25	1.9	0.29
Lung & bronchus	406	78.2	1.78	92.3	2.06	454	69.9	1.51	82.8	1.77
Bones & Joints	6	1.7	0.31	1.6	0.29	5	0.9	0.21	1.0	0.22
Soft Tissue (incl. heart)	20	4.3	0.45	4.8	0.48	15	2.8	0.36	3.1	0.37
Skin (excl. basal & sq.)	171	34.2	1.21	39.8	1.37	127	22.5	0.97	25.7	1.06
Melanomas of the skin	157	31.4	1.16	36.6	1.32	117	20.9	0.93	23.8	1.02
Breast (excl. <i>in situ</i>)	9	1.9	0.29	2.2	0.32	833	144.5	2.38	169.0	2.69
Female Genital System	-	-	-	-	-	328	55.7	1.46	66.1	1.67
Cervix uteri	-	-	-	-	-	29	7.0	0.62	7.3	0.61
Uterus Corpus	-	-	-	-	-	185	30.0	1.03	36.8	1.23
Uterus, NOS ¹	-	-	-	-	-	7	1.0	0.18	1.3	0.22
Ovary	-	-	-	-	-	62	10.7	0.65	12.5	0.73
Male Genital System	552	101.6	2.00	123.5	2.37	-	-	-	-	-
Prostate	521	93.4	1.88	115.1	2.27	-	-	-	-	-
Testis	26	7.1	0.64	7.2	0.63	-	-	-	-	-
Penis	4	0.8	0.18	0.9	0.21	-	-	-	-	-
Urinary System	350	68.6	1.70	80.6	1.94	167	26.4	0.97	30.7	1.10
Bladder (incl. <i>in situ</i>)	231	45.2	1.37	53.0	1.57	88	13.1	0.66	15.2	0.75
Kidney & renal pelvis	111	21.9	0.97	25.8	1.11	73	12.4	0.69	14.4	0.77
Ureter	6	1.1	0.21	1.3	0.24	3	0.5	0.12	0.6	0.14
Eye & Orbit	5	1.1	0.25	1.2	0.25	3	0.5	0.15	0.6	0.15
Brain & Other CNS ¹	35	7.6	0.61	8.5	0.65	35	6.6	0.55	7.2	0.57
Brain	34	7.4	0.60	8.3	0.64	32	6.0	0.51	6.6	0.54
Endocrine System	48	10.5	0.72	11.9	0.77	129	29.5	1.24	31.3	1.26
Thyroid gland	45	9.6	0.68	10.9	0.74	126	28.7	1.22	30.5	1.24
Lymphomas	145	29.7	1.15	34.1	1.28	120	20.6	0.90	23.4	0.99
Hodgkin Lymphoma	16	3.9	0.46	4.2	0.46	15	3.6	0.44	3.7	0.43
Non-Hodgkin Lymphoma	128	25.8	1.06	29.9	1.19	105	17.0	0.79	19.8	0.89
Multiple Myeloma	34	6.6	0.52	7.8	0.60	25	3.8	0.36	4.5	0.41
Leukemias	91	19.0	0.93	21.5	1.02	67	12.0	0.73	13.1	0.75
Acute lymphocytic	5	1.6	0.34	1.5	0.29	5	1.5	0.32	1.4	0.28
Chronic lymphocytic	38	7.4	0.54	8.7	0.64	24	3.7	0.36	4.2	0.40
Acute myeloid	24	5.0	0.47	5.7	0.52	20	3.7	0.41	4.0	0.41
Chronic myeloid	12	2.7	0.36	2.9	0.38	9	1.6	0.26	1.8	0.28
Other leukemias	12	2.4	0.33	2.7	0.36	9	1.6	0.28	1.7	0.28
Mesothelioma	10	2.2	0.31	2.4	0.34	3	0.4	0.12	0.5	0.13
Kaposi Sarcoma	3	0.5	0.15	0.7	0.18	-	-	-	-	-
Ill-defined & Unknown	82	16.3	0.83	19.1	0.95	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	39	8.2	0.61	9.4	0.68	67	12.4	0.73	14.0	0.78
Breast (<i>in situ</i>)	-	-	-	-	-	205	37.4	1.24	43.8	1.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Rhode Island, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	107	416.7	19.50	499.3	22.65	106	353.6	15.73	415.5	18.33
Oral Cavity & Pharynx	3	10.8	3.07	13.5	3.74	2	7.7	2.27	9.6	2.79
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	24	97.5	9.65	115.1	11.05	18	59.7	6.50	71.3	7.66
Esophagus	2	10.6	3.43	11.9	3.73	-	-	-	-	-
Stomach	3	14.5	3.88	16.0	4.19	2	6.3	2.01	7.4	2.35
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	6	25.0	4.94	28.8	5.57	4	15.1	3.37	17.3	3.82
Rectum & rectosigmoid	2	6.9	2.30	8.5	2.75	2	7.7	2.26	9.0	2.63
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	10.7	2.69	14.3	3.52	-	-	-	-	-
Gallbladder	-	-	-	-	-	2	6.8	2.30	7.9	2.65
Pancreas	5	21.5	4.69	25.5	5.40	4	11.7	2.80	14.6	3.47
Respiratory System	19	77.2	8.62	91.4	9.84	13	45.4	5.78	54.7	6.85
Larynx	1	4.8	1.90	5.5	2.14	-	-	-	-	-
Lung & bronchus	17	72.4	8.41	85.9	9.61	13	44.1	5.69	53.3	6.78
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	37	120.4	9.08	140.8	10.54
Female Genital System	-	-	-	-	-	11	35.9	4.89	43.7	5.93
Cervix uteri	-	-	-	-	-	2	5.8	1.94	7.2	2.41
Uterus Corpus	-	-	-	-	-	6	17.4	3.38	22.3	4.25
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	1	4.7	1.79	5.5	2.12
Male Genital System	32	115.3	9.87	144.6	11.91	-	-	-	-	-
Prostate	31	113.1	9.80	142.2	11.85	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	34.0	5.76	40.5	6.63	5	18.0	3.65	20.8	4.20
Bladder (incl. <i>in situ</i>)	3	13.0	3.83	15.0	4.33	2	7.0	2.23	8.7	2.76
Kidney & renal pelvis	5	18.3	4.00	22.2	4.61	3	11.0	2.89	12.1	3.17
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	5.9	2.06	5.5	2.03	-	-	-	-	-
Brain	1	4.8	1.91	4.7	1.94	-	-	-	-	-
Endocrine System	2	9.7	3.04	10.9	3.37	6	20.5	3.67	21.7	3.91
Thyroid gland	2	7.0	2.35	7.9	2.59	6	18.7	3.52	20.0	3.78
Lymphomas	5	17.4	3.81	20.4	4.48	3	11.2	2.79	12.3	3.05
Hodgkin Lymphoma	1	3.2	1.35	3.2	1.36	-	-	-	-	-
Non-Hodgkin Lymphoma	4	14.2	3.56	17.2	4.27	-	-	-	-	-
Multiple Myeloma	5	16.2	3.59	19.5	4.20	3	11.3	3.00	13.1	3.39
Leukemias	4	13.0	3.34	15.4	3.81	2	6.8	2.07	7.9	2.45
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	3.7	1.64	4.5	1.94	-	-	-	-	-
Chronic myeloid	1	3.8	1.57	4.7	1.94	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	5.4	2.06	6.5	2.40	3	10.0	2.81	11.7	3.25
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	6.2	2.36	6.4	2.44	3	9.3	2.45	11.2	2.96
Breast (<i>in situ</i>)	-	-	-	-	-	9	29.7	4.53	35.8	5.39

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


RHODE ISLAND

II-440 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	4,764,153	4,823,793	4,892,253	4,958,235	5,021,219
White	3,294,087	3,337,588	3,388,152	3,436,939	3,484,446
Black	1,361,693	1,373,341	1,386,205	1,398,178	1,408,395
American Indian/Alaskan Native (AI/AN)	27,816	28,194	28,803	29,388	29,901
Asian/Pacific Islander (API)	80,557	84,670	89,093	93,730	98,477


All Races Population 2013-2017: 24,459,653
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	249,695	257,358	266,313	274,793	285,054
Non-Hispanic White	3,083,029	3,120,131	3,162,994	3,204,802	3,243,587
Non-Hispanic Black	1,336,484	1,347,141	1,359,153	1,369,991	1,379,008

Hispanic/Latino Population, Census 2010: 235,682
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SOUTH CAROLINA CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.6	102.9	105.0	103.5	101.8
Missing Race	0.4	0.3	0.4	0.4	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.2	0.3	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.6	2.3	2.2	2.0	1.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Prostate	95.9
Oral Cavity & Pharynx	97.3	Testis	99.6
Esophagus	93.6	Bladder (incl. <i>in situ</i>)	96.4
Stomach	93.9	Kidney & Renal Pelvis	88.5
Colon & Rectum	94.7	Brain & Other CNS ¹	83.9
Liver	56.9	Thyroid	99.1
Pancreas	82.2	Hodgkin Lymphoma	98.1
Lung & Bronchus	88.4	Non-Hodgkin Lymphoma	94.5
Melanomas of the Skin	99.0	Multiple Myeloma	84.9
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	86.7
Cervix uteri	97.2	Brain & Other CNS ¹ <i>non-malig</i>	38.3
Uterus Corpus & Uterus NOS ¹	98.3	Breast <i>in situ</i>	100.0
Ovary	91.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	14,209	511.0	1.99	610.4	2.34	13,117	413.1	1.67	482.8	1.91
Oral Cavity & Pharynx	573	20.1	0.39	24.7	0.47	204	6.3	0.20	7.5	0.24
Lip	14	0.5	0.07	0.6	0.08	5	0.2	0.03	0.2	0.04
Tongue	171	5.9	0.21	7.3	0.25	58	1.8	0.11	2.2	0.13
Major salivary gland	48	1.9	0.12	2.2	0.14	26	0.8	0.08	1.0	0.09
Floor of mouth	31	1.0	0.09	1.3	0.11	11	0.3	0.05	0.4	0.06
Gum & other mouth	58	2.1	0.13	2.5	0.15	46	1.4	0.09	1.6	0.11
Nasopharynx	18	0.7	0.07	0.8	0.08	8	0.3	0.05	0.3	0.05
Oropharynx	36	1.2	0.09	1.5	0.11	10	0.3	0.04	0.4	0.05
Hypopharynx	47	1.6	0.11	2.0	0.13	9	0.2	0.04	0.3	0.05
Digestive System	2,691	97.3	0.87	117.2	1.03	2,091	64.4	0.65	76.2	0.75
Esophagus	228	7.8	0.24	9.6	0.29	61	1.8	0.11	2.2	0.13
Stomach	254	9.3	0.27	11.0	0.32	149	4.6	0.17	5.4	0.20
Small intestine	84	3.1	0.16	3.7	0.18	84	2.6	0.13	3.1	0.15
Colon excl. rectum	819	30.4	0.49	36.2	0.58	809	25.1	0.41	29.5	0.47
Rectum & rectosigmoid	366	13.3	0.32	16.0	0.38	245	7.8	0.23	9.2	0.27
Anus, anal canal & anorectum	37	1.4	0.10	1.6	0.12	71	2.1	0.12	2.7	0.14
Liver	339	11.3	0.28	14.4	0.36	94	2.8	0.13	3.4	0.16
Gallbladder	19	0.8	0.08	0.9	0.09	36	1.1	0.08	1.3	0.10
Pancreas	429	15.6	0.35	18.7	0.41	393	11.9	0.27	14.1	0.32
Respiratory System	2,495	88.8	0.82	106.6	0.98	1,846	54.4	0.58	65.1	0.68
Larynx	221	7.6	0.24	9.5	0.29	49	1.5	0.10	1.8	0.12
Lung & bronchus	2,243	80.1	0.78	95.8	0.93	1,777	52.3	0.57	62.5	0.67
Bones & Joints	30	1.2	0.10	1.3	0.11	21	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	104	4.1	0.18	4.6	0.20	77	2.6	0.14	2.9	0.15
Skin (excl. basal & sq.)	880	33.2	0.52	38.8	0.60	574	19.1	0.37	21.8	0.41
Melanomas of the skin	826	31.0	0.50	36.2	0.58	544	18.2	0.36	20.7	0.40
Breast (excl. <i>in situ</i>)	38	1.4	0.10	1.6	0.12	4,084	129.9	0.94	152.4	1.08
Female Genital System	-	-	-	-	-	1,425	45.3	0.56	53.2	0.64
Cervix uteri	-	-	-	-	-	206	7.9	0.25	8.4	0.27
Uterus Corpus	-	-	-	-	-	743	22.2	0.38	27.1	0.45
Uterus, NOS ¹	-	-	-	-	-	29	0.9	0.08	1.1	0.09
Ovary	-	-	-	-	-	297	9.4	0.25	11.0	0.29
Male Genital System	3,585	119.7	0.92	147.2	1.12	-	-	-	-	-
Prostate	3,464	114.5	0.90	141.9	1.10	-	-	-	-	-
Testis	94	4.2	0.20	4.2	0.19	-	-	-	-	-
Penis	23	0.8	0.08	1.0	0.09	-	-	-	-	-
Urinary System	1,545	58.0	0.68	68.3	0.80	685	21.1	0.37	24.7	0.43
Bladder (incl. <i>in situ</i>)	847	32.7	0.52	38.3	0.61	279	8.4	0.23	9.9	0.27
Kidney & renal pelvis	670	24.2	0.43	28.8	0.51	385	12.0	0.28	14.1	0.33
Ureter	19	0.7	0.08	0.8	0.09	15	0.4	0.05	0.5	0.06
Eye & Orbit	21	0.8	0.08	0.9	0.09	19	0.7	0.07	0.7	0.07
Brain & Other CNS ¹	197	7.6	0.25	8.4	0.27	160	5.4	0.20	5.9	0.21
Brain	189	7.2	0.24	8.0	0.27	150	5.0	0.19	5.6	0.20
Endocrine System	180	6.9	0.24	7.8	0.26	460	16.9	0.37	18.4	0.39
Thyroid gland	161	6.2	0.23	7.0	0.25	438	16.1	0.36	17.5	0.38
Lymphomas	610	23.3	0.44	26.7	0.49	499	16.0	0.33	18.2	0.37
Hodgkin Lymphoma	69	2.8	0.16	3.0	0.16	56	2.1	0.13	2.2	0.13
Non-Hodgkin Lymphoma	542	20.5	0.41	23.7	0.47	443	13.8	0.30	16.0	0.34
Multiple Myeloma	266	10.0	0.28	11.8	0.33	225	6.8	0.21	8.0	0.24
Leukemias	440	17.0	0.38	19.5	0.43	315	10.3	0.27	11.5	0.29
Acute lymphocytic	35	1.5	0.11	1.4	0.11	35	1.4	0.11	1.3	0.10
Chronic lymphocytic	154	5.7	0.21	6.8	0.25	99	2.9	0.13	3.5	0.16
Acute myeloid	138	5.2	0.21	6.0	0.24	101	3.3	0.15	3.7	0.17
Chronic myeloid	63	2.5	0.14	2.8	0.16	50	1.7	0.11	1.9	0.12
Other leukemias	51	2.1	0.14	2.4	0.16	31	1.0	0.08	1.1	0.09
Mesothelioma	36	1.4	0.11	1.6	0.12	14	0.4	0.05	0.5	0.06
Kaposi Sarcoma	10	0.4	0.06	0.4	0.06	-	-	-	-	-
Ill-defined & Unknown	506	19.7	0.41	23.0	0.47	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	214	8.2	0.26	9.3	0.29	473	15.4	0.33	17.7	0.37
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	971	30.9	0.46	36.6	0.53

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	10,738	503.4	2.25	598.4	2.64	9,847	422.6	1.99	493.1	2.27
Oral Cavity & Pharynx	462	21.3	0.46	26.2	0.56	163	6.8	0.25	8.2	0.29
Lip	13	0.6	0.08	0.7	0.09	4	0.2	0.04	0.2	0.04
Tongue	148	6.7	0.25	8.3	0.31	53	2.3	0.15	2.7	0.17
Major salivary gland	42	2.1	0.15	2.4	0.17	17	0.8	0.09	0.9	0.10
Floor of mouth	21	0.9	0.09	1.2	0.12	9	0.3	0.05	0.4	0.06
Gum & other mouth	41	2.0	0.14	2.4	0.17	38	1.5	0.11	1.8	0.13
Nasopharynx	11	0.5	0.07	0.7	0.09	5	0.2	0.05	0.3	0.05
Oropharynx	28	1.3	0.11	1.6	0.14	7	0.3	0.05	0.3	0.06
Hypopharynx	33	1.5	0.12	1.8	0.15	6	0.2	0.04	0.3	0.05
Digestive System	1,940	91.4	0.96	109.9	1.14	1,450	60.1	0.73	71.1	0.85
Esophagus	171	7.7	0.27	9.4	0.33	43	1.7	0.12	2.1	0.14
Stomach	163	7.8	0.28	9.2	0.33	83	3.4	0.17	4.0	0.20
Small intestine	60	2.8	0.17	3.4	0.20	52	2.2	0.14	2.6	0.17
Colon excl. rectum	589	28.6	0.54	33.9	0.64	566	23.7	0.46	27.8	0.53
Rectum & rectosigmoid	264	12.7	0.36	15.2	0.42	176	7.7	0.27	9.1	0.31
Anus, anal canal & anorectum	26	1.2	0.11	1.5	0.13	60	2.5	0.15	3.1	0.18
Liver	247	10.8	0.32	13.9	0.40	67	2.7	0.15	3.2	0.18
Gallbladder	11	0.6	0.08	0.7	0.09	21	0.8	0.08	1.0	0.10
Pancreas	319	15.0	0.39	17.8	0.46	270	10.8	0.30	12.8	0.35
Respiratory System	1,888	86.7	0.92	103.7	1.09	1,486	58.6	0.70	70.1	0.83
Larynx	146	6.7	0.26	8.2	0.31	36	1.5	0.12	1.8	0.14
Lung & bronchus	1,719	78.9	0.88	94.2	1.04	1,437	56.5	0.68	67.6	0.81
Bones & Joints	23	1.3	0.12	1.4	0.13	16	0.8	0.10	0.9	0.10
Soft Tissue (incl. heart)	82	4.3	0.22	4.8	0.24	53	2.4	0.16	2.7	0.17
Skin (excl. basal & sq.)	863	42.0	0.66	49.1	0.76	553	25.7	0.52	29.2	0.57
Melanomas of the skin	815	39.5	0.64	46.3	0.74	530	24.8	0.51	28.1	0.56
Breast (excl. <i>in situ</i>)	27	1.2	0.11	1.5	0.13	3,023	130.8	1.12	153.5	1.28
Female Genital System	-	-	-	-	-	1,011	44.6	0.66	52.3	0.75
Cervix uteri	-	-	-	-	-	133	7.5	0.30	7.9	0.31
Uterus Corpus	-	-	-	-	-	514	21.3	0.44	26.0	0.52
Uterus, NOS ¹	-	-	-	-	-	16	0.7	0.08	0.8	0.09
Ovary	-	-	-	-	-	225	9.7	0.30	11.3	0.34
Male Genital System	2,391	104.1	0.98	126.8	1.18	-	-	-	-	-
Prostate	2,288	97.8	0.94	120.4	1.15	-	-	-	-	-
Testis	85	5.4	0.27	5.4	0.26	-	-	-	-	-
Penis	15	0.7	0.09	0.8	0.10	-	-	-	-	-
Urinary System	1,286	62.2	0.80	73.1	0.93	518	21.5	0.44	25.2	0.50
Bladder (incl. <i>in situ</i>)	754	36.8	0.62	43.1	0.72	222	8.9	0.27	10.4	0.32
Kidney & renal pelvis	506	24.1	0.50	28.5	0.58	281	12.0	0.34	14.0	0.38
Ureter	18	0.9	0.10	1.0	0.11	12	0.5	0.06	0.6	0.07
Eye & Orbit	18	0.8	0.09	1.0	0.11	17	0.8	0.09	0.9	0.10
Brain & Other CNS ¹	167	8.5	0.31	9.5	0.33	131	6.1	0.25	6.7	0.27
Brain	161	8.2	0.30	9.1	0.33	123	5.7	0.24	6.3	0.26
Endocrine System	147	7.6	0.29	8.6	0.32	344	18.3	0.47	19.7	0.48
Thyroid gland	134	7.0	0.28	7.8	0.31	330	17.6	0.46	19.0	0.48
Lymphomas	489	24.2	0.51	27.8	0.57	400	17.1	0.40	19.7	0.45
Hodgkin Lymphoma	48	2.8	0.18	2.9	0.19	39	2.1	0.16	2.2	0.16
Non-Hodgkin Lymphoma	441	21.5	0.47	24.9	0.54	361	15.0	0.37	17.4	0.42
Multiple Myeloma	158	7.7	0.28	9.1	0.33	120	4.8	0.20	5.7	0.24
Leukemias	361	18.1	0.44	20.7	0.50	242	10.7	0.32	12.0	0.35
Acute lymphocytic	26	1.6	0.14	1.5	0.13	27	1.6	0.15	1.5	0.13
Chronic lymphocytic	128	6.1	0.25	7.2	0.29	80	3.1	0.16	3.7	0.19
Acute myeloid	115	5.6	0.24	6.5	0.28	77	3.4	0.18	3.9	0.20
Chronic myeloid	50	2.6	0.17	2.9	0.19	35	1.6	0.12	1.8	0.14
Other leukemias	41	2.2	0.16	2.5	0.18	24	1.0	0.10	1.1	0.11
Mesothelioma	32	1.5	0.13	1.8	0.15	12	0.5	0.06	0.6	0.07
Kaposi Sarcoma	5	0.3	0.06	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	402	20.0	0.46	23.3	0.53	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	167	8.6	0.31	9.7	0.34	335	15.0	0.39	17.2	0.43
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	709	31.4	0.55	36.9	0.63

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,258	534.7	4.48	647.5	5.29	3,059	387.9	3.23	455.6	3.71
Oral Cavity & Pharynx	104	15.9	0.73	19.6	0.88	39	4.8	0.36	5.7	0.41
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	22	3.4	0.34	4.2	0.40	5	0.6	0.13	0.7	0.14
Major salivary gland	5	1.0	0.20	1.1	0.21	8	1.1	0.18	1.2	0.19
Floor of mouth	9	1.4	0.22	1.8	0.26	2	0.3	0.09	0.4	0.11
Gum & other mouth	15	2.3	0.29	2.9	0.34	7	0.9	0.15	1.1	0.18
Nasopharynx	7	1.0	0.18	1.2	0.21	3	0.4	0.11	0.5	0.12
Oropharynx	7	1.1	0.19	1.3	0.22	3	0.4	0.10	0.5	0.12
Hypopharynx	13	1.9	0.25	2.4	0.31	3	0.3	0.09	0.4	0.11
Digestive System	713	119.6	2.15	144.2	2.52	604	76.7	1.43	91.1	1.67
Esophagus	54	8.5	0.55	10.5	0.66	18	2.1	0.23	2.6	0.28
Stomach	87	15.1	0.77	17.9	0.90	61	7.9	0.46	9.2	0.53
Small intestine	23	4.2	0.41	4.9	0.47	31	4.1	0.34	4.7	0.38
Colon excl. rectum	219	37.7	1.22	44.9	1.42	229	28.9	0.88	34.4	1.02
Rectum & rectosigmoid	94	15.7	0.77	18.9	0.91	62	7.8	0.45	9.3	0.53
Anus, anal canal & anorectum	10	1.7	0.25	1.9	0.27	11	1.3	0.18	1.6	0.22
Liver	89	12.6	0.64	16.5	0.80	25	2.9	0.27	3.6	0.33
Gallbladder	7	1.6	0.27	1.8	0.31	14	1.8	0.22	2.2	0.26
Pancreas	106	18.2	0.85	22.0	1.00	119	15.4	0.65	18.2	0.75
Respiratory System	587	98.9	1.96	119.7	2.30	345	42.6	1.06	51.2	1.24
Larynx	73	11.3	0.63	14.2	0.77	13	1.5	0.19	1.9	0.24
Lung & bronchus	506	86.2	1.84	103.9	2.16	325	40.3	1.03	48.4	1.21
Bones & Joints	6	0.8	0.16	0.8	0.16	4	0.5	0.12	0.6	0.13
Soft Tissue (incl. heart)	20	3.3	0.34	3.6	0.37	21	2.8	0.28	3.1	0.30
Skin (excl. basal & sq.)	9	1.4	0.22	1.6	0.24	12	1.7	0.22	1.8	0.24
Melanomas of the skin	3	0.5	0.13	0.6	0.15	6	0.8	0.15	0.9	0.17
Breast (excl. <i>in situ</i>)	11	1.9	0.27	2.2	0.30	1,003	127.2	1.85	149.2	2.12
Female Genital System	-	-	-	-	-	384	47.7	1.12	56.4	1.30
Cervix uteri	-	-	-	-	-	66	9.0	0.51	9.9	0.55
Uterus Corpus	-	-	-	-	-	214	25.3	0.80	31.0	0.96
Uterus, NOS ¹	-	-	-	-	-	12	1.6	0.21	1.8	0.24
Ovary	-	-	-	-	-	65	8.4	0.48	9.7	0.54
Male Genital System	1,126	173.8	2.47	216.8	2.98	-	-	-	-	-
Prostate	1,111	171.3	2.45	214.0	2.97	-	-	-	-	-
Testis	7	1.2	0.20	1.1	0.20	-	-	-	-	-
Penis	7	1.1	0.21	1.4	0.25	-	-	-	-	-
Urinary System	243	41.7	1.28	49.8	1.50	158	20.2	0.74	23.8	0.85
Bladder (incl. <i>in situ</i>)	83	16.4	0.87	19.3	1.01	53	7.0	0.44	8.2	0.51
Kidney & renal pelvis	158	24.9	0.93	30.0	1.10	101	12.6	0.58	14.8	0.67
Ureter	-	-	-	-	-	2	0.3	0.10	0.4	0.11
Eye & Orbit	2	0.4	0.13	0.4	0.14	1	0.2	0.07	0.2	0.07
Brain & Other CNS ¹	27	4.6	0.42	4.9	0.45	27	3.5	0.31	3.9	0.33
Brain	25	4.3	0.40	4.6	0.44	25	3.2	0.30	3.6	0.32
Endocrine System	29	4.7	0.41	5.2	0.45	103	13.5	0.61	15.0	0.67
Thyroid gland	23	3.8	0.37	4.3	0.41	95	12.5	0.59	13.9	0.64
Lymphomas	108	18.0	0.82	20.3	0.91	90	11.8	0.57	13.3	0.63
Hodgkin Lymphoma	20	3.0	0.31	3.2	0.32	16	2.1	0.24	2.2	0.25
Non-Hodgkin Lymphoma	88	15.0	0.76	17.2	0.85	74	9.6	0.52	11.0	0.58
Multiple Myeloma	103	18.8	0.89	22.3	1.03	102	12.9	0.59	15.3	0.68
Leukemias	68	12.2	0.71	14.0	0.81	66	8.8	0.50	9.8	0.54
Acute lymphocytic	7	1.1	0.19	1.1	0.19	7	1.0	0.17	1.0	0.16
Chronic lymphocytic	20	3.6	0.38	4.3	0.45	16	2.1	0.24	2.5	0.28
Acute myeloid	22	3.9	0.40	4.5	0.46	23	3.2	0.30	3.5	0.33
Chronic myeloid	10	1.8	0.26	1.9	0.28	12	1.6	0.21	1.8	0.23
Other leukemias	9	1.9	0.31	2.2	0.35	7	0.9	0.16	1.1	0.18
Mesothelioma	4	0.8	0.19	0.9	0.21	1	0.2	0.07	0.2	0.08
Kaposi Sarcoma	4	0.6	0.14	0.6	0.14	-	-	-	-	-
Ill-defined & Unknown	94	17.3	0.86	20.5	1.00	99	12.9	0.59	15.1	0.68
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	44	7.3	0.52	8.4	0.59	129	16.6	0.67	19.2	0.76
Breast (<i>in situ</i>)	1	0.2	0.09	0.2	0.09	247	30.4	0.89	36.4	1.04

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	70	234.0	13.79	275.5	16.12	109	256.0	11.57	303.4	13.60
Oral Cavity & Pharynx	3	9.6	2.72	11.7	3.24	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	20	69.2	7.51	81.2	8.75	22	54.5	5.59	66.4	6.68
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	3	10.0	2.86	11.7	3.37	3	7.0	1.97	9.1	2.50
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	12.6	3.07	15.2	3.65	9	21.2	3.46	25.8	4.12
Rectum & rectosigmoid	4	16.0	3.76	18.7	4.36	3	7.6	2.05	9.8	2.57
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	6.7	2.00	8.2	2.40	2	6.5	1.97	7.5	2.25
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	10.9	2.99	12.3	3.37	2	5.7	2.01	6.3	2.25
Respiratory System	10	30.0	4.54	36.9	5.45	11	29.1	4.10	34.0	4.72
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	28.5	4.46	34.7	5.31	11	28.2	4.05	33.1	4.67
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	2	4.3	1.42	4.8	1.64
Melanomas of the skin	-	-	-	-	-	1	3.1	1.25	3.5	1.43
Breast (excl. <i>in situ</i>)	-	-	-	-	-	33	72.2	5.86	84.7	6.87
Female Genital System	-	-	-	-	-	14	31.3	3.79	38.2	4.58
Cervix uteri	-	-	-	-	-	2	3.8	1.28	4.4	1.50
Uterus Corpus	-	-	-	-	-	8	16.2	2.68	19.9	3.26
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	6.8	1.66	8.8	2.14
Male Genital System	13	44.4	5.91	52.3	6.87	-	-	-	-	-
Prostate	12	41.9	5.82	49.7	6.79	-	-	-	-	-
Testis	1	2.4	1.00	2.6	1.06	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	5	17.9	3.78	21.5	4.42	4	8.6	2.10	11.0	2.61
Bladder (incl. <i>in situ</i>)	2	7.6	2.68	8.5	2.99	1	2.6	1.08	3.2	1.32
Kidney & renal pelvis	3	9.0	2.32	11.5	2.89	2	5.7	1.77	7.3	2.20
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	1	3.6	1.45	4.0	1.63
Brain	-	-	-	-	-	1	3.6	1.45	4.0	1.63
Endocrine System	1	3.5	1.35	3.4	1.34	7	13.9	2.48	15.2	2.74
Thyroid gland	-	-	-	-	-	6	13.0	2.40	14.2	2.64
Lymphomas	7	22.8	4.41	27.0	5.27	6	14.1	2.85	16.6	3.32
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	7.1	2.56	8.5	3.06	-	-	-	-	-
Leukemias	2	7.2	2.69	8.5	3.20	2	4.5	1.62	5.3	1.90
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	16.0	4.23	18.1	4.83	4	11.2	2.60	12.7	2.94
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.5	1.65	4.5	1.69	4	10.3	2.39	12.5	2.86
Breast (<i>in situ</i>)	-	-	-	-	-	8	17.9	2.87	21.6	3.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17	138.2	17.17	168.2	20.32	18	142.0	15.35	164.1	17.56
Oral Cavity & Pharynx	1	8.5	3.75	10.8	4.53	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	28.5	7.77	34.2	9.08	3	23.5	6.12	27.9	7.19
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	10.5	4.87	12.8	5.77	2	13.4	4.96	15.3	5.60
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	25.5	7.73	30.7	8.94	2	16.8	5.50	19.2	6.24
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	22.6	7.43	27.1	8.57	2	16.8	5.50	19.2	6.24
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	45.3	9.05	51.5	10.21
Female Genital System	-	-	-	-	-	2	16.2	4.75	19.7	5.69
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	41.2	9.65	50.7	11.64	-	-	-	-	-
Prostate	5	40.2	9.59	49.6	11.59	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	15.4	5.80	18.8	6.78	1	8.3	3.40	10.4	4.24
Bladder (incl. <i>in situ</i>)	1	12.9	5.52	15.5	6.38	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	10.1	3.87	10.8	4.11
Thyroid gland	-	-	-	-	-	1	10.1	3.87	10.8	4.11
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	1	9.2	3.78	9.3	3.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	153	246.5	10.71	293.1	12.50	146	203.9	8.51	234.7	9.86
Oral Cavity & Pharynx	3	4.3	1.23	5.6	1.57	1	1.6	0.68	1.9	0.83
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	2.2	1.01	2.9	1.24	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	40	61.5	5.12	74.6	6.05	27	44.6	4.21	52.3	4.89
Esophagus	2	4.7	1.68	5.4	1.89	-	-	-	-	-
Stomach	7	11.5	2.32	13.4	2.67	3	3.3	0.99	3.8	1.15
Small intestine	2	2.5	1.05	3.0	1.27	-	-	-	-	-
Colon excl. rectum	9	14.5	2.53	17.2	2.90	11	18.4	2.71	21.8	3.17
Rectum & rectosigmoid	7	8.5	1.48	11.0	1.96	3	3.9	1.15	4.5	1.34
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	5	7.7	1.72	9.7	2.06	1	2.2	0.98	2.7	1.18
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	5	7.5	1.72	9.2	2.05	5	8.6	1.89	9.9	2.17
Respiratory System	11	22.3	3.42	26.8	3.98	9	14.8	2.42	17.7	2.84
Larynx	1	2.6	1.21	3.0	1.37	-	-	-	-	-
Lung & bronchus	10	18.9	3.15	23.1	3.70	8	13.3	2.32	16.0	2.72
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	2.7	0.92	3.0	1.03	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	2	3.7	1.33	4.5	1.58	1	1.2	0.50	1.4	0.64
Breast (excl. <i>in situ</i>)	-	-	-	-	-	45	58.6	4.32	68.2	5.07
Female Genital System	-	-	-	-	-	19	23.7	2.67	26.8	3.06
Cervix uteri	-	-	-	-	-	7	7.1	1.18	7.3	1.30
Uterus Corpus	-	-	-	-	-	6	9.6	1.87	11.2	2.12
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	4.6	1.11	5.4	1.32
Male Genital System	43	79.4	6.26	95.1	7.26	-	-	-	-	-
Prostate	37	75.0	6.18	90.6	7.19	-	-	-	-	-
Testis	5	3.2	0.62	3.0	0.58	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	13	24.9	3.60	29.7	4.24	5	9.0	1.97	10.0	2.22
Bladder (incl. <i>in situ</i>)	4	10.4	2.57	12.0	2.98	2	3.0	1.15	3.3	1.29
Kidney & renal pelvis	9	14.5	2.53	17.7	3.02	4	6.0	1.60	6.7	1.81
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	2.7	0.95	2.7	0.97	3	3.2	0.96	3.8	1.15
Brain	3	2.5	0.94	2.5	0.97	3	2.8	0.90	3.3	1.07
Endocrine System	4	4.2	1.00	4.5	1.09	10	10.7	1.74	11.6	1.96
Thyroid gland	4	4.1	1.00	4.4	1.08	9	10.0	1.71	11.0	1.94
Lymphomas	11	17.6	2.91	20.0	3.30	7	11.3	2.21	12.7	2.48
Hodgkin Lymphoma	2	2.2	0.87	2.5	0.96	1	1.2	0.46	1.3	0.52
Non-Hodgkin Lymphoma	9	15.4	2.78	17.5	3.16	6	10.2	2.16	11.4	2.43
Multiple Myeloma	2	3.9	1.35	4.7	1.61	2	3.5	1.13	4.5	1.41
Leukemias	8	7.3	1.53	7.7	1.75	7	7.0	1.45	7.4	1.60
Acute lymphocytic	4	2.1	0.50	1.9	0.46	3	2.4	0.78	2.2	0.76
Chronic lymphocytic	1	2.6	1.25	3.2	1.49	-	-	-	-	-
Acute myeloid	2	1.5	0.59	1.4	0.62	2	1.7	0.67	1.9	0.75
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	9.9	2.36	11.5	2.71	6	10.3	2.17	11.9	2.51
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	4.7	1.49	5.0	1.62	5	7.4	1.65	8.7	1.91
Breast (<i>in situ</i>)	-	-	-	-	-	11	14.4	2.07	17.4	2.50

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

SOUTH CAROLINA

II-448 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10,616	511.6	2.30	607.8	2.70	9,726	429.7	2.05	501.0	2.33
Oral Cavity & Pharynx	459	21.9	0.47	26.9	0.57	162	7.0	0.26	8.4	0.30
Lip	13	0.6	0.08	0.8	0.10	4	0.2	0.04	0.2	0.04
Tongue	146	6.9	0.26	8.5	0.32	52	2.4	0.15	2.8	0.18
Major salivary gland	42	2.1	0.15	2.5	0.18	17	0.8	0.09	0.9	0.10
Floor of mouth	21	1.0	0.10	1.2	0.12	9	0.3	0.05	0.4	0.07
Gum & other mouth	41	2.0	0.15	2.4	0.17	38	1.5	0.11	1.8	0.14
Nasopharynx	11	0.6	0.08	0.7	0.09	5	0.2	0.05	0.3	0.06
Oropharynx	28	1.3	0.11	1.6	0.14	7	0.3	0.05	0.3	0.06
Hypopharynx	33	1.5	0.12	1.9	0.15	6	0.2	0.04	0.3	0.06
Digestive System	1,907	92.4	0.98	111.0	1.16	1,427	60.6	0.75	71.6	0.87
Esophagus	169	7.8	0.28	9.5	0.33	43	1.8	0.12	2.1	0.14
Stomach	158	7.7	0.29	9.1	0.33	80	3.3	0.17	3.9	0.20
Small intestine	58	2.9	0.17	3.4	0.20	51	2.3	0.15	2.7	0.17
Colon excl. rectum	581	29.0	0.56	34.4	0.65	556	23.9	0.47	28.0	0.54
Rectum & rectosigmoid	257	12.8	0.37	15.3	0.44	174	7.9	0.28	9.3	0.32
Anus, anal canal & anorectum	26	1.3	0.12	1.5	0.14	59	2.5	0.15	3.2	0.19
Liver	243	11.0	0.32	14.0	0.41	66	2.7	0.15	3.2	0.18
Gallbladder	11	0.6	0.08	0.7	0.09	20	0.8	0.08	1.0	0.10
Pancreas	315	15.2	0.40	18.0	0.47	266	10.9	0.31	12.9	0.36
Respiratory System	1,880	88.3	0.94	105.7	1.11	1,479	59.5	0.71	71.2	0.84
Larynx	146	6.9	0.26	8.4	0.32	36	1.5	0.12	1.9	0.14
Lung & bronchus	1,712	80.3	0.89	95.9	1.06	1,431	57.4	0.70	68.7	0.83
Bones & Joints	23	1.3	0.13	1.4	0.14	15	0.8	0.10	0.9	0.10
Soft Tissue (incl. heart)	79	4.3	0.23	4.8	0.25	52	2.5	0.17	2.8	0.18
Skin (excl. basal & sq.)	861	43.3	0.69	50.5	0.79	552	26.8	0.54	30.3	0.59
Melanomas of the skin	813	40.7	0.67	47.6	0.76	529	25.8	0.53	29.1	0.58
Breast (excl. <i>in situ</i>)	27	1.3	0.12	1.5	0.13	2,986	133.0	1.15	156.1	1.31
Female Genital System	-	-	-	-	-	995	45.4	0.68	53.1	0.77
Cervix uteri	-	-	-	-	-	128	7.5	0.31	8.0	0.32
Uterus Corpus	-	-	-	-	-	509	21.7	0.45	26.4	0.54
Uterus, NOS ¹	-	-	-	-	-	16	0.7	0.08	0.8	0.09
Ovary	-	-	-	-	-	222	9.9	0.31	11.5	0.35
Male Genital System	2,357	105.2	1.00	128.1	1.20	-	-	-	-	-
Prostate	2,259	98.7	0.95	121.5	1.17	-	-	-	-	-
Testis	80	5.6	0.29	5.5	0.28	-	-	-	-	-
Penis	15	0.7	0.09	0.8	0.10	-	-	-	-	-
Urinary System	1,275	63.2	0.82	74.3	0.95	514	21.9	0.45	25.6	0.52
Bladder (incl. <i>in situ</i>)	750	37.3	0.63	43.8	0.73	221	9.1	0.28	10.6	0.32
Kidney & renal pelvis	499	24.6	0.51	29.0	0.59	277	12.2	0.35	14.2	0.39
Ureter	18	0.9	0.10	1.0	0.11	12	0.5	0.06	0.6	0.08
Eye & Orbit	17	0.9	0.10	1.0	0.11	17	0.8	0.10	0.9	0.10
Brain & Other CNS ¹	165	8.8	0.32	9.8	0.35	128	6.3	0.27	6.9	0.28
Brain	159	8.5	0.31	9.4	0.34	121	5.9	0.26	6.4	0.27
Endocrine System	143	7.8	0.31	8.7	0.33	335	18.8	0.49	20.2	0.51
Thyroid gland	131	7.1	0.29	8.0	0.32	323	18.1	0.48	19.5	0.50
Lymphomas	480	24.6	0.52	28.2	0.59	394	17.4	0.41	19.9	0.46
Hodgkin Lymphoma	46	2.9	0.20	3.0	0.20	38	2.2	0.17	2.3	0.17
Non-Hodgkin Lymphoma	434	21.7	0.48	25.2	0.55	357	15.2	0.37	17.7	0.43
Multiple Myeloma	156	7.8	0.29	9.2	0.34	118	4.9	0.21	5.8	0.24
Leukemias	354	18.2	0.45	20.9	0.51	236	10.7	0.33	12.1	0.36
Acute lymphocytic	23	1.5	0.15	1.4	0.13	24	1.6	0.15	1.5	0.14
Chronic lymphocytic	127	6.2	0.26	7.4	0.30	79	3.2	0.16	3.7	0.19
Acute myeloid	113	5.7	0.25	6.6	0.28	75	3.4	0.18	3.9	0.20
Chronic myeloid	50	2.6	0.17	3.0	0.19	34	1.6	0.13	1.8	0.14
Other leukemias	41	2.2	0.16	2.6	0.18	24	1.0	0.10	1.2	0.11
Mesothelioma	32	1.6	0.13	1.8	0.15	12	0.5	0.06	0.6	0.08
Kaposi Sarcoma	5	0.3	0.06	0.3	0.06	-	-	-	-	-
Ill-defined & Unknown	398	20.3	0.47	23.7	0.55	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	164	8.8	0.32	9.9	0.35	332	15.4	0.40	17.6	0.44
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	700	32.0	0.57	37.6	0.65

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Carolina, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,249	538.0	4.51	651.2	5.32	3,054	390.9	3.26	458.9	3.74
Oral Cavity & Pharynx	104	16.1	0.74	19.8	0.89	39	4.9	0.36	5.8	0.42
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	22	3.4	0.34	4.2	0.41	5	0.6	0.13	0.7	0.15
Major salivary gland	5	1.0	0.20	1.1	0.22	8	1.1	0.18	1.2	0.19
Floor of mouth	9	1.5	0.22	1.8	0.27	2	0.3	0.09	0.4	0.11
Gum & other mouth	15	2.4	0.29	2.9	0.35	7	0.9	0.15	1.1	0.18
Nasopharynx	7	1.0	0.18	1.2	0.21	3	0.4	0.11	0.5	0.12
Oropharynx	7	1.1	0.19	1.3	0.23	3	0.4	0.10	0.5	0.12
Hypopharynx	13	1.9	0.25	2.5	0.31	3	0.3	0.09	0.4	0.11
Digestive System	710	120.2	2.16	144.9	2.53	604	77.2	1.44	91.7	1.68
Esophagus	54	8.6	0.56	10.6	0.66	18	2.1	0.23	2.6	0.28
Stomach	86	15.1	0.78	18.0	0.90	61	7.9	0.47	9.3	0.54
Small intestine	23	4.2	0.42	4.9	0.48	31	4.1	0.34	4.8	0.38
Colon excl. rectum	218	37.8	1.22	45.0	1.42	228	29.1	0.88	34.6	1.03
Rectum & rectosigmoid	94	15.8	0.78	18.9	0.91	62	7.8	0.46	9.4	0.54
Anus, anal canal & anorectum	10	1.7	0.25	2.0	0.28	11	1.3	0.18	1.6	0.22
Liver	88	12.7	0.64	16.5	0.81	24	2.9	0.27	3.6	0.33
Gallbladder	7	1.6	0.27	1.8	0.31	14	1.8	0.22	2.2	0.26
Pancreas	105	18.3	0.86	22.1	1.01	119	15.5	0.65	18.3	0.76
Respiratory System	586	99.4	1.97	120.3	2.32	344	42.9	1.06	51.5	1.25
Larynx	73	11.4	0.64	14.3	0.77	13	1.5	0.19	1.9	0.24
Lung & bronchus	505	86.7	1.85	104.5	2.17	325	40.6	1.04	48.7	1.22
Bones & Joints	6	0.8	0.16	0.8	0.16	4	0.5	0.12	0.6	0.13
Soft Tissue (incl. heart)	20	3.3	0.34	3.7	0.38	21	2.9	0.29	3.1	0.30
Skin (excl. basal & sq.)	9	1.4	0.22	1.6	0.25	12	1.7	0.22	1.9	0.24
Melanomas of the skin	3	0.5	0.13	0.6	0.15	6	0.8	0.15	0.9	0.17
Breast (excl. <i>in situ</i>)	11	1.8	0.27	2.2	0.31	1,002	128.3	1.87	150.4	2.14
Female Genital System	-	-	-	-	-	384	48.1	1.13	56.9	1.31
Cervix uteri	-	-	-	-	-	66	9.1	0.52	10.0	0.55
Uterus Corpus	-	-	-	-	-	214	25.5	0.80	31.3	0.96
Uterus, NOS ¹	-	-	-	-	-	12	1.6	0.21	1.8	0.24
Ovary	-	-	-	-	-	65	8.5	0.48	9.8	0.55
Male Genital System	1,122	174.6	2.48	217.7	3.00	-	-	-	-	-
Prostate	1,106	172.0	2.46	214.9	2.98	-	-	-	-	-
Testis	7	1.2	0.20	1.2	0.20	-	-	-	-	-
Penis	7	1.2	0.21	1.4	0.25	-	-	-	-	-
Urinary System	243	42.1	1.29	50.2	1.51	158	20.4	0.75	24.0	0.86
Bladder (incl. <i>in situ</i>)	83	16.5	0.87	19.4	1.01	53	7.0	0.44	8.3	0.51
Kidney & renal pelvis	158	25.1	0.94	30.3	1.11	101	12.7	0.58	15.0	0.67
Ureter	-	-	-	-	-	2	0.3	0.10	0.4	0.11
Eye & Orbit	2	0.4	0.13	0.4	0.15	1	0.2	0.07	0.2	0.07
Brain & Other CNS ¹	27	4.7	0.42	5.0	0.46	27	3.5	0.31	3.9	0.34
Brain	25	4.4	0.41	4.7	0.45	25	3.3	0.30	3.6	0.32
Endocrine System	29	4.8	0.41	5.3	0.45	103	13.6	0.62	15.2	0.67
Thyroid gland	23	3.8	0.37	4.4	0.41	95	12.7	0.60	14.1	0.65
Lymphomas	108	18.2	0.83	20.5	0.92	89	11.8	0.57	13.3	0.63
Hodgkin Lymphoma	20	3.1	0.32	3.2	0.33	16	2.2	0.25	2.3	0.25
Non-Hodgkin Lymphoma	88	15.1	0.76	17.3	0.86	73	9.7	0.52	11.1	0.58
Multiple Myeloma	103	19.0	0.90	22.4	1.04	101	13.0	0.60	15.3	0.69
Leukemias	68	12.3	0.72	14.1	0.82	65	8.8	0.50	9.8	0.55
Acute lymphocytic	7	1.1	0.19	1.1	0.19	7	1.0	0.17	1.0	0.17
Chronic lymphocytic	20	3.6	0.39	4.4	0.46	16	2.1	0.24	2.5	0.28
Acute myeloid	22	3.9	0.41	4.6	0.47	23	3.2	0.31	3.5	0.33
Chronic myeloid	10	1.8	0.26	1.9	0.28	12	1.6	0.21	1.8	0.23
Other leukemias	9	1.9	0.31	2.2	0.35	7	0.9	0.16	1.1	0.18
Mesothelioma	4	0.8	0.19	0.9	0.21	1	0.2	0.07	0.2	0.08
Kaposi Sarcoma	4	0.6	0.14	0.6	0.15	-	-	-	-	-
Ill-defined & Unknown	94	17.4	0.87	20.6	1.01	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	44	7.3	0.52	8.4	0.59	128	16.7	0.68	19.2	0.76
Breast (<i>in situ</i>)	1	0.2	0.09	0.2	0.09	247	30.6	0.90	36.7	1.05

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	842,270	849,088	853,933	862,890	873,286
White	731,779	736,544	738,778	743,077	749,508
Black	18,150	18,780	19,679	21,693	23,768
American Indian/Alaskan Native (AI/AN)	80,858	81,793	82,689	83,823	84,287
Asian/Pacific Islander (API)	11,483	11,971	12,787	14,297	15,723


All Races Population 2013-2017: 4,281,467
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	28,931	30,157	31,202	32,875	34,633
Non-Hispanic White	709,984	714,049	715,755	719,029	723,880
Non-Hispanic Black	17,238	17,846	18,674	20,643	22,629

Hispanic/Latino Population, Census 2010: 22,119
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SOUTH DAKOTA CANCER REGISTRY

Initial Operation: 2001
 Population-based Data Available: 2001
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.3	112.3	100.4	113.2	105.9
Missing Race	0.0	0.0	0.1	0.3	0.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	0.4	0.8	0.8	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.0	Prostate	96.9
Oral Cavity & Pharynx	98.8	Testis	96.6
Esophagus	92.9	Bladder (incl. <i>in situ</i>)	98.3
Stomach	96.0	Kidney & Renal Pelvis	87.5
Colon & Rectum	95.5	Brain & Other CNS ¹	80.6
Liver	45.3	Thyroid	99.1
Pancreas	85.3	Hodgkin Lymphoma	100.0
Lung & Bronchus	89.2	Non-Hodgkin Lymphoma	96.6
Melanomas of the Skin	99.6	Multiple Myeloma	92.2
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	82.5
Cervix uteri	98.7	Brain & Other CNS ¹ <i>non-malig</i>	31.3
Uterus Corpus & Uterus NOS ¹	99.1	Breast <i>in situ</i>	100.0
Ovary	94.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,407	496.7	4.66	586.3	5.38	2,228	434.1	4.30	502.7	4.86
Oral Cavity & Pharynx	94	19.1	0.91	23.0	1.07	34	6.5	0.52	7.7	0.60
Lip	13	2.9	0.36	3.3	0.41	5	1.0	0.20	1.1	0.23
Tongue	25	5.2	0.48	6.2	0.56	10	1.8	0.27	2.2	0.32
Major salivary gland	9	2.0	0.30	2.3	0.34	5	0.9	0.19	1.0	0.21
Floor of mouth	5	1.0	0.19	1.2	0.24	2	0.5	0.16	0.6	0.17
Gum & other mouth	7	1.3	0.22	1.6	0.27	6	1.0	0.18	1.2	0.23
Nasopharynx	3	0.5	0.15	0.6	0.17	-	-	-	-	-
Oropharynx	3	0.6	0.16	0.8	0.20	2	0.4	0.11	0.5	0.14
Hypopharynx	4	0.8	0.19	1.0	0.22	-	-	-	-	-
Digestive System	454	94.0	2.03	111.3	2.35	351	64.5	1.61	75.0	1.83
Esophagus	39	7.6	0.56	9.2	0.66	9	1.6	0.25	2.0	0.30
Stomach	33	6.8	0.55	8.1	0.63	17	3.1	0.36	3.6	0.40
Small intestine	15	3.3	0.39	3.8	0.44	10	1.9	0.28	2.1	0.31
Colon excl. rectum	155	32.8	1.21	38.4	1.39	151	27.4	1.04	31.5	1.17
Rectum & rectosigmoid	69	14.5	0.80	17.3	0.93	48	9.4	0.64	11.0	0.73
Anus, anal canal & anorectum	4	0.8	0.19	1.0	0.23	10	1.8	0.27	2.3	0.33
Liver	42	8.2	0.59	10.1	0.70	12	2.2	0.30	2.5	0.34
Gallbladder	3	0.6	0.18	0.7	0.19	8	1.4	0.23	1.5	0.25
Pancreas	69	14.0	0.77	16.6	0.90	62	11.0	0.65	12.9	0.75
Respiratory System	347	72.6	1.78	85.3	2.06	303	55.9	1.47	66.2	1.72
Larynx	23	4.8	0.46	5.7	0.53	7	1.4	0.23	1.6	0.27
Lung & bronchus	318	66.7	1.71	78.2	1.97	293	54.1	1.45	64.0	1.69
Bones & Joints	3	0.7	0.18	0.7	0.18	2	0.4	0.15	0.4	0.15
Soft Tissue (incl. heart)	15	3.4	0.41	3.7	0.44	13	2.5	0.33	2.8	0.36
Skin (excl. basal & sq.)	145	31.0	1.19	36.0	1.35	-	-	-	-	-
Melanomas of the skin	136	29.0	1.15	33.7	1.31	105	23.1	1.06	25.4	1.13
Breast (excl. <i>in situ</i>)	5	1.1	0.23	1.3	0.26	644	128.3	2.37	149.6	2.69
Female Genital System	-	-	-	-	-	271	53.1	1.51	62.8	1.74
Cervix uteri	-	-	-	-	-	31	7.3	0.62	7.9	0.64
Uterus Corpus	-	-	-	-	-	148	28.4	1.08	34.5	1.28
Uterus, NOS ¹	-	-	-	-	-	2	0.3	0.10	0.4	0.14
Ovary	-	-	-	-	-	59	11.4	0.69	13.5	0.79
Male Genital System	632	122.7	2.25	149.0	2.67	-	-	-	-	-
Prostate	600	114.8	2.15	141.2	2.59	-	-	-	-	-
Testis	24	6.1	0.57	5.9	0.55	-	-	-	-	-
Penis	7	1.5	0.27	1.7	0.30	-	-	-	-	-
Urinary System	280	58.8	1.62	69.1	1.86	110	21.0	0.93	24.5	1.06
Bladder (incl. <i>in situ</i>)	160	34.0	1.23	39.6	1.41	47	8.4	0.57	9.9	0.66
Kidney & renal pelvis	114	23.5	1.02	28.0	1.18	60	11.9	0.72	13.9	0.81
Ureter	3	0.8	0.19	0.9	0.21	3	0.4	0.13	0.5	0.15
Eye & Orbit	5	1.0	0.20	1.2	0.24	4	0.7	0.16	0.8	0.19
Brain & Other CNS ¹	37	8.1	0.61	8.9	0.66	26	5.1	0.47	5.7	0.52
Brain	36	7.8	0.60	8.6	0.65	25	5.0	0.47	5.6	0.51
Endocrine System	38	8.4	0.63	9.4	0.69	85	20.4	1.03	21.7	1.07
Thyroid gland	34	7.6	0.60	8.6	0.66	82	19.8	1.02	21.1	1.06
Lymphomas	117	25.3	1.08	28.9	1.21	95	18.3	0.88	20.8	0.98
Hodgkin Lymphoma	12	2.6	0.35	2.8	0.37	9	2.1	0.33	2.1	0.33
Non-Hodgkin Lymphoma	105	22.6	1.02	26.1	1.15	86	16.1	0.81	18.6	0.92
Multiple Myeloma	42	8.8	0.62	10.4	0.72	25	4.4	0.41	5.3	0.48
Leukemias	93	20.0	0.95	22.8	1.07	68	13.3	0.75	14.8	0.82
Acute lymphocytic	6	1.3	0.25	1.1	0.21	7	1.6	0.28	1.4	0.24
Chronic lymphocytic	39	8.1	0.59	9.6	0.70	24	4.3	0.41	5.2	0.48
Acute myeloid	24	5.3	0.49	6.0	0.55	21	4.3	0.43	4.8	0.47
Chronic myeloid	18	3.8	0.42	4.4	0.47	9	2.0	0.30	2.2	0.32
Other leukemias	7	1.5	0.26	1.7	0.29	7	1.2	0.21	1.4	0.24
Mesothelioma	6	1.1	0.21	1.3	0.25	2	0.3	0.11	0.3	0.12
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	95	20.5	0.96	23.8	1.10	89	15.5	0.77	17.9	0.87
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	38	8.2	0.61	9.4	0.69	66	13.3	0.77	15.2	0.85
Breast (<i>in situ</i>)	-	-	-	-	-	133	27.5	1.12	32.5	1.28

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	2,257	494.5	4.80	583.1	5.53	2,074	435.0	4.51	503.2	5.07
Oral Cavity & Pharynx	88	19.2	0.95	23.0	1.11	32	6.5	0.54	7.7	0.62
Lip	13	2.9	0.38	3.4	0.42	5	1.0	0.22	1.2	0.24
Tongue	23	5.1	0.49	6.0	0.57	9	1.8	0.28	2.2	0.33
Major salivary gland	9	2.1	0.31	2.4	0.35	4	0.9	0.21	1.0	0.23
Floor of mouth	5	0.9	0.20	1.1	0.24	2	0.5	0.16	0.5	0.17
Gum & other mouth	6	1.3	0.23	1.6	0.28	6	1.0	0.19	1.3	0.24
Nasopharynx	2	0.4	0.13	0.5	0.16	-	-	-	-	-
Oropharynx	3	0.7	0.17	0.8	0.21	2	0.3	0.11	0.4	0.14
Hypopharynx	3	0.7	0.18	0.9	0.21	-	-	-	-	-
Digestive System	415	91.1	2.06	107.8	2.39	321	62.7	1.64	72.6	1.87
Esophagus	38	7.8	0.58	9.4	0.69	8	1.6	0.26	2.0	0.31
Stomach	29	6.3	0.54	7.5	0.63	14	2.8	0.35	3.2	0.40
Small intestine	14	3.5	0.42	3.9	0.47	9	2.0	0.30	2.2	0.33
Colon excl. rectum	145	32.4	1.24	38.0	1.42	139	26.7	1.06	30.5	1.19
Rectum & rectosigmoid	63	14.1	0.82	16.7	0.95	43	9.2	0.66	10.6	0.75
Anus, anal canal & anorectum	4	0.9	0.20	1.1	0.24	8	1.7	0.27	2.1	0.33
Liver	32	6.6	0.54	8.1	0.65	9	1.8	0.29	2.0	0.32
Gallbladder	2	0.5	0.16	0.6	0.18	7	1.2	0.22	1.4	0.25
Pancreas	65	13.9	0.79	16.5	0.92	58	10.9	0.67	12.7	0.77
Respiratory System	324	71.2	1.81	83.7	2.09	280	54.9	1.51	65.0	1.76
Larynx	21	4.7	0.47	5.6	0.55	6	1.3	0.24	1.5	0.28
Lung & bronchus	298	65.5	1.73	76.8	2.00	272	53.2	1.48	62.9	1.73
Bones & Joints	3	0.8	0.21	0.8	0.20	2	0.4	0.16	0.4	0.16
Soft Tissue (incl. heart)	13	3.2	0.42	3.6	0.45	12	2.7	0.36	3.0	0.39
Skin (excl. basal & sq.)	142	32.5	1.26	37.8	1.43	-	-	-	-	-
Melanomas of the skin	133	30.5	1.23	35.5	1.39	104	25.1	1.18	27.6	1.25
Breast (excl. <i>in situ</i>)	5	1.2	0.24	1.4	0.27	598	128.5	2.48	149.8	2.81
Female Genital System	-	-	-	-	-	252	52.9	1.57	62.8	1.81
Cervix uteri	-	-	-	-	-	26	6.7	0.63	7.3	0.65
Uterus Corpus	-	-	-	-	-	142	29.0	1.14	35.4	1.35
Uterus, NOS ¹	-	-	-	-	-	2	0.3	0.10	0.3	0.13
Ovary	-	-	-	-	-	55	11.2	0.71	13.3	0.82
Male Genital System	595	122.7	2.32	148.8	2.75	-	-	-	-	-
Prostate	566	114.3	2.21	140.5	2.66	-	-	-	-	-
Testis	22	6.8	0.65	6.5	0.62	-	-	-	-	-
Penis	6	1.4	0.26	1.6	0.29	-	-	-	-	-
Urinary System	263	58.4	1.65	68.5	1.90	101	20.6	0.97	23.9	1.09
Bladder (incl. <i>in situ</i>)	155	34.4	1.26	40.1	1.45	45	8.7	0.61	10.2	0.70
Kidney & renal pelvis	103	22.7	1.04	26.9	1.20	52	11.3	0.74	13.1	0.82
Ureter	3	0.7	0.19	0.8	0.21	2	0.4	0.13	0.5	0.15
Eye & Orbit	5	1.1	0.22	1.3	0.26	3	0.7	0.17	0.8	0.20
Brain & Other CNS ¹	35	8.2	0.65	9.1	0.69	24	5.3	0.51	6.0	0.55
Brain	34	7.9	0.63	8.8	0.68	24	5.3	0.51	5.9	0.55
Endocrine System	35	8.7	0.68	9.7	0.74	79	21.2	1.12	22.6	1.16
Thyroid gland	32	7.8	0.65	8.8	0.71	76	20.5	1.11	22.0	1.15
Lymphomas	110	25.8	1.13	29.3	1.26	90	18.9	0.94	21.5	1.04
Hodgkin Lymphoma	11	2.8	0.39	3.0	0.40	8	2.4	0.38	2.4	0.38
Non-Hodgkin Lymphoma	99	23.0	1.07	26.4	1.20	82	16.5	0.86	19.1	0.97
Multiple Myeloma	39	8.5	0.63	10.1	0.73	23	4.3	0.41	5.1	0.49
Leukemias	89	20.5	1.00	23.4	1.11	64	13.7	0.81	15.2	0.87
Acute lymphocytic	4	1.2	0.27	1.0	0.22	6	1.6	0.31	1.4	0.26
Chronic lymphocytic	38	8.4	0.62	10.0	0.73	23	4.4	0.43	5.4	0.51
Acute myeloid	24	5.5	0.52	6.2	0.58	20	4.5	0.47	5.0	0.51
Chronic myeloid	16	3.8	0.43	4.4	0.48	9	2.1	0.33	2.3	0.35
Other leukemias	-	-	-	-	-	6	1.1	0.22	1.3	0.24
Mesothelioma	6	1.1	0.21	1.4	0.26	1	0.2	0.10	0.3	0.11
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	90	20.3	0.98	23.5	1.12	84	15.5	0.80	17.9	0.90
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	36	8.4	0.65	9.7	0.73	60	12.9	0.79	14.8	0.88
Breast (<i>in situ</i>)	-	-	-	-	-	125	28.3	1.19	33.2	1.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	18	344.2	46.03	423.6	53.33	10	251.9	40.59	296.9	47.28
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	91.3	24.91	107.5	28.03	2	53.9	18.84	64.7	22.12
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	19.7	7.92	24.1	10.02	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	46.6	21.03	55.4	22.58	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	46.6	21.03	55.4	22.58	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	88.5	22.55	111.0	28.14
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	89.0	19.40	118.0	24.69	-	-	-	-	-
Prostate	5	89.0	19.40	118.0	24.69	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	26.4	8.43	35.4	11.70	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	21.6	7.68	29.3	10.64	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	26.6	10.36	32.1	13.04
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	366.3	69.90	424.0	79.26	12	281.4	42.09	331.5	48.16
Oral Cavity & Pharynx	1	46.0	22.39	55.0	25.53	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	142.3	39.06	164.6	43.32	2	61.5	21.59	76.3	25.37
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	1	28.7	13.66	39.0	17.39
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	35.9	19.50	40.7	20.54	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	1	35.4	16.69	40.9	18.03
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	1	35.4	16.69	40.9	18.03
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	4	89.0	22.09	99.0	24.22
Female Genital System	-	-	-	-	-	2	50.5	16.74	61.5	19.44
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCD¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	96	515.0	26.30	612.1	30.56	104	439.4	20.19	514.7	23.34
Oral Cavity & Pharynx	3	16.1	4.93	19.9	5.91	2	7.4	2.71	8.3	2.97
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	6.5	2.63	8.2	3.19	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	25	128.0	12.43	153.6	14.47	21	90.5	9.23	108.3	10.85
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	12.5	4.27	13.9	4.70	2	8.7	2.76	11.1	3.47
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	7	40.0	7.46	46.2	8.36	8	34.4	5.70	40.9	6.68
Rectum & rectosigmoid	5	18.9	4.04	24.2	5.14	4	16.1	3.88	18.9	4.44
Anus, anal canal & anorectum	-	-	-	-	-	1	3.9	1.58	5.1	2.09
Liver	6	30.3	5.89	35.5	6.76	1	6.8	2.69	8.0	3.14
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	13.1	3.91	16.2	4.61	2	10.7	3.18	12.3	3.62
Respiratory System	16	110.6	13.83	127.3	15.73	19	82.5	8.95	98.0	10.43
Larynx	1	7.7	3.28	8.5	3.54	-	-	-	-	-
Lung & bronchus	14	97.2	13.08	112.8	14.97	18	78.8	8.79	93.6	10.23
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	6.1	2.34	6.5	2.51	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	28	111.3	9.75	133.3	11.49
Female Genital System	-	-	-	-	-	13	55.0	7.12	61.8	8.00
Cervix uteri	-	-	-	-	-	4	15.6	3.66	16.2	3.82
Uterus Corpus	-	-	-	-	-	5	18.9	3.99	21.9	4.60
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	12.8	3.71	14.4	4.13
Male Genital System	23	115.9	11.67	143.7	13.98	-	-	-	-	-
Prostate	22	111.8	11.54	140.0	13.89	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	11	61.2	8.78	71.4	10.00	6	27.2	5.02	32.5	5.91
Bladder (incl. <i>in situ</i>)	3	19.1	4.89	21.2	5.32	1	6.7	2.84	7.9	3.29
Kidney & renal pelvis	8	40.2	7.07	48.4	8.28	5	19.9	4.10	23.7	4.82
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	5.4	2.10	5.8	2.22	3	12.0	3.20	12.0	3.20
Thyroid gland	1	4.5	1.86	5.0	2.06	3	12.0	3.20	12.0	3.20
Lymphomas	4	25.7	6.70	30.5	7.94	2	10.8	3.32	12.3	3.81
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	4	24.6	6.65	29.2	7.88	2	10.8	3.32	12.3	3.81
Multiple Myeloma	2	10.2	3.58	12.6	4.26	1	4.4	1.85	5.4	2.23
Leukemias	3	9.9	3.14	10.9	3.52	2	11.2	3.38	12.3	3.78
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	18.4	4.92	22.3	5.95	4	18.3	4.40	21.2	5.00
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	1	5.0	2.19	5.7	2.48	3	13.5	3.65	14.8	4.04
Breast (<i>in situ</i>)	-	-	-	-	-	4	15.8	3.44	20.1	4.31

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCD – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	17	290.3	39.11	330.9	44.11	19	314.5	37.06	355.8	41.32
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	5	67.7	17.46	82.1	20.46	4	68.4	17.97	76.9	19.92
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	13.5	6.85	14.0	7.44	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	2	43.4	15.65	47.4	16.59
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	2	43.4	15.65	47.4	16.59
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	68.1	15.77	81.6	18.61
Female Genital System	-	-	-	-	-	2	23.1	7.13	25.4	8.28
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	81.1	21.22	92.6	24.07	-	-	-	-	-
Prostate	3	71.0	20.90	82.9	23.81	-	-	-	-	-
Testis	1	6.9	2.90	6.2	2.57	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	30.4	12.39	33.6	13.25	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	14.5	6.99	16.9	8.13	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	17.1	7.34	18.2	7.94
Thyroid gland	-	-	-	-	-	1	17.1	7.34	18.2	7.94
Lymphomas	2	31.7	14.07	32.8	15.03	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	1	14.4	5.87	17.6	7.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

SOUTH DAKOTA

II-458 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,244	497.1	4.84	586.4	5.59	2,058	437.1	4.56	505.6	5.12
Oral Cavity & Pharynx	88	19.5	0.96	23.4	1.13	32	6.5	0.54	7.7	0.63
Lip	13	3.0	0.38	3.4	0.43	5	1.0	0.22	1.2	0.25
Tongue	23	5.1	0.50	6.1	0.58	9	1.7	0.27	2.1	0.33
Major salivary gland	9	2.1	0.32	2.4	0.36	4	0.9	0.21	1.1	0.23
Floor of mouth	5	0.9	0.20	1.2	0.24	2	0.5	0.17	0.5	0.17
Gum & other mouth	6	1.3	0.23	1.6	0.28	6	1.0	0.19	1.3	0.24
Nasopharynx	2	0.4	0.13	0.5	0.16	-	-	-	-	-
Oropharynx	3	0.7	0.18	0.9	0.22	2	0.3	0.11	0.4	0.14
Hypopharynx	3	0.7	0.19	0.9	0.21	-	-	-	-	-
Digestive System	411	91.4	2.08	108.1	2.41	318	62.5	1.65	72.6	1.88
Esophagus	37	7.8	0.58	9.4	0.69	8	1.6	0.26	1.9	0.30
Stomach	28	6.1	0.53	7.3	0.63	14	2.7	0.35	3.1	0.39
Small intestine	14	3.5	0.43	4.0	0.48	9	2.0	0.31	2.3	0.34
Colon excl. rectum	144	32.6	1.25	38.2	1.43	138	26.7	1.07	30.6	1.20
Rectum & rectosigmoid	62	14.1	0.83	16.7	0.96	42	9.1	0.66	10.6	0.75
Anus, anal canal & anorectum	4	0.9	0.20	1.1	0.24	8	1.6	0.26	2.1	0.33
Liver	32	6.6	0.54	8.2	0.66	9	1.8	0.29	2.0	0.32
Gallbladder	2	0.5	0.16	0.6	0.18	7	1.3	0.23	1.4	0.25
Pancreas	65	14.0	0.80	16.6	0.93	58	10.9	0.67	12.8	0.77
Respiratory System	323	71.6	1.82	84.2	2.11	279	55.0	1.52	65.2	1.77
Larynx	21	4.8	0.48	5.7	0.56	6	1.3	0.24	1.6	0.28
Lung & bronchus	297	65.8	1.75	77.2	2.02	270	53.3	1.49	63.1	1.74
Bones & Joints	3	0.8	0.22	0.8	0.21	2	0.4	0.16	0.5	0.17
Soft Tissue (incl. heart)	12	3.2	0.42	3.5	0.45	12	2.7	0.37	3.0	0.39
Skin (excl. basal & sq.)	142	32.9	1.28	38.2	1.45	106	26.4	1.23	28.9	1.29
Melanomas of the skin	133	30.9	1.25	35.9	1.40	103	25.6	1.21	28.1	1.27
Breast (excl. <i>in situ</i>)	5	1.2	0.24	1.4	0.27	594	129.5	2.52	150.9	2.84
Female Genital System	-	-	-	-	-	250	53.0	1.58	63.0	1.82
Cervix uteri	-	-	-	-	-	25	6.7	0.63	7.2	0.66
Uterus Corpus	-	-	-	-	-	141	29.1	1.15	35.6	1.37
Uterus, NOS ¹	-	-	-	-	-	2	0.3	0.10	0.4	0.13
Ovary	-	-	-	-	-	54	11.2	0.71	13.3	0.83
Male Genital System	592	123.3	2.34	149.7	2.77	-	-	-	-	-
Prostate	563	114.9	2.22	141.3	2.68	-	-	-	-	-
Testis	22	6.8	0.66	6.6	0.64	-	-	-	-	-
Penis	6	1.4	0.26	1.6	0.29	-	-	-	-	-
Urinary System	262	58.6	1.67	68.8	1.92	100	20.7	0.98	24.0	1.10
Bladder (incl. <i>in situ</i>)	154	34.6	1.27	40.3	1.46	45	8.7	0.61	10.2	0.70
Kidney & renal pelvis	102	22.8	1.05	27.0	1.21	52	11.3	0.75	13.1	0.83
Ureter	3	0.7	0.19	0.9	0.22	2	0.4	0.13	0.5	0.15
Eye & Orbit	5	1.0	0.23	1.2	0.26	3	0.7	0.17	0.8	0.21
Brain & Other CNS ¹	34	8.3	0.66	9.1	0.70	24	5.3	0.51	5.9	0.56
Brain	33	8.0	0.64	8.8	0.69	23	5.2	0.51	5.8	0.55
Endocrine System	35	8.9	0.70	9.9	0.76	78	21.4	1.14	22.8	1.18
Thyroid gland	31	7.9	0.66	8.9	0.72	75	20.7	1.13	22.1	1.16
Lymphomas	109	25.7	1.14	29.3	1.27	90	19.0	0.95	21.6	1.05
Hodgkin Lymphoma	11	2.8	0.40	3.0	0.41	8	2.5	0.39	2.5	0.39
Non-Hodgkin Lymphoma	98	22.8	1.07	26.3	1.20	81	16.6	0.87	19.2	0.98
Multiple Myeloma	39	8.6	0.63	10.2	0.74	23	4.3	0.42	5.2	0.50
Leukemias	89	20.7	1.01	23.6	1.13	63	13.7	0.82	15.3	0.88
Acute lymphocytic	4	1.3	0.28	1.1	0.23	5	1.6	0.32	1.4	0.27
Chronic lymphocytic	38	8.4	0.63	10.0	0.73	23	4.5	0.43	5.4	0.51
Acute myeloid	24	5.6	0.53	6.3	0.58	20	4.5	0.48	5.0	0.52
Chronic myeloid	16	3.9	0.44	4.4	0.49	9	2.1	0.33	2.3	0.35
Other leukemias	7	1.6	0.29	1.8	0.32	5	1.0	0.21	1.2	0.24
Mesothelioma	6	1.1	0.22	1.4	0.26	1	0.2	0.10	0.3	0.11
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	36	8.5	0.66	9.7	0.74	59	13.0	0.80	14.9	0.89
Breast (<i>in situ</i>)	-	-	-	-	-	124	28.4	1.21	33.3	1.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
South Dakota, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	18	366.5	50.26	449.2	57.74	9	257.0	42.70	300.2	49.22
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	98.0	27.25	115.0	30.49	2	57.5	20.16	68.9	23.61
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	20.6	8.29	25.1	10.49	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	50.4	23.32	59.5	24.82	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	50.4	23.32	59.5	24.82	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	83.4	22.86	102.7	27.97
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	93.3	20.63	123.4	26.06	-	-	-	-	-
Prostate	5	93.3	20.63	123.4	26.06	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	27.2	8.69	36.5	12.03	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	22.3	7.93	30.2	10.94	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	2	28.5	11.14	34.5	14.04
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


SOUTH DAKOTA

II-460 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,493,432	6,540,826	6,590,808	6,645,011	6,708,794
White	5,198,992	5,229,299	5,262,326	5,300,761	5,345,951
Black	1,141,820	1,154,160	1,165,483	1,176,019	1,188,604
American Indian/Alaskan Native (AI/AN)	30,321	31,018	31,760	32,540	33,461
Asian/Pacific Islander (API)	122,299	126,349	131,239	135,691	140,778


All Races Population 2013-2017: 32,978,871
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	318,940	328,984	340,088	351,902	366,100
Non-Hispanic White	4,919,678	4,941,995	4,965,322	4,993,345	5,025,772
Non-Hispanic Black	1,120,616	1,131,625	1,142,282	1,152,036	1,163,815

Hispanic/Latino Population, Census 2010: 290,059
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

TENNESSEE CANCER REGISTRY

Initial Operation: 1986
Population-based Data Available: 1986
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	96.9	97.7	102.0	99.6	99.7
Missing Race	0.2	0.3	0.1	0.1	0.5
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.1	2.0	2.2	2.4	2.5
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Prostate	97.2
Oral Cavity & Pharynx	97.3	Testis	98.9
Esophagus	93.8	Bladder (incl. <i>in situ</i>)	98.0
Stomach	95.9	Kidney & Renal Pelvis	89.8
Colon & Rectum	96.0	Brain & Other CNS ¹	85.8
Liver	57.1	Thyroid	99.5
Pancreas	82.5	Hodgkin Lymphoma	99.0
Lung & Bronchus	88.2	Non-Hodgkin Lymphoma	96.3
Melanomas of the Skin	99.3	Multiple Myeloma	87.2
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	87.2
Cervix uteri	97.6	Brain & Other CNS ¹ <i>non-malig</i>	36.7
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	91.2		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	18,932	520.7	1.75	620.7	2.05	17,565	422.1	1.46	493.6	1.68
Oral Cavity & Pharynx	756	20.1	0.34	24.6	0.40	279	6.6	0.18	7.8	0.21
Lip	28	0.8	0.07	1.0	0.08	9	0.2	0.03	0.2	0.04
Tongue	247	6.5	0.19	7.9	0.23	85	2.0	0.10	2.4	0.12
Major salivary gland	56	1.6	0.10	1.9	0.12	38	0.9	0.07	1.1	0.08
Floor of mouth	32	0.8	0.07	1.0	0.08	12	0.3	0.04	0.3	0.04
Gum & other mouth	84	2.3	0.12	2.7	0.14	62	1.4	0.08	1.7	0.10
Nasopharynx	28	0.8	0.07	0.9	0.08	13	0.3	0.04	0.4	0.05
Oropharynx	43	1.1	0.08	1.4	0.09	10	0.2	0.03	0.3	0.04
Hypopharynx	42	1.1	0.08	1.3	0.09	9	0.2	0.03	0.3	0.04
Digestive System	3,555	98.1	0.76	117.8	0.90	2,788	65.3	0.57	77.2	0.66
Esophagus	310	8.3	0.22	10.1	0.26	69	1.6	0.09	1.9	0.10
Stomach	280	7.9	0.22	9.3	0.25	170	4.1	0.14	4.7	0.16
Small intestine	113	3.1	0.14	3.7	0.16	100	2.4	0.11	2.8	0.13
Colon excl. rectum	1,118	31.6	0.44	37.4	0.51	1,124	26.5	0.36	31.1	0.42
Rectum & rectosigmoid	508	14.0	0.29	16.8	0.34	360	8.8	0.21	10.3	0.24
Anus, anal canal & anorectum	62	1.8	0.10	2.1	0.12	118	2.8	0.12	3.4	0.14
Liver	470	12.0	0.25	15.2	0.32	151	3.4	0.13	4.2	0.15
Gallbladder	22	0.7	0.06	0.8	0.07	43	1.0	0.07	1.2	0.08
Pancreas	519	14.4	0.29	17.2	0.34	479	10.9	0.23	13.0	0.27
Respiratory System	3,633	99.8	0.76	119.4	0.90	2,814	64.1	0.55	76.7	0.65
Larynx	269	7.0	0.20	8.6	0.24	82	1.9	0.10	2.4	0.12
Lung & bronchus	3,324	91.6	0.73	109.4	0.86	2,702	61.4	0.54	73.5	0.64
Bones & Joints	35	1.1	0.08	1.1	0.08	27	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	137	4.0	0.16	4.5	0.17	107	2.7	0.12	3.1	0.13
Skin (excl. basal & sq.)	975	28.1	0.42	32.8	0.48	672	17.1	0.30	19.5	0.34
Melanomas of the skin	907	26.0	0.40	30.4	0.46	635	16.2	0.30	18.4	0.33
Breast (excl. <i>in situ</i>)	46	1.3	0.09	1.5	0.10	5,070	122.6	0.79	144.3	0.91
Female Genital System	-	-	-	-	-	1,998	48.7	0.50	57.2	0.58
Cervix uteri	-	-	-	-	-	298	8.4	0.22	9.1	0.24
Uterus Corpus	-	-	-	-	-	1,008	23.5	0.34	28.5	0.40
Uterus, NOS ¹	-	-	-	-	-	42	1.0	0.07	1.2	0.08
Ovary	-	-	-	-	-	438	10.6	0.23	12.4	0.27
Male Genital System	4,578	118.2	0.80	144.7	0.97	-	-	-	-	-
Prostate	4,366	111.5	0.78	137.9	0.94	-	-	-	-	-
Testis	168	5.5	0.19	5.4	0.19	-	-	-	-	-
Penis	38	1.0	0.08	1.3	0.09	-	-	-	-	-
Urinary System	2,151	61.1	0.61	72.0	0.71	942	22.1	0.33	26.0	0.38
Bladder (incl. <i>in situ</i>)	1,183	34.5	0.46	40.4	0.54	372	8.5	0.20	10.0	0.23
Kidney & renal pelvis	919	25.2	0.38	29.9	0.45	544	13.0	0.26	15.3	0.30
Ureter	31	0.9	0.07	1.0	0.08	19	0.4	0.05	0.5	0.05
Eye & Orbit	41	1.2	0.08	1.3	0.09	38	0.9	0.07	1.0	0.08
Brain & Other CNS ¹	261	7.6	0.22	8.4	0.24	210	5.4	0.17	5.9	0.18
Brain	249	7.3	0.21	8.1	0.23	197	5.1	0.17	5.6	0.18
Endocrine System	258	7.4	0.21	8.3	0.23	666	18.8	0.34	20.2	0.35
Thyroid gland	231	6.6	0.20	7.5	0.22	644	18.2	0.33	19.5	0.35
Lymphomas	859	24.8	0.39	28.5	0.44	676	16.4	0.29	18.8	0.32
Hodgkin Lymphoma	96	2.9	0.14	3.0	0.14	76	2.2	0.12	2.3	0.12
Non-Hodgkin Lymphoma	763	21.9	0.37	25.5	0.42	600	14.1	0.26	16.5	0.30
Multiple Myeloma	295	8.3	0.22	9.8	0.26	235	5.4	0.16	6.4	0.19
Leukemias	594	17.4	0.33	19.8	0.37	425	10.6	0.24	11.8	0.26
Acute lymphocytic	54	1.7	0.11	1.6	0.10	47	1.4	0.10	1.3	0.09
Chronic lymphocytic	222	6.3	0.19	7.5	0.23	131	3.0	0.12	3.5	0.14
Acute myeloid	175	5.1	0.18	5.8	0.20	134	3.4	0.13	3.8	0.15
Chronic myeloid	76	2.3	0.12	2.5	0.13	68	1.8	0.10	2.0	0.11
Other leukemias	66	2.0	0.11	2.3	0.13	44	1.1	0.07	1.2	0.08
Mesothelioma	42	1.2	0.09	1.4	0.10	12	0.3	0.04	0.3	0.04
Kaposi Sarcoma	14	0.4	0.05	0.5	0.05	-	-	-	-	-
Ill-defined & Unknown	703	20.6	0.36	24.3	0.42	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	308	9.1	0.24	10.2	0.26	689	17.2	0.30	19.6	0.34
Breast (<i>in situ</i>)	5	0.1	0.03	0.2	0.03	1,017	24.5	0.35	29.2	0.41

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	16,240	517.4	1.87	615.2	2.19	14,938	427.2	1.62	499.3	1.85
Oral Cavity & Pharynx	679	21.0	0.37	25.8	0.45	246	6.9	0.20	8.2	0.24
Lip	27	0.9	0.08	1.1	0.09	9	0.2	0.04	0.3	0.04
Tongue	226	6.9	0.21	8.5	0.26	78	2.2	0.12	2.6	0.13
Major salivary gland	52	1.7	0.11	2.0	0.13	32	1.0	0.08	1.1	0.09
Floor of mouth	28	0.8	0.07	1.0	0.09	10	0.3	0.04	0.3	0.05
Gum & other mouth	74	2.4	0.13	2.8	0.15	55	1.5	0.09	1.7	0.11
Nasopharynx	21	0.7	0.07	0.8	0.08	10	0.3	0.04	0.3	0.05
Oropharynx	35	1.0	0.08	1.3	0.10	8	0.2	0.04	0.3	0.04
Hypopharynx	33	1.0	0.08	1.2	0.10	7	0.2	0.03	0.3	0.04
Digestive System	2,969	95.1	0.80	113.9	0.95	2,283	63.0	0.61	74.5	0.71
Esophagus	274	8.6	0.24	10.4	0.28	56	1.5	0.09	1.8	0.11
Stomach	224	7.3	0.22	8.6	0.26	130	3.6	0.15	4.2	0.17
Small intestine	91	2.9	0.14	3.5	0.17	76	2.1	0.11	2.5	0.13
Colon excl. rectum	936	30.7	0.46	36.2	0.54	933	25.8	0.39	30.2	0.45
Rectum & rectosigmoid	434	14.0	0.31	16.8	0.36	296	8.6	0.23	10.1	0.27
Anus, anal canal & anorectum	53	1.8	0.11	2.1	0.13	106	3.0	0.13	3.6	0.16
Liver	369	11.1	0.26	13.9	0.33	118	3.2	0.13	3.9	0.16
Gallbladder	17	0.6	0.06	0.7	0.07	33	0.9	0.07	1.0	0.08
Pancreas	439	14.0	0.31	16.7	0.36	391	10.5	0.24	12.4	0.28
Respiratory System	3,175	99.9	0.81	119.5	0.96	2,478	66.2	0.61	79.3	0.72
Larynx	227	6.9	0.21	8.5	0.26	70	2.0	0.11	2.4	0.13
Lung & bronchus	2,913	91.9	0.78	109.6	0.92	2,382	63.5	0.59	76.0	0.70
Bones & Joints	29	1.1	0.09	1.1	0.09	24	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	115	4.0	0.17	4.5	0.19	87	2.7	0.14	3.0	0.15
Skin (excl. basal & sq.)	956	31.8	0.47	37.1	0.55	649	20.0	0.37	22.7	0.40
Melanomas of the skin	894	29.5	0.46	34.5	0.52	619	19.1	0.36	21.7	0.40
Breast (excl. <i>in situ</i>)	37	1.2	0.09	1.4	0.11	4,249	122.3	0.87	144.1	1.00
Female Genital System	-	-	-	-	-	1,680	49.3	0.56	57.8	0.64
Cervix uteri	-	-	-	-	-	235	8.4	0.25	8.9	0.26
Uterus Corpus	-	-	-	-	-	856	24.0	0.38	29.1	0.45
Uterus, NOS ¹	-	-	-	-	-	28	0.8	0.07	0.9	0.08
Ovary	-	-	-	-	-	377	10.9	0.26	12.7	0.30
Male Genital System	3,672	110.0	0.83	133.9	1.00	-	-	-	-	-
Prostate	3,481	102.5	0.80	126.3	0.97	-	-	-	-	-
Testis	152	6.3	0.23	6.2	0.22	-	-	-	-	-
Penis	33	1.1	0.08	1.3	0.10	-	-	-	-	-
Urinary System	1,933	63.1	0.66	74.3	0.77	798	22.1	0.36	26.0	0.42
Bladder (incl. <i>in situ</i>)	1,105	36.6	0.51	42.8	0.59	336	9.0	0.22	10.6	0.26
Kidney & renal pelvis	782	25.1	0.41	29.7	0.48	438	12.5	0.28	14.7	0.32
Ureter	29	0.9	0.08	1.1	0.09	19	0.5	0.05	0.6	0.06
Eye & Orbit	38	1.3	0.10	1.4	0.11	36	1.1	0.08	1.2	0.09
Brain & Other CNS ¹	234	8.2	0.25	9.0	0.27	186	5.8	0.20	6.4	0.21
Brain	224	7.8	0.24	8.6	0.26	176	5.5	0.19	6.0	0.21
Endocrine System	234	8.0	0.24	9.0	0.27	577	20.2	0.39	21.7	0.41
Thyroid gland	213	7.3	0.23	8.2	0.25	561	19.7	0.39	21.1	0.40
Lymphomas	756	25.3	0.42	29.2	0.48	589	16.9	0.32	19.4	0.36
Hodgkin Lymphoma	77	2.9	0.15	3.0	0.15	63	2.3	0.13	2.4	0.14
Non-Hodgkin Lymphoma	679	22.4	0.40	26.1	0.46	526	14.5	0.29	17.0	0.34
Multiple Myeloma	227	7.3	0.22	8.6	0.26	163	4.4	0.16	5.2	0.18
Leukemias	527	17.9	0.36	20.5	0.40	365	10.9	0.27	12.1	0.29
Acute lymphocytic	46	1.9	0.12	1.7	0.11	40	1.6	0.12	1.5	0.10
Chronic lymphocytic	201	6.5	0.21	7.8	0.25	118	3.1	0.13	3.7	0.15
Acute myeloid	156	5.3	0.20	6.1	0.22	112	3.4	0.15	3.8	0.16
Chronic myeloid	64	2.2	0.13	2.5	0.14	57	1.8	0.11	2.0	0.12
Other leukemias	60	2.1	0.12	2.4	0.14	38	1.1	0.08	1.2	0.09
Mesothelioma	41	1.4	0.10	1.6	0.11	11	0.3	0.04	0.3	0.05
Kaposi Sarcoma	6	0.2	0.04	0.2	0.04	-	-	-	-	-
Ill-defined & Unknown	612	20.5	0.38	24.2	0.45	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	267	9.2	0.26	10.4	0.29	582	17.4	0.33	19.8	0.37
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	841	24.2	0.39	28.9	0.45

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,422	549.8	5.50	665.0	6.44	2,351	400.4	3.81	470.5	4.39
Oral Cavity & Pharynx	65	12.9	0.77	15.9	0.91	28	4.5	0.40	5.4	0.46
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	18	3.4	0.39	4.3	0.47	6	0.9	0.18	1.2	0.21
Major salivary gland	3	0.6	0.17	0.7	0.19	5	0.8	0.17	0.9	0.18
Floor of mouth	3	0.6	0.17	0.7	0.19	2	0.3	0.10	0.4	0.13
Gum & other mouth	7	1.4	0.26	1.7	0.30	5	0.9	0.18	1.0	0.21
Nasopharynx	5	0.9	0.18	1.0	0.21	2	0.4	0.12	0.5	0.14
Oropharynx	7	1.5	0.26	1.8	0.32	2	0.3	0.11	0.4	0.13
Hypopharynx	8	1.7	0.28	2.1	0.34	2	0.3	0.09	0.3	0.11
Digestive System	526	119.3	2.56	144.5	3.00	463	80.1	1.72	94.7	1.99
Esophagus	32	6.9	0.60	8.5	0.71	12	2.0	0.26	2.4	0.31
Stomach	49	12.2	0.86	14.3	0.98	36	6.5	0.50	7.5	0.56
Small intestine	20	4.6	0.50	5.4	0.57	23	3.8	0.36	4.6	0.43
Colon excl. rectum	167	39.3	1.50	47.1	1.74	177	30.8	1.07	36.3	1.23
Rectum & rectosigmoid	66	15.2	0.92	18.2	1.07	58	9.8	0.59	11.6	0.69
Anus, anal canal & anorectum	9	1.7	0.26	2.0	0.30	11	1.9	0.26	2.2	0.30
Liver	89	16.4	0.83	21.5	1.05	30	4.7	0.40	5.9	0.49
Gallbladder	4	1.1	0.28	1.4	0.32	9	1.5	0.24	1.8	0.28
Pancreas	74	17.7	1.03	21.5	1.20	82	14.8	0.75	17.4	0.87
Respiratory System	427	103.6	2.48	124.6	2.88	312	53.7	1.41	64.5	1.65
Larynx	39	8.2	0.64	10.1	0.76	12	1.9	0.24	2.4	0.31
Lung & bronchus	384	94.4	2.38	113.3	2.76	296	51.4	1.39	61.6	1.62
Bones & Joints	4	1.1	0.27	1.2	0.30	3	0.5	0.13	0.5	0.12
Soft Tissue (incl. heart)	19	4.3	0.48	4.8	0.54	17	2.9	0.32	3.2	0.35
Skin (excl. basal & sq.)	7	1.4	0.26	1.5	0.28	10	1.7	0.25	1.9	0.28
Melanomas of the skin	3	0.6	0.17	0.7	0.19	4	0.7	0.17	0.9	0.19
Breast (excl. <i>in situ</i>)	8	1.9	0.33	2.2	0.37	737	123.6	2.10	145.4	2.42
Female Genital System	-	-	-	-	-	284	47.3	1.29	55.8	1.50
Cervix uteri	-	-	-	-	-	59	9.9	0.59	11.3	0.66
Uterus Corpus	-	-	-	-	-	133	21.5	0.86	26.1	1.02
Uterus, NOS ¹	-	-	-	-	-	13	2.3	0.29	2.7	0.34
Ovary	-	-	-	-	-	53	9.1	0.57	10.6	0.66
Male Genital System	835	180.4	3.05	224.3	3.66	-	-	-	-	-
Prostate	822	177.8	3.04	221.5	3.64	-	-	-	-	-
Testis	9	1.7	0.26	1.6	0.26	-	-	-	-	-
Penis	5	0.9	0.20	1.2	0.25	-	-	-	-	-
Urinary System	198	47.0	1.64	55.7	1.90	132	22.5	0.91	26.7	1.05
Bladder (incl. <i>in situ</i>)	66	18.1	1.10	21.4	1.27	32	5.7	0.47	6.8	0.54
Kidney & renal pelvis	127	27.7	1.19	33.0	1.38	98	16.4	0.77	19.5	0.89
Ureter	1	0.4	0.15	0.4	0.17	-	-	-	-	-
Eye & Orbit	2	0.3	0.09	0.3	0.09	1	0.2	0.09	0.2	0.09
Brain & Other CNS ¹	24	4.6	0.45	5.2	0.51	19	3.2	0.34	3.5	0.37
Brain	21	4.1	0.43	4.7	0.49	17	2.9	0.33	3.1	0.35
Endocrine System	18	3.8	0.44	4.3	0.49	70	11.8	0.65	13.0	0.70
Thyroid gland	12	2.4	0.34	2.8	0.38	65	11.0	0.62	12.0	0.67
Lymphomas	87	18.9	0.99	21.5	1.11	75	12.9	0.69	14.6	0.76
Hodgkin Lymphoma	16	2.9	0.34	3.0	0.35	11	1.8	0.24	1.8	0.24
Non-Hodgkin Lymphoma	71	16.0	0.93	18.5	1.05	64	11.1	0.64	12.8	0.72
Multiple Myeloma	63	15.0	0.92	17.8	1.07	67	11.9	0.67	14.1	0.78
Leukemias	51	12.5	0.86	14.3	0.98	49	8.4	0.55	9.5	0.62
Acute lymphocytic	5	0.9	0.19	0.9	0.20	5	0.8	0.16	0.8	0.16
Chronic lymphocytic	16	4.2	0.52	5.0	0.59	10	1.8	0.26	2.2	0.31
Acute myeloid	15	3.7	0.46	4.2	0.52	19	3.3	0.34	3.7	0.38
Chronic myeloid	10	2.3	0.37	2.6	0.42	9	1.6	0.24	1.7	0.26
Other leukemias	5	1.4	0.30	1.5	0.34	6	1.0	0.20	1.2	0.22
Mesothelioma	1	0.3	0.13	0.3	0.14	1	0.2	0.09	0.2	0.10
Kaposi Sarcoma	7	1.3	0.22	1.3	0.23	-	-	-	-	-
Ill-defined & Unknown	80	21.2	1.18	25.2	1.37	82	14.9	0.76	17.3	0.86
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	36	8.8	0.72	9.9	0.80	94	16.3	0.77	18.5	0.87
Breast (<i>in situ</i>)	1	0.3	0.14	0.4	0.17	157	26.1	0.96	31.0	1.11

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	109	253.7	12.03	300.0	14.11	138	236.7	9.62	274.9	11.19
Oral Cavity & Pharynx	7	12.3	2.11	15.5	2.73	3	5.3	1.45	6.5	1.74
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	3.4	1.14	4.5	1.53	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	3.6	1.13	4.6	1.47	-	-	-	-	-
Nasopharynx	1	2.0	0.82	2.2	0.93	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	30	69.3	6.24	84.6	7.51	23	43.3	4.35	51.6	5.15
Esophagus	1	3.4	1.63	4.3	2.02	-	-	-	-	-
Stomach	3	8.4	2.38	10.1	2.78	3	4.4	1.26	5.1	1.48
Small intestine	1	2.4	1.00	3.2	1.30	-	-	-	-	-
Colon excl. rectum	7	14.8	2.69	17.6	3.14	7	12.5	2.22	14.9	2.64
Rectum & rectosigmoid	4	10.2	2.35	12.3	2.79	4	7.4	1.68	8.6	1.98
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	16.4	2.81	20.4	3.44	3	5.8	1.78	7.0	2.13
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	8.7	2.59	10.5	3.10	3	6.8	1.85	8.0	2.13
Respiratory System	16	44.4	5.38	51.5	6.14	14	26.3	3.36	30.7	3.89
Larynx	2	3.8	1.35	4.5	1.59	-	-	-	-	-
Lung & bronchus	14	39.6	5.14	45.9	5.87	14	25.6	3.32	30.0	3.86
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	1	2.5	1.12	2.5	1.12	2	2.4	0.88	2.8	1.02
Skin (excl. basal & sq.)	-	-	-	-	-	1	2.5	1.03	2.9	1.24
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	46	75.1	5.20	89.3	6.18
Female Genital System	-	-	-	-	-	16	26.3	3.04	30.9	3.57
Cervix uteri	-	-	-	-	-	2	2.8	0.89	3.2	1.03
Uterus Corpus	-	-	-	-	-	9	15.2	2.33	18.3	2.77
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	6.8	1.59	7.6	1.80
Male Genital System	22	54.8	5.67	65.8	6.67	-	-	-	-	-
Prostate	20	52.0	5.60	63.1	6.61	-	-	-	-	-
Testis	2	2.4	0.81	2.2	0.73	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	20.6	3.71	24.7	4.41	5	9.7	2.15	11.0	2.44
Bladder (incl. <i>in situ</i>)	4	12.1	2.99	14.8	3.61	1	3.1	1.30	3.7	1.54
Kidney & renal pelvis	4	8.5	2.20	9.9	2.53	3	5.4	1.49	5.9	1.63
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	2	3.7	1.21	3.9	1.32	2	3.4	1.14	3.5	1.19
Brain	2	3.7	1.21	3.9	1.32	2	3.4	1.14	3.5	1.19
Endocrine System	4	7.0	1.67	7.6	1.85	12	17.6	2.47	18.0	2.58
Thyroid gland	3	6.2	1.59	6.6	1.71	11	16.3	2.40	16.6	2.50
Lymphomas	7	16.4	3.04	18.1	3.43	5	8.8	1.87	10.1	2.15
Hodgkin Lymphoma	1	2.1	0.80	2.3	0.91	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	4	7.6	1.79	8.9	2.08
Multiple Myeloma	2	4.9	1.47	5.7	1.71	1	3.0	1.21	3.4	1.39
Leukemias	4	6.1	1.54	6.3	1.63	4	6.3	1.46	6.8	1.60
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	2.7	1.10	2.6	1.11	2	2.9	1.00	3.5	1.20
Chronic myeloid	1	1.9	0.83	1.9	0.82	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	6.9	2.16	8.1	2.56	3	6.1	1.68	7.1	1.95
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	4.1	1.22	4.6	1.41	7	11.8	2.13	13.4	2.42
Breast (<i>in situ</i>)	-	-	-	-	-	11	18.2	2.58	21.3	3.02

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	218	294.8	10.87	349.4	12.60	239	299.3	9.93	348.1	11.55
Oral Cavity & Pharynx	7	6.9	1.28	8.7	1.63	4	4.9	1.38	5.6	1.56
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	2.0	0.62	2.6	0.86	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	0.9	0.39	1.1	0.49	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	49	70.6	5.42	84.7	6.32	31	46.4	4.16	55.3	4.88
Esophagus	3	4.9	1.51	5.4	1.64	-	-	-	-	-
Stomach	7	10.6	2.15	12.1	2.42	4	5.8	1.43	6.8	1.68
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	11	15.1	2.52	18.5	3.00	8	11.3	2.00	13.8	2.43
Rectum & rectosigmoid	6	8.7	1.90	10.4	2.22	5	6.2	1.39	7.3	1.65
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	11	14.1	2.23	17.7	2.70	5	10.0	2.10	11.6	2.35
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	5	8.9	2.02	10.8	2.34	3	4.4	1.29	5.4	1.51
Respiratory System	23	38.6	4.07	46.3	4.71	21	35.4	3.77	42.0	4.34
Larynx	2	2.6	0.88	3.3	1.09	-	-	-	-	-
Lung & bronchus	21	34.9	3.90	41.7	4.49	19	33.5	3.69	39.6	4.24
Bones & Joints	2	0.9	0.33	0.9	0.34	1	1.0	0.42	1.1	0.53
Soft Tissue (incl. heart)	5	3.2	0.78	3.5	0.91	3	3.0	1.05	3.3	1.22
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	5	9.0	2.09	10.8	2.41	6	8.6	1.71	10.4	2.05
Breast (excl. <i>in situ</i>)	-	-	-	-	-	65	78.1	4.85	90.9	5.67
Female Genital System	-	-	-	-	-	33	36.6	3.18	43.5	3.83
Cervix uteri	-	-	-	-	-	9	9.1	1.55	10.2	1.80
Uterus Corpus	-	-	-	-	-	15	17.0	2.19	21.1	2.70
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	6.9	1.35	8.1	1.63
Male Genital System	50	77.4	5.72	93.4	6.66	-	-	-	-	-
Prostate	42	72.8	5.67	88.4	6.60	-	-	-	-	-
Testis	8	4.0	0.65	4.1	0.70	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	23	36.1	4.07	42.1	4.63	13	16.7	2.41	19.1	2.76
Bladder (incl. <i>in situ</i>)	9	17.6	3.01	20.3	3.39	2	4.4	1.45	5.2	1.66
Kidney & renal pelvis	14	18.3	2.72	21.5	3.14	10	11.9	1.88	13.5	2.17
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	1.8	0.94	2.0	1.07	-	-	-	-	-
Brain & Other CNS ¹	7	4.9	1.04	5.2	1.21	6	5.4	1.28	6.1	1.51
Brain	7	4.9	1.04	5.2	1.21	5	5.3	1.27	6.0	1.51
Endocrine System	5	3.6	0.78	4.0	0.97	16	13.6	1.75	14.3	1.91
Thyroid gland	4	2.9	0.73	3.4	0.93	15	13.2	1.70	13.9	1.85
Lymphomas	14	12.6	1.76	14.4	2.08	14	16.0	2.28	18.3	2.63
Hodgkin Lymphoma	4	2.7	0.81	2.8	0.88	3	1.6	0.46	1.6	0.52
Non-Hodgkin Lymphoma	11	9.8	1.56	11.6	1.89	11	14.4	2.23	16.7	2.58
Multiple Myeloma	4	5.6	1.54	6.4	1.73	4	5.7	1.32	7.0	1.60
Leukemias	15	12.5	1.92	13.9	2.16	12	11.3	1.85	12.9	2.17
Acute lymphocytic	-	-	-	-	-	4	1.7	0.42	1.4	0.35
Chronic lymphocytic	2	3.7	1.27	4.4	1.42	2	2.1	0.79	2.8	1.02
Acute myeloid	4	4.0	1.07	4.8	1.28	3	4.0	1.22	4.6	1.37
Chronic myeloid	1	1.0	0.39	1.1	0.47	2	2.2	0.86	2.7	1.06
Other leukemias	-	-	-	-	-	1	1.2	0.63	1.4	0.73
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	7	8.4	1.78	9.9	2.03	10	14.1	2.42	15.5	2.63
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	6	6.2	1.49	6.7	1.60	11	11.5	1.80	13.7	2.19
Breast (<i>in situ</i>)	-	-	-	-	-	10	11.9	1.84	13.7	2.16

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

TENNESSEE

II-468 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	16,073	523.4	1.90	622.1	2.23	14,749	431.5	1.65	503.9	1.88
Oral Cavity & Pharynx	674	21.4	0.38	26.2	0.46	243	7.0	0.21	8.3	0.24
Lip	27	0.9	0.08	1.1	0.09	9	0.2	0.04	0.3	0.04
Tongue	224	7.0	0.22	8.6	0.26	77	2.2	0.12	2.6	0.14
Major salivary gland	52	1.8	0.11	2.1	0.13	32	1.0	0.08	1.1	0.09
Floor of mouth	28	0.9	0.07	1.1	0.09	10	0.3	0.04	0.3	0.05
Gum & other mouth	74	2.4	0.13	2.9	0.15	54	1.5	0.09	1.8	0.11
Nasopharynx	21	0.7	0.07	0.8	0.08	10	0.3	0.04	0.3	0.05
Oropharynx	35	1.0	0.08	1.3	0.10	8	0.2	0.04	0.3	0.04
Hypopharynx	33	1.0	0.08	1.2	0.10	7	0.2	0.04	0.3	0.04
Digestive System	2,932	96.0	0.82	114.9	0.96	2,258	63.6	0.62	75.1	0.72
Esophagus	272	8.6	0.24	10.5	0.29	56	1.5	0.09	1.8	0.11
Stomach	220	7.3	0.23	8.6	0.26	126	3.6	0.15	4.2	0.17
Small intestine	90	3.0	0.15	3.5	0.17	76	2.2	0.12	2.6	0.13
Colon excl. rectum	928	31.1	0.47	36.7	0.55	927	26.2	0.40	30.6	0.46
Rectum & rectosigmoid	429	14.2	0.32	16.9	0.37	292	8.7	0.24	10.2	0.27
Anus, anal canal & anorectum	53	1.8	0.11	2.1	0.13	105	3.0	0.14	3.7	0.16
Liver	360	11.0	0.27	13.9	0.33	113	3.1	0.13	3.8	0.16
Gallbladder	17	0.6	0.06	0.7	0.07	32	0.9	0.07	1.0	0.08
Pancreas	435	14.1	0.31	16.9	0.37	389	10.6	0.25	12.6	0.29
Respiratory System	3,157	101.1	0.83	121.0	0.98	2,461	66.9	0.62	80.0	0.73
Larynx	225	7.0	0.21	8.6	0.26	69	2.0	0.11	2.4	0.13
Lung & bronchus	2,897	92.9	0.79	110.9	0.94	2,366	64.1	0.60	76.7	0.71
Bones & Joints	28	1.1	0.10	1.1	0.10	23	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	112	4.0	0.17	4.5	0.19	86	2.8	0.14	3.1	0.15
Skin (excl. basal & sq.)	951	32.4	0.49	37.8	0.56	643	20.5	0.38	23.2	0.42
Melanomas of the skin	889	30.2	0.47	35.2	0.54	613	19.6	0.37	22.2	0.41
Breast (excl. <i>in situ</i>)	37	1.2	0.09	1.5	0.11	4,198	123.6	0.89	145.5	1.02
Female Genital System	-	-	-	-	-	1,654	49.8	0.57	58.3	0.65
Cervix uteri	-	-	-	-	-	227	8.4	0.26	8.9	0.27
Uterus Corpus	-	-	-	-	-	845	24.2	0.39	29.4	0.46
Uterus, NOS ¹	-	-	-	-	-	28	0.8	0.07	0.9	0.08
Ovary	-	-	-	-	-	371	10.9	0.26	12.8	0.30
Male Genital System	3,637	111.2	0.85	135.3	1.02	-	-	-	-	-
Prostate	3,450	103.4	0.81	127.3	0.98	-	-	-	-	-
Testis	148	6.6	0.25	6.5	0.24	-	-	-	-	-
Penis	33	1.1	0.09	1.3	0.10	-	-	-	-	-
Urinary System	1,915	63.8	0.67	75.1	0.78	789	22.3	0.37	26.2	0.42
Bladder (incl. <i>in situ</i>)	1,098	36.9	0.51	43.3	0.60	335	9.1	0.23	10.7	0.26
Kidney & renal pelvis	772	25.4	0.42	30.1	0.49	431	12.6	0.28	14.8	0.32
Ureter	29	1.0	0.08	1.1	0.09	18	0.5	0.05	0.6	0.06
Eye & Orbit	37	1.3	0.10	1.4	0.11	35	1.1	0.08	1.2	0.09
Brain & Other CNS ¹	227	8.2	0.25	9.1	0.27	181	5.9	0.21	6.4	0.22
Brain	218	7.8	0.25	8.7	0.27	172	5.5	0.20	6.1	0.21
Endocrine System	229	8.2	0.25	9.2	0.27	563	20.6	0.41	22.1	0.42
Thyroid gland	210	7.5	0.24	8.4	0.26	548	20.1	0.40	21.5	0.42
Lymphomas	744	25.5	0.43	29.5	0.49	577	16.9	0.33	19.4	0.37
Hodgkin Lymphoma	74	2.9	0.16	3.1	0.16	61	2.4	0.14	2.4	0.14
Non-Hodgkin Lymphoma	670	22.6	0.40	26.4	0.46	516	14.5	0.29	17.0	0.34
Multiple Myeloma	225	7.4	0.23	8.7	0.26	160	4.4	0.16	5.2	0.19
Leukemias	516	18.1	0.37	20.6	0.41	356	10.9	0.27	12.1	0.29
Acute lymphocytic	41	1.8	0.13	1.7	0.12	37	1.6	0.12	1.4	0.11
Chronic lymphocytic	199	6.5	0.21	7.8	0.25	116	3.1	0.13	3.7	0.15
Acute myeloid	153	5.4	0.20	6.1	0.22	109	3.4	0.15	3.8	0.16
Chronic myeloid	63	2.2	0.13	2.5	0.14	56	1.8	0.11	2.0	0.12
Other leukemias	60	2.1	0.13	2.5	0.15	37	1.1	0.08	1.2	0.09
Mesothelioma	40	1.4	0.10	1.6	0.11	11	0.3	0.04	0.3	0.05
Kaposi Sarcoma	5	0.2	0.05	0.2	0.05	-	-	-	-	-
Ill-defined & Unknown	608	20.8	0.39	24.5	0.45	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	262	9.3	0.27	10.5	0.29	573	17.6	0.34	20.0	0.38
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	834	24.6	0.40	29.3	0.46

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Tennessee, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,415	553.0	5.54	668.7	6.48	2,340	402.0	3.84	472.2	4.41
Oral Cavity & Pharynx	65	13.1	0.78	16.0	0.92	27	4.5	0.40	5.4	0.47
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	18	3.5	0.39	4.4	0.48	6	0.9	0.18	1.2	0.22
Major salivary gland	3	0.7	0.17	0.7	0.19	5	0.9	0.18	0.9	0.19
Floor of mouth	3	0.6	0.17	0.7	0.19	2	0.3	0.11	0.4	0.13
Gum & other mouth	7	1.4	0.26	1.7	0.30	5	0.8	0.18	1.0	0.21
Nasopharynx	5	0.9	0.18	1.0	0.22	2	0.4	0.12	0.5	0.14
Oropharynx	7	1.5	0.27	1.8	0.32	2	0.3	0.11	0.4	0.13
Hypopharynx	8	1.7	0.29	2.1	0.34	2	0.3	0.09	0.3	0.12
Digestive System	524	119.9	2.58	145.3	3.02	462	80.4	1.73	95.1	2.00
Esophagus	32	6.9	0.60	8.6	0.71	12	2.0	0.27	2.4	0.32
Stomach	49	12.3	0.87	14.4	0.98	36	6.5	0.50	7.5	0.57
Small intestine	20	4.7	0.51	5.4	0.57	23	3.8	0.36	4.5	0.43
Colon excl. rectum	166	39.5	1.51	47.3	1.75	177	30.9	1.08	36.4	1.24
Rectum & rectosigmoid	66	15.4	0.93	18.3	1.08	57	9.8	0.60	11.6	0.69
Anus, anal canal & anorectum	9	1.7	0.26	2.0	0.30	11	1.9	0.26	2.2	0.30
Liver	88	16.5	0.83	21.5	1.05	29	4.7	0.40	5.8	0.49
Gallbladder	4	1.2	0.28	1.4	0.32	9	1.6	0.24	1.9	0.28
Pancreas	74	17.8	1.03	21.6	1.21	82	14.9	0.76	17.5	0.87
Respiratory System	426	104.2	2.50	125.4	2.89	311	53.9	1.42	64.7	1.66
Larynx	39	8.2	0.64	10.2	0.76	12	1.8	0.24	2.3	0.30
Lung & bronchus	383	95.0	2.40	113.9	2.78	296	51.6	1.39	61.9	1.63
Bones & Joints	4	1.2	0.27	1.2	0.30	3	0.5	0.13	0.5	0.12
Soft Tissue (incl. heart)	19	4.3	0.49	4.8	0.54	17	2.9	0.33	3.2	0.36
Skin (excl. basal & sq.)	7	1.4	0.26	1.6	0.28	10	1.7	0.25	2.0	0.28
Melanomas of the skin	3	0.6	0.17	0.7	0.19	4	0.8	0.17	0.9	0.20
Breast (excl. <i>in situ</i>)	8	1.9	0.34	2.2	0.37	734	124.1	2.11	146.0	2.43
Female Genital System	-	-	-	-	-	283	47.5	1.30	56.0	1.50
Cervix uteri	-	-	-	-	-	59	10.0	0.60	11.3	0.66
Uterus Corpus	-	-	-	-	-	133	21.7	0.87	26.3	1.03
Uterus, NOS ¹	-	-	-	-	-	13	2.3	0.30	2.8	0.34
Ovary	-	-	-	-	-	53	9.1	0.58	10.7	0.67
Male Genital System	833	181.3	3.07	225.4	3.68	-	-	-	-	-
Prostate	820	178.7	3.06	222.6	3.66	-	-	-	-	-
Testis	9	1.7	0.27	1.7	0.27	-	-	-	-	-
Penis	4	0.9	0.20	1.1	0.25	-	-	-	-	-
Urinary System	197	47.2	1.65	56.0	1.91	131	22.6	0.91	26.8	1.06
Bladder (incl. <i>in situ</i>)	66	18.1	1.10	21.4	1.27	32	5.7	0.47	6.8	0.55
Kidney & renal pelvis	127	27.9	1.20	33.2	1.39	98	16.5	0.77	19.6	0.90
Ureter	1	0.4	0.15	0.4	0.17	-	-	-	-	-
Eye & Orbit	2	0.3	0.10	0.3	0.09	1	0.2	0.09	0.2	0.08
Brain & Other CNS ¹	24	4.7	0.46	5.3	0.52	19	3.3	0.35	3.5	0.37
Brain	21	4.2	0.43	4.7	0.49	17	3.0	0.33	3.2	0.35
Endocrine System	18	3.8	0.44	4.4	0.49	70	11.9	0.65	13.0	0.70
Thyroid gland	12	2.4	0.34	2.8	0.38	65	11.1	0.63	12.1	0.68
Lymphomas	87	19.0	1.00	21.6	1.12	75	13.0	0.69	14.6	0.77
Hodgkin Lymphoma	16	2.9	0.34	3.0	0.36	11	1.8	0.25	1.8	0.25
Non-Hodgkin Lymphoma	71	16.1	0.94	18.6	1.06	63	11.1	0.65	12.8	0.73
Multiple Myeloma	63	15.0	0.93	17.9	1.07	67	11.9	0.67	14.1	0.78
Leukemias	51	12.6	0.87	14.4	0.99	49	8.4	0.55	9.5	0.62
Acute lymphocytic	5	0.9	0.20	0.9	0.20	5	0.8	0.17	0.8	0.17
Chronic lymphocytic	16	4.3	0.52	5.0	0.60	10	1.7	0.25	2.2	0.30
Acute myeloid	15	3.7	0.47	4.3	0.53	19	3.3	0.34	3.7	0.38
Chronic myeloid	10	2.3	0.37	2.7	0.42	9	1.6	0.24	1.7	0.26
Other leukemias	5	1.4	0.31	1.6	0.34	6	1.0	0.19	1.1	0.22
Mesothelioma	1	0.3	0.13	0.3	0.14	1	0.2	0.09	0.2	0.10
Kaposi Sarcoma	7	1.3	0.22	1.4	0.23	-	-	-	-	-
Ill-defined & Unknown	80	21.3	1.19	25.4	1.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	36	8.9	0.72	9.9	0.81	94	16.4	0.78	18.7	0.87
Breast (<i>in situ</i>)	1	0.3	0.14	0.4	0.17	157	26.3	0.97	31.2	1.12

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


TENNESSEE

II-470 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	26,489,464	26,977,142	27,486,814	27,937,492	28,322,717
White	21,556,100	21,878,463	22,212,541	22,499,241	22,731,367
Black	3,378,131	3,462,836	3,553,873	3,641,536	3,723,355
American Indian/Alaskan Native (AI/AN)	292,710	298,888	304,964	310,294	316,433
Asian/Pacific Islander (API)	1,262,523	1,336,955	1,415,436	1,486,421	1,551,562


All Races Population 2013-2017: 137,213,629
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	10,201,678	10,440,593	10,695,910	10,939,338	11,154,113
Non-Hispanic White	11,834,466	11,934,154	12,030,002	12,089,494	12,123,331
Non-Hispanic Black	3,166,557	3,241,960	3,323,243	3,401,455	3,474,480

Hispanic/Latino Population, Census 2010: 9,460,921
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

TEXAS CANCER REGISTRY

Initial Operation: 1976
Population-based Data Available: 1995
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.0	99.1	100.1	99.5	98.4
Missing Race	0.1	0.2	0.2	0.4	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.6	2.6	2.5	2.4	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	89.6	Prostate	92.7
Oral Cavity & Pharynx	94.6	Testis	97.2
Esophagus	90.1	Bladder (incl. <i>in situ</i>)	95.7
Stomach	93.2	Kidney & Renal Pelvis	86.0
Colon & Rectum	94.6	Brain & Other CNS ¹	80.2
Liver	47.6	Thyroid	98.2
Pancreas	80.0	Hodgkin Lymphoma	95.6
Lung & Bronchus	85.6	Non-Hodgkin Lymphoma	93.4
Melanomas of the Skin	98.0	Multiple Myeloma	84.9
Female Breast (excl. <i>in situ</i>)	97.3	Leukemias	85.0
Cervix uteri	94.0	Brain & Other CNS ¹ <i>non-malig</i>	37.2
Uterus Corpus & Uterus NOS ¹	97.5	Breast <i>in situ</i>	100.0
Ovary	89.6		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	55,935	450.3	0.88	534.4	1.03	54,169	378.4	0.74	441.1	0.85
Oral Cavity & Pharynx	2,250	17.1	0.17	20.8	0.20	831	5.7	0.09	6.8	0.11
Lip	77	0.7	0.03	0.8	0.04	17	0.1	0.01	0.1	0.02
Tongue	709	5.3	0.09	6.5	0.11	259	1.8	0.05	2.1	0.06
Major salivary gland	201	1.7	0.06	2.0	0.06	134	1.0	0.04	1.1	0.04
Floor of mouth	85	0.6	0.03	0.8	0.04	33	0.2	0.02	0.3	0.02
Gum & other mouth	235	1.9	0.06	2.2	0.07	164	1.2	0.04	1.3	0.05
Nasopharynx	95	0.7	0.03	0.8	0.04	38	0.3	0.02	0.3	0.02
Oropharynx	140	1.0	0.04	1.3	0.05	39	0.3	0.02	0.3	0.02
Hypopharynx	122	0.9	0.04	1.1	0.05	28	0.2	0.02	0.2	0.02
Digestive System	12,615	100.4	0.41	120.8	0.49	9,209	63.9	0.30	75.7	0.35
Esophagus	863	6.9	0.11	8.3	0.13	216	1.5	0.05	1.8	0.05
Stomach	1,051	8.7	0.12	10.3	0.14	704	5.0	0.08	5.8	0.10
Small intestine	332	2.7	0.07	3.1	0.08	283	2.0	0.05	2.3	0.06
Colon excl. rectum	3,716	30.3	0.23	36.0	0.27	3,350	23.4	0.18	27.5	0.21
Rectum & rectosigmoid	1,864	14.5	0.15	17.4	0.18	1,174	8.1	0.11	9.7	0.13
Anus, anal canal & anorectum	176	1.4	0.05	1.6	0.06	276	1.9	0.05	2.3	0.06
Liver	2,220	16.2	0.16	20.5	0.20	779	5.3	0.09	6.4	0.10
Gallbladder	94	0.8	0.04	0.9	0.04	207	1.4	0.05	1.7	0.05
Pancreas	1,701	14.1	0.16	16.8	0.19	1,582	11.0	0.13	13.0	0.15
Respiratory System	8,076	67.7	0.35	80.1	0.41	6,293	43.8	0.25	51.8	0.29
Larynx	688	5.3	0.09	6.5	0.11	140	0.9	0.04	1.1	0.04
Lung & bronchus	7,247	61.3	0.33	72.3	0.39	6,070	42.2	0.25	50.0	0.29
Bones & Joints	155	1.2	0.04	1.2	0.05	121	0.9	0.04	0.9	0.04
Soft Tissue (incl. heart)	459	3.6	0.08	4.1	0.09	356	2.5	0.06	2.8	0.07
Skin (excl. basal & sq.)	2,325	19.3	0.19	22.6	0.21	1,459	10.3	0.12	11.8	0.14
Melanomas of the skin	2,155	17.9	0.18	20.9	0.21	1,342	9.5	0.12	10.8	0.13
Breast (excl. <i>in situ</i>)	173	1.4	0.05	1.6	0.06	16,186	112.8	0.40	132.6	0.47
Female Genital System	-	-	-	-	-	6,690	46.4	0.26	54.2	0.30
Cervix uteri	-	-	-	-	-	1,251	9.2	0.12	9.9	0.13
Uterus Corpus	-	-	-	-	-	3,167	21.3	0.17	25.8	0.21
Uterus, NOS ¹	-	-	-	-	-	203	1.4	0.05	1.7	0.05
Ovary	-	-	-	-	-	1,545	10.8	0.12	12.6	0.14
Male Genital System	13,032	100.3	0.41	121.9	0.48	-	-	-	-	-
Prostate	12,174	94.0	0.39	115.4	0.47	-	-	-	-	-
Testis	717	5.2	0.09	5.1	0.09	-	-	-	-	-
Penis	115	1.0	0.04	1.1	0.05	-	-	-	-	-
Urinary System	6,310	52.6	0.31	62.0	0.36	2,921	20.3	0.17	23.9	0.20
Bladder (incl. <i>in situ</i>)	3,011	26.6	0.22	31.2	0.26	881	6.2	0.09	7.3	0.11
Kidney & renal pelvis	3,191	25.0	0.20	29.7	0.24	1,973	13.7	0.14	16.1	0.16
Ureter	67	0.6	0.03	0.7	0.04	45	0.3	0.02	0.4	0.02
Eye & Orbit	109	0.9	0.04	1.0	0.04	96	0.7	0.03	0.7	0.03
Brain & Other CNS ¹	928	7.1	0.11	7.9	0.12	782	5.5	0.09	6.0	0.10
Brain	863	6.7	0.10	7.4	0.12	708	5.0	0.09	5.5	0.09
Endocrine System	931	7.1	0.11	8.0	0.12	2,535	18.3	0.17	19.9	0.18
Thyroid gland	828	6.3	0.10	7.2	0.11	2,434	17.6	0.16	19.2	0.17
Lymphomas	2,887	23.5	0.20	27.0	0.23	2,326	16.4	0.15	18.8	0.17
Hodgkin Lymphoma	348	2.6	0.06	2.8	0.07	286	2.1	0.05	2.1	0.06
Non-Hodgkin Lymphoma	2,539	20.9	0.19	24.2	0.22	2,040	14.3	0.14	16.6	0.17
Multiple Myeloma	1,052	8.8	0.13	10.4	0.15	854	6.0	0.09	7.0	0.11
Leukemias	2,145	17.8	0.18	20.0	0.20	1,528	10.8	0.13	12.0	0.14
Acute lymphocytic	291	2.1	0.06	1.9	0.05	213	1.5	0.05	1.4	0.04
Chronic lymphocytic	723	6.1	0.11	7.3	0.12	483	3.4	0.07	4.0	0.08
Acute myeloid	522	4.4	0.09	5.0	0.10	419	3.0	0.07	3.3	0.07
Chronic myeloid	313	2.6	0.07	2.9	0.08	211	1.5	0.05	1.7	0.05
Other leukemias	297	2.5	0.07	2.9	0.08	202	1.5	0.05	1.6	0.05
Mesothelioma	145	1.3	0.05	1.5	0.06	42	0.3	0.02	0.3	0.02
Kaposi Sarcoma	115	0.9	0.04	0.9	0.04	13	0.1	0.01	0.1	0.01
Ill-defined & Unknown	2,226	19.3	0.19	22.4	0.22	1,930	13.6	0.14	15.7	0.16
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	1,108	9.0	0.12	10.2	0.14	2,369	16.8	0.16	19.2	0.18
Breast (<i>in situ</i>)	18	0.2	0.02	0.2	0.02	3,241	22.5	0.18	26.7	0.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	47,495	450.6	0.95	533.5	1.11	45,756	384.1	0.82	447.3	0.94
Oral Cavity & Pharynx	2,009	18.0	0.18	22.0	0.22	714	5.9	0.10	7.0	0.12
Lip	75	0.7	0.04	0.9	0.05	16	0.1	0.02	0.2	0.02
Tongue	652	5.8	0.10	7.1	0.12	232	1.9	0.06	2.3	0.07
Major salivary gland	180	1.8	0.06	2.1	0.07	109	0.9	0.04	1.0	0.05
Floor of mouth	75	0.7	0.03	0.8	0.04	28	0.2	0.02	0.3	0.02
Gum & other mouth	198	1.8	0.06	2.2	0.07	139	1.1	0.04	1.3	0.05
Nasopharynx	69	0.6	0.03	0.7	0.04	27	0.2	0.02	0.3	0.02
Oropharynx	126	1.1	0.05	1.4	0.05	33	0.3	0.02	0.3	0.03
Hypopharynx	104	1.0	0.04	1.2	0.05	25	0.2	0.02	0.2	0.02
Digestive System	10,534	98.9	0.44	118.8	0.52	7,569	62.6	0.33	74.0	0.38
Esophagus	776	7.3	0.12	8.8	0.14	181	1.5	0.05	1.8	0.06
Stomach	838	8.1	0.13	9.6	0.15	551	4.6	0.09	5.4	0.10
Small intestine	263	2.5	0.07	2.9	0.08	222	1.8	0.06	2.2	0.07
Colon excl. rectum	3,109	29.9	0.25	35.4	0.29	2,744	22.8	0.20	26.8	0.23
Rectum & rectosigmoid	1,583	14.6	0.17	17.5	0.20	971	8.1	0.12	9.6	0.14
Anus, anal canal & anorectum	146	1.3	0.05	1.6	0.06	249	2.0	0.06	2.5	0.07
Liver	1,783	15.5	0.17	19.6	0.21	638	5.2	0.09	6.2	0.11
Gallbladder	76	0.7	0.04	0.9	0.05	168	1.4	0.05	1.6	0.06
Pancreas	1,448	14.1	0.17	16.7	0.20	1,306	10.7	0.13	12.7	0.16
Respiratory System	6,821	66.8	0.37	78.8	0.43	5,385	44.3	0.27	52.4	0.32
Larynx	580	5.3	0.10	6.5	0.12	117	0.9	0.04	1.1	0.05
Lung & bronchus	6,120	60.4	0.35	71.1	0.41	5,198	42.7	0.27	50.5	0.31
Bones & Joints	132	1.2	0.05	1.3	0.05	103	0.9	0.04	0.9	0.04
Soft Tissue (incl. heart)	391	3.7	0.09	4.2	0.10	290	2.5	0.07	2.8	0.07
Skin (excl. basal & sq.)	2,228	21.7	0.21	25.4	0.24	1,389	11.9	0.15	13.6	0.16
Melanomas of the skin	2,076	20.1	0.20	23.6	0.24	1,288	11.1	0.14	12.6	0.16
Breast (excl. <i>in situ</i>)	143	1.4	0.05	1.6	0.06	13,535	113.8	0.45	133.9	0.52
Female Genital System	-	-	-	-	-	5,646	47.7	0.29	55.5	0.33
Cervix uteri	-	-	-	-	-	1,043	9.6	0.14	10.2	0.14
Uterus Corpus	-	-	-	-	-	2,678	21.9	0.19	26.4	0.23
Uterus, NOS ¹	-	-	-	-	-	153	1.3	0.05	1.5	0.05
Ovary	-	-	-	-	-	1,316	11.1	0.14	12.9	0.16
Male Genital System	10,475	95.2	0.43	115.1	0.51	-	-	-	-	-
Prostate	9,680	88.0	0.41	107.7	0.49	-	-	-	-	-
Testis	671	6.0	0.11	6.0	0.10	-	-	-	-	-
Penis	102	1.0	0.04	1.2	0.05	-	-	-	-	-
Urinary System	5,631	54.9	0.34	64.7	0.39	2,545	21.1	0.19	24.8	0.22
Bladder (incl. <i>in situ</i>)	2,759	28.2	0.25	33.0	0.29	783	6.5	0.10	7.6	0.12
Kidney & renal pelvis	2,771	25.7	0.22	30.5	0.26	1,703	14.2	0.16	16.7	0.18
Ureter	64	0.7	0.04	0.8	0.04	42	0.3	0.02	0.4	0.03
Eye & Orbit	103	1.0	0.04	1.1	0.05	90	0.8	0.04	0.8	0.04
Brain & Other CNS ¹	827	7.6	0.12	8.5	0.13	687	5.9	0.10	6.4	0.11
Brain	772	7.1	0.12	8.0	0.13	626	5.4	0.10	5.9	0.11
Endocrine System	805	7.4	0.12	8.3	0.13	2,136	19.2	0.19	20.8	0.20
Thyroid gland	725	6.6	0.11	7.5	0.13	2,061	18.5	0.19	20.1	0.20
Lymphomas	2,505	24.2	0.22	27.8	0.25	2,002	16.9	0.17	19.3	0.19
Hodgkin Lymphoma	285	2.6	0.07	2.8	0.07	236	2.1	0.06	2.2	0.06
Non-Hodgkin Lymphoma	2,220	21.6	0.21	25.0	0.24	1,766	14.7	0.16	17.2	0.18
Multiple Myeloma	826	8.1	0.13	9.5	0.15	639	5.3	0.09	6.2	0.11
Leukemias	1,897	18.6	0.20	20.9	0.22	1,335	11.3	0.14	12.6	0.15
Acute lymphocytic	257	2.3	0.06	2.1	0.06	189	1.7	0.06	1.5	0.05
Chronic lymphocytic	645	6.4	0.12	7.6	0.14	437	3.6	0.08	4.2	0.09
Acute myeloid	457	4.6	0.10	5.2	0.11	356	3.0	0.07	3.4	0.08
Chronic myeloid	272	2.7	0.07	3.0	0.08	180	1.6	0.05	1.8	0.06
Other leukemias	266	2.7	0.08	3.0	0.09	171	1.5	0.05	1.6	0.06
Mesothelioma	133	1.4	0.05	1.6	0.06	38	0.3	0.02	0.4	0.03
Kaposi Sarcoma	80	0.8	0.04	0.8	0.04	8	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,955	19.7	0.21	23.0	0.24	1,645	13.7	0.15	15.8	0.17
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	932	9.0	0.13	10.2	0.15	1,953	16.6	0.17	19.0	0.19
Breast (<i>in situ</i>)	14	0.1	0.02	0.2	0.02	2,598	21.9	0.20	25.9	0.23

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

TEXAS

II-474 Incidence – White

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,548	513.8	3.14	619.8	3.67	6,369	386.5	2.24	454.6	2.60
Oral Cavity & Pharynx	168	12.0	0.45	14.5	0.53	80	4.6	0.24	5.5	0.28
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	37	2.6	0.21	3.2	0.25	15	0.9	0.11	1.1	0.13
Major salivary gland	15	1.1	0.14	1.3	0.16	20	1.2	0.12	1.3	0.13
Floor of mouth	8	0.6	0.10	0.7	0.11	4	0.2	0.05	0.3	0.06
Gum & other mouth	21	1.5	0.17	1.9	0.20	17	1.0	0.11	1.2	0.13
Nasopharynx	15	1.0	0.12	1.1	0.14	5	0.3	0.06	0.3	0.07
Oropharynx	12	0.8	0.12	1.0	0.14	5	0.3	0.06	0.3	0.07
Hypopharynx	14	1.0	0.13	1.2	0.16	3	0.2	0.04	0.2	0.05
Digestive System	1,617	125.4	1.54	152.5	1.82	1,290	79.6	1.03	95.4	1.21
Esophagus	66	5.4	0.33	6.6	0.39	28	1.8	0.15	2.1	0.18
Stomach	159	13.5	0.53	16.0	0.61	109	7.0	0.31	8.2	0.36
Small intestine	62	5.0	0.31	5.9	0.36	55	3.3	0.21	3.9	0.24
Colon excl. rectum	495	39.9	0.89	47.7	1.04	497	30.6	0.64	36.7	0.75
Rectum & rectosigmoid	210	15.7	0.53	19.1	0.63	150	8.8	0.33	10.5	0.39
Anus, anal canal & anorectum	29	2.0	0.18	2.3	0.20	24	1.4	0.14	1.7	0.16
Liver	327	21.3	0.56	27.8	0.71	98	5.6	0.26	7.0	0.32
Gallbladder	14	1.3	0.17	1.5	0.20	30	1.9	0.16	2.3	0.19
Pancreas	198	16.7	0.59	20.1	0.69	226	14.5	0.45	17.3	0.52
Respiratory System	1,037	89.8	1.37	107.1	1.59	733	46.8	0.81	56.1	0.94
Larynx	98	7.6	0.38	9.3	0.45	22	1.3	0.12	1.5	0.15
Lung & bronchus	927	81.4	1.32	96.8	1.52	704	45.1	0.79	54.1	0.93
Bones & Joints	14	0.8	0.10	0.9	0.11	13	0.7	0.09	0.7	0.09
Soft Tissue (incl. heart)	50	3.4	0.23	3.7	0.26	53	3.1	0.20	3.5	0.22
Skin (excl. basal & sq.)	25	1.8	0.18	2.1	0.21	26	1.6	0.14	1.8	0.16
Melanomas of the skin	13	1.1	0.15	1.2	0.17	15	0.9	0.11	1.1	0.13
Breast (excl. <i>in situ</i>)	25	1.9	0.19	2.3	0.22	1,991	117.8	1.22	138.0	1.41
Female Genital System	-	-	-	-	-	774	45.5	0.76	53.9	0.88
Cervix uteri	-	-	-	-	-	157	9.1	0.33	10.1	0.37
Uterus Corpus	-	-	-	-	-	365	21.3	0.52	26.0	0.62
Uterus, NOS ¹	-	-	-	-	-	42	2.6	0.19	3.1	0.22
Ovary	-	-	-	-	-	156	9.3	0.34	10.9	0.40
Male Genital System	2,061	155.0	1.67	192.3	2.00	-	-	-	-	-
Prostate	2,027	152.6	1.66	189.8	1.99	-	-	-	-	-
Testis	21	1.3	0.13	1.3	0.13	-	-	-	-	-
Penis	10	0.9	0.14	1.0	0.16	-	-	-	-	-
Urinary System	529	43.2	0.93	51.3	1.08	315	19.6	0.51	23.2	0.60
Bladder (incl. <i>in situ</i>)	177	16.6	0.62	19.7	0.71	78	5.2	0.27	6.2	0.32
Kidney & renal pelvis	345	26.1	0.69	31.1	0.80	230	14.0	0.43	16.5	0.50
Ureter	2	0.1	0.05	0.2	0.06	2	0.1	0.05	0.2	0.05
Eye & Orbit	3	0.2	0.05	0.2	0.05	4	0.2	0.05	0.2	0.05
Brain & Other CNS ¹	69	4.6	0.27	5.1	0.30	66	3.8	0.22	4.1	0.23
Brain	61	4.2	0.26	4.7	0.29	56	3.2	0.20	3.5	0.22
Endocrine System	70	4.7	0.27	5.5	0.31	223	12.7	0.39	14.3	0.44
Thyroid gland	54	3.6	0.23	4.2	0.27	205	11.7	0.37	13.1	0.42
Lymphomas	272	19.2	0.57	21.9	0.65	236	14.1	0.42	16.0	0.48
Hodgkin Lymphoma	51	3.1	0.20	3.2	0.21	41	2.2	0.16	2.4	0.17
Non-Hodgkin Lymphoma	221	16.1	0.53	18.7	0.61	196	11.9	0.39	13.6	0.45
Multiple Myeloma	190	16.6	0.60	19.7	0.69	193	12.4	0.41	14.6	0.48
Leukemias	173	14.0	0.53	16.0	0.60	144	9.0	0.35	10.1	0.39
Acute lymphocytic	19	1.1	0.12	1.1	0.12	14	0.7	0.09	0.7	0.08
Chronic lymphocytic	61	5.5	0.35	6.5	0.41	38	2.5	0.19	3.0	0.22
Acute myeloid	42	3.4	0.26	3.8	0.29	46	2.8	0.19	3.2	0.22
Chronic myeloid	31	2.4	0.21	2.7	0.24	22	1.4	0.14	1.6	0.16
Other leukemias	21	1.6	0.18	1.8	0.20	24	1.5	0.14	1.7	0.16
Mesothelioma	9	0.9	0.15	1.1	0.17	3	0.2	0.06	0.2	0.06
Kaposi Sarcoma	31	1.8	0.15	1.8	0.15	4	0.3	0.06	0.3	0.06
Ill-defined & Unknown	-	-	-	-	-	221	14.4	0.45	16.7	0.51
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	122	9.4	0.42	10.8	0.48	302	18.6	0.49	21.3	0.56
Breast (<i>in situ</i>)	3	0.3	0.07	0.3	0.08	461	26.8	0.58	32.0	0.68

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,291	259.0	3.53	304.8	4.12	1,570	246.8	2.94	286.6	3.41
Oral Cavity & Pharynx	55	9.7	0.63	11.5	0.74	29	4.5	0.40	5.3	0.46
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	13	2.4	0.31	2.8	0.36	9	1.4	0.22	1.7	0.26
Major salivary gland	5	0.8	0.19	0.9	0.22	4	0.6	0.13	0.7	0.14
Floor of mouth	2	0.2	0.08	0.3	0.11	-	-	-	-	-
Gum & other mouth	13	2.4	0.33	2.8	0.38	7	1.3	0.23	1.5	0.26
Nasopharynx	12	1.9	0.26	2.2	0.31	5	0.7	0.14	0.9	0.17
Oropharynx	2	0.4	0.16	0.5	0.19	-	-	-	-	-
Hypopharynx	3	0.5	0.15	0.6	0.18	-	-	-	-	-
Digestive System	385	77.3	1.93	92.1	2.27	290	50.8	1.42	59.5	1.64
Esophagus	17	3.4	0.40	4.1	0.48	5	0.9	0.20	1.1	0.24
Stomach	49	10.5	0.74	12.2	0.86	37	6.6	0.51	7.6	0.59
Small intestine	6	1.2	0.23	1.4	0.26	5	0.8	0.17	0.9	0.20
Colon excl. rectum	88	17.8	0.93	21.2	1.10	89	15.1	0.76	17.8	0.89
Rectum & rectosigmoid	57	10.3	0.65	12.5	0.78	44	7.3	0.52	8.7	0.61
Anus, anal canal & anorectum	-	-	-	-	-	1	0.2	0.08	0.3	0.11
Liver	97	18.8	0.93	22.7	1.10	36	6.8	0.54	7.9	0.61
Gallbladder	4	1.0	0.26	1.2	0.30	6	1.0	0.19	1.1	0.22
Pancreas	44	9.4	0.69	11.2	0.81	43	7.7	0.56	9.0	0.65
Respiratory System	179	39.3	1.45	46.5	1.69	141	25.4	1.01	29.9	1.18
Larynx	7	1.4	0.25	1.7	0.29	-	-	-	-	-
Lung & bronchus	166	36.9	1.41	43.7	1.65	136	24.5	1.00	28.9	1.16
Bones & Joints	7	1.0	0.18	1.0	0.18	4	0.6	0.13	0.6	0.14
Soft Tissue (incl. heart)	13	2.1	0.27	2.3	0.31	10	1.4	0.21	1.5	0.24
Skin (excl. basal & sq.)	-	-	-	-	-	7	1.2	0.22	1.4	0.24
Melanomas of the skin	7	1.5	0.27	1.7	0.31	4	0.7	0.17	0.8	0.19
Breast (excl. <i>in situ</i>)	4	0.8	0.19	0.9	0.21	520	75.2	1.53	88.1	1.79
Female Genital System	-	-	-	-	-	201	29.5	0.97	34.9	1.15
Cervix uteri	-	-	-	-	-	37	5.3	0.41	6.0	0.47
Uterus Corpus	-	-	-	-	-	89	12.8	0.63	15.6	0.76
Uterus, NOS ¹	-	-	-	-	-	7	1.1	0.21	1.3	0.24
Ovary	-	-	-	-	-	58	8.6	0.53	9.9	0.61
Male Genital System	252	51.3	1.56	61.8	1.84	-	-	-	-	-
Prostate	240	49.5	1.54	60.0	1.83	-	-	-	-	-
Testis	9	1.3	0.19	1.2	0.18	-	-	-	-	-
Penis	2	0.4	0.13	0.5	0.15	-	-	-	-	-
Urinary System	103	22.0	1.06	25.8	1.23	41	7.2	0.54	8.6	0.63
Bladder (incl. <i>in situ</i>)	54	12.8	0.86	15.0	0.99	14	2.8	0.35	3.3	0.41
Kidney & renal pelvis	48	8.9	0.62	10.4	0.72	25	4.1	0.39	4.8	0.45
Ureter	-	-	-	-	-	1	0.2	0.08	0.3	0.11
Eye & Orbit	-	-	-	-	-	2	0.3	0.09	0.3	0.09
Brain & Other CNS ¹	25	4.4	0.43	4.7	0.48	23	3.5	0.34	3.6	0.37
Brain	24	4.1	0.42	4.5	0.47	20	3.1	0.32	3.2	0.35
Endocrine System	40	6.5	0.49	7.2	0.55	137	18.7	0.74	20.5	0.82
Thyroid gland	35	5.6	0.46	6.3	0.52	130	17.8	0.72	19.4	0.80
Lymphomas	86	16.4	0.86	18.7	0.99	67	10.8	0.62	12.2	0.71
Hodgkin Lymphoma	9	1.4	0.20	1.4	0.21	7	1.0	0.17	1.0	0.17
Non-Hodgkin Lymphoma	76	15.1	0.84	17.3	0.96	60	9.8	0.60	11.3	0.69
Multiple Myeloma	28	6.0	0.56	7.0	0.64	18	3.0	0.33	3.5	0.39
Leukemias	55	10.1	0.67	11.1	0.75	34	5.4	0.43	5.9	0.48
Acute lymphocytic	11	1.6	0.22	1.4	0.20	7	1.0	0.18	0.9	0.16
Chronic lymphocytic	10	1.9	0.30	2.4	0.35	5	0.9	0.19	1.0	0.21
Acute myeloid	19	3.7	0.42	4.1	0.48	13	2.1	0.27	2.4	0.31
Chronic myeloid	7	1.2	0.22	1.4	0.24	5	0.7	0.15	0.8	0.18
Other leukemias	8	1.6	0.29	1.8	0.34	5	0.8	0.17	0.9	0.19
Mesothelioma	2	0.4	0.15	0.4	0.17	-	-	-	-	-
Kaposi Sarcoma	1	0.2	0.07	0.2	0.08	-	-	-	-	-
Ill-defined & Unknown	45	9.5	0.70	11.0	0.81	47	9.3	0.65	10.6	0.74
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	42	7.8	0.60	9.0	0.69	89	14.3	0.72	16.7	0.83
Breast (<i>in situ</i>)	-	-	-	-	-	149	21.3	0.80	25.3	0.95

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

TEXAS

II-476 Incidence – API

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	10	247.6	37.84	300.5	45.09	7	158.5	27.13	179.0	30.65
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	59.2	18.74	72.1	22.46	1	35.2	13.70	37.8	14.58
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	1	26.7	11.24	33.1	13.54
Female Genital System	-	-	-	-	-	2	34.5	12.42	40.1	14.45
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	5	117.3	25.74	145.4	31.12	-	-	-	-	-
Prostate	4	110.6	25.30	137.0	30.49	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.
¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)
² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, Hispanic/Latino, All Races

<i>SITES</i>	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	11,816	369.9	1.66	436.7	1.93	12,849	324.3	1.32	377.8	1.54
Oral Cavity & Pharynx	338	10.0	0.26	12.1	0.31	153	3.9	0.15	4.5	0.17
Lip	12	0.4	0.06	0.5	0.07	3	0.1	0.02	0.1	0.03
Tongue	88	2.6	0.13	3.1	0.16	48	1.2	0.08	1.4	0.10
Major salivary gland	34	1.0	0.09	1.2	0.10	34	0.8	0.07	0.9	0.07
Floor of mouth	16	0.5	0.06	0.6	0.07	4	0.1	0.03	0.1	0.03
Gum & other mouth	40	1.3	0.10	1.5	0.12	31	0.8	0.07	1.0	0.08
Nasopharynx	16	0.4	0.05	0.5	0.06	6	0.2	0.03	0.2	0.03
Oropharynx	21	0.6	0.06	0.7	0.08	6	0.1	0.03	0.2	0.03
Hypopharynx	26	0.8	0.08	1.0	0.09	4	0.1	0.02	0.1	0.03
Digestive System	3,500	109.2	0.89	131.5	1.05	2,465	67.1	0.62	79.4	0.73
Esophagus	145	4.7	0.19	5.7	0.22	32	0.9	0.07	1.1	0.09
Stomach	350	11.7	0.30	13.7	0.35	289	7.7	0.21	9.1	0.24
Small intestine	67	2.0	0.12	2.4	0.14	54	1.4	0.09	1.7	0.11
Colon excl. rectum	927	29.5	0.47	35.3	0.55	781	20.8	0.34	24.7	0.40
Rectum & rectosigmoid	546	16.1	0.33	19.4	0.39	294	7.5	0.20	8.9	0.24
Anus, anal canal & anorectum	27	0.7	0.07	0.9	0.08	35	0.9	0.07	1.1	0.09
Liver	858	25.3	0.42	31.4	0.50	330	9.4	0.24	11.1	0.28
Gallbladder	35	1.2	0.09	1.4	0.11	91	2.5	0.12	3.0	0.14
Pancreas	363	12.1	0.31	14.4	0.36	373	10.8	0.26	12.6	0.30
Respiratory System	1,133	41.8	0.59	48.8	0.68	703	20.4	0.35	23.9	0.41
Larynx	147	4.8	0.19	5.8	0.22	18	0.5	0.05	0.6	0.06
Lung & bronchus	948	36.0	0.56	42.0	0.64	665	19.4	0.35	22.7	0.40
Bones & Joints	58	1.2	0.08	1.2	0.08	43	0.9	0.06	0.9	0.07
Soft Tissue (incl. heart)	121	3.1	0.14	3.5	0.16	104	2.4	0.11	2.6	0.12
Skin (excl. basal & sq.)	146	4.7	0.19	5.4	0.22	160	4.0	0.15	4.6	0.17
Melanomas of the skin	121	3.9	0.17	4.5	0.20	129	3.2	0.13	3.6	0.15
Breast (excl. <i>in situ</i>)	33	1.0	0.09	1.2	0.10	3,646	90.0	0.68	106.3	0.81
Female Genital System	-	-	-	-	-	2,057	48.8	0.49	56.5	0.58
Cervix uteri	-	-	-	-	-	515	11.5	0.23	12.5	0.26
Uterus Corpus	-	-	-	-	-	939	22.2	0.33	26.4	0.40
Uterus, NOS ¹	-	-	-	-	-	60	1.6	0.09	1.8	0.11
Ovary	-	-	-	-	-	425	10.4	0.23	12.1	0.27
Male Genital System	2,644	83.3	0.78	99.6	0.92	-	-	-	-	-
Prostate	2,274	76.2	0.76	92.1	0.90	-	-	-	-	-
Testis	315	5.4	0.14	5.3	0.14	-	-	-	-	-
Penis	50	1.6	0.11	1.9	0.13	-	-	-	-	-
Urinary System	1,347	43.1	0.57	50.9	0.66	811	21.1	0.34	24.9	0.40
Bladder (incl. <i>in situ</i>)	399	15.3	0.37	17.8	0.42	140	4.1	0.16	4.8	0.18
Kidney & renal pelvis	932	27.3	0.43	32.4	0.50	660	16.7	0.30	19.7	0.35
Ureter	9	0.3	0.06	0.4	0.06	8	0.2	0.04	0.3	0.05
Eye & Orbit	21	0.5	0.06	0.5	0.06	17	0.4	0.04	0.4	0.05
Brain & Other CNS ¹	218	5.3	0.18	5.8	0.20	211	4.6	0.15	5.0	0.17
Brain	200	4.9	0.17	5.4	0.19	189	4.2	0.14	4.6	0.16
Endocrine System	242	6.0	0.19	6.8	0.21	849	18.6	0.29	20.5	0.33
Thyroid gland	215	5.4	0.18	6.2	0.20	821	18.0	0.29	19.9	0.32
Lymphomas	722	21.3	0.39	24.5	0.45	612	15.7	0.29	18.1	0.34
Hodgkin Lymphoma	114	2.7	0.13	2.9	0.14	91	1.9	0.09	2.0	0.10
Non-Hodgkin Lymphoma	608	18.6	0.37	21.6	0.43	522	13.8	0.28	16.1	0.32
Multiple Myeloma	231	7.7	0.24	9.1	0.28	192	5.4	0.18	6.4	0.21
Leukemias	504	13.1	0.30	14.4	0.33	384	8.8	0.21	9.6	0.24
Acute lymphocytic	162	2.7	0.10	2.6	0.10	118	2.1	0.09	2.0	0.09
Chronic lymphocytic	75	2.7	0.15	3.1	0.17	56	1.6	0.10	1.9	0.12
Acute myeloid	118	3.4	0.16	3.9	0.18	105	2.6	0.12	2.8	0.13
Chronic myeloid	78	2.1	0.12	2.3	0.13	52	1.3	0.08	1.4	0.09
Other leukemias	71	2.2	0.13	2.4	0.15	54	1.3	0.08	1.4	0.09
Mesothelioma	32	1.1	0.10	1.3	0.11	11	0.3	0.04	0.3	0.05
Kaposi Sarcoma	51	1.3	0.09	1.4	0.10	5	0.1	0.03	0.2	0.03
Ill-defined & Unknown	476	16.2	0.36	18.8	0.42	425	12.0	0.27	13.7	0.31
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	267	7.5	0.23	8.5	0.26	583	14.8	0.28	17.1	0.33
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.03	682	16.5	0.29	19.7	0.34

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

TEXAS

II-478 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	35,978	483.9	1.17	573.1	1.36	33,161	411.1	1.05	477.8	1.19
Oral Cavity & Pharynx	1,678	21.7	0.24	26.6	0.29	565	6.9	0.13	8.1	0.16
Lip	64	0.9	0.05	1.0	0.06	13	0.2	0.02	0.2	0.02
Tongue	566	7.2	0.14	8.9	0.17	185	2.3	0.08	2.7	0.09
Major salivary gland	147	2.1	0.08	2.4	0.09	76	1.0	0.05	1.1	0.06
Floor of mouth	59	0.7	0.04	0.9	0.05	24	0.3	0.03	0.3	0.03
Gum & other mouth	158	2.1	0.08	2.5	0.09	108	1.3	0.06	1.5	0.06
Nasopharynx	53	0.7	0.05	0.8	0.05	21	0.3	0.03	0.3	0.03
Oropharynx	105	1.3	0.06	1.6	0.07	28	0.3	0.03	0.4	0.03
Hypopharynx	78	1.0	0.05	1.2	0.06	21	0.2	0.02	0.3	0.03
Digestive System	7,085	94.8	0.52	113.5	0.61	5,146	61.0	0.39	72.0	0.45
Esophagus	633	8.2	0.15	10.0	0.18	151	1.7	0.07	2.1	0.08
Stomach	491	6.6	0.14	7.9	0.16	268	3.2	0.09	3.7	0.10
Small intestine	197	2.7	0.09	3.1	0.10	170	2.1	0.07	2.4	0.08
Colon excl. rectum	2,196	30.2	0.30	35.6	0.34	1,976	23.6	0.25	27.5	0.28
Rectum & rectosigmoid	1,045	14.2	0.20	16.9	0.24	683	8.5	0.15	10.0	0.17
Anus, anal canal & anorectum	120	1.6	0.07	1.9	0.08	214	2.5	0.08	3.1	0.10
Liver	935	11.4	0.17	14.6	0.21	313	3.6	0.09	4.4	0.11
Gallbladder	42	0.6	0.04	0.7	0.05	79	0.9	0.05	1.1	0.05
Pancreas	1,091	14.7	0.20	17.5	0.24	938	10.7	0.16	12.7	0.19
Respiratory System	5,707	76.0	0.46	90.0	0.54	4,695	53.8	0.36	63.7	0.42
Larynx	435	5.6	0.12	6.8	0.15	99	1.1	0.05	1.4	0.06
Lung & bronchus	5,188	69.2	0.44	81.9	0.51	4,545	51.9	0.35	61.6	0.41
Bones & Joints	76	1.2	0.07	1.3	0.07	60	1.0	0.06	1.0	0.06
Soft Tissue (incl. heart)	274	4.0	0.11	4.5	0.12	188	2.5	0.09	2.8	0.09
Skin (excl. basal & sq.)	2,088	29.1	0.29	33.9	0.34	1,235	16.8	0.22	18.8	0.24
Melanomas of the skin	1,959	27.3	0.28	31.8	0.32	1,164	15.9	0.22	17.8	0.24
Breast (excl. <i>in situ</i>)	110	1.5	0.07	1.7	0.08	9,959	124.9	0.58	146.5	0.67
Female Genital System	-	-	-	-	-	3,635	46.1	0.36	53.9	0.41
Cervix uteri	-	-	-	-	-	539	8.5	0.17	8.9	0.17
Uterus Corpus	-	-	-	-	-	1,762	21.0	0.23	25.6	0.28
Uterus, NOS ¹	-	-	-	-	-	94	1.1	0.06	1.3	0.06
Ovary	-	-	-	-	-	899	11.4	0.18	13.2	0.20
Male Genital System	7,964	101.4	0.52	123.1	0.62	-	-	-	-	-
Prostate	7,527	94.0	0.50	115.6	0.60	-	-	-	-	-
Testis	367	6.5	0.15	6.4	0.15	-	-	-	-	-
Penis	54	0.7	0.05	0.9	0.05	-	-	-	-	-
Urinary System	4,310	58.8	0.41	69.3	0.48	1,746	20.8	0.23	24.3	0.26
Bladder (incl. <i>in situ</i>)	2,368	32.7	0.31	38.4	0.36	646	7.4	0.13	8.7	0.15
Kidney & renal pelvis	1,857	24.9	0.27	29.6	0.31	1,051	12.8	0.18	15.0	0.21
Ureter	55	0.8	0.05	0.9	0.05	34	0.4	0.03	0.4	0.03
Eye & Orbit	83	1.2	0.06	1.3	0.07	73	0.9	0.05	1.1	0.06
Brain & Other CNS ¹	613	9.0	0.17	9.9	0.18	481	6.7	0.14	7.2	0.15
Brain	576	8.4	0.16	9.3	0.18	441	6.0	0.14	6.6	0.14
Endocrine System	571	8.3	0.16	9.3	0.18	1,307	20.0	0.26	21.4	0.27
Thyroid gland	517	7.5	0.15	8.4	0.17	1,259	19.3	0.25	20.7	0.26
Lymphomas	1,795	25.5	0.28	29.2	0.31	1,403	17.6	0.22	20.0	0.24
Hodgkin Lymphoma	173	2.8	0.10	2.9	0.10	148	2.4	0.09	2.5	0.09
Non-Hodgkin Lymphoma	1,623	22.7	0.26	26.3	0.30	1,255	15.1	0.20	17.6	0.22
Multiple Myeloma	600	8.1	0.15	9.6	0.18	451	5.2	0.11	6.1	0.13
Leukemias	1,403	20.1	0.25	22.9	0.28	958	12.1	0.18	13.5	0.20
Acute lymphocytic	96	1.7	0.08	1.6	0.07	73	1.3	0.07	1.2	0.06
Chronic lymphocytic	571	7.7	0.15	9.2	0.17	382	4.4	0.10	5.1	0.12
Acute myeloid	342	4.9	0.12	5.6	0.14	254	3.2	0.09	3.6	0.10
Chronic myeloid	197	2.9	0.09	3.2	0.10	130	1.7	0.07	1.9	0.07
Other leukemias	197	2.9	0.09	3.3	0.11	119	1.5	0.06	1.7	0.07
Mesothelioma	101	1.4	0.06	1.6	0.07	27	0.3	0.03	0.4	0.03
Kaposi Sarcoma	31	0.5	0.04	0.5	0.04	4	0.0	0.01	0.1	0.01
Ill-defined & Unknown	1,490	21.1	0.25	24.6	0.29	1,230	14.5	0.19	16.7	0.22
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	671	9.9	0.18	11.1	0.19	1,385	17.8	0.22	20.2	0.25
Breast (<i>in situ</i>)	11	0.2	0.02	0.2	0.02	1,937	24.7	0.26	29.2	0.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Texas, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,470	523.3	3.21	631.2	3.75	6,289	394.2	2.30	463.3	2.66
Oral Cavity & Pharynx	166	12.2	0.46	14.8	0.54	78	4.7	0.25	5.5	0.29
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	37	2.7	0.22	3.3	0.25	15	0.9	0.11	1.1	0.13
Major salivary gland	14	1.1	0.14	1.3	0.16	19	1.2	0.12	1.3	0.14
Floor of mouth	8	0.6	0.10	0.7	0.12	4	0.2	0.06	0.3	0.06
Gum & other mouth	21	1.6	0.17	1.9	0.20	17	1.0	0.12	1.2	0.13
Nasopharynx	14	1.0	0.13	1.2	0.15	5	0.3	0.06	0.3	0.07
Oropharynx	11	0.9	0.12	1.1	0.15	5	0.3	0.06	0.4	0.07
Hypopharynx	14	1.0	0.14	1.3	0.16	3	0.2	0.04	0.2	0.05
Digestive System	1,598	127.8	1.58	155.4	1.86	1,276	81.1	1.05	97.1	1.24
Esophagus	65	5.5	0.34	6.7	0.40	27	1.8	0.16	2.1	0.18
Stomach	157	13.8	0.54	16.3	0.62	107	7.1	0.32	8.3	0.36
Small intestine	61	5.1	0.32	6.0	0.37	54	3.3	0.21	3.9	0.24
Colon excl. rectum	490	40.8	0.91	48.8	1.06	492	31.2	0.65	37.4	0.77
Rectum & rectosigmoid	207	16.0	0.55	19.5	0.64	148	9.0	0.34	10.8	0.40
Anus, anal canal & anorectum	28	2.0	0.18	2.3	0.21	24	1.5	0.14	1.8	0.16
Liver	323	21.7	0.58	28.3	0.73	97	5.7	0.27	7.1	0.33
Gallbladder	14	1.3	0.18	1.6	0.20	30	2.0	0.17	2.4	0.20
Pancreas	196	17.0	0.60	20.5	0.70	224	14.8	0.46	17.7	0.54
Respiratory System	1,029	91.5	1.40	109.2	1.62	727	47.6	0.82	57.1	0.96
Larynx	97	7.7	0.38	9.5	0.46	21	1.3	0.13	1.5	0.15
Lung & bronchus	920	82.9	1.35	98.7	1.55	699	45.9	0.81	55.0	0.94
Bones & Joints	13	0.8	0.10	0.9	0.11	12	0.7	0.10	0.7	0.10
Soft Tissue (incl. heart)	48	3.5	0.24	3.8	0.27	52	3.2	0.20	3.5	0.22
Skin (excl. basal & sq.)	24	1.8	0.19	2.2	0.21	26	1.6	0.15	1.9	0.17
Melanomas of the skin	12	1.1	0.15	1.2	0.18	15	1.0	0.12	1.1	0.13
Breast (excl. <i>in situ</i>)	24	1.9	0.19	2.3	0.22	1,970	120.5	1.25	141.1	1.44
Female Genital System	-	-	-	-	-	761	46.3	0.77	54.7	0.90
Cervix uteri	-	-	-	-	-	154	9.3	0.34	10.4	0.38
Uterus Corpus	-	-	-	-	-	359	21.5	0.53	26.3	0.63
Uterus, NOS ¹	-	-	-	-	-	42	2.7	0.19	3.1	0.22
Ovary	-	-	-	-	-	154	9.4	0.35	11.1	0.41
Male Genital System	2,034	157.4	1.71	195.4	2.04	-	-	-	-	-
Prostate	2,001	155.0	1.70	192.8	2.03	-	-	-	-	-
Testis	21	1.3	0.14	1.3	0.14	-	-	-	-	-
Penis	10	0.9	0.14	1.0	0.16	-	-	-	-	-
Urinary System	523	44.0	0.95	52.3	1.10	312	20.0	0.52	23.6	0.61
Bladder (incl. <i>in situ</i>)	176	16.9	0.63	20.0	0.73	78	5.3	0.28	6.3	0.32
Kidney & renal pelvis	342	26.7	0.70	31.8	0.82	228	14.3	0.44	16.9	0.51
Ureter	2	0.2	0.05	0.2	0.06	2	0.1	0.05	0.2	0.05
Eye & Orbit	3	0.2	0.05	0.2	0.05	4	0.2	0.05	0.2	0.05
Brain & Other CNS ¹	67	4.8	0.28	5.3	0.31	64	3.9	0.22	4.2	0.24
Brain	60	4.3	0.27	4.8	0.30	54	3.3	0.21	3.6	0.22
Endocrine System	69	4.9	0.28	5.6	0.32	220	13.1	0.40	14.7	0.45
Thyroid gland	53	3.7	0.24	4.3	0.28	202	12.0	0.39	13.4	0.43
Lymphomas	268	19.7	0.59	22.4	0.66	232	14.4	0.43	16.3	0.49
Hodgkin Lymphoma	50	3.2	0.21	3.3	0.22	39	2.3	0.16	2.4	0.18
Non-Hodgkin Lymphoma	218	16.5	0.55	19.1	0.63	193	12.1	0.40	13.9	0.46
Multiple Myeloma	188	17.0	0.61	20.1	0.70	191	12.6	0.42	14.9	0.49
Leukemias	171	14.4	0.54	16.4	0.62	141	9.1	0.36	10.3	0.40
Acute lymphocytic	19	1.2	0.13	1.1	0.13	13	0.7	0.09	0.7	0.09
Chronic lymphocytic	60	5.6	0.36	6.7	0.42	38	2.5	0.19	3.0	0.22
Acute myeloid	41	3.4	0.27	3.8	0.30	46	2.9	0.20	3.3	0.22
Chronic myeloid	30	2.5	0.22	2.8	0.25	22	1.5	0.14	1.6	0.16
Other leukemias	21	1.7	0.18	1.9	0.21	23	1.5	0.15	1.7	0.16
Mesothelioma	9	0.9	0.15	1.1	0.17	3	0.2	0.06	0.2	0.06
Kaposi Sarcoma	30	1.8	0.15	1.9	0.16	4	0.3	0.06	0.3	0.06
Ill-defined & Unknown	204	18.8	0.65	22.0	0.75	218	14.6	0.46	17.0	0.52
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	120	9.6	0.43	11.0	0.49	298	19.0	0.51	21.8	0.58
Breast (<i>in situ</i>)	3	0.3	0.07	0.3	0.08	456	27.4	0.59	32.7	0.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	2,897,927	2,937,399	2,982,497	3,042,613	3,103,118
White	2,694,777	2,727,960	2,766,435	2,816,793	2,866,343
Black	47,357	48,773	50,265	52,945	55,890
American Indian/Alaskan Native (AI/AN)	49,483	50,603	51,798	52,908	54,127
Asian/Pacific Islander (API)	106,310	110,063	113,999	119,967	126,758


All Races Population 2013-2017: 14,963,554
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	386,642	395,695	407,337	421,408	435,928
Non-Hispanic White	2,343,720	2,368,920	2,396,996	2,434,726	2,471,134
Non-Hispanic Black	37,353	38,521	39,833	42,044	44,621

Hispanic/Latino Population, Census 2010: 358,340
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

UTAH CANCER REGISTRY

Initial Operation: 1966
Population-based Data Available: 1966
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.8	102.7	103.3	101.1	104.7
Missing Race	0.1	0.0	0.0	0.2	2.2
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.3	0.4	0.5	0.3	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Prostate	97.1
Oral Cavity & Pharynx	98.4	Testis	99.5
Esophagus	97.1	Bladder (incl. <i>in situ</i>)	98.2
Stomach	95.0	Kidney & Renal Pelvis	89.4
Colon & Rectum	96.8	Brain & Other CNS ¹	84.8
Liver	51.6	Thyroid	99.9
Pancreas	77.8	Hodgkin Lymphoma	98.8
Lung & Bronchus	87.4	Non-Hodgkin Lymphoma	96.9
Melanomas of the Skin	99.7	Multiple Myeloma	86.1
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	91.8
Cervix uteri	99.4	Brain & Other CNS ¹ <i>non-malig</i>	36.0
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	92.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,389	439.1	2.75	518.8	3.21	5,041	375.2	2.40	435.2	2.77
Oral Cavity & Pharynx	175	13.8	0.48	16.8	0.57	79	5.8	0.30	6.8	0.35
Lip	23	2.0	0.19	2.3	0.22	9	0.7	0.10	0.8	0.12
Tongue	55	4.2	0.26	5.2	0.31	24	1.7	0.16	2.1	0.19
Major salivary gland	17	1.4	0.16	1.6	0.18	15	1.1	0.13	1.2	0.14
Floor of mouth	6	0.5	0.09	0.6	0.10	3	0.2	0.06	0.3	0.07
Gum & other mouth	15	1.3	0.16	1.5	0.18	17	1.2	0.14	1.4	0.16
Nasopharynx	8	0.6	0.10	0.7	0.12	2	0.1	0.05	0.2	0.05
Oropharynx	8	0.6	0.10	0.8	0.12	2	0.1	0.05	0.2	0.06
Hypopharynx	5	0.3	0.07	0.4	0.09	2	0.2	0.05	0.2	0.06
Digestive System	886	73.3	1.13	87.0	1.33	705	53.1	0.91	62.2	1.06
Esophagus	68	5.6	0.31	6.7	0.37	14	1.0	0.13	1.3	0.15
Stomach	72	6.1	0.33	7.1	0.38	47	3.6	0.24	4.1	0.27
Small intestine	38	3.1	0.23	3.6	0.27	33	2.4	0.19	2.9	0.23
Colon excl. rectum	262	22.2	0.63	26.0	0.73	263	19.9	0.56	23.1	0.64
Rectum & rectosigmoid	133	10.7	0.42	12.7	0.50	95	7.2	0.34	8.5	0.39
Anus, anal canal & anorectum	11	0.9	0.12	1.0	0.14	26	1.9	0.17	2.3	0.21
Liver	103	8.0	0.36	10.0	0.44	37	2.7	0.20	3.2	0.24
Gallbladder	7	0.6	0.11	0.7	0.12	17	1.3	0.14	1.5	0.16
Pancreas	148	12.4	0.47	14.8	0.55	123	9.3	0.38	11.0	0.44
Respiratory System	396	34.0	0.78	40.2	0.91	316	23.7	0.60	28.1	0.71
Larynx	34	2.7	0.22	3.4	0.26	7	0.5	0.09	0.6	0.10
Lung & bronchus	348	30.2	0.74	35.6	0.86	300	22.5	0.59	26.7	0.69
Bones & Joints	22	1.6	0.16	1.7	0.17	15	1.0	0.12	1.1	0.13
Soft Tissue (incl. heart)	52	3.9	0.25	4.4	0.29	42	3.0	0.21	3.3	0.23
Skin (excl. basal & sq.)	654	53.9	0.97	62.9	1.12	462	34.4	0.73	39.0	0.82
Melanomas of the skin	611	50.1	0.93	58.5	1.08	438	32.6	0.71	37.0	0.80
Breast (excl. <i>in situ</i>)	11	0.9	0.13	1.1	0.15	1,518	114.4	1.33	134.3	1.55
Female Genital System	-	-	-	-	-	647	47.3	0.85	56.4	1.00
Cervix uteri	-	-	-	-	-	71	5.4	0.29	5.9	0.32
Uterus Corpus	-	-	-	-	-	366	26.5	0.63	32.3	0.76
Uterus, NOS ¹	-	-	-	-	-	7	0.5	0.09	0.6	0.10
Ovary	-	-	-	-	-	150	11.1	0.41	13.0	0.48
Male Genital System	1,547	121.2	1.41	146.9	1.69	-	-	-	-	-
Prostate	1,425	112.8	1.37	138.3	1.65	-	-	-	-	-
Testis	110	7.4	0.32	7.3	0.32	-	-	-	-	-
Penis	9	0.8	0.12	0.9	0.14	-	-	-	-	-
Urinary System	582	49.7	0.94	58.3	1.10	205	15.3	0.48	17.9	0.56
Bladder (incl. <i>in situ</i>)	337	29.8	0.74	34.9	0.86	74	5.6	0.29	6.5	0.34
Kidney & renal pelvis	235	18.9	0.56	22.3	0.66	124	9.2	0.38	10.8	0.44
Ureter	5	0.4	0.09	0.5	0.11	4	0.3	0.07	0.3	0.08
Eye & Orbit	14	1.1	0.14	1.3	0.16	13	0.9	0.11	1.0	0.13
Brain & Other CNS ¹	109	8.2	0.36	9.1	0.41	79	5.6	0.29	6.1	0.32
Brain	103	7.8	0.35	8.7	0.40	75	5.3	0.28	5.9	0.31
Endocrine System	121	9.2	0.38	10.3	0.43	380	27.8	0.65	29.9	0.70
Thyroid gland	113	8.6	0.37	9.7	0.42	372	27.3	0.64	29.3	0.69
Lymphomas	313	25.4	0.66	29.3	0.76	231	17.0	0.51	19.5	0.58
Hodgkin Lymphoma	36	2.4	0.18	2.6	0.20	33	2.2	0.18	2.3	0.18
Non-Hodgkin Lymphoma	277	23.0	0.64	26.7	0.73	198	14.8	0.48	17.2	0.55
Multiple Myeloma	92	7.8	0.37	9.3	0.44	63	4.7	0.27	5.6	0.32
Leukemias	228	18.5	0.56	21.0	0.64	148	10.6	0.40	11.9	0.45
Acute lymphocytic	27	1.6	0.14	1.4	0.13	25	1.5	0.14	1.4	0.13
Chronic lymphocytic	86	7.4	0.37	8.7	0.43	42	3.2	0.22	3.8	0.26
Acute myeloid	62	5.2	0.30	6.0	0.35	47	3.5	0.23	3.9	0.26
Chronic myeloid	28	2.3	0.20	2.6	0.22	19	1.4	0.14	1.6	0.17
Other leukemias	25	2.0	0.19	2.3	0.21	14	1.1	0.13	1.2	0.15
Mesothelioma	15	1.4	0.16	1.5	0.18	5	0.4	0.08	0.4	0.09
Kaposi Sarcoma	4	0.3	0.07	0.4	0.08	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	198	16.0	0.52	18.2	0.60	417	31.3	0.70	36.0	0.80
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.05	301	22.6	0.59	26.9	0.70

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	5,158	441.0	2.81	521.0	3.29	4,797	377.1	2.47	437.6	2.85
Oral Cavity & Pharynx	166	13.8	0.49	16.8	0.59	75	5.8	0.30	6.9	0.36
Lip	23	2.0	0.20	2.4	0.23	9	0.7	0.11	0.8	0.13
Tongue	53	4.2	0.26	5.2	0.32	23	1.7	0.17	2.1	0.20
Major salivary gland	15	1.4	0.16	1.6	0.18	14	1.1	0.13	1.2	0.15
Floor of mouth	6	0.5	0.09	0.6	0.11	3	0.2	0.06	0.3	0.07
Gum & other mouth	14	1.3	0.16	1.6	0.19	16	1.3	0.14	1.4	0.16
Nasopharynx	6	0.4	0.08	0.5	0.10	1	0.1	0.04	0.1	0.04
Oropharynx	7	0.6	0.10	0.7	0.12	2	0.2	0.05	0.2	0.06
Hypopharynx	4	0.3	0.07	0.4	0.09	2	0.2	0.05	0.2	0.06
Digestive System	832	72.3	1.15	85.8	1.35	657	52.0	0.92	61.0	1.07
Esophagus	66	5.7	0.32	6.9	0.38	14	1.0	0.13	1.3	0.16
Stomach	66	5.9	0.33	6.9	0.38	40	3.2	0.23	3.7	0.26
Small intestine	37	3.2	0.24	3.6	0.27	30	2.4	0.20	2.8	0.23
Colon excl. rectum	247	22.0	0.64	25.7	0.74	247	19.7	0.57	22.9	0.66
Rectum & rectosigmoid	126	10.6	0.43	12.6	0.51	88	7.1	0.34	8.3	0.40
Anus, anal canal & anorectum	10	0.9	0.12	1.0	0.15	26	2.0	0.17	2.4	0.21
Liver	91	7.5	0.36	9.2	0.44	32	2.4	0.19	2.9	0.23
Gallbladder	6	0.6	0.11	0.7	0.12	15	1.2	0.14	1.4	0.16
Pancreas	141	12.4	0.48	14.8	0.56	117	9.3	0.39	10.9	0.45
Respiratory System	379	34.0	0.80	40.1	0.93	301	23.6	0.62	28.0	0.72
Larynx	33	2.8	0.22	3.4	0.27	7	0.5	0.09	0.6	0.11
Lung & bronchus	333	30.1	0.75	35.5	0.88	286	22.4	0.60	26.6	0.71
Bones & Joints	21	1.6	0.17	1.8	0.18	14	1.0	0.13	1.1	0.14
Soft Tissue (incl. heart)	48	3.8	0.26	4.4	0.29	40	3.1	0.22	3.3	0.24
Skin (excl. basal & sq.)	639	55.3	1.00	64.6	1.16	449	35.5	0.76	40.3	0.86
Melanomas of the skin	598	51.5	0.96	60.2	1.12	427	33.7	0.74	38.2	0.84
Breast (excl. <i>in situ</i>)	10	0.9	0.13	1.0	0.15	1,453	115.6	1.38	135.9	1.60
Female Genital System	-	-	-	-	-	606	46.9	0.87	55.9	1.02
Cervix uteri	-	-	-	-	-	64	5.2	0.30	5.7	0.32
Uterus Corpus	-	-	-	-	-	343	26.2	0.64	32.0	0.78
Uterus, NOS ¹	-	-	-	-	-	6	0.5	0.09	0.6	0.10
Ovary	-	-	-	-	-	142	11.1	0.42	13.0	0.49
Male Genital System	1,480	121.5	1.45	147.2	1.73	-	-	-	-	-
Prostate	1,362	112.7	1.40	138.3	1.69	-	-	-	-	-
Testis	105	7.7	0.34	7.6	0.34	-	-	-	-	-
Penis	8	0.8	0.12	0.9	0.14	-	-	-	-	-
Urinary System	565	50.3	0.97	59.1	1.13	198	15.5	0.50	18.2	0.58
Bladder (incl. <i>in situ</i>)	330	30.3	0.76	35.5	0.88	72	5.7	0.30	6.7	0.35
Kidney & renal pelvis	225	19.1	0.58	22.5	0.68	120	9.4	0.39	10.9	0.45
Ureter	5	0.4	0.09	0.5	0.11	4	0.3	0.07	0.3	0.08
Eye & Orbit	14	1.2	0.14	1.4	0.17	12	0.9	0.12	1.0	0.13
Brain & Other CNS ¹	104	8.3	0.37	9.3	0.42	78	5.9	0.30	6.4	0.34
Brain	99	8.0	0.37	8.9	0.41	73	5.6	0.30	6.1	0.33
Endocrine System	116	9.4	0.40	10.5	0.44	360	28.3	0.68	30.4	0.73
Thyroid gland	108	8.8	0.39	9.9	0.43	353	27.7	0.67	29.7	0.72
Lymphomas	303	25.9	0.68	29.8	0.78	222	17.2	0.52	19.6	0.60
Hodgkin Lymphoma	35	2.5	0.20	2.7	0.21	32	2.3	0.19	2.4	0.19
Non-Hodgkin Lymphoma	268	23.4	0.65	27.1	0.76	189	14.9	0.49	17.3	0.57
Multiple Myeloma	85	7.6	0.38	9.0	0.44	59	4.6	0.27	5.5	0.32
Leukemias	218	18.7	0.58	21.2	0.66	140	10.6	0.41	11.9	0.46
Acute lymphocytic	26	1.7	0.15	1.4	0.13	22	1.5	0.14	1.4	0.14
Chronic lymphocytic	84	7.5	0.38	8.9	0.44	40	3.1	0.22	3.7	0.26
Acute myeloid	60	5.3	0.31	6.1	0.36	44	3.4	0.23	3.9	0.26
Chronic myeloid	26	2.2	0.20	2.5	0.23	19	1.5	0.15	1.7	0.18
Other leukemias	23	2.0	0.19	2.3	0.22	14	1.1	0.14	1.2	0.15
Mesothelioma	14	1.3	0.16	1.5	0.18	5	0.4	0.08	0.5	0.09
Kaposi Sarcoma	3	0.3	0.07	0.3	0.08	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	191	16.3	0.54	18.5	0.62	399	31.6	0.72	36.3	0.82
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.05	286	22.8	0.61	27.1	0.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	53	415.2	31.85	504.2	36.66	30	314.3	28.30	364.8	32.59
Oral Cavity & Pharynx	1	7.8	3.02	10.6	4.11	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	13	96.0	13.73	120.5	16.78	6	69.3	13.58	78.5	15.14
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	7.3	2.75	10.0	3.81	1	13.7	6.18	15.1	6.78
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	39.3	10.15	46.8	11.94	2	27.2	8.63	30.3	9.56
Rectum & rectosigmoid	2	9.9	3.06	11.7	3.77	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	20.1	6.04	26.5	7.64	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	7.2	2.99	10.1	4.22	-	-	-	-	-
Respiratory System	4	43.9	12.49	52.8	14.25	3	45.4	11.81	54.7	13.86
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	41.1	12.32	48.9	13.97	3	45.4	11.81	54.7	13.86
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	1	8.2	3.77	8.7	4.32
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	8	79.9	14.16	91.2	16.01
Female Genital System	-	-	-	-	-	5	44.0	9.91	54.0	12.05
Cervix uteri	-	-	-	-	-	1	10.3	4.61	11.6	5.15
Uterus Corpus	-	-	-	-	-	2	17.8	6.69	22.5	8.31
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	19	155.5	19.02	195.0	22.30	-	-	-	-	-
Prostate	18	154.7	19.01	194.4	22.29	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	18.9	5.34	23.6	6.54	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	13.9	4.83	17.1	5.76	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	13.5	4.24	14.1	4.56
Thyroid gland	-	-	-	-	-	2	13.5	4.24	14.1	4.56
Lymphomas	3	17.0	6.44	18.6	6.79	2	23.6	8.73	27.4	10.05
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	2	16.1	6.40	17.6	6.76	2	23.6	8.73	27.4	10.05
Multiple Myeloma	3	22.7	7.64	26.5	8.40	-	-	-	-	-
Leukemias	2	10.9	5.26	11.4	5.39	1	10.3	4.89	12.2	5.84
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	13.8	6.97	14.7	7.09	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	10.9	4.51	13.0	5.31	2	16.6	5.71	20.8	7.25
Breast (<i>in situ</i>)	-	-	-	-	-	3	32.1	9.57	38.5	11.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	102	315.5	15.35	370.4	17.76	148	337.8	13.06	389.3	15.05
Oral Cavity & Pharynx	5	13.8	3.05	15.8	3.45	2	5.4	1.67	5.8	1.80
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	1	3.1	1.31	4.0	1.67	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	2	5.1	1.78	5.5	1.89	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	30	95.3	8.48	112.9	9.86	31	80.2	6.77	93.5	7.80
Esophagus	1	3.1	1.28	3.8	1.56	-	-	-	-	-
Stomach	3	9.4	2.55	10.8	2.90	4	11.3	2.57	13.1	2.94
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	6	22.7	4.43	26.9	5.16	9	23.9	3.68	27.8	4.22
Rectum & rectosigmoid	4	11.9	2.69	13.9	3.07	5	12.2	2.59	14.3	3.01
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	7	24.5	4.37	28.9	5.00	4	9.2	2.31	10.5	2.64
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	5	14.8	3.37	17.6	3.93	4	11.3	2.53	13.7	2.99
Respiratory System	10	34.2	5.22	40.3	5.98	10	26.6	3.93	31.8	4.60
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	9	32.3	5.15	37.8	5.87	9	24.4	3.72	29.5	4.41
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	4.8	1.71	5.8	2.03	-	-	-	-	-
Skin (excl. basal & sq.)	5	13.4	3.09	15.3	3.59	2	6.5	1.96	7.4	2.22
Melanomas of the skin	4	10.3	2.51	11.8	2.95	2	4.5	1.55	5.3	1.85
Breast (excl. <i>in situ</i>)	-	-	-	-	-	43	92.7	6.55	107.0	7.60
Female Genital System	-	-	-	-	-	28	58.5	5.05	68.5	5.97
Cervix uteri	-	-	-	-	-	4	7.1	1.65	8.2	1.96
Uterus Corpus	-	-	-	-	-	18	36.8	4.01	42.4	4.67
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	12.1	2.41	14.3	2.84
Male Genital System	21	67.3	7.10	80.9	8.31	-	-	-	-	-
Prostate	19	64.1	7.03	77.7	8.24	-	-	-	-	-
Testis	2	2.6	0.86	2.5	0.81	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	7	25.1	4.59	29.6	5.33	5	11.6	2.55	13.2	2.87
Bladder (incl. <i>in situ</i>)	3	11.3	3.16	13.4	3.70	2	4.9	1.79	5.4	1.92
Kidney & renal pelvis	4	12.7	3.14	14.9	3.61	3	5.6	1.64	6.5	1.90
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	5.3	1.47	5.9	1.70	-	-	-	-	-
Brain	3	5.0	1.43	5.7	1.69	-	-	-	-	-
Endocrine System	3	7.7	2.20	9.2	2.64	11	21.3	2.93	22.6	3.17
Thyroid gland	3	6.7	2.12	8.4	2.60	11	20.5	2.87	21.6	3.09
Lymphomas	5	13.9	3.09	16.2	3.62	5	11.1	2.47	13.3	2.92
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	4	12.1	2.86	14.2	3.35	4	10.9	2.46	13.0	2.91
Multiple Myeloma	2	8.8	2.78	10.5	3.23	2	4.5	1.65	5.2	1.86
Leukemias	4	10.2	2.62	10.9	2.81	4	7.3	1.84	7.7	1.97
Acute lymphocytic	-	-	-	-	-	1	2.3	0.98	2.2	1.00
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	2	4.9	1.94	5.1	2.00	2	3.2	1.20	3.3	1.27
Chronic myeloid	1	2.5	1.07	3.0	1.30	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	11.5	3.05	12.4	3.37	3	8.2	2.37	9.2	2.64
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	5	13.9	3.27	16.1	3.78	12	29.2	4.01	34.8	4.68
Breast (<i>in situ</i>)	-	-	-	-	-	9	19.3	3.04	23.2	3.62

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	19	275.5	30.02	309.9	33.50	19	220.4	23.52	247.6	26.55
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	79.1	15.63	91.2	17.62	6	83.7	15.49	95.1	17.52
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	30.6	9.85	33.2	10.57	2	22.3	7.67	25.0	8.67
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	18.6	6.70	25.7	9.10	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	4	41.3	9.62	46.6	10.92
Female Genital System	-	-	-	-	-	2	19.1	6.66	23.4	8.12
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	65.0	14.69	71.6	16.17	-	-	-	-	-
Prostate	3	55.4	14.03	62.7	15.65	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	36.0	11.01	39.9	12.36	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	17.0	6.53	18.3	7.14	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	21.2	6.51	21.5	6.72
Thyroid gland	-	-	-	-	-	2	21.2	6.51	21.5	6.72
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	1	14.9	5.81	16.2	6.41
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	336	382.9	10.95	450.1	12.63	421	376.5	9.12	436.3	10.59
Oral Cavity & Pharynx	7	7.5	1.50	9.1	1.76	5	3.8	0.85	4.7	1.06
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	2	1.4	0.53	1.7	0.63	1	1.0	0.47	1.3	0.59
Major salivary gland	1	1.8	0.78	2.1	0.90	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	2	1.5	0.52	1.9	0.66
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	83	98.9	5.56	118.1	6.47	66	69.5	4.18	82.2	4.87
Esophagus	4	4.7	1.22	5.6	1.39	-	-	-	-	-
Stomach	11	13.3	2.07	15.4	2.33	9	8.8	1.48	9.9	1.65
Small intestine	3	3.4	1.10	3.9	1.27	1	1.7	0.71	2.0	0.78
Colon excl. rectum	24	29.1	3.10	34.2	3.58	23	21.9	2.23	25.9	2.63
Rectum & rectosigmoid	11	10.4	1.59	12.9	1.92	10	9.9	1.53	11.3	1.73
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	19	21.6	2.54	26.9	3.04	6	6.5	1.30	8.2	1.59
Gallbladder	-	-	-	-	-	2	2.8	0.86	3.4	1.02
Pancreas	9	12.1	2.00	14.4	2.28	8	10.1	1.66	12.3	1.97
Respiratory System	22	34.8	3.65	40.0	4.13	24	27.4	2.71	32.3	3.12
Larynx	2	2.7	0.89	3.4	1.09	-	-	-	-	-
Lung & bronchus	19	31.6	3.52	36.2	3.97	23	26.7	2.68	31.4	3.08
Bones & Joints	3	2.1	0.70	2.3	0.82	2	1.5	0.49	1.7	0.58
Soft Tissue (incl. heart)	3	2.1	0.64	2.3	0.72	4	2.8	0.77	3.0	0.87
Skin (excl. basal & sq.)	-	-	-	-	-	15	11.6	1.52	12.7	1.71
Melanomas of the skin	8	9.2	1.68	11.2	2.00	13	10.1	1.39	11.1	1.58
Breast (excl. <i>in situ</i>)	-	-	-	-	-	125	109.5	4.77	127.9	5.56
Female Genital System	-	-	-	-	-	57	45.5	2.95	53.9	3.53
Cervix uteri	-	-	-	-	-	11	6.7	0.93	7.2	1.04
Uterus Corpus	-	-	-	-	-	28	23.9	2.16	29.2	2.65
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	13	11.1	1.53	13.1	1.82
Male Genital System	89	99.6	5.38	120.7	6.32	-	-	-	-	-
Prostate	74	92.2	5.29	113.1	6.23	-	-	-	-	-
Testis	14	6.4	0.78	6.3	0.80	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	36	45.3	3.89	52.7	4.42	18	17.2	2.03	19.8	2.33
Bladder (incl. <i>in situ</i>)	12	19.0	2.73	21.5	3.03	4	4.9	1.20	5.5	1.32
Kidney & renal pelvis	23	25.9	2.76	30.7	3.19	13	12.0	1.62	13.9	1.89
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	1	1.0	0.52	1.0	0.54	1	0.7	0.31	0.8	0.39
Brain & Other CNS ¹	8	5.8	1.09	6.6	1.28	8	5.8	1.05	6.7	1.24
Brain	8	5.6	1.08	6.4	1.26	7	5.6	1.04	6.4	1.22
Endocrine System	9	7.1	1.25	7.7	1.38	47	30.8	2.15	33.9	2.45
Thyroid gland	8	6.4	1.21	7.0	1.33	46	30.2	2.13	33.1	2.42
Lymphomas	30	30.2	3.04	34.1	3.43	21	20.7	2.31	23.1	2.60
Hodgkin Lymphoma	5	3.0	0.75	3.0	0.78	3	2.4	0.71	2.5	0.80
Non-Hodgkin Lymphoma	24	27.2	2.95	31.1	3.34	17	18.4	2.20	20.6	2.47
Multiple Myeloma	7	9.4	1.85	10.9	2.10	6	7.3	1.42	8.5	1.64
Leukemias	16	12.4	1.84	13.4	2.07	12	9.9	1.51	11.0	1.71
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	3.1	1.11	3.6	1.27	2	3.4	1.04	4.0	1.17
Acute myeloid	4	4.5	1.19	5.1	1.34	3	2.2	0.67	2.4	0.75
Chronic myeloid	3	1.7	0.55	2.0	0.67	2	1.7	0.62	2.0	0.72
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	10	14.1	2.30	16.1	2.65	10	11.8	1.84	13.6	2.11
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	14	12.8	1.96	14.3	2.23	30	26.5	2.40	30.4	2.76
Breast (<i>in situ</i>)	-	-	-	-	-	25	20.9	2.03	24.3	2.36

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

UTAH

II-488 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	4,837	446.2	2.93	527.0	3.43	4,396	377.1	2.59	437.5	2.98
Oral Cavity & Pharynx	159	14.3	0.52	17.5	0.62	70	6.0	0.32	7.0	0.38
Lip	22	2.1	0.21	2.5	0.24	9	0.8	0.11	0.9	0.14
Tongue	51	4.4	0.28	5.5	0.35	22	1.8	0.18	2.2	0.22
Major salivary gland	14	1.4	0.17	1.5	0.19	13	1.1	0.14	1.3	0.16
Floor of mouth	6	0.5	0.10	0.6	0.12	2	0.2	0.06	0.2	0.07
Gum & other mouth	14	1.4	0.17	1.6	0.19	14	1.2	0.14	1.4	0.16
Nasopharynx	5	0.4	0.09	0.5	0.10	-	-	-	-	-
Oropharynx	7	0.6	0.10	0.7	0.13	2	0.2	0.05	0.2	0.06
Hypopharynx	4	0.3	0.07	0.4	0.10	2	0.1	0.05	0.2	0.06
Digestive System	751	70.6	1.18	83.6	1.38	592	50.6	0.94	59.3	1.10
Esophagus	62	5.7	0.33	6.9	0.39	13	1.1	0.14	1.4	0.17
Stomach	56	5.3	0.32	6.2	0.38	31	2.7	0.22	3.1	0.25
Small intestine	34	3.2	0.25	3.7	0.28	29	2.5	0.21	2.9	0.25
Colon excl. rectum	225	21.6	0.66	25.3	0.76	225	19.4	0.59	22.5	0.67
Rectum & rectosigmoid	115	10.7	0.46	12.7	0.53	78	6.9	0.36	8.1	0.41
Anus, anal canal & anorectum	10	0.9	0.13	1.1	0.16	25	2.0	0.19	2.5	0.23
Liver	73	6.4	0.34	7.9	0.42	26	2.1	0.19	2.5	0.22
Gallbladder	6	0.6	0.11	0.7	0.13	13	1.1	0.14	1.2	0.16
Pancreas	132	12.4	0.49	14.8	0.58	109	9.2	0.40	10.8	0.47
Respiratory System	358	34.1	0.82	40.4	0.96	278	23.4	0.64	27.7	0.75
Larynx	31	2.8	0.23	3.4	0.28	7	0.5	0.10	0.7	0.12
Lung & bronchus	315	30.2	0.78	35.6	0.91	264	22.2	0.62	26.3	0.73
Bones & Joints	18	1.6	0.17	1.7	0.18	12	1.0	0.13	1.0	0.14
Soft Tissue (incl. heart)	45	4.0	0.27	4.5	0.31	37	3.1	0.24	3.4	0.26
Skin (excl. basal & sq.)	631	59.1	1.07	68.8	1.24	434	38.0	0.83	43.0	0.93
Melanomas of the skin	591	55.1	1.03	64.2	1.20	414	36.2	0.81	41.0	0.91
Breast (excl. <i>in situ</i>)	9	0.9	0.14	1.1	0.16	1,333	115.5	1.44	135.9	1.68
Female Genital System	-	-	-	-	-	552	46.7	0.91	55.8	1.07
Cervix uteri	-	-	-	-	-	54	4.9	0.30	5.3	0.33
Uterus Corpus	-	-	-	-	-	316	26.3	0.67	32.1	0.81
Uterus, NOS ¹	-	-	-	-	-	6	0.5	0.09	0.5	0.10
Ovary	-	-	-	-	-	130	11.1	0.44	13.0	0.52
Male Genital System	1,395	123.2	1.51	149.3	1.80	-	-	-	-	-
Prostate	1,293	114.3	1.45	140.3	1.76	-	-	-	-	-
Testis	91	7.8	0.37	7.7	0.37	-	-	-	-	-
Penis	7	0.7	0.12	0.8	0.14	-	-	-	-	-
Urinary System	531	50.6	1.00	59.4	1.17	181	15.3	0.52	18.0	0.60
Bladder (incl. <i>in situ</i>)	317	31.0	0.79	36.3	0.92	68	5.7	0.31	6.8	0.37
Kidney & renal pelvis	204	18.7	0.60	22.0	0.70	107	9.1	0.40	10.7	0.46
Ureter	5	0.5	0.10	0.5	0.11	4	0.3	0.07	0.4	0.08
Eye & Orbit	13	1.2	0.15	1.4	0.18	11	0.9	0.13	1.0	0.14
Brain & Other CNS ¹	97	8.6	0.40	9.6	0.45	70	5.9	0.32	6.4	0.35
Brain	92	8.2	0.39	9.2	0.44	66	5.6	0.31	6.1	0.34
Endocrine System	108	9.8	0.43	10.9	0.48	315	27.9	0.72	29.9	0.77
Thyroid gland	101	9.2	0.42	10.3	0.47	309	27.3	0.71	29.3	0.76
Lymphomas	274	25.5	0.70	29.4	0.81	202	17.0	0.54	19.5	0.62
Hodgkin Lymphoma	30	2.5	0.21	2.6	0.22	29	2.4	0.20	2.4	0.21
Non-Hodgkin Lymphoma	244	23.0	0.67	26.7	0.78	173	14.6	0.50	17.0	0.58
Multiple Myeloma	79	7.5	0.38	8.9	0.45	54	4.5	0.28	5.4	0.33
Leukemias	203	19.0	0.61	21.7	0.69	129	10.7	0.43	12.0	0.48
Acute lymphocytic	19	1.5	0.15	1.3	0.14	18	1.4	0.15	1.3	0.14
Chronic lymphocytic	82	7.8	0.39	9.2	0.46	38	3.2	0.23	3.8	0.28
Acute myeloid	56	5.3	0.32	6.1	0.37	42	3.5	0.25	4.0	0.28
Chronic myeloid	24	2.2	0.21	2.5	0.24	17	1.4	0.16	1.7	0.18
Other leukemias	23	2.1	0.20	2.5	0.23	13	1.2	0.14	1.3	0.16
Mesothelioma	13	1.3	0.17	1.5	0.19	5	0.4	0.08	0.5	0.10
Kaposi Sarcoma	3	0.2	0.06	0.3	0.08	-	-	-	-	-
Ill-defined & Unknown	151	14.8	0.55	17.2	0.64	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	177	16.6	0.57	18.9	0.65	369	31.9	0.76	36.7	0.86
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.06	262	22.9	0.65	27.3	0.76

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Utah, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	51	459.2	35.47	555.7	40.81	28	354.3	32.40	408.6	37.14
Oral Cavity & Pharynx	1	8.9	3.43	12.1	4.65	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	13	110.2	15.74	137.8	19.13	6	79.9	15.68	90.4	17.48
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	1	8.4	3.17	11.5	4.37	1	16.2	7.17	17.8	7.85
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	4	45.6	11.72	54.1	13.74	2	32.1	10.05	35.8	11.12
Rectum & rectosigmoid	2	12.0	3.68	14.0	4.47	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	22.4	6.76	29.5	8.52	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	1	8.0	3.33	11.3	4.67	-	-	-	-	-
Respiratory System	3	47.3	14.08	56.2	16.03	3	52.2	13.48	62.9	15.87
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	44.2	13.89	51.9	15.72	3	52.2	13.48	62.9	15.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	1	10.3	4.66	10.9	5.24
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	7	93.8	16.50	106.7	18.60
Female Genital System	-	-	-	-	-	4	47.9	11.33	57.1	13.44
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	2	19.6	7.64	24.0	9.27
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	18	165.8	20.68	208.1	24.27	-	-	-	-	-
Prostate	18	164.8	20.66	207.3	24.26	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	22.0	6.15	27.1	7.44	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	16.1	5.57	19.7	6.59	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	16.7	5.47	17.2	5.80
Thyroid gland	-	-	-	-	-	2	16.7	5.47	17.2	5.80
Lymphomas	3	19.1	7.18	21.1	7.62	2	25.7	9.82	29.1	11.13
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	24.7	8.51	28.5	9.31	-	-	-	-	-
Leukemias	2	12.7	5.82	13.2	5.97	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	15.4	7.56	16.4	7.72	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	12.5	5.16	14.8	6.00	2	20.0	6.79	24.8	8.57
Breast (<i>in situ</i>)	-	-	-	-	-	3	37.8	11.03	45.1	13.00

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	626,212	625,218	625,197	623,644	624,525
White	603,645	602,060	600,481	598,053	597,685
Black	9,531	9,800	10,223	10,538	10,929
American Indian/Alaskan Native (AI/AN)	3,042	3,060	3,089	3,139	3,170
Asian/Pacific Islander (API)	9,994	10,298	11,404	11,914	12,741


All Races Population 2013-2017: 3,124,796
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	10,658	10,890	11,215	11,633	12,113
Non-Hispanic White	594,262	592,510	590,655	587,888	587,099
Non-Hispanic Black	8,824	9,059	9,455	9,737	10,106

Hispanic/Latino Population, Census 2010: 9,208
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

VERMONT CANCER REGISTRY

Initial Operation: 1992
Population-based Data Available: 1992
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.0	106.9	101.2	104.3	105.3
Missing Race	1.7	1.8	0.5	0.4	0.9
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.4	1.8	1.1	1.8	1.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.3	Prostate	96.7
Oral Cavity & Pharynx	97.8	Testis	99.1
Esophagus	96.0	Bladder (incl. <i>in situ</i>)	97.9
Stomach	99.1	Kidney & Renal Pelvis	89.6
Colon & Rectum	94.3	Brain & Other CNS ¹	92.0
Liver	48.3	Thyroid	99.8
Pancreas	85.0	Hodgkin Lymphoma	100.0
Lung & Bronchus	87.6	Non-Hodgkin Lymphoma	97.3
Melanomas of the Skin	99.8	Multiple Myeloma	87.8
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	84.7
Cervix uteri	100.0	Brain & Other CNS ¹ <i>non-malig</i>	44.3
Uterus Corpus & Uterus NOS ¹	99.0	Breast <i>in situ</i>	100.0
Ovary	91.5		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,875	478.1	5.15	564.5	5.93	1,880	440.7	4.78	512.5	5.37
Oral Cavity & Pharynx	75	18.0	0.98	22.0	1.15	26	6.2	0.57	7.4	0.65
Lip	2	0.6	0.19	0.6	0.20	1	0.2	0.10	0.3	0.12
Tongue	23	5.3	0.52	6.5	0.62	6	1.5	0.28	1.7	0.31
Major salivary gland	6	1.8	0.33	2.1	0.37	4	1.0	0.25	1.1	0.27
Floor of mouth	4	1.0	0.23	1.3	0.27	1	0.3	0.12	0.4	0.15
Gum & other mouth	6	1.4	0.27	1.7	0.31	5	1.0	0.21	1.2	0.26
Nasopharynx	3	0.9	0.23	0.9	0.25	2	0.5	0.19	0.5	0.19
Oropharynx	6	1.5	0.28	1.8	0.33	1	0.3	0.13	0.4	0.16
Hypopharynx	5	1.0	0.22	1.3	0.27	1	0.2	0.10	0.3	0.12
Digestive System	332	84.9	2.17	100.8	2.51	268	60.3	1.72	70.6	1.96
Esophagus	40	9.9	0.72	11.9	0.85	10	2.1	0.30	2.6	0.37
Stomach	29	7.5	0.65	8.9	0.75	17	4.0	0.45	4.6	0.51
Small intestine	8	2.2	0.35	2.4	0.39	7	1.6	0.27	1.9	0.32
Colon excl. rectum	89	23.5	1.16	27.6	1.33	107	24.1	1.08	27.9	1.22
Rectum & rectosigmoid	52	13.2	0.86	15.8	1.00	35	8.2	0.66	9.8	0.76
Anus, anal canal & anorectum	8	2.2	0.36	2.6	0.41	13	2.8	0.35	3.5	0.43
Liver	33	7.8	0.63	9.5	0.75	8	2.0	0.33	2.3	0.36
Gallbladder	2	0.4	0.15	0.5	0.18	7	1.6	0.27	1.8	0.31
Pancreas	56	14.1	0.88	16.7	1.02	44	9.8	0.68	11.5	0.78
Respiratory System	294	74.5	2.02	88.1	2.33	264	57.8	1.64	68.5	1.91
Larynx	22	5.3	0.54	6.4	0.62	6	1.5	0.30	1.8	0.33
Lung & bronchus	268	67.9	1.92	80.4	2.23	255	55.6	1.60	66.0	1.87
Bones & Joints	4	1.3	0.30	1.4	0.30	3	0.8	0.23	0.8	0.21
Soft Tissue (incl. heart)	16	4.4	0.52	5.0	0.57	10	3.2	0.47	3.3	0.46
Skin (excl. basal & sq.)	184	49.0	1.69	56.9	1.91	-	-	-	-	-
Melanomas of the skin	175	46.1	1.63	53.6	1.84	126	31.1	1.31	35.8	1.45
Breast (excl. <i>in situ</i>)	5	1.5	0.30	1.6	0.33	553	131.3	2.63	153.4	2.97
Female Genital System	-	-	-	-	-	237	54.0	1.65	64.4	1.90
Cervix uteri	-	-	-	-	-	14	4.3	0.54	4.6	0.56
Uterus Corpus	-	-	-	-	-	153	33.5	1.27	40.8	1.50
Uterus, NOS ¹	-	-	-	-	-	3	0.6	0.18	0.7	0.21
Ovary	-	-	-	-	-	42	10.1	0.73	11.6	0.81
Male Genital System	407	95.2	2.19	116.1	2.61	-	-	-	-	-
Prostate	382	87.1	2.06	107.8	2.50	-	-	-	-	-
Testis	22	7.3	0.72	7.5	0.73	-	-	-	-	-
Penis	2	0.5	0.17	0.6	0.19	-	-	-	-	-
Urinary System	230	60.3	1.85	70.6	2.12	95	21.5	1.02	25.0	1.16
Bladder (incl. <i>in situ</i>)	148	38.9	1.48	45.6	1.71	50	10.8	0.70	12.8	0.82
Kidney & renal pelvis	76	19.9	1.07	23.2	1.21	42	9.9	0.72	11.3	0.80
Ureter	3	0.7	0.19	0.9	0.24	3	0.7	0.18	0.7	0.19
Eye & Orbit	3	1.0	0.24	1.1	0.26	3	0.8	0.20	0.9	0.22
Brain & Other CNS ¹	28	8.1	0.71	9.0	0.76	24	6.5	0.63	7.1	0.66
Brain	27	7.7	0.69	8.6	0.75	23	6.1	0.61	6.7	0.64
Endocrine System	30	8.4	0.72	9.5	0.78	72	21.6	1.21	22.9	1.23
Thyroid gland	28	7.8	0.69	8.9	0.76	69	20.7	1.19	21.9	1.20
Lymphomas	105	28.3	1.28	32.5	1.44	78	18.5	0.99	21.3	1.09
Hodgkin Lymphoma	10	3.1	0.45	3.2	0.46	8	2.5	0.40	2.6	0.40
Non-Hodgkin Lymphoma	96	25.2	1.20	29.3	1.36	70	16.1	0.90	18.7	1.02
Multiple Myeloma	29	7.4	0.65	8.7	0.74	19	3.9	0.42	4.7	0.49
Leukemias	57	15.9	0.98	18.1	1.09	38	9.1	0.70	10.4	0.77
Acute lymphocytic	6	2.0	0.39	1.9	0.35	4	1.2	0.31	1.1	0.27
Chronic lymphocytic	20	5.1	0.53	6.0	0.62	14	3.0	0.37	3.6	0.43
Acute myeloid	18	4.9	0.53	5.8	0.61	14	3.2	0.41	3.7	0.45
Chronic myeloid	7	2.2	0.38	2.5	0.41	4	1.1	0.26	1.3	0.28
Other leukemias	6	1.7	0.31	1.9	0.36	3	0.5	0.15	0.7	0.19
Mesothelioma	7	2.0	0.35	2.2	0.39	1	0.3	0.12	0.3	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	66	17.9	1.02	20.8	1.16	57	12.5	0.77	14.5	0.87
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	33	9.2	0.75	10.3	0.82	68	17.0	0.97	19.4	1.07
Breast (<i>in situ</i>)	-	-	-	-	-	115	27.6	1.22	32.3	1.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	1,827	474.6	5.18	560.3	5.96	1,839	440.5	4.85	512.2	5.44
Oral Cavity & Pharynx	74	18.1	0.99	22.1	1.17	26	6.3	0.58	7.4	0.66
Lip	2	0.6	0.19	0.6	0.21	1	0.2	0.10	0.3	0.12
Tongue	23	5.4	0.53	6.7	0.64	6	1.5	0.28	1.7	0.32
Major salivary gland	6	1.8	0.34	2.0	0.37	4	1.0	0.26	1.2	0.28
Floor of mouth	4	1.0	0.23	1.3	0.28	1	0.3	0.13	0.4	0.15
Gum & other mouth	6	1.4	0.27	1.7	0.32	5	1.0	0.22	1.2	0.26
Nasopharynx	3	0.8	0.23	0.9	0.25	2	0.5	0.19	0.6	0.19
Oropharynx	6	1.4	0.27	1.7	0.32	1	0.4	0.14	0.4	0.16
Hypopharynx	4	1.0	0.22	1.3	0.27	1	0.2	0.10	0.3	0.12
Digestive System	320	83.5	2.18	99.1	2.52	259	59.4	1.72	69.6	1.96
Esophagus	40	9.8	0.73	11.9	0.86	10	2.1	0.31	2.6	0.37
Stomach	28	7.6	0.66	8.9	0.76	16	3.8	0.44	4.5	0.50
Small intestine	8	2.2	0.36	2.4	0.39	7	1.6	0.27	1.9	0.32
Colon excl. rectum	87	23.4	1.17	27.5	1.34	104	23.8	1.09	27.6	1.23
Rectum & rectosigmoid	49	12.9	0.86	15.5	1.00	34	8.3	0.68	9.9	0.77
Anus, anal canal & anorectum	8	2.3	0.37	2.7	0.42	13	2.8	0.36	3.5	0.44
Liver	29	7.1	0.61	8.7	0.73	8	1.9	0.32	2.2	0.36
Gallbladder	2	0.4	0.15	0.5	0.18	7	1.6	0.28	1.8	0.32
Pancreas	54	13.9	0.88	16.5	1.02	42	9.4	0.67	11.0	0.77
Respiratory System	288	73.9	2.03	87.5	2.35	258	57.6	1.65	68.3	1.92
Larynx	21	5.3	0.54	6.4	0.63	6	1.6	0.30	1.8	0.34
Lung & bronchus	262	67.4	1.93	79.8	2.24	250	55.3	1.61	65.7	1.88
Bones & Joints	4	1.4	0.31	1.4	0.31	3	0.8	0.25	0.8	0.23
Soft Tissue (incl. heart)	15	4.3	0.51	4.9	0.57	10	3.3	0.49	3.4	0.48
Skin (excl. basal & sq.)	181	49.0	1.70	56.8	1.92	-	-	-	-	-
Melanomas of the skin	171	46.1	1.65	53.6	1.86	124	31.5	1.35	36.1	1.48
Breast (excl. <i>in situ</i>)	5	1.4	0.30	1.6	0.33	541	131.5	2.67	153.5	3.01
Female Genital System	-	-	-	-	-	235	54.6	1.68	65.1	1.93
Cervix uteri	-	-	-	-	-	14	4.2	0.54	4.5	0.56
Uterus Corpus	-	-	-	-	-	152	34.1	1.29	41.5	1.53
Uterus, NOS ¹	-	-	-	-	-	3	0.6	0.19	0.8	0.22
Ovary	-	-	-	-	-	42	10.2	0.75	11.7	0.83
Male Genital System	396	94.3	2.20	115.0	2.62	-	-	-	-	-
Prostate	372	86.0	2.06	106.4	2.50	-	-	-	-	-
Testis	22	7.6	0.76	7.8	0.76	-	-	-	-	-
Penis	2	0.5	0.17	0.6	0.19	-	-	-	-	-
Urinary System	226	60.2	1.86	70.5	2.14	93	21.5	1.04	24.9	1.17
Bladder (incl. <i>in situ</i>)	146	39.0	1.49	45.8	1.72	49	10.8	0.71	12.7	0.82
Kidney & renal pelvis	74	19.7	1.08	22.9	1.22	41	9.9	0.73	11.4	0.81
Ureter	3	0.7	0.19	0.9	0.24	3	0.7	0.18	0.7	0.20
Eye & Orbit	3	1.0	0.25	1.1	0.27	3	0.8	0.21	0.9	0.23
Brain & Other CNS ¹	28	8.3	0.74	9.2	0.78	23	6.5	0.64	7.1	0.67
Brain	27	7.9	0.71	8.8	0.77	22	6.1	0.62	6.7	0.65
Endocrine System	30	8.4	0.73	9.5	0.80	71	22.0	1.25	23.3	1.26
Thyroid gland	28	7.7	0.69	8.8	0.77	67	21.0	1.22	22.3	1.24
Lymphomas	104	28.4	1.30	32.7	1.46	76	18.4	1.00	21.1	1.11
Hodgkin Lymphoma	10	3.1	0.47	3.3	0.48	8	2.4	0.41	2.5	0.41
Non-Hodgkin Lymphoma	94	25.3	1.21	29.4	1.38	68	16.0	0.91	18.6	1.03
Multiple Myeloma	27	7.3	0.65	8.5	0.74	18	3.9	0.42	4.7	0.50
Leukemias	57	16.1	1.00	18.3	1.11	37	9.1	0.71	10.4	0.78
Acute lymphocytic	6	2.1	0.41	2.0	0.37	4	1.3	0.33	1.2	0.29
Chronic lymphocytic	19	5.1	0.54	6.0	0.62	14	3.0	0.37	3.5	0.43
Acute myeloid	18	4.9	0.54	5.8	0.62	13	3.2	0.42	3.7	0.46
Chronic myeloid	7	2.3	0.39	2.5	0.42	4	1.1	0.26	1.2	0.29
Other leukemias	6	1.7	0.32	1.9	0.36	3	0.5	0.15	0.7	0.19
Mesothelioma	6	1.9	0.34	2.1	0.38	1	0.3	0.12	0.3	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	63	17.1	1.00	19.9	1.14	55	12.1	0.77	14.0	0.86
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	32	9.1	0.76	10.2	0.82	67	17.2	1.00	19.6	1.10
Breast (<i>in situ</i>)	-	-	-	-	-	113	27.9	1.25	32.6	1.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11	370.9	57.59	449.4	66.55	6	247.6	52.68	272.8	57.81
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	83.5	28.22	99.6	32.19	1	80.2	33.60	84.8	35.75
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	54.6	19.82	61.2	22.95
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	161.7	39.73	196.1	45.17	-	-	-	-	-
Prostate	4	161.7	39.73	196.1	45.17	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	38.1	14.73	45.0	17.77	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	353.3	59.87	398.0	67.67	10	216.7	33.63	251.4	38.35
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	94.3	29.06	113.7	34.84	2	42.7	14.14	50.1	16.87
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	4	85.6	20.98	102.9	24.46
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	37.4	14.36	40.6	16.21	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	20.7	9.00	22.3	9.73
Thyroid gland	-	-	-	-	-	1	20.7	9.00	22.3	9.73
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7	180.6	34.32	206.4	38.88	9	258.8	41.80	289.7	45.78
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	1	35.1	15.99	42.3	18.29	2	42.8	14.78	51.8	17.94
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	1	39.6	16.66	46.0	19.04	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	90.3	25.30	95.5	26.57
Female Genital System	-	-	-	-	-	2	49.1	18.84	55.8	20.65
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	1	37.0	16.66	42.2	18.18
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

VERMONT

II-498 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,821	477.1	5.22	563.2	6.00	1,830	442.2	4.88	514.2	5.48
Oral Cavity & Pharynx	74	18.3	1.00	22.3	1.18	26	6.3	0.59	7.5	0.67
Lip	2	0.6	0.19	0.7	0.21	1	0.3	0.10	0.3	0.12
Tongue	23	5.5	0.54	6.7	0.64	6	1.5	0.28	1.7	0.32
Major salivary gland	6	1.8	0.34	2.0	0.37	4	1.1	0.26	1.2	0.28
Floor of mouth	4	1.1	0.24	1.3	0.28	1	0.3	0.13	0.4	0.15
Gum & other mouth	6	1.5	0.27	1.7	0.32	5	1.0	0.22	1.2	0.26
Nasopharynx	3	0.8	0.23	0.9	0.25	2	0.5	0.20	0.6	0.19
Oropharynx	6	1.4	0.28	1.7	0.32	1	0.4	0.14	0.4	0.16
Hypopharynx	4	1.0	0.22	1.3	0.27	1	0.2	0.10	0.3	0.13
Digestive System	319	84.0	2.19	99.7	2.54	258	59.5	1.73	69.7	1.97
Esophagus	39	9.9	0.73	11.9	0.86	10	2.1	0.31	2.6	0.37
Stomach	28	7.6	0.67	8.9	0.76	16	3.9	0.45	4.5	0.51
Small intestine	8	2.2	0.36	2.4	0.39	7	1.6	0.28	1.9	0.32
Colon excl. rectum	87	23.6	1.18	27.7	1.36	104	23.8	1.09	27.5	1.23
Rectum & rectosigmoid	49	13.0	0.87	15.6	1.01	34	8.4	0.68	10.0	0.78
Anus, anal canal & anorectum	8	2.3	0.38	2.6	0.42	13	2.8	0.36	3.6	0.44
Liver	29	7.2	0.62	8.8	0.74	8	1.9	0.33	2.2	0.36
Gallbladder	2	0.4	0.15	0.5	0.18	7	1.5	0.27	1.8	0.31
Pancreas	53	14.0	0.89	16.5	1.03	41	9.4	0.67	10.9	0.77
Respiratory System	286	74.2	2.04	87.8	2.36	258	58.0	1.66	68.8	1.93
Larynx	21	5.4	0.55	6.4	0.63	6	1.6	0.31	1.8	0.34
Lung & bronchus	261	67.6	1.94	80.1	2.25	249	55.7	1.62	66.1	1.89
Bones & Joints	4	1.4	0.31	1.5	0.32	3	0.9	0.25	0.8	0.23
Soft Tissue (incl. heart)	15	4.3	0.52	4.9	0.57	10	3.4	0.50	3.4	0.49
Skin (excl. basal & sq.)	181	49.3	1.72	57.2	1.94	129	32.8	1.38	37.6	1.51
Melanomas of the skin	171	46.4	1.66	54.0	1.88	124	31.7	1.36	36.4	1.49
Breast (excl. <i>in situ</i>)	5	1.4	0.30	1.6	0.33	538	131.7	2.69	154.0	3.03
Female Genital System	-	-	-	-	-	233	54.8	1.69	65.3	1.94
Cervix uteri	-	-	-	-	-	14	4.2	0.55	4.6	0.57
Uterus Corpus	-	-	-	-	-	151	34.1	1.30	41.5	1.53
Uterus, NOS ¹	-	-	-	-	-	3	0.6	0.19	0.8	0.22
Ovary	-	-	-	-	-	41	10.2	0.75	11.7	0.83
Male Genital System	395	94.8	2.22	115.6	2.64	-	-	-	-	-
Prostate	371	86.4	2.07	106.9	2.52	-	-	-	-	-
Testis	21	7.7	0.77	7.9	0.77	-	-	-	-	-
Penis	2	0.5	0.17	0.6	0.19	-	-	-	-	-
Urinary System	225	60.5	1.87	70.8	2.15	93	21.5	1.04	25.0	1.18
Bladder (incl. <i>in situ</i>)	146	39.3	1.50	46.0	1.73	49	10.8	0.71	12.7	0.82
Kidney & renal pelvis	73	19.8	1.08	23.0	1.22	41	10.0	0.74	11.4	0.82
Ureter	3	0.7	0.19	0.9	0.25	3	0.7	0.18	0.8	0.20
Eye & Orbit	3	1.0	0.25	1.1	0.27	3	0.8	0.21	0.9	0.23
Brain & Other CNS ¹	28	8.2	0.74	9.1	0.79	23	6.5	0.65	7.1	0.68
Brain	27	7.9	0.72	8.8	0.77	22	6.2	0.63	6.8	0.66
Endocrine System	30	8.5	0.74	9.6	0.81	70	22.1	1.26	23.4	1.28
Thyroid gland	28	7.8	0.70	8.9	0.78	67	21.1	1.23	22.4	1.25
Lymphomas	103	28.6	1.31	32.9	1.47	76	18.5	1.01	21.3	1.12
Hodgkin Lymphoma	9	3.1	0.48	3.3	0.48	8	2.5	0.41	2.6	0.42
Non-Hodgkin Lymphoma	94	25.4	1.22	29.6	1.39	68	16.1	0.92	18.7	1.03
Multiple Myeloma	27	7.3	0.65	8.6	0.74	18	3.9	0.42	4.7	0.50
Leukemias	56	16.1	1.00	18.3	1.11	37	9.2	0.72	10.5	0.78
Acute lymphocytic	5	2.1	0.42	1.9	0.38	4	1.3	0.34	1.2	0.29
Chronic lymphocytic	19	5.1	0.54	6.1	0.63	14	3.0	0.37	3.6	0.44
Acute myeloid	18	4.9	0.53	5.8	0.62	13	3.3	0.42	3.7	0.46
Chronic myeloid	7	2.3	0.40	2.6	0.43	4	1.1	0.26	1.3	0.29
Other leukemias	6	1.7	0.32	1.9	0.36	3	0.5	0.15	0.7	0.19
Mesothelioma	6	1.9	0.35	2.1	0.38	1	0.3	0.12	0.3	0.13
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	32	9.2	0.77	10.3	0.83	66	17.3	1.01	19.7	1.11
Breast (<i>in situ</i>)	-	-	-	-	-	113	27.9	1.25	32.6	1.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Vermont, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11	394.3	61.86	476.7	71.34	6	272.5	58.73	298.9	63.86
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	90.4	30.64	107.8	34.91	1	87.7	37.18	92.5	39.20
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	2	58.9	21.31	65.8	24.59
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	4	174.5	42.97	211.5	48.82	-	-	-	-	-
Prostate	4	174.5	42.97	211.5	48.82	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	1	40.8	15.79	48.2	19.09	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


VERMONT

II-500 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	8,253,053	8,312,076	8,362,907	8,410,946	8,465,207
White	5,961,034	5,983,248	5,997,082	6,011,061	6,028,786
Black	1,693,204	1,709,960	1,726,706	1,741,222	1,757,890
American Indian/Alaskan Native (AI/AN)	48,211	48,808	49,417	50,276	51,197
Asian/Pacific Islander (API)	550,604	570,060	589,702	608,387	627,334


All Races Population 2013-2017: 41,804,189
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	707,786	727,263	749,092	771,526	795,801
Non-Hispanic White	5,353,460	5,359,462	5,355,130	5,350,377	5,347,626
Non-Hispanic Black	1,632,145	1,646,512	1,660,937	1,673,245	1,687,334

Hispanic/Latino Population, Census 2010: 631,825
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

VIRGINIA CANCER REGISTRY

Initial Operation: 1970
Population-based Data Available: 1990
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.3	97.7	95.6	97.7	95.4
Missing Race	1.0	1.2	1.7	1.5	2.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.1	0.0	0.1	0.4
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.3	2.5	3.2	2.9	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.3	Prostate	96.6
Oral Cavity & Pharynx	97.5	Testis	99.4
Esophagus	94.0	Bladder (incl. <i>in situ</i>)	97.3
Stomach	95.7	Kidney & Renal Pelvis	92.1
Colon & Rectum	95.6	Brain & Other CNS ¹	86.5
Liver	52.2	Thyroid	99.5
Pancreas	83.1	Hodgkin Lymphoma	98.2
Lung & Bronchus	87.6	Non-Hodgkin Lymphoma	96.5
Melanomas of the Skin	99.1	Multiple Myeloma	88.3
Female Breast (excl. <i>in situ</i>)	98.4	Leukemias	87.1
Cervix uteri	96.8	Brain & Other CNS ¹ <i>non-malig</i>	49.9
Uterus Corpus & Uterus NOS ¹	98.5	Breast <i>in situ</i>	100.0
Ovary	90.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	19,629	445.6	1.47	531.0	1.72	20,071	397.4	1.28	463.9	1.47
Oral Cavity & Pharynx	808	17.4	0.28	21.4	0.34	315	6.1	0.16	7.2	0.18
Lip	29	0.7	0.06	0.8	0.07	8	0.2	0.03	0.2	0.03
Tongue	249	5.3	0.15	6.5	0.19	98	1.9	0.09	2.2	0.10
Major salivary gland	68	1.7	0.09	1.9	0.11	51	1.1	0.07	1.2	0.08
Floor of mouth	40	0.8	0.06	1.0	0.07	16	0.3	0.03	0.4	0.04
Gum & other mouth	84	1.9	0.10	2.3	0.11	66	1.3	0.07	1.5	0.08
Nasopharynx	28	0.6	0.05	0.7	0.06	14	0.3	0.04	0.3	0.04
Oropharynx	49	1.0	0.06	1.3	0.08	11	0.2	0.03	0.2	0.03
Hypopharynx	59	1.3	0.08	1.6	0.09	12	0.2	0.03	0.3	0.04
Digestive System	3,883	88.8	0.66	106.1	0.77	3,145	61.1	0.50	72.0	0.58
Esophagus	319	7.1	0.18	8.6	0.22	92	1.7	0.08	2.1	0.10
Stomach	379	8.8	0.21	10.5	0.24	216	4.3	0.13	5.0	0.15
Small intestine	131	3.0	0.12	3.6	0.14	119	2.3	0.10	2.7	0.11
Colon excl. rectum	1,172	27.6	0.37	32.5	0.43	1,200	23.4	0.31	27.4	0.36
Rectum & rectosigmoid	538	12.1	0.24	14.5	0.28	403	8.1	0.18	9.5	0.21
Anus, anal canal & anorectum	57	1.3	0.08	1.5	0.09	110	2.1	0.09	2.6	0.11
Liver	473	9.9	0.21	12.5	0.26	157	3.0	0.11	3.6	0.13
Gallbladder	29	0.7	0.06	0.8	0.07	67	1.3	0.07	1.5	0.08
Pancreas	598	13.9	0.26	16.5	0.31	570	10.8	0.21	12.9	0.24
Respiratory System	3,141	72.3	0.60	86.2	0.70	2,667	50.9	0.45	60.4	0.53
Larynx	248	5.4	0.16	6.6	0.19	62	1.2	0.07	1.4	0.08
Lung & bronchus	2,845	65.9	0.57	78.3	0.67	2,578	49.2	0.44	58.4	0.52
Bones & Joints	43	1.1	0.07	1.1	0.07	30	0.7	0.06	0.7	0.06
Soft Tissue (incl. heart)	156	3.7	0.14	4.2	0.15	131	2.7	0.11	3.0	0.12
Skin (excl. basal & sq.)	1,192	28.2	0.38	33.0	0.43	825	16.9	0.27	19.3	0.30
Melanomas of the skin	1,115	26.3	0.36	30.8	0.42	773	15.8	0.26	18.1	0.29
Breast (excl. <i>in situ</i>)	58	1.3	0.08	1.6	0.09	6,410	127.3	0.73	149.6	0.84
Female Genital System	-	-	-	-	-	2,325	45.4	0.43	53.9	0.50
Cervix uteri	-	-	-	-	-	268	6.0	0.17	6.5	0.18
Uterus Corpus	-	-	-	-	-	1,275	24.0	0.31	29.4	0.37
Uterus, NOS ¹	-	-	-	-	-	50	1.0	0.06	1.2	0.07
Ovary	-	-	-	-	-	511	10.1	0.20	11.8	0.24
Male Genital System	4,944	104.7	0.68	128.9	0.83	-	-	-	-	-
Prostate	4,728	99.4	0.66	123.4	0.81	-	-	-	-	-
Testis	176	4.3	0.15	4.3	0.15	-	-	-	-	-
Penis	33	0.8	0.07	0.9	0.07	-	-	-	-	-
Urinary System	2,236	52.6	0.51	62.0	0.60	968	18.9	0.28	22.1	0.32
Bladder (incl. <i>in situ</i>)	1,237	30.2	0.40	35.5	0.46	404	7.7	0.17	9.1	0.20
Kidney & renal pelvis	948	21.1	0.32	25.1	0.37	535	10.6	0.21	12.4	0.24
Ureter	32	0.8	0.06	0.9	0.07	20	0.4	0.04	0.4	0.04
Eye & Orbit	35	0.8	0.06	0.9	0.07	27	0.5	0.05	0.6	0.05
Brain & Other CNS ¹	294	6.9	0.18	7.6	0.20	255	5.4	0.15	5.9	0.16
Brain	279	6.5	0.18	7.3	0.20	242	5.0	0.15	5.6	0.16
Endocrine System	309	7.1	0.19	8.0	0.20	913	20.4	0.31	22.0	0.33
Thyroid gland	276	6.3	0.17	7.1	0.19	887	19.9	0.31	21.4	0.32
Lymphomas	984	23.2	0.34	26.6	0.39	814	16.4	0.26	18.8	0.30
Hodgkin Lymphoma	104	2.5	0.11	2.6	0.11	96	2.2	0.10	2.3	0.10
Non-Hodgkin Lymphoma	880	20.7	0.32	24.1	0.37	717	14.2	0.24	16.5	0.28
Multiple Myeloma	335	7.8	0.20	9.3	0.23	256	4.9	0.14	5.8	0.16
Leukemias	546	13.3	0.26	15.0	0.29	444	9.1	0.20	10.2	0.22
Acute lymphocytic	55	1.4	0.08	1.3	0.08	50	1.3	0.08	1.1	0.07
Chronic lymphocytic	172	4.1	0.14	4.8	0.17	114	2.2	0.09	2.6	0.11
Acute myeloid	174	4.2	0.15	4.8	0.17	162	3.3	0.12	3.7	0.13
Chronic myeloid	73	1.8	0.10	2.0	0.11	61	1.3	0.07	1.4	0.08
Other leukemias	73	1.8	0.10	2.1	0.11	57	1.1	0.07	1.3	0.08
Mesothelioma	68	1.7	0.10	2.0	0.11	19	0.4	0.04	0.4	0.05
Kaposi Sarcoma	16	0.4	0.04	0.4	0.05	2	0.0	0.01	0.0	0.01
Ill-defined & Unknown	581	14.2	0.27	16.7	0.32	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	289	6.9	0.18	7.7	0.21	577	11.7	0.22	13.4	0.25
Breast (<i>in situ</i>)	9	0.2	0.03	0.2	0.03	1,658	33.1	0.37	39.2	0.43

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	14,767	430.9	1.63	511.0	1.90	15,222	400.0	1.49	466.4	1.70
Oral Cavity & Pharynx	651	18.1	0.33	22.2	0.39	245	6.3	0.18	7.4	0.21
Lip	26	0.8	0.07	0.9	0.08	7	0.2	0.03	0.2	0.04
Tongue	214	5.8	0.18	7.2	0.22	81	2.1	0.11	2.5	0.12
Major salivary gland	54	1.7	0.10	1.9	0.12	40	1.1	0.08	1.2	0.09
Floor of mouth	31	0.8	0.07	1.0	0.08	13	0.3	0.04	0.4	0.05
Gum & other mouth	62	1.8	0.11	2.2	0.13	49	1.2	0.08	1.4	0.09
Nasopharynx	15	0.4	0.05	0.5	0.06	8	0.2	0.04	0.2	0.04
Oropharynx	38	1.0	0.07	1.3	0.09	9	0.2	0.03	0.3	0.04
Hypopharynx	42	1.2	0.08	1.4	0.10	8	0.2	0.03	0.2	0.04
Digestive System	2,842	83.3	0.72	99.3	0.84	2,258	57.6	0.56	67.7	0.64
Esophagus	269	7.6	0.21	9.2	0.25	69	1.7	0.09	2.0	0.11
Stomach	258	7.6	0.22	9.1	0.26	136	3.5	0.14	4.1	0.16
Small intestine	94	2.8	0.13	3.3	0.15	81	2.1	0.11	2.5	0.12
Colon excl. rectum	863	26.0	0.41	30.5	0.47	881	22.6	0.35	26.3	0.40
Rectum & rectosigmoid	406	11.8	0.27	14.1	0.32	297	8.0	0.21	9.3	0.24
Anus, anal canal & anorectum	43	1.2	0.09	1.5	0.10	93	2.4	0.11	2.9	0.14
Liver	313	8.5	0.22	10.7	0.27	102	2.5	0.11	3.0	0.14
Gallbladder	20	0.6	0.06	0.7	0.07	42	1.0	0.07	1.2	0.08
Pancreas	439	12.9	0.28	15.4	0.33	399	9.8	0.22	11.7	0.26
Respiratory System	2,432	71.0	0.66	84.3	0.77	2,113	52.4	0.52	62.3	0.61
Larynx	186	5.2	0.18	6.4	0.21	47	1.2	0.08	1.4	0.09
Lung & bronchus	2,209	64.6	0.63	76.6	0.74	2,047	50.7	0.51	60.3	0.60
Bones & Joints	30	1.0	0.08	1.0	0.08	20	0.6	0.07	0.6	0.07
Soft Tissue (incl. heart)	122	3.8	0.16	4.3	0.18	93	2.6	0.12	2.9	0.14
Skin (excl. basal & sq.)	1,169	35.2	0.47	41.1	0.54	804	22.2	0.36	25.3	0.40
Melanomas of the skin	1,101	33.0	0.46	38.6	0.53	760	21.1	0.35	24.1	0.39
Breast (excl. <i>in situ</i>)	44	1.3	0.09	1.5	0.10	4,798	126.9	0.84	149.2	0.97
Female Genital System	-	-	-	-	-	1,734	45.1	0.50	53.6	0.58
Cervix uteri	-	-	-	-	-	173	5.5	0.19	5.8	0.20
Uterus Corpus	-	-	-	-	-	960	24.1	0.36	29.5	0.43
Uterus, NOS ¹	-	-	-	-	-	30	0.8	0.06	0.9	0.07
Ovary	-	-	-	-	-	399	10.5	0.24	12.3	0.28
Male Genital System	3,234	88.4	0.71	107.8	0.85	-	-	-	-	-
Prostate	3,051	82.2	0.68	101.5	0.83	-	-	-	-	-
Testis	153	5.2	0.19	5.2	0.19	-	-	-	-	-
Penis	26	0.8	0.07	0.9	0.08	-	-	-	-	-
Urinary System	1,780	53.3	0.58	62.8	0.67	718	18.5	0.32	21.5	0.36
Bladder (incl. <i>in situ</i>)	1,047	32.1	0.45	37.6	0.53	322	7.9	0.20	9.4	0.24
Kidney & renal pelvis	692	19.9	0.35	23.6	0.41	374	9.9	0.24	11.5	0.27
Ureter	28	0.9	0.07	1.0	0.09	17	0.4	0.05	0.5	0.05
Eye & Orbit	30	0.9	0.08	1.1	0.09	24	0.6	0.06	0.7	0.07
Brain & Other CNS ¹	240	7.4	0.22	8.2	0.24	205	5.8	0.19	6.4	0.20
Brain	229	7.0	0.21	7.9	0.23	195	5.5	0.18	6.1	0.20
Endocrine System	241	7.4	0.22	8.3	0.24	646	20.3	0.37	21.7	0.38
Thyroid gland	218	6.6	0.21	7.5	0.23	627	19.7	0.36	21.1	0.38
Lymphomas	784	23.8	0.39	27.4	0.44	641	17.1	0.31	19.5	0.35
Hodgkin Lymphoma	74	2.4	0.13	2.5	0.13	70	2.3	0.13	2.3	0.13
Non-Hodgkin Lymphoma	710	21.4	0.37	24.9	0.42	571	14.8	0.28	17.2	0.32
Multiple Myeloma	214	6.3	0.20	7.5	0.23	158	4.0	0.14	4.7	0.17
Leukemias	432	13.5	0.30	15.3	0.33	344	9.4	0.23	10.4	0.25
Acute lymphocytic	40	1.4	0.10	1.3	0.09	35	1.3	0.10	1.1	0.09
Chronic lymphocytic	140	4.2	0.16	5.0	0.19	95	2.4	0.11	2.8	0.13
Acute myeloid	137	4.2	0.16	4.8	0.19	123	3.3	0.14	3.8	0.15
Chronic myeloid	55	1.7	0.11	2.0	0.12	46	1.3	0.09	1.4	0.10
Other leukemias	60	1.9	0.11	2.2	0.13	44	1.2	0.08	1.3	0.09
Mesothelioma	56	1.8	0.11	2.0	0.12	17	0.4	0.05	0.5	0.06
Kaposi Sarcoma	8	0.3	0.04	0.3	0.05	-	-	-	-	-
Ill-defined & Unknown	459	14.2	0.30	16.6	0.35	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	219	6.8	0.21	7.6	0.23	429	11.6	0.26	13.4	0.29
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	1,194	32.2	0.43	38.0	0.50

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,781	509.8	3.96	618.1	4.67	3,649	389.2	2.95	458.2	3.41
Oral Cavity & Pharynx	114	14.4	0.64	17.7	0.76	44	4.5	0.31	5.4	0.36
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	2.8	0.28	3.5	0.34	7	0.7	0.12	0.9	0.15
Major salivary gland	11	1.7	0.24	1.9	0.27	8	0.9	0.15	1.0	0.16
Floor of mouth	7	0.9	0.16	1.1	0.19	2	0.2	0.07	0.3	0.09
Gum & other mouth	12	1.5	0.21	1.8	0.25	9	1.0	0.15	1.1	0.17
Nasopharynx	7	0.9	0.15	1.1	0.18	4	0.4	0.10	0.5	0.11
Oropharynx	10	1.2	0.17	1.5	0.21	1	0.1	0.05	0.2	0.07
Hypopharynx	15	2.1	0.25	2.5	0.29	3	0.3	0.08	0.4	0.10
Digestive System	787	108.6	1.85	131.1	2.18	686	73.7	1.29	87.5	1.50
Esophagus	40	5.4	0.41	6.7	0.49	18	1.9	0.21	2.3	0.24
Stomach	85	12.6	0.65	14.9	0.75	52	5.8	0.37	6.7	0.42
Small intestine	30	4.3	0.37	5.1	0.44	34	3.7	0.29	4.3	0.33
Colon excl. rectum	246	35.1	1.07	41.7	1.24	256	27.4	0.78	32.6	0.92
Rectum & rectosigmoid	96	12.7	0.62	15.3	0.73	77	8.3	0.43	9.6	0.49
Anus, anal canal & anorectum	12	1.5	0.20	1.8	0.24	12	1.3	0.17	1.5	0.20
Liver	111	12.9	0.58	16.9	0.74	38	3.8	0.28	4.7	0.34
Gallbladder	7	1.1	0.20	1.3	0.23	18	2.0	0.22	2.4	0.25
Pancreas	125	18.3	0.78	21.8	0.91	143	15.5	0.59	18.5	0.69
Respiratory System	602	86.6	1.69	104.3	1.98	461	49.4	1.05	59.0	1.23
Larynx	56	7.3	0.46	9.1	0.56	15	1.5	0.18	1.8	0.22
Lung & bronchus	538	78.4	1.62	94.1	1.89	441	47.3	1.03	56.5	1.21
Bones & Joints	9	1.2	0.19	1.2	0.20	5	0.6	0.12	0.6	0.12
Soft Tissue (incl. heart)	23	3.2	0.31	3.6	0.35	28	3.0	0.26	3.4	0.29
Skin (excl. basal & sq.)	17	2.6	0.31	3.0	0.35	15	1.7	0.20	1.9	0.22
Melanomas of the skin	10	1.5	0.24	1.8	0.28	8	0.9	0.15	1.1	0.17
Breast (excl. <i>in situ</i>)	12	1.5	0.21	1.8	0.24	1,246	131.9	1.71	155.3	1.97
Female Genital System	-	-	-	-	-	413	43.2	0.97	51.4	1.13
Cervix uteri	-	-	-	-	-	61	6.8	0.40	7.5	0.43
Uterus Corpus	-	-	-	-	-	223	22.7	0.70	27.7	0.83
Uterus, NOS ¹	-	-	-	-	-	18	2.0	0.21	2.3	0.24
Ovary	-	-	-	-	-	76	8.1	0.43	9.5	0.49
Male Genital System	1,346	169.5	2.19	212.2	2.66	-	-	-	-	-
Prostate	1,329	167.1	2.17	209.7	2.64	-	-	-	-	-
Testis	11	1.4	0.19	1.4	0.18	-	-	-	-	-
Penis	6	0.9	0.18	1.1	0.21	-	-	-	-	-
Urinary System	362	50.4	1.26	60.1	1.47	209	22.3	0.71	26.3	0.82
Bladder (incl. <i>in situ</i>)	135	20.7	0.86	24.7	1.00	68	7.5	0.42	8.8	0.48
Kidney & renal pelvis	222	29.0	0.92	34.7	1.07	136	14.4	0.57	17.0	0.65
Ureter	3	0.4	0.12	0.5	0.14	2	0.2	0.06	0.2	0.07
Eye & Orbit	3	0.4	0.10	0.4	0.10	2	0.2	0.07	0.2	0.08
Brain & Other CNS ¹	36	4.5	0.35	5.0	0.39	34	3.6	0.28	4.0	0.31
Brain	33	4.2	0.34	4.7	0.38	32	3.4	0.27	3.8	0.30
Endocrine System	35	4.3	0.34	4.9	0.38	123	13.2	0.54	14.9	0.60
Thyroid gland	27	3.4	0.30	3.9	0.34	118	12.7	0.53	14.3	0.59
Lymphomas	140	18.8	0.75	21.5	0.85	128	13.8	0.56	15.7	0.63
Hodgkin Lymphoma	23	2.8	0.26	2.8	0.27	20	2.2	0.23	2.3	0.23
Non-Hodgkin Lymphoma	118	16.1	0.70	18.7	0.81	107	11.6	0.51	13.4	0.58
Multiple Myeloma	104	15.2	0.72	18.2	0.84	86	9.3	0.46	11.1	0.54
Leukemias	80	11.5	0.61	13.2	0.70	69	7.7	0.42	8.6	0.47
Acute lymphocytic	7	0.9	0.15	0.8	0.15	7	0.8	0.14	0.7	0.13
Chronic lymphocytic	25	3.8	0.36	4.6	0.43	15	1.6	0.19	2.0	0.23
Acute myeloid	27	3.9	0.36	4.4	0.40	28	3.1	0.27	3.4	0.30
Chronic myeloid	13	1.7	0.22	2.0	0.26	10	1.2	0.16	1.3	0.18
Other leukemias	8	1.3	0.21	1.4	0.24	9	1.1	0.16	1.2	0.18
Mesothelioma	9	1.6	0.25	1.8	0.28	2	0.2	0.07	0.3	0.09
Kaposi Sarcoma	8	1.0	0.16	1.0	0.17	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	97	10.8	0.50	12.5	0.57
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	48	6.7	0.46	7.8	0.53	108	11.6	0.51	13.3	0.58
Breast (<i>in situ</i>)	4	0.5	0.13	0.6	0.14	336	35.0	0.87	41.8	1.02

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	511	241.2	5.11	283.5	5.97	719	245.4	4.25	284.2	4.91
Oral Cavity & Pharynx	19	8.1	0.88	9.7	1.06	9	3.2	0.49	3.8	0.57
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	1.7	0.36	2.1	0.45	4	1.3	0.29	1.6	0.37
Major salivary gland	2	1.0	0.35	1.2	0.41	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	4	2.0	0.51	2.4	0.60	-	-	-	-	-
Nasopharynx	5	2.0	0.40	2.2	0.46	2	0.8	0.26	0.9	0.27
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	157	74.7	2.85	88.1	3.33	121	45.7	1.94	53.5	2.25
Esophagus	4	1.8	0.46	2.3	0.56	2	1.0	0.30	1.1	0.35
Stomach	23	12.0	1.19	13.9	1.38	19	7.0	0.76	8.0	0.86
Small intestine	3	1.3	0.39	1.6	0.45	2	0.8	0.26	1.0	0.33
Colon excl. rectum	34	15.7	1.28	18.4	1.49	37	14.0	1.07	16.4	1.25
Rectum & rectosigmoid	22	9.0	0.90	10.7	1.07	16	5.3	0.62	6.3	0.72
Anus, anal canal & anorectum	-	-	-	-	-	2	0.6	0.22	0.7	0.25
Liver	35	15.7	1.26	18.7	1.49	12	4.6	0.63	5.4	0.72
Gallbladder	1	0.7	0.30	0.8	0.34	6	2.1	0.41	2.5	0.48
Pancreas	23	11.9	1.19	14.0	1.39	16	6.5	0.76	7.6	0.87
Respiratory System	72	36.6	2.08	43.7	2.45	63	24.3	1.42	28.6	1.66
Larynx	3	1.9	0.51	2.3	0.60	-	-	-	-	-
Lung & bronchus	66	33.7	2.00	40.3	2.36	62	23.6	1.41	27.9	1.64
Bones & Joints	3	0.9	0.26	0.9	0.26	2	0.7	0.21	0.6	0.19
Soft Tissue (incl. heart)	5	2.3	0.46	2.6	0.51	5	1.7	0.32	1.9	0.37
Skin (excl. basal & sq.)	4	1.8	0.43	2.2	0.51	4	1.3	0.30	1.5	0.34
Melanomas of the skin	3	1.1	0.35	1.4	0.42	3	1.0	0.27	1.1	0.30
Breast (excl. <i>in situ</i>)	2	0.6	0.21	0.8	0.27	243	78.9	2.33	92.2	2.72
Female Genital System	-	-	-	-	-	89	28.6	1.39	34.0	1.65
Cervix uteri	-	-	-	-	-	14	4.4	0.55	5.0	0.63
Uterus Corpus	-	-	-	-	-	46	14.5	0.97	17.5	1.17
Uterus, NOS ¹	-	-	-	-	-	1	0.4	0.16	0.5	0.19
Ovary	-	-	-	-	-	22	7.1	0.70	8.4	0.83
Male Genital System	104	48.6	2.25	57.9	2.65	-	-	-	-	-
Prostate	97	46.3	2.21	55.6	2.61	-	-	-	-	-
Testis	5	1.6	0.33	1.6	0.33	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	46	23.4	1.65	27.4	1.92	19	7.2	0.77	8.5	0.90
Bladder (incl. <i>in situ</i>)	25	13.7	1.31	16.1	1.53	5	1.8	0.39	2.2	0.46
Kidney & renal pelvis	19	8.3	0.91	9.7	1.06	13	5.0	0.64	5.8	0.74
Ureter	1	0.6	0.24	0.8	0.30	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	3.0	0.54	3.5	0.63	7	2.5	0.44	2.8	0.49
Brain	7	2.9	0.53	3.4	0.62	6	2.4	0.43	2.6	0.49
Endocrine System	22	8.4	0.83	9.4	0.95	101	30.9	1.39	33.7	1.54
Thyroid gland	21	8.0	0.81	8.9	0.93	100	30.4	1.38	33.1	1.52
Lymphomas	32	13.8	1.17	16.0	1.36	22	8.2	0.81	9.5	0.93
Hodgkin Lymphoma	4	1.7	0.39	1.8	0.44	3	0.9	0.25	0.9	0.25
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	9	4.5	0.71	5.3	0.84	5	2.2	0.45	2.6	0.53
Leukemias	16	7.0	0.85	7.5	0.94	14	5.2	0.64	5.6	0.71
Acute lymphocytic	4	1.5	0.37	1.3	0.35	3	1.0	0.26	0.9	0.23
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	7	3.2	0.60	3.7	0.70	7	2.7	0.47	3.1	0.53
Chronic myeloid	2	1.1	0.34	1.2	0.37	2	0.6	0.22	0.7	0.23
Other leukemias	2	0.8	0.26	0.9	0.29	1	0.5	0.22	0.6	0.25
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	12	7.0	0.96	8.0	1.10	12	4.7	0.64	5.4	0.73
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	10	4.0	0.60	4.4	0.67	24	8.1	0.76	9.5	0.89
Breast (<i>in situ</i>)	-	-	-	-	-	92	29.4	1.40	34.5	1.64

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	436	261.8	6.98	306.1	7.96	639	278.3	5.52	321.6	6.37
Oral Cavity & Pharynx	10	6.5	1.12	7.6	1.29	8	3.5	0.61	3.9	0.71
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	2.3	0.67	2.6	0.75	2	1.0	0.34	1.2	0.41
Major salivary gland	1	0.8	0.37	0.8	0.38	2	0.8	0.25	0.9	0.28
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.8	0.41	1.0	0.47	2	0.8	0.30	0.9	0.34
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	101	61.7	3.41	72.5	3.90	108	54.2	2.59	63.2	2.99
Esophagus	5	3.5	0.85	4.2	0.98	2	1.2	0.40	1.5	0.48
Stomach	20	11.5	1.48	13.0	1.65	18	8.3	0.99	9.5	1.13
Small intestine	4	2.6	0.74	3.0	0.83	2	1.0	0.33	1.2	0.39
Colon excl. rectum	27	17.2	1.84	20.1	2.10	36	18.8	1.54	21.9	1.77
Rectum & rectosigmoid	13	6.4	0.98	8.1	1.20	15	5.8	0.74	6.7	0.86
Anus, anal canal & anorectum	1	0.7	0.33	0.8	0.37	3	1.5	0.45	1.8	0.52
Liver	13	8.1	1.21	9.5	1.36	9	5.3	0.85	6.2	0.98
Gallbladder	-	-	-	-	-	3	1.6	0.44	1.9	0.53
Pancreas	11	7.9	1.26	9.2	1.45	13	7.4	1.00	8.7	1.15
Respiratory System	38	30.6	2.59	35.3	2.91	40	22.7	1.74	26.6	1.99
Larynx	3	1.7	0.54	1.9	0.60	-	-	-	-	-
Lung & bronchus	33	28.3	2.53	32.6	2.83	39	22.0	1.71	25.8	1.96
Bones & Joints	2	0.7	0.26	0.8	0.28	2	0.7	0.21	0.8	0.26
Soft Tissue (incl. heart)	6	2.6	0.63	3.0	0.73	5	2.4	0.55	2.7	0.62
Skin (excl. basal & sq.)	-	-	-	-	-	13	5.3	0.74	6.0	0.83
Melanomas of the skin	7	4.1	0.85	4.8	0.97	12	4.6	0.66	5.2	0.76
Breast (excl. <i>in situ</i>)	1	0.3	0.14	0.4	0.17	191	79.6	2.83	92.7	3.29
Female Genital System	-	-	-	-	-	88	36.5	1.93	42.6	2.26
Cervix uteri	-	-	-	-	-	24	8.4	0.84	9.4	0.98
Uterus Corpus	-	-	-	-	-	35	15.0	1.24	17.8	1.46
Uterus, NOS ¹	-	-	-	-	-	2	1.1	0.36	1.3	0.42
Ovary	-	-	-	-	-	22	9.6	1.04	11.3	1.20
Male Genital System	117	72.4	3.59	86.5	4.12	-	-	-	-	-
Prostate	101	67.7	3.52	81.7	4.04	-	-	-	-	-
Testis	14	3.4	0.50	3.5	0.54	-	-	-	-	-
Penis	2	1.3	0.53	1.4	0.58	-	-	-	-	-
Urinary System	42	27.7	2.34	32.3	2.65	25	11.6	1.14	13.8	1.35
Bladder (incl. <i>in situ</i>)	16	12.4	1.67	14.5	1.89	6	3.2	0.65	4.0	0.77
Kidney & renal pelvis	26	14.4	1.57	16.8	1.77	19	7.9	0.90	9.3	1.06
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.6	0.25	0.6	0.27	-	-	-	-	-
Brain & Other CNS ¹	16	5.8	0.85	6.5	0.99	14	5.0	0.72	5.2	0.79
Brain	15	5.5	0.84	6.2	0.97	13	4.9	0.72	5.0	0.78
Endocrine System	16	5.7	0.84	6.5	0.98	71	22.3	1.27	24.2	1.43
Thyroid gland	14	5.2	0.80	5.9	0.94	69	21.5	1.24	23.3	1.39
Lymphomas	35	18.0	1.77	20.5	2.01	32	14.9	1.35	16.9	1.52
Hodgkin Lymphoma	7	2.0	0.45	2.1	0.50	5	1.5	0.34	1.6	0.37
Non-Hodgkin Lymphoma	28	15.9	1.71	18.3	1.94	27	13.4	1.30	15.4	1.47
Multiple Myeloma	10	6.3	1.07	7.4	1.24	8	4.0	0.71	4.9	0.85
Leukemias	19	8.5	1.15	9.6	1.34	20	7.2	0.84	8.1	0.98
Acute lymphocytic	8	1.8	0.31	1.7	0.32	6	1.5	0.27	1.3	0.26
Chronic lymphocytic	2	1.1	0.48	1.4	0.59	3	1.6	0.48	1.9	0.56
Acute myeloid	5	3.3	0.80	3.8	0.91	7	2.4	0.47	2.8	0.54
Chronic myeloid	2	1.0	0.39	1.3	0.49	2	0.6	0.19	0.7	0.25
Other leukemias	3	1.2	0.46	1.4	0.53	2	1.1	0.38	1.4	0.48
Mesothelioma	2	1.2	0.47	1.5	0.56	-	-	-	-	-
Kaposi Sarcoma	2	0.7	0.35	0.7	0.39	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	12	7.7	1.07	9.0	1.23
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	11	4.8	0.86	5.3	0.96	23	9.5	1.00	11.1	1.18
Breast (<i>in situ</i>)	-	-	-	-	-	57	22.3	1.41	26.6	1.69

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

VIRGINIA

II-508 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	14,449	441.8	1.69	523.8	1.97	14,735	409.8	1.57	477.4	1.78
Oral Cavity & Pharynx	643	18.9	0.34	23.2	0.41	238	6.4	0.19	7.6	0.22
Lip	26	0.8	0.07	1.0	0.09	7	0.2	0.03	0.2	0.04
Tongue	211	6.1	0.19	7.5	0.23	80	2.2	0.11	2.6	0.13
Major salivary gland	53	1.7	0.11	2.0	0.12	38	1.1	0.08	1.2	0.09
Floor of mouth	31	0.9	0.07	1.1	0.09	12	0.3	0.04	0.4	0.05
Gum & other mouth	61	1.9	0.11	2.2	0.13	47	1.2	0.08	1.4	0.10
Nasopharynx	14	0.4	0.05	0.5	0.06	7	0.2	0.03	0.2	0.04
Oropharynx	38	1.0	0.08	1.3	0.10	9	0.2	0.03	0.3	0.04
Hypopharynx	42	1.2	0.09	1.5	0.10	8	0.2	0.03	0.3	0.04
Digestive System	2,771	85.1	0.74	101.4	0.87	2,176	58.2	0.58	68.4	0.66
Esophagus	265	7.9	0.22	9.5	0.26	68	1.7	0.10	2.1	0.11
Stomach	243	7.5	0.22	8.9	0.26	123	3.3	0.14	3.8	0.16
Small intestine	92	2.9	0.14	3.4	0.16	78	2.1	0.11	2.5	0.13
Colon excl. rectum	843	26.6	0.42	31.3	0.49	852	23.0	0.36	26.6	0.41
Rectum & rectosigmoid	395	12.2	0.28	14.5	0.33	286	8.1	0.22	9.5	0.25
Anus, anal canal & anorectum	41	1.3	0.09	1.5	0.11	91	2.5	0.12	3.0	0.14
Liver	305	8.7	0.23	10.9	0.28	96	2.5	0.12	3.0	0.14
Gallbladder	20	0.7	0.07	0.8	0.08	39	1.0	0.07	1.2	0.09
Pancreas	432	13.2	0.29	15.8	0.34	390	10.0	0.23	11.9	0.27
Respiratory System	2,401	72.7	0.68	86.5	0.80	2,081	53.8	0.54	64.0	0.63
Larynx	184	5.4	0.18	6.6	0.22	47	1.2	0.08	1.5	0.10
Lung & bronchus	2,182	66.2	0.65	78.5	0.76	2,015	52.1	0.53	61.9	0.62
Bones & Joints	28	1.0	0.09	1.1	0.09	19	0.7	0.07	0.7	0.07
Soft Tissue (incl. heart)	117	3.9	0.17	4.4	0.18	89	2.7	0.13	3.0	0.14
Skin (excl. basal & sq.)	1,161	36.8	0.50	43.0	0.57	791	23.6	0.39	26.8	0.43
Melanomas of the skin	1,094	34.5	0.48	40.4	0.55	749	22.5	0.38	25.4	0.42
Breast (excl. <i>in situ</i>)	43	1.3	0.09	1.6	0.11	4,648	130.4	0.89	153.2	1.02
Female Genital System	-	-	-	-	-	1,671	46.1	0.52	54.8	0.61
Cervix uteri	-	-	-	-	-	159	5.6	0.21	5.9	0.21
Uterus Corpus	-	-	-	-	-	934	24.7	0.37	30.3	0.45
Uterus, NOS ¹	-	-	-	-	-	28	0.7	0.06	0.9	0.08
Ovary	-	-	-	-	-	384	10.6	0.25	12.5	0.29
Male Genital System	3,154	90.1	0.74	109.9	0.88	-	-	-	-	-
Prostate	2,983	83.6	0.70	103.3	0.85	-	-	-	-	-
Testis	141	5.6	0.21	5.6	0.21	-	-	-	-	-
Penis	24	0.8	0.07	0.9	0.08	-	-	-	-	-
Urinary System	1,748	54.6	0.60	64.3	0.70	700	18.9	0.33	22.1	0.38
Bladder (incl. <i>in situ</i>)	1,036	32.9	0.47	38.6	0.54	317	8.2	0.21	9.6	0.24
Kidney & renal pelvis	671	20.4	0.36	24.2	0.42	361	10.2	0.25	11.7	0.28
Ureter	27	0.9	0.08	1.0	0.09	16	0.4	0.05	0.5	0.05
Eye & Orbit	29	0.9	0.08	1.1	0.09	24	0.7	0.07	0.8	0.07
Brain & Other CNS ¹	230	7.7	0.23	8.5	0.25	195	6.0	0.20	6.6	0.21
Brain	218	7.3	0.23	8.1	0.25	186	5.6	0.19	6.2	0.21
Endocrine System	229	7.6	0.23	8.5	0.25	591	20.4	0.39	21.8	0.41
Thyroid gland	207	6.9	0.22	7.7	0.24	573	19.9	0.39	21.2	0.40
Lymphomas	757	24.3	0.41	27.9	0.46	616	17.4	0.33	19.8	0.36
Hodgkin Lymphoma	67	2.5	0.14	2.6	0.14	66	2.4	0.14	2.5	0.14
Non-Hodgkin Lymphoma	689	21.8	0.38	25.4	0.44	550	15.0	0.29	17.4	0.34
Multiple Myeloma	207	6.4	0.20	7.6	0.24	154	4.0	0.15	4.8	0.17
Leukemias	418	13.8	0.31	15.7	0.35	330	9.6	0.25	10.7	0.27
Acute lymphocytic	35	1.4	0.11	1.3	0.10	31	1.3	0.11	1.1	0.09
Chronic lymphocytic	139	4.4	0.17	5.2	0.20	93	2.4	0.12	2.9	0.13
Acute myeloid	133	4.3	0.17	4.9	0.19	118	3.4	0.14	3.8	0.16
Chronic myeloid	53	1.8	0.11	2.0	0.12	45	1.3	0.09	1.5	0.10
Other leukemias	58	2.0	0.12	2.2	0.13	43	1.2	0.09	1.3	0.09
Mesothelioma	55	1.8	0.11	2.1	0.13	17	0.5	0.05	0.5	0.06
Kaposi Sarcoma	6	0.2	0.04	0.2	0.04	-	-	-	-	-
Ill-defined & Unknown	453	14.5	0.31	17.1	0.36	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	213	7.1	0.23	7.9	0.25	410	11.8	0.27	13.6	0.30
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.03	1,152	33.2	0.46	39.1	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Virginia, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,763	515.5	4.00	625.0	4.73	3,623	393.5	2.99	463.0	3.45
Oral Cavity & Pharynx	114	14.6	0.65	17.9	0.77	43	4.6	0.32	5.4	0.37
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	23	2.9	0.29	3.5	0.34	7	0.7	0.12	0.9	0.15
Major salivary gland	11	1.7	0.24	2.0	0.28	8	0.9	0.15	1.1	0.17
Floor of mouth	7	0.9	0.16	1.0	0.19	2	0.2	0.07	0.3	0.09
Gum & other mouth	12	1.5	0.21	1.9	0.25	9	1.0	0.15	1.2	0.17
Nasopharynx	7	0.9	0.16	1.1	0.18	4	0.5	0.11	0.5	0.11
Oropharynx	10	1.2	0.17	1.5	0.22	1	0.1	0.05	0.2	0.07
Hypopharynx	15	2.1	0.25	2.5	0.29	3	0.3	0.08	0.4	0.10
Digestive System	783	109.8	1.87	132.5	2.20	681	74.2	1.30	88.1	1.52
Esophagus	40	5.5	0.42	6.8	0.50	18	1.9	0.21	2.3	0.25
Stomach	85	12.7	0.66	15.0	0.76	51	5.8	0.37	6.7	0.42
Small intestine	30	4.3	0.37	5.1	0.44	34	3.7	0.29	4.4	0.34
Colon excl. rectum	245	35.5	1.08	42.1	1.25	254	27.6	0.79	32.8	0.93
Rectum & rectosigmoid	96	12.9	0.63	15.6	0.74	76	8.3	0.44	9.7	0.50
Anus, anal canal & anorectum	12	1.5	0.20	1.9	0.24	12	1.3	0.17	1.5	0.20
Liver	111	13.1	0.59	17.1	0.75	37	3.8	0.28	4.7	0.34
Gallbladder	7	1.1	0.20	1.3	0.23	18	2.0	0.22	2.4	0.25
Pancreas	125	18.5	0.79	22.0	0.92	143	15.6	0.60	18.7	0.70
Respiratory System	601	87.7	1.71	105.6	2.00	460	49.9	1.06	59.6	1.25
Larynx	56	7.4	0.47	9.2	0.57	14	1.5	0.18	1.9	0.22
Lung & bronchus	538	79.3	1.64	95.2	1.91	440	47.7	1.04	57.1	1.22
Bones & Joints	9	1.2	0.19	1.3	0.21	5	0.6	0.12	0.6	0.12
Soft Tissue (incl. heart)	23	3.2	0.31	3.6	0.35	28	3.1	0.27	3.5	0.30
Skin (excl. basal & sq.)	17	2.6	0.31	3.1	0.36	15	1.7	0.21	2.0	0.23
Melanomas of the skin	10	1.5	0.24	1.8	0.28	8	0.9	0.15	1.1	0.17
Breast (excl. <i>in situ</i>)	11	1.6	0.22	1.8	0.25	1,237	133.5	1.74	157.1	2.00
Female Genital System	-	-	-	-	-	410	43.7	0.99	52.0	1.15
Cervix uteri	-	-	-	-	-	61	6.9	0.41	7.6	0.44
Uterus Corpus	-	-	-	-	-	222	22.9	0.71	28.1	0.84
Uterus, NOS ¹	-	-	-	-	-	18	2.0	0.22	2.3	0.24
Ovary	-	-	-	-	-	76	8.2	0.43	9.7	0.50
Male Genital System	1,340	171.3	2.21	214.5	2.69	-	-	-	-	-
Prostate	1,323	168.8	2.20	211.9	2.67	-	-	-	-	-
Testis	11	1.5	0.20	1.4	0.19	-	-	-	-	-
Penis	6	0.9	0.18	1.1	0.21	-	-	-	-	-
Urinary System	360	51.0	1.28	60.8	1.49	207	22.6	0.72	26.6	0.83
Bladder (incl. <i>in situ</i>)	133	20.8	0.86	24.7	1.00	68	7.6	0.42	8.9	0.49
Kidney & renal pelvis	222	29.4	0.93	35.2	1.08	135	14.6	0.58	17.2	0.66
Ureter	3	0.4	0.12	0.5	0.14	2	0.2	0.06	0.2	0.07
Eye & Orbit	3	0.4	0.11	0.4	0.11	2	0.2	0.07	0.2	0.08
Brain & Other CNS ¹	36	4.6	0.36	5.1	0.40	33	3.6	0.29	4.1	0.32
Brain	33	4.3	0.35	4.8	0.39	31	3.4	0.28	3.8	0.31
Endocrine System	35	4.4	0.35	5.0	0.39	122	13.4	0.56	15.1	0.61
Thyroid gland	27	3.5	0.31	4.0	0.35	117	12.9	0.55	14.5	0.60
Lymphomas	140	19.2	0.77	21.9	0.86	126	14.0	0.57	15.9	0.64
Hodgkin Lymphoma	23	2.9	0.27	2.9	0.28	20	2.3	0.23	2.4	0.24
Non-Hodgkin Lymphoma	117	16.3	0.72	18.9	0.82	106	11.7	0.52	13.5	0.59
Multiple Myeloma	103	15.3	0.72	18.2	0.84	86	9.4	0.47	11.2	0.54
Leukemias	79	11.6	0.62	13.4	0.71	68	7.8	0.43	8.7	0.47
Acute lymphocytic	7	0.9	0.16	0.8	0.15	7	0.8	0.14	0.7	0.13
Chronic lymphocytic	25	3.8	0.37	4.6	0.43	15	1.6	0.19	1.9	0.23
Acute myeloid	27	4.0	0.36	4.5	0.41	27	3.1	0.27	3.5	0.30
Chronic myeloid	13	1.7	0.22	2.0	0.26	10	1.2	0.17	1.3	0.18
Other leukemias	8	1.3	0.21	1.4	0.24	9	1.1	0.16	1.2	0.18
Mesothelioma	9	1.6	0.25	1.8	0.28	2	0.2	0.07	0.3	0.09
Kaposi Sarcoma	8	1.0	0.16	1.1	0.17	-	-	-	-	-
Ill-defined & Unknown	96	14.6	0.71	17.2	0.83	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	48	6.8	0.47	7.9	0.54	107	11.8	0.52	13.5	0.59
Breast (<i>in situ</i>)	4	0.5	0.13	0.6	0.14	333	35.4	0.89	42.2	1.04

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


VIRGINIA

II-510 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	6,962,906	7,052,439	7,163,543	7,294,680	7,425,432
White	5,803,916	5,851,658	5,915,564	5,996,802	6,072,697
Black	343,060	352,198	363,404	376,426	390,097
American Indian/Alaskan Native (AI/AN)	157,902	161,242	164,547	167,994	171,004
Asian/Pacific Islander (API)	658,028	687,341	720,028	753,458	791,634


All Races Population 2013-2017: 35,899,000
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	827,430	852,279	879,230	912,669	943,301
Non-Hispanic White	5,081,130	5,108,244	5,149,408	5,202,111	5,251,657
Non-Hispanic Black	311,639	319,724	329,856	341,451	353,676

Hispanic/Latino Population, Census 2010: 755,790
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WASHINGTON CANCER REGISTRY

Initial Operation: 1992
 Population-based Data Available: 1992
 Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.8	105.5	102.4	103.9	101.9
Missing Race	1.3	1.4	1.2	1.6	2.1
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.6	1.6	1.3	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Prostate	96.3
Oral Cavity & Pharynx	98.1	Testis	99.3
Esophagus	94.7	Bladder (incl. <i>in situ</i>)	97.1
Stomach	95.8	Kidney & Renal Pelvis	87.1
Colon & Rectum	95.9	Brain & Other CNS ¹	84.5
Liver	34.7	Thyroid	99.0
Pancreas	81.7	Hodgkin Lymphoma	98.9
Lung & Bronchus	85.8	Non-Hodgkin Lymphoma	96.8
Melanomas of the Skin	99.6	Multiple Myeloma	88.8
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	92.6
Cervix uteri	97.6	Brain & Other CNS ¹ <i>non-malig</i>	33.9
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	92.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	18,199	473.6	1.62	560.0	1.88	18,227	429.8	1.46	500.7	1.67
Oral Cavity & Pharynx	733	18.2	0.31	22.2	0.37	303	7.0	0.18	8.3	0.21
Lip	55	1.5	0.09	1.8	0.11	31	0.7	0.06	0.9	0.07
Tongue	257	6.2	0.18	7.6	0.22	92	2.1	0.10	2.5	0.12
Major salivary gland	50	1.4	0.09	1.6	0.10	39	1.0	0.07	1.1	0.08
Floor of mouth	29	0.7	0.06	0.9	0.07	15	0.3	0.04	0.4	0.05
Gum & other mouth	81	2.1	0.11	2.5	0.13	63	1.4	0.08	1.7	0.10
Nasopharynx	27	0.7	0.06	0.8	0.07	10	0.3	0.04	0.3	0.04
Oropharynx	33	0.8	0.06	1.0	0.08	7	0.2	0.03	0.2	0.03
Hypopharynx	35	0.8	0.07	1.0	0.08	8	0.2	0.03	0.2	0.04
Digestive System	3,561	92.0	0.71	110.1	0.84	2,750	63.8	0.56	74.9	0.64
Esophagus	320	8.2	0.21	9.9	0.25	83	1.9	0.09	2.3	0.11
Stomach	294	7.8	0.21	9.2	0.24	164	3.9	0.14	4.5	0.16
Small intestine	99	2.6	0.12	3.0	0.14	88	2.0	0.10	2.4	0.12
Colon excl. rectum	961	25.8	0.38	30.3	0.44	985	23.2	0.34	26.9	0.39
Rectum & rectosigmoid	533	13.5	0.27	16.3	0.32	376	8.9	0.21	10.5	0.24
Anus, anal canal & anorectum	59	1.5	0.09	1.8	0.11	112	2.5	0.11	3.1	0.13
Liver	505	11.7	0.24	14.9	0.30	168	3.7	0.13	4.5	0.16
Gallbladder	30	0.8	0.07	1.0	0.08	54	1.2	0.08	1.5	0.09
Pancreas	538	14.2	0.28	16.8	0.33	500	11.4	0.23	13.4	0.27
Respiratory System	2,401	63.9	0.60	75.4	0.70	2,260	51.8	0.50	60.9	0.58
Larynx	156	3.9	0.15	4.8	0.17	40	0.9	0.06	1.1	0.08
Lung & bronchus	2,201	58.8	0.58	69.3	0.67	2,195	50.3	0.49	59.2	0.57
Bones & Joints	43	1.2	0.08	1.2	0.09	29	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	153	4.2	0.16	4.6	0.17	108	2.7	0.12	3.0	0.13
Skin (excl. basal & sq.)	1,318	35.3	0.45	41.2	0.51	994	24.1	0.35	27.6	0.39
Melanomas of the skin	1,180	31.3	0.42	36.5	0.48	917	22.3	0.34	25.5	0.38
Breast (excl. <i>in situ</i>)	39	1.0	0.08	1.2	0.09	5,692	134.3	0.82	158.0	0.94
Female Genital System	-	-	-	-	-	2,133	49.6	0.50	58.8	0.57
Cervix uteri	-	-	-	-	-	248	6.7	0.20	7.1	0.20
Uterus Corpus	-	-	-	-	-	1,148	25.6	0.35	31.4	0.42
Uterus, NOS ¹	-	-	-	-	-	19	0.5	0.05	0.5	0.06
Ovary	-	-	-	-	-	462	10.9	0.23	12.8	0.27
Male Genital System	4,360	106.2	0.74	128.8	0.88	-	-	-	-	-
Prostate	4,087	98.7	0.71	121.1	0.86	-	-	-	-	-
Testis	235	6.5	0.19	6.5	0.19	-	-	-	-	-
Penis	26	0.7	0.07	0.9	0.08	-	-	-	-	-
Urinary System	2,193	59.3	0.58	69.7	0.68	885	20.5	0.32	23.9	0.36
Bladder (incl. <i>in situ</i>)	1,339	37.2	0.47	43.5	0.54	390	8.9	0.21	10.4	0.24
Kidney & renal pelvis	798	20.5	0.33	24.3	0.39	465	10.9	0.23	12.7	0.27
Ureter	25	0.7	0.06	0.8	0.07	18	0.4	0.04	0.5	0.05
Eye & Orbit	46	1.2	0.08	1.4	0.09	35	0.8	0.07	0.9	0.07
Brain & Other CNS ¹	323	8.6	0.22	9.5	0.24	235	6.0	0.18	6.4	0.19
Brain	304	8.1	0.21	8.9	0.23	219	5.5	0.17	6.0	0.18
Endocrine System	299	7.9	0.21	8.8	0.23	774	20.4	0.34	22.1	0.36
Thyroid gland	268	7.0	0.20	7.9	0.22	748	19.7	0.33	21.4	0.35
Lymphomas	996	26.9	0.39	30.9	0.44	758	18.1	0.30	20.8	0.34
Hodgkin Lymphoma	103	2.8	0.13	3.0	0.13	77	2.1	0.11	2.2	0.11
Non-Hodgkin Lymphoma	893	24.1	0.37	27.9	0.42	681	16.0	0.28	18.6	0.32
Multiple Myeloma	300	7.9	0.21	9.4	0.25	209	4.8	0.15	5.7	0.18
Leukemias	693	18.8	0.33	21.4	0.37	466	11.1	0.24	12.5	0.26
Acute lymphocytic	64	1.9	0.11	1.7	0.10	55	1.6	0.10	1.5	0.09
Chronic lymphocytic	290	7.5	0.20	9.0	0.24	171	3.8	0.13	4.6	0.16
Acute myeloid	182	5.0	0.17	5.7	0.19	150	3.6	0.13	4.0	0.15
Chronic myeloid	96	2.7	0.12	3.0	0.14	52	1.2	0.08	1.4	0.09
Other leukemias	61	1.7	0.10	1.9	0.11	39	0.9	0.07	1.0	0.08
Mesothelioma	71	2.1	0.11	2.4	0.13	22	0.5	0.05	0.6	0.06
Kaposi Sarcoma	18	0.5	0.05	0.5	0.06	3	0.1	0.02	0.1	0.02
Ill-defined & Unknown	653	18.5	0.33	21.4	0.38	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	461	12.4	0.27	14.0	0.30	923	22.3	0.34	25.5	0.38
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.03	1,371	32.6	0.41	38.7	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	16,153	474.7	1.72	560.8	2.00	16,099	436.2	1.59	508.1	1.81
Oral Cavity & Pharynx	661	18.7	0.34	22.7	0.40	268	7.1	0.20	8.4	0.23
Lip	51	1.6	0.10	1.9	0.12	28	0.7	0.06	0.9	0.07
Tongue	238	6.6	0.20	8.0	0.24	81	2.2	0.11	2.5	0.13
Major salivary gland	44	1.4	0.10	1.6	0.11	34	1.0	0.08	1.1	0.08
Floor of mouth	26	0.7	0.06	0.9	0.08	14	0.3	0.04	0.4	0.05
Gum & other mouth	72	2.2	0.12	2.6	0.14	58	1.5	0.09	1.8	0.11
Nasopharynx	15	0.4	0.05	0.5	0.06	5	0.1	0.03	0.2	0.03
Oropharynx	30	0.8	0.07	1.0	0.08	7	0.2	0.03	0.2	0.04
Hypopharynx	30	0.8	0.07	1.0	0.08	7	0.2	0.03	0.2	0.04
Digestive System	3,050	88.9	0.74	106.5	0.87	2,371	62.7	0.59	73.7	0.68
Esophagus	297	8.6	0.23	10.3	0.27	76	2.0	0.10	2.3	0.12
Stomach	241	7.2	0.21	8.5	0.25	121	3.2	0.14	3.8	0.16
Small intestine	86	2.5	0.13	3.0	0.15	77	2.0	0.11	2.4	0.12
Colon excl. rectum	836	25.4	0.40	29.8	0.47	865	23.2	0.36	26.9	0.41
Rectum & rectosigmoid	452	13.0	0.28	15.7	0.33	322	8.8	0.23	10.4	0.26
Anus, anal canal & anorectum	53	1.5	0.09	1.8	0.11	105	2.7	0.12	3.3	0.15
Liver	389	10.1	0.24	12.9	0.30	125	3.1	0.13	3.8	0.15
Gallbladder	27	0.8	0.07	1.0	0.08	44	1.2	0.08	1.3	0.09
Pancreas	477	14.1	0.30	16.7	0.35	446	11.5	0.25	13.5	0.29
Respiratory System	2,160	64.2	0.64	75.7	0.74	2,044	53.0	0.54	62.3	0.62
Larynx	137	3.9	0.15	4.7	0.18	36	0.9	0.07	1.1	0.08
Lung & bronchus	1,984	59.1	0.61	69.7	0.71	1,987	51.5	0.53	60.6	0.61
Bones & Joints	36	1.2	0.09	1.2	0.09	26	0.8	0.08	0.9	0.08
Soft Tissue (incl. heart)	130	4.1	0.17	4.6	0.18	93	2.7	0.13	3.0	0.14
Skin (excl. basal & sq.)	1,252	38.0	0.49	44.2	0.57	941	26.7	0.40	30.5	0.45
Melanomas of the skin	1,129	34.0	0.47	39.6	0.53	874	24.9	0.39	28.4	0.43
Breast (excl. <i>in situ</i>)	35	1.0	0.08	1.2	0.09	5,012	136.1	0.89	160.3	1.02
Female Genital System	-	-	-	-	-	1,862	49.9	0.54	59.2	0.62
Cervix uteri	-	-	-	-	-	199	6.5	0.21	6.9	0.22
Uterus Corpus	-	-	-	-	-	1,005	25.7	0.38	31.6	0.45
Uterus, NOS ¹	-	-	-	-	-	17	0.5	0.05	0.6	0.06
Ovary	-	-	-	-	-	408	11.1	0.25	13.0	0.29
Male Genital System	3,808	104.7	0.78	126.7	0.93	-	-	-	-	-
Prostate	3,566	96.5	0.74	118.3	0.90	-	-	-	-	-
Testis	210	7.2	0.22	7.2	0.22	-	-	-	-	-
Penis	22	0.7	0.07	0.8	0.08	-	-	-	-	-
Urinary System	1,993	60.5	0.62	71.0	0.72	796	21.0	0.34	24.5	0.39
Bladder (incl. <i>in situ</i>)	1,239	38.3	0.50	44.8	0.58	357	9.2	0.22	10.8	0.26
Kidney & renal pelvis	704	20.6	0.36	24.3	0.42	412	11.1	0.25	12.9	0.29
Ureter	24	0.7	0.07	0.8	0.08	16	0.4	0.05	0.5	0.05
Eye & Orbit	43	1.3	0.09	1.5	0.10	32	0.9	0.07	1.0	0.08
Brain & Other CNS ¹	293	9.1	0.24	10.0	0.26	213	6.4	0.20	6.9	0.21
Brain	276	8.5	0.24	9.4	0.26	199	5.9	0.20	6.4	0.21
Endocrine System	261	8.0	0.23	8.9	0.25	646	20.4	0.37	22.1	0.39
Thyroid gland	236	7.2	0.22	8.1	0.24	623	19.7	0.37	21.3	0.39
Lymphomas	884	27.1	0.42	31.2	0.47	672	18.5	0.33	21.2	0.37
Hodgkin Lymphoma	88	2.8	0.14	3.0	0.14	66	2.2	0.13	2.3	0.13
Non-Hodgkin Lymphoma	796	24.2	0.40	28.2	0.45	607	16.3	0.30	18.9	0.35
Multiple Myeloma	262	7.8	0.22	9.2	0.26	177	4.6	0.16	5.4	0.18
Leukemias	621	19.1	0.35	21.8	0.40	419	11.5	0.26	13.0	0.29
Acute lymphocytic	52	1.8	0.12	1.7	0.11	45	1.6	0.11	1.5	0.10
Chronic lymphocytic	270	7.8	0.22	9.4	0.26	161	4.1	0.15	4.9	0.17
Acute myeloid	158	4.9	0.18	5.6	0.20	132	3.6	0.15	4.1	0.16
Chronic myeloid	85	2.7	0.13	3.0	0.15	47	1.3	0.09	1.5	0.10
Other leukemias	56	1.8	0.11	2.0	0.12	34	0.9	0.07	1.1	0.08
Mesothelioma	66	2.1	0.12	2.5	0.14	20	0.5	0.05	0.6	0.06
Kaposi Sarcoma	13	0.4	0.05	0.5	0.06	2	0.0	0.02	0.0	0.02
Ill-defined & Unknown	585	18.5	0.35	21.4	0.40	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	393	12.2	0.28	13.8	0.31	776	21.7	0.36	24.8	0.40
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.03	1,147	31.6	0.43	37.5	0.50

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	580	474.3	10.11	567.4	11.69	461	384.1	8.52	452.9	9.87
Oral Cavity & Pharynx	16	11.8	1.46	14.3	1.71	4	3.3	0.73	4.1	0.90
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.9	0.90	4.8	1.03	1	1.2	0.47	1.6	0.60
Major salivary gland	2	1.8	0.62	2.0	0.72	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.3	0.43	1.7	0.55	-	-	-	-	-
Nasopharynx	2	1.0	0.34	1.3	0.44	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	136	109.8	4.81	132.5	5.60	89	77.9	3.94	92.9	4.60
Esophagus	6	4.8	0.94	6.0	1.12	2	2.2	0.66	2.6	0.77
Stomach	12	11.3	1.68	13.3	1.93	8	7.9	1.31	9.2	1.49
Small intestine	5	3.3	0.74	4.1	0.88	6	4.5	0.91	5.6	1.11
Colon excl. rectum	35	28.9	2.49	33.9	2.84	28	24.4	2.20	28.9	2.56
Rectum & rectosigmoid	16	12.6	1.60	15.1	1.89	12	9.5	1.33	11.4	1.55
Anus, anal canal & anorectum	3	1.8	0.58	2.2	0.69	3	3.1	0.80	3.7	0.93
Liver	32	22.1	1.92	28.3	2.35	9	7.2	1.14	8.9	1.36
Gallbladder	-	-	-	-	-	2	2.4	0.75	2.7	0.82
Pancreas	20	18.0	2.06	21.7	2.40	11	10.4	1.47	12.7	1.74
Respiratory System	72	70.2	4.22	82.2	4.77	53	48.3	3.17	57.3	3.65
Larynx	7	5.1	1.01	6.2	1.16	2	2.4	0.74	2.7	0.82
Lung & bronchus	63	63.9	4.06	74.6	4.58	49	45.2	3.06	53.8	3.53
Bones & Joints	2	0.9	0.30	0.8	0.29	-	-	-	-	-
Soft Tissue (incl. heart)	6	3.8	0.78	3.8	0.80	4	2.9	0.66	3.1	0.71
Skin (excl. basal & sq.)	4	3.0	0.75	3.5	0.87	3	2.9	0.78	3.3	0.88
Melanomas of the skin	2	1.3	0.50	1.4	0.57	2	2.1	0.69	2.3	0.78
Breast (excl. <i>in situ</i>)	2	1.4	0.56	1.7	0.61	144	116.4	4.58	137.1	5.30
Female Genital System	-	-	-	-	-	54	43.3	2.81	51.8	3.29
Cervix uteri	-	-	-	-	-	9	6.7	1.05	7.6	1.18
Uterus Corpus	-	-	-	-	-	31	25.4	2.17	31.3	2.59
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	8	6.3	1.09	7.3	1.25
Male Genital System	186	142.7	5.28	176.7	6.24	-	-	-	-	-
Prostate	182	140.2	5.25	174.0	6.21	-	-	-	-	-
Testis	3	1.3	0.36	1.3	0.35	-	-	-	-	-
Penis	1	1.0	0.44	1.2	0.49	-	-	-	-	-
Urinary System	57	52.1	3.57	61.4	4.09	26	22.2	2.07	26.3	2.41
Bladder (incl. <i>in situ</i>)	22	24.6	2.66	28.4	3.01	8	7.6	1.31	8.9	1.50
Kidney & renal pelvis	34	25.4	2.23	30.4	2.58	18	14.3	1.57	17.2	1.86
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.0	0.79	4.5	0.87	5	3.6	0.79	3.8	0.87
Brain	6	3.7	0.76	4.1	0.85	3	2.6	0.70	2.8	0.77
Endocrine System	7	4.0	0.73	4.9	0.89	21	14.0	1.43	15.7	1.61
Thyroid gland	6	3.2	0.67	4.0	0.83	20	13.5	1.41	15.1	1.58
Lymphomas	28	19.9	1.90	22.5	2.14	19	15.3	1.68	17.7	1.92
Hodgkin Lymphoma	6	3.3	0.62	3.5	0.67	4	2.8	0.64	2.8	0.65
Non-Hodgkin Lymphoma	22	16.6	1.80	18.9	2.04	-	-	-	-	-
Multiple Myeloma	18	15.8	1.90	18.9	2.18	13	11.2	1.50	13.4	1.75
Leukemias	19	15.0	1.81	17.0	2.06	12	9.6	1.36	11.0	1.55
Acute lymphocytic	2	1.2	0.36	1.1	0.34	2	1.1	0.41	1.1	0.42
Chronic lymphocytic	7	6.1	1.15	7.2	1.31	3	3.0	0.78	3.6	0.90
Acute myeloid	5	3.7	0.84	4.0	0.90	5	4.1	0.93	4.7	1.07
Chronic myeloid	3	3.0	0.93	3.5	1.10	1	1.0	0.36	1.1	0.41
Other leukemias	1	1.0	0.50	1.3	0.62	-	-	-	-	-
Mesothelioma	1	1.9	0.85	2.3	1.02	-	-	-	-	-
Kaposi Sarcoma	2	1.3	0.39	1.4	0.43	-	-	-	-	-
Ill-defined & Unknown	16	16.2	2.09	18.7	2.40	13	11.9	1.57	13.9	1.82
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	12.0	1.59	14.0	1.83	30	24.6	2.15	28.3	2.46
Breast (<i>in situ</i>)	-	-	-	-	-	45	35.4	2.48	42.8	2.92

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	834	321.8	5.25	378.1	6.11	1,140	306.9	4.16	355.4	4.78
Oral Cavity & Pharynx	31	10.7	0.89	12.9	1.07	20	5.3	0.54	6.0	0.62
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	7	2.6	0.45	3.0	0.53	7	1.9	0.32	2.2	0.38
Major salivary gland	2	0.8	0.27	0.9	0.31	3	0.7	0.19	0.8	0.21
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	4	1.5	0.35	1.8	0.43	3	0.8	0.21	0.9	0.24
Nasopharynx	9	2.8	0.42	3.5	0.52	4	1.1	0.24	1.2	0.27
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	0.8	0.26	1.0	0.32	-	-	-	-	-
Digestive System	262	100.1	2.91	119.0	3.41	212	59.7	1.88	70.1	2.18
Esophagus	10	3.6	0.55	4.4	0.66	3	0.8	0.22	1.0	0.26
Stomach	32	13.0	1.08	15.3	1.25	29	8.1	0.68	9.3	0.79
Small intestine	5	1.9	0.39	2.1	0.44	4	1.1	0.25	1.3	0.29
Colon excl. rectum	60	22.7	1.39	26.9	1.62	61	17.3	1.01	20.3	1.17
Rectum & rectosigmoid	43	15.1	1.07	18.3	1.28	28	7.4	0.63	9.0	0.76
Anus, anal canal & anorectum	2	0.8	0.28	1.0	0.33	2	0.6	0.19	0.7	0.22
Liver	63	23.1	1.36	27.8	1.62	28	8.1	0.70	9.5	0.81
Gallbladder	2	0.8	0.27	1.0	0.32	6	1.6	0.31	1.9	0.36
Pancreas	28	11.7	1.04	13.7	1.20	33	9.6	0.77	11.2	0.88
Respiratory System	119	50.5	2.17	59.4	2.51	115	33.0	1.41	38.9	1.64
Larynx	5	2.3	0.47	2.8	0.55	-	-	-	-	-
Lung & bronchus	111	47.2	2.10	55.6	2.44	112	32.2	1.40	38.0	1.62
Bones & Joints	3	1.0	0.26	1.0	0.26	1	0.4	0.15	0.4	0.15
Soft Tissue (incl. heart)	10	3.4	0.51	3.6	0.56	8	2.0	0.33	2.1	0.35
Skin (excl. basal & sq.)	5	1.8	0.38	2.1	0.44	-	-	-	-	-
Melanomas of the skin	3	1.0	0.28	1.1	0.32	6	1.6	0.30	1.7	0.32
Breast (excl. <i>in situ</i>)	2	0.6	0.22	0.8	0.26	374	97.1	2.28	113.2	2.65
Female Genital System	-	-	-	-	-	156	40.1	1.46	47.1	1.71
Cervix uteri	-	-	-	-	-	28	7.1	0.61	7.7	0.66
Uterus Corpus	-	-	-	-	-	80	20.2	1.03	24.5	1.24
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	34	8.9	0.69	10.3	0.80
Male Genital System	156	59.2	2.22	71.1	2.62	-	-	-	-	-
Prostate	144	55.7	2.17	67.5	2.57	-	-	-	-	-
Testis	9	2.3	0.35	2.2	0.34	-	-	-	-	-
Penis	1	0.5	0.21	0.6	0.23	-	-	-	-	-
Urinary System	77	30.5	1.65	36.5	1.94	37	10.5	0.79	12.2	0.92
Bladder (incl. <i>in situ</i>)	36	16.0	1.25	18.8	1.45	14	4.2	0.52	4.9	0.59
Kidney & renal pelvis	37	13.2	1.01	16.1	1.22	20	5.5	0.56	6.4	0.65
Ureter	-	-	-	-	-	2	0.5	0.18	0.6	0.21
Eye & Orbit	1	0.4	0.15	0.4	0.14	-	-	-	-	-
Brain & Other CNS ¹	16	5.7	0.66	6.0	0.70	11	3.0	0.42	3.2	0.45
Brain	15	5.2	0.63	5.5	0.68	10	2.8	0.41	3.0	0.44
Endocrine System	23	7.3	0.71	7.9	0.78	76	19.3	1.01	20.7	1.09
Thyroid gland	19	6.2	0.65	6.8	0.72	74	18.6	0.98	20.0	1.06
Lymphomas	50	19.0	1.26	21.6	1.44	45	11.9	0.82	13.8	0.94
Hodgkin Lymphoma	5	1.5	0.30	1.5	0.33	4	0.9	0.21	0.9	0.21
Non-Hodgkin Lymphoma	45	17.5	1.22	20.1	1.40	-	-	-	-	-
Multiple Myeloma	13	5.3	0.69	6.2	0.80	14	4.3	0.52	4.8	0.58
Leukemias	29	10.5	0.92	11.6	1.03	23	6.4	0.61	6.8	0.65
Acute lymphocytic	4	1.3	0.28	1.1	0.25	4	1.2	0.26	1.0	0.23
Chronic lymphocytic	5	2.0	0.42	2.2	0.47	2	0.7	0.21	0.8	0.23
Acute myeloid	13	5.0	0.64	5.6	0.73	11	3.1	0.43	3.5	0.47
Chronic myeloid	5	1.7	0.35	1.9	0.40	2	0.7	0.20	0.7	0.21
Other leukemias	2	0.7	0.25	0.7	0.27	3	0.7	0.21	0.8	0.23
Mesothelioma	2	0.8	0.29	1.0	0.33	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	34	14.8	1.19	17.0	1.37	38	11.0	0.82	12.5	0.93
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	31	11.6	0.97	13.2	1.12	82	22.2	1.13	25.9	1.30
Breast (<i>in situ</i>)	-	-	-	-	-	137	35.3	1.37	41.6	1.61

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	240	466.5	15.58	552.8	18.12	276	454.0	13.14	530.2	15.06
Oral Cavity & Pharynx	12	19.5	2.79	24.6	3.40	5	9.1	1.96	10.9	2.29
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	6.7	1.83	8.9	2.30	1	1.6	0.65	2.0	0.80
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	2	2.2	0.78	2.9	1.03	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	1	2.6	1.17	3.3	1.43
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	3.1	1.19	3.6	1.32	-	-	-	-	-
Digestive System	69	134.7	8.57	160.9	10.10	50	86.4	5.88	101.0	6.72
Esophagus	4	8.7	2.18	10.5	2.53	2	2.0	0.73	2.7	0.97
Stomach	5	11.6	2.86	13.1	3.29	4	6.5	1.62	6.9	1.70
Small intestine	1	2.5	0.96	2.8	1.09	-	-	-	-	-
Colon excl. rectum	16	30.9	4.11	36.1	4.78	19	33.1	3.71	38.6	4.22
Rectum & rectosigmoid	9	16.6	2.75	19.2	3.15	7	12.6	2.23	14.3	2.49
Anus, anal canal & anorectum	-	-	-	-	-	1	2.1	0.87	2.7	1.08
Liver	18	30.2	3.78	38.6	4.66	5	8.7	1.84	10.3	2.10
Gallbladder	-	-	-	-	-	1	2.5	1.14	3.1	1.35
Pancreas	8	19.3	3.67	22.8	4.32	7	11.9	2.14	14.4	2.54
Respiratory System	33	67.5	6.00	80.8	6.93	34	63.3	5.18	73.4	5.87
Larynx	4	7.5	1.73	9.3	2.03	-	-	-	-	-
Lung & bronchus	28	59.8	5.74	71.2	6.62	33	60.5	5.06	69.9	5.72
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	3	6.9	2.01	7.7	2.31	2	2.8	0.91	3.1	1.01
Skin (excl. basal & sq.)	-	-	-	-	-	4	7.0	1.61	8.1	1.84
Melanomas of the skin	6	10.1	2.02	11.9	2.33	4	5.6	1.35	6.6	1.57
Breast (excl. <i>in situ</i>)	-	-	-	-	-	82	131.3	6.92	154.5	8.00
Female Genital System	-	-	-	-	-	34	49.5	4.01	57.8	4.60
Cervix uteri	-	-	-	-	-	7	10.9	1.84	11.2	1.88
Uterus Corpus	-	-	-	-	-	17	23.8	2.70	29.4	3.27
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	6	9.4	1.84	10.7	2.05
Male Genital System	42	78.4	6.02	92.8	6.91	-	-	-	-	-
Prostate	37	71.3	5.83	85.5	6.74	-	-	-	-	-
Testis	4	5.9	1.28	5.9	1.29	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	27	54.7	5.49	65.9	6.47	13	22.3	2.95	26.4	3.42
Bladder (incl. <i>in situ</i>)	13	30.2	4.36	36.5	5.15	4	7.9	2.00	9.1	2.28
Kidney & renal pelvis	13	23.0	3.08	27.5	3.59	10	14.1	2.15	17.0	2.52
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	4	7.8	1.90	8.5	2.12	3	3.2	0.89	3.6	1.01
Brain	4	7.1	1.85	7.9	2.07	3	3.0	0.86	3.4	0.99
Endocrine System	2	4.4	1.52	4.9	1.66	13	18.4	2.32	20.0	2.51
Thyroid gland	2	3.8	1.37	4.3	1.53	13	18.2	2.30	19.6	2.49
Lymphomas	13	25.3	3.51	29.1	4.01	13	24.0	3.26	28.0	3.73
Hodgkin Lymphoma	2	2.4	0.81	2.4	0.84	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	5	10.8	2.52	12.3	2.83	5	8.2	1.85	9.9	2.20
Leukemias	10	17.1	2.88	19.4	3.35	5	7.3	1.54	8.2	1.75
Acute lymphocytic	3	2.9	0.82	2.6	0.74	1	1.7	0.67	1.7	0.68
Chronic lymphocytic	2	4.2	1.47	4.8	1.66	-	-	-	-	-
Acute myeloid	4	7.2	2.16	8.9	2.62	2	2.9	0.99	3.2	1.07
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	10	21.6	3.66	25.5	4.25	10	17.6	2.70	21.0	3.15
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	7	12.2	2.57	13.8	2.97	16	25.8	3.07	29.9	3.50
Breast (<i>in situ</i>)	-	-	-	-	-	20	30.7	3.20	36.7	3.73

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, Hispanic/Latino, All Races

<i>SITES</i>	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	654	350.2	7.42	412.2	8.56	792	356.0	6.41	416.5	7.45
Oral Cavity & Pharynx	18	8.7	1.09	10.4	1.26	9	4.3	0.71	5.2	0.85
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	2.6	0.57	3.1	0.66	2	1.5	0.47	1.8	0.54
Major salivary gland	2	0.9	0.37	1.0	0.42	2	0.9	0.33	1.0	0.38
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.0	0.38	1.1	0.41	2	0.9	0.30	1.1	0.36
Nasopharynx	1	0.4	0.15	0.4	0.18	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	164	88.4	3.67	106.1	4.27	126	64.3	2.87	76.5	3.37
Esophagus	9	5.5	0.96	6.7	1.13	2	1.1	0.41	1.2	0.46
Stomach	20	11.8	1.42	13.7	1.61	15	7.0	0.90	8.2	1.07
Small intestine	4	2.1	0.57	2.5	0.66	3	1.3	0.39	1.6	0.47
Colon excl. rectum	38	20.7	1.79	24.2	2.05	40	20.4	1.64	23.8	1.91
Rectum & rectosigmoid	30	14.0	1.36	17.1	1.62	18	7.4	0.83	9.0	1.02
Anus, anal canal & anorectum	-	-	-	-	-	4	1.7	0.42	2.2	0.54
Liver	32	16.4	1.51	20.4	1.78	13	7.3	1.01	8.7	1.17
Gallbladder	2	1.7	0.60	2.0	0.70	5	3.1	0.67	3.6	0.77
Pancreas	17	10.7	1.36	12.9	1.58	17	9.8	1.17	11.6	1.35
Respiratory System	62	41.7	2.72	48.8	3.10	58	33.8	2.16	39.8	2.48
Larynx	6	3.5	0.72	4.2	0.84	2	0.7	0.27	1.0	0.35
Lung & bronchus	52	36.6	2.58	42.7	2.94	53	32.1	2.12	37.7	2.43
Bones & Joints	3	0.7	0.22	0.7	0.22	3	1.1	0.37	1.1	0.39
Soft Tissue (incl. heart)	10	4.1	0.76	4.6	0.86	11	3.4	0.55	3.8	0.64
Skin (excl. basal & sq.)	15	8.4	1.15	10.0	1.33	26	11.3	1.16	13.1	1.32
Melanomas of the skin	13	6.8	1.01	8.0	1.16	22	9.6	1.04	11.1	1.20
Breast (excl. <i>in situ</i>)	2	1.0	0.37	1.2	0.45	235	101.9	3.27	121.1	3.86
Female Genital System	-	-	-	-	-	106	45.5	2.22	53.4	2.60
Cervix uteri	-	-	-	-	-	21	6.5	0.69	6.8	0.76
Uterus Corpus	-	-	-	-	-	51	22.6	1.56	27.8	1.87
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	23	9.9	1.06	11.5	1.23
Male Genital System	152	82.8	3.58	98.3	4.13	-	-	-	-	-
Prostate	122	76.2	3.52	91.6	4.07	-	-	-	-	-
Testis	28	5.8	0.56	5.7	0.58	-	-	-	-	-
Penis	2	0.9	0.33	1.0	0.38	-	-	-	-	-
Urinary System	70	42.4	2.70	49.8	3.10	38	19.7	1.60	23.0	1.82
Bladder (incl. <i>in situ</i>)	28	21.7	2.11	25.0	2.41	10	6.3	0.99	7.2	1.10
Kidney & renal pelvis	41	19.8	1.64	23.7	1.91	27	12.7	1.22	14.9	1.41
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	2	0.6	0.23	0.7	0.25	1	0.5	0.22	0.7	0.28
Brain & Other CNS ¹	18	5.8	0.80	6.3	0.89	16	4.8	0.67	5.2	0.77
Brain	17	5.4	0.78	6.0	0.87	15	4.6	0.67	5.0	0.76
Endocrine System	19	7.2	0.90	8.2	1.04	64	19.8	1.24	21.4	1.39
Thyroid gland	17	6.4	0.84	7.3	0.97	62	19.3	1.22	21.0	1.37
Lymphomas	47	22.7	1.85	26.2	2.12	41	19.1	1.52	22.3	1.77
Hodgkin Lymphoma	10	3.3	0.64	3.8	0.74	7	2.1	0.41	2.2	0.46
Non-Hodgkin Lymphoma	37	19.4	1.74	22.5	1.99	34	17.0	1.47	20.1	1.71
Multiple Myeloma	13	7.5	1.12	9.0	1.30	10	5.3	0.83	6.2	0.95
Leukemias	34	12.1	1.27	13.6	1.47	29	9.5	0.97	10.4	1.09
Acute lymphocytic	12	2.3	0.32	2.2	0.33	-	-	-	-	-
Chronic lymphocytic	5	3.8	0.85	4.5	0.98	3	1.6	0.45	1.7	0.49
Acute myeloid	7	2.8	0.61	3.3	0.72	8	3.4	0.61	3.8	0.70
Chronic myeloid	6	2.0	0.47	2.2	0.54	3	1.3	0.37	1.5	0.42
Other leukemias	3	1.3	0.45	1.4	0.52	-	-	-	-	-
Mesothelioma	2	1.2	0.44	1.5	0.52	-	-	-	-	-
Kaposi Sarcoma	3	1.2	0.43	1.4	0.52	-	-	-	-	-
Ill-defined & Unknown	20	13.6	1.66	15.6	1.90	19	11.2	1.27	13.1	1.45
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	22	8.5	1.03	9.5	1.18	45	20.5	1.55	23.7	1.79
Breast (<i>in situ</i>)	-	-	-	-	-	55	22.1	1.44	26.2	1.71

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

WASHINGTON

II-518 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,566	482.4	1.79	569.7	2.07	15,389	441.8	1.66	514.2	1.88
Oral Cavity & Pharynx	645	19.3	0.35	23.5	0.42	260	7.2	0.21	8.6	0.24
Lip	50	1.6	0.11	1.9	0.12	28	0.8	0.07	0.9	0.08
Tongue	234	6.9	0.21	8.4	0.25	79	2.2	0.12	2.6	0.13
Major salivary gland	43	1.4	0.10	1.6	0.11	32	1.0	0.08	1.1	0.09
Floor of mouth	26	0.7	0.07	0.9	0.08	14	0.4	0.05	0.4	0.05
Gum & other mouth	70	2.2	0.12	2.6	0.14	56	1.5	0.09	1.8	0.11
Nasopharynx	14	0.4	0.05	0.5	0.06	5	0.1	0.03	0.2	0.03
Oropharynx	29	0.8	0.07	1.0	0.09	6	0.2	0.03	0.2	0.04
Hypopharynx	30	0.8	0.07	1.0	0.09	7	0.2	0.03	0.2	0.04
Digestive System	2,903	89.3	0.77	106.8	0.90	2,259	62.8	0.61	73.7	0.70
Esophagus	289	8.7	0.24	10.5	0.28	75	2.0	0.11	2.4	0.13
Stomach	223	7.0	0.22	8.2	0.25	108	3.0	0.13	3.5	0.15
Small intestine	82	2.6	0.13	3.0	0.15	74	2.1	0.11	2.4	0.13
Colon excl. rectum	800	25.7	0.42	30.2	0.48	830	23.4	0.38	27.1	0.43
Rectum & rectosigmoid	426	13.1	0.29	15.8	0.35	307	8.9	0.24	10.5	0.27
Anus, anal canal & anorectum	52	1.6	0.10	1.9	0.12	102	2.8	0.13	3.4	0.15
Liver	361	9.8	0.24	12.6	0.30	113	3.0	0.13	3.6	0.15
Gallbladder	25	0.8	0.08	0.9	0.08	39	1.1	0.08	1.2	0.09
Pancreas	462	14.3	0.31	17.0	0.36	430	11.5	0.26	13.6	0.30
Respiratory System	2,103	65.3	0.66	77.0	0.76	1,992	53.8	0.55	63.3	0.64
Larynx	132	4.0	0.16	4.8	0.19	34	0.9	0.07	1.1	0.09
Lung & bronchus	1,936	60.1	0.63	70.9	0.73	1,939	52.4	0.55	61.6	0.63
Bones & Joints	33	1.2	0.10	1.3	0.10	23	0.8	0.08	0.9	0.08
Soft Tissue (incl. heart)	122	4.2	0.18	4.6	0.19	84	2.6	0.14	2.9	0.14
Skin (excl. basal & sq.)	1,238	39.9	0.52	46.4	0.60	918	28.2	0.44	32.0	0.48
Melanomas of the skin	1,117	35.8	0.50	41.6	0.56	853	26.4	0.42	29.9	0.47
Breast (excl. <i>in situ</i>)	33	1.0	0.08	1.2	0.10	4,799	138.2	0.93	162.6	1.07
Female Genital System	-	-	-	-	-	1,771	50.3	0.56	59.7	0.64
Cervix uteri	-	-	-	-	-	182	6.6	0.23	6.9	0.23
Uterus Corpus	-	-	-	-	-	962	26.0	0.39	31.9	0.47
Uterus, NOS ¹	-	-	-	-	-	16	0.5	0.05	0.5	0.06
Ovary	-	-	-	-	-	388	11.1	0.26	13.1	0.30
Male Genital System	3,672	106.0	0.81	128.3	0.96	-	-	-	-	-
Prostate	3,457	97.6	0.76	119.8	0.92	-	-	-	-	-
Testis	185	7.4	0.25	7.3	0.24	-	-	-	-	-
Penis	21	0.7	0.07	0.8	0.08	-	-	-	-	-
Urinary System	1,931	61.3	0.64	72.0	0.74	761	21.1	0.36	24.6	0.40
Bladder (incl. <i>in situ</i>)	1,215	39.1	0.52	45.7	0.60	349	9.4	0.23	11.0	0.27
Kidney & renal pelvis	666	20.6	0.37	24.4	0.43	387	11.0	0.26	12.8	0.30
Ureter	23	0.7	0.07	0.8	0.08	16	0.4	0.05	0.5	0.05
Eye & Orbit	41	1.3	0.09	1.5	0.11	31	1.0	0.08	1.1	0.09
Brain & Other CNS ¹	276	9.4	0.26	10.3	0.28	199	6.6	0.22	7.0	0.23
Brain	261	8.8	0.25	9.7	0.27	187	6.1	0.21	6.6	0.22
Endocrine System	243	8.2	0.24	9.1	0.26	588	20.6	0.40	22.2	0.42
Thyroid gland	220	7.3	0.23	8.2	0.25	566	19.8	0.39	21.5	0.41
Lymphomas	840	27.4	0.44	31.6	0.49	635	18.5	0.34	21.2	0.38
Hodgkin Lymphoma	79	2.9	0.15	3.1	0.16	60	2.3	0.14	2.4	0.14
Non-Hodgkin Lymphoma	761	24.5	0.41	28.5	0.47	575	16.2	0.32	18.9	0.36
Multiple Myeloma	251	7.8	0.23	9.2	0.26	168	4.6	0.16	5.4	0.19
Leukemias	593	19.4	0.37	22.2	0.41	394	11.4	0.27	12.9	0.30
Acute lymphocytic	43	1.8	0.13	1.7	0.11	34	1.4	0.12	1.3	0.10
Chronic lymphocytic	266	8.1	0.23	9.7	0.27	158	4.2	0.15	5.0	0.18
Acute myeloid	152	5.0	0.19	5.7	0.21	124	3.6	0.15	4.1	0.17
Chronic myeloid	80	2.7	0.14	3.0	0.15	44	1.3	0.09	1.5	0.10
Other leukemias	53	1.8	0.11	2.0	0.13	33	1.0	0.08	1.1	0.09
Mesothelioma	64	2.2	0.12	2.5	0.14	19	0.5	0.06	0.6	0.06
Kaposi Sarcoma	11	0.4	0.06	0.4	0.06	2	0.0	0.02	0.1	0.02
Ill-defined & Unknown	567	18.8	0.36	21.7	0.41	487	13.4	0.28	15.4	0.32
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malignant)	374	12.5	0.30	14.1	0.33	734	22.0	0.38	25.0	0.42
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.03	1,097	32.2	0.46	38.2	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Washington, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	572	485.5	10.36	581.0	11.99	449	394.0	8.82	464.0	10.19
Oral Cavity & Pharynx	16	12.3	1.52	14.9	1.78	4	3.3	0.75	4.1	0.93
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	4.1	0.93	5.0	1.07	1	1.2	0.49	1.6	0.62
Major salivary gland	2	1.9	0.64	2.1	0.74	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	2	1.3	0.44	1.8	0.57	-	-	-	-	-
Nasopharynx	2	1.1	0.36	1.4	0.46	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	135	112.9	4.93	136.3	5.75	87	80.0	4.07	95.5	4.75
Esophagus	6	5.0	0.97	6.2	1.16	2	2.3	0.69	2.7	0.81
Stomach	12	11.6	1.72	13.8	1.99	8	8.1	1.36	9.4	1.54
Small intestine	5	3.4	0.77	4.2	0.91	6	4.8	0.95	5.9	1.16
Colon excl. rectum	34	29.6	2.54	34.8	2.90	27	24.8	2.26	29.3	2.62
Rectum & rectosigmoid	16	12.6	1.61	15.2	1.91	12	10.0	1.39	12.0	1.63
Anus, anal canal & anorectum	3	1.9	0.61	2.3	0.71	3	3.2	0.83	3.8	0.96
Liver	32	22.8	1.99	29.2	2.43	9	7.5	1.19	9.3	1.42
Gallbladder	-	-	-	-	-	2	2.0	0.70	2.4	0.77
Pancreas	20	18.7	2.12	22.4	2.47	11	10.8	1.52	13.2	1.81
Respiratory System	71	72.0	4.32	84.3	4.89	51	49.2	3.25	58.4	3.75
Larynx	7	5.0	0.98	6.1	1.15	2	2.5	0.76	2.9	0.85
Lung & bronchus	63	65.8	4.18	76.8	4.71	48	46.0	3.14	54.8	3.62
Bones & Joints	2	1.0	0.33	0.9	0.31	-	-	-	-	-
Soft Tissue (incl. heart)	6	4.0	0.82	4.0	0.83	4	3.0	0.69	3.2	0.74
Skin (excl. basal & sq.)	4	3.0	0.77	3.5	0.90	3	3.0	0.81	3.4	0.92
Melanomas of the skin	1	1.1	0.50	1.3	0.58	2	2.1	0.72	2.4	0.81
Breast (excl. <i>in situ</i>)	2	1.5	0.58	1.7	0.63	141	120.6	4.78	141.7	5.51
Female Genital System	-	-	-	-	-	52	43.8	2.88	52.4	3.37
Cervix uteri	-	-	-	-	-	9	6.9	1.07	7.8	1.21
Uterus Corpus	-	-	-	-	-	30	25.6	2.21	31.5	2.64
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	7	6.3	1.11	7.3	1.27
Male Genital System	184	146.1	5.43	181.0	6.42	-	-	-	-	-
Prostate	179	143.5	5.39	178.2	6.38	-	-	-	-	-
Testis	3	1.4	0.39	1.4	0.38	-	-	-	-	-
Penis	1	1.1	0.46	1.3	0.51	-	-	-	-	-
Urinary System	56	52.7	3.63	62.1	4.15	26	23.0	2.15	27.1	2.50
Bladder (incl. <i>in situ</i>)	22	24.8	2.69	28.7	3.05	7	7.7	1.34	9.0	1.54
Kidney & renal pelvis	33	25.7	2.28	30.8	2.64	18	14.9	1.65	17.8	1.94
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.3	0.83	4.7	0.91	5	3.8	0.84	4.1	0.91
Brain	6	3.9	0.80	4.4	0.88	3	2.8	0.74	3.0	0.81
Endocrine System	7	4.2	0.77	5.1	0.93	20	14.6	1.51	16.3	1.69
Thyroid gland	6	3.4	0.71	4.2	0.86	19	14.1	1.49	15.7	1.66
Lymphomas	27	20.3	1.96	22.9	2.20	18	15.4	1.73	17.8	1.97
Hodgkin Lymphoma	6	3.1	0.60	3.3	0.64	4	2.7	0.65	2.7	0.65
Non-Hodgkin Lymphoma	22	17.2	1.86	19.6	2.10	14	12.7	1.60	15.1	1.86
Multiple Myeloma	18	16.2	1.95	19.4	2.24	12	11.2	1.54	13.5	1.80
Leukemias	18	15.3	1.86	17.3	2.10	11	9.9	1.41	11.3	1.60
Acute lymphocytic	2	1.2	0.38	1.1	0.36	-	-	-	-	-
Chronic lymphocytic	7	6.1	1.17	7.2	1.33	3	3.1	0.81	3.7	0.94
Acute myeloid	5	3.9	0.88	4.2	0.94	4	4.2	0.96	4.8	1.09
Chronic myeloid	3	3.0	0.95	3.5	1.12	1	1.0	0.40	1.1	0.44
Other leukemias	1	1.0	0.51	1.3	0.63	-	-	-	-	-
Mesothelioma	1	1.9	0.87	2.3	1.04	-	-	-	-	-
Kaposi Sarcoma	2	1.3	0.40	1.4	0.44	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	12	11.6	1.59	13.5	1.82
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	12.5	1.64	14.5	1.88	29	25.7	2.25	29.6	2.56
Breast (<i>in situ</i>)	-	-	-	-	-	43	35.8	2.55	43.3	3.01

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

SEATTLE/PUGET SOUND CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	4,777,091	4,847,386	4,931,036	5,028,590	5,122,251
White	3,799,343	3,833,029	3,875,542	3,929,382	3,975,183
Black	294,787	302,224	311,854	322,821	334,254
American Indian/Alaskan Native (AI/AN)	95,487	97,582	99,369	101,293	103,045
Asian/Pacific Islander (API)	587,474	614,551	644,271	675,094	709,769


All Races Population 2013-2017: 24,706,354
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	439,302	454,599	470,176	489,941	508,490
Non-Hispanic White	3,429,576	3,450,677	3,480,173	3,517,370	3,547,515
Non-Hispanic Black	271,824	278,529	287,413	297,308	307,630

Hispanic/Latino Population, Census 2010: 399,157
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SEATTLE/PUGET SOUND CANCER REGISTRY

Initial Operation: 1974
 Population-based Data Available: 1974
 Coverage Area: County

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.3	113.1	112.6	112.4	112.2
Missing Race	0.4	0.6	0.7	0.9	1.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.3	0.4	0.4	0.4	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Prostate	96.3
Oral Cavity & Pharynx	98.9	Testis	99.7
Esophagus	97.0	Bladder (incl. <i>in situ</i>)	97.0
Stomach	96.9	Kidney & Renal Pelvis	86.1
Colon & Rectum	96.5	Brain & Other CNS ¹	85.4
Liver	36.0	Thyroid	98.9
Pancreas	81.7	Hodgkin Lymphoma	99.4
Lung & Bronchus	86.9	Non-Hodgkin Lymphoma	97.4
Melanomas of the Skin	99.8	Multiple Myeloma	89.0
Female Breast (excl. <i>in situ</i>)	99.2	Leukemias	94.1
Cervix uteri	97.8	Brain & Other CNS ¹ <i>non-malig</i>	30.8
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	93.9		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,175	508.3	2.05	600.7	2.38	13,056	448.9	1.81	522.5	2.06
Oral Cavity & Pharynx	538	19.7	0.39	23.9	0.47	226	7.6	0.23	9.0	0.27
Lip	41	1.7	0.12	2.0	0.14	25	0.8	0.08	1.0	0.09
Tongue	189	6.7	0.23	8.2	0.27	69	2.3	0.13	2.8	0.15
Major salivary gland	36	1.5	0.11	1.7	0.13	29	1.0	0.09	1.1	0.10
Floor of mouth	20	0.7	0.07	0.9	0.09	11	0.4	0.05	0.4	0.06
Gum & other mouth	59	2.3	0.14	2.8	0.16	45	1.5	0.10	1.8	0.12
Nasopharynx	21	0.8	0.08	0.9	0.09	8	0.3	0.05	0.3	0.05
Oropharynx	22	0.8	0.08	1.0	0.09	5	0.2	0.03	0.2	0.04
Hypopharynx	24	0.9	0.08	1.0	0.10	6	0.2	0.04	0.2	0.04
Digestive System	2,527	96.6	0.89	115.4	1.04	1,952	66.0	0.69	77.6	0.79
Esophagus	205	7.9	0.25	9.4	0.30	58	1.9	0.12	2.3	0.14
Stomach	214	8.5	0.27	10.0	0.31	124	4.3	0.18	5.0	0.20
Small intestine	71	2.7	0.15	3.2	0.17	63	2.1	0.12	2.5	0.14
Colon excl. rectum	689	27.3	0.48	32.0	0.55	693	23.7	0.41	27.6	0.47
Rectum & rectosigmoid	385	14.2	0.33	17.1	0.39	266	9.1	0.26	10.8	0.30
Anus, anal canal & anorectum	45	1.7	0.11	2.0	0.14	81	2.6	0.13	3.3	0.16
Liver	374	12.8	0.31	16.2	0.38	119	3.8	0.16	4.6	0.19
Gallbladder	20	0.8	0.08	0.9	0.10	36	1.2	0.09	1.4	0.11
Pancreas	359	14.1	0.35	16.7	0.40	349	11.7	0.29	13.7	0.33
Respiratory System	1,642	65.6	0.75	77.1	0.87	1,570	52.8	0.61	62.1	0.71
Larynx	105	3.9	0.18	4.8	0.21	27	0.8	0.08	1.0	0.09
Lung & bronchus	1,505	60.3	0.72	70.9	0.83	1,524	51.3	0.60	60.3	0.70
Bones & Joints	29	1.2	0.10	1.2	0.10	19	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	98	4.0	0.18	4.4	0.20	73	2.7	0.14	2.9	0.15
Skin (excl. basal & sq.)	1,038	41.2	0.59	48.0	0.68	776	27.3	0.45	31.2	0.50
Melanomas of the skin	914	35.9	0.55	41.8	0.63	709	25.0	0.43	28.5	0.48
Breast (excl. <i>in situ</i>)	25	1.0	0.09	1.2	0.11	4,080	140.3	1.01	164.8	1.16
Female Genital System	-	-	-	-	-	1,527	51.6	0.61	61.1	0.70
Cervix uteri	-	-	-	-	-	181	7.0	0.24	7.4	0.25
Uterus Corpus	-	-	-	-	-	821	26.6	0.43	32.6	0.51
Uterus, NOS ¹	-	-	-	-	-	8	0.3	0.05	0.3	0.05
Ovary	-	-	-	-	-	324	11.2	0.29	13.1	0.33
Male Genital System	3,233	116.6	0.95	141.4	1.13	-	-	-	-	-
Prostate	3,032	108.7	0.91	133.3	1.10	-	-	-	-	-
Testis	173	6.7	0.23	6.8	0.23	-	-	-	-	-
Penis	18	0.8	0.08	0.9	0.09	-	-	-	-	-
Urinary System	1,553	62.4	0.73	73.4	0.85	612	20.8	0.39	24.3	0.44
Bladder (incl. <i>in situ</i>)	943	39.0	0.59	45.7	0.68	270	9.1	0.25	10.6	0.29
Kidney & renal pelvis	568	21.6	0.42	25.7	0.49	321	11.0	0.28	12.8	0.32
Ureter	18	0.7	0.08	0.8	0.09	12	0.4	0.05	0.5	0.06
Eye & Orbit	31	1.2	0.10	1.4	0.11	23	0.8	0.08	0.9	0.09
Brain & Other CNS ¹	228	8.9	0.27	9.8	0.29	168	6.3	0.22	6.8	0.23
Brain	214	8.3	0.26	9.2	0.29	155	5.8	0.21	6.2	0.22
Endocrine System	218	8.3	0.26	9.3	0.28	556	21.0	0.41	22.7	0.43
Thyroid gland	198	7.5	0.24	8.4	0.27	539	20.4	0.40	22.0	0.43
Lymphomas	726	28.9	0.50	33.2	0.56	543	18.9	0.37	21.7	0.42
Hodgkin Lymphoma	74	2.9	0.16	3.1	0.16	54	2.1	0.13	2.2	0.14
Non-Hodgkin Lymphoma	652	26.0	0.47	30.2	0.54	489	16.8	0.35	19.5	0.40
Multiple Myeloma	220	8.7	0.27	10.3	0.32	153	5.2	0.19	6.1	0.22
Leukemias	518	20.7	0.42	23.7	0.47	342	11.9	0.30	13.5	0.33
Acute lymphocytic	44	1.9	0.13	1.8	0.12	34	1.4	0.11	1.3	0.10
Chronic lymphocytic	232	8.9	0.27	10.7	0.32	134	4.4	0.17	5.2	0.20
Acute myeloid	127	5.2	0.21	6.0	0.24	106	3.7	0.17	4.2	0.18
Chronic myeloid	74	3.0	0.16	3.4	0.18	41	1.4	0.10	1.6	0.11
Other leukemias	40	1.6	0.12	1.9	0.13	26	0.9	0.08	1.0	0.09
Mesothelioma	50	2.2	0.14	2.5	0.16	15	0.5	0.06	0.6	0.07
Kaposi Sarcoma	16	0.6	0.07	0.7	0.08	3	0.1	0.03	0.1	0.03
Ill-defined & Unknown	484	20.5	0.43	23.7	0.49	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	377	14.8	0.35	16.9	0.39	772	27.0	0.45	30.9	0.50
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	1,031	35.6	0.51	42.2	0.59

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	11,505	518.4	2.23	612.1	2.59	11,255	462.3	2.02	538.2	2.29
Oral Cavity & Pharynx	479	20.6	0.43	25.1	0.52	195	7.8	0.26	9.3	0.30
Lip	39	1.9	0.14	2.2	0.16	23	0.9	0.09	1.1	0.10
Tongue	174	7.3	0.25	8.9	0.30	60	2.5	0.15	2.9	0.17
Major salivary gland	31	1.5	0.12	1.7	0.14	24	1.0	0.10	1.2	0.11
Floor of mouth	18	0.8	0.08	0.9	0.10	10	0.4	0.06	0.5	0.07
Gum & other mouth	53	2.4	0.15	2.9	0.18	41	1.6	0.12	1.9	0.13
Nasopharynx	10	0.4	0.06	0.5	0.07	3	0.1	0.04	0.2	0.04
Oropharynx	20	0.8	0.09	1.0	0.10	5	0.2	0.04	0.2	0.05
Hypopharynx	20	0.8	0.09	1.0	0.10	4	0.2	0.04	0.2	0.05
Digestive System	2,083	93.1	0.94	111.2	1.10	1,622	64.8	0.74	76.2	0.86
Esophagus	186	8.3	0.28	10.0	0.33	52	2.0	0.13	2.4	0.15
Stomach	169	7.8	0.28	9.2	0.32	86	3.5	0.17	4.1	0.20
Small intestine	60	2.7	0.16	3.2	0.19	52	2.1	0.13	2.5	0.15
Colon excl. rectum	580	27.0	0.52	31.7	0.60	591	23.9	0.45	27.8	0.52
Rectum & rectosigmoid	315	13.7	0.36	16.5	0.42	220	9.1	0.28	10.7	0.33
Anus, anal canal & anorectum	39	1.7	0.12	2.0	0.15	74	2.9	0.15	3.5	0.19
Liver	270	10.7	0.30	13.6	0.37	81	3.1	0.16	3.7	0.19
Gallbladder	17	0.8	0.09	0.9	0.10	27	1.1	0.09	1.2	0.11
Pancreas	307	14.0	0.37	16.6	0.43	303	11.9	0.31	13.9	0.36
Respiratory System	1,434	66.1	0.81	77.7	0.93	1,386	54.7	0.67	64.3	0.78
Larynx	91	4.0	0.19	4.8	0.23	23	0.9	0.08	1.1	0.10
Lung & bronchus	1,316	60.8	0.77	71.4	0.89	1,347	53.2	0.66	62.5	0.77
Bones & Joints	24	1.2	0.11	1.3	0.12	17	0.8	0.10	0.8	0.09
Soft Tissue (incl. heart)	83	4.0	0.20	4.5	0.22	60	2.6	0.16	2.9	0.17
Skin (excl. basal & sq.)	1,007	46.8	0.68	54.4	0.78	744	32.0	0.54	36.4	0.60
Melanomas of the skin	892	41.1	0.63	47.8	0.72	684	29.5	0.52	33.6	0.58
Breast (excl. <i>in situ</i>)	21	1.0	0.10	1.1	0.11	3,504	144.2	1.13	169.6	1.29
Female Genital System	-	-	-	-	-	1,299	52.5	0.67	62.3	0.78
Cervix uteri	-	-	-	-	-	142	6.9	0.27	7.3	0.28
Uterus Corpus	-	-	-	-	-	700	27.0	0.47	33.2	0.57
Uterus, NOS ¹	-	-	-	-	-	7	0.3	0.05	0.3	0.06
Ovary	-	-	-	-	-	277	11.4	0.32	13.3	0.36
Male Genital System	2,801	117.8	1.03	142.6	1.22	-	-	-	-	-
Prostate	2,624	109.0	0.98	133.5	1.18	-	-	-	-	-
Testis	153	7.7	0.28	7.7	0.28	-	-	-	-	-
Penis	15	0.8	0.09	0.9	0.10	-	-	-	-	-
Urinary System	1,395	65.0	0.80	76.4	0.93	537	21.6	0.43	25.1	0.49
Bladder (incl. <i>in situ</i>)	870	41.3	0.65	48.4	0.75	243	9.5	0.28	11.2	0.32
Kidney & renal pelvis	488	21.9	0.46	25.9	0.53	276	11.3	0.32	13.1	0.36
Ureter	16	0.8	0.09	0.9	0.10	11	0.4	0.06	0.5	0.07
Eye & Orbit	29	1.3	0.11	1.5	0.13	21	0.9	0.09	1.0	0.10
Brain & Other CNS ¹	202	9.5	0.31	10.5	0.33	150	6.9	0.26	7.4	0.27
Brain	190	8.9	0.30	9.9	0.32	139	6.4	0.25	6.9	0.26
Endocrine System	184	8.5	0.29	9.5	0.32	443	21.0	0.46	22.7	0.49
Thyroid gland	169	7.7	0.27	8.7	0.30	429	20.3	0.45	22.0	0.48
Lymphomas	631	29.6	0.54	34.1	0.61	474	19.8	0.42	22.6	0.47
Hodgkin Lymphoma	60	2.9	0.18	3.1	0.18	44	2.3	0.16	2.3	0.16
Non-Hodgkin Lymphoma	571	26.6	0.51	31.0	0.59	429	17.5	0.39	20.3	0.44
Multiple Myeloma	189	8.7	0.29	10.2	0.34	125	4.9	0.20	5.8	0.24
Leukemias	458	21.5	0.46	24.6	0.52	304	12.6	0.33	14.3	0.37
Acute lymphocytic	35	1.9	0.15	1.8	0.14	27	1.5	0.13	1.4	0.12
Chronic lymphocytic	216	9.6	0.30	11.5	0.36	127	4.9	0.20	5.8	0.23
Acute myeloid	108	5.2	0.23	5.9	0.26	91	3.8	0.18	4.3	0.20
Chronic myeloid	64	3.1	0.18	3.5	0.20	36	1.5	0.11	1.7	0.13
Other leukemias	36	1.7	0.13	1.9	0.15	22	0.9	0.09	1.1	0.10
Mesothelioma	46	2.3	0.16	2.6	0.18	13	0.5	0.07	0.6	0.08
Kaposi Sarcoma	12	0.6	0.08	0.6	0.08	1	0.1	0.02	0.1	0.02
Ill-defined & Unknown	427	20.9	0.46	24.1	0.53	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	319	14.9	0.38	17.0	0.43	635	26.8	0.49	30.6	0.55
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	834	34.7	0.56	41.2	0.64

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	554	525.4	11.45	628.2	13.24	437	410.2	9.35	484.1	10.82
Oral Cavity & Pharynx	15	11.6	1.50	14.3	1.80	4	3.8	0.83	4.7	1.03
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.7	0.91	4.7	1.08	1	1.3	0.53	1.7	0.68
Major salivary gland	2	2.0	0.71	2.3	0.83	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	0.9	0.36	1.3	0.49	-	-	-	-	-
Nasopharynx	2	1.0	0.36	1.3	0.48	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	132	125.3	5.57	150.2	6.45	85	83.9	4.34	100.1	5.06
Esophagus	6	5.5	1.13	6.7	1.31	2	2.3	0.73	2.7	0.85
Stomach	12	13.4	2.00	15.7	2.30	8	9.1	1.48	10.6	1.70
Small intestine	5	3.7	0.87	4.7	1.06	5	4.9	1.02	6.1	1.23
Colon excl. rectum	34	34.3	2.95	39.9	3.33	27	26.7	2.46	31.5	2.86
Rectum & rectosigmoid	16	14.4	1.86	17.0	2.17	10	9.4	1.39	11.3	1.64
Anus, anal canal & anorectum	3	2.4	0.70	2.9	0.82	3	3.0	0.78	3.6	0.94
Liver	30	23.6	2.12	30.2	2.60	9	7.7	1.26	9.4	1.49
Gallbladder	-	-	-	-	-	3	3.0	0.90	3.4	0.98
Pancreas	19	19.9	2.31	23.8	2.69	12	11.7	1.64	14.2	1.94
Respiratory System	68	75.3	4.66	88.5	5.28	50	52.6	3.54	62.0	4.04
Larynx	6	5.4	1.08	6.7	1.27	2	2.5	0.81	2.9	0.91
Lung & bronchus	59	68.6	4.49	80.2	5.07	47	49.2	3.42	58.0	3.91
Bones & Joints	1	0.8	0.29	0.6	0.24	-	-	-	-	-
Soft Tissue (incl. heart)	5	3.4	0.81	3.5	0.84	4	3.0	0.76	3.3	0.83
Skin (excl. basal & sq.)	4	2.9	0.82	3.4	0.95	2	1.9	0.60	2.1	0.67
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	2	1.8	0.65	2.1	0.72	138	124.9	5.02	147.5	5.82
Female Genital System	-	-	-	-	-	50	45.0	3.04	53.9	3.55
Cervix uteri	-	-	-	-	-	8	7.0	1.14	8.0	1.29
Uterus Corpus	-	-	-	-	-	29	26.4	2.33	32.5	2.79
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	8	7.4	1.24	8.7	1.42
Male Genital System	181	162.5	6.10	200.1	7.17	-	-	-	-	-
Prostate	177	160.1	6.07	197.7	7.14	-	-	-	-	-
Testis	2	1.3	0.39	1.2	0.37	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	56	56.9	3.95	67.1	4.54	25	24.0	2.28	28.3	2.65
Bladder (incl. <i>in situ</i>)	21	25.5	2.83	29.4	3.19	8	8.6	1.47	10.1	1.69
Kidney & renal pelvis	33	28.6	2.55	34.3	2.96	17	15.0	1.72	17.8	2.01
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.7	0.96	5.2	1.08	5	3.9	0.88	4.1	0.95
Brain	5	4.3	0.93	4.8	1.05	3	2.9	0.79	3.1	0.86
Endocrine System	8	4.9	0.87	5.9	1.05	21	15.9	1.64	17.7	1.83
Thyroid gland	6	4.0	0.80	4.9	0.98	20	15.4	1.61	17.0	1.79
Lymphomas	27	22.6	2.20	25.5	2.49	17	14.7	1.73	17.4	2.01
Hodgkin Lymphoma	6	3.9	0.72	4.0	0.76	3	2.6	0.65	2.6	0.67
Non-Hodgkin Lymphoma	21	18.7	2.08	21.5	2.37	-	-	-	-	-
Multiple Myeloma	15	15.2	2.03	18.2	2.35	12	11.4	1.60	13.8	1.88
Leukemias	18	17.0	2.09	19.4	2.39	11	10.8	1.53	12.3	1.76
Acute lymphocytic	2	1.2	0.38	1.1	0.36	2	1.2	0.46	1.2	0.48
Chronic lymphocytic	7	7.3	1.34	8.6	1.52	3	3.4	0.88	4.0	1.01
Acute myeloid	5	4.2	0.99	4.6	1.09	4	3.8	0.95	4.5	1.11
Chronic myeloid	3	3.4	1.06	3.9	1.26	2	1.3	0.49	1.5	0.56
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	2.1	0.97	2.6	1.16	-	-	-	-	-
Kaposi Sarcoma	2	1.6	0.45	1.6	0.49	-	-	-	-	-
Ill-defined & Unknown	14	16.6	2.28	19.4	2.62	12	13.1	1.76	15.4	2.04
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	15.3	2.03	17.6	2.32	29	27.7	2.43	32.0	2.77
Breast (<i>in situ</i>)	-	-	-	-	-	43	38.2	2.73	46.1	3.21

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	804	345.2	5.73	405.9	6.67	1,078	322.8	4.49	373.7	5.17
Oral Cavity & Pharynx	30	11.4	0.98	13.7	1.17	19	5.4	0.57	6.2	0.66
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	6	2.5	0.48	2.9	0.56	6	1.7	0.32	2.0	0.38
Major salivary gland	2	0.9	0.29	1.0	0.33	3	0.7	0.20	0.8	0.22
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	4	1.5	0.36	1.9	0.45	3	1.0	0.25	1.1	0.28
Nasopharynx	9	3.0	0.45	3.7	0.56	4	1.1	0.26	1.3	0.30
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	2	1.1	0.32	1.3	0.38	-	-	-	-	-
Digestive System	250	106.4	3.16	126.6	3.71	202	63.1	2.03	74.3	2.36
Esophagus	9	3.7	0.58	4.6	0.70	3	0.9	0.24	1.1	0.29
Stomach	29	13.2	1.15	15.6	1.33	28	8.6	0.75	10.0	0.86
Small intestine	5	1.8	0.39	2.0	0.45	5	1.4	0.29	1.6	0.34
Colon excl. rectum	58	24.8	1.53	29.3	1.79	58	18.2	1.09	21.3	1.27
Rectum & rectosigmoid	42	16.2	1.17	19.7	1.40	28	8.0	0.69	9.8	0.84
Anus, anal canal & anorectum	2	1.0	0.32	1.2	0.38	2	0.8	0.23	0.9	0.27
Liver	61	24.8	1.49	30.0	1.78	25	8.1	0.74	9.5	0.86
Gallbladder	2	0.8	0.29	1.0	0.34	6	1.7	0.33	2.1	0.39
Pancreas	26	12.2	1.12	14.1	1.29	31	10.0	0.83	11.6	0.95
Respiratory System	114	53.8	2.36	63.2	2.74	107	33.9	1.50	40.1	1.75
Larynx	5	2.3	0.49	2.7	0.57	-	-	-	-	-
Lung & bronchus	107	50.6	2.29	59.6	2.66	104	33.1	1.49	39.2	1.73
Bones & Joints	3	1.1	0.28	1.0	0.28	1	0.4	0.15	0.3	0.15
Soft Tissue (incl. heart)	9	3.4	0.53	3.6	0.57	8	2.2	0.36	2.4	0.40
Skin (excl. basal & sq.)	5	1.9	0.41	2.2	0.48	-	-	-	-	-
Melanomas of the skin	2	1.0	0.30	1.1	0.34	6	1.7	0.33	1.9	0.36
Breast (excl. <i>in situ</i>)	2	0.7	0.24	0.8	0.29	353	102.1	2.47	118.8	2.86
Female Genital System	-	-	-	-	-	148	42.4	1.58	49.9	1.86
Cervix uteri	-	-	-	-	-	25	7.2	0.65	7.6	0.70
Uterus Corpus	-	-	-	-	-	76	21.5	1.12	26.1	1.35
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	33	9.5	0.76	11.1	0.88
Male Genital System	155	65.4	2.47	78.5	2.91	-	-	-	-	-
Prostate	142	61.5	2.41	74.5	2.85	-	-	-	-	-
Testis	9	2.6	0.39	2.6	0.39	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	73	32.5	1.79	38.8	2.11	34	11.0	0.86	12.8	0.99
Bladder (incl. <i>in situ</i>)	36	17.4	1.37	20.4	1.58	13	4.3	0.55	5.0	0.63
Kidney & renal pelvis	35	13.8	1.09	16.8	1.31	19	5.9	0.62	6.9	0.71
Ureter	-	-	-	-	-	2	0.5	0.19	0.6	0.21
Eye & Orbit	2	0.5	0.18	0.5	0.17	-	-	-	-	-
Brain & Other CNS ¹	16	5.9	0.70	6.2	0.76	11	3.4	0.47	3.6	0.50
Brain	14	5.4	0.67	5.8	0.73	10	3.1	0.45	3.4	0.48
Endocrine System	21	7.7	0.78	8.3	0.85	72	20.4	1.09	21.9	1.18
Thyroid gland	18	6.6	0.71	7.2	0.79	70	19.7	1.07	21.1	1.15
Lymphomas	50	20.9	1.40	23.9	1.60	42	12.5	0.88	14.3	1.01
Hodgkin Lymphoma	5	1.6	0.33	1.7	0.36	4	1.0	0.23	1.0	0.23
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	13	6.0	0.78	7.0	0.90	12	4.2	0.54	4.7	0.60
Leukemias	27	10.9	0.99	12.0	1.10	21	6.5	0.65	7.0	0.70
Acute lymphocytic	4	1.3	0.30	1.2	0.27	3	1.0	0.26	0.9	0.24
Chronic lymphocytic	4	1.7	0.40	1.9	0.46	2	0.8	0.23	0.9	0.26
Acute myeloid	12	5.0	0.69	5.7	0.78	10	3.2	0.46	3.5	0.50
Chronic myeloid	6	2.1	0.43	2.4	0.49	2	0.7	0.22	0.8	0.24
Other leukemias	2	0.7	0.27	0.8	0.30	3	0.8	0.22	0.9	0.24
Mesothelioma	2	1.0	0.33	1.2	0.38	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	32	15.6	1.29	17.9	1.47	37	11.9	0.90	13.6	1.02
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	30	12.3	1.06	14.0	1.21	82	25.0	1.26	29.0	1.45
Breast (<i>in situ</i>)	-	-	-	-	-	129	37.2	1.49	43.9	1.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	171	538.0	21.69	638.2	25.15	192	503.3	17.69	587.1	20.31
Oral Cavity & Pharynx	10	25.5	4.11	32.2	5.04	4	11.4	2.83	14.3	3.47
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	3	9.1	2.83	11.6	3.50	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	1	2.6	1.08	3.5	1.43	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	47	148.2	11.67	177.4	13.75	34	91.5	7.69	107.3	8.81
Esophagus	3	8.1	2.49	10.1	2.97	1	2.8	1.07	3.8	1.42
Stomach	2	8.9	3.06	9.9	3.48	2	5.0	1.82	5.5	1.97
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	11	36.1	5.76	41.8	6.63	12	35.5	4.95	41.3	5.63
Rectum & rectosigmoid	6	15.3	2.98	17.4	3.34	5	14.8	3.03	16.4	3.30
Anus, anal canal & anorectum	-	-	-	-	-	1	3.0	1.38	3.8	1.67
Liver	13	36.0	5.36	45.7	6.55	4	9.9	2.58	11.7	2.93
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	6	24.0	5.64	28.8	6.69	4	8.7	2.19	10.4	2.59
Respiratory System	23	77.4	8.29	92.8	9.57	24	72.7	7.22	84.0	8.16
Larynx	3	8.6	2.40	10.4	2.78	-	-	-	-	-
Lung & bronchus	20	68.8	7.94	82.4	9.15	23	69.3	7.02	79.9	7.90
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	7.0	2.73	8.2	3.20	2	3.9	1.33	3.9	1.33
Skin (excl. basal & sq.)	5	14.1	3.04	16.3	3.41	4	10.1	2.64	11.7	3.05
Melanomas of the skin	4	10.8	2.49	13.0	2.92	3	8.1	2.22	9.5	2.60
Breast (excl. <i>in situ</i>)	-	-	-	-	-	58	150.4	9.51	175.8	10.96
Female Genital System	-	-	-	-	-	20	47.2	4.92	55.1	5.63
Cervix uteri	-	-	-	-	-	4	9.1	2.11	8.8	2.03
Uterus Corpus	-	-	-	-	-	10	22.5	3.27	28.0	3.95
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	4	10.2	2.42	11.7	2.72
Male Genital System	33	102.8	9.14	121.5	10.47	-	-	-	-	-
Prostate	30	95.4	8.93	114.1	10.28	-	-	-	-	-
Testis	3	6.3	1.60	6.3	1.60	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	18	57.2	7.20	69.1	8.43	9	24.5	3.97	29.2	4.63
Bladder (incl. <i>in situ</i>)	9	32.2	5.72	38.8	6.71	3	10.4	2.94	12.3	3.44
Kidney & renal pelvis	8	24.5	4.35	29.7	5.07	6	13.8	2.64	16.3	3.05
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	3	9.0	2.60	10.0	2.88	2	3.0	1.01	3.4	1.22
Brain	3	8.5	2.55	9.6	2.85	2	2.7	0.96	3.1	1.17
Endocrine System	1	5.3	2.34	6.1	2.60	11	23.6	3.23	25.3	3.46
Thyroid gland	1	4.2	2.06	5.0	2.35	11	23.2	3.20	24.7	3.42
Lymphomas	9	30.0	5.31	33.9	6.01	8	23.6	4.08	27.9	4.72
Hodgkin Lymphoma	1	2.5	1.02	2.6	1.09	1	3.8	1.58	4.0	1.63
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	3	11.9	3.68	13.6	4.18	4	10.7	2.73	13.1	3.25
Leukemias	8	19.3	3.77	21.8	4.40	4	9.0	2.20	10.1	2.47
Acute lymphocytic	2	4.4	1.31	3.9	1.21	1	2.4	0.98	2.4	1.02
Chronic lymphocytic	1	5.0	2.11	5.7	2.41	-	-	-	-	-
Acute myeloid	2	6.4	2.53	8.1	3.14	1	3.2	1.32	3.3	1.37
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	7	23.9	4.78	28.5	5.53	6	16.8	3.33	20.3	3.93
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	4	12.8	3.38	14.4	3.85	13	36.1	4.79	41.8	5.47
Breast (<i>in situ</i>)	-	-	-	-	-	13	31.9	4.15	37.4	4.78

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	409	438.5	12.06	517.2	13.92	521	446.6	9.97	523.8	11.59
Oral Cavity & Pharynx	13	12.4	1.85	14.8	2.13	6	4.8	0.99	5.8	1.19
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	4.3	1.06	5.2	1.22	2	1.9	0.70	2.3	0.82
Major salivary gland	-	-	-	-	-	1	1.0	0.44	1.2	0.52
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	100	106.8	5.87	127.9	6.83	84	84.0	4.61	100.2	5.41
Esophagus	5	6.4	1.52	7.6	1.74	1	1.6	0.68	1.9	0.79
Stomach	12	13.9	2.18	16.1	2.47	12	10.7	1.59	12.6	1.87
Small intestine	2	2.2	0.90	2.5	1.02	-	-	-	-	-
Colon excl. rectum	22	25.2	3.03	29.7	3.51	27	26.2	2.58	31.1	3.03
Rectum & rectosigmoid	19	16.9	2.08	20.6	2.44	12	9.6	1.36	11.8	1.65
Anus, anal canal & anorectum	-	-	-	-	-	2	2.2	0.72	2.9	0.91
Liver	20	19.5	2.31	24.2	2.74	8	8.7	1.54	10.3	1.78
Gallbladder	2	2.2	0.93	2.6	1.11	3	4.2	1.14	4.9	1.32
Pancreas	10	12.9	2.16	15.5	2.51	12	12.6	1.84	14.8	2.12
Respiratory System	40	55.2	4.61	64.9	5.28	43	47.1	3.52	55.1	4.01
Larynx	5	6.2	1.48	7.3	1.71	-	-	-	-	-
Lung & bronchus	33	46.5	4.27	54.7	4.88	40	44.7	3.45	52.3	3.92
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	6	3.5	0.84	4.0	1.00	6	4.1	0.87	4.6	0.96
Skin (excl. basal & sq.)	14	15.7	2.31	18.7	2.70	22	18.4	2.05	21.3	2.34
Melanomas of the skin	11	12.3	1.98	14.5	2.26	19	15.5	1.83	18.1	2.13
Breast (excl. <i>in situ</i>)	2	1.2	0.47	1.4	0.55	161	131.3	5.15	155.9	6.05
Female Genital System	-	-	-	-	-	62	50.6	3.25	59.2	3.77
Cervix uteri	-	-	-	-	-	12	7.2	1.02	7.4	1.09
Uterus Corpus	-	-	-	-	-	29	24.4	2.21	30.2	2.67
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	14	11.2	1.58	12.8	1.79
Male Genital System	92	97.3	5.49	116.1	6.33	-	-	-	-	-
Prostate	75	90.3	5.41	109.0	6.25	-	-	-	-	-
Testis	16	6.4	0.90	6.5	0.96	-	-	-	-	-
Penis	1	0.6	0.25	0.7	0.29	-	-	-	-	-
Urinary System	47	56.0	4.49	65.6	5.16	23	22.5	2.36	26.2	2.67
Bladder (incl. <i>in situ</i>)	19	29.6	3.54	34.2	4.04	7	8.5	1.59	9.7	1.76
Kidney & renal pelvis	26	23.7	2.55	28.3	2.96	16	13.1	1.68	15.5	1.95
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	1	0.9	0.40	1.1	0.49
Brain & Other CNS ¹	10	7.2	1.46	8.1	1.68	9	5.6	1.05	6.1	1.20
Brain	9	6.8	1.43	7.6	1.65	8	5.3	1.04	5.9	1.19
Endocrine System	13	10.0	1.64	11.5	1.89	39	22.8	1.81	25.1	2.07
Thyroid gland	11	8.4	1.46	9.8	1.71	38	22.0	1.76	24.2	2.02
Lymphomas	29	28.1	2.96	32.7	3.40	26	21.8	2.22	25.8	2.61
Hodgkin Lymphoma	6	4.9	1.21	5.6	1.41	5	3.0	0.71	3.1	0.78
Non-Hodgkin Lymphoma	23	23.2	2.71	27.1	3.09	21	18.9	2.10	22.7	2.49
Multiple Myeloma	5	6.0	1.48	7.3	1.73	6	6.4	1.27	7.5	1.43
Leukemias	21	15.2	2.01	17.0	2.31	16	11.1	1.52	12.4	1.71
Acute lymphocytic	8	2.7	0.48	2.6	0.52	-	-	-	-	-
Chronic lymphocytic	3	4.1	1.16	5.0	1.36	2	2.4	0.84	2.7	0.91
Acute myeloid	4	3.9	1.11	4.7	1.31	5	4.1	0.90	4.6	1.06
Chronic myeloid	4	3.3	1.02	3.5	1.13	2	1.8	0.63	2.1	0.70
Other leukemias	2	1.1	0.44	1.2	0.48	-	-	-	-	-
Mesothelioma	2	2.2	0.89	2.8	1.06	-	-	-	-	-
Kaposi Sarcoma	3	1.7	0.70	1.9	0.84	-	-	-	-	-
Ill-defined & Unknown	12	18.9	2.93	21.5	3.35	13	13.7	1.92	16.1	2.22
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	13	10.2	1.69	11.9	2.02	34	29.6	2.60	34.2	3.00
Breast (<i>in situ</i>)	-	-	-	-	-	41	30.9	2.34	36.6	2.77

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

Seattle/Puget Sound

II-528 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11,139	522.8	2.29	616.9	2.65	10,789	463.7	2.08	539.3	2.35
Oral Cavity & Pharynx	469	21.1	0.45	25.6	0.53	190	8.0	0.27	9.4	0.31
Lip	39	1.9	0.14	2.3	0.16	23	0.9	0.09	1.1	0.10
Tongue	171	7.5	0.26	9.1	0.32	59	2.5	0.15	2.9	0.17
Major salivary gland	30	1.5	0.13	1.8	0.14	23	1.0	0.10	1.2	0.11
Floor of mouth	17	0.8	0.08	0.9	0.10	10	0.4	0.06	0.5	0.07
Gum & other mouth	52	2.5	0.16	3.0	0.19	40	1.7	0.12	1.9	0.14
Nasopharynx	10	0.4	0.06	0.5	0.07	3	0.1	0.04	0.2	0.04
Oropharynx	20	0.9	0.09	1.1	0.11	5	0.2	0.04	0.2	0.05
Hypopharynx	19	0.8	0.09	1.0	0.11	4	0.2	0.04	0.2	0.05
Digestive System	1,994	92.9	0.96	110.9	1.12	1,547	64.2	0.76	75.4	0.87
Esophagus	181	8.4	0.29	10.0	0.34	50	2.0	0.13	2.4	0.15
Stomach	159	7.6	0.28	8.9	0.32	75	3.1	0.17	3.7	0.19
Small intestine	58	2.7	0.17	3.2	0.19	52	2.2	0.14	2.5	0.16
Colon excl. rectum	560	27.2	0.53	31.9	0.61	568	23.9	0.47	27.7	0.53
Rectum & rectosigmoid	299	13.7	0.37	16.5	0.43	210	9.1	0.29	10.7	0.34
Anus, anal canal & anorectum	38	1.7	0.13	2.1	0.15	72	2.9	0.16	3.6	0.19
Liver	252	10.3	0.30	13.2	0.38	74	2.9	0.15	3.5	0.19
Gallbladder	15	0.8	0.09	0.9	0.10	24	1.0	0.09	1.1	0.11
Pancreas	298	14.0	0.38	16.6	0.44	291	11.8	0.32	13.8	0.37
Respiratory System	1,397	66.5	0.82	78.1	0.95	1,347	54.8	0.69	64.5	0.79
Larynx	86	3.9	0.19	4.7	0.23	22	0.9	0.08	1.1	0.10
Lung & bronchus	1,286	61.3	0.79	72.0	0.91	1,311	53.4	0.68	62.8	0.78
Bones & Joints	23	1.2	0.12	1.3	0.12	16	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	78	4.0	0.21	4.5	0.23	55	2.5	0.16	2.8	0.17
Skin (excl. basal & sq.)	994	48.4	0.71	56.1	0.81	724	33.1	0.58	37.5	0.63
Melanomas of the skin	882	42.6	0.66	49.4	0.75	666	30.6	0.56	34.7	0.61
Breast (excl. <i>in situ</i>)	20	1.0	0.10	1.1	0.11	3,359	144.8	1.16	170.2	1.33
Female Genital System	-	-	-	-	-	1,244	52.6	0.70	62.5	0.80
Cervix uteri	-	-	-	-	-	131	6.9	0.28	7.3	0.29
Uterus Corpus	-	-	-	-	-	675	27.2	0.49	33.4	0.58
Uterus, NOS ¹	-	-	-	-	-	6	0.3	0.05	0.3	0.05
Ovary	-	-	-	-	-	265	11.4	0.32	13.3	0.37
Male Genital System	2,720	118.8	1.05	143.8	1.25	-	-	-	-	-
Prostate	2,559	109.8	1.00	134.6	1.20	-	-	-	-	-
Testis	138	7.9	0.31	7.9	0.30	-	-	-	-	-
Penis	14	0.7	0.09	0.9	0.10	-	-	-	-	-
Urinary System	1,352	65.3	0.82	76.7	0.94	516	21.6	0.44	25.1	0.50
Bladder (incl. <i>in situ</i>)	853	41.7	0.66	48.9	0.76	237	9.6	0.29	11.2	0.33
Kidney & renal pelvis	464	21.8	0.47	25.7	0.54	262	11.3	0.32	13.0	0.36
Ureter	15	0.7	0.09	0.9	0.10	10	0.4	0.06	0.5	0.07
Eye & Orbit	28	1.4	0.12	1.6	0.13	20	0.9	0.10	1.0	0.11
Brain & Other CNS ¹	193	9.8	0.33	10.8	0.35	142	7.1	0.28	7.6	0.29
Brain	182	9.1	0.31	10.1	0.34	132	6.5	0.27	7.0	0.28
Endocrine System	173	8.6	0.30	9.6	0.33	406	20.9	0.48	22.5	0.51
Thyroid gland	159	7.8	0.29	8.8	0.31	394	20.2	0.48	21.9	0.50
Lymphomas	604	29.8	0.56	34.2	0.63	450	19.7	0.43	22.5	0.48
Hodgkin Lymphoma	54	3.0	0.19	3.1	0.19	40	2.3	0.17	2.4	0.17
Non-Hodgkin Lymphoma	550	26.8	0.53	31.2	0.60	410	17.4	0.40	20.2	0.45
Multiple Myeloma	184	8.7	0.30	10.3	0.34	120	4.9	0.21	5.8	0.24
Leukemias	440	21.6	0.48	24.8	0.54	290	12.5	0.34	14.2	0.38
Acute lymphocytic	29	1.8	0.15	1.7	0.14	22	1.4	0.14	1.3	0.12
Chronic lymphocytic	213	9.8	0.31	11.8	0.37	125	5.0	0.20	5.9	0.24
Acute myeloid	105	5.2	0.24	6.0	0.27	86	3.7	0.19	4.3	0.21
Chronic myeloid	59	3.0	0.18	3.4	0.20	34	1.4	0.12	1.7	0.13
Other leukemias	34	1.7	0.14	1.9	0.15	22	1.0	0.10	1.1	0.11
Mesothelioma	44	2.3	0.16	2.6	0.18	13	0.5	0.07	0.6	0.08
Kaposi Sarcoma	10	0.5	0.07	0.6	0.08	1	0.1	0.02	0.1	0.02
Ill-defined & Unknown	417	21.1	0.48	24.4	0.54	349	14.6	0.36	16.7	0.41
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	306	15.1	0.40	17.2	0.45	605	26.8	0.51	30.6	0.56
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	797	34.8	0.58	41.3	0.66

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Seattle/Puget Sound, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	546	532.7	11.63	637.2	13.45	424	416.1	9.58	490.5	11.08
Oral Cavity & Pharynx	15	11.9	1.54	14.6	1.85	4	3.7	0.85	4.7	1.05
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	4	3.9	0.93	4.8	1.10	1	1.4	0.55	1.8	0.70
Major salivary gland	2	2.1	0.73	2.4	0.85	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	1.0	0.37	1.3	0.51	-	-	-	-	-
Nasopharynx	2	1.1	0.38	1.4	0.50	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	131	127.9	5.68	153.4	6.58	83	85.5	4.45	102.0	5.19
Esophagus	6	5.7	1.16	6.9	1.34	2	2.4	0.75	2.8	0.87
Stomach	12	13.7	2.05	16.1	2.35	8	9.2	1.52	10.8	1.74
Small intestine	5	3.8	0.90	4.8	1.09	5	5.1	1.05	6.4	1.27
Colon excl. rectum	34	34.8	2.99	40.6	3.38	26	26.8	2.50	31.6	2.90
Rectum & rectosigmoid	15	14.3	1.86	17.0	2.17	10	9.8	1.44	11.8	1.70
Anus, anal canal & anorectum	3	2.5	0.72	3.0	0.85	3	3.1	0.81	3.8	0.97
Liver	29	24.2	2.18	31.0	2.67	9	8.0	1.30	9.8	1.55
Gallbladder	-	-	-	-	-	2	2.6	0.85	3.0	0.93
Pancreas	19	20.4	2.36	24.5	2.75	12	12.1	1.70	14.7	2.00
Respiratory System	67	76.1	4.72	89.6	5.36	49	53.1	3.61	62.8	4.13
Larynx	6	5.1	1.04	6.5	1.25	2	2.6	0.83	3.0	0.94
Lung & bronchus	59	69.6	4.57	81.6	5.17	46	49.6	3.48	58.6	3.98
Bones & Joints	1	0.8	0.32	0.7	0.26	-	-	-	-	-
Soft Tissue (incl. heart)	4	3.4	0.83	3.6	0.87	3	3.0	0.78	3.3	0.85
Skin (excl. basal & sq.)	4	3.0	0.84	3.5	0.97	2	1.9	0.63	2.2	0.70
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	2	1.8	0.67	2.2	0.74	134	127.5	5.18	150.1	5.99
Female Genital System	-	-	-	-	-	48	45.1	3.08	54.1	3.61
Cervix uteri	-	-	-	-	-	8	7.0	1.15	8.0	1.31
Uterus Corpus	-	-	-	-	-	28	26.4	2.36	32.5	2.83
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	8	7.4	1.25	8.6	1.43
Male Genital System	178	164.4	6.20	202.7	7.30	-	-	-	-	-
Prostate	175	162.0	6.17	200.2	7.27	-	-	-	-	-
Testis	2	1.4	0.42	1.3	0.40	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	54	57.0	3.99	67.2	4.57	24	24.6	2.35	28.9	2.72
Bladder (incl. <i>in situ</i>)	21	25.5	2.84	29.4	3.20	8	8.7	1.50	10.2	1.72
Kidney & renal pelvis	32	28.5	2.58	34.2	3.00	17	15.5	1.78	18.3	2.08
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	4.9	1.00	5.5	1.12	4	3.9	0.91	4.1	0.98
Brain	5	4.5	0.97	5.0	1.09	3	3.0	0.81	3.1	0.88
Endocrine System	7	5.1	0.90	6.1	1.08	20	16.3	1.70	18.1	1.90
Thyroid gland	6	4.2	0.83	5.2	1.01	19	15.8	1.68	17.4	1.86
Lymphomas	27	23.0	2.25	26.0	2.54	16	14.9	1.77	17.5	2.05
Hodgkin Lymphoma	6	3.7	0.71	3.9	0.74	3	2.4	0.64	2.4	0.65
Non-Hodgkin Lymphoma	21	19.3	2.14	22.1	2.43	13	12.5	1.65	15.1	1.95
Multiple Myeloma	14	15.4	2.08	18.5	2.39	11	11.4	1.64	13.9	1.92
Leukemias	18	17.2	2.12	19.7	2.43	11	10.9	1.57	12.5	1.80
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	7	7.3	1.35	8.6	1.54	3	3.5	0.91	4.2	1.05
Acute myeloid	5	4.4	1.03	4.8	1.13	4	3.8	0.96	4.4	1.12
Chronic myeloid	3	3.5	1.08	4.0	1.28	2	1.4	0.51	1.6	0.58
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	1	2.2	0.98	2.6	1.17	-	-	-	-	-
Kaposi Sarcoma	2	1.5	0.46	1.6	0.50	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	11	12.5	1.76	14.6	2.02
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	15.7	2.08	18.1	2.38	28	28.3	2.51	32.7	2.86
Breast (<i>in situ</i>)	-	-	-	-	-	41	38.2	2.78	46.3	3.28

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	1,853,873	1,849,467	1,841,996	1,830,929	1,817,048
White	1,759,228	1,753,810	1,745,624	1,734,019	1,720,230
Black	73,930	74,452	74,765	74,767	74,777
American Indian/Alaskan Native (AI/AN)	4,456	4,522	4,598	4,668	4,680
Asian/Pacific Islander (API)	16,259	16,683	17,009	17,475	17,361


All Races Population 2013-2017: 9,193,313
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	25,835	26,917	27,865	28,734	29,262
Non-Hispanic White	1,736,176	1,729,818	1,720,812	1,708,469	1,694,251
Non-Hispanic Black	72,120	72,547	72,818	72,783	72,738

Hispanic/Latino Population, Census 2010: 22,268
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WEST VIRGINIA CANCER REGISTRY

Initial Operation: 1993
Population-based Data Available: 1993
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.0	100.3	101.5	104.2	109.1
Missing Race	0.1	0.2	0.4	0.4	0.4
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.9	0.8	1.0	0.7	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.8	Prostate	97.8
Oral Cavity & Pharynx	97.7	Testis	100.0
Esophagus	96.9	Bladder (incl. <i>in situ</i>)	98.2
Stomach	97.1	Kidney & Renal Pelvis	87.8
Colon & Rectum	96.6	Brain & Other CNS ¹	87.4
Liver	61.9	Thyroid	99.6
Pancreas	83.9	Hodgkin Lymphoma	99.6
Lung & Bronchus	85.7	Non-Hodgkin Lymphoma	96.6
Melanomas of the Skin	99.4	Multiple Myeloma	89.6
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	88.0
Cervix uteri	98.9	Brain & Other CNS ¹ <i>non-malig</i>	38.1
Uterus Corpus & Uterus NOS ¹	98.9	Breast <i>in situ</i>	100.0
Ovary	93.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6,038	512.7	3.05	609.8	3.56	5,801	457.1	2.82	533.8	3.20
Oral Cavity & Pharynx	243	20.6	0.61	25.1	0.73	94	7.4	0.35	8.7	0.41
Lip	10	0.8	0.12	1.0	0.15	4	0.3	0.06	0.3	0.08
Tongue	73	6.0	0.33	7.3	0.39	28	2.2	0.19	2.6	0.22
Major salivary gland	18	1.7	0.18	2.0	0.21	13	1.2	0.15	1.3	0.17
Floor of mouth	12	1.0	0.13	1.3	0.17	3	0.3	0.07	0.3	0.08
Gum & other mouth	32	2.7	0.22	3.2	0.26	21	1.6	0.16	1.9	0.19
Nasopharynx	7	0.6	0.11	0.7	0.13	4	0.3	0.07	0.4	0.09
Oropharynx	17	1.5	0.16	1.7	0.19	5	0.3	0.07	0.4	0.09
Hypopharynx	15	1.2	0.15	1.5	0.18	3	0.2	0.06	0.3	0.08
Digestive System	1,186	101.2	1.36	121.1	1.60	949	71.2	1.07	83.9	1.24
Esophagus	115	9.3	0.40	11.4	0.48	27	1.9	0.17	2.3	0.21
Stomach	89	7.7	0.37	9.1	0.44	56	4.2	0.26	4.9	0.30
Small intestine	28	2.4	0.21	2.9	0.25	26	2.1	0.20	2.5	0.22
Colon excl. rectum	410	35.7	0.82	42.3	0.95	406	30.3	0.70	35.4	0.80
Rectum & rectosigmoid	193	16.9	0.56	20.1	0.65	135	10.6	0.43	12.5	0.49
Anus, anal canal & anorectum	19	1.6	0.17	1.9	0.20	40	3.1	0.23	3.8	0.28
Liver	124	9.8	0.41	12.4	0.50	40	2.8	0.21	3.4	0.24
Gallbladder	6	0.5	0.09	0.6	0.11	13	0.9	0.12	1.1	0.14
Pancreas	155	13.1	0.49	15.6	0.57	152	11.2	0.42	13.2	0.48
Respiratory System	1,251	103.3	1.34	124.5	1.60	994	72.2	1.05	86.9	1.25
Larynx	98	7.9	0.37	9.9	0.45	34	2.6	0.21	3.2	0.25
Lung & bronchus	1,138	94.0	1.28	113.1	1.52	951	68.9	1.02	82.8	1.22
Bones & Joints	9	1.0	0.15	1.0	0.15	10	1.0	0.16	1.0	0.15
Soft Tissue (incl. heart)	38	3.5	0.27	4.0	0.30	31	2.8	0.24	3.0	0.25
Skin (excl. basal & sq.)	314	28.4	0.74	32.9	0.84	211	18.4	0.60	20.7	0.65
Melanomas of the skin	295	26.6	0.72	30.9	0.82	198	17.4	0.58	19.5	0.63
Breast (excl. <i>in situ</i>)	12	1.0	0.13	1.2	0.15	1,481	117.5	1.43	138.5	1.64
Female Genital System	-	-	-	-	-	714	57.8	1.02	68.1	1.16
Cervix uteri	-	-	-	-	-	88	9.2	0.46	9.7	0.47
Uterus Corpus	-	-	-	-	-	391	30.1	0.72	36.7	0.84
Uterus, NOS ¹	-	-	-	-	-	15	1.2	0.14	1.4	0.16
Ovary	-	-	-	-	-	152	12.0	0.46	14.1	0.52
Male Genital System	1,246	98.9	1.29	120.4	1.55	-	-	-	-	-
Prostate	1,183	92.1	1.23	113.4	1.49	-	-	-	-	-
Testis	45	5.3	0.36	5.3	0.35	-	-	-	-	-
Penis	15	1.3	0.16	1.5	0.18	-	-	-	-	-
Urinary System	746	64.7	1.09	76.2	1.27	341	25.9	0.65	30.5	0.75
Bladder (incl. <i>in situ</i>)	437	37.7	0.83	44.5	0.97	139	10.2	0.40	12.0	0.46
Kidney & renal pelvis	293	25.6	0.70	30.1	0.80	196	15.2	0.51	18.0	0.59
Ureter	11	1.0	0.13	1.2	0.16	5	0.3	0.07	0.4	0.08
Eye & Orbit	15	1.4	0.17	1.6	0.19	11	0.9	0.13	1.0	0.14
Brain & Other CNS ¹	87	8.3	0.42	9.1	0.44	67	6.2	0.36	6.6	0.37
Brain	83	8.0	0.41	8.7	0.43	62	5.7	0.34	6.1	0.35
Endocrine System	88	8.4	0.42	9.3	0.45	261	26.7	0.78	28.4	0.80
Thyroid gland	79	7.5	0.39	8.4	0.43	257	26.3	0.77	27.9	0.79
Lymphomas	283	25.4	0.70	29.2	0.79	236	18.7	0.57	21.6	0.64
Hodgkin Lymphoma	27	2.8	0.25	3.0	0.26	21	2.3	0.23	2.4	0.23
Non-Hodgkin Lymphoma	256	22.5	0.65	26.2	0.74	215	16.4	0.52	19.2	0.60
Multiple Myeloma	88	7.5	0.37	8.9	0.43	63	4.5	0.26	5.4	0.31
Leukemias	204	18.6	0.60	21.2	0.67	147	11.9	0.46	13.3	0.50
Acute lymphocytic	11	1.3	0.18	1.2	0.16	9	1.0	0.16	1.0	0.14
Chronic lymphocytic	82	6.9	0.35	8.3	0.42	46	3.3	0.22	3.9	0.26
Acute myeloid	60	5.5	0.33	6.2	0.37	54	4.4	0.28	4.9	0.31
Chronic myeloid	26	2.5	0.23	2.8	0.25	24	2.1	0.20	2.3	0.22
Other leukemias	24	2.2	0.21	2.5	0.23	13	1.1	0.14	1.2	0.15
Mesothelioma	22	2.0	0.19	2.3	0.22	5	0.4	0.09	0.5	0.09
Kaposi Sarcoma	3	0.3	0.08	0.3	0.09	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	91	8.7	0.42	9.7	0.46	173	14.4	0.52	16.3	0.57
Breast (<i>in situ</i>)	-	-	-	-	-	270	21.7	0.62	26.0	0.72

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	5,803	511.9	3.11	608.5	3.63	5,610	459.0	2.88	535.9	3.27
Oral Cavity & Pharynx	237	20.9	0.63	25.5	0.75	91	7.4	0.36	8.7	0.42
Lip	9	0.8	0.13	1.0	0.15	4	0.3	0.06	0.3	0.08
Tongue	72	6.1	0.34	7.6	0.40	28	2.3	0.20	2.7	0.23
Major salivary gland	18	1.7	0.19	2.0	0.21	12	1.1	0.15	1.3	0.17
Floor of mouth	12	1.0	0.14	1.3	0.17	3	0.3	0.07	0.3	0.08
Gum & other mouth	31	2.7	0.23	3.2	0.26	20	1.6	0.16	1.9	0.19
Nasopharynx	6	0.6	0.11	0.6	0.12	4	0.3	0.07	0.4	0.09
Oropharynx	17	1.5	0.17	1.8	0.20	5	0.4	0.08	0.4	0.09
Hypopharynx	13	1.2	0.15	1.5	0.18	3	0.2	0.06	0.3	0.08
Digestive System	1,136	100.7	1.38	120.5	1.62	914	71.1	1.09	83.7	1.26
Esophagus	113	9.5	0.41	11.7	0.50	26	2.0	0.18	2.4	0.21
Stomach	86	7.6	0.38	9.0	0.44	51	3.9	0.25	4.6	0.29
Small intestine	26	2.3	0.21	2.8	0.25	25	2.1	0.20	2.5	0.22
Colon excl. rectum	393	35.6	0.83	42.0	0.96	393	30.5	0.71	35.5	0.82
Rectum & rectosigmoid	187	17.0	0.58	20.2	0.67	130	10.7	0.44	12.6	0.50
Anus, anal canal & anorectum	18	1.6	0.17	1.9	0.20	39	3.1	0.24	3.9	0.28
Liver	115	9.6	0.41	12.0	0.51	37	2.8	0.21	3.3	0.24
Gallbladder	5	0.5	0.09	0.5	0.11	13	0.9	0.12	1.1	0.14
Pancreas	147	12.9	0.49	15.4	0.58	147	11.1	0.42	13.1	0.49
Respiratory System	1,211	103.7	1.37	125.0	1.63	968	72.8	1.07	87.6	1.28
Larynx	96	8.1	0.38	10.1	0.47	33	2.6	0.21	3.2	0.26
Lung & bronchus	1,102	94.3	1.31	113.4	1.55	926	69.5	1.05	83.6	1.25
Bones & Joints	8	0.9	0.15	0.9	0.15	10	1.1	0.16	1.0	0.15
Soft Tissue (incl. heart)	36	3.5	0.27	4.0	0.30	29	2.8	0.24	3.0	0.26
Skin (excl. basal & sq.)	310	29.1	0.77	33.7	0.87	204	18.6	0.62	20.8	0.67
Melanomas of the skin	291	27.3	0.74	31.6	0.84	192	17.5	0.60	19.7	0.65
Breast (excl. <i>in situ</i>)	11	1.0	0.13	1.2	0.16	1,427	117.4	1.46	138.4	1.68
Female Genital System	-	-	-	-	-	694	58.4	1.05	68.8	1.19
Cervix uteri	-	-	-	-	-	85	9.3	0.47	9.8	0.48
Uterus Corpus	-	-	-	-	-	380	30.5	0.74	37.1	0.87
Uterus, NOS ¹	-	-	-	-	-	13	1.1	0.14	1.2	0.16
Ovary	-	-	-	-	-	148	12.1	0.47	14.3	0.54
Male Genital System	1,169	96.6	1.30	117.3	1.56	-	-	-	-	-
Prostate	1,108	89.5	1.23	109.9	1.50	-	-	-	-	-
Testis	45	5.6	0.38	5.6	0.38	-	-	-	-	-
Penis	15	1.4	0.16	1.5	0.18	-	-	-	-	-
Urinary System	727	65.3	1.12	77.0	1.30	334	26.3	0.67	31.0	0.77
Bladder (incl. <i>in situ</i>)	429	38.3	0.85	45.2	0.99	135	10.3	0.41	12.1	0.47
Kidney & renal pelvis	282	25.6	0.71	30.2	0.82	192	15.5	0.53	18.3	0.60
Ureter	11	1.0	0.14	1.2	0.16	5	0.3	0.07	0.4	0.08
Eye & Orbit	15	1.4	0.17	1.6	0.19	11	0.9	0.14	1.0	0.14
Brain & Other CNS ¹	85	8.5	0.43	9.3	0.46	65	6.2	0.37	6.7	0.38
Brain	81	8.1	0.42	8.9	0.45	60	5.7	0.35	6.2	0.36
Endocrine System	84	8.4	0.43	9.3	0.46	252	27.0	0.80	28.7	0.82
Thyroid gland	77	7.6	0.41	8.5	0.44	248	26.6	0.79	28.3	0.82
Lymphomas	274	25.5	0.72	29.3	0.81	228	18.8	0.59	21.6	0.65
Hodgkin Lymphoma	26	2.9	0.26	3.1	0.27	20	2.3	0.24	2.4	0.24
Non-Hodgkin Lymphoma	247	22.6	0.67	26.3	0.76	208	16.5	0.53	19.2	0.61
Multiple Myeloma	83	7.3	0.37	8.7	0.43	57	4.2	0.26	5.1	0.30
Leukemias	197	18.6	0.61	21.2	0.69	141	11.9	0.47	13.3	0.51
Acute lymphocytic	11	1.3	0.19	1.2	0.17	9	1.0	0.16	0.9	0.15
Chronic lymphocytic	80	6.9	0.36	8.3	0.42	44	3.3	0.23	3.8	0.26
Acute myeloid	58	5.6	0.34	6.3	0.37	53	4.4	0.29	5.0	0.31
Chronic myeloid	25	2.5	0.23	2.8	0.25	24	2.1	0.21	2.3	0.22
Other leukemias	24	2.3	0.21	2.6	0.24	12	1.1	0.14	1.2	0.15
Mesothelioma	22	2.0	0.19	2.3	0.22	5	0.4	0.09	0.5	0.09
Kaposi Sarcoma	2	0.2	0.07	0.2	0.07	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	86	8.6	0.43	9.7	0.47	170	14.7	0.53	16.7	0.59
Breast (<i>in situ</i>)	-	-	-	-	-	260	21.6	0.63	25.9	0.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	185	531.6	19.16	644.7	22.45	135	378.1	15.03	450.8	17.51
Oral Cavity & Pharynx	5	13.7	3.13	16.3	3.58	2	6.1	2.03	6.9	2.18
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	3.4	1.59	4.4	1.99	-	-	-	-	-
Digestive System	40	113.2	8.77	137.4	10.30	27	74.6	6.59	90.8	7.84
Esophagus	1	3.6	1.55	4.0	1.68	-	-	-	-	-
Stomach	3	9.2	2.49	11.0	2.84	2	6.9	2.07	7.8	2.26
Small intestine	2	9.0	2.88	10.1	3.22	1	3.8	1.61	4.1	1.70
Colon excl. rectum	12	35.1	4.90	42.0	5.69	11	28.0	3.96	34.6	4.79
Rectum & rectosigmoid	5	12.6	2.89	15.8	3.50	4	10.3	2.49	12.6	2.98
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	15.8	2.57	22.0	3.57	2	4.4	1.49	5.8	1.95
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	6	20.5	3.97	24.3	4.58	5	13.5	2.83	16.3	3.35
Respiratory System	32	100.2	8.81	120.6	10.20	21	57.8	5.78	70.4	6.90
Larynx	2	4.8	1.65	6.3	2.04	1	4.2	1.62	5.0	1.90
Lung & bronchus	29	93.7	8.59	112.6	9.94	19	52.9	5.50	64.7	6.60
Bones & Joints	1	3.6	1.60	3.8	1.74	-	-	-	-	-
Soft Tissue (incl. heart)	1	4.4	1.81	4.9	2.00	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	116.3	8.48	137.2	9.78
Female Genital System	-	-	-	-	-	14	38.4	4.76	46.5	5.60
Cervix uteri	-	-	-	-	-	2	4.6	1.66	5.5	1.98
Uterus Corpus	-	-	-	-	-	7	17.5	3.07	22.4	3.81
Uterus, NOS ¹	-	-	-	-	-	1	3.3	1.37	4.0	1.65
Ovary	-	-	-	-	-	3	9.6	2.45	10.8	2.73
Male Genital System	65	171.1	10.26	215.4	12.38	-	-	-	-	-
Prostate	64	168.8	10.20	213.4	12.34	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	14	41.8	5.41	50.5	6.39	6	15.1	2.92	18.1	3.46
Bladder (incl. <i>in situ</i>)	5	16.4	3.51	20.1	4.18	2	5.5	1.70	6.6	2.00
Kidney & renal pelvis	9	24.9	4.09	29.7	4.80	3	9.5	2.38	11.5	2.83
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	4	9.8	2.38	10.8	2.55	5	14.7	3.09	16.0	3.30
Thyroid gland	3	7.4	2.10	8.0	2.23	5	14.7	3.09	16.0	3.30
Lymphomas	7	19.0	3.46	21.8	3.91	5	14.0	2.87	16.5	3.32
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	4	11.2	2.55	13.4	3.02
Multiple Myeloma	4	12.5	3.08	15.0	3.58	5	12.2	2.63	14.7	3.08
Leukemias	5	20.0	4.22	22.5	4.72	4	10.9	2.61	12.7	2.95
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	9.8	3.12	11.0	3.51	1	3.7	1.45	4.5	1.73
Acute myeloid	2	5.3	2.13	6.1	2.35	1	3.7	1.56	4.1	1.69
Chronic myeloid	1	4.0	1.75	4.4	1.99	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	16.6	3.76	19.7	4.40	4	9.6	2.30	11.6	2.74
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	9.3	2.67	10.3	2.98	2	6.9	2.15	7.3	2.24
Breast (<i>in situ</i>)	-	-	-	-	-	8	22.2	3.72	26.1	4.27

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	11	187.7	28.17	229.6	34.14	20	228.1	23.66	259.6	26.98
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	66.1	17.92	80.7	21.71	3	42.0	10.74	51.5	12.91
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	23.5	9.52	28.8	11.44	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	38.4	9.98	48.9	12.69	2	24.3	7.63	28.3	8.72
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	3	36.0	9.69	45.2	12.13	2	22.7	7.46	26.2	8.46
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	8	92.8	14.77	104.7	16.76
Female Genital System	-	-	-	-	-	2	19.1	6.46	19.5	6.66
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	1	21.1	8.44	27.2	10.59	-	-	-	-	-
Prostate	1	15.7	6.49	21.0	8.59	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	1	20.4	8.70	22.7	9.69	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	15.5	5.93	16.3	6.34
Thyroid gland	-	-	-	-	-	1	15.5	5.93	16.3	6.34
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	1	13.7	5.24	18.2	6.93

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

insufficient data for the calculation of AI/AN PRCDA statistics

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	24	276.3	26.98	323.6	31.09	20	213.8	21.68	254.0	25.83
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	6	63.5	12.69	75.5	14.75	4	45.2	10.28	52.5	11.86
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	2	19.6	6.95	22.3	7.80	1	14.0	5.81	16.2	6.66
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	1	12.9	5.62	17.1	7.23	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	3	32.0	9.43	37.8	10.97	2	24.5	7.09	32.9	9.51
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	2	30.2	9.27	35.9	10.80	2	24.5	7.09	32.9	9.51
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	58.8	11.39	68.2	13.29
Female Genital System	-	-	-	-	-	2	17.4	5.83	21.7	7.43
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	6	80.9	15.03	96.0	17.29	-	-	-	-	-
Prostate	6	80.9	15.03	96.0	17.29	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	3	40.4	10.75	46.4	12.15	1	13.2	5.53	15.9	6.57
Bladder (incl. <i>in situ</i>)	1	18.9	7.77	20.3	8.40	-	-	-	-	-
Kidney & renal pelvis	2	21.5	7.42	26.0	8.78	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	1	10.9	4.51	12.5	5.38
Thyroid gland	-	-	-	-	-	1	10.9	4.51	12.5	5.38
Lymphomas	1	9.8	4.02	11.3	4.88	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	1	13.6	5.60	15.5	6.39	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	2	17.7	6.38	20.4	7.35

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

WEST VIRGINIA

II-538 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	5,785	514.1	3.13	611.1	3.65	5,596	461.5	2.90	538.6	3.29
Oral Cavity & Pharynx	236	21.0	0.64	25.7	0.76	90	7.4	0.36	8.7	0.42
Lip	9	0.9	0.13	1.0	0.15	4	0.3	0.07	0.3	0.08
Tongue	72	6.2	0.34	7.6	0.41	28	2.3	0.20	2.7	0.23
Major salivary gland	18	1.7	0.19	2.0	0.22	12	1.1	0.15	1.3	0.17
Floor of mouth	12	1.0	0.14	1.3	0.17	3	0.3	0.07	0.3	0.08
Gum & other mouth	31	2.7	0.23	3.3	0.27	20	1.6	0.17	1.9	0.19
Nasopharynx	6	0.6	0.11	0.6	0.12	4	0.3	0.07	0.4	0.09
Oropharynx	17	1.5	0.17	1.8	0.20	5	0.4	0.08	0.4	0.09
Hypopharynx	13	1.1	0.15	1.4	0.18	3	0.2	0.06	0.3	0.08
Digestive System	1,132	101.1	1.39	120.9	1.63	911	71.4	1.10	84.0	1.27
Esophagus	113	9.6	0.42	11.7	0.50	26	2.0	0.18	2.3	0.21
Stomach	85	7.7	0.38	9.1	0.45	51	3.9	0.25	4.6	0.29
Small intestine	26	2.4	0.22	2.8	0.25	25	2.1	0.20	2.5	0.23
Colon excl. rectum	392	35.7	0.84	42.2	0.97	392	30.6	0.72	35.7	0.82
Rectum & rectosigmoid	186	17.1	0.58	20.3	0.67	130	10.7	0.44	12.6	0.51
Anus, anal canal & anorectum	18	1.6	0.17	1.9	0.21	39	3.2	0.24	3.9	0.29
Liver	114	9.5	0.41	12.0	0.51	37	2.8	0.21	3.3	0.25
Gallbladder	5	0.5	0.09	0.6	0.11	13	0.9	0.12	1.1	0.14
Pancreas	147	12.9	0.49	15.4	0.58	146	11.2	0.43	13.1	0.50
Respiratory System	1,209	104.2	1.38	125.6	1.64	966	73.2	1.08	88.0	1.29
Larynx	96	8.1	0.38	10.1	0.47	33	2.6	0.21	3.2	0.26
Lung & bronchus	1,100	94.8	1.31	114.0	1.56	925	69.8	1.05	84.0	1.25
Bones & Joints	7	0.9	0.15	0.9	0.15	10	1.1	0.16	1.1	0.16
Soft Tissue (incl. heart)	36	3.5	0.28	4.0	0.30	29	2.8	0.24	3.0	0.26
Skin (excl. basal & sq.)	309	29.3	0.77	33.9	0.88	204	18.7	0.62	21.0	0.67
Melanomas of the skin	290	27.5	0.75	31.8	0.85	192	17.7	0.61	19.8	0.66
Breast (excl. <i>in situ</i>)	11	1.0	0.14	1.2	0.16	1,423	117.9	1.47	139.1	1.69
Female Genital System	-	-	-	-	-	692	58.8	1.06	69.2	1.20
Cervix uteri	-	-	-	-	-	84	9.4	0.48	9.8	0.49
Uterus Corpus	-	-	-	-	-	380	30.7	0.74	37.3	0.87
Uterus, NOS ¹	-	-	-	-	-	13	1.1	0.14	1.3	0.16
Ovary	-	-	-	-	-	147	12.2	0.47	14.4	0.54
Male Genital System	1,164	96.8	1.31	117.6	1.56	-	-	-	-	-
Prostate	1,102	89.6	1.24	110.1	1.50	-	-	-	-	-
Testis	45	5.7	0.39	5.7	0.38	-	-	-	-	-
Penis	15	1.4	0.16	1.6	0.18	-	-	-	-	-
Urinary System	725	65.6	1.13	77.3	1.31	333	26.4	0.68	31.1	0.78
Bladder (incl. <i>in situ</i>)	428	38.5	0.85	45.4	1.00	135	10.4	0.41	12.2	0.48
Kidney & renal pelvis	281	25.7	0.72	30.3	0.82	192	15.5	0.53	18.4	0.61
Ureter	11	1.0	0.14	1.2	0.16	5	0.3	0.07	0.4	0.08
Eye & Orbit	15	1.4	0.17	1.6	0.20	11	1.0	0.14	1.1	0.15
Brain & Other CNS ¹	85	8.6	0.44	9.4	0.46	64	6.3	0.37	6.7	0.38
Brain	81	8.2	0.43	9.0	0.45	60	5.8	0.35	6.2	0.37
Endocrine System	84	8.4	0.43	9.4	0.47	252	27.3	0.81	29.0	0.83
Thyroid gland	76	7.6	0.41	8.5	0.44	248	26.9	0.81	28.6	0.83
Lymphomas	273	25.7	0.72	29.5	0.81	228	18.9	0.59	21.7	0.66
Hodgkin Lymphoma	26	3.0	0.27	3.1	0.28	20	2.4	0.25	2.4	0.24
Non-Hodgkin Lymphoma	247	22.7	0.67	26.4	0.76	208	16.6	0.54	19.3	0.61
Multiple Myeloma	83	7.4	0.37	8.7	0.44	57	4.3	0.26	5.1	0.31
Leukemias	197	18.7	0.62	21.3	0.69	140	11.9	0.48	13.3	0.51
Acute lymphocytic	11	1.4	0.19	1.2	0.17	8	1.0	0.16	0.9	0.15
Chronic lymphocytic	79	6.9	0.36	8.3	0.42	44	3.3	0.23	3.9	0.26
Acute myeloid	58	5.6	0.34	6.3	0.38	52	4.5	0.29	5.0	0.32
Chronic myeloid	25	2.5	0.24	2.8	0.25	24	2.1	0.21	2.4	0.22
Other leukemias	24	2.3	0.21	2.6	0.24	12	1.1	0.14	1.2	0.15
Mesothelioma	22	2.0	0.20	2.3	0.23	5	0.4	0.09	0.5	0.09
Kaposi Sarcoma	2	0.2	0.07	0.2	0.08	-	-	-	-	-
Ill-defined & Unknown	196	18.3	0.60	21.6	0.70	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	86	8.6	0.43	9.7	0.48	170	14.8	0.54	16.8	0.59
Breast (<i>in situ</i>)	-	-	-	-	-	258	21.7	0.63	26.0	0.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
West Virginia, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	184	537.0	19.40	651.4	22.74	134	379.4	15.14	452.4	17.63
Oral Cavity & Pharynx	4	13.3	3.11	15.8	3.57	2	6.2	2.06	6.9	2.21
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	1	3.5	1.62	4.5	2.03	-	-	-	-	-
Digestive System	40	114.8	8.90	139.4	10.44	27	74.5	6.61	90.8	7.87
Esophagus	1	3.7	1.56	4.1	1.70	-	-	-	-	-
Stomach	3	9.3	2.51	11.2	2.87	2	7.0	2.10	7.9	2.29
Small intestine	2	9.1	2.92	10.3	3.27	1	3.9	1.63	4.2	1.72
Colon excl. rectum	12	35.6	4.97	42.6	5.77	11	28.2	3.99	34.9	4.83
Rectum & rectosigmoid	5	12.8	2.94	16.1	3.56	4	10.5	2.52	12.7	3.01
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	16.0	2.61	22.3	3.62	2	4.4	1.51	5.9	1.96
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	6	20.8	4.03	24.7	4.65	5	13.6	2.86	16.4	3.37
Respiratory System	32	101.0	8.90	121.5	10.31	21	57.6	5.79	70.1	6.91
Larynx	2	4.9	1.67	6.4	2.07	1	4.3	1.63	5.1	1.92
Lung & bronchus	29	94.3	8.68	113.4	10.04	19	52.7	5.51	64.4	6.60
Bones & Joints	1	3.7	1.63	3.8	1.76	-	-	-	-	-
Soft Tissue (incl. heart)	1	4.5	1.84	5.0	2.03	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	40	117.6	8.59	138.7	9.89
Female Genital System	-	-	-	-	-	14	38.9	4.82	47.0	5.66
Cervix uteri	-	-	-	-	-	2	4.7	1.69	5.6	2.01
Uterus Corpus	-	-	-	-	-	7	17.7	3.10	22.6	3.85
Uterus, NOS ¹	-	-	-	-	-	1	3.3	1.38	4.1	1.66
Ovary	-	-	-	-	-	3	9.7	2.48	10.9	2.76
Male Genital System	65	172.7	10.37	217.5	12.52	-	-	-	-	-
Prostate	64	170.3	10.30	215.4	12.47	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	14	42.5	5.51	51.3	6.51	6	15.2	2.95	18.2	3.49
Bladder (incl. <i>in situ</i>)	5	16.7	3.57	20.5	4.26	2	5.6	1.71	6.6	2.01
Kidney & renal pelvis	9	25.3	4.17	30.3	4.88	3	9.6	2.41	11.6	2.86
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	4	10.0	2.42	11.0	2.60	5	15.0	3.17	16.3	3.37
Thyroid gland	3	7.5	2.14	8.2	2.27	5	15.0	3.17	16.3	3.37
Lymphomas	7	19.4	3.51	22.2	3.97	5	13.4	2.81	16.0	3.29
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	4	12.6	3.12	15.2	3.62	5	12.3	2.66	14.8	3.11
Leukemias	5	19.9	4.26	22.5	4.79	4	11.0	2.64	12.9	2.98
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	2	9.9	3.17	11.2	3.57	1	3.7	1.47	4.6	1.75
Acute myeloid	1	5.0	2.10	5.8	2.35	1	3.8	1.59	4.2	1.71
Chronic myeloid	1	4.1	1.79	4.5	2.04	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	5	16.9	3.83	20.0	4.50	4	9.6	2.31	11.6	2.76
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	9.5	2.73	10.6	3.05	2	7.0	2.19	7.5	2.28
Breast (<i>in situ</i>)	-	-	-	-	-	8	22.5	3.77	26.4	4.32

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System


WEST VIRGINIA

II-540 Incidence – Non-Hispanic Black

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	5,736,952	5,751,974	5,761,406	5,772,958	5,792,051
White	5,097,525	5,100,933	5,099,334	5,100,459	5,109,192
Black	408,173	412,498	416,246	419,746	423,734
American Indian/Alaskan Native (AI/AN)	71,143	72,136	73,106	74,293	75,185
Asian/Pacific Islander (API)	160,111	166,407	172,720	178,460	183,940


All Races Population 2013-2017: 28,815,341
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	361,391	368,625	376,554	385,643	394,097
Non-Hispanic White	4,775,673	4,772,994	4,764,744	4,758,178	4,759,470
Non-Hispanic Black	388,663	392,472	395,767	398,685	402,109

Hispanic/Latino Population, Census 2010: 336,056
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WISCONSIN CANCER REGISTRY

Initial Operation: 1976
Population-based Data Available: 1978
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.8	110.9	109.2	106.2	104.2
Missing Race	0.8	0.4	0.6	0.9	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.9	1.7	1.1	1.0	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.1	Prostate	97.0
Oral Cavity & Pharynx	98.5	Testis	99.8
Esophagus	96.9	Bladder (incl. <i>in situ</i>)	98.0
Stomach	97.7	Kidney & Renal Pelvis	89.5
Colon & Rectum	96.5	Brain & Other CNS ¹	85.0
Liver	52.4	Thyroid	99.4
Pancreas	86.3	Hodgkin Lymphoma	99.1
Lung & Bronchus	89.9	Non-Hodgkin Lymphoma	97.8
Melanomas of the Skin	99.8	Multiple Myeloma	92.4
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	91.1
Cervix uteri	98.7	Brain & Other CNS ¹ <i>non-malig</i>	35.0
Uterus Corpus & Uterus NOS ¹	99.2	Breast <i>in situ</i>	100.0
Ovary	94.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	16,693	503.7	1.79	597.4	2.08	15,899	438.3	1.61	510.8	1.83
Oral Cavity & Pharynx	612	17.7	0.33	21.6	0.39	263	7.1	0.20	8.4	0.23
Lip	37	1.2	0.09	1.4	0.10	13	0.4	0.05	0.4	0.05
Tongue	191	5.4	0.18	6.7	0.22	80	2.1	0.11	2.6	0.13
Major salivary gland	56	1.8	0.11	2.1	0.12	38	1.1	0.08	1.3	0.09
Floor of mouth	33	0.9	0.07	1.2	0.09	16	0.4	0.05	0.5	0.06
Gum & other mouth	65	2.0	0.11	2.3	0.13	57	1.5	0.09	1.8	0.11
Nasopharynx	16	0.5	0.06	0.6	0.06	7	0.2	0.04	0.2	0.04
Oropharynx	29	0.8	0.07	1.0	0.08	8	0.2	0.03	0.3	0.04
Hypopharynx	41	1.2	0.08	1.4	0.10	11	0.3	0.04	0.4	0.05
Digestive System	3,066	93.5	0.78	110.9	0.90	2,358	62.4	0.59	73.2	0.68
Esophagus	297	8.9	0.24	10.6	0.28	82	2.1	0.11	2.5	0.13
Stomach	273	8.4	0.23	9.9	0.27	141	3.8	0.15	4.4	0.17
Small intestine	108	3.3	0.15	3.9	0.17	81	2.2	0.11	2.6	0.13
Colon excl. rectum	882	27.7	0.43	32.4	0.49	927	24.7	0.37	28.5	0.42
Rectum & rectosigmoid	446	13.4	0.29	16.0	0.34	287	7.9	0.22	9.3	0.25
Anus, anal canal & anorectum	38	1.2	0.09	1.4	0.10	78	2.1	0.11	2.5	0.13
Liver	318	9.0	0.23	11.1	0.28	103	2.7	0.12	3.2	0.14
Gallbladder	26	0.8	0.08	1.0	0.09	48	1.2	0.08	1.5	0.10
Pancreas	518	15.8	0.32	18.7	0.37	446	11.4	0.25	13.5	0.29
Respiratory System	2,420	73.2	0.68	86.8	0.80	2,118	55.3	0.55	65.6	0.64
Larynx	195	5.6	0.19	6.8	0.22	48	1.2	0.08	1.5	0.10
Lung & bronchus	2,194	66.6	0.65	78.9	0.76	2,049	53.5	0.54	63.4	0.63
Bones & Joints	29	1.0	0.08	1.0	0.09	22	0.7	0.07	0.7	0.07
Soft Tissue (incl. heart)	123	4.0	0.17	4.5	0.18	102	3.0	0.14	3.4	0.15
Skin (excl. basal & sq.)	1,012	31.5	0.46	36.8	0.52	710	21.1	0.37	23.8	0.40
Melanomas of the skin	953	29.6	0.44	34.6	0.50	666	19.9	0.36	22.5	0.39
Breast (excl. <i>in situ</i>)	51	1.6	0.10	1.8	0.12	4,677	131.5	0.89	154.1	1.02
Female Genital System	-	-	-	-	-	1,979	54.1	0.56	64.5	0.65
Cervix uteri	-	-	-	-	-	191	6.4	0.22	6.9	0.22
Uterus Corpus	-	-	-	-	-	1,169	30.8	0.42	37.8	0.50
Uterus, NOS ¹	-	-	-	-	-	40	1.1	0.08	1.3	0.09
Ovary	-	-	-	-	-	419	11.5	0.26	13.5	0.30
Male Genital System	4,158	117.2	0.84	143.6	1.00	-	-	-	-	-
Prostate	3,939	109.3	0.80	135.5	0.97	-	-	-	-	-
Testis	186	6.9	0.23	6.9	0.23	-	-	-	-	-
Penis	25	0.8	0.07	0.9	0.08	-	-	-	-	-
Urinary System	2,123	65.8	0.66	77.4	0.76	855	23.0	0.36	26.7	0.41
Bladder (incl. <i>in situ</i>)	1,237	39.0	0.51	45.7	0.59	380	9.8	0.23	11.5	0.27
Kidney & renal pelvis	845	25.5	0.40	30.1	0.47	452	12.5	0.27	14.5	0.31
Ureter	29	0.9	0.08	1.1	0.09	16	0.4	0.05	0.5	0.05
Eye & Orbit	37	1.1	0.08	1.3	0.10	32	0.9	0.07	1.0	0.08
Brain & Other CNS ¹	250	8.0	0.23	8.9	0.25	197	5.8	0.19	6.4	0.21
Brain	238	7.6	0.23	8.5	0.25	186	5.4	0.18	6.0	0.20
Endocrine System	244	7.8	0.23	8.8	0.25	637	21.1	0.39	22.7	0.41
Thyroid gland	223	7.1	0.22	8.0	0.24	618	20.5	0.38	22.1	0.40
Lymphomas	906	28.7	0.44	32.9	0.49	707	19.6	0.34	22.5	0.38
Hodgkin Lymphoma	105	3.6	0.16	3.8	0.17	73	2.5	0.13	2.6	0.14
Non-Hodgkin Lymphoma	800	25.1	0.41	29.1	0.46	634	17.1	0.31	19.9	0.36
Multiple Myeloma	282	8.6	0.24	10.2	0.27	216	5.6	0.17	6.7	0.20
Leukemias	673	21.1	0.37	24.4	0.42	446	12.3	0.27	13.9	0.30
Acute lymphocytic	44	1.6	0.11	1.5	0.10	33	1.2	0.09	1.1	0.09
Chronic lymphocytic	290	8.7	0.24	10.4	0.28	170	4.3	0.15	5.2	0.18
Acute myeloid	174	5.6	0.19	6.4	0.22	130	3.7	0.15	4.1	0.16
Chronic myeloid	99	3.2	0.15	3.6	0.16	70	2.0	0.11	2.2	0.12
Other leukemias	66	2.1	0.12	2.4	0.13	43	1.1	0.08	1.3	0.09
Mesothelioma	63	2.1	0.12	2.4	0.14	22	0.6	0.06	0.7	0.06
Kaposi Sarcoma	6	0.2	0.04	0.2	0.04	-	-	-	-	-
Ill-defined & Unknown	639	20.6	0.37	23.9	0.43	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	316	10.2	0.26	11.5	0.29	680	19.4	0.35	22.1	0.38
Breast (<i>in situ</i>)	6	0.2	0.04	0.2	0.04	1,158	33.4	0.46	39.2	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, White

<i>SITES</i>	MALES (WHITE)					FEMALES (WHITE)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	15,479	496.1	1.84	587.2	2.13	14,703	434.8	1.67	506.3	1.90
Oral Cavity & Pharynx	574	17.6	0.34	21.6	0.41	243	7.0	0.21	8.3	0.24
Lip	36	1.2	0.09	1.4	0.11	13	0.4	0.05	0.4	0.05
Tongue	184	5.6	0.19	6.9	0.23	77	2.2	0.12	2.6	0.14
Major salivary gland	53	1.8	0.11	2.1	0.13	33	1.0	0.09	1.2	0.09
Floor of mouth	31	0.9	0.08	1.1	0.09	16	0.4	0.05	0.5	0.06
Gum & other mouth	60	1.9	0.11	2.3	0.13	54	1.5	0.10	1.8	0.11
Nasopharynx	13	0.4	0.05	0.5	0.06	4	0.1	0.03	0.1	0.03
Oropharynx	27	0.8	0.07	1.0	0.09	8	0.2	0.04	0.3	0.04
Hypopharynx	36	1.1	0.08	1.3	0.10	10	0.3	0.04	0.3	0.05
Digestive System	2,796	90.6	0.79	107.1	0.91	2,138	60.1	0.60	70.3	0.69
Esophagus	282	8.9	0.24	10.6	0.29	72	2.0	0.11	2.3	0.12
Stomach	246	8.0	0.23	9.4	0.27	121	3.4	0.15	4.0	0.17
Small intestine	99	3.3	0.15	3.8	0.17	71	2.1	0.11	2.4	0.13
Colon excl. rectum	809	27.0	0.44	31.5	0.50	848	23.9	0.38	27.5	0.43
Rectum & rectosigmoid	410	13.2	0.30	15.7	0.35	259	7.6	0.22	9.0	0.25
Anus, anal canal & anorectum	34	1.1	0.09	1.3	0.10	75	2.1	0.12	2.6	0.14
Liver	261	7.9	0.22	9.7	0.27	87	2.5	0.12	2.9	0.14
Gallbladder	23	0.8	0.07	0.9	0.08	42	1.2	0.08	1.4	0.09
Pancreas	485	15.6	0.33	18.5	0.38	410	11.0	0.25	13.1	0.29
Respiratory System	2,235	71.3	0.69	84.5	0.81	1,959	54.2	0.56	64.3	0.65
Larynx	179	5.5	0.19	6.7	0.22	44	1.2	0.08	1.5	0.10
Lung & bronchus	2,026	64.9	0.66	76.7	0.77	1,895	52.4	0.55	62.1	0.64
Bones & Joints	28	1.0	0.09	1.1	0.09	20	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	111	3.9	0.17	4.3	0.19	93	3.0	0.15	3.3	0.16
Skin (excl. basal & sq.)	965	31.9	0.47	37.2	0.54	667	21.6	0.39	24.4	0.43
Melanomas of the skin	910	30.0	0.46	35.0	0.52	624	20.3	0.38	23.0	0.42
Breast (excl. <i>in situ</i>)	47	1.6	0.10	1.8	0.12	4,349	131.5	0.93	154.1	1.06
Female Genital System	-	-	-	-	-	1,832	53.8	0.59	64.1	0.68
Cervix uteri	-	-	-	-	-	158	5.9	0.22	6.3	0.23
Uterus Corpus	-	-	-	-	-	1,090	30.8	0.43	37.8	0.52
Uterus, NOS ¹	-	-	-	-	-	35	1.0	0.08	1.2	0.09
Ovary	-	-	-	-	-	393	11.6	0.27	13.6	0.31
Male Genital System	3,796	113.8	0.85	139.0	1.02	-	-	-	-	-
Prostate	3,587	105.2	0.81	130.3	0.98	-	-	-	-	-
Testis	177	7.5	0.26	7.5	0.25	-	-	-	-	-
Penis	25	0.8	0.08	1.0	0.09	-	-	-	-	-
Urinary System	2,018	66.0	0.67	77.6	0.78	794	22.7	0.37	26.4	0.42
Bladder (incl. <i>in situ</i>)	1,196	39.6	0.52	46.4	0.60	363	9.9	0.24	11.6	0.28
Kidney & renal pelvis	781	25.1	0.41	29.7	0.48	411	12.2	0.28	14.1	0.32
Ureter	29	1.0	0.08	1.1	0.09	15	0.4	0.05	0.5	0.05
Eye & Orbit	36	1.2	0.09	1.4	0.10	31	0.9	0.08	1.1	0.09
Brain & Other CNS ¹	235	8.1	0.25	9.1	0.27	186	6.0	0.21	6.6	0.22
Brain	225	7.7	0.24	8.7	0.26	176	5.6	0.20	6.2	0.21
Endocrine System	229	8.0	0.24	8.9	0.27	584	21.6	0.42	23.2	0.43
Thyroid gland	210	7.3	0.23	8.2	0.26	567	21.0	0.41	22.6	0.43
Lymphomas	854	28.8	0.45	33.1	0.51	661	19.6	0.36	22.6	0.40
Hodgkin Lymphoma	94	3.6	0.17	3.8	0.17	66	2.5	0.14	2.6	0.15
Non-Hodgkin Lymphoma	759	25.2	0.42	29.3	0.48	595	17.1	0.33	20.0	0.37
Multiple Myeloma	252	8.2	0.24	9.6	0.27	189	5.2	0.17	6.2	0.20
Leukemias	636	21.2	0.39	24.5	0.44	416	12.2	0.28	13.9	0.31
Acute lymphocytic	40	1.6	0.12	1.5	0.11	30	1.2	0.10	1.1	0.09
Chronic lymphocytic	278	8.9	0.24	10.6	0.29	162	4.4	0.16	5.3	0.19
Acute myeloid	164	5.5	0.20	6.4	0.22	122	3.6	0.15	4.1	0.17
Chronic myeloid	93	3.1	0.15	3.6	0.17	62	1.8	0.11	2.1	0.12
Other leukemias	61	2.1	0.12	2.4	0.14	40	1.1	0.08	1.3	0.09
Mesothelioma	60	2.1	0.13	2.4	0.14	21	0.6	0.06	0.7	0.07
Kaposi Sarcoma	4	0.1	0.03	0.2	0.04	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	290	10.1	0.27	11.3	0.30	610	18.7	0.36	21.3	0.39
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.04	1,059	33.0	0.47	38.8	0.54

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	824	641.0	11.03	781.6	13.03	767	478.0	8.04	566.4	9.39
Oral Cavity & Pharynx	24	17.1	1.70	21.2	2.06	11	6.3	0.89	7.5	1.05
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.0	0.64	4.0	0.84	1	0.9	0.36	1.1	0.41
Major salivary gland	2	1.0	0.34	1.2	0.41	3	1.7	0.46	2.0	0.55
Floor of mouth	2	1.1	0.39	1.4	0.50	-	-	-	-	-
Gum & other mouth	3	2.4	0.66	2.9	0.80	2	1.4	0.42	1.7	0.50
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	2	1.3	0.51	1.5	0.56	-	-	-	-	-
Hypopharynx	4	3.5	0.83	4.3	1.02	-	-	-	-	-
Digestive System	191	145.9	5.20	178.1	6.16	146	93.0	3.59	112.0	4.24
Esophagus	11	7.6	1.12	9.3	1.33	7	4.5	0.78	5.5	0.94
Stomach	19	16.8	1.91	20.2	2.22	11	7.8	1.07	9.0	1.23
Small intestine	6	5.1	1.00	6.1	1.15	8	4.4	0.74	5.5	0.90
Colon excl. rectum	53	42.7	2.93	51.4	3.43	54	35.0	2.21	41.6	2.58
Rectum & rectosigmoid	23	16.2	1.63	19.6	1.91	16	9.6	1.09	11.6	1.31
Anus, anal canal & anorectum	3	1.9	0.51	2.1	0.55	3	2.0	0.55	2.4	0.65
Liver	42	27.8	2.05	36.2	2.58	10	5.8	0.86	7.5	1.07
Gallbladder	2	2.3	0.70	2.6	0.78	3	2.2	0.57	2.6	0.66
Pancreas	25	19.6	1.92	23.9	2.27	27	18.1	1.62	21.8	1.91
Respiratory System	145	122.7	5.03	149.1	5.90	111	72.7	3.22	88.1	3.81
Larynx	13	9.4	1.25	11.5	1.49	3	1.9	0.49	2.4	0.60
Lung & bronchus	132	113.0	4.87	137.3	5.71	108	70.6	3.18	85.6	3.75
Bones & Joints	-	-	-	-	-	1	0.6	0.25	0.7	0.29
Soft Tissue (incl. heart)	8	5.3	0.94	6.2	1.09	6	3.8	0.69	4.0	0.73
Skin (excl. basal & sq.)	2	1.9	0.62	2.1	0.69	2	1.2	0.40	1.5	0.48
Melanomas of the skin	-	-	-	-	-	1	0.7	0.27	0.9	0.35
Breast (excl. <i>in situ</i>)	3	2.0	0.55	2.6	0.69	224	136.5	4.23	160.9	4.92
Female Genital System	-	-	-	-	-	90	53.5	2.61	64.2	3.09
Cervix uteri	-	-	-	-	-	20	11.5	1.19	12.9	1.32
Uterus Corpus	-	-	-	-	-	47	28.3	1.91	35.2	2.32
Uterus, NOS ¹	-	-	-	-	-	3	2.2	0.54	2.5	0.62
Ovary	-	-	-	-	-	16	9.5	1.10	11.2	1.29
Male Genital System	252	188.9	5.82	238.7	7.07	-	-	-	-	-
Prostate	249	187.0	5.80	236.8	7.05	-	-	-	-	-
Testis	2	1.2	0.37	1.2	0.38	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	74	59.4	3.39	70.1	3.92	45	28.6	1.99	33.9	2.33
Bladder (incl. <i>in situ</i>)	26	23.5	2.26	27.9	2.61	13	9.0	1.17	10.6	1.35
Kidney & renal pelvis	47	35.3	2.51	41.5	2.90	30	18.5	1.56	21.9	1.83
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.6	0.82	5.3	0.97	7	3.6	0.66	3.9	0.73
Brain	7	4.0	0.74	4.8	0.91	5	3.0	0.60	3.4	0.69
Endocrine System	8	5.4	0.95	6.5	1.12	30	17.1	1.44	19.4	1.63
Thyroid gland	7	4.9	0.93	5.9	1.09	28	15.6	1.36	17.7	1.55
Lymphomas	30	21.7	1.96	23.9	2.14	28	17.2	1.51	19.5	1.71
Hodgkin Lymphoma	7	4.0	0.73	4.0	0.74	5	2.7	0.54	2.8	0.56
Non-Hodgkin Lymphoma	23	17.7	1.81	19.9	2.01	23	14.5	1.42	16.6	1.61
Multiple Myeloma	24	20.6	2.07	24.0	2.34	22	15.1	1.49	17.8	1.72
Leukemias	25	20.3	2.04	23.5	2.33	20	12.9	1.35	14.4	1.51
Acute lymphocytic	2	0.9	0.31	0.9	0.34	2	0.8	0.26	0.7	0.25
Chronic lymphocytic	9	8.3	1.33	10.1	1.56	6	4.0	0.79	4.8	0.93
Acute myeloid	6	5.4	1.08	6.2	1.23	5	3.3	0.68	3.5	0.74
Chronic myeloid	4	2.9	0.76	3.2	0.83	6	3.5	0.70	3.8	0.76
Other leukemias	3	2.7	0.74	3.0	0.82	2	1.3	0.41	1.6	0.49
Mesothelioma	2	1.3	0.48	1.5	0.55	-	-	-	-	-
Kaposi Sarcoma	2	1.0	0.34	1.1	0.35	-	-	-	-	-
Ill-defined & Unknown	25	22.5	2.27	27.2	2.67	22	15.1	1.51	17.7	1.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	12.6	1.57	14.5	1.81	48	31.6	2.11	36.3	2.41
Breast (<i>in situ</i>)	-	-	-	-	-	71	44.0	2.40	51.9	2.79

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	111	283.9	13.69	333.2	15.93	173	309.3	11.24	360.7	13.11
Oral Cavity & Pharynx	5	11.3	2.41	12.6	2.69	5	8.3	1.71	9.5	1.99
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	1	1.8	0.72	2.2	0.90
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	2	5.3	1.72	5.6	1.87	2	3.6	1.14	3.9	1.27
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	34	88.9	7.61	105.3	8.85	33	65.4	5.37	77.6	6.32
Esophagus	1	3.2	1.41	3.8	1.66	-	-	-	-	-
Stomach	4	13.2	3.16	15.2	3.62	5	10.9	2.24	13.0	2.65
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	20.3	3.57	24.1	4.19	11	20.9	3.02	24.4	3.50
Rectum & rectosigmoid	5	11.4	2.47	14.2	3.00	5	9.8	2.06	11.0	2.33
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	8	20.7	3.71	24.5	4.34	3	6.3	1.67	7.8	2.01
Gallbladder	-	-	-	-	-	1	2.9	1.23	3.3	1.38
Pancreas	3	10.0	2.57	11.7	2.94	4	9.1	2.03	11.3	2.48
Respiratory System	14	44.9	5.83	52.4	6.71	21	46.8	4.74	54.6	5.43
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	13	41.9	5.70	48.7	6.55	21	45.9	4.71	53.3	5.37
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	2	3.5	1.62	4.0	1.92	1	2.0	0.84	2.0	0.86
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	45	75.3	5.26	89.3	6.29
Female Genital System	-	-	-	-	-	26	42.3	3.91	49.3	4.59
Cervix uteri	-	-	-	-	-	6	10.8	2.02	12.5	2.35
Uterus Corpus	-	-	-	-	-	13	21.4	2.79	24.8	3.26
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	5	8.0	1.66	9.6	1.99
Male Genital System	20	52.5	5.89	62.7	6.91	-	-	-	-	-
Prostate	18	50.6	5.86	60.9	6.88	-	-	-	-	-
Testis	2	1.9	0.61	1.8	0.56	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	8	23.9	4.04	28.4	4.72	4	8.8	1.94	10.2	2.24
Bladder (incl. <i>in situ</i>)	4	12.1	3.06	14.1	3.54	1	3.1	1.20	3.7	1.42
Kidney & renal pelvis	5	11.8	2.64	14.3	3.12	3	4.9	1.40	5.4	1.54
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	3	5.2	1.69	6.1	2.01	2	1.9	0.68	2.0	0.78
Brain	3	5.2	1.69	6.1	2.01	1	1.7	0.65	1.8	0.77
Endocrine System	3	5.7	1.59	6.7	1.91	13	17.0	2.29	18.3	2.53
Thyroid gland	3	5.7	1.59	6.7	1.91	13	16.8	2.28	18.1	2.53
Lymphomas	9	19.0	3.36	22.0	3.95	9	18.5	2.95	21.4	3.37
Hodgkin Lymphoma	2	2.8	1.19	2.9	1.35	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	2	5.9	1.93	7.2	2.25	2	3.0	1.10	3.9	1.40
Leukemias	4	9.7	2.73	10.8	3.14	5	8.3	1.84	9.4	2.12
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	5.4	2.27	6.1	2.64	2	4.0	1.30	4.4	1.46
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	4	7.7	2.12	8.9	2.45	5	10.4	2.32	11.8	2.62
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	4	9.5	2.30	10.9	2.68	10	18.5	2.80	20.8	3.15
Breast (<i>in situ</i>)	-	-	-	-	-	13	21.0	2.68	24.7	3.19

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	93	637.4	35.16	763.0	41.37	108	599.1	27.07	701.4	31.07
Oral Cavity & Pharynx	5	23.6	4.88	28.8	5.94	2	12.6	3.81	15.1	4.42
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	1	6.2	2.57	7.0	2.86	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	24	167.9	18.57	202.7	21.96	21	115.7	11.92	137.1	13.77
Esophagus	2	17.5	6.85	20.9	8.13	1	7.0	3.03	8.3	3.49
Stomach	3	21.4	6.87	25.0	7.87	2	11.9	4.03	12.1	4.08
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	6	42.7	9.88	52.7	11.94	7	36.2	6.49	45.5	7.98
Rectum & rectosigmoid	5	32.0	6.85	37.5	7.86	4	22.6	5.44	25.7	6.08
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	4	27.3	7.88	34.7	9.61	2	9.5	3.36	11.7	3.96
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	3	19.0	5.68	22.8	6.57	2	10.3	3.59	12.1	4.08
Respiratory System	13	94.4	13.57	111.3	15.73	18	107.2	11.83	124.6	13.43
Larynx	1	7.9	3.19	10.1	3.89	-	-	-	-	-
Lung & bronchus	11	85.0	13.10	99.6	15.17	17	102.9	11.61	119.3	13.17
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	2	7.5	2.68	9.1	3.23
Melanomas of the skin	-	-	-	-	-	1	6.6	2.51	7.9	2.99
Breast (excl. <i>in situ</i>)	-	-	-	-	-	29	153.3	13.36	181.1	15.49
Female Genital System	-	-	-	-	-	13	68.7	9.05	81.7	10.64
Cervix uteri	-	-	-	-	-	3	17.2	4.63	18.2	4.99
Uterus Corpus	-	-	-	-	-	7	37.7	6.66	46.3	8.00
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	9.1	3.39	11.3	4.16
Male Genital System	23	142.2	15.21	172.1	17.90	-	-	-	-	-
Prostate	20	131.6	14.88	161.9	17.64	-	-	-	-	-
Testis	2	10.5	3.16	10.2	3.01	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	11	76.8	12.39	92.4	14.60	6	35.9	6.85	42.6	7.99
Bladder (incl. <i>in situ</i>)	4	38.0	9.94	45.3	11.74	2	10.1	3.82	12.4	4.55
Kidney & renal pelvis	6	36.7	7.09	45.1	8.43	4	24.1	5.43	28.6	6.35
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	1	6.9	2.72	8.0	3.22	2	9.0	3.27	10.0	3.57
Brain	1	6.9	2.72	8.0	3.22	2	9.0	3.27	10.0	3.57
Endocrine System	-	-	-	-	-	4	19.4	4.51	21.8	5.01
Thyroid gland	-	-	-	-	-	4	17.7	4.19	20.2	4.72
Lymphomas	5	34.6	8.57	40.8	10.07	3	18.1	4.50	21.3	5.21
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	4	32.0	8.44	38.1	9.94	3	15.2	4.19	18.1	4.87
Multiple Myeloma	2	16.2	6.21	19.8	7.44	2	10.5	3.82	11.4	4.07
Leukemias	4	24.0	7.29	26.9	8.47	2	9.9	3.41	11.3	3.88
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	1	8.5	4.08	9.8	4.72	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	29.6	9.79	34.8	11.49	4	27.3	6.30	29.5	6.77
Selected tumors (non-invasive)										
Brain & Other CNS ² (non-malig)	2	11.2	4.02	12.5	4.37	4	21.7	5.13	23.4	5.49
Breast (<i>in situ</i>)	-	-	-	-	-	5	27.0	5.47	32.8	6.48

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
 - Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.
¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)
² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	294	357.8	11.13	423.3	12.84	301	310.3	8.88	363.7	10.38
Oral Cavity & Pharynx	7	7.1	1.46	8.8	1.77	4	4.1	0.95	4.7	1.11
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	1	1.4	0.68	1.9	0.87	1	1.3	0.53	1.5	0.63
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	79	97.0	5.74	115.2	6.59	47	57.3	4.06	67.3	4.70
Esophagus	5	5.8	1.39	6.6	1.54	-	-	-	-	-
Stomach	10	12.2	2.02	14.4	2.32	7	7.7	1.49	8.7	1.69
Small intestine	3	4.1	1.27	4.7	1.39	2	2.2	0.78	2.5	0.88
Colon excl. rectum	14	17.4	2.50	20.3	2.85	15	18.6	2.34	21.6	2.67
Rectum & rectosigmoid	11	11.3	1.73	13.8	2.05	6	6.3	1.23	7.4	1.43
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	18	21.4	2.59	26.5	3.06	4	5.7	1.32	7.0	1.56
Gallbladder	-	-	-	-	-	2	1.8	0.64	2.3	0.81
Pancreas	11	15.8	2.42	18.5	2.73	7	9.4	1.72	11.1	1.98
Respiratory System	30	47.1	4.38	55.3	4.98	20	25.8	2.76	31.1	3.23
Larynx	4	5.9	1.50	7.3	1.75	-	-	-	-	-
Lung & bronchus	24	40.2	4.10	46.7	4.63	20	25.6	2.76	30.9	3.23
Bones & Joints	1	1.2	0.61	1.3	0.70	-	-	-	-	-
Soft Tissue (incl. heart)	4	3.9	1.11	3.9	1.14	4	4.0	1.01	4.8	1.22
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	4	6.6	1.63	7.8	1.90	4	3.5	0.85	4.4	1.07
Breast (excl. <i>in situ</i>)	-	-	-	-	-	81	82.7	4.48	97.8	5.27
Female Genital System	-	-	-	-	-	49	47.2	3.27	57.1	3.98
Cervix uteri	-	-	-	-	-	11	8.3	1.18	8.9	1.35
Uterus Corpus	-	-	-	-	-	25	24.9	2.37	31.4	2.97
Uterus, NOS ¹	-	-	-	-	-	2	1.9	0.71	2.3	0.86
Ovary	-	-	-	-	-	10	10.5	1.63	12.8	1.98
Male Genital System	73	86.2	5.24	105.4	6.16	-	-	-	-	-
Prostate	61	79.4	5.13	98.2	6.06	-	-	-	-	-
Testis	11	5.1	0.72	5.1	0.74	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	34	42.4	3.84	50.2	4.47	16	15.9	2.00	18.4	2.33
Bladder (incl. <i>in situ</i>)	10	15.5	2.57	18.2	2.96	4	4.9	1.24	5.7	1.44
Kidney & renal pelvis	24	25.0	2.69	30.0	3.18	12	11.0	1.57	12.6	1.83
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	6	5.7	1.34	6.3	1.52	4	3.6	0.91	3.9	1.03
Brain	6	5.4	1.33	6.0	1.52	4	3.4	0.89	3.7	1.01
Endocrine System	6	4.1	0.88	4.5	1.02	26	19.2	1.84	20.8	2.08
Thyroid gland	5	3.8	0.86	4.2	1.00	25	18.4	1.80	19.9	2.03
Lymphomas	18	18.8	2.52	21.3	2.85	19	21.0	2.44	23.7	2.73
Hodgkin Lymphoma	3	2.5	0.90	2.8	1.00	2	1.8	0.62	1.9	0.68
Non-Hodgkin Lymphoma	15	16.3	2.36	18.5	2.67	16	19.1	2.36	21.8	2.65
Multiple Myeloma	4	6.7	1.73	7.5	1.93	4	5.5	1.30	6.7	1.54
Leukemias	14	12.2	1.86	13.6	2.14	10	8.0	1.38	8.6	1.54
Acute lymphocytic	-	-	-	-	-	4	2.5	0.69	2.5	0.79
Chronic lymphocytic	3	4.7	1.33	5.5	1.56	-	-	-	-	-
Acute myeloid	4	3.0	0.90	3.3	1.00	2	1.7	0.56	1.9	0.66
Chronic myeloid	2	1.9	0.76	2.2	0.87	3	2.6	0.84	2.8	0.91
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	2	4.5	1.51	5.1	1.69	-	-	-	-	-
Kaposi Sarcoma	1	0.9	0.40	1.0	0.48	-	-	-	-	-
Ill-defined & Unknown	9	11.7	2.07	14.1	2.46	8	10.0	1.74	11.7	2.03
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	9	11.6	2.14	12.9	2.38	21	21.5	2.35	24.9	2.72
Breast (<i>in situ</i>)	-	-	-	-	-	27	28.1	2.64	33.4	3.10

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

WISCONSIN

II-548 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	15,210	499.9	1.87	591.6	2.16	14,429	438.8	1.71	510.6	1.94
Oral Cavity & Pharynx	568	17.9	0.35	21.9	0.41	238	7.0	0.21	8.4	0.25
Lip	36	1.2	0.09	1.4	0.11	13	0.4	0.05	0.4	0.05
Tongue	183	5.7	0.19	7.0	0.23	75	2.2	0.12	2.6	0.14
Major salivary gland	52	1.8	0.11	2.1	0.13	32	1.0	0.09	1.2	0.09
Floor of mouth	30	0.9	0.08	1.2	0.09	16	0.4	0.05	0.6	0.06
Gum & other mouth	59	1.9	0.12	2.3	0.14	54	1.6	0.10	1.8	0.11
Nasopharynx	13	0.4	0.05	0.5	0.06	4	0.1	0.03	0.1	0.03
Oropharynx	27	0.8	0.07	1.0	0.09	7	0.2	0.04	0.3	0.04
Hypopharynx	35	1.1	0.08	1.3	0.10	9	0.3	0.04	0.3	0.05
Digestive System	2,722	90.4	0.80	106.9	0.92	2,095	60.2	0.61	70.4	0.70
Esophagus	277	9.0	0.25	10.7	0.29	71	2.0	0.11	2.4	0.13
Stomach	236	7.8	0.23	9.2	0.27	115	3.3	0.14	3.9	0.16
Small intestine	97	3.2	0.15	3.8	0.18	69	2.1	0.12	2.4	0.13
Colon excl. rectum	796	27.3	0.44	31.8	0.51	834	24.0	0.39	27.7	0.44
Rectum & rectosigmoid	399	13.3	0.31	15.8	0.36	253	7.7	0.23	9.0	0.26
Anus, anal canal & anorectum	34	1.1	0.09	1.3	0.10	74	2.2	0.12	2.7	0.14
Liver	244	7.5	0.22	9.3	0.27	83	2.4	0.12	2.8	0.14
Gallbladder	22	0.8	0.07	0.9	0.08	41	1.1	0.08	1.3	0.09
Pancreas	474	15.6	0.33	18.5	0.38	404	11.1	0.25	13.2	0.30
Respiratory System	2,207	71.8	0.70	85.2	0.82	1,940	54.8	0.57	64.9	0.67
Larynx	175	5.5	0.19	6.7	0.23	44	1.2	0.09	1.5	0.10
Lung & bronchus	2,004	65.4	0.67	77.4	0.78	1,877	53.0	0.56	62.7	0.65
Bones & Joints	26	1.0	0.09	1.1	0.10	19	0.7	0.08	0.8	0.08
Soft Tissue (incl. heart)	107	3.9	0.18	4.4	0.19	88	3.0	0.15	3.3	0.16
Skin (excl. basal & sq.)	961	32.7	0.49	38.1	0.55	663	22.4	0.41	25.2	0.45
Melanomas of the skin	906	30.8	0.47	35.9	0.54	621	21.1	0.40	23.8	0.44
Breast (excl. <i>in situ</i>)	47	1.6	0.11	1.8	0.12	4,276	133.3	0.96	155.9	1.08
Female Genital System	-	-	-	-	-	1,787	53.9	0.60	64.3	0.69
Cervix uteri	-	-	-	-	-	149	5.9	0.23	6.2	0.23
Uterus Corpus	-	-	-	-	-	1,067	30.9	0.44	37.9	0.53
Uterus, NOS ¹	-	-	-	-	-	34	1.0	0.08	1.2	0.09
Ovary	-	-	-	-	-	384	11.7	0.28	13.7	0.32
Male Genital System	3,731	114.7	0.86	140.0	1.03	-	-	-	-	-
Prostate	3,534	105.9	0.82	131.2	0.99	-	-	-	-	-
Testis	167	7.7	0.27	7.6	0.26	-	-	-	-	-
Penis	24	0.8	0.08	0.9	0.09	-	-	-	-	-
Urinary System	1,985	66.4	0.69	78.1	0.79	779	22.7	0.38	26.5	0.43
Bladder (incl. <i>in situ</i>)	1,187	40.1	0.53	47.0	0.61	359	10.0	0.24	11.7	0.28
Kidney & renal pelvis	759	25.0	0.42	29.6	0.48	400	12.2	0.28	14.1	0.32
Ureter	28	1.0	0.08	1.1	0.09	15	0.4	0.05	0.5	0.06
Eye & Orbit	36	1.2	0.09	1.4	0.11	30	0.9	0.08	1.1	0.09
Brain & Other CNS ¹	230	8.3	0.26	9.2	0.27	181	6.1	0.22	6.7	0.23
Brain	220	7.9	0.25	8.8	0.27	172	5.7	0.21	6.3	0.22
Endocrine System	224	8.1	0.26	9.1	0.28	559	21.8	0.44	23.3	0.45
Thyroid gland	206	7.5	0.24	8.4	0.26	544	21.2	0.43	22.7	0.44
Lymphomas	837	29.1	0.47	33.4	0.52	644	19.7	0.36	22.6	0.41
Hodgkin Lymphoma	92	3.7	0.18	3.9	0.18	64	2.6	0.15	2.7	0.15
Non-Hodgkin Lymphoma	745	25.4	0.43	29.5	0.49	580	17.0	0.33	19.9	0.38
Multiple Myeloma	249	8.2	0.24	9.7	0.28	185	5.2	0.17	6.1	0.20
Leukemias	623	21.4	0.40	24.7	0.45	406	12.2	0.29	14.0	0.32
Acute lymphocytic	36	1.6	0.12	1.5	0.11	26	1.1	0.11	1.1	0.09
Chronic lymphocytic	275	9.0	0.25	10.7	0.29	162	4.5	0.16	5.4	0.19
Acute myeloid	161	5.6	0.20	6.4	0.23	120	3.7	0.16	4.2	0.17
Chronic myeloid	91	3.1	0.15	3.6	0.17	59	1.8	0.11	2.0	0.12
Other leukemias	60	2.1	0.13	2.4	0.14	40	1.1	0.09	1.3	0.10
Mesothelioma	58	2.1	0.13	2.4	0.14	21	0.6	0.06	0.7	0.07
Kaposi Sarcoma	3	0.1	0.03	0.1	0.03	-	-	-	-	-
Ill-defined & Unknown	595	20.7	0.39	23.9	0.44	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	281	10.1	0.28	11.4	0.31	591	18.7	0.36	21.3	0.40
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.04	1,035	33.4	0.49	39.1	0.55

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wisconsin, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	822	654.9	11.27	798.4	13.32	763	487.7	8.21	577.4	9.58
Oral Cavity & Pharynx	24	17.5	1.74	21.6	2.10	11	6.5	0.91	7.7	1.07
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	5	3.1	0.66	4.1	0.86	1	0.9	0.37	1.1	0.42
Major salivary gland	2	1.1	0.35	1.3	0.42	3	1.7	0.47	2.0	0.56
Floor of mouth	2	1.1	0.40	1.4	0.51	-	-	-	-	-
Gum & other mouth	3	2.5	0.68	3.0	0.82	2	1.5	0.43	1.7	0.51
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	2	1.3	0.52	1.5	0.57	-	-	-	-	-
Hypopharynx	4	3.6	0.85	4.5	1.04	-	-	-	-	-
Digestive System	191	149.3	5.33	182.3	6.31	145	94.7	3.66	114.0	4.32
Esophagus	11	7.8	1.15	9.5	1.36	7	4.6	0.79	5.7	0.95
Stomach	19	17.3	1.95	20.7	2.27	11	7.8	1.07	9.0	1.23
Small intestine	6	5.2	1.02	6.2	1.18	8	4.5	0.75	5.6	0.92
Colon excl. rectum	53	43.8	3.00	52.7	3.51	54	35.8	2.26	42.6	2.64
Rectum & rectosigmoid	23	16.6	1.67	20.1	1.96	16	9.9	1.12	11.9	1.34
Anus, anal canal & anorectum	3	2.0	0.53	2.1	0.57	3	2.1	0.56	2.5	0.66
Liver	42	28.5	2.09	37.0	2.64	10	5.7	0.86	7.3	1.08
Gallbladder	2	2.3	0.72	2.6	0.80	3	2.3	0.58	2.7	0.67
Pancreas	25	19.8	1.96	24.1	2.32	27	18.5	1.66	22.3	1.95
Respiratory System	145	125.1	5.13	152.0	6.03	111	74.1	3.28	89.7	3.88
Larynx	13	9.6	1.28	11.7	1.52	3	2.0	0.50	2.4	0.61
Lung & bronchus	131	115.2	4.97	139.9	5.82	107	71.9	3.24	87.1	3.82
Bones & Joints	-	-	-	-	-	1	0.6	0.24	0.6	0.28
Soft Tissue (incl. heart)	8	5.4	0.97	6.4	1.12	6	3.9	0.72	4.1	0.76
Skin (excl. basal & sq.)	2	2.0	0.64	2.2	0.71	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	1	0.7	0.28	0.9	0.36
Breast (excl. <i>in situ</i>)	3	2.0	0.56	2.7	0.70	223	139.5	4.32	164.2	5.02
Female Genital System	-	-	-	-	-	89	54.5	2.67	65.4	3.15
Cervix uteri	-	-	-	-	-	20	11.8	1.22	13.2	1.36
Uterus Corpus	-	-	-	-	-	47	28.7	1.95	35.7	2.37
Uterus, NOS ¹	-	-	-	-	-	3	2.2	0.56	2.6	0.64
Ovary	-	-	-	-	-	16	9.7	1.13	11.5	1.32
Male Genital System	251	192.4	5.94	243.4	7.22	-	-	-	-	-
Prostate	248	190.5	5.91	241.4	7.20	-	-	-	-	-
Testis	2	1.2	0.39	1.3	0.39	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	74	60.6	3.46	71.5	3.99	44	29.1	2.03	34.4	2.37
Bladder (incl. <i>in situ</i>)	26	24.1	2.31	28.5	2.66	12	8.9	1.18	10.5	1.36
Kidney & renal pelvis	47	35.9	2.55	42.2	2.95	30	18.9	1.60	22.4	1.87
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	8	4.7	0.84	5.4	1.00	7	3.7	0.68	4.1	0.75
Brain	7	4.1	0.77	4.9	0.94	5	3.1	0.62	3.5	0.71
Endocrine System	8	5.6	0.98	6.7	1.15	30	17.3	1.47	19.7	1.67
Thyroid gland	7	5.0	0.95	6.0	1.11	27	15.7	1.39	17.9	1.58
Lymphomas	30	22.4	2.01	24.6	2.19	28	17.8	1.56	20.0	1.75
Hodgkin Lymphoma	7	4.2	0.76	4.2	0.76	5	2.8	0.56	3.0	0.59
Non-Hodgkin Lymphoma	23	18.2	1.86	20.5	2.05	23	14.9	1.45	17.0	1.65
Multiple Myeloma	24	21.1	2.12	24.6	2.40	22	15.4	1.52	18.2	1.75
Leukemias	25	20.8	2.08	24.0	2.38	20	13.2	1.38	14.8	1.55
Acute lymphocytic	2	1.0	0.33	1.0	0.35	2	0.8	0.28	0.8	0.26
Chronic lymphocytic	9	8.5	1.36	10.4	1.60	6	4.1	0.80	4.9	0.95
Acute myeloid	6	5.6	1.10	6.4	1.26	5	3.4	0.70	3.6	0.76
Chronic myeloid	4	2.9	0.78	3.2	0.85	6	3.6	0.72	3.9	0.78
Other leukemias	3	2.8	0.76	3.1	0.84	2	1.4	0.42	1.6	0.50
Mesothelioma	2	1.3	0.49	1.5	0.56	-	-	-	-	-
Kaposi Sarcoma	2	1.1	0.35	1.1	0.37	-	-	-	-	-
Ill-defined & Unknown	25	23.1	2.32	27.9	2.74	22	15.5	1.54	18.1	1.79
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	16	12.9	1.62	14.9	1.85	48	32.3	2.16	37.1	2.46
Breast (<i>in situ</i>)	-	-	-	-	-	71	45.0	2.46	53.0	2.85

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.


- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Race-Specific Population Counts by Year¹

Race	2013	2014	2015	2016	2017
All Races	582,123	582,548	585,668	584,290	578,934
White	547,855	548,562	551,538	549,909	544,321
Black	10,817	10,139	9,846	9,886	10,007
American Indian/Alaskan Native (AI/AN)	16,851	17,209	17,363	17,395	17,322
Asian/Pacific Islander (API)	6,600	6,638	6,921	7,100	7,284


All Races Population 2013-2017: 2,913,563
Distribution of Population by Race




Hispanic/Latino Population Counts by Year¹

Ethnicity	2013	2014	2015	2016	2017
Hispanic/Latino, All Races	55,312	56,164	57,122	57,867	57,792
Non-Hispanic White	498,010	498,116	500,330	498,084	492,636
Non-Hispanic Black	9,568	8,883	8,566	8,562	8,665

Hispanic/Latino Population, Census 2010: 50,231
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WYOMING CANCER REGISTRY

Initial Operation: 1967
Population-based Data Available: 1962
Coverage Area: State

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	90.0	97.1	96.3	98.8	98.7
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.5	0.6	1.1	0.7	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Prostate	97.7
Oral Cavity & Pharynx	99.2	Testis	100.0
Esophagus	97.9	Bladder (incl. <i>in situ</i>)	98.4
Stomach	96.6	Kidney & Renal Pelvis	93.8
Colon & Rectum	97.0	Brain & Other CNS ¹	87.1
Liver	57.5	Thyroid	100.0
Pancreas	80.2	Hodgkin Lymphoma	98.4
Lung & Bronchus	85.6	Non-Hodgkin Lymphoma	97.7
Melanomas of the Skin	99.9	Multiple Myeloma	88.6
Female Breast (excl. <i>in situ</i>)	99.1	Leukemias	87.2
Cervix uteri	98.9	Brain & Other CNS ¹ <i>non-malig</i>	54.5
Uterus Corpus & Uterus NOS ¹	99.0	Breast <i>in situ</i>	100.0
Ovary	95.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,446	431.5	5.28	511.2	6.12	1,262	376.6	4.92	437.3	5.57
Oral Cavity & Pharynx	51	14.8	0.97	17.8	1.13	20	5.7	0.59	6.8	0.69
Lip	3	0.9	0.24	1.0	0.28	1	0.4	0.15	0.5	0.18
Tongue	17	4.8	0.56	5.9	0.65	6	1.4	0.27	1.8	0.34
Major salivary gland	5	1.7	0.35	1.9	0.37	3	0.8	0.23	0.9	0.25
Floor of mouth	2	0.5	0.18	0.7	0.22	1	0.3	0.14	0.4	0.17
Gum & other mouth	5	1.5	0.31	1.7	0.36	5	1.5	0.31	1.7	0.34
Nasopharynx	1	0.4	0.15	0.4	0.18	-	-	-	-	-
Oropharynx	3	0.9	0.22	1.1	0.28	-	-	-	-	-
Hypopharynx	2	0.7	0.22	0.9	0.26	-	-	-	-	-
Digestive System	263	78.7	2.26	93.4	2.62	185	53.8	1.82	63.1	2.10
Esophagus	23	6.8	0.66	8.0	0.76	5	1.4	0.28	1.7	0.34
Stomach	21	6.5	0.66	7.5	0.75	9	2.6	0.41	3.0	0.46
Small intestine	10	2.9	0.43	3.5	0.51	8	2.2	0.37	2.6	0.43
Colon excl. rectum	74	22.9	1.24	26.7	1.41	73	21.6	1.16	24.9	1.32
Rectum & rectosigmoid	43	13.0	0.92	15.4	1.06	25	7.6	0.71	8.8	0.80
Anus, anal canal & anorectum	4	1.3	0.28	1.5	0.32	6	1.7	0.31	2.1	0.38
Liver	32	8.3	0.68	10.6	0.85	10	2.7	0.38	3.3	0.47
Gallbladder	2	0.5	0.19	0.6	0.22	6	1.7	0.32	2.0	0.37
Pancreas	43	12.8	0.91	15.2	1.06	32	8.8	0.71	10.6	0.84
Respiratory System	165	50.1	1.81	59.2	2.09	148	42.1	1.58	50.0	1.85
Larynx	14	3.8	0.47	4.7	0.57	5	1.5	0.30	1.9	0.36
Lung & bronchus	148	45.2	1.73	53.2	1.99	141	40.0	1.54	47.4	1.80
Bones & Joints	3	1.1	0.28	1.1	0.29	2	0.7	0.24	0.7	0.22
Soft Tissue (incl. heart)	11	3.3	0.46	3.9	0.53	11	3.3	0.47	3.6	0.50
Skin (excl. basal & sq.)	99	30.8	1.44	36.2	1.66	-	-	-	-	-
Melanomas of the skin	88	27.0	1.34	31.8	1.55	64	19.7	1.15	22.6	1.28
Breast (excl. <i>in situ</i>)	5	1.7	0.35	2.0	0.40	376	112.5	2.70	131.9	3.08
Female Genital System	-	-	-	-	-	147	43.3	1.67	51.5	1.92
Cervix uteri	-	-	-	-	-	19	6.4	0.70	6.8	0.72
Uterus Corpus	-	-	-	-	-	78	21.9	1.16	26.9	1.38
Uterus, NOS ¹	-	-	-	-	-	2	0.6	0.19	0.7	0.22
Ovary	-	-	-	-	-	36	10.9	0.84	12.7	0.97
Male Genital System	420	117.0	2.65	142.1	3.14	-	-	-	-	-
Prostate	394	108.1	2.53	133.1	3.04	-	-	-	-	-
Testis	23	8.1	0.77	7.9	0.75	-	-	-	-	-
Penis	2	0.7	0.21	0.8	0.25	-	-	-	-	-
Urinary System	173	54.2	1.92	63.2	2.19	63	18.3	1.07	21.4	1.22
Bladder (incl. <i>in situ</i>)	109	34.8	1.54	40.5	1.77	29	8.0	0.69	9.6	0.81
Kidney & renal pelvis	61	18.4	1.10	21.5	1.25	33	9.8	0.79	11.2	0.88
Ureter	3	0.9	0.26	1.1	0.29	-	-	-	-	-
Eye & Orbit	4	1.2	0.27	1.3	0.31	2	0.7	0.21	0.7	0.21
Brain & Other CNS ¹	22	7.1	0.70	7.9	0.77	20	6.1	0.64	6.8	0.69
Brain	21	6.8	0.68	7.7	0.76	19	5.7	0.62	6.4	0.67
Endocrine System	26	7.9	0.73	9.1	0.81	69	24.4	1.37	25.6	1.40
Thyroid gland	24	7.5	0.70	8.6	0.79	66	23.8	1.36	24.8	1.38
Lymphomas	74	23.3	1.26	27.0	1.43	51	15.2	0.99	17.6	1.11
Hodgkin Lymphoma	8	2.7	0.43	2.8	0.46	5	1.8	0.37	1.8	0.36
Non-Hodgkin Lymphoma	66	20.7	1.18	24.1	1.36	-	-	-	-	-
Multiple Myeloma	21	6.1	0.62	7.3	0.73	16	4.7	0.53	5.5	0.61
Leukemias	51	15.9	1.03	18.4	1.17	33	9.7	0.78	11.1	0.87
Acute lymphocytic	4	1.5	0.33	1.4	0.31	5	1.8	0.36	1.6	0.32
Chronic lymphocytic	19	5.7	0.60	6.9	0.71	10	2.7	0.39	3.3	0.47
Acute myeloid	15	4.8	0.58	5.5	0.65	10	2.9	0.42	3.5	0.49
Chronic myeloid	7	2.1	0.38	2.5	0.43	4	1.3	0.29	1.5	0.33
Other leukemias	-	-	-	-	-	4	1.0	0.24	1.2	0.28
Mesothelioma	5	1.7	0.36	2.0	0.40	3	0.8	0.23	0.9	0.25
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	51	16.2	1.05	19.1	1.21	48	14.4	0.95	16.3	1.06
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	26	8.3	0.76	9.3	0.83	45	14.4	1.00	16.0	1.08
Breast (<i>in situ</i>)	1	0.4	0.17	0.5	0.20	58	18.2	1.12	21.2	1.27

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, White

SITES	MALES (WHITE)					FEMALES (WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,403	432.3	5.37	512.5	6.22	1,221	378.1	5.03	439.3	5.69
Oral Cavity & Pharynx	49	14.8	0.99	17.9	1.16	20	5.7	0.60	6.9	0.71
Lip	3	0.9	0.25	1.0	0.28	1	0.4	0.15	0.5	0.19
Tongue	16	5.0	0.58	6.0	0.68	5	1.4	0.28	1.8	0.35
Major salivary gland	5	1.7	0.36	1.8	0.38	3	0.8	0.24	0.9	0.26
Floor of mouth	2	0.6	0.18	0.7	0.23	1	0.3	0.15	0.4	0.18
Gum & other mouth	5	1.4	0.31	1.7	0.36	5	1.4	0.32	1.6	0.34
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	3	0.8	0.22	1.1	0.28	-	-	-	-	-
Hypopharynx	2	0.8	0.23	0.9	0.27	-	-	-	-	-
Digestive System	252	77.6	2.28	92.1	2.64	178	53.5	1.85	62.8	2.13
Esophagus	22	6.8	0.67	8.0	0.77	5	1.3	0.27	1.6	0.33
Stomach	20	6.4	0.67	7.5	0.76	8	2.4	0.40	2.8	0.45
Small intestine	10	3.0	0.45	3.6	0.53	8	2.3	0.39	2.7	0.45
Colon excl. rectum	70	22.4	1.25	26.0	1.42	70	21.6	1.19	24.9	1.34
Rectum & rectosigmoid	41	12.8	0.93	15.1	1.07	24	7.5	0.72	8.7	0.81
Anus, anal canal & anorectum	4	1.3	0.29	1.5	0.33	6	1.7	0.33	2.2	0.40
Liver	30	8.0	0.67	10.3	0.85	10	2.6	0.38	3.2	0.47
Gallbladder	2	0.5	0.18	0.6	0.20	6	1.7	0.32	2.0	0.37
Pancreas	41	12.8	0.93	15.2	1.08	32	9.0	0.73	10.8	0.86
Respiratory System	161	50.2	1.83	59.3	2.13	143	41.8	1.60	49.7	1.88
Larynx	14	3.8	0.49	4.8	0.59	5	1.5	0.30	1.8	0.37
Lung & bronchus	144	45.2	1.75	53.3	2.02	136	39.8	1.56	47.3	1.83
Bones & Joints	3	1.0	0.28	1.1	0.29	2	0.7	0.24	0.7	0.23
Soft Tissue (incl. heart)	10	3.2	0.47	3.8	0.54	10	3.3	0.47	3.6	0.51
Skin (excl. basal & sq.)	98	31.4	1.47	36.9	1.70	-	-	-	-	-
Melanomas of the skin	87	27.7	1.38	32.6	1.59	63	20.6	1.20	23.5	1.34
Breast (excl. <i>in situ</i>)	5	1.8	0.35	2.1	0.41	363	112.7	2.76	132.2	3.15
Female Genital System	-	-	-	-	-	142	43.3	1.70	51.6	1.96
Cervix uteri	-	-	-	-	-	18	6.5	0.72	7.0	0.74
Uterus Corpus	-	-	-	-	-	75	21.9	1.18	27.0	1.41
Uterus, NOS ¹	-	-	-	-	-	2	0.5	0.16	0.5	0.19
Ovary	-	-	-	-	-	35	10.9	0.86	12.8	0.99
Male Genital System	411	118.1	2.71	143.5	3.21	-	-	-	-	-
Prostate	386	108.8	2.57	134.1	3.10	-	-	-	-	-
Testis	22	8.4	0.81	8.3	0.79	-	-	-	-	-
Penis	2	0.7	0.22	0.9	0.26	-	-	-	-	-
Urinary System	168	54.4	1.95	63.5	2.23	61	18.5	1.10	21.6	1.25
Bladder (incl. <i>in situ</i>)	107	35.2	1.57	41.0	1.81	28	8.0	0.70	9.6	0.83
Kidney & renal pelvis	58	18.2	1.11	21.3	1.27	32	10.0	0.82	11.5	0.91
Ureter	3	1.0	0.27	1.1	0.30	-	-	-	-	-
Eye & Orbit	4	1.2	0.28	1.4	0.32	2	0.7	0.22	0.7	0.22
Brain & Other CNS ¹	22	7.4	0.73	8.2	0.80	19	6.1	0.65	6.8	0.71
Brain	21	7.1	0.72	7.9	0.79	18	5.7	0.63	6.4	0.69
Endocrine System	25	8.0	0.75	9.3	0.84	67	25.1	1.43	26.3	1.46
Thyroid gland	24	7.6	0.73	8.8	0.82	65	24.4	1.41	25.5	1.43
Lymphomas	72	23.6	1.29	27.3	1.47	50	15.4	1.02	17.8	1.14
Hodgkin Lymphoma	8	2.8	0.46	2.9	0.47	5	1.9	0.39	1.9	0.38
Non-Hodgkin Lymphoma	64	20.9	1.21	24.4	1.39	-	-	-	-	-
Multiple Myeloma	20	5.9	0.62	7.1	0.73	16	4.7	0.54	5.4	0.62
Leukemias	48	15.6	1.04	18.0	1.18	32	9.6	0.79	11.0	0.88
Acute lymphocytic	4	1.5	0.34	1.4	0.32	4	1.6	0.36	1.4	0.31
Chronic lymphocytic	18	5.4	0.59	6.5	0.70	10	2.8	0.41	3.4	0.48
Acute myeloid	14	4.6	0.57	5.3	0.65	10	2.9	0.42	3.4	0.50
Chronic myeloid	7	2.2	0.40	2.6	0.45	4	1.4	0.30	1.6	0.35
Other leukemias	-	-	-	-	-	3	1.0	0.25	1.2	0.29
Mesothelioma	5	1.8	0.37	2.0	0.41	3	0.8	0.23	1.0	0.26
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	49	16.1	1.07	18.8	1.23	46	14.2	0.96	16.2	1.07
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	25	8.4	0.78	9.4	0.86	44	14.6	1.03	16.3	1.12
Breast (<i>in situ</i>)	1	0.5	0.18	0.6	0.21	56	18.3	1.15	21.5	1.30

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, Black

SITES	MALES (BLACK)					FEMALES (BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9	300.9	53.52	337.7	58.47	6	201.2	41.07	221.7	44.47
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	91.6	29.18	99.3	30.64	1	45.5	19.11	55.5	22.35
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	95.4	29.58	111.7	33.68	-	-	-	-	-
Prostate	3	95.4	29.58	111.7	33.68	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.
 - Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.
¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, Asian/Pacific Islander (API)

SITES	MALES (API)					FEMALES (API)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	6	306.3	59.56	364.0	69.42	8	299.5	49.12	341.2	54.85
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	2	140.5	42.39	165.0	48.81	1	45.6	19.83	52.7	22.31
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	2	65.1	24.33	72.8	26.57
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	1	61.2	24.01	66.8	25.87
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	3	86.6	24.61	106.6	29.84
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	-	-	-	-	-	-	-	-	-	-
Prostate	-	-	-	-	-	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, American Indian/Alaskan Native (AI/AN) for PRCDA¹ Counties

SITES	MALES (AI/AN)					FEMALES (AI/AN)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	16	633.1	84.48	729.0	95.29	17	442.6	49.74	509.3	56.29
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	4	164.9	44.47	193.4	51.10	3	72.7	20.11	87.1	23.55
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	1	46.0	24.72	57.4	29.24	2	38.1	14.01	48.3	17.22
Rectum & rectosigmoid	1	57.5	25.75	69.4	29.90	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	2	94.5	36.65	104.1	39.54	2	70.2	21.07	80.5	23.55
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	1	83.6	35.79	90.9	38.42	2	63.7	20.03	73.6	22.51
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	6	134.0	25.91	161.4	30.71
Female Genital System	-	-	-	-	-	2	61.8	18.40	71.5	20.97
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ²	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	120.4	34.04	142.3	38.81	-	-	-	-	-
Prostate	3	117.1	33.88	138.9	38.66	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	81.9	27.19	94.8	29.65	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	2	39.4	14.07	50.8	18.02	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ²	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ² (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ PRCDA – Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G)

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, Hispanic/Latino, All Races

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	56	305.0	19.81	356.7	22.77	59	319.0	19.44	369.9	22.37
Oral Cavity & Pharynx	1	8.4	3.48	9.3	3.71	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	16	89.1	10.63	108.3	12.67	12	69.4	9.19	83.7	10.89
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	5	32.0	6.61	37.7	7.70	5	30.8	6.28	37.3	7.39
Rectum & rectosigmoid	3	14.5	3.93	17.5	4.73	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	3	13.8	3.91	18.0	4.89	1	6.6	2.76	8.3	3.41
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	13.2	4.10	16.3	4.93	1	6.1	2.50	8.0	3.29
Respiratory System	5	32.9	7.05	37.6	7.96	5	37.1	7.44	40.4	8.02
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	4	31.1	6.96	35.5	7.83	5	36.1	7.37	39.5	7.97
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	2	8.4	2.87	10.1	3.47
Breast (excl. <i>in situ</i>)	-	-	-	-	-	14	78.6	9.59	90.8	11.04
Female Genital System	-	-	-	-	-	9	45.5	6.93	55.1	8.35
Cervix uteri	-	-	-	-	-	2	10.5	3.42	11.2	3.67
Uterus Corpus	-	-	-	-	-	4	20.2	4.52	24.5	5.48
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	3	13.2	3.81	16.9	4.80
Male Genital System	16	83.5	10.10	97.6	11.57	-	-	-	-	-
Prostate	13	73.6	9.76	88.3	11.30	-	-	-	-	-
Testis	3	9.1	2.46	8.0	2.16	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	6	31.5	6.45	35.4	7.14	4	20.8	5.18	23.9	5.83
Bladder (incl. <i>in situ</i>)	2	15.5	4.75	17.8	5.27	-	-	-	-	-
Kidney & renal pelvis	3	16.0	4.37	17.6	4.82	2	13.1	4.00	15.3	4.60
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	1	5.5	2.12	6.0	2.38	3	13.6	3.56	13.2	3.50
Thyroid gland	1	5.5	2.12	6.0	2.38	3	13.6	3.56	13.2	3.50
Lymphomas	2	13.3	4.31	14.4	4.56	2	10.9	3.34	12.9	4.03
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	1	9.1	3.75	9.3	3.87
Leukemias	2	14.1	4.70	15.6	5.27	1	5.4	2.18	5.9	2.47
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	3	14.6	4.16	17.6	4.91	2	12.4	3.72	15.4	4.54
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	2	7.9	3.08	8.7	3.52	2	11.8	3.66	13.7	4.23
Breast (<i>in situ</i>)	-	-	-	-	-	2	10.9	3.54	12.6	4.08

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

N.B. In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

WYOMING

II-558 Incidence – Hispanic/Latino, All Races

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, Non-Hispanic White

SITES	MALES (NON-HISPANIC WHITE)					FEMALES (NON-HISPANIC WHITE)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	1,351	438.7	5.56	520.2	6.44	1,165	381.7	5.23	443.2	5.89
Oral Cavity & Pharynx	48	15.3	1.04	18.4	1.21	19	5.9	0.63	7.1	0.73
Lip	3	0.9	0.26	1.1	0.30	1	0.4	0.16	0.5	0.20
Tongue	16	5.2	0.61	6.3	0.71	5	1.5	0.29	1.9	0.37
Major salivary gland	4	1.6	0.36	1.8	0.39	3	0.9	0.25	1.0	0.27
Floor of mouth	2	0.6	0.20	0.8	0.24	1	0.4	0.16	0.4	0.19
Gum & other mouth	5	1.5	0.33	1.8	0.38	5	1.5	0.34	1.7	0.37
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	3	0.9	0.23	1.1	0.29	-	-	-	-	-
Hypopharynx	2	0.7	0.23	0.9	0.27	-	-	-	-	-
Digestive System	236	77.0	2.34	91.2	2.70	166	52.7	1.89	61.7	2.17
Esophagus	21	6.8	0.69	8.1	0.79	5	1.3	0.29	1.7	0.34
Stomach	19	6.5	0.69	7.6	0.79	7	2.3	0.40	2.7	0.45
Small intestine	9	3.1	0.46	3.7	0.55	7	2.4	0.41	2.8	0.47
Colon excl. rectum	65	22.0	1.27	25.6	1.45	65	21.2	1.22	24.4	1.37
Rectum & rectosigmoid	38	12.5	0.95	14.8	1.09	23	7.7	0.76	8.9	0.85
Anus, anal canal & anorectum	4	1.3	0.30	1.5	0.34	5	1.6	0.33	2.0	0.40
Liver	28	7.7	0.68	9.9	0.86	8	2.4	0.37	3.0	0.46
Gallbladder	2	0.5	0.19	0.6	0.21	5	1.5	0.30	1.9	0.36
Pancreas	39	12.8	0.95	15.2	1.11	31	9.0	0.75	10.9	0.88
Respiratory System	157	51.1	1.90	60.5	2.20	138	42.2	1.65	50.4	1.93
Larynx	13	4.0	0.51	5.0	0.62	5	1.5	0.32	1.9	0.39
Lung & bronchus	140	46.1	1.81	54.4	2.09	131	40.2	1.61	47.9	1.89
Bones & Joints	3	1.1	0.30	1.1	0.30	2	0.8	0.27	0.7	0.25
Soft Tissue (incl. heart)	10	3.2	0.49	3.8	0.56	10	3.4	0.50	3.8	0.54
Skin (excl. basal & sq.)	97	32.9	1.55	38.6	1.78	66	22.8	1.32	25.9	1.45
Melanomas of the skin	86	29.0	1.45	34.0	1.67	62	21.5	1.28	24.4	1.41
Breast (excl. <i>in situ</i>)	5	1.8	0.37	2.2	0.43	350	114.8	2.88	134.6	3.27
Female Genital System	-	-	-	-	-	133	42.8	1.75	51.0	2.01
Cervix uteri	-	-	-	-	-	16	6.2	0.73	6.6	0.75
Uterus Corpus	-	-	-	-	-	71	21.8	1.21	27.0	1.45
Uterus, NOS ¹	-	-	-	-	-	1	0.4	0.16	0.5	0.19
Ovary	-	-	-	-	-	32	10.8	0.89	12.5	1.01
Male Genital System	396	119.6	2.80	145.6	3.32	-	-	-	-	-
Prostate	374	110.6	2.65	136.4	3.20	-	-	-	-	-
Testis	19	8.1	0.84	8.1	0.83	-	-	-	-	-
Penis	2	0.8	0.24	0.9	0.27	-	-	-	-	-
Urinary System	163	55.3	2.01	64.6	2.31	58	18.4	1.12	21.4	1.28
Bladder (incl. <i>in situ</i>)	105	36.1	1.63	42.1	1.87	27	8.1	0.72	9.7	0.85
Kidney & renal pelvis	55	18.2	1.14	21.4	1.31	30	9.8	0.84	11.2	0.93
Ureter	3	1.0	0.28	1.2	0.32	-	-	-	-	-
Eye & Orbit	4	1.3	0.30	1.5	0.34	2	0.7	0.23	0.7	0.23
Brain & Other CNS ¹	21	7.8	0.78	8.7	0.85	18	6.3	0.69	7.1	0.75
Brain	20	7.4	0.76	8.3	0.84	17	6.0	0.67	6.7	0.72
Endocrine System	24	8.1	0.78	9.4	0.87	64	25.9	1.52	27.2	1.55
Thyroid gland	22	7.6	0.75	8.8	0.85	61	25.2	1.50	26.3	1.52
Lymphomas	70	24.3	1.35	28.1	1.53	47	15.6	1.05	17.9	1.18
Hodgkin Lymphoma	8	2.9	0.49	3.1	0.51	4	1.7	0.38	1.7	0.38
Non-Hodgkin Lymphoma	62	21.4	1.26	25.0	1.45	43	13.9	0.98	16.3	1.12
Multiple Myeloma	19	6.1	0.64	7.2	0.75	15	4.4	0.53	5.2	0.61
Leukemias	46	15.7	1.08	18.2	1.22	30	9.8	0.82	11.2	0.92
Acute lymphocytic	4	1.5	0.37	1.4	0.35	4	1.6	0.38	1.4	0.33
Chronic lymphocytic	18	5.5	0.61	6.6	0.72	10	2.9	0.42	3.5	0.50
Acute myeloid	13	4.5	0.58	5.2	0.66	9	2.9	0.44	3.5	0.51
Chronic myeloid	7	2.3	0.42	2.7	0.47	4	1.3	0.31	1.5	0.35
Other leukemias	6	1.9	0.37	2.2	0.43	3	1.0	0.26	1.2	0.30
Mesothelioma	5	1.9	0.38	2.1	0.43	3	0.9	0.25	1.0	0.27
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	24	8.5	0.81	9.5	0.89	42	14.8	1.08	16.5	1.16
Breast (<i>in situ</i>)	1	0.5	0.19	0.6	0.23	55	19.0	1.22	22.2	1.37

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Wyoming, 2013-2017, Non-Hispanic Black

SITES	MALES (NON-HISPANIC BLACK)					FEMALES (NON-HISPANIC BLACK)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	8	313.8	56.91	352.2	62.11	5	207.2	43.36	228.2	46.62
Oral Cavity & Pharynx	-	-	-	-	-	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	3	88.1	29.66	95.4	30.95	1	39.5	18.07	49.2	21.46
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	-	-	-	-	-	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	-	-	-	-	-	-	-	-	-	-
Rectum & rectosigmoid	-	-	-	-	-	-	-	-	-	-
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	-	-	-	-	-	-	-	-	-	-
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	-	-	-	-	-	-	-	-	-	-
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Female Genital System	-	-	-	-	-	-	-	-	-	-
Cervix uteri	-	-	-	-	-	-	-	-	-	-
Uterus Corpus	-	-	-	-	-	-	-	-	-	-
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	101.8	31.63	119.4	36.07	-	-	-	-	-
Prostate	3	101.8	31.63	119.4	36.07	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	-	-	-	-	-	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	-	-	-	-	-	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	-	-	-	-	-
Thyroid gland	-	-	-	-	-	-	-	-	-	-
Lymphomas	-	-	-	-	-	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	-	-	-	-	-	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1950
Population-based Data Available: 1950
Coverage Area: U.S. Territory

Total Population Counts by Year¹

2013	2014	2015	2016	2017
3,593,077	3,534,874	3,473,166	3,406,495	1,662,501

Data Quality Indicators¹ (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	93.7	94.2	94.7	93.9	101.7
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.8	0.7	0.9	0.6	0.4
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.8	3.0	2.8	2.5	2.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation¹ (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.1	Prostate	95.5
Oral Cavity & Pharynx	96.3	Testis	99.5
Esophagus	90.5	Bladder (incl. <i>in situ</i>)	96.2
Stomach	90.9	Kidney & Renal Pelvis	90.7
Colon & Rectum	94.2	Brain & Other CNS ²	84.6
Liver	54.8	Thyroid	99.4
Pancreas	73.8	Hodgkin Lymphoma	95.9
Lung & Bronchus	82.8	Non-Hodgkin Lymphoma	94.9
Melanomas of the Skin	97.5	Multiple Myeloma	85.9
Female Breast (excl. <i>in situ</i>)	97.6	Leukemias	89.7
Cervix uteri	96.4	Brain & Other CNS ² <i>non-malig</i>	62.5
Uterus Corpus & Uterus NOS ²	97.5	Breast <i>in situ</i>	99.9
Ovary	88.3		

¹ Puerto Rico data have been adjusted to accommodate the impact of Hurricane Maria, see Technical Notes.

² Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Puerto Rico, 2013-2017, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	7,556	409.4	2.15	487.9	2.54	6,957	333.7	1.86	384.7	2.10
Oral Cavity & Pharynx	297	16.2	0.43	19.8	0.52	106	4.8	0.21	5.6	0.25
Lip	18	1.0	0.11	1.2	0.13	12	0.5	0.07	0.6	0.08
Tongue	73	3.9	0.21	4.8	0.26	25	1.1	0.10	1.3	0.12
Major salivary gland	28	1.6	0.14	1.9	0.16	17	0.8	0.09	0.9	0.10
Floor of mouth	13	0.7	0.09	0.9	0.11	3	0.1	0.04	0.2	0.04
Gum & other mouth	46	2.5	0.17	3.0	0.20	28	1.3	0.11	1.5	0.13
Nasopharynx	13	0.7	0.09	0.8	0.11	5	0.2	0.05	0.3	0.06
Oropharynx	17	0.9	0.10	1.2	0.13	3	0.1	0.04	0.2	0.04
Hypopharynx	25	1.3	0.12	1.6	0.15	2	0.1	0.03	0.1	0.03
Digestive System	1,788	97.1	1.05	116.5	1.25	1,372	60.4	0.75	71.2	0.87
Esophagus	107	5.7	0.25	6.9	0.30	23	1.0	0.09	1.1	0.10
Stomach	177	9.8	0.33	11.5	0.39	141	6.2	0.24	7.2	0.28
Small intestine	38	2.1	0.16	2.5	0.18	29	1.3	0.11	1.5	0.13
Colon excl. rectum	650	35.5	0.63	42.3	0.75	575	25.4	0.49	30.0	0.57
Rectum & rectosigmoid	286	15.5	0.42	18.8	0.50	207	9.6	0.31	11.3	0.36
Anus, anal canal & anorectum	23	1.3	0.13	1.6	0.15	42	1.8	0.13	2.2	0.16
Liver	236	12.4	0.37	15.3	0.45	96	4.0	0.19	4.7	0.22
Gallbladder	13	0.7	0.09	0.9	0.11	25	1.1	0.10	1.3	0.12
Pancreas	178	9.7	0.33	11.5	0.39	161	7.0	0.25	8.2	0.29
Respiratory System	581	31.3	0.59	37.1	0.70	306	13.1	0.34	15.6	0.40
Larynx	125	6.6	0.27	8.0	0.33	12	0.5	0.07	0.6	0.08
Lung & bronchus	439	23.6	0.51	27.9	0.60	283	12.0	0.33	14.4	0.39
Bones & Joints	18	1.1	0.12	1.2	0.12	11	0.6	0.09	0.6	0.09
Soft Tissue (incl. heart)	50	3.0	0.20	3.4	0.21	42	2.1	0.15	2.3	0.16
Skin (excl. basal & sq.)	109	6.2	0.27	7.2	0.31	82	4.1	0.21	4.6	0.23
Melanomas of the skin	80	4.5	0.23	5.3	0.27	61	3.1	0.19	3.5	0.20
Breast (excl. <i>in situ</i>)	18	1.0	0.11	1.2	0.13	1,977	93.9	0.98	110.4	1.13
Female Genital System	-	-	-	-	-	1,072	53.4	0.76	61.4	0.85
Cervix uteri	-	-	-	-	-	222	13.0	0.40	13.6	0.41
Uterus Corpus	-	-	-	-	-	573	27.4	0.53	32.6	0.62
Uterus, NOS ¹	-	-	-	-	-	21	1.0	0.10	1.1	0.11
Ovary	-	-	-	-	-	174	8.4	0.30	9.7	0.34
Male Genital System	2,905	150.6	1.27	183.5	1.54	-	-	-	-	-
Prostate	2,783	142.5	1.22	175.2	1.50	-	-	-	-	-
Testis	74	5.4	0.28	5.2	0.27	-	-	-	-	-
Penis	44	2.4	0.17	2.9	0.20	-	-	-	-	-
Urinary System	536	29.5	0.58	35.0	0.68	241	10.9	0.32	12.7	0.37
Bladder (incl. <i>in situ</i>)	303	16.6	0.43	19.5	0.51	106	4.5	0.20	5.3	0.23
Kidney & renal pelvis	218	12.1	0.38	14.5	0.44	126	6.0	0.25	6.9	0.28
Ureter	8	0.4	0.07	0.5	0.08	6	0.3	0.05	0.3	0.05
Eye & Orbit	19	1.1	0.12	1.3	0.13	10	0.5	0.08	0.5	0.08
Brain & Other CNS ¹	84	5.1	0.25	5.5	0.27	70	3.7	0.21	3.9	0.21
Brain	79	4.8	0.25	5.1	0.26	65	3.4	0.20	3.6	0.20
Endocrine System	208	12.9	0.41	14.4	0.45	810	46.0	0.75	50.1	0.80
Thyroid gland	197	12.1	0.40	13.6	0.44	801	45.6	0.75	49.6	0.79
Lymphomas	343	20.2	0.50	22.9	0.56	307	14.7	0.39	16.8	0.44
Hodgkin Lymphoma	45	3.0	0.20	3.1	0.21	39	2.3	0.17	2.4	0.17
Non-Hodgkin Lymphoma	299	17.2	0.45	19.8	0.52	268	12.4	0.35	14.4	0.40
Multiple Myeloma	136	7.5	0.29	8.8	0.34	128	5.7	0.23	6.7	0.27
Leukemias	203	11.9	0.38	13.3	0.42	176	8.8	0.31	9.6	0.33
Acute lymphocytic	22	1.6	0.15	1.5	0.14	23	1.6	0.15	1.4	0.13
Chronic lymphocytic	62	3.4	0.19	4.0	0.23	45	1.9	0.13	2.3	0.15
Acute myeloid	58	3.4	0.20	3.8	0.23	55	2.8	0.18	3.1	0.19
Chronic myeloid	38	2.3	0.17	2.5	0.19	35	1.6	0.13	1.9	0.15
Other leukemias	22	1.3	0.12	1.5	0.14	19	0.8	0.09	1.0	0.10
Mesothelioma	6	0.3	0.06	0.4	0.07	2	0.1	0.03	0.1	0.03
Kaposi Sarcoma	17	1.1	0.12	1.2	0.13	4	0.2	0.04	0.2	0.04
Ill-defined & Unknown	240	13.3	0.39	15.5	0.45	241	10.8	0.32	12.3	0.36
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	69	4.2	0.23	4.7	0.25	128	6.4	0.26	7.3	0.29
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.03	396	18.9	0.44	22.5	0.52

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

** Puerto Rico data have been adjusted to accommodate the impact of Hurricane Maria, see Technical Notes.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1942
 Population-based Data Available: 1974
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
3,981,011	4,083,648	4,144,491	4,196,061	4,243,543

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.3	105.9	107.6	103.8	98.6
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.1	0.1	0.1	0.1	0.1
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.1	Prostate	93.4
Oral Cavity & Pharynx	98.8	Testis	99.7
Esophagus	98.4	Bladder (incl. <i>in situ</i>)	97.6
Stomach	97.3	Kidney & Renal Pelvis	88.5
Colon & Rectum	96.7	Brain & Other CNS ¹	83.1
Liver	55.6	Thyroid	99.6
Pancreas	76.4	Hodgkin Lymphoma	100.0
Lung & Bronchus	84.9	Non-Hodgkin Lymphoma	98.4
Melanomas of the Skin	100.0	Multiple Myeloma	93.0
Female Breast (excl. <i>in situ</i>)	99.2	Leukemias	99.6
Cervix uteri	99.2	Brain & Other CNS ¹ <i>non-malig</i>	57.4
Uterus Corpus & Uterus NOS ¹	99.2	Breast <i>in situ</i>	100.0
Ovary	93.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Alberta, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	9,525	482.2	2.29	569.4	2.66	9,003	415.9	1.99	485.8	2.30
Oral Cavity & Pharynx	290	13.3	0.36	16.3	0.43	128	5.9	0.24	6.9	0.27
Lip	15	0.9	0.10	1.0	0.11	3	0.2	0.04	0.2	0.04
Tongue	95	4.2	0.20	5.3	0.24	38	1.7	0.13	2.0	0.15
Major salivary gland	20	1.0	0.10	1.1	0.12	21	1.0	0.10	1.1	0.11
Floor of mouth	15	0.7	0.08	0.8	0.10	6	0.3	0.05	0.3	0.06
Gum & other mouth	28	1.4	0.12	1.7	0.14	26	1.2	0.11	1.4	0.12
Nasopharynx	19	0.9	0.09	1.0	0.10	7	0.4	0.06	0.4	0.07
Oropharynx	15	0.6	0.08	0.8	0.10	4	0.2	0.04	0.2	0.05
Hypopharynx	17	0.9	0.10	1.0	0.11	5	0.2	0.05	0.3	0.06
Digestive System	2,130	108.6	1.09	128.7	1.27	1,555	71.8	0.83	84.6	0.96
Esophagus	156	7.7	0.29	9.4	0.34	41	1.9	0.13	2.3	0.16
Stomach	179	9.5	0.33	11.1	0.38	90	4.2	0.20	4.9	0.23
Small intestine	50	2.5	0.17	3.0	0.19	45	2.1	0.14	2.5	0.16
Colon excl. rectum	720	37.7	0.65	44.1	0.75	643	29.9	0.54	35.0	0.62
Rectum & rectosigmoid	460	22.6	0.49	27.0	0.57	262	11.9	0.34	14.2	0.39
Anus, anal canal & anorectum	18	0.9	0.09	1.1	0.11	43	1.9	0.13	2.4	0.16
Liver	175	8.2	0.29	10.1	0.35	55	2.5	0.15	3.0	0.18
Gallbladder	17	0.9	0.10	1.0	0.12	31	1.5	0.12	1.7	0.14
Pancreas	249	13.1	0.38	15.5	0.45	231	10.7	0.32	12.6	0.37
Respiratory System	1,215	65.0	0.86	76.2	0.99	1,151	54.2	0.73	63.8	0.84
Larynx	67	3.3	0.19	4.0	0.22	10	0.5	0.07	0.5	0.08
Lung & bronchus	1,125	60.5	0.83	70.8	0.96	1,127	53.1	0.72	62.5	0.83
Bones & Joints	21	1.1	0.11	1.1	0.11	15	0.8	0.09	0.8	0.09
Soft Tissue (incl. heart)	76	3.9	0.21	4.4	0.23	50	2.3	0.15	2.6	0.16
Skin (excl. basal & sq.)	415	20.9	0.48	24.5	0.55	355	16.2	0.39	18.7	0.45
Melanomas of the skin	370	18.6	0.45	21.8	0.52	331	15.1	0.38	17.5	0.43
Breast (excl. <i>in situ</i>)	18	0.9	0.10	1.0	0.11	2,667	122.6	1.08	144.3	1.25
Female Genital System	-	-	-	-	-	1,125	50.7	0.69	60.2	0.81
Cervix uteri	-	-	-	-	-	174	8.2	0.28	8.6	0.30
Uterus Corpus	-	-	-	-	-	608	26.9	0.50	33.0	0.60
Uterus, NOS ¹	-	-	-	-	-	6	0.3	0.05	0.3	0.06
Ovary	-	-	-	-	-	219	9.9	0.31	11.7	0.36
Male Genital System	2,506	120.8	1.12	146.0	1.32	-	-	-	-	-
Prostate	2,324	112.3	1.08	137.4	1.29	-	-	-	-	-
Testis	149	6.7	0.25	6.6	0.24	-	-	-	-	-
Penis	27	1.5	0.13	1.7	0.15	-	-	-	-	-
Urinary System	1,114	58.2	0.81	68.4	0.93	421	19.4	0.43	22.9	0.50
Bladder (incl. <i>in situ</i>)	688	37.5	0.66	43.7	0.76	200	9.2	0.30	11.0	0.35
Kidney & renal pelvis	399	19.2	0.45	22.9	0.52	205	9.3	0.30	11.1	0.35
Ureter	16	0.9	0.10	1.1	0.12	10	0.5	0.07	0.5	0.08
Eye & Orbit	23	1.1	0.10	1.2	0.12	24	1.1	0.10	1.2	0.11
Brain & Other CNS ¹	157	7.6	0.28	8.5	0.31	113	5.3	0.23	5.8	0.25
Brain	151	7.3	0.27	8.2	0.31	108	5.0	0.22	5.5	0.24
Endocrine System	158	7.3	0.27	8.2	0.29	393	18.6	0.42	19.9	0.45
Thyroid gland	141	6.5	0.25	7.3	0.28	377	17.8	0.42	19.1	0.44
Lymphomas	512	25.9	0.53	29.6	0.60	387	18.1	0.42	20.8	0.47
Hodgkin Lymphoma	63	3.0	0.17	3.1	0.18	44	2.1	0.14	2.2	0.15
Non-Hodgkin Lymphoma	449	22.9	0.50	26.5	0.57	344	16.0	0.39	18.6	0.45
Multiple Myeloma	150	7.9	0.30	9.3	0.35	95	4.5	0.21	5.2	0.24
Leukemias	378	19.5	0.46	22.4	0.53	238	11.3	0.33	12.7	0.37
Acute lymphocytic	25	1.3	0.11	1.1	0.10	21	1.1	0.11	1.0	0.10
Chronic lymphocytic	168	8.5	0.30	10.2	0.36	94	4.3	0.20	5.1	0.24
Acute myeloid	101	5.4	0.25	6.1	0.28	72	3.4	0.18	3.8	0.20
Chronic myeloid	46	2.4	0.16	2.7	0.18	30	1.5	0.12	1.6	0.13
Other leukemias	38	2.0	0.15	2.3	0.17	21	0.9	0.09	1.1	0.11
Mesothelioma	43	2.5	0.17	2.8	0.20	9	0.4	0.06	0.5	0.07
Kaposi Sarcoma	6	0.3	0.05	0.3	0.06	2	0.1	0.03	0.1	0.03
Ill-defined & Unknown	316	17.5	0.45	20.3	0.52	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	140	7.0	0.27	7.9	0.30	224	10.4	0.32	11.9	0.36
Breast (<i>in situ</i>)	-	-	-	-	-	372	17.0	0.40	20.2	0.47

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1966
 Population-based Data Available: 1969
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
4,630,077	4,707,103	4,776,388	4,859,250	4,924,233

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.6	97.9	99.8	97.3	94.0
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.4	0.4	0.5	0.6	1.3
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.9	Prostate	93.8
Oral Cavity & Pharynx	96.8	Testis	98.9
Esophagus	95.6	Bladder (incl. <i>in situ</i>)	96.1
Stomach	95.1	Kidney & Renal Pelvis	87.1
Colon & Rectum	95.0	Brain & Other CNS ¹	83.2
Liver	34.3	Thyroid	98.7
Pancreas	69.9	Hodgkin Lymphoma	100.0
Lung & Bronchus	80.1	Non-Hodgkin Lymphoma	96.7
Melanomas of the Skin	98.9	Multiple Myeloma	91.6
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	98.1
Cervix uteri	98.2	Brain & Other CNS ¹ <i>non-malig</i>	64.3
Uterus Corpus & Uterus NOS ¹	98.8	Breast <i>in situ</i>	100.0
Ovary	90.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
British Columbia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	13,343	449.0	1.78	528.7	2.06	12,558	388.2	1.60	453.2	1.82
Oral Cavity & Pharynx	471	15.3	0.32	18.6	0.39	210	6.5	0.21	7.6	0.24
Lip	20	0.7	0.07	0.8	0.08	11	0.3	0.05	0.4	0.05
Tongue	147	4.7	0.18	5.7	0.21	56	1.7	0.11	2.1	0.12
Major salivary gland	36	1.3	0.10	1.5	0.11	33	1.1	0.09	1.2	0.10
Floor of mouth	19	0.6	0.06	0.7	0.08	12	0.3	0.05	0.4	0.06
Gum & other mouth	54	1.8	0.11	2.1	0.13	47	1.4	0.10	1.6	0.11
Nasopharynx	38	1.3	0.10	1.5	0.11	15	0.5	0.06	0.6	0.07
Oropharynx	30	0.9	0.08	1.1	0.09	5	0.2	0.03	0.2	0.04
Hypopharynx	23	0.8	0.07	0.9	0.08	7	0.2	0.03	0.2	0.04
Digestive System	3,353	111.6	0.88	132.8	1.03	2,445	72.9	0.67	85.8	0.78
Esophagus	240	7.8	0.23	9.4	0.27	80	2.4	0.12	2.8	0.14
Stomach	271	9.2	0.25	10.8	0.30	127	3.8	0.16	4.5	0.18
Small intestine	67	2.2	0.13	2.6	0.15	51	1.6	0.10	1.8	0.12
Colon excl. rectum	1,130	38.3	0.52	45.0	0.60	1,022	30.5	0.44	35.6	0.50
Rectum & rectosigmoid	674	22.1	0.39	26.5	0.46	403	12.2	0.28	14.6	0.33
Anus, anal canal & anorectum	40	1.3	0.10	1.6	0.11	74	2.2	0.12	2.7	0.14
Liver	352	10.9	0.27	13.6	0.33	112	3.3	0.15	4.0	0.17
Gallbladder	22	0.8	0.07	0.9	0.08	38	1.1	0.08	1.4	0.10
Pancreas	383	12.9	0.30	15.3	0.35	359	10.5	0.25	12.3	0.29
Respiratory System	1,760	58.9	0.64	69.6	0.75	1,752	51.7	0.56	61.0	0.66
Larynx	103	3.3	0.15	4.0	0.18	15	0.4	0.05	0.5	0.06
Lung & bronchus	1,622	54.5	0.62	64.2	0.72	1,719	50.7	0.56	59.8	0.65
Bones & Joints	28	1.1	0.10	1.2	0.10	22	0.9	0.09	0.9	0.09
Soft Tissue (incl. heart)	89	3.3	0.16	3.6	0.17	68	2.3	0.13	2.6	0.14
Skin (excl. basal & sq.)	673	23.2	0.41	27.0	0.47	533	17.1	0.34	19.6	0.38
Melanomas of the skin	614	21.0	0.39	24.6	0.45	499	16.0	0.33	18.4	0.37
Breast (excl. <i>in situ</i>)	28	0.9	0.08	1.1	0.09	3,537	110.8	0.86	130.2	0.99
Female Genital System	-	-	-	-	-	1,507	46.8	0.56	55.4	0.64
Cervix uteri	-	-	-	-	-	180	6.8	0.23	7.2	0.24
Uterus Corpus	-	-	-	-	-	767	22.8	0.38	27.9	0.45
Uterus, NOS ¹	-	-	-	-	-	16	0.5	0.06	0.6	0.07
Ovary	-	-	-	-	-	355	11.1	0.27	13.0	0.31
Male Genital System	3,051	99.2	0.82	118.2	0.96	-	-	-	-	-
Prostate	2,871	91.8	0.78	110.6	0.93	-	-	-	-	-
Testis	147	6.3	0.24	6.2	0.23	-	-	-	-	-
Penis	25	0.9	0.08	1.0	0.09	-	-	-	-	-
Urinary System	1,641	56.2	0.63	65.8	0.73	599	18.1	0.34	21.1	0.39
Bladder (incl. <i>in situ</i>)	1,112	38.4	0.52	44.8	0.60	322	9.5	0.24	11.2	0.28
Kidney & renal pelvis	489	16.4	0.34	19.4	0.39	255	7.9	0.23	9.2	0.26
Ureter	26	0.9	0.08	1.1	0.09	15	0.5	0.05	0.5	0.06
Eye & Orbit	25	0.9	0.08	1.0	0.09	20	0.7	0.07	0.8	0.08
Brain & Other CNS ¹	217	7.9	0.25	8.8	0.27	150	5.2	0.20	5.7	0.21
Brain	211	7.7	0.25	8.5	0.26	143	4.9	0.19	5.4	0.20
Endocrine System	151	5.6	0.21	6.2	0.23	348	12.7	0.32	13.8	0.33
Thyroid gland	127	4.7	0.19	5.2	0.21	328	12.0	0.31	13.0	0.32
Lymphomas	702	24.6	0.43	28.2	0.48	551	17.4	0.34	20.0	0.38
Hodgkin Lymphoma	69	2.8	0.15	2.9	0.16	48	2.0	0.13	2.0	0.13
Non-Hodgkin Lymphoma	633	21.8	0.40	25.3	0.45	503	15.4	0.32	18.0	0.36
Multiple Myeloma	213	7.2	0.23	8.5	0.26	147	4.4	0.16	5.1	0.19
Leukemias	448	15.9	0.34	18.1	0.38	300	9.8	0.27	10.9	0.29
Acute lymphocytic	28	1.4	0.12	1.2	0.10	29	1.4	0.12	1.3	0.11
Chronic lymphocytic	180	6.0	0.20	7.1	0.24	105	3.0	0.13	3.7	0.16
Acute myeloid	128	4.6	0.18	5.2	0.21	97	3.1	0.15	3.5	0.16
Chronic myeloid	61	2.2	0.13	2.5	0.14	38	1.2	0.09	1.4	0.10
Other leukemias	50	1.7	0.11	2.0	0.13	31	1.0	0.09	1.1	0.09
Mesothelioma	77	2.7	0.14	3.1	0.16	18	0.5	0.06	0.6	0.07
Kaposi Sarcoma	7	0.3	0.05	0.3	0.05	1	0.0	0.02	0.0	0.02
Ill-defined & Unknown	409	14.3	0.32	16.7	0.37	-	-	-	-	-
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	134	5.0	0.20	5.5	0.21	236	7.8	0.24	8.9	0.26
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	569	17.9	0.35	21.4	0.40

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1937
 Population-based Data Available: 1956
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
1,264,620	1,279,014	1,292,227	1,314,139	1,335,018

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.0	100.2	100.2	101.7	96.5
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.0	0.0	0.0	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.7	Prostate	94.3
Oral Cavity & Pharynx	98.9	Testis	100.0
Esophagus	97.6	Bladder (incl. <i>in situ</i>)	97.8
Stomach	97.6	Kidney & Renal Pelvis	78.9
Colon & Rectum	95.8	Brain & Other CNS ¹	80.9
Liver	31.6	Thyroid	99.6
Pancreas	67.4	Hodgkin Lymphoma	100.0
Lung & Bronchus	76.5	Non-Hodgkin Lymphoma	97.4
Melanomas of the Skin	99.8	Multiple Myeloma	93.4
Female Breast (excl. <i>in situ</i>)	99.0	Leukemias	99.7
Cervix uteri	98.3	Brain & Other CNS ¹ <i>non-malig</i>	51.7
Uterus Corpus & Uterus NOS ¹	99.1	Breast <i>in situ</i>	100.0
Ovary	93.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Manitoba, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	3,369	480.3	3.78	564.9	4.37	3,347	425.6	3.38	498.7	3.89
Oral Cavity & Pharynx	122	16.9	0.70	20.3	0.83	58	7.2	0.43	8.6	0.51
Lip	36	5.3	0.41	6.2	0.46	14	1.7	0.21	1.9	0.24
Tongue	33	4.5	0.36	5.3	0.42	13	1.7	0.21	2.1	0.25
Major salivary gland	5	0.7	0.14	0.8	0.16	6	0.8	0.14	0.9	0.16
Floor of mouth	6	0.8	0.15	1.0	0.18	3	0.4	0.10	0.5	0.12
Gum & other mouth	7	0.9	0.15	1.1	0.19	10	1.3	0.18	1.5	0.21
Nasopharynx	5	0.7	0.14	0.8	0.17	2	0.3	0.09	0.3	0.10
Oropharynx	4	0.5	0.12	0.6	0.14	2	0.2	0.07	0.2	0.09
Hypopharynx	7	0.9	0.16	1.1	0.20	2	0.2	0.08	0.3	0.10
Digestive System	804	114.4	1.84	135.6	2.15	618	75.8	1.40	89.2	1.63
Esophagus	50	7.1	0.45	8.5	0.54	16	1.9	0.22	2.3	0.26
Stomach	78	11.3	0.58	13.2	0.67	40	4.9	0.36	5.7	0.41
Small intestine	18	2.5	0.27	3.0	0.32	13	1.7	0.21	2.0	0.25
Colon excl. rectum	280	40.5	1.10	47.6	1.28	262	31.9	0.90	37.2	1.04
Rectum & rectosigmoid	184	26.0	0.87	31.0	1.03	108	13.7	0.60	16.1	0.70
Anus, anal canal & anorectum	9	1.1	0.18	1.4	0.22	13	1.7	0.21	2.0	0.25
Liver	49	6.6	0.43	8.1	0.52	20	2.5	0.25	3.0	0.30
Gallbladder	8	1.1	0.17	1.3	0.20	17	2.1	0.23	2.4	0.27
Pancreas	91	12.9	0.62	15.3	0.72	94	11.3	0.53	13.4	0.63
Respiratory System	475	68.1	1.42	80.1	1.65	481	59.1	1.23	70.1	1.44
Larynx	26	3.6	0.32	4.4	0.38	3	0.4	0.10	0.5	0.12
Lung & bronchus	442	63.5	1.38	74.7	1.60	473	58.0	1.22	68.8	1.43
Bones & Joints	6	0.9	0.17	0.9	0.17	6	0.9	0.17	0.9	0.17
Soft Tissue (incl. heart)	26	3.9	0.35	4.3	0.38	19	2.7	0.28	2.9	0.30
Skin (excl. basal & sq.)	147	21.5	0.81	25.0	0.93	126	16.3	0.67	18.8	0.76
Melanomas of the skin	133	19.3	0.76	22.6	0.88	112	14.5	0.63	16.7	0.72
Breast (excl. <i>in situ</i>)	5	0.8	0.16	0.9	0.18	859	110.9	1.74	131.1	2.02
Female Genital System	-	-	-	-	-	459	59.6	1.28	70.8	1.49
Cervix uteri	-	-	-	-	-	48	7.2	0.48	7.7	0.50
Uterus Corpus	-	-	-	-	-	278	35.1	0.96	42.8	1.16
Uterus, NOS ¹	-	-	-	-	-	4	0.6	0.12	0.7	0.14
Ovary	-	-	-	-	-	84	11.1	0.56	13.0	0.64
Male Genital System	759	105.5	1.75	125.5	2.05	-	-	-	-	-
Prostate	704	96.9	1.67	116.7	1.98	-	-	-	-	-
Testis	39	6.2	0.45	6.2	0.44	-	-	-	-	-
Penis	14	2.0	0.25	2.3	0.28	-	-	-	-	-
Urinary System	398	57.2	1.31	67.6	1.52	160	20.0	0.73	23.3	0.84
Bladder (incl. <i>in situ</i>)	229	33.7	1.01	39.4	1.17	76	9.4	0.49	10.9	0.56
Kidney & renal pelvis	157	21.8	0.79	26.1	0.94	77	9.9	0.52	11.7	0.60
Ureter	6	0.8	0.16	1.0	0.18	4	0.5	0.12	0.6	0.13
Eye & Orbit	5	0.6	0.13	0.8	0.16	5	0.7	0.14	0.7	0.15
Brain & Other CNS ¹	49	7.1	0.47	7.9	0.51	38	5.2	0.39	5.7	0.42
Brain	47	6.8	0.45	7.6	0.50	36	4.8	0.37	5.4	0.40
Endocrine System	47	6.9	0.46	7.7	0.50	115	17.0	0.73	18.5	0.77
Thyroid gland	40	5.8	0.42	6.6	0.47	110	16.2	0.71	17.7	0.76
Lymphomas	192	27.6	0.91	31.9	1.03	154	19.6	0.72	22.7	0.82
Hodgkin Lymphoma	23	3.5	0.33	3.7	0.35	15	2.2	0.27	2.2	0.26
Non-Hodgkin Lymphoma	169	24.1	0.85	28.2	0.97	140	17.4	0.67	20.4	0.78
Multiple Myeloma	56	7.9	0.48	9.4	0.56	41	4.9	0.35	5.9	0.42
Leukemias	128	18.7	0.75	21.4	0.85	81	10.4	0.53	11.6	0.59
Acute lymphocytic	11	1.7	0.24	1.6	0.22	10	1.6	0.23	1.4	0.20
Chronic lymphocytic	61	8.5	0.50	10.3	0.59	33	3.9	0.31	4.7	0.37
Acute myeloid	31	4.6	0.38	5.2	0.42	23	2.9	0.28	3.3	0.31
Chronic myeloid	15	2.3	0.27	2.6	0.30	10	1.3	0.19	1.5	0.21
Other leukemias	10	1.5	0.22	1.6	0.24	5	0.7	0.14	0.8	0.15
Mesothelioma	17	2.5	0.28	2.9	0.32	5	0.6	0.12	0.7	0.14
Kaposi Sarcoma	3	0.4	0.12	0.5	0.12	-	-	-	-	-
Ill-defined & Unknown	131	19.4	0.77	22.3	0.88	122	14.7	0.61	17.1	0.70
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	40	5.9	0.42	6.8	0.48	74	9.7	0.52	11.1	0.59
Breast (<i>in situ</i>)	-	-	-	-	-	113	14.6	0.63	17.5	0.74

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1952
Population-based Data Available: 1989
Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
758,544	758,976	758,842	763,350	766,762

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	116.9	113.3	109.5	107.9	100.7
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.1	0.1	0.1	0.1	0.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.6	Prostate	96.6
Oral Cavity & Pharynx	98.5	Testis	100.0
Esophagus	96.0	Bladder (incl. <i>in situ</i>)	97.9
Stomach	96.6	Kidney & Renal Pelvis	90.7
Colon & Rectum	94.5	Brain & Other CNS ¹	77.6
Liver	60.2	Thyroid	99.6
Pancreas	70.8	Hodgkin Lymphoma	100.0
Lung & Bronchus	83.6	Non-Hodgkin Lymphoma	98.3
Melanomas of the Skin	100.0	Multiple Myeloma	93.9
Female Breast (excl. <i>in situ</i>)	98.6	Leukemias	98.2
Cervix uteri	99.3	Brain & Other CNS ¹ <i>non-malignant</i>	74.6
Uterus Corpus & Uterus NOS ¹	99.1	Breast <i>in situ</i>	100.0
Ovary	88.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
New Brunswick, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,589	500.3	4.56	593.2	5.30	2,368	421.2	4.04	492.6	4.60
Oral Cavity & Pharynx	85	15.7	0.79	19.4	0.96	33	5.8	0.47	6.9	0.54
Lip	6	1.3	0.24	1.6	0.29	3	0.5	0.13	0.5	0.14
Tongue	25	4.6	0.42	5.7	0.52	9	1.4	0.22	1.7	0.27
Major salivary gland	4	0.9	0.20	1.0	0.22	3	0.7	0.19	0.8	0.19
Floor of mouth	4	0.7	0.16	0.9	0.19	2	0.3	0.11	0.4	0.14
Gum & other mouth	7	1.3	0.23	1.6	0.28	7	1.1	0.20	1.3	0.23
Nasopharynx	3	0.6	0.15	0.7	0.18	2	0.3	0.10	0.4	0.13
Oropharynx	5	1.0	0.20	1.2	0.24	-	-	-	-	-
Hypopharynx	3	0.5	0.15	0.6	0.17	-	-	-	-	-
Digestive System	582	113.7	2.18	134.8	2.54	422	71.1	1.59	83.5	1.84
Esophagus	36	6.8	0.53	8.2	0.63	10	1.6	0.24	1.9	0.27
Stomach	65	12.6	0.73	15.1	0.85	29	4.8	0.41	5.8	0.48
Small intestine	15	2.8	0.33	3.3	0.39	9	1.5	0.23	1.8	0.28
Colon excl. rectum	210	41.8	1.34	49.1	1.54	196	33.1	1.09	38.4	1.24
Rectum & rectosigmoid	126	24.0	0.99	28.6	1.16	63	11.2	0.66	13.1	0.75
Anus, anal canal & anorectum	5	1.0	0.20	1.1	0.24	16	2.7	0.31	3.3	0.38
Liver	24	4.6	0.43	5.5	0.50	9	1.5	0.23	1.7	0.26
Gallbladder	3	0.7	0.17	0.8	0.20	6	1.0	0.18	1.1	0.21
Pancreas	75	14.8	0.79	17.7	0.93	62	10.0	0.58	11.9	0.69
Respiratory System	474	92.1	1.95	108.6	2.27	378	62.7	1.47	74.9	1.74
Larynx	25	4.7	0.43	5.7	0.51	4	0.6	0.15	0.8	0.18
Lung & bronchus	445	86.7	1.89	102.0	2.20	372	61.8	1.46	73.7	1.72
Bones & Joints	4	0.9	0.23	0.9	0.22	3	0.8	0.23	0.7	0.20
Soft Tissue (incl. heart)	13	3.0	0.39	3.2	0.41	11	2.3	0.33	2.5	0.35
Skin (excl. basal & sq.)	113	22.7	0.99	26.6	1.14	105	20.3	0.93	23.2	1.03
Melanomas of the skin	100	19.8	0.93	23.3	1.06	95	18.5	0.90	21.1	0.99
Breast (excl. <i>in situ</i>)	5	1.1	0.22	1.2	0.25	617	111.0	2.09	130.9	2.39
Female Genital System	-	-	-	-	-	267	48.6	1.40	57.4	1.60
Cervix uteri	-	-	-	-	-	29	7.3	0.63	7.6	0.64
Uterus Corpus	-	-	-	-	-	152	25.5	0.95	31.7	1.16
Uterus, NOS ¹	-	-	-	-	-	1	0.2	0.09	0.3	0.10
Ovary	-	-	-	-	-	58	10.7	0.66	12.3	0.73
Male Genital System	552	98.4	1.94	120.5	2.33	-	-	-	-	-
Prostate	524	90.8	1.83	112.8	2.23	-	-	-	-	-
Testis	21	6.1	0.61	5.9	0.59	-	-	-	-	-
Penis	7	1.3	0.23	1.5	0.26	-	-	-	-	-
Urinary System	330	64.5	1.64	76.2	1.91	138	23.9	0.94	28.3	1.09
Bladder (incl. <i>in situ</i>)	199	39.1	1.28	46.1	1.49	61	10.3	0.60	12.2	0.70
Kidney & renal pelvis	124	23.7	0.99	28.1	1.15	72	13.0	0.71	15.3	0.82
Ureter	5	1.1	0.22	1.3	0.26	3	0.5	0.13	0.6	0.16
Eye & Orbit	2	0.3	0.11	0.4	0.13	-	-	-	-	-
Brain & Other CNS ¹	37	7.6	0.59	8.8	0.65	27	5.8	0.54	6.2	0.55
Brain	36	7.4	0.58	8.5	0.65	26	5.4	0.52	5.8	0.53
Endocrine System	36	7.7	0.60	8.8	0.66	80	17.6	0.94	19.3	0.99
Thyroid gland	34	7.1	0.57	8.0	0.63	78	17.3	0.93	18.9	0.98
Lymphomas	133	27.1	1.09	31.1	1.23	112	20.7	0.92	23.6	1.02
Hodgkin Lymphoma	13	3.3	0.43	3.4	0.43	9	2.3	0.36	2.4	0.35
Non-Hodgkin Lymphoma	120	23.8	1.01	27.8	1.15	103	18.4	0.85	21.3	0.95
Multiple Myeloma	37	7.3	0.55	8.7	0.65	28	4.8	0.41	5.6	0.48
Leukemias	100	20.1	0.94	23.2	1.06	71	12.9	0.72	14.7	0.79
Acute lymphocytic	5	1.4	0.30	1.3	0.27	3	1.0	0.26	0.9	0.23
Chronic lymphocytic	50	9.5	0.62	11.4	0.73	37	6.1	0.46	7.4	0.55
Acute myeloid	27	5.5	0.49	6.3	0.55	20	3.8	0.41	4.2	0.43
Chronic myeloid	11	2.2	0.30	2.5	0.35	7	1.3	0.22	1.4	0.25
Other leukemias	-	-	-	-	-	4	0.7	0.18	0.8	0.19
Mesothelioma	9	1.9	0.29	2.2	0.34	3	0.5	0.13	0.6	0.16
Kaposi Sarcoma	1	0.3	0.12	0.4	0.15	-	-	-	-	-
Ill-defined & Unknown	75	15.8	0.84	18.1	0.95	71	12.1	0.66	13.9	0.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	15	3.5	0.41	3.8	0.44	30	6.1	0.53	6.9	0.57
Breast (<i>in situ</i>)	-	-	-	-	-	71	12.8	0.71	15.4	0.83

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

NEWFOUNDLAND AND LABRADOR CANCER REGISTRY

Initial Operation: 1955
 Population-based Data Available: 1955
 Coverage Area: Newfoundland and Labrador

Total Population Counts by Year

2013	2014	2015	2016	2017
527,114	528,159	528,117	529,426	528,356

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.5	103.0	105.8	108.2	104.1
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.9	1.2	0.7	0.3	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.5	Prostate	98.1
Oral Cavity & Pharynx	98.8	Testis	96.2
Esophagus	96.3	Bladder (incl. <i>in situ</i>)	98.9
Stomach	96.0	Kidney & Renal Pelvis	89.8
Colon & Rectum	96.2	Brain & Other CNS ¹	89.4
Liver	40.7	Thyroid	99.7
Pancreas	62.0	Hodgkin Lymphoma	100.0
Lung & Bronchus	80.7	Non-Hodgkin Lymphoma	98.1
Melanomas of the Skin	99.6	Multiple Myeloma	92.0
Female Breast (excl. <i>in situ</i>)	98.7	Leukemias	94.9
Cervix uteri	97.4	Brain & Other CNS ¹ <i>non-malig</i>	75.7
Uterus Corpus & Uterus NOS ¹	98.6	Breast <i>in situ</i>	100.0
Ovary	89.4		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Newfoundland and Labrador, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	1,900	526.3	5.68	624.6	6.60	1,759	465.0	5.16	543.1	5.86
Oral Cavity & Pharynx	62	16.8	1.00	20.3	1.18	21	5.6	0.58	6.6	0.65
Lip	10	2.9	0.43	3.4	0.49	1	0.3	0.13	0.4	0.15
Tongue	14	3.9	0.49	4.7	0.57	5	1.4	0.28	1.7	0.33
Major salivary gland	3	0.8	0.22	0.9	0.25	3	1.0	0.27	1.1	0.28
Floor of mouth	4	1.1	0.25	1.4	0.30	-	-	-	-	-
Gum & other mouth	6	1.5	0.29	1.8	0.34	3	0.7	0.20	0.8	0.23
Nasopharynx	3	0.8	0.22	1.0	0.25	2	0.5	0.17	0.5	0.18
Oropharynx	3	0.7	0.21	0.9	0.25	1	0.3	0.11	0.3	0.14
Hypopharynx	3	0.9	0.25	1.1	0.29	-	-	-	-	-
Digestive System	519	145.8	3.01	172.6	3.50	388	100.7	2.35	118.0	2.70
Esophagus	31	8.4	0.71	10.2	0.85	7	1.6	0.29	2.0	0.35
Stomach	52	15.2	0.99	18.1	1.16	27	7.4	0.66	8.3	0.72
Small intestine	10	2.6	0.39	3.2	0.46	11	2.8	0.38	3.3	0.45
Colon excl. rectum	219	61.9	1.96	72.6	2.26	203	52.6	1.70	61.6	1.95
Rectum & rectosigmoid	126	34.9	1.46	41.7	1.71	66	17.1	0.97	20.3	1.12
Anus, anal canal & anorectum	4	1.2	0.27	1.4	0.31	6	1.6	0.30	1.9	0.35
Liver	17	4.7	0.54	5.6	0.64	7	1.9	0.33	2.1	0.36
Gallbladder	4	1.3	0.28	1.4	0.32	5	1.2	0.25	1.4	0.30
Pancreas	35	9.6	0.77	11.4	0.90	34	8.5	0.67	10.1	0.79
Respiratory System	301	84.3	2.28	99.5	2.64	232	57.8	1.74	68.4	2.02
Larynx	21	6.1	0.62	7.3	0.74	3	0.8	0.20	0.9	0.24
Lung & bronchus	277	77.3	2.18	91.1	2.53	227	56.6	1.72	67.0	2.00
Bones & Joints	2	0.9	0.28	0.9	0.28	1	0.4	0.18	0.4	0.18
Soft Tissue (incl. heart)	10	3.5	0.51	3.8	0.54	6	1.9	0.36	2.0	0.38
Skin (excl. basal & sq.)	68	20.3	1.16	23.1	1.29	54	15.4	0.98	17.5	1.08
Melanomas of the skin	60	17.9	1.09	20.3	1.20	48	13.7	0.93	15.5	1.01
Breast (excl. <i>in situ</i>)	4	1.2	0.27	1.4	0.32	465	121.8	2.63	143.5	3.01
Female Genital System	-	-	-	-	-	209	56.6	1.83	66.2	2.07
Cervix uteri	-	-	-	-	-	31	10.6	0.89	11.1	0.90
Uterus Corpus	-	-	-	-	-	108	27.2	1.21	33.3	1.44
Uterus, NOS ¹	-	-	-	-	-	3	0.7	0.20	0.9	0.24
Ovary	-	-	-	-	-	40	10.7	0.79	12.4	0.90
Male Genital System	447	113.1	2.50	139.2	3.01	-	-	-	-	-
Prostate	432	107.3	2.40	133.1	2.93	-	-	-	-	-
Testis	10	4.4	0.62	4.3	0.60	-	-	-	-	-
Penis	5	1.3	0.28	1.6	0.32	-	-	-	-	-
Urinary System	230	64.7	2.01	77.1	2.35	102	25.6	1.17	30.7	1.37
Bladder (incl. <i>in situ</i>)	131	38.1	1.57	44.9	1.82	46	11.4	0.78	13.5	0.90
Kidney & renal pelvis	95	25.2	1.21	30.6	1.44	55	13.8	0.87	16.8	1.03
Ureter	4	1.0	0.25	1.2	0.29	1	0.3	0.11	0.3	0.14
Eye & Orbit	3	0.9	0.23	1.1	0.28	2	0.5	0.16	0.5	0.19
Brain & Other CNS ¹	23	7.0	0.69	7.9	0.74	20	5.9	0.63	6.5	0.66
Brain	22	6.7	0.67	7.6	0.73	19	5.7	0.61	6.2	0.64
Endocrine System	32	9.7	0.81	10.9	0.88	94	28.9	1.41	32.1	1.50
Thyroid gland	30	8.9	0.77	10.1	0.85	93	28.3	1.39	31.4	1.48
Lymphomas	92	26.3	1.29	30.6	1.46	78	21.0	1.12	24.5	1.26
Hodgkin Lymphoma	7	2.2	0.41	2.4	0.42	7	2.4	0.44	2.5	0.45
Non-Hodgkin Lymphoma	86	24.1	1.22	28.2	1.39	71	18.6	1.03	21.9	1.17
Multiple Myeloma	21	5.8	0.58	7.0	0.69	18	4.4	0.47	5.3	0.56
Leukemias	37	11.5	0.91	12.6	0.95	26	7.2	0.67	8.2	0.73
Acute lymphocytic	4	2.0	0.46	1.7	0.38	2	0.8	0.28	0.8	0.25
Chronic lymphocytic	9	2.4	0.38	2.9	0.44	4	1.0	0.23	1.2	0.27
Acute myeloid	14	4.1	0.52	4.7	0.57	9	2.5	0.39	2.9	0.44
Chronic myeloid	6	1.8	0.36	2.0	0.39	6	1.6	0.32	1.8	0.36
Other leukemias	4	1.2	0.28	1.3	0.30	5	1.2	0.25	1.4	0.29
Mesothelioma	4	1.2	0.27	1.4	0.32	1	0.3	0.12	0.4	0.15
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	41	13.1	0.96	14.9	1.09	40	10.7	0.77	12.4	0.88
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	10	3.2	0.47	3.8	0.54	18	4.8	0.53	5.6	0.60
Breast (<i>in situ</i>)	-	-	-	-	-	73	18.8	1.03	22.3	1.18

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

NEWFOUNDLAND AND LABRADOR

II-572 Incidence – All Races

NORTHWEST TERRITORIES CANCER REGISTRY

Initial Operation: 1986
 Population-based Data Available: 1950
 Coverage Area: Territory

Total Population Counts by Year

2013	2014	2015	2016	2017
43,805	43,884	44,237	44,649	44,908

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	131.5	208.8	144.6	156.8	162.1
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	1.8	2.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	0.0	0.0	0.5	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Prostate	98.6
Oral Cavity & Pharynx	100.0	Testis	100.0
Esophagus	100.0	Bladder (incl. <i>in situ</i>)	100.0
Stomach	95.5	Kidney & Renal Pelvis	90.2
Colon & Rectum	99.3	Brain & Other CNS ¹	92.3
Liver	45.5	Thyroid	100.0
Pancreas	73.3	Hodgkin Lymphoma	100.0
Lung & Bronchus	81.1	Non-Hodgkin Lymphoma	100.0
Melanomas of the Skin	100.0	Multiple Myeloma	90.0
Female Breast (excl. <i>in situ</i>)	100.0	Leukemias	100.0
Cervix uteri	100.0	Brain & Other CNS ¹ <i>non-malig</i>	~
Uterus Corpus & Uterus NOS ¹	100.0	Breast <i>in situ</i>	100.0
Ovary	100.0		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System
 ~ no cases reported

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Northwest Territories, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	82	490.8	28.21	571.0	31.72	76	453.5	26.24	525.0	29.71
Oral Cavity & Pharynx	4	21.4	5.51	24.3	6.04	-	-	-	-	-
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	26	163.9	16.84	188.8	18.80	18	108.6	13.08	126.6	14.64
Esophagus	1	8.0	3.81	8.9	3.99	-	-	-	-	-
Stomach	4	19.7	5.79	23.0	6.85	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	8	55.6	10.15	62.5	10.97	7	49.8	9.36	57.7	10.42
Rectum & rectosigmoid	7	45.2	8.80	52.6	10.06	6	27.7	5.82	34.1	6.93
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	2	9.3	3.93	11.2	4.46	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	2	9.8	3.37	12.1	3.98	-	-	-	-	-
Respiratory System	14	97.6	13.45	111.9	14.92	9	76.3	12.39	87.5	13.83
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	13	94.2	13.28	107.8	14.72	9	76.3	12.39	87.5	13.83
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	2	11.5	3.96	13.3	4.32	2	10.2	3.39	11.9	3.91
Melanomas of the skin	2	11.5	3.96	13.3	4.32	2	9.5	3.31	10.9	3.80
Breast (excl. <i>in situ</i>)	-	-	-	-	-	23	125.0	12.99	146.7	15.00
Female Genital System	-	-	-	-	-	9	44.1	7.46	51.6	8.59
Cervix uteri	-	-	-	-	-	2	7.8	2.93	7.9	2.99
Uterus Corpus	-	-	-	-	-	5	24.5	5.67	29.5	6.55
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	2	7.7	2.75	9.3	3.36
Male Genital System	16	83.8	10.99	100.9	12.60	-	-	-	-	-
Prostate	14	77.1	10.76	93.8	12.37	-	-	-	-	-
Testis	2	6.0	2.16	6.2	2.22	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	9	45.5	7.51	53.5	8.58	3	20.2	5.99	23.2	6.77
Bladder (incl. <i>in situ</i>)	3	13.2	4.15	15.9	4.81	-	-	-	-	-
Kidney & renal pelvis	6	29.8	5.76	34.9	6.52	2	12.3	4.64	14.4	5.23
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	1	5.1	2.11	5.5	2.26	1	6.4	2.44	6.0	2.29
Brain	1	5.1	2.11	5.5	2.26	1	6.4	2.44	6.0	2.29
Endocrine System	-	-	-	-	-	3	11.0	3.09	11.2	3.14
Thyroid gland	-	-	-	-	-	2	10.0	2.91	10.3	3.01
Lymphomas	4	17.9	4.45	20.6	4.93	3	18.5	5.15	22.0	6.00
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	3	15.6	4.21	18.2	4.72	3	17.8	5.10	21.2	5.95
Multiple Myeloma	-	-	-	-	-	1	9.1	4.14	10.2	4.60
Leukemias	2	15.8	5.75	19.4	6.94	1	5.3	2.20	5.9	2.49
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	1	7.6	3.74	9.8	4.65	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	2	13.3	4.61	15.9	5.34	2	11.7	4.27	13.9	5.00
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	3	15.8	4.84	19.5	5.81

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1964
 Population-based Data Available: 1970
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
940,434	938,545	936,525	942,790	950,401

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.5	111.3	109.1	106.4	100.8
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	0.9	0.9	1.1	1.2
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	88.0	Prostate	93.8
Oral Cavity & Pharynx	97.4	Testis	97.9
Esophagus	92.5	Bladder (incl. <i>in situ</i>)	96.0
Stomach	90.2	Kidney & Renal Pelvis	83.8
Colon & Rectum	90.5	Brain & Other CNS ¹	84.3
Liver	40.2	Thyroid	99.4
Pancreas	49.3	Hodgkin Lymphoma	100.0
Lung & Bronchus	76.6	Non-Hodgkin Lymphoma	95.8
Melanomas of the Skin	99.8	Multiple Myeloma	91.4
Female Breast (excl. <i>in situ</i>)	97.8	Leukemias	90.3
Cervix uteri	97.4	Brain & Other CNS ¹ <i>non-malig</i>	70.6
Uterus Corpus & Uterus NOS ¹	97.1	Breast <i>in situ</i>	100.0
Ovary	86.3		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nova Scotia, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	3,343	540.2	4.33	635.0	5.00	3,154	450.5	3.75	526.7	4.26
Oral Cavity & Pharynx	118	17.5	0.75	21.6	0.90	46	6.5	0.44	7.7	0.52
Lip	7	1.1	0.20	1.3	0.23	2	0.3	0.10	0.4	0.12
Tongue	39	5.8	0.43	7.2	0.52	13	1.8	0.24	2.2	0.27
Major salivary gland	8	1.3	0.22	1.5	0.25	6	0.9	0.18	1.0	0.19
Floor of mouth	4	0.6	0.13	0.8	0.16	3	0.4	0.11	0.5	0.14
Gum & other mouth	9	1.4	0.22	1.7	0.26	11	1.6	0.21	1.9	0.25
Nasopharynx	3	0.5	0.14	0.6	0.16	1	0.2	0.07	0.2	0.09
Oropharynx	5	0.7	0.14	0.9	0.18	-	-	-	-	-
Hypopharynx	9	1.3	0.20	1.6	0.24	-	-	-	-	-
Digestive System	799	129.1	2.11	152.5	2.46	598	81.3	1.53	95.5	1.77
Esophagus	70	10.8	0.60	13.1	0.71	19	2.5	0.26	2.9	0.31
Stomach	57	9.3	0.57	11.1	0.67	32	4.5	0.36	5.1	0.41
Small intestine	17	3.0	0.33	3.4	0.37	17	2.4	0.27	2.9	0.31
Colon excl. rectum	299	49.3	1.32	57.9	1.53	280	37.9	1.04	44.3	1.20
Rectum & rectosigmoid	172	27.2	0.96	32.3	1.12	99	13.6	0.63	16.2	0.74
Anus, anal canal & anorectum	9	1.5	0.23	1.8	0.27	19	2.5	0.27	3.1	0.33
Liver	48	7.3	0.48	8.9	0.58	14	2.0	0.25	2.3	0.28
Gallbladder	6	1.1	0.20	1.3	0.23	12	1.6	0.22	1.8	0.24
Pancreas	88	14.1	0.70	16.6	0.81	75	10.0	0.53	11.7	0.61
Respiratory System	547	86.4	1.70	102.2	1.99	509	67.8	1.37	80.8	1.61
Larynx	31	4.6	0.38	5.6	0.46	8	1.1	0.17	1.3	0.21
Lung & bronchus	511	81.0	1.65	95.6	1.92	497	66.0	1.35	78.8	1.59
Bones & Joints	5	1.1	0.22	1.1	0.22	3	0.6	0.17	0.6	0.16
Soft Tissue (incl. heart)	16	3.1	0.37	3.3	0.38	18	2.9	0.33	3.2	0.35
Skin (excl. basal & sq.)	210	35.3	1.14	40.8	1.28	167	25.8	0.95	29.4	1.04
Melanomas of the skin	191	31.9	1.08	37.0	1.22	158	24.5	0.93	28.0	1.01
Breast (excl. <i>in situ</i>)	8	1.1	0.18	1.4	0.22	794	115.2	1.91	135.7	2.19
Female Genital System	-	-	-	-	-	350	50.7	1.27	60.1	1.46
Cervix uteri	-	-	-	-	-	38	7.2	0.55	7.7	0.56
Uterus Corpus	-	-	-	-	-	182	25.0	0.86	30.6	1.03
Uterus, NOS ¹	-	-	-	-	-	7	0.9	0.15	1.1	0.18
Ovary	-	-	-	-	-	79	11.3	0.60	13.2	0.68
Male Genital System	679	104.4	1.85	124.8	2.18	-	-	-	-	-
Prostate	640	96.1	1.75	116.2	2.08	-	-	-	-	-
Testis	29	6.6	0.57	6.7	0.56	-	-	-	-	-
Penis	9	1.3	0.21	1.6	0.26	-	-	-	-	-
Urinary System	415	67.9	1.54	79.7	1.78	186	26.0	0.89	30.5	1.01
Bladder (incl. <i>in situ</i>)	243	40.0	1.18	46.8	1.37	82	11.1	0.56	13.0	0.65
Kidney & renal pelvis	163	26.5	0.97	31.3	1.11	100	14.3	0.67	16.8	0.76
Ureter	4	0.8	0.17	0.9	0.19	3	0.4	0.11	0.4	0.12
Eye & Orbit	3	0.5	0.14	0.6	0.16	2	0.5	0.15	0.5	0.14
Brain & Other CNS ¹	44	7.8	0.56	8.8	0.60	33	5.2	0.44	5.7	0.46
Brain	43	7.8	0.56	8.7	0.60	32	5.1	0.44	5.6	0.46
Endocrine System	41	7.9	0.58	8.5	0.60	103	18.5	0.87	20.0	0.90
Thyroid gland	36	6.9	0.54	7.4	0.56	98	17.7	0.85	19.1	0.88
Lymphomas	174	29.7	1.05	34.0	1.17	134	19.6	0.80	22.7	0.89
Hodgkin Lymphoma	14	2.9	0.36	3.0	0.36	8	1.7	0.28	1.8	0.28
Non-Hodgkin Lymphoma	160	26.8	0.99	31.0	1.12	126	17.9	0.75	20.9	0.85
Multiple Myeloma	49	7.7	0.51	9.2	0.60	34	4.6	0.37	5.4	0.42
Leukemias	100	17.4	0.82	19.5	0.89	65	10.2	0.61	11.1	0.63
Acute lymphocytic	8	1.9	0.32	1.7	0.27	7	1.5	0.29	1.4	0.25
Chronic lymphocytic	37	5.8	0.44	6.9	0.52	21	2.9	0.29	3.4	0.33
Acute myeloid	30	5.3	0.45	6.0	0.49	23	3.7	0.37	4.0	0.38
Chronic myeloid	15	2.6	0.32	2.9	0.34	7	1.1	0.20	1.3	0.21
Other leukemias	10	1.8	0.26	2.1	0.29	7	0.9	0.17	1.0	0.18
Mesothelioma	14	2.3	0.29	2.6	0.33	2	0.3	0.09	0.4	0.11
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	121	20.7	0.87	24.1	1.00	109	14.8	0.65	17.2	0.75
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	25	4.6	0.43	5.1	0.46	41	6.5	0.48	7.3	0.52
Breast (<i>in situ</i>)	-	-	-	-	-	118	17.5	0.76	20.8	0.87

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1999 (1950 as part of Northwest Territories)
 Population-based Data Available: 1999 (1950 as part of Northwest Territories)
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
35,337	35,971	36,488	36,975	37,559

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	No	No	Yes	Yes	Yes
Completeness of Case Ascertainment	83.7	82.3	105.6	101.3	111.5
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.0	0.0	0.0	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	97.2	Prostate	100.0
Oral Cavity & Pharynx	100.0	Testis	100.0
Esophagus	100.0	Bladder (incl. <i>in situ</i>)	100.0
Stomach	100.0	Kidney & Renal Pelvis	100.0
Colon & Rectum	96.3	Brain & Other CNS ¹	100.0
Liver	100.0	Thyroid	100.0
Pancreas	100.0	Hodgkin Lymphoma	100.0
Lung & Bronchus	94.1	Non-Hodgkin Lymphoma	100.0
Melanomas of the Skin	100.0	Multiple Myeloma	100.0
Female Breast (excl. <i>in situ</i>)	100.0	Leukemias	100.0
Cervix uteri	100.0	Brain & Other CNS ¹ <i>non-malig</i>	50.0
Uterus Corpus & Uterus NOS ¹	100.0	Breast <i>in situ</i>	100.0
Ovary	~		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System
 ~ no cases reported

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Nunavut, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	34	364.9	33.26	424.9	37.34	37	436.4	40.26	512.1	46.25
Oral Cavity & Pharynx	2	24.9	8.78	26.8	9.34	1	12.5	5.51	14.9	6.49
Lip	-	-	-	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-	-	-	-
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	-	-	-	-	-	-	-	-	-	-
Gum & other mouth	-	-	-	-	-	-	-	-	-	-
Nasopharynx	1	15.1	6.67	16.6	7.24	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	12	109.7	16.48	131.2	18.79	10	147.2	25.87	174.3	29.95
Esophagus	-	-	-	-	-	-	-	-	-	-
Stomach	2	20.1	7.95	22.8	8.69	-	-	-	-	-
Small intestine	-	-	-	-	-	-	-	-	-	-
Colon excl. rectum	3	32.7	9.65	37.6	10.61	6	102.0	23.41	117.4	26.67
Rectum & rectosigmoid	5	36.6	7.72	46.2	9.68	2	24.9	9.16	31.6	11.17
Anus, anal canal & anorectum	-	-	-	-	-	-	-	-	-	-
Liver	-	-	-	-	-	-	-	-	-	-
Gallbladder	-	-	-	-	-	-	-	-	-	-
Pancreas	-	-	-	-	-	-	-	-	-	-
Respiratory System	10	137.8	22.74	159.8	25.29	11	144.2	22.72	171.9	25.67
Larynx	-	-	-	-	-	-	-	-	-	-
Lung & bronchus	10	137.8	22.74	159.8	25.29	11	142.5	22.65	169.1	25.52
Bones & Joints	-	-	-	-	-	-	-	-	-	-
Soft Tissue (incl. heart)	-	-	-	-	-	-	-	-	-	-
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	-	-	-	-	-	-	-	-	-	-
Breast (excl. <i>in situ</i>)	-	-	-	-	-	5	48.6	11.28	56.1	13.13
Female Genital System	-	-	-	-	-	3	25.5	6.43	29.1	7.71
Cervix uteri	-	-	-	-	-	2	12.1	4.11	10.7	3.63
Uterus Corpus	-	-	-	-	-	1	9.6	4.09	13.3	5.70
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	-	-	-	-	-
Male Genital System	3	33.6	9.72	39.5	10.88	-	-	-	-	-
Prostate	3	30.7	9.57	36.2	10.70	-	-	-	-	-
Testis	-	-	-	-	-	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	2	14.1	4.58	17.7	5.92	-	-	-	-	-
Bladder (incl. <i>in situ</i>)	-	-	-	-	-	-	-	-	-	-
Kidney & renal pelvis	1	8.2	3.45	10.3	4.50	-	-	-	-	-
Ureter	-	-	-	-	-	-	-	-	-	-
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	-	-	-	-	-	-	-	-	-	-
Brain	-	-	-	-	-	-	-	-	-	-
Endocrine System	-	-	-	-	-	2	16.0	8.13	18.2	9.33
Thyroid gland	-	-	-	-	-	2	16.0	8.13	18.2	9.33
Lymphomas	2	11.0	4.01	11.8	4.54	-	-	-	-	-
Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Non-Hodgkin Lymphoma	1	8.2	3.50	9.5	4.24	-	-	-	-	-
Multiple Myeloma	-	-	-	-	-	-	-	-	-	-
Leukemias	1	7.2	2.82	7.6	3.19	-	-	-	-	-
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	-	-	-	-	-	-	-	-	-	-
Acute myeloid	-	-	-	-	-	-	-	-	-	-
Chronic myeloid	-	-	-	-	-	-	-	-	-	-
Other leukemias	-	-	-	-	-	-	-	-	-	-
Mesothelioma	-	-	-	-	-	-	-	-	-	-
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	-	-	-	-	-	-	-	-	-	-
Selected tumors (non-invasive)	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹ (non-malig)	-	-	-	-	-	-	-	-	-	-
Breast (<i>in situ</i>)	-	-	-	-	-	-	-	-	-	-

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1964
 Population-based Data Available: 1964
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
13,510,781	13,617,553	13,707,118	13,875,394	14,072,615

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.0	102.1	104.9	103.5	107.6
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.5	1.4	1.5	1.5	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	89.8	Prostate	96.3
Oral Cavity & Pharynx	95.4	Testis	97.1
Esophagus	93.2	Bladder (incl. <i>in situ</i>)	97.4
Stomach	93.1	Kidney & Renal Pelvis	91.1
Colon & Rectum	93.4	Brain & Other CNS ¹	83.0
Liver	56.5	Thyroid	99.4
Pancreas	67.1	Hodgkin Lymphoma	93.2
Lung & Bronchus	83.6	Non-Hodgkin Lymphoma	94.2
Melanomas of the Skin	98.1	Multiple Myeloma	68.6
Female Breast (excl. <i>in situ</i>)	97.7	Leukemias	74.2
Cervix uteri	97.8	Brain & Other CNS ¹ <i>non-malig</i>	36.5
Uterus Corpus & Uterus NOS ¹	97.8	Breast <i>in situ</i>	100.0
Ovary	89.9		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Ontario, 2013-2017, All Races

<i>SITES</i>	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>	<i>Avg. Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 Cdn</i>	<i>S.E.</i>
All Sites (invasive & in situ bladder)	40,168	509.5	1.16	599.6	1.34	40,450	453.1	1.03	528.0	1.18
Oral Cavity & Pharynx	1,422	17.3	0.21	21.0	0.25	643	7.1	0.13	8.4	0.15
Lip	85	1.1	0.05	1.3	0.06	32	0.3	0.03	0.4	0.03
Tongue	402	4.8	0.11	5.9	0.13	177	1.9	0.07	2.3	0.08
Major salivary gland	160	2.1	0.08	2.5	0.09	101	1.2	0.05	1.3	0.06
Floor of mouth	84	1.0	0.05	1.2	0.06	35	0.4	0.03	0.5	0.03
Gum & other mouth	178	2.2	0.08	2.7	0.09	146	1.6	0.06	1.8	0.07
Nasopharynx	92	1.2	0.06	1.4	0.06	36	0.4	0.03	0.5	0.04
Oropharynx	60	0.7	0.04	0.9	0.05	20	0.2	0.02	0.3	0.03
Hypopharynx	79	1.0	0.05	1.2	0.06	16	0.2	0.02	0.2	0.02
Digestive System	9,084	115.0	0.55	136.1	0.64	7,025	75.4	0.41	88.5	0.48
Esophagus	599	7.4	0.14	8.9	0.16	204	2.1	0.07	2.5	0.08
Stomach	986	12.6	0.18	14.9	0.21	564	6.1	0.12	7.1	0.14
Small intestine	249	3.1	0.09	3.7	0.11	225	2.5	0.08	2.9	0.09
Colon excl. rectum	3,078	39.7	0.33	46.5	0.38	2,908	31.2	0.26	36.3	0.30
Rectum & rectosigmoid	1,638	20.5	0.23	24.3	0.27	1,057	11.6	0.16	13.7	0.19
Anus, anal canal & anorectum	106	1.3	0.06	1.6	0.07	184	2.0	0.07	2.4	0.08
Liver	756	9.2	0.15	11.2	0.18	249	2.6	0.08	3.1	0.09
Gallbladder	65	0.8	0.05	1.0	0.06	127	1.4	0.05	1.6	0.06
Pancreas	1,049	13.2	0.19	15.7	0.22	968	10.2	0.15	12.0	0.17
Respiratory System	5,412	68.6	0.42	81.0	0.49	5,078	53.8	0.34	64.0	0.40
Larynx	348	4.2	0.10	5.1	0.12	66	0.7	0.04	0.8	0.05
Lung & bronchus	4,961	63.0	0.41	74.3	0.47	4,945	52.4	0.34	62.3	0.40
Bones & Joints	90	1.2	0.06	1.3	0.06	79	1.0	0.05	1.1	0.06
Soft Tissue (incl. heart)	394	5.3	0.12	5.9	0.13	308	3.7	0.10	4.1	0.11
Skin (excl. basal & sq.)	2,355	30.5	0.29	35.6	0.33	1,818	20.9	0.23	24.0	0.25
Melanomas of the skin	2,114	27.2	0.27	31.8	0.31	1,630	18.8	0.21	21.6	0.24
Breast (excl. <i>in situ</i>)	88	1.1	0.05	1.3	0.06	10,877	123.1	0.54	144.9	0.63
Female Genital System	-	-	-	-	-	4,955	55.5	0.36	65.9	0.42
Cervix uteri	-	-	-	-	-	565	7.5	0.15	8.0	0.15
Uterus Corpus	-	-	-	-	-	2,593	27.9	0.25	34.3	0.30
Uterus, NOS ¹	-	-	-	-	-	59	0.6	0.04	0.7	0.04
Ovary	-	-	-	-	-	1,226	13.9	0.18	16.3	0.21
Male Genital System	8,686	105.6	0.52	127.0	0.61	-	-	-	-	-
Prostate	8,124	97.4	0.49	118.6	0.59	-	-	-	-	-
Testis	432	6.5	0.14	6.4	0.14	-	-	-	-	-
Penis	101	1.3	0.06	1.5	0.07	-	-	-	-	-
Urinary System	4,907	63.0	0.41	73.9	0.47	1,954	21.1	0.22	24.8	0.25
Bladder (incl. <i>in situ</i>)	3,058	39.7	0.33	46.4	0.38	967	10.2	0.15	12.0	0.17
Kidney & renal pelvis	1,565	19.5	0.23	23.1	0.26	854	9.5	0.15	11.2	0.17
Ureter	37	0.5	0.04	0.6	0.04	26	0.3	0.02	0.3	0.03
Eye & Orbit	96	1.2	0.06	1.4	0.07	78	0.9	0.05	1.0	0.05
Brain & Other CNS ¹	612	8.1	0.15	9.1	0.16	478	5.8	0.12	6.4	0.13
Brain	577	7.6	0.15	8.5	0.16	448	5.4	0.12	6.0	0.13
Endocrine System	864	11.4	0.18	12.8	0.19	2,419	31.7	0.30	34.3	0.31
Thyroid gland	778	10.3	0.17	11.5	0.18	2,344	30.7	0.29	33.3	0.31
Lymphomas	2,090	27.3	0.27	31.2	0.31	1,694	19.3	0.22	22.1	0.24
Hodgkin Lymphoma	216	3.1	0.10	3.2	0.10	185	2.6	0.09	2.6	0.09
Non-Hodgkin Lymphoma	1,874	24.2	0.25	28.0	0.29	1,509	16.8	0.20	19.5	0.23
Multiple Myeloma	780	10.0	0.16	11.8	0.19	593	6.3	0.12	7.5	0.14
Leukemias	1,740	23.1	0.25	26.2	0.28	1,225	13.9	0.18	15.7	0.20
Acute lymphocytic	149	2.5	0.09	2.2	0.08	98	1.6	0.07	1.4	0.06
Chronic lymphocytic	833	10.5	0.17	12.5	0.19	554	5.8	0.11	6.9	0.13
Acute myeloid	346	4.6	0.11	5.2	0.13	268	3.1	0.09	3.5	0.10
Chronic myeloid	184	2.5	0.08	2.8	0.09	131	1.5	0.06	1.7	0.07
Other leukemias	229	3.1	0.09	3.5	0.10	173	1.9	0.07	2.2	0.08
Mesothelioma	164	2.2	0.08	2.5	0.09	51	0.6	0.04	0.7	0.04
Kaposi Sarcoma	39	0.5	0.04	0.6	0.04	8	0.1	0.01	0.1	0.01
Ill-defined & Unknown	1,346	18.1	0.22	20.8	0.26	1,169	12.7	0.17	14.5	0.19
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	956	12.8	0.19	14.3	0.21	1,395	16.3	0.20	18.5	0.22
Breast (<i>in situ</i>)	6	0.1	0.01	0.1	0.02	1,547	17.5	0.20	21.1	0.24

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

PRINCE EDWARD ISLAND CANCER REGISTRY

Initial Operation: 1969
Population-based Data Available: 1969
Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
144,094	144,283	144,546	146,969	150,483

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.4	115.6	119.4	111.3	105.7
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.1	0.4	0.3	0.3	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	89.2	Prostate	95.9
Oral Cavity & Pharynx	99.3	Testis	100.0
Esophagus	92.9	Bladder (incl. <i>in situ</i>)	96.1
Stomach	96.3	Kidney & Renal Pelvis	87.7
Colon & Rectum	93.3	Brain & Other CNS ¹	74.1
Liver	52.9	Thyroid	100.0
Pancreas	56.7	Hodgkin Lymphoma	100.0
Lung & Bronchus	72.1	Non-Hodgkin Lymphoma	98.2
Melanomas of the Skin	100.0	Multiple Myeloma	90.7
Female Breast (excl. <i>in situ</i>)	98.8	Leukemias	98.2
Cervix uteri	100.0	Brain & Other CNS ¹ <i>non-malig</i>	42.9
Uterus Corpus & Uterus NOS ¹	98.4	Breast <i>in situ</i>	100.0
Ovary	78.8		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Prince Edward Island, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	487	517.9	10.88	611.1	12.63	452	423.5	9.26	497.1	10.60
Oral Cavity & Pharynx	20	21.8	2.24	26.3	2.65	9	8.4	1.32	10.1	1.54
Lip	6	6.5	1.27	7.7	1.46	2	1.4	0.50	1.9	0.66
Tongue	5	5.2	1.06	6.6	1.32	3	2.7	0.75	3.2	0.86
Major salivary gland	-	-	-	-	-	-	-	-	-	-
Floor of mouth	1	1.0	0.43	1.4	0.57	-	-	-	-	-
Gum & other mouth	1	1.7	0.68	1.9	0.73	2	1.9	0.62	2.2	0.70
Nasopharynx	-	-	-	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-	-	-	-
Digestive System	121	127.5	5.37	151.3	6.28	84	77.0	3.87	89.7	4.42
Esophagus	9	8.0	1.24	10.2	1.55	2	2.0	0.59	2.5	0.72
Stomach	11	12.0	1.63	14.4	1.94	5	4.1	0.87	4.9	1.04
Small intestine	2	2.1	0.69	2.5	0.81	1	1.2	0.47	1.4	0.52
Colon excl. rectum	46	48.7	3.33	57.6	3.90	39	36.2	2.66	41.6	3.00
Rectum & rectosigmoid	25	26.1	2.43	30.6	2.79	15	14.5	1.71	17.0	1.97
Anus, anal canal & anorectum	-	-	-	-	-	2	1.7	0.62	1.8	0.66
Liver	7	8.0	1.36	9.2	1.54	3	2.4	0.66	3.0	0.80
Gallbladder	1	1.6	0.61	1.9	0.74	1	1.2	0.47	1.4	0.54
Pancreas	13	14.8	1.87	17.6	2.18	11	9.3	1.32	10.9	1.51
Respiratory System	73	78.3	4.22	91.7	4.88	76	67.7	3.52	80.0	4.12
Larynx	4	3.9	0.95	4.7	1.13	-	-	-	-	-
Lung & bronchus	69	73.3	4.07	85.6	4.70	75	66.1	3.47	78.2	4.07
Bones & Joints	1	1.4	0.59	1.6	0.66	-	-	-	-	-
Soft Tissue (incl. heart)	4	4.4	1.06	4.6	1.10	3	3.3	0.87	3.6	0.92
Skin (excl. basal & sq.)	-	-	-	-	-	-	-	-	-	-
Melanomas of the skin	33	36.5	2.97	42.1	3.36	27	27.7	2.51	32.1	2.80
Breast (excl. <i>in situ</i>)	1	1.8	0.67	2.0	0.78	119	112.1	4.79	132.7	5.52
Female Genital System	-	-	-	-	-	48	45.7	3.10	54.4	3.56
Cervix uteri	-	-	-	-	-	7	8.4	1.47	9.4	1.57
Uterus Corpus	-	-	-	-	-	26	22.8	2.10	28.3	2.53
Uterus, NOS ¹	-	-	-	-	-	-	-	-	-	-
Ovary	-	-	-	-	-	10	10.2	1.48	11.7	1.65
Male Genital System	101	99.3	4.58	121.2	5.50	-	-	-	-	-
Prostate	98	95.9	4.46	117.6	5.40	-	-	-	-	-
Testis	2	3.3	1.01	3.4	1.03	-	-	-	-	-
Penis	-	-	-	-	-	-	-	-	-	-
Urinary System	54	57.2	3.59	67.4	4.19	27	24.6	2.20	28.8	2.51
Bladder (incl. <i>in situ</i>)	34	36.5	2.87	42.7	3.33	12	10.6	1.42	12.4	1.61
Kidney & renal pelvis	19	20.0	2.12	24.0	2.51	14	12.7	1.60	14.9	1.83
Ureter	-	-	-	-	-	1	1.3	0.48	1.5	0.57
Eye & Orbit	-	-	-	-	-	-	-	-	-	-
Brain & Other CNS ¹	7	8.1	1.46	9.1	1.59	4	4.1	0.97	4.7	1.08
Brain	6	7.5	1.41	8.5	1.53	4	3.9	0.96	4.5	1.05
Endocrine System	4	5.5	1.22	6.0	1.30	7	7.9	1.40	8.8	1.51
Thyroid gland	4	4.4	1.07	5.0	1.19	7	7.9	1.40	8.8	1.51
Lymphomas	24	26.8	2.58	30.6	2.86	14	14.0	1.76	16.2	1.97
Hodgkin Lymphoma	3	3.5	1.02	3.5	1.00	2	2.0	0.71	2.3	0.78
Non-Hodgkin Lymphoma	-	-	-	-	-	-	-	-	-	-
Multiple Myeloma	9	9.2	1.45	11.0	1.69	6	5.4	0.97	6.4	1.15
Leukemias	13	14.6	1.91	16.6	2.11	9	8.9	1.40	10.0	1.52
Acute lymphocytic	-	-	-	-	-	-	-	-	-	-
Chronic lymphocytic	6	6.2	1.20	7.5	1.43	4	3.6	0.82	4.3	0.97
Acute myeloid	3	3.2	0.89	3.5	0.94	2	1.9	0.59	2.2	0.69
Chronic myeloid	2	2.7	0.86	2.9	0.89	-	-	-	-	-
Other leukemias	1	1.4	0.56	1.8	0.68	1	1.6	0.64	1.6	0.64
Mesothelioma	2	2.9	0.85	3.3	0.96	1	1.1	0.47	1.2	0.51
Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
Ill-defined & Unknown	17	18.7	2.12	21.7	2.43	14	12.8	1.56	14.9	1.79
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	3	3.2	0.86	3.5	0.92	7	6.5	1.18	7.7	1.34
Breast (<i>in situ</i>)	-	-	-	-	-	19	18.1	1.91	21.6	2.23

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Initial Operation: 1932
 Population-based Data Available: 1932
 Coverage Area: Province

Total Population Counts by Year

2013	2014	2015	2016	2017
1,099,736	1,112,979	1,120,967	1,135,987	1,150,926

Data Quality Indicators (2013-2017)

Indicators (%)	2013	2014	2015	2016	2017
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	113.6	103.7	104.3	114.9	108.3
Missing Race	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	0.7	0.6	0.6	0.4
Passing Edits	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2013-2017)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.3	Prostate	90.9
Oral Cavity & Pharynx	98.3	Testis	100.0
Esophagus	96.7	Bladder (incl. <i>in situ</i>)	96.3
Stomach	96.8	Kidney & Renal Pelvis	86.7
Colon & Rectum	95.4	Brain & Other CNS ¹	88.3
Liver	63.9	Thyroid	99.0
Pancreas	73.8	Hodgkin Lymphoma	100.0
Lung & Bronchus	80.1	Non-Hodgkin Lymphoma	96.7
Melanomas of the Skin	99.5	Multiple Myeloma	93.1
Female Breast (excl. <i>in situ</i>)	98.3	Leukemias	95.8
Cervix uteri	97.9	Brain & Other CNS ¹ <i>non-malignant</i>	67.7
Uterus Corpus & Uterus NOS ¹	98.4	Breast <i>in situ</i>	100.0
Ovary	88.9		

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System

Average Annual Cancer Cases and Age-adjusted Incidence Rates*
Saskatchewan, 2013-2017, All Races

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.	Avg. Annual Cases	Adj. Rate 2000 U.S.	S.E.	Adj. Rate 2011 Cdn	S.E.
All Sites (invasive & in situ bladder)	2,932	470.8	3.97	556.4	4.61	2,769	408.6	3.58	476.9	4.11
Oral Cavity & Pharynx	84	12.9	0.65	15.7	0.77	37	5.3	0.40	6.2	0.46
Lip	8	1.2	0.21	1.5	0.24	2	0.3	0.09	0.3	0.10
Tongue	23	3.4	0.33	4.3	0.40	10	1.4	0.21	1.7	0.24
Major salivary gland	8	1.4	0.22	1.5	0.24	5	0.8	0.17	0.9	0.18
Floor of mouth	4	0.7	0.15	0.8	0.17	4	0.5	0.11	0.6	0.15
Gum & other mouth	8	1.3	0.20	1.5	0.24	9	1.2	0.19	1.4	0.22
Nasopharynx	4	0.5	0.13	0.7	0.16	-	-	-	-	-
Oropharynx	4	0.6	0.14	0.7	0.16	-	-	-	-	-
Hypopharynx	4	0.6	0.14	0.8	0.17	-	-	-	-	-
Digestive System	738	118.5	1.99	140.8	2.32	526	74.1	1.49	86.4	1.72
Esophagus	43	6.7	0.47	8.1	0.56	12	1.6	0.22	1.9	0.26
Stomach	65	10.6	0.60	12.5	0.69	30	4.2	0.35	4.9	0.41
Small intestine	13	2.1	0.27	2.5	0.31	16	2.4	0.28	2.7	0.31
Colon excl. rectum	287	47.0	1.26	55.0	1.46	247	34.8	1.03	40.2	1.17
Rectum & rectosigmoid	162	25.4	0.91	30.7	1.08	88	12.7	0.63	15.0	0.73
Anus, anal canal & anorectum	6	0.9	0.17	1.0	0.20	10	1.5	0.22	1.8	0.26
Liver	36	5.3	0.41	6.6	0.50	13	1.8	0.23	2.1	0.27
Gallbladder	6	1.0	0.18	1.2	0.21	8	1.2	0.19	1.4	0.21
Pancreas	81	13.0	0.66	15.4	0.77	69	9.3	0.52	11.0	0.60
Respiratory System	409	66.8	1.50	78.4	1.74	406	58.0	1.31	68.2	1.53
Larynx	23	3.5	0.33	4.3	0.40	4	0.6	0.13	0.7	0.15
Lung & bronchus	379	62.1	1.45	72.7	1.67	399	56.9	1.30	67.0	1.52
Bones & Joints	6	1.0	0.18	1.1	0.20	5	0.9	0.18	0.9	0.18
Soft Tissue (incl. heart)	18	2.9	0.31	3.4	0.36	13	1.9	0.25	2.1	0.27
Skin (excl. basal & sq.)	105	17.1	0.76	20.0	0.87	103	16.2	0.74	18.5	0.83
Melanomas of the skin	97	15.6	0.72	18.3	0.84	97	15.4	0.72	17.5	0.81
Breast (excl. <i>in situ</i>)	7	1.1	0.19	1.3	0.23	758	115.2	1.93	135.8	2.23
Female Genital System	-	-	-	-	-	337	50.8	1.28	60.0	1.48
Cervix uteri	-	-	-	-	-	47	8.6	0.58	8.9	0.59
Uterus Corpus	-	-	-	-	-	175	25.4	0.88	31.4	1.07
Uterus, NOS ¹	-	-	-	-	-	4	0.5	0.12	0.6	0.14
Ovary	-	-	-	-	-	76	11.4	0.60	13.3	0.69
Male Genital System	710	109.8	1.88	132.9	2.24	-	-	-	-	-
Prostate	666	102.2	1.81	125.0	2.17	-	-	-	-	-
Testis	33	5.7	0.46	5.7	0.45	-	-	-	-	-
Penis	9	1.5	0.22	1.8	0.26	-	-	-	-	-
Urinary System	358	58.9	1.42	68.7	1.63	155	22.0	0.82	25.8	0.94
Bladder (incl. <i>in situ</i>)	221	36.6	1.12	42.7	1.29	72	9.7	0.53	11.4	0.61
Kidney & renal pelvis	130	21.0	0.84	24.5	0.97	79	11.8	0.61	13.9	0.71
Ureter	4	0.6	0.15	0.7	0.16	2	0.3	0.10	0.4	0.11
Eye & Orbit	3	0.6	0.14	0.6	0.15	4	0.6	0.14	0.7	0.16
Brain & Other CNS ¹	44	7.3	0.50	8.1	0.55	31	4.9	0.41	5.5	0.45
Brain	43	7.0	0.49	7.8	0.54	30	4.8	0.40	5.3	0.44
Endocrine System	35	5.8	0.45	6.4	0.49	70	12.0	0.66	13.1	0.71
Thyroid gland	32	5.4	0.43	5.9	0.47	67	11.5	0.65	12.6	0.70
Lymphomas	147	24.0	0.91	27.7	1.02	124	18.2	0.76	21.1	0.86
Hodgkin Lymphoma	14	2.4	0.29	2.6	0.31	12	2.0	0.26	2.2	0.28
Non-Hodgkin Lymphoma	132	21.6	0.86	25.1	0.98	113	16.3	0.71	18.9	0.81
Multiple Myeloma	51	8.2	0.52	9.7	0.61	33	4.7	0.37	5.6	0.44
Leukemias	126	20.7	0.84	23.9	0.96	81	12.0	0.62	13.5	0.68
Acute lymphocytic	9	1.6	0.24	1.5	0.22	7	1.4	0.23	1.2	0.20
Chronic lymphocytic	67	10.8	0.60	12.8	0.70	38	5.3	0.40	6.3	0.47
Acute myeloid	24	3.9	0.36	4.6	0.42	18	2.8	0.30	3.2	0.34
Chronic myeloid	13	2.1	0.27	2.5	0.31	9	1.4	0.21	1.5	0.23
Other leukemias	13	2.2	0.28	2.6	0.32	8	1.1	0.19	1.3	0.21
Mesothelioma	13	2.2	0.27	2.4	0.31	3	0.5	0.13	0.6	0.14
Kaposi Sarcoma	1	0.3	0.10	0.3	0.10	-	-	-	-	-
Ill-defined & Unknown	77	12.9	0.67	14.9	0.76	83	11.3	0.57	12.9	0.65
Selected tumors (non-invasive)										
Brain & Other CNS ¹ (non-malig)	19	3.2	0.34	3.6	0.37	38	5.9	0.45	6.7	0.50
Breast (<i>in situ</i>)	-	-	-	-	-	105	16.2	0.73	19.4	0.86

* Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Population Standard.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

¹ Abbreviations: NOS - Not Otherwise Specified; CNS - Central Nervous System



Section III

Registry-specific Stage at Diagnosis by Age for Select Cancer Sites



**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Alabama, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	97	40.6	4.0	69	42.9	4.2	24	34.1	3.7	-	-	-	1	58.3	3.1	4	58.1	4.5
Regional	79	32.9	3.0	52	32.8	2.9	24	33.5	3.5	-	-	-	-	-	-	2	35.5	3.0
Distant	29	12.1	1.0	19	12.1	1.0	9	12.8	1.3	-	-	-	-	-	-	-	-	-
Unknown	34	14.3	1.3	20	12.3	1.1	14	19.6	2.0	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	55	4.0	1.9	40	3.8	1.8	13	4.1	2.3	-	-	-	-	-	-	-	-	-
Localized	516	37.2	19.5	386	37.3	18.7	111	34.6	20.6	-	-	-	3	40.5	11.4	5	42.1	9.4
Regional	458	33.0	17.3	355	34.2	17.1	98	30.7	18.8	-	-	-	3	43.2	12.2	4	35.1	10.9
Distant	255	18.4	9.6	186	18.0	9.0	67	20.9	12.0	-	-	-	-	-	-	2	15.8	3.7
Unknown	103	7.4	4.0	69	6.7	3.5	31	9.6	6.0	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	3	2.3	0.2	3	2.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	51	34.1	3.5	37	34.4	3.5	12	29.7	3.3	-	-	-	-	-	-	1	60.0	1.6
Regional	54	35.8	3.7	39	36.8	3.7	14	35.4	3.9	-	-	-	-	-	-	-	-	-
Distant	34	22.8	2.4	23	21.4	2.2	11	28.7	3.1	-	-	-	-	-	-	-	-	-
Unknown	8	5.1	0.5	5	4.9	0.5	2	4.6	0.5	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	52	4.2	6.4	37	4.0	5.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	465	37.6	61.3	350	37.6	58.5	99	35.3	65.8	-	-	-	-	-	-	4	38.3	29.8
Regional	404	32.7	52.8	316	34.0	52.1	84	30.0	58.0	-	-	-	-	-	-	4	42.6	39.4
Distant	221	17.8	28.6	163	17.6	27.0	56	19.8	35.1	-	-	-	-	-	-	-	-	-
Unknown	96	7.7	13.2	64	6.9	11.3	29	10.3	20.5	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	45	3.6	1.4	31	3.5	1.3	13	4.0	1.8	-	-	-	-	-	-	-	-	-
Localized	457	36.7	14.4	324	36.7	13.5	113	34.3	15.4	-	-	-	4	45.8	13.2	4	36.7	9.9
Regional	411	33.0	13.1	306	34.7	13.1	99	29.8	13.7	-	-	-	4	39.6	11.9	4	35.0	9.3
Distant	227	18.2	7.2	154	17.4	6.4	72	21.6	9.9	-	-	-	1	12.5	2.8	3	21.7	5.9
Unknown	105	8.4	3.2	68	7.7	2.8	34	10.3	4.7	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	5	3.1	0.3	4	3.6	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	52	35.4	3.4	34	33.5	3.2	15	35.9	3.3	-	-	-	-	-	-	1	35.3	2.1
Regional	52	35.3	3.4	40	39.6	3.9	11	27.2	2.6	-	-	-	-	-	-	1	41.2	2.2
Distant	28	19.1	1.9	17	17.1	1.7	11	26.2	2.6	-	-	-	-	-	-	-	-	-
Unknown	11	7.2	0.7	6	6.2	0.6	4	8.7	0.8	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	40	3.7	4.3	27	3.5	3.8	-	-	-	-	-	-	-	-	-	-	-	-
Localized	405	36.9	43.3	291	37.2	40.6	99	34.0	47.0	-	-	-	-	-	-	3	37.2	30.1
Regional	359	32.7	38.4	266	34.1	37.3	88	30.2	42.8	-	-	-	-	-	-	3	32.6	28.0
Distant	199	18.1	21.0	136	17.4	18.9	61	21.0	29.0	-	-	-	-	-	-	-	-	-
Unknown	94	8.6	9.9	62	7.9	8.4	30	10.5	14.9	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Alabama, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	746	16.6	24.3	527	16.1	23.2	199	17.6	26.9	-	-	-	9	25.1	22.5	7	17.4	13.4
Localized	2,344	52.1	75.1	1,769	54.0	75.6	530	46.8	71.4	-	-	-	16	48.0	44.6	19	51.1	36.2
Regional	987	21.9	32.8	700	21.4	31.5	275	24.3	37.1	1	50.0	27.8	6	17.5	15.0	9	24.2	15.4
Distant	228	5.1	7.3	147	4.5	6.3	79	7.0	10.6	-	-	-	-	-	-	1	3.7	3.0
Unknown	194	4.3	6.3	131	4.0	5.6	50	4.4	7.0	-	-	-	3	8.2	9.6	1	3.7	2.8
<i>Age < 50</i>																		
In Situ	136	17.4	9.1	90	17.7	8.7	38	15.7	9.1	-	-	-	4	27.7	12.0	2	13.6	4.4
Localized	362	46.3	24.1	241	47.4	23.4	108	44.0	24.9	-	-	-	6	49.2	21.6	8	46.9	13.8
Regional	210	26.9	14.1	137	27.0	13.4	68	27.9	15.8	-	-	-	2	18.5	7.9	5	33.3	10.0
Distant	40	5.1	2.7	21	4.2	2.1	18	7.2	4.1	-	-	-	-	-	-	-	-	-
Unknown	34	4.3	2.2	19	3.7	1.8	13	5.3	2.9	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	610	16.4	63.9	438	15.8	61.2	161	18.1	73.4	-	-	-	5	23.6	50.0	4	20.2	36.8
Localized	1,982	53.3	208.7	1,529	55.3	212.5	422	47.5	192.9	-	-	-	10	47.2	104.8	12	54.1	94.9
Regional	777	20.9	81.9	563	20.3	79.0	207	23.3	93.0	-	-	-	4	17.0	33.6	4	17.4	29.4
Distant	188	5.1	19.5	125	4.5	17.2	61	6.9	27.6	-	-	-	-	-	-	-	-	-
Unknown	160	4.3	17.0	112	4.0	15.4	37	4.2	17.9	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	4	0.2	0.2	4	0.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	429	18.8	16.1	356	19.8	16.8	68	14.7	12.7	-	-	-	2	20.0	10.8	1	17.9	3.8
Regional	549	24.0	19.8	442	24.6	20.2	102	22.1	18.8	-	-	-	2	22.0	12.5	1	17.9	3.5
Distant	1,034	45.3	37.7	785	43.6	36.5	242	52.4	43.3	-	-	-	4	44.0	21.6	3	38.5	7.5
Unknown	268	11.7	10.5	215	11.9	10.6	49	10.7	10.3	-	-	-	1	14.0	6.8	2	25.6	6.5
<i>Female</i>																		
In Situ	4	0.2	0.1	3	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	416	24.7	12.4	356	25.7	13.8	55	20.0	7.6	-	-	-	2	23.8	7.4	3	39.0	8.3
Regional	388	23.1	11.6	323	23.3	12.6	62	22.4	8.3	1	85.7	22.6	1	14.3	3.4	2	26.8	6.1
Distant	684	40.7	20.4	552	39.9	21.8	126	45.4	16.7	-	-	-	5	57.1	17.4	3	31.7	6.7
Unknown	188	11.2	5.6	151	10.9	5.8	33	12.0	4.9	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,650	76.0	90.7	1,669	75.7	72.9	815	74.6	134.4	1	87.5	28.3	8	58.3	36.2	19	77.6	47.4
Regional	354	10.2	11.5	257	11.7	10.7	94	8.6	14.2	-	-	-	2	13.9	7.2	2	9.6	4.6
Distant	154	4.4	5.8	90	4.1	4.4	63	5.7	11.7	-	-	-	-	-	-	1	5.6	2.9
Unknown	328	9.4	13.0	188	8.5	9.5	120	11.0	26.3	-	-	-	3	20.8	18.9	2	7.2	4.7
<i>Age < 65</i>																		
Localized	1,156	77.9	41.4	648	77.5	30.7	449	77.6	70.1	-	-	-	3	66.7	10.8	10	76.1	18.4
Regional	187	12.6	6.7	122	14.6	5.8	63	10.9	9.8	-	-	-	-	-	-	-	-	-
Distant	53	3.6	1.9	24	2.8	1.1	29	5.0	4.5	-	-	-	-	-	-	-	-	-
Unknown	88	5.9	3.1	43	5.1	2.0	37	6.5	5.7	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,494	74.6	430.8	1,021	74.6	365.2	365	71.3	578.6	-	-	-	5	54.2	211.9	9	79.3	248.0
Regional	168	8.4	44.9	135	9.9	45.0	31	6.0	44.8	-	-	-	-	-	-	-	-	-
Distant	101	5.0	32.8	66	4.9	27.0	34	6.6	61.6	-	-	-	-	-	-	-	-	-
Unknown	240	12.0	81.2	146	10.6	60.9	83	16.2	168.6	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Alaska, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	13	55.8	3.9	10	60.2	4.0	-	-	-	2	41.4	4.5	-	-	-	-	-	-
Regional	6	25.8	2.1	4	21.7	1.7	-	-	-	2	37.9	5.0	-	-	-	-	-	-
Distant	4	15.8	1.0	2	14.5	0.9	-	-	-	1	20.7	2.6	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	4	2.6	1.2	2	2.2	0.9	-	-	-	2	4.1	3.1	-	-	-	-	-	-
Localized	57	35.5	15.7	40	36.4	13.6	-	-	-	13	33.5	29.7	3	32.5	15.0	1	28.6	9.2
Regional	51	32.1	15.1	35	32.0	12.8	2	47.1	16.7	12	31.0	29.6	3	35.0	13.3	-	-	-
Distant	37	23.0	10.7	23	21.3	8.6	-	-	-	11	28.9	26.1	2	25.0	9.8	-	-	-
Unknown	11	6.8	3.6	9	8.1	3.8	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	6	30.9	2.5	4	31.6	2.2	-	-	-	1	24.1	4.4	-	-	-	-	-	-
Regional	6	34.0	2.8	4	35.1	2.4	-	-	-	2	31.0	5.2	-	-	-	-	-	-
Distant	5	25.5	2.0	3	22.8	1.5	-	-	-	2	34.5	5.4	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	51	36.1	50.4	36	37.0	43.7	-	-	-	12	35.1	96.0	-	-	-	-	-	-
Regional	45	31.9	47.3	31	31.6	40.2	-	-	-	10	31.0	93.5	-	-	-	-	-	-
Distant	32	22.7	33.4	21	21.1	27.2	-	-	-	9	28.0	80.3	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	4	2.8	1.0	2	2.9	0.9	-	-	-	1	2.7	2.4	-	-	-	-	-	-
Localized	49	35.6	14.4	28	33.5	11.2	-	-	-	18	40.6	36.9	2	24.2	5.0	2	52.9	12.7
Regional	45	32.8	13.9	28	34.0	11.3	-	-	-	15	32.6	33.4	2	27.3	6.2	-	-	-
Distant	31	22.5	9.4	18	22.2	7.6	-	-	-	9	20.1	19.8	3	39.4	7.9	-	-	-
Unknown	9	6.3	3.0	6	7.5	2.8	-	-	-	2	4.0	4.4	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	9	39.3	4.3	5	36.9	3.2	-	-	-	4	48.9	13.7	-	-	-	-	-	-
Regional	7	28.2	3.0	4	29.2	2.5	-	-	-	2	24.4	6.3	-	-	-	-	-	-
Distant	6	23.9	2.5	3	23.1	2.0	-	-	-	2	22.2	5.8	-	-	-	-	-	-
Unknown	2	6.8	0.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	1	3.4	8.5	-	-	-	-	-	-
Localized	40	34.9	40.7	23	32.9	32.1	-	-	-	14	38.5	97.7	2	30.8	18.0	-	-	-
Regional	38	33.8	42.6	24	34.9	34.4	-	-	-	12	34.6	104.3	-	-	-	-	-	-
Distant	25	22.2	27.4	15	22.0	22.4	-	-	-	7	19.6	56.5	-	-	-	-	-	-
Unknown	7	6.2	8.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Alaska, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	101	19.3	27.6	80	20.1	28.6	2	16.4	23.5	14	17.5	28.8	5	16.8	18.0	2	13.3	19.4
Localized	262	50.2	75.0	197	49.6	76.2	6	46.3	59.1	44	53.4	85.4	14	50.3	50.7	8	42.2	61.9
Regional	110	21.0	31.1	84	21.1	32.3	3	20.9	23.8	17	20.1	32.3	6	22.4	20.1	6	31.1	37.0
Distant	29	5.5	8.0	20	5.0	7.4	1	9.0	8.6	6	7.3	11.9	2	6.3	6.5	2	10.0	15.9
Unknown	21	3.9	6.1	17	4.2	6.6	-	-	-	1	1.7	2.8	1	4.2	3.9	-	-	-
<i>Age < 50</i>																		
In Situ	21	18.8	10.2	15	18.9	10.3	-	-	-	4	19.4	12.8	2	19.5	7.9	-	-	-
Localized	51	45.3	24.1	37	45.4	24.5	1	43.8	16.5	8	41.8	24.6	4	53.7	21.6	2	41.4	16.9
Regional	30	26.7	13.8	21	26.6	14.2	-	-	-	6	28.6	16.1	2	22.0	8.1	3	48.3	20.3
Distant	5	4.7	2.5	4	4.5	2.4	-	-	-	2	8.2	5.1	-	-	-	-	-	-
Unknown	5	4.5	2.4	4	4.7	2.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	80	19.5	73.1	64	20.4	76.6	-	-	-	11	16.9	70.8	3	15.7	44.3	2	19.7	70.3
Localized	211	51.5	208.4	160	50.7	211.5	5	47.1	170.9	36	57.0	244.9	10	49.0	127.1	5	42.6	179.7
Regional	80	19.5	76.2	62	19.7	79.6	-	-	-	11	17.5	74.6	5	22.5	51.5	3	23.0	80.7
Distant	24	5.8	22.4	16	5.1	20.5	1	11.8	31.3	4	7.0	29.7	2	8.8	23.7	-	-	-
Unknown	16	3.8	15.6	13	4.1	17.3	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	35	17.1	11.7	28	18.4	12.0	-	-	-	5	13.1	11.6	-	-	-	-	-	-
Regional	42	20.8	13.2	29	19.5	11.5	1	25.0	16.4	10	26.2	25.7	2	17.4	10.4	-	-	-
Distant	105	51.9	32.4	76	50.9	29.4	2	41.7	24.0	22	56.5	56.8	5	54.3	24.5	3	70.0	27.2
Unknown	20	10.0	7.5	16	10.8	7.4	-	-	-	2	4.2	5.4	2	17.4	11.5	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	31	20.2	9.4	22	20.2	8.7	-	-	-	8	22.0	15.9	-	-	-	-	-	-
Regional	33	21.4	10.1	25	23.3	10.2	-	-	-	6	17.9	13.1	1	14.6	4.1	-	-	-
Distant	79	50.8	24.5	52	47.3	21.1	2	57.9	29.0	20	57.8	42.4	5	65.9	21.8	1	58.3	12.3
Unknown	11	7.2	3.6	10	8.8	4.3	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	189	62.4	49.2	160	62.8	52.2	9	60.6	73.1	13	60.6	27.9	4	51.2	23.5	3	57.1	29.4
Regional	41	13.5	10.3	34	13.5	10.7	2	15.5	13.7	2	11.0	6.2	2	18.6	7.6	-	-	-
Distant	29	9.4	9.9	21	8.3	8.5	-	-	-	5	22.0	16.0	2	18.6	10.4	-	-	-
Unknown	44	14.7	14.1	39	15.4	15.3	2	16.9	26.9	1	6.4	6.1	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	86	65.6	18.6	70	65.0	19.3	6	63.3	41.4	7	79.1	12.4	1	46.7	4.9	2	53.3	10.4
Regional	23	17.8	5.0	19	17.8	5.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	8	6.0	1.7	7	6.1	1.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	14	10.6	3.0	12	11.1	3.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	103	60.0	260.8	90	61.1	279.7	2	54.5	292.4	6	48.5	135.1	3	53.6	152.3	2	61.5	160.5
Regional	18	10.2	46.4	15	10.3	48.7	-	-	-	-	-	-	-	-	-	-	-	-
Distant	21	12.1	66.3	15	9.9	55.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	31	17.7	91.1	27	18.6	98.8	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Arizona, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	102	45.8	3.1	91	45.9	3.3	4	40.0	2.2	3	42.1	1.7	3	53.6	2.0	34	45.4	3.7
Regional	62	27.5	1.7	54	27.2	1.8	4	40.0	2.3	2	26.3	1.2	1	21.4	0.8	20	26.6	2.3
Distant	29	13.1	0.8	27	13.4	0.8	-	-	-	-	-	-	-	-	-	9	12.1	1.1
Unknown	30	13.5	0.9	27	13.5	0.9	-	-	-	1	18.4	0.9	-	-	-	12	15.9	1.5

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	33	2.2	0.8	29	2.2	0.8	2	3.9	1.0	2	3.6	1.1	-	-	-	5	2.0	0.8
Localized	480	33.0	12.4	441	33.1	12.5	13	30.6	9.0	15	33.9	11.3	7	32.7	7.3	73	29.2	12.5
Regional	469	32.3	12.3	433	32.5	12.5	10	25.2	8.0	14	30.4	10.8	7	32.7	8.1	86	34.2	14.9
Distant	289	19.9	7.6	264	19.8	7.7	11	26.7	8.8	9	19.2	6.7	4	19.5	4.6	55	22.1	8.5
Unknown	183	12.6	4.9	165	12.4	4.8	6	13.6	4.6	6	12.9	5.5	3	14.2	3.9	31	12.5	5.8
<i>Age < 50</i>																		
In Situ	2	1.6	0.1	2	1.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	38	26.9	1.8	31	26.5	1.8	3	40.5	2.8	2	22.7	1.8	-	-	-	8	23.9	1.2
Regional	47	33.8	2.3	41	35.3	2.4	1	16.7	1.2	2	27.3	2.2	2	45.0	1.7	13	38.1	2.1
Distant	38	27.5	1.9	32	27.3	1.9	2	26.2	1.6	3	34.1	2.6	-	-	-	10	28.4	1.6
Unknown	14	10.2	0.7	11	9.6	0.6	-	-	-	1	13.6	0.9	-	-	-	3	9.1	0.5
<i>Age ≥ 50</i>																		
In Situ	30	2.3	2.8	27	2.2	2.7	-	-	-	-	-	-	-	-	-	-	-	-
Localized	443	33.7	40.3	410	33.7	40.7	9	28.0	25.5	13	36.7	36.4	-	-	-	65	30.1	42.1
Regional	422	32.1	38.5	392	32.3	39.0	9	27.4	25.9	11	31.1	33.3	6	30.1	24.7	72	33.6	48.4
Distant	251	19.1	22.7	232	19.1	23.0	9	26.8	27.6	6	15.6	17.2	-	-	-	45	21.0	26.7
Unknown	168	12.8	15.8	154	12.7	15.6	-	-	-	5	12.8	17.4	-	-	-	28	13.0	19.6
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	19	1.6	0.4	16	1.5	0.4	1	2.7	0.9	1	3.4	0.6	-	-	-	4	2.1	0.6
Localized	428	34.9	9.9	395	35.5	10.2	12	27.4	8.4	11	29.8	6.6	7	26.8	5.2	58	30.8	8.4
Regional	407	33.2	9.6	366	32.9	9.6	16	36.1	12.2	12	33.7	8.5	10	39.0	8.0	67	35.9	9.5
Distant	221	18.0	5.2	200	18.0	5.3	9	21.0	6.8	7	19.7	4.6	5	18.7	3.4	35	18.6	4.8
Unknown	152	12.4	3.5	136	12.2	3.4	6	12.8	4.7	5	13.5	3.3	4	14.6	3.2	24	12.6	3.5
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	39	31.7	1.9	34	32.6	2.0	2	23.5	1.4	1	25.9	1.3	-	-	-	9	24.0	1.3
Regional	43	35.5	2.2	38	35.9	2.2	3	38.2	2.5	1	25.9	1.2	1	33.3	1.3	15	43.0	2.4
Distant	28	22.5	1.4	23	22.3	1.4	1	20.6	1.4	2	29.6	1.4	1	28.6	1.1	8	21.2	1.2
Unknown	12	9.6	0.6	9	8.6	0.5	-	-	-	-	-	-	-	-	-	4	10.6	0.6
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	1	4.0	2.2	-	-	-	-	-	-
Localized	389	35.2	31.0	361	35.8	31.6	10	28.1	26.7	9	30.5	20.6	-	-	-	49	32.4	27.0
Regional	363	32.9	29.2	328	32.6	28.9	13	35.7	37.5	11	35.1	27.7	8	40.2	25.5	52	34.2	28.2
Distant	193	17.5	15.4	176	17.5	15.4	8	21.1	20.8	5	17.9	13.1	3	16.7	9.6	27	18.0	14.3
Unknown	140	12.7	11.0	127	12.6	10.9	-	-	-	-	-	-	-	-	-	20	13.1	11.1

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Arizona, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	994	17.3	24.2	896	17.1	24.6	40	21.7	28.2	15	14.4	9.3	31	21.1	21.3	148	17.4	19.0
Localized	3,015	52.6	71.8	2,790	53.3	74.2	80	43.1	56.8	51	47.9	32.3	69	47.6	48.5	408	48.0	53.9
Regional	1,183	20.6	29.7	1,070	20.4	30.5	46	24.7	31.5	27	25.7	16.8	32	21.9	22.2	205	24.1	26.1
Distant	230	4.0	5.6	207	3.9	5.6	10	5.3	6.3	5	5.1	3.3	6	4.4	4.9	37	4.4	4.8
Unknown	306	5.3	7.2	272	5.2	7.0	10	5.4	7.5	7	6.9	5.3	7	5.0	4.9	52	6.1	7.1
<i>Age < 50</i>																		
In Situ	175	18.4	8.8	151	18.5	9.1	9	18.8	8.3	3	11.6	2.6	11	21.1	10.2	41	17.3	6.6
Localized	424	44.8	21.3	367	45.0	22.0	18	38.9	16.3	10	42.1	9.4	23	45.7	21.9	107	44.6	16.8
Regional	269	28.4	13.5	234	28.6	14.0	14	30.1	12.9	7	28.1	6.1	14	26.6	12.5	68	28.5	10.5
Distant	40	4.2	2.0	31	3.8	1.9	3	7.4	3.2	3	13.2	2.6	1	2.3	1.1	9	3.9	1.4
Unknown	39	4.2	2.0	33	4.0	2.0	2	4.8	2.0	1	5.0	1.1	2	4.3	2.0	14	5.7	2.1
<i>Age ≥ 50</i>																		
In Situ	819	17.1	64.5	745	16.9	65.2	32	22.6	80.2	13	15.3	27.1	20	21.1	50.3	107	17.5	51.7
Localized	2,590	54.2	204.0	2,423	54.8	210.6	63	44.5	163.0	41	49.6	92.5	46	48.6	118.0	302	49.3	151.0
Regional	913	19.1	72.4	836	18.9	73.6	32	22.9	80.4	21	24.9	44.6	18	19.4	47.7	137	22.4	66.9
Distant	191	4.0	15.2	175	4.0	15.4	6	4.5	14.6	2	2.7	5.2	5	5.5	14.7	28	4.5	13.7
Unknown	267	5.6	20.7	239	5.4	20.4	8	5.5	22.0	6	7.5	16.2	5	5.3	12.4	39	6.3	20.0

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	3	0.1	0.1	3	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	416	20.5	10.6	391	20.6	10.8	14	21.3	14.7	3	15.7	3.2	5	16.6	5.6	27	15.7	5.3
Regional	410	20.3	10.3	382	20.1	10.4	16	24.0	14.9	5	24.5	4.9	6	20.7	7.0	29	16.8	5.7
Distant	877	43.3	22.2	824	43.4	22.6	25	37.5	19.5	9	45.1	9.1	16	55.9	18.5	85	50.1	16.7
Unknown	318	15.7	8.2	300	15.8	8.3	11	17.1	11.0	3	14.7	2.8	2	6.9	2.8	30	17.4	6.6
<i>Female</i>																		
In Situ	8	0.4	0.2	7	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	503	25.7	11.1	480	26.1	11.6	11	22.4	9.2	5	19.7	3.0	7	18.9	5.5	35	21.8	5.6
Regional	388	19.8	8.5	366	19.9	8.8	8	15.3	5.7	6	23.9	3.8	7	20.6	5.4	32	20.0	5.0
Distant	780	39.9	17.3	726	39.5	17.6	24	47.8	18.3	10	44.4	7.6	17	47.4	13.2	67	41.5	10.3
Unknown	277	14.2	6.1	260	14.1	6.3	7	13.7	5.5	3	12.0	2.1	5	13.1	4.7	26	16.2	4.5

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,099	64.6	50.3	1,899	65.1	49.8	101	66.6	70.3	26	48.4	22.6	25	65.4	26.3	244	63.0	39.5
Regional	426	13.1	10.0	389	13.3	10.1	21	13.6	14.0	6	11.4	4.8	6	15.4	5.6	51	13.1	7.3
Distant	235	7.2	6.1	212	7.3	5.9	10	6.5	9.0	9	17.2	10.2	3	6.9	3.3	35	9.1	6.7
Unknown	489	15.1	12.7	418	14.3	11.7	20	13.3	20.1	13	23.1	14.1	5	12.2	6.7	57	14.8	12.4
<i>Age < 65</i>																		
Localized	800	70.3	22.3	701	70.9	22.1	61	71.6	39.3	9	50.0	5.8	9	66.2	8.8	117	66.4	16.2
Regional	193	16.9	5.3	172	17.4	5.4	12	14.7	7.9	3	17.4	2.1	3	23.9	3.2	32	18.0	4.4
Distant	56	5.0	1.6	49	4.9	1.5	4	4.3	2.3	3	16.3	1.9	-	-	-	14	7.8	1.9
Unknown	89	7.8	2.4	68	6.8	2.1	8	9.5	5.1	3	16.3	1.9	-	-	-	14	7.8	1.9
<i>Age ≥ 65</i>																		
Localized	1,299	61.5	243.6	1,198	62.1	241.5	40	60.2	284.6	18	47.6	138.8	15	65.0	147.9	127	60.2	200.2
Regional	233	11.1	42.4	217	11.2	42.4	8	12.3	56.1	3	8.6	23.9	2	10.3	22.2	19	9.0	27.5
Distant	179	8.5	37.1	163	8.4	36.1	6	9.3	55.2	7	17.6	67.2	-	-	-	22	10.2	40.1
Unknown	400	19.0	83.8	351	18.2	78.6	12	18.3	123.8	10	26.2	98.5	-	-	-	43	20.6	84.7

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Arkansas, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	60	41.4	4.2	50	44.8	4.3	7	28.9	2.9	Insufficient data for the calculation of AI/AN PRCDA statistics			2	42.1	5.7	4	41.9	4.7
Regional	51	34.7	3.2	38	33.5	2.9	11	44.6	4.4				2	42.1	5.0	3	30.2	5.8
Distant	22	14.8	1.4	17	14.8	1.3	4	18.2	2.0				-	-	-	1	16.3	2.4
Unknown	13	9.1	0.8	8	6.9	0.5	2	8.3	0.9				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	17	1.9	1.0	13	1.8	0.8	3	2.8	1.6	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	275	32.1	16.6	237	33.1	16.5	31	26.7	16.7				2	27.8	11.6	6	33.0	11.2
Regional	305	35.6	18.7	261	36.3	18.5	37	31.7	18.7				2	30.6	13.9	7	40.9	11.6
Distant	188	21.9	11.5	153	21.4	10.9	31	26.4	15.5				2	30.6	11.1	3	19.3	4.5
Unknown	73	8.5	4.4	53	7.4	3.7	14	12.4	8.4				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	25	25.1	2.8	20	24.8	2.7	4	26.5	2.9				-	-	-	-	-	-
Regional	41	41.8	4.7	34	43.5	4.8	4	32.4	3.5				-	-	-	3	50.0	3.8
Distant	27	27.1	3.1	20	25.8	2.9	5	36.8	3.9				-	-	-	2	32.1	2.5
Unknown	5	5.1	0.6	4	5.1	0.5	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	250	33.0	52.7	218	34.1	52.4	27	26.8	52.8				-	-	-	-	-	-
Regional	264	34.8	55.4	226	35.5	54.5	32	31.6	58.4				-	-	-	4	36.7	31.8
Distant	161	21.2	33.5	133	20.8	31.9	26	25.0	45.8				-	-	-	2	13.3	9.5
Unknown	68	8.9	14.5	49	7.7	12.1	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	14	1.9	0.7	12	1.9	0.7	1	1.1	0.5	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	233	31.5	12.0	196	32.1	11.8	31	28.5	13.2				4	41.7	20.6	4	27.9	12.2
Regional	269	36.2	14.1	227	37.1	13.8	36	33.0	14.7				3	31.3	15.8	6	45.6	14.2
Distant	151	20.3	8.0	119	19.5	7.4	28	26.1	11.8				2	20.8	8.2	3	19.1	5.2
Unknown	75	10.1	3.8	57	9.4	3.3	12	11.3	5.4				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	1	1.5	0.1	-	-	-	-	-	-				-	-	-	-	-	-
Localized	22	26.5	2.4	17	27.9	2.3	3	21.0	2.3				-	-	-	-	-	-
Regional	30	37.1	3.4	23	37.7	3.2	6	34.6	3.7				-	-	-	1	53.8	2.1
Distant	22	26.8	2.5	16	26.2	2.3	5	32.1	3.5				-	-	-	-	-	-
Unknown	7	8.1	0.7	4	6.6	0.6	2	12.3	1.4				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	13	1.9	2.2	-	-	-	1	1.3	1.8				-	-	-	-	-	-
Localized	212	32.1	37.4	179	32.6	36.6	27	29.8	41.5				-	-	-	-	-	-
Regional	238	36.1	42.0	204	37.0	41.5	30	32.7	43.2				-	-	-	5	43.6	46.1
Distant	129	19.5	22.4	103	18.8	20.8	23	25.1	33.6				-	-	-	-	-	-
Unknown	68	10.4	11.8	53	9.7	10.5	10	11.1	16.0				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Arkansas, 2013-2017**

Female Breast, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
Stage at Diagnosis																		
All Ages																		
In Situ	487	18.2	26.7	398	17.9	26.0	68	18.8	26.6				7	21.8	30.1	11	19.4	18.5
Localized	1,329	49.6	70.7	1,131	50.9	70.5	158	43.5	63.8				18	52.9	81.5	27	46.9	53.6
Regional	586	21.9	32.7	479	21.5	31.6	93	25.6	38.3				7	20.0	26.7	14	25.0	25.7
Distant	149	5.5	8.1	112	5.0	7.1	33	9.2	13.5				-	-	-	2	4.2	4.4
Unknown	129	4.8	6.7	104	4.7	6.3	11	2.9	4.5				-	-	-	3	4.5	7.2
Age < 50																		
In Situ	88	19.9	10.0	69	20.8	9.9	11	14.0	7.9	Insufficient data for the calculation of AI/AN PRCDA statistics			3	26.3	15.1	6	26.9	9.2
Localized	190	43.2	21.6	145	43.6	20.7	35	43.4	24.0				5	43.9	23.4	8	36.5	12.0
Regional	121	27.4	13.7	90	27.0	12.8	26	31.6	17.6				2	21.1	11.1	6	26.9	8.8
Distant	27	6.2	3.1	18	5.5	2.6	8	9.8	5.5				-	-	-	1	5.8	1.9
Unknown	14	3.2	1.6	10	3.1	1.5	-	-	-				-	-	-	-	-	-
Age ≥ 50																		
In Situ	399	17.8	70.3	328	17.4	67.9	57	20.2	75.5				4	19.5	69.4	6	15.2	43.0
Localized	1,138	50.9	199.4	986	52.2	200.9	122	43.5	167.9				13	57.5	233.6	19	52.7	162.5
Regional	465	20.8	82.5	389	20.6	80.6	67	23.9	92.5				4	19.5	67.6	9	23.9	69.8
Distant	121	5.4	21.3	94	5.0	19.1	25	9.0	34.6				-	-	-	1	3.3	10.8
Unknown	115	5.1	19.9	94	5.0	18.7	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>
Stage at Diagnosis																		
Male																		
In Situ	2	0.1	0.1	2	0.1	0.1	-	-	-				-	-	-	-	-	-
Localized	351	21.6	20.7	310	22.0	20.7	38	19.1	21.0				-	-	-	3	17.9	9.0
Regional	357	21.9	20.7	312	22.1	20.6	42	21.2	22.4				1	13.6	6.6	3	16.7	8.5
Distant	788	48.3	46.1	673	47.8	44.9	103	51.5	55.1				6	70.5	37.5	9	51.2	19.1
Unknown	131	8.1	8.3	111	7.9	7.9	16	8.2	10.5				-	-	-	2	14.3	6.7
Female																		
In Situ	3	0.3	0.2	3	0.3	0.2	-	-	-				-	-	-	-	-	-
Localized	312	24.7	15.4	283	25.3	16.1	24	19.5	9.9				2	26.8	13.0	3	23.2	9.8
Regional	281	22.3	14.0	249	22.2	14.4	29	23.6	11.8				2	22.0	8.9	3	18.8	5.9
Distant	559	44.3	28.0	490	43.7	28.5	61	50.0	25.1				4	48.8	17.9	7	49.3	18.5
Unknown	107	8.5	5.3	95	8.5	5.3	8	6.7	3.3				-	-	-	1	8.7	4.9

Prostate, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,586	78.7	87.8	1,243	79.3	78.9	304	80.4	146.9	Insufficient data for the calculation of AI/AN PRCDA statistics	7	75.0	44.9	27	78.7	70.6		
Regional	212	10.5	11.4	173	11.0	10.7	36	9.5	16.7		-	-	-	4	11.5	9.9		
Distant	130	6.4	7.8	98	6.3	6.8	29	7.7	16.0		1	13.6	8.0	2	4.6	5.7		
Unknown	88	4.4	5.3	54	3.4	3.7	9	2.4	5.6		-	-	-	2	5.2	6.0		
<i>Age < 65</i>																		
Localized	635	79.9	37.9	445	80.2	31.5	175	81.4	77.2	Insufficient data for the calculation of AI/AN PRCDA statistics	3	69.6	16.4	12	84.5	20.0		
Regional	100	12.6	6.0	75	13.5	5.3	23	10.9	10.6		-	-	-	2	12.7	2.9		
Distant	38	4.8	2.3	23	4.2	1.7	14	6.4	5.8		-	-	-	-	-	-		
Unknown	21	2.7	1.2	12	2.1	0.8	3	1.4	1.3		-	-	-	-	-	-		
<i>Age ≥ 65</i>																		
Localized	951	77.8	432.2	798	78.7	406.5	129	79.2	629.1		3	81.0	242.0	15	74.8	420.9		
Regional	112	9.2	49.1	98	9.7	48.1	13	7.7	59.3		-	-	-	2	10.7	58.1		
Distant	92	7.5	46.4	75	7.4	42.7	15	9.3	86.7		-	-	-	-	-	-		
Unknown	67	5.5	33.6	42	4.1	24.1	6	3.7	35.2		-	-	-	-	-	-		

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
California, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	640	43.9	3.3	489	44.9	3.5	34	35.4	2.5	4	43.1	2.6	97	41.8	2.7	243	44.0	3.7
Regional	505	34.7	2.5	376	34.5	2.5	34	35.6	2.4	4	37.3	2.3	87	37.5	2.4	199	36.1	3.2
Distant	233	16.0	1.1	173	15.9	1.1	21	21.6	1.4	-	-	-	38	16.2	1.0	82	14.9	1.4
Unknown	78	5.4	0.4	51	4.7	0.3	7	7.3	0.5	-	-	-	11	4.6	0.3	28	5.1	0.5

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	284	3.6	1.5	204	3.4	1.3	23	4.3	2.0	1	4.1	1.2	44	3.8	1.5	62	3.4	1.4
Localized	2,775	34.9	14.4	2,111	34.8	14.2	176	32.9	14.8	10	33.1	7.2	408	35.5	13.6	595	32.8	12.8
Regional	2,803	35.3	14.7	2,187	36.1	14.9	169	31.6	14.3	10	35.2	8.3	409	35.6	13.7	667	36.8	14.6
Distant	1,606	20.2	8.3	1,237	20.4	8.3	129	24.0	10.8	5	18.6	4.1	222	19.3	7.4	378	20.8	8.0
Unknown	474	6.0	2.6	327	5.4	2.3	39	7.3	3.7	3	9.0	3.1	66	5.7	2.3	112	6.2	2.7
<i>Age < 50</i>																		
In Situ	20	2.1	0.2	14	1.9	0.1	2	2.8	0.2	-	-	-	2	1.6	0.1	6	1.7	0.1
Localized	272	28.8	2.1	209	29.0	2.2	16	24.5	1.8	-	-	-	38	28.3	1.8	91	28.4	1.8
Regional	374	39.6	3.0	289	40.1	3.1	21	32.6	2.4	1	46.7	1.2	57	42.3	2.8	126	39.0	2.5
Distant	248	26.2	2.0	188	26.1	2.0	22	33.9	2.5	-	-	-	34	25.1	1.7	88	27.4	1.8
Unknown	31	3.3	0.2	20	2.8	0.2	4	6.2	0.4	-	-	-	4	2.7	0.2	11	3.4	0.2
<i>Age ≥ 50</i>																		
In Situ	265	3.8	4.9	190	3.6	4.5	21	4.5	6.8	1	4.6	4.3	42	4.1	5.1	56	3.8	4.7
Localized	2,503	35.8	46.4	1,902	35.6	45.7	160	34.0	49.0	-	-	-	370	36.5	44.2	504	33.8	41.8
Regional	2,429	34.7	45.2	1,898	35.5	45.8	148	31.4	45.6	9	33.8	26.8	352	34.7	42.3	541	36.3	46.3
Distant	1,358	19.4	25.0	1,049	19.6	24.9	107	22.7	32.5	-	-	-	188	18.5	22.6	289	19.4	24.5
Unknown	442	6.3	8.6	307	5.7	7.7	35	7.4	12.1	3	10.0	11.2	62	6.1	7.9	101	6.8	9.2
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	213	3.0	0.9	145	2.7	0.8	20	3.7	1.3	-	-	-	38	3.7	1.0	50	3.2	0.9
Localized	2,545	35.5	11.4	1,932	35.5	11.4	196	37.0	13.7	11	32.3	7.0	348	33.7	9.2	553	35.1	10.0
Regional	2,526	35.3	11.3	1,948	35.8	11.5	163	30.8	11.6	13	39.5	8.8	383	37.0	10.2	563	35.7	10.4
Distant	1,405	19.6	6.3	1,073	19.7	6.4	117	22.2	8.3	8	24.0	5.8	200	19.3	5.4	313	19.9	5.7
Unknown	471	6.6	2.0	342	6.3	1.9	33	6.3	2.4	1	3.6	0.8	65	6.3	1.7	97	6.2	1.9
<i>Age < 50</i>																		
In Situ	18	2.0	0.1	13	2.0	0.1	1	1.9	0.1	-	-	-	3	2.1	0.1	7	2.1	0.1
Localized	283	32.8	2.2	215	33.3	2.3	22	35.7	2.5	2	47.4	1.5	35	26.2	1.5	100	32.6	2.0
Regional	311	36.0	2.5	230	35.6	2.6	23	37.3	2.6	1	31.6	1.1	54	40.5	2.3	108	35.2	2.2
Distant	222	25.8	1.8	168	26.1	1.9	14	22.5	1.6	-	-	-	38	29.0	1.6	81	26.4	1.7
Unknown	28	3.3	0.2	19	3.0	0.2	2	2.6	0.2	-	-	-	3	2.1	0.1	12	3.8	0.2
<i>Age ≥ 50</i>																		
In Situ	195	3.1	3.0	132	2.7	2.7	18	3.9	4.5	-	-	-	35	3.9	3.2	44	3.4	2.9
Localized	2,262	35.9	35.3	1,717	35.8	35.3	173	37.2	43.2	9	30.4	21.4	314	34.8	29.6	453	35.7	31.1
Regional	2,215	35.2	34.5	1,718	35.8	35.1	140	30.0	35.2	12	40.5	29.2	329	36.5	31.0	455	35.8	31.8
Distant	1,183	18.8	18.3	905	18.9	18.4	103	22.2	25.7	-	-	-	162	17.9	15.1	232	18.3	16.2
Unknown	443	7.0	6.6	323	6.7	6.2	32	6.8	8.4	1	4.1	3.1	62	6.9	5.8	86	6.7	6.3

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
California, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	6,098	18.6	27.9	4,382	17.5	26.9	417	19.5	28.5	19	17.8	11.5	1,146	23.3	30.4	1,247	18.7	21.2
Localized	17,155	52.5	77.7	13,436	53.8	80.9	993	46.5	69.3	55	52.0	34.6	2,430	49.5	64.6	3,162	47.5	55.1
Regional	7,401	22.6	34.6	5,658	22.6	35.5	545	25.5	38.3	25	23.5	15.3	1,078	22.0	29.1	1,816	27.3	30.3
Distant	1,450	4.4	6.6	1,107	4.4	6.7	137	6.4	9.6	4	4.2	3.2	189	3.9	5.1	305	4.6	5.3
Unknown	593	1.8	2.6	399	1.6	2.3	45	2.1	3.2	3	2.5	1.8	66	1.3	1.7	130	2.0	2.3
<i>Age < 50</i>																		
In Situ	1,271	19.5	10.3	876	18.9	9.9	68	16.5	7.9	4	17.6	3.3	291	22.4	12.5	347	17.4	7.4
Localized	2,866	44.1	23.2	2,056	44.2	23.1	167	40.1	19.1	9	43.1	7.9	588	45.3	25.3	823	41.3	17.3
Regional	1,969	30.3	16.0	1,447	31.1	16.3	138	33.1	15.9	7	34.3	6.2	351	27.1	15.1	692	34.7	14.4
Distant	304	4.7	2.4	211	4.5	2.4	35	8.4	3.9	-	-	-	55	4.2	2.3	96	4.8	2.0
Unknown	93	1.4	0.7	57	1.2	0.6	8	2.0	0.9	-	-	-	12	0.9	0.5	36	1.8	0.7
<i>Age ≥ 50</i>																		
In Situ	4,827	18.4	74.0	3,506	17.2	71.6	349	20.3	82.4	15	17.9	32.8	855	23.7	77.2	900	19.3	57.2
Localized	14,289	54.6	220.2	11,380	56.0	232.1	826	48.0	200.6	46	54.1	104.5	1,841	51.0	167.7	2,339	50.1	154.1
Regional	5,432	20.7	83.2	4,212	20.7	85.7	408	23.7	97.2	18	20.9	39.1	727	20.1	65.8	1,124	24.1	71.8
Distant	1,146	4.4	17.6	897	4.4	18.2	102	5.9	24.4	-	-	-	134	3.7	12.4	209	4.5	13.9
Unknown	501	1.9	7.5	342	1.7	6.7	37	2.1	9.1	-	-	-	53	1.5	4.9	95	2.0	6.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	24	0.3	0.1	19	0.3	0.1	1	0.2	0.1	-	-	-	3	0.2	0.1	3	0.3	0.1
Localized	1,707	20.0	9.5	1,359	20.8	9.8	112	16.9	10.8	8	19.3	6.9	214	17.2	7.7	171	15.9	5.0
Regional	1,730	20.3	9.4	1,337	20.5	9.4	137	20.7	12.5	9	22.3	7.1	239	19.2	8.4	201	18.7	5.6
Distant	4,444	52.1	23.9	3,329	51.0	23.1	364	54.9	32.2	18	46.2	16.3	709	57.0	24.8	613	57.0	16.7
Unknown	626	7.3	3.5	486	7.4	3.5	48	7.3	4.8	5	11.7	4.8	78	6.3	2.9	87	8.1	2.6
<i>Female</i>																		
In Situ	42	0.5	0.2	33	0.5	0.2	2	0.4	0.2	-	-	-	6	0.6	0.1	6	0.5	0.1
Localized	2,122	24.8	9.5	1,744	25.6	10.3	137	21.6	9.8	8	20.3	5.7	220	21.6	5.9	232	22.8	4.9
Regional	1,689	19.7	7.5	1,366	20.0	8.0	132	20.9	9.2	9	22.8	6.3	174	17.1	4.7	182	17.9	3.7
Distant	4,119	48.1	18.2	3,198	46.9	18.6	326	51.5	22.8	20	49.7	13.5	554	54.4	14.8	523	51.3	10.6
Unknown	591	6.9	2.5	477	7.0	2.6	36	5.6	2.6	3	7.1	2.3	64	6.3	1.7	77	7.6	1.7

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	12,843	68.5	62.9	9,754	69.7	61.8	1,243	70.9	95.0	37	67.6	27.4	1,040	69.2	33.9	2,276	65.8	52.1
Regional	2,636	14.1	12.4	2,134	15.2	13.1	230	13.1	16.7	8	14.9	5.4	227	15.1	7.1	494	14.3	10.4
Distant	1,603	8.6	8.7	1,257	9.0	8.8	180	10.3	16.4	5	9.5	4.6	140	9.3	5.1	309	8.9	8.3
Unknown	1,661	8.9	8.9	853	6.1	6.1	101	5.8	9.8	4	8.0	4.6	95	6.3	3.5	382	11.0	10.6
<i>Age < 65</i>																		
Localized	5,163	71.6	24.5	3,806	72.7	23.5	700	74.4	49.7	17	71.6	10.1	368	71.9	11.4	1,000	68.6	17.8
Regional	1,204	16.7	5.7	943	18.0	5.8	141	15.0	10.1	4	16.4	2.3	98	19.2	3.0	251	17.2	4.5
Distant	422	5.9	2.0	316	6.0	2.0	67	7.1	4.7	2	8.6	1.2	32	6.3	1.0	105	7.2	1.9
Unknown	417	5.8	2.0	167	3.2	1.0	33	3.5	2.3	-	-	-	13	2.5	0.4	101	6.9	1.8
<i>Age ≥ 65</i>																		
Localized	7,680	66.6	328.7	5,948	67.8	326.2	543	66.8	408.3	21	64.8	147.4	672	67.8	189.3	1,276	63.7	289.5
Regional	1,432	12.4	59.0	1,192	13.6	63.1	89	10.9	63.0	4	13.8	27.1	129	13.0	35.0	242	12.1	51.7
Distant	1,181	10.2	55.0	941	10.7	56.1	113	13.9	97.6	3	10.1	28.1	108	10.9	33.1	203	10.2	52.4
Unknown	1,244	10.8	57.1	686	7.8	40.8	68	8.3	61.3	-	-	-	82	8.3	24.9	280	14.0	71.0

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Greater California, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	355	43.1	3.4	290	43.9	3.6	14	35.3	2.4	4	43.1	2.6	37	38.2	2.7	129	43.4	3.7
Regional	294	35.7	2.7	230	34.9	2.6	16	39.7	2.8	4	37.3	2.3	42	43.3	3.0	107	35.9	3.3
Distant	132	16.0	1.1	107	16.2	1.2	8	19.1	1.3	-	-	-	16	16.2	1.1	45	15.1	1.4
Unknown	43	5.2	0.4	33	5.0	0.4	2	5.9	0.4	-	-	-	2	2.3	0.2	17	5.6	0.5

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	147	3.3	1.3	112	3.1	1.2	8	3.7	1.8	1	4.1	1.2	17	4.1	1.5	31	3.2	1.2
Localized	1,559	35.4	14.5	1,285	35.3	14.4	73	32.7	14.2	10	33.1	7.3	147	35.3	13.0	326	33.5	13.3
Regional	1,541	35.0	14.5	1,292	35.5	14.7	76	34.1	15.2	10	35.1	8.4	149	35.8	13.1	356	36.6	14.9
Distant	889	20.2	8.3	746	20.5	8.4	50	22.3	9.6	5	18.2	4.1	82	19.6	7.3	205	21.1	8.1
Unknown	267	6.1	2.6	201	5.5	2.4	16	7.2	3.6	3	9.5	3.2	22	5.2	2.0	55	5.6	2.5
<i>Age < 50</i>																		
In Situ	10	2.0	0.1	8	1.9	0.1	-	-	-	-	-	-	1	2.5	0.2	3	1.5	0.1
Localized	140	27.8	2.0	114	28.2	2.1	7	25.5	1.7	-	-	-	13	23.6	1.6	49	28.0	1.8
Regional	195	38.7	2.9	158	39.0	3.0	10	34.0	2.3	1	46.7	1.2	22	40.0	2.7	64	36.9	2.4
Distant	142	28.2	2.1	113	27.9	2.1	10	34.8	2.3	-	-	-	17	30.5	2.1	52	29.9	2.0
Unknown	17	3.3	0.2	12	3.0	0.2	-	-	-	-	-	-	2	3.3	0.2	6	3.7	0.2
<i>Age ≥ 50</i>																		
In Situ	137	3.5	4.5	105	3.2	4.1	-	-	-	1	4.5	4.3	16	4.3	5.0	28	3.5	4.2
Localized	1,418	36.4	47.1	1,171	36.2	46.5	66	33.8	47.1	-	-	-	134	37.1	42.9	277	34.7	43.3
Regional	1,347	34.5	45.0	1,135	35.1	45.3	66	34.1	48.8	9	33.8	27.2	127	35.1	40.4	291	36.6	47.7
Distant	747	19.2	24.6	633	19.6	24.9	40	20.5	28.6	-	-	-	65	17.9	20.8	153	19.1	24.2
Unknown	250	6.4	8.8	189	5.8	7.9	-	-	-	3	10.5	11.7	20	5.5	6.8	48	6.0	8.5
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	110	2.8	0.9	79	2.4	0.8	7	3.6	1.2	-	-	-	17	4.3	1.1	21	2.6	0.7
Localized	1,413	35.8	11.5	1,167	35.8	11.6	77	39.0	13.8	11	32.0	7.0	121	31.5	8.5	289	35.6	10.2
Regional	1,383	35.0	11.4	1,151	35.3	11.5	61	30.9	11.4	13	39.1	8.8	148	38.7	10.5	286	35.2	10.2
Distant	788	19.9	6.5	657	20.1	6.6	42	21.3	7.3	8	23.7	5.8	77	20.1	5.5	170	20.9	6.0
Unknown	256	6.5	2.0	208	6.4	1.9	10	5.2	2.1	2	4.7	1.1	20	5.3	1.5	47	5.8	1.8
<i>Age < 50</i>																		
In Situ	8	1.7	0.1	6	1.7	0.1	-	-	-	-	-	-	1	2.5	0.2	3	1.7	0.1
Localized	155	33.0	2.3	125	33.3	2.4	10	37.7	2.5	2	47.4	1.5	13	23.8	1.4	58	33.7	2.2
Regional	174	36.9	2.6	137	36.4	2.7	11	41.5	2.7	1	31.6	1.1	23	41.9	2.5	62	35.7	2.4
Distant	119	25.2	1.8	96	25.6	1.9	4	16.9	1.2	-	-	-	17	30.0	1.8	44	25.5	1.7
Unknown	15	3.1	0.2	11	2.9	0.2	-	-	-	-	-	-	-	-	-	6	3.3	0.2
<i>Age ≥ 50</i>																		
In Situ	102	2.9	2.8	73	2.5	2.5	-	-	-	-	-	-	15	4.6	3.6	18	2.8	2.3
Localized	1,258	36.2	35.7	1,041	36.1	35.6	67	39.2	43.3	9	30.0	21.4	107	32.8	27.0	231	36.1	31.2
Regional	1,209	34.7	34.3	1,014	35.1	34.5	50	29.3	33.9	12	40.0	29.2	125	38.1	31.5	224	35.1	30.6
Distant	669	19.2	18.8	560	19.4	19.0	38	21.9	23.3	-	-	-	60	18.5	15.1	125	19.6	17.1
Unknown	241	6.9	6.6	197	6.8	6.3	-	-	-	2	5.3	4.1	-	-	-	41	6.4	6.0

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Greater California, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	3,214	18.0	26.8	2,558	17.2	26.3	161	19.2	27.0	19	17.9	11.7	393	22.3	26.8	645	18.2	21.0
Localized	9,429	52.7	77.6	7,987	53.8	80.2	378	45.0	66.1	56	51.9	35.2	862	48.9	59.5	1,690	47.7	56.9
Regional	4,059	22.7	34.7	3,351	22.6	35.3	225	26.7	38.9	25	23.3	15.4	410	23.3	28.5	960	27.1	30.5
Distant	836	4.7	7.0	690	4.6	7.1	61	7.3	10.6	4	4.1	3.2	74	4.2	5.2	176	5.0	5.9
Unknown	340	1.9	2.8	249	1.7	2.4	16	1.9	2.8	3	2.8	2.2	23	1.3	1.6	70	2.0	2.5
<i>Age < 50</i>																		
In Situ	625	18.8	9.6	481	18.5	9.5	27	15.7	7.2	4	17.5	3.3	95	20.1	10.2	186	17.2	7.4
Localized	1,447	43.5	22.2	1,136	43.8	22.4	65	38.0	17.1	9	42.7	7.9	213	45.2	22.9	445	41.1	17.5
Regional	1,031	31.0	15.8	811	31.3	16.0	61	35.2	15.8	7	35.0	6.4	138	29.3	14.8	377	34.7	14.7
Distant	167	5.0	2.5	129	5.0	2.5	15	8.8	3.8	-	-	-	20	4.3	2.1	56	5.2	2.1
Unknown	53	1.6	0.8	36	1.4	0.7	4	2.2	1.0	-	-	-	5	1.1	0.5	20	1.8	0.8
<i>Age ≥ 50</i>																		
In Situ	2,588	17.8	71.9	2,078	17.0	70.4	134	20.0	78.9	16	18.0	33.6	298	23.1	70.2	459	18.7	56.6
Localized	7,982	54.8	222.7	6,852	56.0	231.8	313	46.8	194.2	47	54.0	106.6	650	50.3	155.2	1,245	50.7	160.0
Regional	3,028	20.8	84.2	2,539	20.7	85.9	164	24.5	99.2	18	20.6	38.8	272	21.1	64.4	583	23.7	71.9
Distant	669	4.6	18.7	560	4.6	19.0	46	6.9	28.2	-	-	-	54	4.2	13.2	120	4.9	15.6
Unknown	287	2.0	7.9	213	1.7	6.9	12	1.8	7.8	-	-	-	18	1.4	4.3	51	2.1	6.9

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	13	0.3	0.1	11	0.3	0.1	-	-	-	-	-	-	1	0.3	0.1	1	0.2	0.1
Localized	1,005	20.1	10.0	876	20.7	10.3	42	16.4	9.8	8	19.2	6.9	72	16.3	6.8	92	16.0	5.1
Regional	1,023	20.4	9.9	873	20.6	10.0	54	21.0	11.9	9	22.2	7.1	82	18.6	7.8	110	19.1	5.8
Distant	2,571	51.4	24.7	2,138	50.5	24.4	143	55.2	30.7	18	46.0	16.3	259	58.7	24.1	325	56.4	16.8
Unknown	391	7.8	3.9	336	7.9	4.0	19	7.3	4.6	5	12.1	5.1	27	6.1	2.8	47	8.2	2.7
<i>Female</i>																		
In Situ	20	0.4	0.2	19	0.4	0.2	-	-	-	-	-	-	-	-	-	3	0.5	0.1
Localized	1,301	25.2	10.6	1,145	25.6	11.2	53	22.4	10.1	8	20.2	5.7	87	22.9	6.2	132	23.3	5.5
Regional	1,039	20.2	8.4	904	20.2	8.8	53	22.5	9.4	9	22.7	6.3	68	18.0	4.9	101	17.9	4.1
Distant	2,430	47.1	19.5	2,085	46.6	20.1	117	49.7	21.2	20	50.0	13.6	195	51.8	14.1	287	50.6	11.5
Unknown	368	7.1	2.9	321	7.2	3.0	12	5.0	2.3	3	7.1	2.3	27	7.0	1.9	44	7.8	1.9

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	7,364	69.2	64.5	5,938	69.6	62.2	537	71.8	96.6	38	67.8	28.4	384	69.3	32.9	1,245	67.4	55.0
Regional	1,535	14.4	12.9	1,317	15.4	13.3	105	14.0	17.8	8	14.5	5.4	86	15.5	6.9	271	14.7	10.8
Distant	915	8.6	8.8	774	9.1	8.9	73	9.8	16.7	5	9.2	4.6	53	9.5	5.1	164	8.9	8.4
Unknown	831	7.8	8.1	503	5.9	5.9	32	4.3	7.9	5	8.5	4.7	31	5.7	3.2	166	9.0	9.0
<i>Age < 65</i>																		
Localized	2,860	71.7	24.6	2,247	72.3	23.5	307	74.2	49.2	17	70.8	10.3	135	71.0	10.8	526	68.8	17.8
Regional	685	17.2	5.9	568	18.3	5.9	67	16.3	10.8	4	15.8	2.3	38	19.7	3.0	137	17.9	4.6
Distant	250	6.3	2.1	203	6.5	2.1	29	7.0	4.6	2	8.3	1.2	14	7.1	1.1	58	7.6	2.0
Unknown	196	4.9	1.7	92	2.9	1.0	11	2.6	1.7	1	5.0	0.7	4	2.2	0.3	44	5.8	1.5
<i>Age ≥ 65</i>																		
Localized	4,504	67.7	340.6	3,692	68.1	330.1	231	68.9	424.3	21	65.6	153.6	248	68.5	185.3	719	66.5	312.2
Regional	850	12.8	61.6	749	13.8	64.5	38	11.3	66.2	4	13.5	27.1	48	13.2	33.5	134	12.4	53.7
Distant	666	10.0	55.2	571	10.5	55.6	44	13.3	100.6	3	9.8	28.1	39	10.8	32.6	106	9.8	52.8
Unknown	635	9.5	52.2	411	7.6	40.4	22	6.5	50.5	4	11.0	32.6	27	7.5	22.9	122	11.3	60.6

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Greater Bay Area, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	113	50.0	2.9	78	53.1	3.4	5	37.9	2.0	Insufficient data for the calculation of AI/AN PRCDA statistics			28	45.2	2.3	33	52.4	4.0
Regional	67	29.5	1.7	41	28.0	1.7	4	31.8	1.7				21	33.8	1.7	18	28.9	2.3
Distant	38	16.8	0.9	24	16.7	1.0	4	27.3	1.3				10	15.3	0.8	10	16.5	1.4
Unknown	8	3.6	0.2	3	2.2	0.1	-	-	-				4	5.7	0.3	1	2.2	0.2

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	47	3.2	1.2	30	3.0	1.2	3	3.2	1.4	Insufficient data for the calculation of AI/AN PRCDA statistics			12	3.2	1.2	5	2.2	0.8
Localized	553	37.0	14.5	359	36.3	14.2	36	34.5	15.1				145	38.9	14.4	73	33.5	12.8
Regional	532	35.6	14.1	362	36.5	14.4	35	33.1	15.0				131	35.1	13.2	80	36.8	13.3
Distant	307	20.5	8.1	204	20.6	8.1	27	25.4	11.5				73	19.6	7.4	50	23.1	8.8
Unknown	56	3.7	1.5	36	3.6	1.5	4	3.8	1.9				12	3.3	1.3	10	4.4	1.8
<i>Age < 50</i>																		
In Situ	3	1.6	0.1	2	1.4	0.1	-	-	-				-	-	-	-	-	-
Localized	62	31.9	2.4	41	31.1	2.5	2	21.7	1.3				16	34.8	2.2	15	30.8	2.1
Regional	77	39.8	3.1	53	40.2	3.4	3	28.3	1.5				20	43.8	2.8	19	40.5	2.9
Distant	48	24.9	1.9	34	25.6	2.1	4	41.3	2.3				9	20.2	1.3	12	25.7	1.9
Unknown	4	1.9	0.1	2	1.8	0.1	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	44	3.4	4.2	28	3.2	3.9	-	-	-				-	-	-	-	-	-
Localized	492	37.7	46.1	318	37.1	44.8	34	35.7	51.3				129	39.4	46.2	58	34.2	40.9
Regional	456	35.0	42.9	309	36.0	43.3	32	33.6	50.4				111	33.9	40.4	61	35.8	40.7
Distant	259	19.9	24.4	170	19.8	23.8	23	23.9	35.4				64	19.5	23.3	38	22.4	26.8
Unknown	52	4.0	5.1	33	3.9	4.9	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	32	2.4	0.7	21	2.3	0.7	2	1.8	0.7	Insufficient data for the calculation of AI/AN PRCDA statistics			8	2.6	0.6	6	2.8	0.8
Localized	501	37.4	11.5	330	37.0	11.8	42	38.1	15.3				122	37.9	9.8	70	34.6	10.3
Regional	485	36.1	11.1	334	37.5	11.9	36	32.1	12.8				111	34.7	9.0	80	39.6	12.0
Distant	258	19.3	6.0	168	18.8	6.0	26	23.0	9.3				63	19.5	5.1	37	18.5	5.6
Unknown	65	4.9	1.4	39	4.4	1.2	6	5.0	2.0				17	5.4	1.3	9	4.5	1.4
<i>Age < 50</i>																		
In Situ	3	1.9	0.1	2	1.9	0.1	-	-	-				-	-	-	-	-	-
Localized	57	34.2	2.3	37	34.8	2.5	5	39.1	3.1				13	30.0	1.6	12	31.4	1.9
Regional	60	36.0	2.4	38	35.9	2.6	5	35.9	2.8				16	38.6	2.0	14	37.7	2.3
Distant	42	25.4	1.7	27	25.6	1.9	3	20.3	1.7				12	28.6	1.5	10	26.2	1.6
Unknown	4	2.5	0.2	2	1.9	0.1	-	-	-				-	-	-	1	3.7	0.2
<i>Age ≥ 50</i>																		
In Situ	29	2.4	2.3	19	2.4	2.3	-	-	-				-	-	-	-	-	-
Localized	444	37.8	35.6	293	37.3	36.1	37	37.9	47.3				109	39.1	31.5	58	35.3	32.3
Regional	425	36.2	33.7	296	37.7	36.0	31	31.6	39.2				95	34.1	27.4	66	40.1	37.5
Distant	216	18.4	17.1	140	17.9	16.9	23	23.3	29.4				51	18.1	14.7	27	16.7	15.9
Unknown	61	5.2	4.6	37	4.7	4.1	-	-	-				-	-	-	8	4.6	4.6

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Greater Bay Area, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,371	20.3	32.5	824	18.3	31.1	85	20.0	29.4				443	25.4	35.8	175	20.0	23.9
Localized	3,616	53.6	84.4	2,507	55.7	91.5	202	47.8	72.8				871	50.0	70.4	427	48.9	60.3
Regional	1,440	21.3	34.6	958	21.3	36.4	107	25.2	39.1				357	20.5	29.2	233	26.6	31.4
Distant	254	3.8	5.9	168	3.7	6.1	24	5.7	8.8				59	3.4	4.9	32	3.6	4.6
Unknown	68	1.0	1.5	43	1.0	1.4	5	1.3	1.9				13	0.7	1.1	8	0.9	1.1
<i>Age < 50</i>																		
In Situ	323	22.1	13.3	182	20.8	12.7	14	16.8	8.7	Insufficient data for the calculation of AI/AN PRCDA statistics			121	25.1	15.2	53	19.4	9.0
Localized	667	45.6	27.2	409	46.6	28.2	34	40.3	21.0				216	44.9	26.9	117	42.4	19.4
Regional	412	28.2	16.8	254	29.0	17.6	28	33.3	17.3				125	25.9	15.4	94	34.1	15.3
Distant	54	3.7	2.2	29	3.3	2.0	7	8.9	4.4				17	3.6	2.1	10	3.7	1.6
Unknown	7	0.5	0.3	3	0.3	0.2	-	-	-				3	0.5	0.3	1	0.4	0.2
<i>Age ≥ 50</i>																		
In Situ	1,049	19.8	82.9	642	17.7	79.2	71	20.8	83.7				321	25.5	89.7	122	20.3	62.8
Localized	2,950	55.8	234.1	2,098	57.9	257.1	168	49.6	208.4				654	51.9	184.3	311	51.8	167.5
Regional	1,028	19.4	81.0	704	19.4	85.8	79	23.3	96.2				232	18.4	65.1	139	23.2	73.5
Distant	200	3.8	15.8	140	3.9	16.8	17	4.9	20.3				42	3.3	12.1	22	3.6	12.3
Unknown	61	1.2	4.6	40	1.1	4.6	-	-	-				10	0.8	3.0	6	1.1	3.4

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	4	0.2	0.1	2	0.2	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	344	21.5	9.8	231	23.0	9.8	31	21.3	14.8				79	18.1	8.7	29	19.0	6.5
Regional	320	20.0	8.9	205	20.4	8.6	29	20.4	13.4				83	19.1	8.9	26	17.0	6.2
Distant	854	53.5	23.5	519	51.6	21.3	76	52.9	34.0				254	58.0	27.0	90	59.2	20.1
Unknown	76	4.7	2.2	48	4.7	2.0	7	5.0	3.5				20	4.7	2.4	7	4.8	1.8
<i>Female</i>																		
In Situ	7	0.4	0.2	4	0.3	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			3	0.7	0.2	-	-	-
Localized	390	24.4	8.9	282	25.5	9.9	32	23.9	11.4				74	20.9	6.1	34	24.4	5.6
Regional	312	19.5	7.1	227	20.5	7.9	28	21.2	9.9				57	16.0	4.7	25	17.6	4.1
Distant	818	51.1	18.6	541	49.0	18.8	68	51.2	23.9				206	57.7	16.7	74	52.7	12.0
Unknown	74	4.6	1.6	52	4.7	1.7	5	3.6	1.7				17	4.7	1.3	7	4.9	1.2

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,737	74.9	68.4	1,885	74.7	69.8	267	72.7	100.6				407	73.8	40.7	332	74.1	61.0
Regional	439	12.0	10.5	324	12.9	11.6	44	12.0	16.1				65	11.9	6.2	50	11.1	8.1
Distant	336	9.2	9.4	231	9.2	9.7	44	12.0	19.6				57	10.4	6.3	45	10.0	9.9
Unknown	144	3.9	3.9	84	3.3	3.4	12	3.3	6.3				22	3.9	2.4	22	4.9	4.8
<i>Age < 65</i>																		
Localized	1,126	77.2	27.1	767	77.1	27.8	153	77.6	54.9	Insufficient data for the calculation of AI/AN PRCDA statistics			141	75.8	13.2	159	75.6	22.4
Regional	216	14.8	5.2	157	15.8	5.7	26	13.2	9.4				31	16.6	2.9	30	14.5	4.3
Distant	76	5.2	1.8	49	4.9	1.8	15	7.7	5.3				11	6.0	1.0	13	6.3	1.9
Unknown	40	2.7	0.9	22	2.2	0.8	3	1.5	1.1				3	1.6	0.3	8	3.6	1.1
<i>Age ≥ 65</i>																		
Localized	1,611	73.3	353.5	1,118	73.1	360.1	114	67.0	415.9				266	72.8	231.3	173	72.7	327.3
Regional	223	10.1	47.4	167	10.9	52.3	18	10.6	62.4				35	9.5	29.0	19	8.1	34.5
Distant	260	11.8	62.1	182	11.9	64.4	29	17.0	118.5				46	12.6	43.0	32	13.3	65.3
Unknown	104	4.7	24.3	63	4.1	21.4	9	5.4	42.7				19	5.1	17.1	14	6.0	30.3

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Los Angeles, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	171	42.0	3.3	121	42.8	3.3	14	33.8	2.7	Insufficient data for the calculation of AI/AN PRCDA statistics			31	43.1	3.2	81	41.9	3.6
Regional	145	35.7	2.7	105	37.2	2.9	14	33.8	2.6				24	33.1	2.3	75	38.8	3.5
Distant	63	15.6	1.1	42	14.8	1.1	9	22.2	1.7				12	16.9	1.2	27	14.1	1.3
Unknown	27	6.7	0.5	14	5.1	0.4	4	10.1	0.7				5	6.9	0.5	10	5.2	0.5

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	90	4.4	1.9	62	4.3	1.8	11	5.4	2.7	Insufficient data for the calculation of AI/AN PRCDA statistics			15	4.2	1.7	27	4.3	1.8
Localized	678	33.2	14.2	479	33.3	14.1	67	32.4	15.3				117	32.7	13.5	198	31.8	12.3
Regional	713	34.9	15.1	519	36.1	15.4	58	28.0	13.3				127	35.5	14.9	229	36.6	14.4
Distant	411	20.1	8.6	289	20.0	8.4	52	25.1	11.8				67	18.7	7.7	123	19.7	7.7
Unknown	152	7.4	3.3	91	6.3	2.8	19	9.1	4.6				32	8.9	3.8	48	7.6	3.3
<i>Age < 50</i>																		
In Situ	6	2.6	0.2	4	2.4	0.2	-	-	-				-	-	-	2	2.4	0.1
Localized	72	28.9	2.1	55	30.0	2.2	7	24.4	2.2				9	26.5	1.8	28	28.0	1.7
Regional	101	40.6	3.0	76	41.7	3.1	9	32.6	3.0				15	44.1	3.0	42	41.6	2.5
Distant	58	23.3	1.7	42	22.7	1.6	8	30.4	2.9				8	22.9	1.5	24	24.1	1.4
Unknown	12	4.7	0.3	6	3.3	0.2	3	10.4	0.9				2	5.3	0.4	4	3.9	0.2
<i>Age ≥ 50</i>																		
In Situ	84	4.7	6.4	57	4.6	6.1	-	-	-				-	-	-	24	4.6	6.1
Localized	606	33.8	46.0	424	33.8	45.5	60	33.6	49.6				108	33.4	44.2	170	32.5	40.2
Regional	612	34.1	46.7	443	35.3	47.6	49	27.3	40.2				112	34.6	46.1	186	35.7	45.6
Distant	353	19.7	26.5	247	19.7	26.1	44	24.3	35.2				59	18.2	23.9	99	18.9	24.2
Unknown	140	7.8	11.1	85	6.8	9.4	16	8.9	14.4				30	9.2	12.8	44	8.3	11.2
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	71	3.8	1.2	45	3.5	1.1	10	4.7	1.7				13	4.0	1.2	24	4.2	1.2
Localized	640	34.2	11.2	444	34.5	11.2	76	34.5	12.9				108	32.5	9.7	196	34.9	9.9
Regional	646	34.5	11.2	453	35.2	11.3	67	30.3	11.4				120	36.3	10.9	194	34.4	9.9
Distant	361	19.3	6.3	248	19.3	6.3	50	22.5	8.6				62	18.6	5.6	107	19.0	5.3
Unknown	152	8.1	2.5	97	7.5	2.3	18	8.0	3.0				28	8.6	2.4	42	7.4	2.3
<i>Age < 50</i>																		
In Situ	6	2.8	0.2	5	2.8	0.2	-	-	-				-	-	-	3	3.3	0.2
Localized	73	32.3	2.1	54	33.5	2.2	7	30.8	2.1				9	26.3	1.6	30	31.5	1.8
Regional	75	33.4	2.2	53	32.6	2.2	8	33.3	2.4				14	38.9	2.3	31	32.4	1.9
Distant	61	27.3	1.8	44	27.2	1.8	7	29.9	2.2				10	29.1	1.7	27	28.2	1.6
Unknown	10	4.3	0.3	6	3.9	0.3	-	-	-				1	3.4	0.2	4	4.6	0.3
<i>Age ≥ 50</i>																		
In Situ	65	4.0	4.0	40	3.6	3.5	-	-	-				-	-	-	21	4.4	3.7
Localized	567	34.5	34.8	389	34.6	34.6	69	34.9	40.9				98	33.2	31.1	166	35.6	31.0
Regional	571	34.7	34.8	400	35.6	35.1	59	29.9	35.1				107	36.0	33.3	162	34.9	30.9
Distant	299	18.2	18.1	204	18.2	18.0	43	21.7	25.5				51	17.4	15.7	80	17.1	15.0
Unknown	143	8.7	8.4	90	8.0	7.6	-	-	-				27	9.2	8.2	37	8.0	7.5

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Los Angeles, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,513	18.7	26.9	999	17.7	25.6	172	19.6	29.5				311	22.1	29.2	427	19.0	20.4
Localized	4,096	50.8	72.4	2,932	51.9	74.8	411	47.0	70.5				695	49.4	64.9	1,045	46.5	50.7
Regional	1,915	23.7	34.5	1,359	24.1	35.4	216	24.7	37.6				314	22.3	29.9	624	27.8	29.5
Distant	360	4.5	6.4	249	4.4	6.4	52	6.0	9.0				56	4.0	5.4	98	4.4	4.7
Unknown	186	2.3	3.2	107	1.9	2.6	24	2.7	4.1				31	2.2	2.8	52	2.3	2.6
<i>Age < 50</i>																		
In Situ	323	18.7	9.7	214	18.1	9.0	27	17.0	8.5	Insufficient data for the calculation of AI/AN PRCDA statistics			76	21.7	12.7	107	16.8	6.7
Localized	755	43.7	22.5	513	43.4	21.6	68	42.3	20.6				160	46.0	26.8	263	41.3	16.2
Regional	529	30.7	15.8	383	32.4	16.2	49	30.5	15.1				91	26.0	15.2	221	34.8	13.6
Distant	84	4.8	2.5	53	4.5	2.2	12	7.7	3.8				17	4.9	2.9	30	4.8	1.9
Unknown	35	2.0	1.0	19	1.6	0.8	4	2.5	1.3				5	1.4	0.8	15	2.4	0.9
<i>Age ≥ 50</i>																		
In Situ	1,189	18.7	71.9	785	17.6	69.0	144	20.2	84.4				235	22.3	72.3	319	19.9	56.1
Localized	3,341	52.7	203.2	2,419	54.2	214.0	343	48.1	201.2				534	50.6	164.7	782	48.6	140.8
Regional	1,385	21.8	83.5	976	21.9	85.6	167	23.4	96.8				223	21.1	68.4	403	25.0	71.0
Distant	277	4.4	16.7	196	4.4	17.2	40	5.6	22.8				39	3.7	12.0	68	4.2	12.1
Unknown	151	2.4	8.9	87	2.0	7.4	20	2.7	11.6				26	2.4	7.9	37	2.3	6.9

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.4	0.2	6	0.4	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	2	0.6	0.2
Localized	353	18.3	8.2	249	19.3	8.1	38	14.5	9.5				62	17.0	7.6	49	14.1	4.3
Regional	383	19.8	8.6	255	19.7	8.1	53	20.5	12.6				72	19.8	8.5	65	18.6	5.1
Distant	1,030	53.3	22.7	679	52.6	21.2	146	56.3	33.6				198	54.4	23.6	199	57.2	15.3
Unknown	160	8.3	3.7	103	8.0	3.4	22	8.6	5.7				31	8.6	3.8	33	9.5	2.8
<i>Female</i>																		
In Situ	15	0.8	0.3	11	0.9	0.3	2	0.6	0.3	Insufficient data for the calculation of AI/AN PRCDA statistics			2	0.8	0.2	2	0.8	0.1
Localized	421	23.4	7.5	309	24.9	8.0	50	19.1	8.6				58	20.3	5.2	65	20.6	3.7
Regional	335	18.6	5.9	235	19.0	6.0	51	19.3	8.5				47	16.6	4.3	56	17.9	3.1
Distant	883	49.0	15.4	580	46.8	14.7	142	53.7	23.9				156	54.8	14.0	164	52.3	9.1
Unknown	150	8.3	2.5	104	8.4	2.5	19	7.3	3.2				21	7.5	1.8	27	8.5	1.5

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,733	61.5	54.6	1,922	65.3	54.2	438	68.5	90.2				250	62.8	27.5	698	59.8	44.6
Regional	665	15.0	12.9	498	16.9	13.6	81	12.7	15.9				75	18.9	8.1	173	14.9	10.6
Distant	352	7.9	7.8	252	8.6	7.9	63	9.8	14.6				31	7.8	3.8	100	8.6	7.5
Unknown	691	15.6	15.1	269	9.2	8.5	57	9.0	13.9				42	10.5	5.1	195	16.7	15.0
<i>Age < 65</i>																		
Localized	1,177	66.5	22.2	791	69.5	20.7	241	72.7	47.9	Insufficient data for the calculation of AI/AN PRCDA statistics			92	67.8	10.0	315	64.9	16.1
Regional	309	17.5	5.8	224	19.7	5.9	48	14.6	9.6				30	22.0	3.2	85	17.6	4.4
Distant	96	5.4	1.8	64	5.6	1.7	23	6.8	4.4				8	5.6	0.9	34	7.0	1.7
Unknown	187	10.6	3.5	59	5.2	1.5	20	5.9	3.8				6	4.6	0.7	51	10.5	2.6
<i>Age ≥ 65</i>																		
Localized	1,556	58.3	278.3	1,131	62.7	286.1	197	64.0	382.8				158	60.2	148.1	383	56.2	241.6
Regional	356	13.3	61.7	273	15.2	67.0	33	10.7	59.9				46	17.3	42.5	88	12.9	53.4
Distant	256	9.6	49.2	188	10.4	51.2	40	13.0	85.5				23	8.9	23.7	66	9.7	47.3
Unknown	503	18.8	95.2	211	11.7	56.9	38	12.3	83.9				36	13.6	35.6	144	21.2	101.0

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Colorado, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	88	50.7	3.2	79	50.8	3.3	3	43.8	2.4	-	-	-	2	52.2	2.1	20	47.8	3.9
Regional	52	30.1	1.9	47	30.1	1.8	2	31.3	1.6	-	-	-	1	30.4	1.4	14	33.2	3.0
Distant	26	15.1	0.9	23	15.0	0.9	2	25.0	1.7	-	-	-	-	-	-	6	15.6	1.5
Unknown	7	4.1	0.2	7	4.2	0.2	-	-	-	-	-	-	-	-	-	1	3.4	0.4

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	50	4.8	1.8	47	4.9	1.8	2	3.6	1.9	-	-	-	-	-	-	7	4.4	1.9
Localized	359	34.3	13.2	321	33.9	12.8	17	36.9	16.8	-	-	-	9	36.3	13.8	50	32.0	13.9
Regional	363	34.7	13.5	332	35.1	13.3	14	30.2	14.0	-	-	-	9	37.9	12.9	53	34.4	15.8
Distant	225	21.5	8.3	203	21.4	8.1	11	24.9	11.4	-	-	-	5	19.4	6.5	37	23.6	10.9
Unknown	50	4.7	2.0	45	4.7	1.9	2	4.4	2.8	-	-	-	1	4.8	1.7	9	5.7	3.3
<i>Age < 50</i>																		
In Situ	3	2.3	0.2	3	2.7	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	43	31.0	2.4	38	31.3	2.3	2	28.6	2.1	-	-	-	-	-	-	7	29.1	1.8
Regional	54	39.1	3.0	47	39.2	3.0	2	31.4	2.3	-	-	-	3	59.1	3.8	10	37.8	2.6
Distant	35	25.7	2.0	30	25.2	1.9	2	34.3	2.5	-	-	-	-	-	-	7	28.3	1.8
Unknown	3	1.9	0.1	2	1.7	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	47	5.2	5.9	44	5.3	5.9	2	4.2	7.0	-	-	-	-	-	-	-	-	-
Localized	317	34.9	41.6	284	34.3	40.1	15	38.4	55.4	-	-	-	-	-	-	42	32.5	45.6
Regional	309	34.0	40.8	285	34.5	40.5	11	30.0	44.7	-	-	-	7	33.3	36.7	44	33.7	50.6
Distant	189	20.8	24.7	173	20.9	24.4	9	23.2	34.7	-	-	-	-	-	-	29	22.7	34.6
Unknown	47	5.2	6.9	43	5.1	6.7	-	-	-	-	-	-	1	5.9	6.3	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	41	4.4	1.3	37	4.3	1.3	2	5.2	1.8	-	-	-	1	5.6	1.4	5	4.1	1.3
Localized	335	35.7	11.2	303	35.6	11.0	14	40.5	13.1	-	-	-	7	26.6	6.9	44	33.3	11.5
Regional	328	34.9	10.9	297	34.8	10.7	11	32.9	11.3	-	-	-	11	43.5	11.8	47	36.1	12.3
Distant	184	19.6	6.1	169	19.8	6.1	6	18.5	6.3	-	-	-	5	19.4	5.0	28	21.6	7.5
Unknown	50	5.4	1.6	47	5.5	1.6	-	-	-	-	-	-	1	4.8	1.6	6	4.9	2.0
<i>Age < 50</i>																		
In Situ	5	4.1	0.3	5	4.5	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	40	34.7	2.3	34	33.7	2.2	3	48.5	3.7	-	-	-	-	-	-	5	26.7	1.5
Regional	41	35.6	2.4	37	36.4	2.5	2	36.4	3.0	-	-	-	-	-	-	8	39.6	2.3
Distant	27	23.2	1.6	23	22.7	1.5	-	-	-	-	-	-	2	44.4	2.0	6	27.7	1.6
Unknown	3	2.4	0.2	3	2.7	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	36	4.4	4.1	32	4.3	4.0	2	6.4	6.3	-	-	-	-	-	-	-	-	-
Localized	294	35.8	34.3	269	35.8	33.9	11	38.6	37.6	-	-	-	-	-	-	38	34.5	37.6
Regional	286	34.8	33.1	260	34.6	32.4	9	32.1	32.9	-	-	-	-	-	-	39	35.4	38.3
Distant	157	19.1	17.9	146	19.4	17.9	-	-	-	-	-	-	3	15.1	13.1	23	20.4	23.1
Unknown	48	5.8	5.5	44	5.8	5.5	-	-	-	-	-	-	1	5.7	5.9	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Colorado, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	862	18.2	28.3	792	18.0	28.4	28	18.9	25.1	-	-	-	26	24.5	25.2	93	17.5	22.0
Localized	2,563	54.1	83.6	2,398	54.6	85.1	67	44.6	63.8	1	50.0	53.5	55	50.8	53.3	264	49.5	64.8
Regional	1,048	22.1	35.4	963	21.9	35.7	43	28.6	37.9	-	-	-	21	19.7	20.0	143	26.9	33.0
Distant	201	4.3	6.6	184	4.2	6.5	10	6.8	9.6	-	-	-	4	3.7	4.0	26	4.9	6.7
Unknown	62	1.3	2.0	58	1.3	2.0	2	1.1	1.9	-	-	-	1	1.3	1.5	6	1.2	1.8
<i>Age < 50</i>																		
In Situ	184	19.4	11.0	167	19.5	11.2	5	14.0	6.2	-	-	-	8	21.7	9.4	28	17.6	8.4
Localized	437	45.9	25.8	395	46.1	26.3	14	40.7	17.8	-	-	-	17	48.0	20.4	67	41.8	19.0
Regional	293	30.8	17.3	263	30.7	17.5	13	37.2	16.1	-	-	-	9	25.1	11.0	58	36.6	16.6
Distant	33	3.4	1.9	28	3.3	1.9	3	7.6	3.4	-	-	-	1	4.0	1.8	5	3.4	1.5
Unknown	4	0.4	0.2	3	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	678	17.9	73.5	625	17.7	73.4	23	20.4	74.8	-	-	-	19	25.8	66.5	65	17.5	57.9
Localized	2,126	56.2	235.0	2,003	56.6	238.8	53	45.8	184.3	-	-	-	38	52.2	139.5	197	52.8	184.7
Regional	755	19.9	82.8	700	19.8	83.3	30	26.0	95.0	-	-	-	12	17.0	43.6	85	22.8	76.1
Distant	169	4.5	18.7	156	4.4	18.6	8	6.6	25.8	-	-	-	3	3.6	9.7	21	5.6	20.1
Unknown	58	1.5	6.6	54	1.5	6.6	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	6	0.5	0.2	5	0.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	259	22.6	10.2	238	22.4	10.1	12	26.6	14.3	-	-	-	6	26.3	11.3	17	16.4	5.9
Regional	259	22.6	9.9	241	22.6	9.8	9	20.3	9.6	-	-	-	5	20.2	8.0	25	24.1	9.2
Distant	547	47.6	20.7	507	47.6	20.6	21	48.2	25.3	-	-	-	10	45.6	15.9	52	50.3	18.8
Unknown	78	6.8	3.3	73	6.9	3.3	2	4.5	3.0	-	-	-	2	7.9	3.8	9	8.5	3.7
<i>Female</i>																		
In Situ	8	0.6	0.2	7	0.7	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	321	26.5	10.6	302	26.6	10.8	10	26.9	10.2	-	-	-	5	18.9	5.5	29	25.0	8.6
Regional	250	20.6	8.3	232	20.4	8.3	10	26.9	10.0	-	-	-	5	18.9	5.8	24	21.0	7.3
Distant	548	45.2	17.8	510	44.9	17.8	16	44.1	16.3	-	-	-	14	55.1	16.6	54	46.9	15.9
Unknown	87	7.2	2.9	84	7.4	3.0	-	-	-	-	-	-	2	6.3	2.1	8	6.9	2.7

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,045	75.0	67.9	1,728	73.4	61.9	109	77.9	96.3	-	-	-	20	74.8	30.3	163	71.2	49.4
Regional	323	11.8	10.1	302	12.8	10.2	12	8.9	10.6	-	-	-	3	12.2	4.2	29	12.8	8.2
Distant	231	8.5	9.2	210	8.9	9.0	15	10.9	19.0	-	-	-	2	6.9	3.4	26	11.4	9.6
Unknown	128	4.7	5.4	114	4.9	5.2	3	2.3	5.2	-	-	-	2	6.1	2.8	11	4.6	4.3
<i>Age < 65</i>																		
Localized	876	78.2	27.9	717	76.7	24.9	68	81.0	52.9	-	-	-	6	63.6	7.2	74	74.6	18.2
Regional	156	13.9	4.9	142	15.2	4.8	9	10.2	6.7	-	-	-	-	-	-	15	14.9	3.6
Distant	62	5.5	2.0	54	5.8	1.9	6	7.3	4.8	-	-	-	-	-	-	8	8.1	1.9
Unknown	27	2.4	0.9	22	2.3	0.7	1	1.4	0.9	-	-	-	-	-	-	2	2.4	0.6
<i>Age ≥ 65</i>																		
Localized	1,169	72.8	344.4	1,011	71.2	317.7	40	73.2	396.0	-	-	-	14	80.5	189.9	89	68.6	265.4
Regional	167	10.4	46.0	160	11.3	46.9	4	6.9	37.1	-	-	-	-	-	-	14	11.1	39.8
Distant	169	10.5	59.5	156	11.0	58.3	9	16.3	117.1	-	-	-	-	-	-	18	13.9	62.5
Unknown	101	6.3	36.8	93	6.5	36.1	2	3.6	34.7	-	-	-	-	-	-	8	6.3	29.8

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Connecticut, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	56	47.0	3.2	48	50.3	3.4	4	28.0	1.9	-	-	-	1	40.0	1.3	12	56.4	4.8
Regional	40	33.8	1.9	30	31.8	1.7	7	45.3	3.1	-	-	-	1	40.0	1.3	7	32.7	3.3
Distant	17	14.6	0.7	13	13.9	0.7	3	22.7	1.6	-	-	-	-	-	-	1	5.5	0.5
Unknown	5	4.6	0.3	4	4.0	0.3	-	-	-	-	-	-	-	-	-	1	5.5	0.7

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	59	6.8	2.8	50	6.7	2.7	6	7.6	3.2	-	-	-	-	-	-	6	7.5	3.5
Localized	344	39.9	17.0	296	39.8	16.6	29	37.4	18.6	-	-	-	7	44.4	10.3	32	40.2	19.8
Regional	258	29.9	13.0	223	30.0	12.8	23	29.8	14.0	-	-	-	5	30.9	8.1	23	29.4	15.7
Distant	163	18.9	8.2	143	19.2	8.1	15	19.9	9.2	-	-	-	2	13.6	3.0	14	17.6	9.6
Unknown	39	4.5	2.0	31	4.2	1.8	4	5.2	2.7	-	-	-	1	7.4	1.9	4	5.3	3.3
<i>Age < 50</i>																		
In Situ	6	5.9	0.5	4	5.7	0.5	-	-	-	-	-	-	-	-	-	1	7.9	0.7
Localized	35	35.8	3.1	28	36.5	3.1	3	21.3	1.9	-	-	-	2	60.0	2.9	6	42.1	3.3
Regional	30	30.9	2.8	25	31.9	2.8	3	27.9	2.6	-	-	-	-	-	-	4	28.9	2.3
Distant	24	24.3	2.2	18	23.1	2.0	5	39.3	3.5	-	-	-	-	-	-	3	18.4	1.6
Unknown	3	3.1	0.3	2	2.8	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	53	7.0	8.7	46	6.8	8.3	-	-	-	-	-	-	-	-	-	5	7.5	11.1
Localized	309	40.4	53.4	268	40.2	51.9	26	40.5	62.5	-	-	-	5	40.9	29.8	26	39.8	63.1
Regional	228	29.8	39.8	199	29.8	38.8	19	30.2	44.0	-	-	-	-	-	-	19	29.5	50.8
Distant	139	18.2	24.0	125	18.8	24.0	10	16.2	24.3	-	-	-	-	-	-	11	17.4	30.6
Unknown	36	4.7	6.4	29	4.4	5.8	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	42	5.1	1.7	36	5.1	1.7	3	4.4	1.5	-	-	-	-	-	-	4	6.4	2.4
Localized	326	39.9	13.3	282	39.9	13.1	29	40.2	13.4	-	-	-	4	32.8	6.3	26	38.1	12.7
Regional	245	30.0	9.8	211	29.9	9.6	21	29.2	9.9	-	-	-	5	37.3	6.7	23	33.7	12.3
Distant	161	19.7	6.4	139	19.6	6.3	17	23.2	7.8	-	-	-	2	16.4	3.7	13	18.9	6.9
Unknown	43	5.3	1.5	39	5.5	1.5	2	3.0	1.1	-	-	-	1	9.0	1.7	2	2.9	1.2
<i>Age < 50</i>																		
In Situ	4	4.2	0.3	3	4.0	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	38	42.1	3.4	30	43.1	3.4	4	37.0	2.5	-	-	-	-	-	-	8	41.9	4.1
Regional	27	29.9	2.3	21	29.6	2.3	3	24.1	1.7	-	-	-	2	57.1	2.4	7	35.5	3.5
Distant	19	20.6	1.6	15	21.0	1.5	3	27.8	1.9	-	-	-	-	-	-	3	16.1	1.5
Unknown	3	3.1	0.2	2	2.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	38	5.3	5.4	33	5.2	5.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	288	39.6	39.4	252	39.5	38.7	25	40.7	41.8	-	-	-	-	-	-	18	36.7	35.3
Regional	218	30.0	29.4	191	29.9	28.7	19	30.1	31.5	-	-	-	3	32.1	17.9	17	33.1	35.4
Distant	142	19.6	19.2	124	19.5	18.8	14	22.4	23.3	-	-	-	-	-	-	10	19.9	21.1
Unknown	40	5.5	4.9	37	5.8	5.0	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Connecticut, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	967	22.9	43.4	830	22.5	43.8	86	24.7	37.7	2	26.7	14.7	26	26.1	31.2	82	24.6	37.8
Localized	2,286	54.1	97.5	2,034	55.2	99.9	157	45.2	70.7	2	40.0	25.5	50	50.3	62.7	171	51.1	83.9
Regional	748	17.7	33.6	624	16.9	32.8	82	23.7	36.4	2	26.7	17.8	19	19.2	22.2	69	20.7	31.6
Distant	175	4.1	7.4	149	4.0	7.2	19	5.6	8.6	-	-	-	3	3.2	4.0	10	3.1	5.2
Unknown	53	1.3	2.0	47	1.3	2.0	3	0.9	1.4	-	-	-	1	1.2	1.9	2	0.5	0.9
<i>Age < 50</i>																		
In Situ	245	28.8	21.1	203	29.3	21.9	22	26.4	14.5	-	-	-	12	28.9	16.8	31	27.0	16.9
Localized	378	44.4	32.6	313	45.1	33.6	31	36.7	20.5	-	-	-	20	50.2	29.2	49	43.6	26.9
Regional	195	23.0	17.2	154	22.2	17.0	26	30.4	17.0	-	-	-	8	20.4	11.8	28	25.1	15.1
Distant	27	3.2	2.3	20	2.9	2.2	5	5.9	3.2	-	-	-	-	-	-	4	3.7	2.2
Unknown	5	0.6	0.4	4	0.5	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	722	21.4	101.9	627	21.0	101.3	63	24.2	98.5	-	-	-	15	24.3	68.7	52	23.4	92.6
Localized	1,909	56.5	267.6	1,721	57.6	273.7	125	47.9	202.0	-	-	-	30	50.3	150.6	121	54.9	233.1
Regional	553	16.4	76.6	470	15.7	74.0	56	21.5	87.1	-	-	-	11	18.3	49.6	41	18.5	74.8
Distant	148	4.4	20.5	128	4.3	20.1	14	5.5	22.9	-	-	-	3	5.3	14.6	6	2.8	13.0
Unknown	48	1.4	6.2	43	1.4	6.1	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	3	0.2	0.1	3	0.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	329	25.0	16.4	303	25.5	16.8	22	21.8	15.2	-	-	-	-	-	-	18	26.3	14.4
Regional	311	23.6	15.3	279	23.5	15.2	24	24.4	16.7	-	-	-	3	25.0	5.7	16	23.1	13.3
Distant	632	48.0	31.1	567	47.7	31.1	51	50.7	36.0	-	-	-	8	58.8	14.5	32	47.4	24.3
Unknown	42	3.2	2.1	37	3.1	2.1	3	3.2	2.7	-	-	-	1	8.8	2.0	2	2.9	1.8
<i>Female</i>																		
In Situ	10	0.7	0.4	9	0.7	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	408	28.8	16.4	374	28.9	17.0	24	25.4	11.4	-	-	-	5	31.9	6.5	18	26.3	10.7
Regional	307	21.6	12.3	278	21.4	12.5	23	24.7	11.0	-	-	-	2	16.7	4.4	15	22.2	8.4
Distant	643	45.4	25.3	589	45.4	26.1	43	46.1	19.9	-	-	-	7	47.2	11.2	32	47.6	19.9
Unknown	50	3.5	1.8	46	3.6	1.9	3	3.2	1.4	-	-	-	-	-	-	2	2.7	1.3

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,804	73.7	81.6	1,505	73.5	76.5	217	77.7	125.1	1	60.0	24.8	18	74.6	30.5	113	73.7	74.4
Regional	366	15.0	15.9	319	15.6	15.5	31	11.0	16.6	-	-	-	4	16.9	6.5	22	14.3	13.4
Distant	187	7.7	9.5	161	7.8	9.0	22	7.8	15.0	-	-	-	1	5.9	3.0	14	8.9	11.4
Unknown	89	3.6	4.3	63	3.1	3.4	10	3.4	7.6	-	-	-	-	-	-	5	3.1	4.2
<i>Age < 65</i>																		
Localized	761	75.2	34.0	606	75.1	30.8	117	78.7	60.1	-	-	-	7	79.5	9.9	58	75.9	30.6
Regional	186	18.3	8.3	157	19.5	8.0	20	13.8	10.6	-	-	-	1	15.9	2.0	12	15.7	6.3
Distant	38	3.8	1.7	28	3.5	1.5	8	5.5	4.2	-	-	-	-	-	-	5	6.3	2.5
Unknown	27	2.7	1.2	15	1.9	0.8	3	2.0	1.6	-	-	-	-	-	-	2	2.1	0.9
<i>Age ≥ 65</i>																		
Localized	1,043	72.7	410.5	899	72.5	392.2	100	76.6	574.2	-	-	-	11	71.6	172.5	55	71.5	377.4
Regional	180	12.6	67.9	161	13.0	67.3	10	7.9	57.7	-	-	-	3	17.6	37.7	10	12.8	62.2
Distant	149	10.4	63.1	132	10.7	61.2	14	10.4	89.7	-	-	-	-	-	-	9	11.5	73.3
Unknown	61	4.3	25.7	47	3.8	21.4	7	5.0	49.4	-	-	-	-	-	-	3	4.2	27.4

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Delaware, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	18	44.7	3.8	14	48.3	4.2	3	34.7	3.4	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	12	29.1	2.2	8	27.6	2.0	3	34.7	3.0				-	-	-	-	-	-
Distant	9	22.6	1.5	6	20.7	1.4	3	28.6	2.4				-	-	-	-	-	-
Unknown	1	3.5	0.2	-	-	-	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	10	4.2	1.9	9	4.5	1.9	1	2.6	1.4	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	86	34.9	15.8	67	34.8	15.3	16	34.5	17.7				2	44.4	10.1	4	40.9	15.4
Regional	91	37.1	17.1	72	37.5	17.1	17	35.8	19.6				-	-	-	3	38.6	16.3
Distant	50	20.3	9.4	39	20.0	9.2	10	22.0	12.3				-	-	-	2	18.2	6.2
Unknown	9	3.6	1.7	6	3.3	1.6	2	5.2	3.2				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	8	31.3	2.9	5	26.1	2.3	2	41.4	3.6				-	-	-	-	-	-
Regional	10	38.3	3.5	7	42.0	3.9	2	27.6	2.3				-	-	-	1	46.2	4.0
Distant	6	24.2	2.3	5	26.1	2.4	1	24.1	2.2				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	78	35.4	49.8	63	35.6	49.3	14	33.5	54.5				-	-	-	-	-	-
Regional	81	36.9	52.6	65	37.0	51.8	15	36.9	64.9				-	-	-	2	35.5	48.7
Distant	44	19.8	28.1	34	19.4	26.8	9	21.7	38.6				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	2	5.9	11.7				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	8	3.6	1.2	5	3.1	1.0	2	4.8	1.9	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	88	40.9	13.8	68	41.1	13.7	18	39.5	14.7				-	-	-	4	43.2	19.0
Regional	68	31.7	10.7	54	32.4	10.6	13	28.5	11.3				-	-	-	4	40.9	20.9
Distant	41	19.1	6.7	30	18.2	6.3	11	23.7	9.7				-	-	-	-	-	-
Unknown	10	4.7	1.5	9	5.2	1.6	2	3.5	1.6				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	11	42.1	3.6	7	43.0	3.8	3	36.8	3.5				-	-	-	-	-	-
Regional	7	28.6	2.5	5	27.9	2.4	2	31.6	3.3				-	-	-	-	-	-
Distant	6	25.4	2.2	4	25.6	2.2	2	26.3	2.7				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	78	40.8	40.3	61	40.9	39.5	15	40.0	44.0				-	-	-	-	-	-
Regional	61	32.1	32.1	49	32.9	32.1	11	27.9	32.4				-	-	-	-	-	-
Distant	35	18.2	18.5	26	17.3	17.1	9	23.2	28.1				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Delaware, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	199	19.3	32.8	149	18.7	32.6	44	21.2	36.2				6	24.6	28.7	8	24.5	30.0
Localized	568	54.8	89.9	452	56.7	91.8	99	48.1	81.8				12	51.8	63.2	15	45.4	66.1
Regional	209	20.2	35.3	152	19.1	33.3	50	24.4	42.6				4	19.3	21.2	7	21.5	29.7
Distant	47	4.5	7.7	35	4.4	7.6	10	4.6	8.0				-	-	-	2	6.7	7.3
Unknown	12	1.2	1.9	9	1.1	1.6	3	1.6	3.2				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	40	22.9	13.8	28	24.3	14.5	9	20.4	12.4	Insufficient data for the calculation of AI/AN PRCDA statistics			2	22.5	13.2	3	26.5	10.8
Localized	77	44.4	26.9	52	44.7	26.8	19	42.7	25.8				4	50.0	28.9	3	32.7	12.6
Regional	47	27.1	16.3	30	25.5	15.2	14	32.0	19.4				2	22.5	12.0	3	30.6	11.8
Distant	8	4.8	2.9	5	4.5	2.8	2	4.4	2.5				-	-	-	-	-	-
Unknown	1	0.8	0.5	1	1.0	0.6	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	160	18.5	82.6	121	17.8	80.0	35	21.4	98.6				4	25.7	69.3	5	23.7	80.2
Localized	491	56.9	254.9	400	58.8	261.9	80	49.6	228.6				8	52.7	152.9	12	50.9	206.1
Regional	163	18.8	85.0	122	18.0	80.8	36	22.3	103.2				3	17.6	45.1	4	17.5	76.5
Distant	38	4.5	20.1	30	4.4	20.2	8	4.7	22.3				-	-	-	-	-	-
Unknown	11	1.3	5.6	7	1.1	4.5	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	99	23.9	18.0	83	23.8	18.0	14	22.7	17.5				1	38.9	11.5	2	42.3	14.0
Regional	94	22.5	16.9	78	22.4	17.2	14	23.0	18.0				-	-	-	1	26.9	9.2
Distant	202	48.6	36.3	170	48.8	37.5	30	49.3	34.5				1	38.9	10.8	2	30.8	9.6
Unknown	21	5.0	4.1	17	4.9	4.0	3	4.9	4.2				-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	116	27.9	17.1	97	28.2	17.7	17	26.5	15.7				-	-	-	2	29.6	9.3
Regional	90	21.7	13.2	75	21.9	13.8	13	20.4	11.9				-	-	-	1	22.2	5.8
Distant	192	46.2	28.1	157	45.5	28.7	33	50.3	28.9				2	52.6	11.5	2	40.7	8.9
Unknown	17	4.1	2.4	15	4.4	2.5	2	2.7	1.6				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	584	78.1	96.1	412	77.7	83.2	157	79.0	158.0	Insufficient data for the calculation of AI/AN PRCDA statistics			7	78.3	48.8	16	73.6	85.3
Regional	70	9.3	11.4	52	9.7	10.4	16	8.3	15.7				2	17.4	11.7	3	12.3	12.6
Distant	57	7.6	10.5	40	7.6	9.1	16	7.9	18.2				-	-	-	2	7.5	9.3
Unknown	37	5.0	6.6	26	4.9	5.6	10	4.8	10.8				-	-	-	1	6.6	10.4
<i>Age < 65</i>																		
Localized	237	78.8	43.1	143	77.5	33.1	88	81.1	85.6	Insufficient data for the calculation of AI/AN PRCDA statistics			1	63.6	8.9	7	67.3	26.1
Regional	37	12.4	7.0	26	14.0	6.1	11	9.7	10.5				-	-	-	-	-	-
Distant	14	4.7	2.6	7	4.0	1.7	6	5.9	6.2				-	-	-	-	-	-
Unknown	12	4.1	2.2	8	4.4	1.8	4	3.3	3.5				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	347	77.6	461.8	269	77.8	429.6	68	76.5	657.9				6	82.9	325.0	9	78.9	494.4
Regional	33	7.3	41.8	26	7.5	39.6	6	6.5	51.8				-	-	-	-	-	-
Distant	43	9.5	65.0	33	9.5	60.3	9	10.3	101.5				-	-	-	-	-	-
Unknown	25	5.6	37.0	18	5.2	32.1	6	6.7	61.4				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
District of Columbia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	11	35.5	3.2	3	37.1	1.7	6	34.0	3.5	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	1	41.2	3.8
Regional	10	32.9	2.7	3	45.7	2.0	6	31.9	2.9				-	-	-	1	35.3	3.7
Distant	5	14.8	1.4	-	-	-	4	20.2	2.0				-	-	-	-	-	-
Unknown	5	16.8	1.4	-	-	-	3	13.8	1.2				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	10	8.2	3.4	2	5.1	1.3	4	5.0	2.5	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	39	30.4	13.5	10	32.9	8.2	24	30.2	15.9				1	31.6	22.2	2	31.3	11.0
Regional	37	29.0	13.1	11	36.1	9.3	22	27.7	15.0				2	42.1	18.5	2	37.5	11.4
Distant	28	21.8	9.4	7	20.9	4.8	20	25.0	13.2				-	-	-	1	21.9	4.4
Unknown	14	10.7	4.9	2	5.1	1.4	10	12.1	6.7				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	2	9.0	0.9	-	-	-	-	-	-				-	-	-	-	-	-
Localized	6	28.8	2.6	2	31.4	1.4	3	28.1	3.6				-	-	-	-	-	-
Regional	6	27.9	3.0	2	34.3	2.3	3	28.1	3.6				-	-	-	-	-	-
Distant	6	27.0	2.7	2	31.4	1.8	3	29.8	3.8				-	-	-	-	-	-
Unknown	2	7.2	0.8	-	-	-	1	12.3	1.6				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	8	8.0	9.9	2	6.5	4.8	-	-	-				-	-	-	-	-	-
Localized	32	30.7	41.9	8	33.3	26.2	21	30.5	48.2				-	-	-	-	-	-
Regional	31	29.2	39.5	9	36.6	27.9	19	27.7	44.9				-	-	-	-	-	-
Distant	22	20.7	26.9	4	17.9	12.7	17	24.2	37.9				-	-	-	-	-	-
Unknown	12	11.4	15.8	-	-	-	8	12.1	20.2				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	11	7.5	3.0	2	5.8	1.3	5	4.9	2.2	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	42	29.3	11.7	10	32.1	8.1	30	30.1	13.4				-	-	-	2	42.3	9.8
Regional	39	27.2	10.7	10	31.4	7.3	27	27.4	12.1				-	-	-	-	-	-
Distant	33	23.2	9.2	7	22.4	5.5	24	24.8	11.1				-	-	-	-	-	-
Unknown	18	12.8	4.9	3	8.3	2.0	13	12.8	5.4				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	7	31.4	3.0	2	30.6	2.3	4	35.2	3.6				-	-	-	-	-	-
Regional	5	25.7	2.3	3	38.9	2.6	2	18.5	1.8				-	-	-	-	-	-
Distant	6	30.5	2.7	2	25.0	1.6	4	33.3	3.3				-	-	-	-	-	-
Unknown	2	7.6	0.7	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	35	28.9	34.4	8	32.5	23.4	26	29.5	38.9				-	-	-	-	-	-
Regional	34	27.5	33.0	7	29.2	19.8	25	28.5	39.0				-	-	-	-	-	-
Distant	27	21.9	26.0	5	21.7	15.8	21	23.7	31.7				-	-	-	-	-	-
Unknown	17	13.7	16.0	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
District of Columbia, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	137	21.9	40.4	48	22.8	40.7	77	21.0	37.2				4	24.7	31.5	9	28.9	32.0
Localized	291	46.4	82.5	102	48.2	81.7	167	45.3	77.9				9	51.7	67.5	13	45.0	52.0
Regional	147	23.4	42.0	48	22.5	37.8	89	24.3	43.4				3	18.0	24.3	7	22.1	26.0
Distant	37	5.8	10.4	8	3.8	6.7	26	7.2	12.4				-	-	-	-	-	-
Unknown	15	2.5	4.4	6	2.8	4.5	8	2.2	3.7				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	33	22.5	16.4	13	22.2	16.0	14	21.0	13.3	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			3	28.0	24.1	4	30.8	18.9
Localized	60	41.0	28.5	25	42.7	26.9	26	39.0	25.1				5	46.0	38.8	5	38.5	23.3
Regional	41	28.2	18.8	17	28.3	17.3	20	31.1	19.7				2	18.0	14.8	3	23.1	13.1
Distant	8	5.4	3.6	2	3.8	2.4	4	6.7	4.2				-	-	-	-	-	-
Unknown	4	2.9	1.9	2	3.1	1.7	1	2.1	1.3				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	104	21.7	103.3	35	23.0	105.4	64	21.0	99.7				2	20.5	51.0	5	27.4	66.2
Localized	230	48.0	224.1	77	50.3	225.0	141	46.7	216.1				5	59.0	142.5	8	50.0	127.3
Regional	105	21.9	102.9	31	20.2	91.5	69	22.8	105.5				1	17.9	49.4	4	21.4	59.7
Distant	29	6.0	28.3	6	3.8	17.8	22	7.3	33.9				-	-	-	-	-	-
Unknown	11	2.3	10.8	4	2.7	11.9	7	2.2	10.1				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	24	17.2	8.6	4	13.4	3.4	20	18.3	12.6				-	-	-	-	-	-
Regional	29	20.3	10.6	6	20.4	5.5	22	19.9	14.3				-	-	-	-	-	-
Distant	67	47.4	22.8	13	46.5	11.0	52	48.0	31.7				2	52.9	26.8	2	60.0	11.8
Unknown	21	14.6	7.8	5	18.3	4.9	15	13.7	10.0				-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	39	23.9	10.5	10	28.9	8.5	28	22.3	11.6				-	-	-	-	-	-
Regional	36	21.7	9.9	6	15.6	4.5	30	24.1	13.4				-	-	-	-	-	-
Distant	72	43.5	19.5	15	42.8	13.1	54	43.5	23.0				2	53.3	13.9	2	60.0	8.7
Unknown	17	10.5	4.6	4	11.7	3.7	13	10.2	5.1				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	274	72.9	91.9	74	73.2	59.6	174	75.1	105.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			5	92.0	61.0	8	74.5	47.5
Regional	39	10.3	12.3	15	14.7	11.7	21	9.1	11.9				-	-	-	-	-	-
Distant	29	7.7	10.4	6	6.0	5.6	22	9.4	13.9				-	-	-	1	10.9	10.2
Unknown	34	9.1	12.8	6	6.2	5.6	15	6.4	10.5				-	-	-	1	10.9	7.5
<i>Age < 65</i>																		
Localized	130	75.6	42.1	29	75.5	23.2	89	77.2	51.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			3	100.0	31.9	5	85.7	19.9
Regional	22	12.6	7.1	7	17.7	5.5	14	12.1	8.4				-	-	-	-	-	-
Distant	11	6.2	3.4	2	4.2	1.3	9	7.4	4.8				-	-	-	-	-	-
Unknown	10	5.7	3.3	-	-	-	4	3.3	2.4				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	144	70.7	435.9	45	71.7	310.8	85	73.0	472.8				2	83.3	262.3	3	63.0	238.7
Regional	17	8.5	48.4	8	12.9	54.5	7	6.2	35.8				-	-	-	-	-	-
Distant	18	8.9	59.1	4	7.1	35.0	13	11.4	76.9				-	-	-	-	-	-
Unknown	24	11.9	78.4	-	-	-	11	9.5	66.9				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Florida, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	391	39.1	3.7	303	39.6	3.7	65	35.8	3.8	-	-	-	8	42.9	2.2	99	40.2	3.8
Regional	362	36.1	3.2	280	36.6	3.1	69	37.5	3.9	-	-	-	7	36.7	1.9	86	35.0	3.3
Distant	156	15.5	1.3	120	15.6	1.2	30	16.6	1.7	-	-	-	3	13.3	0.7	36	14.7	1.4
Unknown	93	9.3	0.8	63	8.2	0.6	18	10.1	1.1	-	-	-	1	7.1	0.3	25	10.1	0.9

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	296	5.2	2.2	256	5.4	2.2	30	4.4	2.1	-	-	-	3	4.1	1.1	41	4.4	2.0
Localized	1,793	31.7	13.8	1,529	32.3	13.5	193	28.9	14.4	-	-	-	27	34.2	9.9	303	32.0	14.5
Regional	1,886	33.4	14.8	1,603	33.8	14.5	221	33.1	15.9	-	-	-	27	34.4	9.9	329	34.7	15.5
Distant	1,159	20.5	9.1	954	20.1	8.7	166	24.9	11.8	-	-	-	18	22.5	6.3	177	18.7	8.3
Unknown	514	9.1	3.9	399	8.4	3.5	58	8.6	4.5	-	-	-	4	4.8	1.3	97	10.3	4.8
<i>Age < 50</i>																		
In Situ	17	3.3	0.3	12	3.1	0.3	4	4.2	0.4	-	-	-	-	-	-	3	2.4	0.2
Localized	137	26.2	2.2	108	26.9	2.2	20	21.7	1.9	-	-	-	4	30.6	2.0	37	31.5	2.1
Regional	200	38.2	3.3	155	38.4	3.2	34	38.1	3.3	-	-	-	5	34.7	2.3	46	38.6	2.6
Distant	137	26.2	2.2	103	25.6	2.1	27	30.4	2.6	-	-	-	4	30.6	2.0	25	21.4	1.4
Unknown	32	6.1	0.5	24	6.0	0.5	5	5.5	0.5	-	-	-	-	-	-	7	6.2	0.4
<i>Age ≥ 50</i>																		
In Situ	279	5.4	7.4	244	5.6	7.4	26	4.5	6.5	-	-	-	-	-	-	38	4.6	6.8
Localized	1,656	32.3	44.1	1,421	32.7	43.2	173	30.0	47.2	-	-	-	23	35.0	30.6	265	32.1	47.0
Regional	1,686	32.9	44.9	1,448	33.4	44.1	186	32.3	48.8	-	-	-	22	34.4	29.8	283	34.2	49.5
Distant	1,022	19.9	27.1	851	19.6	25.9	139	24.1	35.8	-	-	-	13	20.7	17.6	151	18.3	26.2
Unknown	482	9.4	12.8	375	8.6	11.3	53	9.1	15.1	-	-	-	-	-	-	90	10.9	16.5
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	229	4.6	1.5	188	4.6	1.5	32	5.1	1.8	-	-	-	2	3.5	0.6	36	4.0	1.3
Localized	1,629	32.8	10.8	1,378	33.4	10.6	188	29.9	10.9	1	46.2	11.3	20	29.5	5.7	279	31.6	10.4
Regional	1,688	34.0	11.3	1,423	34.4	11.1	208	33.2	11.9	-	-	-	23	33.9	6.5	306	34.6	11.4
Distant	986	19.8	6.8	801	19.4	6.5	151	24.1	8.7	-	-	-	17	25.4	5.0	170	19.2	6.3
Unknown	434	8.7	2.7	341	8.3	2.4	48	7.7	2.9	-	-	-	5	7.7	1.6	94	10.6	3.4
<i>Age < 50</i>																		
In Situ	15	3.2	0.2	12	3.2	0.2	3	3.1	0.2	-	-	-	-	-	-	3	2.7	0.2
Localized	135	28.5	2.2	106	29.3	2.3	22	26.7	1.9	-	-	-	3	21.7	1.2	35	29.5	2.0
Regional	168	35.4	2.7	129	35.8	2.7	29	34.5	2.5	-	-	-	5	36.2	1.9	45	37.9	2.6
Distant	128	27.0	2.1	96	26.5	2.0	24	29.4	2.2	-	-	-	5	34.8	1.8	29	24.0	1.6
Unknown	28	5.9	0.4	19	5.2	0.4	5	6.3	0.5	-	-	-	-	-	-	7	5.8	0.4
<i>Age ≥ 50</i>																		
In Situ	214	4.8	4.9	176	4.7	4.7	30	5.4	6.0	-	-	-	-	-	-	32	4.2	4.2
Localized	1,494	33.3	33.4	1,272	33.7	32.6	165	30.4	34.3	1	54.5	41.1	17	31.5	17.4	244	31.9	32.4
Regional	1,520	33.8	33.9	1,293	34.3	33.1	179	33.0	36.7	-	-	-	18	33.3	18.3	260	34.1	34.7
Distant	857	19.1	19.3	705	18.7	18.4	127	23.3	25.7	-	-	-	12	23.0	13.3	141	18.4	18.6
Unknown	406	9.0	8.7	322	8.5	7.8	43	7.9	9.3	-	-	-	-	-	-	87	11.4	11.4

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Florida, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	3,693	18.3	27.1	3,037	18.1	26.7	467	19.7	26.1	1	13.6	11.6	79	21.1	20.4	655	19.6	24.6
Localized	10,410	51.7	72.8	9,007	53.6	74.4	990	41.8	55.9	5	54.5	41.8	175	46.9	46.1	1,606	48.0	60.1
Regional	4,388	21.8	33.6	3,529	21.0	32.4	657	27.8	37.1	3	29.5	24.3	95	25.4	25.0	799	23.9	30.1
Distant	970	4.8	7.1	764	4.6	6.6	171	7.2	9.6	-	-	-	18	4.8	4.4	149	4.5	5.6
Unknown	683	3.4	4.7	453	2.7	3.5	83	3.5	4.8	-	-	-	7	1.9	1.8	137	4.1	5.1
<i>Age < 50</i>																		
In Situ	642	19.5	10.4	499	20.1	10.4	96	16.9	8.6	-	-	-	23	20.3	9.1	172	21.2	9.8
Localized	1,379	41.8	22.3	1,088	43.8	22.9	196	34.5	17.3	1	42.9	17.5	51	44.0	19.5	330	40.7	18.7
Regional	1,008	30.6	16.5	735	29.6	15.7	208	36.6	18.3	-	-	-	34	29.6	13.1	245	30.3	14.0
Distant	172	5.2	2.8	115	4.6	2.5	48	8.4	4.1	-	-	-	5	4.7	2.1	36	4.4	2.0
Unknown	97	2.9	1.6	49	2.0	1.0	21	3.7	1.8	-	-	-	2	1.4	0.6	27	3.3	1.5
<i>Age ≥ 50</i>																		
In Situ	3,051	18.1	70.7	2,539	17.7	69.3	371	20.6	72.1	-	-	-	55	21.4	50.2	483	19.1	63.3
Localized	9,031	53.6	205.1	7,919	55.4	209.5	794	44.1	156.8	4	60.0	105.5	125	48.1	115.9	1,275	50.3	168.5
Regional	3,380	20.1	78.4	2,793	19.5	76.2	449	25.0	86.3	-	-	-	61	23.5	56.2	554	21.8	72.5
Distant	797	4.7	18.3	649	4.5	17.4	123	6.8	24.1	-	-	-	13	4.9	10.4	113	4.5	14.9
Unknown	586	3.5	12.9	404	2.8	10.1	62	3.4	12.6	-	-	-	5	2.1	5.0	110	4.3	14.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	16	0.2	0.1	15	0.2	0.1	-	-	-	-	-	-	-	-	-	3	0.3	0.1
Localized	1,809	20.1	13.4	1,654	20.8	13.8	116	15.1	9.2	-	-	-	12	14.8	4.7	194	19.1	10.1
Regional	2,027	22.5	15.0	1,816	22.8	15.3	167	21.7	12.5	-	-	-	17	21.3	6.2	229	22.5	11.5
Distant	4,219	46.9	31.3	3,699	46.5	31.4	408	52.9	29.7	-	-	-	47	59.1	17.4	470	46.3	23.2
Unknown	920	10.2	6.8	775	9.7	6.4	79	10.2	6.4	-	-	-	4	4.8	1.6	120	11.8	6.3
<i>Female</i>																		
In Situ	17	0.2	0.1	15	0.2	0.1	-	-	-	-	-	-	-	-	-	1	0.2	0.0
Localized	2,043	25.4	12.7	1,868	25.7	13.4	138	24.0	8.2	-	-	-	16	20.8	4.9	190	25.5	7.1
Regional	1,799	22.4	11.3	1,635	22.5	12.0	131	22.8	7.5	-	-	-	15	19.0	4.0	159	21.4	6.0
Distant	3,509	43.6	22.3	3,166	43.5	23.3	258	44.9	14.7	-	-	-	45	57.4	13.2	316	42.5	11.7
Unknown	678	8.4	4.1	586	8.1	4.1	47	8.1	2.8	-	-	-	2	2.3	0.5	77	10.3	2.9

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	9,349	71.8	67.2	7,441	73.8	61.3	1,599	74.4	106.9	3	72.7	32.4	89	78.1	31.2	1,446	70.9	68.0
Regional	1,441	11.1	10.3	1,188	11.8	9.8	206	9.6	13.0	-	-	-	12	10.1	3.8	252	12.3	11.3
Distant	892	6.8	6.6	689	6.8	5.7	177	8.2	13.5	-	-	-	7	6.5	2.8	135	6.6	6.8
Unknown	1,342	10.3	9.8	768	7.6	6.3	167	7.8	13.7	-	-	-	6	5.2	2.6	208	10.2	10.8
<i>Age < 65</i>																		
Localized	3,323	74.4	28.6	2,401	75.3	24.8	805	75.9	50.3	2	72.7	14.2	28	76.2	9.4	558	73.3	25.0
Regional	647	14.5	5.6	490	15.4	5.0	133	12.5	8.4	-	-	-	6	15.1	1.9	118	15.5	5.3
Distant	245	5.5	2.1	163	5.1	1.7	74	7.0	4.6	-	-	-	3	7.6	0.9	42	5.5	1.9
Unknown	253	5.7	2.1	134	4.2	1.4	50	4.7	3.0	-	-	-	-	-	-	43	5.7	1.9
<i>Age ≥ 65</i>																		
Localized	6,026	70.4	334.0	5,040	73.1	314.1	795	73.0	498.7	2	72.7	158.4	61	79.1	182.2	889	69.4	364.8
Regional	795	9.3	43.0	698	10.1	42.6	74	6.8	44.9	-	-	-	6	7.8	17.0	134	10.4	52.9
Distant	647	7.6	37.5	526	7.6	33.8	103	9.5	75.1	-	-	-	5	5.9	15.8	93	7.3	40.4
Unknown	1,089	12.7	63.1	633	9.2	40.7	118	10.8	87.0	-	-	-	-	-	-	165	12.9	72.0

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Georgia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	177	42.2	3.5	119	44.7	3.9	49	36.1	2.8	Insufficient data for the calculation of AI/AN PRCDA statistics			7	48.6	3.1	17	48.6	4.8
Regional	147	35.0	2.7	90	34.0	2.7	50	36.9	3.0				6	40.3	2.7	13	37.1	3.6
Distant	70	16.7	1.2	41	15.4	1.1	27	20.1	1.6				1	9.7	0.7	3	8.0	0.9
Unknown	26	6.1	0.5	16	5.9	0.5	9	6.8	0.6				-	-	-	2	6.3	0.8

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	54	2.3	1.1	35	2.1	1.0	17	2.5	1.4	Insufficient data for the calculation of AI/AN PRCDA statistics			2	2.5	1.3	2	2.6	0.9
Localized	902	37.3	18.4	621	37.5	17.8	254	37.1	20.1				21	32.8	13.4	26	34.0	13.1
Regional	776	32.1	15.8	546	33.0	15.5	204	29.8	17.2				23	36.0	14.2	26	34.0	12.8
Distant	546	22.6	11.1	362	21.9	10.4	170	24.8	14.0				13	19.9	7.8	19	24.9	9.6
Unknown	139	5.7	3.2	90	5.5	2.8	40	5.8	4.0				6	8.8	3.9	3	4.4	2.0
<i>Age < 50</i>																		
In Situ	7	2.2	0.2	4	2.0	0.2	3	2.7	0.3				-	-	-	-	-	-
Localized	86	28.2	2.6	57	29.2	2.7	27	27.6	2.7				1	13.0	0.8	5	28.1	1.5
Regional	115	37.7	3.5	72	36.7	3.5	37	38.0	3.7				6	55.6	3.7	7	35.4	1.9
Distant	84	27.7	2.6	55	28.0	2.6	27	27.6	2.7				3	25.9	1.7	6	29.2	1.7
Unknown	13	4.2	0.4	8	4.1	0.4	4	4.1	0.4				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	48	2.3	3.5	31	2.1	3.1	15	2.5	4.5				2	3.0	4.7	-	-	-
Localized	816	38.6	59.7	564	38.7	57.4	228	38.6	65.7				19	36.9	46.5	21	36.0	43.3
Regional	661	31.3	47.9	474	32.5	47.1	168	28.4	52.4				17	31.9	41.5	19	33.6	41.4
Distant	462	21.9	33.4	307	21.0	30.7	143	24.3	43.6				10	18.6	23.6	14	23.5	30.3
Unknown	126	6.0	10.4	82	5.6	9.2	36	6.1	13.3				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	53	2.5	0.9	34	2.5	0.8	17	2.6	1.1	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	2	2.2	0.6
Localized	803	38.0	13.8	525	38.0	13.3	255	37.6	15.4				20	41.0	10.6	27	37.8	12.7
Regional	672	31.7	11.5	453	32.8	11.4	202	29.7	12.4				16	33.9	8.3	23	32.2	11.3
Distant	453	21.4	7.8	282	20.4	7.1	160	23.5	9.8				9	19.2	5.4	17	23.6	8.1
Unknown	136	6.4	2.3	87	6.3	2.1	45	6.6	3.0				2	4.2	1.1	3	4.2	1.9
<i>Age < 50</i>																		
In Situ	3	1.1	0.1	2	1.1	0.1	1	1.1	0.1				-	-	-	-	-	-
Localized	111	38.8	3.2	68	40.4	3.3	37	35.0	3.1				5	56.8	2.8	8	36.8	2.5
Regional	89	31.1	2.6	54	32.3	2.7	33	30.8	2.7				2	18.2	0.9	7	34.0	2.5
Distant	73	25.6	2.1	39	23.2	1.9	32	30.1	2.7				2	20.5	1.0	5	23.6	1.7
Unknown	9	3.3	0.3	5	3.1	0.3	3	3.0	0.3				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	50	2.7	2.9	33	2.7	2.8	16	2.8	3.5				-	-	-	-	-	-
Localized	693	37.8	41.5	457	37.7	39.3	218	38.0	47.4				15	37.4	31.3	19	38.2	39.2
Regional	583	31.8	34.9	399	32.8	34.1	169	29.5	37.8				15	37.4	27.7	16	31.5	34.3
Distant	380	20.7	22.6	243	20.1	20.7	128	22.3	28.5				7	19.0	16.8	12	23.6	24.9
Unknown	126	6.9	7.8	82	6.7	6.9	42	7.3	10.2				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Georgia, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,698	18.7	28.9	1,086	17.9	27.9	557	20.1	32.2				50	21.8	23.2	64	19.1	24.5
Localized	4,633	50.9	78.8	3,282	54.1	82.4	1,235	44.6	72.8				105	45.3	50.0	153	46.0	64.5
Regional	2,174	23.9	37.8	1,347	22.2	35.5	760	27.4	44.2				62	26.8	30.1	94	28.4	34.1
Distant	479	5.3	8.3	285	4.7	7.2	180	6.5	10.7				13	5.7	6.8	19	5.6	8.0
Unknown	111	1.2	1.9	71	1.2	1.7	37	1.4	2.5				-	-	-	3	0.9	1.5
<i>Age < 50</i>																		
In Situ	367	19.9	10.9	221	20.5	10.9	122	18.2	10.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			23	25.9	13.0	25	19.5	8.7
Localized	798	43.2	23.6	492	45.5	24.3	270	40.2	23.1				34	38.4	19.3	51	40.2	17.2
Regional	575	31.1	17.0	317	29.3	15.8	229	34.1	19.5				27	30.2	15.0	45	35.3	15.3
Distant	94	5.1	2.8	45	4.2	2.2	44	6.6	3.7				5	5.5	2.6	6	4.7	2.0
Unknown	12	0.7	0.4	6	0.6	0.3	6	0.9	0.5				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,330	18.4	75.9	865	17.3	72.2	434	20.7	88.9				28	19.3	49.8	39	18.9	65.9
Localized	3,835	52.9	223.3	2,790	55.9	234.5	965	46.0	203.1				71	49.6	130.4	102	49.6	188.5
Regional	1,599	22.1	92.3	1,030	20.6	86.9	531	25.3	108.9				35	24.6	69.5	49	24.0	83.5
Distant	385	5.3	22.7	239	4.8	20.3	136	6.5	29.1				8	5.9	17.9	13	6.2	23.8
Unknown	99	1.4	6.1	65	1.3	5.5	32	1.5	7.7				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	8	0.2	0.2	5	0.2	0.2	2	0.2	0.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	707	18.8	15.4	562	20.0	16.5	138	15.4	13.0				6	15.1	5.0	12	20.9	8.9
Regional	823	21.9	17.2	621	22.1	17.5	193	21.6	17.9				8	19.8	6.1	13	21.9	10.0
Distant	2,026	54.0	41.9	1,476	52.5	41.8	523	58.4	45.3				24	62.0	16.8	33	55.9	21.5
Unknown	188	5.0	4.5	147	5.2	4.6	39	4.3	4.3				1	3.1	1.3	-	-	-
<i>Female</i>																		
In Situ	9	0.3	0.2	6	0.3	0.2	2	0.4	0.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	705	23.4	12.1	568	24.4	13.7	128	20.2	8.3				8	19.6	4.8	11	19.9	6.6
Regional	667	22.2	11.1	512	22.0	12.2	147	23.1	9.2				6	15.6	3.9	10	18.4	5.1
Distant	1,476	49.1	24.7	1,115	47.9	26.7	335	52.6	20.9				24	59.3	13.8	31	57.7	17.4
Unknown	151	5.0	2.6	124	5.3	3.0	24	3.7	1.6				2	4.0	0.9	2	3.7	1.5

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	5,055	77.9	95.0	3,004	77.1	78.6	1,952	79.2	147.7	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			61	80.1	43.6	119	74.7	70.0
Regional	681	10.5	12.2	466	11.9	11.7	205	8.3	14.3				8	10.5	4.6	18	11.3	9.4
Distant	421	6.5	9.3	236	6.1	7.2	180	7.3	17.2				4	4.7	3.1	13	8.1	8.9
Unknown	334	5.1	7.7	193	4.9	6.0	127	5.1	14.1				4	4.7	2.4	9	5.9	8.0
<i>Age < 65</i>																		
Localized	2,210	78.9	40.9	1,120	77.6	30.0	1,054	80.8	70.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			20	76.0	10.7	59	74.7	22.7
Regional	356	12.7	6.6	219	15.2	5.9	131	10.1	8.8				4	15.5	2.2	11	13.4	4.0
Distant	144	5.1	2.7	64	4.4	1.7	78	6.0	5.2				-	-	-	6	8.1	2.4
Unknown	89	3.2	1.6	41	2.8	1.1	42	3.2	2.8				1	4.7	0.7	3	3.8	1.2
<i>Age ≥ 65</i>																		
Localized	2,844	77.1	469.0	1,884	76.8	414.5	899	77.5	681.2				41	82.1	271.1	60	74.6	397.2
Regional	325	8.8	51.0	247	10.1	51.6	74	6.4	52.3				4	7.9	21.5	7	9.2	46.4
Distant	277	7.5	54.9	172	7.0	44.7	102	8.8	100.1				-	-	-	7	8.2	53.7
Unknown	245	6.6	49.9	152	6.2	40.1	85	7.3	92.0				2	4.8	14.8	6	8.0	55.3

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Hawaii, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	23	47.6	3.5	6	50.8	3.9	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			16	45.9	3.1	2	47.6	3.4
Regional	15	31.3	2.0	3	23.8	1.9	-	-	-				12	35.3	2.0	2	38.1	3.8
Distant	8	15.4	0.9	2	19.0	1.0	-	-	-				5	14.1	0.9	-	-	-
Unknown	3	5.7	0.4	-	-	-	-	-	-				2	4.7	0.3	-	-	-

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	19	4.7	2.2	5	4.2	1.8	-	-	-				14	4.8	2.4	-	-	-
Localized	158	38.4	18.7	42	38.2	16.3	2	31.0	15.1				112	38.6	20.1	6	35.7	18.7
Regional	136	33.2	16.7	36	32.6	14.4	3	44.8	21.8				97	33.5	18.0	6	38.1	19.8
Distant	68	16.5	8.1	19	17.6	7.4	-	-	-				47	16.3	8.6	3	16.7	10.5
Unknown	30	7.3	3.6	8	7.4	3.4	-	-	-				20	6.8	3.5	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	15	33.8	3.5	5	40.7	4.4	-	-	-				10	31.6	3.3	-	-	-
Regional	16	36.4	3.8	4	33.9	3.4	-	-	-				12	37.3	4.0	-	-	-
Distant	10	21.8	2.3	3	22.0	2.2	-	-	-				7	22.2	2.3	-	-	-
Unknown	3	6.2	0.6	-	-	-	-	-	-				2	6.3	0.6	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	5	4.7	6.5	-	-	-				-	-	-	-	-	-
Localized	142	39.0	58.7	37	37.9	47.3	-	-	-				102	39.4	64.2	-	-	-
Regional	120	32.8	50.6	32	32.5	43.1	-	-	-				85	33.1	54.6	-	-	-
Distant	58	15.8	23.5	17	17.0	21.1	-	-	-				40	15.5	25.0	-	-	-
Unknown	27	7.4	11.5	-	-	-	-	-	-				18	6.8	10.9	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	13	3.7	1.4	3	4.0	1.5	-	-	-				8	3.3	1.2	-	-	-
Localized	121	35.3	13.1	32	37.4	14.7	-	-	-				87	35.1	12.8	7	38.7	20.0
Regional	120	35.0	13.2	28	33.2	13.0	1	75.0	20.1				89	35.9	13.3	7	36.6	19.0
Distant	59	17.3	6.4	15	17.6	6.9	-	-	-				44	17.8	6.6	3	16.1	7.6
Unknown	30	8.7	2.9	7	7.8	2.6	-	-	-				20	8.0	2.6	1	6.5	3.8
<i>Age < 50</i>																		
In Situ	1	3.4	0.3	-	-	-	-	-	-				-	-	-	-	-	-
Localized	11	26.1	2.5	3	40.5	3.7	-	-	-				7	22.9	2.2	-	-	-
Regional	16	40.4	3.9	3	31.0	2.6	-	-	-				13	42.5	4.1	2	61.5	4.8
Distant	9	22.7	2.2	2	21.4	2.0	-	-	-				7	24.2	2.3	-	-	-
Unknown	3	7.4	0.7	-	-	-	-	-	-				2	7.8	0.7	-	-	-
<i>Age ≥ 50</i>																		
In Situ	11	3.7	4.1	-	-	-	-	-	-				-	-	-	-	-	-
Localized	110	36.5	40.8	28	37.1	43.3	-	-	-				80	36.8	40.6	-	-	-
Regional	103	34.3	37.5	26	33.4	40.3	-	-	-				76	34.9	37.2	5	32.5	55.9
Distant	50	16.6	17.7	13	17.2	19.5	-	-	-				37	16.9	17.8	-	-	-
Unknown	27	8.8	8.8	-	-	-	-	-	-				17	8.0	7.4	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Hawaii, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	301	19.9	35.3	61	16.2	27.8	2	18.3	25.2				233	21.0	37.8	13	16.6	29.4
Localized	834	55.1	94.3	203	53.9	90.6	7	55.0	67.0				617	55.7	96.7	43	54.3	106.0
Regional	282	18.6	33.7	81	21.5	38.6	2	15.0	17.0				197	17.8	32.5	16	20.2	36.8
Distant	60	4.0	6.8	19	5.0	9.0	-	-	-				40	3.6	6.2	5	6.6	13.6
Unknown	38	2.5	4.2	13	3.3	5.2	-	-	-				21	1.9	3.0	2	2.3	4.5
<i>Age < 50</i>																		
In Situ	55	20.2	13.3	10	15.7	11.2	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			42	21.5	13.5	2	13.5	6.9
Localized	131	48.6	31.2	31	49.0	33.5	2	57.9	25.5				97	48.9	30.2	8	43.8	23.1
Regional	68	25.2	16.3	17	27.9	19.5	-	-	-				49	25.0	15.5	6	32.6	16.6
Distant	9	3.4	2.2	3	5.1	3.5	-	-	-				6	2.9	1.8	-	-	-
Unknown	7	2.6	1.7	1	2.2	1.4	-	-	-				3	1.7	1.1	-	-	-
<i>Age ≥ 50</i>																		
In Situ	247	19.8	93.0	51	16.3	71.2	-	-	-				191	20.9	101.6	11	17.5	88.3
Localized	703	56.4	259.6	172	54.9	240.2	4	53.7	175.5				521	57.2	270.6	35	57.4	322.9
Regional	214	17.2	79.3	63	20.2	88.8	-	-	-				148	16.2	76.9	10	16.5	89.7
Distant	51	4.1	18.9	16	5.0	23.4	-	-	-				34	3.8	17.6	-	-	-
Unknown	31	2.5	10.6	11	3.6	15.1	-	-	-				18	1.9	7.9	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	1	0.3	0.1	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	82	17.2	10.0	24	18.2	9.2	-	-	-				57	16.8	10.3	3	12.1	14.0
Regional	97	20.4	11.5	28	21.4	10.1	1	33.3	14.4				68	19.8	12.2	8	29.5	29.8
Distant	257	53.7	30.7	68	51.6	25.2	2	52.4	24.0				186	54.5	33.4	13	49.2	50.8
Unknown	41	8.5	5.0	11	8.7	4.7	-	-	-				29	8.6	5.2	2	9.1	13.0
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	68	18.9	6.8	19	19.8	7.9	-	-	-				47	18.7	6.4	4	18.2	13.8
Regional	69	19.4	7.2	19	19.8	8.2	-	-	-				48	19.2	6.9	4	18.2	11.9
Distant	186	51.9	19.1	49	49.7	20.0	2	56.3	29.7				133	52.9	18.6	13	55.4	42.8
Unknown	34	9.5	3.3	10	10.6	4.6	-	-	-				22	8.9	2.7	2	8.3	7.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	446	57.8	51.3	136	54.9	47.5	16	70.1	110.5	Insufficient data for the calculation of AI/AN PRCDA statistics			285	60.0	50.5	18	58.7	57.8
Regional	131	17.0	14.1	47	18.9	14.5	3	13.7	20.6				80	16.8	13.6	6	20.7	16.4
Distant	77	10.0	9.0	27	10.9	10.5	2	9.4	17.7				46	9.7	8.0	3	9.3	9.4
Unknown	118	15.3	13.9	38	15.3	13.7	2	6.8	13.7				64	13.5	11.5	3	11.3	13.4
<i>Age < 65</i>																		
Localized	141	59.9	16.9	47	55.9	16.5	12	73.2	75.8				80	62.9	15.1	6	51.9	12.8
Regional	49	20.6	5.7	19	22.3	6.6	-	-	-				27	21.4	5.1	3	25.9	6.5
Distant	18	7.5	2.0	6	7.4	2.0	-	-	-				10	8.0	1.9	-	-	-
Unknown	28	12.0	3.3	12	14.4	4.2	-	-	-				10	7.7	1.8	1	13.0	3.2
<i>Age ≥ 65</i>																		
Localized	304	56.9	289.0	90	54.4	261.8	4	62.9	350.4				205	59.0	294.9	12	62.5	368.9
Regional	82	15.4	71.9	28	17.2	69.6	-	-	-				52	15.1	72.0	3	17.7	84.6
Distant	59	11.0	56.9	21	12.7	68.8	-	-	-				36	10.4	50.1	-	-	-
Unknown	90	16.7	87.1	26	15.7	79.6	-	-	-				54	15.6	78.6	2	10.4	84.1

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Idaho, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	25	49.0	3.3	24	49.2	3.3	-	-	-	-	-	-	-	-	-	3	50.0	4.6
Regional	16	30.9	2.0	15	31.6	2.0	-	-	-	-	-	-	-	-	-	2	37.5	3.2
Distant	7	13.9	0.8	6	13.1	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	3	6.2	0.4	3	6.1	0.4	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	7	2.0	0.7	7	2.0	0.7	-	-	-	-	-	-	-	-	-	-	-	-
Localized	112	31.6	12.5	108	31.5	12.4	-	-	-	-	-	-	1	53.8	18.4	5	28.9	10.5
Regional	134	37.7	15.1	130	38.1	15.1	-	-	-	-	-	-	-	-	-	7	39.8	12.6
Distant	78	22.1	9.1	76	22.2	9.1	-	-	-	-	-	-	-	-	-	5	27.7	9.7
Unknown	23	6.5	2.8	21	6.2	2.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	9	24.9	1.8	9	26.0	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Regional	16	43.1	3.2	15	42.8	3.2	-	-	-	-	-	-	-	-	-	1	33.3	2.0
Distant	10	27.1	2.0	9	27.2	2.0	-	-	-	-	-	-	-	-	-	1	33.3	1.9
Unknown	1	3.9	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	103	32.4	40.5	99	32.1	39.9	-	-	-	-	-	-	1	70.0	66.6	-	-	-
Regional	118	37.1	46.0	116	37.5	46.3	-	-	-	-	-	-	-	-	-	5	41.5	40.2
Distant	69	21.6	27.6	67	21.6	27.5	-	-	-	-	-	-	-	-	-	3	26.2	30.2
Unknown	22	6.8	9.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	4	1.3	0.4	4	1.2	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	102	33.7	10.9	98	33.4	10.8	-	-	-	-	-	-	-	-	-	4	28.1	6.0
Regional	116	38.2	12.1	113	38.6	12.1	-	-	-	-	-	-	-	-	-	5	35.9	9.7
Distant	64	21.2	6.9	62	21.3	7.0	-	-	-	1	53.8	31.3	-	-	-	4	31.3	7.1
Unknown	17	5.7	1.7	16	5.5	1.6	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	13	39.4	2.7	13	40.5	2.8	-	-	-	-	-	-	-	-	-	-	-	-
Regional	11	32.1	2.3	10	31.0	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	9	26.1	1.8	8	26.6	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	89	33.0	32.4	85	32.5	31.9	-	-	-	-	-	-	-	-	-	-	-	-
Regional	105	38.9	37.7	104	39.5	38.1	-	-	-	-	-	-	-	-	-	-	-	-
Distant	56	20.6	20.2	54	20.6	20.2	-	-	-	1	53.8	113.1	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Idaho, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	212	15.1	23.4	205	15.1	23.5	-	-	-	-	-	-	3	15.9	18.1	10	15.2	16.8
Localized	769	54.8	80.7	745	54.9	80.9	-	-	-	5	51.0	74.1	8	48.8	51.3	31	46.8	59.7
Regional	337	24.0	36.9	324	23.9	36.8	-	-	-	4	38.8	57.6	5	30.5	31.0	21	31.9	35.9
Distant	66	4.7	7.0	63	4.7	6.9	-	-	-	-	-	-	-	-	-	4	6.1	7.0
Unknown	20	1.4	2.0	18	1.4	1.9	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	47	19.7	10.3	46	20.1	10.4	-	-	-	-	-	-	-	-	-	5	19.7	9.4
Localized	105	43.8	22.5	99	43.9	22.5	-	-	-	-	-	-	2	37.5	15.6	8	33.1	16.1
Regional	75	31.5	16.0	71	31.2	15.8	-	-	-	1	75.0	24.4	2	45.8	19.1	11	41.7	19.6
Distant	10	4.3	2.1	10	4.2	2.1	-	-	-	-	-	-	-	-	-	1	5.5	2.5
Unknown	1	0.6	0.3	1	0.5	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	165	14.2	57.8	160	14.1	57.7	-	-	-	-	-	-	-	-	-	5	12.4	36.2
Localized	664	57.0	233.3	645	57.1	233.8	-	-	-	-	-	-	6	53.4	144.5	22	55.4	174.0
Regional	261	22.4	91.8	253	22.4	91.9	-	-	-	3	31.7	144.3	3	24.1	62.1	10	25.7	78.5
Distant	56	4.8	19.7	54	4.8	19.6	-	-	-	-	-	-	-	-	-	3	6.4	18.8
Unknown	19	1.6	6.6	17	1.5	6.3	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	1	0.3	0.1	1	0.3	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	102	21.3	11.8	100	21.2	11.8	-	-	-	-	-	-	-	-	-	2	12.9	6.0
Regional	87	18.0	9.4	85	18.0	9.4	-	-	-	-	-	-	-	-	-	2	17.1	6.0
Distant	257	53.4	29.0	251	53.5	29.0	1	53.8	50.2	1	66.7	23.9	1	41.2	13.5	9	67.1	25.9
Unknown	34	7.1	4.1	33	7.0	4.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	1	0.3	0.1	1	0.3	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	115	25.5	11.7	111	25.3	11.6	-	-	-	2	40.0	37.5	1	30.0	8.1	3	18.6	6.2
Regional	86	19.1	8.8	83	19.0	8.7	-	-	-	-	-	-	-	-	-	3	21.4	7.9
Distant	228	50.5	23.1	223	50.6	23.2	-	-	-	2	40.0	35.2	2	55.0	17.2	8	54.3	19.4
Unknown	21	4.7	2.2	21	4.8	2.2	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	688	68.5	71.1	651	68.4	69.1	5	75.0	106.1	2	47.6	30.4	3	61.5	29.9	19	64.8	42.6
Regional	137	13.6	13.5	132	13.9	13.4	-	-	-	-	-	-	-	-	-	5	16.6	12.4
Distant	88	8.8	10.1	85	9.0	10.1	-	-	-	-	-	-	-	-	-	3	11.7	10.6
Unknown	92	9.2	10.5	83	8.7	9.8	-	-	-	-	-	-	-	-	-	2	6.9	6.3
<i>Age < 65</i>																		
Localized	250	73.5	27.5	234	74.0	26.7	3	73.7	42.4	-	-	-	-	-	-	9	73.3	14.1
Regional	53	15.5	5.6	50	15.8	5.5	-	-	-	-	-	-	-	-	-	2	16.7	3.2
Distant	19	5.5	2.0	17	5.4	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	19	5.5	2.0	15	4.8	1.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	438	65.9	372.6	417	65.6	362.1	2	76.9	546.4	-	-	-	-	-	-	10	58.8	239.2
Regional	84	12.7	68.4	82	12.9	68.2	-	-	-	-	-	-	-	-	-	3	16.5	75.8
Distant	69	10.4	66.0	68	10.8	66.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	74	11.1	69.6	68	10.7	65.5	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Illinois, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	235	44.3	3.6	183	45.7	3.7	44	41.0	4.4	Insufficient data for the calculation of AI/AN PRCA statistics			7	36.7	1.7	38	49.0	4.4
Regional	184	34.6	2.6	134	33.6	2.4	38	35.4	3.7				9	50.0	2.3	28	35.2	3.4
Distant	92	17.2	1.2	68	16.9	1.1	22	20.4	2.0				2	10.0	0.5	10	13.0	1.4
Unknown	21	3.9	0.3	15	3.8	0.2	3	3.2	0.4				-	-	-	2	2.8	0.3

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	223	6.4	3.3	168	6.0	3.0	40	7.8	5.2				10	8.3	3.1	16	6.3	2.4
Localized	1,197	34.2	18.1	981	34.8	17.8	158	30.8	20.3				41	35.0	13.4	80	32.3	12.8
Regional	1,193	34.1	18.0	980	34.8	17.8	158	30.7	20.7				44	37.4	14.6	84	34.0	14.1
Distant	693	19.8	10.3	550	19.5	9.9	119	23.1	15.1				19	16.2	5.7	56	22.7	9.3
Unknown	191	5.5	3.0	139	4.9	2.6	40	7.7	5.8				4	3.0	1.4	11	4.6	2.1
<i>Age < 50</i>																		
In Situ	15	4.4	0.4	12	4.5	0.4	2	3.6	0.3				-	-	-	2	4.6	0.3
Localized	99	29.7	2.4	78	29.0	2.4	14	32.3	2.5				5	31.6	1.9	12	28.6	1.6
Regional	126	37.7	3.1	102	37.9	3.2	15	35.0	2.8				7	43.0	2.6	15	35.0	2.0
Distant	84	25.2	2.1	69	25.6	2.2	12	27.3	2.3				3	20.3	1.2	12	28.1	1.6
Unknown	10	3.0	0.3	8	3.1	0.3	-	-	-				-	-	-	2	3.7	0.2
<i>Age ≥ 50</i>																		
In Situ	209	6.6	10.9	156	6.1	9.8	38	8.2	17.9				-	-	-	14	6.7	8.1
Localized	1,098	34.7	59.0	903	35.4	58.1	144	30.6	66.7				36	35.5	43.4	67	33.1	42.0
Regional	1,067	33.7	57.1	879	34.5	56.0	142	30.3	67.6				37	36.5	46.2	69	33.8	46.0
Distant	608	19.2	31.9	481	18.9	30.2	107	22.7	48.9				16	15.6	17.5	44	21.5	29.3
Unknown	180	5.7	10.4	130	5.1	8.9	-	-	-				-	-	-	10	4.8	7.1
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	177	5.6	2.2	126	5.0	1.9	45	8.4	4.0				4	4.7	1.2	15	7.4	2.3
Localized	1,100	35.0	13.8	885	35.4	13.6	172	32.5	15.6				29	32.4	8.0	75	36.8	11.3
Regional	1,083	34.5	13.5	878	35.2	13.3	161	30.5	14.8				37	41.7	10.0	71	34.7	11.0
Distant	592	18.8	7.4	456	18.3	7.0	119	22.5	10.9				16	17.6	4.2	33	16.4	5.0
Unknown	192	6.1	2.2	151	6.1	2.0	32	6.1	3.0				3	3.6	1.0	10	4.7	1.7
<i>Age < 50</i>																		
In Situ	15	4.8	0.4	11	4.4	0.4	4	6.6	0.6				-	-	-	3	6.0	0.4
Localized	116	35.8	2.8	90	36.7	2.9	20	34.1	3.1				4	23.1	1.2	17	36.2	2.3
Regional	113	34.9	2.8	86	34.9	2.8	19	32.1	2.9				7	47.4	2.6	17	35.3	2.4
Distant	71	21.8	1.8	52	21.2	1.7	14	24.8	2.3				4	26.9	1.5	9	20.0	1.3
Unknown	9	2.7	0.2	7	2.8	0.2	1	2.4	0.2				-	-	-	1	2.6	0.2
<i>Age ≥ 50</i>																		
In Situ	161	5.7	7.0	115	5.1	6.1	41	8.7	13.0				-	-	-	12	7.9	7.2
Localized	984	34.9	42.4	795	35.3	41.6	152	32.3	48.3				25	34.3	25.7	58	37.0	34.9
Regional	970	34.4	41.5	792	35.2	41.0	142	30.3	46.0				30	40.5	29.3	54	34.5	33.6
Distant	521	18.5	22.2	404	18.0	20.9	104	22.2	33.6				12	15.7	11.3	24	15.3	14.7
Unknown	184	6.5	7.3	145	6.4	6.8	31	6.6	10.4				3	4.3	3.6	8	5.3	5.6

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Illinois, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	2,488	19.5	33.0	1,954	19.0	32.6	392	21.1	35.6				116	23.0	29.4	182	20.3	24.2
Localized	6,685	52.4	85.9	5,529	53.7	88.1	857	46.1	78.3				252	50.1	64.2	418	46.8	58.9
Regional	2,805	22.0	37.4	2,211	21.5	36.9	458	24.6	42.7				113	22.5	28.8	246	27.5	31.5
Distant	633	5.0	8.1	482	4.7	7.6	128	6.9	11.8				19	3.8	4.8	39	4.4	5.1
Unknown	147	1.2	1.7	115	1.1	1.6	26	1.4	2.4				3	0.6	0.8	10	1.1	1.4
<i>Age < 50</i>																		
In Situ	539	22.3	13.5	425	22.7	13.8	67	18.8	10.6	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			39	24.7	14.2	63	20.5	9.4
Localized	1,066	44.1	26.5	841	44.8	27.2	140	39.4	22.3				74	47.6	26.8	124	40.7	18.3
Regional	697	28.8	17.3	530	28.2	17.2	123	34.4	19.3				38	24.1	13.5	103	33.8	14.9
Distant	100	4.1	2.5	72	3.8	2.3	23	6.6	3.7				4	2.8	1.5	12	3.8	1.6
Unknown	14	0.6	0.4	10	0.5	0.3	3	0.9	0.5				1	0.8	0.4	3	1.1	0.5
<i>Age ≥ 50</i>																		
In Situ	1,948	18.8	84.1	1,529	18.2	81.7	326	21.6	101.0				77	22.3	69.3	119	20.2	62.9
Localized	5,619	54.3	241.5	4,688	55.7	247.6	717	47.6	225.1				178	51.2	162.4	294	49.9	165.2
Regional	2,108	20.4	89.9	1,681	20.0	88.2	335	22.3	104.0				76	21.8	68.7	143	24.2	75.0
Distant	533	5.2	22.8	410	4.9	21.5	104	6.9	33.1				15	4.2	13.3	27	4.6	14.3
Unknown	132	1.3	5.3	105	1.2	5.0	22	1.5	7.3				2	0.5	1.7	6	1.1	3.9

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.1	0.1	6	0.2	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,006	20.7	15.6	856	21.3	15.9	125	17.7	16.8				21	19.0	7.4	23	15.0	5.1
Regional	1,126	23.2	17.0	936	23.3	16.9	160	22.7	20.7				24	22.1	7.9	34	22.1	7.0
Distant	2,428	50.0	36.6	1,996	49.6	36.0	366	51.9	47.8				60	54.5	20.9	87	55.7	17.9
Unknown	289	6.0	4.6	229	5.7	4.4	54	7.6	7.6				5	4.3	2.0	11	6.9	2.6
<i>Female</i>																		
In Situ	11	0.2	0.1	9	0.2	0.1	2	0.2	0.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,207	26.1	14.9	1,031	26.8	15.6	156	23.0	14.3				16	21.5	4.3	33	23.3	5.8
Regional	1,034	22.4	12.7	854	22.2	12.9	162	23.8	14.4				15	20.2	4.1	29	20.4	4.7
Distant	2,134	46.2	26.0	1,763	45.7	26.3	327	48.2	29.4				39	53.1	11.2	70	50.3	12.1
Unknown	233	5.0	2.7	197	5.1	2.7	32	4.8	3.0				3	4.6	1.1	8	5.7	1.6

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	5,779	73.7	79.6	4,502	74.3	74.7	1,064	73.9	122.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			114	70.2	35.3	365	73.1	63.2
Regional	1,136	14.5	15.0	923	15.2	14.6	175	12.2	19.4				26	16.2	7.6	77	15.5	12.3
Distant	577	7.4	8.9	419	6.9	7.8	137	9.5	17.9				16	9.8	5.9	34	6.9	6.9
Unknown	351	4.5	5.6	215	3.5	4.1	64	4.4	10.0				6	3.8	2.0	23	4.6	5.3
<i>Age < 65</i>																		
Localized	2,518	75.1	34.2	1,865	75.6	30.6	573	75.6	62.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			36	70.5	10.7	173	73.3	22.6
Regional	585	17.5	8.0	462	18.7	7.6	106	14.0	11.7				10	19.8	3.1	43	18.2	5.6
Distant	170	5.1	2.3	102	4.1	1.7	64	8.4	6.9				3	6.2	0.9	14	5.8	1.8
Unknown	80	2.4	1.1	39	1.6	0.6	15	2.0	1.7				2	3.5	0.5	6	2.7	0.8
<i>Age ≥ 65</i>																		
Localized	3,261	72.6	393.9	2,637	73.4	379.2	491	72.0	537.8				77	70.1	204.7	192	72.8	343.8
Regional	551	12.3	63.4	461	12.8	63.0	69	10.1	72.7				16	14.5	39.0	35	13.1	58.9
Distant	407	9.1	54.7	318	8.8	50.2	73	10.8	93.5				13	11.4	40.4	21	7.8	42.4
Unknown	272	6.0	36.6	176	4.9	27.7	49	7.1	67.5				4	4.0	12.2	16	6.2	36.3

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Indiana, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	120	43.7	3.8	108	44.3	3.9	10	37.7	3.0	-	-	-	1	40.0	1.5	8	41.9	4.6
Regional	107	39.1	3.1	92	38.0	3.1	13	51.5	4.1	-	-	-	1	40.0	1.7	7	36.6	4.5
Distant	39	14.1	1.0	35	14.6	1.1	2	8.5	0.7	-	-	-	-	-	-	3	17.2	2.0
Unknown	9	3.1	0.2	8	3.1	0.2	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	75	4.3	2.1	61	3.8	1.8	6	4.8	2.5	-	-	-	-	-	-	2	4.8	1.9
Localized	603	34.3	17.3	556	34.7	17.4	37	28.1	14.6	-	-	-	5	42.2	11.8	13	34.9	13.3
Regional	627	35.6	18.1	576	36.0	18.2	45	34.4	19.0	-	-	-	4	34.4	9.4	12	32.8	11.7
Distant	366	20.8	10.5	329	20.6	10.3	34	26.3	14.8	-	-	-	3	21.9	7.4	8	22.2	7.7
Unknown	88	5.0	2.7	77	4.8	2.6	8	6.5	4.4	-	-	-	-	-	-	2	5.3	2.5
<i>Age < 50</i>																		
In Situ	4	2.4	0.2	3	1.9	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	54	29.5	2.6	48	29.9	2.7	4	23.0	2.1	-	-	-	-	-	-	3	37.1	1.6
Regional	71	39.3	3.6	64	40.1	3.7	7	39.1	3.5	-	-	-	-	-	-	2	25.7	1.2
Distant	48	26.4	2.4	42	26.0	2.4	6	32.2	3.0	-	-	-	-	-	-	2	31.4	1.5
Unknown	4	2.3	0.2	3	2.1	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	71	4.5	7.0	58	4.0	6.2	-	-	-	-	-	-	-	-	-	2	5.8	7.0
Localized	550	34.8	55.9	508	35.3	56.2	33	28.9	47.2	-	-	-	-	-	-	11	34.4	44.0
Regional	555	35.2	56.3	512	35.6	56.3	38	33.7	59.6	-	-	-	-	-	-	11	34.4	39.1
Distant	318	20.2	31.7	288	20.0	31.0	29	25.4	45.9	-	-	-	-	-	-	6	20.1	23.9
Unknown	84	5.3	9.4	74	5.1	8.9	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	68	4.2	1.7	57	3.9	1.5	6	5.0	2.0	-	-	-	-	-	-	1	3.6	1.3
Localized	589	36.6	14.4	533	36.5	14.4	49	38.4	15.8	-	-	-	3	28.8	5.6	12	35.7	11.6
Regional	546	34.0	13.3	502	34.5	13.5	40	30.9	12.7	-	-	-	4	36.5	8.0	12	36.3	11.7
Distant	317	19.7	7.8	287	19.7	7.8	27	20.9	8.7	-	-	-	3	28.8	4.3	6	18.5	5.3
Unknown	88	5.5	2.0	79	5.4	1.9	6	4.7	2.1	-	-	-	-	-	-	2	6.0	2.1
<i>Age < 50</i>																		
In Situ	6	3.8	0.3	5	3.3	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	61	36.2	3.0	55	36.2	3.1	6	38.9	2.6	-	-	-	-	-	-	2	31.4	1.7
Regional	57	33.6	2.8	52	34.4	3.0	4	27.8	1.9	-	-	-	-	-	-	2	34.3	1.9
Distant	41	24.4	2.1	37	24.4	2.2	3	22.2	1.6	-	-	-	-	-	-	2	31.4	1.7
Unknown	3	2.0	0.2	3	1.7	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	61	4.3	5.2	52	4.0	4.8	-	-	-	-	-	-	-	-	-	1	4.5	4.7
Localized	528	36.7	44.3	478	36.6	43.8	44	38.4	50.4	-	-	-	-	-	-	10	36.8	37.5
Regional	490	34.0	40.7	450	34.5	40.8	36	31.3	41.0	-	-	-	-	-	-	10	36.8	37.1
Distant	276	19.2	22.6	250	19.2	22.4	24	20.8	27.5	-	-	-	-	-	-	4	15.0	14.6
Unknown	85	5.9	6.8	76	5.8	6.6	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Indiana, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,071	17.9	27.2	944	17.5	26.6	108	21.5	33.9	-	-	-	14	23.9	23.7	31	22.5	24.8
Localized	3,273	54.7	81.0	2,990	55.4	81.9	243	48.3	75.5	-	-	-	28	47.2	49.1	68	49.4	59.8
Regional	1,269	21.2	32.8	1,135	21.0	32.7	114	22.8	36.0	-	-	-	15	24.9	23.4	31	22.8	24.6
Distant	303	5.1	7.5	267	4.9	7.3	33	6.5	10.5	-	-	-	2	3.7	4.1	6	4.2	4.9
Unknown	71	1.2	1.6	64	1.2	1.6	5	0.9	1.5	-	-	-	-	-	-	1	1.0	1.0
<i>Age < 50</i>																		
In Situ	201	20.2	10.2	172	19.9	10.0	23	22.4	11.6	-	-	-	5	21.3	8.8	10	23.5	8.6
Localized	459	46.2	23.0	408	47.2	23.7	40	38.3	19.2	-	-	-	10	45.4	17.9	18	41.6	15.1
Regional	286	28.7	14.4	244	28.3	14.3	33	32.0	16.1	-	-	-	7	30.6	11.6	12	27.1	9.5
Distant	44	4.4	2.2	36	4.2	2.1	7	6.7	3.5	-	-	-	-	-	-	3	6.8	2.5
Unknown	5	0.5	0.2	4	0.5	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	870	17.4	71.6	772	17.0	70.1	85	21.2	92.2	-	-	-	10	25.4	62.9	20	22.0	67.0
Localized	2,813	56.4	232.6	2,582	56.9	234.6	203	51.0	222.8	-	-	-	19	48.2	130.7	49	53.1	176.7
Regional	983	19.7	80.9	890	19.6	80.8	81	20.4	88.1	-	-	-	8	21.8	54.3	19	20.7	64.4
Distant	259	5.2	21.5	230	5.1	21.0	26	6.4	29.0	-	-	-	-	-	-	3	3.0	11.2
Unknown	66	1.3	5.2	60	1.3	5.1	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	4	0.1	0.1	4	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	611	20.2	17.7	575	20.4	18.0	33	17.6	16.1	-	-	-	1	13.7	3.2	5	17.4	6.3
Regional	695	23.0	19.8	648	23.0	20.0	42	22.2	18.7	-	-	-	3	27.5	7.3	7	23.9	8.7
Distant	1,573	52.1	44.7	1,456	51.7	45.0	108	57.2	45.8	-	-	-	6	58.8	15.7	15	55.1	17.6
Unknown	137	4.5	4.2	130	4.6	4.3	6	3.1	3.0	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	5	0.2	0.1	5	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	657	25.2	15.5	609	25.4	15.7	43	23.5	14.3	-	-	-	2	19.6	4.1	8	29.5	8.6
Regional	583	22.4	13.8	538	22.4	14.0	40	21.8	12.5	-	-	-	3	25.5	4.9	7	27.3	7.6
Distant	1,263	48.6	30.0	1,160	48.3	30.2	96	52.0	30.8	-	-	-	6	54.9	13.1	10	37.9	9.9
Unknown	94	3.6	2.2	89	3.7	2.2	5	2.6	1.6	-	-	-	-	-	-	1	4.5	1.2

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,602	73.9	69.0	2,257	73.9	65.2	304	75.9	118.7	-	-	-	11	70.1	29.5	45	72.3	47.3
Regional	481	13.7	11.9	435	14.2	11.7	42	10.5	15.0	-	-	-	3	18.2	7.9	8	13.2	8.3
Distant	289	8.2	8.8	247	8.1	8.1	40	9.9	19.0	-	-	-	1	7.8	3.6	6	9.6	8.2
Unknown	149	4.2	4.6	116	3.8	3.9	15	3.6	7.7	-	-	-	-	-	-	3	4.8	3.4
<i>Age < 65</i>																		
Localized	1,054	75.1	27.3	877	74.8	25.0	160	77.7	55.3	-	-	-	3	69.6	6.5	22	76.2	16.9
Regional	243	17.3	6.2	214	18.2	6.0	27	13.3	9.4	-	-	-	-	-	-	3	10.9	2.5
Distant	77	5.5	2.0	61	5.2	1.8	15	7.5	5.3	-	-	-	-	-	-	2	8.2	1.9
Unknown	30	2.1	0.8	21	1.8	0.6	3	1.6	1.1	-	-	-	-	-	-	1	4.8	1.1
<i>Age ≥ 65</i>																		
Localized	1,548	73.1	357.3	1,379	73.3	343.5	144	74.0	556.9	-	-	-	8	70.4	188.4	23	68.9	257.1
Regional	239	11.3	50.8	221	11.7	50.6	15	7.6	53.7	-	-	-	-	-	-	5	15.2	48.4
Distant	212	10.0	55.3	186	9.9	52.2	24	12.6	113.9	-	-	-	-	-	-	4	11.0	52.2
Unknown	119	5.6	31.0	95	5.0	26.8	11	5.9	53.3	-	-	-	-	-	-	2	4.9	19.4

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Iowa, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	52	45.0	3.6	49	45.2	3.7	2	66.7	4.0	-	-	-	-	-	-	3	51.7	4.2
Regional	41	35.8	2.6	38	35.6	2.5	-	-	-	-	-	-	2	57.1	5.9	2	34.5	5.0
Distant	20	17.0	1.1	19	17.2	1.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	3	2.2	0.1	2	2.0	0.1	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	14	1.6	0.8	14	1.7	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Localized	321	36.9	18.4	311	37.0	18.4	6	32.6	20.3	-	-	-	3	33.3	13.2	5	35.7	13.5
Regional	320	36.7	18.5	309	36.8	18.6	6	32.6	14.1	-	-	-	4	42.9	21.4	5	37.1	13.7
Distant	178	20.5	10.2	171	20.3	10.1	5	30.2	17.5	-	-	-	2	23.8	7.7	3	18.6	9.3
Unknown	37	4.3	2.2	36	4.3	2.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	28	33.6	3.0	27	34.3	3.2	-	-	-	-	-	-	-	-	-	-	-	-
Regional	35	42.0	3.9	33	41.6	3.9	1	54.5	3.1	-	-	-	-	-	-	-	-	-
Distant	18	21.8	2.0	17	21.8	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	1.9	0.2	1	1.5	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	293	37.3	58.6	284	37.3	58.4	-	-	-	-	-	-	-	-	-	-	-	-
Regional	285	36.2	56.9	276	36.3	56.9	4	29.3	43.1	-	-	-	-	-	-	-	-	-
Distant	160	20.3	31.5	154	20.2	31.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	36	4.5	7.6	35	4.5	7.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	13	1.6	0.6	13	1.6	0.7	-	-	-	-	-	-	-	-	-	-	-	-
Localized	312	38.1	15.1	302	38.1	15.1	5	38.2	13.8	-	-	-	2	32.4	10.9	3	34.1	5.3
Regional	299	36.6	14.5	290	36.6	14.5	4	30.9	12.5	-	-	-	3	50.0	13.8	4	40.9	9.8
Distant	143	17.5	7.1	139	17.5	7.1	3	25.0	9.4	-	-	-	-	-	-	2	20.5	5.3
Unknown	50	6.1	2.0	49	6.2	2.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	31	39.0	3.4	29	38.6	3.4	-	-	-	-	-	-	-	-	-	1	46.7	2.9
Regional	28	34.5	3.1	26	35.1	3.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	19	23.3	2.1	17	23.1	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	2.5	0.2	2	2.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	280	38.0	45.9	273	38.1	45.8	-	-	-	-	-	-	-	-	-	2	27.6	11.6
Regional	271	36.8	44.3	263	36.7	44.0	-	-	-	-	-	-	-	-	-	-	-	-
Distant	125	16.9	20.2	121	16.9	20.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	48	6.5	6.6	47	6.6	6.6	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Iowa, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	519	17.4	28.1	499	17.3	28.2	11	21.0	30.7	-	-	-	6	20.3	20.0	9	20.6	18.1
Localized	1,661	55.7	85.5	1,619	56.1	86.4	21	42.5	62.7	2	62.5	121.0	16	49.4	55.5	17	38.8	35.3
Regional	638	21.4	35.2	611	21.2	35.1	16	31.0	41.9	-	-	-	8	26.6	28.9	14	31.8	27.0
Distant	133	4.5	6.9	129	4.5	7.0	2	4.8	5.5	-	-	-	-	-	-	3	6.1	4.9
Unknown	32	1.1	1.3	30	1.0	1.3	-	-	-	-	-	-	-	-	-	1	2.8	3.0
<i>Age < 50</i>																		
In Situ	95	19.6	11.0	90	19.7	11.2	3	16.5	8.5	-	-	-	2	18.8	7.0	4	21.0	9.2
Localized	219	45.1	25.0	208	45.4	25.6	5	34.2	17.8	-	-	-	5	47.9	16.9	7	34.0	14.4
Regional	149	30.7	17.1	137	30.1	17.0	7	45.6	23.8	-	-	-	3	33.3	11.3	7	35.0	14.6
Distant	21	4.3	2.4	20	4.4	2.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	0.3	0.2	2	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	424	17.0	72.9	409	16.8	72.5	8	23.1	88.6	-	-	-	5	20.9	53.9	5	20.2	41.3
Localized	1,443	57.7	243.7	1,411	58.0	245.5	16	46.2	180.2	-	-	-	11	50.0	156.4	10	43.0	90.0
Regional	490	19.6	82.7	474	19.5	82.5	8	24.3	89.4	-	-	-	5	23.6	74.8	7	28.9	59.3
Distant	112	4.5	18.8	109	4.5	18.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	30	1.2	4.4	29	1.2	4.2	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	4	0.3	0.2	4	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	244	18.2	13.9	236	18.1	13.7	6	21.1	23.0	-	-	-	2	20.0	16.4	-	-	-
Regional	280	20.9	15.4	275	21.1	15.6	4	15.0	14.2	-	-	-	-	-	-	2	24.2	6.0
Distant	749	55.8	41.6	723	55.6	41.3	17	58.5	54.1	1	85.7	92.2	6	68.9	34.4	4	63.6	16.2
Unknown	65	4.8	3.9	63	4.9	3.8	1	4.8	7.3	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	3	0.2	0.1	2	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	250	21.7	12.0	245	21.8	12.0	4	18.2	11.0	-	-	-	-	-	-	2	29.7	6.4
Regional	242	21.0	11.6	237	21.1	11.7	4	20.2	12.4	-	-	-	-	-	-	1	18.9	4.8
Distant	601	52.2	28.6	584	52.0	28.6	11	57.6	36.3	-	-	-	4	65.5	18.5	4	48.6	11.1
Unknown	56	4.9	2.4	55	4.9	2.4	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,468	71.2	76.8	1,400	71.1	75.5	42	70.0	125.1	1	100.0	101.6	5	74.2	22.7	13	57.9	42.6
Regional	381	18.5	18.8	367	18.6	18.7	11	18.5	27.0	-	-	-	-	-	-	6	26.3	14.8
Distant	170	8.3	9.7	163	8.3	9.6	6	9.4	16.3	-	-	-	-	-	-	4	15.8	10.6
Unknown	41	2.0	2.4	40	2.0	2.4	1	2.0	6.2	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	576	70.7	30.3	542	70.7	29.6	24	66.1	56.5	-	-	-	2	83.3	8.7	7	59.0	14.9
Regional	191	23.5	10.0	182	23.7	9.9	8	22.8	19.4	-	-	-	-	-	-	3	24.6	6.1
Distant	42	5.2	2.3	38	4.9	2.1	4	10.6	9.0	-	-	-	-	-	-	2	16.4	4.0
Unknown	5	0.6	0.3	5	0.6	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	892	71.6	397.9	859	71.3	392.1	18	76.1	599.7	-	-	-	3	68.4	119.1	6	56.6	234.1
Regional	190	15.2	79.5	186	15.4	79.7	3	12.0	80.1	-	-	-	-	-	-	3	28.3	74.7
Distant	128	10.3	61.2	126	10.4	61.2	2	7.7	67.2	-	-	-	-	-	-	2	15.1	56.4
Unknown	36	2.9	17.3	35	2.9	17.0	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Kansas, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	49	46.1	3.7	42	46.4	3.5	2	39.3	2.5	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	4	40.7	3.6
Regional	33	31.0	2.3	30	33.1	2.3	2	32.1	2.1				-	-	-	4	38.9	4.3
Distant	16	14.6	1.0	12	13.8	0.9	1	25.0	1.8				-	-	-	2	16.7	1.7
Unknown	9	8.4	0.6	6	6.7	0.4	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	36	5.0	2.3	31	4.7	2.1	2	5.9	2.7				-	-	-	1	3.7	1.3
Localized	269	37.5	17.6	244	37.6	17.2	14	38.2	20.4				4	32.1	12.3	12	37.0	17.6
Regional	232	32.4	15.3	214	33.0	15.2	10	27.4	15.1				5	42.9	14.7	9	27.8	11.9
Distant	138	19.2	9.1	122	18.8	8.8	9	24.2	13.6				3	23.2	9.7	8	25.3	9.6
Unknown	42	5.9	2.8	38	5.9	2.7	2	4.3	2.3				-	-	-	2	6.2	3.2
<i>Age < 50</i>																		
In Situ	3	3.4	0.3	2	3.0	0.3	-	-	-				-	-	-	-	-	-
Localized	29	37.1	3.3	25	37.0	3.3	1	33.3	2.0				-	-	-	2	25.0	1.6
Regional	26	34.3	3.2	23	34.9	3.2	1	28.6	2.2				1	42.9	3.6	2	37.5	2.2
Distant	18	22.9	2.1	15	23.0	2.1	1	28.6	2.2				-	-	-	2	31.3	2.1
Unknown	2	2.3	0.2	1	2.1	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	33	5.2	7.4	29	4.9	6.9	-	-	-				-	-	-	-	-	-
Localized	240	37.5	55.0	219	37.7	53.7	13	38.8	68.5				-	-	-	10	40.0	59.6
Regional	206	32.2	47.0	190	32.7	46.5	9	27.3	49.1				4	42.9	44.0	7	25.4	37.0
Distant	120	18.8	27.6	107	18.3	26.3	8	23.6	43.4				-	-	-	6	23.8	29.4
Unknown	40	6.3	9.6	37	6.3	9.3	-	-	-	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	27	4.3	1.6	23	4.0	1.5	1	4.1	1.4				-	-	-	1	5.0	1.2
Localized	240	37.9	13.6	223	38.9	13.6	9	30.3	11.3				2	21.3	4.9	8	34.2	8.9
Regional	209	33.0	11.9	188	32.7	11.5	10	35.2	13.4				5	57.4	14.3	8	35.0	9.9
Distant	118	18.7	6.8	108	18.8	6.8	6	20.7	7.2				1	12.8	3.3	5	22.5	5.7
Unknown	38	6.0	2.0	32	5.6	1.8	3	9.7	3.2				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	3	4.7	0.4	3	5.2	0.5	-	-	-				-	-	-	-	-	-
Localized	26	36.6	3.0	23	37.5	3.1	1	27.3	2.5				-	-	-	2	34.3	2.3
Regional	25	34.4	3.0	20	32.7	2.8	2	45.5	4.1				-	-	-	3	40.0	3.1
Distant	15	21.2	1.8	14	22.0	1.9	-	-	-				-	-	-	1	20.0	1.4
Unknown	2	3.1	0.3	2	2.6	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	24	4.2	4.6	20	3.9	4.2	1	4.9	5.0				-	-	-	-	-	-
Localized	214	38.1	41.1	200	39.0	41.2	8	30.9	34.4				-	-	-	6	34.1	26.2
Regional	184	32.9	35.3	168	32.7	34.5	8	33.3	37.6				-	-	-	6	32.9	27.7
Distant	103	18.4	19.9	94	18.4	19.6	-	-	-				-	-	-	4	23.5	17.1
Unknown	36	6.4	6.6	30	5.9	5.9	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Kansas, 2013-2017**

Female Breast, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	425	16.6	25.7	380	16.3	25.2	23	18.5	27.6				7	19.4	18.5	15	14.5	15.1
Localized	1,386	54.1	80.8	1,279	54.8	80.8	58	46.5	71.6				19	51.1	48.9	47	45.2	52.8
Regional	569	22.2	34.7	514	22.0	34.2	35	27.8	42.4				8	22.0	19.8	33	32.4	33.0
Distant	116	4.5	6.8	104	4.5	6.6	7	5.3	7.3				2	4.3	3.5	5	4.5	4.2
Unknown	67	2.6	3.7	56	2.4	3.3	2	1.9	3.1				1	3.2	2.4	4	3.5	4.1
<i>Age < 50</i>																		
In Situ	77	18.1	9.6	68	18.4	9.6	4	15.9	8.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics	2	15.1	6.8	7	17.3	8.1		
Localized	196	45.8	24.0	171	46.3	23.7	12	43.5	23.6		7	47.9	21.2	15	37.1	16.9		
Regional	127	29.6	15.4	109	29.4	15.0	9	33.3	17.4		4	27.4	11.5	15	37.1	16.1		
Distant	19	4.3	2.3	15	4.2	2.2	1	4.3	1.8		-	-	-	2	4.5	2.1		
Unknown	9	2.2	1.1	6	1.7	0.8	-	-	-		-	-	-	2	4.0	1.6		
<i>Age ≥ 50</i>																		
In Situ	348	16.3	68.0	312	15.9	66.0	19	19.2	76.3				5	22.1	49.1	8	12.7	33.4
Localized	1,190	55.7	229.3	1,108	56.4	230.2	46	47.4	197.3				12	53.1	121.5	32	50.3	146.9
Regional	442	20.7	85.4	405	20.6	84.6	25	26.2	108.0				4	18.6	41.6	18	29.3	77.4
Distant	97	4.6	18.5	89	4.5	18.2	5	5.6	21.7				-	-	-	3	4.5	9.7
Unknown	58	2.7	10.6	50	2.5	9.8	-	-	-				-	-	-	2	3.2	10.8

Lung and Bronchus, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>
Stage at Diagnosis																		
<i>Male</i>																		
In Situ	3	0.3	0.2	2	0.2	0.2	-	-	-				-	-	-	-	-	-
Localized	208	20.8	13.9	192	20.8	13.6	13	22.7	20.3				1	14.0	5.3	3	16.3	5.6
Regional	231	23.1	15.0	213	23.1	14.8	14	24.5	19.6				2	18.6	7.2	4	25.6	6.9
Distant	494	49.4	31.7	455	49.4	31.4	27	47.6	39.0				5	62.8	18.7	9	52.3	15.6
Unknown	64	6.4	4.3	59	6.4	4.3	3	4.5	4.1				-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.2	0.1	2	0.2	0.1	-	-	-				-	-	-	-	-	-
Localized	227	25.1	12.5	210	25.2	12.5	11	25.3	14.8				3	25.9	9.3	3	14.2	4.6
Regional	216	23.9	12.1	201	24.1	12.1	11	24.4	13.2				2	16.7	5.0	6	30.2	9.3
Distant	410	45.3	22.4	377	45.3	22.2	20	44.4	24.1				5	50.0	16.0	10	47.2	14.9
Unknown	49	5.4	2.7	43	5.2	2.5	2	5.3	3.1				-	-	-	2	8.5	2.4

Prostate, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
All Ages																		
Localized	1,357	76.3	82.6	1,162	76.5	76.1	89	75.9	115.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics	8	71.7	29.0	44	71.3	62.6		
Regional	209	11.7	12.0	189	12.4	11.7	13	10.9	14.2		2	15.1	5.2	10	15.6	12.7		
Distant	106	6.0	6.9	93	6.1	6.5	10	8.5	15.6		-	-	-	5	8.1	8.1		
Unknown	105	5.9	6.8	75	4.9	5.3	6	4.8	9.5		-	-	-	3	4.9	5.7		
Age < 65																		
Localized	527	77.4	31.4	438	77.8	28.5	50	76.6	56.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics	3	70.0	8.8	21	74.1	20.9		
Regional	95	14.0	5.6	83	14.7	5.4	9	13.7	9.7		-	-	-	4	15.8	4.5		
Distant	31	4.6	1.9	25	4.5	1.6	5	7.0	5.1		-	-	-	2	7.9	2.1		
Unknown	27	4.0	1.6	18	3.1	1.2	2	2.7	1.9		-	-	-	-	-	-		
Age ≥ 65																		
Localized	830	75.7	436.1	724	75.7	405.0	39	75.0	523.5		5	72.7	169.0	23	69.0	350.7		
Regional	113	10.3	56.0	106	11.1	55.9	4	7.3	45.8		-	-	-	5	15.5	69.6		
Distant	75	6.9	41.7	68	7.1	40.1	5	10.4	88.0		-	-	-	3	8.3	49.4		
Unknown	78	7.1	42.7	58	6.0	33.6	4	7.3	61.8		-	-	-	-	-	-		

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Kentucky, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	98	45.3	4.6	88	45.0	4.6	6	41.6	3.7	Insufficient data for the calculation of AI/AN PRCA statistics			1	66.7	3.9	3	77.8	4.8
Regional	76	34.8	3.2	69	35.3	3.2	5	32.5	2.7				-	-	-	-	-	-
Distant	38	17.5	1.6	34	17.4	1.6	4	23.4	1.9				-	-	-	-	-	-
Unknown	5	2.4	0.2	5	2.4	0.2	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	93	6.5	3.8	82	6.2	3.6	7	7.7	4.8	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	552	38.3	22.9	501	37.9	22.5	35	37.8	22.8				4	50.0	19.0	5	41.4	13.0
Regional	472	32.7	19.8	441	33.4	20.0	27	29.0	18.8				2	25.0	13.1	3	27.6	7.0
Distant	264	18.3	11.0	241	18.2	10.8	22	23.2	15.8				-	-	-	2	19.0	7.8
Unknown	61	4.2	2.8	57	4.3	2.8	2	2.4	2.1				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	8	5.2	0.6	7	4.8	0.6	-	-	-				-	-	-	-	-	-
Localized	58	35.9	4.2	52	35.5	4.3	3	28.6	2.5				-	-	-	2	62.5	3.3
Regional	57	35.5	4.2	54	36.6	4.4	4	36.7	3.2				-	-	-	-	-	-
Distant	34	21.1	2.5	31	21.0	2.5	3	28.6	2.5				-	-	-	-	-	-
Unknown	4	2.4	0.3	3	2.2	0.3	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	85	6.6	12.1	75	6.3	11.5	-	-	-				-	-	-	-	-	-
Localized	494	38.6	71.7	449	38.2	70.2	32	38.8	76.1				-	-	-	3	33.3	38.3
Regional	415	32.4	60.5	388	33.0	60.7	23	28.1	59.6				2	31.3	47.3	-	-	-
Distant	230	17.9	33.3	210	17.9	32.6	19	22.5	50.6				-	-	-	-	-	-
Unknown	57	4.5	9.3	54	4.6	9.3	2	2.6	7.6				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	73	5.9	2.6	58	5.1	2.2	12	12.4	6.6	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	492	39.5	17.4	444	39.3	17.1	38	40.1	19.8				2	33.3	10.4	4	40.0	11.6
Regional	390	31.3	13.8	364	32.2	13.9	23	24.1	12.4				2	33.3	9.1	2	24.4	5.2
Distant	236	19.0	8.4	214	19.0	8.3	20	20.7	10.6				2	24.2	4.7	2	22.2	5.9
Unknown	54	4.3	1.8	49	4.4	1.8	3	2.7	1.5				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	9	6.3	0.6	7	5.3	0.5	2	13.6	1.4				-	-	-	-	-	-
Localized	57	39.4	4.1	51	39.8	4.1	4	30.5	3.0				-	-	-	-	-	-
Regional	42	29.0	3.0	38	29.4	3.1	3	28.8	3.0				-	-	-	-	-	-
Distant	34	23.5	2.5	30	23.6	2.5	3	25.4	2.6				-	-	-	-	-	-
Unknown	3	1.8	0.2	2	1.9	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	64	5.8	7.7	51	5.1	6.7	10	12.3	20.2				-	-	-	-	-	-
Localized	435	39.6	52.4	393	39.2	51.1	34	41.4	63.7				-	-	-	-	-	-
Regional	348	31.6	41.9	326	32.6	42.4	19	23.4	37.2				-	-	-	-	-	-
Distant	202	18.4	24.1	184	18.4	23.7	17	20.0	31.5				-	-	-	-	-	-
Unknown	51	4.6	6.1	47	4.7	6.0	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Kentucky, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	717	17.0	26.1	651	16.8	25.9	57	19.7	30.3				6	21.4	19.6	5	13.7	11.6
Localized	2,302	54.7	82.7	2,135	55.1	83.3	144	49.7	77.5				14	49.0	47.7	19	55.4	49.8
Regional	928	22.1	34.7	849	21.9	34.6	70	24.2	37.3				6	20.0	17.6	8	23.2	18.2
Distant	217	5.2	7.8	196	5.1	7.6	17	5.9	9.4				3	9.7	7.9	3	7.7	8.4
Unknown	44	1.0	1.5	41	1.1	1.5	1	0.5	0.8				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	134	18.7	9.9	123	19.0	10.1	10	16.8	8.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			1	11.1	4.5	2	16.9	5.7
Localized	339	47.2	25.0	308	47.7	25.3	24	41.8	22.1				5	48.1	19.1	7	50.8	15.8
Regional	210	29.2	15.5	185	28.7	15.4	20	34.2	17.9				3	27.8	10.8	4	27.7	8.6
Distant	32	4.4	2.3	26	4.0	2.1	4	6.5	3.3				1	13.0	4.7	-	-	-
Unknown	4	0.6	0.3	4	0.6	0.3	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	583	16.7	68.7	528	16.4	67.5	47	20.4	86.2				5	27.5	59.1	2	11.7	26.9
Localized	1,963	56.3	233.5	1,827	56.6	235.0	120	51.7	222.7				9	49.5	122.6	12	58.3	138.8
Regional	718	20.6	84.9	664	20.6	85.1	50	21.6	88.1				3	15.4	35.3	4	20.4	43.1
Distant	185	5.3	22.2	170	5.3	22.0	13	5.8	25.3				1	7.7	16.2	-	-	-
Unknown	39	1.1	4.6	37	1.2	4.7	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	5	0.2	0.2	4	0.2	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	478	18.0	19.7	452	18.1	20.0	23	16.9	16.8				-	-	-	1	14.3	5.6
Regional	629	23.7	25.4	597	23.8	25.8	31	22.3	22.5				-	-	-	2	24.5	7.9
Distant	1,365	51.5	55.8	1,286	51.3	56.4	74	54.1	54.6				4	69.2	17.1	5	53.1	17.2
Unknown	175	6.6	8.0	165	6.6	8.1	9	6.6	7.9				-	-	-	-	-	-
<i>Female</i>																		
In Situ	4	0.2	0.1	4	0.2	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	493	21.6	16.8	467	21.8	17.1	24	18.3	13.5				2	21.6	6.9	1	22.6	5.5
Regional	542	23.8	18.5	509	23.8	18.7	31	23.5	17.4				2	21.6	7.8	1	19.4	5.3
Distant	1,123	49.2	38.2	1,048	49.0	38.5	70	53.3	38.3				4	51.4	16.8	3	48.4	11.1
Unknown	119	5.2	4.0	112	5.2	4.0	6	4.9	3.9				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,952	71.7	73.7	1,623	72.0	66.0	168	74.6	105.4	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			5	80.0	26.3	12	69.4	37.1
Regional	332	12.2	11.9	298	13.2	11.5	26	11.6	14.5				-	-	-	3	15.3	8.5
Distant	174	6.4	7.7	155	6.9	7.4	18	7.8	13.4				-	-	-	2	9.4	4.4
Unknown	263	9.7	10.9	178	7.9	8.1	13	5.9	11.6				-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	820	72.4	31.3	647	72.5	26.8	92	75.7	49.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			2	90.0	7.4	7	75.6	15.6
Regional	177	15.6	6.8	155	17.4	6.5	18	15.2	10.4				-	-	-	1	13.3	2.9
Distant	48	4.2	1.9	40	4.5	1.7	8	6.3	4.0				-	-	-	-	-	-
Unknown	88	7.8	3.4	50	5.6	2.1	3	2.8	1.8				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,132	71.2	366.6	977	71.7	336.7	77	73.4	491.5				3	75.0	156.4	5	62.5	185.3
Regional	156	9.8	47.0	143	10.5	45.9	8	7.5	43.2				-	-	-	1	17.5	47.2
Distant	126	7.9	47.7	115	8.5	46.3	10	9.6	78.5				-	-	-	-	-	-
Unknown	175	11.0	62.7	128	9.4	49.8	10	9.6	79.2				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Louisiana, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	89	41.2	3.9	58	45.6	4.0	30	35.3	4.0	-	-	-	-	-	-	4	39.6	3.9
Regional	79	36.5	3.3	42	33.1	2.7	34	40.3	4.6	-	-	-	3	70.0	6.4	4	39.6	4.4
Distant	37	16.9	1.4	20	15.6	1.2	16	19.6	2.1	-	-	-	-	-	-	1	12.5	1.6
Unknown	12	5.4	0.5	7	5.6	0.5	4	4.8	0.6	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	48	3.6	1.9	28	3.1	1.6	18	4.4	2.8	-	-	-	-	-	-	-	-	-
Localized	496	37.4	20.7	342	38.4	19.9	145	35.3	23.4	-	-	-	6	36.3	15.8	10	39.8	13.6
Regional	446	33.7	18.5	314	35.2	18.0	125	30.4	19.9	-	-	-	6	35.0	15.0	7	28.9	8.5
Distant	278	21.0	11.4	172	19.3	9.9	101	24.5	15.8	-	-	-	3	17.5	8.4	5	21.1	6.6
Unknown	57	4.3	2.6	34	3.8	2.1	22	5.3	4.1	-	-	-	-	-	-	2	6.3	2.0
<i>Age < 50</i>																		
In Situ	3	2.3	0.2	1	1.6	0.2	2	4.1	0.3	-	-	-	-	-	-	-	-	-
Localized	41	31.1	2.9	29	32.9	3.1	11	27.4	2.6	-	-	-	-	-	-	1	25.0	1.5
Regional	50	38.1	3.7	34	38.5	3.7	15	37.6	3.7	-	-	-	-	-	-	1	25.0	1.9
Distant	34	26.2	2.5	22	25.0	2.4	11	27.9	2.8	-	-	-	-	-	-	2	42.9	3.1
Unknown	3	2.3	0.2	2	2.0	0.2	1	3.0	0.3	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	45	3.8	6.4	27	3.3	5.2	17	4.5	9.3	-	-	-	-	-	-	-	-	-
Localized	455	38.1	67.3	313	39.1	63.8	134	36.2	77.7	-	-	-	-	-	-	9	44.0	45.4
Regional	396	33.2	57.2	279	34.9	55.5	110	29.6	62.6	-	-	-	-	-	-	6	30.0	25.9
Distant	243	20.4	34.7	150	18.7	29.6	90	24.2	50.0	-	-	-	-	-	-	3	15.0	15.8
Unknown	54	4.5	8.7	32	4.0	7.1	21	5.5	14.0	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	38	3.3	1.3	22	3.1	1.1	15	3.8	1.7	-	-	-	-	-	-	-	-	-
Localized	418	37.1	14.9	270	37.1	14.0	141	36.8	17.1	-	-	-	4	46.5	11.2	8	42.9	9.8
Regional	382	33.9	13.6	260	35.6	13.3	118	30.9	14.9	-	-	-	3	34.9	7.4	5	27.6	6.5
Distant	238	21.1	8.4	148	20.3	7.5	88	23.0	11.0	-	-	-	-	-	-	3	16.3	4.0
Unknown	52	4.6	1.8	29	4.0	1.4	21	5.5	2.8	-	-	-	-	-	-	2	8.2	2.1
<i>Age < 50</i>																		
In Situ	3	2.3	0.2	2	2.1	0.2	1	2.4	0.2	-	-	-	-	-	-	-	-	-
Localized	53	38.3	3.7	35	39.7	3.9	18	36.3	3.8	-	-	-	-	-	-	2	39.3	2.9
Regional	48	34.4	3.4	31	35.8	3.5	16	31.5	3.4	-	-	-	-	-	-	3	50.0	4.0
Distant	30	21.8	2.2	17	20.0	2.0	13	25.4	2.6	-	-	-	-	-	-	-	-	-
Unknown	4	3.2	0.3	2	2.5	0.2	2	4.4	0.5	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	34	3.5	4.1	21	3.2	3.5	13	4.0	5.7	-	-	-	-	-	-	-	-	-
Localized	365	36.9	44.1	236	36.7	40.4	123	36.9	52.0	-	-	-	-	-	-	6	44.3	28.1
Regional	334	33.8	40.3	228	35.5	38.8	102	30.8	45.1	-	-	-	-	-	-	3	18.6	12.9
Distant	208	21.0	24.8	131	20.3	22.0	75	22.7	32.8	-	-	-	-	-	-	-	-	-
Unknown	47	4.8	5.7	27	4.2	4.5	19	5.7	8.8	-	-	-	-	-	-	2	11.4	7.7

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Louisiana, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	704	16.8	25.3	460	16.3	24.3	234	17.8	28.7	-	-	-	7	17.3	16.3	16	17.6	19.8
Localized	2,164	51.7	77.3	1,519	54.0	78.2	616	46.8	76.6	-	-	-	20	48.5	44.8	46	51.4	59.4
Regional	1,018	24.3	37.8	653	23.2	35.6	351	26.6	43.9	-	-	-	11	26.2	24.1	21	23.6	25.6
Distant	246	5.9	8.8	145	5.2	7.4	98	7.4	12.1	-	-	-	3	6.4	6.3	5	5.3	5.6
Unknown	56	1.3	2.0	36	1.3	1.7	19	1.4	2.5	-	-	-	-	-	-	2	2.0	2.3
<i>Age < 50</i>																		
In Situ	114	16.0	8.4	73	16.9	8.3	38	14.5	8.5	-	-	-	3	16.7	8.3	4	16.8	6.0
Localized	319	44.8	23.0	198	45.9	22.5	111	42.6	24.1	-	-	-	7	46.2	22.9	10	46.7	15.9
Regional	233	32.7	16.7	137	31.8	15.5	90	34.4	19.2	-	-	-	5	32.1	15.9	7	32.7	11.0
Distant	40	5.6	2.9	19	4.5	2.2	20	7.7	4.2	-	-	-	-	-	-	-	-	-
Unknown	6	0.9	0.4	4	0.9	0.4	2	0.8	0.4	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	589	17.0	69.8	387	16.2	66.2	196	18.6	81.6	-	-	-	4	17.7	37.3	12	17.8	55.9
Localized	1,845	53.1	219.3	1,322	55.5	224.2	505	47.8	214.1	-	-	-	12	50.0	102.0	36	52.9	173.2
Regional	785	22.6	93.1	516	21.7	88.1	261	24.7	108.6	-	-	-	6	22.6	45.5	14	20.8	64.0
Distant	206	5.9	24.3	126	5.3	21.0	78	7.4	32.8	-	-	-	-	-	-	-	-	-
Unknown	50	1.4	5.9	32	1.4	5.2	17	1.6	8.0	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	5	0.2	0.2	3	0.2	0.2	2	0.3	0.3	-	-	-	-	-	-	-	-	-
Localized	368	18.5	15.8	262	19.2	15.3	102	17.1	17.7	-	-	-	2	14.7	7.7	3	15.0	5.1
Regional	448	22.5	18.6	310	22.7	17.6	134	22.4	22.2	-	-	-	3	21.3	8.8	2	7.5	1.9
Distant	1,087	54.8	44.7	738	53.9	41.7	337	56.4	55.0	-	-	-	9	62.7	27.5	15	71.0	21.4
Unknown	78	3.9	3.5	54	3.9	3.2	23	3.8	4.2	-	-	-	-	-	-	1	5.6	2.3
<i>Female</i>																		
In Situ	3	0.2	0.1	2	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	350	22.3	12.1	278	23.6	13.5	70	18.6	8.6	-	-	-	1	14.3	3.3	5	22.8	6.9
Regional	375	23.9	12.8	278	23.6	13.4	93	24.7	11.4	-	-	-	3	30.6	8.7	4	16.7	5.2
Distant	776	49.5	26.6	569	48.4	27.6	199	52.8	24.8	-	-	-	5	49.0	14.5	13	56.1	17.1
Unknown	64	4.1	2.2	49	4.1	2.3	14	3.7	1.8	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,666	78.3	102.5	1,692	78.3	89.9	937	78.5	140.6	1	100.0	62.9	12	75.6	34.1	49	74.1	70.8
Regional	452	13.3	16.4	299	13.8	15.2	149	12.5	20.1	-	-	-	2	12.8	5.4	9	13.3	11.8
Distant	193	5.7	8.3	114	5.3	6.8	76	6.4	13.0	-	-	-	1	7.7	3.7	5	8.1	8.6
Unknown	92	2.7	4.1	57	2.7	3.4	32	2.7	6.2	-	-	-	-	-	-	3	4.5	4.9
<i>Age < 65</i>																		
Localized	1,156	77.8	44.1	667	77.7	36.4	473	77.7	64.4	-	-	-	4	71.4	9.3	20	74.4	22.5
Regional	240	16.2	9.2	146	17.0	8.0	92	15.2	12.6	-	-	-	-	-	-	4	16.5	5.0
Distant	65	4.4	2.4	31	3.6	1.7	33	5.4	4.4	-	-	-	-	-	-	2	6.8	2.0
Unknown	26	1.7	1.0	15	1.7	0.8	10	1.7	1.4	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,510	78.8	505.5	1,025	78.6	459.3	464	79.3	667.4	-	-	-	8	78.0	205.2	29	73.9	404.7
Regional	212	11.0	66.3	153	11.8	64.9	56	9.6	71.7	-	-	-	-	-	-	4	11.1	58.6
Distant	128	6.7	49.0	83	6.3	42.1	43	7.4	72.7	-	-	-	-	-	-	4	9.0	54.2
Unknown	67	3.5	25.4	43	3.3	21.3	22	3.7	39.5	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Maine, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	23	51.6	3.3	22	51.6	3.3	-	-	-	-	-	-	-	-	-	-	-	-
Regional	15	33.5	1.9	14	33.3	1.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	6	13.6	0.7	6	13.6	0.7	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	15	4.2	1.6	15	4.3	1.7	-	-	-	-	-	-	-	-	-	-	-	-
Localized	141	38.8	16.4	138	38.7	16.3	-	-	-	-	-	-	-	-	-	-	-	-
Regional	116	31.9	13.5	114	32.0	13.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	71	19.7	8.3	69	19.5	8.3	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	20	5.4	2.4	20	5.5	2.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	12	38.5	3.0	11	38.3	3.0	-	-	-	-	-	-	-	-	-	-	-	-
Regional	11	34.0	2.7	10	34.2	2.7	-	-	-	-	-	-	-	-	-	-	-	-
Distant	8	24.4	1.9	7	24.2	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	129	38.9	51.6	126	38.7	51.3	-	-	-	-	-	-	-	-	-	-	-	-
Regional	105	31.7	42.0	104	31.8	42.1	-	-	-	-	-	-	-	-	-	-	-	-
Distant	64	19.2	25.2	62	19.1	25.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	11	3.3	1.2	11	3.2	1.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	129	37.6	13.1	126	37.4	13.0	-	-	-	-	-	-	-	-	-	-	-	-
Regional	117	34.1	11.7	116	34.3	11.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	65	19.0	6.8	64	19.1	6.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	21	6.1	1.8	20	6.0	1.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	1	3.5	0.3	1	3.6	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	15	42.7	3.6	14	41.8	3.6	-	-	-	-	-	-	-	-	-	-	-	-
Regional	10	30.4	2.6	10	30.9	2.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	8	22.8	1.9	8	23.6	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	10	3.2	3.4	10	3.2	3.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	115	37.0	38.0	112	36.9	37.8	-	-	-	-	-	-	-	-	-	-	-	-
Regional	107	34.5	35.7	105	34.7	35.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	58	18.6	19.7	56	18.6	19.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	20	6.7	6.3	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Maine, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	271	18.4	29.4	266	18.4	29.4	-	-	-	-	-	-	2	27.8	19.5	-	-	-
Localized	836	56.7	87.0	823	56.9	87.4	3	51.7	49.5	3	51.6	122.8	3	47.2	35.0	5	69.4	71.4
Regional	295	20.0	33.2	289	20.0	33.4	-	-	-	2	29.0	51.4	1	19.4	13.5	2	22.2	21.0
Distant	59	4.0	6.1	57	3.9	5.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	13	0.9	1.2	13	0.9	1.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	50	20.7	12.1	48	20.4	12.0	-	-	-	-	-	-	-	-	-	-	-	-
Localized	115	47.7	28.4	111	47.8	28.5	1	46.2	22.0	-	-	-	2	47.1	23.5	1	77.8	23.6
Regional	69	28.4	17.1	67	28.8	17.4	-	-	-	-	-	-	-	-	-	-	-	-
Distant	7	2.8	1.7	6	2.6	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	221	18.0	74.7	218	18.0	75.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	721	58.5	240.3	712	58.6	241.5	2	56.3	121.3	-	-	-	2	47.4	65.2	4	66.7	196.7
Regional	226	18.4	75.3	222	18.3	75.3	-	-	-	2	34.6	186.0	-	-	-	-	-	-
Distant	52	4.2	17.5	51	4.2	17.4	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.2	0.2	2	0.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	148	20.7	16.9	147	20.7	17.0	-	-	-	-	-	-	-	-	-	-	-	-
Regional	175	24.4	19.2	171	24.2	19.2	1	36.8	16.9	1	35.3	34.0	-	-	-	-	-	-
Distant	350	48.7	39.0	346	48.8	39.2	1	31.6	25.5	2	47.1	53.1	-	-	-	-	-	-
Unknown	44	6.1	5.2	43	6.1	5.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.3	0.2	2	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	167	24.6	16.4	166	24.7	16.5	-	-	-	-	-	-	-	-	-	-	-	-
Regional	168	24.6	16.2	166	24.7	16.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	311	45.7	30.3	305	45.5	30.3	-	-	-	2	62.5	56.2	2	66.7	24.9	-	-	-
Unknown	33	4.8	2.9	33	4.9	3.0	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	611	71.4	62.2	595	71.7	61.7	5	76.5	77.8	3	76.5	88.7	-	-	-	2	70.6	41.1
Regional	130	15.2	12.5	127	15.3	12.4	-	-	-	-	-	-	-	-	-	-	-	-
Distant	89	10.4	10.4	87	10.5	10.3	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	26	3.0	3.1	20	2.5	2.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	231	73.9	24.5	222	74.2	24.2	3	82.4	35.3	-	-	-	-	-	-	-	-	-
Regional	57	18.2	5.9	56	18.7	5.9	-	-	-	-	-	-	-	-	-	-	-	-
Distant	19	6.1	2.1	18	6.1	2.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	6	1.8	0.6	3	0.9	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	380	70.0	322.5	373	70.4	321.1	2	70.6	371.7	-	-	-	-	-	-	-	-	-
Regional	73	13.4	58.3	71	13.4	57.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	70	12.9	67.6	69	13.0	67.4	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	20	3.7	20.1	18	3.3	18.0	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Maryland, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	92	41.8	2.9	58	45.1	3.1	25	35.0	2.4	Insufficient data for the calculation of AI/AN PRCA statistics			5	40.0	2.1	10	55.4	4.1
Regional	73	33.1	2.1	42	32.7	2.1	24	33.3	2.1				4	35.0	1.8	6	33.7	3.0
Distant	34	15.6	1.0	19	14.9	0.9	14	19.5	1.3				1	11.7	0.6	-	-	-
Unknown	21	9.5	0.6	9	7.3	0.5	9	12.1	0.8				2	13.3	0.7	-	-	-

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
Male																		
All Ages																		
In Situ	166	11.9	5.1	115	12.3	5.1	37	9.5	4.5				10	16.1	5.3	4	11.2	3.0
Localized	396	28.2	12.9	273	29.4	13.0	104	26.5	13.7				15	24.8	8.7	9	24.7	5.4
Regional	432	30.9	14.2	292	31.4	14.1	117	29.7	15.3				20	32.2	10.5	13	35.4	8.4
Distant	269	19.2	8.8	170	18.3	8.1	86	22.0	11.5				9	14.8	5.1	6	15.7	3.5
Unknown	138	9.9	4.7	79	8.5	3.9	48	12.3	6.7				8	12.2	4.1	5	12.9	3.7
Age < 50																		
In Situ	13	8.3	0.7	10	9.6	0.8	2	5.0	0.4				-	-	-	-	-	-
Localized	42	26.2	2.2	29	28.7	2.5	10	21.8	1.8				2	27.3	1.7	3	26.0	1.1
Regional	60	37.0	3.2	37	36.7	3.2	18	37.7	3.1				3	34.1	2.1	5	46.0	2.1
Distant	35	21.6	1.9	20	19.9	1.8	12	25.5	2.1				2	20.5	1.3	2	22.0	1.0
Unknown	11	6.9	0.6	5	5.2	0.5	5	10.0	0.8				-	-	-	-	-	-
Age ≥ 50																		
In Situ	153	12.3	16.5	105	12.7	16.4	35	10.1	15.3				-	-	-	4	15.6	11.0
Localized	354	28.5	40.9	244	29.5	40.5	93	27.1	44.9				13	24.3	27.2	6	24.2	16.5
Regional	373	30.1	43.2	255	30.8	42.5	99	28.6	47.1				17	31.8	32.6	8	31.3	24.8
Distant	234	18.9	26.9	150	18.1	24.7	74	21.5	36.0				7	13.9	15.3	3	13.3	9.9
Unknown	127	10.2	15.3	74	9.0	12.8	44	12.7	22.1				-	-	-	-	-	-
Insufficient data for the calculation of AI/AN PRCD ¹ statistics																		
Female																		
All Ages																		
In Situ	150	10.8	3.9	94	10.6	3.8	43	10.4	3.9				8	14.5	3.5	3	9.0	1.8
Localized	423	30.5	11.4	278	31.3	11.5	124	29.8	11.6				14	25.5	6.5	10	32.7	6.1
Regional	426	30.8	11.5	278	31.3	11.3	124	29.8	11.9				18	33.5	8.6	10	30.8	6.3
Distant	252	18.2	6.7	160	17.9	6.5	82	19.8	7.8				6	11.6	2.9	6	17.9	3.2
Unknown	135	9.7	3.5	80	9.0	3.0	42	10.1	4.0				8	14.9	4.0	3	9.6	1.9
Age < 50																		
In Situ	15	9.0	0.8	8	8.5	0.7	5	8.4	0.7				1	14.6	0.9	-	-	-
Localized	54	31.2	2.7	34	34.5	3.0	16	27.7	2.4				2	25.0	1.5	3	36.6	1.5
Regional	52	30.4	2.6	29	29.7	2.6	19	32.6	2.7				3	27.1	1.6	3	34.1	1.5
Distant	38	22.1	1.9	21	21.2	1.9	13	23.5	1.9				2	20.8	1.3	2	22.0	1.0
Unknown	12	7.2	0.6	6	6.1	0.5	4	7.7	0.7				1	12.5	0.7	-	-	-
Age ≥ 50																		
In Situ	135	11.1	12.2	86	10.8	11.9	38	10.7	12.2				7	14.5	10.6	-	-	-
Localized	369	30.4	34.1	244	30.8	33.6	108	30.2	35.9				12	25.6	19.7	7	31.3	18.2
Regional	374	30.8	34.6	249	31.4	34.1	106	29.4	35.9				16	34.8	27.2	7	29.6	19.1
Distant	214	17.6	19.4	139	17.5	18.7	69	19.2	23.3				4	9.7	7.3	4	16.5	9.1
Unknown	122	10.1	10.9	74	9.4	9.5	38	10.5	12.6				7	15.4	12.6	3	13.0	6.9

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Maryland, 2013-2017**

Female Breast, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,162	19.2	31.8	704	18.2	30.8	375	20.6	33.9				67	23.7	28.5	27	18.2	13.6
Localized	3,042	50.2	81.7	2,073	53.4	86.7	812	44.6	74.6				125	44.4	54.0	69	45.8	38.1
Regional	1,370	22.6	38.1	820	21.1	35.9	463	25.4	42.7				68	24.1	29.4	39	26.0	20.0
Distant	285	4.7	7.6	166	4.3	6.8	107	5.8	9.8				10	3.5	4.3	7	4.5	3.7
Unknown	206	3.4	5.5	117	3.0	4.5	66	3.6	6.3				12	4.2	5.4	8	5.5	5.0
<i>Age < 50</i>																		
In Situ	263	21.7	13.3	154	22.8	13.6	77	19.0	11.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			24	25.9	15.0	10	18.5	5.7
Localized	516	42.7	26.1	306	45.3	27.2	164	40.3	24.4				35	36.9	21.2	23	41.7	12.6
Regional	353	29.2	18.0	183	27.1	16.4	131	32.2	19.7				29	31.0	17.6	16	29.2	8.3
Distant	46	3.8	2.3	19	2.8	1.7	24	5.8	3.5				2	2.3	1.3	3	5.2	1.5
Unknown	32	2.7	1.7	13	1.9	1.2	11	2.7	1.7				4	3.8	2.2	3	5.5	1.7
<i>Age ≥ 50</i>																		
In Situ	899	18.5	80.2	550	17.2	75.9	297	21.0	92.7				42	22.6	63.8	17	18.1	34.4
Localized	2,527	52.0	227.3	1,767	55.1	242.5	648	45.8	205.9				90	48.2	139.9	46	48.1	104.9
Regional	1,017	20.9	90.7	636	19.9	86.8	332	23.4	102.9				39	20.7	60.0	23	24.2	50.7
Distant	239	4.9	21.5	147	4.6	20.1	83	5.9	26.3				8	4.1	11.9	4	4.2	9.3
Unknown	174	3.6	15.4	104	3.2	13.4	55	3.9	18.5				8	4.4	13.9	5	5.4	13.9

Lung and Bronchus, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>
Stage at Diagnosis																		
Male																		
In Situ	4	0.2	0.1	3	0.2	0.1	-	-	-				-	-	-	-	-	-
Localized	390	20.5	13.2	295	21.5	14.1	83	17.7	12.0				10	18.9	6.5	3	17.4	3.4
Regional	450	23.7	14.8	333	24.3	15.5	102	21.8	14.0				13	24.4	8.2	3	17.4	3.4
Distant	884	46.5	28.9	627	45.8	29.2	224	47.7	30.2				27	50.7	16.6	10	55.4	10.4
Unknown	175	9.2	6.0	112	8.2	5.4	59	12.5	8.6				3	5.9	2.1	2	9.8	2.3
Female																		
In Situ	8	0.4	0.2	6	0.4	0.2	2	0.4	0.2				-	-	-	-	-	-
Localized	525	26.4	13.8	384	27.0	15.1	129	25.3	12.6				10	20.6	4.8	5	20.9	3.1
Regional	452	22.7	11.9	325	22.8	12.9	117	22.8	10.8				10	20.6	4.7	4	20.0	2.7
Distant	847	42.6	22.0	599	42.1	23.3	220	43.1	20.5				23	49.8	10.7	9	40.9	6.5
Unknown	157	7.9	4.0	109	7.6	4.0	43	8.4	4.3				4	8.6	2.3	4	18.2	3.2

Prostate, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
Stage at Diagnosis																		
All Ages																		
Localized	2,582	61.5	75.5	1,485	60.5	63.2	1,003	63.9	115.5				69	61.0	37.2	51	69.2	41.0
Regional	424	10.1	11.8	270	11.0	11.0	138	8.8	14.6				14	12.0	6.8	8	10.3	5.4
Distant	224	5.3	7.5	127	5.2	6.1	88	5.6	12.1				6	5.5	4.2	4	5.9	4.9
Unknown	965	23.0	29.8	573	23.3	25.3	340	21.7	44.2				24	21.5	13.7	11	14.6	11.0
Age < 65																		
Localized	1,234	64.7	35.9	625	63.4	26.9	570	67.1	61.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			28	63.6	14.1	28	73.0	15.5
Regional	247	13.0	7.2	144	14.6	6.2	94	11.1	10.1				7	17.1	3.8	5	14.3	3.0
Distant	65	3.4	1.9	28	2.8	1.2	36	4.2	3.8				-	-	-	1	3.7	0.8
Unknown	360	18.9	10.2	190	19.2	8.0	150	17.6	15.9				8	17.5	3.7	3	9.0	1.9
Age ≥ 65																		
Localized	1,347	58.9	349.5	860	58.6	314.0	433	60.2	491.0				42	59.4	197.4	24	65.2	216.8
Regional	177	7.7	43.5	126	8.6	43.8	44	6.1	45.8				6	8.9	27.5	2	6.1	21.8
Distant	160	7.0	46.5	99	6.7	39.7	52	7.3	69.7				-	-	-	3	8.3	33.6
Unknown	605	26.4	165.4	383	26.1	145.5	191	26.5	239.8				17	24.0	82.4	7	20.4	73.8

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Massachusetts, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	90	46.0	2.6	71	45.9	2.5	9	40.2	3.1	-	-	-	7	48.6	2.7	10	42.3	3.3
Regional	72	36.8	1.9	56	36.3	1.7	9	40.2	3.3	-	-	-	6	42.9	2.6	11	43.1	3.6
Distant	28	14.4	0.7	23	14.8	0.6	4	17.0	1.3	-	-	-	1	8.6	0.6	3	12.2	1.2
Unknown	5	2.7	0.1	5	3.0	0.1	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	69	4.6	1.8	63	4.7	1.8	2	2.2	1.2	-	-	-	2	4.1	1.2	3	4.5	1.5
Localized	585	38.5	16.1	512	38.2	15.9	36	35.7	16.0	-	-	-	25	45.8	14.9	25	38.0	12.2
Regional	506	33.3	14.0	451	33.6	14.0	33	32.3	14.7	-	-	-	17	31.7	10.6	24	35.8	12.3
Distant	290	19.1	7.9	253	18.9	7.7	26	25.4	11.9	-	-	-	8	14.4	4.6	12	18.1	5.6
Unknown	69	4.5	2.0	61	4.6	2.0	4	4.4	2.4	-	-	-	2	4.1	1.8	2	3.6	1.8
<i>Age < 50</i>																		
In Situ	4	2.4	0.2	3	2.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	57	33.1	2.7	49	34.0	2.8	4	24.7	2.2	-	-	-	3	35.0	1.8	6	40.0	2.6
Regional	65	37.9	3.1	55	38.2	3.2	6	39.5	3.5	-	-	-	2	30.0	1.4	5	33.8	2.3
Distant	43	24.8	2.0	34	23.8	2.0	6	34.6	3.0	-	-	-	2	27.5	1.3	3	20.0	1.3
Unknown	3	1.7	0.1	3	1.8	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	65	4.8	6.0	60	5.0	6.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	528	39.2	51.1	463	38.7	50.1	32	37.8	52.3	-	-	-	22	47.6	49.1	19	37.3	37.4
Regional	440	32.7	42.3	396	33.1	42.3	26	31.0	44.1	-	-	-	15	32.0	34.7	18	36.5	38.7
Distant	247	18.4	23.3	219	18.3	22.9	20	23.6	35.4	-	-	-	6	12.1	13.3	9	17.5	17.0
Unknown	66	4.9	6.9	59	4.9	6.7	4	5.2	8.7	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	51	3.5	1.1	45	3.5	1.1	2	2.6	0.8	-	-	-	2	4.6	1.1	3	5.6	1.2
Localized	570	38.9	12.8	508	38.8	12.9	36	39.5	12.2	-	-	-	18	36.5	9.0	22	36.5	8.5
Regional	496	33.8	11.0	445	34.1	11.1	28	31.1	10.1	-	-	-	17	34.4	8.6	23	37.8	9.0
Distant	267	18.2	6.0	236	18.0	6.0	19	21.0	6.8	-	-	-	9	19.1	4.8	11	18.1	4.3
Unknown	82	5.6	1.5	74	5.6	1.5	5	5.7	2.0	-	-	-	3	5.4	1.8	1	2.0	0.6
<i>Age < 50</i>																		
In Situ	5	2.8	0.2	4	2.6	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	69	40.2	3.1	59	40.9	3.3	6	40.6	2.7	-	-	-	3	26.9	1.6	5	33.3	2.1
Regional	57	32.8	2.6	46	31.9	2.6	4	31.9	2.2	-	-	-	5	46.2	2.6	7	40.7	2.8
Distant	40	23.1	1.9	33	23.2	1.9	3	24.6	1.7	-	-	-	3	25.0	1.5	4	23.5	1.6
Unknown	2	1.2	0.1	2	1.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	46	3.6	3.5	42	3.6	3.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	501	38.7	38.2	449	38.6	38.0	30	39.3	37.0	-	-	-	15	39.2	28.4	17	37.7	25.3
Regional	440	34.0	33.1	400	34.3	33.2	24	31.0	30.7	-	-	-	12	31.2	24.0	16	36.8	25.2
Distant	227	17.5	17.0	202	17.4	16.8	16	20.3	20.1	-	-	-	7	17.5	13.5	7	16.1	11.6
Unknown	80	6.2	5.3	72	6.2	5.1	5	6.8	7.2	-	-	-	3	6.9	6.4	1	2.7	2.3

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Massachusetts, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,634	21.6	39.6	1,443	21.4	40.2	101	23.1	34.3	-	-	-	70	25.9	32.0	76	23.1	26.6
Localized	4,284	56.7	98.7	3,877	57.4	101.1	212	48.5	73.6	2	43.5	28.7	141	52.2	66.0	170	51.6	61.8
Regional	1,319	17.5	32.2	1,149	17.0	32.2	101	23.2	34.2	2	34.8	20.3	52	19.1	23.6	71	21.5	23.9
Distant	245	3.2	5.6	217	3.2	5.6	18	4.2	6.5	-	-	-	6	2.2	2.9	11	3.4	4.1
Unknown	73	1.0	1.5	64	0.9	1.4	5	1.1	1.7	-	-	-	2	0.7	0.9	1	0.4	0.6
<i>Age < 50</i>																		
In Situ	408	27.4	18.7	345	27.9	19.2	28	23.2	13.8	-	-	-	28	27.0	16.4	23	21.6	9.4
Localized	676	45.4	31.0	561	45.5	31.4	52	42.8	25.1	-	-	-	51	48.5	28.7	48	45.4	19.4
Regional	358	24.1	16.6	294	23.8	16.7	34	28.0	16.7	-	-	-	23	22.4	13.1	30	28.6	11.9
Distant	40	2.7	1.9	31	2.5	1.8	6	4.8	2.9	-	-	-	2	1.7	1.0	4	4.2	1.8
Unknown	6	0.4	0.3	3	0.3	0.2	1	1.2	0.7	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,227	20.2	94.4	1,098	19.9	95.3	73	23.1	87.8	-	-	-	42	25.2	72.9	53	23.8	71.6
Localized	3,608	59.5	275.8	3,317	60.1	283.7	161	50.7	200.4	2	55.6	103.9	91	54.5	163.7	122	54.5	172.8
Regional	961	15.8	72.8	856	15.5	72.7	68	21.3	80.2	-	-	-	28	17.0	51.2	41	18.1	55.3
Distant	205	3.4	15.4	186	3.4	15.5	12	3.9	16.1	-	-	-	4	2.5	7.8	7	3.0	10.0
Unknown	67	1.1	4.7	60	1.1	4.6	3	1.0	4.5	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.3	0.2	6	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	612	25.5	16.9	572	26.1	17.5	21	20.2	11.1	-	-	-	14	18.2	9.4	15	23.0	8.7
Regional	543	22.6	14.6	495	22.5	14.8	27	25.1	13.0	-	-	-	16	21.1	11.0	15	24.0	9.1
Distant	1,101	45.9	29.9	995	45.3	30.0	53	50.0	25.3	-	-	-	42	55.2	28.5	31	48.6	18.0
Unknown	137	5.7	4.0	127	5.8	4.1	5	4.5	2.9	-	-	-	4	5.5	3.4	2	3.8	2.2
<i>Female</i>																		
In Situ	16	0.6	0.4	15	0.6	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	856	31.2	18.9	800	31.2	19.7	35	32.7	12.7	-	-	-	14	23.1	7.6	19	31.8	8.5
Regional	623	22.7	13.6	588	23.0	14.4	22	20.6	7.8	-	-	-	9	15.9	5.4	16	26.7	6.9
Distant	1,099	40.0	23.8	1,014	39.6	24.4	45	41.9	15.9	-	-	-	32	53.9	17.3	23	38.9	9.6
Unknown	154	5.6	3.0	145	5.7	3.1	5	4.5	1.9	-	-	-	3	5.8	2.1	1	2.4	0.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	3,022	73.1	74.6	2,527	72.7	69.7	276	74.1	113.2	1	66.7	14.9	64	76.5	40.3	138	73.0	68.4
Regional	672	16.3	15.9	583	16.8	15.3	59	15.8	24.2	-	-	-	14	16.2	8.6	31	16.3	15.1
Distant	276	6.7	7.7	236	6.8	7.3	28	7.4	15.5	-	-	-	5	6.2	3.8	14	7.2	8.8
Unknown	163	3.9	4.4	127	3.7	3.9	10	2.7	5.8	-	-	-	-	-	-	7	3.5	4.7
<i>Age < 65</i>																		
Localized	1,362	74.5	33.6	1,099	73.7	30.6	163	77.7	60.3	-	-	-	25	77.5	13.4	75	75.7	31.0
Regional	354	19.4	8.7	305	20.4	8.4	35	16.9	13.1	-	-	-	5	15.6	2.7	16	16.6	6.7
Distant	69	3.8	1.7	56	3.8	1.5	8	3.9	3.0	-	-	-	2	6.3	1.1	5	5.3	2.2
Unknown	44	2.4	1.1	33	2.2	0.9	3	1.5	1.2	-	-	-	-	-	-	2	2.4	1.0
<i>Age ≥ 65</i>																		
Localized	1,660	72.1	358.2	1,428	72.1	339.8	114	69.5	478.2	-	-	-	40	75.9	226.7	63	70.1	326.9
Regional	318	13.8	65.6	278	14.1	63.0	24	14.4	100.8	-	-	-	9	16.5	49.3	14	15.9	73.6
Distant	207	9.0	49.7	180	9.1	47.4	19	11.8	101.3	-	-	-	3	6.1	22.8	8	9.3	54.6
Unknown	119	5.1	27.6	95	4.8	24.3	7	4.3	38.0	-	-	-	-	-	-	4	4.6	30.3

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Michigan, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	157	45.5	3.3	127	46.4	3.3	22	39.6	3.0	-	-	-	4	66.7	2.5	6	39.5	3.3
Regional	117	34.0	2.2	91	33.2	2.1	23	41.1	3.1	-	-	-	1	23.3	1.0	7	44.4	4.0
Distant	51	14.9	0.9	42	15.5	0.9	8	14.6	1.0	-	-	-	-	-	-	2	13.6	1.3
Unknown	19	5.6	0.3	13	4.9	0.3	3	4.6	0.4	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	98	4.0	1.7	83	4.1	1.6	10	3.1	1.6	-	-	-	1	3.6	1.2	3	6.1	2.0
Localized	845	34.7	15.1	703	34.7	14.5	119	35.3	19.8	3	23.8	17.2	10	31.3	9.0	13	29.4	10.0
Regional	832	34.2	15.1	703	34.7	14.8	106	31.4	17.7	6	46.0	28.5	12	36.1	12.1	17	36.8	12.4
Distant	486	20.0	8.8	392	19.3	8.2	81	24.0	13.4	3	22.2	15.9	8	22.9	6.4	11	23.7	9.2
Unknown	174	7.1	3.2	144	7.1	3.1	21	6.2	3.8	-	-	-	2	6.0	2.2	2	3.9	1.4
<i>Age < 50</i>																		
In Situ	6	2.3	0.2	5	2.6	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	78	29.0	2.6	62	29.4	2.5	14	28.9	3.3	-	-	-	-	-	-	2	28.6	1.5
Regional	100	37.0	3.3	80	38.1	3.3	16	33.9	3.9	1	43.8	9.7	1	26.1	1.0	5	57.1	3.2
Distant	72	26.8	2.4	54	25.4	2.2	15	30.5	3.5	1	37.5	8.7	3	56.5	2.2	1	14.3	0.9
Unknown	13	4.9	0.4	10	4.5	0.4	3	5.4	0.6	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	92	4.2	5.4	78	4.3	5.3	-	-	-	-	-	-	1	4.2	4.3	3	7.5	7.2
Localized	767	35.4	48.0	641	35.4	46.0	105	36.4	63.0	-	-	-	-	-	-	11	29.6	32.1
Regional	732	33.8	45.9	623	34.3	44.8	90	31.0	53.6	4	46.8	77.7	11	37.8	41.1	12	32.3	36.6
Distant	414	19.1	25.6	338	18.6	24.0	66	22.9	39.5	2	17.0	35.0	5	17.5	17.5	10	25.8	31.1
Unknown	161	7.4	10.5	134	7.4	10.0	18	6.3	12.3	-	-	-	-	-	-	2	4.8	4.9
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	83	3.6	1.3	71	3.8	1.3	9	2.7	1.0	-	-	-	-	-	-	2	5.9	1.4
Localized	780	34.3	12.0	640	34.0	11.7	119	35.9	14.6	3	34.1	11.6	8	30.6	6.4	13	34.1	9.1
Regional	780	34.3	11.9	662	35.1	11.8	103	31.1	13.0	3	31.7	12.4	8	31.3	6.9	11	30.3	7.4
Distant	457	20.1	7.0	364	19.3	6.6	81	24.4	10.0	2	29.3	12.2	8	28.4	5.7	8	22.7	5.8
Unknown	175	7.7	2.5	148	7.9	2.4	19	5.9	2.4	-	-	-	2	6.7	1.7	3	7.0	2.0
<i>Age < 50</i>																		
In Situ	9	3.5	0.3	7	3.8	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	82	33.6	2.7	65	34.0	2.7	14	32.4	2.9	-	-	-	-	-	-	3	32.5	1.7
Regional	83	34.0	2.8	66	34.3	2.7	15	35.2	3.2	-	-	-	1	24.0	1.0	2	27.5	1.5
Distant	60	24.6	2.0	45	23.3	1.9	12	28.2	2.5	-	-	-	2	48.0	1.9	2	27.5	1.6
Unknown	10	4.2	0.3	9	4.6	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	74	3.7	3.9	64	3.8	3.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	698	34.4	36.5	575	34.0	35.0	105	36.5	45.3	-	-	-	-	-	-	10	34.5	28.4
Regional	696	34.3	35.9	596	35.2	35.6	88	30.5	38.6	-	-	-	7	33.0	22.2	9	31.0	22.9
Distant	397	19.5	20.2	319	18.8	18.9	69	23.8	29.8	-	-	-	5	23.9	15.6	6	21.4	16.8
Unknown	165	8.1	8.0	139	8.2	7.8	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Michigan, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,976	20.4	32.0	1,618	19.9	31.5	287	22.6	35.5	9	27.4	41.7	36	22.5	23.7	39	25.2	24.9
Localized	5,018	51.8	78.7	4,327	53.2	80.2	565	44.6	71.0	12	36.3	53.5	82	51.8	56.0	70	44.8	45.5
Regional	2,051	21.2	34.0	1,680	20.7	33.4	312	24.6	39.2	9	27.4	42.4	34	21.4	22.2	37	23.9	22.2
Distant	445	4.6	6.9	345	4.2	6.4	90	7.1	11.2	1	4.2	5.1	5	3.3	3.5	8	4.9	5.1
Unknown	195	2.0	2.9	160	2.0	2.8	12	1.0	1.6	2	4.8	8.1	2	1.0	1.1	2	1.3	1.3
<i>Age < 50</i>																		
In Situ	389	23.0	13.0	316	23.3	13.3	48	19.7	10.2	3	33.3	19.6	15	24.9	12.2	13	25.3	9.4
Localized	733	43.3	24.4	594	43.8	24.9	101	41.4	21.6	2	26.2	15.2	28	48.5	23.6	19	39.0	13.9
Regional	478	28.3	16.1	379	28.0	16.2	77	31.6	16.4	3	33.3	19.4	14	23.2	11.2	16	31.3	10.9
Distant	68	4.0	2.3	49	3.6	2.1	15	6.2	3.2	-	-	-	2	3.4	1.6	2	3.6	1.2
Unknown	23	1.4	0.8	17	1.3	0.7	3	1.1	0.6	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,587	19.9	81.8	1,302	19.2	79.0	239	23.3	101.7	6	25.4	99.8	21	21.1	53.9	27	25.1	65.4
Localized	4,285	53.6	221.1	3,733	55.1	225.2	464	45.4	200.5	10	39.7	153.9	53	53.7	140.8	50	47.5	128.2
Regional	1,572	19.7	80.7	1,301	19.2	78.4	235	23.0	98.9	6	25.4	102.6	20	20.3	51.0	22	20.4	51.9
Distant	377	4.7	19.2	296	4.4	17.6	75	7.3	32.1	-	-	-	3	3.2	8.3	6	5.5	15.1
Unknown	172	2.1	8.5	143	2.1	8.2	10	1.0	4.3	-	-	-	2	1.6	4.1	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.2	0.1	6	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	784	19.2	14.1	688	19.6	14.1	84	16.7	14.8	4	16.5	23.5	5	16.1	5.9	6	16.1	5.9
Regional	912	22.3	15.9	790	22.5	15.7	105	21.0	18.6	6	26.6	27.8	6	19.6	5.4	8	20.8	7.2
Distant	2,038	49.8	35.5	1,706	48.6	34.0	288	57.3	48.4	9	42.2	48.9	17	59.4	16.9	19	50.0	17.3
Unknown	350	8.6	6.4	317	9.0	6.6	24	4.9	4.5	3	14.7	17.0	1	4.9	2.0	5	13.0	5.2
<i>Female</i>																		
In Situ	14	0.4	0.2	12	0.3	0.2	2	0.5	0.3	-	-	-	-	-	-	-	-	-
Localized	894	23.0	13.2	785	23.6	13.5	92	19.6	11.3	4	14.7	17.5	6	19.8	5.6	8	18.3	5.8
Regional	886	22.8	13.1	759	22.8	13.1	107	22.7	13.1	8	31.0	41.3	7	22.8	6.3	7	16.3	5.3
Distant	1,812	46.6	26.6	1,525	45.8	26.3	246	52.1	30.0	10	40.3	48.4	16	50.0	13.3	23	55.3	17.8
Unknown	282	7.2	4.0	248	7.5	4.1	24	5.1	3.0	4	14.0	21.1	2	7.4	1.9	4	8.7	3.0

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	4,701	71.7	76.0	3,774	72.9	70.1	791	75.4	120.4	11	74.3	60.2	42	70.7	39.1	62	69.7	48.3
Regional	951	14.5	14.5	780	15.1	13.7	149	14.1	21.0	3	17.6	10.5	11	18.0	8.6	12	13.3	8.9
Distant	362	5.5	6.5	274	5.3	5.7	80	7.6	13.9	-	-	-	4	7.0	4.7	6	6.8	6.1
Unknown	540	8.2	9.3	349	6.7	6.9	30	2.9	5.6	-	-	-	3	4.3	2.7	9	10.2	8.7
<i>Age < 65</i>																		
Localized	2,009	72.7	32.8	1,521	73.6	28.7	432	75.5	62.9	5	65.8	21.0	16	69.0	12.6	30	72.2	19.1
Regional	487	17.6	7.9	380	18.4	7.1	96	16.8	14.0	-	-	-	6	24.1	4.5	6	14.8	3.9
Distant	109	3.9	1.8	72	3.5	1.4	35	6.1	5.0	-	-	-	-	-	-	3	6.2	1.6
Unknown	158	5.7	2.5	93	4.5	1.7	9	1.6	1.3	-	-	-	-	-	-	3	6.7	1.8
<i>Age ≥ 65</i>																		
Localized	2,692	71.0	374.3	2,252	72.4	355.6	360	75.2	517.7	6	83.3	331.3	26	71.7	221.9	31	67.4	250.0
Regional	464	12.2	60.6	401	12.9	59.6	52	10.9	69.4	-	-	-	5	14.1	37.4	6	12.0	43.0
Distant	253	6.7	39.2	202	6.5	35.4	45	9.5	75.7	-	-	-	-	-	-	3	7.3	37.3
Unknown	382	10.1	56.6	256	8.2	43.0	21	4.4	35.1	-	-	-	-	-	-	6	13.3	56.5

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Metropolitan Detroit, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	61	43.0	3.0	43	44.8	3.2	15	36.8	2.8	Insufficient data for the calculation of AI/AN PRCDA statistics			2	60.0	2.2	3	33.3	3.4
Regional	53	37.6	2.5	35	35.9	2.3	17	41.6	3.2				1	40.0	1.5	3	41.0	4.9
Distant	24	17.0	1.0	17	17.4	1.0	7	17.7	1.3				-	-	-	2	25.6	3.1
Unknown	3	2.4	0.1	2	1.9	0.1	2	3.8	0.3				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	16	1.6	0.7	8	1.1	0.5	7	2.6	1.4	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	367	36.8	17.6	257	36.4	16.2	100	37.7	23.8				8	38.0	9.8	5	26.5	13.0
Regional	353	35.4	17.2	264	37.4	17.0	81	30.7	19.4				7	33.0	10.5	8	39.2	17.3
Distant	221	22.1	10.7	151	21.3	9.7	64	24.2	15.3				5	25.0	6.6	5	26.5	11.8
Unknown	42	4.2	2.1	27	3.8	1.8	13	4.8	3.6				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	35	30.4	2.9	23	30.1	2.6	11	31.1	4.0				-	-	-	-	-	-
Regional	45	38.7	3.7	31	41.1	3.7	13	35.6	4.8				-	-	-	2	52.4	4.0
Distant	32	27.5	2.6	20	25.9	2.3	10	28.8	3.7				2	60.0	2.3	1	33.3	2.6
Unknown	3	2.6	0.2	2	2.1	0.2	1	3.4	0.4				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	332	37.6	56.2	234	37.1	51.8	89	38.7	75.8				-	-	-	-	-	-
Regional	308	34.9	52.6	233	36.9	51.8	69	30.0	57.9				-	-	-	6	35.8	52.3
Distant	189	21.4	31.9	131	20.8	28.9	54	23.5	45.5				3	18.8	17.6	4	24.7	35.9
Unknown	39	4.4	7.1	25	4.0	6.0	12	5.1	11.9				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	12	1.3	0.5	7	1.0	0.4	5	2.0	0.9	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	354	36.5	13.9	248	36.1	13.3	97	37.2	16.2				5	32.5	6.8	7	38.5	15.1
Regional	340	35.0	13.2	253	36.8	13.3	82	31.2	14.0				5	28.9	6.4	6	29.2	9.8
Distant	221	22.8	8.6	149	21.7	7.9	65	25.0	11.0				6	33.7	6.9	5	26.0	9.8
Unknown	44	4.5	1.5	31	4.5	1.4	12	4.6	1.9				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	2	2.0	0.1	-	-	-	-	-	-				-	-	-	-	-	-
Localized	36	35.6	2.9	23	35.3	2.8	12	36.3	3.4				-	-	-	2	42.1	2.7
Regional	36	35.4	2.9	25	37.5	3.0	11	33.1	3.1				-	-	-	-	-	-
Distant	27	26.0	2.1	16	24.8	2.0	9	27.5	2.6				1	35.3	1.6	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	10	1.2	1.3	-	-	-	-	-	-				-	-	-	-	-	-
Localized	318	36.6	42.8	224	36.1	40.7	86	37.4	49.8				-	-	-	6	37.7	47.5
Regional	304	35.0	40.4	228	36.8	40.4	71	30.9	42.3				-	-	-	-	-	-
Distant	194	22.4	25.4	132	21.3	23.3	57	24.7	33.0				4	33.3	20.8	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Metropolitan Detroit, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	868	20.9	35.6	619	20.3	36.0	220	22.2	37.1				22	22.2	24.3	18	20.3	32.5
Localized	2,111	50.8	85.0	1,604	52.7	89.2	447	45.0	76.3				52	52.6	59.2	44	49.6	78.1
Regional	929	22.4	38.8	657	21.6	38.6	247	24.9	42.6				21	20.8	22.3	22	24.1	35.0
Distant	216	5.2	8.6	139	4.6	7.4	72	7.3	12.2				4	4.0	4.1	5	5.8	10.0
Unknown	32	0.8	1.1	25	0.8	1.2	5	0.5	0.9				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	181	23.4	14.3	132	24.5	15.8	37	19.3	10.8	Insufficient data for the calculation of AI/AN PRCDA statistics			9	26.5	12.5	4	16.8	8.7
Localized	334	43.3	26.6	238	43.9	28.5	80	41.6	23.5				15	45.3	21.3	12	45.0	22.2
Regional	225	29.1	18.1	153	28.3	18.6	63	32.9	18.7				8	22.9	10.5	9	35.1	17.0
Distant	30	3.9	2.4	16	3.0	2.0	11	5.8	3.3				2	5.3	2.4	-	-	-
Unknown	2	0.3	0.2	2	0.3	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	687	20.3	91.4	487	19.5	88.7	183	22.9	106.1				13	19.9	55.2	14	21.8	94.7
Localized	1,777	52.5	238.0	1,367	54.6	248.4	367	45.8	214.4				37	56.4	158.3	33	51.4	224.7
Regional	704	20.8	93.1	504	20.1	91.0	184	23.0	105.2				13	19.6	53.5	12	19.6	82.0
Distant	187	5.5	24.6	122	4.9	21.7	61	7.7	35.6				2	3.4	8.5	-	-	-
Unknown	29	0.9	3.6	24	1.0	3.8	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.1	0.1	2	0.2	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	302	18.8	15.1	244	20.2	15.8	56	14.9	13.7				2	10.4	4.3	3	14.8	8.1
Regional	349	21.7	17.0	267	22.2	16.8	78	20.9	19.7				3	16.7	4.1	6	26.9	14.7
Distant	891	55.5	42.8	644	53.5	40.5	228	61.3	54.6				14	70.8	21.4	11	51.9	28.9
Unknown	61	3.8	3.1	47	3.9	3.1	10	2.8	2.8				-	-	-	1	6.5	4.7
<i>Female</i>																		
In Situ	4	0.3	0.2	2	0.1	0.1	3	0.7	0.4	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	375	22.7	14.4	305	24.3	15.8	65	17.7	10.7				3	14.0	3.6	4	17.0	6.9
Regional	369	22.4	14.1	282	22.5	14.7	82	22.4	13.4				4	21.5	6.0	3	12.5	6.4
Distant	847	51.4	32.1	624	49.8	32.0	207	56.5	34.2				11	61.3	15.2	15	66.1	31.1
Unknown	53	3.2	1.9	41	3.3	1.9	10	2.8	1.7				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,258	77.9	100.1	1,574	78.6	91.7	618	75.9	135.0	Insufficient data for the calculation of AI/AN PRCDA statistics			36	76.4	51.7	39	83.7	87.3
Regional	418	14.4	17.2	291	14.5	15.8	118	14.5	23.6				7	15.0	8.6	4	9.4	8.1
Distant	171	5.9	8.4	103	5.1	6.6	65	8.0	15.9				3	5.6	4.1	2	5.2	6.3
Unknown	51	1.8	2.5	35	1.7	2.2	14	1.7	3.8				1	3.0	2.4	-	-	-
<i>Age < 65</i>																		
Localized	1,007	76.8	43.4	651	77.7	36.9	330	74.9	70.1	Insufficient data for the calculation of AI/AN PRCDA statistics			12	74.7	15.2	17	82.1	30.2
Regional	235	17.9	10.0	153	18.2	8.6	78	17.7	16.5				3	18.1	3.8	2	10.4	3.7
Distant	55	4.2	2.4	26	3.1	1.5	29	6.5	6.0				-	-	-	1	5.7	2.1
Unknown	13	1.0	0.6	8	0.9	0.4	4	0.9	0.8				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,251	78.8	492.3	922	79.3	470.6	288	77.0	583.4				23	77.3	304.0	22	85.0	481.6
Regional	183	11.5	66.7	138	11.8	65.6	40	10.6	72.6				4	13.3	42.0	2	8.7	38.4
Distant	115	7.3	49.8	77	6.6	42.3	36	9.7	84.4				-	-	-	1	4.7	35.6
Unknown	38	2.4	16.0	27	2.3	14.2	10	2.6	23.8				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Minnesota, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	79	51.2	3.0	69	54.3	3.1	3	35.4	2.4	Insufficient data for the calculation of AI/AN PRCA statistics			4	36.7	2.8	4	45.5	4.1
Regional	47	30.7	1.6	37	28.6	1.4	4	41.7	3.6				4	40.8	3.5	3	36.4	4.1
Distant	18	11.6	0.6	15	11.4	0.5	1	14.6	1.3				-	-	-	1	13.6	1.9
Unknown	10	6.5	0.3	7	5.6	0.3	-	-	-				1	12.2	1.0	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	24	1.9	0.8	23	1.9	0.8	1	2.6	1.8	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	474	37.3	16.0	439	37.5	15.9	19	41.9	16.5				9	32.4	11.7	9	38.6	17.8
Regional	436	34.3	14.9	401	34.2	14.6	14	29.7	14.9				12	43.2	14.3	6	27.2	10.9
Distant	252	19.9	8.6	231	19.7	8.5	10	21.4	11.8				6	20.9	7.8	6	28.1	10.3
Unknown	84	6.6	3.1	78	6.7	3.0	2	4.4	3.5				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	1	0.9	0.1	-	-	-	-	-	-				-	-	-	-	-	-
Localized	50	33.4	2.9	44	34.1	3.0	5	49.0	3.9				1	15.0	1.4	2	38.7	2.3
Regional	54	35.5	3.2	45	35.2	3.1	2	24.5	2.3				4	55.0	4.8	2	29.0	1.9
Distant	39	25.8	2.3	33	25.9	2.3	2	22.4	2.1				2	25.0	2.1	2	25.8	1.8
Unknown	7	4.4	0.4	5	4.1	0.4	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	23	2.1	2.6	-	-	-	1	3.3	6.5				-	-	-	-	-	-
Localized	424	37.8	50.3	395	37.9	49.9	14	40.0	49.5				8	39.4	38.8	6	38.6	58.4
Regional	382	34.1	45.5	356	34.1	44.9	11	31.1	48.0				8	38.4	39.0	4	26.5	34.7
Distant	213	19.0	25.0	198	18.9	24.5	8	21.1	37.3				4	19.2	22.4	5	28.9	32.4
Unknown	77	6.9	10.1	73	7.0	10.0	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	14	1.2	0.4	13	1.2	0.4	-	-	-	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	424	36.4	12.7	392	36.3	12.5	14	38.2	14.5				9	34.1	10.3	8	35.0	12.1
Regional	410	35.2	12.2	382	35.3	12.0	12	31.7	10.9				9	36.5	10.7	7	31.6	13.1
Distant	220	18.9	6.6	204	18.9	6.6	8	22.6	7.3				5	20.6	5.9	6	24.8	10.2
Unknown	95	8.2	2.5	89	8.2	2.5	2	5.4	2.7				2	7.9	2.2	2	8.5	4.5
<i>Age < 50</i>																		
In Situ	2	1.4	0.1	2	1.5	0.1	-	-	-				-	-	-	-	-	-
Localized	44	34.1	2.6	37	33.7	2.6	4	40.0	3.2				2	29.4	2.2	2	35.5	2.4
Regional	46	35.8	2.8	38	35.2	2.7	3	37.8	3.3				2	35.3	2.6	2	29.0	2.2
Distant	32	24.8	1.9	28	25.8	2.0	2	20.0	1.7				2	23.5	1.8	2	29.0	2.2
Unknown	5	3.9	0.3	4	3.9	0.3	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	13	1.2	1.3	11	1.2	1.3	-	-	-				-	-	-	-	-	-
Localized	380	36.7	39.0	356	36.6	38.5	11	37.6	43.9				7	35.9	31.6	6	34.9	37.6
Regional	364	35.2	36.6	344	35.4	36.5	8	29.8	30.8				7	37.0	31.7	6	32.6	41.6
Distant	188	18.2	18.8	176	18.1	18.7	7	23.4	21.7				4	19.6	16.9	4	23.3	31.1
Unknown	90	8.7	8.3	85	8.7	8.1	2	7.1	9.6				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Minnesota, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	960	18.2	30.2	894	18.1	30.6	28	18.5	23.9				22	21.0	21.6	20	21.9	29.6
Localized	2,869	54.4	87.1	2,718	55.0	88.8	67	44.5	58.8				52	49.7	50.0	42	46.2	63.6
Regional	1,117	21.2	35.8	1,031	20.9	36.0	46	30.1	37.9				26	25.0	24.3	25	27.4	30.0
Distant	206	3.9	6.3	189	3.8	6.2	9	6.1	8.2				4	4.0	3.7	3	2.9	4.4
Unknown	120	2.3	3.3	109	2.2	3.2	1	0.8	1.6				-	-	-	1	1.5	3.5
<i>Age < 50</i>																		
In Situ	197	20.7	12.2	177	21.2	12.6	7	12.8	6.7	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			8	19.5	9.6	5	16.7	6.5
Localized	417	43.9	25.6	369	44.1	26.2	22	40.8	20.6				19	46.2	21.2	13	44.0	16.3
Regional	294	30.9	17.9	256	30.5	18.1	21	39.2	18.9				12	29.0	12.9	11	37.3	13.2
Distant	36	3.8	2.2	29	3.5	2.1	4	6.8	3.4				2	5.2	2.1	-	-	-
Unknown	7	0.8	0.4	7	0.8	0.5	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	763	17.7	77.4	717	17.5	77.8	21	21.5	69.0				14	22.0	53.0	15	24.5	89.9
Localized	2,451	56.7	248.1	2,349	57.2	252.9	46	46.5	158.9				32	52.1	125.5	29	47.4	187.4
Regional	823	19.1	82.5	775	18.9	82.8	25	25.2	87.8				14	22.3	54.0	14	22.5	74.2
Distant	170	3.9	16.9	160	3.9	16.9	6	5.7	20.5				2	3.2	8.1	-	-	-
Unknown	113	2.6	10.9	103	2.5	10.4	-	-	-				-	-	-	1	2.3	12.6

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	5	0.3	0.2	4	0.3	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	428	23.4	14.7	400	23.5	14.6	14	21.7	15.8				7	22.5	11.7	3	16.0	10.2
Regional	406	22.2	13.5	378	22.2	13.3	14	22.9	14.4				6	18.1	8.6	6	26.4	13.9
Distant	858	47.0	28.6	799	46.9	28.2	31	49.4	41.9				16	49.4	24.7	12	54.7	25.2
Unknown	130	7.1	4.6	122	7.1	4.6	3	5.1	4.5				3	10.0	5.9	-	-	-
<i>Female</i>																		
In Situ	5	0.3	0.2	5	0.3	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	491	27.1	14.4	453	26.8	14.1	18	35.8	19.5				6	23.3	6.9	6	34.1	13.9
Regional	373	20.6	10.9	352	20.8	10.9	10	20.5	10.8				4	15.0	3.6	3	20.7	6.8
Distant	791	43.8	22.8	742	43.9	22.6	20	39.4	20.9				13	52.5	15.5	6	37.8	12.5
Unknown	148	8.2	4.1	140	8.3	4.1	2	3.9	3.0				2	9.2	3.1	1	7.3	3.1

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,401	68.1	73.3	2,250	69.4	72.9	106	68.7	103.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			18	61.0	27.0	31	70.8	64.9
Regional	598	17.0	17.5	557	17.2	17.4	27	17.4	24.7				7	24.0	10.7	6	13.4	9.7
Distant	264	7.5	9.2	243	7.5	8.9	14	9.2	19.5				3	11.0	7.0	4	8.3	11.0
Unknown	262	7.4	8.8	194	6.0	6.9	7	4.7	11.0				1	4.1	2.1	3	7.4	9.8
<i>Age < 65</i>																		
Localized	1,029	70.7	30.7	939	71.8	30.1	69	70.3	54.3	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			8	69.6	9.5	14	70.7	18.9
Regional	295	20.3	8.8	269	20.6	8.7	19	19.6	15.2				3	23.2	3.2	4	18.2	5.0
Distant	62	4.3	1.9	54	4.1	1.8	7	6.7	5.3				-	-	-	1	6.1	1.6
Unknown	68	4.7	2.0	46	3.5	1.5	3	3.3	2.6				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,372	66.3	367.6	1,312	67.8	368.6	37	65.8	440.8				10	55.6	148.3	17	70.9	382.7
Regional	303	14.6	77.6	288	14.9	77.3	8	13.5	90.6				4	24.4	63.2	2	9.4	42.4
Distant	201	9.7	59.5	189	9.8	58.2	8	13.5	117.6				-	-	-	2	10.3	75.7
Unknown	193	9.3	55.6	147	7.6	44.5	4	7.1	68.8				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Mississippi, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	62	41.8	4.2	40	47.5	4.6	21	34.2	3.7	-	-	-	-	-	-	-	-	-
Regional	56	38.2	3.5	29	34.1	3.0	27	43.8	4.5	-	-	-	-	-	-	1	70.0	3.8
Distant	23	15.5	1.3	11	13.4	1.1	11	18.4	1.9	-	-	-	-	-	-	-	-	-
Unknown	7	4.5	0.4	4	5.0	0.4	2	3.6	0.4	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	40	4.3	2.5	23	3.9	2.1	16	4.9	3.5	-	-	-	-	-	-	-	-	-
Localized	298	32.2	18.9	194	33.1	17.5	101	30.5	22.0	-	-	-	-	-	-	2	26.2	8.6
Regional	338	36.6	21.5	223	37.9	20.6	113	34.1	24.2	-	-	-	1	53.8	10.0	3	38.1	10.8
Distant	206	22.3	13.2	122	20.7	11.4	84	25.4	18.6	-	-	-	-	-	-	2	28.6	7.5
Unknown	42	4.6	2.9	25	4.3	2.4	17	5.1	4.2	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	3	3.2	0.3	2	3.0	0.3	1	3.5	0.4	-	-	-	-	-	-	-	-	-
Localized	26	27.4	3.0	14	24.0	2.6	11	33.3	3.8	-	-	-	-	-	-	-	-	-
Regional	36	37.5	4.1	25	41.6	4.5	10	29.8	3.3	-	-	-	-	-	-	1	41.2	3.9
Distant	27	28.6	3.2	17	28.0	3.1	10	30.4	3.4	-	-	-	-	-	-	-	-	-
Unknown	3	3.4	0.4	2	3.4	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	37	4.4	8.1	21	4.1	6.8	15	5.1	11.6	-	-	-	-	-	-	-	-	-
Localized	272	32.8	60.5	180	34.1	56.7	89	30.2	69.6	-	-	-	-	-	-	-	-	-
Regional	303	36.5	67.2	198	37.5	62.7	103	34.6	78.7	-	-	-	-	-	-	2	36.0	28.8
Distant	179	21.6	39.6	105	19.9	33.2	73	24.8	58.5	-	-	-	-	-	-	-	-	-
Unknown	39	4.7	9.4	23	4.4	7.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	31	3.9	1.7	17	3.5	1.4	13	4.5	2.1	-	-	-	-	-	-	-	-	-
Localized	272	34.0	14.5	173	34.8	13.7	96	32.8	15.9	-	-	-	2	47.4	12.2	-	-	-
Regional	294	36.8	15.7	186	37.4	14.7	105	35.7	17.6	2	47.6	55.0	1	31.6	7.8	-	-	-
Distant	166	20.8	8.9	101	20.3	8.1	63	21.5	10.7	-	-	-	-	-	-	-	-	-
Unknown	36	4.5	1.9	19	3.9	1.4	16	5.5	2.9	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	3	4.0	0.4	2	4.2	0.4	1	4.1	0.4	-	-	-	-	-	-	-	-	-
Localized	25	29.7	2.7	17	34.6	3.1	8	23.8	2.2	-	-	-	-	-	-	-	-	-
Regional	31	36.8	3.4	16	33.8	3.1	14	39.5	3.7	-	-	-	-	-	-	-	-	-
Distant	22	25.9	2.4	12	24.6	2.2	10	28.5	2.6	-	-	-	-	-	-	-	-	-
Unknown	3	3.6	0.3	1	2.9	0.3	1	4.1	0.4	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	28	3.9	5.0	15	3.4	4.1	12	4.6	6.6	-	-	-	-	-	-	-	-	-
Localized	247	34.5	45.4	156	34.8	41.6	88	34.0	51.9	-	-	-	-	-	-	-	-	-
Regional	263	36.8	47.7	170	37.8	44.9	91	35.2	53.8	-	-	-	-	-	-	-	-	-
Distant	144	20.2	26.0	89	19.9	23.6	53	20.6	31.9	-	-	-	-	-	-	-	-	-
Unknown	33	4.6	6.0	18	4.0	4.5	15	5.7	9.4	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Mississippi, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	450	17.4	24.7	277	16.6	23.5	167	18.7	27.3	-	-	-	5	24.5	28.6	3	18.9	10.5
Localized	1,298	50.2	71.0	900	54.1	73.9	387	43.2	64.8	-	-	-	10	49.0	54.0	8	51.4	29.4
Regional	634	24.5	35.9	372	22.4	32.5	256	28.5	42.7	-	-	-	4	22.4	22.3	3	20.3	12.8
Distant	161	6.2	8.8	88	5.3	7.4	72	8.1	11.8	-	-	-	-	-	-	1	8.1	5.2
Unknown	41	1.6	2.3	27	1.6	2.1	14	1.5	2.5	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	75	16.4	8.3	43	17.0	8.2	30	15.2	8.3	-	-	-	2	29.6	12.4	2	24.2	7.3
Localized	205	44.6	22.6	120	46.9	22.7	82	41.7	22.6	-	-	-	3	48.1	19.5	4	57.6	15.4
Regional	143	31.2	15.7	74	29.0	14.1	68	34.4	18.4	-	-	-	-	-	-	-	-	-
Distant	29	6.4	3.2	14	5.6	2.7	15	7.4	4.0	-	-	-	-	-	-	-	-	-
Unknown	7	1.4	0.7	4	1.5	0.7	3	1.3	0.7	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	375	17.6	67.5	233	16.6	63.4	138	19.7	77.1	-	-	-	3	22.5	71.0	1	14.6	18.8
Localized	1,094	51.5	197.9	780	55.4	207.8	305	43.6	175.4	-	-	-	7	49.3	144.2	4	46.3	66.2
Regional	491	23.1	88.7	298	21.2	80.7	188	26.9	106.4	-	-	-	-	-	-	-	-	-
Distant	132	6.2	23.6	73	5.2	19.6	58	8.3	32.4	-	-	-	-	-	-	-	-	-
Unknown	35	1.6	6.2	23	1.6	5.8	11	1.6	6.9	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	313	20.5	20.2	229	21.8	20.5	84	17.8	19.6	-	-	-	-	-	-	1	20.7	6.7
Regional	371	24.3	23.5	259	24.6	22.8	111	23.6	25.5	-	-	-	1	24.0	10.1	1	24.1	6.4
Distant	773	50.6	49.1	514	48.9	46.0	256	54.4	57.3	-	-	-	3	56.0	25.3	3	44.8	9.9
Unknown	68	4.5	4.7	48	4.6	4.5	20	4.2	5.5	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.2	0.1	2	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	285	25.3	14.7	218	25.8	16.2	65	23.7	11.2	-	-	-	2	25.0	14.9	2	30.8	10.3
Regional	265	23.6	13.6	204	24.2	15.4	59	21.5	9.9	-	-	-	2	22.2	12.1	1	23.1	6.3
Distant	532	47.4	27.4	390	46.3	29.7	138	50.5	23.2	-	-	-	3	47.2	23.6	2	46.2	12.2
Unknown	40	3.6	2.0	28	3.4	2.1	11	4.1	1.8	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,707	78.8	100.1	968	78.6	81.1	724	79.2	146.6	1	75.0	37.1	5	75.0	47.8	11	80.6	54.8
Regional	244	11.3	13.6	151	12.2	12.2	92	10.1	17.0	-	-	-	1	16.7	9.6	1	10.4	5.8
Distant	143	6.6	9.3	75	6.1	7.0	68	7.4	15.3	-	-	-	-	-	-	-	-	-
Unknown	71	3.3	4.7	39	3.1	3.6	31	3.4	8.0	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	734	78.7	44.5	348	78.1	31.9	380	79.2	70.1	-	-	-	2	80.0	16.3	4	87.0	14.2
Regional	123	13.1	7.4	66	14.9	6.1	56	11.6	10.1	-	-	-	-	-	-	-	-	-
Distant	54	5.8	3.3	21	4.6	1.8	34	7.0	6.2	-	-	-	-	-	-	-	-	-
Unknown	21	2.3	1.3	11	2.4	1.0	10	2.2	1.9	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	972	78.9	484.2	621	78.8	421.2	345	79.2	675.0	-	-	-	3	71.4	265.4	7	77.3	335.7
Regional	121	9.9	56.9	84	10.7	54.1	36	8.4	64.7	-	-	-	-	-	-	-	-	-
Distant	89	7.2	50.9	55	6.9	42.6	34	7.8	77.9	-	-	-	-	-	-	-	-	-
Unknown	49	4.0	28.6	28	3.6	21.9	20	4.7	50.3	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Missouri, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	116	45.8	3.9	98	46.4	3.9	13	39.9	3.6	Insufficient data for the calculation of AI/AN PRCDA statistics			3	52.0	3.7	4	58.1	5.0
Regional	91	36.1	2.9	76	36.1	2.8	12	36.3	3.3				2	36.0	2.5	2	35.5	2.7
Distant	38	15.0	1.0	31	14.5	1.0	7	20.2	1.7				-	-	-	-	-	-
Unknown	8	3.1	0.2	6	3.0	0.2	1	3.6	0.3				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	87	5.3	2.5	69	4.8	2.2	15	9.1	4.9	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	548	33.3	16.4	485	33.4	16.2	53	32.6	18.6				5	32.4	11.3	7	35.7	12.1
Regional	591	35.9	17.9	530	36.5	17.9	50	31.0	18.0				5	35.2	11.8	7	34.7	10.3
Distant	338	20.6	10.1	296	20.4	9.9	36	22.6	12.8				3	19.7	6.7	4	21.4	6.7
Unknown	80	4.9	2.6	70	4.9	2.5	8	4.7	3.3				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	5	3.1	0.3	5	3.2	0.3	-	-	-				-	-	-	-	-	-
Localized	50	28.7	2.7	41	27.9	2.7	7	34.4	3.2				-	-	-	1	21.4	1.5
Regional	70	40.6	3.9	61	41.2	4.0	7	34.4	3.2				2	61.5	3.6	2	42.9	3.2
Distant	44	25.3	2.5	38	25.5	2.5	5	25.0	2.4				-	-	-	1	21.4	1.5
Unknown	4	2.3	0.2	3	2.2	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	81	5.5	8.1	65	5.0	7.2	-	-	-				-	-	-	-	-	-
Localized	499	33.9	52.3	444	34.1	51.5	46	32.4	59.1				-	-	-	6	41.4	40.0
Regional	521	35.4	54.4	469	36.0	54.2	43	30.6	57.0				3	29.3	33.3	4	31.4	28.7
Distant	294	20.0	30.0	258	19.8	29.2	32	22.3	40.2				-	-	-	3	21.4	20.2
Unknown	76	5.2	8.7	67	5.2	8.4	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	64	4.4	1.6	53	4.2	1.5	8	5.1	2.2	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	506	34.6	12.8	437	34.4	12.5	60	36.1	15.4				5	33.3	9.5	6	33.3	9.5
Regional	513	35.1	12.9	455	35.9	12.9	49	29.7	12.7				6	35.9	10.2	7	37.9	10.4
Distant	296	20.2	7.6	250	19.7	7.3	41	24.8	10.6				3	19.2	5.3	3	17.2	4.1
Unknown	83	5.7	1.9	74	5.8	1.9	7	4.2	1.9				-	-	-	1	6.9	2.0
<i>Age < 50</i>																		
In Situ	5	3.4	0.3	5	3.7	0.3	-	-	-				-	-	-	-	-	-
Localized	51	34.4	2.8	42	33.8	2.7	7	37.4	3.1				-	-	-	1	36.8	1.9
Regional	49	33.5	2.7	42	33.9	2.8	6	32.3	2.7				-	-	-	-	-	-
Distant	39	26.2	2.2	32	25.8	2.1	5	27.3	2.3				-	-	-	1	31.6	1.5
Unknown	4	2.6	0.2	3	2.7	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	59	4.5	5.1	49	4.3	4.7	-	-	-				-	-	-	-	-	-
Localized	455	34.7	39.1	395	34.5	38.0	52	36.0	47.7				-	-	-	4	32.4	29.2
Regional	464	35.3	39.5	413	36.1	39.3	43	29.3	39.0				-	-	-	-	-	-
Distant	257	19.6	21.8	218	19.0	20.8	36	24.5	32.3				-	-	-	2	13.2	10.9
Unknown	79	6.0	6.3	70	6.1	6.2	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Missouri, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,025	17.2	27.3	871	16.7	26.6	130	19.8	33.5				15	20.3	23.5	14	21.5	20.2
Localized	3,234	54.1	84.1	2,875	55.3	85.1	299	45.6	76.9				39	52.7	63.0	31	46.8	47.0
Regional	1,344	22.5	36.9	1,143	22.0	35.9	173	26.4	45.3				16	21.6	24.1	17	26.3	23.3
Distant	304	5.1	7.9	252	4.8	7.3	47	7.2	12.5				3	4.6	6.0	3	4.5	3.9
Unknown	69	1.2	1.6	60	1.2	1.5	6	0.9	1.7				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	183	18.2	10.3	149	18.1	10.0	26	18.3	11.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			5	20.6	10.6	4	21.2	6.6
Localized	463	46.0	25.7	393	47.5	26.1	53	37.8	22.9				12	46.6	24.0	8	37.5	11.3
Regional	314	31.2	17.5	252	30.4	16.8	49	34.8	21.0				8	31.3	15.4	7	35.6	10.8
Distant	43	4.3	2.4	30	3.7	2.0	12	8.5	5.0				-	-	-	-	-	-
Unknown	4	0.4	0.2	3	0.4	0.2	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	842	16.9	72.1	722	16.5	70.1	105	20.3	91.9				10	20.1	57.3	10	21.6	55.8
Localized	2,771	55.8	237.0	2,482	56.7	239.6	246	47.7	218.2				27	56.1	164.9	23	51.1	140.4
Regional	1,030	20.7	87.9	892	20.4	86.1	125	24.1	108.9				8	16.3	46.9	10	22.0	56.0
Distant	261	5.3	22.3	221	5.1	21.2	35	6.9	32.1				-	-	-	-	-	-
Unknown	65	1.3	5.2	57	1.3	5.1	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.2	0.2	6	0.2	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	592	20.7	17.6	539	21.0	17.7	49	18.0	18.8				3	17.8	6.3	3	20.5	8.0
Regional	634	22.1	18.4	573	22.3	18.3	56	20.9	20.6				2	12.3	4.7	3	20.5	5.7
Distant	1,408	49.2	40.8	1,243	48.5	39.9	147	54.3	52.2				10	65.8	25.6	8	50.6	16.8
Unknown	223	7.8	6.9	203	7.9	6.8	18	6.7	7.5				-	-	-	1	8.4	3.0
<i>Female</i>																		
In Situ	6	0.2	0.1	5	0.2	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	674	25.8	16.3	607	26.0	16.5	61	24.2	15.9				3	21.6	6.1	4	19.6	7.1
Regional	577	22.1	14.1	511	21.9	14.2	60	23.9	15.2				3	17.6	4.8	3	18.5	6.2
Distant	1,186	45.4	28.7	1,050	45.0	28.7	119	47.4	30.2				8	51.4	13.2	9	51.1	15.6
Unknown	172	6.6	4.0	159	6.8	4.1	10	4.2	2.9				1	9.5	4.0	2	10.9	3.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,477	73.6	66.6	2,106	73.7	63.0	336	73.3	105.6	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			11	78.1	27.1	22	73.2	38.1
Regional	499	14.8	12.9	433	15.1	12.5	61	13.3	18.0				2	12.3	4.9	4	13.1	6.3
Distant	264	7.8	7.9	214	7.5	7.2	45	9.9	16.8				1	8.2	3.8	3	9.2	7.0
Unknown	124	3.7	3.9	106	3.7	3.7	16	3.4	7.3				-	-	-	1	4.6	3.3
<i>Age < 65</i>																		
Localized	1,050	75.1	29.3	837	75.0	26.3	195	75.0	56.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			4	91.3	9.0	11	78.1	15.6
Regional	256	18.3	7.1	213	19.1	6.7	41	15.7	12.0				-	-	-	2	15.1	2.9
Distant	75	5.3	2.1	52	4.7	1.6	21	8.0	6.1				-	-	-	-	-	-
Unknown	17	1.2	0.5	14	1.2	0.4	3	1.2	0.9				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,428	72.6	324.7	1,269	72.8	316.7	142	71.1	441.9				7	72.0	152.6	11	68.8	193.7
Regional	243	12.4	52.9	220	12.6	52.6	20	10.2	59.2				-	-	-	2	11.3	29.5
Distant	189	9.6	48.4	162	9.3	45.4	25	12.3	91.4				1	12.0	29.8	-	-	-
Unknown	106	5.4	27.9	92	5.3	26.2	13	6.3	51.4				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Montana, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	17	46.5	3.3	16	48.0	3.4	-	-	-	-	-	-	-	-	-	-	-	-
Regional	12	32.1	2.4	10	29.2	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Distant	6	16.0	0.9	6	17.5	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	5.3	0.3	2	5.3	0.3	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	6	1.9	0.9	5	1.9	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Localized	97	33.5	14.9	93	34.8	15.0	-	-	-	3	20.8	13.5	-	-	-	2	30.8	16.6
Regional	105	36.6	16.8	96	36.1	16.0	-	-	-	6	43.1	38.7	-	-	-	3	50.0	27.7
Distant	64	22.3	10.2	58	21.9	9.7	-	-	-	3	23.6	15.1	-	-	-	-	-	-
Unknown	16	5.6	2.7	14	5.3	2.5	-	-	-	1	9.7	10.3	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	6	23.3	2.0	6	25.7	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Regional	11	42.1	3.9	9	40.7	3.4	-	-	-	1	53.8	9.7	-	-	-	-	-	-
Distant	8	30.1	2.7	6	28.3	2.3	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	90	34.6	48.8	87	35.6	48.9	-	-	-	-	-	-	-	-	-	2	33.3	60.0
Regional	94	36.0	50.6	87	35.7	48.8	-	-	-	5	40.7	114.6	-	-	-	-	-	-
Distant	56	21.6	29.8	52	21.3	28.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	1	11.9	37.4	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	3	1.5	0.5	3	1.5	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	85	37.9	12.6	80	38.8	12.6	-	-	-	4	28.8	15.5	-	-	-	2	47.1	13.2
Regional	76	34.2	11.1	70	33.9	10.7	-	-	-	5	37.9	21.9	-	-	-	-	-	-
Distant	47	21.2	7.1	43	20.8	6.9	-	-	-	4	28.8	16.3	-	-	-	-	-	-
Unknown	11	5.1	1.6	10	5.0	1.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	8	40.8	2.7	7	40.0	2.7	-	-	-	-	-	-	-	-	-	-	-	-
Regional	6	30.6	2.2	5	30.0	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Distant	5	23.5	1.6	4	24.4	1.7	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	77	37.6	38.5	73	38.6	38.4	-	-	-	-	-	-	-	-	-	-	-	-
Regional	70	34.6	34.6	65	34.3	33.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	43	21.0	21.5	39	20.5	20.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Montana, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	172	17.0	27.2	163	17.0	27.4	-	-	-	6	14.9	23.5	2	20.5	31.3	1	8.7	8.6
Localized	551	54.2	82.2	526	54.9	83.2	-	-	-	16	42.0	64.1	3	38.5	55.5	8	56.5	67.3
Regional	231	22.7	37.3	213	22.2	36.5	-	-	-	13	34.6	55.1	3	33.3	45.6	4	30.4	35.9
Distant	43	4.3	6.5	40	4.1	6.1	-	-	-	2	5.9	10.6	-	-	-	-	-	-
Unknown	19	1.9	2.5	17	1.8	2.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	31	20.8	11.1	29	21.4	11.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	63	42.2	22.4	58	43.2	22.9	-	-	-	2	26.3	12.2	-	-	-	2	47.4	19.0
Regional	49	33.3	17.8	44	32.6	17.4	-	-	-	3	44.7	20.7	-	-	-	1	36.8	15.0
Distant	4	3.0	1.6	3	2.2	1.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	142	16.3	69.4	135	16.3	69.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	488	56.2	238.6	468	56.8	241.2	-	-	-	14	46.0	199.9	-	-	-	6	60.0	193.8
Regional	182	20.9	88.4	169	20.5	86.3	-	-	-	10	32.0	145.0	-	-	-	3	28.0	90.6
Distant	39	4.5	19.3	37	4.4	19.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	3	0.9	0.5	3	0.8	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	66	18.9	10.4	64	19.5	10.5	-	-	-	1	8.6	7.8	-	-	-	1	54.5	16.1
Regional	80	22.7	12.2	75	22.8	12.0	-	-	-	3	24.3	17.8	-	-	-	-	-	-
Distant	180	51.3	27.1	167	50.7	26.2	-	-	-	8	57.1	43.2	-	-	-	-	-	-
Unknown	22	6.2	3.6	20	6.1	3.5	-	-	-	1	8.6	9.3	-	-	-	-	-	-
<i>Female</i>																		
In Situ	4	1.0	0.5	4	1.0	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	94	23.9	13.2	88	24.1	13.0	-	-	-	4	22.1	19.6	-	-	-	1	28.6	11.4
Regional	81	20.6	11.1	73	20.1	10.5	-	-	-	4	25.6	20.8	-	-	-	-	-	-
Distant	191	48.4	27.0	178	48.7	26.5	-	-	-	7	41.9	37.0	-	-	-	2	52.4	23.3
Unknown	24	6.2	3.3	22	6.1	3.1	-	-	-	2	10.5	10.4	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	632	74.3	86.8	595	74.1	85.4	2	75.0	137.4	15	68.1	69.5	-	-	-	5	57.1	47.7
Regional	123	14.5	16.3	117	14.6	16.2	-	-	-	4	18.6	20.5	-	-	-	2	26.2	21.9
Distant	68	8.0	10.6	65	8.1	10.5	-	-	-	2	9.7	9.4	-	-	-	-	-	-
Unknown	27	3.2	4.6	25	3.2	4.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	233	77.9	34.1	220	77.8	34.1	-	-	-	7	71.7	26.7	-	-	-	2	57.9	18.4
Regional	50	16.7	7.2	48	16.9	7.3	-	-	-	2	17.4	6.3	-	-	-	-	-	-
Distant	15	4.9	2.2	14	4.8	2.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	0.5	0.2	1	0.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	399	72.4	451.0	375	72.1	439.9	-	-	-	9	65.7	365.1	-	-	-	3	56.5	250.7
Regional	73	13.3	79.4	70	13.4	78.2	-	-	-	3	19.4	118.6	-	-	-	-	-	-
Distant	53	9.7	68.8	52	9.9	69.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	26	4.6	34.8	24	4.6	33.8	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Nebraska, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	32	44.8	3.8	30	45.3	3.9	2	40.0	3.5	-	-	-	-	-	-	3	45.5	4.9
Regional	25	34.5	2.6	22	33.8	2.5	2	45.0	5.2	-	-	-	-	-	-	2	33.3	4.7
Distant	11	14.6	1.1	10	15.1	1.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	4	6.1	0.4	4	5.7	0.4	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	17	3.3	1.6	15	3.3	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	175	35.2	17.5	163	35.1	17.2	6	31.3	18.2	-	-	-	2	52.6	19.1	7	38.8	16.4
Regional	177	35.8	17.7	167	35.9	17.6	7	36.4	22.3	-	-	-	1	31.6	6.6	5	31.8	9.8
Distant	92	18.5	9.2	87	18.7	9.2	4	18.2	11.5	-	-	-	-	-	-	3	17.6	8.9
Unknown	35	7.1	3.5	33	7.0	3.4	2	9.1	6.9	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	14	30.6	2.6	13	30.5	2.5	1	40.0	4.3	-	-	-	-	-	-	-	-	-
Regional	18	38.3	3.3	16	37.6	3.2	1	40.0	4.1	-	-	-	-	-	-	2	47.1	2.3
Distant	12	24.7	2.1	11	25.2	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	4.3	0.3	2	4.8	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	160	35.7	56.5	151	35.6	55.7	5	29.8	54.4	-	-	-	-	-	-	-	-	-
Regional	159	35.5	55.5	151	35.7	55.3	6	35.7	70.0	-	-	-	-	-	-	4	27.9	29.7
Distant	80	17.9	27.9	76	18.0	27.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	33	7.4	11.8	31	7.3	11.4	2	10.7	25.1	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	10	2.3	0.9	9	2.2	0.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	159	35.2	13.8	149	35.1	13.8	4	29.7	11.0	-	-	-	1	43.8	6.4	6	39.2	10.8
Regional	167	37.0	14.4	158	37.2	14.3	5	33.8	15.1	1	50.0	41.3	2	50.0	11.8	5	35.1	12.8
Distant	78	17.4	7.0	75	17.6	7.1	3	20.3	7.8	-	-	-	-	-	-	2	16.2	7.5
Unknown	36	8.0	2.7	34	7.9	2.5	2	10.8	4.3	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	18	41.4	3.2	17	41.6	3.3	-	-	-	-	-	-	-	-	-	2	60.0	2.6
Regional	14	31.8	2.6	13	31.2	2.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	11	24.1	2.0	10	25.2	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	140	34.5	41.5	132	34.4	41.1	-	-	-	-	-	-	-	-	-	4	33.9	32.3
Regional	153	37.6	45.4	145	37.8	45.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	68	16.7	20.1	64	16.8	20.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Nebraska, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	289	17.1	27.0	269	16.8	26.9	10	19.5	27.7	-	-	-	5	28.2	25.4	7	13.5	14.8
Localized	918	54.2	82.0	878	54.7	83.4	25	48.3	65.9	3	45.9	44.2	7	40.0	36.1	26	48.9	56.0
Regional	376	22.2	35.6	354	22.1	35.9	13	25.7	35.6	2	29.7	33.5	5	28.2	24.3	17	32.0	34.2
Distant	72	4.3	6.5	69	4.3	6.5	2	4.6	5.9	-	-	-	-	-	-	3	5.3	5.7
Unknown	38	2.2	3.0	36	2.2	3.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	53	19.2	10.1	48	19.0	10.3	-	-	-	-	-	-	3	37.1	15.8	3	15.4	5.4
Localized	123	44.7	23.2	115	45.1	24.0	4	41.2	15.3	-	-	-	2	28.6	12.4	8	42.9	14.7
Regional	85	30.9	15.9	79	30.8	16.3	4	41.2	15.6	-	-	-	2	25.7	10.6	7	37.4	12.6
Distant	11	3.9	2.0	9	3.7	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	4	1.4	0.7	3	1.3	0.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	236	16.6	71.1	221	16.4	70.4	-	-	-	-	-	-	2	22.0	50.5	4	12.6	39.3
Localized	795	56.1	236.2	763	56.5	238.9	21	50.0	198.5	-	-	-	5	48.0	98.3	18	52.0	164.1
Regional	291	20.5	87.2	275	20.4	87.1	9	21.9	88.0	-	-	-	3	30.0	60.1	10	29.1	90.8
Distant	62	4.3	18.3	59	4.4	18.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	34	2.4	9.2	32	2.4	9.0	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	141	21.4	14.3	134	21.4	14.2	5	22.2	17.0	-	-	-	-	-	-	3	22.4	10.1
Regional	157	23.8	15.5	150	24.0	15.6	4	20.4	14.3	-	-	-	-	-	-	2	19.0	6.7
Distant	312	47.5	30.7	296	47.2	30.5	11	50.9	39.6	1	66.7	20.8	3	63.0	32.0	6	55.2	18.9
Unknown	47	7.2	4.8	46	7.3	4.8	1	6.5	5.8	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.3	0.2	2	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	148	24.6	12.7	141	24.9	12.7	5	19.2	13.9	-	-	-	-	-	-	3	22.1	9.8
Regional	130	21.5	11.0	120	21.2	10.8	7	27.7	20.1	-	-	-	-	-	-	-	-	-
Distant	273	45.4	23.3	257	45.4	23.0	12	46.9	33.4	1	41.2	27.2	2	52.9	11.6	8	61.8	23.0
Unknown	49	8.2	3.9	46	8.2	3.8	2	6.2	4.3	-	-	-	-	-	-	1	8.8	4.2

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	900	71.3	82.6	823	71.3	79.2	45	66.6	133.6	2	61.5	27.6	5	72.7	50.8	20	68.9	54.9
Regional	189	15.0	16.5	174	15.1	16.0	12	17.0	33.2	-	-	-	1	18.2	9.0	5	17.6	12.1
Distant	82	6.5	8.3	73	6.3	7.7	7	10.6	23.1	-	-	-	-	-	-	2	6.1	7.0
Unknown	92	7.3	9.3	83	7.2	8.8	4	5.9	13.3	-	-	-	-	-	-	2	7.4	8.0
<i>Age < 65</i>																		
Localized	366	73.1	33.2	328	73.1	31.6	25	70.2	61.9	-	-	-	2	80.0	11.0	9	67.7	16.3
Regional	89	17.8	8.0	83	18.5	8.0	5	14.9	12.7	-	-	-	-	-	-	3	24.6	5.9
Distant	22	4.4	2.0	17	3.9	1.7	4	9.9	8.7	-	-	-	-	-	-	-	-	-
Unknown	24	4.8	2.2	20	4.5	2.0	2	5.0	4.3	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	534	70.1	424.2	495	70.2	408.3	20	62.5	629.3	-	-	-	3	69.6	325.9	12	69.9	321.4
Regional	100	13.1	74.7	91	13.0	71.6	6	19.4	175.0	-	-	-	-	-	-	2	12.0	55.5
Distant	60	7.9	51.6	56	7.9	49.4	4	11.3	123.2	-	-	-	-	-	-	-	-	-
Unknown	68	8.9	58.3	63	8.9	55.9	2	6.9	75.2	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Nevada, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	54	41.8	3.9	43	42.4	4.0	4	38.5	3.0	-	-	-	5	43.5	3.2	12	40.8	3.5
Regional	41	31.7	2.7	33	32.5	2.8	2	21.2	1.6	-	-	-	4	32.3	2.2	11	36.8	3.6
Distant	17	12.9	1.1	13	12.5	1.1	2	17.3	1.2	-	-	-	2	14.5	1.0	3	9.2	0.8
Unknown	18	13.5	1.2	13	12.7	1.1	2	23.1	1.7	-	-	-	1	9.7	0.7	4	13.2	1.3

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	9	1.5	0.6	7	1.4	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	194	30.2	12.2	162	31.4	12.2	11	22.8	9.8	2	34.3	14.0	14	28.2	10.7	22	30.5	10.5
Regional	201	31.4	12.9	161	31.2	12.4	18	36.2	15.3	2	22.9	9.4	15	30.7	11.8	22	30.5	10.0
Distant	137	21.3	8.6	109	21.0	8.2	12	23.6	9.5	1	17.1	6.4	11	22.8	8.4	16	21.7	6.6
Unknown	100	15.6	6.6	77	15.0	6.1	8	15.9	8.5	2	22.9	7.0	9	17.8	7.1	12	16.2	5.6
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	12	19.0	1.2	10	20.4	1.2	-	-	-	-	-	-	1	20.6	1.5	2	16.9	0.8
Regional	25	38.9	2.7	18	38.7	2.4	3	48.4	3.3	-	-	-	2	35.3	2.7	6	40.8	2.0
Distant	19	29.0	1.9	13	27.2	1.7	2	29.0	2.0	-	-	-	2	35.3	2.6	4	28.2	1.5
Unknown	7	11.5	0.8	5	11.5	0.7	-	-	-	-	-	-	-	-	-	2	12.7	0.6
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	181	31.4	40.8	152	32.5	40.8	-	-	-	2	38.7	50.6	12	29.5	34.9	20	33.8	35.9
Regional	176	30.5	39.9	143	30.4	38.5	15	34.4	46.5	2	25.8	34.2	12	30.0	35.5	16	28.0	30.8
Distant	118	20.5	26.0	96	20.4	25.3	10	22.8	29.1	-	-	-	9	20.8	23.6	12	20.1	20.0
Unknown	93	16.1	22.0	72	15.3	20.3	-	-	-	-	-	-	-	-	-	10	17.1	18.7
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	8	1.5	0.5	6	1.5	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	172	32.7	10.3	138	32.7	10.3	15	35.6	11.2	3	50.0	11.4	13	30.3	6.9	21	32.5	7.7
Regional	169	32.2	10.2	136	32.3	10.3	13	31.7	10.1	2	38.5	7.7	13	31.3	7.4	20	30.6	8.2
Distant	102	19.5	6.2	81	19.3	6.1	7	17.1	5.3	-	-	-	9	21.3	5.2	14	21.3	5.3
Unknown	74	14.1	4.5	60	14.3	4.5	6	13.7	4.6	-	-	-	7	16.1	4.0	9	14.1	3.7
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	19	32.8	2.0	15	33.5	2.1	2	32.1	1.9	-	-	-	-	-	-	6	39.0	2.3
Regional	19	33.1	2.1	14	32.6	2.1	2	32.1	2.0	-	-	-	2	44.0	1.9	4	26.8	1.7
Distant	13	23.0	1.4	9	21.3	1.4	1	25.0	1.5	-	-	-	2	36.0	1.6	4	26.8	1.7
Unknown	6	9.8	0.6	5	11.3	0.7	-	-	-	-	-	-	-	-	-	1	7.3	0.5
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	153	32.7	32.0	123	32.6	31.9	13	36.2	35.4	-	-	-	-	-	-	14	30.3	21.8
Regional	150	32.0	31.4	122	32.3	31.8	11	31.6	31.6	-	-	-	11	29.6	21.7	15	31.9	25.2
Distant	89	19.1	18.6	72	19.1	18.6	6	15.8	15.2	-	-	-	7	19.4	14.5	9	19.3	14.7
Unknown	69	14.7	14.6	55	14.6	14.4	-	-	-	-	-	-	-	-	-	8	16.4	12.3

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Nevada, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	352	16.1	20.8	265	15.3	19.8	27	16.1	20.6	3	16.7	12.6	44	21.2	22.5	45	17.1	15.5
Localized	1,131	51.7	67.0	925	53.2	68.8	74	44.3	54.9	11	52.0	44.6	97	47.3	51.6	126	48.0	46.4
Regional	499	22.8	30.8	391	22.5	30.5	46	27.7	34.4	5	23.5	20.2	46	22.2	24.6	68	25.8	22.9
Distant	106	4.9	6.4	81	4.6	6.0	11	6.4	8.0	-	-	-	11	5.3	6.1	12	4.6	4.4
Unknown	99	4.5	6.1	76	4.4	5.8	9	5.5	7.2	-	-	-	8	4.0	4.7	12	4.5	5.0
<i>Age < 50</i>																		
In Situ	66	16.4	7.3	48	16.4	7.0	4	10.8	4.8	-	-	-	10	20.8	8.6	13	15.3	5.2
Localized	174	43.6	19.3	131	45.1	19.3	15	37.3	16.7	2	50.0	12.6	20	43.2	18.0	38	44.0	14.6
Regional	125	31.4	13.8	91	31.1	13.3	16	38.2	16.8	1	31.8	8.2	13	26.7	11.2	28	32.6	10.9
Distant	21	5.2	2.3	13	4.3	1.8	3	7.8	3.3	-	-	-	3	6.8	2.9	4	4.9	1.6
Unknown	14	3.4	1.5	9	3.2	1.3	2	5.9	2.6	-	-	-	1	2.5	1.1	3	3.2	1.0
<i>Age ≥ 50</i>																		
In Situ	287	16.0	56.2	218	15.0	53.3	23	17.8	61.9	-	-	-	34	21.4	59.0	32	18.0	42.6
Localized	957	53.5	192.0	794	54.9	198.7	59	46.6	155.2	8	52.5	128.3	77	48.5	139.4	88	50.0	129.8
Regional	374	20.9	75.3	300	20.7	75.6	31	24.3	80.4	3	21.3	51.4	33	20.9	59.8	40	22.5	54.6
Distant	86	4.8	17.3	68	4.7	17.0	8	6.0	20.2	-	-	-	8	4.8	14.5	8	4.4	11.9
Unknown	86	4.8	18.0	67	4.6	17.5	7	5.4	19.4	-	-	-	7	4.4	14.3	9	5.1	15.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.3	0.2	2	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	154	18.3	10.0	133	18.7	10.3	9	16.7	8.7	-	-	-	8	17.0	6.3	5	11.5	3.4
Regional	160	19.1	10.0	140	19.6	10.4	8	14.5	7.8	2	37.9	12.7	9	18.7	7.3	8	17.3	4.3
Distant	360	42.9	22.5	300	42.0	22.3	27	48.2	23.7	2	37.9	11.8	22	45.6	17.5	22	48.2	12.0
Unknown	164	19.5	11.3	139	19.5	11.4	11	20.7	10.8	-	-	-	9	18.7	8.3	10	23.0	7.1
<i>Female</i>																		
In Situ	6	0.7	0.4	5	0.7	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	198	22.4	11.6	171	22.7	12.3	12	20.2	9.9	2	22.9	7.4	11	21.1	6.2	10	19.9	5.1
Regional	169	19.0	9.5	145	19.2	10.2	11	18.8	8.7	1	17.1	6.4	9	16.6	4.4	12	22.2	5.6
Distant	344	38.8	20.0	291	38.5	20.9	23	38.7	17.4	3	48.6	15.0	23	42.6	13.0	22	41.8	9.8
Unknown	170	19.1	10.4	143	19.0	10.7	13	21.9	10.7	-	-	-	10	18.1	5.8	8	15.7	4.6

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	982	67.9	56.8	825	68.5	57.0	86	65.5	68.7	6	59.6	29.4	44	70.5	32.0	88	62.5	43.0
Regional	135	9.4	7.3	113	9.4	7.4	13	9.6	9.0	-	-	-	6	9.8	4.2	14	10.3	5.2
Distant	103	7.2	6.9	81	6.8	6.5	13	10.1	11.1	1	13.5	6.4	5	7.9	4.4	12	8.3	6.9
Unknown	225	15.5	14.2	185	15.4	13.8	19	14.8	19.3	2	17.3	11.2	7	11.7	6.3	27	19.0	15.4
<i>Age < 65</i>																		
Localized	344	68.8	21.0	279	69.3	20.7	43	66.6	32.9	2	64.7	8.5	12	67.4	8.2	40	63.4	14.5
Regional	71	14.2	4.4	57	14.1	4.3	9	14.1	7.1	-	-	-	3	19.8	2.5	10	15.3	3.4
Distant	30	6.0	1.8	22	5.4	1.6	7	10.4	5.1	-	-	-	-	-	-	5	8.3	1.9
Unknown	55	11.1	3.3	45	11.3	3.3	6	8.9	4.3	-	-	-	1	7.0	0.9	8	13.1	3.1
<i>Age ≥ 65</i>																		
Localized	638	67.5	304.2	546	68.1	307.8	43	64.5	315.9	4	57.1	173.5	33	71.6	196.5	48	61.8	240.2
Regional	64	6.8	27.4	56	7.0	28.5	3	5.2	22.0	-	-	-	3	6.1	16.0	5	6.2	17.7
Distant	73	7.8	41.9	60	7.4	40.5	6	9.7	52.4	-	-	-	-	-	-	6	8.3	41.4
Unknown	169	17.9	88.9	140	17.4	86.2	14	20.6	122.4	-	-	-	6	13.5	43.4	18	23.8	100.5

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Hampshire, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	17	48.3	2.5	16	48.2	2.5	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	12	34.1	1.5	11	33.9	1.5	-	-	-				-	-	-	-	-	-
Distant	4	12.5	0.5	4	12.5	0.5	-	-	-				-	-	-	-	-	-
Unknown	2	5.1	0.2	2	5.4	0.2	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
Male																		
All Ages																		
In Situ	21	6.0	2.5	19	5.7	2.4	-	-	-				-	-	-	-	-	-
Localized	121	34.5	15.2	116	34.3	15.1	1	42.9	17.5				2	50.0	12.1	2	42.9	11.8
Regional	120	34.1	15.4	117	34.5	15.6	-	-	-				1	33.3	8.8	-	-	-
Distant	69	19.5	8.5	68	20.0	8.7	-	-	-				-	-	-	-	-	-
Unknown	21	5.9	2.8	19	5.6	2.7	-	-	-				-	-	-	-	-	-
Age < 50																		
In Situ	1	2.9	0.3	-	-	-	-	-	-				-	-	-	-	-	-
Localized	13	31.7	3.2	12	31.3	3.3	-	-	-				-	-	-	-	-	-
Regional	15	37.1	3.8	15	38.4	4.0	-	-	-				-	-	-	-	-	-
Distant	9	22.4	2.2	9	22.7	2.3	-	-	-				-	-	-	-	-	-
Unknown	2	5.9	0.6	2	5.6	0.6	-	-	-				-	-	-	-	-	-
Age ≥ 50																		
In Situ	20	6.4	8.3	-	-	-	-	-	-				-	-	-	-	-	-
Localized	108	34.9	46.7	104	34.7	46.0	1	42.9	63.2				-	-	-	-	-	-
Regional	105	33.8	45.9	102	33.9	45.8	-	-	-				1	40.0	31.9	-	-	-
Distant	59	19.1	25.1	59	19.6	25.5	-	-	-				-	-	-	-	-	-
Unknown	18	5.9	8.6	17	5.6	8.3	-	-	-				-	-	-	-	-	-
Insufficient data for the calculation of AI/AN PRCDA statistics																		
Female																		
All Ages																		
In Situ	19	6.2	2.1	17	5.6	1.9	-	-	-				-	-	-	-	-	-
Localized	108	35.2	12.2	105	35.4	12.2	-	-	-				1	37.5	10.3	-	-	-
Regional	106	34.5	11.4	105	35.1	11.6	-	-	-				-	-	-	-	-	-
Distant	54	17.7	6.1	53	17.7	6.1	-	-	-				-	-	-	-	-	-
Unknown	20	6.5	2.0	19	6.2	1.9	-	-	-				-	-	-	-	-	-
Age < 50																		
In Situ	2	7.0	0.6	2	5.5	0.5	-	-	-				-	-	-	-	-	-
Localized	13	38.4	3.2	13	39.0	3.3	-	-	-				-	-	-	-	-	-
Regional	10	29.7	2.4	10	30.5	2.5	-	-	-				-	-	-	-	-	-
Distant	7	21.5	1.8	7	21.3	1.8	-	-	-				-	-	-	-	-	-
Unknown	1	3.5	0.3	1	3.7	0.3	-	-	-				-	-	-	-	-	-
Age ≥ 50																		
In Situ	17	6.1	6.1	15	5.6	5.5	-	-	-				-	-	-	-	-	-
Localized	95	34.8	35.6	93	34.9	35.5	-	-	-				1	42.9	37.3	-	-	-
Regional	96	35.1	35.1	95	35.7	35.3	-	-	-				-	-	-	-	-	-
Distant	47	17.2	17.5	46	17.3	17.4	-	-	-				-	-	-	-	-	-
Unknown	19	6.9	6.6	17	6.6	6.2	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Hampshire, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	312	19.6	36.0	304	19.5	36.2	2	23.7	25.3				4	21.8	22.6	3	17.0	16.8
Localized	893	56.0	99.3	875	56.1	100.3	3	42.1	44.4				12	57.4	63.3	9	52.3	61.3
Regional	313	19.6	36.9	306	19.6	37.3	2	26.3	32.5				4	17.8	16.5	5	26.1	25.9
Distant	60	3.8	6.8	59	3.8	6.9	-	-	-				-	-	-	-	-	-
Unknown	16	1.0	1.7	15	1.0	1.6	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	65	22.8	15.3	61	22.6	15.4	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			2	23.7	11.9	1	18.8	8.8
Localized	134	47.1	31.6	129	47.4	32.4	-	-	-				4	47.4	24.0	3	43.8	20.2
Regional	74	26.2	17.9	71	26.1	18.1	-	-	-				2	28.9	13.4	2	31.3	14.6
Distant	10	3.4	2.3	9	3.5	2.4	-	-	-				-	-	-	-	-	-
Unknown	1	0.5	0.3	1	0.4	0.3	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	248	18.9	90.1	242	18.8	90.7	-	-	-				3	20.6	50.5	2	16.1	37.6
Localized	760	57.9	276.5	746	58.0	278.3	-	-	-				8	63.5	166.0	6	57.1	168.9
Regional	238	18.2	86.6	235	18.2	87.5	-	-	-				1	11.1	24.6	3	23.2	55.3
Distant	51	3.9	18.6	49	3.8	18.6	-	-	-				-	-	-	-	-	-
Unknown	15	1.1	5.3	14	1.1	5.2	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	110	20.3	14.0	108	20.4	14.1	-	-	-				-	-	-	-	-	-
Regional	133	24.5	16.2	130	24.5	16.3	-	-	-				-	-	-	-	-	-
Distant	269	49.6	33.0	264	49.7	33.1	1	50.0	25.6				2	64.7	22.4	3	61.9	22.6
Unknown	30	5.5	3.9	28	5.2	3.7	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.3	0.2	2	0.3	0.2	-	-	-				-	-	-	-	-	-
Localized	160	27.3	17.2	158	27.5	17.3	-	-	-				1	23.1	10.9	-	-	-
Regional	135	23.1	14.3	133	23.2	14.4	-	-	-				1	23.1	9.4	1	35.0	12.6
Distant	261	44.5	27.5	257	44.7	27.7	-	-	-				3	53.8	18.5	1	35.0	12.6
Unknown	28	4.8	2.9	25	4.4	2.6	-	-	-				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	737	74.4	80.0	711	74.9	79.0	8	69.1	97.8	Insufficient data for the calculation of AI/AN PRCDA statistics			3	60.7	28.9	8	74.5	67.7
Regional	144	14.5	15.0	139	14.6	14.9	2	16.4	21.6				-	-	-	2	15.7	11.3
Distant	68	6.9	9.0	66	6.9	8.8	-	-	-				-	-	-	-	-	-
Unknown	42	4.3	5.2	34	3.6	4.3	-	-	-				-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	319	76.7	34.3	309	77.4	34.1	4	66.7	37.4	Insufficient data for the calculation of AI/AN PRCDA statistics			1	70.0	10.2	4	71.4	27.4
Regional	69	16.5	7.4	66	16.5	7.3	-	-	-				-	-	-	-	-	-
Distant	15	3.6	1.7	15	3.7	1.7	-	-	-				-	-	-	-	-	-
Unknown	13	3.2	1.4	10	2.4	1.1	-	-	-				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	418	72.6	396.0	403	73.0	389.7	4	72.0	515.7				2	55.6	158.0	4	78.3	346.4
Regional	75	13.0	67.6	73	13.3	67.7	-	-	-				-	-	-	-	-	-
Distant	53	9.2	59.8	51	9.3	58.5	-	-	-				-	-	-	-	-	-
Unknown	29	5.1	31.6	24	4.4	27.0	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Jersey, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	149	38.9	3.3	113	40.3	3.5	25	33.8	3.4	Insufficient data for the calculation of AI/AN PRCDA statistics			8	37.3	1.7	35	40.9	4.3
Regional	135	35.3	2.6	95	33.8	2.5	30	40.5	4.0				9	40.9	2.0	32	37.1	4.1
Distant	67	17.4	1.2	50	17.9	1.2	13	16.9	1.7				4	16.4	0.9	13	15.2	1.8
Unknown	32	8.3	0.6	22	8.0	0.6	7	8.8	0.9				1	5.5	0.2	6	6.8	0.8

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	105	4.5	2.1	79	4.2	2.0	18	6.3	3.3				5	4.1	1.3	13	5.0	2.3
Localized	794	34.1	16.8	649	34.6	17.1	87	30.3	15.9				41	33.6	11.0	84	33.2	15.0
Regional	762	32.7	16.1	631	33.6	16.6	83	28.7	14.8				42	34.6	10.9	81	31.8	14.4
Distant	483	20.8	10.1	385	20.5	10.0	73	25.3	13.5				23	18.9	5.8	56	22.2	9.6
Unknown	184	7.9	4.0	133	7.1	3.6	27	9.4	5.5				11	8.9	2.9	20	7.9	3.8
<i>Age < 50</i>																		
In Situ	5	2.1	0.2	3	1.9	0.2	1	3.2	0.3				-	-	-	-	-	-
Localized	77	31.8	2.7	58	32.5	2.8	10	27.1	2.3				7	34.0	2.1	14	33.3	2.2
Regional	85	35.1	3.0	65	36.2	3.1	12	33.0	2.9				7	33.0	2.1	13	32.4	2.1
Distant	60	24.8	2.1	44	24.7	2.1	12	30.9	2.7				5	22.3	1.4	10	24.2	1.6
Unknown	15	6.2	0.5	8	4.7	0.4	2	5.9	0.5				2	8.7	0.5	3	7.7	0.5
<i>Age ≥ 50</i>																		
In Situ	100	4.8	7.3	75	4.4	6.8	17	6.8	11.1				-	-	-	-	-	-
Localized	716	34.4	53.7	591	34.8	54.5	77	30.8	51.4				34	33.5	34.1	70	33.2	48.4
Regional	676	32.4	50.3	566	33.3	51.8	70	28.0	46.1				35	34.9	33.9	67	31.7	46.6
Distant	423	20.3	30.9	341	20.1	30.6	61	24.5	41.9				18	18.1	17.2	46	21.8	30.4
Unknown	169	8.1	13.0	125	7.3	11.8	25	9.9	18.7				9	8.9	9.1	17	7.9	12.5
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	93	4.2	1.6	73	4.1	1.5	12	4.0	1.6				4	4.1	0.9	14	5.8	2.0
Localized	745	33.7	12.8	598	33.7	12.8	101	33.3	13.5				30	30.7	7.2	82	35.0	11.8
Regional	747	33.8	12.7	608	34.3	12.9	96	31.7	13.0				38	38.8	9.1	74	31.7	11.0
Distant	445	20.1	7.6	356	20.1	7.6	69	22.9	9.1				17	17.1	3.9	46	19.8	6.9
Unknown	182	8.2	2.8	137	7.7	2.6	24	8.0	3.3				9	9.3	2.4	18	7.7	2.7
<i>Age < 50</i>																		
In Situ	7	3.0	0.2	5	3.1	0.2	-	-	-				-	-	-	2	5.9	0.4
Localized	84	36.2	2.9	62	36.9	3.0	13	32.7	2.7				5	32.1	1.4	15	37.4	2.5
Regional	78	33.7	2.7	56	33.7	2.7	13	33.2	2.7				6	39.7	1.8	12	28.6	1.9
Distant	53	22.8	1.8	38	22.9	1.8	12	28.7	2.3				2	15.4	0.7	10	23.6	1.6
Unknown	10	4.3	0.3	6	3.4	0.3	1	3.0	0.2				1	9.0	0.4	2	4.4	0.3
<i>Age ≥ 50</i>																		
In Situ	86	4.3	5.0	68	4.2	5.0	-	-	-				-	-	-	11	5.8	6.2
Localized	661	33.4	38.8	536	33.4	38.7	88	33.4	41.7				25	30.4	22.3	67	34.4	36.2
Regional	670	33.8	38.9	552	34.4	39.6	82	31.5	39.8				32	38.6	28.2	63	32.4	34.9
Distant	392	19.8	22.7	317	19.8	22.8	58	22.1	26.7				14	17.4	12.3	37	19.0	20.7
Unknown	172	8.7	9.4	132	8.2	8.5	23	8.8	11.2				8	9.4	7.7	16	8.4	9.0

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Jersey, 2013-2017**

Female Breast, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	2,245	22.7	41.2	1,750	22.3	41.9	265	21.3	34.2				177	26.8	37.5	245	23.3	31.8
Localized	4,945	49.9	87.5	4,038	51.4	91.6	537	43.3	70.7				313	47.5	67.1	490	46.6	67.0
Regional	1,925	19.4	35.5	1,461	18.6	35.0	305	24.6	40.1				129	19.6	27.4	238	22.7	31.5
Distant	507	5.1	8.8	388	4.9	8.4	91	7.4	11.9				24	3.7	5.4	46	4.4	6.3
Unknown	291	2.9	4.9	213	2.7	4.4	42	3.4	5.5				16	2.4	3.5	32	3.1	4.6
<i>Age < 50</i>																		
In Situ	564	27.7	19.0	417	28.3	19.7	62	21.8	12.7	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			66	29.4	19.1	78	24.8	13.3
Localized	859	42.2	29.2	639	43.3	30.5	110	38.8	22.9				96	43.0	27.9	130	41.3	22.0
Regional	493	24.2	17.1	347	23.5	17.1	83	29.2	17.4				51	23.0	14.7	88	27.9	14.8
Distant	72	3.6	2.5	45	3.0	2.2	21	7.3	4.3				6	2.6	1.7	10	3.2	1.7
Unknown	46	2.3	1.6	27	1.8	1.3	8	2.9	1.7				4	2.0	1.3	9	2.9	1.5
<i>Age ≥ 50</i>																		
In Situ	1,682	21.3	99.1	1,332	20.9	100.1	203	21.2	90.4				111	25.5	85.6	167	22.7	80.3
Localized	4,087	51.9	240.1	3,399	53.3	251.4	427	44.6	195.8				217	49.8	169.9	360	48.9	184.7
Regional	1,432	18.2	83.5	1,114	17.5	82.1	222	23.3	99.6				78	17.9	60.5	150	20.4	75.4
Distant	435	5.5	25.2	343	5.4	24.8	70	7.4	31.8				19	4.3	15.3	36	4.8	18.5
Unknown	245	3.1	13.6	186	2.9	12.6	33	3.5	15.6				11	2.6	9.5	23	3.2	12.9

Lung and Bronchus, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>	<i>Avg. Annual Cases</i>	<i>%</i>	<i>Rate²</i>
Stage at Diagnosis																		
Male																		
In Situ	6	0.2	0.1	5	0.2	0.1	-	-	-				-	-	-	-	-	-
Localized	596	21.0	13.0	526	21.9	14.0	46	14.7	9.7				20	18.1	6.1	32	16.9	7.0
Regional	634	22.3	13.5	541	22.5	14.1	65	20.7	13.2				24	22.2	7.3	42	22.1	8.5
Distant	1,384	48.7	29.3	1,151	47.9	29.8	171	54.2	32.9				57	53.0	16.6	102	54.1	20.1
Unknown	223	7.8	5.0	181	7.5	4.9	32	10.2	7.1				7	6.7	2.5	13	6.7	3.2
Female																		
In Situ	12	0.4	0.2	10	0.4	0.2	1	0.3	0.2				-	-	-	-	-	-
Localized	811	26.0	13.6	716	26.7	15.0	72	20.8	9.5				18	22.1	4.5	41	22.6	6.5
Regional	673	21.5	11.3	585	21.8	12.3	73	21.3	9.6				12	14.6	2.9	43	23.4	6.6
Distant	1,386	44.4	23.0	1,165	43.4	24.1	171	49.8	22.5				46	55.2	11.3	79	43.2	12.0
Unknown	242	7.8	3.8	206	7.7	3.9	27	7.7	3.6				6	7.4	1.9	19	10.2	3.1

Prostate, 2013-2017

	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
All Ages																		
Localized	4,825	71.8	93.4	3,683	73.9	88.6	779	72.5	131.6	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			164	71.5	43.1	489	73.0	87.3
Regional	652	9.7	12.0	526	10.5	12.0	86	8.0	13.7				29	12.6	7.4	58	8.6	9.1
Distant	371	5.5	8.0	279	5.6	7.3	75	7.0	15.0				13	5.6	3.9	32	4.7	6.8
Unknown	875	13.0	17.8	496	10.0	12.6	135	12.5	26.8				24	10.3	7.5	91	13.6	18.6
Age < 65																		
Localized	2,086	73.6	39.6	1,516	76.0	36.3	414	75.5	63.7	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			58	74.2	13.3	232	75.1	33.1
Regional	354	12.5	6.7	280	14.0	6.7	56	10.1	8.6				12	14.9	2.7	36	11.6	5.1
Distant	98	3.4	1.8	63	3.2	1.5	29	5.4	4.5				4	4.6	0.8	10	3.4	1.5
Unknown	296	10.5	5.6	136	6.8	3.2	49	9.0	7.5				5	6.2	1.1	31	9.9	4.4
Age ≥ 65																		
Localized	2,738	70.4	465.8	2,167	72.5	450.2	365	69.3	600.8				107	70.1	249.0	257	71.2	461.6
Regional	299	7.7	48.3	246	8.2	48.5	30	5.8	49.0				17	11.4	39.8	22	6.0	36.5
Distant	274	7.0	50.5	216	7.2	47.6	46	8.7	87.4				9	6.1	25.0	21	5.9	43.5
Unknown	579	14.9	102.4	360	12.0	77.1	85	16.2	160.1				19	12.4	51.8	61	16.8	117.0

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Mexico, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	38	45.8	4.0	34	48.0	4.3	-	-	-	3	29.5	2.5	-	-	-	20	48.3	4.4
Regional	28	33.7	2.6	23	32.3	2.4	-	-	-	4	47.7	4.4	-	-	-	14	34.3	3.0
Distant	11	12.9	1.0	9	12.6	1.0	-	-	-	1	13.6	1.3	-	-	-	5	11.1	1.0
Unknown	6	7.6	0.6	5	7.0	0.5	-	-	-	-	-	-	-	-	-	3	6.3	0.6

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	10	2.2	0.9	9	2.2	0.8	-	-	-	-	-	-	-	-	-	4	2.1	0.9
Localized	148	33.3	12.5	131	33.5	12.3	2	24.2	6.4	13	33.9	16.2	2	37.5	13.7	57	32.5	13.6
Regional	151	33.9	13.1	132	33.6	12.7	3	39.4	9.8	13	36.0	17.3	2	33.3	9.2	62	35.5	14.8
Distant	99	22.2	8.6	88	22.6	8.7	2	24.2	5.8	7	19.4	9.0	-	-	-	38	21.6	8.9
Unknown	37	8.3	3.3	32	8.1	3.2	-	-	-	3	9.1	4.7	-	-	-	15	8.3	3.7
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	11	26.1	1.8	8	24.7	1.7	-	-	-	2	33.3	3.2	-	-	-	5	30.7	1.8
Regional	15	36.5	2.6	12	35.3	2.4	-	-	-	2	40.0	3.7	-	-	-	6	34.1	2.1
Distant	13	29.9	2.1	11	32.4	2.2	-	-	-	1	20.0	1.9	-	-	-	5	28.4	1.8
Unknown	3	6.2	0.4	2	6.5	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	137	34.1	40.6	123	34.3	40.3	2	28.6	23.3	11	34.0	50.3	-	-	-	52	32.7	44.6
Regional	136	33.7	40.4	120	33.5	39.7	-	-	-	11	35.3	53.0	-	-	-	56	35.7	48.2
Distant	86	21.4	25.6	77	21.7	25.6	-	-	-	6	19.2	27.5	-	-	-	33	20.8	27.5
Unknown	34	8.5	10.9	29	8.2	10.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	8	1.9	0.6	7	1.9	0.6	-	-	-	-	-	-	-	-	-	4	2.4	0.8
Localized	135	34.2	10.2	118	34.3	10.1	2	28.1	8.7	12	33.1	11.3	1	31.8	6.2	52	33.0	10.8
Regional	128	32.4	9.7	110	32.0	9.5	3	40.6	11.4	12	34.3	11.8	1	31.8	5.7	50	31.7	10.3
Distant	86	21.7	6.7	74	21.5	6.5	2	28.1	7.7	8	22.9	8.8	2	36.4	7.8	36	22.9	7.5
Unknown	38	9.7	2.8	35	10.2	2.9	-	-	-	3	8.0	3.1	-	-	-	16	9.9	3.3
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	12	28.0	1.9	10	28.3	1.9	-	-	-	1	24.0	1.8	-	-	-	6	29.1	1.9
Regional	15	36.7	2.5	12	34.7	2.4	-	-	-	2	48.0	3.5	-	-	-	6	30.1	2.1
Distant	12	30.0	2.1	11	31.2	2.1	-	-	-	1	28.0	2.2	-	-	-	7	35.9	2.5
Unknown	2	3.9	0.3	2	4.6	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	124	35.0	32.0	108	35.0	31.4	-	-	-	10	34.7	36.0	-	-	-	46	33.6	33.9
Regional	113	31.9	28.6	98	31.7	28.0	-	-	-	10	32.0	33.3	-	-	-	44	32.0	32.0
Distant	73	20.8	18.7	63	20.4	18.1	2	33.3	27.8	7	22.0	26.1	2	40.0	28.2	29	21.0	20.7
Unknown	37	10.4	9.4	34	10.9	9.6	-	-	-	3	9.3	11.3	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New Mexico, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	260	15.3	20.5	235	15.2	21.2	4	17.0	15.2	12	14.6	11.3	6	21.5	21.3	92	15.6	18.9
Localized	911	53.6	69.7	834	54.1	72.6	10	42.9	41.0	44	53.0	42.1	12	46.2	48.3	303	51.0	62.3
Regional	394	23.2	32.0	357	23.2	33.3	6	28.6	27.5	20	24.3	19.2	6	23.1	23.6	153	25.8	32.1
Distant	79	4.7	6.2	70	4.6	6.4	2	8.0	7.4	4	5.4	4.8	2	6.2	6.3	29	4.8	5.9
Unknown	54	3.2	3.9	45	2.9	3.6	-	-	-	2	2.7	2.1	-	-	-	16	2.7	3.4
<i>Age < 50</i>																		
In Situ	42	16.6	7.2	36	16.6	7.5	-	-	-	3	14.0	4.2	2	22.9	9.5	18	14.3	6.1
Localized	112	44.4	19.1	97	44.2	19.8	2	39.1	11.6	9	50.5	14.7	3	42.9	18.1	55	44.9	19.0
Regional	83	32.7	14.0	72	33.0	14.8	2	34.8	11.5	6	31.2	8.6	2	28.6	11.6	44	35.9	15.1
Distant	13	5.2	2.3	12	5.4	2.4	-	-	-	-	-	-	-	-	-	5	3.9	1.6
Unknown	3	1.0	0.4	2	0.8	0.4	-	-	-	-	-	-	-	-	-	1	1.0	0.4
<i>Age ≥ 50</i>																		
In Situ	218	15.1	55.5	198	15.0	57.2	-	-	-	9	14.8	30.1	4	21.1	52.4	75	15.9	52.4
Localized	798	55.2	202.2	737	55.8	210.7	8	43.8	117.9	34	53.8	113.9	9	47.4	127.6	247	52.7	175.6
Regional	312	21.6	79.1	285	21.5	81.7	5	27.0	69.6	14	22.3	47.1	4	21.1	54.8	109	23.2	76.5
Distant	66	4.6	16.7	58	4.4	16.7	-	-	-	-	-	-	-	-	-	24	5.1	17.0
Unknown	51	3.5	12.8	44	3.3	12.3	-	-	-	-	-	-	-	-	-	15	3.2	11.1

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	88	17.2	7.7	83	17.3	8.0	3	22.6	14.1	-	-	-	-	-	-	19	14.3	5.2
Regional	99	19.5	8.4	94	19.6	8.8	3	21.0	13.8	2	16.1	2.7	-	-	-	22	16.3	5.7
Distant	224	43.8	18.8	209	43.6	19.4	4	33.9	18.6	6	57.1	10.2	2	47.6	13.9	64	46.8	15.7
Unknown	99	19.4	9.0	92	19.3	9.2	3	22.6	14.0	2	19.6	4.1	-	-	-	31	22.5	8.7
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	98	20.7	7.2	93	20.9	7.6	2	25.6	9.8	1	14.9	1.7	1	16.7	6.0	23	18.6	5.1
Regional	92	19.4	6.6	86	19.4	7.0	2	20.5	7.6	2	19.1	1.8	2	19.0	6.9	23	18.2	4.8
Distant	195	41.2	14.1	180	40.5	14.7	4	51.3	17.4	5	55.3	5.7	4	52.4	19.6	53	42.1	11.2
Unknown	88	18.6	6.4	85	19.0	6.9	-	-	-	-	-	-	-	-	-	26	21.1	5.7

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	782	74.8	61.0	686	74.6	59.3	25	78.1	88.8	24	65.0	33.5	10	72.9	64.6	222	72.8	51.2
Regional	117	11.2	8.8	106	11.5	8.8	3	8.1	8.0	3	8.7	4.1	2	15.7	13.6	35	11.6	7.6
Distant	95	9.1	8.2	82	8.9	7.8	4	12.5	13.1	8	21.9	12.8	-	-	-	36	11.6	9.0
Unknown	51	4.9	4.8	46	5.0	4.7	-	-	-	2	4.4	2.7	-	-	-	12	4.0	3.5
<i>Age < 65</i>																		
Localized	296	77.9	24.5	255	78.1	24.0	14	75.8	46.6	9	72.1	9.4	4	64.3	19.4	90	74.8	19.5
Regional	50	13.2	4.2	45	13.7	4.3	-	-	-	-	-	-	-	-	-	17	13.9	3.6
Distant	27	7.1	2.3	22	6.6	2.1	2	12.6	7.9	2	18.0	2.4	-	-	-	12	9.6	2.5
Unknown	7	1.8	0.5	5	1.5	0.5	-	-	-	-	-	-	-	-	-	2	1.7	0.4
<i>Age ≥ 65</i>																		
Localized	486	73.0	313.3	431	72.7	303.1	11	81.5	380.5	15	61.5	200.3	7	78.6	376.8	132	71.4	270.3
Regional	67	10.0	40.5	61	10.3	40.6	-	-	-	-	-	-	-	-	-	19	10.1	35.3
Distant	68	10.2	49.0	60	10.1	47.1	2	12.3	49.4	6	23.8	84.6	-	-	-	24	13.0	53.6
Unknown	45	6.7	34.0	41	6.9	33.8	-	-	-	-	-	-	-	-	-	10	5.5	25.0

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New York, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	360	41.9	3.5	241	43.9	3.4	69	34.4	3.5	-	-	-	36	44.7	3.7	78	45.7	4.4
Regional	313	36.4	2.7	191	34.9	2.4	85	42.0	4.1	-	-	-	30	37.3	3.2	65	38.2	3.7
Distant	124	14.4	1.0	78	14.3	0.9	35	17.2	1.7	-	-	-	9	11.5	1.0	20	11.6	1.2
Unknown	63	7.3	0.5	38	7.0	0.4	13	6.4	0.6	-	-	-	5	6.4	0.5	8	4.6	0.5

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	439	8.7	4.1	324	8.4	3.9	66	8.7	4.3	-	-	-	31	9.0	3.7	53	9.0	3.9
Localized	1,679	33.2	16.2	1,306	33.9	16.2	235	30.8	16.2	-	-	-	113	32.5	13.8	189	32.0	15.2
Regional	1,622	32.1	15.8	1,264	32.8	15.8	225	29.5	15.7	1	29.2	7.8	117	33.7	14.4	191	32.4	15.2
Distant	974	19.3	9.4	729	18.9	9.1	181	23.7	12.3	2	33.3	9.1	56	16.2	7.0	119	20.1	9.6
Unknown	340	6.7	3.4	235	6.1	3.0	56	7.4	4.2	-	-	-	30	8.7	4.0	38	6.5	3.3
<i>Age < 50</i>																		
In Situ	32	5.8	0.5	22	5.7	0.5	6	6.4	0.6	-	-	-	2	3.4	0.3	7	7.6	0.6
Localized	160	29.3	2.6	117	29.9	2.7	24	25.3	2.2	-	-	-	14	30.0	2.4	29	30.2	2.3
Regional	196	35.8	3.2	140	35.9	3.2	33	34.7	3.1	-	-	-	18	38.2	3.1	34	35.5	2.7
Distant	132	24.2	2.2	94	24.2	2.2	26	27.7	2.4	-	-	-	10	22.3	1.8	21	22.4	1.7
Unknown	27	4.9	0.4	17	4.4	0.4	6	6.0	0.5	-	-	-	3	6.0	0.5	4	4.2	0.3
<i>Age ≥ 50</i>																		
In Situ	407	9.0	13.3	302	8.7	12.7	60	9.0	14.1	-	-	-	30	9.8	12.8	46	9.2	12.7
Localized	1,518	33.7	51.6	1,189	34.3	51.6	212	31.6	53.0	-	-	-	99	32.8	43.7	161	32.4	48.9
Regional	1,426	31.6	48.6	1,123	32.4	48.7	193	28.8	48.5	-	-	-	99	33.0	44.3	158	31.8	47.8
Distant	841	18.7	28.3	635	18.3	27.3	155	23.1	38.1	-	-	-	46	15.3	20.7	98	19.7	30.2
Unknown	313	6.9	11.0	218	6.3	9.7	51	7.5	13.9	-	-	-	27	9.1	13.1	34	6.9	11.1
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	346	7.3	2.7	253	7.0	2.6	61	7.8	2.8	-	-	-	20	7.3	2.1	47	8.7	2.7
Localized	1,579	33.2	12.3	1,196	33.1	12.3	262	33.1	12.3	2	34.3	10.6	91	33.6	9.7	180	33.6	10.8
Regional	1,549	32.5	12.0	1,208	33.4	12.2	232	29.3	11.1	3	42.9	15.0	90	33.3	10.0	172	32.0	10.4
Distant	921	19.4	7.1	689	19.1	7.0	176	22.3	8.4	1	20.0	6.3	48	17.7	5.1	101	18.9	6.1
Unknown	364	7.6	2.6	269	7.5	2.4	59	7.5	2.8	-	-	-	22	8.1	2.4	36	6.8	2.2
<i>Age < 50</i>																		
In Situ	33	6.4	0.5	23	6.5	0.5	6	6.5	0.5	-	-	-	2	5.0	0.4	6	6.6	0.4
Localized	175	33.7	2.8	125	35.2	2.9	31	31.1	2.5	-	-	-	14	28.5	2.1	29	33.6	2.2
Regional	172	33.0	2.7	116	32.7	2.7	32	32.5	2.6	-	-	-	18	38.0	2.8	28	33.3	2.3
Distant	113	21.7	1.8	75	21.1	1.8	24	24.0	1.9	-	-	-	12	24.8	1.8	18	21.4	1.5
Unknown	27	5.2	0.4	16	4.6	0.4	6	5.9	0.5	-	-	-	2	3.7	0.3	4	5.2	0.3
<i>Age ≥ 50</i>																		
In Situ	313	7.4	8.4	229	7.0	8.2	55	7.9	8.8	-	-	-	17	7.8	6.7	41	9.1	8.6
Localized	1,404	33.1	37.4	1,071	32.9	37.1	232	33.4	38.1	2	40.0	38.2	77	34.7	29.6	151	33.6	33.0
Regional	1,377	32.5	36.3	1,091	33.5	37.2	200	28.9	33.3	-	-	-	72	32.3	28.9	143	31.8	31.8
Distant	808	19.1	21.1	614	18.8	20.8	153	22.0	25.2	-	-	-	36	16.2	13.9	83	18.4	18.1
Unknown	337	7.9	8.2	253	7.8	7.7	53	7.7	8.8	-	-	-	20	9.1	8.1	32	7.1	6.9

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
New York, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	4,984	23.5	42.3	3,729	22.9	43.5	769	23.5	36.5	6	27.9	27.7	389	28.8	40.0	625	25.7	36.0
Localized	10,705	50.4	86.7	8,522	52.4	92.6	1,423	43.5	67.5	9	39.6	43.2	626	46.4	64.7	1,120	46.1	65.5
Regional	4,153	19.6	35.2	3,039	18.7	35.1	793	24.2	38.4	5	24.3	25.4	268	19.8	27.4	537	22.1	30.7
Distant	939	4.4	7.5	672	4.1	7.2	212	6.5	10.2	2	8.1	9.5	44	3.3	4.5	106	4.3	6.3
Unknown	441	2.1	3.3	303	1.9	2.9	75	2.3	3.6	-	-	-	23	1.7	2.4	43	1.8	2.6
<i>Age < 50</i>																		
In Situ	1,227	28.2	19.8	888	28.9	20.8	162	22.5	13.2	2	32.1	12.2	146	31.5	22.6	184	27.9	15.4
Localized	1,825	41.9	29.2	1,317	42.9	30.7	278	38.7	22.6	2	32.1	13.3	193	41.6	29.5	259	39.2	21.3
Regional	1,087	25.0	17.5	742	24.2	17.4	220	30.5	18.0	2	28.6	11.4	106	22.8	15.9	182	27.6	14.8
Distant	157	3.6	2.5	95	3.1	2.2	47	6.6	3.8	-	-	-	12	2.7	1.8	25	3.7	2.0
Unknown	55	1.3	0.9	27	0.9	0.6	13	1.8	1.0	-	-	-	7	1.4	1.0	10	1.5	0.8
<i>Age ≥ 50</i>																		
In Situ	3,757	22.3	101.5	2,841	21.5	103.0	608	23.8	97.3	4	26.5	68.4	243	27.4	85.6	440	24.9	90.1
Localized	8,881	52.6	237.4	7,205	54.6	254.9	1,145	44.8	185.3	7	42.2	121.7	433	48.9	156.8	861	48.7	181.3
Regional	3,066	18.2	81.7	2,297	17.4	81.3	574	22.5	91.7	4	22.9	62.1	162	18.2	57.7	354	20.0	72.3
Distant	781	4.6	20.7	577	4.4	20.1	165	6.5	26.7	-	-	-	32	3.6	11.5	81	4.6	17.5
Unknown	386	2.3	9.6	276	2.1	8.7	62	2.4	10.2	-	-	-	16	1.8	6.3	33	1.9	7.1

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	14	0.2	0.1	10	0.2	0.1	2	0.2	0.1	-	-	-	2	0.4	0.3	-	-	-
Localized	1,592	23.1	15.5	1,330	23.9	16.4	156	18.3	11.2	2	18.6	7.9	97	23.6	12.6	99	19.5	8.9
Regional	1,542	22.4	14.8	1,256	22.5	15.3	186	21.9	13.1	2	27.9	17.1	89	21.8	11.8	118	23.2	10.2
Distant	3,343	48.6	32.0	2,661	47.7	32.4	467	54.9	32.1	4	46.5	27.1	200	48.8	27.0	259	51.1	22.5
Unknown	386	5.6	3.9	316	5.7	4.0	41	4.8	3.1	-	-	-	22	5.3	3.3	31	6.1	2.9
<i>Female</i>																		
In Situ	27	0.4	0.2	23	0.4	0.2	2	0.3	0.1	-	-	-	1	0.5	0.1	2	0.4	0.1
Localized	2,036	28.6	15.5	1,728	29.0	17.2	202	24.6	9.5	2	19.6	10.0	92	29.9	9.8	123	26.1	7.5
Regional	1,520	21.3	11.5	1,280	21.5	12.7	179	21.8	8.3	3	29.4	15.0	53	17.2	5.9	95	20.1	5.8
Distant	3,131	43.9	23.5	2,580	43.3	25.3	395	48.0	18.4	5	49.0	23.8	144	46.9	15.8	223	47.4	13.5
Unknown	413	5.8	2.9	346	5.8	3.1	43	5.3	2.1	-	-	-	17	5.5	1.9	28	5.9	1.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	9,187	65.6	81.1	6,666	66.5	75.7	2,022	66.5	125.7	11	71.3	61.5	292	57.1	34.8	988	64.4	75.3
Regional	1,615	11.5	13.8	1,241	12.4	13.7	280	9.2	16.5	2	12.5	8.8	69	13.5	8.0	160	10.5	11.5
Distant	968	6.9	9.4	669	6.7	8.2	252	8.3	18.4	-	-	-	38	7.4	5.4	108	7.0	9.9
Unknown	2,245	16.0	20.7	1,446	14.4	17.0	484	15.9	32.8	2	12.5	12.9	112	21.9	14.4	278	18.1	23.8
<i>Age < 65</i>																		
Localized	4,076	68.9	36.2	2,790	70.2	32.5	1,067	69.3	62.5	6	71.4	28.4	111	60.3	11.9	483	67.8	32.5
Regional	823	13.9	7.3	601	15.1	7.0	177	11.5	10.5	-	-	-	30	16.3	3.2	96	13.4	6.5
Distant	255	4.3	2.2	153	3.9	1.8	90	5.9	5.3	-	-	-	9	4.7	0.9	32	4.5	2.2
Unknown	760	12.8	6.6	428	10.8	4.8	205	13.3	11.9	-	-	-	35	18.7	3.7	101	14.2	6.8
<i>Age ≥ 65</i>																		
Localized	5,112	63.1	391.3	3,876	64.1	374.4	956	63.7	562.4	5	71.1	290.7	180	55.3	193.5	505	61.5	371.2
Regional	791	9.8	58.5	640	10.6	59.6	103	6.9	58.6	-	-	-	39	12.0	41.1	65	7.9	46.5
Distant	714	8.8	58.8	515	8.5	52.6	162	10.8	109.6	-	-	-	29	9.0	36.4	76	9.2	63.3
Unknown	1,486	18.3	118.0	1,018	16.8	101.4	279	18.6	177.6	-	-	-	77	23.7	88.7	176	21.4	140.8

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
North Carolina, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	172	45.3	3.4	119	46.0	3.3	40	41.6	3.3	-	-	-	4	48.8	2.9	13	59.3	4.2
Regional	134	35.2	2.4	92	35.6	2.3	34	35.6	2.7	-	-	-	3	39.0	2.2	7	29.2	2.2
Distant	57	15.0	1.0	37	14.2	0.9	17	18.1	1.3	-	-	-	-	-	-	2	8.0	0.7
Unknown	17	4.4	0.3	11	4.2	0.2	5	4.8	0.4	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	106	4.5	1.9	76	4.3	1.7	26	5.3	2.6	-	-	-	1	5.1	1.1	1	3.2	0.6
Localized	778	33.0	14.6	594	33.5	14.1	157	31.8	16.3	2	38.5	23.5	9	37.3	8.9	11	25.0	6.6
Regional	845	35.8	16.0	657	37.0	15.7	161	32.6	17.3	2	30.8	14.6	9	36.4	8.1	19	43.6	10.2
Distant	495	21.0	9.3	359	20.2	8.6	121	24.4	12.4	1	23.1	11.2	4	18.6	4.3	10	23.6	5.3
Unknown	133	5.7	2.7	88	4.9	2.2	29	5.9	3.5	-	-	-	-	-	-	2	4.5	1.9
<i>Age < 50</i>																		
In Situ	7	2.3	0.2	4	2.2	0.2	2	2.4	0.3	-	-	-	-	-	-	-	-	-
Localized	74	26.4	2.3	53	27.1	2.3	16	23.8	2.4	-	-	-	2	31.0	1.5	3	24.6	1.0
Regional	114	40.7	3.7	80	41.0	3.5	29	42.1	4.3	-	-	-	2	37.9	1.8	6	49.2	1.9
Distant	78	27.6	2.5	54	27.8	2.4	19	28.2	2.9	-	-	-	2	27.6	1.4	3	26.2	1.1
Unknown	8	3.0	0.3	4	1.8	0.2	2	3.5	0.3	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	99	4.8	6.3	72	4.6	5.8	24	5.7	8.8	-	-	-	-	-	-	1	4.5	2.2
Localized	704	33.9	46.7	541	34.3	45.0	141	33.1	52.6	2	47.6	85.0	7	39.3	28.3	8	25.2	21.4
Regional	731	35.2	48.3	577	36.5	47.6	133	31.1	51.2	-	-	-	6	36.0	24.7	13	41.3	31.9
Distant	417	20.1	27.1	304	19.3	24.9	102	23.8	37.1	-	-	-	3	15.7	11.7	7	22.6	16.3
Unknown	125	6.0	9.0	84	5.3	7.5	27	6.2	11.9	-	-	-	-	-	-	2	6.5	7.0
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	86	4.0	1.3	56	3.5	1.1	26	5.3	2.0	-	-	-	-	-	-	1	4.0	0.7
Localized	720	33.5	11.4	534	33.8	11.0	160	32.8	12.4	2	36.4	19.0	9	34.3	8.0	11	29.9	6.0
Regional	769	35.7	12.1	590	37.3	12.1	157	32.1	12.3	1	27.3	10.4	9	34.3	7.1	13	36.2	6.8
Distant	450	20.9	7.1	317	20.0	6.6	119	24.3	9.3	1	27.3	12.4	5	19.0	4.7	9	26.0	4.5
Unknown	127	5.9	1.9	87	5.5	1.6	27	5.5	2.1	-	-	-	3	9.5	2.9	1	4.0	1.1
<i>Age < 50</i>																		
In Situ	7	2.6	0.2	4	2.3	0.2	2	3.4	0.3	-	-	-	-	-	-	-	-	-
Localized	87	31.9	2.6	62	32.5	2.7	20	29.9	2.5	-	-	-	2	33.3	1.7	2	23.4	0.8
Regional	100	36.6	3.1	71	37.4	3.1	23	35.7	3.0	-	-	-	3	43.3	2.1	4	40.4	1.4
Distant	70	25.8	2.2	49	25.7	2.1	19	28.7	2.4	-	-	-	-	-	-	3	34.0	1.2
Unknown	8	3.1	0.3	4	2.1	0.2	2	2.4	0.2	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	79	4.2	4.2	51	3.7	3.6	24	5.6	6.4	-	-	-	-	-	-	1	5.4	2.4
Localized	633	33.7	34.2	472	33.9	32.7	140	33.2	38.3	-	-	-	7	34.6	24.6	8	32.3	19.8
Regional	669	35.6	35.8	518	37.2	35.5	133	31.6	36.7	-	-	-	7	31.8	20.2	9	34.6	21.0
Distant	379	20.2	20.1	268	19.2	18.2	100	23.7	27.2	1	31.6	44.8	-	-	-	6	23.1	13.2
Unknown	119	6.3	6.3	83	5.9	5.4	25	5.9	7.2	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
North Carolina, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,855	18.1	29.9	1,376	17.8	29.5	406	19.1	30.9	2	17.5	18.1	31	22.2	22.2	30	16.7	11.9
Localized	5,494	53.7	86.6	4,322	55.8	89.1	1,001	47.1	77.2	5	47.4	60.6	70	50.1	51.4	84	47.3	38.6
Regional	2,255	22.0	37.3	1,616	20.8	35.5	553	26.0	43.1	3	26.3	29.4	31	22.3	22.0	54	30.1	21.0
Distant	485	4.7	7.8	331	4.3	7.0	135	6.4	10.5	-	-	-	6	4.6	4.4	8	4.5	3.3
Unknown	150	1.5	2.3	104	1.3	2.0	30	1.4	2.5	-	-	-	1	0.9	1.4	3	1.5	1.8
<i>Age < 50</i>																		
In Situ	369	19.7	11.4	264	20.1	11.5	82	18.5	10.6	-	-	-	9	17.7	8.1	14	17.4	5.4
Localized	834	44.5	25.7	605	46.1	26.3	173	39.4	22.4	1	54.5	15.6	27	50.4	22.7	34	41.6	12.5
Regional	562	30.0	17.5	380	28.9	16.7	149	33.8	19.3	-	-	-	14	25.9	11.3	30	36.2	10.7
Distant	95	5.1	2.9	57	4.3	2.5	32	7.3	4.1	-	-	-	3	5.3	2.3	4	4.4	1.2
Unknown	15	0.8	0.5	7	0.5	0.3	5	1.0	0.6	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,486	17.8	78.3	1,113	17.3	76.6	324	19.2	84.0	-	-	-	22	24.9	59.3	16	16.1	29.1
Localized	4,660	55.7	246.1	3,717	57.7	253.5	828	49.1	220.6	4	45.7	178.6	43	49.9	126.6	50	52.1	106.7
Regional	1,693	20.2	89.4	1,236	19.2	84.9	405	24.0	105.4	-	-	-	17	20.1	50.0	24	25.0	47.9
Distant	390	4.7	20.6	275	4.3	18.7	103	6.1	27.3	-	-	-	4	4.2	9.9	4	4.5	9.0
Unknown	135	1.6	7.0	97	1.5	6.3	26	1.5	7.5	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	9	0.2	0.2	8	0.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	905	20.4	17.4	747	21.3	17.7	140	17.0	16.2	1	27.3	12.6	5	16.4	4.8	6	16.9	5.3
Regional	1,022	23.1	18.8	804	22.9	18.5	197	24.0	21.2	-	-	-	5	17.1	5.2	7	22.3	7.2
Distant	2,227	50.3	41.3	1,742	49.7	40.4	428	52.2	45.5	2	45.5	32.7	18	62.9	21.4	19	56.6	13.2
Unknown	264	6.0	5.3	204	5.8	5.0	55	6.7	6.9	-	-	-	-	-	-	1	4.2	1.7
<i>Female</i>																		
In Situ	10	0.3	0.1	8	0.3	0.2	2	0.3	0.1	-	-	-	-	-	-	-	-	-
Localized	938	25.0	14.2	792	25.7	15.3	129	21.7	10.1	2	30.3	23.5	6	18.2	6.1	7	23.4	5.7
Regional	902	24.0	13.6	733	23.8	14.2	152	25.5	11.6	1	21.2	14.7	7	20.8	6.4	7	22.2	4.3
Distant	1,696	45.1	25.5	1,372	44.5	26.5	282	47.3	21.6	3	42.4	30.1	18	56.6	16.6	15	48.7	10.1
Unknown	212	5.6	3.2	176	5.7	3.3	31	5.1	2.5	-	-	-	1	4.4	1.9	2	5.7	1.4

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	5,165	75.9	87.8	3,593	77.0	76.8	1,402	77.4	133.2	4	77.8	50.7	30	75.6	34.3	67	71.8	43.4
Regional	808	11.9	13.2	594	12.7	12.2	194	10.7	17.1	-	-	-	5	13.2	5.0	14	14.7	8.1
Distant	460	6.8	9.1	307	6.6	7.6	142	7.8	16.8	-	-	-	4	9.1	4.7	8	8.6	6.6
Unknown	375	5.5	7.4	173	3.7	4.5	74	4.1	9.8	-	-	-	-	-	-	5	5.0	3.9
<i>Age < 65</i>																		
Localized	2,212	77.7	39.3	1,390	78.7	31.9	748	79.2	67.0	2	76.9	21.8	11	75.0	10.0	34	72.9	15.0
Regional	409	14.4	7.2	276	15.6	6.3	122	12.9	10.9	-	-	-	2	15.3	2.0	8	17.8	3.7
Distant	131	4.6	2.3	71	4.0	1.7	55	5.8	4.8	-	-	-	1	8.3	1.1	3	5.9	1.2
Unknown	95	3.3	1.7	30	1.7	0.7	19	2.0	1.7	-	-	-	-	-	-	2	3.4	0.6
<i>Age ≥ 65</i>																		
Localized	2,953	74.5	422.9	2,203	76.0	386.8	654	75.4	591.0	2	78.6	250.9	19	76.0	202.0	32	70.6	239.8
Regional	399	10.1	54.1	318	11.0	52.9	72	8.3	60.1	-	-	-	3	12.0	26.1	5	11.4	38.7
Distant	329	8.3	55.8	235	8.1	48.4	87	10.0	99.5	-	-	-	2	9.6	29.3	5	11.4	44.1
Unknown	280	7.1	47.0	143	4.9	30.6	55	6.3	66.0	-	-	-	-	-	-	3	6.6	26.3

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
North Dakota, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	9	46.4	2.8	7	48.7	2.6	-	-	-	-	-	-	-	-	-	-	-	-
Regional	6	32.0	1.6	5	30.3	1.3	-	-	-	-	-	-	-	-	-	-	-	-
Distant	4	18.6	0.9	3	18.4	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	2	1.2	0.5	2	1.1	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	76	38.9	18.8	71	39.3	18.7	-	-	-	3	38.1	30.7	-	-	-	-	-	-
Regional	71	36.8	18.0	67	36.7	17.6	-	-	-	3	40.5	35.0	-	-	-	-	-	-
Distant	36	18.5	9.2	33	18.3	8.9	-	-	-	2	19.0	21.1	-	-	-	-	-	-
Unknown	9	4.5	2.3	8	4.6	2.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	7	35.3	3.3	7	37.4	3.5	-	-	-	-	-	-	-	-	-	-	-	-
Regional	7	36.3	3.4	6	33.0	3.1	-	-	-	-	-	-	-	-	-	-	-	-
Distant	5	22.5	2.2	4	23.1	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	68	39.4	59.2	65	39.5	58.5	-	-	-	-	-	-	-	-	-	-	-	-
Regional	64	36.8	56.5	61	37.1	55.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	31	18.1	27.4	29	17.7	26.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	3	1.6	0.6	2	1.5	0.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	64	37.4	14.6	59	37.0	14.1	-	-	-	2	34.4	20.3	-	-	-	-	-	-
Regional	63	36.8	14.5	59	37.0	14.1	-	-	-	2	34.4	19.1	-	-	-	-	-	-
Distant	33	19.2	7.5	31	19.4	7.4	-	-	-	2	25.0	14.8	-	-	-	-	-	-
Unknown	8	4.9	1.7	8	5.2	1.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	5	32.4	2.4	4	30.8	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Regional	5	36.5	2.9	5	35.4	2.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	4	25.7	1.9	4	27.7	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	59	37.9	46.7	55	37.5	45.2	-	-	-	-	-	-	-	-	-	-	-	-
Regional	58	36.9	44.8	54	37.1	43.7	-	-	-	-	-	-	-	-	-	-	-	-
Distant	29	18.6	22.2	27	18.6	21.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
North Dakota, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	103	16.4	26.6	97	16.4	26.7	-	-	-	2	10.7	13.4	-	-	-	-	-	-
Localized	343	54.6	82.6	325	54.8	82.3	-	-	-	8	50.0	72.0	2	55.6	49.2	2	63.2	50.7
Regional	146	23.2	37.3	137	23.0	37.2	-	-	-	6	35.7	48.7	1	33.3	20.8	-	-	-
Distant	29	4.6	6.9	27	4.5	6.7	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	8	1.2	1.8	8	1.3	1.9	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	21	20.2	11.4	19	20.7	11.8	-	-	-	-	-	-	-	-	-	-	-	-
Localized	44	42.6	23.4	39	42.3	23.1	-	-	-	1	41.2	17.7	-	-	-	-	-	-
Regional	32	31.2	16.8	29	31.3	17.0	-	-	-	2	47.1	17.9	-	-	-	-	-	-
Distant	5	4.5	2.5	4	3.9	2.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	1.6	0.9	2	1.7	1.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	83	15.7	66.4	78	15.6	65.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	299	56.9	237.8	286	57.0	237.2	-	-	-	7	52.2	214.2	-	-	-	-	-	-
Regional	114	21.6	90.8	108	21.5	90.0	-	-	-	4	32.8	129.2	-	-	-	-	-	-
Distant	24	4.6	18.6	23	4.6	18.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	6	1.2	4.1	6	1.2	4.2	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	56	21.5	14.3	54	22.1	14.3	-	-	-	-	-	-	-	-	-	-	-	-
Regional	64	24.7	16.2	60	24.8	15.9	-	-	-	2	22.0	28.4	-	-	-	-	-	-
Distant	127	49.0	31.7	118	48.7	30.9	-	-	-	5	54.0	68.0	-	-	-	-	-	-
Unknown	12	4.6	3.1	10	4.3	2.8	-	-	-	1	14.0	20.0	-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	63	27.4	14.7	59	27.4	14.1	-	-	-	3	28.6	36.9	-	-	-	-	-	-
Regional	48	21.0	11.2	46	21.4	11.1	-	-	-	1	12.5	13.7	-	-	-	-	-	-
Distant	109	47.5	24.7	101	47.3	23.7	-	-	-	6	51.8	52.0	-	-	-	-	-	-
Unknown	9	3.8	1.7	8	3.6	1.6	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	371	76.1	86.5	349	75.9	84.7	4	84.0	84.7	7	73.3	71.1	-	-	-	2	90.9	62.4
Regional	69	14.2	15.1	66	14.3	15.0	-	-	-	1	15.6	17.4	-	-	-	-	-	-
Distant	38	7.7	9.4	35	7.7	9.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	10	2.0	2.5	9	2.0	2.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	155	76.7	34.8	143	77.1	34.0	-	-	-	3	63.6	23.8	-	-	-	-	-	-
Regional	34	17.0	7.5	31	16.9	7.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	11	5.6	2.6	10	5.2	2.3	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	0.8	0.4	2	0.9	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	217	75.7	444.2	206	75.2	434.9	-	-	-	4	82.6	398.1	-	-	-	-	-	-
Regional	35	12.3	67.6	34	12.6	68.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	26	9.2	56.4	26	9.4	56.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	8	2.8	17.1	8	2.8	17.2	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Ohio, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	217	45.0	3.8	187	45.8	3.9	25	41.6	3.3	Insufficient data for the calculation of AI/AN PRCDA statistics			2	47.6	1.5	4	45.7	2.7
Regional	176	36.6	2.8	148	36.5	2.7	24	39.0	3.1				2	47.6	1.7	5	50.0	3.5
Distant	67	13.9	1.0	56	13.7	1.0	10	17.0	1.3				-	-	-	-	-	-
Unknown	22	4.5	0.3	16	4.0	0.3	1	2.3	0.2				-	-	-	-	-	-

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	153	4.8	2.3	127	4.6	2.1	19	6.1	2.8				2	8.2	2.5	1	3.3	1.0
Localized	985	30.9	15.3	878	31.7	15.4	91	29.6	14.3				6	21.6	6.2	12	33.9	11.9
Regional	1,120	35.1	17.5	1,004	36.3	17.8	96	31.0	15.1				12	43.3	13.1	12	33.3	11.1
Distant	635	19.9	9.7	552	19.9	9.6	74	24.1	11.7				5	18.7	4.5	5	14.4	5.5
Unknown	296	9.3	4.6	206	7.4	3.7	29	9.2	5.0				2	8.2	2.4	5	15.0	4.5
<i>Age < 50</i>																		
In Situ	9	2.8	0.3	6	2.3	0.2	1	3.4	0.3				-	-	-	-	-	-
Localized	87	26.9	2.4	76	28.0	2.6	9	26.7	2.0				-	-	-	2	24.2	1.2
Regional	126	38.8	3.6	111	40.6	3.8	13	35.8	2.9				2	35.7	2.1	2	36.4	1.7
Distant	80	24.7	2.3	67	24.6	2.3	10	29.0	2.4				2	35.7	1.9	1	21.2	1.1
Unknown	22	6.8	0.6	12	4.4	0.4	2	5.1	0.4				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	144	5.0	7.5	121	4.8	7.1	18	6.5	9.5				-	-	-	-	-	-
Localized	897	31.3	49.0	802	32.1	49.2	82	29.9	46.3				-	-	-	11	36.1	39.8
Regional	994	34.7	53.9	893	35.8	54.4	83	30.4	47.1				10	45.3	42.1	10	32.7	35.7
Distant	555	19.4	29.2	485	19.4	28.7	64	23.4	36.1				3	14.2	11.5	4	12.9	17.0
Unknown	274	9.6	15.1	194	7.8	12.2	27	9.8	17.1				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	126	4.2	1.6	106	4.1	1.6	16	5.1	1.9				-	-	-	2	6.9	1.6
Localized	968	32.7	12.5	849	33.0	12.5	105	33.2	12.7				7	34.7	6.3	10	33.8	8.0
Regional	1,022	34.5	13.2	912	35.4	13.3	96	30.5	11.8				8	39.6	7.4	10	33.1	8.0
Distant	555	18.7	7.3	475	18.4	7.2	75	23.7	9.1				3	13.9	2.5	5	15.9	3.6
Unknown	294	9.9	3.6	234	9.1	3.1	24	7.5	2.8				2	7.9	1.2	3	10.3	2.6
<i>Age < 50</i>																		
In Situ	12	4.0	0.3	10	4.0	0.3	2	4.3	0.4				-	-	-	-	-	-
Localized	89	30.6	2.5	74	30.7	2.5	12	33.0	2.6				1	33.3	1.2	2	31.3	1.5
Regional	99	33.9	2.8	86	35.4	2.9	11	29.2	2.3				2	44.4	1.5	2	37.5	2.0
Distant	75	25.7	2.1	62	25.6	2.1	12	31.9	2.5				-	-	-	2	25.0	1.4
Unknown	17	5.7	0.5	10	4.3	0.4	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	114	4.3	5.0	97	4.1	4.8	14	5.2	6.0				-	-	-	-	-	-
Localized	879	32.9	38.7	775	33.2	38.5	93	33.3	39.1				6	34.9	19.5	8	34.5	25.0
Regional	923	34.5	40.2	826	35.4	40.7	85	30.6	36.5				6	38.6	22.7	7	31.9	23.7
Distant	479	17.9	20.9	413	17.7	20.5	63	22.6	26.5				-	-	-	3	13.3	9.5
Unknown	277	10.4	11.7	223	9.6	10.5	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Ohio, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	2,085	17.9	28.5	1,780	17.5	28.2	258	19.9	31.4				30	24.1	24.0	19	18.2	14.0
Localized	6,189	53.1	82.3	5,494	54.1	83.6	591	45.7	72.5				61	48.7	49.9	53	51.0	42.2
Regional	2,576	22.1	36.2	2,186	21.5	35.4	340	26.3	42.3				28	22.5	22.6	24	23.1	17.4
Distant	590	5.1	7.8	498	4.9	7.5	83	6.4	10.1				4	2.9	2.5	5	5.2	4.0
Unknown	213	1.8	2.6	187	1.8	2.6	21	1.6	2.6				2	1.9	2.1	3	2.5	2.3
<i>Age < 50</i>																		
In Situ	374	19.7	10.7	316	19.9	10.8	42	17.7	9.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			11	24.3	11.5	6	17.0	4.9
Localized	853	44.9	24.4	727	45.7	24.9	94	39.7	20.3				21	45.7	21.1	16	47.9	13.7
Regional	569	30.0	16.4	466	29.3	16.1	83	35.2	17.7				12	26.1	12.1	9	27.3	7.7
Distant	83	4.4	2.4	64	4.1	2.2	15	6.3	3.2				1	2.6	1.2	2	6.7	2.0
Unknown	20	1.0	0.5	16	1.0	0.5	3	1.1	0.6				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,711	17.5	75.2	1,464	17.1	73.6	216	20.4	89.8				19	23.9	56.8	13	18.8	37.8
Localized	5,336	54.7	233.8	4,766	55.7	237.5	497	47.1	209.3				40	50.4	125.3	37	52.4	117.0
Regional	2,008	20.6	88.1	1,720	20.1	86.0	257	24.3	106.8				16	20.4	50.3	15	21.1	42.6
Distant	507	5.2	22.0	434	5.1	21.4	68	6.4	28.3				2	3.0	6.2	3	4.6	9.4
Unknown	194	2.0	8.0	171	2.0	8.0	18	1.7	7.8				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	11	0.2	0.2	11	0.2	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,030	19.5	16.0	923	19.7	16.0	96	17.8	16.7				6	22.0	6.7	6	19.0	7.1
Regional	1,241	23.5	18.6	1,111	23.7	18.7	121	22.5	19.4				4	15.2	5.2	6	18.5	7.6
Distant	2,509	47.6	37.7	2,213	47.2	37.3	272	50.4	43.7				14	53.0	17.7	18	53.0	19.7
Unknown	482	9.1	7.6	427	9.1	7.5	50	9.3	9.2				2	9.1	4.0	3	8.9	3.2
<i>Female</i>																		
In Situ	16	0.3	0.2	13	0.3	0.2	2	0.4	0.3	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,129	24.0	14.3	1,002	24.1	14.4	116	23.1	14.0				7	22.1	6.6	6	20.3	5.0
Regional	1,086	23.1	13.6	953	22.9	13.6	124	24.6	14.7				6	20.1	6.6	5	18.1	4.4
Distant	2,104	44.7	26.4	1,854	44.6	26.5	229	45.5	27.6				14	47.0	13.2	13	48.6	11.8
Unknown	369	7.9	4.4	333	8.0	4.5	32	6.4	3.9				2	8.1	2.8	3	12.3	3.4

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	5,082	68.8	70.9	4,210	70.3	66.2	774	72.6	111.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			28	68.0	30.7	52	71.6	52.1
Regional	1,045	14.1	13.9	895	14.9	13.4	134	12.6	18.2				7	17.7	7.6	11	15.2	9.0
Distant	470	6.4	7.3	380	6.3	6.6	84	7.9	13.7				3	7.9	4.4	5	6.9	6.1
Unknown	793	10.7	11.9	502	8.4	8.5	73	6.9	12.9				3	6.4	2.7	5	6.3	5.7
<i>Age < 65</i>																		
Localized	2,174	70.3	30.5	1,691	71.3	26.9	442	74.5	60.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			9	71.2	9.3	24	70.0	18.1
Regional	550	17.8	7.8	452	19.1	7.3	89	15.1	12.3				3	21.2	2.7	7	20.6	5.4
Distant	145	4.7	2.0	105	4.4	1.7	39	6.5	5.2				-	-	-	2	5.3	1.4
Unknown	225	7.3	3.1	124	5.2	1.9	23	3.9	3.1				-	-	-	1	4.1	1.1
<i>Age ≥ 65</i>																		
Localized	2,908	67.7	350.1	2,519	69.7	337.5	332	70.3	464.4				18	66.4	178.3	28	73.1	286.6
Regional	495	11.5	56.4	442	12.2	56.1	45	9.4	58.8				4	16.1	41.6	4	10.4	34.0
Distant	325	7.6	43.3	274	7.6	40.5	45	9.6	72.4				-	-	-	3	8.3	38.4
Unknown	568	13.2	73.1	378	10.5	54.3	50	10.6	80.4				-	-	-	3	8.3	37.9

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Oklahoma, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	72	41.1	3.9	57	42.5	3.9	4	36.7	2.4	9	37.8	4.9	2	40.0	4.2	7	46.3	5.1
Regional	61	34.4	3.2	46	34.4	3.0	4	36.7	2.7	8	33.6	4.4	2	44.0	4.8	5	33.8	4.0
Distant	27	15.1	1.3	19	14.4	1.2	2	18.4	1.2	4	17.6	2.3	-	-	-	2	11.3	1.6
Unknown	16	9.3	0.8	12	8.7	0.7	-	-	-	3	10.9	1.6	-	-	-	1	8.8	1.1

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	25	2.4	1.2	20	2.5	1.1	1	2.2	1.1	1	1.3	1.0	-	-	-	-	-	-
Localized	331	32.9	16.2	275	34.0	15.7	20	31.7	16.6	30	27.2	21.1	3	24.2	12.0	12	34.7	13.4
Regional	325	32.3	15.9	263	32.5	15.1	20	31.1	16.2	36	32.8	23.9	5	34.8	13.9	9	27.1	10.3
Distant	206	20.4	10.0	161	19.9	9.2	16	24.5	13.2	24	22.0	15.8	3	19.7	9.5	8	22.4	8.6
Unknown	120	11.9	6.0	89	11.1	5.2	7	10.6	6.1	18	16.7	13.2	2	18.2	7.4	5	13.5	5.9
<i>Age < 50</i>																		
In Situ	2	1.4	0.1	2	1.9	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	35	29.7	3.0	27	32.2	3.0	3	30.6	3.2	4	23.8	3.4	-	-	-	2	26.2	1.7
Regional	41	34.7	3.6	28	33.6	3.2	3	28.6	2.9	7	40.5	6.0	2	50.0	4.7	4	45.2	3.3
Distant	29	24.8	2.6	20	23.9	2.3	4	36.7	4.0	4	25.0	3.7	-	-	-	1	16.7	1.2
Unknown	11	9.4	1.0	7	8.3	0.8	-	-	-	2	10.7	1.6	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	23	2.6	3.9	19	2.6	3.6	1	2.6	4.1	1	1.5	3.7	-	-	-	-	-	-
Localized	296	33.3	50.8	248	34.2	49.1	17	31.9	51.7	26	27.8	67.4	-	-	-	10	37.5	44.2
Regional	285	32.0	48.2	234	32.4	46.1	17	31.5	51.0	29	31.5	70.8	3	30.0	38.0	5	21.1	28.5
Distant	177	19.9	29.3	141	19.5	27.3	12	22.3	37.2	20	21.5	47.7	-	-	-	6	24.2	27.9
Unknown	109	12.3	19.4	82	11.4	16.9	-	-	-	16	17.8	43.6	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	20	2.3	0.8	16	2.3	0.8	1	2.1	0.9	2	2.1	1.0	-	-	-	-	-	-
Localized	301	34.3	12.6	247	35.0	12.1	19	33.0	13.2	29	31.1	17.0	5	35.2	13.4	9	33.1	10.3
Regional	276	31.5	11.7	223	31.7	11.1	17	29.8	11.7	31	32.6	18.2	5	32.4	13.3	10	37.7	12.0
Distant	183	20.9	7.9	143	20.3	7.3	15	26.3	10.4	20	21.6	11.8	4	26.8	11.1	5	19.2	6.2
Unknown	97	11.1	4.0	76	10.8	3.6	5	8.8	3.8	12	12.7	7.1	-	-	-	2	9.2	2.5
<i>Age < 50</i>																		
In Situ	2	1.9	0.2	1	2.0	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	29	30.4	2.5	22	31.8	2.5	2	18.2	1.6	4	28.4	3.1	2	61.5	4.5	2	31.6	1.8
Regional	33	34.0	2.9	24	33.8	2.7	3	36.4	3.0	5	35.8	4.3	-	-	-	2	31.6	2.4
Distant	25	26.3	2.3	19	27.0	2.2	3	29.5	2.7	3	22.4	2.6	-	-	-	2	28.9	2.0
Unknown	7	7.5	0.6	4	5.4	0.4	-	-	-	2	13.4	1.4	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	18	2.3	2.6	15	2.3	2.4	-	-	-	2	2.5	3.6	-	-	-	-	-	-
Localized	271	34.8	38.9	224	35.3	37.3	17	35.7	43.3	26	31.5	53.6	3	29.3	37.0	6	33.7	32.3
Regional	244	31.2	34.7	199	31.4	33.3	14	28.6	34.3	26	32.0	54.8	-	-	-	7	40.2	37.3
Distant	158	20.2	22.5	124	19.5	20.7	12	25.7	30.5	17	21.4	35.9	-	-	-	3	15.2	17.1
Unknown	90	11.5	12.8	72	11.4	11.8	-	-	-	10	12.6	22.0	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Oklahoma, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	478	14.5	21.0	386	14.3	20.3	35	16.4	23.2	42	13.3	22.6	9	18.2	21.1	19	16.5	18.1
Localized	1,707	51.7	73.2	1,419	52.6	71.8	88	41.2	60.3	165	52.4	93.2	25	50.2	56.0	52	45.6	54.6
Regional	797	24.1	35.7	638	23.7	34.2	63	29.5	42.5	77	24.5	42.0	12	25.1	26.0	34	30.2	31.2
Distant	181	5.5	7.8	144	5.4	7.3	18	8.2	12.2	16	5.0	9.3	2	3.2	4.0	6	4.9	6.9
Unknown	142	4.3	5.9	108	4.0	5.2	10	4.8	7.2	15	4.8	8.7	2	3.2	4.4	3	2.8	3.5
<i>Age < 50</i>																		
In Situ	82	15.2	7.4	62	16.0	7.2	7	12.9	7.3	7	10.6	6.7	3	17.1	8.4	8	20.2	8.5
Localized	235	43.9	21.1	172	44.3	19.7	19	37.3	20.1	34	48.0	29.4	7	43.9	20.8	15	36.5	14.5
Regional	175	32.6	15.5	126	32.5	14.4	19	36.9	19.3	22	31.4	18.7	5	30.5	14.4	16	38.0	15.2
Distant	29	5.4	2.6	19	4.9	2.2	5	9.0	4.6	4	5.4	3.5	-	-	-	-	-	-
Unknown	16	2.9	1.4	9	2.3	1.0	2	3.9	2.0	3	4.6	2.8	-	-	-	1	2.9	1.2
<i>Age ≥ 50</i>																		
In Situ	396	14.3	56.5	324	14.0	54.6	28	17.4	64.9	34	14.1	64.3	6	18.8	54.1	10	14.4	43.2
Localized	1,472	53.2	209.7	1,247	54.0	208.4	69	42.4	165.7	131	53.7	260.3	18	53.3	148.1	37	50.8	159.5
Regional	622	22.5	88.6	512	22.2	86.0	44	27.1	103.4	55	22.5	103.0	7	22.4	56.4	19	25.7	73.1
Distant	152	5.5	21.7	125	5.4	20.9	13	8.0	32.0	12	4.9	24.5	-	-	-	-	-	-
Unknown	126	4.6	17.9	99	4.3	16.3	8	5.0	21.0	12	4.8	24.0	-	-	-	2	2.8	9.3

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.1	0.1	2	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	312	18.5	15.2	270	19.0	15.1	13	13.2	11.8	27	17.9	20.3	2	13.1	8.2	3	11.8	5.6
Regional	358	21.2	16.9	304	21.4	16.6	20	21.1	17.4	31	20.4	22.3	2	14.8	8.1	7	28.6	10.6
Distant	779	46.2	36.6	648	45.6	35.2	53	55.6	44.6	69	45.7	48.9	8	63.9	26.9	11	46.2	16.1
Unknown	235	13.9	11.7	198	13.9	11.2	10	10.0	9.8	24	16.0	19.3	-	-	-	3	13.4	5.6
<i>Female</i>																		
In Situ	2	0.1	0.1	1	0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	298	21.1	12.1	255	21.4	12.0	14	18.4	10.1	27	20.2	15.5	2	17.4	6.9	4	21.0	7.0
Regional	318	22.5	12.9	265	22.2	12.6	19	25.9	13.7	32	23.8	18.4	2	13.0	4.5	4	19.0	5.7
Distant	634	44.8	25.5	533	44.7	25.1	34	46.5	22.7	59	44.4	33.8	7	52.2	18.7	11	51.4	15.4
Unknown	163	11.5	6.6	138	11.6	6.3	6	8.6	4.9	15	11.6	10.0	2	17.4	7.5	2	8.6	2.7

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,369	66.2	61.2	1,091	67.5	56.8	143	67.7	106.1	96	63.4	63.3	10	72.9	36.2	29	64.6	38.7
Regional	213	10.3	9.1	168	10.4	8.4	23	10.9	15.5	19	12.3	10.6	2	15.7	6.6	5	10.2	5.7
Distant	137	6.6	6.6	106	6.5	5.9	17	8.1	15.1	13	8.4	9.9	-	-	-	5	10.2	7.3
Unknown	348	16.8	16.8	251	15.6	14.0	28	13.3	28.2	24	15.9	18.8	-	-	-	7	15.0	12.2
<i>Age < 65</i>																		
Localized	561	69.1	26.0	420	70.6	23.3	83	70.0	54.7	43	64.9	24.7	3	73.9	9.1	14	66.4	12.6
Regional	108	13.3	5.0	78	13.1	4.3	16	13.6	10.5	13	19.2	7.3	-	-	-	3	15.0	2.9
Distant	44	5.4	2.0	31	5.2	1.7	8	6.6	5.2	4	5.5	2.2	-	-	-	2	10.3	1.9
Unknown	99	12.2	4.5	66	11.1	3.7	12	9.8	7.4	7	10.4	3.9	-	-	-	2	8.4	1.6
<i>Age ≥ 65</i>																		
Localized	808	64.3	304.8	671	65.7	288.4	61	64.8	461.2	54	62.2	330.1	7	72.3	223.5	15	63.0	219.3
Regional	105	8.3	37.6	90	8.8	36.9	7	7.5	50.5	6	7.0	33.2	-	-	-	1	5.9	24.7
Distant	94	7.4	38.4	75	7.3	34.8	9	10.0	83.3	9	10.7	63.2	-	-	-	2	10.1	44.6
Unknown	250	19.9	101.7	185	18.1	85.2	17	17.7	171.9	17	20.2	121.4	-	-	-	5	21.0	85.4

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Oregon, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	80	54.7	4.0	73	55.3	4.1	-	-	-	2	47.6	5.3	4	52.9	3.0	7	53.7	3.8
Regional	39	27.1	1.8	35	26.6	1.8	-	-	-	2	38.1	4.1	2	23.5	1.4	4	32.8	2.1
Distant	19	13.2	0.8	17	12.8	0.8	-	-	-	-	-	-	1	20.6	1.7	1	9.0	1.0
Unknown	7	5.0	0.3	7	5.3	0.3	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	82	8.4	3.4	75	8.3	3.4	1	10.1	2.7	1	10.4	5.6	3	9.9	3.8	4	8.9	3.0
Localized	306	31.6	13.3	287	31.7	13.3	4	30.4	11.6	3	23.9	11.1	10	32.2	11.2	13	27.2	10.2
Regional	344	35.5	15.1	319	35.3	15.0	5	33.3	11.3	6	47.8	20.1	11	37.5	15.8	19	39.6	16.4
Distant	184	19.0	8.0	175	19.3	8.1	3	21.7	9.5	2	14.9	5.6	4	13.8	5.6	9	20.0	7.6
Unknown	54	5.5	2.5	49	5.4	2.4	-	-	-	-	-	-	2	6.6	3.1	2	4.3	1.9
<i>Age < 50</i>																		
In Situ	4	3.8	0.3	4	3.9	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	25	24.8	2.0	22	24.6	2.0	-	-	-	-	-	-	1	27.3	1.6	2	24.0	1.4
Regional	42	42.4	3.3	38	41.9	3.4	-	-	-	-	-	-	2	50.0	3.1	5	46.0	2.7
Distant	26	25.8	2.0	24	26.5	2.1	-	-	-	-	-	-	-	-	-	2	22.0	1.2
Unknown	3	3.2	0.3	3	3.1	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	78	9.0	11.6	72	8.8	11.4	1	11.7	9.8	1	11.7	20.1	-	-	-	-	-	-
Localized	282	32.4	42.9	265	32.5	42.8	-	-	-	-	-	-	9	33.1	36.5	10	28.1	33.1
Regional	302	34.7	45.9	281	34.5	45.4	-	-	-	-	-	-	9	35.4	49.1	14	37.8	52.3
Distant	158	18.2	23.5	150	18.5	23.7	-	-	-	2	16.7	20.2	-	-	-	7	19.5	24.3
Unknown	50	5.8	8.4	46	5.7	8.1	-	-	-	-	-	-	2	7.7	11.3	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	62	7.1	2.4	55	6.9	2.3	2	14.3	5.1	2	14.5	4.0	2	5.6	1.7	4	9.0	2.5
Localized	291	33.7	11.2	272	34.0	11.3	4	34.9	11.5	3	27.3	9.8	10	31.9	9.8	12	30.0	9.7
Regional	289	33.5	11.1	269	33.6	11.1	3	23.8	8.3	4	32.7	10.5	12	36.3	11.6	15	37.0	11.9
Distant	164	19.1	6.3	154	19.2	6.4	2	17.5	5.9	2	16.4	5.2	6	17.5	5.2	8	19.0	5.6
Unknown	57	6.6	2.1	51	6.3	1.9	1	9.5	4.6	-	-	-	3	8.8	2.9	2	5.0	1.7
<i>Age < 50</i>																		
In Situ	5	5.9	0.4	5	6.2	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	30	35.7	2.4	27	36.5	2.5	-	-	-	-	-	-	2	31.0	2.1	3	30.4	1.7
Regional	26	31.0	2.1	23	30.5	2.1	-	-	-	-	-	-	2	31.0	2.0	3	30.4	1.9
Distant	20	24.1	1.7	17	23.5	1.6	-	-	-	-	-	-	2	31.0	2.1	2	26.1	1.6
Unknown	3	3.3	0.2	2	3.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	57	7.3	7.4	51	7.0	7.1	2	17.6	18.5	-	-	-	2	6.9	6.0	-	-	-
Localized	261	33.5	34.3	245	33.7	34.3	-	-	-	-	-	-	8	32.1	29.9	9	29.9	30.7
Regional	262	33.7	34.6	246	33.9	34.6	-	-	-	-	-	-	10	37.4	36.8	12	39.0	38.1
Distant	144	18.5	18.6	137	18.8	18.8	-	-	-	-	-	-	4	14.5	13.3	5	16.9	16.0
Unknown	54	7.0	6.8	48	6.7	6.3	1	11.8	16.8	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Oregon, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	633	16.5	25.4	583	16.2	25.3	11	21.0	29.6	6	15.4	16.5	27	21.7	23.5	28	17.1	19.0
Localized	2,140	55.8	82.3	2,016	56.2	83.2	24	44.9	66.0	21	53.2	58.9	64	51.4	58.1	80	48.8	60.9
Regional	835	21.8	34.4	779	21.7	34.8	13	24.7	33.8	9	22.4	22.9	28	22.3	24.0	46	28.2	31.3
Distant	163	4.3	6.4	150	4.2	6.3	5	8.6	12.6	2	5.0	5.2	5	3.9	4.2	8	4.6	4.8
Unknown	67	1.7	2.5	61	1.7	2.4	-	-	-	2	4.0	5.2	-	-	-	2	1.2	2.1
<i>Age < 50</i>																		
In Situ	119	19.0	9.9	106	18.9	9.9	2	13.1	6.0	-	-	-	10	22.6	11.0	11	17.8	7.4
Localized	279	44.4	22.8	248	44.3	23.0	6	50.8	22.1	3	41.2	10.9	19	45.3	21.8	25	42.4	17.2
Regional	196	31.2	16.0	177	31.5	16.4	3	24.6	10.1	3	38.2	10.6	12	28.3	13.4	20	34.3	13.5
Distant	27	4.3	2.2	23	4.2	2.1	1	11.5	5.0	-	-	-	1	3.3	1.6	3	4.7	1.8
Unknown	7	1.1	0.6	6	1.1	0.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	514	16.0	66.0	478	15.8	65.7	10	23.3	91.5	-	-	-	17	21.2	56.3	18	16.7	49.4
Localized	1,861	58.0	238.0	1,768	58.4	241.1	18	43.2	181.1	19	55.7	184.6	45	54.5	153.2	55	52.5	175.4
Regional	639	19.9	82.4	602	19.9	83.2	10	24.8	95.7	6	19.2	55.3	16	19.2	51.6	26	24.7	78.0
Distant	136	4.2	17.4	127	4.2	17.3	3	7.8	32.4	-	-	-	3	4.1	10.9	5	4.6	12.8
Unknown	60	1.9	7.4	55	1.8	7.3	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	4	0.3	0.2	4	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	308	22.4	13.5	288	22.5	13.3	7	26.4	22.4	5	21.8	17.0	6	16.1	9.5	5	18.2	5.8
Regional	302	22.0	12.8	281	21.9	12.6	6	24.0	17.5	5	20.9	15.5	8	22.8	11.4	8	28.0	9.7
Distant	650	47.3	27.4	607	47.3	27.2	11	43.2	28.4	11	49.1	36.7	19	52.2	26.3	14	47.6	16.2
Unknown	110	8.0	5.0	103	8.1	4.9	2	6.4	5.7	2	8.2	7.2	3	7.8	4.9	2	6.3	2.5
<i>Female</i>																		
In Situ	5	0.4	0.2	5	0.4	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	357	25.9	13.3	339	26.1	13.4	4	20.0	12.2	6	27.2	19.1	7	22.0	7.7	6	18.1	6.9
Regional	302	22.0	11.2	285	21.9	11.2	4	23.3	13.0	5	24.3	15.4	7	22.0	7.4	9	27.7	9.1
Distant	604	43.9	22.2	570	43.8	22.3	9	50.0	27.1	8	40.8	25.6	16	47.6	15.9	15	46.4	16.0
Unknown	107	7.8	3.9	101	7.8	3.9	1	6.7	4.3	2	7.8	5.9	3	7.9	3.1	2	7.2	2.6

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,643	68.9	63.4	1,500	68.4	61.3	43	71.4	109.3	11	67.9	30.5	26	71.1	34.5	50	64.2	47.6
Regional	411	17.2	15.4	389	17.8	15.5	9	14.3	22.3	3	19.2	8.9	7	18.3	8.9	16	19.9	13.3
Distant	187	7.8	8.1	174	8.0	8.1	7	11.3	19.7	-	-	-	3	8.3	4.6	9	11.5	12.0
Unknown	145	6.1	6.4	129	5.9	6.0	2	3.0	6.1	-	-	-	-	-	-	3	4.3	5.6
<i>Age < 65</i>																		
Localized	595	71.6	24.2	535	71.2	23.5	26	74.7	54.2	5	71.1	14.2	10	77.6	11.5	23	67.9	15.4
Regional	166	20.0	6.7	156	20.7	6.8	5	15.5	11.1	2	23.7	4.6	2	13.4	2.0	9	26.2	6.1
Distant	44	5.2	1.8	39	5.2	1.7	2	6.9	4.9	-	-	-	-	-	-	2	6.0	1.3
Unknown	26	3.2	1.0	22	2.9	0.9	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,048	67.4	333.7	964	66.9	322.5	17	66.9	490.1	5	65.0	143.3	15	67.3	193.0	27	61.4	269.7
Regional	245	15.7	75.8	233	16.2	75.8	3	12.6	100.1	1	15.0	38.7	5	21.2	56.9	7	15.2	63.6
Distant	143	9.2	52.0	135	9.4	51.7	4	17.3	121.3	-	-	-	-	-	-	7	15.7	85.6
Unknown	119	7.6	43.2	107	7.5	41.1	-	-	-	-	-	-	-	-	-	3	7.6	44.2

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Pennsylvania, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	222	43.6	3.5	179	43.8	3.4	32	43.0	4.3	Insufficient data for the calculation of AI/AN PRCDA statistics			7	51.4	3.1	15	43.4	4.1
Regional	183	35.9	2.5	147	36.0	2.3	27	35.8	3.4				6	38.9	2.5	15	42.8	4.7
Distant	82	16.1	1.0	67	16.5	1.0	12	16.3	1.5				1	8.3	0.5	3	9.8	1.0
Unknown	22	4.3	0.3	15	3.6	0.2	4	4.8	0.4				-	-	-	1	4.0	0.6

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	319	8.3	4.1	275	8.1	4.0	29	9.2	4.5	Insufficient data for the calculation of AI/AN PRCDA statistics			7	11.9	4.1	10	10.2	3.9
Localized	1,202	31.4	16.1	1,065	31.3	16.0	96	30.3	16.1				19	34.9	11.6	27	28.7	11.6
Regional	1,303	34.0	17.7	1,174	34.5	17.8	99	31.4	16.5				19	33.5	12.1	34	36.0	15.4
Distant	798	20.9	10.8	713	21.0	10.8	72	22.8	12.3				9	16.9	6.6	18	19.1	7.7
Unknown	206	5.4	2.8	172	5.1	2.6	20	6.3	3.7				2	2.9	0.8	6	6.0	3.4
<i>Age < 50</i>																		
In Situ	21	5.8	0.5	17	5.6	0.5	2	6.4	0.5				-	-	-	-	-	-
Localized	95	26.2	2.4	81	26.0	2.5	8	23.3	1.8				1	20.7	0.8	6	34.9	2.0
Regional	140	38.9	3.7	122	39.2	3.8	14	40.7	3.0				3	48.3	1.9	7	39.8	2.4
Distant	94	26.0	2.5	84	26.9	2.6	9	25.6	2.0				-	-	-	3	20.5	1.3
Unknown	11	3.1	0.3	7	2.3	0.2	1	4.1	0.3				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	298	8.6	13.5	257	8.3	13.0	27	9.5	15.2				-	-	-	-	-	-
Localized	1,108	31.9	52.0	984	31.9	51.3	88	31.2	53.8				18	36.5	40.1	21	27.4	36.8
Regional	1,162	33.5	54.4	1,052	34.1	54.5	85	30.3	51.9				16	31.7	39.0	27	35.1	49.3
Distant	705	20.3	32.5	629	20.4	32.1	63	22.4	39.4				-	-	-	15	18.9	24.4
Unknown	195	5.6	9.4	165	5.3	8.8	19	6.6	12.5				-	-	-	6	7.2	12.2
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	242	6.9	2.7	199	6.5	2.5	34	9.7	4.2	Insufficient data for the calculation of AI/AN PRCDA statistics			3	5.1	1.5	8	9.6	2.6
Localized	1,126	31.9	12.4	977	31.8	12.1	116	33.3	14.1				20	33.8	9.7	22	27.3	7.8
Regional	1,229	34.8	13.5	1,096	35.7	13.5	98	28.1	12.0				23	38.6	11.7	28	35.9	10.7
Distant	703	19.9	7.9	610	19.8	7.7	78	22.3	9.7				11	19.1	5.5	17	21.8	6.7
Unknown	229	6.5	2.1	192	6.2	1.9	23	6.5	2.7				2	3.4	1.6	4	5.3	1.9
<i>Age < 50</i>																		
In Situ	18	5.5	0.5	16	5.9	0.5	-	-	-				-	-	-	-	-	-
Localized	100	30.9	2.5	84	31.8	2.6	10	26.3	2.1				3	24.1	1.5	6	30.8	2.0
Regional	116	36.1	3.0	95	36.0	3.0	14	34.3	2.7				5	42.6	2.7	7	38.5	2.6
Distant	80	24.7	2.1	63	23.9	2.0	13	32.8	2.7				3	29.6	1.8	4	20.9	1.4
Unknown	9	2.7	0.2	6	2.3	0.2	2	4.0	0.3				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	224	7.0	8.6	183	6.5	7.9	-	-	-				-	-	-	-	-	-
Localized	1,027	32.0	38.3	893	31.8	37.0	106	34.2	45.7				17	36.0	31.1	16	26.3	23.0
Regional	1,113	34.7	41.0	1,001	35.6	41.1	85	27.3	36.4				18	37.7	35.5	21	35.2	31.9
Distant	623	19.4	22.9	547	19.4	22.5	65	20.9	28.1				8	16.7	15.2	13	22.0	20.6
Unknown	220	6.9	7.1	186	6.6	6.5	21	6.8	8.9				2	4.2	5.7	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Pennsylvania, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	2,735	19.7	33.9	2,350	19.2	33.5	299	22.7	36.8				59	25.5	26.2	78	23.0	26.2
Localized	7,396	53.2	86.3	6,637	54.2	88.3	597	45.3	73.7				111	48.2	52.2	153	45.3	55.8
Regional	2,843	20.4	35.5	2,454	20.0	35.2	317	24.1	39.7				49	21.3	21.5	86	25.4	28.3
Distant	742	5.3	8.5	643	5.2	8.4	83	6.3	10.1				11	4.6	5.1	18	5.2	6.9
Unknown	196	1.4	2.0	167	1.4	1.8	22	1.7	2.8				-	-	-	4	1.1	1.3
<i>Age < 50</i>																		
In Situ	561	23.6	14.6	467	23.5	14.7	61	22.4	12.6	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			24	27.7	14.6	26	23.4	10.6
Localized	1,041	43.8	27.0	888	44.7	27.9	105	38.8	21.9				36	41.4	21.6	41	36.8	16.2
Regional	659	27.7	17.3	541	27.2	17.3	88	32.3	18.1				22	25.2	12.7	39	34.3	14.6
Distant	100	4.2	2.6	79	4.0	2.5	16	5.8	3.3				4	5.0	2.5	5	4.1	1.8
Unknown	16	0.7	0.4	11	0.6	0.4	2	0.7	0.4				-	-	-	2	1.4	0.6
<i>Age ≥ 50</i>																		
In Situ	2,174	18.8	84.2	1,883	18.3	82.8	238	22.8	100.2				34	24.2	56.7	51	22.8	67.0
Localized	6,355	55.1	241.6	5,749	56.0	246.4	491	47.0	209.2				75	52.4	132.5	111	49.5	159.3
Regional	2,184	18.9	83.1	1,913	18.6	82.2	229	21.9	96.1				27	18.8	44.5	47	20.9	64.2
Distant	643	5.6	24.0	564	5.5	23.7	67	6.4	28.1				6	4.4	11.7	13	5.8	20.2
Unknown	180	1.6	6.0	156	1.5	5.7	20	1.9	8.9				-	-	-	2	1.0	3.1

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	9	0.2	0.1	9	0.2	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,132	20.2	15.0	1,019	20.3	14.9	96	19.7	17.1				10	16.8	7.0	14	16.5	8.3
Regional	1,292	23.1	16.8	1,167	23.2	16.8	104	21.3	18.1				13	21.9	7.9	20	24.0	11.1
Distant	2,818	50.3	36.8	2,518	50.1	36.4	252	51.6	43.8				33	56.5	22.3	45	53.5	22.5
Unknown	352	6.3	4.8	308	6.1	4.6	36	7.4	7.3				3	4.5	2.5	5	5.8	3.0
<i>Female</i>																		
In Situ	21	0.4	0.2	18	0.4	0.2	2	0.3	0.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	1,359	25.7	14.8	1,204	25.8	14.7	138	25.1	17.1				10	19.7	5.8	18	29.0	7.9
Regional	1,203	22.7	13.0	1,047	22.4	12.7	140	25.4	17.0				11	21.6	6.1	16	24.6	6.5
Distant	2,395	45.2	25.7	2,114	45.3	25.5	244	44.2	29.6				29	54.5	16.0	24	38.5	10.0
Unknown	316	6.0	3.0	283	6.1	2.9	28	5.1	3.4				2	3.4	1.1	5	7.3	2.2

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	6,218	73.2	75.6	5,089	73.3	68.9	729	71.8	110.0	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			56	73.2	34.0	137	70.0	63.7
Regional	1,133	13.3	13.1	972	14.0	12.5	135	13.3	19.2				11	15.0	6.4	29	14.6	11.0
Distant	676	8.0	9.0	564	8.1	8.3	97	9.6	17.1				6	8.2	4.3	18	9.1	10.6
Unknown	466	5.5	6.1	321	4.6	4.6	54	5.3	10.7				3	3.7	2.3	12	6.2	7.4
<i>Age < 65</i>																		
Localized	2,667	74.5	33.3	2,083	74.4	29.4	415	73.9	58.0	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			23	79.6	11.9	67	69.3	24.0
Regional	608	17.0	7.6	507	18.1	7.1	89	15.9	12.6				4	14.8	2.2	19	19.5	6.8
Distant	181	5.0	2.3	135	4.8	1.9	41	7.3	5.7				1	4.9	0.7	6	6.6	2.3
Unknown	125	3.5	1.5	76	2.7	1.1	16	2.8	2.2				-	-	-	4	4.6	1.6
<i>Age ≥ 65</i>																		
Localized	3,551	72.3	367.7	3,006	72.5	341.9	314	69.3	469.2				33	69.3	187.4	70	70.8	338.4
Regional	525	10.7	51.3	465	11.2	50.0	46	10.1	65.2				7	15.1	35.4	10	9.9	40.1
Distant	496	10.1	55.3	429	10.3	52.2	56	12.3	95.5				5	10.1	29.2	11	11.5	68.2
Unknown	341	6.9	37.3	245	5.9	29.4	38	8.3	69.3				-	-	-	8	7.9	47.4

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Rhode Island, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	19	49.0	3.9	16	47.0	3.7	-	-	-	-	-	-	1	66.7	5.9	2	40.7	3.0
Regional	13	32.3	2.0	11	32.7	1.9	1	54.5	3.1	-	-	-	-	-	-	2	44.4	4.0
Distant	6	14.6	0.9	5	16.1	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	4.0	0.2	1	4.2	0.2	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	6	2.8	1.1	5	2.6	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Localized	82	36.7	14.2	77	37.3	14.3	3	29.2	8.1	-	-	-	1	36.8	13.0	4	32.3	9.5
Regional	72	32.1	12.7	67	32.6	12.8	3	31.3	9.3	-	-	-	1	36.8	12.4	4	35.5	11.9
Distant	45	20.0	7.8	41	19.9	7.7	3	27.1	8.7	-	-	-	-	-	-	3	22.6	7.7
Unknown	19	8.3	3.3	16	7.7	3.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	7	31.0	2.2	6	32.0	2.3	-	-	-	-	-	-	-	-	-	1	46.7	2.8
Regional	8	36.2	2.6	7	36.0	2.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	6	25.0	1.8	5	24.0	1.7	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	1	5.2	0.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	75	37.3	45.4	71	37.9	45.9	-	-	-	-	-	-	-	-	-	3	27.7	27.2
Regional	64	31.7	39.0	60	32.2	39.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	39	19.5	23.5	36	19.4	23.4	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	17	8.6	11.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	4	1.9	0.6	4	1.8	0.6	-	-	-	-	-	-	-	-	-	-	-	-
Localized	82	36.4	11.1	76	36.6	11.0	3	35.7	8.3	-	-	-	2	52.2	15.8	4	34.5	8.3
Regional	77	34.0	10.5	71	34.1	10.5	2	28.6	6.6	-	-	-	2	34.8	10.8	5	43.1	9.2
Distant	46	20.3	6.3	43	20.5	6.4	2	21.4	5.1	-	-	-	-	-	-	2	17.2	3.7
Unknown	17	7.4	2.0	14	6.8	1.8	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	7	30.8	2.0	5	29.2	1.8	-	-	-	-	-	-	-	-	-	-	-	-
Regional	8	38.3	2.5	7	37.1	2.4	-	-	-	-	-	-	-	-	-	2	66.7	4.8
Distant	6	27.1	1.7	5	30.3	1.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	76	37.0	35.0	71	37.3	35.2	-	-	-	-	-	-	-	-	-	-	-	-
Regional	69	33.6	31.5	64	33.9	31.7	-	-	-	-	-	-	-	-	-	3	32.5	20.7
Distant	40	19.6	18.3	37	19.6	18.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Rhode Island, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	238	20.2	36.1	219	20.1	36.8	10	20.8	26.3	-	-	-	3	17.2	16.4	17	27.1	28.7
Localized	656	55.7	95.1	616	56.4	97.8	23	46.0	57.6	-	-	-	10	55.2	55.1	29	46.1	53.2
Regional	226	19.2	34.6	205	18.8	34.8	12	24.8	31.8	-	-	-	4	23.0	23.0	14	22.6	24.4
Distant	39	3.3	5.7	35	3.2	5.4	3	6.8	8.4	-	-	-	-	-	-	1	2.3	3.3
Unknown	19	1.6	2.4	17	1.6	2.4	-	-	-	-	-	-	-	-	-	1	1.9	2.5
<i>Age < 50</i>																		
In Situ	52	24.5	15.7	46	24.8	16.3	3	17.6	9.2	-	-	-	-	-	-	6	25.9	11.8
Localized	97	45.7	29.3	86	46.0	30.3	7	44.6	22.6	-	-	-	3	44.8	20.2	9	42.6	18.6
Regional	56	26.5	17.1	49	26.1	17.4	5	31.1	15.7	-	-	-	2	31.0	14.7	6	29.6	13.2
Distant	5	2.6	1.7	4	2.2	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	0.9	0.6	1	0.7	0.5	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	186	19.2	89.6	173	19.1	90.6	8	22.2	71.2	-	-	-	-	-	-	11	27.7	73.1
Localized	559	57.9	267.5	530	58.5	274.5	16	46.6	149.1	-	-	-	7	60.3	146.7	19	48.0	143.6
Regional	170	17.6	80.6	157	17.3	80.5	8	22.2	74.0	-	-	-	2	19.0	44.8	8	18.8	54.0
Distant	34	3.5	16.1	30	3.4	15.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	17	1.7	7.2	16	1.7	7.3	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	99	22.2	17.0	94	22.6	17.6	3	18.3	9.4	-	-	-	-	-	-	2	14.5	5.4
Regional	100	22.4	16.7	92	22.0	16.6	6	34.4	23.2	-	-	-	-	-	-	3	25.8	7.9
Distant	207	46.4	34.7	192	46.1	34.9	8	45.2	27.9	-	-	-	3	78.9	22.2	7	54.8	21.5
Unknown	39	8.8	6.9	38	9.1	7.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	2	0.4	0.2	2	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	140	28.7	19.1	131	28.3	19.4	5	33.8	14.0	-	-	-	2	40.0	11.7	4	40.4	11.6
Regional	102	20.9	13.9	97	20.8	14.2	3	22.5	8.1	-	-	-	1	30.0	8.7	1	11.5	2.9
Distant	213	43.7	28.8	206	44.4	30.2	5	33.8	13.6	-	-	-	1	30.0	6.1	5	46.2	11.3
Unknown	31	6.3	3.8	29	6.2	3.7	1	8.5	3.6	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	410	66.9	64.5	371	67.1	63.4	25	71.3	75.5	-	-	-	3	71.4	19.6	18	63.4	51.7
Regional	88	14.4	12.8	81	14.6	12.8	5	13.5	11.3	-	-	-	-	-	-	5	16.6	11.2
Distant	46	7.6	7.8	42	7.7	7.7	3	7.9	8.7	-	-	-	-	-	-	3	11.0	11.8
Unknown	69	11.2	11.3	58	10.6	10.5	3	7.3	9.8	-	-	-	-	-	-	3	9.0	11.3
<i>Age < 65</i>																		
Localized	174	66.9	27.0	152	67.6	26.1	15	68.9	36.7	-	-	-	1	77.8	9.1	9	70.8	19.3
Regional	51	19.8	8.0	46	20.3	7.8	-	-	-	-	-	-	-	-	-	2	18.5	4.9
Distant	13	4.9	2.0	11	5.1	2.0	1	6.6	3.5	-	-	-	-	-	-	-	-	-
Unknown	22	8.4	3.3	16	7.0	2.6	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	237	66.9	324.1	219	66.8	321.5	11	75.0	343.3	-	-	-	2	66.7	91.7	9	57.5	275.5
Regional	37	10.4	46.2	35	10.7	47.5	-	-	-	-	-	-	-	-	-	2	15.0	54.2
Distant	34	9.5	48.2	31	9.5	47.2	1	9.7	45.3	-	-	-	-	-	-	-	-	-
Unknown	47	13.2	66.8	43	13.0	65.1	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
South Carolina, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	85	41.3	3.4	59	44.6	3.6	22	33.1	3.0	-	-	-	1	66.7	2.5	3	43.2	2.9
Regional	75	36.3	2.8	45	34.1	2.4	27	41.3	3.8	-	-	-	-	-	-	3	35.1	2.6
Distant	33	15.8	1.1	20	14.7	1.0	13	19.3	1.7	-	-	-	-	-	-	1	16.2	1.2
Unknown	13	6.5	0.5	9	6.6	0.4	4	6.3	0.6	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	46	3.7	1.6	34	3.8	1.6	10	3.0	1.5	-	-	-	-	-	-	-	-	-
Localized	424	34.5	15.4	312	35.1	14.8	105	32.4	17.2	-	-	-	3	31.7	9.6	5	27.9	6.8
Regional	408	33.2	15.1	299	33.7	14.6	103	31.8	17.4	-	-	-	4	51.2	13.2	7	39.5	8.4
Distant	251	20.4	9.2	175	19.8	8.5	74	22.8	12.5	-	-	-	-	-	-	4	22.1	5.3
Unknown	101	8.2	4.0	67	7.6	3.4	32	10.0	6.3	-	-	-	-	-	-	1	7.0	2.5
<i>Age < 50</i>																		
In Situ	4	2.7	0.3	2	2.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	41	29.0	2.8	27	27.9	2.6	12	31.3	3.2	-	-	-	-	-	-	1	29.2	1.4
Regional	54	38.3	3.7	40	41.1	3.9	13	31.8	3.5	-	-	-	-	-	-	2	50.0	2.6
Distant	36	25.6	2.5	25	25.5	2.4	11	28.3	3.0	-	-	-	-	-	-	-	-	-
Unknown	6	4.4	0.4	3	3.1	0.3	3	7.1	0.8	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	42	3.8	5.1	32	4.0	5.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	384	35.2	48.4	284	36.0	46.7	92	32.5	53.6	-	-	-	3	34.2	34.7	3	27.4	20.8
Regional	354	32.5	45.0	259	32.8	42.6	90	31.8	54.0	-	-	-	-	-	-	4	35.5	23.6
Distant	215	19.7	26.8	151	19.1	24.4	63	22.1	37.2	-	-	-	-	-	-	-	-	-
Unknown	95	8.7	13.3	64	8.1	11.4	29	10.4	20.8	-	-	-	-	-	-	1	9.7	9.2
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	37	3.4	1.1	28	3.7	1.2	8	2.7	0.9	-	-	-	-	-	-	-	-	-
Localized	395	36.2	12.3	286	37.1	12.0	102	34.0	12.7	-	-	-	4	31.1	9.0	5	37.7	8.7
Regional	345	31.6	10.8	243	31.5	10.3	94	31.6	11.8	-	-	-	6	45.9	13.4	5	37.7	7.8
Distant	226	20.7	7.1	153	19.8	6.6	70	23.4	8.8	-	-	-	1	11.5	3.5	3	18.8	3.9
Unknown	88	8.1	2.7	61	7.9	2.5	25	8.4	3.3	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	4	2.8	0.2	3	3.1	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	43	34.1	2.8	29	35.1	2.8	13	32.8	2.9	-	-	-	-	-	-	1	42.9	1.5
Regional	44	35.0	2.9	26	32.0	2.6	16	40.8	3.6	-	-	-	-	-	-	-	-	-
Distant	30	23.8	2.0	21	24.9	2.0	9	21.9	2.0	-	-	-	-	-	-	-	-	-
Unknown	5	4.3	0.3	4	4.8	0.4	1	3.0	0.2	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	34	3.5	3.5	26	3.7	3.6	-	-	-	-	-	-	-	-	-	-	-	-
Localized	351	36.4	37.0	257	37.3	36.2	88	34.2	38.3	-	-	-	-	-	-	4	36.4	27.4
Regional	301	31.2	31.5	216	31.5	30.6	78	30.1	33.5	-	-	-	-	-	-	-	-	-
Distant	196	20.3	20.4	132	19.2	18.5	61	23.6	26.8	-	-	-	-	-	-	-	-	-
Unknown	83	8.6	9.0	57	8.3	8.2	24	9.2	11.3	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
South Carolina, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	971	19.2	30.9	709	19.0	31.4	247	19.8	30.4	1	18.2	9.2	8	20.1	17.9	11	19.7	14.4
Localized	2,604	51.5	81.4	2,005	53.7	85.1	561	44.8	70.3	3	48.5	26.3	22	52.9	47.8	26	46.6	35.8
Regional	1,143	22.6	37.8	787	21.1	35.8	339	27.1	43.5	2	33.3	19.0	10	24.0	21.1	15	26.9	17.7
Distant	230	4.5	7.4	151	4.0	6.6	77	6.2	9.9	-	-	-	-	-	-	3	5.0	3.4
Unknown	107	2.1	3.3	81	2.2	3.3	26	2.1	3.4	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	175	20.3	11.7	129	22.1	12.7	41	16.0	9.4	-	-	-	2	15.4	5.9	4	15.8	4.9
Localized	376	43.6	25.0	260	44.8	25.5	105	40.7	23.8	-	-	-	6	44.6	17.0	9	40.4	12.0
Regional	260	30.2	17.3	163	28.1	16.1	90	34.9	20.4	-	-	-	5	38.5	14.5	8	36.8	10.1
Distant	43	4.9	2.8	24	4.1	2.3	19	7.2	4.2	-	-	-	-	-	-	1	5.3	1.5
Unknown	8	1.0	0.6	5	0.9	0.5	3	1.2	0.7	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	796	19.0	81.2	580	18.4	80.3	206	20.7	85.4	-	-	-	6	22.3	49.4	7	22.4	39.5
Localized	2,228	53.1	229.1	1,745	55.4	241.4	456	45.9	192.1	-	-	-	16	56.8	128.3	17	50.9	97.9
Regional	883	21.1	91.2	624	19.8	87.3	249	25.1	104.0	2	45.8	68.7	5	17.3	38.5	7	20.0	37.7
Distant	187	4.5	19.5	127	4.0	17.7	59	5.9	25.1	-	-	-	-	-	-	2	4.8	8.2
Unknown	99	2.4	10.5	75	2.4	10.5	23	2.3	10.6	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	5	0.2	0.2	3	0.2	0.1	2	0.4	0.4	-	-	-	-	-	-	-	-	-
Localized	465	20.7	16.8	378	22.0	17.4	84	16.6	14.9	-	-	-	1	15.6	4.4	2	20.8	3.1
Regional	547	24.3	19.1	416	24.1	18.7	126	24.9	21.4	-	-	-	2	22.2	5.8	2	18.8	3.5
Distant	1,023	45.5	36.2	765	44.4	35.0	249	49.0	41.4	-	-	-	5	53.3	15.3	6	58.3	11.6
Unknown	209	9.3	7.9	160	9.3	7.8	46	9.1	8.5	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	6	0.3	0.2	5	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	449	25.2	13.2	374	25.9	14.6	73	22.3	9.1	-	-	-	1	10.9	3.0	2	28.6	4.4
Regional	415	23.3	12.2	334	23.1	13.1	78	24.0	9.7	-	-	-	2	21.8	6.6	2	21.4	2.5
Distant	768	43.1	22.6	613	42.5	24.2	147	45.3	18.0	-	-	-	7	60.0	16.7	3	31.0	4.0
Unknown	145	8.1	4.3	117	8.1	4.6	27	8.2	3.5	-	-	-	-	-	-	1	14.3	2.4

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,600	75.1	84.5	1,717	75.1	72.4	834	75.1	124.6	2	50.0	22.1	9	75.0	31.5	30	80.2	58.5
Regional	381	11.0	12.0	271	11.9	11.0	104	9.4	14.8	1	29.2	8.7	2	15.0	5.0	4	10.2	7.4
Distant	191	5.5	7.0	118	5.2	5.7	71	6.4	12.2	-	-	-	-	-	-	3	7.0	7.0
Unknown	292	8.4	11.1	180	7.9	8.7	102	9.1	19.7	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	1,034	76.2	36.8	595	76.1	28.7	422	76.6	60.8	-	-	-	2	71.4	5.7	14	81.9	18.0
Regional	179	13.2	6.3	114	14.6	5.4	62	11.3	9.0	-	-	-	-	-	-	2	9.6	2.0
Distant	65	4.8	2.3	31	3.9	1.5	33	6.0	4.7	-	-	-	-	-	-	-	-	-
Unknown	80	5.9	2.8	42	5.4	2.0	33	6.1	4.8	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,565	74.3	414.0	1,123	74.5	374.9	413	73.7	565.4	-	-	-	7	76.1	210.1	16	78.8	338.4
Regional	202	9.6	50.7	158	10.5	49.8	42	7.5	55.0	-	-	-	-	-	-	2	10.6	44.3
Distant	126	6.0	39.9	88	5.8	34.6	37	6.7	64.4	-	-	-	-	-	-	-	-	-
Unknown	212	10.1	67.8	138	9.2	54.9	68	12.2	122.1	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
South Dakota, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	14	44.4	3.4	11	43.0	3.2	-	-	-	2	63.2	9.7	-	-	-	-	-	-
Regional	11	35.9	2.6	10	37.5	2.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	5	15.0	0.9	4	15.6	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	1	4.6	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	16	6.7	3.4	16	7.0	3.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	81	33.6	16.8	77	34.4	16.9	-	-	-	3	24.1	16.2	-	-	-	-	-	-
Regional	83	34.5	17.7	76	34.2	17.4	-	-	-	4	34.5	20.0	-	-	-	-	-	-
Distant	48	20.0	10.0	43	19.4	9.6	-	-	-	3	25.9	14.5	-	-	-	-	-	-
Unknown	13	5.2	2.8	11	4.9	2.6	-	-	-	2	13.8	8.3	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	4	18.6	1.5	4	20.7	1.6	-	-	-	-	-	-	-	-	-	-	-	-
Regional	9	46.1	4.0	8	43.7	3.7	-	-	-	-	-	-	-	-	-	-	-	-
Distant	5	24.5	2.0	4	24.1	2.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	1	5.9	0.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	77	35.0	56.8	73	35.6	56.9	-	-	-	3	27.5	58.5	-	-	-	-	-	-
Regional	73	33.4	53.8	69	33.4	53.3	-	-	-	-	-	-	-	-	-	-	-	-
Distant	43	19.6	31.0	39	19.0	29.8	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	11	5.2	8.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	13	6.1	2.5	13	6.5	2.5	-	-	-	-	-	-	-	-	-	-	-	-
Localized	77	36.2	14.3	72	36.9	14.1	-	-	-	3	26.7	13.7	-	-	-	-	-	-
Regional	70	32.9	12.8	64	32.8	12.5	-	-	-	4	36.7	19.7	-	-	-	-	-	-
Distant	41	19.3	7.7	36	18.5	7.3	-	-	-	3	28.3	13.1	-	-	-	-	-	-
Unknown	12	5.5	1.9	11	5.4	1.8	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	6	36.4	2.7	6	35.4	2.8	-	-	-	-	-	-	-	-	-	-	-	-
Regional	5	28.4	2.1	5	29.1	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	5	28.4	2.2	4	27.8	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	70	36.2	44.5	66	37.0	43.9	-	-	-	-	-	-	-	-	-	-	-	-
Regional	65	33.3	40.9	59	33.1	39.4	-	-	-	-	-	-	-	-	-	-	-	-
Distant	36	18.5	22.4	32	17.7	20.7	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
South Dakota, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	133	17.1	27.5	125	17.3	28.3	-	-	-	4	13.6	15.8	-	-	-	1	20.0	14.4
Localized	445	57.4	87.3	418	57.8	88.4	2	52.4	58.0	17	51.9	67.0	3	64.0	73.4	3	43.3	41.8
Regional	157	20.3	33.0	142	19.6	32.0	-	-	-	10	30.9	39.5	-	-	-	1	23.3	19.1
Distant	31	3.9	6.0	29	4.0	6.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	10	1.3	2.0	9	1.3	1.9	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	23	19.1	10.5	21	19.7	10.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	57	46.2	25.0	51	47.7	26.0	-	-	-	2	34.3	13.5	1	54.5	25.5	-	-	-
Regional	36	29.4	15.8	30	27.5	15.0	-	-	-	3	45.7	18.1	-	-	-	-	-	-
Distant	5	4.1	2.1	4	4.1	2.2	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	1.3	0.7	1	1.1	0.6	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	110	16.8	72.1	104	16.9	73.6	-	-	-	-	-	-	-	-	-	-	-	-
Localized	389	59.4	250.4	366	59.5	251.9	-	-	-	14	56.7	207.0	2	71.4	198.8	-	-	-
Regional	121	18.6	77.8	112	18.2	76.7	-	-	-	7	26.8	95.7	-	-	-	-	-	-
Distant	26	3.9	16.2	25	4.0	16.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	9	1.3	5.2	8	1.3	5.2	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.6	0.4	2	0.7	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	70	21.8	15.0	67	22.5	15.2	-	-	-	2	13.0	9.4	-	-	-	-	-	-
Regional	66	20.7	13.8	64	21.2	13.9	-	-	-	2	15.9	18.6	-	-	-	-	-	-
Distant	168	52.3	34.6	154	51.3	33.4	-	-	-	9	65.2	61.5	-	-	-	-	-	-
Unknown	15	4.6	3.2	13	4.4	3.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	80	27.1	14.8	74	27.0	14.5	-	-	-	5	28.4	22.0	-	-	-	-	-	-
Regional	69	23.3	12.9	64	23.5	12.8	-	-	-	4	22.7	17.7	-	-	-	-	-	-
Distant	134	45.4	24.4	123	45.2	24.0	-	-	-	8	45.5	35.7	-	-	-	-	-	-
Unknown	11	3.9	1.9	11	4.0	1.9	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	459	76.5	87.5	434	76.7	87.5	4	76.9	62.8	17	76.1	82.3	-	-	-	3	92.9	67.9
Regional	84	14.1	15.3	81	14.2	15.5	-	-	-	2	8.3	9.6	-	-	-	-	-	-
Distant	36	5.9	7.7	32	5.7	7.3	-	-	-	2	10.1	13.6	-	-	-	-	-	-
Unknown	21	3.5	4.3	19	3.3	4.1	-	-	-	1	5.5	6.2	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	185	77.9	35.3	171	78.2	35.2	3	77.8	42.4	9	75.4	36.6	-	-	-	-	-	-
Regional	39	16.6	7.4	37	16.9	7.5	-	-	-	-	-	-	-	-	-	-	-	-
Distant	8	3.5	1.7	7	3.4	1.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	5	2.0	0.9	3	1.6	0.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	274	75.6	448.7	263	75.8	448.9	1	75.0	203.8	8	76.9	398.4	-	-	-	-	-	-
Regional	45	12.4	70.1	44	12.6	71.0	-	-	-	-	-	-	-	-	-	-	-	-
Distant	27	7.5	49.2	25	7.2	46.9	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	16	4.5	27.7	15	4.4	27.2	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Tennessee, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	135	45.3	4.0	109	46.5	4.1	23	39.5	3.8	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	4	46.7	3.2
Regional	102	34.1	2.8	80	34.2	2.8	20	33.8	3.4				-	-	-	3	31.1	3.3
Distant	45	15.2	1.2	33	14.2	1.1	12	20.3	2.0				-	-	-	-	-	-
Unknown	16	5.4	0.4	12	5.1	0.4	4	6.4	0.6				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	42	2.5	1.2	35	2.5	1.1	7	2.8	1.5	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	559	33.5	15.6	478	34.0	15.5	71	29.5	15.9				4	36.2	9.1	6	34.5	7.7
Regional	593	35.5	16.8	515	36.7	16.9	71	29.5	16.6				4	32.8	8.5	5	31.0	8.4
Distant	357	21.4	9.9	285	20.3	9.2	67	28.0	15.6				3	24.1	5.7	4	24.1	6.0
Unknown	118	7.0	3.4	92	6.5	3.0	24	10.1	6.4				-	-	-	1	6.9	1.7
<i>Age < 50</i>																		
In Situ	4	2.2	0.2	3	2.1	0.2	-	-	-				-	-	-	-	-	-
Localized	62	31.8	3.0	53	33.0	3.2	7	22.5	2.1				1	60.0	2.6	2	40.0	1.5
Regional	73	37.6	3.6	61	38.3	3.7	11	37.1	3.5				-	-	-	1	30.0	1.0
Distant	48	24.9	2.4	38	23.9	2.3	9	31.1	2.9				-	-	-	-	-	-
Unknown	7	3.6	0.3	4	2.8	0.3	2	7.3	0.7				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	38	2.6	3.7	32	2.5	3.5	-	-	-				-	-	-	-	-	-
Localized	497	33.7	48.5	425	34.2	47.8	64	30.6	52.0				3	31.3	26.2	4	32.8	23.6
Regional	520	35.2	51.4	454	36.5	51.5	59	28.4	50.9				-	-	-	4	31.3	27.9
Distant	309	20.9	29.5	247	19.8	27.2	58	27.6	49.1				-	-	-	-	-	-
Unknown	111	7.5	11.3	87	7.0	10.2	22	10.5	21.3				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	33	2.2	0.8	28	2.2	0.8	5	2.1	0.9	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	-	-	-
Localized	518	34.1	12.3	431	34.3	12.1	79	33.0	13.5				5	39.7	8.1	3	24.6	4.4
Regional	553	36.5	13.1	467	37.2	13.0	78	32.7	13.6				4	36.2	6.3	5	40.0	7.7
Distant	314	20.7	7.5	250	19.9	7.1	61	25.6	10.7				2	17.2	3.7	3	20.0	3.1
Unknown	99	6.5	2.3	81	6.5	2.2	16	6.6	2.8				-	-	-	2	12.3	2.3
<i>Age < 50</i>																		
In Situ	3	1.5	0.1	2	1.5	0.1	-	-	-				-	-	-	-	-	-
Localized	59	32.9	2.8	46	33.7	2.8	10	29.7	2.7				-	-	-	-	-	-
Regional	62	34.7	3.0	47	34.4	2.9	12	33.7	3.2				2	50.0	2.8	2	47.1	1.6
Distant	48	26.7	2.3	36	26.1	2.2	11	31.4	2.9				-	-	-	-	-	-
Unknown	8	4.3	0.4	6	4.4	0.4	1	3.4	0.3				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	30	2.3	2.5	26	2.3	2.5	-	-	-				-	-	-	-	-	-
Localized	459	34.3	37.2	384	34.4	36.4	69	33.6	41.7				-	-	-	-	-	-
Regional	491	36.7	39.5	420	37.5	39.4	67	32.5	40.9				3	31.0	15.4	4	37.5	23.8
Distant	266	19.9	21.3	214	19.1	20.1	50	24.6	31.0				-	-	-	-	-	-
Unknown	92	6.8	7.4	75	6.7	7.0	15	7.1	9.4				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Tennessee, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,017	16.7	24.5	841	16.5	24.2	157	17.6	26.1				11	19.0	18.2	10	13.5	11.9
Localized	3,306	54.3	78.9	2,832	55.6	80.2	426	47.7	71.4				28	48.9	45.9	41	54.4	50.8
Regional	1,342	22.1	33.6	1,093	21.5	32.8	226	25.3	37.9				13	22.9	20.6	18	23.9	19.8
Distant	294	4.8	7.2	221	4.3	6.4	68	7.6	11.2				3	5.3	4.6	3	4.5	3.9
Unknown	127	2.1	3.0	104	2.0	2.8	18	2.0	3.1				2	3.9	4.0	3	3.7	3.7
<i>Age < 50</i>																		
In Situ	172	16.6	8.3	131	16.3	8.0	34	17.3	9.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			3	18.2	6.2	5	13.9	5.0
Localized	494	47.6	23.9	393	48.9	24.1	88	44.3	23.5				7	39.8	13.5	16	47.3	17.2
Regional	309	29.8	15.0	236	29.3	14.5	62	31.0	16.4				6	35.2	11.8	10	29.1	9.9
Distant	49	4.8	2.4	36	4.5	2.2	12	5.8	3.1				-	-	-	2	6.1	1.8
Unknown	13	1.3	0.6	9	1.1	0.5	3	1.5	0.8				-	-	-	1	3.6	1.4
<i>Age ≥ 50</i>																		
In Situ	844	16.7	66.9	710	16.6	66.7	123	17.6	70.4				8	19.4	49.3	6	13.2	29.9
Localized	2,812	55.7	222.8	2,439	56.9	227.3	338	48.6	196.9				21	53.1	130.8	25	59.9	138.9
Regional	1,033	20.5	82.3	857	20.0	80.8	164	23.6	94.3				7	17.3	43.7	8	19.8	45.6
Distant	245	4.9	19.6	185	4.3	17.4	56	8.0	32.3				-	-	-	1	3.3	9.3
Unknown	114	2.3	9.1	95	2.2	8.8	15	2.1	9.0				-	-	-	2	3.8	9.6

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.2	0.2	6	0.2	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	671	20.2	18.8	601	20.6	19.2	65	17.0	16.7				2	15.5	7.1	4	19.4	7.3
Regional	819	24.6	22.3	724	24.8	22.6	90	23.3	21.3				3	23.9	7.3	5	23.3	7.9
Distant	1,543	46.3	42.0	1,344	46.0	42.0	186	48.3	44.9				8	54.9	22.8	11	51.5	16.3
Unknown	291	8.7	8.5	245	8.4	8.1	43	11.3	11.6				-	-	-	1	5.8	3.4
<i>Female</i>																		
In Situ	8	0.3	0.2	7	0.3	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	670	24.7	15.2	602	25.2	16.0	62	20.8	10.8				3	25.0	7.3	5	24.7	8.6
Regional	681	25.1	15.4	595	24.9	15.8	81	27.4	13.9				3	23.5	5.8	4	19.6	7.0
Distant	1,176	43.4	26.8	1,032	43.2	27.6	133	44.9	22.8				7	51.5	12.4	9	47.4	15.4
Unknown	175	6.5	4.0	154	6.4	4.0	20	6.7	3.8				-	-	-	2	8.2	2.6

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	3,365	77.1	85.0	2,674	76.8	78.0	642	78.1	135.0	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			15	75.0	38.1	32	76.9	55.1
Regional	577	13.2	14.0	485	13.9	13.7	85	10.4	16.2				4	18.0	8.6	4	10.6	6.9
Distant	218	5.0	6.3	163	4.7	5.4	52	6.4	13.6				-	-	-	3	7.7	6.0
Unknown	206	4.7	6.2	159	4.6	5.4	42	5.2	12.9				-	-	-	2	4.8	4.8
<i>Age < 65</i>																		
Localized	1,387	78.7	36.8	1,023	78.4	32.3	348	79.8	64.0	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			4	70.0	8.6	14	78.0	16.5
Regional	255	14.5	6.7	201	15.4	6.3	51	11.8	9.3				2	26.7	3.3	2	9.9	2.1
Distant	70	4.0	1.8	45	3.5	1.4	24	5.4	4.2				-	-	-	2	8.8	1.9
Unknown	50	2.8	1.3	34	2.6	1.1	13	3.0	2.4				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,978	76.0	418.6	1,651	75.8	394.2	294	76.3	625.9				11	77.1	241.7	18	76.1	321.8
Regional	322	12.4	65.0	284	13.0	64.7	34	8.8	63.8				2	14.3	45.8	3	11.1	40.2
Distant	148	5.7	37.1	118	5.4	33.0	29	7.4	79.0				-	-	-	2	6.8	34.3
Unknown	156	6.0	39.9	124	5.7	35.3	29	7.6	85.4				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Texas, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	509	40.7	3.8	436	41.8	4.1	51	32.6	2.9	-	-	-	16	42.9	2.1	211	41.0	4.6
Regional	407	32.6	3.0	338	32.4	3.1	55	35.4	3.2	-	-	-	11	29.9	1.7	177	34.4	4.0
Distant	175	14.0	1.2	141	13.5	1.2	29	18.5	1.7	-	-	-	4	10.9	0.6	69	13.5	1.6
Unknown	160	12.8	1.2	128	12.2	1.1	21	13.5	1.3	-	-	-	6	16.3	0.9	57	11.1	1.3

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	193	3.3	1.5	143	3.0	1.3	43	5.7	3.3	-	-	-	4	2.7	0.8	35	2.3	1.1
Localized	1,823	31.6	14.7	1,547	32.0	14.7	222	29.7	17.8	-	-	-	41	27.3	7.7	467	30.9	14.6
Regional	1,963	34.0	15.7	1,671	34.6	15.8	229	30.7	18.0	-	-	-	52	35.1	10.1	520	34.5	16.0
Distant	1,194	20.7	9.3	978	20.2	9.1	178	23.8	13.5	-	-	-	32	21.2	5.8	335	22.2	9.9
Unknown	599	10.4	5.0	495	10.2	4.9	76	10.1	6.4	-	-	-	21	13.8	4.5	152	10.0	5.1
<i>Age < 50</i>																		
In Situ	13	1.8	0.1	9	1.5	0.1	3	3.4	0.3	-	-	-	-	-	-	2	0.7	0.0
Localized	184	25.9	2.1	155	26.5	2.2	21	22.2	1.9	-	-	-	6	21.5	1.1	59	26.2	1.7
Regional	275	38.5	3.2	227	38.8	3.3	36	37.9	3.3	-	-	-	10	39.2	2.0	86	38.1	2.5
Distant	186	26.1	2.1	149	25.4	2.1	28	29.2	2.5	-	-	-	8	30.8	1.6	64	28.4	1.9
Unknown	55	7.8	0.6	46	7.8	0.7	7	7.2	0.6	-	-	-	2	6.9	0.3	15	6.6	0.4
<i>Age ≥ 50</i>																		
In Situ	180	3.6	4.9	135	3.2	4.3	39	6.0	11.3	-	-	-	-	-	-	34	2.6	3.8
Localized	1,639	32.4	47.8	1,392	32.8	47.5	201	30.8	59.3	-	-	-	35	28.5	25.0	407	31.8	48.3
Regional	1,688	33.4	48.6	1,444	34.0	48.7	194	29.6	56.6	-	-	-	42	34.2	31.3	434	33.8	51.3
Distant	1,009	19.9	28.1	829	19.5	27.2	150	23.0	42.2	-	-	-	24	19.1	16.8	271	21.1	30.8
Unknown	544	10.7	16.5	449	10.6	15.9	69	10.5	21.5	-	-	-	19	15.2	15.5	137	10.7	17.4
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	117	2.5	0.8	96	2.5	0.8	18	2.7	1.1	-	-	-	3	2.1	0.4	26	2.4	0.7
Localized	1,516	32.7	10.5	1,251	32.8	10.4	214	32.2	12.9	-	-	-	42	31.2	6.8	360	32.7	9.5
Regional	1,559	33.6	10.9	1,297	34.0	10.9	205	30.8	12.4	-	-	-	47	34.8	8.1	369	33.5	9.6
Distant	941	20.3	6.5	746	19.6	6.2	159	24.0	9.7	-	-	-	31	23.0	5.1	230	20.8	5.9
Unknown	508	10.9	3.5	421	11.0	3.4	69	10.3	4.4	-	-	-	12	9.0	2.5	116	10.5	3.1
<i>Age < 50</i>																		
In Situ	12	2.0	0.1	11	2.1	0.2	1	1.5	0.1	-	-	-	-	-	-	4	2.0	0.1
Localized	176	28.5	2.0	141	28.5	2.0	26	28.4	2.2	-	-	-	7	27.4	1.2	52	26.3	1.5
Regional	220	35.6	2.5	179	36.1	2.6	31	34.0	2.6	-	-	-	9	35.5	1.6	70	35.0	2.1
Distant	155	25.1	1.8	122	24.6	1.8	25	27.3	2.1	-	-	-	7	27.4	1.2	54	27.1	1.6
Unknown	55	8.8	0.6	43	8.7	0.6	8	8.9	0.7	-	-	-	2	8.9	0.4	19	9.7	0.6
<i>Age ≥ 50</i>																		
In Situ	105	2.6	2.5	85	2.6	2.4	16	2.9	3.6	-	-	-	-	-	-	22	2.5	2.2
Localized	1,340	33.3	32.9	1,110	33.5	32.3	187	32.8	40.9	-	-	-	36	32.1	21.5	308	34.1	30.6
Regional	1,339	33.3	32.8	1,119	33.7	32.5	173	30.3	37.9	-	-	-	38	34.6	25.0	300	33.2	29.4
Distant	786	19.5	19.0	624	18.8	17.9	134	23.4	29.7	-	-	-	24	22.0	15.1	176	19.5	17.3
Unknown	453	11.3	11.0	378	11.4	10.8	60	10.6	14.1	-	-	-	10	9.0	7.9	97	10.7	9.9

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Texas, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	3,241	16.7	22.5	2,598	16.1	21.9	461	18.8	26.8	-	-	-	149	22.2	21.3	682	15.8	16.5
Localized	9,809	50.5	68.1	8,362	51.8	69.9	1,057	43.1	62.9	-	-	-	315	47.0	45.5	2,038	47.1	50.8
Regional	4,377	22.5	30.8	3,572	22.1	30.5	626	25.5	36.4	-	-	-	144	21.6	20.4	1,134	26.2	27.2
Distant	962	5.0	6.7	754	4.7	6.3	176	7.2	10.3	-	-	-	28	4.2	4.1	237	5.5	5.9
Unknown	1,037	5.3	7.2	848	5.3	7.1	134	5.4	8.2	-	-	-	33	5.0	5.3	237	5.5	6.2
<i>Age < 50</i>																		
In Situ	703	17.0	8.2	541	16.8	8.0	101	16.1	8.7	-	-	-	50	21.4	9.3	200	15.9	6.1
Localized	1,820	44.1	21.1	1,451	45.1	21.3	246	39.1	20.8	-	-	-	103	43.7	18.6	520	41.4	15.7
Regional	1,211	29.3	14.0	935	29.1	13.7	202	32.1	16.9	-	-	-	62	26.6	11.1	411	32.8	12.3
Distant	200	4.8	2.3	141	4.4	2.0	48	7.7	4.0	-	-	-	10	4.3	1.8	66	5.2	2.0
Unknown	195	4.7	2.2	148	4.6	2.2	32	5.1	2.7	-	-	-	10	4.1	1.7	59	4.7	1.7
<i>Age ≥ 50</i>																		
In Situ	2,538	16.6	59.7	2,057	15.9	58.1	360	19.7	74.4	-	-	-	99	22.7	52.8	482	15.7	43.7
Localized	7,989	52.2	191.1	6,911	53.5	196.9	811	44.5	173.2	-	-	-	212	48.8	115.7	1,518	49.4	142.5
Regional	3,166	20.7	74.9	2,637	20.4	74.6	424	23.2	87.7	-	-	-	82	18.8	44.5	723	23.5	66.0
Distant	762	5.0	18.1	613	4.7	17.4	127	7.0	26.7	-	-	-	18	4.1	10.2	171	5.6	16.3
Unknown	842	5.5	20.4	700	5.4	20.0	101	5.6	22.6	-	-	-	24	5.4	14.5	178	5.8	17.8

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	12	0.2	0.1	10	0.2	0.1	2	0.2	0.1	-	-	-	-	-	-	-	-	-
Localized	1,383	19.1	12.1	1,193	19.5	12.1	157	16.9	14.4	-	-	-	25	15.0	6.0	153	16.1	6.0
Regional	1,550	21.4	13.0	1,311	21.4	12.8	202	21.7	17.6	-	-	-	31	18.6	6.6	183	19.3	6.8
Distant	3,400	46.8	28.1	2,843	46.4	27.5	456	49.2	38.7	-	-	-	88	53.2	18.8	490	51.7	18.2
Unknown	913	12.6	8.1	774	12.6	7.9	112	12.1	10.7	-	-	-	22	13.3	5.5	122	12.9	5.0
<i>Female</i>																		
In Situ	17	0.3	0.1	15	0.3	0.1	2	0.3	0.1	-	-	-	-	-	-	2	0.3	0.1
Localized	1,356	22.3	9.6	1,184	22.7	9.8	138	19.5	9.0	-	-	-	27	19.7	4.8	141	21.1	4.1
Regional	1,295	21.3	9.0	1,114	21.4	9.1	151	21.4	9.7	-	-	-	24	17.7	4.2	118	17.7	3.4
Distant	2,677	44.0	18.4	2,250	43.2	18.4	343	48.6	21.4	-	-	-	71	51.9	12.6	318	47.7	9.1
Unknown	741	12.2	5.2	649	12.5	5.4	72	10.3	5.0	-	-	-	14	10.2	2.8	88	13.2	2.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	8,013	65.8	60.0	6,353	65.6	56.2	1,356	66.9	96.5	3	71.4	72.8	149	62.3	28.7	1,457	64.1	47.0
Regional	1,561	12.8	11.0	1,268	13.1	10.6	245	12.1	15.9	-	-	-	35	14.8	6.6	258	11.3	7.5
Distant	895	7.4	7.7	706	7.3	7.1	166	8.2	15.1	-	-	-	19	7.8	4.6	211	9.3	7.9
Unknown	1,705	14.0	15.2	1,354	14.0	14.0	261	12.9	25.1	-	-	-	36	15.1	9.7	348	15.3	13.9
<i>Age < 65</i>																		
Localized	3,512	70.8	25.4	2,599	70.7	22.5	778	70.7	48.4	1	77.8	30.9	61	70.6	10.2	594	67.9	15.2
Regional	798	16.1	5.7	616	16.7	5.3	160	14.5	9.9	-	-	-	15	17.0	2.5	128	14.7	3.3
Distant	270	5.4	1.9	193	5.3	1.7	71	6.4	4.4	-	-	-	5	5.5	0.8	71	8.2	1.8
Unknown	383	7.7	2.7	269	7.3	2.3	92	8.3	5.6	-	-	-	6	6.9	1.0	82	9.3	2.1
<i>Age ≥ 65</i>																		
Localized	4,501	62.4	299.7	3,753	62.5	289.1	578	62.3	429.2	2	66.7	362.8	88	57.6	157.2	863	61.7	266.4
Regional	763	10.6	47.7	652	10.9	47.2	85	9.2	57.8	-	-	-	21	13.5	34.9	129	9.2	36.2
Distant	625	8.7	47.8	512	8.5	44.9	95	10.3	88.9	-	-	-	14	9.2	30.7	140	10.0	49.8
Unknown	1,322	18.3	101.1	1,084	18.1	94.7	169	18.2	159.5	-	-	-	30	19.8	69.6	267	19.1	95.2

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Utah, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	38	53.4	2.9	35	55.0	2.9	-	-	-	-	-	-	1	31.6	2.0	8	70.4	4.6
Regional	22	31.4	1.7	19	30.0	1.6	-	-	-	-	-	-	2	57.9	4.2	3	25.9	1.8
Distant	9	12.4	0.6	8	12.5	0.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	2	2.8	0.2	2	2.5	0.1	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	22	5.4	1.8	21	5.2	1.7	-	-	-	-	-	-	-	-	-	2	4.4	1.3
Localized	158	37.7	13.0	150	38.0	13.0	2	25.7	11.6	-	-	-	4	32.8	12.2	14	38.7	15.4
Regional	133	31.9	11.0	127	32.2	11.0	2	25.7	12.2	-	-	-	4	31.0	10.6	12	32.6	13.7
Distant	89	21.3	7.4	82	20.8	7.2	3	40.0	23.6	1	46.2	16.6	3	22.4	8.9	8	22.1	9.1
Unknown	16	3.7	1.4	14	3.7	1.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	3	4.7	0.4	3	4.5	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	25	33.9	2.6	22	33.6	2.6	-	-	-	-	-	-	-	-	-	3	33.3	2.0
Regional	27	37.5	3.0	25	37.9	3.0	-	-	-	-	-	-	-	-	-	3	33.3	2.0
Distant	16	22.0	1.8	14	21.8	1.8	-	-	-	-	-	-	-	-	-	2	25.6	1.6
Unknown	1	1.9	0.2	1	2.1	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	19	5.5	5.5	18	5.4	5.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	133	38.6	40.3	127	38.9	40.3	-	-	-	-	-	-	-	-	-	11	40.1	50.6
Regional	106	30.7	31.9	102	31.1	32.0	-	-	-	-	-	-	-	-	-	9	32.4	44.2
Distant	73	21.1	21.9	68	20.6	21.3	-	-	-	-	-	-	-	-	-	6	21.1	28.7
Unknown	14	4.1	4.8	13	4.0	4.6	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	18	4.7	1.3	17	4.8	1.3	-	-	-	-	-	-	-	-	-	1	3.5	1.5
Localized	143	38.2	10.7	134	38.0	10.6	-	-	-	1	46.2	11.6	6	43.2	16.6	15	44.2	13.8
Regional	121	32.2	9.1	114	32.4	9.1	-	-	-	-	-	-	4	27.0	10.1	11	32.0	11.0
Distant	74	19.8	5.7	69	19.7	5.7	-	-	-	-	-	-	3	23.0	8.1	6	16.9	5.7
Unknown	19	5.1	1.5	18	5.2	1.5	-	-	-	-	-	-	-	-	-	1	3.5	1.3
<i>Age < 50</i>																		
In Situ	2	3.5	0.3	2	3.7	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	27	39.6	2.9	26	39.6	3.0	-	-	-	-	-	-	-	-	-	5	47.9	3.7
Regional	22	32.1	2.6	21	31.9	2.6	-	-	-	-	-	-	-	-	-	3	33.3	2.7
Distant	16	23.4	1.9	15	23.2	1.9	-	-	-	-	-	-	-	-	-	1	14.6	1.1
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	15	5.0	4.0	14	5.0	4.0	-	-	-	-	-	-	-	-	-	-	-	-
Localized	116	37.9	31.2	108	37.6	30.6	-	-	-	-	-	-	-	-	-	11	42.7	40.3
Regional	99	32.2	26.4	94	32.5	26.2	-	-	-	-	-	-	-	-	-	8	31.5	32.9
Distant	58	19.0	15.7	54	18.9	15.4	-	-	-	-	-	-	-	-	-	4	17.7	17.8
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Utah, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	301	16.5	22.6	286	16.5	22.8	3	28.3	32.1	-	-	-	9	16.7	19.3	25	16.6	20.9
Localized	945	51.9	71.0	908	52.2	71.9	4	34.0	42.6	3	69.6	34.8	26	49.8	56.7	72	47.6	65.8
Regional	463	25.5	35.1	443	25.5	35.6	3	30.2	29.6	-	-	-	13	25.7	27.1	45	30.1	36.3
Distant	95	5.2	7.1	90	5.2	7.2	-	-	-	-	-	-	3	6.2	6.3	8	5.2	6.3
Unknown	15	0.8	1.2	13	0.7	1.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	71	18.0	8.7	67	18.3	8.9	-	-	-	-	-	-	2	11.3	6.1	10	17.3	8.7
Localized	166	42.1	20.1	154	42.0	20.2	-	-	-	-	-	-	9	47.4	24.8	24	40.1	20.5
Regional	135	34.3	15.9	125	34.2	16.0	1	43.8	13.0	-	-	-	7	34.0	17.1	21	35.4	17.2
Distant	22	5.6	2.5	20	5.5	2.5	-	-	-	-	-	-	1	6.2	3.0	4	6.8	3.4
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	230	16.1	59.0	219	16.0	59.2	-	-	-	-	-	-	6	20.0	53.8	15	16.2	52.9
Localized	779	54.7	204.1	754	54.9	207.3	-	-	-	-	-	-	16	51.3	140.4	48	52.4	184.1
Regional	328	23.0	85.4	317	23.1	86.9	2	24.3	72.9	-	-	-	7	20.6	53.5	24	26.6	86.5
Distant	73	5.1	19.1	70	5.1	19.4	-	-	-	-	-	-	2	6.3	15.0	4	4.1	13.9
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	1	0.4	0.1	1	0.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	70	20.1	6.1	67	20.2	6.1	-	-	-	-	-	-	2	21.7	8.0	3	16.5	6.2
Regional	66	18.9	5.8	64	19.1	5.8	-	-	-	-	-	-	-	-	-	3	13.4	5.1
Distant	193	55.1	16.5	184	54.9	16.4	1	41.2	17.4	-	-	-	6	65.2	20.2	12	63.9	18.2
Unknown	19	5.4	1.8	18	5.4	1.8	-	-	-	-	-	-	-	-	-	1	6.2	2.1
<i>Female</i>																		
In Situ	2	0.7	0.2	2	0.8	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	69	22.7	5.2	65	22.7	5.2	-	-	-	-	-	-	2	25.5	6.8	5	22.8	6.7
Regional	65	21.4	4.9	61	21.2	4.8	2	52.9	23.8	-	-	-	2	17.0	4.4	5	22.8	5.8
Distant	146	48.3	10.9	139	48.3	10.8	-	-	-	-	-	-	5	57.4	13.3	11	49.1	12.3
Unknown	21	6.9	1.7	20	7.0	1.7	-	-	-	-	-	-	-	-	-	1	5.3	1.8

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	1,071	75.2	84.3	1,026	75.3	84.4	14	73.9	116.1	2	64.7	36.3	14	74.0	46.6	56	75.4	67.4
Regional	196	13.8	14.4	190	13.9	14.7	3	18.5	26.2	-	-	-	2	8.3	3.7	9	12.7	10.5
Distant	94	6.6	8.5	90	6.6	8.4	-	-	-	-	-	-	2	9.4	7.7	6	8.6	10.4
Unknown	63	4.4	5.5	56	4.1	5.2	-	-	-	-	-	-	2	8.3	6.1	2	3.2	3.9
<i>Age < 65</i>																		
Localized	403	74.3	30.6	384	74.5	30.9	7	66.0	41.7	-	-	-	5	69.4	12.7	27	77.8	23.9
Regional	102	18.9	7.8	98	19.0	8.0	-	-	-	-	-	-	-	-	-	5	15.2	4.6
Distant	21	3.9	1.6	20	3.9	1.6	-	-	-	-	-	-	-	-	-	2	5.3	1.6
Unknown	16	2.9	1.2	14	2.6	1.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	668	75.7	455.6	642	75.8	454.6	7	84.6	630.3	-	-	-	9	76.7	281.1	29	73.4	368.3
Regional	94	10.6	60.0	92	10.9	61.1	-	-	-	-	-	-	-	-	-	4	10.6	51.0
Distant	73	8.3	55.8	70	8.3	55.4	-	-	-	-	-	-	-	-	-	5	11.6	71.8
Unknown	47	5.4	35.5	43	5.1	33.3	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Vermont, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	9	62.0	2.7	9	63.2	2.7	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	3	22.5	0.9	3	22.1	0.9	-	-	-				-	-	-	-	-	-
Distant	2	14.1	0.6	2	13.2	0.5	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
Stage at Diagnosis	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	6	4.0	1.5	5	3.8	1.4	-	-	-				-	-	-	-	-	-
Localized	54	36.7	13.6	52	36.5	13.4	-	-	-				-	-	-	-	-	-
Regional	47	32.1	12.4	46	32.2	12.2	-	-	-				-	-	-	-	-	-
Distant	32	22.0	8.5	32	22.5	8.6	-	-	-				-	-	-	-	-	-
Unknown	8	5.2	2.2	7	5.0	2.0	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	4	29.4	2.2	4	30.3	2.3	-	-	-				-	-	-	-	-	-
Regional	4	32.4	2.3	4	30.3	2.2	-	-	-				-	-	-	-	-	-
Distant	4	30.9	2.4	4	31.8	2.5	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	50	37.5	43.4	48	37.1	42.5	-	-	-				-	-	-	-	-	-
Regional	43	32.1	38.7	42	32.4	38.4	-	-	-				-	-	-	-	-	-
Distant	28	21.1	24.6	28	21.5	24.8	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	4	2.7	0.9	4	2.8	1.0	-	-	-				-	-	-	-	-	-
Localized	49	33.8	11.1	48	33.4	10.9	-	-	-				-	-	-	-	-	-
Regional	49	33.7	11.3	48	33.8	11.2	-	-	-				-	-	-	-	-	-
Distant	37	25.3	8.6	37	25.8	8.7	-	-	-				-	-	-	-	-	-
Unknown	7	4.5	1.4	6	4.2	1.3	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	4	26.7	2.2	4	26.8	2.2	-	-	-				-	-	-	-	-	-
Regional	6	37.3	2.9	5	35.2	2.7	-	-	-				-	-	-	-	-	-
Distant	5	30.7	2.5	5	32.4	2.6	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
Localized	45	34.6	34.5	44	34.1	33.7	-	-	-				-	-	-	-	-	-
Regional	44	33.2	33.2	43	33.6	33.5	-	-	-				-	-	-	-	-	-
Distant	32	24.7	24.5	32	25.1	24.7	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Vermont, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	115	17.2	27.6	113	17.3	27.9	-	-	-				-	-	-	-	-	-
Localized	401	60.2	93.8	393	60.1	93.8	1	87.5	47.2				3	68.2	60.0	2	61.1	70.0
Regional	119	17.8	30.0	117	17.9	30.5	-	-	-				-	-	-	-	-	-
Distant	26	3.9	6.1	26	3.9	6.1	-	-	-				-	-	-	-	-	-
Unknown	6	1.0	1.4	5	0.7	1.1	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	21	19.7	11.5	21	19.7	11.7	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	56	52.0	30.0	54	51.3	29.9	-	-	-				-	-	-	-	-	-
Regional	27	24.9	14.5	27	25.5	14.9	-	-	-				-	-	-	-	-	-
Distant	3	2.8	1.6	3	2.9	1.7	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	93	16.7	69.7	93	16.9	70.3	-	-	-				-	-	-	-	-	-
Localized	345	61.7	260.9	340	61.8	261.1	-	-	-				-	-	-	-	-	-
Regional	92	16.4	70.9	90	16.5	71.1	-	-	-				-	-	-	-	-	-
Distant	23	4.1	17.8	23	4.1	17.5	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	58	21.6	14.7	57	21.8	14.9	-	-	-				-	-	-	-	-	-
Regional	67	25.0	16.8	66	25.1	16.7	-	-	-				-	-	-	-	-	-
Distant	134	50.0	33.8	132	50.5	33.9	-	-	-				-	-	-	-	-	-
Unknown	9	3.5	2.5	7	2.5	1.9	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	68	26.5	14.7	67	26.6	14.7	-	-	-				-	-	-	-	-	-
Regional	60	23.3	13.0	59	23.6	13.1	-	-	-				-	-	-	-	-	-
Distant	118	46.3	25.9	117	46.7	26.0	-	-	-				-	-	-	-	-	-
Unknown	9	3.6	2.0	7	2.8	1.5	-	-	-				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	269	70.4	60.5	262	70.5	59.9	4	81.8	134.2	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	67	17.5	14.2	66	17.8	14.3	-	-	-				-	-	-	-	-	-
Distant	38	9.8	10.0	37	9.8	9.9	-	-	-				-	-	-	-	-	-
Unknown	8	2.2	2.4	7	1.9	1.9	-	-	-				-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	98	70.7	22.2	95	70.5	21.9	2	78.6	56.6	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	30	21.3	6.6	29	21.7	6.6	-	-	-				-	-	-	-	-	-
Distant	11	7.6	2.6	10	7.4	2.6	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	171	70.3	325.8	168	70.5	322.4	1	87.5	670.7				-	-	-	-	-	-
Regional	37	15.4	67.1	37	15.6	67.3	-	-	-				-	-	-	-	-	-
Distant	27	11.1	61.0	27	11.2	60.8	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Virginia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	115	42.7	2.7	77	44.4	2.6	24	38.8	2.6	Insufficient data for the calculation of AI/AN PRCA statistics			5	38.2	1.6	12	52.1	3.9
Regional	92	34.2	2.0	58	33.6	1.7	24	38.4	2.6				6	45.6	2.0	8	35.3	3.2
Distant	36	13.3	0.8	25	14.5	0.7	8	13.0	0.9				2	13.2	0.6	-	-	-
Unknown	26	9.8	0.6	13	7.5	0.4	6	9.8	0.7				-	-	-	2	8.4	0.8

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	80	4.5	1.8	59	4.5	1.7	17	4.6	2.1	Insufficient data for the calculation of AI/AN PRCA statistics			2	3.1	0.8	2	3.8	0.9
Localized	596	33.3	13.8	446	33.6	13.2	115	32.2	15.6				18	30.8	7.9	16	37.3	9.9
Regional	611	34.1	14.2	469	35.4	14.0	110	30.7	15.6				22	37.8	9.3	14	33.5	7.4
Distant	373	20.9	8.5	265	20.0	7.8	90	25.2	12.4				12	20.3	5.2	8	20.1	4.7
Unknown	129	7.2	3.2	87	6.6	2.8	26	7.3	4.2				5	8.0	2.2	2	5.3	1.6
<i>Age < 50</i>																		
In Situ	6	3.1	0.2	5	3.3	0.2	1	3.3	0.3				-	-	-	-	-	-
Localized	57	28.0	2.1	37	26.2	1.9	13	30.5	2.4				3	30.2	1.5	3	33.3	1.1
Regional	77	37.9	2.9	57	40.6	3.0	14	34.3	2.8				4	35.8	1.7	4	46.7	1.4
Distant	50	24.5	1.9	35	24.7	1.8	11	25.7	2.1				3	28.3	1.4	1	15.6	0.5
Unknown	13	6.6	0.5	7	5.2	0.4	3	6.2	0.5				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	74	4.7	5.9	55	4.6	5.6	15	4.8	7.0				2	3.9	2.7	-	-	-
Localized	539	34.0	44.3	409	34.5	42.9	103	32.4	50.1				14	30.9	24.7	13	38.4	33.2
Regional	534	33.7	43.8	412	34.7	42.8	96	30.3	49.3				18	38.2	29.0	10	29.9	23.1
Distant	324	20.4	25.8	231	19.4	23.4	80	25.1	39.3				9	18.5	15.2	7	21.3	15.6
Unknown	116	7.3	10.2	80	6.7	9.0	23	7.4	14.0				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	58	3.5	1.1	41	3.4	1.0	14	4.1	1.5	Insufficient data for the calculation of AI/AN PRCA statistics			-	-	-	2	3.4	0.8
Localized	576	34.7	11.4	424	34.8	11.1	117	33.6	12.5				16	30.5	5.9	17	31.3	7.1
Regional	562	33.8	11.1	427	35.0	11.1	106	30.6	11.3				21	38.3	7.0	20	38.1	9.8
Distant	326	19.6	6.5	233	19.1	6.1	78	22.4	8.3				11	20.1	4.1	11	21.1	5.8
Unknown	139	8.4	2.6	94	7.7	2.3	32	9.3	3.6				5	9.7	2.3	3	6.0	1.9
<i>Age < 50</i>																		
In Situ	6	2.9	0.2	4	2.4	0.2	2	4.6	0.4				-	-	-	-	-	-
Localized	71	33.6	2.6	51	34.1	2.7	13	29.6	2.2				2	22.9	0.9	5	36.6	1.9
Regional	73	34.4	2.7	52	34.5	2.7	16	36.6	2.8				4	37.5	1.5	4	29.6	1.6
Distant	50	23.6	1.8	36	24.0	1.9	10	22.7	1.7				3	31.3	1.2	4	25.4	1.4
Unknown	12	5.5	0.4	7	4.9	0.4	3	6.5	0.5				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	52	3.6	3.5	37	3.5	3.3	12	4.0	4.6				-	-	-	-	-	-
Localized	505	34.8	34.3	373	34.9	32.9	104	34.2	39.3				14	32.1	19.1	11	29.4	20.6
Regional	489	33.7	32.9	375	35.1	32.9	90	29.7	33.7				17	38.5	21.4	16	41.2	31.0
Distant	276	19.0	18.6	197	18.4	17.3	68	22.3	25.5				8	17.6	11.5	8	19.6	17.5
Unknown	127	8.8	8.5	87	8.1	7.3	29	9.7	11.6				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Virginia, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,658	20.6	33.1	1,194	19.9	32.2	336	21.2	35.0				92	27.5	29.4	57	22.9	22.3
Localized	4,165	51.6	81.8	3,209	53.6	83.8	733	46.3	77.3				161	48.1	52.6	113	45.6	48.9
Regional	1,693	21.0	34.6	1,204	20.1	33.2	391	24.7	41.5				63	18.7	19.6	62	24.8	22.9
Distant	369	4.6	7.3	259	4.3	6.8	90	5.7	9.7				12	3.6	4.1	12	4.7	5.0
Unknown	182	2.3	3.6	125	2.1	3.2	32	2.0	3.4				7	2.2	2.6	5	2.0	2.8
<i>Age < 50</i>																		
In Situ	352	22.8	13.1	246	23.2	13.1	63	19.5	11.3	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			30	26.8	12.7	20	21.5	8.5
Localized	667	43.1	24.7	468	44.2	24.8	127	39.3	22.7				52	45.8	21.5	37	39.5	15.1
Regional	438	28.3	16.3	290	27.4	15.6	108	33.4	19.3				25	22.0	10.3	31	32.5	12.1
Distant	65	4.2	2.4	39	3.7	2.1	20	6.1	3.5				4	3.9	1.8	5	5.5	2.1
Unknown	26	1.7	1.0	16	1.5	0.9	5	1.6	0.9				2	1.6	0.7	-	-	-
<i>Age ≥ 50</i>																		
In Situ	1,306	20.0	85.6	948	19.2	82.3	273	21.6	96.9				62	27.8	73.1	36	23.7	58.4
Localized	3,498	53.7	231.4	2,741	55.6	238.1	606	48.1	220.2				109	49.2	133.9	76	49.4	137.3
Regional	1,255	19.3	82.4	913	18.5	79.3	284	22.5	99.8				38	17.0	43.9	31	20.1	51.4
Distant	304	4.7	20.2	220	4.5	19.2	70	5.6	25.7				8	3.4	10.0	6	4.2	12.7
Unknown	156	2.4	10.3	110	2.2	9.3	27	2.1	10.0				6	2.5	7.6	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.3	0.2	6	0.3	0.2	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	574	20.1	13.6	462	20.8	13.8	97	18.1	14.5				10	15.4	5.2	6	16.7	5.5
Regional	658	23.1	15.0	507	22.9	14.6	129	24.0	18.5				15	23.3	8.2	7	22.0	5.4
Distant	1,404	49.2	32.0	1,077	48.6	31.1	275	50.9	39.1				35	53.2	17.7	17	50.6	13.9
Unknown	209	7.3	5.3	163	7.4	5.1	37	6.9	6.3				5	7.9	2.7	3	10.1	3.5
<i>Female</i>																		
In Situ	8	0.3	0.1	6	0.3	0.1	1	0.3	0.1	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	634	24.5	12.2	517	25.2	12.9	97	22.0	10.5				13	20.4	5.2	7	18.6	4.1
Regional	585	22.6	11.2	464	22.6	11.6	103	23.3	10.9				13	20.4	4.8	7	17.0	3.6
Distant	1,127	43.6	21.4	877	42.7	21.7	206	46.5	21.9				31	49.0	11.2	19	47.9	9.9
Unknown	232	9.0	4.4	188	9.2	4.5	35	7.9	4.0				5	8.6	2.4	6	16.5	4.4

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	3,639	77.0	75.2	2,340	76.7	62.2	1,042	78.4	127.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			75	77.4	35.0	71	70.0	46.1
Regional	516	10.9	10.2	360	11.8	9.1	133	10.0	15.5				12	12.5	5.2	13	12.8	6.3
Distant	298	6.3	7.2	199	6.5	6.1	88	6.7	13.3				6	6.4	3.9	8	8.3	7.1
Unknown	274	5.8	6.7	151	4.9	4.8	66	4.9	10.8				4	3.7	2.1	9	8.9	8.2
<i>Age < 65</i>																		
Localized	1,631	78.7	34.1	934	78.3	25.6	581	80.2	66.5	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			26	79.0	10.6	37	70.8	15.7
Regional	276	13.3	5.8	180	15.1	4.9	85	11.8	9.8				5	15.0	2.0	9	17.8	3.9
Distant	82	4.0	1.7	45	3.8	1.2	34	4.7	3.9				-	-	-	3	5.3	1.2
Unknown	82	4.0	1.7	34	2.9	0.9	24	3.3	2.7				1	3.6	0.5	3	6.1	1.4
<i>Age ≥ 65</i>																		
Localized	2,008	75.6	359.7	1,406	75.7	315.4	461	76.3	549.3				49	76.6	204.1	33	69.0	256.0
Regional	240	9.0	40.8	180	9.7	38.1	47	7.8	54.8				7	11.3	27.6	4	7.4	23.2
Distant	216	8.1	45.3	155	8.3	40.1	54	8.9	78.5				-	-	-	6	11.6	47.7
Unknown	192	7.2	41.0	117	6.3	31.1	42	7.0	67.1				2	3.8	13.7	6	12.0	55.5

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Washington, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	124	50.1	3.5	100	50.5	3.4	4	47.8	2.8	3	45.9	4.8	13	46.0	3.2	11	53.4	3.1
Regional	71	28.8	1.9	56	28.0	1.8	3	37.0	2.3	2	29.7	3.3	10	34.5	2.5	6	30.1	2.1
Distant	31	12.6	0.8	26	13.3	0.8	-	-	-	-	-	-	3	12.2	0.9	2	11.7	0.9
Unknown	21	8.5	0.5	16	8.2	0.5	-	-	-	-	-	-	2	7.2	0.5	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	15	1.0	0.3	13	1.0	0.4	-	-	-	-	-	-	-	-	-	2	2.3	0.6
Localized	528	35.0	13.8	453	34.8	13.4	18	35.1	14.0	10	38.7	19.9	34	32.9	12.3	24	34.5	12.0
Regional	532	35.3	14.0	463	35.6	13.8	17	32.0	13.1	8	33.1	16.2	38	36.8	14.1	25	35.6	13.5
Distant	312	20.7	8.2	269	20.7	8.0	12	22.4	9.7	5	21.8	8.7	23	22.6	8.5	14	20.1	6.4
Unknown	122	8.1	3.3	102	7.9	3.2	5	8.9	4.7	2	6.5	2.8	8	7.4	3.0	5	7.5	2.9
<i>Age < 50</i>																		
In Situ	1	0.6	0.0	1	0.8	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	59	31.3	2.6	47	30.8	2.5	3	35.0	2.2	2	33.3	4.3	5	26.4	1.9	5	33.3	1.8
Regional	72	37.9	3.1	58	37.8	3.1	3	42.5	2.9	2	30.0	3.8	8	43.7	3.1	5	30.9	1.8
Distant	47	24.8	2.0	39	25.7	2.1	2	20.0	1.4	1	23.3	3.2	4	23.0	1.6	5	32.1	1.8
Unknown	10	5.4	0.4	8	5.0	0.4	-	-	-	-	-	-	1	6.9	0.5	-	-	-
<i>Age ≥ 50</i>																		
In Situ	13	1.0	1.1	12	1.0	1.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	469	35.5	43.2	406	35.4	42.1	15	35.2	45.0	8	40.4	60.8	29	34.2	39.5	19	34.8	38.6
Regional	460	34.9	42.5	405	35.3	42.0	13	30.1	40.0	6	34.0	48.6	30	35.3	42.8	20	37.1	44.2
Distant	265	20.1	24.2	230	20.0	23.6	10	22.8	31.5	4	21.3	23.0	19	22.6	26.6	9	16.5	18.3
Unknown	112	8.5	10.9	95	8.3	10.4	-	-	-	-	-	-	6	7.4	9.5	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	11	0.8	0.3	10	0.8	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	491	35.7	11.8	430	35.9	11.8	15	37.3	12.3	8	32.6	13.9	30	33.4	8.3	24	41.7	11.1
Regional	501	36.5	11.8	436	36.4	11.6	14	34.3	12.4	11	41.1	20.4	36	39.4	9.7	21	35.9	10.5
Distant	256	18.6	6.0	223	18.7	6.0	7	17.4	5.7	5	20.9	8.5	18	19.7	4.8	10	17.6	4.4
Unknown	114	8.3	2.5	99	8.2	2.5	4	9.5	3.5	1	5.4	2.9	6	6.6	1.8	3	4.5	1.7
<i>Age < 50</i>																		
In Situ	1	0.8	0.1	1	0.8	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	66	38.1	2.9	54	38.2	3.0	3	35.7	2.5	2	50.0	3.1	4	32.8	1.5	8	48.8	2.8
Regional	59	33.8	2.6	47	32.7	2.6	3	40.5	3.3	1	43.8	3.0	5	37.3	1.8	5	30.2	2.0
Distant	39	22.3	1.7	33	23.2	1.8	1	16.7	1.4	-	-	-	3	25.4	1.2	3	19.8	1.4
Unknown	9	4.9	0.4	7	5.1	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	10	0.8	0.8	9	0.8	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Localized	424	35.4	35.0	375	35.6	35.1	12	37.7	38.0	7	30.1	42.2	26	33.5	26.1	16	38.7	33.0
Regional	442	36.9	35.7	389	36.9	35.4	10	32.7	36.2	9	40.7	65.9	31	39.7	30.6	16	38.2	32.9
Distant	217	18.1	17.1	190	18.1	17.1	6	17.6	17.1	-	-	-	14	18.7	14.4	7	16.7	12.4
Unknown	105	8.8	8.2	91	8.7	7.9	-	-	-	1	6.2	10.4	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Washington, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,371	19.4	32.6	1,147	18.6	31.6	45	23.8	35.4	20	20.0	30.7	137	26.7	35.3	55	18.9	22.1
Localized	3,711	52.5	86.5	3,308	53.7	88.4	82	43.2	66.4	47	46.5	75.1	232	45.4	60.4	132	45.5	60.1
Regional	1,470	20.8	35.8	1,273	20.7	36.0	45	23.7	35.0	25	24.1	40.7	106	20.8	27.1	82	28.1	31.8
Distant	267	3.8	6.3	234	3.8	6.4	9	4.8	7.7	5	4.9	7.7	16	3.1	4.1	13	4.6	5.7
Unknown	244	3.5	5.7	198	3.2	5.2	9	4.5	7.2	5	4.5	7.7	20	4.0	5.4	8	2.9	4.3
<i>Age < 50</i>																		
In Situ	270	21.8	12.3	206	21.1	11.6	11	21.9	11.2	5	19.5	11.3	43	26.0	15.7	22	21.1	9.0
Localized	527	42.5	23.8	423	43.1	23.6	21	42.6	21.1	9	36.6	20.4	67	41.0	24.5	37	36.1	15.2
Regional	360	29.1	16.3	288	29.4	16.1	14	29.8	14.8	8	32.5	18.0	42	25.8	15.1	37	36.1	14.8
Distant	47	3.8	2.1	40	4.0	2.2	1	2.5	1.2	1	5.7	3.3	4	2.7	1.5	5	4.7	1.8
Unknown	35	2.9	1.6	23	2.3	1.3	2	3.3	1.8	1	5.7	3.1	7	4.5	2.7	2	2.0	0.8
<i>Age ≥ 50</i>																		
In Situ	1,101	18.9	85.7	940	18.2	83.8	34	24.4	98.7	16	20.2	81.7	94	27.1	86.7	33	17.7	56.5
Localized	3,184	54.7	250.4	2,885	55.7	258.3	61	43.5	185.1	38	49.6	218.6	165	47.4	154.4	95	50.6	177.6
Regional	1,110	19.1	86.9	985	19.0	88.2	30	21.6	88.0	17	21.4	100.3	64	18.5	58.8	45	23.7	76.4
Distant	220	3.8	17.4	194	3.7	17.4	8	5.5	24.7	4	4.7	19.3	11	3.3	10.9	9	4.6	15.6
Unknown	208	3.6	16.4	175	3.4	15.6	7	5.0	21.6	3	4.1	19.9	13	3.7	12.6	6	3.4	13.7

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	11	0.5	0.3	10	0.5	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	438	19.8	12.0	399	20.0	12.2	12	19.2	12.3	4	13.5	8.2	20	17.5	8.4	7	13.8	4.8
Regional	484	21.9	12.7	437	21.9	12.8	12	18.9	11.9	8	28.4	15.3	23	20.4	9.7	14	26.9	9.7
Distant	1,079	48.8	28.4	970	48.7	28.5	32	50.5	31.7	12	43.3	28.0	59	52.6	24.4	28	53.1	19.1
Unknown	200	9.0	5.7	178	8.9	5.6	7	11.0	7.9	4	14.2	8.3	10	9.1	4.7	3	6.2	2.9
<i>Female</i>																		
In Situ	22	1.0	0.5	21	1.0	0.5	-	-	-	-	-	-	1	1.2	0.4	1	2.2	0.8
Localized	561	25.3	13.1	511	25.4	13.4	14	28.3	14.1	9	26.7	16.7	24	21.0	7.1	14	24.9	8.2
Regional	478	21.6	10.9	435	21.7	11.2	11	22.3	9.4	7	21.2	12.5	22	19.1	5.9	11	20.1	6.1
Distant	970	43.7	22.1	871	43.4	22.5	22	43.7	19.2	14	43.0	26.4	57	50.7	16.3	24	44.7	14.7
Unknown	186	8.4	4.3	170	8.4	4.3	3	5.7	2.5	3	8.5	4.9	9	8.0	2.9	4	8.1	3.1

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	3,026	74.0	72.1	2,629	73.7	70.4	139	76.5	102.4	27	73.0	52.2	102	71.0	38.5	88	72.6	53.4
Regional	612	15.0	14.0	548	15.4	14.1	22	12.0	16.2	6	16.2	10.6	24	16.4	8.6	16	13.5	9.8
Distant	337	8.2	9.3	297	8.3	9.1	18	9.8	18.0	3	8.1	6.6	16	10.8	7.4	14	11.5	9.8
Unknown	113	2.8	3.2	92	2.6	3.0	3	1.7	3.6	-	-	-	3	1.8	1.2	3	2.5	3.2
<i>Age < 65</i>																		
Localized	1,172	76.7	27.5	984	76.1	26.4	82	79.4	49.3	9	65.3	13.7	36	75.8	12.0	43	77.2	17.2
Regional	255	16.7	5.9	225	17.4	6.0	13	12.7	8.1	3	23.6	5.2	9	19.2	3.0	8	13.8	3.0
Distant	82	5.4	1.9	70	5.4	1.9	7	7.1	4.4	1	8.3	1.7	2	4.2	0.6	5	8.3	1.9
Unknown	20	1.3	0.5	14	1.1	0.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,854	72.5	381.0	1,645	72.4	374.3	57	72.8	469.2	18	77.9	318.2	66	68.5	221.6	46	68.8	303.5
Regional	357	14.0	69.9	323	14.2	70.0	9	11.1	72.8	3	11.5	48.0	14	15.0	47.3	9	13.2	56.4
Distant	255	10.0	60.4	227	10.0	59.2	10	13.4	112.3	2	8.0	40.1	14	14.2	54.0	9	14.1	64.7
Unknown	93	3.6	22.2	78	3.4	20.8	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Seattle/Puget Sound, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	90	49.6	3.6	70	49.2	3.6	4	47.6	3.0	2	47.4	4.3	13	50.0	3.5	7	53.2	3.1
Regional	58	31.8	2.2	43	30.6	2.1	3	40.5	2.6	2	42.1	3.7	9	35.7	2.6	4	32.3	2.6
Distant	26	14.1	0.9	21	15.1	1.0	-	-	-	-	-	-	3	12.7	1.0	1	11.3	1.0
Unknown	8	4.5	0.3	7	5.2	0.3	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	3	0.3	0.1	3	0.3	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	392	36.4	15.1	324	36.1	14.7	19	38.5	18.8	8	45.2	25.3	34	34.0	13.7	17	41.1	16.0
Regional	390	36.2	15.1	332	37.0	15.1	16	32.1	15.1	5	27.4	13.6	36	36.4	15.1	14	33.8	16.6
Distant	233	21.6	8.9	194	21.6	8.8	11	22.2	10.8	4	21.4	9.0	24	24.4	9.9	8	19.8	7.5
Unknown	58	5.4	2.4	46	5.1	2.2	3	6.7	4.0	-	-	-	5	5.2	2.3	2	4.3	2.0
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	48	33.2	2.9	38	33.3	3.0	3	37.1	2.4	2	38.1	5.2	4	25.3	2.0	4	41.7	2.3
Regional	54	37.4	3.3	42	37.0	3.2	3	42.9	2.9	1	33.3	4.4	7	42.5	3.3	2	25.0	1.5
Distant	37	25.2	2.2	30	26.1	2.3	1	17.1	1.2	-	-	-	5	26.4	2.1	3	29.2	1.7
Unknown	6	4.1	0.4	4	3.7	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	3	0.3	0.4	3	0.4	0.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	344	36.9	46.9	286	36.5	45.3	17	38.7	61.9	6	47.6	78.0	30	35.8	44.4	13	40.9	51.9
Regional	336	36.1	46.1	290	37.0	46.1	13	30.4	47.0	3	25.4	37.6	29	35.1	45.9	12	36.5	56.2
Distant	196	21.1	26.6	164	20.9	25.8	10	23.0	35.9	-	-	-	20	24.0	30.2	5	17.0	22.7
Unknown	52	5.6	7.8	41	5.3	7.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	3	0.3	0.1	2	0.3	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	353	36.7	12.3	299	36.8	12.5	14	38.4	13.3	7	37.1	16.9	30	34.5	9.0	14	36.8	12.7
Regional	359	37.3	12.2	302	37.1	12.1	13	35.7	13.5	7	39.3	21.8	36	41.5	10.8	16	41.5	14.9
Distant	191	19.9	6.5	161	19.8	6.6	8	20.5	7.2	4	20.2	9.7	17	20.3	5.3	7	17.6	5.9
Unknown	56	5.8	1.8	48	6.0	1.8	2	5.4	2.1	-	-	-	3	3.5	1.0	2	4.1	2.3
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	48	38.8	2.9	37	38.7	3.1	3	37.5	2.9	1	58.3	4.2	4	33.8	1.7	3	34.8	1.9
Regional	43	35.2	2.7	33	34.4	2.7	3	42.5	3.8	-	-	-	5	40.0	2.1	4	43.5	2.7
Distant	27	22.3	1.7	22	22.8	1.8	2	20.0	1.8	-	-	-	3	24.6	1.3	2	19.6	1.3
Unknown	4	3.6	0.3	4	3.9	0.3	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	305	36.4	36.8	262	36.6	37.2	11	38.6	40.2	5	33.8	50.1	25	34.6	28.3	11	37.4	41.2
Regional	316	37.7	37.0	269	37.5	36.7	10	33.8	38.9	-	-	-	30	41.8	33.7	12	40.8	46.9
Distant	164	19.5	19.0	139	19.4	19.0	6	20.7	21.4	-	-	-	14	19.5	15.8	5	17.0	18.0
Unknown	51	6.1	5.8	45	6.2	5.7	2	6.9	7.5	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Seattle/Puget Sound, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,031	20.2	35.6	834	19.2	34.7	43	23.8	38.2	13	18.5	31.9	129	26.8	37.2	41	20.4	30.9
Localized	2,734	53.5	93.1	2,374	54.7	96.5	83	45.8	75.9	34	47.3	87.8	227	47.1	66.1	96	47.6	82.7
Regional	1,076	21.0	37.9	904	20.8	38.5	45	24.6	38.9	18	24.9	45.3	102	21.2	29.2	55	27.2	40.3
Distant	211	4.1	7.2	177	4.1	7.3	9	5.2	8.9	5	6.7	12.2	18	3.8	5.2	8	4.1	6.7
Unknown	60	1.2	2.0	49	1.1	1.9	1	0.7	1.2	2	2.5	5.1	5	1.0	1.6	2	0.8	1.5
<i>Age < 50</i>																		
In Situ	212	22.4	13.7	154	21.5	12.8	10	22.0	12.2	4	19.6	13.9	41	25.9	16.7	17	23.6	12.5
Localized	419	44.2	26.7	320	44.9	26.4	19	41.8	22.5	7	35.1	23.9	68	43.4	27.7	27	38.7	20.2
Regional	271	28.6	17.2	207	29.0	17.1	15	31.9	17.1	6	33.0	21.9	41	26.1	16.4	24	34.2	17.5
Distant	38	4.0	2.4	29	4.0	2.4	2	3.4	1.8	2	9.3	6.5	6	3.7	2.2	2	2.8	1.4
Unknown	8	0.8	0.5	4	0.6	0.3	-	-	-	-	-	-	1	0.9	0.6	-	-	-
<i>Age ≥ 50</i>																		
In Situ	819	19.7	93.0	680	18.8	92.0	33	24.4	106.3	9	18.1	78.8	88	27.2	91.0	25	18.6	79.2
Localized	2,315	55.6	266.9	2,054	56.7	279.9	64	47.2	215.5	27	51.9	255.0	159	49.0	166.4	69	52.3	246.5
Regional	804	19.3	92.2	697	19.2	94.8	30	22.0	96.1	11	21.9	106.7	61	18.8	62.8	31	23.5	100.0
Distant	173	4.2	19.9	149	4.1	20.2	8	5.8	27.5	3	5.8	27.1	13	3.9	13.2	6	4.7	20.6
Unknown	52	1.3	6.0	45	1.3	6.1	-	-	-	-	-	-	4	1.1	4.1	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	7	0.5	0.3	7	0.5	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	312	20.7	13.0	277	20.9	13.3	11	19.2	13.2	3	14.9	10.4	20	19.0	9.9	7	20.2	9.7
Regional	335	22.2	13.2	295	22.3	13.4	12	19.9	13.2	6	28.7	17.6	22	20.3	10.3	8	25.8	11.8
Distant	787	52.0	30.9	683	51.6	30.9	33	55.9	37.8	9	42.6	31.1	61	57.1	28.6	17	50.9	22.4
Unknown	71	4.7	3.1	62	4.7	3.1	3	5.1	4.4	3	12.9	9.7	4	3.3	1.9	-	-	-
<i>Female</i>																		
In Situ	19	1.2	0.6	18	1.3	0.7	-	-	-	-	-	-	1	1.3	0.5	-	-	-
Localized	412	26.7	14.1	367	26.9	14.7	14	29.4	15.8	8	33.9	24.9	22	21.3	7.4	9	21.3	9.6
Regional	330	21.4	11.0	293	21.5	11.5	11	23.8	10.9	5	23.5	15.1	20	18.8	6.2	9	22.8	9.9
Distant	705	45.7	23.6	619	45.3	24.3	20	43.4	20.6	9	40.0	27.6	56	53.0	17.6	20	50.5	23.0
Unknown	77	5.0	2.6	68	5.0	2.6	2	3.4	1.8	-	-	-	6	5.5	2.0	2	4.0	2.2

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,230	73.5	79.1	1,927	73.5	79.4	134	75.8	116.6	20	68.2	65.6	97	68.3	41.0	54	72.5	64.0
Regional	478	15.8	16.1	418	15.9	16.3	22	12.6	18.5	6	19.6	17.8	26	18.3	10.6	11	15.2	13.0
Distant	272	9.0	11.2	233	8.9	11.0	19	10.5	22.5	3	10.1	10.7	17	11.8	8.6	8	10.4	10.0
Unknown	52	1.7	2.3	45	1.7	2.3	2	1.1	2.6	-	-	-	2	1.7	1.3	1	1.9	3.4
<i>Age < 65</i>																		
Localized	871	75.2	29.6	721	74.9	29.0	76	77.2	52.1	7	60.3	15.9	34	71.9	12.4	26	75.0	20.4
Regional	215	18.5	7.3	183	19.0	7.3	14	14.7	10.2	3	22.4	6.0	10	21.7	3.7	6	16.5	4.4
Distant	67	5.8	2.2	55	5.7	2.2	7	7.5	5.0	2	13.8	3.6	2	5.1	0.9	3	8.5	2.4
Unknown	6	0.5	0.2	3	0.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,359	72.5	421.1	1,206	72.6	427.3	59	74.0	562.3	13	73.3	409.0	63	66.5	239.1	28	70.2	364.7
Regional	263	14.1	77.3	235	14.2	78.7	8	10.1	75.8	3	17.8	99.1	16	16.6	58.1	6	14.1	72.5
Distant	205	11.0	73.1	178	10.7	71.9	11	14.1	143.4	1	7.8	59.6	14	15.1	62.1	5	12.1	62.4
Unknown	46	2.4	16.7	42	2.5	17.3	-	-	-	-	-	-	-	-	-	1	3.5	26.7

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
West Virginia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	38	43.4	4.3	38	44.4	4.5	-	-	-	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Regional	30	33.9	3.0	29	34.3	3.0	-	-	-				-	-	-	-	-	-
Distant	16	18.4	1.5	16	18.4	1.5	-	-	-				-	-	-	-	-	-
Unknown	4	4.3	0.3	2	2.8	0.2	-	-	-				-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	36	5.7	2.9	34	5.6	2.8	2	8.7	5.1	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	237	37.1	20.5	227	37.0	20.5	7	39.1	21.6				-	-	-	-	-	-
Regional	203	31.8	18.0	196	31.9	18.1	5	29.3	14.3				-	-	-	1	37.5	12.3
Distant	134	21.0	11.5	130	21.2	11.6	3	16.3	8.9				-	-	-	-	-	-
Unknown	29	4.5	2.6	26	4.3	2.4	1	6.5	2.9				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	2	2.6	0.3	1	2.4	0.3	-	-	-				-	-	-	-	-	-
Localized	21	33.2	3.7	19	32.2	3.6	2	61.5	6.9				-	-	-	-	-	-
Regional	25	40.0	4.4	24	40.4	4.5	-	-	-				-	-	-	-	-	-
Distant	14	22.9	2.6	14	23.6	2.6	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	35	6.0	9.7	33	5.9	9.6	2	10.1	18.4				-	-	-	-	-	-
Localized	216	37.5	64.7	208	37.5	64.7	6	35.4	60.2				-	-	-	-	-	-
Regional	178	30.9	53.6	172	31.0	53.7	-	-	-				-	-	-	-	-	-
Distant	120	20.8	34.8	116	21.0	35.1	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	1	7.6	10.4				-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	25	4.5	1.8	24	4.4	1.8	1	7.8	3.4	Insufficient data for the calculation of AI/AN PRCDA statistics			-	-	-	-	-	-
Localized	232	41.0	17.6	225	41.0	17.6	6	40.3	17.0				-	-	-	-	-	-
Regional	174	30.7	13.2	169	30.9	13.3	4	27.3	11.9				-	-	-	-	-	-
Distant	109	19.2	8.4	106	19.3	8.5	3	19.5	7.4				-	-	-	-	-	-
Unknown	26	4.6	1.8	25	4.5	1.8	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	1	2.4	0.2	1	2.4	0.2	-	-	-				-	-	-	-	-	-
Localized	21	41.7	3.9	20	41.0	4.0	-	-	-				-	-	-	-	-	-
Regional	16	31.9	2.9	16	32.1	3.0	-	-	-				-	-	-	-	-	-
Distant	11	22.0	2.1	11	22.5	2.2	-	-	-				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	24	4.7	6.1	23	4.6	6.0	1	8.3	12.1				-	-	-	-	-	-
Localized	211	41.0	53.3	204	41.0	53.4	-	-	-				-	-	-	-	-	-
Regional	158	30.6	40.2	153	30.7	40.2	-	-	-				-	-	-	-	-	-
Distant	98	18.9	24.9	94	19.0	24.9	3	20.8	26.9				-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
West Virginia, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	270	15.4	21.7	260	15.4	21.6	8	16.0	22.2				1	14.6	13.7	2	22.9	17.7
Localized	970	55.4	75.4	937	55.6	75.4	24	51.3	70.7				6	60.4	66.0	3	45.7	35.6
Regional	383	21.9	32.0	367	21.8	31.8	12	25.6	36.4				2	18.8	21.1	1	17.1	12.8
Distant	102	5.8	8.1	98	5.8	8.2	3	5.5	6.9				-	-	-	-	-	-
Unknown	26	1.5	2.1	24	1.4	2.0	-	-	-				-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	44	16.4	8.0	42	16.5	7.9	2	17.8	9.2	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	125	46.8	22.8	118	46.7	22.5	4	44.4	22.0				2	75.0	40.1	1	42.9	17.9
Regional	78	29.2	14.3	74	29.3	14.2	3	33.3	16.1				-	-	-	-	-	-
Distant	15	5.8	2.8	15	6.0	2.9	-	-	-				-	-	-	-	-	-
Unknown	5	1.8	0.9	4	1.5	0.7	-	-	-				-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	226	15.2	57.5	218	15.2	57.6	6	15.5	56.2				-	-	-	-	-	-
Localized	845	56.9	213.0	819	57.1	213.9	20	52.8	198.5				3	53.1	133.9	2	47.6	81.9
Regional	305	20.5	78.2	293	20.4	78.1	9	23.8	89.3				-	-	-	-	-	-
Distant	87	5.8	22.1	83	5.8	22.0	-	-	-				-	-	-	-	-	-
Unknown	21	1.4	5.3	20	1.4	5.2	-	-	-				-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	2	0.1	0.1	2	0.1	0.1	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	243	21.4	20.1	237	21.5	20.3	5	18.5	19.8				-	-	-	-	-	-
Regional	269	23.6	22.0	258	23.4	21.9	10	34.9	29.4				-	-	-	-	-	-
Distant	582	51.1	48.0	565	51.3	48.3	13	45.9	43.4				2	57.1	20.3	1	50.0	18.5
Unknown	44	3.8	3.9	41	3.7	3.8	-	-	-				-	-	-	-	-	-
<i>Female</i>																		
In Situ	1	0.1	0.1	-	-	-	-	-	-	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	-	-	-
Localized	252	26.4	18.2	246	26.5	18.4	5	26.3	14.2				-	-	-	-	-	-
Regional	226	23.7	16.4	220	23.8	16.6	5	23.2	13.3				-	-	-	-	-	-
Distant	447	46.9	32.4	434	46.8	32.6	10	48.5	25.4				1	70.0	15.5	-	-	-
Unknown	27	2.8	1.8	26	2.8	1.9	-	-	-				-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	948	80.1	73.0	889	80.3	71.1	53	82.0	134.7	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	6	93.8	77.3
Regional	92	7.8	6.8	86	7.8	6.6	5	8.1	11.5				-	-	-	-	-	-
Distant	90	7.6	7.7	85	7.7	7.6	4	6.8	15.5				-	-	-	-	-	-
Unknown	54	4.5	4.6	47	4.3	4.2	2	3.1	7.1				-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	353	81.3	29.2	321	81.3	27.8	29	84.0	68.9	Insufficient data for the calculation of AI/AN PRCD ¹ statistics			-	-	-	2	85.7	24.4
Regional	47	10.9	4.0	43	10.9	3.7	-	-	-				-	-	-	-	-	-
Distant	21	4.7	1.7	20	5.0	1.6	-	-	-				-	-	-	-	-	-
Unknown	13	3.0	1.1	11	2.9	0.9	-	-	-				-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	595	79.4	375.4	568	79.7	370.8	23	79.6	589.3				-	-	-	4	100.0	443.4
Regional	44	5.9	26.2	43	6.0	26.2	-	-	-				-	-	-	-	-	-
Distant	69	9.2	49.7	65	9.2	48.5	-	-	-				-	-	-	-	-	-
Unknown	41	5.4	29.1	36	5.1	26.8	-	-	-				-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Wisconsin, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	96	50.3	3.4	80	50.6	3.2	10	49.0	5.2	2	60.0	9.9	2	38.7	3.8	7	62.5	4.5
Regional	62	32.4	2.0	51	32.1	1.8	6	32.0	3.9	-	-	-	3	45.2	5.1	3	28.6	2.9
Distant	29	15.4	0.9	25	15.9	0.8	3	16.0	1.9	-	-	-	-	-	-	-	-	-
Unknown	4	1.9	0.1	2	1.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	60	4.3	1.8	50	4.0	1.6	8	9.1	6.3	-	-	-	-	-	-	-	-	-
Localized	499	35.9	15.3	454	35.7	14.8	34	40.8	24.3	4	37.5	24.3	4	27.8	9.6	8	31.5	7.9
Regional	480	34.6	15.0	447	35.2	14.8	20	24.5	16.2	4	39.3	33.6	5	37.5	11.2	10	39.2	12.9
Distant	296	21.3	9.1	268	21.1	8.8	19	22.5	15.6	3	23.2	16.9	3	23.6	8.9	6	23.8	7.2
Unknown	54	3.9	1.8	50	3.9	1.7	3	3.1	2.9	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	4	2.8	0.2	3	2.1	0.2	1	9.2	1.1	-	-	-	-	-	-	-	-	-
Localized	49	33.6	2.7	42	32.9	2.6	5	36.9	4.1	1	54.5	8.9	-	-	-	2	32.3	1.4
Regional	54	37.1	3.1	49	38.4	3.1	3	24.6	2.8	-	-	-	1	40.0	2.4	3	41.9	2.3
Distant	37	25.2	2.1	32	25.3	2.1	4	27.7	3.0	-	-	-	-	-	-	1	22.6	1.1
Unknown	2	1.4	0.1	2	1.4	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	56	4.5	5.8	48	4.2	5.3	6	9.1	19.9	-	-	-	-	-	-	-	-	-
Localized	450	36.2	48.2	412	36.1	46.7	29	41.5	77.1	3	33.3	64.4	-	-	-	6	31.3	25.2
Regional	426	34.3	46.1	398	34.9	45.5	17	24.4	51.1	-	-	-	4	36.8	34.2	8	38.4	40.5
Distant	259	20.8	27.5	236	20.7	26.5	15	21.6	48.5	-	-	-	-	-	-	5	24.2	23.1
Unknown	52	4.2	6.2	48	4.2	6.0	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	44	3.5	1.2	37	3.2	1.1	6	7.8	3.4	-	-	-	-	-	-	-	-	-
Localized	457	36.4	12.4	413	36.2	12.0	33	43.5	20.8	4	40.0	24.0	3	19.5	6.1	10	44.2	12.0
Regional	442	35.1	11.8	409	35.7	11.6	21	27.1	13.8	3	29.1	18.8	6	37.8	12.3	7	31.0	7.7
Distant	250	19.9	6.8	225	19.7	6.5	15	20.1	9.3	3	25.5	13.1	5	31.7	9.8	4	19.5	5.0
Unknown	65	5.2	1.5	60	5.2	1.4	1	1.6	0.8	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	5	3.8	0.3	4	3.6	0.3	-	-	-	-	-	-	-	-	-	-	-	-
Localized	48	36.5	2.7	42	37.3	2.7	5	37.1	3.7	-	-	-	-	-	-	3	37.1	2.3
Regional	45	33.8	2.6	38	34.4	2.5	3	24.2	2.6	-	-	-	2	40.0	3.0	2	34.3	2.4
Distant	32	24.2	1.8	26	23.7	1.7	4	29.0	3.1	-	-	-	2	45.0	3.1	2	22.9	1.3
Unknown	2	1.7	0.1	1	1.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	39	3.5	3.5	33	3.2	3.1	-	-	-	-	-	-	-	-	-	-	-	-
Localized	409	36.3	37.9	372	36.0	36.3	29	44.7	65.6	-	-	-	-	-	-	7	47.4	37.5
Regional	397	35.3	36.0	370	35.9	35.5	18	27.6	43.1	-	-	-	5	37.1	36.7	5	29.5	21.6
Distant	218	19.3	19.7	198	19.2	18.9	12	18.3	25.5	3	29.2	47.4	3	27.4	27.4	3	17.9	14.5
Unknown	63	5.6	5.2	58	5.7	5.0	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Wisconsin, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	1,158	19.8	33.4	1,059	19.6	33.0	71	24.2	44.0	5	15.4	27.0	13	22.1	21.0	27	24.7	28.1
Localized	3,145	53.9	87.3	2,947	54.5	87.8	132	44.5	80.3	18	52.7	93.8	29	50.5	49.4	52	48.1	56.2
Regional	1,245	21.3	36.4	1,140	21.1	36.1	74	25.1	44.9	10	28.4	53.9	14	23.9	22.9	24	22.6	21.8
Distant	244	4.2	6.8	222	4.1	6.6	17	5.8	10.4	-	-	-	2	3.5	2.9	5	4.3	4.3
Unknown	43	0.7	1.0	40	0.7	1.0	1	0.4	1.0	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	230	22.6	13.7	205	22.7	13.7	16	21.8	14.4	-	-	-	5	25.7	10.9	8	22.3	8.0
Localized	451	44.2	26.4	404	44.7	26.7	30	39.5	24.5	3	42.1	25.0	9	42.9	15.7	14	39.7	13.2
Regional	295	29.0	17.4	260	28.7	17.3	25	33.2	20.7	3	36.8	23.7	5	25.7	10.0	12	33.5	11.3
Distant	40	3.9	2.3	33	3.7	2.2	4	5.3	3.3	-	-	-	-	-	-	2	4.5	1.5
Unknown	2	0.2	0.1	2	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	927	19.3	85.1	854	19.0	83.8	55	25.0	121.5	-	-	-	7	20.1	47.2	19	25.8	80.9
Localized	2,694	55.9	246.8	2,543	56.5	248.1	102	46.3	226.3	15	55.7	274.0	20	54.9	137.7	38	52.2	168.9
Regional	950	19.7	86.3	881	19.6	85.3	49	22.4	108.4	7	26.0	133.0	8	22.8	56.9	12	17.2	49.3
Distant	204	4.2	18.3	188	4.2	18.0	13	5.9	28.8	-	-	-	-	-	-	3	4.2	11.6
Unknown	41	0.8	3.4	38	0.9	3.4	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	6	0.3	0.2	5	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	469	21.3	14.6	436	21.5	14.3	25	19.2	24.8	2	19.3	14.1	2	15.6	6.6	5	21.3	8.2
Regional	516	23.5	15.5	478	23.6	15.2	30	22.7	25.0	2	21.1	15.9	3	20.3	8.8	5	21.3	8.9
Distant	1,136	51.6	34.2	1,041	51.3	33.1	74	55.9	60.9	7	57.9	53.5	8	64.1	26.6	13	54.1	21.6
Unknown	74	3.4	2.4	70	3.4	2.4	2	1.8	2.4	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	9	0.4	0.2	9	0.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-
Localized	533	25.9	14.0	499	26.2	13.9	23	21.7	14.8	3	19.8	22.8	5	25.7	13.0	6	28.3	7.9
Regional	469	22.8	12.3	436	22.9	12.1	24	22.1	15.4	5	26.7	25.6	3	12.4	5.5	4	20.2	4.5
Distant	978	47.5	25.5	896	47.1	24.8	57	53.3	38.4	8	47.7	48.6	12	58.1	26.0	10	51.5	13.2
Unknown	69	3.3	1.7	63	3.3	1.6	3	2.8	2.0	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	2,863	72.7	78.6	2,608	72.7	75.8	189	75.7	137.5	15	73.3	92.7	13	71.6	33.7	45	73.7	54.9
Regional	625	15.9	16.3	578	16.1	16.0	36	14.5	25.4	4	21.8	28.9	2	9.1	3.8	8	13.2	9.7
Distant	368	9.3	11.7	341	9.5	11.4	22	8.7	21.2	-	-	-	3	18.2	11.9	7	11.2	12.5
Unknown	82	2.1	2.7	60	1.7	2.1	3	1.0	2.9	-	-	-	-	-	-	1	2.0	2.2
<i>Age < 65</i>																		
Localized	1,217	74.6	33.2	1,076	74.6	31.4	112	76.7	71.0	9	83.3	47.2	5	82.1	9.5	22	77.8	20.9
Regional	313	19.2	8.5	284	19.7	8.2	24	16.2	15.0	2	16.7	9.2	-	-	-	4	13.9	3.8
Distant	87	5.3	2.4	76	5.3	2.2	10	6.6	6.0	-	-	-	-	-	-	2	6.9	1.8
Unknown	16	1.0	0.4	7	0.5	0.2	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	1,646	71.4	392.4	1,532	71.4	382.8	77	74.3	597.6	6	61.7	407.0	8	66.7	200.9	22	70.0	289.6
Regional	312	13.5	70.7	295	13.7	69.8	13	12.2	97.3	3	27.7	164.7	-	-	-	4	12.5	50.6
Distant	281	12.2	76.0	265	12.3	74.6	12	11.8	126.0	-	-	-	-	-	-	5	15.0	86.8
Unknown	66	2.9	18.1	53	2.5	15.2	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Wyoming, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	10	53.8	3.5	10	55.6	3.7	-	-	-	-	-	-	-	-	-	-	-	-
Regional	5	24.7	1.6	4	24.4	1.6	-	-	-	-	-	-	-	-	-	-	-	-
Distant	3	16.1	1.0	3	16.7	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCDA ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
<i>All Ages</i>																		
In Situ	3	2.5	0.9	3	2.6	0.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	51	42.3	15.7	47	41.0	14.9	-	-	-	2	69.2	53.7	-	-	-	3	37.2	20.6
Regional	43	35.5	12.9	42	36.8	13.1	-	-	-	-	-	-	-	-	-	3	34.9	14.3
Distant	17	14.5	5.5	17	14.6	5.4	-	-	-	-	-	-	-	-	-	2	20.9	9.0
Unknown	6	5.2	1.9	6	4.9	1.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	4	34.4	2.5	4	34.5	2.4	-	-	-	-	-	-	-	-	-	-	-	-
Regional	6	43.8	3.3	5	43.1	3.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	3	20.3	1.6	2	20.7	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	3	2.8	3.3	3	2.9	3.4	-	-	-	-	-	-	-	-	-	-	-	-
Localized	46	43.3	50.3	43	41.8	47.7	-	-	-	2	75.0	194.5	-	-	-	-	-	-
Regional	37	34.5	38.3	37	36.1	39.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	15	13.8	15.7	14	13.9	15.4	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
<i>All Ages</i>																		
In Situ	3	2.8	0.9	3	2.9	0.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	37	37.2	11.2	36	37.6	11.3	-	-	-	-	-	-	-	-	-	2	36.7	13.3
Regional	33	32.8	10.1	31	32.0	9.8	-	-	-	-	-	-	-	-	-	2	33.3	11.2
Distant	21	21.0	6.2	21	21.4	6.3	-	-	-	-	-	-	-	-	-	1	23.3	8.7
Unknown	6	6.2	1.8	6	6.2	1.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	4	37.3	2.3	4	36.7	2.3	-	-	-	-	-	-	-	-	-	-	-	-
Regional	4	43.1	2.8	4	42.9	2.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	1	13.7	0.9	1	14.3	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	33	37.2	34.6	33	37.6	34.8	-	-	-	-	-	-	-	-	-	2	36.7	48.2
Regional	28	31.6	29.2	27	30.7	28.2	-	-	-	-	-	-	-	-	-	2	33.3	40.5
Distant	20	21.8	19.9	19	22.2	20.2	-	-	-	-	-	-	-	-	-	1	23.3	31.3
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCDA - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age and Race and Hispanic Ethnicity for Select Cancer Sites
Wyoming, 2013-2017**

Female Breast, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
In Situ	58	13.3	18.2	56	13.4	18.3	-	-	-	-	-	-	-	-	-	2	12.3	10.9
Localized	246	56.8	73.4	239	57.0	73.9	-	-	-	4	62.1	84.2	1	37.5	33.6	8	46.9	41.0
Regional	102	23.4	31.2	97	23.0	30.9	-	-	-	2	34.5	49.8	1	43.8	47.2	5	30.9	28.9
Distant	20	4.6	5.4	19	4.6	5.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	8	1.9	2.4	8	1.9	2.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 50</i>																		
In Situ	14	18.4	9.1	13	18.3	8.9	-	-	-	-	-	-	-	-	-	-	-	-
Localized	37	48.9	23.8	35	49.4	23.9	-	-	-	-	-	-	-	-	-	2	44.0	15.7
Regional	22	28.4	13.4	20	28.1	13.2	-	-	-	-	-	-	-	-	-	2	32.0	11.4
Distant	3	3.4	1.5	2	3.4	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 50</i>																		
In Situ	44	12.2	41.9	43	12.4	43.0	-	-	-	-	-	-	-	-	-	-	-	-
Localized	209	58.4	203.1	204	58.6	204.9	-	-	-	-	-	-	-	-	-	5	48.2	107.1
Regional	80	22.3	77.9	77	22.0	77.3	-	-	-	-	-	-	-	-	-	3	30.4	74.9
Distant	17	4.8	15.6	17	4.9	16.0	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>Male</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	41	27.6	12.7	39	27.3	12.6	-	-	-	-	-	-	-	-	-	1	27.3	7.6
Regional	29	19.8	8.6	29	19.8	8.6	-	-	-	-	-	-	-	-	-	1	27.3	10.1
Distant	63	42.9	19.2	62	43.0	19.3	-	-	-	-	-	-	-	-	-	2	36.4	10.7
Unknown	14	9.7	4.6	14	9.8	4.7	-	-	-	-	-	-	-	-	-	-	-	-
<i>Female</i>																		
In Situ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Localized	41	29.1	11.6	40	29.5	11.7	-	-	-	-	-	-	-	-	-	2	36.0	14.5
Regional	27	19.0	7.7	26	19.1	7.8	-	-	-	-	-	-	-	-	-	-	-	-
Distant	62	44.0	17.4	60	43.8	17.3	-	-	-	-	-	-	-	-	-	2	40.0	12.6
Unknown	11	7.6	3.1	10	7.3	3.0	-	-	-	-	-	-	-	-	-	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races			White			Black			AI/AN PRCD ¹			API ¹			Hispanic, All Races		
	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>																		
Localized	316	80.2	86.5	310	80.3	87.2	2	85.7	76.9	2	75.0	84.5	-	-	-	11	85.9	63.0
Regional	44	11.1	11.0	43	11.0	11.1	-	-	-	-	-	-	-	-	-	1	9.4	6.0
Distant	23	5.9	7.2	22	5.8	7.1	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	11	2.8	3.4	11	2.9	3.4	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age < 65</i>																		
Localized	128	81.6	33.8	125	81.7	34.2	-	-	-	-	-	-	-	-	-	4	91.7	20.2
Regional	21	13.1	5.3	20	12.9	5.3	-	-	-	-	-	-	-	-	-	-	-	-
Distant	6	3.7	1.5	6	3.7	1.5	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	3	1.7	0.7	3	1.7	0.8	-	-	-	-	-	-	-	-	-	-	-	-
<i>Age ≥ 65</i>																		
Localized	188	79.3	451.3	184	79.3	453.9	-	-	-	-	-	-	-	-	-	7	82.5	359.2
Regional	23	9.7	50.5	23	9.8	51.2	-	-	-	-	-	-	-	-	-	-	-	-
Distant	17	7.3	46.3	17	7.2	45.6	-	-	-	-	-	-	-	-	-	-	-	-
Unknown	9	3.6	21.6	8	3.6	21.7	-	-	-	-	-	-	-	-	-	-	-	-

¹ Abbreviations: AI/AN PRCD¹ - American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area (See Appendix G); API¹ - Asian/Pacific Islander

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Puerto Rico*, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	92	38.4	5.1
Regional	64	26.4	3.3
Distant	19	8.1	1.0
Unknown	65	27.1	3.3

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	35	3.4	1.7
Localized	406	38.6	19.7
Regional	332	31.6	16.3
Distant	161	15.3	8.0
Unknown	117	11.2	5.8
<i>Age < 50</i>			
In Situ	2	2.0	0.2
Localized	34	38.3	3.4
Regional	28	31.8	2.8
Distant	17	19.1	1.7
Unknown	8	8.7	0.8
<i>Age ≥ 50</i>			
In Situ	34	3.5	5.6
Localized	372	38.6	62.5
Regional	304	31.6	51.8
Distant	144	15.0	24.4
Unknown	110	11.4	19.0
<i>Female</i>			
<i>All Ages</i>			
In Situ	28	3.2	1.1
Localized	349	39.7	14.1
Regional	272	31.0	11.0
Distant	121	13.8	5.0
Unknown	108	12.3	4.2
<i>Age < 50</i>			
In Situ	1	1.3	0.1
Localized	36	39.3	3.2
Regional	31	33.8	2.8
Distant	16	17.1	1.4
Unknown	8	8.6	0.7
<i>Age ≥ 50</i>			
In Situ	27	3.4	3.7
Localized	313	39.8	42.4
Regional	241	30.6	32.6
Distant	106	13.4	14.3
Unknown	100	12.8	13.2

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	429	16.7	18.5
Localized	1,246	48.5	52.4
Regional	591	23.0	26.3
Distant	110	4.3	4.7
Unknown	194	7.5	8.2
<i>Age < 50</i>			
In Situ	78	17.0	7.1
Localized	196	42.5	17.7
Regional	133	28.8	12.1
Distant	20	4.4	1.8
Unknown	34	7.3	3.1
<i>Age ≥ 50</i>			
In Situ	351	16.6	48.3
Localized	1,050	49.8	143.1
Regional	459	21.7	63.5
Distant	89	4.2	12.3
Unknown	160	7.6	21.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	2	0.3	0.1
Localized	95	19.7	4.6
Regional	74	15.2	3.5
Distant	183	37.9	8.8
Unknown	130	26.8	6.4
<i>Female</i>			
In Situ	-	-	-
Localized	68	22.3	2.7
Regional	45	14.6	1.7
Distant	102	33.4	3.9
Unknown	91	29.7	3.4

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	1,957	65.3	89.1
Regional	140	4.7	6.3
Distant	102	3.4	4.9
Unknown	797	26.6	37.4
<i>Age < 65</i>			
Localized	728	72.9	39.4
Regional	72	7.2	3.9
Distant	20	2.0	1.1
Unknown	180	18.0	9.5
<i>Age ≥ 65</i>			
Localized	1,229	61.6	432.5
Regional	68	3.4	23.3
Distant	82	4.1	31.3
Unknown	617	30.9	230.4

* Puerto Rico data have been adjusted to accommodate the impact of Hurricane Maria, see Technical Notes.

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Alberta, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	99	57.3	4.7
Regional	57	32.8	2.7
Distant	14	7.9	0.6
Unknown	3	2.0	0.2

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	211	15.2	10.3
Localized	452	32.5	22.7
Regional	449	32.3	23.0
Distant	248	17.8	12.6
Unknown	31	2.2	1.9
<i>Age < 50</i>			
In Situ	10	8.7	0.7
Localized	40	33.2	2.7
Regional	41	34.7	2.9
Distant	27	22.8	1.9
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	201	15.8	35.4
Localized	413	32.5	75.3
Regional	407	32.0	75.6
Distant	221	17.4	40.8
Unknown	-	-	-
<i>Female</i>			
<i>All Ages</i>			
In Situ	118	11.6	5.3
Localized	335	32.8	15.5
Regional	334	32.6	15.6
Distant	206	20.2	9.4
Unknown	29	2.9	1.3
<i>Age < 50</i>			
In Situ	8	8.1	0.6
Localized	37	37.2	2.6
Regional	31	31.4	2.3
Distant	23	23.1	1.7
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	110	11.9	17.7
Localized	298	32.3	49.3
Regional	303	32.8	50.5
Distant	184	19.9	29.7
Unknown	-	-	-

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	372	12.2	17.0
Localized	1,654	54.4	75.9
Regional	838	27.6	38.6
Distant	165	5.4	7.6
Unknown	10	0.3	0.4
<i>Age < 50</i>			
In Situ	85	13.7	6.4
Localized	280	45.3	20.7
Regional	221	35.8	16.2
Distant	31	5.1	2.3
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	287	11.9	45.0
Localized	1,374	56.8	220.5
Regional	617	25.5	97.3
Distant	134	5.5	21.6
Unknown	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	2	0.2	0.1
Localized	170	15.1	9.3
Regional	264	23.4	14.2
Distant	686	60.8	36.6
Unknown	6	0.5	0.3
<i>Female</i>			
In Situ	4	0.3	0.2
Localized	240	21.2	11.4
Regional	273	24.2	12.9
Distant	611	54.0	28.7
Unknown	4	0.3	0.2

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	1,662	71.5	79.2
Regional	417	17.9	18.7
Distant	222	9.5	12.8
Unknown	24	1.0	1.6
<i>Age < 65</i>			
Localized	723	74.3	30.9
Regional	205	21.0	8.6
Distant	44	4.5	1.8
Unknown	1	0.1	0.1
<i>Age ≥ 65</i>			
Localized	939	69.5	413.0
Regional	212	15.7	88.8
Distant	178	13.2	88.5
Unknown	22	1.7	12.0

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
British Columbia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	91	50.3	3.7
Regional	57	31.7	2.1
Distant	26	14.2	0.9
Unknown	7	3.8	0.2

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	134	6.9	4.3
Localized	671	34.6	22.2
Regional	653	33.7	21.9
Distant	353	18.2	11.8
Unknown	127	6.6	4.5
<i>Age < 50</i>			
In Situ	4	3.2	0.2
Localized	30	26.7	1.9
Regional	47	41.5	3.0
Distant	26	23.2	1.7
Unknown	6	5.3	0.4
<i>Age ≥ 50</i>			
In Situ	130	7.1	14.9
Localized	641	35.1	75.3
Regional	606	33.2	71.3
Distant	327	17.9	38.4
Unknown	121	6.6	15.3
<i>Female</i>			
<i>All Ages</i>			
In Situ	72	4.8	2.1
Localized	530	35.4	16.0
Regional	520	34.7	15.6
Distant	256	17.1	7.8
Unknown	120	8.0	3.4
<i>Age < 50</i>			
In Situ	3	3.1	0.2
Localized	35	34.3	2.3
Regional	39	37.8	2.5
Distant	22	21.1	1.4
Unknown	4	3.7	0.2
<i>Age ≥ 50</i>			
In Situ	69	4.9	7.2
Localized	495	35.5	51.9
Regional	481	34.5	50.1
Distant	234	16.8	24.5
Unknown	116	8.3	11.5

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	569	13.9	17.9
Localized	2,162	52.6	66.9
Regional	1,134	27.6	36.6
Distant	191	4.6	5.9
Unknown	50	1.2	1.4
<i>Age < 50</i>			
In Situ	106	15.5	6.6
Localized	308	44.8	19.3
Regional	244	35.5	15.5
Distant	26	3.8	1.7
Unknown	3	0.4	0.2
<i>Age ≥ 50</i>			
In Situ	463	13.5	47.5
Localized	1,854	54.2	191.6
Regional	890	26.0	91.7
Distant	164	4.8	17.0
Unknown	48	1.4	4.6

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	3	0.2	0.1
Localized	219	13.5	7.4
Regional	448	27.6	15.2
Distant	905	55.7	30.2
Unknown	49	3.0	1.8
<i>Female</i>			
In Situ	10	0.6	0.3
Localized	292	16.9	8.7
Regional	468	27.1	13.8
Distant	912	52.7	26.8
Unknown	47	2.7	1.3

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	1,892	65.9	60.0
Regional	529	18.4	16.0
Distant	337	11.7	11.6
Unknown	113	3.9	4.1
<i>Age < 65</i>			
Localized	559	69.0	17.7
Regional	183	22.6	5.7
Distant	57	7.0	1.8
Unknown	12	1.5	0.4
<i>Age ≥ 65</i>			
Localized	1,333	64.7	352.4
Regional	346	16.8	87.4
Distant	280	13.6	79.7
Unknown	101	4.9	30.0

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Manitoba, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	20	41.8	3.2
Regional	24	49.8	3.4
Distant	4	8.4	0.5
Unknown	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	231	33.2	32.0
Localized	155	22.2	22.4
Regional	205	29.4	29.1
Distant	97	14.0	13.7
Unknown	8	1.1	1.2
<i>Age < 50</i>			
In Situ	13	26.8	3.4
Localized	11	22.4	2.7
Regional	16	32.8	4.1
Distant	9	17.6	2.2
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	218	33.7	107.1
Localized	143	22.2	73.8
Regional	188	29.2	94.6
Distant	88	13.7	44.0
Unknown	-	-	-
<i>Female</i>			
<i>All Ages</i>			
In Situ	140	27.4	17.7
Localized	134	26.3	16.5
Regional	146	28.7	18.1
Distant	82	16.0	10.1
Unknown	8	1.6	0.8
<i>Age < 50</i>			
In Situ	10	22.8	2.5
Localized	12	28.3	3.1
Regional	11	25.6	2.8
Distant	10	22.8	2.5
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	130	27.8	57.5
Localized	122	26.1	51.8
Regional	135	29.0	58.0
Distant	72	15.4	30.2
Unknown	-	-	-

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	113	11.6	14.6
Localized	521	53.6	65.9
Regional	277	28.5	37.3
Distant	59	6.1	7.5
Unknown	2	0.2	0.2
<i>Age < 50</i>			
In Situ	15	10.0	3.8
Localized	62	42.2	15.9
Regional	63	42.3	15.9
Distant	8	5.5	2.1
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	98	11.9	43.0
Localized	458	55.6	197.0
Regional	214	26.0	93.4
Distant	51	6.2	21.7
Unknown	2	0.2	0.6

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	-	-	-
Localized	88	19.9	12.9
Regional	103	23.4	14.9
Distant	248	56.1	35.4
Unknown	2	0.5	0.3
<i>Female</i>			
In Situ	1	0.3	0.2
Localized	121	25.6	14.8
Regional	116	24.5	14.4
Distant	234	49.3	28.7
Unknown	1	0.3	0.1

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	484	68.7	67.3
Regional	126	18.0	15.4
Distant	88	12.5	13.3
Unknown	6	0.8	0.9
<i>Age < 65</i>			
Localized	135	62.6	17.7
Regional	66	30.6	8.6
Distant	14	6.7	2.0
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	348	71.5	410.7
Regional	60	12.3	62.3
Distant	73	15.1	91.4
Unknown	-	-	-

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
New Brunswick, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	29	100.0	7.3

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	79	19.1	14.4
Localized	130	31.2	25.0
Regional	107	25.8	20.7
Distant	73	17.7	14.3
Unknown	26	6.2	5.7
<i>Age < 50</i>			
In Situ	2	9.9	0.9
Localized	5	21.6	1.9
Regional	8	34.2	3.2
Distant	5	23.4	2.2
Unknown	2	10.8	1.1
<i>Age ≥ 50</i>			
In Situ	77	19.6	49.7
Localized	125	31.8	85.4
Regional	99	25.3	66.7
Distant	68	17.3	46.2
Unknown	23	6.0	17.9
<i>Female</i>			
<i>All Ages</i>			
In Situ	45	14.9	7.8
Localized	105	34.4	17.8
Regional	76	25.1	13.2
Distant	55	18.2	9.2
Unknown	23	7.4	4.1
<i>Age < 50</i>			
In Situ	2	12.2	0.9
Localized	4	22.2	1.6
Regional	5	28.9	2.2
Distant	3	15.6	1.1
Unknown	4	21.1	1.6
<i>Age ≥ 50</i>			
In Situ	43	15.0	25.9
Localized	101	35.2	60.1
Regional	71	24.9	41.9
Distant	53	18.4	30.5
Unknown	19	6.6	10.6

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	71	10.4	12.8
Localized	380	55.2	66.4
Regional	197	28.6	37.3
Distant	35	5.1	6.6
Unknown	5	0.7	0.7
<i>Age < 50</i>			
In Situ	9	10.0	3.8
Localized	39	41.2	15.8
Regional	39	41.9	16.4
Distant	6	6.8	2.7
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	62	10.4	36.3
Localized	342	57.4	199.1
Regional	158	26.5	91.9
Distant	29	4.8	16.9
Unknown	5	0.8	2.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	3	0.7	0.6
Localized	92	20.5	18.1
Regional	120	26.8	23.2
Distant	232	51.9	45.1
Unknown	-	-	-
<i>Female</i>			
In Situ	2	0.4	0.3
Localized	106	28.4	17.8
Regional	103	27.6	17.1
Distant	161	43.0	26.5
Unknown	2	0.5	0.3

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	400	76.4	68.3
Regional	73	13.9	11.8
Distant	48	9.2	10.0
Unknown	3	0.5	0.7
<i>Age < 65</i>			
Localized	156	76.6	28.6
Regional	40	19.6	7.4
Distant	8	3.8	1.4
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	244	76.2	343.0
Regional	33	10.3	42.4
Distant	40	12.6	69.0
Unknown	3	0.9	5.6

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Newfoundland and Labrador, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	17	56.1	6.4
Regional	11	36.8	3.6
Distant	-	-	-
Unknown	1	3.9	0.3

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	99	22.3	26.1
Localized	144	32.3	40.6
Regional	126	28.3	34.4
Distant	67	15.1	18.5
Unknown	9	2.0	3.3
<i>Age < 50</i>			
In Situ	4	17.3	2.2
Localized	7	31.7	3.8
Regional	7	34.6	4.1
Distant	3	13.5	1.7
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	96	22.5	88.6
Localized	137	32.3	136.9
Regional	119	28.0	113.8
Distant	64	15.2	62.5
Unknown	-	-	-
<i>Female</i>			
<i>All Ages</i>			
In Situ	72	21.0	18.2
Localized	115	33.6	30.0
Regional	95	27.8	24.5
Distant	50	14.7	12.7
Unknown	10	2.8	2.5
<i>Age < 50</i>			
In Situ	7	27.5	3.9
Localized	8	32.1	4.8
Regional	6	23.7	3.5
Distant	4	16.8	2.4
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	65	20.5	55.5
Localized	106	33.8	96.0
Regional	89	28.2	79.7
Distant	46	14.5	39.7
Unknown	10	3.0	9.2

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	73	13.6	18.8
Localized	294	54.7	75.4
Regional	132	24.6	36.0
Distant	33	6.2	9.1
Unknown	5	0.9	1.3
<i>Age < 50</i>			
In Situ	11	14.2	6.2
Localized	36	45.3	19.6
Regional	26	33.1	14.8
Distant	6	7.4	3.2
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	62	13.5	51.6
Localized	259	56.3	221.3
Regional	106	23.1	91.7
Distant	27	6.0	24.5
Unknown	5	1.1	4.7

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	1	0.5	0.4
Localized	66	23.9	19.1
Regional	62	22.4	16.7
Distant	143	51.5	39.9
Unknown	5	1.7	1.7
<i>Female</i>			
In Situ	2	1.0	0.5
Localized	67	29.2	16.9
Regional	48	21.1	11.9
Distant	108	47.1	26.8
Unknown	4	1.7	1.1

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	322	74.5	78.9
Regional	75	17.4	17.2
Distant	30	7.0	9.4
Unknown	5	1.1	1.7
<i>Age < 65</i>			
Localized	131	72.3	33.1
Regional	45	24.5	11.4
Distant	5	2.9	1.3
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	190	76.2	396.2
Regional	31	12.2	57.5
Distant	25	10.0	65.2
Unknown	-	-	-

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Northwest Territories, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	-	-	-
Localized	6	41.6	45.2
Regional	6	36.4	31.3
Distant	3	22.1	24.3
Unknown	-	-	-
<i>Age < 50</i>			
In Situ	-	-	-
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	-	-	-
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	-	-	-
<i>Female</i>			
<i>All Ages</i>			
In Situ	-	-	-
Localized	4	34.4	22.7
Regional	6	43.8	35.3
Distant	3	21.9	19.5
Unknown	-	-	-
<i>Age < 50</i>			
In Situ	-	-	-
Localized	1	66.7	7.5
Regional	-	-	-
Distant	-	-	-
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	-	-	-
Localized	3	29.1	62.5
Regional	-	-	-
Distant	3	25.5	70.6
Unknown	-	-	-

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	3	10.9	15.8
Localized	15	60.2	87.9
Regional	6	24.2	30.0
Distant	-	-	-
Unknown	-	-	-
<i>Age < 50</i>			
In Situ	-	-	-
Localized	4	55.9	25.7
Regional	2	29.4	13.6
Distant	-	-	-
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	-	-	-
Localized	12	61.7	250.9
Regional	4	22.3	73.0
Distant	-	-	-
Unknown	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	-	-	-
Localized	2	12.3	9.7
Regional	4	27.7	31.4
Distant	8	58.5	51.4
Unknown	-	-	-
<i>Female</i>			
In Situ	-	-	-
Localized	1	13.0	10.5
Regional	2	23.9	17.3
Distant	6	60.9	46.1
Unknown	-	-	-

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	8	59.4	39.7
Regional	3	20.3	16.4
Distant	3	18.8	18.6
Unknown	-	-	-
<i>Age < 65</i>			
Localized	5	68.6	18.3
Regional	1	20.0	5.4
Distant	-	-	-
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	3	50.0	187.5
Regional	1	20.6	92.0
Distant	-	-	-
Unknown	-	-	-

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.
- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.
Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Nova Scotia, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	17	44.2	3.6
Regional	15	40.5	2.7
Distant	5	13.7	0.8
Unknown	-	-	-

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	50	9.5	7.7
Localized	163	31.4	26.3
Regional	179	34.3	28.7
Distant	116	22.3	19.0
Unknown	13	2.4	2.5
<i>Age < 50</i>			
In Situ	2	9.4	0.8
Localized	6	22.0	2.0
Regional	8	33.1	2.9
Distant	9	34.6	3.1
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	47	9.5	25.9
Localized	158	31.9	89.9
Regional	170	34.4	96.4
Distant	107	21.7	60.8
Unknown	-	-	-
<i>Female</i>			
<i>All Ages</i>			
In Situ	32	7.8	4.4
Localized	133	32.4	17.9
Regional	144	35.1	19.9
Distant	79	19.1	11.0
Unknown	23	5.6	2.7
<i>Age < 50</i>			
In Situ	2	7.7	0.5
Localized	4	21.2	1.5
Regional	9	42.3	3.0
Distant	6	28.8	2.0
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	31	7.8	14.4
Localized	129	33.0	60.7
Regional	136	34.7	64.3
Distant	73	18.6	34.7
Unknown	23	5.9	9.9

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	118	12.9	17.5
Localized	490	53.8	69.5
Regional	237	26.0	36.5
Distant	53	5.9	7.6
Unknown	13	1.4	1.6
<i>Age < 50</i>			
In Situ	20	15.2	6.6
Localized	54	41.6	18.0
Regional	51	38.9	17.0
Distant	5	4.0	1.8
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	98	12.6	46.2
Localized	436	55.8	204.2
Regional	186	23.8	87.7
Distant	48	6.2	22.8
Unknown	-	-	-

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	2	0.3	0.2
Localized	106	20.7	16.9
Regional	116	22.7	18.3
Distant	281	54.8	44.6
Unknown	8	1.5	1.2
<i>Female</i>			
In Situ	3	0.6	0.4
Localized	133	26.7	17.8
Regional	112	22.4	14.8
Distant	245	49.0	32.6
Unknown	7	1.4	0.9

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	449	70.1	66.4
Regional	107	16.8	14.9
Distant	69	10.7	11.7
Unknown	15	2.4	3.1
<i>Age < 65</i>			
Localized	146	71.2	22.4
Regional	45	21.7	6.6
Distant	13	6.4	2.0
Unknown	1	0.6	0.2
<i>Age ≥ 65</i>			
Localized	302	69.5	370.4
Regional	63	14.4	71.7
Distant	56	12.8	79.1
Unknown	14	3.3	23.2

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Ontario, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	274	48.5	3.9
Regional	168	29.7	2.1
Distant	58	10.2	0.7
Unknown	65	11.5	0.8

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	^	^	^
Localized	1,649	35.0	21.0
Regional	1,562	33.1	19.8
Distant	774	16.4	9.9
Unknown	731	15.5	9.4
<i>Age < 50</i>			
In Situ	^	^	^
Localized	115	30.6	2.6
Regional	126	33.6	2.8
Distant	76	20.2	1.7
Unknown	58	15.6	1.3
<i>Age ≥ 50</i>			
In Situ	^	^	^
Localized	1,534	35.3	69.4
Regional	1,436	33.1	64.3
Distant	699	16.1	31.1
Unknown	672	15.5	30.7
<i>Female</i>			
<i>All Ages</i>			
In Situ	^	^	^
Localized	1,365	34.4	14.9
Regional	1,266	31.9	13.7
Distant	647	16.3	7.1
Unknown	687	17.3	7.1
<i>Age < 50</i>			
In Situ	^	^	^
Localized	121	33.2	2.6
Regional	114	31.4	2.5
Distant	73	20.0	1.6
Unknown	56	15.4	1.2
<i>Age ≥ 50</i>			
In Situ	^	^	^
Localized	1,244	34.5	47.0
Regional	1,153	32.0	43.0
Distant	574	15.9	21.5
Unknown	631	17.5	22.7

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	1,547	12.5	17.5
Localized	4,612	37.1	51.5
Regional	2,501	20.1	29.3
Distant	2,703	21.8	30.6
Unknown	1,061	8.5	11.8
<i>Age < 50</i>			
In Situ	269	12.2	5.9
Localized	677	30.7	14.8
Regional	605	27.4	13.3
Distant	483	21.9	10.6
Unknown	170	7.7	3.7
<i>Age ≥ 50</i>			
In Situ	1,278	12.5	48.0
Localized	3,935	38.5	147.6
Regional	1,896	18.6	71.1
Distant	2,220	21.7	83.1
Unknown	891	8.7	32.8

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	-	-	-
Localized	770	15.5	9.8
Regional	1,001	20.2	12.6
Distant	2,305	46.5	29.0
Unknown	885	17.8	11.6
<i>Female</i>			
In Situ	-	-	-
Localized	968	19.6	10.4
Regional	978	19.8	10.4
Distant	2,059	41.6	21.8
Unknown	940	19.0	9.7

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	1,994	24.5	23.9
Regional	494	6.1	5.5
Distant	5,585	68.7	67.2
Unknown	52	0.6	0.8
<i>Age < 65</i>			
Localized	698	25.0	8.3
Regional	234	8.4	2.8
Distant	1,856	66.5	21.9
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	1,296	24.3	131.8
Regional	260	4.9	24.7
Distant	3,729	69.9	380.7
Unknown	-	-	-

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

^ Ontario does not submit in situ Colon and Rectum cases.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Prince Edward Island, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	-	-	-
Regional	2	21.6	1.6
Distant	-	-	-
Unknown	4	59.5	5.0

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	26	26.8	26.0
Localized	17	17.9	17.9
Regional	18	18.9	19.0
Distant	7	7.3	8.2
Unknown	28	29.1	29.7
<i>Age < 50</i>			
In Situ	2	32.0	3.5
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	1	24.0	2.8
<i>Age ≥ 50</i>			
In Situ	24	26.5	84.8
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	27	29.4	100.4
<i>Female</i>			
<i>All Ages</i>			
In Situ	19	25.6	17.1
Localized	15	20.2	13.6
Regional	13	17.2	11.7
Distant	7	9.5	6.6
Unknown	20	27.5	18.7
<i>Age < 50</i>			
In Situ	-	-	-
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	1	30.4	3.1
<i>Age ≥ 50</i>			
In Situ	-	-	-
Localized	-	-	-
Regional	-	-	-
Distant	-	-	-
Unknown	19	27.3	59.7

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	19	13.9	18.1
Localized	45	32.6	42.0
Regional	23	16.8	22.3
Distant	5	3.5	4.4
Unknown	46	33.2	43.5
<i>Age < 50</i>			
In Situ	2	11.9	4.3
Localized	5	32.1	11.5
Regional	3	19.0	7.0
Distant	-	-	-
Unknown	6	34.5	12.5
<i>Age ≥ 50</i>			
In Situ	17	14.2	54.2
Localized	40	32.7	121.7
Regional	20	16.5	62.3
Distant	-	-	-
Unknown	40	33.0	124.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	-	-	-
Localized	5	7.8	5.9
Regional	10	15.0	11.0
Distant	24	35.3	25.4
Unknown	29	41.3	30.9
<i>Female</i>			
In Situ	-	-	-
Localized	11	14.1	9.6
Regional	9	12.3	8.0
Distant	24	31.5	20.6
Unknown	31	41.9	28.0

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	41	42.0	39.1
Regional	8	7.7	7.2
Distant	3	3.3	3.5
Unknown	46	47.0	46.0
<i>Age < 65</i>			
Localized	14	42.1	14.0
Regional	3	9.8	3.2
Distant	-	-	-
Unknown	15	46.3	15.1
<i>Age ≥ 65</i>			
Localized	27	41.9	212.3
Regional	4	6.7	35.1
Distant	-	-	-
Unknown	31	47.4	259.6

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.

**Average Annual Stage at Diagnosis Cases and Age-adjusted Rates
by Age for Select Cancer Sites
Saskatchewan, 2013-2017**

Cervix, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	22	46.0	4.3
Regional	17	36.3	2.9
Distant	7	15.2	1.2
Unknown	1	2.5	0.2

Colon and Rectum, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
<i>All Ages</i>			
In Situ	130	22.5	20.3
Localized	200	34.5	32.0
Regional	138	23.8	22.5
Distant	98	16.9	15.7
Unknown	13	2.3	2.2
<i>Age < 50</i>			
In Situ	6	16.0	1.6
Localized	9	26.9	2.7
Regional	12	34.9	3.6
Distant	8	22.3	2.2
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	125	22.9	69.4
Localized	190	35.0	108.9
Regional	126	23.1	72.0
Distant	90	16.5	50.9
Unknown	13	2.4	8.0
<i>Female</i>			
<i>All Ages</i>			
In Situ	73	17.9	10.6
Localized	142	34.8	20.4
Regional	106	26.1	15.2
Distant	72	17.6	10.3
Unknown	15	3.6	1.6
<i>Age < 50</i>			
In Situ	4	12.2	1.3
Localized	11	32.3	3.1
Regional	8	24.4	2.5
Distant	10	30.5	3.1
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	69	18.4	35.1
Localized	131	35.0	65.7
Regional	98	26.2	48.4
Distant	62	16.5	29.1
Unknown	-	-	-

Female Breast, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
In Situ	105	12.1	16.2
Localized	452	52.4	68.1
Regional	241	27.9	37.8
Distant	59	6.8	8.6
Unknown	7	0.8	0.7
<i>Age < 50</i>			
In Situ	13	10.1	4.1
Localized	55	42.4	17.0
Regional	53	41.2	16.5
Distant	8	6.3	2.4
Unknown	-	-	-
<i>Age ≥ 50</i>			
In Situ	92	12.5	48.1
Localized	397	54.2	201.9
Regional	188	25.6	93.8
Distant	50	6.9	24.8
Unknown	7	0.9	2.5

Lung and Bronchus, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>Male</i>			
In Situ	-	-	-
Localized	55	14.5	9.2
Regional	81	21.4	13.3
Distant	239	63.0	38.9
Unknown	4	1.1	0.7
<i>Female</i>			
In Situ	-	-	-
Localized	67	16.8	9.5
Regional	92	23.1	13.2
Distant	234	58.6	33.5
Unknown	6	1.4	0.6

Prostate, 2013-2017

Stage at Diagnosis	All Races		
	Avg. Annual Cases	%	Rate ²
<i>All Ages</i>			
Localized	429	64.5	65.1
Regional	118	17.7	17.3
Distant	101	15.2	16.9
Unknown	17	2.6	2.9
<i>Age < 65</i>			
Localized	175	73.1	25.9
Regional	50	21.0	7.2
Distant	14	5.8	2.0
Unknown	-	-	-
<i>Age ≥ 65</i>			
Localized	254	59.6	336.1
Regional	68	15.9	86.8
Distant	87	20.5	119.7
Unknown	-	-	-

² Rates are per 100,000 population and were age-adjusted using 19 age groups to the 2000 U.S. Standard Population.

- Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

Note: Percentages based upon small cell sizes should be used with caution.